,approvalStatus,efficacyEvidence,evidenceType,id,indication.id,indication.name,indication.source,molecularProfile.id,molecularProfile.profileName,responseType,therapy.id,therapy.therapyName,Gene_id,,,,
0,Preclinical,"In a preclinical study, treatment with Sprycel (dasatinib) in decreased CRKL phosphorylation and reduced viability of lung adenocarcinoma cells harboring ABL1 R332W (also reported as R351W) in culture (PMID: 26758680).",Actionable,7337,3910,lung adenocarcinoma,DOID,25102,ABL1 R332W,sensitive,717,Dasatinib,25,26758680,,,
1,Preclinical - Cell line xenograft,"In a preclinical study, Gleevec (imatinib) inhibited growth of a lung adenocarcinoma cell line harboring ABL1 R332W (also reported as R351W) in culture, and inhibited tumor growth in xenograft models (PMID: 26758680).",Actionable,7334,3910,lung adenocarcinoma,DOID,25102,ABL1 R332W,sensitive,770,Imatinib,25,26758680,,,
2,Preclinical,"In a preclinical study, lung adenocarcinoma cells harboring ABL1 R332W (also reported as R351W) and expressing ABL1 T315I demonstrated resistance to Sprycel (dasatinib) in culture (PMID: 26758680).",Actionable,7339,3910,lung adenocarcinoma,DOID,25103,ABL1 R332W ABL1 T315I,resistant,717,Dasatinib,25,26758680,,,
3,Preclinical - Cell line xenograft,"In a preclinical study, lung adenocarcinoma cells harboring ABL1 R332W (also reported as R351W) and expressing ABL1 T315I demonstrated resistance to Gleevec (imatinib) in culture and in xenograft models (PMID: 26758680).",Actionable,7336,3910,lung adenocarcinoma,DOID,25103,ABL1 R332W ABL1 T315I,resistant,770,Imatinib,25,26758680,,,
4,Preclinical,"In a preclinical study, Gleevec (imatinib) inhibited growth of a lung adenocarcinoma cell line harboring ABL1 G321L (also reported as G340L) in culture (PMID: 26758680).",Actionable,7335,3910,lung adenocarcinoma,DOID,25109,ABL1 G321L,sensitive,770,Imatinib,25,26758680,,,
5,Preclinical,"In a preclinical study, treatment with Sprycel (dasatinib) in decreased CRKL phosphorylation and reduced viability of lung adenocarcinoma cells harboring ABL1 G321L (also reported as G340L) in culture (PMID: 26758680).",Actionable,7338,3910,lung adenocarcinoma,DOID,25109,ABL1 G321L,sensitive,717,Dasatinib,25,26758680,,,
6,Clinical Study,"In a clinical study, Tasigna (nilotinib) treatment resulted in no benefit in a patient with oral cavity cancer harboring ABL1 G250R and G251D (PMID: 28514312). ",Actionable,11048,8618,oral cavity cancer,DOID,27899,ABL1 G250R ABL1 G251D,no benefit,829,Nilotinib,25,28514312,,,
0,Phase II,"In a Phase II trial, Ipatasertib (GDC-0068) in combination with Abraxane (paclitaxel) resulted in improved progression free survival (6.2 vs 4.9 months) compared to placebo in triple-receptor negative breast cancer patients harboring mutations in PIK3CA, AKT1, or PTEN (J Clin Oncol 35, 2017 (suppl; abstr 1009)).",Actionable,11169,60081,triple-receptor negative breast cancer,DOID,1209,AKT1 mutant,predicted â€“ sensitive,1588,Ipatasertib + Paclitaxel,207,None,,,
1,Phase II,"In a Phase II trial, Apitolisib (GDC-0980) was poorly tolerated, but demonstrated efficacy in endometrial cancer patients harboring mutations in PIK3CA, PTEN, or AKT1 (J Clin Oncol 32:5s, 2014 (suppl; abstr 5513)).",Actionable,5205,1380,endometrial cancer,DOID,1209,AKT1 mutant,sensitive,750,GDC-0980,207,None,,,
2,Phase II,"In a retrospective study of a Phase II trial, Torisel (temsirolimus) treatment resulted in an increased progression-free survival (HR 0.16) and response rate (response difference 0.83) in advanced endometrial cancer patients harboring AKT1 mutations (PMID: 27016228).",Actionable,6401,1380,endometrial cancer,DOID,1209,AKT1 mutant,predicted â€“ sensitive,936,Temsirolimus,207,27016228,,,
3,Phase II,"In a Phase II trial, AKT1 mutations were more frequent in  muscle-invasive urothelial bladder cancer patients that did not respond to Nexavar (sorafenib), Platinol (cisplatin) and Gemzar (gemcitabine) combination therapy than those who did respond (J Clin Oncol 35, 2017 (suppl 6S; abstract 345)).",Actionable,10325,6477,invasive bladder transitional cell carcinoma,DOID,1209,AKT1 mutant,predicted â€“ resistant,5462,Cisplatin + Gemcitabine + Sorafenib,207,None,,,
4,Preclinical - Cell line xenograft,"In a preclinical study, Rapamune (sirolimus) and Adriamycin (doxorubicin) combination treatment resulted in improved survival and prolonged remission in cell line xenograft animal models of lymphoma overexpressing constitutively active Akt (PMID: 18708578).",Actionable,4856,60058,lymphoma,DOID,1281,AKT1 act mut,predicted â€“ sensitive,3663,Doxorubicin + Sirolimus,207,18708578,,,
5,Preclinical - Cell line xenograft,"In a preclinical study, lymphoma cells overexpressing constitutively active Akt demonstrated reduced sensitivity to Adriamycin (doxorubicin) treatment in cell line xenograft models (PMID: 18708578).",Actionable,4851,60058,lymphoma,DOID,1281,AKT1 act mut,decreased response,1009,Doxorubicin,207,18708578,,,
6,Preclinical - Cell line xenograft,"In a preclinical study, Rapamune (sirolimus) treatment did not improve survival in cell line xenograft animal models of lymphoma overexpressing constitutively active Akt (PMID: 18708578).",Actionable,4853,60058,lymphoma,DOID,1281,AKT1 act mut,no benefit,917,Sirolimus,207,18708578,,,
7,Phase I,"In a Phase I trial, Triciribine (API-2) demonstrated safety, but lacked efficacy as a monotherapy in advanced solid tumor patients with activated Akt (PMID: 20644979).",Actionable,2891,10000003,Advanced Solid Tumor,JAX,1281,AKT1 act mut,no benefit,948,Triciribine,207,20644979,,,
8,Preclinical - Cell line xenograft,"In a preclinical study, Perifosine (KRX-0401) inhibited Akt1 signaling, inhibited proliferation, and induced apoptosis in human ovarian clear cell cancer cells with activated Akt1 in culture and inhibited tumor growth in cell line xenografts (PMID: 25519148).",Actionable,4720,50934,ovarian clear cell carcinoma,DOID,26309,AKT1 positive,predicted â€“ sensitive,855,Perifosine,207,25519148,,,
9,Preclinical - Cell culture,"In a preclinical study, Perifosine (KRX-0401) enhanced the sensitivity of human ovarian clear cell cancer cells with activated Akt1 to Platinol (cisplatin) treatment in culture (PMID: 25519148).",Actionable,4721,50934,ovarian clear cell carcinoma,DOID,26309,AKT1 positive,predicted â€“ sensitive,3600,Cisplatin + Perifosine,207,25519148,,,
10,Preclinical - Cell line xenograft,"In a preclinical study, ONC201 (TIC-10) inhibited Akt activation and induced apoptosis and tumor regression in a variety of cell line xenograft models (PMID: 23390247). ",Actionable,3624,10000003,Advanced Solid Tumor,JAX,3110,AKT1 amp,predicted â€“ sensitive,1687,ONC201,207,23390247,,,
11,Clinical Study,"In a clinical study, a patient with lung adenocarcinoma harboring AKT1 E17K demonstrated a partial response when treated with AZD5363 (PMID: 28489509). ",Actionable,11436,3910,lung adenocarcinoma,DOID,643,AKT1 E17K,sensitive,655,AZD5363,207,28489509,,,
12,Phase I,"In a Phase I clinical trial in patients with advanced solid tumors, AZD5363 demonstrated safety and preliminary antitumor activity, with stable disease in 27% (10/37) of patients and partial response in two patients, both of whom harbored an AKT1 E17K mutation (PMID: 26931343).",Actionable,1336,10000003,Advanced Solid Tumor,JAX,643,AKT1 E17K,sensitive,655,AZD5363,207,None,26931343,,
13,Phase I,"In a Phase I clinical study, a patient with endometrioid ovarian carcinoma harboring AKT1 E17K had a sustained partial response to AZD5363 for more than two years (PMID: 26351323).",Actionable,3621,6212,ovarian endometrial cancer,DOID,643,AKT1 E17K,sensitive,655,AZD5363,207,26351323,,,
14,Preclinical,"In a preclinical study, AZD5363 inhibited growth and colony formation of breast cancer cells expressing AKT E17K in cell culture and in xenografts as well as breast cancer explant models harboring AKT E17K (PMID: 26351323).",Actionable,3633,1612,breast cancer,DOID,643,AKT1 E17K,sensitive,655,AZD5363,207,26351323,,,
15,Clinical Study,"In a clinical study, four patients with ESR1-positive breast cancer harboring AKT1 E17K demonstrated a partial response when treated with AZD5363 (PMID: 28489509).",Actionable,11432,1612,breast cancer,DOID,643,AKT1 E17K,sensitive,655,AZD5363,207,28489509,,,
16,Clinical Study,"In a clinical study, a patient with cervical cancer harboring AKT1 E17K demonstrated a partial response when treated with AZD5363 (PMID: 28489509). ",Actionable,11434,4362,cervical cancer,DOID,643,AKT1 E17K,sensitive,655,AZD5363,207,28489509,,,
17,Preclinical,"In a preclinical study, the pan AKT inhibitor GSK2141795 displayed similar levels of inhibition against ATK1 E17K (activating mutation) as ATK1 wild-type (PMID: 24978597).",Actionable,1227,162,cancer,DOID,643,AKT1 E17K,sensitive,764,GSK2141795,207,24978597,,,
18,Phase I,"In a Phase I clinical trial, a patient with ER-positive, ERBB2 (HER2)-negative papillary breast carcinoma harboring AKT1 E17K had a sustained partial response to AZD5363 (PMID: 26351323).",Actionable,3622,5592,breast papillary carcinoma,DOID,643,AKT1 E17K,sensitive,655,AZD5363,207,26351323,,,
19,Phase I,"In a Phase I trial, a patient with ERBB2 (HER2)-receptor negative breast cancer harboring AKT1 E17K demonstrated a complete metabolic response when treated with Ipatasertib (GDC-0068) (PMID: 27872130). ",Actionable,9713,60080,Her2-receptor negative breast cancer,DOID,643,AKT1 E17K,sensitive,747,Ipatasertib,207,27872130,,,
20,Preclinical - Cell culture,"In a preclinical study, Uprosertib (GSK2141795) inhibited the growth of melanoma cells harboring AKT1 E17K in culture (PMID: 24735930).",Actionable,10809,1909,melanoma,DOID,643,AKT1 E17K,sensitive,764,GSK2141795,207,24735930,,,
21,Preclinical - Pdx,"In a preclinical study, treatment with BAY1125976 reduced tumor growth and resulted in partial tumor regression or stable disease in anal cancer patient-derived xenograft (PDX) models harboring AKT1 E17K (PMID: 27699769).",Actionable,3828,50688,anal canal cancer,DOID,643,AKT1 E17K,sensitive,994,BAY1125976,207,None,27699769,,
22,Preclinical - Cell line xenograft,"In a preclinical study, an endometrial cell line xenograft model harboring AKT E17K was sensitive to ARQ 751, demonstrating inhibition of tumor growth (PMID: 26469692). ",Actionable,10279,1380,endometrial cancer,DOID,643,AKT1 E17K,sensitive,4331,ARQ 751,207,26469692,,,
23,Clinical Study,"In a clinical case study, a patient with meningothelial meningioma harboring AKT1 E17K demonstrated stable disease and some tumor regression when treated with AZD5363 (PMID: 28376212). ",Actionable,10807,7212,meningothelial meningioma,DOID,643,AKT1 E17K,sensitive,655,AZD5363,207,28376212,,,
24,Clinical Study,"In a clinical study, a patient with triple-receptor negative breast cancer harboring AKT1 E17K demonstrated a partial response when treated with AZD5363 (PMID: 28489509). ",Actionable,11435,60081,triple-receptor negative breast cancer,DOID,643,AKT1 E17K,sensitive,655,AZD5363,207,28489509,,,
25,Phase I,"In a Phase I trial, a patient with ovarian granulosa cell tumor cancer harboring subclonal AKT E17K demonstrated an overall tumor regression of 24% when treated with AZD5363, which lasted 253 days (PMID: 28489509). ",Actionable,11452,2999,granulosa cell tumor,DOID,643,AKT1 E17K,sensitive,655,AZD5363,207,28489509,,,
26,Preclinical - Cell line xenograft,"In a preclinical study, an endometrial cell line xenograft model harboring AKT E17K was sensitive to ARQ092, demonstrating inhibition of tumor growth (PMID: 26469692). ",Actionable,10278,1380,endometrial cancer,DOID,643,AKT1 E17K,sensitive,635,ARQ092,207,26469692,,,
27,Clinical Study,"In a clinical study, two patients with endometrial cancer harboring AKT1 E17K demonstrated a partial response when treated with AZD5363 (PMID: 28489509). ",Actionable,11433,1380,endometrial cancer,DOID,643,AKT1 E17K,sensitive,655,AZD5363,207,28489509,,,
28,Preclinical - Pdx,"In a preclinical study, BAY1125976 induced complete tumor regression in a patient-derived xenograft (PDX) model of breast cancer harboring AKT E17K (PMID: 27699769).",Actionable,8807,1612,breast cancer,DOID,643,AKT1 E17K,sensitive,994,BAY1125976,207,27699769,,,
29,Clinical Study,"In a retrospective study, 100% (2/2) colorectal carcinoma patients harboring an AKT1 E17K mutation and wild-type KRAS/BRAF demonstrated resistance to Erbitux (cetuximab) in combination with Camptosar (irinotecan) (PMID: 25714871).",Actionable,3614,9256,colorectal cancer,DOID,13841,AKT1 E17K KRAS wild-type BRAF wild-type,resistant,1874,Cetuximab + Irinotecan,207,25714871,,,
30,Preclinical,"In a preclinical study, the combined therapy of AZD5363 and AZD4547 resulted in tumor regression in urinary bladder cancer xenograft models simultaneously harboring the mutations, AKT1 E17K and FGFR3 Y373C (PMID: 26351323). ",Actionable,3811,11054,urinary bladder cancer,DOID,14066,AKT1 E17K FGFR3 Y373C,sensitive,3346,AZD5363 + AZD4547,207,26351323,,,
31,Preclinical - Cell culture,"In a preclinical study, BAY1125976 inhibited Akt activation and downstream signaling in bladder cancer cell lines carrying both Akt1 E17K and Nras Q61R mutations (AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3685).",Actionable,3830,4007,bladder carcinoma,DOID,16525,AKT1 E17K NRAS Q61R,sensitive,994,BAY1125976,207,None,,,
32,Preclinical - Cell line xenograft,"In a preclinical study, BAY1125976 inhibited proliferation of a prostate cancer cell line harboring AKT E17K and NRAS G12D in culture, and demonstrated antitumor activity in xenograft models (PMID: 27699769).",Actionable,8810,10283,prostate cancer,DOID,26446,AKT1 E17K NRAS G12D,sensitive,994,BAY1125976,207,27699769,,,
33,Preclinical - Cell culture,"In a preclinical study, expression of AKT1 E17K in a wild-type PTEN-expressing BRAF V600-mutant melanoma cell line conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 24265152).",Actionable,8103,1909,melanoma,DOID,26172,AKT1 E17K BRAF V600X PTEN pos,resistant,342,Vemurafenib,207,24265152,,,
34,Clinical Study,"In a clinical study, an ovarian cancer patient harboring AKT1 Q79K demonstrated tumor regression that lasted 14 months when treated with AZD5363 (PMID: 28489509). ",Actionable,11437,2394,ovarian cancer,DOID,2989,AKT1 Q79K,sensitive,655,AZD5363,207,28489509,,,
35,Preclinical - Cell culture,"In a preclinical study, the combination of MK2206 and Zelboraf (vemurafenib) inhibited AKT activation and growth of PTEN-expressing BRAF V600-mutant melanoma cells expressing AKT1 Q79K in culture, with increased efficacy over either agent alone (PMID: 24265152).",Actionable,8125,1909,melanoma,DOID,26173,AKT1 Q79K BRAF V600X PTEN pos,sensitive,4635,MK2206 + Vemurafenib,207,24265152,,,
36,Preclinical - Cell culture,"In a preclinical study, expression of AKT1 Q79K in a wild-type PTEN-expressing BRAF V600-mutant melanoma cell line conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 24265152).",Actionable,8106,1909,melanoma,DOID,26173,AKT1 Q79K BRAF V600X PTEN pos,resistant,342,Vemurafenib,207,24265152,,,
37,Preclinical - Cell culture,"In a preclinical study, Akt1 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Alpelisib (BYL719) in culture (PMID: 27604488).",Actionable,8881,1612,breast cancer,DOID,26496,AKT1 over exp PIK3CA H1047R,resistant,691,BYL719,207,27604488,,,
38,Preclinical - Cell culture,"In a preclinical study, Akt1 over expression in breast cancer cells harboring PIK3CA E545K resulted in resistance to Pictilisib (GDC-0941) in culture (PMID: 27604488).",Actionable,8896,1612,breast cancer,DOID,26498,AKT1 over exp PIK3CA E545K,resistant,749,GDC-0941,207,27604488,,,
39,Phase Ib/II,"In a Phase I/II trial, RX-0201 and Afinitor (everolimus) combination therapy resulted in stable disease in 40% (2/5) of patients with metastatic clear cell renal carcinoma (J Clin Oncol 34, 2016 (suppl 2S; abstr 550)).",Actionable,5997,4467,renal clear cell carcinoma,DOID,372,AKT1 wild-type,sensitive,2262,Everolimus + RX-0201,207,None,,,
40,Phase I,"In a Phase I trial, GSK2141795 treatment resulted in Akt inhibition and clinical benefit in 27% (3/11) of ovarian cancer patients (PMID: 26429956).",Actionable,6032,2394,ovarian cancer,DOID,372,AKT1 wild-type,predicted â€“ sensitive,764,GSK2141795,207,26429956,,,
41,Preclinical,"In a preclinical study, GSK2141795 inhibited all isoforms of AKT in human cancer cell lines (PMID: 23795919).",Actionable,835,162,cancer,DOID,372,AKT1 wild-type,sensitive,764,GSK2141795,207,23795919,,,
42,Preclinical,"In a preclinical study, breast cancer cells expressing AKT1 W80A were resistant to MK2206 in culture, resulting in repression of induced cell death when compared to wild-type AKT1 (PMID: 25551293). ",Actionable,4033,1612,breast cancer,DOID,3021,AKT1 W80A,resistant,816,MK2206,207,25551293,,,
0,Preclinical,"In a preclinical study, transformed cells expressing an ALK fusion with ALK S1206Y were resistant to Xalkori (crizotinib) (PMID: 25806224, PMID: 22277784).",Actionable,2956,10000003,Advanced Solid Tumor,JAX,10724,ALK fusion ALK S1206Y,resistant,706,Crizotinib,238,22277784,25806224,,
1,Clinical Study,"In a clinical study, an ALK S1206Y secondary mutation in the context of EML4-ALK was associated with resistance to Xalkori (crizotinib) in a patient with non-small cell lung cancer, and resistance was replicated in cell culture studies (PMID: 22277784).",Actionable,1001,3908,non-small cell lung carcinoma,DOID,5338,EML4-ALK ALK S1206Y,resistant,706,Crizotinib,238,22277784,,,
2,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing S1206Y in the context of EML4-ALK in culture (PMID: 27780853).",Actionable,9263,10000003,Advanced Solid Tumor,JAX,5338,EML4-ALK ALK S1206Y,sensitive,634,AP26113,238,27780853,,,
3,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK S1206Y demonstrated growth inhibition with Zykadia (ceritinib) treatment in culture (PMID: 24675041). ",Actionable,2099,10000003,Advanced Solid Tumor,JAX,5338,EML4-ALK ALK S1206Y,sensitive,789,Ceritinib,238,24675041,,,
4,Preclinical - Cell culture,"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell proliferation of transformed cells over expressing ALK S1206Y in the context of EML4-ALK in culture  (PMID: 26144315). ",Actionable,8296,10000003,Advanced Solid Tumor,JAX,5338,EML4-ALK ALK S1206Y,sensitive,869,PF-06463922,238,26144315,,,
5,Preclinical,"In a preclinical trial, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3466,10000003,Advanced Solid Tumor,JAX,13320,NPM1-ALK ALK L1196M,decreased response,698,Alectinib,238,25421750,,,
6,Preclinical,"In a preclinical trial, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M in culture (PMID: 25421750).",Actionable,3485,10000003,Advanced Solid Tumor,JAX,13320,NPM1-ALK ALK L1196M,sensitive,789,Ceritinib,238,25421750,,,
7,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with  ALK L1196M were resistant to ASP3026 treatment in culture (PMID: 25421750).",Actionable,3554,10000003,Advanced Solid Tumor,JAX,13320,NPM1-ALK ALK L1196M,resistant,643,ASP3026,238,25421750,,,
8,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M in culture (PMID: 25421750).",Actionable,3437,10000003,Advanced Solid Tumor,JAX,13320,NPM1-ALK ALK L1196M,sensitive,634,AP26113,238,25421750,,,
9,Preclinical,"In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3454,10000003,Advanced Solid Tumor,JAX,13320,NPM1-ALK ALK L1196M,decreased response,706,Crizotinib,238,25421750,,,
10,Preclinical,"In a preclinical study, TPX-0005 inhibited cell proliferation in transformed cell lines over expressing ALK L1196M in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).",Actionable,5834,10000003,Advanced Solid Tumor,JAX,537,ALK L1196M,sensitive,3950,TPX-0005,238,None,,,
11,Preclinical - Cell line xenograft,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK L196M in the context of EML4-ALK in culture and reduced tumor growth in cell line xenograft models (PMID: 27780853).",Actionable,5702,10000003,Advanced Solid Tumor,JAX,5335,EML4-ALK ALK L1196M,sensitive,634,AP26113,238,27780853,,,
12,Preclinical - Cell line xenograft,"In a preclinical study, Zykadia (ceritinib) inhibited cell survival and PI3K/AKT, MEK/ERK, and mTOR signaling in two human non-small cell lung carcinoma cell lines harboring the Xalkori (crizotinib) resistance mutation EML4-ALK ALK L1196M in culture and inhibited tumor growth in xenograft models of one of those cell lines (PMID: 24675041).",Actionable,2056,3908,non-small cell lung carcinoma,DOID,5335,EML4-ALK ALK L1196M,sensitive,789,Ceritinib,238,24675041,,,
13,Preclinical,"In preclinical studies, transformed cells expressing EML4-ALK ALK L1196M were insensitive to Xalkori (crizotinib) as demonstrated by lack of growth inhibition and Alk phosphorylation in culture (PMID: 21613408, PMID: 26698910). ",Actionable,2094,10000003,Advanced Solid Tumor,JAX,5335,EML4-ALK ALK L1196M,resistant,706,Crizotinib,238,21613408,26698910,,
14,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910), however, in another study, comparable cells demonstrated sensitivity in culture (PMID: 27432227). ",Actionable,5708,10000003,Advanced Solid Tumor,JAX,5335,EML4-ALK ALK L1196M,conflicting,869,PF-06463922,238,26698910,27432227,,
15,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M were sensitive to Entrectinib (RXDX-101), resulting in anti-proliferative activity (PMID: 26939704).",Actionable,5638,10000003,Advanced Solid Tumor,JAX,5335,EML4-ALK ALK L1196M,sensitive,1455,Entrectinib,238,26939704,,,
16,Preclinical,"In a preclinical study, Ensartinib (X-396) inhibited growth and Alk phosphorylation in cells expressing the Xalkori (crizotinib) resistance mutation, EML4-ALK ALK L1196M (PMID: 21613408).",Actionable,2095,10000003,Advanced Solid Tumor,JAX,5335,EML4-ALK ALK L1196M,sensitive,961,X-396,238,21613408,,,
17,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M demonstrated decreased sensitivity to Alecensa (alectinib) compared to cells expressing EML4-ALK with wild-type ALK, in culture (PMID: 26698910).",Actionable,5701,10000003,Advanced Solid Tumor,JAX,5335,EML4-ALK ALK L1196M,conflicting,698,Alectinib,238,26698910,,,
18,Preclinical - Cell line xenograft,"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing an EML4-ALK fusion and ALK L1196M in culture and in xenograft models (PMID: 21575866).",Actionable,10341,10000003,Advanced Solid Tumor,JAX,5335,EML4-ALK ALK L1196M,conflicting,698,Alectinib,238,21575866,,,
19,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK L1196M demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).  ",Actionable,8634,10000003,Advanced Solid Tumor,JAX,5335,EML4-ALK ALK L1196M,sensitive,789,Ceritinib,238,27432227,,,
20,Preclinical - Cell culture,"In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing EML4-ALK with ALK L1196M in culture (PMID: 26698910)",Actionable,10342,10000003,Advanced Solid Tumor,JAX,5335,EML4-ALK ALK L1196M,sensitive,789,Ceritinib,238,26698910,,,
21,Preclinical - Cell culture,"In a preclinical study, TPX-0005 inhibited Alk activity and proliferation of transformed cells over expressing ALK L1196M in the context of EML4-ALK in culture (European Journal of Cancer , Volume 69, S32).",Actionable,10345,10000003,Advanced Solid Tumor,JAX,5335,EML4-ALK ALK L1196M,sensitive,3950,TPX-0005,238,None,,,
22,Preclinical - Cell line xenograft,"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and proliferation of non-small cell lung carcinoma cells over expressing ALK L1196M in the context of EML4-ALK in culture, and resulted in tumor regression in cell line xenograft models (PMID: 26144315). ",Actionable,2650,3908,non-small cell lung carcinoma,DOID,5335,EML4-ALK ALK L1196M,sensitive,869,PF-06463922,238,26144315,,,
23,Preclinical,"In a preclinical study, ASP3026 inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N in culture (PMID: 25421750).",Actionable,3550,10000003,Advanced Solid Tumor,JAX,13342,NPM1-ALK ALK L1196M ALK D1203N,sensitive,643,ASP3026,238,25421750,,,
24,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N were resistant to Brigatinib (AP26113) treatment in culture (PMID: 25421750).",Actionable,3442,10000003,Advanced Solid Tumor,JAX,13342,NPM1-ALK ALK L1196M ALK D1203N,resistant,634,AP26113,238,25421750,,,
25,Preclinical,"In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3483,10000003,Advanced Solid Tumor,JAX,13342,NPM1-ALK ALK L1196M ALK D1203N,decreased response,789,Ceritinib,238,25421750,,,
26,Preclinical,"In a preclinical trial, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3467,10000003,Advanced Solid Tumor,JAX,13342,NPM1-ALK ALK L1196M ALK D1203N,decreased response,698,Alectinib,238,25421750,,,
27,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N were resistant to Xalkori (crizotinib) treatment in culture (PMID: 25421750).",Actionable,3452,10000003,Advanced Solid Tumor,JAX,13342,NPM1-ALK ALK L1196M ALK D1203N,resistant,706,Crizotinib,238,25421750,,,
28,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).",Actionable,3460,10000003,Advanced Solid Tumor,JAX,13328,NPM1-ALK ALK L1122V ALK L1196M,resistant,698,Alectinib,238,25421750,,,
29,Preclinical,"In a preclinical study, anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Brigatinib (AP26113) in culture (PMID: 25421750).",Actionable,3435,50744,anaplastic large cell lymphoma,DOID,13328,NPM1-ALK ALK L1122V ALK L1196M,resistant,634,AP26113,238,25421750,,,
30,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Xalkori (crizotinib) treatment in culture (PMID: 25421750).",Actionable,3451,10000003,Advanced Solid Tumor,JAX,13328,NPM1-ALK ALK L1122V ALK L1196M,resistant,706,Crizotinib,238,25421750,,,
31,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to ASP3026 treatment in culture (PMID: 25421750).",Actionable,3552,10000003,Advanced Solid Tumor,JAX,13328,NPM1-ALK ALK L1122V ALK L1196M,resistant,643,ASP3026,238,25421750,,,
32,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Brigatinib (AP26113) treatment in culture (PMID: 25421750).",Actionable,3440,10000003,Advanced Solid Tumor,JAX,13328,NPM1-ALK ALK L1122V ALK L1196M,resistant,634,AP26113,238,25421750,,,
33,Clinical Study,"In multiple clinical trials, ALK L1196M conferred resistance to Xalkori (crizotinib) in the context of ALK positive aberrations in non-small cell lung carcinoma patients (PMID: 22277784, PMID: 25806224).",Actionable,187,3908,non-small cell lung carcinoma,DOID,10720,ALK fusion ALK L1196M,resistant,706,Crizotinib,238,22277784,25806224,,
34,Preclinical,"In a preclinical study, brigatinib (AP26113) inhibited growth of cell lines expressing ALK L1196M in the context of EML4-ALK in culture (PMID: 21502504).",Actionable,2965,3908,non-small cell lung carcinoma,DOID,10720,ALK fusion ALK L1196M,sensitive,634,AP26113,238,21502504,,,
35,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F were resistant to growth inhibition mediated by Brigatinib (AP26113) in culture (PMID: 26698910).",Actionable,5707,10000003,Advanced Solid Tumor,JAX,21376,EML4-ALK ALK L1196M ALK L1198F,resistant,634,AP26113,238,26698910,,,
36,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).",Actionable,5704,10000003,Advanced Solid Tumor,JAX,21376,EML4-ALK ALK L1196M ALK L1198F,resistant,789,Ceritinib,238,26698910,,,
37,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).",Actionable,5706,10000003,Advanced Solid Tumor,JAX,21376,EML4-ALK ALK L1196M ALK L1198F,resistant,869,PF-06463922,238,26698910,,,
38,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).",Actionable,5705,10000003,Advanced Solid Tumor,JAX,21376,EML4-ALK ALK L1196M ALK L1198F,resistant,698,Alectinib,238,26698910,,,
39,Preclinical,"In a preclinical study, Xalkori (crizotinib) resistance was reduced in transformed cells expressing EML4-ALK with ALK L1196M with the addition of ALK L1198F in culture (PMID: 26698910).",Actionable,5703,10000003,Advanced Solid Tumor,JAX,21376,EML4-ALK ALK L1196M ALK L1198F,resistant,706,Crizotinib,238,26698910,,,
40,Preclinical,"In a preclinical study, a transformed cell line expressing ALK R1275Q was sensitive to Brigatinib (AP26113) in culture and in vivo, resulting in cell growth inhibition (PMID: 27049722). ",Actionable,5876,10000003,Advanced Solid Tumor,JAX,1416,ALK R1275Q,sensitive,634,AP26113,238,27049722,,,
41,Preclinical - Cell line xenograft,"In a preclinical study, Xalkori (crizotinib) did not inhibit growth of neuroblastoma cells over expressing ALK R1275Q in culture, and only delayed tumor growth in cell line xenograft models (PMID: 26554404).",Actionable,8371,769,neuroblastoma,DOID,1416,ALK R1275Q,resistant,706,Crizotinib,238,26554404,,,
42,Preclinical - Cell line xenograft,"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation, resulted in growth inhibition of neuroblastoma cells over expressing ALK R1275Q in culture and irapid and sustained complete tumor regression in cell line xenograft models (PMID: 26554404).",Actionable,8376,769,neuroblastoma,DOID,1416,ALK R1275Q,sensitive,869,PF-06463922,238,26554404,,,
43,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Xalkori (crizotinib), Topotecan, and Cytoxan (cyclophosphamide) synergized to sustain tumor regression in human neuroblastoma cell line xenograft models harboring ALK R1275Q and wild-type TP53 (PMID: 26438783).",Actionable,4730,769,neuroblastoma,DOID,1416,ALK R1275Q,sensitive,3601,Crizotinib + Cyclophosphamide + Topotecan,238,26438783,,,
44,Preclinical - Cell culture,"In a preclinical study, Lorlatinib (PF-06463922) inhibited foci formation more efficiently than Xalkori (crizotinib) in transformed cells over expressing ALK R1275Q in culture (PMID: 26554404).",Actionable,8382,10000003,Advanced Solid Tumor,JAX,1416,ALK R1275Q,sensitive,869,PF-06463922,238,26554404,,,
45,Phase I,"In a Phase I trial, ALK C1156Y mediates resistance to Xalkori (crizotinib) in ALK positive non-small cell lung cancer tumors (PMID: 25806224, PMID: 20979473).",Actionable,2895,3908,non-small cell lung carcinoma,DOID,10721,ALK fusion ALK C1156Y,resistant,706,Crizotinib,238,20979473,25806224,,
46,Preclinical,"In a preclinical study, Alecensa (alectinib) was able to inhibit ALK C1156Y in the context of transformed cells expressing an ALK fusion (PMID: 25806224, PMID: 21575866). ",Actionable,2961,10000003,Advanced Solid Tumor,JAX,10721,ALK fusion ALK C1156Y,sensitive,698,Alectinib,238,21575866,25806224,,
47,Preclinical,"In a preclinical study, transformed human cells expressing the ALK fusion resistance mutation, ALK C1156Y, demonstrated minimal sensitivity to Zykadia (ceritinib) (PMID: 24675041).",Actionable,2960,10000003,Advanced Solid Tumor,JAX,10721,ALK fusion ALK C1156Y,sensitive,789,Ceritinib,238,24675041,25806224,,
48,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).",Actionable,5684,10000003,Advanced Solid Tumor,JAX,21372,EML4-ALK ALK C1156Y ALK L1198F,resistant,698,Alectinib,238,26698910,,,
49,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).",Actionable,5679,10000003,Advanced Solid Tumor,JAX,21372,EML4-ALK ALK C1156Y ALK L1198F,resistant,869,PF-06463922,238,26698910,,,
50,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F were resistant to growth inhibition mediated by Brigatinib (AP26113) in culture (PMID: 26698910).",Actionable,5688,10000003,Advanced Solid Tumor,JAX,21372,EML4-ALK ALK C1156Y ALK L1198F,resistant,634,AP26113,238,26698910,,,
51,Phase I,"In a Phase I clinical trial, a patient with EML4-ALK positive non-small lung cancer initially responded to Xalkori (crizotinib) but developed resistance with the emergence of a secondary ALK mutation C1156Y, and subsequently redeveloped sensitivity to Xalkori (crizotinib) upon the emergence of a second ALK mutation, L1198F arising from resistance to Lorlatinib (PF-06463922) (PMID: 26698910).",Actionable,5673,3908,non-small cell lung carcinoma,DOID,21372,EML4-ALK ALK C1156Y ALK L1198F,sensitive,706,Crizotinib,238,26698910,,,
52,Preclinical,"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F in culture (PMID: 26698910).",Actionable,5676,10000003,Advanced Solid Tumor,JAX,21372,EML4-ALK ALK C1156Y ALK L1198F,sensitive,706,Crizotinib,238,26698910,,,
53,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).",Actionable,5687,10000003,Advanced Solid Tumor,JAX,21372,EML4-ALK ALK C1156Y ALK L1198F,resistant,789,Ceritinib,238,26698910,,,
54,Phase I,"In a Phase I clinical trial, a patient with EML4-ALK positive non-small lung cancer with a secondary Xalkori (critzotinib) resistance mutation C1156Y, responded to Lorlatinib (PF-06463922) but subsequently developed resistance upon the emergence of a second ALK mutation, L1198F (PMID: 26698910).",Actionable,5672,3908,non-small cell lung carcinoma,DOID,21372,EML4-ALK ALK C1156Y ALK L1198F,resistant,869,PF-06463922,238,26698910,,,
55,Preclinical,"In a preclinical study, ALK C1156Y was sensitive to Alecensa (alectinib) in an in vitro assay (PMID: 21575866).",Actionable,3061,10000003,Advanced Solid Tumor,JAX,1982,ALK C1156Y,sensitive,698,Alectinib,238,21575866,,,
56,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK C1156Y were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).",Actionable,5410,50744,anaplastic large cell lymphoma,DOID,20770,NPM1-ALK ALK C1156Y,resistant,643,ASP3026,238,25749034,,,
57,Phase I,"In a Phase I clinical study, a patient with EML4-ALK positive non-small cell lung cancer with a secondary Xalkori (crizotinib) resistance mutation ALK C1156Y, was treated with Lorlatinib (PF-06463922) and displayed a 41% reduction in tumor growth after 5 weeks of treatment (PMID: 26698910).",Actionable,5669,3908,non-small cell lung carcinoma,DOID,5336,EML4-ALK ALK C1156Y,sensitive,869,PF-06463922,238,26698910,,,
58,Preclinical,"In a preclinical study, Lorlatinib (PF-06463922) inhibited growth and ALK phosphorylation of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910).",Actionable,5677,10000003,Advanced Solid Tumor,JAX,5336,EML4-ALK ALK C1156Y,sensitive,869,PF-06463922,238,26698910,,,
59,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y were sensitive to Entrectinib (RXDX-101), resulting in anti-proliferative activity (PMID: 26939704). ",Actionable,5637,10000003,Advanced Solid Tumor,JAX,5336,EML4-ALK ALK C1156Y,sensitive,1455,Entrectinib,238,26939704,,,
60,Preclinical,"In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910).",Actionable,5685,10000003,Advanced Solid Tumor,JAX,5336,EML4-ALK ALK C1156Y,sensitive,789,Ceritinib,238,26698910,,,
61,Preclinical,"In a preclinical study, transformed human cells expressing EML4-ALK with ALK C1156Y were sensitive to Alecensa (alectinib) in culture (PMID: 21575866).",Actionable,2981,10000003,Advanced Solid Tumor,JAX,5336,EML4-ALK ALK C1156Y,sensitive,698,Alectinib,238,21575866,,,
62,Preclinical,"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910).",Actionable,5682,10000003,Advanced Solid Tumor,JAX,5336,EML4-ALK ALK C1156Y,sensitive,698,Alectinib,238,26698910,,,
63,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y were resistant to growth inhibition mediated by Xalkori (crizotinib) in culture (PMID: 26698910).",Actionable,5674,10000003,Advanced Solid Tumor,JAX,5336,EML4-ALK ALK C1156Y,resistant,706,Crizotinib,238,26698910,,,
64,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK ALK C1156Y were insensitive to Xalkori (crizotinib) as demonstrated by lack of growth inhibition and lack of kinase inhibition in culture (PMID: 21613408). ",Actionable,2092,10000003,Advanced Solid Tumor,JAX,5336,EML4-ALK ALK C1156Y,resistant,706,Crizotinib,238,21613408,,,
65,Preclinical,"In a preclinical study, Ensartinib (X-396) inhibited growth and Alk phosphorylation in cells expressing the Xalkori (crizotinib) resistance mutation, EML4-ALK C1156Y (PMID: 21613408). ",Actionable,2093,10000003,Advanced Solid Tumor,JAX,5336,EML4-ALK ALK C1156Y,sensitive,961,X-396,238,21613408,,,
66,Clinical Study,"In a clinical study, a patient with EML4-ALK positive non-small cell lung cancer with an ALK C1156Y secondary Xalkori (crizotinib) resistance mutation did not respond to Luminespib (AUY922) therapy (PMID: 26698910).",Actionable,5671,3908,non-small cell lung carcinoma,DOID,5336,EML4-ALK ALK C1156Y,resistant,647,AUY922,238,26698910,,,
67,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910).",Actionable,5689,10000003,Advanced Solid Tumor,JAX,5336,EML4-ALK ALK C1156Y,sensitive,634,AP26113,238,26698910,,,
68,Clinical Study,"In a clinical study, a patient with EML4-ALK positive non-small cell lung cancer developed resistance to Xalkori (crizotinib) with the emergence of ALK C1156Y, a secondary resistance mutation (PMID: 26698910).",Actionable,5668,3908,non-small cell lung carcinoma,DOID,5336,EML4-ALK ALK C1156Y,resistant,706,Crizotinib,238,26698910,,,
69,Preclinical - Cell line xenograft,"In a preclinical study, Zykadia (ceritinib) demonstrated tumor growth inhibition in xenograft models of a human non-small cell lung cancer cell line harboring EML4-ALK with ALK C1156Y when compared to Xalkori (crizotinib) (PMID: 24675041).",Actionable,2982,3908,non-small cell lung carcinoma,DOID,5336,EML4-ALK ALK C1156Y,conflicting,789,Ceritinib,238,24675041,,,
70,Clinical Study,"In a clinical study, a patient with EML4-ALK positive non-small cell lung cancer with a secondary Xalkori (crizotinib) resistance mutation C1156Y, did not respond to Zykadia (ceritinib) therapy (PMID: 26698910).",Actionable,5720,3908,non-small cell lung carcinoma,DOID,5336,EML4-ALK ALK C1156Y,conflicting,789,Ceritinib,238,26698910,,,
71,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK N1178H were resistant to Brigatinib (AP26113) in culture (PMID: 25749034).",Actionable,5430,10000003,Advanced Solid Tumor,JAX,20899,NPM1-ALK ALK N1178H,resistant,634,AP26113,238,25749034,,,
72,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK N1178H were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).",Actionable,5417,50744,anaplastic large cell lymphoma,DOID,20899,NPM1-ALK ALK N1178H,resistant,643,ASP3026,238,25749034,,,
73,Preclinical,"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK N1178H in culture (PMID: 25749034).",Actionable,5482,10000003,Advanced Solid Tumor,JAX,20899,NPM1-ALK ALK N1178H,sensitive,706,Crizotinib,238,25749034,,,
74,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK N1178H were resistant to ASP3026 in culture (PMID: 25749034).",Actionable,5425,10000003,Advanced Solid Tumor,JAX,20899,NPM1-ALK ALK N1178H,decreased response,643,ASP3026,238,25749034,,,
75,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK N1178H were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).",Actionable,5499,10000003,Advanced Solid Tumor,JAX,20899,NPM1-ALK ALK N1178H,resistant,869,PF-06463922,238,25749034,,,
76,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK N1178H were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).",Actionable,5489,10000003,Advanced Solid Tumor,JAX,20899,NPM1-ALK ALK N1178H,resistant,789,Ceritinib,238,25749034,,,
77,Preclinical,"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK N1178H in culture (PMID: 25749034).",Actionable,5434,10000003,Advanced Solid Tumor,JAX,20899,NPM1-ALK ALK N1178H,sensitive,698,Alectinib,238,25749034,,,
78,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to Xalkori (Crizotinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5354,10000003,Advanced Solid Tumor,JAX,20661,NPM1-ALK ALK R1192P,resistant,706,Crizotinib,238,27009859,,,
79,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P had a reduced response to AZD3463 mediated growth inhibition in culture relative to NPM1-ALK (PMID: 27009859).",Actionable,5359,10000003,Advanced Solid Tumor,JAX,20661,NPM1-ALK ALK R1192P,decreased response,1586,AZD3463,238,27009859,,,
80,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited the growth of transformed cells expressing NPM1-ALK with ALK R1192P in culture (PMID: 27009859).",Actionable,5357,10000003,Advanced Solid Tumor,JAX,20661,NPM1-ALK ALK R1192P,sensitive,634,AP26113,238,27009859,,,
81,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5358,10000003,Advanced Solid Tumor,JAX,20661,NPM1-ALK ALK R1192P,resistant,643,ASP3026,238,27009859,,,
82,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5356,10000003,Advanced Solid Tumor,JAX,20661,NPM1-ALK ALK R1192P,resistant,698,Alectinib,238,27009859,,,
83,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK R1192P were resistant to Xalkori (crizotinib) in culture (PMID: 27009859).",Actionable,5350,50744,anaplastic large cell lymphoma,DOID,20661,NPM1-ALK ALK R1192P,resistant,706,Crizotinib,238,27009859,,,
84,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5355,10000003,Advanced Solid Tumor,JAX,20661,NPM1-ALK ALK R1192P,resistant,789,Ceritinib,238,27009859,,,
85,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK R1192P were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5364,10000003,Advanced Solid Tumor,JAX,20660,EML4-ALK ALK R1192P,resistant,643,ASP3026,238,27009859,,,
86,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK R1192P were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5361,10000003,Advanced Solid Tumor,JAX,20660,EML4-ALK ALK R1192P,resistant,789,Ceritinib,238,27009859,,,
87,Preclinical,"In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859).",Actionable,5365,10000003,Advanced Solid Tumor,JAX,20660,EML4-ALK ALK R1192P,sensitive,1586,AZD3463,238,27009859,,,
88,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859).",Actionable,5363,10000003,Advanced Solid Tumor,JAX,20660,EML4-ALK ALK R1192P,sensitive,634,AP26113,238,27009859,,,
89,Preclinical,"In a preclinical study, Alecensa (alectinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859).",Actionable,5362,10000003,Advanced Solid Tumor,JAX,20660,EML4-ALK ALK R1192P,sensitive,698,Alectinib,238,27009859,,,
90,Preclinical,"In a preclinical study, Xalkori (crizotinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859).",Actionable,5360,10000003,Advanced Solid Tumor,JAX,20660,EML4-ALK ALK R1192P,sensitive,706,Crizotinib,238,27009859,,,
91,Preclinical,"In a preclinical study, a transformed cell line expressing ALK R1192P was sensitive to Brigatinib (AP26113) in culture, resulting in cell growth inhibition (PMID: 27049722). ",Actionable,5874,10000003,Advanced Solid Tumor,JAX,1415,ALK R1192P,sensitive,634,AP26113,238,27049722,,,
92,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK T1151dup in the context of EML4-ALK in culture (PMID: 27780853).",Actionable,9258,10000003,Advanced Solid Tumor,JAX,26807,EML4-ALK ALK T1151dup,sensitive,634,AP26113,238,27780853,,,
93,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing ALK T1151dup in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) in culture (PMID: 27780853).",Actionable,9264,10000003,Advanced Solid Tumor,JAX,26807,EML4-ALK ALK T1151dup,decreased response,706,Crizotinib,238,27780853,,,
94,Preclinical,"In a preclinical study, transformed cells expressing an ALK fusion with ALK T1151dup were resistant to Xalkori (crizotinib) (PMID: 25806224, PMID: 22277784).",Actionable,2958,10000003,Advanced Solid Tumor,JAX,10719,ALK fusion ALK T1151dup,resistant,706,Crizotinib,238,22277784,25806224,,
95,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK with ALK F1174I were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).",Actionable,5392,50744,anaplastic large cell lymphoma,DOID,20772,NPM1-ALK ALK F1174I,resistant,643,ASP3026,238,25749034,,,
96,Preclinical,"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).",Actionable,5433,10000003,Advanced Solid Tumor,JAX,20772,NPM1-ALK ALK F1174I,sensitive,698,Alectinib,238,25749034,,,
97,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).",Actionable,5435,10000003,Advanced Solid Tumor,JAX,20772,NPM1-ALK ALK F1174I,sensitive,634,AP26113,238,25749034,,,
98,Preclinical,"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).",Actionable,5481,10000003,Advanced Solid Tumor,JAX,20772,NPM1-ALK ALK F1174I,sensitive,706,Crizotinib,238,25749034,,,
99,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174I were resistant to ASP3026 relative to wild type NPM1-ALK in culture (PMID: 25749034).",Actionable,5424,10000003,Advanced Solid Tumor,JAX,20772,NPM1-ALK ALK F1174I,resistant,643,ASP3026,238,25749034,,,
100,Preclinical,"In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).",Actionable,5484,10000003,Advanced Solid Tumor,JAX,20772,NPM1-ALK ALK F1174I,sensitive,789,Ceritinib,238,25749034,,,
101,Preclinical,"In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).",Actionable,5493,10000003,Advanced Solid Tumor,JAX,20772,NPM1-ALK ALK F1174I,sensitive,869,PF-06463922,238,25749034,,,
102,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5341,10000003,Advanced Solid Tumor,JAX,20659,NPM1-ALK ALK F1174L,resistant,698,Alectinib,238,27009859,,,
103,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK F1174L were resistant to Zykadia (ceritinib) in culture (PMID: 27009859).",Actionable,5352,50744,anaplastic large cell lymphoma,DOID,20659,NPM1-ALK ALK F1174L,resistant,789,Ceritinib,238,27009859,,,
104,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5346,10000003,Advanced Solid Tumor,JAX,20659,NPM1-ALK ALK F1174L,resistant,643,ASP3026,238,27009859,,,
105,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5337,10000003,Advanced Solid Tumor,JAX,20659,NPM1-ALK ALK F1174L,resistant,706,Crizotinib,238,27009859,,,
106,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited the growth of transformed cells expressing NPM1-ALK with ALK F1174L in culture (PMID: 27009859).",Actionable,5344,10000003,Advanced Solid Tumor,JAX,20659,NPM1-ALK ALK F1174L,sensitive,634,AP26113,238,27009859,,,
107,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5339,10000003,Advanced Solid Tumor,JAX,20659,NPM1-ALK ALK F1174L,resistant,789,Ceritinib,238,27009859,,,
108,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to AZD3463 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5347,10000003,Advanced Solid Tumor,JAX,20659,NPM1-ALK ALK F1174L,resistant,1586,AZD3463,238,27009859,,,
109,Preclinical - Cell culture,"In a preclinical study, a transformed cell line expressing ALK F1174L was sensitive to Alunbrig (brigatinib) in culture, resulting in cell growth inhibition (PMID: 27049722). ",Actionable,5873,10000003,Advanced Solid Tumor,JAX,698,ALK F1174L,sensitive,634,AP26113,238,27049722,,,
110,Preclinical - Pdx & cell culture,"In a preclinical study, Xalkori (crizotinib) did not inhibit growth of neuroblastoma cells over expressing ALK F1174L in culture, and only delayed tumor growth in patient-derived and cell line xenograft models harboring ALK F1174L (PMID: 26554404).",Actionable,8369,769,neuroblastoma,DOID,698,ALK F1174L,resistant,706,Crizotinib,238,26554404,,,
111,Preclinical - Pdx & cell culture,"In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of neuroblastoma cells over expressing ALK F1174L in culture, and induced rapid and sustained complete tumor regression in both patient-derived and cell line xenograft models harboring ALK F1174L (PMID: 26554404).",Actionable,8374,769,neuroblastoma,DOID,698,ALK F1174L,sensitive,869,PF-06463922,238,26554404,,,
112,Preclinical - Cell culture,"In a preclinical study, Lorlatinib (PF-06463922) inhibited foci formation more efficiently than Xalkori (crizotinib) in transformed cells over expressing ALK F1174L in culture (PMID: 26554404).",Actionable,8383,10000003,Advanced Solid Tumor,JAX,698,ALK F1174L,sensitive,869,PF-06463922,238,26554404,,,
113,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174L were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5345,10000003,Advanced Solid Tumor,JAX,20658,EML4-ALK ALK F1174L,resistant,643,ASP3026,238,27009859,,,
114,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174L were resistant to Brigatinib (AP26113) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5343,10000003,Advanced Solid Tumor,JAX,20658,EML4-ALK ALK F1174L,resistant,634,AP26113,238,27009859,,,
115,Preclinical,"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK with ALK F1174L in culture (PMID: 27009859).",Actionable,5342,10000003,Advanced Solid Tumor,JAX,20658,EML4-ALK ALK F1174L,sensitive,698,Alectinib,238,27009859,,,
116,Preclinical - Cell culture,"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell proliferation of transformed cells over expressing ALK F1174L in the context of EML4-ALK in culture  (PMID: 26144315). ",Actionable,8297,10000003,Advanced Solid Tumor,JAX,20658,EML4-ALK ALK F1174L,sensitive,869,PF-06463922,238,26144315,,,
117,Preclinical,"In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK F1174L in culture (PMID: 27009859).",Actionable,5348,10000003,Advanced Solid Tumor,JAX,20658,EML4-ALK ALK F1174L,resistant,1586,AZD3463,238,27009859,,,
118,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174L were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5340,10000003,Advanced Solid Tumor,JAX,20658,EML4-ALK ALK F1174L,resistant,789,Ceritinib,238,27009859,,,
119,Preclinical - Cell culture,"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing EML4-ALK with ALK F1174L in culture (PMID: 27009859).",Actionable,5338,10000003,Advanced Solid Tumor,JAX,20658,EML4-ALK ALK F1174L,conflicting,706,Crizotinib,238,27009859,,,
120,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing ALK F1174L in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) in culture (PMID: 27780853).",Actionable,9266,10000003,Advanced Solid Tumor,JAX,20658,EML4-ALK ALK F1174L,conflicting,706,Crizotinib,238,27780853,,,
121,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Xalkori (crizotinib), Topotecan, and Cytoxan (cyclophosphamide) synergized to sustain tumor regression in xenograft models of a crizotinib-resistant human neuroblastoma cell line harboring ALK F1174L and wild-type TP53 (PMID: 26438783).",Actionable,4731,769,neuroblastoma,DOID,18879,"ALK	F1174L TP53	wild-type",sensitive,3601,Crizotinib + Cyclophosphamide + Topotecan,238,26438783,,,
122,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated a decreased response to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227). ",Actionable,8654,10000003,Advanced Solid Tumor,JAX,26387,EML4-ALK ALK D1203N ALK F1174C,decreased response,869,PF-06463922,238,27432227,,,
123,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated a decreased response to treatment with Alecensa (alectinib) in culture (PMID: 27432227). ",Actionable,8652,10000003,Advanced Solid Tumor,JAX,26387,EML4-ALK ALK D1203N ALK F1174C,decreased response,698,Alectinib,238,27432227,,,
124,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated resistance to treatment with Xalkori (crizotinib) in culture (PMID: 27432227). ",Actionable,8651,10000003,Advanced Solid Tumor,JAX,26387,EML4-ALK ALK D1203N ALK F1174C,resistant,706,Crizotinib,238,27432227,,,
125,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated resistance to treatment with Zykadia (ceritinib) in culture (PMID: 27432227). ",Actionable,8666,10000003,Advanced Solid Tumor,JAX,26387,EML4-ALK ALK D1203N ALK F1174C,resistant,789,Ceritinib,238,27432227,,,
126,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated a decreased response to treatment with Brigatinib (AP26113) in culture (PMID: 27432227). ",Actionable,8653,10000003,Advanced Solid Tumor,JAX,26387,EML4-ALK ALK D1203N ALK F1174C,decreased response,634,AP26113,238,27432227,,,
127,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).",Actionable,5698,10000003,Advanced Solid Tumor,JAX,21375,EML4-ALK ALK F1174C ALK L1198F,resistant,789,Ceritinib,238,26698910,,,
128,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F were resistant to growth inhibition mediated by Brigatinib (AP26113) in culture (PMID: 26698910).",Actionable,5696,10000003,Advanced Solid Tumor,JAX,21375,EML4-ALK ALK F1174C ALK L1198F,resistant,634,AP26113,238,26698910,,,
129,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F displayed enhanced resistance to growth inhibition by Alecensa (alectinib) in culture (PMID: 26698910).",Actionable,5700,10000003,Advanced Solid Tumor,JAX,21375,EML4-ALK ALK F1174C ALK L1198F,resistant,698,Alectinib,238,26698910,,,
130,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).",Actionable,5694,10000003,Advanced Solid Tumor,JAX,21375,EML4-ALK ALK F1174C ALK L1198F,resistant,869,PF-06463922,238,26698910,,,
131,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C were re-sensitized to Xalkori (crizotinib) mediated growth inhibition with the introduction of an additional ALK mutation L1198F, in culture (PMID: 26698910).",Actionable,5692,10000003,Advanced Solid Tumor,JAX,21375,EML4-ALK ALK F1174C ALK L1198F,sensitive,706,Crizotinib,238,26698910,,,
132,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910), however, in another study, comparable cells demonstrated sensitivity in culture (PMID: 27432227).",Actionable,5697,10000003,Advanced Solid Tumor,JAX,21374,EML4-ALK ALK F1174C,conflicting,789,Ceritinib,238,26698910,27432227,,
133,Preclinical,"In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing EML4-ALK with ALK F1174C in culture (PMID: 26698910).",Actionable,5693,10000003,Advanced Solid Tumor,JAX,21374,EML4-ALK ALK F1174C,sensitive,869,PF-06463922,238,26698910,,,
134,Preclinical,"In a preclinical study, Brigatinib (AP26113) modestly inhibited growth of transformed cells expressing EML4-ALK with ALK F1174C in culture (PMID: 26698910).",Actionable,5695,10000003,Advanced Solid Tumor,JAX,21374,EML4-ALK ALK F1174C,decreased response,634,AP26113,238,26698910,,,
135,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C were resistant to growth inhibition mediated by Xalkori (crizotinib) in culture (PMID: 26698910).",Actionable,5691,10000003,Advanced Solid Tumor,JAX,21374,EML4-ALK ALK F1174C,resistant,706,Crizotinib,238,26698910,,,
136,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C demonstrated decreased sensitivity to Alecensa (alectinib) in culture compared to cells expressing EML4-ALK with wild-type ALK (PMID: 26698910), however, in another study, comparable cells demonstrated sensitivity in culture (PMID: 27432227). ",Actionable,5699,10000003,Advanced Solid Tumor,JAX,21374,EML4-ALK ALK F1174C,conflicting,698,Alectinib,238,26698910,27432227,,
137,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK C1156F were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).",Actionable,5416,50744,anaplastic large cell lymphoma,DOID,20881,NPM1-ALK ALK C1156F,resistant,643,ASP3026,238,25749034,,,
138,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Brigatinib (AP26113) in culture (PMID: 25749034).",Actionable,5427,10000003,Advanced Solid Tumor,JAX,20881,NPM1-ALK ALK C1156F,resistant,634,AP26113,238,25749034,,,
139,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).",Actionable,5486,10000003,Advanced Solid Tumor,JAX,20881,NPM1-ALK ALK C1156F,resistant,789,Ceritinib,238,25749034,,,
140,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).",Actionable,5495,10000003,Advanced Solid Tumor,JAX,20881,NPM1-ALK ALK C1156F,resistant,869,PF-06463922,238,25749034,,,
141,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to ASP3026 in culture (PMID: 25749034).",Actionable,5421,10000003,Advanced Solid Tumor,JAX,20881,NPM1-ALK ALK C1156F,resistant,643,ASP3026,238,25749034,,,
142,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Alecensa (alectinib) in culture (PMID: 25749034).",Actionable,5436,10000003,Advanced Solid Tumor,JAX,20881,NPM1-ALK ALK C1156F,resistant,698,Alectinib,238,25749034,,,
143,Preclinical,"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK C1156F in culture (PMID: 25749034).",Actionable,5480,10000003,Advanced Solid Tumor,JAX,20881,NPM1-ALK ALK C1156F,sensitive,706,Crizotinib,238,25749034,,,
144,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and D1203N were resistant to Brigatinib (AP26113) in culture (PMID: 25749034).",Actionable,5432,10000003,Advanced Solid Tumor,JAX,20896,NPM1-ALK ALK C1156F ALK D1203N,resistant,634,AP26113,238,25749034,,,
145,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and ALK D1203N were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).",Actionable,5502,10000003,Advanced Solid Tumor,JAX,20896,NPM1-ALK ALK C1156F ALK D1203N,resistant,869,PF-06463922,238,25749034,,,
146,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and D1203N were resistant to Alecensa (alectinib) in culture (PMID: 25749034).",Actionable,5440,10000003,Advanced Solid Tumor,JAX,20896,NPM1-ALK ALK C1156F ALK D1203N,resistant,698,Alectinib,238,25749034,,,
147,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and D1203N were resistant to Xalkori (critzotinb) in culture (PMID: 25749034).",Actionable,5479,10000003,Advanced Solid Tumor,JAX,20896,NPM1-ALK ALK C1156F ALK D1203N,resistant,706,Crizotinib,238,25749034,,,
148,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK with ALK C1156F and D1203N were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).",Actionable,5414,50744,anaplastic large cell lymphoma,DOID,20896,NPM1-ALK ALK C1156F ALK D1203N,resistant,643,ASP3026,238,25749034,,,
149,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and ALK D1203N were resistant to ASP3026 in culture (PMID: 25749034).",Actionable,5423,10000003,Advanced Solid Tumor,JAX,20896,NPM1-ALK ALK C1156F ALK D1203N,resistant,643,ASP3026,238,25749034,,,
150,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with C1156F and D1203N were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).",Actionable,5491,10000003,Advanced Solid Tumor,JAX,20896,NPM1-ALK ALK C1156F ALK D1203N,resistant,789,Ceritinib,238,25749034,,,
151,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing NPM1-ALK with ALK G1128S in culture (PMID: 25749034).",Actionable,5426,10000003,Advanced Solid Tumor,JAX,20894,NPM1-ALK ALK G1128S,sensitive,634,AP26113,238,25749034,,,
152,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to ASP3026 in culture (PMID: 25749034).",Actionable,5420,10000003,Advanced Solid Tumor,JAX,20894,NPM1-ALK ALK G1128S,resistant,643,ASP3026,238,25749034,,,
153,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to Alecensa (alectinib) in culture (PMID: 25749034).",Actionable,5441,10000003,Advanced Solid Tumor,JAX,20894,NPM1-ALK ALK G1128S,resistant,698,Alectinib,238,25749034,,,
154,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK G1128S were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).",Actionable,5413,50744,anaplastic large cell lymphoma,DOID,20894,NPM1-ALK ALK G1128S,resistant,643,ASP3026,238,25749034,,,
155,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).",Actionable,5494,10000003,Advanced Solid Tumor,JAX,20894,NPM1-ALK ALK G1128S,resistant,869,PF-06463922,238,25749034,,,
156,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).",Actionable,5485,10000003,Advanced Solid Tumor,JAX,20894,NPM1-ALK ALK G1128S,resistant,789,Ceritinib,238,25749034,,,
157,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to Xalkori (critzotinb) in culture (PMID: 25749034).",Actionable,5476,10000003,Advanced Solid Tumor,JAX,20894,NPM1-ALK ALK G1128S,resistant,706,Crizotinib,238,25749034,,,
158,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated a decreased response to treatment with Xalkori (crizotinib) in culture (PMID: 27432227). ",Actionable,8655,10000003,Advanced Solid Tumor,JAX,26388,EML4-ALK ALK D1203N ALK E1210K,decreased response,706,Crizotinib,238,27432227,,,
159,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated a decreased response to treatment with Brigatinib (AP26113) in culture (PMID: 27432227). ",Actionable,8658,10000003,Advanced Solid Tumor,JAX,26388,EML4-ALK ALK D1203N ALK E1210K,decreased response,634,AP26113,238,27432227,,,
160,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227). ",Actionable,8659,10000003,Advanced Solid Tumor,JAX,26388,EML4-ALK ALK D1203N ALK E1210K,sensitive,869,PF-06463922,238,27432227,,,
161,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated a decreased response to treatment with Zykadia (ceritinib) in culture (PMID: 27432227). ",Actionable,8656,10000003,Advanced Solid Tumor,JAX,26388,EML4-ALK ALK D1203N ALK E1210K,decreased response,789,Ceritinib,238,27432227,,,
162,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated a decreased response to treatment with Alecensa (alectinib) in culture (PMID: 27432227). ",Actionable,8657,10000003,Advanced Solid Tumor,JAX,26388,EML4-ALK ALK D1203N ALK E1210K,decreased response,698,Alectinib,238,27432227,,,
163,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Alecensa (alectinib) in culture (PMID: 27432227).  ",Actionable,8643,10000003,Advanced Solid Tumor,JAX,26386,EML4-ALK ALK D1203N,sensitive,698,Alectinib,238,27432227,,,
164,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated a decreased response to treatment with Xalkori (crizotinib) in culture (PMID: 27432227).  ",Actionable,8641,10000003,Advanced Solid Tumor,JAX,26386,EML4-ALK ALK D1203N,decreased response,706,Crizotinib,238,27432227,,,
165,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Brigatinib (AP26113) in culture (PMID: 27432227).  ",Actionable,8644,10000003,Advanced Solid Tumor,JAX,26386,EML4-ALK ALK D1203N,sensitive,634,AP26113,238,27432227,,,
166,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).  ",Actionable,8642,10000003,Advanced Solid Tumor,JAX,26386,EML4-ALK ALK D1203N,sensitive,789,Ceritinib,238,27432227,,,
167,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).  ",Actionable,8645,10000003,Advanced Solid Tumor,JAX,26386,EML4-ALK ALK D1203N,sensitive,869,PF-06463922,238,27432227,,,
168,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).  ",Actionable,8647,10000003,Advanced Solid Tumor,JAX,20889,EML4-ALK ALK E1210K,sensitive,789,Ceritinib,238,27432227,,,
169,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Brigatinib (AP26113) in culture (PMID: 27432227).  ",Actionable,8649,10000003,Advanced Solid Tumor,JAX,20889,EML4-ALK ALK E1210K,sensitive,634,AP26113,238,27432227,,,
170,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Alecensa (alectinib) in culture (PMID: 27432227).  ",Actionable,8648,10000003,Advanced Solid Tumor,JAX,20889,EML4-ALK ALK E1210K,sensitive,698,Alectinib,238,27432227,,,
171,Clinical Study,"In a clinical study, a lung cancer patient harboring EML4-ALK demonstrated progression when treated with Xalkori (crizotinib) due to the secondary acquired resistance mutation, ALK E1210K, however, in vitro transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Xalkori (crizotinib) in culture (PMID: 27432227).  ",Actionable,8646,10000003,Advanced Solid Tumor,JAX,20889,EML4-ALK ALK E1210K,conflicting,706,Crizotinib,238,27432227,,,
172,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).  ",Actionable,8650,10000003,Advanced Solid Tumor,JAX,20889,EML4-ALK ALK E1210K,sensitive,869,PF-06463922,238,27432227,,,
173,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to ASP3026 in culture (PMID: 25749034).",Actionable,5422,10000003,Advanced Solid Tumor,JAX,20888,NPM1-ALK ALK E1210K,resistant,643,ASP3026,238,25749034,,,
174,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).",Actionable,5501,10000003,Advanced Solid Tumor,JAX,20888,NPM1-ALK ALK E1210K,resistant,869,PF-06463922,238,25749034,,,
175,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK with ALK E1210K were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).",Actionable,5415,50744,anaplastic large cell lymphoma,DOID,20888,NPM1-ALK ALK E1210K,resistant,643,ASP3026,238,25749034,,,
176,Preclinical,"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK E1210K in culture (PMID: 25749034).",Actionable,5483,10000003,Advanced Solid Tumor,JAX,20888,NPM1-ALK ALK E1210K,sensitive,706,Crizotinib,238,25749034,,,
177,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with E1210K were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).",Actionable,5490,10000003,Advanced Solid Tumor,JAX,20888,NPM1-ALK ALK E1210K,resistant,789,Ceritinib,238,25749034,,,
178,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to Brigatinib (AP26113) in culture (PMID: 25749034).",Actionable,5431,10000003,Advanced Solid Tumor,JAX,20888,NPM1-ALK ALK E1210K,resistant,634,AP26113,238,25749034,,,
179,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to Alecensa (alectinib) in culture (PMID: 25749034).",Actionable,5439,10000003,Advanced Solid Tumor,JAX,20888,NPM1-ALK ALK E1210K,resistant,698,Alectinib,238,25749034,,,
180,Preclinical,"In a preclinical study, transformed cells expressing an ALK fusion and ALK G1269A were resistant to Xalkori (crizotinib) (PMID: 25806224, PMID: 22235099).",Actionable,2897,10000003,Advanced Solid Tumor,JAX,10723,ALK fusion ALK G1269A,resistant,706,Crizotinib,238,22235099,25806224,,
181,Phase Ib/II,"In a phase I/II clinical trial, AP26113 was determined to be safe and efficacious in patients with advanced, ALK-fusion positive NSCLC (PMID: 24091716).",Actionable,2964,3908,non-small cell lung carcinoma,DOID,2446,ALK fusion,sensitive,634,AP26113,238,24091716,,,
182,FDA approved,"In clinical trials that supported FDA approval, treatment with Xalkori (crizotinib) resulted in an objective response rate of 61.2% (71/116) in the Phase I expansion trial, and 50% (68/135) in the Phase II trial in patients with ALK-positive non-small cell lung cancer (PMID: 24573551).",Actionable,1959,3908,non-small cell lung carcinoma,DOID,2446,ALK fusion,sensitive,706,Crizotinib,238,24573551,,,
183,Phase Ib/II,"In a Phase Ib/II trial, treatment with Xalkori (crizotinib) resulted in an objective response rate of 83% (5/6, all complete responses), at the 165 mg/m^2 dose, and 90% (18/20), with complete response in 80% (16/20), at the recommended phase 2 dose of 280 mg/m^2, in patients with anaplastic large cell lymphoma harboring an ALK fusion (PMID: 28787259; NCT00939770).",Actionable,11798,50744,anaplastic large cell lymphoma,DOID,2446,ALK fusion,sensitive,706,Crizotinib,238,28787259,,,
184,Phase I,"In a Phase I clinical trial, Entrectinib (RXDX-101) treatment resulted in partial response for more than 3 months in a colorectal cancer patient harboring a CAD-ALK gene fusion (PMID: 26633560).",Actionable,3948,9256,colorectal cancer,DOID,2446,ALK fusion,sensitive,1455,Entrectinib,238,26633560,,,
185,Phase Ib/II,"In a Phase Ib/II trial, treatment with Xalkori (crizotinib) resulted in an objective response rate of 86% (12/14), with complete response in 36% (5/14), in patients with inflammatory myofibroblastic tumor harboring an ALK fusion (PMID: 28787259; NCT00939770).",Actionable,11797,50905,inflammatory myofibroblastic tumor,DOID,2446,ALK fusion,sensitive,706,Crizotinib,238,28787259,,,
186,Phase II,"In a Phase II clincial trial, treatment with Alecensa (alectinib) resulted in a 49% (60/122) overall response rate in non-small cell lung cancer patients positive for an ALK fusion who had previously progressed on Xalkori (crizotinib) therapy (J Clin Oncol 33, 2015 (suppl; abstr 8008))",Actionable,2963,3908,non-small cell lung carcinoma,DOID,2446,ALK fusion,sensitive,698,Alectinib,238,None,,,
187,Phase III,"In a Phase III clinical trial, treatment with Alecensa (alectinib) resulted in improved progression-free survival compared to treatment with Xalkori (crizotinib) (Hazard ratio: 0.34)  in ALK-positive non-small cell lung cancer patients (J Clin Oncol 34, 2016 (suppl; abstr 9008)).",Actionable,6816,3908,non-small cell lung carcinoma,DOID,2446,ALK fusion,sensitive,698,Alectinib,238,None,,,
188,Phase I,"In a Phase I clinical trial, Lorlatinib (PF-06463922) demonstrated safety and resulted in a 50% (26/52) overall response rate in patients with ALK-positive or ROS1-positive non-small cell lung cancer, including intracranial responses in patients with CNS metastasis (J Clin Oncol 34, 2016 (suppl; abstr 9009)).",Actionable,6817,3908,non-small cell lung carcinoma,DOID,2446,ALK fusion,sensitive,869,PF-06463922,238,None,,,
189,FDA approved,Zykadia (ceritinib) is FDA approved for the treatment of ALK fusion positive metastatic non-small cell lung cancer (NSCLC) in patients previously treated with crizotinib (FDA.gov).,Actionable,2959,3908,non-small cell lung carcinoma,DOID,2446,ALK fusion,sensitive,789,Ceritinib,238,None,,,
190,FDA approved,"In a Phase I trial that supported FDA approval, Zykadia (ceritinib) resulted in a 58% (66/114) overall response rate in non-small cell lung cancer patients positive for an ALK fusion and a 56% (45/80) overall response rate in non-small cell lung cancer patients positive for an ALK fusion who had previously received Xalkori (crizotinib) (PMID: 24670165). ",Actionable,2983,3908,non-small cell lung carcinoma,DOID,2446,ALK fusion,sensitive,789,Ceritinib,238,24670165,,,
191,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring an ALK fusion and ALK L1152R were resistant to Xalkori (crizotinib) (PMID: 25806224, PMID: 21791641).",Actionable,2896,3908,non-small cell lung carcinoma,DOID,10722,ALK fusion ALK L1152R,resistant,706,Crizotinib,238,21791641,25806224,,
192,Preclinical,"In a preclinical study, transformed cells expressing an ALK fusion and ALK G1202R were resistant to Xalkori (crizotinib) (PMID: 25806224, PMID: 22277784).",Actionable,2957,10000003,Advanced Solid Tumor,JAX,10725,ALK fusion ALK G1202R,resistant,706,Crizotinib,238,22277784,25806224,,
193,Phase I,"In a Phase I clinical trial, treatment with Lorlatinib (PF-06463922) demonstrated safety and resulted in durable responses in patients with ALK-positive non-small cell lung cancer, including patients harboring ALK G1202R (J Clin Oncol 34, 2016 (suppl; abstr 9009)).",Actionable,6820,3908,non-small cell lung carcinoma,DOID,10725,ALK fusion ALK G1202R,sensitive,869,PF-06463922,238,None,,,
194,FDA approved,"In a Phase II trial that supported FDA approval, Alunbrig (brigatinib) treatment resulted an overall response rate of 46% (51/112) in the 90mg arm and 54% (59/110) in the 180mg arm, and median progression-free survival of 8.8 mo and 11.0 mo respectively, in ALK-positive non-small cell lung carcinoma patients who progressed on Xalkori (crizotinib) (J Clin Oncol 34, 2016 (suppl; abstr 9007)).",Actionable,6704,3908,non-small cell lung carcinoma,DOID,1772,ALK positive,sensitive,634,AP26113,238,None,,,
195,FDA approved,Zykadia (ceritinib) is FDA approved for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) in patients previously treated with crizotinib (FDA.gov).,Actionable,1481,3908,non-small cell lung carcinoma,DOID,1772,ALK positive,sensitive,789,Ceritinib,238,None,,,
196,Phase III,"In a Phase III trial, Alecensa (alectinib) treatment resulted in improved median progression-free survival (not reached vs. 11.1 months), and 12 month event-free survival rate (68.4% vs. 48.7%), when compared to Xalkori (crizotinib) treatment in ALK-positive non-small cell lung carcinoma patients (PMID: 28586279; NCT02075840).",Actionable,11293,3908,non-small cell lung carcinoma,DOID,1772,ALK positive,sensitive,698,Alectinib,238,None,28586279,,
197,Phase I,"In a Phase I trial, Entrectinib (RXDX-101) treatment resulted in stable disease in a patient with ALK-positive non-small cell lung carcinoma (J Clin Oncol 32:5s, 2014 (suppl; abstr 2502)).",Actionable,10350,3908,non-small cell lung carcinoma,DOID,1772,ALK positive,predicted â€“ sensitive,1455,Entrectinib,238,None,,,
198,Phase I,"In a Phase I clinical trial, Belizatinib (TSR-011) treatment resulted in a partial response in 60% (3/5) of non-small cell lung cancer patients positive for Alk (J Clin Oncol 32, 2014 (suppl; abstr e19005)).",Actionable,3954,3908,non-small cell lung carcinoma,DOID,1772,ALK positive,sensitive,949,TSR-011,238,None,,,
199,Phase Ib/II,"In a Phase I trial, Belizatinib (TSR-011) treatment resulted in a response in 100% (3/3) of patients with ALK positive advanced solid tumors when administered at higher doses, and stable disease for 7 months or longer in 56% (5/9) of patients at lower dose (J Clin Oncol 33, 2015 (suppl; abstr 8063)).",Actionable,10344,10000003,Advanced Solid Tumor,JAX,1772,ALK positive,sensitive,949,TSR-011,238,None,,,
200,Phase III,"In a Phase III trial, Xalkori (crizotinib) treatment resulted in improved objective response (87.5%, 90/103 vs 45.6%, 47/103) and median progression free survival (11.1 vs 6.8 mo) compared to pemetrexed, cisplatin and carboplatinin combination treatment in treatment-naive ALK positive advanced non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9058)).",Actionable,7060,3908,non-small cell lung carcinoma,DOID,1772,ALK positive,sensitive,706,Crizotinib,238,None,,,
201,Phase Ib/II,"In a Phase Ib/II trial, Ensartinib (X-396) treatment resulted in partial response (PR) in 60% (19/30) and stable disease in 7% (2/30) of ALK positive non-small cell lung carcinoma patients, PR was 88% (7/8) in crizotinib-naÃ¯ve patients and 83% (10/12) in patients with prior crizotinib treatment (J Clin Oncol 34, 2016 (suppl; abstr 9056)).",Actionable,1785,3908,non-small cell lung carcinoma,DOID,1772,ALK positive,sensitive,961,X-396,238,None,,,
202,Phase II,"In a Phase II trial, Onalespib (AT13387) and Xalkori (crizotinib) combination treatment did not significantly improve median progression free survival (269 vs 266 days) or objective response rate (55.4%, 38/68 vs 45.3%, 31/68) compared to Xalkori (crizotinib) single treatment in ALK positive non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9059)).",Actionable,7062,3908,non-small cell lung carcinoma,DOID,1772,ALK positive,no benefit,4355,Crizotinib + Onalespib,238,None,,,
203,Phase I,"In a Phase I trial, Entrectinib (RXDX-101) treatment resulted in partial response in a patient with ALK-positive neuroblastoma (J Clin Oncol 32:5s, 2014 (suppl; abstr 2502)).",Actionable,10349,769,neuroblastoma,DOID,1772,ALK positive,predicted â€“ sensitive,1455,Entrectinib,238,None,,,
204,Preclinical,"In a preclinical trial, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S in culture (PMID: 25421750).",Actionable,3464,10000003,Advanced Solid Tumor,JAX,13329,NPM1-ALK ALK P1139S,sensitive,698,Alectinib,238,25421750,,,
205,Preclinical,"In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S in culture (PMID: 25421750).",Actionable,3455,10000003,Advanced Solid Tumor,JAX,13329,NPM1-ALK ALK P1139S,sensitive,706,Crizotinib,238,25421750,,,
206,Preclinical,"In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3486,10000003,Advanced Solid Tumor,JAX,13329,NPM1-ALK ALK P1139S,decreased response,789,Ceritinib,238,25421750,,,
207,Preclinical,"In a preclinical study, ASP3026 inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S in culture (PMID: 25421750).",Actionable,3549,10000003,Advanced Solid Tumor,JAX,13329,NPM1-ALK ALK P1139S,sensitive,643,ASP3026,238,25421750,,,
208,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing NPM1-ALK P1139S in culture (PMID: 25421750).",Actionable,3446,10000003,Advanced Solid Tumor,JAX,13329,NPM1-ALK ALK P1139S,sensitive,634,AP26113,238,25421750,,,
209,Preclinical,"In a preclinical study, a transformed cell line expressing ALK G1269A was sensitive to Brigatinib (AP26113) in culture, resulting in cell growth inhibition (PMID: 27049722). ",Actionable,5878,10000003,Advanced Solid Tumor,JAX,4863,ALK G1269A,sensitive,634,AP26113,238,27049722,,,
210,Preclinical - Patient cell culture,"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and growth of non-small cell lung cancer (NSCLC) cells over expressing ALK G1269A in the context of EML4-ALK in culture and in cell line xenograft models, as well as inhibited  growth of patient derived NSCLC cells harboring EML4-ALK ALK G1269A in culture (PMID: 26144315). ",Actionable,3159,3908,non-small cell lung carcinoma,DOID,5334,EML4-ALK ALK G1269A,sensitive,869,PF-06463922,238,26144315,,,
211,Preclinical,"In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 27009859).",Actionable,5389,10000003,Advanced Solid Tumor,JAX,5334,EML4-ALK ALK G1269A,sensitive,1586,AZD3463,238,27009859,,,
212,Preclinical,"In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 26698910).",Actionable,5721,10000003,Advanced Solid Tumor,JAX,5334,EML4-ALK ALK G1269A,sensitive,869,PF-06463922,238,26698910,,,
213,Preclinical,"In preclinical studies, Brigatinib (AP26113) inhibited the growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 27009859, PMID: 26698910).",Actionable,5388,10000003,Advanced Solid Tumor,JAX,5334,EML4-ALK ALK G1269A,sensitive,634,AP26113,238,27009859,26698910,,
214,Clinical Study,"In a clinical case study, a patient with EML4-ALK fusion positive non-small cell lung cancer with ALK G1269A had a partial response to Alecensa (alectinib) treatment (PMID: 26849637).",Actionable,4621,3908,non-small cell lung carcinoma,DOID,5334,EML4-ALK ALK G1269A,sensitive,698,Alectinib,238,26849637, 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26849637'}],,
215,Preclinical - Cell line xenograft,"In a preclinical study, Alecensa (alectinib) inhibited proliferation of a Xalkori (crizotinib)-resistant human non-small cell lung cancer (NSCLC) cell line harboring an EML-ALK fusion with ALK G1269A in culture and induced tumor regression in xenograft models (PMID: 26849637, PMID: 23344087).",Actionable,4462,3908,non-small cell lung carcinoma,DOID,5334,EML4-ALK ALK G1269A,sensitive,698,Alectinib,238,23344087,26849637,,
216,Preclinical,"In preclinical studies, Zykadia (ceritinib) inhibited growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 26698910, PMID: 27009859).",Actionable,5385,10000003,Advanced Solid Tumor,JAX,5334,EML4-ALK ALK G1269A,sensitive,789,Ceritinib,238,27009859,26698910,,
217,Preclinical,"In preclinical studies, human lung cancer cell lines expressing EML4-ALK G1269A demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 22235099, PMID: 23344087, PMID: 24675041).",Actionable,2054,3908,non-small cell lung carcinoma,DOID,5334,EML4-ALK ALK G1269A,resistant,706,Crizotinib,238,23344087,22235099,24675041,
218,Preclinical,"In a preclinical study, human lung cancer cell lines harboring EML4-ALK with ALK G1269A demonstrated sensitivity to Zykadia (ceritinib) in culture (PMID: 24675041).",Actionable,2055,3908,non-small cell lung carcinoma,DOID,5334,EML4-ALK ALK G1269A,sensitive,789,Ceritinib,238,24675041,,,
219,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A demonstrated a decreased response when treated with Entrectinib (RXDX-101) (PMID: 26939704). ",Actionable,5640,10000003,Advanced Solid Tumor,JAX,5334,EML4-ALK ALK G1269A,decreased response,1455,Entrectinib,238,26939704,,,
220,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5387,10000003,Advanced Solid Tumor,JAX,5334,EML4-ALK ALK G1269A,resistant,643,ASP3026,238,27009859,,,
221,Preclinical,"In a preclinical study, Alecensa (alectinib) modestly inhibited growth of transformed cells expression EML4-ALK with ALK G1269A in culture (PMID: 26698910).",Actionable,5722,10000003,Advanced Solid Tumor,JAX,5334,EML4-ALK ALK G1269A,conflicting,698,Alectinib,238,26698910,,,
222,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5386,10000003,Advanced Solid Tumor,JAX,5334,EML4-ALK ALK G1269A,conflicting,698,Alectinib,238,27009859,,,
223,Preclinical,"In preclinical studies, transformed cells expressing EML4-ALK with ALK G1269A were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859, PMID: 26698910).",Actionable,5384,10000003,Advanced Solid Tumor,JAX,5334,EML4-ALK ALK G1269A,resistant,706,Crizotinib,238,27009859,26698910,,
224,Preclinical,"In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing NPM1-ALK with ALK G1269A in culture (PMID: 27009859).",Actionable,5383,10000003,Advanced Solid Tumor,JAX,20662,NPM1-ALK ALK G1269A,sensitive,1586,AZD3463,238,27009859,,,
225,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited the growth of transformed cells expressing NPM1-ALK with ALK G1269A in culture (PMID: 27009859).",Actionable,5381,10000003,Advanced Solid Tumor,JAX,20662,NPM1-ALK ALK G1269A,sensitive,634,AP26113,238,27009859,,,
226,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1269A were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5380,10000003,Advanced Solid Tumor,JAX,20662,NPM1-ALK ALK G1269A,resistant,698,Alectinib,238,27009859,,,
227,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK G1269A were resistant to Xalkori (crizotinib) in culture (PMID: 27009859).",Actionable,5351,50744,anaplastic large cell lymphoma,DOID,20662,NPM1-ALK ALK G1269A,resistant,706,Crizotinib,238,27009859,,,
228,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1269A were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5379,10000003,Advanced Solid Tumor,JAX,20662,NPM1-ALK ALK G1269A,resistant,789,Ceritinib,238,27009859,,,
229,Preclinical,"In a preclinical study, ASP3026 inhibited the growth of transformed cells expressing NPM1-ALK with ALK G1269A in culture (PMID: 27009859).",Actionable,5382,10000003,Advanced Solid Tumor,JAX,20662,NPM1-ALK ALK G1269A,sensitive,643,ASP3026,238,27009859,,,
230,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1269A were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5378,10000003,Advanced Solid Tumor,JAX,20662,NPM1-ALK ALK G1269A,resistant,706,Crizotinib,238,27009859,,,
231,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A and ALK L1198F were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).",Actionable,5725,10000003,Advanced Solid Tumor,JAX,21453,EML4-ALK ALK L1198F ALK G1269A,resistant,869,PF-06463922,238,26698910,,,
232,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with G1269A were re-sensitized and modestly sensitive to Xalkori (crizotinib) with the introduction of an additional ALK mutation L1198F, in culture (PMID: 26698910).",Actionable,5723,10000003,Advanced Solid Tumor,JAX,21453,EML4-ALK ALK L1198F ALK G1269A,sensitive,706,Crizotinib,238,26698910,,,
233,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A and ALK L1198F were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).",Actionable,5726,10000003,Advanced Solid Tumor,JAX,21453,EML4-ALK ALK L1198F ALK G1269A,resistant,789,Ceritinib,238,26698910,,,
234,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A and ALK L1198F were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).",Actionable,5727,10000003,Advanced Solid Tumor,JAX,21453,EML4-ALK ALK L1198F ALK G1269A,resistant,698,Alectinib,238,26698910,,,
235,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing EML4-ALK with ALK G1269A and L1198F in culture (PMID: 26698910).",Actionable,5724,10000003,Advanced Solid Tumor,JAX,21453,EML4-ALK ALK L1198F ALK G1269A,sensitive,634,AP26113,238,26698910,,,
236,Phase I,"In a Phase I trial, Entrectinib (RXDX-101) treatment resulted in partial response that lasted 8.3 months in a patient with neuroblastoma harboring ALK F1245V, who remained on treatment for over 3.5 years due to clinical benefit (PMID: 28183697).",Actionable,10489,769,neuroblastoma,DOID,27527,ALK F1245V,predicted â€“ sensitive,1455,Entrectinib,238,28183697,,,
237,Preclinical - Patient cell culture,"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell growth in patient derived non-small cell lung cancer cells harboring ALK I1171T in the context of EML4-ALK in culture (PMID: 26144315).",Actionable,3160,3908,non-small cell lung carcinoma,DOID,5340,EML4-ALK ALK I1171T,sensitive,869,PF-06463922,238,26144315,,,
238,Preclinical,"In a preclinical study, TAE684 inhibited growth of a transformed cell line expressing EML4-ALK ALK I1171T in culture (PMID: 25228534).",Actionable,3399,10000003,Advanced Solid Tumor,JAX,5340,EML4-ALK ALK I1171T,sensitive,2386,TAE684,238,25228534,,,
239,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171T demonstrated a decreased response to treatment with Xalkori (crizotinib) in culture (PMID: 27432227).  ",Actionable,8632,10000003,Advanced Solid Tumor,JAX,5340,EML4-ALK ALK I1171T,decreased response,706,Crizotinib,238,27432227,,,
240,Preclinical,"In a preclinical study, Zykadia (ceritinib) inhibited growth of a transformed cell line expressing EML4-ALK with ALK I1171T in culture (PMID: 25228534).",Actionable,2058,10000003,Advanced Solid Tumor,JAX,5340,EML4-ALK ALK I1171T,sensitive,789,Ceritinib,238,25228534,,,
241,Preclinical,"In a preclinical study, a transformed cell line expressing EML4-ALK with ALK I1171T was resistant to ASP3026 treatment in culture (PMID: 25228534).",Actionable,3407,10000003,Advanced Solid Tumor,JAX,5340,EML4-ALK ALK I1171T,resistant,643,ASP3026,238,25228534,,,
242,Preclinical,"In a preclinical study, a transformed cell line expressing EML4-ALK with ALK I1171T was resistant to Alecensa (alectinib) treatment in culture (PMID: 25228534), however, another study with comparable cells demonstrated sensitivity in culture (PMID: 27432227). ",Actionable,3397,10000003,Advanced Solid Tumor,JAX,5340,EML4-ALK ALK I1171T,conflicting,698,Alectinib,238,25228534,27432227,,
243,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171T demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).  ",Actionable,8633,10000003,Advanced Solid Tumor,JAX,5340,EML4-ALK ALK I1171T,sensitive,869,PF-06463922,238,27432227,,,
244,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited growth of a transformed cell line expressing EML4-ALK I1171T but to a lesser degree than EML4-ALK in culture (PMID: 25228534).",Actionable,3404,10000003,Advanced Solid Tumor,JAX,5340,EML4-ALK ALK I1171T,decreased response,634,AP26113,238,25228534,,,
245,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to ASP3026 in culture (PMID: 25749034).",Actionable,5419,10000003,Advanced Solid Tumor,JAX,5337,NPM1-ALK ALK I1171T,resistant,643,ASP3026,238,25749034,,,
246,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).",Actionable,5497,10000003,Advanced Solid Tumor,JAX,5337,NPM1-ALK ALK I1171T,resistant,869,PF-06463922,238,25749034,,,
247,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK I1171T were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).",Actionable,5411,50744,anaplastic large cell lymphoma,DOID,5337,NPM1-ALK ALK I1171T,resistant,643,ASP3026,238,25749034,,,
248,Preclinical,"In a preclinical study, an anaplastic large-cell lymphoma cell line expressing NPM-ALK I1171T demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 24509625).",Actionable,2057,50744,anaplastic large cell lymphoma,DOID,5337,NPM1-ALK ALK I1171T,resistant,706,Crizotinib,238,24509625,,,
249,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Xalkori (critzotinb) in culture (PMID: 25749034).",Actionable,5478,10000003,Advanced Solid Tumor,JAX,5337,NPM1-ALK ALK I1171T,resistant,706,Crizotinib,238,25749034,,,
250,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Alecensa (alectinib) in culture (PMID: 25749034).",Actionable,5438,10000003,Advanced Solid Tumor,JAX,5337,NPM1-ALK ALK I1171T,resistant,698,Alectinib,238,25749034,,,
251,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).",Actionable,5488,10000003,Advanced Solid Tumor,JAX,5337,NPM1-ALK ALK I1171T,resistant,789,Ceritinib,238,25749034,,,
252,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Brigatinib (AP26113) in culture (PMID: 25749034).",Actionable,5429,10000003,Advanced Solid Tumor,JAX,5337,NPM1-ALK ALK I1171T,resistant,634,AP26113,238,25749034,,,
253,Clinical Study,"In a clinical case study, a patient with a lung adenocarcinoma tumor harboring an ALK rearrangement with ALK I1171T progressed on Alecensa (alectinib) therapy after 4 months and resistance was confirmed using cell culture with cells derived from the patientâ€™s tumor (PMID: 25228534). ",Actionable,3394,3910,lung adenocarcinoma,DOID,13309,ALK rearrange ALK I1171T,resistant,698,Alectinib,238,25228534,,,
254,Clinical Study,"In a clinical case study, a de novo ALK I1171N mutation was identified in the liver metastasis site and circulating DNA of a non-small cell lung cancer patient harboring ALK rearrangement after the disease progressed while on Alecensa (alectinib) treatment (PMID: 27565911).",Actionable,10417,3908,non-small cell lung carcinoma,DOID,13309,ALK rearrange ALK I1171T,predicted â€“ resistant,698,Alectinib,238,27565911,,,
255,Clinical Study,"In a clinical case study, a patient with a lung adenocarcinoma tumor harboring ALK rearrange and ALK I1171T progressed on Xalkori (crizotinib) therapy after 8 months and resistance was confirmed using cell culture with cells derived from the patientâ€™s tumor (PMID: 25228534). ",Actionable,3395,3910,lung adenocarcinoma,DOID,13309,ALK rearrange ALK I1171T,resistant,706,Crizotinib,238,25228534,,,
256,Phase II,"In a Phase I trial, Xalkori (crizotinib) treatment resulted in an objective response rate of 69% (89/129), and a median duration of treatment of 7.8 months in ALK negative, ROS1 positive non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9022)).",Actionable,6993,3908,non-small cell lung carcinoma,DOID,24174,ALK neg ROS1 pos,sensitive,706,Crizotinib,238,None,,,
257,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK containing ALK L1196Q were resistant to Xalkori (crizotinib) in culture (PMID: 25749034).",Actionable,5504,50744,anaplastic large cell lymphoma,DOID,20952,NPM1-ALK ALK L1196Q,resistant,706,Crizotinib,238,25749034,,,
258,Preclinical,"In a preclinical study, ASP3026 inhibited growth of human anaplastic large cell lymphoma cell lines harboring NPM1-ALK containing the crizotinib-resistant mutation ALK L1196Q in culture (PMID: 25749034).",Actionable,5503,50744,anaplastic large cell lymphoma,DOID,20952,NPM1-ALK ALK L1196Q,sensitive,643,ASP3026,238,25749034,,,
259,Preclinical,"In a preclinical study, a transformed cell line expressing ALK Y1278S was sensitive to Brigatinib (AP26113) in culture, resulting in cell growth inhibition (PMID: 27049722). ",Actionable,5877,10000003,Advanced Solid Tumor,JAX,13480,ALK Y1278S,sensitive,634,AP26113,238,27049722,,,
260,Preclinical - Cell culture,"In a preclinical study, AZD3463 treatment enhanced the cytotoxic effects of Adriamycin (doxorubicin) in a neuroblastoma cell line harboring ALK D1091N, demonstrating increased apoptotic activity and decreased cell viability in culture (PMID: 28455243). ",Actionable,11451,769,neuroblastoma,DOID,23761,ALK D1091N,sensitive,5990,AZD3463 + Doxorubicin,238,28455243,,,
261,Preclinical - Cell culture,"In a preclinical study, AZD3463 treatment in a neuroblastoma cell line harboring ALK D1091N resulted in inhibition of colony formation, repression of Pi3k signaling, and induction of apoptosis in culture (PMID: 26786851). ",Actionable,11450,769,neuroblastoma,DOID,23761,ALK D1091N,predicted â€“ sensitive,1586,AZD3463,238,26786851,,,
262,Preclinical - Cell culture,"In a preclinical study, Alecensa (alectinib) treatment in a neuroblastoma cell line harboring ALK D1091N resulted in decreased cell viability, inhibition of colony formation, and inhibition of Pi3k pathway signaling in culture (PMID: 28455243). ",Actionable,11448,769,neuroblastoma,DOID,23761,ALK D1091N,predicted â€“ sensitive,698,Alectinib,238,28455243,,,
263,Preclinical - Cell culture,"In a preclinical study, Alecensa (alectinib) treatment enhanced the cytotoxic effects of Adriamycin (doxorubicin) in a neuroblastoma cell line harboring ALK D1091N, demonstrating increased apoptotic activity and decreased cell viability in culture (PMID: 28455243). ",Actionable,11449,769,neuroblastoma,DOID,23761,ALK D1091N,predicted â€“ sensitive,5989,Alectinib + Doxorubicin,238,28455243,,,
264,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing ALK L1152P in the context of EML4-ALK demonstrated reduced sensitivity to Zykadia (ceritinib) in culture (PMID: 27780853).",Actionable,9269,10000003,Advanced Solid Tumor,JAX,26806,EML4-ALK ALK L1152P,decreased response,789,Ceritinib,238,27780853,,,
265,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing ALK L1152P in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) in culture (PMID: 27780853).",Actionable,9265,10000003,Advanced Solid Tumor,JAX,26806,EML4-ALK ALK L1152P,decreased response,706,Crizotinib,238,27780853,,,
266,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK L1152P in the context of EML4-ALK in culture (PMID: 27780853).",Actionable,9260,10000003,Advanced Solid Tumor,JAX,26806,EML4-ALK ALK L1152P,sensitive,634,AP26113,238,27780853,,,
267,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated a decreased response to treatment with Xalkori (crizotinib) in culture (PMID: 27432227).  ",Actionable,8626,10000003,Advanced Solid Tumor,JAX,26384,EML4-ALK ALK I1171N,decreased response,706,Crizotinib,238,27432227,,,
268,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).  ",Actionable,8630,10000003,Advanced Solid Tumor,JAX,26384,EML4-ALK ALK I1171N,sensitive,869,PF-06463922,238,27432227,,,
269,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated sensitivity to treatment with Brigatinib (AP26113) in culture (PMID: 27432227).  ",Actionable,8629,10000003,Advanced Solid Tumor,JAX,26384,EML4-ALK ALK I1171N,sensitive,634,AP26113,238,27432227,,,
270,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).  ",Actionable,8627,10000003,Advanced Solid Tumor,JAX,26384,EML4-ALK ALK I1171N,sensitive,789,Ceritinib,238,27432227,,,
271,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated resistance to treatment with Alecensa (alectinib) in culture (PMID: 27432227).  ",Actionable,8628,10000003,Advanced Solid Tumor,JAX,26384,EML4-ALK ALK I1171N,resistant,698,Alectinib,238,27432227,,,
272,Preclinical,"In a preclinical study, a transformed cell line expressing ALK I1171N was sensitive to Brigatinib (AP26113) in culture, resulting in cell growth inhibition (PMID: 27049722). ",Actionable,5872,10000003,Advanced Solid Tumor,JAX,1407,ALK I1171N,sensitive,634,AP26113,238,27049722,,,
273,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK I1171N were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).",Actionable,5412,50744,anaplastic large cell lymphoma,DOID,20769,NPM1-ALK ALK I1171N,resistant,643,ASP3026,238,25749034,,,
274,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Alecensa (alectinib) in culture (PMID: 25749034).",Actionable,5437,10000003,Advanced Solid Tumor,JAX,20769,NPM1-ALK ALK I1171N,resistant,698,Alectinib,238,25749034,,,
275,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to ASP3026 in culture (PMID: 25749034).",Actionable,5418,10000003,Advanced Solid Tumor,JAX,20769,NPM1-ALK ALK I1171N,resistant,643,ASP3026,238,25749034,,,
276,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).",Actionable,5496,10000003,Advanced Solid Tumor,JAX,20769,NPM1-ALK ALK I1171N,resistant,869,PF-06463922,238,25749034,,,
277,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Brigatinib (AP26113) in culture (PMID: 25749034).",Actionable,5428,10000003,Advanced Solid Tumor,JAX,20769,NPM1-ALK ALK I1171N,resistant,634,AP26113,238,25749034,,,
278,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Xalkori (critzotinb) in culture (PMID: 25749034).",Actionable,5477,10000003,Advanced Solid Tumor,JAX,20769,NPM1-ALK ALK I1171N,resistant,706,Crizotinib,238,25749034,,,
279,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).",Actionable,5487,10000003,Advanced Solid Tumor,JAX,20769,NPM1-ALK ALK I1171N,resistant,789,Ceritinib,238,25749034,,,
280,Preclinical,"In a preclinical study, ASP3026 inhibited growth of a transformed cell line expressing EML4-ALK with ALK V1180L in culture (PMID: 25228534).",Actionable,3406,10000003,Advanced Solid Tumor,JAX,12072,EML4-ALK ALK V1180L,sensitive,643,ASP3026,238,25228534,,,
281,Preclinical,"In a preclinical study, a human non-small cell lung cancer cell line harboring EML4-ALK with ALK V1180L was resistant to Alecensa (alectinib) treatment in culture (PMID: 25228534).",Actionable,3392,3908,non-small cell lung carcinoma,DOID,12072,EML4-ALK ALK V1180L,resistant,698,Alectinib,238,25228534,,,
282,Preclinical,"In a preclinical study, a human non-small cell lung cancer cell line harboring EML4-ALK ALK V1180L was resistant to Xalkori (crizotinib) treatment in culture (PMID: 25228534).",Actionable,3393,3908,non-small cell lung carcinoma,DOID,12072,EML4-ALK ALK V1180L,resistant,706,Crizotinib,238,25228534,,,
283,Preclinical,"In a preclinical study, Zykadia (ceritinib) inhibited growth of a transformed cell line expressing EML4-ALK with ALK V1180L in culture (PMID: 25228534).",Actionable,3400,10000003,Advanced Solid Tumor,JAX,12072,EML4-ALK ALK V1180L,sensitive,789,Ceritinib,238,25228534,,,
284,Preclinical - Cell culture,"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation, reduced proliferation, and induced apoptosis of non-small cell lung carcinoma cells harboring ALK V1180L in the context of EML4-ALK in culture (PMID: 26144315). ",Actionable,2648,3908,non-small cell lung carcinoma,DOID,12072,EML4-ALK ALK V1180L,sensitive,869,PF-06463922,238,26144315,,,
285,Preclinical,"In a preclinical study, TAE684 inhibited growth of a transformed cell line expressing EML4-ALK ALK V1180L in culture (PMID: 25228534).",Actionable,3398,10000003,Advanced Solid Tumor,JAX,12072,EML4-ALK ALK V1180L,sensitive,2386,TAE684,238,25228534,,,
286,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited growth of a transformed cell line expressing EML4-ALK ALK V1180L in culture (PMID: 25228534).",Actionable,3403,10000003,Advanced Solid Tumor,JAX,12072,EML4-ALK ALK V1180L,sensitive,634,AP26113,238,25228534,,,
287,Preclinical,"In a preclinical study, a transformed cell line expressing EML4-ALK with ALK V1180L was resistant to Alecensa (alectinib) treatment in culture (PMID: 25228534).",Actionable,3396,10000003,Advanced Solid Tumor,JAX,12072,EML4-ALK ALK V1180L,resistant,698,Alectinib,238,25228534,,,
288,Clinical Study,"In a retrospective analysis, patients with ALK-rearrangement positive non-small cell lung cancer that acquired ALK drug resistance mutations following Xalkori (crizotinib) treatment had a median progression-free survival (mPFS) of 5.4 months on Zykadia (ceritinib), which was not significantly different than the mPFS of 6.5 months for patients without ALK mutations (PMID: 25724526).",Actionable,3297,3908,non-small cell lung carcinoma,DOID,13109,ALK rearrange ALK mut,sensitive,789,Ceritinib,238,25724526,,,
289,Preclinical,"In a preclinical study, Xalkori (crizotinib) demonstrated synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) in patient-derived neuroblastoma cell lines harboring Alk mutations and functional TP53, resulting in growth inhibition in culture and tumor regression in animal models (PMID: 26438783).",Actionable,4736,769,neuroblastoma,DOID,18888,ALK mutant TP53 wild-type,sensitive,3601,Crizotinib + Cyclophosphamide + Topotecan,238,26438783,,,
290,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).  ",Actionable,8640,10000003,Advanced Solid Tumor,JAX,26385,EML4-ALK ALK G1202del,sensitive,869,PF-06463922,238,27432227,,,
291,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated a decreased response to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).  ",Actionable,8637,10000003,Advanced Solid Tumor,JAX,26385,EML4-ALK ALK G1202del,decreased response,789,Ceritinib,238,27432227,,,
292,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated a decreased response to treatment with Brigatinib (AP26113) in culture (PMID: 27432227).  ",Actionable,8639,10000003,Advanced Solid Tumor,JAX,26385,EML4-ALK ALK G1202del,decreased response,634,AP26113,238,27432227,,,
293,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated a decreased response to treatment with Alecensa (alectinib) in culture (PMID: 27432227).  ",Actionable,8638,10000003,Advanced Solid Tumor,JAX,26385,EML4-ALK ALK G1202del,decreased response,698,Alectinib,238,27432227,,,
294,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated a decreased response to treatment with Xalkori (crizotinib) in culture (PMID: 27432227).  ",Actionable,8636,10000003,Advanced Solid Tumor,JAX,26385,EML4-ALK ALK G1202del,decreased response,706,Crizotinib,238,27432227,,,
295,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V were resistant to ASP3026 treatment in culture (PMID: 25421750).",Actionable,3551,10000003,Advanced Solid Tumor,JAX,13326,NPM1-ALK ALK L1122V,resistant,643,ASP3026,238,25421750,,,
296,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).",Actionable,3459,10000003,Advanced Solid Tumor,JAX,13326,NPM1-ALK ALK L1122V,resistant,698,Alectinib,238,25421750,,,
297,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750).",Actionable,3480,10000003,Advanced Solid Tumor,JAX,13326,NPM1-ALK ALK L1122V,resistant,789,Ceritinib,238,25421750,,,
298,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V were resistant to Brigatinib (AP26113) treatment in culture (PMID: 25421750).",Actionable,3441,10000003,Advanced Solid Tumor,JAX,13326,NPM1-ALK ALK L1122V,resistant,634,AP26113,238,25421750,,,
299,Preclinical,"In a preclinical study, a transformed cell line expressing ALK G1128A was sensitive to Brigatinib (AP26113) in culture, resulting in cell growth inhibition (PMID: 27049722). ",Actionable,5871,10000003,Advanced Solid Tumor,JAX,1404,ALK G1128A,sensitive,634,AP26113,238,27049722,,,
300,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK S1206F in the context of EML4-ALK in culture (PMID: 27780853).",Actionable,9262,10000003,Advanced Solid Tumor,JAX,26804,EML4-ALK ALK S1206F,sensitive,634,AP26113,238,27780853,,,
301,Preclinical - Patient cell culture,"In a preclinical study, NSCLC patient derived cells harboring an ALK rearrangement demonstrated resistance to Zykadia (ceritinib) due to the acquired mutation MAP2K1 K57N, however, sensitivity was restored to Zykadia (ceritinib) with the addition of AZD6244, resulting in decreased cell survival in culture and reduced tumor volume in xenograft models (PMID: 25394791).",Actionable,8661,3908,non-small cell lung carcinoma,DOID,26393,ALK rearrange MAP2K1 K57N,sensitive,4786,Ceritinib + Selumetinib,238,25394791,,,
302,Clinical Study,"In a clinical study, three patients with non-small cell lung carcinoma co-harboring an ALK rearrangement and ALK amplification demonstrated resistance to Xalkori (crizotinib) treatment (PMID: 27432227).",Actionable,8660,3908,non-small cell lung carcinoma,DOID,26389,ALK rearrange ALK amp,resistant,706,Crizotinib,238,27432227,,,
303,Clinical Study,"In a clinical case study, RB1 C706F and loss of exons 1-11 in TP53 were identified in the pericardium infiltrating small cell lung cancer that developed while on Lorlatinib (PF-06463922) treatment in a patient with ALK-rearranged non-small cell lung carcinoma (PMID: 28285684).",Actionable,10437,5409,lung small cell carcinoma,DOID,27462,ALK rearrange RB1 C706F TP53 loss,predicted â€“ resistant,869,PF-06463922,238,28285684,,,
304,Clinical Study,"In a clinical case study, ALK G1202R was identified in a patient with ALK-rearranged non-small cell lung carcinoma after the disease progressed while on Zykadia (ceritinib) followed by Alecensa (alectinib) therapy (PMID: 28285684).",Actionable,10436,3908,non-small cell lung carcinoma,DOID,27461,ALK rearrange ALK G1202R,predicted â€“ resistant,698,Alectinib,238,28285684,,,
305,Clinical Study,"In a retrospective study, non-small cell lung cancer patients with brain metastases harboring an ALK rearrangement demonstrated prolonged survival following treatment with the combination of an ALK-targeted tyrosine kinase inhibitor, including Ensartinib (X-396), and radiotherapy (PMID: 26438117).",Actionable,3665,3908,non-small cell lung carcinoma,DOID,1248,ALK rearrange,sensitive,961,X-396,238,26438117,,,
306,Clinical Study,"In a retrospective study, non-small cell lung cancer patients with brain metastases harboring an ALK rearrangement demonstrated prolonged survival following treatment with the combination of an ALK-targeted tyrosine kinase inhibitor, including Brigatinib (AP26113), and radiotherapy (PMID: 26438117).",Actionable,3663,3908,non-small cell lung carcinoma,DOID,1248,ALK rearrange,sensitive,634,AP26113,238,26438117,,,
307,Phase Ib/II,"In a Phase I/II trial, Brigatinib (AP26113) treatment resulted in an objective response rate of 100% (8/8) in ALK inhibitor-naive ALK-rearranged non-small cell lung cancer (NSCLC) patients, 72% (51/71) in crizotinib-treated ALK-rearranged NSCLC patients, and 83% (5/6) in ALK-rearranged NSCLC patients with CNS metastases (PMID: 27836716).",Actionable,9228,3908,non-small cell lung carcinoma,DOID,1248,ALK rearrange,sensitive,634,AP26113,238,27836716,,,
308,Phase II,"In a Phase II trial, non-small cell lung cancer patients with brain metastases harboring an ALK rearrangement and previously treated with Xalkori (crizotinib) and chemotherapy demonstrated strong responses for overall response, time to response, and progression free survival when treated with Zykadia (ceritinib) (PMID: 27432917). ",Actionable,8210,3908,non-small cell lung carcinoma,DOID,1248,ALK rearrange,sensitive,789,Ceritinib,238,27432917,,,
309,Phase III,"In a Phase III trial, first-line treatment with Zykadia (ceritinib) resulted in an improved median progression-free survival of 16.1 months, compared to 8.1 months with chemotherapy, in patients with ALK-rearranged non-squamous non-small cell lung cancer (PMID: 28126333).",Actionable,9560,3908,non-small cell lung carcinoma,DOID,1248,ALK rearrange,sensitive,789,Ceritinib,238,None,28126333,,
310,Clinical Study,"In a retrospective study, non-small cell lung cancer patients with brain metastases harboring an ALK rearrangement demonstrated prolonged survival following treatment with the combination of an ALK-targeted tyrosine kinase inhibitor, including Zykadia (ceritinib), and radiotherapy (PMID: 26438117).",Actionable,3662,3908,non-small cell lung carcinoma,DOID,1248,ALK rearrange,sensitive,789,Ceritinib,238,26438117,,,
311,Clinical Study,"In a retrospective study, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Durvalumab (MEDI4736), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694).",Actionable,8429,3908,non-small cell lung carcinoma,DOID,1248,ALK rearrange,decreased response,1312,Nivolumab,238,27225694,,,
312,Clinical Study,"In a retrospective study, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Imfinzi (durvalumab), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694).",Actionable,8431,3908,non-small cell lung carcinoma,DOID,1248,ALK rearrange,decreased response,1356,Durvalumab,238,27225694,,,
313,Phase III,"In a Phase III trial, Xalkori (crizotinib) treatment resulted in improved progression-free survival (PFS) (PFS=10.9 months, n=172) relative to chemotherapy (PFS=7.0 months, n=171) in NSCLC patients with ALK rearrangements, including patients with and without brain metastases at baseline, and improved intracranial disease rate in patients with brain metastases at baseline (PMID: 27022118).",Actionable,5667,3908,non-small cell lung carcinoma,DOID,1248,ALK rearrange,sensitive,706,Crizotinib,238,27022118,,,
314,FDA approved,Xalkori (crizotinib) is FDA approved for the use in NSCLC patients harboring ALK rearrangements independently of any prior treatment the patients have received (PMID: 25806224). ,Actionable,2866,3908,non-small cell lung carcinoma,DOID,1248,ALK rearrange,sensitive,706,Crizotinib,238,25806224,,,
315,FDA approved,"In a Phase II clinical trial that supported FDA approval, Alecensa (alectinib) treatment was effective in treating non-small cell lung cancer patients with ALK rearrangement, resulting in a 50% (61/122) objective response rate (ORR) in all patients, a 45% (43/96) ORR in Crizotinib-refractory patients, and an 83% (70/84) CNS disease control rate (PMID: 26598747).",Actionable,3730,3908,non-small cell lung carcinoma,DOID,1248,ALK rearrange,sensitive,698,Alectinib,238,26598747,,,
316,Clinical Study,"In a retrospective study, non-small cell lung cancer patients with brain metastases harboring an ALK rearrangement demonstrated prolonged survival following treatment with the combination of an ALK-targeted tyrosine kinase inhibitor, including Alecensa (alectinib), and radiotherapy (PMID: 26438117).",Actionable,3664,3908,non-small cell lung carcinoma,DOID,1248,ALK rearrange,sensitive,698,Alectinib,238,26438117,,,
317,Clinical Study,"In a retrospective analysis of patients with ALK-rearrangement positive non-small cell lung cancer, the combined median progression-free survival for sequential treatment with Xalkori (crizotinib) and Zykadia (ceritinib) without intervening treatments was 17.0 months, and overall survival was 49.4 months (PMID: 25724526).",Actionable,3296,3908,non-small cell lung carcinoma,DOID,1248,ALK rearrange,sensitive,3108,Ceritinib + Crizotinib,238,25724526,,,
318,Clinical Study,"In a retrospective study, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Durvalumab (MEDI4736), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694).",Actionable,8432,3908,non-small cell lung carcinoma,DOID,1248,ALK rearrange,decreased response,1201,Atezolizumab,238,27225694,,,
319,Phase I,"In a Phase I trial, Entrectinib (RXDX-101) treatment resulted in objection response in 67% (4/6) of patients with advanced solid tumors harboring rearrangement in ALK gene (AACR Apr 2016, Abstract # CT007).",Actionable,6729,10000003,Advanced Solid Tumor,JAX,1248,ALK rearrange,sensitive,1455,Entrectinib,238,None,,,
320,Phase I,"In a clinical study analyzing combined results of 2 Phase I trials, Entrectinib (RXDX-101) treatment resulted in an objective response rate of 57% (4/7) in patients with ALK rearranged advanced solid tumors that were treatment-naive, but no response (0/19) in patients received prior Alk inhibitor treatments (PMID: 28183697).",Actionable,10496,10000003,Advanced Solid Tumor,JAX,1248,ALK rearrange,sensitive,1455,Entrectinib,238,28183697,,,
321,Clinical Study,"In a retrospective study, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Durvalumab (MEDI4736), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694).",Actionable,8430,3908,non-small cell lung carcinoma,DOID,1248,ALK rearrange,decreased response,1447,Pembrolizumab,238,27225694,,,
322,Preclinical - Patient cell culture,"In a preclinical study, the combination of Saracatinib (AZD0530) and (Zykadia) ceritinib demonstrated efficacy in non-small cell lung cancer patient derived cells harboring an ALK fusion and upregulation of SRC in culture (PMID: 25394791).",Actionable,1618,3908,non-small cell lung carcinoma,DOID,26396,ALK rearrange SRC pos,sensitive,1939,Saracatinib + Ceritinib,238,25394791,,,
323,Preclinical - Cell line xenograft,"In a preclinical study, TPX-0005 inhibited ALK G1202R and suppressed tumor growth in cell line xenograft models with ALK G1202R (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).",Actionable,5833,10000003,Advanced Solid Tumor,JAX,1681,ALK G1202R,sensitive,3950,TPX-0005,238,None,,,
324,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).",Actionable,5716,10000003,Advanced Solid Tumor,JAX,21377,EML4-ALK ALK L1198F ALK G1202R,resistant,698,Alectinib,238,26698910,,,
325,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).",Actionable,5718,10000003,Advanced Solid Tumor,JAX,21377,EML4-ALK ALK L1198F ALK G1202R,resistant,789,Ceritinib,238,26698910,,,
326,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Brigatinib (AP26113) in culture (PMID: 26698910).",Actionable,5717,10000003,Advanced Solid Tumor,JAX,21377,EML4-ALK ALK L1198F ALK G1202R,resistant,634,AP26113,238,26698910,,,
327,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were re-sensitized to Xalkori (crizotinib) mediated growth inhibition with the introduction of an additional ALK mutation L1198F, in culture (PMID: 26698910).",Actionable,5714,10000003,Advanced Solid Tumor,JAX,21377,EML4-ALK ALK L1198F ALK G1202R,sensitive,706,Crizotinib,238,26698910,,,
328,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).",Actionable,5715,10000003,Advanced Solid Tumor,JAX,21377,EML4-ALK ALK L1198F ALK G1202R,resistant,869,PF-06463922,238,26698910,,,
329,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).",Actionable,5710,10000003,Advanced Solid Tumor,JAX,5339,EML4-ALK ALK G1202R,resistant,698,Alectinib,238,26698910,,,
330,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202R demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).  ",Actionable,8635,10000003,Advanced Solid Tumor,JAX,5339,EML4-ALK ALK G1202R,sensitive,869,PF-06463922,238,27432227,,,
331,Preclinical - Cell line xenograft,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK G1202R in the context of EML4-ALK in culture and reduced tumor growth in cell line xenograft models (PMID: 27780853).",Actionable,5713,10000003,Advanced Solid Tumor,JAX,5339,EML4-ALK ALK G1202R,sensitive,634,AP26113,238,27780853,,,
332,Preclinical - Cell line xenograft,"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation, reduced proliferation, and induced apoptosis in transformed cells over expressing ALK G1202R in the context of EML4-ALK in culture and in cell line xenograft models (PMID: 26144315). ",Actionable,2649,1324,lung cancer,DOID,5339,EML4-ALK ALK G1202R,conflicting,869,PF-06463922,238,26144315,,,
333,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).",Actionable,8294,1324,lung cancer,DOID,5339,EML4-ALK ALK G1202R,conflicting,869,PF-06463922,238,26698910,,,
334,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).",Actionable,5711,10000003,Advanced Solid Tumor,JAX,5339,EML4-ALK ALK G1202R,resistant,789,Ceritinib,238,26698910,,,
335,Preclinical - Cell line xenograft,"In a preclinical study, TPX-0005 inhibited Alk activity and proliferation of transformed cells over expressing ALK G1201R in the context of EML4-ALK in culture, resulted in tumor regression in cell line xenograft models (European Journal of Cancer , Volume 69, S32).",Actionable,10346,10000003,Advanced Solid Tumor,JAX,5339,EML4-ALK ALK G1202R,sensitive,3950,TPX-0005,238,None,,,
336,Clinical Study,"In a clinical study, an ALK G1202R secondary mutation in the context of EML4-ALK was associated with resistance to Xalkori (crizotinib) in a patient with non-small cell lung cancer, and resistance was replicated in cell culture studies (PMID: 22277784).",Actionable,1000,3908,non-small cell lung carcinoma,DOID,5339,EML4-ALK ALK G1202R,resistant,706,Crizotinib,238,22277784,,,
337,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Xalkori (crizotinib) in culture (PMID: 26698910).",Actionable,5709,10000003,Advanced Solid Tumor,JAX,5339,EML4-ALK ALK G1202R,resistant,706,Crizotinib,238,26698910,,,
338,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were insensitive to Zykadia (ceritinib) in culture (PMID: 24675041). ",Actionable,2097,3908,non-small cell lung carcinoma,DOID,5339,EML4-ALK ALK G1202R,resistant,789,Ceritinib,238,24675041,,,
339,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to RXDX-101 (PMID: 26939704). ",Actionable,5639,10000003,Advanced Solid Tumor,JAX,5339,EML4-ALK ALK G1202R,resistant,1455,Entrectinib,238,26939704,,,
340,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F were resistant to ASP3026 treatment in culture (PMID: 25421750).",Actionable,3553,10000003,Advanced Solid Tumor,JAX,13333,NPM1-ALK ALK F1174V ALK L1198F,resistant,643,ASP3026,238,25421750,,,
341,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).",Actionable,3461,10000003,Advanced Solid Tumor,JAX,13333,NPM1-ALK ALK F1174V ALK L1198F,resistant,698,Alectinib,238,25421750,,,
342,Preclinical,"In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F in culture (PMID: 25421750).",Actionable,3458,10000003,Advanced Solid Tumor,JAX,13333,NPM1-ALK ALK F1174V ALK L1198F,sensitive,706,Crizotinib,238,25421750,,,
343,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750).",Actionable,3482,10000003,Advanced Solid Tumor,JAX,13333,NPM1-ALK ALK F1174V ALK L1198F,resistant,789,Ceritinib,238,25421750,,,
344,Preclinical,"In a preclinical study, anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK F1174V and ALK L1198F were resistant to Brigatinib (AP26113) in culture (PMID: 25421750).",Actionable,3434,50744,anaplastic large cell lymphoma,DOID,13333,NPM1-ALK ALK F1174V ALK L1198F,resistant,634,AP26113,238,25421750,,,
345,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK1198F were resistant to Brigatinib (AP26113) treatment in culture (PMID: 25421750).",Actionable,3438,10000003,Advanced Solid Tumor,JAX,13333,NPM1-ALK ALK F1174V ALK L1198F,resistant,634,AP26113,238,25421750,,,
346,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).",Actionable,3462,10000003,Advanced Solid Tumor,JAX,13325,NPM1-ALK ALK L1198F,resistant,698,Alectinib,238,25421750,,,
347,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to Brigatinib (AP26113) treatment in culture (PMID: 25421750).",Actionable,3444,10000003,Advanced Solid Tumor,JAX,13325,NPM1-ALK ALK L1198F,resistant,634,AP26113,238,25421750,,,
348,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to ASP3026 treatment in culture (PMID: 25421750).",Actionable,3555,10000003,Advanced Solid Tumor,JAX,13325,NPM1-ALK ALK L1198F,resistant,643,ASP3026,238,25421750,,,
349,Preclinical,"In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1198F in culture (PMID: 25421750).",Actionable,3457,10000003,Advanced Solid Tumor,JAX,13325,NPM1-ALK ALK L1198F,sensitive,706,Crizotinib,238,25421750,,,
350,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750).",Actionable,3481,10000003,Advanced Solid Tumor,JAX,13325,NPM1-ALK ALK L1198F,resistant,789,Ceritinib,238,25421750,,,
351,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with L1198F were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).",Actionable,5686,10000003,Advanced Solid Tumor,JAX,21373,EML4-ALK ALK L1198F,resistant,789,Ceritinib,238,26698910,,,
352,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing EML4-ALK with L1198F in culture (PMID: 26698910).",Actionable,5690,10000003,Advanced Solid Tumor,JAX,21373,EML4-ALK ALK L1198F,sensitive,634,AP26113,238,26698910,,,
353,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1198F were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910), however, in another study, comparable cells demonstrated sensitivity in culture (PMID: 27432227).",Actionable,5683,10000003,Advanced Solid Tumor,JAX,21373,EML4-ALK ALK L1198F,conflicting,698,Alectinib,238,26698910,27432227,,
354,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with L1198F had reduced sensitivity to growth inhibition mediated by Lorlatinib (PF-06463922) in comparison to EML4-ALK wild type in culture (PMID: 26698910).",Actionable,5680,10000003,Advanced Solid Tumor,JAX,21373,EML4-ALK ALK L1198F,decreased response,869,PF-06463922,238,26698910,,,
355,Preclinical,"In a preclinical study, Xalkori (crizotinib) enhanced growth inhibition of transformed cells expressing EML4-ALK with L1198F in culture (PMID: 26698910).",Actionable,5675,10000003,Advanced Solid Tumor,JAX,21373,EML4-ALK ALK L1198F,sensitive,706,Crizotinib,238,26698910,,,
356,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK S1206C were resistant to Brigatinib (AP26113) treatment in culture (PMID: 25421750).",Actionable,3439,10000003,Advanced Solid Tumor,JAX,13332,NPM1-ALK ALK S1206C,resistant,634,AP26113,238,25421750,,,
357,Preclinical,"In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK S1206C to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3487,10000003,Advanced Solid Tumor,JAX,13332,NPM1-ALK ALK S1206C,decreased response,789,Ceritinib,238,25421750,,,
358,Preclinical,"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK ALK S1206C to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3453,10000003,Advanced Solid Tumor,JAX,13332,NPM1-ALK ALK S1206C,decreased response,706,Crizotinib,238,25421750,,,
359,Preclinical,"In a preclinical study, anaplastic large cell lymphoma cell lines harboring NPM1-ALK ALK S1206C were resistant to brigatinib (AP26113) in culture (PMID: 25421750).",Actionable,3436,50744,anaplastic large cell lymphoma,DOID,13332,NPM1-ALK ALK S1206C,resistant,634,AP26113,238,25421750,,,
360,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK and ALK S1206C were resistant to ASP3026 treatment in culture (PMID: 25421750).",Actionable,3556,10000003,Advanced Solid Tumor,JAX,13332,NPM1-ALK ALK S1206C,resistant,643,ASP3026,238,25421750,,,
361,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK S1206C were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).",Actionable,3463,10000003,Advanced Solid Tumor,JAX,13332,NPM1-ALK ALK S1206C,resistant,698,Alectinib,238,25421750,,,
362,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Xalkori (crizotinib), Topotecan, and Cytoxan (cyclophosphamide) synergized to delay tumor growth in xenograft models of a human neuroblastoma cell line harboring constitutively phosphorylated wild-type Alk and wild-type TP53 (PMID: 26438783).",Actionable,4733,769,neuroblastoma,DOID,18886,ALK act mut TP53 wild-type,predicted â€“ sensitive,3601,Crizotinib + Cyclophosphamide + Topotecan,238,26438783,,,
363,Preclinical,"In a preclinical study, neuroblastoma cells harboring ALK F1174V were sensitive to Brigatinib (AP26113) in culture and in vivo, resulting in inhibition of both Alk activity and cell proliferation (PMID: 27049722). ",Actionable,5880,769,neuroblastoma,DOID,3081,ALK F1174V,sensitive,634,AP26113,238,27049722,,,
364,Preclinical,"In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V in culture (PMID: 25421750).",Actionable,3456,10000003,Advanced Solid Tumor,JAX,13321,NPM1-ALK ALK F1174V,sensitive,706,Crizotinib,238,25421750,,,
365,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V in culture (PMID: 25421750).",Actionable,3443,10000003,Advanced Solid Tumor,JAX,13321,NPM1-ALK ALK F1174V,sensitive,634,AP26113,238,25421750,,,
366,Preclinical,"In a preclinical trial, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V in culture (PMID: 25421750).",Actionable,3484,10000003,Advanced Solid Tumor,JAX,13321,NPM1-ALK ALK F1174V,sensitive,789,Ceritinib,238,25421750,,,
367,Preclinical,"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3465,10000003,Advanced Solid Tumor,JAX,13321,NPM1-ALK ALK F1174V,decreased response,698,Alectinib,238,25421750,,,
368,Preclinical,"In a preclinical trial, ASP3026 inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3557,10000003,Advanced Solid Tumor,JAX,13321,NPM1-ALK ALK F1174V,decreased response,643,ASP3026,238,25421750,,,
369,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing ALK F1174V in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) in culture (PMID: 27780853).",Actionable,9267,10000003,Advanced Solid Tumor,JAX,26808,EML4-ALK ALK F1174V,decreased response,706,Crizotinib,238,27780853,,,
370,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK F1174V in the context of EML4-ALK in culture (PMID: 27780853).",Actionable,9261,10000003,Advanced Solid Tumor,JAX,26808,EML4-ALK ALK F1174V,sensitive,634,AP26113,238,27780853,,,
371,Preclinical - Pdx,"In a preclinical study, Xalkori (crizotinib) worked synergistically with Topotecan and Cytoxan (cyclophosphamide), resulting in sustained tumor regression in crizotinib-resistant neuroblastoma PDX models harboring ALK F1245C and wild-type Tp53 (PMID: 26438783).",Actionable,4732,769,neuroblastoma,DOID,18883,"ALK	F1245C TP53	wild-type",sensitive,3601,Crizotinib + Cyclophosphamide + Topotecan,238,26438783,,,
372,Clinical Study,"In a clinical case study, a non-small cell lung cancer patient harboring EML4-ALK variant 3 that demonstrated resistance to treatment with Xalkori (crizotinib) after acquisition of ALK F1245C, achieved a complete radiographic response with no evidence of progression at 6 months following treatment with Zykadia (ceritinib) (PMID: 26775591).",Actionable,10734,3908,non-small cell lung carcinoma,DOID,27740,EML4-ALK ALK F1245C,sensitive,789,Ceritinib,238,26775591,,,
373,Clinical Study,"In a clinical case study, a non-small cell lung cancer patient harboring EML4-ALK variant 3 demonstrated an initial response to treatment with Xalkori (crizotinib), but progressed after 27 months and was found to have acquired ALK F1245C (PMID: 26775591).",Actionable,10733,3908,non-small cell lung carcinoma,DOID,27740,EML4-ALK ALK F1245C,resistant,706,Crizotinib,238,26775591,,,
374,Preclinical,"In a preclinical study, a transformed cell line expressing ALK F1245C was sensitive to Brigatinib (AP26113) in culture, resulting in cell growth inhibition (PMID: 27049722). ",Actionable,5875,10000003,Advanced Solid Tumor,JAX,1414,ALK F1245C,sensitive,634,AP26113,238,27049722,,,
375,Preclinical - Pdx & cell culture,"In a preclinical study, Xalkori (crizotinib) did not inhibit growth of neuroblastoma cells over expressing ALK F1245C in culture, and only delayed tumor growth in patient-derived xenograft models harboring ALK F1245C (PMID: 26554404).",Actionable,8370,769,neuroblastoma,DOID,1414,ALK F1245C,resistant,706,Crizotinib,238,26554404,,,
376,Preclinical - Pdx & cell culture,"In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of neuroblastoma cells over expressing ALK F1245C in culture, and induced rapid and sustained complete tumor regression in patient-derived xenograft models harboring ALK F1245C (PMID: 26554404).",Actionable,8375,769,neuroblastoma,DOID,1414,ALK F1245C,sensitive,869,PF-06463922,238,26554404,,,
377,Preclinical - Cell culture,"In a preclinical study, Lorlatinib (PF-06463922) inhibited foci formation more efficiently than Xalkori (crizotinib) in transformed cells over expressing ALK F1245C in culture (PMID: 26554404).",Actionable,8384,10000003,Advanced Solid Tumor,JAX,1414,ALK F1245C,sensitive,869,PF-06463922,238,26554404,,,
378,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5367,10000003,Advanced Solid Tumor,JAX,20657,NPM1-ALK ALK T1151M,resistant,789,Ceritinib,238,27009859,,,
379,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5368,10000003,Advanced Solid Tumor,JAX,20657,NPM1-ALK ALK T1151M,resistant,698,Alectinib,238,27009859,,,
380,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5370,10000003,Advanced Solid Tumor,JAX,20657,NPM1-ALK ALK T1151M,resistant,643,ASP3026,238,27009859,,,
381,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to AZD3463 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5371,10000003,Advanced Solid Tumor,JAX,20657,NPM1-ALK ALK T1151M,resistant,1586,AZD3463,238,27009859,,,
382,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to Brigatinib (AP26113) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5369,10000003,Advanced Solid Tumor,JAX,20657,NPM1-ALK ALK T1151M,resistant,634,AP26113,238,27009859,,,
383,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK T1151M were resistant to Zykadia (ceritinib) in culture (PMID: 27009859).",Actionable,5353,50744,anaplastic large cell lymphoma,DOID,20657,NPM1-ALK ALK T1151M,resistant,789,Ceritinib,238,27009859,,,
384,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5366,10000003,Advanced Solid Tumor,JAX,20657,NPM1-ALK ALK T1151M,resistant,706,Crizotinib,238,27009859,,,
385,Preclinical,"In a preclinical study, Xalkori (crizotinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859).",Actionable,5372,10000003,Advanced Solid Tumor,JAX,20656,EML4-ALK ALK T1151M,sensitive,706,Crizotinib,238,27009859,,,
386,Preclinical,"In a preclinical study, transformed cell lines harboring EML4-ALK with ALK T1151M were resistant to ASP3026 in culture (PMID: 27009859).",Actionable,5377,10000003,Advanced Solid Tumor,JAX,20656,EML4-ALK ALK T1151M,resistant,643,ASP3026,238,27009859,,,
387,Preclinical,"In a preclinical study, Alecensa (alectinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859).",Actionable,5373,10000003,Advanced Solid Tumor,JAX,20656,EML4-ALK ALK T1151M,sensitive,698,Alectinib,238,27009859,,,
388,Preclinical,"In a preclinical study, transformed cell lines harboring EML4-ALK with ALK T1151M were resistant to Zykadia (ceritinib) in culture (PMID: 27009859).",Actionable,5376,10000003,Advanced Solid Tumor,JAX,20656,EML4-ALK ALK T1151M,resistant,789,Ceritinib,238,27009859,,,
389,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859).",Actionable,5374,10000003,Advanced Solid Tumor,JAX,20656,EML4-ALK ALK T1151M,sensitive,634,AP26113,238,27009859,,,
390,Preclinical,"In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859).",Actionable,5375,10000003,Advanced Solid Tumor,JAX,20656,EML4-ALK ALK T1151M,sensitive,1586,AZD3463,238,27009859,,,
391,Preclinical,"In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and TP53 P177T in culture (PMID: 26438783).",Actionable,4738,769,neuroblastoma,DOID,18889,"ALK	wild-type TP53 P177T",no benefit,3601,Crizotinib + Cyclophosphamide + Topotecan,238,26438783,,,
392,Preclinical,"In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and TP53 C176F in culture (PMID: 26438783).",Actionable,4737,769,neuroblastoma,DOID,18880,"ALK	wild-type TP53 C176F",no benefit,3601,Crizotinib + Cyclophosphamide + Topotecan,238,26438783,,,
393,Preclinical - Cell line xenograft,"In a preclinical study, TPX-0005 inhibited cell proliferation in transformed cell lines over expressing wild-type ALK in culture and suppressed tumor growth in xenograft models (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).",Actionable,5832,10000003,Advanced Solid Tumor,JAX,391,ALK wild-type,sensitive,3950,TPX-0005,238,None,,,
394,Preclinical - Cell line xenograft,"In a preclinical study, Dalantercept (ACE-041) in combination with Platinol (cisplatin) resulted in decreased tumor growth in cell line xenograft models of breast cancer (PMID: 26373572).",Actionable,5322,1612,breast cancer,DOID,391,ALK wild-type,predicted â€“ sensitive,3834,Dalantercept + Cisplatin,238,26373572,,,
395,Preclinical - Cell line xenograft,"In a preclinical study, Dalantercept (ACE-041) in combination with Adria (doxorubicin) resulted in decreased tumor growth in cell line xenograft models of melanoma, with increased efficacy over either agent alone (PMID: 26373572).",Actionable,5323,1909,melanoma,DOID,391,ALK wild-type,sensitive,3837,Dalantercept + Doxorubicin,238,26373572,,,
396,Phase II,"In a Phase II clinical trial, treatment with Dalantercept (ACE-041) did not demonstrate activity as single agent in recurrent or persistent endometrial cancer, with a median progression-free survival (PFS) of 2.1 months, overall survival of 14.5 months, no objective responses, and stable disease in 57% (16/28) of patients (PMID: 25888978).",Actionable,5320,1380,endometrial cancer,DOID,391,ALK wild-type,no benefit,1244,dalantercept  ,238,25888978,,,
397,Preclinical - Cell culture,"In a preclinical study, Lorlatinib (PF-06463922) did not inhibit growth of ALK wild-type neuroblastoma cells in culture (PMID: 26554404).",Actionable,8380,769,neuroblastoma,DOID,391,ALK wild-type,resistant,869,PF-06463922,238,26554404,,,
398,Preclinical - Cell line xenograft,"In a preclinical study, the addition of Dalantercept (ACE-041) to Platinol (cisplatin) treatment resulted in increased cytoxicity and decreased tumor growth in cell line xenograft models of head and neck cancer (PMID: 26373572).",Actionable,5321,11934,head and neck cancer,DOID,391,ALK wild-type,predicted â€“ sensitive,3834,Dalantercept + Cisplatin,238,26373572,,,
399,Preclinical - Cell line xenograft,"In a preclinical study, Xalkori (crizotinib) did not improve the effect of Topotecan and Cytoxan (cyclophosphamide) on tumor growth suppression in xenograft models of a human neuroblastoma cell line harboring wild-type ALK and TP53 H168R (PMID: 26438783).",Actionable,4734,769,neuroblastoma,DOID,18884,"ALK	wild-type TP53 H168R",no benefit,3601,Crizotinib + Cyclophosphamide + Topotecan,238,26438783,,,
400,Preclinical,"In a preclinical study, Topotecan and Cytoxan (cyclophosphamide) combination treatment resulted in mild  tumor growth suppression in neuroblastoma xenograft models harboring wild-type Alk and TP53 H168R (PMID: 26438783).",Actionable,4742,769,neuroblastoma,DOID,18884,"ALK	wild-type TP53 H168R",not applicable,2590,Cyclophosphamide + Topotecan,238,26438783,,,
401,Preclinical,"In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and wild-type TP53 in culture (PMID: 26438783).",Actionable,4741,769,neuroblastoma,DOID,18892,ALK wild-type TP53 wild-type,no benefit,3601,Crizotinib + Cyclophosphamide + Topotecan,238,26438783,,,
402,Preclinical,"In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and TP53 mutations in culture (PMID: 26438783).",Actionable,4739,769,neuroblastoma,DOID,18890,"ALK	wild-type TP53 mutant",no benefit,3601,Crizotinib + Cyclophosphamide + Topotecan,238,26438783,,,
403,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859), however, in another study comparable cells demonstrated sensitivity (PMID: (PMID: (PMID: 27432227).",Actionable,5328,10000003,Advanced Solid Tumor,JAX,20653,EML4-ALK ALK I1171S,conflicting,789,Ceritinib,238,27009859,27432227,,
404,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5330,10000003,Advanced Solid Tumor,JAX,20653,EML4-ALK ALK I1171S,resistant,698,Alectinib,238,27009859,,,
405,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171S demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).  ",Actionable,8631,10000003,Advanced Solid Tumor,JAX,20653,EML4-ALK ALK I1171S,sensitive,869,PF-06463922,238,27432227,,,
406,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Brigatinib (AP26113) mediated growth inhibition in culture (PMID: 27009859), however, another study with comparable cells demonstrated sensitivity (PMID: 27432227). ",Actionable,5331,10000003,Advanced Solid Tumor,JAX,20653,EML4-ALK ALK I1171S,resistant,634,AP26113,238,27009859,27432227,,
407,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5333,10000003,Advanced Solid Tumor,JAX,20653,EML4-ALK ALK I1171S,resistant,643,ASP3026,238,27009859,,,
408,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to AZD3463 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5336,10000003,Advanced Solid Tumor,JAX,20653,EML4-ALK ALK I1171S,resistant,1586,AZD3463,238,27009859,,,
409,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5325,10000003,Advanced Solid Tumor,JAX,20653,EML4-ALK ALK I1171S,resistant,706,Crizotinib,238,27009859,,,
410,Clinical Study,"In a clinical study, a patient with EML4-ALK positive non-small cell lung cancer initially responded to Alecensa (alectinib) but progressed with the emergence of a secondary ALK I1171S mutation (PMID: 25393796).",Actionable,5391,3908,non-small cell lung carcinoma,DOID,20653,EML4-ALK ALK I1171S,resistant,698,Alectinib,238,25393796,,,
411,Preclinical,"In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing NPM1-ALK with ALK I1171S in culture (PMID: 27009859).",Actionable,5335,10000003,Advanced Solid Tumor,JAX,20654,NPM1-ALK ALK I1171S,sensitive,1586,AZD3463,238,27009859,,,
412,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171S were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5334,10000003,Advanced Solid Tumor,JAX,20654,NPM1-ALK ALK I1171S,resistant,643,ASP3026,238,27009859,,,
413,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited the growth of transformed cells expressing NPM1-ALK with ALK I1171S in culture (PMID: 27009859).",Actionable,5332,10000003,Advanced Solid Tumor,JAX,20654,NPM1-ALK ALK I1171S,sensitive,634,AP26113,238,27009859,,,
414,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171S were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5329,10000003,Advanced Solid Tumor,JAX,20654,NPM1-ALK ALK I1171S,resistant,698,Alectinib,238,27009859,,,
415,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK I1161S were resistant to Xalkori (crizotinib) in culture (PMID: 27009859).",Actionable,5349,50744,anaplastic large cell lymphoma,DOID,20654,NPM1-ALK ALK I1171S,resistant,706,Crizotinib,238,27009859,,,
416,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171S were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5326,10000003,Advanced Solid Tumor,JAX,20654,NPM1-ALK ALK I1171S,resistant,706,Crizotinib,238,27009859,,,
417,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171S were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5327,10000003,Advanced Solid Tumor,JAX,20654,NPM1-ALK ALK I1171S,resistant,789,Ceritinib,238,27009859,,,
418,Preclinical,"In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK were resistant to Brigatinib (AP26113) in culture (PMID: 25421750).",Actionable,3432,50744,anaplastic large cell lymphoma,DOID,13319,NPM1-ALK amp,resistant,634,AP26113,238,25421750,,,
419,Preclinical,"In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK demonstrated a decreased response compared to parental cell lines harboring NPM1-ALK when treated with Alecensa (alectinib) in culture (PMID: 25421750).",Actionable,3427,50744,anaplastic large cell lymphoma,DOID,13319,NPM1-ALK amp,decreased response,698,Alectinib,238,25421750,,,
420,Preclinical,"In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK were resistant to ASP3026 treatment in culture (PMID: 25421750).",Actionable,3431,50744,anaplastic large cell lymphoma,DOID,13319,NPM1-ALK amp,resistant,643,ASP3026,238,25421750,,,
421,Preclinical,"In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK were resistant to Xalkori (crizotinib) treatment in culture (PMID: 25421750).",Actionable,3425,50744,anaplastic large cell lymphoma,DOID,13319,NPM1-ALK amp,resistant,706,Crizotinib,238,25421750,,,
422,Preclinical,"In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750).",Actionable,3426,50744,anaplastic large cell lymphoma,DOID,13319,NPM1-ALK amp,resistant,789,Ceritinib,238,25421750,,,
423,Preclinical,"In a preclinical study, Xalkori (crizotinib) demonstrated synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) in neuroblastoma cell lines harboring Alk amplification and functional TP53, resulting in growth inhibition in culture (PMID: 26438783).",Actionable,4740,769,neuroblastoma,DOID,18891,ALK amp Tp53 wild-type,sensitive,3601,Crizotinib + Cyclophosphamide + Topotecan,238,26438783,,,
424,Preclinical - Cell culture,"In a preclinical study, ALK amplified neuroblastoma cells demonstrated decreased response to Xalkori (crizotinib) induced growth of inhibition in culture (PMID: 26554404).",Actionable,8373,769,neuroblastoma,DOID,1760,ALK amp,decreased response,706,Crizotinib,238,26554404,,,
425,Preclinical - Cell culture,"In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of ALK amplified neuroblastoma cells in culture (PMID: 26554404).",Actionable,8379,769,neuroblastoma,DOID,1760,ALK amp,sensitive,869,PF-06463922,238,26554404,,,
426,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing ALK L1152R in the context of EML4-ALK demonstrated reduced sensitivity to Zykadia (ceritinib) in culture (PMID: 27780853).",Actionable,9268,10000003,Advanced Solid Tumor,JAX,5425,EML4-ALK ALK L1152R,decreased response,789,Ceritinib,238,27780853,,,
427,Preclinical - Cell culture,"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell proliferation of transformed cells over expressing ALK L1152R in the context of EML4-ALK in culture  (PMID: 26144315). ",Actionable,8295,10000003,Advanced Solid Tumor,JAX,5425,EML4-ALK ALK L1152R,sensitive,869,PF-06463922,238,26144315,,,
428,Preclinical,"In preclinical studies, transformed cell lines expressing EML4-ALK L1152R demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 21791641).",Actionable,2144,10000003,Advanced Solid Tumor,JAX,5425,EML4-ALK ALK L1152R,resistant,706,Crizotinib,238,21791641,,,
429,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK L1152R in the context of EML4-ALK in culture (PMID: 27780853).",Actionable,9259,10000003,Advanced Solid Tumor,JAX,5425,EML4-ALK ALK L1152R,sensitive,634,AP26113,238,27780853,,,
0,Preclinical - Cell culture,"In a preclinical study, TASIN-1 inhibited survival of colorectal cancer cells harboring APC L1488* in culture (PMID: 27798265).",Actionable,9090,9256,colorectal cancer,DOID,4327,APC L1488*,sensitive,4896,TASIN-1,324,27798265,,,
1,Preclinical - Cell culture,"In a preclinical study, a colorectal cancer cell line harboring APC  N1819fs*7 and a wild-type copy of APC demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with IWR-1 in culture (PMID: 28179481).",Actionable,10559,9256,colorectal cancer,DOID,27591,APC N1819fs,resistant,2455,IWR-1,324,28179481,,,
2,Preclinical - Cell culture,"In a preclinical study, a colorectal cancer cell line harboring APC  N1819fs (reported as N1819fs*7) and a wild-type copy of APC demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with G007-LK in culture (PMID: 28179481).",Actionable,10552,9256,colorectal cancer,DOID,27619,APC N1819fs APC wild-type,resistant,2991,G007-LK,324,28179481,,,
3,Preclinical - Cell culture,"In a preclinical study, a colorectal cancer cell line harboring APC  N1819fs (reported as N1819fs*7) and a wild-type copy of APC demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with XAV939 in culture (PMID: 28179481).",Actionable,10565,9256,colorectal cancer,DOID,27619,APC N1819fs APC wild-type,resistant,1732,XAV939,324,28179481,,,
4,Preclinical - Cell culture,"In a preclinical study, TASIN-1 inhibited survival of colorectal cancer cell lines harboring APC G11416* in culture (PMID: 27798265).",Actionable,9091,9256,colorectal cancer,DOID,26725,APC G1416*,sensitive,4896,TASIN-1,324,27798265,,,
5,Preclinical - Cell culture,"In a preclinical study, TASIN-1 inhibited survival of colorectal cancer cells harboring APC Q1131* and Q1303* in culture (PMID: 27798265).",Actionable,9088,9256,colorectal cancer,DOID,26729,APC Q1131* APC Q1303*,sensitive,4896,TASIN-1,324,27798265,,,
6,Preclinical,"In a preclinical study, combination of BEZ235 and Binimetinib (MEK162) resulted in reduced tumor growth and additive effect on survival compared to single agent in transgenic animal models of colorectal cancer driven by APC inactivation and KRAS G12D (PMID: 26206338).",Actionable,9200,9256,colorectal cancer,DOID,26771,APC inact mut KRAS G12D,sensitive,4932,BEZ235 + Binimetinib,324,26206338,,,
7,Preclinical,"In a preclinical study, Binimetinib (MEK162) increased apoptosis in tumors and improved survival in transgenic animal models of colorectal cancer driven by APC inactivation and KRAS G12D (PMID: 26206338).",Actionable,9193,9256,colorectal cancer,DOID,26771,APC inact mut KRAS G12D,sensitive,807,Binimetinib,324,26206338,,,
8,Preclinical,"In a preclinical study, BEZ235 inhibited  PI3K/mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC inactivation and KRAS G12D (PMID: 26206338).",Actionable,9190,9256,colorectal cancer,DOID,26771,APC inact mut KRAS G12D,sensitive,672,BEZ235,324,26206338,,,
9,Preclinical,"In a preclinical study, Binimetinib (MEK162) reduced proliferation in tumors acutely but did not improve survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338).",Actionable,9192,9256,colorectal cancer,DOID,26770,APC inact mut PTEN inact mut,no benefit,807,Binimetinib,324,26206338,,,
10,Preclinical,"In a preclinical study, combination of BEZ235 and Binimetinib (MEK162) did not improve survival compared to single agent in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338).",Actionable,9199,9256,colorectal cancer,DOID,26770,APC inact mut PTEN inact mut,no benefit,4932,BEZ235 + Binimetinib,324,26206338,,,
11,Preclinical,"In a preclinical study, BEZ235 inhibited  PI3K/mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338).",Actionable,9189,9256,colorectal cancer,DOID,26770,APC inact mut PTEN inact mut,sensitive,672,BEZ235,324,26206338,,,
12,Preclinical,"In a preclinical study, Binimetinib (MEK162) increased both apoptosis and proliferation in tumors, resulted in no improvement in survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation and KRAS G12D (PMID: 26206338).",Actionable,9194,9256,colorectal cancer,DOID,26772,APC inact mut KRAS G12D PTEN inact mut,no benefit,807,Binimetinib,324,26206338,,,
13,Preclinical,"In a preclinical study, BEZ235 inhibited mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation, and KRAS G12D (PMID: 26206338).",Actionable,9191,9256,colorectal cancer,DOID,26772,APC inact mut KRAS G12D PTEN inact mut,sensitive,672,BEZ235,324,26206338,,,
14,Preclinical,"In a preclinical study, combination of BEZ235 and Binimetinib (MEK162) increased survival compared to single agent in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation and KRAS G12D (PMID: 26206338).",Actionable,9201,9256,colorectal cancer,DOID,26772,APC inact mut KRAS G12D PTEN inact mut,sensitive,4932,BEZ235 + Binimetinib,324,26206338,,,
15,Preclinical,"In a preclinical study, iCRT-5 induced cell-cycle arrest and inhibited proliferation of colon cancer cells harboring APC inactivating mutations in culture (PMID: 21393571).",Actionable,3151,219,colon cancer,DOID,1734,APC inact mut,sensitive,2452,iCRT-5,324,21393571,,,
16,Preclinical,"In a preclinical study, colorectal cancer mouse models carrying APC inactivating mutations had reduced intestinal tumor burden after treatment with Clinoril (sulindac) (PMID: 19755659).",Actionable,1714,9256,colorectal cancer,DOID,1734,APC inact mut,sensitive,2126,Sulindac,324,19755659,,,
17,Preclinical,"In a preclinical study, the combination of Sprycel (dasatinib) and curcumin inhibited tumor growth in a mouse model of colorectal cancer harboring an Apc mutation (PMID: 20473900).",Actionable,1716,9256,colorectal cancer,DOID,1734,APC inact mut,sensitive,717,Dasatinib,324,20473900,,,
18,Preclinical,"In a preclinical study, Caprelsa (vandetanib) reduced the number of dextran sodium sulfate-induced tumors in an APC-deficient mouse model for colon cancer (PMID: 20811697).",Actionable,1029,219,colon cancer,DOID,1734,APC inact mut,sensitive,953,Vandetanib,324,20811697,,,
19,Preclinical,"In a preclinical study, XAV939 inhibited growth of colorectal cancer cells harboring APC inactivating mutations in culture (PMID: 19759537).",Actionable,3122,9256,colorectal cancer,DOID,1734,APC inact mut,sensitive,1732,XAV939,324,19759537,,,
20,Preclinical,"In a preclinical study, iCRT-3 induced cell-cycle arrest and inhibited proliferation of colon cancer cells harboring APC inactivating mutations in culture (PMID: 21393571).",Actionable,3146,219,colon cancer,DOID,1734,APC inact mut,sensitive,2404,iCRT-3,324,21393571,,,
21,Preclinical,"In a preclinical study, CCT036477 inhibited Wnt pathway activation and growth of colorectal cancer cell lines harboring APC inactivating mutations in culture (PMID: 20610623).",Actionable,3143,9256,colorectal cancer,DOID,1734,APC inact mut,sensitive,2398,CCT036477,324,20610623,,,
22,Preclinical,"In a preclinical study, PKF115-584 inhibited proliferation of colorectal cancer cell line harboring an APC inactivating mutation in culture (PMID: 14749129).",Actionable,1726,219,colon cancer,DOID,1734,APC inact mut,sensitive,2081,PKF115-584,324,14749129,,,
23,Preclinical - Cell line xenograft,"In a preclinical study, ibuprofen, in combination with Tarceva (erlotinib), demonstrated efficacy in reducing tumor number and volume in APC inactivating mutant mice and in cell line xenograft models of colorectal cancer (PMID: 17909047).",Actionable,1715,9256,colorectal cancer,DOID,1734,APC inact mut,sensitive,2127,Erlotinib + Ibuprofen,324,17909047,,,
24,Preclinical,"In a preclinical study, ICG-001 decreased cell proliferation in colon cancer cell lines and in mouse models carrying APC inactivating mutations (PMID: 15314234). ",Actionable,1722,219,colon cancer,DOID,1734,APC inact mut,sensitive,2084,ICG-001,324,15314234,,,
25,Preclinical,"In a preclinical study, mouse models of colon cancer carrying an APC 716del mutation had reduced polyp formation after treatment with MF tricyclic (PMID: 23843721).",Actionable,1723,219,colon cancer,DOID,1734,APC inact mut,sensitive,2089,MF tricyclic,324,23843721,,,
26,Preclinical - Cell line xenograft,"In a preclinical study, iCRT-14 induced cell-cycle arrest and inhibited proliferation of colon cancer cells harboring APC inactivating mutations in culture and decreased initial tumor growth in APC-mutant colon cancer cell line xenograft models (PMID: 21393571).",Actionable,3152,219,colon cancer,DOID,1734,APC inact mut,sensitive,2453,iCRT-14,324,21393571,,,
27,Preclinical - Cell line xenograft,"In a preclinical study, NC043 inhibited Wnt pathway activation and growth of colorectal cancer cell lines harboring APC truncation mutations in culture and in cell line xenograft models (PMID: 21321609).",Actionable,3147,9256,colorectal cancer,DOID,1734,APC inact mut,sensitive,2405,NC043,324,21321609,,,
28,Preclinical - Cell line xenograft,"In a preclinical study, TASIN-1 efficiently inhibited survival of colorectal cancer cell lines harboring APC truncation mutations in culture and in cell line xenograft models (PMID: 27798265).",Actionable,9085,9256,colorectal cancer,DOID,1734,APC inact mut,sensitive,4896,TASIN-1,324,27798265,,,
29,Preclinical,"In a preclinical study, Pyrvinium inhibited Wnt signaling and decreased viability of colon cancer cells harboring APC mutations in culture (PMID: 20890287).",Actionable,3150,9256,colorectal cancer,DOID,1734,APC inact mut,sensitive,2412,Pyrvinium,324,20890287,,,
30,Preclinical,"In a preclinical study, StAx-35 inhibited proliferation of colon cancer cell lines carrying APC deletions in culture (PMID: 23071338).",Actionable,1729,219,colon cancer,DOID,1734,APC inact mut,sensitive,2085,StAx-35,324,23071338,,,
31,Preclinical,"In a preclinical study, CCT070535 inhibited Wnt pathway activation and growth of colorectal cancer cell lines harboring APC inactivating mutations in culture (PMID: 20610623).",Actionable,3144,9256,colorectal cancer,DOID,1734,APC inact mut,sensitive,2399,CCT070535,324,20610623,,,
32,Preclinical,"In a preclinical study, Niclosamide inhibited proliferation of colorectal cancer cells harboring APC mutations in culture (PMID: 21531761).",Actionable,3161,9256,colorectal cancer,DOID,1734,APC inact mut,sensitive,3072,Niclosamide,324,21531761,,,
33,Preclinical,"In a preclinical study, JW55 inhibited proliferation of colorectal cancer cells with an APC truncation mutation in culture and decreased tumor development in a mouse model expressing a conditional APC truncation mutation (PMID: 22440753).",Actionable,3149,219,colon cancer,DOID,1734,APC inact mut,sensitive,2411,JW55,324,22440753,,,
34,Preclinical,"In a preclinical study, PKF118-310 inhibited proliferation of colorectal cancer cell line harboring an APC inactivating mutation in culture (PMID: 14749129).",Actionable,3142,9256,colorectal cancer,DOID,1734,APC inact mut,sensitive,2397,PKF118-310,324,14749129,,,
35,Preclinical,"In a preclinical study, FH535 inhibited beta-catenin/TCF-dependent transactivation and demonstrated toxicity in colon carcinoma cells harboring an APC mutation in culture (PMID: 18347139).",Actionable,3140,1520,colon carcinoma,DOID,1734,APC inact mut,sensitive,2083,FH535,324,18347139,,,
36,Preclinical - Cell line xenograft,"In a preclinical study, G007-LK inhibited growth of APC-mutant colorectal cancer cell lines in culture and in xenograft models (PMID: 23539443).",Actionable,3153,219,colon cancer,DOID,1734,APC inact mut,sensitive,2991,G007-LK,324,23539443,,,
37,Preclinical,"In preclinical trials, Sirolimus (rapamycin) was shown effective in reducing tumors in mouse models of familial adenomatous polyposis and colon cancer with APC deficient tumors (PMID: 18768809, PMID: 20080688).",Actionable,1020,219,colon cancer,DOID,1734,APC inact mut,sensitive,917,Sirolimus,324,18768809,20080688,,
38,Preclinical,"In a preclinical study, CGP049090 inhibited proliferation of a colorectal cancer cell line harboring an APC inactivating mutation in culture (PMID: 14749129).",Actionable,1717,219,colon cancer,DOID,1734,APC inact mut,sensitive,2082,CGP049090,324,14749129,,,
39,Preclinical,"In a preclinical study, APC inactivating mutant mouse models of colon cancer had reduced polyp formation after treatment with Celebra (celecoxib) (PMID: 17909047).",Actionable,1713,9256,colorectal cancer,DOID,1734,APC inact mut,sensitive,2124,Celecoxib,324,17909047,,,
40,Preclinical,"In preclinical studies, cells deficient in Apc protein had increased sensitivity to Navelbine (vinorelbine) compared to wild-type cells, and Navelbine (vinorelbine) treament decreased adenoma size in an Apc-deficient mouse model (PMID: 22399804).",Actionable,1024,219,colon cancer,DOID,1734,APC inact mut,sensitive,1685,Vinorelbine,324,22399804,,,
41,Preclinical,"In a preclinical study, CCT031374 inhibited Wnt pathway activation and growth of colorectal cancer cell lines harboring APC inactivating mutations in culture (PMID: 20610623).",Actionable,3145,9256,colorectal cancer,DOID,1734,APC inact mut,sensitive,2400,CCT031374,324,20610623,,,
42,Preclinical - Cell line xenograft,"In a preclinical study, Celebra (celecoxib), in combination with Tarceva (erlotinib), demonstrated efficacy in reducing tumor number and volume in APC inactivating mutant mice and in human colorectal cancer cell line xenograft models (PMID: 17909047).",Actionable,1712,9256,colorectal cancer,DOID,1734,APC inact mut,sensitive,2125,Celecoxib + Erlotinib,324,17909047,,,
43,Preclinical - Cell culture,"In a preclinical study, a colorectal cancer cell line harboring APC E853* and APC T1556fs*3 demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with XAV939 in culture (PMID: 28179481).",Actionable,10567,9256,colorectal cancer,DOID,27597,APC E853* APC T1556fs,resistant,1732,XAV939,324,28179481,,,
44,Preclinical - Cell culture,"In a preclinical study, a colorectal cancer cell line harboring APC E853* and APC T1556fs*3 demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with IWR-1 in culture (PMID: 28179481).",Actionable,10557,9256,colorectal cancer,DOID,27597,APC E853* APC T1556fs,resistant,2455,IWR-1,324,28179481,,,
45,Preclinical - Cell culture,"In a preclinical study, a colorectal cancer cell line harboring APC E853* and APC T1556fs*3 demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with G007-LK in culture (PMID: 28179481).",Actionable,10551,9256,colorectal cancer,DOID,27597,APC E853* APC T1556fs,resistant,2991,G007-LK,324,28179481,,,
46,Preclinical - Cell line xenograft,"In a preclinical study, TASIN-1 efficiently inhibited survival of colorectal cancer cells harboring APC E853* and K1555* in culture and in cell line xenograft models (PMID: 27798265).",Actionable,9087,9256,colorectal cancer,DOID,26728,APC E853* APC K1555*,sensitive,4896,TASIN-1,324,27798265,,,
47,Preclinical - Patient cell culture,"In a preclinical study, G007-LK inhibited growth of a patient-derived colorectal cancer cell line harboring APC I1164fs in culture (PMID: 28179481).",Actionable,10572,9256,colorectal cancer,DOID,27625,APC I1164fs,sensitive,2991,G007-LK,324,28179481,,,
48,Preclinical - Cell culture,"In a preclinical study, IWR-1 inhibited growth of a patient-derived colorectal cancer cell line harboring APC I1164fs in culture (PMID: 28179481).",Actionable,10573,9256,colorectal cancer,DOID,27625,APC I1164fs,sensitive,2455,IWR-1,324,28179481,,,
49,Preclinical - Cell line xenograft,"In a preclinical study, TASIN-1 efficiently inhibited survival of colorectal cancer cells harboring APC E1309* in culture and in cell line xenograft models (PMID: 27798265).",Actionable,9086,9256,colorectal cancer,DOID,4281,APC E1309*,sensitive,4896,TASIN-1,324,27798265,,,
50,Clinical Study,"In a clinical case study, a rectal adenocarcinoma patient harboring APC Q1429fs, BRAF N581S, and ERBB2 L755S did not respond to Herceptin (trastuzumab) treatment in combination with Fluorouracil and Wellcovorin (leucovorin) (PMID: 27626067).",Actionable,9333,1996,rectum adenocarcinoma,DOID,26822,APC Q1429fs BRAF N581S ERBB2 L755S,no benefit,4970,Fluorouracil + Leucovorin + Trastuzumab,324,27626067,,,
51,Preclinical - Pdx,"In a preclinical study, Vantictumab (OMP-18R5) inhibited tumor growth in patient-derived xenograft models of colon cancer with wild-type CTNNB1 (beta-catenin) and APC (PMID: 22753465).",Actionable,7164,219,colon cancer,DOID,24535,APC wild-type CTNNB1 wild-type,predicted â€“ sensitive,4397,Vantictumab,324,22753465,,,
52,Preclinical - Cell line xenograft,"In a preclinical study, TASIN-1 did not inhibit survival of APC wild-type colorectal cancer cells in culture or in cell line xenograft models (PMID: 27798265).",Actionable,9084,9256,colorectal cancer,DOID,508,APC wild-type,resistant,4896,TASIN-1,324,27798265,,,
53,Preclinical - Cell culture,"In a preclinical study, IWR-1 inhibited growth of a patient-derived colorectal cancer cell line harboring APC R216* in culture (PMID: 28179481).",Actionable,10571,9256,colorectal cancer,DOID,4408,APC R216*,sensitive,2455,IWR-1,324,28179481,,,
54,Preclinical - Cell culture,"In a preclinical study, a patient-derived colorectal cancer cell line harboring APC R216* demonstrated sensitivity to G007-LK in culture (PMID: 28179481).",Actionable,10570,9256,colorectal cancer,DOID,4408,APC R216*,sensitive,2991,G007-LK,324,28179481,,,
55,Preclinical - Cell culture,"In a preclinical study, G007-LK inhibited growth of a patient-derived colorectal cancer cell line harboring APC W553* in culture (PMID: 28179481).",Actionable,10575,9256,colorectal cancer,DOID,27627,APC W553*,sensitive,2991,G007-LK,324,28179481,,,
56,Preclinical - Cell culture,"In a preclinical study, IWR-1 inhibited growth of a patient-derived colorectal cancer cell line harboring APC W553* in culture (PMID: 28179481).",Actionable,10574,9256,colorectal cancer,DOID,27627,APC W553*,sensitive,2455,IWR-1,324,28179481,,,
57,Preclinical - Cell culture,"In a preclinical study, treatment with IWR-1 decreased active beta-catenin levels and reduced growth of a colorectal cancer cell line harboring APC S811* in culture (PMID: 28179481).",Actionable,10553,9256,colorectal cancer,DOID,27569,APC S811*,sensitive,2455,IWR-1,324,28179481,,,
58,Preclinical - Cell culture,"In a preclinical study, XAV939 inhibited growth of a colorectal cancer cell line harboring APC S811* in culture (PMID: 28179481).",Actionable,10562,9256,colorectal cancer,DOID,27569,APC S811*,sensitive,1732,XAV939,324,28179481,,,
59,Preclinical - Cell culture,"In a preclinical study, treatment with G007-LK decreased active beta-catenin levels and Tcf/LEF activity, and reduced growth of a colorectal cancer cell line harboring APC S811* in culture (PMID: 28179481).",Actionable,10543,9256,colorectal cancer,DOID,27569,APC S811*,sensitive,2991,G007-LK,324,28179481,,,
60,Preclinical,"In a preclinical study, JW67 inhibited Wnt signaling and decreased proliferation of colorectal cancer cells harboring APC Q1338* in culture (PMID: 21199802).",Actionable,3289,9256,colorectal cancer,DOID,4364,APC Q1338*,sensitive,3103,JW67,324,21199802,,,
61,Preclinical - Cell culture,"In a preclinical study, TASIN-1 inhibited survival of colorectal cancer cell lines harboring APC Q1338* in culture (PMID: 27798265).",Actionable,9089,9256,colorectal cancer,DOID,4364,APC Q1338*,sensitive,4896,TASIN-1,324,27798265,,,
62,Preclinical,"In a preclinical study, JW74 inhibited Wnt signaling and decreased growth of colorectal cancer cells harboring APC Q1338* in culture and in xenograft models (PMID: 21199802).",Actionable,3290,9256,colorectal cancer,DOID,4364,APC Q1338*,sensitive,3104,JW74,324,21199802,,,
63,Preclinical - Cell culture,"In a preclinical study, treatment with IWR-1 decreased active beta-catenin levels and Tcf/LEF activity, and reduced growth of a colorectal cancer cell line harboring APC S1197* and APC S1278* in culture (PMID: 28179481).",Actionable,10554,9256,colorectal cancer,DOID,27595,APC S1197* APC S1278*,sensitive,2455,IWR-1,324,28179481,,,
64,Preclinical - Cell culture,"In a preclinical study, treatment with G007-LK decreased active beta-catenin levels and Tcf/LEF activity, and reduced growth of a colorectal cancer cell line harboring APC S1197* and APC S1278* in culture (PMID: 28179481).",Actionable,10546,9256,colorectal cancer,DOID,27595,APC S1197* APC S1278*,sensitive,2991,G007-LK,324,28179481,,,
65,Preclinical - Cell culture,"In a preclinical study, XAV939 inhibited growth of a colorectal cancer cell line harboring APC S1197* and APC S1278* in culture (PMID: 28179481).",Actionable,10564,9256,colorectal cancer,DOID,27595,APC S1197* APC S1278*,sensitive,1732,XAV939,324,28179481,,,
66,Preclinical - Cell culture,"In a preclinical study, a colorectal cancer cell line harboring APC L665* and APC R1450* demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with XAV939 in culture (PMID: 28179481).",Actionable,10566,9256,colorectal cancer,DOID,27596,APC L665* APC R1450*,sensitive,1732,XAV939,324,28179481,,,
67,Preclinical - Cell culture,"In a preclinical study, a colorectal cancer cell line harboring APC L665* and APC R1450* demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with IWR-1 in culture (PMID: 28179481).",Actionable,10558,9256,colorectal cancer,DOID,27596,APC L665* APC R1450*,sensitive,2455,IWR-1,324,28179481,,,
68,Preclinical - Cell culture,"In a preclinical study, a colorectal cancer cell line harboring APC L665* and APC R1450* demonstrated low levels of Tcf/LEF activity, and was resistant to treatment with G007-LK in culture (PMID: 28179481).",Actionable,10550,9256,colorectal cancer,DOID,27596,APC L665* APC R1450*,resistant,2991,G007-LK,324,28179481,,,
69,Preclinical,"In a preclinical study, a rapamycin-resistant colorectal cancer cell line harboring mutations in APC, BRAF, PIK3CA, SMAD4 and TP53 was sensitive to Sapanisertib (MLN0128) resulting in inhibition of MTORC1 signaling (PMID: 25261369). ",Actionable,2135,9256,colorectal cancer,DOID,5415,APC mut BRAF mut PIK3CA mut SMAD4 mut TP53 mut,sensitive,1282,Sapanisertib,324,25261369,,,
70,Clinical Study,"In a clinical case study, Stivarga (regorafenib) treatment resulted in durable partial response in a colorectal cancer patient harboring KDR R961W and mutations in APC and KRAS (PMID: 27004155).",Actionable,5559,9256,colorectal cancer,DOID,21268,APC mutant KRAS mutant KDR R961W,sensitive,890,Regorafenib,324,27004155,,,
71,Preclinical - Cell line xenograft,"In a preclinical study, G-631 inhibited Wnt pathway signaling in colorectal cancer cell line xenograft models harboring an APC mutation, but demonstrated little anti-tumor activity and led to intestinal toxicity (PMID: 26692561).",Actionable,4287,9256,colorectal cancer,DOID,5414,APC mutant,no benefit,3471,G-631,324,26692561,,,
72,Preclinical,"In a preclinical study, JW74 reduced tumor formation and growth in a mouse model of colorectal cancer harboring an APC mutation (PMID: 21199802).",Actionable,3291,9256,colorectal cancer,DOID,5414,APC mutant,sensitive,3104,JW74,324,21199802,,,
73,Preclinical,"In a preclinical study, K-756 inhibited Wnt signaling and reduced growth of 2/3 tested APC-mutant colorectal cancer cell lines in culture (PMID: 27196752).",Actionable,7260,9256,colorectal cancer,DOID,5414,APC mutant,predicted â€“ sensitive,4427,K-756,324,27196752,,,
0,Clinical Study,"In clinical analyses, mutations in ASXL1 were associated with poor prognosis in patients in patients with myelodysplastic syndrome (PMID: 24220272, PMID: 21714648).",Prognostic,6036,50908,myelodysplastic syndrome,DOID,3486,ASXL1 mutant,not applicable,1776,N/A,171023,24220272,21714648,,
1,Clinical Study,"In a clinical study, myelodysplastic syndrome patients carrying wild-type ASXL1 and TET2 mutations demonstrated increased response to the DNA hypomethylating agents Dacogen (decitabine) or Vidaza (azacitidine) (PMID: 25224413).",Actionable,6169,4972,myelodysplastic/myeloproliferative neoplasm,DOID,22786,ASXL1 wild-type TET2 mutant,sensitive,651,Azacitidine,171023,25224413,,,
2,Clinical Study,"In a clinical study, myelodysplastic syndrome patients carrying wild-type ASXL1 and TET2 mutations demonstrated increased response to the DNA hypomethylating agents Dacogen (decitabine) or Vidaza (azacitidine) (PMID: 25224413).",Actionable,6170,4972,myelodysplastic/myeloproliferative neoplasm,DOID,22786,ASXL1 wild-type TET2 mutant,sensitive,650,Decitabine,171023,25224413,,,
3,Clinical Study,"In multiple clinical studies, nonsense and frameshift mutations in ASXL1 were associated with decreased overall survival in patients with chronic myelomonocytic leukemia (PMID: 26849014, PMID: 23690417, PMID: 20880116).",Prognostic,3320,4972,myelodysplastic/myeloproliferative neoplasm,DOID,22424,ASXL1 inact mut,not applicable,1776,N/A,171023,20880116,26849014,23690417,
0,Preclinical,"In a preclinical study, a KRAS G12D driven lung adenocarcinoma mouse model with homozygous deletion of ATM was sensitive to Lynparza (olaparib), demonstrating reduced tumor volume and greater overall survival when compared to models treated with control (PMID: 28363999).",Actionable,11387,3910,lung adenocarcinoma,DOID,27978,ATM del KRAS G12D,sensitive,837,Olaparib,472,28363999,,,
1,Preclinical,"In a preclinical study, a KRAS G12D driven lung adenocarcinoma mouse model with homozygous deletion of ATM was sensitive to VX-970, demonstrating decreased tumor volume and greater overall survival compared to control treated models (PMID: 28363999). ",Actionable,11388,3910,lung adenocarcinoma,DOID,27978,ATM del KRAS G12D,sensitive,2879,VX-970,472,28363999,,,
2,Clinical Study,"In a clinical case study, addition of Afinitor (everolimus)  to Caprelsa (vandetanib) treatment resulted in significant tumor reduction in a medullary thyroid carcinoma patient harboring ATM L804fs*4, ATM S978fs*12, and RET M918T, that achieved prolonged stable disease on Caprelsa (vandetanib) treatment alone (PMID: 27683183).",Actionable,10637,3973,thyroid medullary carcinoma,DOID,27653,ATM L804fs*4 ATM S978fs*12 RET M918T ,predicted â€“ sensitive,1163,Vandetanib + Everolimus,472,27683183,,,
3,Preclinical,"In a preclinical study, E7449 inhibited proliferation of a ATM-deficient cell line in culture, which demonstrated increased sensitivity compared to cells without DNA repair pathway mutations (PMID: 26513298).",Actionable,6507,10000003,Advanced Solid Tumor,JAX,522,ATM inact mut,sensitive,724,E7449,472,26513298,,,
4,Preclinical - Cell culture,"In a preclinical study, an ATM-deficient cell line demonstrated increased sensitivity to Veliparib (ABT-888) compared to an ATM-reconstituted cell line, in culture (PMID: 21300883).",Actionable,8423,10000003,Advanced Solid Tumor,JAX,522,ATM inact mut,sensitive,954,Veliparib,472,21300883,,,
5,Phase II,"In a Phase II clinical trial, 80% (4/5) of metastatic, castration-resistant prostate cancer patients harboring an ATM inactivating mutation responded to Lynparza (olaparib) (PMID: 26510020).",Actionable,3635,10283,prostate cancer,DOID,522,ATM inact mut,sensitive,837,Olaparib,472,26510020,,,
6,Preclinical - Cell line xenograft,"In a preclinical study, a mantle cell lymphoma cell line with ATM inactivation demonstrated sensitivity to Lynparza (olaparib) in culture and in xenograft models (PMID: 20739657).",Actionable,7681,50746,mantle cell lymphoma,DOID,522,ATM inact mut,sensitive,837,Olaparib,472,20739657,,,
7,Preclinical - Patient cell culture,"In a preclinical study, patient-derived chronic lymphocytic leukemia cells with inactivating mutations in ATM, that had been induced to proliferate in culture, demonstrated increased sensitivity to growth inhibition by Lynparza (olaparib) compared to ATM wild-type cells (PMID: 20739657).",Actionable,7688,1040,chronic lymphocytic leukemia,DOID,522,ATM inact mut,sensitive,837,Olaparib,472,20739657,,,
8,Preclinical - Patient cell culture,"In a preclinical study, lymphoblastoid cell lines with ATM inactivation derived from ataxia-telangiectasia patients demonstrated increased sensitivity to Lynparza (olaparib) in culture, compared to ATM wild-type cell lines (PMID: 20739657).",Actionable,185,1037,lymphoblastic leukemia,DOID,522,ATM inact mut,sensitive,837,Olaparib,472,20739657,,,
9,Preclinical - Cell culture,"In a preclinical study, Lynparza (olaparib) sensitized a mantle cell lymphoma cell line harboring an ATM inactivating mutation to Fludara (fludarabine) in cell culture, resulting in decreased cell survival (PMID: 20739657).",Actionable,7701,50746,mantle cell lymphoma,DOID,522,ATM inact mut,sensitive,4550,Fludarabine + Olaparib,472,20739657,,,
10,Preclinical - Cell culture,"In a preclinical study, Lynparza (olaparib) sensitized a mantle cell lymphoma cell line harboring an ATM inactivating mutation to Treanda (bendamustine) in cell culture, resulting in growth inhibition (PMID: 20739657).",Actionable,7693,50746,mantle cell lymphoma,DOID,522,ATM inact mut,sensitive,4548,Bendamustine + Olaparib,472,20739657,,,
11,Preclinical - Cell culture,"In a preclinical study, the combination of Lynparza (olaparib) an valproic acid worked synergistically to inhibit growth of a mantle cell lymphoma cell line harboring an ATM inactivating mutation in culture (PMID: 20739657).",Actionable,7696,50746,mantle cell lymphoma,DOID,522,ATM inact mut,sensitive,4549,Olaparib + Valproic Acid,472,20739657,,,
12,Preclinical - Cell line xenograft,"In a preclinical study, knockdown of ATM in a gastric cancer cell line resulted in increased sensitivity to Veliparib (ABT-888) in culture and in xenograft models (PMID:  27638859).",Actionable,8422,10534,stomach cancer,DOID,1391,ATM dec exp,sensitive,954,Veliparib,472,27638859,,,
13,Phase II,"In a Phase II trial, addition of Lynparza (olaparib) to Taxol (paclitaxel) did not significantly improve progression free survival (5.29 vs 3.68 months) compared to Taxol alone, but did significantly prolong overall survival (HR = 0.35) in metastatic gastric cancer patients with decreased Atm expression (PMID: 26282658).",Actionable,8766,10534,stomach cancer,DOID,1391,ATM dec exp,predicted â€“ sensitive,4807,Olaparib + Paclitaxel,472,26282658,,,
14,Preclinical,"In a preclinical study, knockdown of ATM expression sensitized breast cancer cells to treatment with Talazoparib (BMN-673) in culture (PMID: 23881923).",Actionable,864,1612,breast cancer,DOID,1391,ATM dec exp,sensitive,682,Talazoparib,472,23881923,,,
15,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Camptosar (irinotecan) and Veliparib (ABT-888) demonstrated synergy in gastric cancer cell lines with high ATM expression, resulting in increased apoptosis in culture, and enhanced tumor growth inhibition in cell line xenograft models (PMID: 27638859).",Actionable,9554,10534,stomach cancer,DOID,26891,ATM over exp,sensitive,3314,Irinotecan + Veliparib,472,27638859,,,
16,Preclinical - Cell culture,"In a preclinical study, high ATM expression was associated with decreased response to Camptosaur (irinotecan) in gastric cancer cell lines in culture (PMID: 27638859).",Actionable,9555,10534,stomach cancer,DOID,26891,ATM over exp,decreased response,1074,Irinotecan,472,27638859,,,
17,Preclinical - Cell culture,"In a preclinical study, high ATM expression was associated with decreased response to Veliparib (ABT-888) in gastric cancer cell lines in culture (PMID: 27638859).",Actionable,9553,10534,stomach cancer,DOID,26891,ATM over exp,decreased response,954,Veliparib,472,27638859,,,
18,Phase II,"In a Phase II clinical trial, 80% (4/5) of metastatic castration-resistant prostate cancer patients with ATM truncation mutations demonstrated response to Lynparza (olaparib) treatment (Cancer Res August 1, 2015 75:CT322).",Actionable,3285,10283,prostate cancer,DOID,3274,ATM mutant,sensitive,837,Olaparib,472,None,,,
19,Clinical Study,"In a clinical study, a melanoma patient harboring an ATM mutation and NRAS Q61R demonstrated a partial response and 16 month progression free survival when treated with Binimetinib (MEK162) (PMID: 28514312). ",Actionable,11054,1909,melanoma,DOID,27905,ATM mut NRAS Q61R,sensitive,807,Binimetinib,472,28514312,,,
20,Preclinical,"In a preclinical study, YU238259 demonstrated increased cytotoxicity in ATM-deficient transformed human cell lines in culture (PMID: 26116172).",Actionable,5531,10000003,Advanced Solid Tumor,JAX,11378,ATM loss,sensitive,3880,YU238259,472,26116172,,,
21,Preclinical,"In a preclinical study, AZD6482 induced cell death in ATM-deficient chronic lymphocytic leukemia cells in culture and inhibited tumor growth in xenograft models (PMID: 26563132).",Actionable,5522,1040,chronic lymphocytic leukemia,DOID,11378,ATM loss,sensitive,659,AZD6482,472,26563132,,,
22,Preclinical,"In a preclinical study, AZD6738 and Platinol (cisplatin) synergistically induced cell death in ATM-deficient non-small cell lung carcinoma cell lines in culture, and caused rapid tumor regression in xenograft models (PMID: 26517239).",Actionable,5520,3908,non-small cell lung carcinoma,DOID,11378,ATM loss,sensitive,3876,AZD6738 + Cisplatin,472,26517239,,,
23,Preclinical,"In a preclinical study, AZD6738 sensitized ATM-deficient chronic lymphocytic leukemia cells to Imbruvica (Ibrutinib) treatment in culture (PMID: 26563132).",Actionable,5524,1040,chronic lymphocytic leukemia,DOID,11378,ATM loss,sensitive,3877,AZD6738 + Ibrutinib,472,26563132,,,
24,Preclinical - Cell culture,"In a preclinical study, the combination of AZD6738 and Lynparza (olaparib) resulted in a synergistic effect, demonstrating cell death in head and neck cancer cells harboring ATM loss in culture (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr C60).",Actionable,11900,11934,head and neck cancer,DOID,11378,ATM loss,predicted â€“ sensitive,4739,AZD6738 + Olaparib,472,None,,,
25,Phase I,"In a Phase I trial, VX-970 treatment resulted in complete response for more than 19 months in a colorectal cancer patient harboring ATM loss (J Clin Oncol 34, 2016 (suppl; abstr 2504)).",Actionable,6709,9256,colorectal cancer,DOID,11378,ATM loss,sensitive,2879,VX-970,472,None,,,
0,Preclinical,"In a preclinical study, E7449 inhibited proliferation of a ATRX-deficient cell line in culture, which demonstrated increased sensitivity compared to cells without DNA repair pathway mutations (PMID: 26513298).",Actionable,6510,10000003,Advanced Solid Tumor,JAX,23602,ATRX inact mut,sensitive,724,E7449,546,26513298,,,
1,Preclinical,"In a preclinical study, loss of ATRX sensitized glioblastoma cell lines to double-stranded DNA-damaging agents, including Adriamycin (doxorubicin), Topotecan, and Camptosar (irinotecan) in culture (PMID: 26936505).",Actionable,6204,3068,glioblastoma multiforme,DOID,22832,ATRX loss,sensitive,942,Topotecan,546,26936505,,,
2,Preclinical,"In a preclinical study, loss of ATRX sensitized glioblastoma cell lines to double-stranded DNA-damaging agents, including Adriamycin (doxorubicin), Topotecan, and Camptosar (irinotecan) in culture (PMID: 26936505).",Actionable,6203,3068,glioblastoma multiforme,DOID,22832,ATRX loss,sensitive,1074,Irinotecan,546,26936505,,,
3,Preclinical,"In a preclinical study, loss of ATRX sensitized glioblastoma cell lines to double-stranded DNA-damaging agents, including Adriamycin (doxorubicin), Topotecan, and Camptosar (irinotecan) in culture (PMID: 26936505).",Actionable,6202,3068,glioblastoma multiforme,DOID,22832,ATRX loss,sensitive,1009,Doxorubicin,546,26936505,,,
4,Phase I,"In a Phase I trial, Gemzar (gemcitabine) plus radiation therapy resulted in median overall survival of 73.5 months in 7 high-grade glioma patients with IDH mutated, non-codeleted tumors with ATRX loss (PMID: 26853339).",Actionable,6205,3070,malignant glioma,DOID,22833,ATRX loss IDH1 mutant,predicted â€“ sensitive,4093,Gemcitabine + Radiotherapy,546,26853339,,,
0,Clinical Study,"In multiple clinical analyses, internal tandem duplications of the BCOR gene were consistently found in clear cell sarcoma of the kidney (PMID: 26098867, PMID: 26516930, PMID: 26573325, PMID: 26150234), suggesting that this may serve as a future diagnostic biomarker.",Emerging,6206,4880,kidney clear cell sarcoma,DOID,22834,BCOR mutant,not applicable,1776,N/A,54880,26098867,26516930,26573325,26150234
1,Clinical Study,"In a clinical case study, a patient with acute promyelocytic leukemia harboring BCOR-RARA demonstrated sensitivity to treatment with Vesanoid (tretinoin) and achieved a complete response (PMID: 25790901). ",Actionable,7912,60318,acute promyelocytic leukemia,DOID,24667,BCOR-RARA,sensitive,1877,Tretinoin  ,54880,25790901,,,
0,Clinical Study,"In a clinical study, BCORL1 over expression was associated with decreased overall survival and recurrence-free survival in patients with hepatocellular carcinoma (PMID: 26879601), suggesting that this may serve as a future prognostic biomarker.",Emerging,6207,684,hepatocellular carcinoma,DOID,22835,BCORL1 over exp,not applicable,1776,N/A,63035,26879601,,,
0,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF K601T (PMID: 26343582).",Actionable,9417,10000003,Advanced Solid Tumor,JAX,3573,BRAF K601T,resistant,342,Vemurafenib,673,26343582,,,
1,Preclinical,"In a preclinical study, CI-1040 (PD184352) inhibited Erk phosphorylation in transformed cells expressing BRAF V600E and the gatekeeper mutation BRAF T529I in culture (PMID: 20538618).",Actionable,6843,10000003,Advanced Solid Tumor,JAX,23818,BRAF V600E BRAF T529I,sensitive,699,CI-1040,673,20538618,,,
2,Preclinical,"In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529I were insensitive to PLX4720-mediated inhibition of ERK signaling in culture (PMID: 20538618).",Actionable,6835,10000003,Advanced Solid Tumor,JAX,23818,BRAF V600E BRAF T529I,predicted â€“ resistant,1060,PLX4720,673,20538618,,,
3,Preclinical,"In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529I were insensitive to SB590885-mediated inhibition of ERK signaling in culture (PMID: 20538618).",Actionable,6826,10000003,Advanced Solid Tumor,JAX,23818,BRAF V600E BRAF T529I,predicted â€“ resistant,4281,SB590885,673,20538618,,,
4,Preclinical,"In a preclinical study, RAF265 inhibited kinase activity in vitro, and downstream Erk phosphorylation in cells expressing BRAF V600E and the gatekeeper mutation BRAF T529I to a similar degree as transformed cells expressing BRAF V600E in culture (PMID: 20538618).",Actionable,6830,10000003,Advanced Solid Tumor,JAX,23818,BRAF V600E BRAF T529I,predicted â€“ sensitive,884,RAF265,673,20538618,,,
5,Preclinical,"In a preclinical study, Nexavar (sorafenib) inhibited kinase activity in vitro, and downstream Erk phosphorylation in cells expressing BRAF V600E and the gatekeeper mutation BRAF T529I to a similar degree as transformed cells expressing BRAF V600E in culture (PMID: 20538618).",Actionable,6840,10000003,Advanced Solid Tumor,JAX,23818,BRAF V600E BRAF T529I,predicted â€“ sensitive,920,Sorafenib,673,20538618,,,
6,Preclinical,"In a preclinical study, LY3009120 modestly inhibited soft agar growth of human melanoma cancer cells harboring NRAS R167L, BRAF K601E, and BRAF A665V in culture (PMID: 26343583).",Actionable,6597,1909,melanoma,DOID,23641,NRAS R167L BRAF K601E BRAF A665V,decreased response,3268,LY3009120,673,26343583,,,
7,Preclinical,"In a preclinical study, human melanoma cells harboring BRAF K601E, BRAF A665V, and NRAS R167L were insensitive to Selumetinib (AZD6244) in culture (PMID: 26343583).",Actionable,6605,1909,melanoma,DOID,23641,NRAS R167L BRAF K601E BRAF A665V,resistant,913,Selumetinib,673,26343583,,,
8,Phase II,"In a Phase II trial, a melanoma patient harboring BRAF K601E demonstrated a partial response and a progression free survival of 32 weeks when treated with Mekinist (trametinib) (PMID: 23248257; NCT01037127).",Actionable,12070,1909,melanoma,DOID,655,BRAF K601E,sensitive,2,Trametinib,673,23248257,,,
9,Clinical Study,"In a clinical case study, a melanoma patient with BRAF K601E demonstrated a 48% reduction in lymphadenopathy when treated with Mekinist (trametinib) and after more than 36 months of treatment showed a complete response (PMID: 28344857). ",Actionable,12068,1909,melanoma,DOID,655,BRAF K601E,sensitive,2,Trametinib,673,28344857,,,
10,Preclinical - Cell culture,"In a preclinical study, the MEK inhibitor, Mekinist (trametinib) decreased activation of MEK and ERK in cells expressing BRAF K601E in culture (PMID: 22798288).",Actionable,697,10000003,Advanced Solid Tumor,JAX,655,BRAF K601E,sensitive,2,Trametinib,673,22798288,,,
11,Preclinical,"In a preclinical study, treatment of cells expressing BRAF K601E with the BRAF inhibitor, Zelboraf (vemurafenib), decreased activation of MEK and ERK (PMID: 22798288).",Actionable,698,10000003,Advanced Solid Tumor,JAX,655,BRAF K601E,conflicting,342,Vemurafenib,673,22798288,,,
12,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF K601E (PMID: 26343582).",Actionable,9408,10000003,Advanced Solid Tumor,JAX,655,BRAF K601E,conflicting,342,Vemurafenib,673,26343582,,,
13,Phase I,"In a Phase I trial, no responses were demonstrated among three melanoma patients with non-V600 BRAF mutations, including two patients harboring BRAF K601E, following treatment with Tafinlar (dabrafenib), compared to a confirmed response rate of 50% in patients harboring BRAF V600 mutations (PMID: 22608338).",Actionable,12069,1909,melanoma,DOID,655,BRAF K601E,no benefit,3,Dabrafenib,673,22608338, 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/22608338'}],,
14,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF K601N (PMID: 26343582).",Actionable,9418,10000003,Advanced Solid Tumor,JAX,2437,BRAF K601N,resistant,342,Vemurafenib,673,26343582,,,
15,Preclinical - Cell culture,"In a preclinical study, a hematological tumor cell line harboring BRAF K601N demonstrated sensitivity to LY3009120 in culture (PMID: 26732095).",Actionable,12071,2531,hematologic cancer,DOID,2437,BRAF K601N,sensitive,3268,LY3009120,673,22798288,,,
16,Preclinical,"Preclinical studies demonstrated the MEK inhibitor, Mekinist (trametinib) caused decreased activation of MEK and ERK in cells expressing BRAF L597S (PMID: 22798288).",Actionable,696,10000003,Advanced Solid Tumor,JAX,994,BRAF L597S,sensitive,2,Trametinib,673,22798288,,,
17,Phase I,"In a Phase I trial, one metastatic melanoma patient carrying a BRAF L597S mutation, had a partial response to the MEK inhibitor, TAK-33 (PMID: 22798288).",Actionable,699,1909,melanoma,DOID,994,BRAF L597S,sensitive,932,TAK-733,673,22798288,,,
18,Preclinical,"In a preclinical study, treatment of cells expressing BRAF L597S with the BRAF inhibitor, Zelboraf (vemurafenib), decreased activation of MEK and ERK (PMID: 22798288).",Actionable,695,10000003,Advanced Solid Tumor,JAX,994,BRAF L597S,sensitive,342,Vemurafenib,673,22798288,,,
19,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF G464R (PMID: 26343582).",Actionable,9412,10000003,Advanced Solid Tumor,JAX,2961,BRAF G464R,resistant,342,Vemurafenib,673,26343582,,,
20,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 V211D in culture (PMID: 28655712).",Actionable,12155,1909,melanoma,DOID,21654,BRAF V600E MAP2K1 V211D,sensitive,342,Vemurafenib,673,28655712,,,
21,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 V211D demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",Actionable,12152,1909,melanoma,DOID,21654,BRAF V600E MAP2K1 V211D,resistant,2,Trametinib,673,28655712,,,
22,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) in culture (PMID: 27312529).",Actionable,7700,9256,colorectal cancer,DOID,21654,BRAF V600E MAP2K1 V211D,resistant,1916,Cetuximab + Encorafenib,673,27312529,,,
23,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Erbitux (cetuximab) combination treatment in culture, likely due to the acquired secondary resistant mutation of MAP2K1 V211D (PMID: 27312529).",Actionable,7629,9256,colorectal cancer,DOID,21654,BRAF V600E MAP2K1 V211D,resistant,4536,Cetuximab + Selumetinib,673,27312529,,,
24,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K V211D demonstrated resistance to growth inhibition by Selumetinib (AZD6244) in cell culture (PMID: 19915144).",Actionable,5821,1909,melanoma,DOID,21654,BRAF V600E MAP2K1 V211D,resistant,913,Selumetinib,673,19915144,,,
25,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib) in culture (PMID: 27312529).",Actionable,7702,9256,colorectal cancer,DOID,21654,BRAF V600E MAP2K1 V211D,resistant,1066,Trametinib + Dabrafenib,673,27312529,,,
26,Preclinical - Cell culture,"In a preclinical study, BVD-523 (Ulixertinib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 V211D in culture (PMID: 28655712). ",Actionable,12158,1909,melanoma,DOID,21654,BRAF V600E MAP2K1 V211D,sensitive,997,BVD-523,673,28655712,,,
27,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).",Actionable,7704,9256,colorectal cancer,DOID,21654,BRAF V600E MAP2K1 V211D,resistant,2618,SCH772984,673,27312529,,,
28,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K V211D demonstrated resistance to growth inhibition by CI-1040 in cell culture (PMID: 19915144).",Actionable,5820,1909,melanoma,DOID,21654,BRAF V600E MAP2K1 V211D,resistant,699,CI-1040,673,19915144,,,
29,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) in culture (PMID: 27312529).",Actionable,7703,9256,colorectal cancer,DOID,21654,BRAF V600E MAP2K1 V211D,resistant,4541,Cetuximab + Dabrafenib + Trametinib,673,27312529,,,
30,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 I111N demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",Actionable,12149,1909,melanoma,DOID,28495,BRAF V600E MAP2K1 I111N,resistant,2,Trametinib,673,28655712,,,
31,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 I111N  in culture (PMID: 28655712).",Actionable,12153,1909,melanoma,DOID,28495,BRAF V600E MAP2K1 I111N,sensitive,342,Vemurafenib,673,28655712,,,
32,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).",Actionable,5956,1909,melanoma,DOID,22037,BRAF V600E NRAS A146T MAP2K1 P387S,resistant,342,Vemurafenib,673,22389471,,,
33,Preclinical,"In a preclinical study, Talfinlar (dabrafenib) in combination with Omipalisib (GSK2126458) did not improve the response to human melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S in culture (PMID: 22389471).",Actionable,5989,1909,melanoma,DOID,22037,BRAF V600E NRAS A146T MAP2K1 P387S,no benefit,4004,Dabrafenib + GSK2126458,673,22389471,,,
34,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were >20-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E and also had reduced sensitivity in comparison to cell lines harboring BRAF V600E and NRAS A146T in culture (PMID: 22389471).",Actionable,5960,1909,melanoma,DOID,22037,BRAF V600E NRAS A146T MAP2K1 P387S,decreased response,2,Trametinib,673,22389471,,,
35,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5966,1909,melanoma,DOID,22037,BRAF V600E NRAS A146T MAP2K1 P387S,decreased response,763,GSK2126458,673,22389471,,,
36,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).",Actionable,5950,1909,melanoma,DOID,22037,BRAF V600E NRAS A146T MAP2K1 P387S,resistant,3,Dabrafenib,673,22389471,,,
37,Preclinical,"In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).",Actionable,5992,1909,melanoma,DOID,22037,BRAF V600E NRAS A146T MAP2K1 P387S,sensitive,3027,GSK2126458 + Trametinib,673,22389471,,,
38,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and SCH772984 in culture (PMID: 27312529).",Actionable,7679,9256,colorectal cancer,DOID,25923,BRAF V600E KRAS G13D,resistant,4543,Cetuximab + SCH772984,673,27312529,,,
39,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7673,9256,colorectal cancer,DOID,25923,BRAF V600E KRAS G13D,resistant,1711,Vemurafenib + Cetuximab,673,27312529,,,
40,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Selumetinib (AZD6244) in culture (PMID: 27312529).",Actionable,7675,9256,colorectal cancer,DOID,25923,BRAF V600E KRAS G13D,resistant,4536,Cetuximab + Selumetinib,673,27312529,,,
41,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Tafinlar (dabrafenib) in culture (PMID: 27312529).",Actionable,7668,9256,colorectal cancer,DOID,25923,BRAF V600E KRAS G13D,resistant,4525,Cetuximab + Dabrafenib,673,27312529,,,
42,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) in culture (PMID: 27312529).",Actionable,7677,9256,colorectal cancer,DOID,25923,BRAF V600E KRAS G13D,resistant,4541,Cetuximab + Dabrafenib + Trametinib,673,27312529,,,
43,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib) in culture (PMID: 27312529).",Actionable,7676,9256,colorectal cancer,DOID,25923,BRAF V600E KRAS G13D,resistant,1066,Trametinib + Dabrafenib,673,27312529,,,
44,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment in culture, likely due to the acquisition of KRAS G13D (PMID: 27312529).",Actionable,7622,9256,colorectal cancer,DOID,25923,BRAF V600E KRAS G13D,resistant,1916,Cetuximab + Encorafenib,673,27312529,,,
45,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).",Actionable,7678,9256,colorectal cancer,DOID,25923,BRAF V600E KRAS G13D,resistant,2618,SCH772984,673,27312529,,,
46,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) in culture (PMID: 27312529).",Actionable,7674,9256,colorectal cancer,DOID,25923,BRAF V600E KRAS G13D,resistant,1917,LGX818 + Cetuximab + BYL719,673,27312529,,,
47,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Erbitux (cetuximab) combination treatment in culture, likely due to the acquired BRAF V600E amplification (PMID: 27312529).",Actionable,7630,9256,colorectal cancer,DOID,25928,BRAF amp BRAF V600E,resistant,4536,Cetuximab + Selumetinib,673,27312529,,,
48,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired BRAF V600E amplification and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7705,9256,colorectal cancer,DOID,25928,BRAF amp BRAF V600E,resistant,1711,Vemurafenib + Cetuximab,673,27312529,,,
49,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired BRAF V600E amplification and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).",Actionable,7706,9256,colorectal cancer,DOID,25928,BRAF amp BRAF V600E,resistant,2618,SCH772984,673,27312529,,,
50,Preclinical - Cell line xenograft,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and growth of colorectal cancer cells harboring BRAF V600E, PIK3CA P449T, and TP53 R273H in culture and in cell line xenograft models, but did not have synergistic effect on apoptosis (PMID: 26272063).",Actionable,8565,9256,colorectal cancer,DOID,26358,BRAF V600E PIK3CA P449T TP53 R273H,sensitive,4771,MLN0128 + PD-0325901,673,26272063,,,
51,Preclinical,"In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529N were insensitive to SB590885 in culture (PMID: 20538618).",Actionable,6833,10000003,Advanced Solid Tumor,JAX,23816,BRAF V600E BRAF T529N,resistant,4281,SB590885,673,20538618,,,
52,Preclinical,"In a preclinical study, CI-1040 (PD184352) inhibited Erk phosphorylation and growth of transformed cells expressing BRAF V600E and the gatekeeper mutation BRAF T529N in culture (PMID: 20538618).",Actionable,6841,10000003,Advanced Solid Tumor,JAX,23816,BRAF V600E BRAF T529N,sensitive,699,CI-1040,673,20538618,,,
53,Preclinical,"In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529N were insensitive to PLX4720 in culture (PMID: 20538618).",Actionable,6837,10000003,Advanced Solid Tumor,JAX,23816,BRAF V600E BRAF T529N,resistant,1060,PLX4720,673,20538618,,,
54,Preclinical,"In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529N were insensitive to Nexavar (sorafenib)-mediated inhibition of Erk phosphorylation but were equally as sensitive to Nexavar (sorafenib)-mediated growth inhibition as transformed cells expressing BRAF V600E in culture (PMID: 20538618).",Actionable,6838,10000003,Advanced Solid Tumor,JAX,23816,BRAF V600E BRAF T529N,conflicting,920,Sorafenib,673,20538618,,,
55,Preclinical,"In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529N were insensitive to RAF265 in culture (PMID: 20538618).",Actionable,6829,10000003,Advanced Solid Tumor,JAX,23816,BRAF V600E BRAF T529N,resistant,884,RAF265,673,20538618,,,
56,Preclinical - Pdx,"In a preclinical study, a melanoma patient-derived xenograft (PDX) model harboring BRAF V600E and PIK3CA H1047K was sensitive to the combination treatment of ARQ092 and Mekinist (trametinib), demonstrating a greater inhibition of tumor growth when compared to either agent alone (PMID: 26469692). ",Actionable,10288,1909,melanoma,DOID,27343,BRAF V600E PIK3CA H1047K,sensitive,5456,ARQ092 + Trametinib,673,26469692,,,
57,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Erbitux (cetuximab) in culture (PMID: 27312529).",Actionable,7639,9256,colorectal cancer,DOID,25926,BRAF V600E EGFR G465R,resistant,694,Cetuximab,673,27312529,,,
58,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Vectibix (panitumumab) in culture (PMID: 27312529).",Actionable,7640,9256,colorectal cancer,DOID,25926,BRAF V600E EGFR G465R,resistant,845,Panitumumab,673,27312529,,,
59,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7694,9256,colorectal cancer,DOID,25926,BRAF V600E EGFR G465R,sensitive,4542,Cetuximab + Dabrafenib + SCH772984,673,27312529,,,
60,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Iressa (gefitinib) and Zelboraf (vemurafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7645,9256,colorectal cancer,DOID,25926,BRAF V600E EGFR G465R,sensitive,1709,Vemurafenib + Gefitinib,673,27312529,,,
61,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Iressa (gefitinib) in culture (PMID: 27312529).",Actionable,7642,9256,colorectal cancer,DOID,25926,BRAF V600E EGFR G465R,resistant,751,Gefitinib,673,27312529,,,
62,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment in culture, likely due to the acquired secondary resistance mutation of EGFR G465R (PMID: 27312529).",Actionable,7627,9256,colorectal cancer,DOID,25926,BRAF V600E EGFR G465R,resistant,1711,Vemurafenib + Cetuximab,673,27312529,,,
63,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Vectibix (panitumumab) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).",Actionable,7643,9256,colorectal cancer,DOID,25926,BRAF V600E EGFR G465R,resistant,1717,Vemurafenib + Panitumumab,673,27312529,,,
64,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7692,9256,colorectal cancer,DOID,25926,BRAF V600E EGFR G465R,sensitive,4544,Dabrafenib + SCH772984,673,27312529,,,
65,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7641,9256,colorectal cancer,DOID,25926,BRAF V600E EGFR G465R,resistant,342,Vemurafenib,673,27312529,,,
66,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E and NRAS A146T were resistant to Tafinlar (dabrafenib) growth inhibition in culture (PMID: 22389471).",Actionable,5951,1909,melanoma,DOID,22042,BRAF V600E NRAS A146T,resistant,3,Dabrafenib,673,22389471,,,
67,Preclinical,"In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E and NRAS A146T in culture, compared to either agent alone (PMID: 22389471).",Actionable,5991,1909,melanoma,DOID,22042,BRAF V600E NRAS A146T,sensitive,3027,GSK2126458 + Trametinib,673,22389471,,,
68,Preclinical,"In a preclinical study, Talfinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E and NRAS A146T in culture, compared to either agent alone (PMID: 22389471).",Actionable,5988,1909,melanoma,DOID,22042,BRAF V600E NRAS A146T,sensitive,4004,Dabrafenib + GSK2126458,673,22389471,,,
69,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E and NRAS A146T were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).",Actionable,5955,1909,melanoma,DOID,22042,BRAF V600E NRAS A146T,resistant,342,Vemurafenib,673,22389471,,,
70,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E and NRAS A146T had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5965,1909,melanoma,DOID,22042,BRAF V600E NRAS A146T,decreased response,763,GSK2126458,673,22389471,,,
71,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E and NRAS A146T were >10-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5959,1909,melanoma,DOID,22042,BRAF V600E NRAS A146T,decreased response,2,Trametinib,673,22389471,,,
72,Preclinical,"In a preclinical study, Tafinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of melanoma cell lines harboring BRAF V600E and NRAS A146T in culture, compared to either agent alone (PMID: 22389471).",Actionable,5977,1909,melanoma,DOID,22042,BRAF V600E NRAS A146T,sensitive,1066,Trametinib + Dabrafenib,673,22389471,,,
73,Preclinical - Cell line xenograft,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring BRAF V600E and PTEN loss in culture and in cell line xenograft models (PMID: 26272063).",Actionable,8569,9256,colorectal cancer,DOID,26362,BRAF V600E PTEN loss TP53 wild-type,sensitive,4771,MLN0128 + PD-0325901,673,26272063,,,
74,Preclinical - Cell culture,"In a preclinical study, over expression of wild type EGFR in colorectal cancer cells harboring BRAF V600E resulted in sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).",Actionable,7631,9256,colorectal cancer,DOID,25929,BRAF V600E EGFR over exp,resistant,3773,Selumetinib + Vemurafenib,673,27312529,,,
75,Preclinical - Cell line xenograft,"In a preclinical study, a colorectal cancer cell line xenograft model co-harboring BRAF V600E and a PIK3CA mutation demonstrated tumor growth inhibition when treated with ASN003 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B100).",Actionable,11042,9256,colorectal cancer,DOID,27895,BRAF V600E PIK3CA mut,sensitive,5827,ASN003,673,None,,,
76,Preclinical,"In a preclinical study, Nexavar (sorafenib) inhibited kinase activity in vitro, and downstream Erk phosphorylation in cells expressing BRAF V600E and the gatekeeper mutation BRAF T529M to a similar degree as transformed cells expressing BRAF V600E in culture (PMID: 20538618).",Actionable,6839,10000003,Advanced Solid Tumor,JAX,23817,BRAF V600E BRAF T529M,predicted â€“ sensitive,920,Sorafenib,673,20538618,,,
77,Preclinical,"In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529M were insensitive to PLX4720-mediated inhibition of ERK signaling in culture (PMID: 20538618).",Actionable,6834,10000003,Advanced Solid Tumor,JAX,23817,BRAF V600E BRAF T529M,predicted â€“ resistant,1060,PLX4720,673,20538618,,,
78,Preclinical,"In a preclinical study, CI-1040 (PD184352) inhibited Erk phosphorylation in transformed cells expressing BRAF V600E and the gatekeeper mutation BRAF T529M in culture (PMID: 20538618).",Actionable,6842,10000003,Advanced Solid Tumor,JAX,23817,BRAF V600E BRAF T529M,predicted â€“ sensitive,699,CI-1040,673,20538618,,,
79,Preclinical,"In a preclinical study, RAF265 inhibited kinase activity in vitro, and downstream Erk phosphorylation in cells expressing BRAF V600E and the gatekeeper mutation BRAF T529M to a similar degree as transformed cells expressing BRAF V600E in culture (PMID: 20538618).",Actionable,6831,10000003,Advanced Solid Tumor,JAX,23817,BRAF V600E BRAF T529M,predicted â€“ sensitive,884,RAF265,673,20538618,,,
80,Preclinical,"In a preclinical study, transformed cells expressing BRAF V600E and the gatepkeeper mutation BRAF T529M were insensitive to SB590885-mediated inhibition of ERK signaling in culture (PMID: 20538618).",Actionable,6828,10000003,Advanced Solid Tumor,JAX,23817,BRAF V600E BRAF T529M,predicted â€“ resistant,4281,SB590885,673,20538618,,,
81,Preclinical - Cell culture,"In a preclinical study, expression of MAP2K1 K57E in a melanoma cell line harboring BRAF V600E conferred resistance to Tafinlar (dabrafenib) in culture (PMID: 25370473).",Actionable,7592,1909,melanoma,DOID,25914,BRAF V600E MAP2K1 K57E,resistant,3,Dabrafenib,673,25370473,,,
82,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124L demonstrated a decreased response to treatment with Zelboraf (vemurafenib) in culture (PMID: 28655712).",Actionable,12163,1909,melanoma,DOID,28498,BRAF V600E MAP2K1 P124L,decreased response,342,Vemurafenib,673,28655712,,,
83,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124L demonstrated a decreased response to treatment with Mekinist (trametinib) in culture (PMID: 28655712). ",Actionable,12162,1909,melanoma,DOID,28498,BRAF V600E MAP2K1 P124L,decreased response,2,Trametinib,673,28655712,,,
84,Preclinical - Pdx,"In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib)  combination treatment did not result in enhanced antitumor activity compared to Ibrance (palbociclib) alone in PDX models of KRAS wild-type colorectal cancer harboring BRAF V600E (PMID: 26369631).",Actionable,5623,9256,colorectal cancer,DOID,21304,BRAF V600E KRAS wild-type,no benefit,1368,Palbociclib + Trametinib,673,26369631,,,
85,Preclinical,"In a preclinical study, human colorectal cancer cells harboring BRAF V600E and PIK3CA P449T were resistant to Erbitux (cetuximab) in culture (PMID: 25838391).",Actionable,4936,9256,colorectal cancer,DOID,19841,BRAF V600E PIK3CA P449T,resistant,694,Cetuximab,673,25838391,,,
86,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).",Actionable,8204,9256,colorectal cancer,DOID,19841,BRAF V600E PIK3CA P449T,sensitive,4657,Pimasertib + Regorafenib,673,23629727,,,
87,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).",Actionable,8194,9256,colorectal cancer,DOID,19841,BRAF V600E PIK3CA P449T,sensitive,4656,Everolimus + Pimasertib,673,23629727,,,
88,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).",Actionable,8189,9256,colorectal cancer,DOID,19841,BRAF V600E PIK3CA P449T,sensitive,871,Pimasertib,673,23629727,,,
89,Preclinical,"In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis of human colorectal cancer cell lines harboring BRAF V600E and PIK3CA P449T in culture (PMID: 25838391).",Actionable,4950,9256,colorectal cancer,DOID,19841,BRAF V600E PIK3CA P449T,sensitive,1305,Regorafenib + Cetuximab,673,25838391,,,
90,Preclinical,"In a preclinical study, human colorectal cancer cells harboring BRAF V600E and PIK3CA P449T were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).",Actionable,4940,9256,colorectal cancer,DOID,19841,BRAF V600E PIK3CA P449T,resistant,890,Regorafenib,673,25838391,,,
91,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).",Actionable,8199,9256,colorectal cancer,DOID,19841,BRAF V600E PIK3CA P449T,sensitive,1659,Pimasertib + Sorafenib,673,23629727,,,
92,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment in culture, likely due to the acquisition of KRAS G12D (PMID: 27312529).",Actionable,7626,9256,colorectal cancer,DOID,25922,BRAF V600E KRAS G12D,resistant,1711,Vemurafenib + Cetuximab,673,27312529,,,
93,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a KRAS G12D mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7691,9256,colorectal cancer,DOID,25922,BRAF V600E KRAS G12D,sensitive,4543,Cetuximab + SCH772984,673,27312529,,,
94,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a KRAS G12D mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7690,9256,colorectal cancer,DOID,25922,BRAF V600E KRAS G12D,sensitive,4541,Cetuximab + Dabrafenib + Trametinib,673,27312529,,,
95,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G12D mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) in culture (PMID: 27312529).",Actionable,7689,9256,colorectal cancer,DOID,25922,BRAF V600E KRAS G12D,resistant,1917,LGX818 + Cetuximab + BYL719,673,27312529,,,
96,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).",Actionable,7005,1909,melanoma,DOID,24283,BRAF V600E MAP2K1 G128V,sensitive,4351,VRT11E,673,24265153,,,
97,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).",Actionable,7058,1909,melanoma,DOID,24283,BRAF V600E MAP2K1 G128V,resistant,3,Dabrafenib,673,24265153,,,
98,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated resistance to treatment with Mekinist (trametinib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).",Actionable,7059,1909,melanoma,DOID,24283,BRAF V600E MAP2K1 G128V,resistant,2,Trametinib,673,24265153,,,
99,Preclinical,"In a preclinical study, MAP2K1 G128V conferred resistance to the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF V600E-mutant melanoma cells in culture (PMID: 24265154).",Actionable,7033,1909,melanoma,DOID,24283,BRAF V600E MAP2K1 G128V,resistant,1066,Trametinib + Dabrafenib,673,24265154,,,
100,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS A146V and A146T mutations and subsequent resistance to Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7698,9256,colorectal cancer,DOID,25927,BRAF V600E KRAS A146T KRAS A146V,resistant,1711,Vemurafenib + Cetuximab,673,27312529,,,
101,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS A146V and A146T mutations and subsequent resistance to Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Selumetinib (AZD6244) in culture (PMID: 27312529).",Actionable,7699,9256,colorectal cancer,DOID,25927,BRAF V600E KRAS A146T KRAS A146V,resistant,4536,Cetuximab + Selumetinib,673,27312529,,,
102,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS A146V and A146T mutations and subsequent resistance to Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) in culture (PMID: 27312529).",Actionable,7695,9256,colorectal cancer,DOID,25927,BRAF V600E KRAS A146T KRAS A146V,resistant,1916,Cetuximab + Encorafenib,673,27312529,,,
103,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to combination treatment consisting of Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) in culture, likely due to the acquisition of KRAS A146V and A146T secondary resistance mutations (PMID: 27312529).",Actionable,7628,9256,colorectal cancer,DOID,25927,BRAF V600E KRAS A146T KRAS A146V,resistant,1917,LGX818 + Cetuximab + BYL719,673,27312529,,,
104,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS A146V and A146T mutations and subsequent resistance to Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Tafinlar (dabrafenib) in culture (PMID: 27312529).",Actionable,7697,9256,colorectal cancer,DOID,25927,BRAF V600E KRAS A146T KRAS A146V,resistant,4525,Cetuximab + Dabrafenib,673,27312529,,,
105,Preclinical - Cell culture,"In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P124Q demonstrated decreased sensitivity to Tafinlar (dabrafenib) in cell culture (PMID: 25370473).",Actionable,7593,1909,melanoma,DOID,25915,BRAF V600E MAP2K1 P124Q,decreased response,3,Dabrafenib,673,25370473,,,
106,Preclinical,"In a preclinical study, E6201 inhibited Mapk pathway activation and proliferation of melanoma cell line harboring BRAF V600E mutation and overexpressing MAP2K1 C121S in culture (PMID: 24448821).",Actionable,4029,1909,melanoma,DOID,17135,BRAF V600E MAP2K1 C121S,sensitive,1011,E6201,673,24448821,,,
107,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 C121S demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",Actionable,12159,1909,melanoma,DOID,17135,BRAF V600E MAP2K1 C121S,resistant,2,Trametinib,673,28655712,,,
108,Preclinical,"In a preclinical study, MAP2K1 C121S conferred resistance to the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF V600E-mutant melanoma cells in culture (PMID: 24265154).",Actionable,7032,1909,melanoma,DOID,17135,BRAF V600E MAP2K1 C121S,resistant,1066,Trametinib + Dabrafenib,673,24265154,,,
109,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 C121S demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).",Actionable,7003,1909,melanoma,DOID,17135,BRAF V600E MAP2K1 C121S,sensitive,4351,VRT11E,673,24265153,,,
110,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E mutation and overexpressing MAP2K1 C121S were less sensitive than those overexpressing wild-type MAP2K1 to Selumetinib (AZD6244)-induced inhibition of Mapk pathway activation and cell proliferation in culture (PMID: 24448821).",Actionable,4031,1909,melanoma,DOID,17135,BRAF V600E MAP2K1 C121S,decreased response,913,Selumetinib,673,24448821,,,
111,Clinical Study,"In a clinical case study, a patient harboring BRAF V600E demonstrated an initial response to treatment with Zelboraf (vemurafenib), but progressed following emergence of a MAP2K1 C121S mutation (PMID: 21383288).",Actionable,7037,1909,melanoma,DOID,17135,BRAF V600E MAP2K1 C121S,decreased response,342,Vemurafenib,673,21383288,,,
112,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E mutation and overexpressing MAP2K1 C121S were less sensitive than those overexpressing wild-type MAP2K1 to Zelboraf (vemurafenib)-induced inhibition of Mapk pathway activation and cell proliferation in culture (PMID: 24448821).",Actionable,4030,1909,melanoma,DOID,17135,BRAF V600E MAP2K1 C121S,decreased response,342,Vemurafenib,673,24448821,,,
113,Preclinical,"In a preclinical study, expression of MAP2K1 C121S conferred resistance to PLX4720 in melanoma cells harboring BRAF V600E in culture (PMID: 21383288).",Actionable,7038,1909,melanoma,DOID,17135,BRAF V600E MAP2K1 C121S,resistant,1060,PLX4720,673,21383288,,,
114,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5968,1909,melanoma,DOID,22046,BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S,decreased response,763,GSK2126458,673,22389471,,,
115,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S were resistant Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).",Actionable,5954,1909,melanoma,DOID,22046,BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S,resistant,3,Dabrafenib,673,22389471,,,
116,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S were resistant to growth inhibition by Mekinist (trametinib) in culture (PMID: 22389471).",Actionable,5963,1909,melanoma,DOID,22046,BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S,resistant,2,Trametinib,673,22389471,,,
117,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, A146T and MAP2K1 P387S were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).",Actionable,5958,1909,melanoma,DOID,22046,BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S,resistant,342,Vemurafenib,673,22389471,,,
118,Preclinical,"In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).",Actionable,5994,1909,melanoma,DOID,22046,BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S,sensitive,3027,GSK2126458 + Trametinib,673,22389471,,,
119,Clinical Study,"In a clinical case study, a melanoma patient harboring BRAF V600E  treated with Zelboraf (vemurafenib) subsequently demonstrated resistance likely due to the secondary resistance mutation, BRAF L505H (PMID: 25515853).",Actionable,3564,1909,melanoma,DOID,13538,BRAF V600E BRAF L505H,resistant,342,Vemurafenib,673,25515853,,,
120,Preclinical - Cell culture,"In a preclinical study, BVD-523 (ulixertinib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 E203K in culture (PMID: 28655712). ",Actionable,12166,1909,melanoma,DOID,28497,BRAF V600E MAP2K1 E203K,sensitive,997,BVD-523,673,28655712,,,
121,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 E203K demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",Actionable,12160,1909,melanoma,DOID,28497,BRAF V600E MAP2K1 E203K,resistant,2,Trametinib,673,28655712,,,
122,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 E203K demonstrated resistance to treatment with Zelboraf (vemurafenib) in culture (PMID: 28655712).",Actionable,12161,1909,melanoma,DOID,28497,BRAF V600E MAP2K1 E203K,resistant,342,Vemurafenib,673,28655712,,,
123,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E treated with Selumetinib (AZD6244) in culture demonstrated resistance, which was a result of the resistance mutation, MAP2K1 H119P (PMID: 19915144).",Actionable,6895,1909,melanoma,DOID,23996,BRAF V600E MAP2K1 H119P,resistant,913,Selumetinib,673,19915144,,,
124,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment in culture, likely due to the acquired KRAS amplification (PMID: 27312529).",Actionable,7625,9256,colorectal cancer,DOID,25925,BRAF V600E KRAS amp,resistant,4525,Cetuximab + Dabrafenib,673,27312529,,,
125,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS amplification and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) in culture (PMID: 27312529).",Actionable,7683,9256,colorectal cancer,DOID,25925,BRAF V600E KRAS amp,resistant,1916,Cetuximab + Encorafenib,673,27312529,,,
126,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS amplification and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to combination therapy consisting of Tafinlar (dabrafenib) and SCH772984 in culture (PMID: 27312529).",Actionable,7686,9256,colorectal cancer,DOID,25925,BRAF V600E KRAS amp,resistant,4544,Dabrafenib + SCH772984,673,27312529,,,
127,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS amplification and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).",Actionable,7685,9256,colorectal cancer,DOID,25925,BRAF V600E KRAS amp,resistant,2618,SCH772984,673,27312529,,,
128,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS amplification and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7684,9256,colorectal cancer,DOID,25925,BRAF V600E KRAS amp,resistant,1711,Vemurafenib + Cetuximab,673,27312529,,,
129,Preclinical,"In a preclinical study, over expression of BRAF V600E in KRAS-mutant colorectal cancer cells resulted in resistance to growth inhibition by PD-0325901 in cell culture (PMID: 26267534).",Actionable,5813,9256,colorectal cancer,DOID,21629,BRAF V600E KRAS mutant,resistant,849,PD-0325901,673,26267534,,,
130,Preclinical - Cell culture,"In a preclinical study, DEL-22379 inhibited growth of KRAS-mutant melanoma cells over expressing BRAF V600E in culture (PMID: 26267534).",Actionable,5815,9256,colorectal cancer,DOID,21629,BRAF V600E KRAS mutant,sensitive,3769,DEL-22379,673,26267534,,,
131,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were >20-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5962,1909,melanoma,DOID,22043,BRAF V600E NRAS Q61K MAP2K1 P387S,decreased response,2,Trametinib,673,22389471,,,
132,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5967,1909,melanoma,DOID,22043,BRAF V600E NRAS Q61K MAP2K1 P387S,decreased response,763,GSK2126458,673,22389471,,,
133,Preclinical,"In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E, NRAS Q61K, and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).",Actionable,5993,1909,melanoma,DOID,22043,BRAF V600E NRAS Q61K MAP2K1 P387S,sensitive,3027,GSK2126458 + Trametinib,673,22389471,,,
134,Preclinical,"In a preclinical study, the response of human melanoma cell lines harboring BRAF V600E, NRAS Q61K, and MAP2K1 P387S to Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) was conflicting as one cell line with this mutation profile responded to the combination and another cell line with the mutation profile did not (PMID: 22389471).",Actionable,5990,1909,melanoma,DOID,22043,BRAF V600E NRAS Q61K MAP2K1 P387S,conflicting,4004,Dabrafenib + GSK2126458,673,22389471,,,
135,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).",Actionable,5952,1909,melanoma,DOID,22043,BRAF V600E NRAS Q61K MAP2K1 P387S,resistant,3,Dabrafenib,673,22389471,,,
136,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were resistant to growth inhibition by Zelboraf (vemurafenib) in culture (PMID: 22389471).",Actionable,5961,1909,melanoma,DOID,22043,BRAF V600E NRAS Q61K MAP2K1 P387S,resistant,342,Vemurafenib,673,22389471,,,
137,Preclinical,"In a preclinical study, over expression of MAPK21 I103N in melanoma cells harboring BRAF V600E resulted in insensitivity to growth inhibition by PD-0325901 in cell culture (PMID: 26267534).",Actionable,5811,1909,melanoma,DOID,21628,BRAF V600E MAP2K1 I103N,resistant,849,PD-0325901,673,26267534,,,
138,Preclinical - Cell culture,"In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I103N in culture (PMID: 26267534).",Actionable,5816,1909,melanoma,DOID,21628,BRAF V600E MAP2K1 I103N,sensitive,3769,DEL-22379,673,26267534,,,
139,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E expressing NRAS Q61K were resistant to Tafinlar (dabrafenib) mediated growth inhibition and retained MEK and ERK signaling (PMID: 22389471).",Actionable,5949,1909,melanoma,DOID,6906,BRAF V600E NRAS Q61K,resistant,3,Dabrafenib,673,22389471,,,
140,Preclinical,"In a preclinical study, treatment with XL888 resulted in increased apoptosis and decreased growth of Zelboraf (vemurafenib)-resistant melanoma cells harboring BRAF V600E along with NRAS Q61K in cell culture (PMID: 22351686).",Actionable,2275,1909,melanoma,DOID,6906,BRAF V600E NRAS Q61K,sensitive,970,XL888,673,22351686,,,
141,Preclinical,"In a preclinical study, a NRAS Q61K mutation conferred resistance to Zelboraf (vemurafenib) in melanoma cells harboring BRAF V600E in culture (PMID: 21107323).",Actionable,2279,1909,melanoma,DOID,6906,BRAF V600E NRAS Q61K,resistant,342,Vemurafenib,673,21107323,,,
142,Preclinical,"In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of melanoma cell lines harboring BRAF V600E and NRAS Q61K in culture, compared to either agent alone (PMID: 22389471).",Actionable,5978,1909,melanoma,DOID,6906,BRAF V600E NRAS Q61K,sensitive,1066,Trametinib + Dabrafenib,673,22389471,,,
143,Preclinical,"In a preclinical study, melanoma cells harboring the MAP2K1 Q56P mutation in the presence of BRAF V600E were resistant to the MEK inhibitor selumetinib (AZD6244) cell culture.",Actionable,183,1909,melanoma,DOID,520,MAP2K1 Q56P BRAF V600E,resistant,913,Selumetinib,673,19915144,,,
144,Preclinical,"In a preclinical study, combined treatment with selumetinib and PLX4720 strongly suppressed the emergence of resistant MAP2K1 mutations in BRAF V600E cells in culture (PMID: 19915144).",Actionable,506,1909,melanoma,DOID,520,MAP2K1 Q56P BRAF V600E,sensitive,1061,Selumetinib + PLX4720,673,19915144,,,
145,Preclinical,"In a preclinical study, melanoma cells harboring the MAP2K1 Q56P mutation in the presence of BRAF V600E were resistant to the B-RAF inhibitor PLX4720 in culture (PMID: 19915144).",Actionable,505,1909,melanoma,DOID,520,MAP2K1 Q56P BRAF V600E,resistant,1060,PLX4720,673,19915144,,,
146,Preclinical,"In a preclinical study, expression of NRAS G12V in melanoma cells harboring BRAF V600E conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 26267534).",Actionable,5785,1909,melanoma,DOID,21619,BRAF V600E NRAS G12V,resistant,342,Vemurafenib,673,26267534,,,
147,Preclinical - Cell culture,"In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and over expressing NRAS G12V in culture (PMID: 26267534).",Actionable,5786,1909,melanoma,DOID,21619,BRAF V600E NRAS G12V,sensitive,3769,DEL-22379,673,26267534,,,
148,Preclinical - Cell line xenograft,"In a preclinical study, a melanoma cell line xenograft model co-harboring BRAF V600E and a PTEN mutation demonstrated tumor growth inhibition when treated with ASN003 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B100).",Actionable,11043,1909,melanoma,DOID,27896,BRAF V600E PTEN mut,sensitive,5827,ASN003,673,None,,,
149,Phase II,"In a Phase II study, Nexavar (sorafenib) displayed negligible efficacy in melanoma patients with BRAF V600E mutations (PMID: 16880785, PMID: 22394203).",Actionable,509,1909,melanoma,DOID,1,BRAF V600E,no benefit,920,Sorafenib,673,22394203,16880785,,
150,Phase I,"In a Phase I trial, BGB-283 resulted in partial response in 1 thyroid cancer patient harboring BRAF V600E, who remained on treatment for over 481 days (AACR Annual Meeting, Apr 2016, abstract # CT005).",Actionable,7231,1781,thyroid cancer,DOID,1,BRAF V600E,sensitive,4025,BGB-283,673,None,,,
151,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture (PMID: 23629727).",Actionable,8188,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,871,Pimasertib,673,23629727,,,
152,Preclinical,"In a preclinical study, saracatinib inhibited proliferation of human melanoma cell lines harboring BRAF V600E that are resistant to Braf inhibition in culture (PMID: 23242808).",Actionable,3336,1909,melanoma,DOID,1,BRAF V600E,sensitive,912,Saracatinib,673,23242808,,,
153,Preclinical - Pdx,"In a preclinical study, DEL-22379 inhibited tumor growth in a colorectal adenocarcinoma patient-derived xenograft model harboring BRAF V600E (PMID: 26267534).",Actionable,5780,50861,colorectal adenocarcinoma,DOID,1,BRAF V600E,sensitive,3769,DEL-22379,673,26267534,,,
154,Preclinical,"In a preclinical study, PD-0325901 inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 26267534).",Actionable,5777,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,849,PD-0325901,673,26267534,,,
155,Preclinical - Cell line xenograft,"In a preclinical study, PLX4720 and TAK-632 combination treatment resulted in durable inhibition of Erk signaling and tumor growth in xenograft models of colorectal cancer cells harboring BRAF V600E (PMID: 27523909). ",Actionable,7966,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,4607,PLX4720 + TAK-632,673,27523909,,,
156,Preclinical,"In a preclinical study, SBI-755199 induced cell death in human melanoma cell lines harboring BRAF V600E in culture (PMID: 26603897).",Actionable,3789,1909,melanoma,DOID,1,BRAF V600E,sensitive,3309,SBI-755199,673,26603897,,,
157,Preclinical,"In a preclinical study, colorectal cancer cells harboring a BRAF V600E mutation had increased sensitivity to Mekinist (trametinib) compared to other colorectal cancer lines in culture (PMID: 25309914).",Actionable,1319,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,2,Trametinib,673,25309914,,,
158,Preclinical - Cell line xenograft,"In a preclinical study, treatment with Ibrance (palbociclib) in a melanoma cell line xenograft model harboring BRAF V600E resulted in no benefit, demonstrating low but continuous growth (PMID: 27488531). ",Actionable,8548,1909,melanoma,DOID,1,BRAF V600E,no benefit,850,Palbociclib,673,27488531,,,
159,Preclinical - Cell culture,"In a preclinical study, Mekinist (trametinib) inhibited growth of both parental thyroid cancer cell lines harboring BRAF V600E and those acquired Sprycel (dasatinib)-resistance in culture (PMID: 27222538).",Actionable,7838,1781,thyroid cancer,DOID,1,BRAF V600E,predicted â€“ sensitive,2,Trametinib,673,27222538,,,
160,Preclinical - Cell line xenograft,"In a preclinical study, the combination treatment of PD-0325901 and Ibrance (palbociclib) resulted in significant tumor regression in melanoma cell line xenograft models harboring BRAF V600E and demonstrated a 56% (5/9) complete response rate (PMID: 27488531). ",Actionable,8549,1909,melanoma,DOID,1,BRAF V600E,sensitive,1823,PD-0325901 + Palbociclib,673,27488531,,,
161,Phase II,"In a Phase II trial, a favorable response rate to selumetinib (AZD6244) was observed in mutant BRAF but not BRAF wild-type melanoma patients (PMID: 22048237).",Actionable,1131,1909,melanoma,DOID,1,BRAF V600E,sensitive,913,Selumetinib,673,22048237,,,
162,Preclinical - Cell line xenograft,"In preclinical studies, Encorafenib (LGX818) treatment of human melanoma xenograft models with BRAF V600E significantly decreased Mek activation and resulted in tumor regression (Cancer Res: 72(8) Suppl 1, Abstract #3790). ",Actionable,686,1909,melanoma,DOID,1,BRAF V600E,sensitive,796,Encorafenib,673,None,,,
163,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture (PMID: 23629727).",Actionable,8193,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,4656,Everolimus + Pimasertib,673,23629727,,,
164,Preclinical,"In a preclinical study, CI-1040 (PD184352) inhibited Erk phosphorylation and growth of transformed cells expressing BRAF V600E in culture (PMID: 20538618).",Actionable,6844,10000003,Advanced Solid Tumor,JAX,1,BRAF V600E,sensitive,699,CI-1040,673,20538618,,,
165,Preclinical - Cell line xenograft,"In a preclinical study, PLX4720 inhibited growth of melanoma cells harboring BRAF V600E in culture and in cell line xenograft models (PMID: 18287029).",Actionable,503,1909,melanoma,DOID,1,BRAF V600E,sensitive,1060,PLX4720,673,18287029,,,
166,Preclinical - Cell line xenograft,"In a preclinical study, BGB-283 in combination with Erbitux (cetuximab) demonstrated enhanced tumor suppression in colorectal cancer cell line xenograft models harboring BRAF V600E (PMID: 26208524).",Actionable,8069,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,4628,BGB-283 + Cetuximab,673,26208524,,,
167,Preclinical,"In a preclinical study, SCH772984 inhibited growth of melanoma cell lines harboring BRAF V600E in culture (PMID: 26267534).",Actionable,5776,1909,melanoma,DOID,1,BRAF V600E,sensitive,2618,SCH772984,673,26267534,,,
168,Preclinical,"In a preclinical study, Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5986,1909,melanoma,DOID,1,BRAF V600E,sensitive,4004,Dabrafenib + GSK2126458,673,22389471,,,
169,Preclinical,"In a preclinical study, SCH772984 inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 26267534).",Actionable,5779,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,2618,SCH772984,673,26267534,,,
170,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and SCH772984 inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",Actionable,7651,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,4543,Cetuximab + SCH772984,673,27312529,,,
171,Preclinical - Cell line xenograft,"In a preclinical study, PLX7904 inhibited survival of colorectal cancer cells harboring BRAF V600E in culture and demonstrated anti-tumor activity in cell line xenograft models (PMID: 26466569).",Actionable,7901,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,4606,PLX7904,673,26466569,,,
172,Preclinical,"In a preclinical study, TW-37 enhanced the inhibitory effect of Zelboraf (vemurafenib) on human non-small cell lung cancer cells harboring BRAF V600E in culture (PMID: 25665005).",Actionable,4534,3908,non-small cell lung carcinoma,DOID,1,BRAF V600E,sensitive,3531,Vemurafenib + TW-37,673,25665005,,,
173,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Alpelisib (BYL719) and PLX4720 enhanced antitumor activity in a melanoma cell line harboring BRAF V600E, demonstrating decreased cell survival and increased apoptotic activity in xenograft models, and decreased Akt signaling in culture (PMID: 27924459).",Actionable,9662,1909,melanoma,DOID,1,BRAF V600E,sensitive,5119,Alpelisib + PLX4720,673,27924459,,,
174,Preclinical - Cell culture,"In a preclinical study, TAK-632 inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture (PMID: 27523909).",Actionable,7943,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,3300,TAK-632,673,27523909,,,
175,Preclinical - Cell line xenograft,"In a preclinical study, GDC0879 inhibited survival of colon cancer cell lines harboring BRAF V600E in cell culture and cell line xenograft models (PMID: 19276360).",Actionable,7874,219,colon cancer,DOID,1,BRAF V600E,sensitive,1095,GDC0879,673,19276360,,,
176,Phase Ib/II,"In a Phase Ib/II trial, Encorafenib (LGX818) and Kisqali (ribociclib) combination treatment resulted in confirmed partial response in 7.1% (2/28), unconfirmed partial response in 10.7% (3/28), and stable disease in 35.7% (10/28) of patients with melanoma harboring BRAF V600E (PMID: 28351928). ",Actionable,11415,1909,melanoma,DOID,1,BRAF V600E,sensitive,1260,Encorafenib + Ribociclib,673,28351928,,,
177,Preclinical - Cell line xenograft,"In a preclinical study, PLX4720 inhibited growth of colon cancer cells harboring BRAF V600E in culture and in cell line xenograft models (PMID: 18287029).",Actionable,8002,219,colon cancer,DOID,1,BRAF V600E,sensitive,1060,PLX4720,673,18287029,,,
178,Preclinical,"In a preclinical study, Refametinib (BAY86-9766) inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture and suppressed tumor growth in cell line xenograft models (PMID: 19706763).",Actionable,1343,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,888,Refametinib,673,19706763,,,
179,Preclinical - Cell line xenograft,"In preclinical studies, CEP-32496 (RXDX-105) reduced tumor volume and promoted tumor regression in xenograft models of a BRAF V600E mutant human melanoma cell line (PMID: 22319199).",Actionable,306,1909,melanoma,DOID,1,BRAF V600E,sensitive,1002,CEP-32496,673,22319199,,,
180,Preclinical - Pdx & cell culture,"In a preclinical study, BGB-283 inhibited Braf phosphorylation and cell proliferation in colorectal cancer cell lines harboring BRAF V600E in culture, and resulted in partial tumor regression in both cell line and patient-derived xenograft models (PMID: 26208524).",Actionable,8057,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,4025,BGB-283,673,26208524,,,
181,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",Actionable,7650,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,4541,Cetuximab + Dabrafenib + Trametinib,673,27312529,,,
182,Preclinical,"In a preclinical study, colorectal cancer cells harboring BRAF V600E were sensitive to the combination of BI 882370 and Erbitux (cetuximab) in xenograft models, resulting in tumor growth inhibition and partial tumor regression (PMID: 26916115). ",Actionable,4984,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,3711,BI 882370 + Cetuximab,673,26916115,,,
183,Preclinical - Cell line xenograft,"In a preclinical study, DT01 increased sensitivity of human colorectal cancer (CRC) cells harboring BRAF V600E to Eloxatin (oxaliplatin) and Adrucil (5-fluorouracil), and the combination resulted in decreased liver tumor growth in CRC cell line xenograft metastasis models (PMID: 26637369).",Actionable,6180,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,4083,DT01 + Fluorouracil + Oxaliplatin,673,26637369,,,
184,Preclinical - Cell line xenograft,"In a preclinical study, CI-1040 inhibited growth of a human ovarian cancer cell line harboring BRAF V600E in culture, and inhibited tumor growth in xenograft models (PMID: 19018267).",Actionable,2742,2394,ovarian cancer,DOID,1,BRAF V600E,sensitive,699,CI-1040,673,19018267,,,
185,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Cotellic (cobimetinib) and Zelboraf (vemurafenib) inhibited tumor growth in a cell line xenograft model of colorectal cancer harboring BRAF V600E (PMID: 28649441).",Actionable,11939,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,1657,Vemurafenib + Cobimetinib,673,28649441,,,
186,Guideline,Colorectal cancer patients harboring BRAF V600E may not be responsive to Erbitux (cetuximab) as a single therapy or in combination with a chemotherapeutic (Guidelines).,Actionable,9947,9256,colorectal cancer,DOID,1,BRAF V600E,predicted â€“ resistant,694,Cetuximab,673,None,,,
187,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cell lines harboring BRAF V600E were resistant to Erbitux (cetuximab) in culture (PMID: 27312529).",Actionable,7614,9256,colorectal cancer,DOID,1,BRAF V600E,predicted â€“ resistant,694,Cetuximab,673,27312529,,,
188,Preclinical - Cell line xenograft,"In a preclinical study, treatment with BI-847325 resulted in decreased expression of Mcl-1 and Mek, and inhibited growth of melanoma cell lines harboring BRAF V600E in culture, and inhibited tumor growth in xenograft models of BRAF V600E-positive melanoma, including models with BRAF-inhibitor resistance (PMID: 25873592).",Actionable,7823,1909,melanoma,DOID,1,BRAF V600E,sensitive,1059,BI-847325,673,25873592,,,
189,Preclinical - Cell line xenograft,"In a preclinical study, Selumetinib (AZD6244) decreased tumor growth in a cell line xenograft model of colorectal cancer harboring BRAF V600E (PMID: 23942066).",Actionable,2528,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,913,Selumetinib,673,23942066,,,
190,Preclinical - Cell culture,"In a preclinical study, thyroid cancer cells harboring BRAF V600E demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909).",Actionable,7959,1781,thyroid cancer,DOID,1,BRAF V600E,decreased response,342,Vemurafenib,673,27523909,,,
191,Preclinical,"In a preclinical study, colorectal cancer cell lines harboring a BRAF V600E mutation were sensitive to Nexavar (sorafenib) in culture (PMID: 24885690).",Actionable,1320,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,920,Sorafenib,673,24885690,,,
192,Preclinical,"In a preclinical study, Sprycel (dasatinib) inhibited cell invasion, cell signaling, and proliferation in human melanoma cell lines harboring BRAF V600E that are resistant to Braf inhibition in culture and in animal models (PMID: 23242808).",Actionable,3335,1909,melanoma,DOID,1,BRAF V600E,sensitive,717,Dasatinib,673,23242808,,,
193,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",Actionable,7652,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,4544,Dabrafenib + SCH772984,673,27312529,,,
194,Phase II,"In two Phase II clinical studies, patients with refractory hairy cell leukemia harboring BRAF V600E responded to Zelboraf (vemurafenib) with overall response rates of 96% (25/26) and 100% (24/24) as well as complete response rates of 35% (9/26) and 42% (10/24) with median follow up times of 8 and 12 weeks, respectively (PMID: 26352686).",Actionable,3620,285,hairy cell leukemia,DOID,1,BRAF V600E,sensitive,342,Vemurafenib,673,26352686,,,
195,Preclinical - Cell culture,"In a preclinical study, a glioblastoma cell line harboring BRAF V600E demonstrated sensitivity to BI2536 in culture (PMID: 26573800).",Actionable,10194,3068,glioblastoma multiforme,DOID,1,BRAF V600E,sensitive,676,BI2536,673,26573800,,,
196,FDA approved,"In a Phase III trial that supported FDA approval, Zelboraf (vemurafenib), as compared to Deticene (dacarbazine), resulted in an improved overall survival rate of 84% at 6 months in patients with BRAF V600E positive metastatic melanoma (PMID: 21639808).",Actionable,586,1909,melanoma,DOID,1,BRAF V600E,sensitive,342,Vemurafenib,673,21639808,,,
197,Guideline,Zelboraf (vemurafenib) is an active regimen for melanoma patients with BRAF V600E (Guidelines).,Actionable,1510,1909,melanoma,DOID,1,BRAF V600E,sensitive,342,Vemurafenib,673,None,,,
198,Preclinical - Cell line xenograft,"In a preclinical study, Selumetinib (AZD6244) and PLX4720 synergistically inhibited growth and induced apoptosis in glioma cell lines in culture, resulted in prolonged survival in cell line xenograft models (PMID: 27217440).",Actionable,9107,3070,malignant glioma,DOID,1,BRAF V600E,predicted â€“ sensitive,1061,Selumetinib + PLX4720,673,27217440,,,
199,Clinical Study,"In a clinical case report, Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment resulted in a clinical and radiologic response that lasted for 9 months in an anaplastic thyroid cancer patient harboring BRAF V600E (PMID: 27697975).",Actionable,8711,1781,thyroid cancer,DOID,1,BRAF V600E,sensitive,1066,Trametinib + Dabrafenib,673,27697975,,,
200,Preclinical,"In a preclinical study, PLX8394 had been shown to block survival and growth of vemurafenib/PLX4720-resistant cells harboring distinct BRAF V600E splice variants (PMID: 24422853).",Actionable,442,10000003,Advanced Solid Tumor,JAX,1,BRAF V600E,sensitive,1041,PLX8394,673,24422853,,,
201,Preclinical - Cell culture,"In a preclincial study, colorectal cancer cell lines harboring BRAF V600E demonstrated resistance to SHP099 in culture (PMID: 27362227).",Actionable,7521,9256,colorectal cancer,DOID,1,BRAF V600E,resistant,4504,SHP099,673,27362227,,,
202,Preclinical - Cell culture,"In a preclinical study, BGB-283 inhibited viability of a variety of cancer cell lines harboring BRAF V600E in culture (PMID: 26208524).",Actionable,8066,10000003,Advanced Solid Tumor,JAX,1,BRAF V600E,sensitive,4025,BGB-283,673,26208524,,,
203,Preclinical,"In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Mekinist (trametinib) on human melanoma cells harboring BRAF V600E in culture (PMID: 25665005).",Actionable,4529,1909,melanoma,DOID,1,BRAF V600E,sensitive,1386,Trametinib + Navitoclax,673,25665005,,,
204,Preclinical - Cell line xenograft,"In a preclinical study, DETD-35 inhibited proliferation and colony formation of melanoma cells harboring BRAF V600E in culture and reduced tumor size in xenograft models (PMID: 27048951).",Actionable,6673,1909,melanoma,DOID,1,BRAF V600E,sensitive,4230,DETD-35,673,27048951,,,
205,Preclinical,"In a preclinical study, TW-37 enhanced the inhibitory effect of Mekinist (trametinib) on human non-small cell lung cancer cells harboring BRAF V600E in culture (PMID: 25665005).",Actionable,4531,3908,non-small cell lung carcinoma,DOID,1,BRAF V600E,sensitive,3532,Trametinib + TW-37,673,25665005,,,
206,Guideline,Mekinist (trametinib) is an active regimen for melanoma patients with BRAF V600E (Guidelines).,Actionable,1512,1909,melanoma,DOID,1,BRAF V600E,sensitive,2,Trametinib,673,None,,,
207,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and SCH772984 inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",Actionable,7653,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,4542,Cetuximab + Dabrafenib + SCH772984,673,27312529,,,
208,Preclinical,"In a preclinical study, SBI-0640756 inhibited proliferation and Akt/mTOR signaling in human melanoma cell lines harboring BRAF V600E in culture (PMID: 26603897, PMID: 20531415).",Actionable,3784,1909,melanoma,DOID,1,BRAF V600E,sensitive,3306,SBI-0640756,673,26603897,20531415,,
209,Preclinical,"In a preclinical study, SBI-0640726 inhibited proliferation and Akt/mTOR signaling in human melanoma cell lines harboring BRAF V600E in culture (PMID: 26603897, PMID: 20531415).",Actionable,3785,1909,melanoma,DOID,1,BRAF V600E,sensitive,3307,SBI-0640726,673,26603897,20531415,,
210,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Tafinlar (dabrafenib) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",Actionable,7647,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,4525,Cetuximab + Dabrafenib,673,27312529,,,
211,Preclinical,"In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) inhibited growth of melanoma cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5985,1909,melanoma,DOID,1,BRAF V600E,sensitive,3027,GSK2126458 + Trametinib,673,22389471,,,
212,Preclinical - Cell culture,"In a preclinical study, RO4987655 inhibited proliferation of melanoma cells harboring BRAF V600E in culture (PMID: 26438159).",Actionable,8461,1909,melanoma,DOID,1,BRAF V600E,sensitive,903,RO4987655,673,26438159,,,
213,Clinical Study,"In a clinical case study, Mekinist (trametinib) and Zelboraf (vemurafenib) combination treatment resulted in a rapid and sustained clinical response in a patient with a rectal neuroendocrine tumor harboring a BRAF V600E mutation (PMID: 27048246).",Actionable,6681,169,neuroendocrine tumor,DOID,1,BRAF V600E,sensitive,4234,Trametinib + Vemurafenib,673,27048246,,,
214,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) and Selumetinib (AZD6244) synergistically inhibited proliferation and induced apoptosis in both parental thyroid cancer cell lines harboring BRAF V600E and those acquired Sprycel (dasatinib)-resistance in culture (PMID: 27222538).",Actionable,7862,1781,thyroid cancer,DOID,1,BRAF V600E,sensitive,4600,Dasatinib + Selumetinib,673,27222538,,,
215,Preclinical - Cell line xenograft,"In a preclinical study, a melanoma xenograft model harboring BRAF V600E demonstrated tumor regression when treated with ASN003 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B100).",Actionable,11041,1909,melanoma,DOID,1,BRAF V600E,sensitive,5827,ASN003,673,None,,,
216,FDA approved,"In a Phase III clinical trial that supported FDA approval, Tafinlar (dabrafenib) improved progression free survival compared to Deticene (dacarbazine) in patients with BRAF V600E positive melanoma (PMID: 22735384).",Actionable,554,1909,melanoma,DOID,1,BRAF V600E,sensitive,3,Dabrafenib,673,22735384,,,
217,Guideline,Tafinlar (dabrafenib) is an active regimen for melanoma patients with BRAF V600E (Guidelines).,Actionable,1507,1909,melanoma,DOID,1,BRAF V600E,sensitive,3,Dabrafenib,673,None,,,
218,Preclinical,"In a preclinical study, Iressa (gefitinib) in combination with PLX4720 inhibited proliferation and tumorigenicity in human melanoma cell line harboring BRAF V600E and resistant to Braf inhibition in culture and in animal models (PMID: 23242808).",Actionable,3334,1909,melanoma,DOID,1,BRAF V600E,sensitive,3131,Gefitinib + PLX4720,673,23242808,,,
219,Phase II,"In a Phase II trial, 20% (8/41) of melanoma patients with BRAF V600 mutations had a partial response to Binimetinib (MEK162) (PMID: 23414587).",Actionable,1121,1909,melanoma,DOID,1,BRAF V600E,sensitive,807,Binimetinib,673,23414587,,,
220,Preclinical - Cell line xenograft,"In a preclinical study, Selumetinib (AZD6244) and Afinitor (everolimus) synergistically inhibited growth and induced apoptosis in glioma cell lines in culture, resulted in prolonged survival in cell line xenograft models (PMID: 27217440).",Actionable,9106,3070,malignant glioma,DOID,1,BRAF V600E,predicted â€“ sensitive,4901,Everolimus + Selumetinib,673,27217440,,,
221,Preclinical - Cell line xenograft,"In a preclinical study, PD-0325901 demonstrated antitumor activity against BRAF V600E colon cancer cell line xenografts (PMID: 16273091).",Actionable,1782,219,colon cancer,DOID,1,BRAF V600E,sensitive,849,PD-0325901,673,16273091,,,
222,Preclinical,"In a preclinical study, colorectal cancer cells harboring BRAF V600E were sensitive to the combination of BI 882370 and Gilotrif (afatinib) in xenograft models, resulting in tumor growth inhibition and partial tumor regression (PMID: 26916115). ",Actionable,4985,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,3712,BI 882370 + Afatinib,673,26916115,,,
223,Preclinical,"In a preclinical study, PLX4720, Cediranib (AZD-2171) and Selumetinib (AZD6244) worked synergistically to inhibit cell growth in PLX4720-resistant melanoma cell lines harboring BRAF V600E in culture (PMID: 26461489).",Actionable,4955,1909,melanoma,DOID,1,BRAF V600E,sensitive,3699,Cediranib + Selumetinib + PLX4720,673,26461489,,,
224,Preclinical,"In a preclinical study, PLX4720 and Selumetinib (AZD6244) worked synergistically to inhibit cell growth in PLX4720-resistant melanoma cell lines harboring BRAF V600E in culture (PMID: 26461489).",Actionable,4954,1909,melanoma,DOID,1,BRAF V600E,sensitive,1061,Selumetinib + PLX4720,673,26461489,,,
225,Preclinical - Pdx & cell culture,"In a preclinical study, GDC0879 inhibited survival of melanoma cell lines harboring BRAF V600E in cell culture, cell line xenograft and patient-derived xenograft (PDX) models (PMID: 19276360).",Actionable,7873,1909,melanoma,DOID,1,BRAF V600E,sensitive,1095,GDC0879,673,19276360,,,
226,Preclinical - Pdx,"In a preclinical study, LSN3074753 demonstrated modest efficacy in patient-derived xenograft models of colorectal cancer harboring BRAF V600E, resulted in tumor growth inhibition or regression, but relapse upon discontinuation of treatment (PMID: 28611205).",Actionable,12192,9256,colorectal cancer,DOID,1,BRAF V600E,predicted â€“ sensitive,6337,LSN3074753,673,28611205,,,
227,Preclinical,"In a preclinical study, Sprycel (dasatinib) failed to induce apoptosis in lung carcinoma cells expressing BRAF V600E (PMID: 22649091).",Actionable,692,3905,lung carcinoma,DOID,1,BRAF V600E,resistant,717,Dasatinib,673,22649091,,,
228,Preclinical,"In a preclinical study, BI-69A11 inhibited proliferation and Akt/mTOR signaling in human melanoma cell lines harboring BRAF V600E in culture (PMID: 26603897, PMID: 20531415).",Actionable,3783,1909,melanoma,DOID,1,BRAF V600E,sensitive,3308,BI-69A11,673,26603897,20531415,,
229,Phase Ib/II,"In a Phase Ib/II trial, treatment with the combination of Vectibix (panitumumab) and Tafinlar (dabrafenib) resulted in stable disease in 7/8 colorectal cancer patients harboring a BRAF V600E mutation (J Clin Oncol 32:5s, 2014 (suppl; abstr 3515)).",Actionable,1345,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,1718,Panitumumab + Dabrafenib,673,None,,,
230,Preclinical - Cell culture,"In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring either monomeric BRAF V600E or dimeric isoform of V600E which conferred Zelboraf (vemurafenib)-resistance in culture (PMID: 27523909).",Actionable,7936,1909,melanoma,DOID,1,BRAF V600E,sensitive,3300,TAK-632,673,27523909,,,
231,Preclinical - Cell culture,"In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited growth of transformed cells over expressing BRAF V600E in culture, while single agent inhibition had no effect (PMID: 26140595).",Actionable,10250,10000003,Advanced Solid Tumor,JAX,1,BRAF V600E,predicted â€“ sensitive,5443,PF3644022 + PF-477736,673,26140595,,,
232,Clinical Study,"In a clinical case study, Tafinlar (dabrafenib) treatment resulted in a near complete response and resolution of leptomeningeal dissemination in a patient with pilocytic astrocytoma harboring BRAF V600E (PMID: 28784858).",Actionable,11710,4851,pilocytic astrocytoma,DOID,1,BRAF V600E,sensitive,3,Dabrafenib,673,28784858,,,
233,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture (PMID: 23629727).",Actionable,8198,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,1659,Pimasertib + Sorafenib,673,23629727,,,
234,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) and Erbitux (cetuximab) combination treatment inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",Actionable,7618,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,4536,Cetuximab + Selumetinib,673,27312529,,,
235,Preclinical - Cell line xenograft,"In a preclinical study, Selumetinib (AZD6244) inhibited growth of both parental thyroid cancer cell lines harboring BRAF V600E and those acquired Sprycel (dasatinib)-resistance in culture (PMID: 27222538).",Actionable,7856,1781,thyroid cancer,DOID,1,BRAF V600E,sensitive,913,Selumetinib,673,27222538,,,
236,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) and SCH772984 synergistically inhibited proliferation and induced apoptosis in both parental thyroid cancer cell lines harboring BRAF V600E and those acquired Sprycel (dasatinib)-resistance in culture (PMID: 27222538).",Actionable,7863,1781,thyroid cancer,DOID,1,BRAF V600E,sensitive,4601,Dasatinib + SCH772984,673,27222538,,,
237,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",Actionable,7649,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,1066,Trametinib + Dabrafenib,673,27312529,,,
238,Preclinical - Cell culture,"In a preclinical study, the addition of PAC-1 to Mekinist (trametinib) and Zelboraf (vemurafenib) led to greater levels of caspase-3 activity and apoptosis in melanoma cells harboring BRAF V600E when compared to Zelboraf (vemurafenib) and Mekinist (trametinib) treatment without PAC-1 (PMID: 27297867). ",Actionable,7872,1909,melanoma,DOID,1,BRAF V600E,sensitive,4603,PAC-1 + Trametinib + Vemurafenib,673,27297867,,,
239,Preclinical - Cell line xenograft,"In a preclinical study, the Hsp90 inhibitor Ganetespib destabilized BRAF, especially BRAF V600E, resulted in loss of cell viability in culture and antitumor effects in cell line xenograft models of melanoma (PMID: 24398428).",Actionable,3,8923,skin melanoma,DOID,1,BRAF V600E,sensitive,745,Ganetespib,673,24398428,,,
240,Preclinical,"In a preclinical study, PLX4720 inhibited Erk phosphorylation and cell proliferation of transformed cells expression BRAF V600E in culture (PMID: 20538618).",Actionable,6836,10000003,Advanced Solid Tumor,JAX,1,BRAF V600E,sensitive,1060,PLX4720,673,20538618,,,
241,Phase III,"In a post-hoc analysis of a Phase III trial, BRAF V600E mutations in colon adenocarcinoma patients with microsatellite stable tumors were associated with a shorter disease-free survival and overall survival compared to those patients with microsatellite instability tumors, suggesting that BRAF V600E may serve as a future prognostic biomarker in this patient population (PMID: 26768652). ",Emerging,6437,234,colon adenocarcinoma,DOID,1,BRAF V600E,not applicable,1776,N/A,673,26768652,,,
242,Preclinical - Cell culture,"In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring either monomeric BRAF V600E or dimeric isoform of V600E which conferred Zelboraf (vemurafenib)-resistance in culture (PMID: 27523909).",Actionable,7906,1909,melanoma,DOID,1,BRAF V600E,sensitive,1093,AZ628,673,27523909,,,
243,Preclinical,"In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Zelboraf (vemurafenib) on human non-small cell lung cancer cells harboring BRAF V600E in culture (PMID: 25665005).",Actionable,4524,3908,non-small cell lung carcinoma,DOID,1,BRAF V600E,sensitive,3530,Navitoclax + Vemurafenib,673,25665005,,,
244,Preclinical - Pdx,"In a preclinical study, CCT196969 inhibited growth of a human melanoma cell line harboring BRAF V600E in culture, and induced tumor regression in several BRAF V600E-mutant melanoma patient-derived xenograft models (PMID: 25500121).",Actionable,3306,1909,melanoma,DOID,1,BRAF V600E,sensitive,3105,CCT196969,673,25500121,,,
245,Preclinical,"In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Mekinist (trametinib) on human non-small cell lung cancer cells harboring BRAF V600E in culture (PMID: 25665005).",Actionable,4527,3908,non-small cell lung carcinoma,DOID,1,BRAF V600E,sensitive,1386,Trametinib + Navitoclax,673,25665005,,,
246,Preclinical,"In a preclinical study, TW-37 enhanced the inhibitory effect of Mekinist (trametinib) on human melanoma cells harboring BRAF V600E in culture (PMID: 25665005).",Actionable,4530,1909,melanoma,DOID,1,BRAF V600E,sensitive,3532,Trametinib + TW-37,673,25665005,,,
247,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Zelboraf (vemurafenib) and Tarceva (erlotinib) resulted in improved inhibition of tumor growth in BRAF V600E mutant human colon cancer cell line xenograft models compared to either drug as monotherapy (PMID: 22448344).",Actionable,1325,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,1710,Vemurafenib + Erlotinib,673,22448344,,,
248,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Gleevec (imatinib) and PLX4720 enhanced antitumor efficacy of melanoma cells harboring BRAF V600E, demonstrating decreased cell survival in xenograft models, and decreased phosphorylation of Mapk1 in culture (PMID: 27924459). ",Actionable,9660,1909,melanoma,DOID,1,BRAF V600E,sensitive,5118,Imatinib + PLX4720,673,27924459,,,
249,Preclinical,"In a preclinical study, CLM3 inhibited growth, Egfr signaling, and CCND1 expression in thyroid cancer cells harboring BRAF V600E in culture (PMID: 24423321).",Actionable,4417,1781,thyroid cancer,DOID,1,BRAF V600E,sensitive,3502,CLM3,673,24423321,,,
250,Preclinical,"In a preclinical study, RAF265 inhibited Erk phosphorylation and cell proliferation in BRAF V600E expressing cells in culture (PMID: 20538618).",Actionable,6832,10000003,Advanced Solid Tumor,JAX,1,BRAF V600E,sensitive,884,RAF265,673,20538618,,,
251,Preclinical - Cell culture,"In a preclinical study, a glioblastoma cell line harboring BRAF V600E demonstrated a decreased response to treatment with PD-0325901, demonstrating increased viability of CD133 positive cells in culture (PMID: 26573800). ",Actionable,10191,3068,glioblastoma multiforme,DOID,1,BRAF V600E,decreased response,849,PD-0325901,673,26573800,,,
252,Preclinical,"In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Mekinist (trametinib) on human colon cancer cells harboring BRAF V600E in culture (PMID: 25665005).",Actionable,4528,219,colon cancer,DOID,1,BRAF V600E,sensitive,1386,Trametinib + Navitoclax,673,25665005,,,
253,Clinical Study,"In a clinical case report, a patient with metastatic colon cancer harboring BRAF V600E demonstrated a mixed radiographic response, with slight progression in some locations, however, response or stable disease for 7 months in other locations following treatment with the combination of Nexavar (sorafenib) and Erbitux (cetuximab) (PMID: 23792568).",Actionable,11930,219,colon cancer,DOID,1,BRAF V600E,predicted â€“ sensitive,6209,Cetuxmab + Sorafenib,673,23792568,,,
254,FDA approved,"In a Phase II trial that supported FDA approval, treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) resulted in an overall response rate of 66.7% (38/57) in patients with non-small cell lung cancer harboring BRAF V600E, versus 32.1% (25/78) with Tafinlar (dabrafenib) alone (J Clin Onc. 35, no. 15_suppl (May 2017) 9075).",Actionable,11287,3908,non-small cell lung carcinoma,DOID,1,BRAF V600E,sensitive,1066,Trametinib + Dabrafenib,673,None,,,
255,Preclinical - Cell line xenograft,"In a preclinical study, the Hsp90 inhibitor, Ganetespib, in combination with the MEK1/2 inhibitor TAK-733, caused the regression of tumors in vemurafenib-resistant cell line xenograft models of melanoma (PMID: 24398428). ",Actionable,1267,1909,melanoma,DOID,1,BRAF V600E,sensitive,1684,Ganetespib + TAK-733,673,24398428,,,
256,Preclinical,"In a preclinical study, RO5126766 inhibited Mek signaling and increased radioiodide uptake and response in transgenic animal models of papillary thyroid carcinoma driven by BRAF V600E (PMID: 27669459).",Actionable,9182,3969,papillary thyroid carcinoma,DOID,1,BRAF V600E,sensitive,2011,RO5126766,673,27669459,,,
257,Preclinical - Cell line xenograft,"In a preclinical study, Zelboraf (vemurafenib) in combination with SBI-0640756 inhibited the association of eIF4G1 and eIF4E in Zelboraf (vemurafenib) resistant human melanoma cell lines harboring BRAF V600E in culture and reduced tumor growth in xenograft models (PMID: 26603897).",Actionable,3790,1909,melanoma,DOID,1,BRAF V600E,sensitive,3310,Vemurafenib + SBI-060756,673,26603897,,,
258,Preclinical,"In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Zelboraf (vemurafenib) on human colon cancer cells harboring BRAF V600E in culture (PMID: 25665005).",Actionable,4525,219,colon cancer,DOID,1,BRAF V600E,sensitive,3530,Navitoclax + Vemurafenib,673,25665005,,,
259,Clinical Study,"In a clinical case study, a non-small cell lung cancer patient harboring a BRAF V600E mutation had a complete response after treatment with Zelboraf (vemurafenib) (PMID: 23733758).",Actionable,705,3908,non-small cell lung carcinoma,DOID,1,BRAF V600E,sensitive,342,Vemurafenib,673,23733758,,,
260,Guideline,Colorectal cancer patients harboring BRAF V600E may not be responsive to Vectibix (panitumumab) as a single therapy or in combination with a chemotherapeutic (Guidelines).,Actionable,9944,9256,colorectal cancer,DOID,1,BRAF V600E,predicted â€“ resistant,845,Panitumumab,673,None,,,
261,Preclinical,"In a preclinical study, CCT241161 inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 25500121, PMID: 15294323).",Actionable,3311,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,3106,CCT241161,673,25500121,15294323,,
262,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",Actionable,7646,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,1916,Cetuximab + Encorafenib,673,27312529,,,
263,Preclinical,"In a preclinical study, S3I-201 inhibited cell invasion and Stat3 signaling in human melanoma cell lines harboring BRAF V600E that are resistant to Braf inhibition in culture (PMID: 23242808).",Actionable,3341,1909,melanoma,DOID,1,BRAF V600E,sensitive,3124,S3I-201,673,23242808,,,
264,Preclinical,"In a preclinical study, CCT196969 inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 25500121, PMID: 15294323).",Actionable,3310,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,3105,CCT196969,673,25500121,15294323,,
265,Preclinical - Cell culture,"In a preclinical study, RO5126766 inhibited proliferation of melanoma cells harboring BRAF V600E in culture (PMID: 26438159).",Actionable,8478,1909,melanoma,DOID,1,BRAF V600E,sensitive,2011,RO5126766,673,26438159,,,
266,Preclinical - Cell culture,"In a preclinical study, TAK-632 inhibited proliferation of thyroid cancer cells harboring BRAF V600E in culture (PMID: 27523909).",Actionable,7944,1781,thyroid cancer,DOID,1,BRAF V600E,sensitive,3300,TAK-632,673,27523909,,,
267,Guideline,"BRAF V600E is used in the diagnosis of hairy cell leukemia (Guidelines, PMID: 25110197, PMID: 23848818). ",Actionable,12170,285,hairy cell leukemia,DOID,1,BRAF V600E,not applicable,1776,N/A,673,25110197,23848818,None,
268,Preclinical - Cell line xenograft,"In a preclinical study, the combination of PLX4720 and Adriamycin (doxorubicin) resulted in antitumor efficacy in a melanoma cell line harboring BRAF V600E, demonstrating decreased cell survival and increased apoptotic activity in xenograft models, and inhibition of cell growth in culture (PMID: 27924459).",Actionable,9664,1909,melanoma,DOID,1,BRAF V600E,sensitive,5122,PLX4720 + Doxorubicin,673,27924459,,,
269,Preclinical - Cell line xenograft,"In a preclinical study, the combination of BI 2536 and PLX4720 resulted in suppression of downstream signaling, increased apoptotic activity, inhibition of cell proliferation, and tumor growth suppression in glioblastoma cell line xenograft models harboring BRAF V600E (PMID: 26573800). ",Actionable,10196,3068,glioblastoma multiforme,DOID,1,BRAF V600E,sensitive,5422,BI2536 + PLX4720,673,26573800,,,
270,Preclinical - Cell line xenograft,"In a preclinical study, DETD-35 and Zelboraf (vemurafenib) synergistically inhibited proliferation and colony formation of melanoma cells harboring BRAF V600E in culture and reduced tumor size in xenograft models (PMID: 27048951).",Actionable,6674,1909,melanoma,DOID,1,BRAF V600E,sensitive,4232,DETD-35 + Vemurafenib,673,27048951,,,
271,Preclinical - Cell line xenograft,"In a preclinical study, the combination of PLX4720 and Erbitux (cetuximab) inhibited tumor growth in colorectal cancer cell line xenograft models harboring BRAF V600E (PMID: 22281684).",Actionable,11929,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,6208,Cetuximab + PLX4720,673,22281684,,,
272,Preclinical - Cell line xenograft,"In a preclinical study, colorectal cancer cell lines were not sensitive to growth inhibition by Zelboraf (vemurafenib) in culture or xenograft models, due to feedback activation of EGFR signaling (PMID: 22281684).",Actionable,11927,9256,colorectal cancer,DOID,1,BRAF V600E,no benefit,342,Vemurafenib,673,22281684,,,
273,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cell lines harboring BRAF V600E demonstrated decreased response to Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7615,9256,colorectal cancer,DOID,1,BRAF V600E,no benefit,342,Vemurafenib,673,27312529,,,
274,Phase II,"In a Phase II trial, Zelboraf (vemurafenib) did not demonstrate clinical activity as a single agent in patients with metastatic colorectal cancer harboring BRAF V600E (PMID: 26460303).",Actionable,9421,9256,colorectal cancer,DOID,1,BRAF V600E,no benefit,342,Vemurafenib,673,26460303,,,
275,Preclinical - Cell line xenograft,"In a preclinical study, DEL-22379 inhibited growth of melanoma cells harboring BRAF V600E with high levels of ERK dimerization in culture and inhibited tumor progression in melanoma xenograft models harboring BRAF V600E (PMID: 26267534).",Actionable,5564,1909,melanoma,DOID,1,BRAF V600E,sensitive,3769,DEL-22379,673,26267534,,,
276,Preclinical - Cell line xenograft,"In a preclinical study, a melanoma cell line xenograft model harboring BRAF V600E treated with PD-0325901 demonstrated stable tumor growth, but by day 44, growth ensued and thus, demonstrated no benefit (PMID: 27488531). ",Actionable,8547,1909,melanoma,DOID,1,BRAF V600E,conflicting,849,PD-0325901,673,27488531,,,
277,Preclinical - Cell culture,"In a preclinical study, PD-0325901 inhibited growth of melanoma cell lines harboring BRAF V600E in culture (PMID: 26267534).",Actionable,5778,1909,melanoma,DOID,1,BRAF V600E,conflicting,849,PD-0325901,673,26267534,,,
278,Clinical Study,"In a clinical case study, the combination of Zelboraf (vemurafenib) and Erbitux (cetuximab) was tolerated and showed clinical benefit in a patient with BRAF V600E mutant colorectal cancer (PMID: 24523613).",Actionable,1326,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,1711,Vemurafenib + Cetuximab,673,24523613,,,
279,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) and Erbitux (cetuximab) combination treatment inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",Actionable,7616,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,1711,Vemurafenib + Cetuximab,673,27312529,,,
280,Preclinical,"In a preclinical study, Tykerb (lapatinib) and Faridak (panobinostat) worked synergistically to inhibit growth of BRAF V600E mutant colorectal cancer cells in culture (PMID: 21464044).",Actionable,1323,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,1708,Lapatinib + Panobinostat,673,21464044,,,
281,Preclinical,"In a preclinical study, LY3009120 inhibited growth, downstream MAPK signaling and soft agar growth in human melanoma cell lines harboring BRAF V600E in culture (PMID: 26343583).",Actionable,6589,1909,melanoma,DOID,1,BRAF V600E,sensitive,3268,LY3009120,673,26343583,,,
282,Preclinical - Cell culture,"In a preclinical study, SB590885 inhibited proliferation of melanoma cell lines harboring either monomeric BRAF V600E or dimeric isoform of V600E which conferred Zelboraf (vemurafenib)-resistance in culture (PMID: 27523909).",Actionable,7946,1909,melanoma,DOID,1,BRAF V600E,sensitive,4281,SB590885,673,27523909,,,
283,Preclinical,"In a preclinical study, the combination of Tykerb (lapatinib) and Zelboraf (vemurafenib) inhibited growth of thyroid cancer cells harboring a BRAF V600E mutation in culture and in BRAF-mutant mouse models of thyroid cancer (PMID: 23365119).",Actionable,1322,1781,thyroid cancer,DOID,1,BRAF V600E,sensitive,1707,Lapatinib + Vemurafenib,673,23365119,,,
284,Preclinical,"In a preclinical study, Omipalisib (GSK2126458) inhibited the growth of melanoma cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5970,1909,melanoma,DOID,1,BRAF V600E,sensitive,763,GSK2126458,673,22389471,,,
285,Preclinical,"In a preclinical study, PLX4720 and Tivozanib (AV-951) worked synergistically to inhibit cell growth in PLX4720-resistant melanoma cell lines harboring BRAF V600E in culture (PMID: 26461489).",Actionable,4956,1909,melanoma,DOID,1,BRAF V600E,sensitive,3700,PLX4720 + Tivozanib,673,26461489,,,
286,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) and Mekinist (trametinib) synergistically inhibited proliferation and induced apoptosis in both parental thyroid cancer cell lines harboring BRAF V600E and those acquired Sprycel (dasatinib)-resistance in culture (PMID: 27222538).",Actionable,7861,1781,thyroid cancer,DOID,1,BRAF V600E,sensitive,4599,Dasatinib + Trametinib,673,27222538,,,
287,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818) and Alpelisib (BYL719) inhibited survival of colorectal cancer cell lines harboring BRAF V600E in culture (PMID: 27312529).",Actionable,7648,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,1917,LGX818 + Cetuximab + BYL719,673,27312529,,,
288,Clinical Study,"In a clinical case study, Mekinist (trametinib) and Tafinlar (dabrafenib) combination treatment resulted in a rapid and sustained clinical response in a patient with a rectal neuroendocrine tumor harboring a BRAF V600E mutation (PMID: 27048246).",Actionable,6680,169,neuroendocrine tumor,DOID,1,BRAF V600E,sensitive,1066,Trametinib + Dabrafenib,673,27048246,,,
289,Phase II,"In a Phase II trial, BRAF V600E positive melanoma patients who progressed on treatment with BRAF inhibitors or the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) were treated again with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) after 12 weeks off treatment, demonstrating a partial response in 35% (8/25) and stable disease in 40% (10/25) (PMID: 28268064). ",Actionable,10549,1909,melanoma,DOID,1,BRAF V600E,sensitive,1066,Trametinib + Dabrafenib,673,28268064,,,
290,Preclinical,"In a preclinical study, Tafinlar (dabrafenib) in combination with Mekinist (trametinib) inhibited growth of melanoma cells harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5987,1909,melanoma,DOID,1,BRAF V600E,sensitive,1066,Trametinib + Dabrafenib,673,22389471,,,
291,Preclinical - Cell line xenograft,"In a preclinical study, the combination of PLX4720 and Tarceva (erlotinib) resulted in antitumor efficacy in a melanoma cell line harboring BRAF V600E, demonstrating decreased cell survival and increased apoptotic activity in xenograft models and culture (PMID: 27924459).",Actionable,9665,1909,melanoma,DOID,1,BRAF V600E,sensitive,5120,Erlotinib + PLX4720,673,27924459,,,
292,Preclinical,"In a preclinical study, SHP099 did not inhibit proliferation or ERK activation in a melanoma cell line harboring BRAF V600E in culture (PMID: 27362227).",Actionable,7515,1909,melanoma,DOID,1,BRAF V600E,no benefit,4504,SHP099,673,27362227,,,
293,Preclinical - Cell line xenograft,"In a preclinical study, the combination of PAC-1 and Zelboraf (vemurafenib) resulted in a synergistic effect when treating melanoma cells harboring BRAF V600E in culture and xenograft models, demonstrating increased apoptosis and decreased tumor volume (PMID: 27297867). ",Actionable,7871,1909,melanoma,DOID,1,BRAF V600E,sensitive,4604,PAC-1 + Vemurafenib,673,27297867,,,
294,Preclinical - Cell line xenograft,"In preclinical studies, CEP-32496 (RXDX-105) reduced tumor volume and promoted tumor regression in xenograft models of a BRAF V600E mutant human colon carcinoma cell line (PMID: 22319199).",Actionable,307,1520,colon carcinoma,DOID,1,BRAF V600E,sensitive,1002,CEP-32496,673,22319199,,,
295,Phase I,"In a Phase I trial, 83% (10/12) of patients with colorectal cancer carrying a BRAF V600E mutation demonstrated tumor regression when treated with a combination of Zelboraf (vemurafenib) and Vectibix (panitumumab) (PMID: 25589621).",Actionable,1849,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,1717,Vemurafenib + Panitumumab,673,25589621,,,
296,Preclinical - Cell line xenograft,"In a preclinical study, Stivarga (regorafenib) inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture and suppressed angiogenesis and tumor growth in cell line xenograft models (PMID: 21170960).",Actionable,1312,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,890,Regorafenib,673,21170960,,,
297,Preclinical - Cell culture,"In a preclinical study, Afinitor (everolimus) and PLX4720 synergistically inhibited growth and induced apoptosis in glioma cell lines in culture (PMID: 27217440).",Actionable,9108,3070,malignant glioma,DOID,1,BRAF V600E,predicted â€“ sensitive,4902,Everolimus + PLX4720,673,27217440,,,
298,Preclinical - Cell line xenograft,"In a preclinical study, INU-152 inhibited growth of colorectal cancer cell lines harboring BRAF V600E in culture, and reduced tumor growth in BRAF V600E-mutant colorectal cancer cell line xenograft models (PMID: 28645859).",Actionable,12058,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,6241,INU-152,673,28645859,,,
299,Preclinical,"In a preclinical study, TW-37 enhanced the inhibitory effect of Zelboraf (vemurafenib) on human melanoma cells harboring BRAF V600E in culture (PMID: 25665005).",Actionable,4533,1909,melanoma,DOID,1,BRAF V600E,sensitive,3531,Vemurafenib + TW-37,673,25665005,,,
300,Preclinical,"In a preclinical study, xenograft models of melanoma harboring BRAF V600E treated with the combination of BI 882370 and Mekinist (trametinib) demonstrated tumor regression with no regrowth during the 5 weeks of treatment (PMID: 26916115). ",Actionable,4981,1909,melanoma,DOID,1,BRAF V600E,sensitive,3709,BI 882370 + Trametinib,673,26916115,,,
301,Preclinical - Cell line xenograft,"In a preclinical study, PLX4720 and navitoclax (ABT-263) worked synergistically to inhibit growth and increase apoptosis of BRAF V600E mutant melanoma cells in culture and in xenografts (PMID: 24983357).",Actionable,2614,1909,melanoma,DOID,1,BRAF V600E,sensitive,2960,PLX4720 + Navitoclax,673,24983357,,,
302,Preclinical,"In a preclinical study, colorectal cancer cells harboring BRAF V600E were sensitive to the combination of BI 882370 and Mekinist (trametinib) in xenograft models, resulting in tumor growth inhibition and partial tumor regression (PMID: 26916115). ",Actionable,4986,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,3709,BI 882370 + Trametinib,673,26916115,,,
303,Preclinical - Cell line xenograft,"In a preclinical study, INU-152 reduced MEK and ERK phosphorylation and growth of a melanona cell line harboring BRAF V600E in culture, and inhibited tumor growth in xenograft models (PMID: 28645859).",Actionable,12057,1909,melanoma,DOID,1,BRAF V600E,sensitive,6241,INU-152,673,28645859,,,
304,Preclinical - Cell culture,"In a preclinical study, PLX7904 inhibited survival of melanoma cell lines harboring monomeric BRAF V600E as well as cells harboring the Zelboraf (vemurafenib)-resistant dimeric BRAF V600E in culture (PMID: 26466569).",Actionable,7900,1909,melanoma,DOID,1,BRAF V600E,sensitive,4606,PLX7904,673,26466569,,,
305,Preclinical - Pdx,"In a preclinical study, CCT241161 inhibited growth of a human melanoma cell line harboring BRAF V600E in culture, and induced tumor regression in several BRAF V600E-mutant melanoma patient-derived xenograft models (PMID: 25500121).",Actionable,3307,1909,melanoma,DOID,1,BRAF V600E,sensitive,3106,CCT241161,673,25500121,,,
306,Preclinical - Cell line xenograft,"In a preclinical study, PLX4720 and Cediranib (AZD-2171) worked synergistically to inhibit cell growth and induce apoptosis in PLX4720-resistant human melanoma cell lines harboring BRAF V600E in culture and to suppress tumor growth in xenograft models (PMID: 26461489).",Actionable,4953,1909,melanoma,DOID,1,BRAF V600E,sensitive,3698,Cediranib + PLX4720,673,26461489,,,
307,Clinical Study,"In a clinical case study, a patient with metastatic renal cell carcinoma harboring BRAF V600E demonstrated a partial response following treatment with Zelboraf (vemurafenib) (PMID: 26918217).",Actionable,5648,4450,renal cell carcinoma,DOID,1,BRAF V600E,sensitive,342,Vemurafenib,673,26918217,,,
308,Preclinical,"In a preclinical study, SB590885 inhibited inhibited Erk phosphorylation and cell proliferation of transformed cells expression BRAF V600E in culture (PMID: 20538618).",Actionable,6827,10000003,Advanced Solid Tumor,JAX,1,BRAF V600E,sensitive,4281,SB590885,673,20538618,,,
309,Preclinical - Cell line xenograft,"In a preclinical study, Refametinib (BAY86-9766) inhibited growth of melanoma cell lines harboring BRAF V600E in culture and suppressed tumor growth in cell line xenograft models (PMID: 19706763).",Actionable,1130,1909,melanoma,DOID,1,BRAF V600E,sensitive,888,Refametinib,673,19706763,,,
310,Preclinical,"In a preclinical study, the combination of Zelboraf (vemurafenib) and Iressa (gefitinib) decreased the number of viable colorectal cancer cells harboring a BRAF V600E mutation in cell culture (PMID: 22448344).",Actionable,1324,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,1709,Vemurafenib + Gefitinib,673,22448344,,,
311,Preclinical - Cell culture,"In a preclinical study, BGB-283 inhibited Braf phosphorylation and cell proliferation in melanoma cell lines harboring BRAF V600E in culture (PMID: 26208524).",Actionable,8056,1909,melanoma,DOID,1,BRAF V600E,sensitive,4025,BGB-283,673,26208524,,,
312,Phase I,"In a Phase I trial, BGB-283 resulted in partial response in 1 of 2 melanoma patients harboring BRAF V600E, who remained on treatment for over 249 days (AACR Annual Meeting, Apr 2016, abstract # CT005).",Actionable,7229,1909,melanoma,DOID,1,BRAF V600E,sensitive,4025,BGB-283,673,None,,,
313,Phase I,"In a Phase I trial, Encorafenib (LGX818) showed activity in patients with advanced metastatic colorectal cancer harboring a BRAF V600E mutation, with a response of stable disease in 66.7% (12/18) (Ann Oncol (2014) 25 (suppl 4): iv182-iv183).",Actionable,1341,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,796,Encorafenib,673,None,,,
314,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E in culture (PMID: 23629727).",Actionable,8203,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,4657,Pimasertib + Regorafenib,673,23629727,,,
315,Preclinical - Cell line xenograft,"In a preclinical study, the combination of PLX4720 and Zolinza (vorinostat) resulted in antitumor efficacy in a melanoma cell line harboring BRAF V600E, demonstrating decreased cell survival and increased apoptotic activity in xenograft models, and decreased Rb phosphorylation in culture (PMID: 27924459).",Actionable,9663,1909,melanoma,DOID,1,BRAF V600E,sensitive,5121,PLX4720 + Vorinostat,673,27924459,,,
316,Phase II,"In a Phase II trial, 33% (26/78) of previously treated non-small cell lung carcinoma patients harboring BRAF V600E demonstrated an overall response, which included all partial responses, when treated with Tafinlar (dabrafenib) while 67% (4/6) receiving Tafinlar (dabrafenib) as a first-line treatment achieved partial responses (PMID: 27080216).",Actionable,706,3908,non-small cell lung carcinoma,DOID,1,BRAF V600E,sensitive,3,Dabrafenib,673,27080216,,,
317,Preclinical,"In a preclinical study, Gedatolisib (PKI-587) inhibited Braf V600E in vitro and inhibited growth of human colon cancer cells harboring BRAF V600E in culture (PMID: 21325073, PMID: 24042735).",Actionable,3130,219,colon cancer,DOID,1,BRAF V600E,sensitive,1040,PF-05212384,673,21325073,,24042735,
318,Preclinical,"In a preclinical study, colorectal cancer cell lines harboring a BRAF V600E mutation had increased sensitivity to Tafinlar (dabrafenib) in culture compared to cell lines with wild-type BRAF (PMID: 24885690).",Actionable,1321,9256,colorectal cancer,DOID,1,BRAF V600E,sensitive,3,Dabrafenib,673,24885690,,,
319,Preclinical - Cell line xenograft,"In a preclinical study, a glioblastoma cell line harboring BRAF V600E demonstrated a decreased response to treatment with PLX4720, demonstrating increased viability of CD133 positive cells in culture and in xenograft models (PMID: 26573800). ",Actionable,10192,3068,glioblastoma multiforme,DOID,1,BRAF V600E,decreased response,1060,PLX4720,673,26573800,,,
320,Phase I,"In a Phase I trial, Cotellic (cobimetinib) treatment resulted in a confirmed partial response in six melanoma patients harboring BRAF V600E (PMID: 27424159).",Actionable,12087,1909,melanoma,DOID,1,BRAF V600E,sensitive,1004,Cobimetinib,673,27424159,,,
321,Preclinical,"In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Zelboraf (vemurafenib) on human melanoma cells harboring BRAF V600E in culture (PMID: 25665005).",Actionable,4526,1909,melanoma,DOID,1,BRAF V600E,sensitive,3530,Navitoclax + Vemurafenib,673,25665005,,,
322,Preclinical,"In a preclinical study, E6201 inhibited Mapk pathway activation and proliferation of melanoma cell lines harboring BRAF V600E mutation in culture (PMID: 24448821).",Actionable,4028,1909,melanoma,DOID,1,BRAF V600E,sensitive,1011,E6201,673,24448821,,,
323,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E expressing MAP2K1 Q56P displayed reduced sensitivity to Mekinist (trametinib) mediated growth inhibition and retained MEK and ERK signaling (PMID: 22389471).",Actionable,5976,1909,melanoma,DOID,22096,BRAF V600E MAP2K1 Q56P,decreased response,2,Trametinib,673,22389471,,,
324,Preclinical - Cell culture,"In a preclinical study, BVD-523 (ulixertinib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 Q56P in culture (PMID: 28655712). ",Actionable,12165,1909,melanoma,DOID,22096,BRAF V600E MAP2K1 Q56P,sensitive,997,BVD-523,673,28655712,,,
325,Preclinical,"In a preclinical study, the combination of Talfinlar (dabrafenib)    and Mekinist (trametinib) resulted in improved growth inhibition in melanoma cells harboring BRAF V600E and expressing MAP2K1 Q56P in culture (PMID: 22389471).",Actionable,5982,1909,melanoma,DOID,22096,BRAF V600E MAP2K1 Q56P,sensitive,1066,Trametinib + Dabrafenib,673,22389471,,,
326,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E expressing MAP2K1 Q56P were resistant to Tafinlar (dabrafenib) mediated growth inhibition and retained MEK and ERK signaling in culture (PMID: 22389471).",Actionable,5975,1909,melanoma,DOID,22096,BRAF V600E MAP2K1 Q56P,resistant,3,Dabrafenib,673,22389471,,,
327,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 Q56P demonstrated resistance to treatment with Zelboraf (vemurafenib) in culture (PMID: 28655712). ",Actionable,12164,1909,melanoma,DOID,22096,BRAF V600E MAP2K1 Q56P,resistant,342,Vemurafenib,673,28655712,,,
328,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).",Actionable,7665,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,resistant,2618,SCH772984,673,27312529,,,
329,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment in culture (PMID: 27312529).",Actionable,7633,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,resistant,4536,Cetuximab + Selumetinib,673,27312529,,,
330,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Selumetinib (AZD6244), and Zelboraf (vemurafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).",Actionable,7634,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,sensitive,4540,Cetuximab + Selumetinib + Vemurafenib,673,27312529,,,
331,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Erbitux (cetuximab) in culture (PMID: 27312529).",Actionable,7635,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,resistant,694,Cetuximab,673,27312529,,,
332,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Selumetinib (AZD6244) in culture (PMID: 27312529).",Actionable,7637,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,resistant,913,Selumetinib,673,27312529,,,
333,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture, likely due to the acquired EGFR amplification (PMID: 27312529).",Actionable,7621,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,resistant,3773,Selumetinib + Vemurafenib,673,27312529,,,
334,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).",Actionable,7632,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,resistant,1711,Vemurafenib + Cetuximab,673,27312529,,,
335,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).",Actionable,7666,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,sensitive,4542,Cetuximab + Dabrafenib + SCH772984,673,27312529,,,
336,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) in culture (PMID: 27312529).",Actionable,7663,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,resistant,1916,Cetuximab + Encorafenib,673,27312529,,,
337,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7636,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,resistant,342,Vemurafenib,673,27312529,,,
338,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib) in culture (PMID: 27312529).",Actionable,7664,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,resistant,1066,Trametinib + Dabrafenib,673,27312529,,,
339,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",Actionable,7660,9256,colorectal cancer,DOID,21627,BRAF V600E MAP2K1 L115P,sensitive,4543,Cetuximab + SCH772984,673,27312529,,,
340,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 L115P demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",Actionable,12151,1909,melanoma,DOID,21627,BRAF V600E MAP2K1 L115P,resistant,2,Trametinib,673,28655712,,,
341,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",Actionable,7654,9256,colorectal cancer,DOID,21627,BRAF V600E MAP2K1 L115P,sensitive,1916,Cetuximab + Encorafenib,673,27312529,,,
342,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Tafinlar (dabrafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",Actionable,7655,9256,colorectal cancer,DOID,21627,BRAF V600E MAP2K1 L115P,sensitive,4525,Cetuximab + Dabrafenib,673,27312529,,,
343,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818) and Alpelisib (BYL719) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",Actionable,7657,9256,colorectal cancer,DOID,21627,BRAF V600E MAP2K1 L115P,sensitive,1917,LGX818 + Cetuximab + BYL719,673,27312529,,,
344,Preclinical - Cell culture,"In a preclinical study, SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",Actionable,7659,9256,colorectal cancer,DOID,21627,BRAF V600E MAP2K1 L115P,sensitive,2618,SCH772984,673,27312529,,,
345,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 L115P in culture (PMID: 28655712).",Actionable,12154,1909,melanoma,DOID,21627,BRAF V600E MAP2K1 L115P,sensitive,342,Vemurafenib,673,28655712,,,
346,Preclinical,"In a preclinical study, over expression of MAPK21 L115P in melanoma cells harboring BRAF V600E resulted in insensitivity to growth inhibition by PD-0325901 in cell culture (PMID: 26267534).",Actionable,5812,1909,melanoma,DOID,21627,BRAF V600E MAP2K1 L115P,resistant,849,PD-0325901,673,26267534,,,
347,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture, likely due to the acquired secondary resistance mutation MAP2K1 L115P (PMID: 27312529).",Actionable,7620,9256,colorectal cancer,DOID,21627,BRAF V600E MAP2K1 L115P,resistant,1066,Trametinib + Dabrafenib,673,27312529,,,
348,Preclinical - Cell culture,"In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 L115P in culture (PMID: 26267534).",Actionable,5817,1909,melanoma,DOID,21627,BRAF V600E MAP2K1 L115P,sensitive,3769,DEL-22379,673,26267534,,,
349,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",Actionable,7662,9256,colorectal cancer,DOID,21627,BRAF V600E MAP2K1 L115P,sensitive,4542,Cetuximab + Dabrafenib + SCH772984,673,27312529,,,
350,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",Actionable,7656,9256,colorectal cancer,DOID,21627,BRAF V600E MAP2K1 L115P,sensitive,1711,Vemurafenib + Cetuximab,673,27312529,,,
351,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",Actionable,7658,9256,colorectal cancer,DOID,21627,BRAF V600E MAP2K1 L115P,sensitive,4541,Cetuximab + Dabrafenib + Trametinib,673,27312529,,,
352,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",Actionable,7661,9256,colorectal cancer,DOID,21627,BRAF V600E MAP2K1 L115P,sensitive,4544,Dabrafenib + SCH772984,673,27312529,,,
353,Preclinical,"In a preclinical study, a melanoma mouse model harboring BRAF V600E treated with Zelboraf (vemurafenib) demonstrated a greater drug induced sensitivity when treatment was combined with PLX3397, resulting in increased infiltration of lymphocytes via Csf1r inhibition and elevated antitumor activity (PMID: 25939769).",Actionable,6075,1909,melanoma,DOID,22385,BRAF V600E CSF1R positive,sensitive,1339,PLX3397 + Vemurafenib,673,25939769,,,
354,Clinical Study,"In a clinical study, a colon cancer patient harboring BRAF V600E and TP53 Q192K demonstrated a partial response when treated with a combination of Zelboraf (vemurafenib) and Vectibix (panitumumab) (PMID: 28514312). ",Actionable,11052,219,colon cancer,DOID,27902,BRAF V600E TP53 Q192K,sensitive,1717,Vemurafenib + Panitumumab,673,28514312,,,
355,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5969,1909,melanoma,DOID,22045,BRAF V600E MAP2K1 K59del,decreased response,763,GSK2126458,673,22389471,,,
356,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to growth inhibition by Mekinist (trametinib) in culture (PMID: 22389471).",Actionable,5964,1909,melanoma,DOID,22045,BRAF V600E MAP2K1 K59del,resistant,2,Trametinib,673,22389471,,,
357,Preclinical,"In a preclinical study, Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del in culture, compared to either agent alone (PMID: 22389471).",Actionable,5983,1909,melanoma,DOID,22045,BRAF V600E MAP2K1 K59del,sensitive,4004,Dabrafenib + GSK2126458,673,22389471,,,
358,Preclinical,"In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E harboring MAP2K1 K59del in culture (PMID: 22389471).",Actionable,5980,1909,melanoma,DOID,22045,BRAF V600E MAP2K1 K59del,sensitive,1066,Trametinib + Dabrafenib,673,22389471,,,
359,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).",Actionable,5953,1909,melanoma,DOID,22045,BRAF V600E MAP2K1 K59del,resistant,3,Dabrafenib,673,22389471,,,
360,Preclinical,"In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del in culture, compared to either agent alone (PMID: 22389471).",Actionable,5984,1909,melanoma,DOID,22045,BRAF V600E MAP2K1 K59del,sensitive,3027,GSK2126458 + Trametinib,673,22389471,,,
361,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).",Actionable,5957,1909,melanoma,DOID,22045,BRAF V600E MAP2K1 K59del,resistant,342,Vemurafenib,673,22389471,,,
362,Preclinical,"In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of human melanoma cells harboring BRAF V600E and NRAS A146T and NRAS Q61K in culture (PMID: 22389471).",Actionable,5979,1909,melanoma,DOID,22097,BRAF V600E NRAS Q61K NRAS A146T,sensitive,1066,Trametinib + Dabrafenib,673,22389471,,,
363,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 V60E demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).",Actionable,7056,1909,melanoma,DOID,24281,BRAF V600E MAP2K1 V60E,resistant,3,Dabrafenib,673,24265153,,,
364,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 V60E demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).",Actionable,7002,1909,melanoma,DOID,24281,BRAF V600E MAP2K1 V60E,sensitive,4351,VRT11E,673,24265153,,,
365,Clinical Study,"In a clinical case study, a patient with anaplastic thyroid carcinoma co-harboring BRAF V600E and PIK3CA H1047R demonstrated resistance to treatment with Afinitor (everolimus) (PMID: 27797976). ",Actionable,10814,3963,thyroid carcinoma,DOID,26356,BRAF V600E PIK3CA H1047R,resistant,735,Everolimus,673,27797976,,,
366,Clinical Study,"In a clinical case study, a patient with anaplastic thyroid carcinoma co-harboring BRAF V600E and PIK3CA H1047R demonstrated resistance to the combination therapy, Mekinist (trametinib) and Tafinlar (dabrafenib) (PMID: 27797976).",Actionable,10815,3963,thyroid carcinoma,DOID,26356,BRAF V600E PIK3CA H1047R,resistant,1066,Trametinib + Dabrafenib,673,27797976,,,
367,Clinical Study,"In a clinical case study, a patient with anaplastic thyroid carcinoma co-harboring BRAF V600E and PIK3CA H1047R demonstrated tumor regression when treated with the triple combination, Tafinlar (dabrafenib), Mekinist (trametinib), and Afinitor (everolimus) (PMID: 27797976).",Actionable,10812,3963,thyroid carcinoma,DOID,26356,BRAF V600E PIK3CA H1047R,sensitive,5650,Dabrafenib + Everolimus + Trametinib,673,27797976,,,
368,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS A146T mutation and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) in culture (PMID: 27312529).",Actionable,7687,9256,colorectal cancer,DOID,25924,BRAF V600E KRAS A146T,resistant,1917,LGX818 + Cetuximab + BYL719,673,27312529,,,
369,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment in culture, likely due to the acquired secondary resistance mutation KRAS A146T (PMID: 27312529).",Actionable,7623,9256,colorectal cancer,DOID,25924,BRAF V600E KRAS A146T,resistant,1916,Cetuximab + Encorafenib,673,27312529,,,
370,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS A146T mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7680,9256,colorectal cancer,DOID,25924,BRAF V600E KRAS A146T,resistant,1711,Vemurafenib + Cetuximab,673,27312529,,,
371,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment in culture, likely due to the acquired secondary resistance mutation KRAS A146T (PMID: 27312529).",Actionable,7624,9256,colorectal cancer,DOID,25924,BRAF V600E KRAS A146T,resistant,4525,Cetuximab + Dabrafenib,673,27312529,,,
372,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) inhibited survival of colorectal cancer cell lines harboring BRAF V600E that acquired a KRAS A146T mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment in culture (PMID: 27312529).",Actionable,7682,9256,colorectal cancer,DOID,25924,BRAF V600E KRAS A146T,sensitive,4541,Cetuximab + Dabrafenib + Trametinib,673,27312529,,,
373,Clinical Study,"In a clinical study, a colorectal cancer patient harboring EGFR amplification, BRAF V600E, and EGFR S492R demonstrated resistance to Erbitux (cetuximab) (PMID: 22270724). ",Actionable,3221,9256,colorectal cancer,DOID,12768,EGFR amp EGFR S492R BRAF V600E,resistant,694,Cetuximab,673,22270724,,,
374,Preclinical,"In a preclinical study, treatment with the combination of GSK2636771 and a PD-1 antibody resulted in greater tumor infiltration of T-cells and tumor growth inhibition in mouse melanoma models expressing BRAF V600E with PTEN loss compared to either agent alone (PMID: 26645196).",Actionable,10891,1909,melanoma,DOID,23099,BRAF V600E PTEN loss,sensitive,5673,GSK2636771 + unspecified PD-1 antibody,673,26645196,,,
375,Preclinical - Cell line xenograft,"In a preclinical study, XL147 inhibited tumor growth in xenograft models of a PTEN-deficient human melanoma cell line harboring BRAF V600E (PMID: 25637314).",Actionable,6318,1909,melanoma,DOID,23099,BRAF V600E PTEN loss,sensitive,1050,XL147,673,25637314,,,
376,Clinical Study,"In a clinical study, a melanoma patient harboring PTEN loss and BRAF V600E demonstrated resistance to Afinitor (everolimus) treatment, resulting in progressive disease (PMID: 20664172).",Actionable,1233,1909,melanoma,DOID,23099,BRAF V600E PTEN loss,resistant,735,Everolimus,673,20664174,20664172,,
377,Preclinical - Cell culture,"In a preclinical study, GDC0879 and Pictilisib (GDC-0941) synergistically inhibited survival of melanoma cell lines harboring BFAF V600E and PTEN loss in cell culture (PMID: 19276360).",Actionable,7899,1909,melanoma,DOID,23099,BRAF V600E PTEN loss,sensitive,4605,GDC0879 + GDC-0941,673,19276360,,,
378,Preclinical,"In a preclinical study, a melanoma cell line harboring BRAF V600E and PTEN loss demonstrated sensitivity when treated with a combination of Pictilisib (GDC-0941) and PLX4720, resulting in decreased cell proliferation in culture (PMID: 24265153).",Actionable,7081,1909,melanoma,DOID,23099,BRAF V600E PTEN loss,sensitive,4358,GDC-0941 + PLX4720,673,24265153,,,
379,Preclinical - Cell culture,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring BRAF V600E and PIK3CA H1047R in culture (PMID: 26272063).",Actionable,8568,9256,colorectal cancer,DOID,26361,BRAF V600E PIK3CA H1047R TP53 wild-type,sensitive,4771,MLN0128 + PD-0325901,673,26272063,,,
380,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture (PMID: 24265153).",Actionable,7057,1909,melanoma,DOID,24282,BRAF V600E MAP2K1 P124S,resistant,3,Dabrafenib,673,24265153,,,
381,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 24265153).",Actionable,7061,1909,melanoma,DOID,24282,BRAF V600E MAP2K1 P124S,resistant,2,Trametinib,673,24265153,,,
382,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and MAP2K1 P124S demonstrated decreased sensitivity to Selumetinib (AZD6244) compared to cells harboring BRAF V600E alone in culture (PMID: 22197931).",Actionable,7035,1909,melanoma,DOID,24282,BRAF V600E MAP2K1 P124S,decreased response,913,Selumetinib,673,22197931,,,
383,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).",Actionable,7004,1909,melanoma,DOID,24282,BRAF V600E MAP2K1 P124S,sensitive,4351,VRT11E,673,24265153,,,
384,Clinical Study,"In a clinical case study, a patient with synchronous BRAF wild-type hepatocellular carcinoma and non-small cell lung cancer harboring BRAF G469V demonstrated a partial response in primary lung lesions and complete response in the lung metastasis following treatment with Nexavar (sorafenib) (PMID: 27388325). ",Actionable,9613,3908,non-small cell lung carcinoma,DOID,1777,BRAF G469V,sensitive,920,Sorafenib,673,27388325,,,
385,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF G469V (PMID: 26343582).",Actionable,9414,10000003,Advanced Solid Tumor,JAX,1777,BRAF G469V,resistant,342,Vemurafenib,673,26343582,,,
386,Clinical Study,"In a clinical case study, a rectal adenocarcinoma patient harboring APC Q1429fs, BRAF N581S, and ERBB2 L755S did not respond to Herceptin (trastuzumab) treatment in combination with Fluorouracil and Wellcovorin (leucovorin) (PMID: 27626067).",Actionable,9333,1996,rectum adenocarcinoma,DOID,26822,APC Q1429fs BRAF N581S ERBB2 L755S,no benefit,4970,Fluorouracil + Leucovorin + Trastuzumab,673,27626067,,,
387,Preclinical - Patient cell culture,"In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 combination treatment resulted in significant apoptosis in primary tumor cells isolated from a lung adenocarcinoma patient harboring BRAF N581S in culture (PMID: 26140595).",Actionable,10261,3910,lung adenocarcinoma,DOID,3326,BRAF N581S,predicted â€“ sensitive,5443,PF3644022 + PF-477736,673,26140595,,,
388,Preclinical - Pdx,"In a preclinical study, treatment with Mekinist (trametinib) inhibited tumor growth and reduced ERK signaling in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).",Actionable,11661,4464,collecting duct carcinoma,DOID,28180,BRAF D594N BRAF G466A EGFR over exp MET over exp,sensitive,2,Trametinib,673,28783719,,,
389,Preclinical - Pdx,"In a preclinical study, the combination of Mekinist (trametinib) and Capmatinib (INC280) induced tumor regression in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).",Actionable,11662,4464,collecting duct carcinoma,DOID,28180,BRAF D594N BRAF G466A EGFR over exp MET over exp,sensitive,6103,INC280 + Trametinib,673,28783719,,,
390,Preclinical - Pdx,"In a preclinical study, treatment with Capmatinib (INC280) inhibited tumor growth and reduced ERK signaling in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).",Actionable,11660,4464,collecting duct carcinoma,DOID,28180,BRAF D594N BRAF G466A EGFR over exp MET over exp,sensitive,1065,Capmatinib,673,28783719,,,
391,Preclinical - Cell culture,"In a preclinical study, non-small cell lung cancer cells harboring BRAF L485Y were resistant to GDC0879 induced growth inhibition in culture (PMID: 19276360).",Actionable,7876,3908,non-small cell lung carcinoma,DOID,26081,BRAF L485Y,resistant,1095,GDC0879,673,19276360,,,
392,Clinical Study,"In a clinical case study, a lung adenocarcinoma patient harboring BRAF G469L did not respond to Zelboraf (vemurafenib) therapy (PMID: 24035431).",Actionable,9610,3910,lung adenocarcinoma,DOID,4782,BRAF G469L,no benefit,342,Vemurafenib,673,24035431,,,
393,Clinical Study,"In a clinical study, mutant BRAF correlated with prolonged duration on Opdivo (nivolumab) therapy compared to wild-type BRAF in non-small cell lung carcinoma patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #1138PD).",Actionable,12099,3908,non-small cell lung carcinoma,DOID,465,BRAF mutant,predicted â€“ sensitive,1312,Nivolumab,673,None,,,
394,Preclinical - Cell culture,"In a preclinical study, MLN2480 inhibited downstream signaling and proliferation of several BRAF mutant solid tumor cell lines in culture (EJC Supp, Nov 2010, Vol 8(7), p40-41).",Actionable,9609,10000003,Advanced Solid Tumor,JAX,465,BRAF mutant,predicted â€“ sensitive,1034,MLN2480,673,None,,,
395,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) resulted in some reduced cell growth in colon cancer cells harboring a BRAF mutation in culture (PMID: 27655129). ",Actionable,10057,219,colon cancer,DOID,465,BRAF mutant,predicted â€“ sensitive,913,Selumetinib,673,27655129,,,
396,Phase I,"In a Phase I study, selumetinib demonstrated an increase in iodine uptake and retention in a subgroup of patients with thyroid cancer that was refractory to radioiodine; including patients with BRAF and NRAS mutations disease (PMID: 23406027).",Actionable,1028,1781,thyroid cancer,DOID,465,BRAF mutant,sensitive,913,Selumetinib,673,23406027,,,
397,Phase I,"In a Phase I clinical trial, Tafinlar (dabrafenib) demonstrated safety and efficacy in patients with BRAF V600E positive solid tumors (PMID: 22608338).",Actionable,701,10000003,Advanced Solid Tumor,JAX,465,BRAF mutant,sensitive,3,Dabrafenib,673,22608338,,,
398,Preclinical - Pdx,"In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of BRAF-mutant gastric carcinoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",Actionable,11701,5517,stomach carcinoma,DOID,465,BRAF mutant,predicted â€“ sensitive,5747,KO-947,673,None,,,
399,Phase I,"In a Phase I trial, Encorafenib (LGX818) treatment resulted in an overall response rate (ORR) of 60% (15/25) and a median progression-free survival (mPFS) of 12.4 months in BRAF inhibitor-naÃ¯ve melanoma patients harboring BRAF mutations, and an ORR of 22% (6/29) and mPFS of 1.9 months in BRAF inhibitor-pretreated patients (PMID: 28611198; NCT01436656).",Actionable,12133,1909,melanoma,DOID,465,BRAF mutant,sensitive,796,Encorafenib,673,28611198,,,
400,Preclinical - Cell culture,"In a preclinical study, combination of S63845 and Mekinist (trametinib) resulted in potent cytotoxic effects in BRAF-mutated melanoma cells in culture compared to the cytostatic effect of Mekinist (trametinib) alone (PMID: 27760111).",Actionable,9039,1909,melanoma,DOID,465,BRAF mutant,sensitive,4864,S63845 + Trametinib,673,27760111,,,
401,Preclinical - Pdx,"In a preclinical study, LSN3074753 resulted in a disease control rate of 8.3% (1/12) in BRAF mutant patient-derived xenograft models of colorectal cancer (PMID: 28611205).",Actionable,12191,9256,colorectal cancer,DOID,465,BRAF mutant,predicted â€“ sensitive,6337,LSN3074753,673,28611205,,,
402,Phase I,"In a Phase I trial, MLN2480 resulted in a median progression free survival of 4.6 months and a partial response in 50% (8/16) of melanoma patients harboring a BRAF mutation (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 410P; NCT01425008).",Actionable,11978,1909,melanoma,DOID,465,BRAF mutant,sensitive,1034,MLN2480,673,None,,,
403,Preclinical,"In a preclinical study, MLN2480 demonstrated efficacy in BRAF mutant xenograft models of melanoma and colorectal cancer (J Clin Oncol 31, 2013 (suppl; abstr e13529)).",Actionable,1128,1909,melanoma,DOID,465,BRAF mutant,sensitive,1034,MLN2480,673,None,,,
404,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited growth of human multiple myeloma cells harboring mutant BRAF in culture (PMID: 26343583).",Actionable,6687,9538,multiple myeloma,DOID,465,BRAF mutant,sensitive,2,Trametinib,673,26343583,,,
405,Preclinical - Cell culture,"In a preclinical study, BRAF mutant colorectal cancer cell lines demonstrated reduced sensitivity to PLX4720 in culture (PMID: 26351322).",Actionable,8667,9256,colorectal cancer,DOID,465,BRAF mutant,decreased response,1060,PLX4720,673,26351322,,,
406,Preclinical - Cell line xenograft,"In a preclinical study, Buparlisib (BKM120) treatment in human melanoma cell line xenograft models with brain metastases and harboring a BRAF mutation resulted in inhibition of brain tumor growth (PMID: 27307593). ",Actionable,10124,1909,melanoma,DOID,465,BRAF mutant,sensitive,680,BKM120,673,27307593,,,
407,Preclinical,"In a preclinical study, MLN2480 demonstrated efficacy in BRAF mutant xenograft models of melanoma and colorectal cancer (J Clin Oncol 31, 2013 (suppl; abstr e13529)).",Actionable,1127,9256,colorectal cancer,DOID,465,BRAF mutant,sensitive,1034,MLN2480,673,None,,,
408,Phase I,"In a Phase I trial, BGB-283 demonstrated safety and preliminary efficacy, resulted in partial response in 14% (4/29), and prolonged stable disease in 48% (14/29) of advanced solid tumor patients harboring mutations in KRAS, NRAS, and/or BRAF (AACR Annual Meeting, Apr 2016, abstract # CT005).",Actionable,7228,10000003,Advanced Solid Tumor,JAX,465,BRAF mutant,sensitive,4025,BGB-283,673,None,,,
409,Preclinical,"In a preclinical study, E6201 inhibited proliferation of several melanoma cell lines in culture and hypersensitivity was associated with BRAF mutations (PMID: 23039341).",Actionable,5624,1909,melanoma,DOID,465,BRAF mutant,sensitive,1011,E6201,673,23039341,,,
410,Preclinical - Cell line xenograft,"In a preclinical study, PET-16 and Zelboraf (vemurafenib) synergistically inhibited growth of melanoma cell lines in culture, resulted in enhanced tumor growth inhibition in cell ine xenograft models (PMID: 26984758).",Actionable,11223,1909,melanoma,DOID,465,BRAF mutant,sensitive,5911,PET-16 + Vemurafenib,673,26984758,,,
411,Phase Ib/II,"In a Phase I/II trial, treatment with the triple combination of Tafinlar (dabrafenib), Mekinist (trametinib), and Vectibix (panitumumab) resulted in an objective response rate (ORR) of 21% and median progression-free survival (mPFS) of 4.2 mo, compared with 0% ORR and mPFS of 2.6 mo with Mekinist (trametinib) plus Vectibix (panitumumab), and 10% ORR and mPFS of 3.5 mo with Tafinlar (dabrafenib) plus Vectibix (panitumumab) in patients with BRAF-mutant colorectal cancer (PMID: 27770002; NCT01750918).",Actionable,11932,9256,colorectal cancer,DOID,465,BRAF mutant,predicted â€“ sensitive,1992,Panitumumab + Trametinib + Dabrafenib,673,27770002,,,
412,Preclinical - Pdx,"In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of BRAF-mutant pancreatic cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",Actionable,11697,1793,pancreatic cancer,DOID,465,BRAF mutant,predicted â€“ sensitive,5747,KO-947,673,None,,,
413,Preclinical - Pdx,"In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of BRAF-mutant colorectal cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",Actionable,11699,9256,colorectal cancer,DOID,465,BRAF mutant,predicted â€“ sensitive,5747,KO-947,673,None,,,
414,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited growth of lung adenocarcinoma cells harboring mutant BRAF in culture (PMID: 26343583).",Actionable,6697,3910,lung adenocarcinoma,DOID,465,BRAF mutant,sensitive,2,Trametinib,673,26343583,,,
415,Preclinical,"In a preclinical study, E6201 and LY294002 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations in culture, regardless of PTEN mutation status (PMID: 23039341).",Actionable,5627,1909,melanoma,DOID,465,BRAF mutant,sensitive,3911,E6201 + LY294002,673,23039341,,,
416,Preclinical,"In a preclinical study, Tubastatin A inhibited proliferation of BRAF mutant melanoma cell lines in culture (PMID: 25957812).",Actionable,4764,1909,melanoma,DOID,465,BRAF mutant,sensitive,3635,Tubastatin A,673,25957812,,,
417,Phase I,"In a Phase Ia trial, CC-90003 treatment did not result in any objective responses and demonstrated toxicity in advanced solid tumor patients harboring KRAS, NRAS, or BRAF mutations (AJ Clin Oncol 35, 2017 (suppl; abstr 2577)).",Actionable,11066,10000003,Advanced Solid Tumor,JAX,465,BRAF mutant,no benefit,2874,CC-90003,673,None,,,
418,Preclinical - Pdx,"In a preclinical study, LSN3074753 and Erbitux (cetuximab) synergistically inhibited tumor growth in patient-derived xenograft models of colorectal cancer harboring BRAF mutations, resulted in a disease control rate of 41.7% (5/12) (PMID: 28611205).",Actionable,12194,9256,colorectal cancer,DOID,465,BRAF mutant,sensitive,6338,Cetuximab + LSN3074753,673,28611205,,,
419,Preclinical,"In a preclinical study, a majority of human colorectal cancer cell lines (4/7) harboring mutant BRAF were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",Actionable,6738,9256,colorectal cancer,DOID,465,BRAF mutant,resistant,2,Trametinib,673,26343583,,,
420,Phase I,"In a Phase I trial, Voruciclib (P1446A-05) and Zelboraf (vemurafenib) combination therapy demonstrated safety and preliminary efficacy, resulted in complete response in 33% (1/3) and partial response in 67% (2/3) of BRAFi-naÃ¯ve melanoma patients harboring BRAF mutations (J Clin Oncol 33, 2015 (suppl; abstr 9076)).",Actionable,5891,1909,melanoma,DOID,465,BRAF mutant,sensitive,1238,Vemurafenib + Voruciclib,673,None,,,
421,Preclinical - Cell line xenograft,"In a preclinical study, treatment with BI-847325 resulted in decreased expression of Mcl-1 and Mek, and inhibited growth of BRAF-mutant melanoma cell lines in culture, and inhibited tumor growth melanoma cell line xenograft models harboring BRAF mutations, including models with BRAF inhibitor resistance (PMID: 25873592).",Actionable,7827,1909,melanoma,DOID,465,BRAF mutant,predicted â€“ sensitive,1059,BI-847325,673,25873592,,,
422,Preclinical - Pdx,"In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of BRAF-mutant cervical carcinoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",Actionable,11703,2893,cervix carcinoma,DOID,465,BRAF mutant,predicted â€“ sensitive,5747,KO-947,673,None,,,
423,Phase I,"In a Phase I trial, Binimetinib (MEK162) treatment resulted in an estimated progression free survival of 1.4 months and overall survival of 7.1 months in colorectal cancer patients harboring BRAF mutations (PMID: 28152546).",Actionable,10459,9256,colorectal cancer,DOID,465,BRAF mutant,predicted â€“ sensitive,807,Binimetinib,673,28152546,,,
424,Preclinical - Pdx,"In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of BRAF-mutant non-small cell lung cancer harboring (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",Actionable,11695,3908,non-small cell lung carcinoma,DOID,465,BRAF mutant,predicted â€“ sensitive,5747,KO-947,673,None,,,
425,Preclinical,"In a preclinical study, obatoclax decreased proliferation in human tumor cell lines with BRAF mutation in culture (PMID: 22460902).",Actionable,1823,10000003,Advanced Solid Tumor,JAX,465,BRAF mutant,sensitive,834,Obatoclax,673,22460902,,,
426,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited growth of human pancreatic adenocarcinoma cells harboring mutant BRAF in culture (PMID: 26343583).",Actionable,6731,4074,pancreatic adenocarcinoma,DOID,465,BRAF mutant,sensitive,2,Trametinib,673,26343583,,,
427,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) and AZ628 synergistically inhibited Mapk signaling and cell proliferation in BRAF mutant colorectal cancer cell lines in culture (PMID: 26351322).",Actionable,8676,9256,colorectal cancer,DOID,465,BRAF mutant,sensitive,4791,AZ628 + Selumetinib,673,26351322,,,
428,Preclinical - Cell culture,"In a preclinical study, combination of S63845 and Zelboraf (vemurafenib) resulted in potent cytotoxic effects in BRAF-mutated melanoma cells in culture compared to the cytostatic effect of Zelboraf (vemurafenib) alone (PMID: 27760111).",Actionable,9041,1909,melanoma,DOID,465,BRAF mutant,sensitive,4865,S63845 + Vemurafenib,673,27760111,,,
429,Preclinical - Cell culture,"In a preclinical study, treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) resulted in decreased proliferation and increased apoptosis and enhanced ERK inhibition compared to either agent alone in non-small cell lung cancer cell lines harboring non-BRAF V600 mutations in culture (PMID: 27577079).",Actionable,9612,3908,non-small cell lung carcinoma,DOID,465,BRAF mutant,predicted â€“ sensitive,1066,Trametinib + Dabrafenib,673,27577079,,,
430,Preclinical - Cell culture,"In a preclinical study, a melanoma cell line harboring a BRAF mutation demonstrated greater sensitivity to the combination treatment of Mekinist (trametinib) and Ibrance (palbociclib) in culture when compared to either agent alone (PMID: 27488531). ",Actionable,8542,1909,melanoma,DOID,465,BRAF mutant,sensitive,1368,Palbociclib + Trametinib,673,27488531,,,
431,Preclinical - Cell line xenograft,"In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of BRAF mutant colon cancer (PMID: 26140595).",Actionable,10259,219,colon cancer,DOID,465,BRAF mutant,predicted â€“ sensitive,5443,PF3644022 + PF-477736,673,26140595,,,
432,Preclinical - Pdx,"In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of BRAF-mutant melanoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",Actionable,11693,1909,melanoma,DOID,465,BRAF mutant,predicted â€“ sensitive,5747,KO-947,673,None,,,
433,Phase II,"In a Phase II trial in patients with advanced melanoma, 5/6 patients exhibiting a response to selumetinib had BRAF-mutant tumors (PMID: 22048237).",Actionable,713,1909,melanoma,DOID,465,BRAF mutant,sensitive,913,Selumetinib,673,22048237,,,
434,Preclinical - Pdx,"In a preclinical study, KO-947 resulted in tumor regression in patient derived xenograft (PDX) models harboring either a BRAF mutation, NRAS mutation, or KRAS mutation (EJC Dec 2016, 69:1; S126).",Actionable,10965,10000003,Advanced Solid Tumor,JAX,465,BRAF mutant,predicted â€“ sensitive,5747,KO-947,673,None,,,
435,Preclinical,"In a preclinical study, tumor cell lines harboring BRAF mutations demonstrated limited sensitivity to XL147 treatment in culture (PMID: 25637314).",Actionable,6302,10000003,Advanced Solid Tumor,JAX,465,BRAF mutant,decreased response,1050,XL147,673,25637314,,,
436,Phase Ib/II,"In a Phase Ib/II trial, the combination therapy of Erbitux (cetuximab) and Encorafenib (LGX818) in colorectal cancer patients harboring a BRAF mutation resulted in an overall response rate of 19% (5/26), including 1 patient with a complete response and 4 patients with a partial response, and led to a median progression free survival of 3.7 months and response duration of 46 weeks (PMID: 28363909).",Actionable,11203,9256,colorectal cancer,DOID,465,BRAF mutant,sensitive,1916,Cetuximab + Encorafenib,673,28363909,,,
437,Preclinical,"In a preclinical study, PLX8394 blocked survival and growth of vemurafenib/PLX4720-resistant melanoma cells harboring BRAF V600E splice variants in culture (PMID: 24422853).",Actionable,2529,1909,melanoma,DOID,465,BRAF mutant,sensitive,1041,PLX8394,673,24422853,,,
438,Preclinical - Cell culture,"In a preclinical study, the combination of Binimetinib (MEK162) and Buparlisib (BKM120) resulted in improved cell growth inhibition compared to either agent alone in a metastatic melanoma cell line harboring a BRAF mutation in culture (PMID: 27307593). ",Actionable,10120,1909,melanoma,DOID,465,BRAF mutant,sensitive,5400,Binimetinib + BKM120,673,27307593,,,
439,Phase Ib/II,"In a Phase Ib/II trial, the triple combination therapy of Encorafenib (LGX818), Erbitux (cetuximab), and Alpelisib (BYL719) resulted in an overall response rate of 18% (5/28), including 5 patients with a partial response, and led to a median progression free survival of 4.2 months and response duration of 12 weeks (PMID: 28363909).",Actionable,6961,9256,colorectal cancer,DOID,465,BRAF mutant,sensitive,1917,LGX818 + Cetuximab + BYL719,673,None,28363909,,
440,Preclinical - Cell culture,"In a preclinical study, the combination of Buparlisib (BKM120) and Encorafenib (LGX818) resulted in improved cell growth inhibition compared to either agent alone in a metastatic melanoma cell line harboring a BRAF mutation in culture (PMID: 27307593). ",Actionable,10123,1909,melanoma,DOID,465,BRAF mutant,sensitive,1337,Encorafenib + BKM120,673,27307593,,,
441,Preclinical - Cell line xenograft,"In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited growth of various cancer cell lines harboring BRAF mutations in culture and in cell line xenograft models (PMID: 26140595).",Actionable,10254,10000003,Advanced Solid Tumor,JAX,465,BRAF mutant,predicted â€“ sensitive,5443,PF3644022 + PF-477736,673,26140595,,,
442,Preclinical - Cell culture,"In a preclinical study, treatment with BI-847325 inhibited growth of a BRAF-mutant melanoma cell line with BRAF-inhibitor resistance due to a KRAS mutation in culture (PMID: 25873592).",Actionable,7831,1909,melanoma,DOID,26062,BRAF mut KRAS mut,predicted â€“ sensitive,1059,BI-847325,673,25873592,,,
443,Preclinical - Cell culture,"In a preclinical study, BRAF mutant melanoma cells over-expressing KRAS G12V were resistant to Selumetinib (AZD6244) and AZ628 combination treatment in culture (PMID: 26351322).",Actionable,8682,1909,melanoma,DOID,26406,BRAF mut KRAS G12V,resistant,4791,AZ628 + Selumetinib,673,26351322,,,
444,Preclinical - Cell line xenograft,"In a preclinical study, E6201 resulted in a cytostatic response in melanoma cell lines harboring both BRAF and PTEN mutations in culture and only inhibited tumor growth at very high doses in cell line xenograft models (PMID: 23039341).",Actionable,5628,1909,melanoma,DOID,21306,BRAF mut PTEN mut,decreased response,1011,E6201,673,23039341,,,
445,Preclinical - Cell culture,"In a preclinical study, knocking down of Ptpn11 expression via shRNA sensitized BRAF mutant colorectal cancer cell lines to PLX4720 in culture (PMID: 26351322).",Actionable,8668,9256,colorectal cancer,DOID,26402,BRAF mut PTPN11 dec exp,sensitive,1060,PLX4720,673,26351322,,,
446,Preclinical,"In a preclinical study, AZD6482 and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6103,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,4044,AZD6482 + NVP-AEW541,673,26577700,,,
447,Preclinical - Cell line xenograft,"In a preclinical study, the combination of GSK2636771 and Alpelisib (BYL719) synergized to inhibit proliferation of human melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture, and inhibited tumor growth in xenograft models of one cell line harboring these mutations (PMID: 26577700).",Actionable,6102,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,4042,BYL719 + GSK2636771,673,26577700,,,
448,Preclinical,"In a preclinical study, GSK2636771 and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6111,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,4055,GSK2636771 + LGX818,673,26577700,,,
449,Preclinical - Cell line xenograft,"In a preclinical study, combination treatment consisting of GSK2636771 and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).",Actionable,6136,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,4067,GSK2636771 + unspecified IGF-1R antibody,673,26577700,,,
450,Preclinical,"In a preclinical study, Pictilisib (GDC-0941) and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6109,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,4056,GDC-0941 + LGX818,673,26577700,,,
451,Preclinical - Cell line xenograft,"In a preclinical study, the combination of GSK2636771, Encorafenib (LGX818), and Alpelisib (BYL719) efficiently inhibited tumor growth in xenograft models of a human melanoma cell line harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).",Actionable,6133,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,4065,BYL719 + GSK2636771 + LGX818,673,26577700,,,
452,Preclinical - Cell line xenograft,"In a preclinical study, combination treatment consisting of GSK2636771, Encorafenib (LGX818), and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).",Actionable,6138,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,4069,GSK2636771 + LGX818 + unspecified IGF-1R antibody,673,26577700,,,
453,Preclinical,"In a preclinical study, Alpelisib (BYL719) and Encorafenib (LGX818) combination treatment did not enhance growth inhibition in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6113,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,no benefit,4049,BYL719 + LGX818,673,26577700,,,
454,Preclinical,"In a preclinical study, Pictilisib (GDC-0941) and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6115,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,4053,GDC-0941 + Binimetinib,673,26577700,,,
455,Preclinical,"In a preclinical study, combination treatment consisting of AZD6482, Encorafenib (LGX818), and Alpelisib (BYL719) efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6125,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,4062,AZD6482 + LGX818 + BYL719,673,26577700,,,
456,Preclinical,"In a preclinical study, AZD6482 and Alpelisib (BYL719) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6101,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,3714,AZD6482 + BYL719,673,26577700,,,
457,Preclinical,"In a preclinical study, AZD6482 and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6117,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,4054,AZD6482 + Binimetinib,673,26577700,,,
458,Preclinical,"In a preclincal study, Pictilisib (GDC-0941) inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6099,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,749,GDC-0941,673,26577700,,,
459,Preclinical,"In a preclinical study, combination treatment consists of Encorafenib (LGX818) and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).",Actionable,6137,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,4068,LGX818 + unspecified IGF-1R antibody,673,26577700,,,
460,Preclinical,"In a preclinical study, combination treatment consists of AZD6482, Encorafenib (LGX818), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6126,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,4061,AZD6482 + LGX818 + NVP-AEW541,673,26577700,,,
461,Preclinical,"In a preclinical study, GSK2636771 and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6118,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,4052,GSK2636771 + Binimetinib,673,26577700,,,
462,Preclinical,"In a preclinical study, combination treatment consisting of AZD6482, Binimetinib (MEK162), Encorafenib (LGX818), and Alpelisib (BYL719) efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6131,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,4063,AZD6482 + Binimetinib + LGX818 + BYL719,673,26577700,,,
463,Preclinical,"In a preclinical study, Alpelisib (BYL719) and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6119,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,no benefit,1311,BYL719 + MEK162,673,26577700,,,
464,Preclinical,"In a preclinical study, GSK2636771 and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6104,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,4045,GSK2636771 + NVP-AEW541,673,26577700,,,
465,Preclinical,"In a preclincal study, TGX-221 inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6098,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,2514,TGX-221,673,26577700,,,
466,Preclinical,"In a preclinical study, Pictilisib (GDC-0941) and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6105,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,4046,GDC-0941 + NVP-AEW541,673,26577700,,,
467,Preclinical,"In a preclinical study, AZD6482 and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6110,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,4048,AZD6482 + LGX818,673,26577700,,,
468,Preclinical,"In a preclincal study, AZD6482 inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6097,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,659,AZD6482,673,26577700,,,
469,Preclinical,"In a preclinical study, Alpelisib (BYL719) and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6106,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,no benefit,4047,BYL719 + NVP-AEW541,673,26577700,,,
470,Preclinical,"In a preclinical study, combination treatment consists of AZD6482, Binimetinib (MEK162), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6128,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,4060,AZD6482 + Binimetinib + NVP-AEW541,673,26577700,,,
471,Preclinical,"In a preclinical study, combination treatment consists of AZD6482, Binimetinib (MEK162), Encorafenib (LGX818), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6130,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,4064,AZD6482 + Binimetinib + LGX818 + NVP-AEW541,673,26577700,,,
472,Preclinical,"In a preclincal study, melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations were less sensitive to Alpelisib (BYL719)-induced growth inhibition in culture (PMID: 26577700).",Actionable,6100,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,decreased response,691,BYL719,673,26577700,,,
473,Preclinical - Cell culture,"In a preclinical study, combination treatment consisting of AZD6482, Binimetinib (MEK162), and Alpelisib (BYL719) efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6127,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,4059,AZD6482 + Binimetinib + BYL719,673,26577700,,,
474,Preclinical - Cell culture,"In a preclinical study, a melanoma cell line with a BRAF mutation and loss of RB1 demonstrated minimal sensitivity when treated with the combination of Ibrance (palbociclib) and Mekinist (trametinib) in culture (PMID: 27488531). ",Actionable,8546,1909,melanoma,DOID,26352,BRAF mut RB1 loss,decreased response,1368,Palbociclib + Trametinib,673,27488531,,,
475,Preclinical - Cell culture,"In a preclinical study, a melanoma cell line harboring a BRAF mutation and loss of RB1 demonstrated a decreased response to Ibrance (palbociclib) treatment in culture when compared to treatment of melanoma cell lines wild-type for BRAF (PMID: 27488531). ",Actionable,8536,1909,melanoma,DOID,26352,BRAF mut RB1 loss,decreased response,850,Palbociclib,673,27488531,,,
476,Preclinical - Cell culture,"In a preclinical study, a melanoma cell line harboring a BRAF mutation and RB1 loss demonstrated reduced sensitivity when treated with Mekinist (trametinib) in culture (PMID: 27488531). ",Actionable,8539,1909,melanoma,DOID,26352,BRAF mut RB1 loss,decreased response,2,Trametinib,673,27488531,,,
477,Preclinical - Cell culture,"In a preclinical study, the combination of Navitoclax (ABT-263), Alpelisib (BYL719), Tafinlar (dabrafenib), and Tarceva (erlotinib) resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a BRAF mutation and TP53 mutation in culture compared to the double or triple combinations of the therapies (PMID: 27659046). ",Actionable,9934,9256,colorectal cancer,DOID,27213,BRAF mut TP53 mut,sensitive,5318,ABT-263 + Alpelisib + Dabrafenib + Erlotinib,673,27659046,,,
478,Preclinical - Cell line xenograft,"In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cell lines resulted in decreased response to Zelboraf (vemurafenib) both in culture and in cell line xenograft models (PMID: 27500726).",Actionable,7791,1909,melanoma,DOID,26042,BRAF mut STAG2 dec exp,decreased response,342,Vemurafenib,673,27500726,,,
479,Preclinical - Cell culture,"In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cells resulted in decreased response to Mekinist (trametinib) and Tafinlar (dabrafenib) combination treatment in culture (PMID: 27500726).",Actionable,7793,1909,melanoma,DOID,26042,BRAF mut STAG2 dec exp,decreased response,1066,Trametinib + Dabrafenib,673,27500726,,,
480,Preclinical - Cell culture,"In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cell lines resulted in decreased response to Tafinlar (dabrafenib) in culture (PMID: 27500726).",Actionable,7790,1909,melanoma,DOID,26042,BRAF mut STAG2 dec exp,decreased response,3,Dabrafenib,673,27500726,,,
481,Preclinical - Cell culture,"In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cells resulted in decreased response to Mekinist (trametinib) in culture (PMID: 27500726).",Actionable,7792,1909,melanoma,DOID,26042,BRAF mut STAG2 dec exp,decreased response,2,Trametinib,673,27500726,,,
482,Preclinical,"In a preclinical study, the combination of CGM097 and Encorafenib (LGX818) synergized to inhibit cell growth of a human melanoma cell line harboring mutant BRAF and wild-type TP53 in culture, and promoted tumor regression in xenograft models (Cancer Res October 1, 2014 74; 5466).",Actionable,1787,1909,melanoma,DOID,3307,BRAF mut + TP53 wild-type,sensitive,2285,CGM097 + LGX818,673,None,,,
483,Preclinical - Cell line xenograft,"In a preclinical study, AMG 232 inhibited growth of a melanoma cell line with wild-type TP53, that also harbored a BRAF mutation, in culture and inhibited tumor growth in a TP53 wild-type BRAF-mutant melanoma cell line xenograft model (PMID: 25567130).",Actionable,8097,1909,melanoma,DOID,3307,BRAF mut + TP53 wild-type,sensitive,1452,AMG 232,673,25567130,,,
484,Preclinical - Cell culture,"In a preclinical study, the combination of Navitoclax (ABT-263), CGM097, Tafinlar (dabrafenib), and PF04217903 resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a BRAF mutation and wild-type TP53 in culture compared to the double or triple combinations of the therapies (PMID: 27659046). ",Actionable,9933,9256,colorectal cancer,DOID,3307,BRAF mut + TP53 wild-type,sensitive,5317,ABT-263 + CGM097 + Dabrafenib + PF-04217903,673,27659046,,,
485,Preclinical,"In a preclinical study, a rapamycin-resistant colorectal cancer cell line harboring mutations in APC, BRAF, PIK3CA, SMAD4 and TP53 was sensitive to Sapanisertib (MLN0128) resulting in inhibition of MTORC1 signaling (PMID: 25261369). ",Actionable,2135,9256,colorectal cancer,DOID,5415,APC mut BRAF mut PIK3CA mut SMAD4 mut TP53 mut,sensitive,1282,Sapanisertib,673,25261369,,,
486,Preclinical - Pdx & cell culture,"In a preclinical study, mutations in BRAF, KRAS, or NRAS were associated with sensitivity to TAK-733 in colorectal cancer cell lines in culture, and patient-derived xenograft models harboring KRAS or BRAF mutations with wild-type PIK3CA demonstrated a trend toward higher tumor growth inhibition following TAK-733 treatment (PMID: 26439693).",Actionable,10776,9256,colorectal cancer,DOID,27794,BRAF mut PIK3CA wild-type,predicted â€“ sensitive,932,TAK-733,673,26439693,,,
487,Phase I,"In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 100% (5/5) of melanoma patients harboring BRAF mutations and wild-type NRAS (PMID: 26169970).",Actionable,3796,1909,melanoma,DOID,15931,BRAF mut NRAS wild-type,sensitive,792,Lenvatinib,673,26169970,,,
488,Preclinical,"In a preclinical study, human triple negative breast cancer cells harboring mutant BRAF, KRAS, and CDKN2A were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",Actionable,6690,60081,triple-receptor negative breast cancer,DOID,23670,BRAF mut KRAS mut CDKN2A mut,resistant,2,Trametinib,673,26343583,,,
489,Phase I,"In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 50% (1/2) of melanoma patients harboring both BRAF and NRAS mutations (PMID: 26169970).",Actionable,3688,1909,melanoma,DOID,14782,BRAF mut NRAS mut,sensitive,792,Lenvatinib,673,26169970,,,
490,Preclinical - Cell culture,"In a preclinical study, treatment with BI-847325 inhibited growth of a BRAF-mutant melanoma cell line with BRAF-inhibitor resistance due to an NRAS mutation in culture (PMID: 25873592).",Actionable,7829,1909,melanoma,DOID,14782,BRAF mut NRAS mut,predicted â€“ sensitive,1059,BI-847325,673,25873592,,,
491,Preclinical,"In a preclinical study, GSK2636771 resulted in no benefit in a melanoma mouse model co-harboring a BRAF mutation and PTEN loss (PMID: 26645196). ",Actionable,4456,1909,melanoma,DOID,18163,BRAF mut PTEN loss,no benefit,765,GSK2636771,673,26645196,,,
492,Preclinical,"In a preclinical study, a melanoma mouse model harboring a BRAF mutation and PTEN loss was sensitive to the combination of GSK2636771 and Keytruda (pembrolizumab), demonstrating greater tumor growth inhibition and improved survival when compared to either therapy alone (PMID: 26645196). ",Actionable,4455,1909,melanoma,DOID,18163,BRAF mut PTEN loss,sensitive,3518,GSK2636771 + Pembrolizumab,673,26645196,,,
493,Preclinical - Cell line xenograft,"In a preclinical study, SAR260301 and Zelboraf (vemurafenib) synergistically inhibited proliferation of PTEN deficient melanoma cells harboring BRAF mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 27196754).",Actionable,7773,1909,melanoma,DOID,18163,BRAF mut PTEN loss,sensitive,1225,SAR260301 + Vemurafenib,673,27196754,,,
494,Preclinical,"In a preclinical study, Keytruda (pembrolizumab) resulted in no benefit in a melanoma mouse model co-harboring a BRAF mutation and PTEN loss (PMID: 26645196). ",Actionable,4457,1909,melanoma,DOID,18163,BRAF mut PTEN loss,no benefit,1447,Pembrolizumab,673,26645196,,,
495,Preclinical - Cell line xenograft,"In a preclinical study, SAR260301 and Selumetinib (AZD6244) synergistically inhibited proliferation of PTEN deficient melanoma cells harboring BRAF mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 27196754).",Actionable,7774,1909,melanoma,DOID,18163,BRAF mut PTEN loss,sensitive,4573,SAR260301 + Selumetinib,673,27196754,,,
496,Preclinical - Cell line xenograft,"In a preclinical study, SAR260301 inhibited proliferation of PTEN deficient melanoma cells harboring BRAF mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 27196754).",Actionable,7771,1909,melanoma,DOID,18163,BRAF mut PTEN loss,sensitive,1052,SAR260301,673,27196754,,,
497,Preclinical,"In a preclinical study, AZD6482 and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",Actionable,6121,1909,melanoma,DOID,21308,BRAF mut PTEN wild-type,no benefit,4054,AZD6482 + Binimetinib,673,26577700,,,
498,Preclinical,"In a preclinical study, AZD6482 and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",Actionable,6107,1909,melanoma,DOID,21308,BRAF mut PTEN wild-type,no benefit,4044,AZD6482 + NVP-AEW541,673,26577700,,,
499,Preclinical - Cell line xenograft,"In a preclinical study, E6201 resulted in a cytocidal response in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture and inhibited tumor growth in cell line xenograft models (PMID: 23039341).",Actionable,5629,1909,melanoma,DOID,21308,BRAF mut PTEN wild-type,sensitive,1011,E6201,673,23039341,,,
500,Preclinical,"In a preclinical study, GSK2636771 and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",Actionable,6122,1909,melanoma,DOID,21308,BRAF mut PTEN wild-type,no benefit,4052,GSK2636771 + Binimetinib,673,26577700,,,
501,Preclinical,"In a preclinical study, GSK2636771 and Encorafenib (LGX818) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",Actionable,6124,1909,melanoma,DOID,21308,BRAF mut PTEN wild-type,no benefit,4055,GSK2636771 + LGX818,673,26577700,,,
502,Preclinical,"In a preclinical study, GSK2636771 and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",Actionable,6108,1909,melanoma,DOID,21308,BRAF mut PTEN wild-type,no benefit,4045,GSK2636771 + NVP-AEW541,673,26577700,,,
503,Preclinical,"In a preclinical study, AZD6482 and Encorafenib (LGX818) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",Actionable,6123,1909,melanoma,DOID,21308,BRAF mut PTEN wild-type,no benefit,4048,AZD6482 + LGX818,673,26577700,,,
504,Preclinical,"In a preclinical study, PLX8394 had been shown to block survival and growth of vemurafenib/PLX4720-resistant cells harboring distinct BRAF activating mutations (PMID: 24422853).",Actionable,1027,10000003,Advanced Solid Tumor,JAX,696,BRAF act mut,sensitive,1041,PLX8394,673,24422853,,,
505,Preclinical - Cell culture,"In a preclinical study, inhibition of Erk signaling by VX-11e did not sensitize colorectal cancer cell lines harboring KRAS or BRAF activating mutations to Venclexta (venetoclax) in culture (PMID: 27974663).",Actionable,10077,9256,colorectal cancer,DOID,696,BRAF act mut,no benefit,5375,Venetoclax + VX-11e,673,27974663,,,
506,Preclinical - Cell culture,"In a preclinical study, inhibition of Erk signaling by VX-11e sensitized colorectal cancer cell lines harboring KRAS or BRAF activating mutations to WEHI-539 in culture (PMID: 27974663).",Actionable,10075,9256,colorectal cancer,DOID,696,BRAF act mut,predicted â€“ sensitive,5374,VX-11e + WEHI-539,673,27974663,,,
507,Phase II,"In a Phase II study, Nexavar (sorafenib) displayed negligible efficacy in melanoma patients with BRAF mutations (PMID: 16880785, PMID: 22394203).",Actionable,510,1909,melanoma,DOID,696,BRAF act mut,no benefit,920,Sorafenib,673,22394203,16880785,,
508,Preclinical - Cell line xenograft,"In a preclinical study, Cobimetinib (GDC-0973) induced cell death in human melanoma cell lines harboring BRAF activating mutations in culture and inhibited tumor growth in xenograft models (PMID: 22084396).",Actionable,552,1909,melanoma,DOID,696,BRAF act mut,sensitive,1004,Cobimetinib,673,22084396,,,
509,Phase I,"In a Phase I trial, Zelboraf (vemurafenib) demonstrated safety and efficacy in metastatic papillary thyroid cancer patients carrying BRAF activating mutations (PMID: 23489023).",Actionable,891,1781,thyroid cancer,DOID,696,BRAF act mut,sensitive,342,Vemurafenib,673,23489023,,,
510,Phase Ib/II,"In a Phase Ib/II trial, Binimetinib (MEK162), in combination with Encorafenib (LGX818), demonstrated safety and efficacy in patients with BRAF mutant advanced solid tumors (J Clin Oncol 31, 2013 (suppl; abstr 9029)).",Actionable,1025,10000003,Advanced Solid Tumor,JAX,696,BRAF act mut,sensitive,1100,Binimetinib + Encorafenib,673,None,,,
511,Preclinical - Pdx,"In a preclinical study, LSN3074753 and Erbitux (cetuximab) worked synergistically, resulting in tumor regression in a patient-derived xenograft model of colorectal cancer harboring BRAF G596V and NRAS G13R (PMID: 28611205).",Actionable,12197,9256,colorectal cancer,DOID,28547,BRAF G596V NRAS G13R,sensitive,6338,Cetuximab + LSN3074753,673,28611205,,,
512,Preclinical - Cell culture,"In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring BRAF V600R in culture (PMID: 27523909).",Actionable,7910,1909,melanoma,DOID,654,BRAF V600R,sensitive,1093,AZ628,673,27523909,,,
513,Preclinical - Cell culture,"In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring BRAF V600R in culture (PMID: 27523909).",Actionable,7940,1909,melanoma,DOID,654,BRAF V600R,sensitive,3300,TAK-632,673,27523909,,,
514,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600R in culture (PMID: 27523909).",Actionable,7954,1909,melanoma,DOID,654,BRAF V600R,sensitive,342,Vemurafenib,673,27523909,,,
515,Preclinical - Cell culture,"In a preclinical study, PLX7904 inhibited proliferation of melanoma cells harboring BRAF V600R in culture (PMID: 27523909).",Actionable,7950,1909,melanoma,DOID,654,BRAF V600R,sensitive,4606,PLX7904,673,27523909,,,
516,Preclinical - Cell culture,"In a preclinical study, Tafinlar (dabrafenib) inhibited proliferation of melanoma cells harboring BRAF V600R in culture (PMID: 27523909).",Actionable,7962,1909,melanoma,DOID,654,BRAF V600R,sensitive,3,Dabrafenib,673,27523909,,,
517,Clinical Study,"In a clinical case study, a melanoma patient harboring BRAF V600R treated with Tafinlar (dabrafenib) demonstrated a reduction in lesion size after 2.5 months and at 5 months, stable disease, however, after 7 months progression ensued (PMID: 27255157). ",Actionable,9030,1909,melanoma,DOID,654,BRAF V600R,sensitive,3,Dabrafenib,673,27255157,,,
518,Preclinical - Cell culture,"In a preclinical study, non-small cell lung cancer cells harboring BRAF G466V demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909).",Actionable,7958,3908,non-small cell lung carcinoma,DOID,669,BRAF G466V,decreased response,342,Vemurafenib,673,27523909,,,
519,Preclinical - Pdx,"In a preclinical study, treatment with Mekinist (trametinib) delayed tumor growth in a colorectal cancer patient-derived xenograft (PDX) model harboring BRAF G466V, and wild-type RAS and NF1 (PMID: 28783719).",Actionable,11658,9256,colorectal cancer,DOID,669,BRAF G466V,sensitive,2,Trametinib,673,28783719,,,
520,Preclinical - Pdx,"In a preclinical study, Zelboraf (vemurafenib) did not inhibit ERK signaling or tumor growth in a colorectal cancer patient-derived xenograft (PDX) model harboring BRAF G466V, and wild-type RAS and NF1 (PMID: 28783719).",Actionable,11659,9256,colorectal cancer,DOID,669,BRAF G466V,no benefit,342,Vemurafenib,673,28783719,,,
521,Clinical Study,"In a clinical case study, a patient with metastatic colorectal cancer harboring BRAF G466V, and with wild-type RAS and NF1, demonstrated tumor regression following treatment with Vectibix (panitumumab) plus Camptosar (irinotecan) (PMID: 28783719).",Actionable,11663,9256,colorectal cancer,DOID,669,BRAF G466V,predicted â€“ sensitive,4138,Irinotecan + Panitumumab,673,28783719,,,
522,Preclinical - Pdx,"In a preclinical study, treatment with Erbitux (cetuximab) reduced ERK signaling and resulted in tumor regression in a colorectal cancer patient-derived xenograft (PDX) model harboring BRAF G466V, and wild-type RAS and NF1 (PMID: 28783719).",Actionable,11657,9256,colorectal cancer,DOID,669,BRAF G466V,sensitive,694,Cetuximab,673,28783719,,,
523,Preclinical - Cell culture,"In a preclinical study, Mekinist (trametinib) reduced ERK signaling and inhibited proliferation of non-small cell lung cancer cell lines harboring BRAF G466V in culture (PMID: 28783719).",Actionable,11653,3908,non-small cell lung carcinoma,DOID,669,BRAF G466V,sensitive,2,Trametinib,673,28783719,,,
524,Preclinical - Cell culture,"In a preclinical study, TAK-632 inhibited proliferation of non-small cell lung cancer cells harboring BRAF G466V in culture (PMID: 27523909).",Actionable,7942,3908,non-small cell lung carcinoma,DOID,669,BRAF G466V,sensitive,3300,TAK-632,673,27523909,,,
525,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) induced apoptosis in non-small cell lung cancer cells expressing BRAF G466V in culture (PMID: 22649091).",Actionable,691,3908,non-small cell lung carcinoma,DOID,669,BRAF G466V,sensitive,717,Dasatinib,673,22649091,,,
526,Preclinical - Cell culture,"In a preclinical study, PLX8394 decreased growth of lung adenocarcinoma cell lines harboring BRAF G466V in culture (PMID: 27834212).",Actionable,12073,3910,lung adenocarcinoma,DOID,669,BRAF G466V,sensitive,1041,PLX8394,673,27834212,,,
527,Preclinical - Cell culture,"In a preclinical study, treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) resulted in decreased proliferation and increased apoptosis, and enhanced ERK inhibition compared to either agent alone in a non-small cell lung cancer cell line harboring BRAF G466V in culture (PMID: 27577079).",Actionable,11736,3908,non-small cell lung carcinoma,DOID,669,BRAF G466V,sensitive,1066,Trametinib + Dabrafenib,673,27577079,,,
528,Preclinical,"In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring BRAF G466V mutation in culture (PMID: 26090892).",Actionable,3934,3908,non-small cell lung carcinoma,DOID,669,BRAF G466V,sensitive,2086,TAE226,673,26090892,,,
529,Preclinical - Cell culture,"In a preclinical study, Mekinist (trametinib) growth of a non-small cell lung cancer cell line harboring BRAF G466V and expressing NRAS Q61K in culture (PMID: 28783719).",Actionable,11667,3908,non-small cell lung carcinoma,DOID,28181,BRAF G466V NRAS Q61K,sensitive,2,Trametinib,673,28783719,,,
530,Preclinical - Cell line xenograft,"In a preclinical study, Ganetespib treatment resulted in decreased activation of MEK, AKT, and ERK and inhibited growth of a non-small cell lung cancer cell line with wild-type EGFR and BRAF G466V in culture, and inhibited tumor growth in xenograft models (PMID: 25077897).",Actionable,8231,3908,non-small cell lung carcinoma,DOID,26202,BRAF G466V EGFR wild-type,sensitive,745,Ganetespib,673,25077897,,,
531,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) did not reduce activation of Mek in transformed cells expressing BRAF D594N in culture (PMID: 28783719).",Actionable,11666,10000003,Advanced Solid Tumor,JAX,987,BRAF D594N,predicted â€“ resistant,342,Vemurafenib,673,28783719,,,
532,Preclinical,"In a preclinical study, Selumetinib (AZD6244) modestly inhibited proliferation of human melanoma cells harboring BRAF G469R and NRAS Q61K in culture (PMID: 26343583).",Actionable,6603,1909,melanoma,DOID,23638,BRAF G469R NRAS Q61K,decreased response,913,Selumetinib,673,26343583,,,
533,Preclinical,"In a preclinical study, human melanoma cells harboring BRAF G469R and NRAS G61K were insensitive to Zelboraf (vemurafenib) in culture (PMID: 26343583).",Actionable,6612,1909,melanoma,DOID,23638,BRAF G469R NRAS Q61K,resistant,342,Vemurafenib,673,26343583,,,
534,Preclinical,"In a preclinical study, LY3009120 inhibited soft agar growth of human melanoma cancer cells harboring BRAF G469R and NRAS Q61K in culture (PMID: 26343583).",Actionable,6592,1909,melanoma,DOID,23638,BRAF G469R NRAS Q61K,sensitive,3268,LY3009120,673,26343583,,,
535,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF L597Q (PMID: 26343582).",Actionable,9416,10000003,Advanced Solid Tumor,JAX,993,BRAF L597Q,resistant,342,Vemurafenib,673,26343582,,,
536,Phase I,"In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 83% (5/6) of melanoma patients harboring NRAS mutations and wild-type BRAF (PMID: 26169970).",Actionable,3797,1909,melanoma,DOID,1299,BRAF wild-type NRAS mutant,sensitive,792,Lenvatinib,673,26169970,,,
537,Preclinical - Cell line xenograft,"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type colon cancer cells harboring KRAS G13D in culture ann in cell line xenograft models (PMID: 19276360).",Actionable,7883,219,colon cancer,DOID,26083,BRAF wild-type KRAS G13D,resistant,1095,GDC0879,673,19276360,,,
538,Preclinical - Pdx,"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type non-small cell lung cancer cells harboring KRAS G12C in patient-derived xenograft models (PMID: 19276360).",Actionable,7893,3908,non-small cell lung carcinoma,DOID,26088,BRAF wild-type KRAS G12C,resistant,1095,GDC0879,673,19276360,,,
539,Preclinical - Cell line xenograft,"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type non-small cell lung cancer cells harboring KRAS Q61K in culture and in cell line xenograft models (PMID: 19276360).",Actionable,7884,3908,non-small cell lung carcinoma,DOID,26085,BRAF wild-type KRAS Q61K,resistant,1095,GDC0879,673,19276360,,,
540,Preclinical - Pdx,"In a preclinical study, LSN3074753 demonstrated limited efficacy in BRAF and KRAS wild-type patient-derived xenograft models of colorectal cancer, resulted in a disease control rate of 3.8% (1/26) (PMID: 28611205).",Actionable,12189,9256,colorectal cancer,DOID,28546,BRAF wild-type KRAS wild-type,decreased response,6337,LSN3074753,673,28611205,,,
541,Preclinical - Cell line xenograft,"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type pancreatic cancer cells harboring KRAS G12D in cell line xenograft models (PMID: 19276360).",Actionable,7887,1793,pancreatic cancer,DOID,26084,BRAF wild-type KRAS G12D,resistant,1095,GDC0879,673,19276360,,,
542,Guideline,Gleevec (imatinib) is an active regimen for melanoma patients with wild-type BRAF and a c-KIT positive mutation (Guidelines). ,Actionable,1938,1909,melanoma,DOID,4361,BRAF wild-type KIT positive,sensitive,770,Imatinib,673,None,,,
543,Preclinical - Pdx,"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type non-small cell lung cancer cells harboring KRAS G12V in patient-derived xenograft models (PMID: 19276360).",Actionable,7895,3908,non-small cell lung carcinoma,DOID,26087,BRAF wild-type KRAS G12V,resistant,1095,GDC0879,673,19276360,,,
544,Clinical Study,"In a retrospective study, Erbitux (cetuximab) treatment, alone or in combination, resulted in disease regression or stable disease in 88% (7/8) KRAS/BRAF-wild type colorectal carcinoma patients harboring a PIK3CA mutation (PMID: 25714871).",Actionable,3671,9256,colorectal cancer,DOID,14283,BRAF wild-type KRAS wild-type PIK3CA mutant,sensitive,694,Cetuximab,673,25714871,,,
545,Preclinical,"In a preclinical study, Erbitux (cetuximab) inhibited growth of human colorectal cancer cells wild-type for BRAF, KRAS, NRAS and PIK3CA in culture (PMID: 25838391).",Actionable,4934,9256,colorectal cancer,DOID,19839,BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type,sensitive,694,Cetuximab,673,25838391,,,
546,Preclinical,"In a preclinical study, colorectal cancer cell lines with wild-type BRAF, KRAS, NRAS and PIK3CA were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).",Actionable,4944,9256,colorectal cancer,DOID,19839,BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type,resistant,890,Regorafenib,673,25838391,,,
547,Phase II,"In a Phase II trial, Erbitux (cetuximab) in combination with FOLFOX resulted in improved median progression-free survival (6.9 months) comparing to FOLFOX alone (5.3 months) in BRAF, KRAS, NRAS, and PIK3CA wild-type colorectal cancer patients (hazard ratio =0.56) (PMID: 27002107).",Actionable,5563,9256,colorectal cancer,DOID,19839,BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type,predicted â€“ sensitive,2182,Cetuximab + FOLFOX,673,27002107,,,
548,Phase I,"In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 44% (4/9) and partial response in 22% (2/9) of melanoma patients carrying wild-type BRAF and NRAS (PMID: 26169970).",Actionable,3798,1909,melanoma,DOID,15933,BRAF wild-type NRAS wild-type,sensitive,792,Lenvatinib,673,26169970,,,
549,Preclinical - Cell culture,"In a preclinical study, TAK-632 inhibited proliferation of BRAF and NRAS wild-type melanoma cells in culture (PMID: 27523909).",Actionable,7945,1909,melanoma,DOID,15933,BRAF wild-type NRAS wild-type,sensitive,3300,TAK-632,673,27523909,,,
550,Preclinical - Cell culture,"In a preclinical study, BRAF and NRAS wild-type melanoma cells were resistant to PLX7904 in culture (PMID: 27523909).",Actionable,7952,1909,melanoma,DOID,15933,BRAF wild-type NRAS wild-type,resistant,4606,PLX7904,673,27523909,,,
551,Preclinical - Cell culture,"In a preclinical study, BRAF and NRAS wild-type melanoma cells were resistant to Zelboraf (vemurafenib) in culture (PMID: 27523909).",Actionable,7960,1909,melanoma,DOID,15933,BRAF wild-type NRAS wild-type,resistant,342,Vemurafenib,673,27523909,,,
552,Preclinical - Cell culture,"In a preclinical study, AZ628 inhibited proliferation of BRAF and NRAS wild-type melanoma cells in culture (PMID: 27523909).",Actionable,7935,1909,melanoma,DOID,15933,BRAF wild-type NRAS wild-type,sensitive,1093,AZ628,673,27523909,,,
553,Preclinical - Cell culture,"In a preclinical study, the combination of Binimetinib (MEK162) and Buparlisib (BKM120) resulted in improved cell growth inhibition compared to either agent alone in a metastatic melanoma cell line with wild-type BRAF and wild-type NRAS in culture (PMID: 27307593). ",Actionable,10122,1909,melanoma,DOID,15933,BRAF wild-type NRAS wild-type,sensitive,5400,Binimetinib + BKM120,673,27307593,,,
554,Preclinical - Pdx & cell culture,"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type non-small cell lung cancer cells in culture and in patient-derived xenograft models (PMID: 19276360).",Actionable,7891,3908,non-small cell lung carcinoma,DOID,4,BRAF wild-type,resistant,1095,GDC0879,673,19276360,,,
555,Phase I,"In a Phase I study, 10% (4/39) of wild-type BRAF melanoma patients had a partial response to Mekinist (trametinib) (PMID: 22805292).",Actionable,1256,1909,melanoma,DOID,4,BRAF wild-type,sensitive,2,Trametinib,673,22805292,,,
556,Preclinical - Cell culture,"In a preclinical study, Afinitor (everolimus) and Selumetinib (AZD6244) synergistically inhibited growth and induced apoptosis in glioma cell lines in culture (PMID: 27217440).",Actionable,9109,3070,malignant glioma,DOID,4,BRAF wild-type,predicted â€“ sensitive,4901,Everolimus + Selumetinib,673,27217440,,,
557,Preclinical - Pdx & cell culture,"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type melanoma cells in cell culture, cell line xenograft models, and patient-derived xenograft models (PMID: 19276360).",Actionable,7890,1909,melanoma,DOID,4,BRAF wild-type,resistant,1095,GDC0879,673,19276360,,,
558,Preclinical - Cell culture,"In a preclinical study, BRAF wild-type melanoma cells demonstrated decreased cell viability when treated with Ibrance (palbociclib) in culture (PMID: 27488531). ",Actionable,8534,1909,melanoma,DOID,4,BRAF wild-type,sensitive,850,Palbociclib,673,27488531,,,
559,Phase II,"In a Phase II trial, a favorable response rate to Selumetinib (AZD6244) was observed in mutant BRAF, but not BRAF wild-type, melanoma patients (PMID: 22048237).",Actionable,714,1909,melanoma,DOID,4,BRAF wild-type,no benefit,913,Selumetinib,673,22048237,,,
560,Preclinical,"In a preclinical study, RAF265 inhibited the growth of melanoma tumors orthotopically implanted in mice, including tumors wild-type for BRAF (PMID: 22351689).",Actionable,452,1909,melanoma,DOID,4,BRAF wild-type,sensitive,884,RAF265,673,22351689,,,
561,Preclinical - Cell culture,"In a preclinical study, a BRAF wild-type melanoma cell line demonstrated minimal sensitivity when treated with the combination of Ibrance (palbociclib) and Mekinist (trametinib) in culture (PMID: 27488531). ",Actionable,8544,1909,melanoma,DOID,4,BRAF wild-type,decreased response,1368,Palbociclib + Trametinib,673,27488531,,,
562,Preclinical,"In a preclinical study, CLM3 inhibited growth, Egfr signaling, and CCND1 expression, in BRAF wild-type thyroid cancer cells in culture (PMID: 24423321). ",Actionable,4418,1781,thyroid cancer,DOID,4,BRAF wild-type,sensitive,3502,CLM3,673,24423321,,,
563,Preclinical - Cell line xenograft,"In a preclinical study, PLX4720 did not inhibit growth of BRAF wild-type melanoma cells in culture or in cell line xenograft models (PMID: 18287029).",Actionable,504,1909,melanoma,DOID,4,BRAF wild-type,resistant,1060,PLX4720,673,18287029,,,
564,Preclinical - Cell culture,"In a preclinical study, a variety of BRAF wild-type tumor cell lines were insensitive to BGB-283 in culture (PMID: 26208524).",Actionable,8068,10000003,Advanced Solid Tumor,JAX,4,BRAF wild-type,resistant,4025,BGB-283,673,26208524,,,
565,Preclinical - Pdx,"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type melanoma cells harboring NRAS Q61K in patient-derived xenograft models (PMID: 19276360).",Actionable,7889,1909,melanoma,DOID,26086,BRAF wild-type NRAS Q61K,resistant,1095,GDC0879,673,19276360,,,
566,Clinical Study,"In a retrospective study, 100% (2/2) colorectal carcinoma patients harboring an AKT1 E17K mutation and wild-type KRAS/BRAF demonstrated resistance to Erbitux (cetuximab) in combination with Camptosar (irinotecan) (PMID: 25714871).",Actionable,3614,9256,colorectal cancer,DOID,13841,AKT1 E17K KRAS wild-type BRAF wild-type,resistant,1874,Cetuximab + Irinotecan,673,25714871,,,
567,Preclinical,"In a preclinical study, a non-small cell lung carcinoma cell line harboring BRAF L485_P490delinsY was sensitive to Mekinist (trametinib), resulting in cell growth inhibition (PMID: 26732095). ",Actionable,4925,3908,non-small cell lung carcinoma,DOID,19835,BRAF L485_P490delinsY,sensitive,2,Trametinib,673,26732095,,,
568,Preclinical,"In a preclinical study, a non-small cell lung carcinoma cell line harboring BRAF L485_P490delinsY was resistant to Tafinlar (dabrafenib) (PMID: 26732095). ",Actionable,4926,3908,non-small cell lung carcinoma,DOID,19835,BRAF L485_P490delinsY,resistant,342,Vemurafenib,673,26732095,,,
569,Preclinical,"In a preclinical study, a non-small cell lung carcinoma cell line harboring BRAF L485_P490delinsY was sensitive to LY3009120 in both culture and xenograft models, resulting in significant tumor regression and inhibition of MEK and ERK phosphorylation (PMID: 26732095). ",Actionable,4924,3908,non-small cell lung carcinoma,DOID,19835,BRAF L485_P490delinsY,sensitive,3268,LY3009120,673,26732095,,,
570,Preclinical - Cell culture,"In a preclinical study, Mekinist (trametinib) reduced ERK signaling and inhibited proliferation of a melanoma cell line harboring BRAF D594G in culture (PMID: 28783719).",Actionable,11654,1909,melanoma,DOID,989,BRAF D594G,sensitive,2,Trametinib,673,28783719,,,
571,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring both BRAF D594G and NRAS G12D demonstrated decreased sensitivity to PLX7904 in culture (PMID: 27523909).",Actionable,7951,1909,melanoma,DOID,26096,BRAF D594G NRAS G12D,decreased response,4606,PLX7904,673,27523909,,,
572,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring both BRAF D594G and NRAS G12D demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 27523909).",Actionable,7965,1909,melanoma,DOID,26096,BRAF D594G NRAS G12D,decreased response,3,Dabrafenib,673,27523909,,,
573,Preclinical - Cell culture,"In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring both BRAF D594G and NRAS G12D in culture (PMID: 27523909).",Actionable,7911,1909,melanoma,DOID,26096,BRAF D594G NRAS G12D,sensitive,1093,AZ628,673,27523909,,,
574,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring both BRAF D594G and NRAS G12D demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909).",Actionable,7957,1909,melanoma,DOID,26096,BRAF D594G NRAS G12D,decreased response,342,Vemurafenib,673,27523909,,,
575,Preclinical - Cell culture,"In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring both BRAF D594G and NRAS G12D in culture (PMID: 27523909).",Actionable,7941,1909,melanoma,DOID,26096,BRAF D594G NRAS G12D,sensitive,3300,TAK-632,673,27523909,,,
576,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF L597V (PMID: 26343582).",Actionable,9415,10000003,Advanced Solid Tumor,JAX,663,BRAF L597V,resistant,342,Vemurafenib,673,26343582,,,
577,Preclinical - Cell culture,"In a preclinical study, non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 27523909).",Actionable,7964,3908,non-small cell lung carcinoma,DOID,26095,BRAF L597V NRAS Q61K,decreased response,3,Dabrafenib,673,27523909,,,
578,Preclinical - Cell culture,"In a preclinical study, AZ628 inhibited proliferation of non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K in culture (PMID: 27523909).",Actionable,7909,3908,non-small cell lung carcinoma,DOID,26095,BRAF L597V NRAS Q61K,sensitive,1093,AZ628,673,27523909,,,
579,Preclinical - Cell culture,"In a preclinical study, non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61L demonstrated decreased sensitivity to PLX7904 in culture (PMID: 27523909).",Actionable,7949,3908,non-small cell lung carcinoma,DOID,26095,BRAF L597V NRAS Q61K,decreased response,4606,PLX7904,673,27523909,,,
580,Preclinical - Cell culture,"In a preclinical study, TAK-632 inhibited proliferation of non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K in culture (PMID: 27523909).",Actionable,7939,3908,non-small cell lung carcinoma,DOID,26095,BRAF L597V NRAS Q61K,sensitive,3300,TAK-632,673,27523909,,,
581,Preclinical - Cell culture,"In a preclinical study, non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909).",Actionable,7956,3908,non-small cell lung carcinoma,DOID,26095,BRAF L597V NRAS Q61K,decreased response,342,Vemurafenib,673,27523909,,,
582,Clinical Study,"In a clinical study, a melanoma patient harboring a BRAF V600 mutation developed resistant mutations, BRAF amplification and NRAS Q61K, during treatment with Zelboraf (vemurafenib) (PMID: 24265153).",Actionable,7070,1909,melanoma,DOID,24387,BRAF amp BRAF V600X NRAS Q61K,resistant,342,Vemurafenib,673,24265153,,,
583,Preclinical - Cell culture,"In a preclinical study, expression of AKT1 E17K in a wild-type PTEN-expressing BRAF V600-mutant melanoma cell line conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 24265152).",Actionable,8103,1909,melanoma,DOID,26172,AKT1 E17K BRAF V600X PTEN pos,resistant,342,Vemurafenib,673,24265152,,,
584,Clinical Study,"In a clinical study, a melanoma patient harboring a BRAF V600 mutation and PTEN H93D treated with Zelboraf (vemurafenib) for 66 weeks demonstrated a partial response (PMID: 24265153).",Actionable,7083,1909,melanoma,DOID,24401,BRAF V600X PTEN H93D,sensitive,342,Vemurafenib,673,24265153,,,
585,Preclinical - Cell culture,"In a preclinical study, lack of PTEN expression was associated with increased sensitivity to GSK2141795 in BRAF V600-mutant melanoma cell lines in culture (PMID: 24265152).",Actionable,8168,1909,melanoma,DOID,26183,BRAF V600X PTEN neg,sensitive,764,GSK2141795,673,24265152,,,
586,Phase II,"In a Phase II clinical trial, treatment with Zelboraf (vemurafenib) in colorectal cancer patients with BRAF V600 mutations did not result in clinical benefit, with no patients achieving response, and 50% (5/10) demonstrating progressive disease (PMID: 26287849).",Actionable,3300,9256,colorectal cancer,DOID,1186,BRAF V600X,no benefit,342,Vemurafenib,673,26287849,,,
587,Guideline,"Tafinlar (dabrafenib), in combination with Mekinist (trametinib), is an active regimen for melanoma patients with BRAF V600 mutations (Guidelines).",Actionable,1519,1909,melanoma,DOID,1186,BRAF V600X,sensitive,1066,Trametinib + Dabrafenib,673,None,,,
588,Phase Ib/II,"In a Phase I/II clinical trial, patients with BRAF V600 mutant melanoma (n=78) treated with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) had a median overall survival of greater than 2 years (PMID: 26811525).",Actionable,4933,1909,melanoma,DOID,1186,BRAF V600X,sensitive,1066,Trametinib + Dabrafenib,673,26811525,,,
589,Preclinical - Pdx,"In a preclinical study, melanoma patient derived xenograft (PDX) model harboring a BRAF V600 mutation demonstrated antitumor activity when treated with ASN003 (J Clin Oncol 35, 2017 (suppl; abstr e14102)). ",Actionable,11044,1909,melanoma,DOID,1186,BRAF V600X,sensitive,5827,ASN003,673,None,,,
590,Phase II,"In a Phase II clinical trial, treatment with Zelboraf (vemurafenib) resulted in an overall response rate of 29% (2/7), with 1 complete response and 1 partial response, in patients with anaplastic thyroid cancer patients with BRAF V600 mutations (PMID:     26287849).",Actionable,3302,1781,thyroid cancer,DOID,1186,BRAF V600X,predicted â€“ sensitive,342,Vemurafenib,673,26287849,,,
591,Phase II,"In a Phase II trial, 20% (8/41) of melanoma patients with BRAF V600 mutations had a partial response to Binimetinib (MEK162) (PMID: 23414587).",Actionable,1120,1909,melanoma,DOID,1186,BRAF V600X,sensitive,807,Binimetinib,673,23414587,,,
592,FDA approved,"In a Phase III clinical trial that supported FDA approval, the combined treatment of Zelboraf (vemurafenib) and Cotellic (cobimetinib) resulted in an improved progression-free survival of 12.3 months compared to 7.2 months with Zelboraf (vemurafenib) alone among patients with BRAF V600-mutated metastatic melanoma (PMID: 25265494, J Clin Oncol 33, 2015 (suppl; abstr 9006)).",Actionable,1211,1909,melanoma,DOID,1186,BRAF V600X,sensitive,1657,Vemurafenib + Cobimetinib,673,25265494,None,,
593,Preclinical - Cell culture,"In a preclinical study, the combination of Buparlisib (BKM120) and Mekinist (trametinib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).",Actionable,8164,1909,melanoma,DOID,1186,BRAF V600X,sensitive,1974,BKM120 + Trametinib,673,24265152,,,
594,Preclinical - Cell culture,"In a preclinical study, the combination of Selumetinib (AZD6244) and Zelboraf (vemurafenib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).",Actionable,8161,1909,melanoma,DOID,1186,BRAF V600X,sensitive,3773,Selumetinib + Vemurafenib,673,24265152,,,
595,Preclinical - Cell culture,"In a preclinical study, the combination of Buparlisib (BKM120) and Zelboraf (vemurafenib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).",Actionable,8163,1909,melanoma,DOID,1186,BRAF V600X,sensitive,1322,BKM120 + Vemurafenib,673,24265152,,,
596,Phase Ib/II,"In a Phase Ib/II trial, treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) resulted in partial response or better in 12% (5/43), including 1 complete response, and stable disease in 51% (22/43) of patients with BRAF V600-mutant colorectal cancer (PMID: 26392102).",Actionable,2525,9256,colorectal cancer,DOID,1186,BRAF V600X,sensitive,1066,Trametinib + Dabrafenib,673,None,26392102,,
597,Phase Ib/II,"In a Phase Ib trial, the addition of Zelboraf (vemurafenib) to Camptosar (irinotecan) plus Erbitux (cetuximab) improved progression-free survival (4.4 mo vs. 2.0 mo), and disease control rate (67% vs. 22%), compared to Camptosar (irinotecan) plus Erbitux (cetuximab) without Zelboraf (vemurafenib), in patients with BRAF V600-mutant colorectal cancer (J Clin Oncol 35, 2017 (suppl 4S; abstract 520)).",Actionable,9868,9256,colorectal cancer,DOID,1186,BRAF V600X,sensitive,1331,Vemurafenib + Cetuximab + Irinotecan ,673,None,,,
598,Guideline,Tafinlar (dabrafenib) is an active regimen for melanoma patients with BRAF V600 mutations (Guidelines).,Actionable,1509,1909,melanoma,DOID,1186,BRAF V600X,sensitive,3,Dabrafenib,673,None,,,
599,Preclinical - Cell culture,"In a preclinical study, the combination of Buparlisib (BKM120) and Selumetinib (AZD6244) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).",Actionable,8165,1909,melanoma,DOID,1186,BRAF V600X,sensitive,4652,BKM120 + Selumetinib,673,24265152,,,
600,Phase I,"In a Phase I trial, the combination therapy of AMG 232, Mekinist (trametinib), and Tafinlar (dabrafenib) in 6 patients with metastatic cutaneous melanoma harboring a BRAF V600 mutation resulted in 4 patients with a partial response and 2 patients with stable disease, and of the 6 patients, all experienced tumor reduction (J Clin Oncol 35, 2017 (suppl; abstr 2575)).",Actionable,11096,1909,melanoma,DOID,1186,BRAF V600X,sensitive,1453,AMG 232 + Trametinib + Dabrafenib,673,None,,,
601,Preclinical - Cell culture,"In a preclinical study, the combination of MK2206 and Mekinist (trametinib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).",Actionable,8167,1909,melanoma,DOID,1186,BRAF V600X,sensitive,4653,MK2206 + Trametinib,673,24265152,,,
602,Guideline,Zelboraf (vemurafenib) is an active regimen for melanoma patients with BRAF V600 mutations (Guidelines).,Actionable,1511,1909,melanoma,DOID,1186,BRAF V600X,sensitive,342,Vemurafenib,673,None,,,
603,Phase II,"In a Phase II clinical trial, treatment with the combination of Zelboraf (vemurafenib) and Erbitux (cetuximab) resulted in an overall response rate of 4% (1/26), stable disease in 69% (18/26), and a median progression-free survival of 3.7 months in patients with BRAF V600-mutant colorectal cancer (PMID: 26287849).",Actionable,3301,9256,colorectal cancer,DOID,1186,BRAF V600X,sensitive,1711,Vemurafenib + Cetuximab,673,26287849,,,
604,Preclinical - Cell culture,"In a preclinical study, the combination of MK2206 and Zelboraf (vemurafenib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).",Actionable,8166,1909,melanoma,DOID,1186,BRAF V600X,sensitive,4635,MK2206 + Vemurafenib,673,24265152,,,
605,Phase II,"In a Phase II clinical trial, treatment with Zelboraf (vemurafenib) resulted in partial response in 12% (1/8) and stable disease in 50% (4/8) of cholangiocarcinoma patients with BRAF V600 mutations (PMID: 26287849).",Actionable,3303,4947,cholangiocarcinoma,DOID,1186,BRAF V600X,sensitive,342,Vemurafenib,673,26287849,,,
606,Preclinical - Cell culture,"In a preclinical study, the combination of Mekinist (trametinib) and Zelboraf (vemurafenib) inhibited growth of BRAF V600-mutant melanoma cell lines in culture, with increased efficacy over either agent alone (PMID: 24265152).",Actionable,8160,1909,melanoma,DOID,1186,BRAF V600X,sensitive,4234,Trametinib + Vemurafenib,673,24265152,,,
607,Phase Ib/II,"In a Phase Ib trial, the combination of Tecentriq (atezolizumab), Cotellic (cobimetinib), and Zelboraf (vemurafenib) resulted in antitumor efficacy in BRAF V600 positive melanoma patients, demonstrating an unconfirmed RECIST response in 85.3% (29/34) of patients, including 6 CRs and 23 PRs, and confirmed PRs in three patients (J Clin Oncol 35, 2017 (suppl; abstr 3063)).",Actionable,11112,1909,melanoma,DOID,1186,BRAF V600X,sensitive,4825,Atezolizumab + Vemurafenib + Cobimetinib,673,None,,,
608,Guideline,Mekinist (trametinib) is an active regimen for melanoma patients with BRAF V600 mutations (Guidelines).,Actionable,1514,1909,melanoma,DOID,1186,BRAF V600X,sensitive,2,Trametinib,673,None,,,
609,Clinical Study,"In a clinical study, a melanoma patient harboring a BRAF V600 mutation developed resistant mutations, MAP2K1 V60E, NRAS T58I, and NRAS Q61R, after 18 weeks of treatment with Zelboraf (vemurafenib) (PMID: 24265153).",Actionable,7068,1909,melanoma,DOID,24385,BRAF V600X MAP2K1 V60E NRAS T58I NRAS Q61R,resistant,342,Vemurafenib,673,24265153,,,
610,Clinical Study,"In a clinical study, the combination of Torisel (temsirolimus) plus Avastin (bevacizumab) and Doxil (pegylated liposomal-doxorubicin) resulted in a partial response in a patient with ovarian clear cell carcinoma harboring PIK3CA H1047 and BRAF V600 mutations (PMID: 21216929).",Actionable,3381,4001,ovarian carcinoma,DOID,13306,PIK3CA H1047X BRAF V600X,sensitive,1121,Bevacizumab + Temsirolimus + Doxil,673,21216929,,,
611,Preclinical - Cell culture,"In a preclinical study, expression of AKT1 Q79K in a wild-type PTEN-expressing BRAF V600-mutant melanoma cell line conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 24265152).",Actionable,8106,1909,melanoma,DOID,26173,AKT1 Q79K BRAF V600X PTEN pos,resistant,342,Vemurafenib,673,24265152,,,
612,Preclinical - Cell culture,"In a preclinical study, the combination of MK2206 and Zelboraf (vemurafenib) inhibited AKT activation and growth of PTEN-expressing BRAF V600-mutant melanoma cells expressing AKT1 Q79K in culture, with increased efficacy over either agent alone (PMID: 24265152).",Actionable,8125,1909,melanoma,DOID,26173,AKT1 Q79K BRAF V600X PTEN pos,sensitive,4635,MK2206 + Vemurafenib,673,24265152,,,
613,Clinical Study,"In a clinical study, a melanoma patient harboring PTEN Y86fs and BRAF V600X developed the resistance mutation, PIK3CA H1047R, after treatment with Zelboraf (vemurafenib) (PMID: 24265153). ",Actionable,7082,1909,melanoma,DOID,24398,BRAF V600X PIK3CA H1047R PTEN Y86fs,resistant,342,Vemurafenib,673,24265153,,,
614,Preclinical,"In a preclinical study, Omipalisib (GSK2126458) inhibited the growth of melanoma cell lines harboring BRAF V600K in culture (PMID: 22389471).",Actionable,5974,1909,melanoma,DOID,22095,BRAF V600K NRAS Q61K,sensitive,763,GSK2126458,673,22389471,,,
615,Preclinical,"In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600K and NRAS Q61K in culture, compared to either agent alone (PMID: 22389471).",Actionable,5995,1909,melanoma,DOID,22095,BRAF V600K NRAS Q61K,sensitive,3027,GSK2126458 + Trametinib,673,22389471,,,
616,Preclinical,"In a preclinical study, Tafinlar (dabrafenib) in combination with Mekinist (trametinib) inhibited growth of melanoma cell lines harboring BRAF V600K and NRAS Q61K in culture (PMID: 22389471).",Actionable,5981,1909,melanoma,DOID,22095,BRAF V600K NRAS Q61K,sensitive,1066,Trametinib + Dabrafenib,673,22389471,,,
617,Preclinical,"In a preclinical study, Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600K and NRAS Q61K in culture (PMID: 22389471).",Actionable,5996,1909,melanoma,DOID,22095,BRAF V600K NRAS Q61K,sensitive,4004,Dabrafenib + GSK2126458,673,22389471,,,
618,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600K and NRAS Q61K were resistant to Tafinlar (dabrafenib) growth inhibition in culture (PMID: 22389471).",Actionable,5971,1909,melanoma,DOID,22095,BRAF V600K NRAS Q61K,resistant,3,Dabrafenib,673,22389471,,,
619,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600K and NRAS Q61K were 3-7 fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600K in culture (PMID: 22389471).",Actionable,5972,1909,melanoma,DOID,22095,BRAF V600K NRAS Q61K,decreased response,2,Trametinib,673,22389471,,,
620,Preclinical - Cell culture,"In a preclinical study, Mekinist (trametinib) inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124L in culture (PMID: 25370473).",Actionable,7603,1909,melanoma,DOID,25916,BRAF V600K MAP2K1 P124L,sensitive,2,Trametinib,673,25370473,,,
621,Preclinical - Cell culture,"In a preclinical study, a melanoma cell line harboring BRAF V600K and MAP2K1 P124L demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 25370473).",Actionable,7599,1909,melanoma,DOID,25916,BRAF V600K MAP2K1 P124L,decreased response,3,Dabrafenib,673,25370473,,,
622,Preclinical,"In a preclinical study, VX-11e inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124L in culture (PMID: 25370473).",Actionable,7600,1909,melanoma,DOID,25916,BRAF V600K MAP2K1 P124L,sensitive,2804,VX-11e,673,25370473,,,
623,Preclinical - Cell culture,"In a preclinical study, VX-11e inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q in culture (PMID: 25370473).",Actionable,7601,1909,melanoma,DOID,25913,BRAF V600K MAP2K1 P124Q,sensitive,2804,VX-11e,673,25370473,,,
624,Preclinical - Cell culture,"In a preclinical study, Mekinist (trametinib) inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q in culture (PMID: 25370473).",Actionable,7602,1909,melanoma,DOID,25913,BRAF V600K MAP2K1 P124Q,sensitive,2,Trametinib,673,25370473,,,
625,Preclinical - Cell culture,"In a preclinical study, a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 25370473).",Actionable,7598,1909,melanoma,DOID,25913,BRAF V600K MAP2K1 P124Q,decreased response,3,Dabrafenib,673,25370473,,,
626,Guideline,Mekinist (trametinib) is an active regimen for melanoma patients with BRAF V600K (Guidelines).,Actionable,1513,1909,melanoma,DOID,2,BRAF V600K,sensitive,2,Trametinib,673,None,None, 'title': '',
627,Preclinical,"In a preclinical study, Omipalisib (GSK2126458) inhibited the growth of melanoma cell lines harboring BRAF V600K in culture (PMID: 22389471).",Actionable,5973,1909,melanoma,DOID,2,BRAF V600K,sensitive,763,GSK2126458,673,22389471,,,
628,Guideline,Tafinlar (dabrafenib) is an active regimen for melanoma patients with BRAF V600K (Guidelines).,Actionable,1508,1909,melanoma,DOID,2,BRAF V600K,sensitive,3,Dabrafenib,673,None,None,,
629,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) induced apoptosis in non-small cell lung carcinoma cells harboring BRAF Y472C in culture (PMID: 22649091).",Actionable,690,3908,non-small cell lung carcinoma,DOID,986,BRAF Y472C,sensitive,717,Dasatinib,673,22649091,,,
630,Preclinical - Cell line xenograft,"In a preclinical study, XL147 inhibited tumor growth in xenograft models of a PTEN-deficient human melanoma cell line harboring BRAF V600D (PMID: 25637314).",Actionable,6320,1909,melanoma,DOID,23100,BRAF V600D PTEN loss,sensitive,1050,XL147,673,25637314,,,
631,Preclinical,"In a preclinical study, CCT241161 inhibited MEK and ERK phosphorylation and growth of melanoma cells harboring BRAF V600D in culture (PMID: 25500121, PMID: 17210691).",Actionable,3309,1909,melanoma,DOID,653,BRAF V600D,sensitive,3106,CCT241161,673,25500121,17210691,,
632,Preclinical,"In a preclinical study, CCT196969 inhibited MEK and ERK phosphorylation and growth of melanoma cells harboring BRAF V600D in culture (PMID: 25500121, PMID: 17210691).",Actionable,3308,1909,melanoma,DOID,653,BRAF V600D,sensitive,3105,CCT196969,673,25500121,17210691,,
633,Preclinical - Cell culture,"In a preclinical study, PLX7904 inhibited proliferation of melanoma cell lines harboring BRAF V600D in culture (PMID: 27523909).",Actionable,7947,1909,melanoma,DOID,653,BRAF V600D,sensitive,4606,PLX7904,673,27523909,,,
634,Preclinical - Cell culture,"In a preclinical study, Tafinlar (dabrafenib) inhibited proliferation of melanoma cells harboring BRAF V600D in culture (PMID: 27523909).",Actionable,7961,1909,melanoma,DOID,653,BRAF V600D,sensitive,3,Dabrafenib,673,27523909,,,
635,Preclinical - Cell culture,"In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring BRAF V600D in culture (PMID: 27523909).",Actionable,7937,1909,melanoma,DOID,653,BRAF V600D,sensitive,3300,TAK-632,673,27523909,,,
636,Preclinical - Cell culture,"In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring BRAF V600D in culture (PMID: 27523909).",Actionable,7907,1909,melanoma,DOID,653,BRAF V600D,sensitive,1093,AZ628,673,27523909,,,
637,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600D in culture (PMID: 27523909).",Actionable,7953,1909,melanoma,DOID,653,BRAF V600D,sensitive,342,Vemurafenib,673,27523909,,,
638,Clinical Study,"In a clinical case study, single Tafinlar (dabrafenib) and subsequent Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment resulted in disease stablization in a patient with pilocytic astrocytoma harboring BRAF V600D (PMID: 28784858).",Actionable,11711,4851,pilocytic astrocytoma,DOID,653,BRAF V600D,sensitive,1066,Trametinib + Dabrafenib,673,28784858,,,
639,Preclinical - Cell culture,"In a preclinical study, colon cancer cells harboring BRAF N581Y were resistant to GDC0879 induced growth inhibition in culture (PMID: 19276360).",Actionable,7875,219,colon cancer,DOID,23804,BRAF N581Y,resistant,1095,GDC0879,673,19276360,,,
640,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing BRAF F247L demonstrated sensitivity to Tafinlar (dabrafenib) in culture (PMID: 28512244).",Actionable,11371,10000003,Advanced Solid Tumor,JAX,27972,BRAF F247L,sensitive,3,Dabrafenib,673,28512244,,,
641,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing BRAF F247L demonstrated sensitivity to Mekinist (trametinib) in culture (PMID: 28512244).",Actionable,11370,10000003,Advanced Solid Tumor,JAX,27972,BRAF F247L,sensitive,2,Trametinib,673,28512244,,,
642,Preclinical,"In a preclinical study, Mekinist (trametinib) treatment demonstrated enhanced growth inhibition and sustained inhibition of Erk signaling in lung cancer cells harboring KRAS G12C with decreased Braf expression through shRNA knockdown in culture (PMID: 27338794).",Actionable,7359,1324,lung cancer,DOID,25302,BRAF dec exp KRAS G12C,sensitive,2,Trametinib,673,27338794,,,
643,Preclinical,"In a preclinical study, Selumetinib (AZD6244) and Zelboraf (vemurafenib) worked synergistically to inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).",Actionable,5184,1909,melanoma,DOID,20300,BRAF V600E/K PIK3CA wild-type,sensitive,3773,Selumetinib + Vemurafenib,673,26137449,,,
644,Preclinical,"In a preclinical study, A66 did not inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).",Actionable,5190,1909,melanoma,DOID,20300,BRAF V600E/K PIK3CA wild-type,no benefit,617,A66,673,26137449,,,
645,Preclinical,"In a preclinical study, Zydelig (idelalisib) did not inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).",Actionable,5192,1909,melanoma,DOID,20300,BRAF V600E/K PIK3CA wild-type,no benefit,1023,Idelalisib,673,26137449,,,
646,Preclinical - Cell line xenograft,"In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment inhibited proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture, and synergitically inhibited tumor growth in cell line xenograft models (PMID: 26137449).",Actionable,5188,1909,melanoma,DOID,20300,BRAF V600E/K PIK3CA wild-type,sensitive,1420,Selumetinib + BEZ235,673,26137449,,,
647,Preclinical,"In a preclinical study, ZSTK474 and Zelboraf (vemurafenib) worked synergistically to inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).",Actionable,5186,1909,melanoma,DOID,20300,BRAF V600E/K PIK3CA wild-type,sensitive,3772,Vemurafenib + ZSTK474,673,26137449,,,
648,Preclinical,"In a preclinical study, BEZ235 and Zelboraf (vemurafenib) worked synergistically to inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).",Actionable,5185,1909,melanoma,DOID,20300,BRAF V600E/K PIK3CA wild-type,sensitive,3774,BEZ235 + Vemurafenib,673,26137449,,,
649,Preclinical,"In a preclinical study, TGX-221 did not inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).",Actionable,5191,1909,melanoma,DOID,20300,BRAF V600E/K PIK3CA wild-type,no benefit,2514,TGX-221,673,26137449,,,
650,Preclinical - Cell line xenograft,"In a preclinical study, Selumetinib (AZD6244) and ZSTK474 combination treatment inhibited proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture, and synergistically inhibited tumor growth in cell line xenograft models (PMID: 26137449).",Actionable,5187,1909,melanoma,DOID,20300,BRAF V600E/K PIK3CA wild-type,sensitive,3771,Selumetinib + ZSTK474,673,26137449,,,
651,Phase I,"In a Phase I trial, Mekinist (trametinib) resulted in complete response in 7% (2/30), partial response in 33% (10/30), and stable disease in 37% (11/30) of BRAF-mutant melanoma patients (PMID: 22805292).",Actionable,178,1909,melanoma,DOID,499,BRAF V600E/K,sensitive,2,Trametinib,673,22805292,,,
652,FDA approved,"In a Phase III trial that supported FDA approval, Mekinist (trametinib) resulted in improved progression free survival and an overall six month survival rate of 81% in patients with BRAF V600E/K positive metastatic melanoma (PMID: 22663011). ",Actionable,1912,1909,melanoma,DOID,499,BRAF V600E/K,sensitive,2,Trametinib,673,None,22663011,,
653,Guideline,Mekinist (trametinib) is an active regimen for melanoma patients with BRAF V600E or V600K (Guidelines).,Actionable,1515,1909,melanoma,DOID,499,BRAF V600E/K,sensitive,2,Trametinib,673,None,None,,
654,FDA approved,"In a Phase III trial that supported FDA approval, Tafinlar (dabrafenib) in combination with Mekinist (trametinib) significantly improved progression-free survival in patients with BRAF V600E/K-positive metastatic melanoma (PMID: 25265492, J Clin Oncol 32:5s, 2014 (Suppl; abstr 9011)). ",Actionable,1909,1909,melanoma,DOID,499,BRAF V600E/K,sensitive,1066,Trametinib + Dabrafenib,673,None,None,25265492,
655,Phase III,"In a Phase III trial, treatment with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) resulted in an improved estimated 3-year relapse-free survival rate (58% vs 39%, HR=0.47, P<0.001) and 3-year overall survival rate (86% vs 77%, HR=0.57; 95% CI, 0.42 to 0.79, P=0.0006) compared to placebo in stage III melanoma patients harboring BRAF V600E or V600K mutations (PMID: 28891408; NCT01682083).",Actionable,12034,1909,melanoma,DOID,499,BRAF V600E/K,sensitive,1066,Trametinib + Dabrafenib,673,28891408,,,
656,Guideline,"Tafinlar (dabrafenib), in combination with Mekinist (trametinib), is an active regimen for melanoma patients with BRAF V600E or V600K (Guidelines).",Actionable,1518,1909,melanoma,DOID,499,BRAF V600E/K,sensitive,1066,Trametinib + Dabrafenib,673,None,None,,
657,Preclinical,"In a preclinical study, melanoma cells expressing BRAF L505H were resistant to Zelboraf (vemurafenib) (PMID: 24283590). ",Actionable,1475,1909,melanoma,DOID,2594,BRAF L505H,resistant,342,Vemurafenib,673,24283590,,,
658,Preclinical - Cell culture,"In a preclinical study, treatment with Zelboraf (vemurafenib) did not reduce activation of Mek and Erk by BRAF F595L in transformed cells in culture (PMID: 26582644).",Actionable,11664,10000003,Advanced Solid Tumor,JAX,2417,BRAF F595L,resistant,342,Vemurafenib,673,26582644,,,
659,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF G464V (PMID: 26343582).",Actionable,9411,10000003,Advanced Solid Tumor,JAX,664,BRAF G464V,resistant,342,Vemurafenib,673,26343582,,,
660,Preclinical - Cell line xenograft,"In a preclinical study, CH5132799 demonstrated decreased response to tumor growth inhibition in xenograft models of human breast cancer cell lines harboring KRAS G13D and BRAF G464V (PMID: 21558396).",Actionable,2973,1612,breast cancer,DOID,10754,BRAF G464V KRAS G13D,decreased response,2152,CH5132799,673,21558396,,,
661,Preclinical - Cell line xenograft,"In a preclinical study, Stivarga (regorafenib) inhibited proliferation of breast cancer cells harboring BRAF G464V and KRAS G13D in culture and inhibited angiogenesis and tumor growth in cell line xenograft models (PMID: 21170960).",Actionable,1075,1612,breast cancer,DOID,10754,BRAF G464V KRAS G13D,sensitive,890,Regorafenib,673,21170960,,,
662,Preclinical,"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human breast cancer cells harboring BRAF G464V and KRAS G13D in culture (PMID: 21325073, PMID: 17314276).",Actionable,3129,1612,breast cancer,DOID,10754,BRAF G464V KRAS G13D,sensitive,1040,PF-05212384,673,21325073,,17314276,
663,Preclinical - Cell line xenograft,"In a preclinical study, DHM25 increased cell death and decreased migration of a triple-negative breast cancer cell line harboring KRAS G13D and BRAF G464V in culture, and reduced tumor growth and lung metastasis in xenograft models (PMID: 26237138).",Actionable,10363,60081,triple-receptor negative breast cancer,DOID,10754,BRAF G464V KRAS G13D,sensitive,5494,DHM25,673,26237138,,,
664,Preclinical,"In a preclinical study, Tafinlar (dabrafenib) resulted in minimal growth inhibitory activity of an ovarian cancer cell line harboring BRAF N486_P490del (PMID: 26732095). ",Actionable,4919,2394,ovarian cancer,DOID,19833,BRAF N486_P490del,predicted â€“ resistant,3,Dabrafenib,673,26732095,,,
665,Preclinical,"In a preclinical study, an ovarian cancer cell line harboring BRAF  N486_P490del was sensitive to LY3009120, resulting in inhibition of cell growth and decreased phosphorylation of MEK and ERK in culture (PMID: 26732095). ",Actionable,4916,2394,ovarian cancer,DOID,19833,BRAF N486_P490del,sensitive,3268,LY3009120,673,26732095,,,
666,Preclinical,"In a preclinical study, an ovarian cancer cell line harboring BRAF N486_P490del was resistant to Zelboraf (vemurafenib), resulting in minimal inhibition of both cell growth and phosphorylation of MEK and ERK in culture (PMID: 26732095). ",Actionable,4918,2394,ovarian cancer,DOID,19833,BRAF N486_P490del,resistant,342,Vemurafenib,673,26732095,,,
667,Preclinical,"In a preclinical study, an ovarian cancer cell line harboring BRAF  N486_P490del was sensitive to Mekinist (trametinib), resulting in inhibition of cell growth in culture (PMID: 26732095). ",Actionable,4917,2394,ovarian cancer,DOID,19833,BRAF N486_P490del,sensitive,2,Trametinib,673,26732095,,,
668,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF G464E (PMID: 26343582).",Actionable,9410,10000003,Advanced Solid Tumor,JAX,1779,BRAF G464E,resistant,342,Vemurafenib,673,26343582,,,
669,Preclinical,"In a preclinical study, treatment of cells expressing BRAF L597R with the BRAF inhibitor, Zelboraf (vemurafenib), decreased activation of MEK and ERK (PMID: 22798288).",Actionable,694,10000003,Advanced Solid Tumor,JAX,992,BRAF L597R,sensitive,342,Vemurafenib,673,22798288,,,
670,Preclinical,"Preclinical studies demonstrated the MEK inhibitor, Mekinist (trametinib) caused decreased activation of MEK and ERK in cells expressing BRAF L597R (PMID: 22798288).",Actionable,693,10000003,Advanced Solid Tumor,JAX,992,BRAF L597R,sensitive,2,Trametinib,673,22798288,,,
671,Preclinical - Cell culture,"In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring BRAF G466E in culture (PMID: 27523909).",Actionable,7938,1909,melanoma,DOID,3324,BRAF G466E,sensitive,3300,TAK-632,673,27523909,,,
672,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF G466E demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 27523909).",Actionable,7963,1909,melanoma,DOID,3324,BRAF G466E,decreased response,3,Dabrafenib,673,27523909,,,
673,Preclinical - Cell culture,"In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring BRAF G466E in culture (PMID: 27523909).",Actionable,7908,1909,melanoma,DOID,3324,BRAF G466E,sensitive,1093,AZ628,673,27523909,,,
674,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF G466E demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909).",Actionable,7955,1909,melanoma,DOID,3324,BRAF G466E,decreased response,342,Vemurafenib,673,27523909,,,
675,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF G466E demonstrated decreased sensitivity to PLX7904 in culture (PMID: 27523909).",Actionable,7948,1909,melanoma,DOID,3324,BRAF G466E,decreased response,4606,PLX7904,673,27523909,,,
676,Preclinical - Cell culture,"In a preclinical study, Mekinist (trametinib) reduced ERK signaling and inhibited proliferation of a melanoma cell line harboring BRAF G466E and HRAS Q61K in culture (PMID: 28783719).",Actionable,11656,1909,melanoma,DOID,28179,BRAF G466E HRAS Q61K,sensitive,2,Trametinib,673,28783719,,,
677,Preclinical - Cell line xenograft,"In a preclinical study, a human pancreatic cancer cell line harboring BRAF V487_P492delinsA was resistant to treatment with Zelboraf (vemurafenib) in both culture and xenograft models (PMID: 26732095).",Actionable,4922,1793,pancreatic cancer,DOID,19834,BRAF V487_P492delinsA,resistant,342,Vemurafenib,673,26732095,,,
678,Preclinical,"In a preclinical study, a pancreatic cancer cell line harboring BRAF V487_P492delinsA was resistant to Tafinlar (dabrafenib) (PMID: 26732095). ",Actionable,4923,1793,pancreatic cancer,DOID,19834,BRAF V487_P492delinsA,resistant,3,Dabrafenib,673,26732095,,,
679,Preclinical,"In a preclinical study, a pancreatic cancer cell line harboring BRAF V487_P492delinsA was sensitive to Mekinist (trametinib) in culture, resulting in cell growth inhibition (PMID: 26732095). ",Actionable,4921,1793,pancreatic cancer,DOID,19834,BRAF V487_P492delinsA,sensitive,2,Trametinib,673,26732095,,,
680,Preclinical,"In a preclinical study, a pancreatic cancer cell line harboring BRAF V487_P492delinsA were sensitive to LY3009120 in culture and in xenograft models, resulting in inhibition of tumor growth and partial tumor regression (PMID: 26732095).",Actionable,4920,1793,pancreatic cancer,DOID,19834,BRAF V487_P492delinsA,sensitive,3268,LY3009120,673,26732095,,,
681,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) did not inhibit MEK and ERK activation in transformed cells over expressing the constitutively dimerized BRAF G469A (PMID: 26343582).",Actionable,9413,10000003,Advanced Solid Tumor,JAX,651,BRAF G469A,resistant,342,Vemurafenib,673,26343582,,,
682,Preclinical - Cell culture,"In a preclinical study, Mekinist (trametinib) induced apoptosis and inhibited growth of a non-small cell lung cancer cell line harboring BRAF G469A in culture (PMID: 25706985).",Actionable,9615,3908,non-small cell lung carcinoma,DOID,651,BRAF G469A,sensitive,2,Trametinib,673,25706985,,,
683,Preclinical - Cell culture,"In a preclinical study, a non-small cell lung cancer cell line harboring BRAF G469A demonstrated resistance to induction of apoptosis by Zelboraf (vemurafenib,) and treatment with Zelboraf (vemurafenib) was not effective in inhibiting growth in culture (PMID: 25706985).",Actionable,9614,3908,non-small cell lung carcinoma,DOID,651,BRAF G469A,resistant,342,Vemurafenib,673,25706985,,,
684,Preclinical - Cell culture,"In a preclinical study, the combination of Mekinist (trametinib) and Zelboraf (vemurafenib) inhibited growth of  a non-small cell lung cancer cell line harboring BRAF G469A in culture, and prevented Mekinist (trametinib)-related activation of AKT and resulted in increased induction of apoptosis compared to either agent alone (PMID: 25706985).",Actionable,9616,3908,non-small cell lung carcinoma,DOID,651,BRAF G469A,sensitive,4234,Trametinib + Vemurafenib,673,25706985,,,
685,Preclinical - Cell culture,"In a preclinical study, treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) resulted in decreased viability and enhanced ERK inhibition compared to either agent alone, in a non-small cell lung cancer cell line harboring BRAF G469A in culture (PMID: 27577079).",Actionable,9611,3908,non-small cell lung carcinoma,DOID,651,BRAF G469A,sensitive,1066,Trametinib + Dabrafenib,673,27577079,,,
686,Preclinical - Cell line xenograft,"In a preclinical study, PLX8394 decreased growth of lung adenocarcinoma cell lines harboring BRAF G469A in culture, and reduced tumor growth in xenograft models (PMID: 27834212).",Actionable,12072,3910,lung adenocarcinoma,DOID,651,BRAF G469A,sensitive,1041,PLX8394,673,27834212,,,
687,Preclinical,"In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring BRAF G469A mutation in culture (PMID: 26090892).",Actionable,3933,3908,non-small cell lung carcinoma,DOID,651,BRAF G469A,sensitive,2086,TAE226,673,26090892,,,
688,Preclinical - Cell culture,"In a preclinical study, treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) resulted in decreased proliferation and increased apoptosis, and enhanced ERK inhibition compared to either agent alone in a colorectal cancer cell line harboring BRAF G596R in culture (PMID: 27577079).",Actionable,11737,9256,colorectal cancer,DOID,2416,BRAF G596R,sensitive,1066,Trametinib + Dabrafenib,673,27577079,,,
689,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) did not reduce activation of Erk and Mek in a colorectal cancer cell line harboring BRAF G596R in culture (PMID: 28783719).",Actionable,11665,9256,colorectal cancer,DOID,2416,BRAF G596R,resistant,342,Vemurafenib,673,28783719,,,
690,Preclinical - Cell culture,"In a preclinical study, Mekinist (trametinib) reduced Erk signaling and inhibited proliferation of a colorectal cancer cell line harboring BRAF G596R in culture (PMID: 28783719).",Actionable,11655,9256,colorectal cancer,DOID,2416,BRAF G596R,sensitive,2,Trametinib,673,28783719,,,
691,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cells harboring both BRAF G596R and PIK3CA E545K in culture (PMID: 26243863).",Actionable,7117,9256,colorectal cancer,DOID,24419,BRAF G596R PIK3CA E545K,sensitive,828,Neratinib,673,26243863,,,
0,Clinical Study,"In a clinical study, an ovarian carcinoma patient harboring a BRCA1 L392Qfs*5 germline mutation demonstrated a partial response when treated with Rubraca (rucaparib) (PMID: 28588062). ",Actionable,12052,4001,ovarian carcinoma,DOID,28324,BRCA1 L392Qfs*5,sensitive,906,Rucaparib,672,28588062,,,
1,Preclinical,"In a preclinical study, Lynparza (olaparib) inhibited growth of human breast cancer cells harboring BRCA1 L1795Pfs*3 (referred to as BRCA1 5382insC) in culture, and resulted in prolonged overall survival in transgenic mouse models of breast cancer (PMID: 27454287).",Actionable,8664,1612,breast cancer,DOID,26391,BRCA1 L1795Pfs*3,sensitive,837,Olaparib,672,27454287,,,
2,Preclinical,"In a preclinical study, triple-receptor negative breast cancer cells wild-type for BRCA1/2 demonstrated an increased sensitivity to Lynparza (olaparib) when treatment was combined with KU-0063794, resulting in greater decreased cell proliferation and apoptosis in culture (PMID: 26546619). ",Actionable,6059,60081,triple-receptor negative breast cancer,DOID,22293,BRCA1 wild-type BRCA2 wild-type,sensitive,4015,Olaparib + KU-0063794,672,26546619,,,
3,Preclinical,"In a preclinical study, triple-receptor negative breast cancer cells wild-type for BRCA1/2 demonstrated an increased sensitivity to Talazoparib (BMN673) when treatment was combined with KU-0063794, resulting in greater decreased cell proliferation and apoptosis in culture (PMID: 26546619). ",Actionable,6057,60081,triple-receptor negative breast cancer,DOID,22293,BRCA1 wild-type BRCA2 wild-type,sensitive,4013,KU-0063794 + Talazoparib,672,26546619,,,
4,Preclinical,"In a preclinical study, triple-receptor negative breast cancer cells wild-type for BRCA1/2 demonstrated an increased sensitivity to Lynparza (olaparib) when treatment was combined with Afinitor (everolimus), resulting in greater decreased cell proliferation and apoptosis in culture (PMID: 26546619). ",Actionable,6058,60081,triple-receptor negative breast cancer,DOID,22293,BRCA1 wild-type BRCA2 wild-type,sensitive,4014,Olaparib + Everolimus,672,26546619,,,
5,Phase III,"In a Phase III trial that supported FDA approval, Zejula (niraparib) maintenance therapy improved median progression-free survival compared to placebo (9.3 vs. 3.9 months, HR=0.45) in platinum-sensitive, recurrent ovarian cancer patients without germline BRCA mutations, with and without homologous recombination deficiency (12.9 vs. 3.8 months, HR=0.38) (PMID: 27717299).",Actionable,9006,2394,ovarian cancer,DOID,22293,BRCA1 wild-type BRCA2 wild-type,predicted â€“ sensitive,832,Niraparib,672,27717299,,,
6,Phase I,"In a Phase I trial, VX-970 in combination with Platinol (cisplatin) resulted in an objective response rate of 38.9% (7/18, all partial responses) and a disease control rate of 72.2% (13/18) in patients with BRCA1/2 wild-type triple-receptor negative breast cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 242PD; NCT02157792).",Actionable,12060,60081,triple-receptor negative breast cancer,DOID,22293,BRCA1 wild-type BRCA2 wild-type,predicted â€“ sensitive,3109,Cisplatin + VX-970,672,None,,,
7,Preclinical,"In a preclinical study, triple-receptor negative breast cancer cells wild-type for BRCA1/2 demonstrated an increased sensitivity to Talazoparib (BMN673) when treatment was combined with Afinitor (everolimus), resulting in greater decreased cell proliferation and apoptosis in culture and reduced tumor volume in xenograft models (PMID: 26546619). ",Actionable,6056,60081,triple-receptor negative breast cancer,DOID,22293,BRCA1 wild-type BRCA2 wild-type,sensitive,4012,Everolimus + Talazoparib,672,26546619,,,
8,Preclinical,"In a preclinical study, BRCA1 proficient transgenic mouse models of breast cancer did not respond to Lynparza (olaparib) treatment (PMID: 27454287).",Actionable,8662,1612,breast cancer,DOID,518,BRCA1 wild-type,resistant,837,Olaparib,672,27454287,,,
9,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Veliparib (ABT-888) and Paraplatin (carboplatin) provided no survival benefit in an intracranial human BRCA wild-type triple-negative breast cancer cell line xenograft model (PMID: 25824335).",Actionable,2194,60081,triple-receptor negative breast cancer,DOID,518,BRCA1 wild-type,no benefit,2704,Veliparib + Carboplatin,672,25824335,,,
10,Preclinical,"In a preclinical study,  Lynparza (olaparib) inhibited the growth of triple-receptor negative breast cancer cell lines expressing wild-type BRCA1 under hypoxic conditions (PMID: 25193512).",Actionable,2868,60081,triple-receptor negative breast cancer,DOID,518,BRCA1 wild-type,sensitive,837,Olaparib,672,25193512,,,
11,Phase I,"In a Phase I trial, the combination of Talazoparib (BMN673) and Temodar (temozolomide) resulted in a partial response in 50% (2/4) of ovarian cancer patients harboring wild-type BRCA1 (European Journal of Cancer, Sep 2015, 51:3, S60). ",Actionable,9961,2394,ovarian cancer,DOID,518,BRCA1 wild-type,sensitive,1377,Talazoparib + Temozolomide,672,None,,,
12,Preclinical,"In a preclinical study, knockdown of BRCA1 increased sensitivity of triple-negative breast cancer cells to Platinol (cisplatin) under hypoxic conditions (PMID: 25193512).",Actionable,2870,60081,triple-receptor negative breast cancer,DOID,2485,BRCA1 dec exp,sensitive,700,Cisplatin,672,25193512,,,
13,Preclinical,"In a preclinical study, BRCA1 knockdown enhanced growth inhibition by Ambochlorin (chlorambucil) in triple-receptor negative breast cancer cell lines in culture (PMID: 25193512).",Actionable,2878,60081,triple-receptor negative breast cancer,DOID,2485,BRCA1 dec exp,sensitive,3035,Chlorambucil,672,25193512,,,
14,Preclinical,"In a preclinical study, decreasing Brca1 expression via shRNA knockdown did not sensitize triple-receptor negative breast cancer cells with Met over expression to Rubraca (rucaparib) in culture (PMID: 26779812).",Actionable,6150,60081,triple-receptor negative breast cancer,DOID,22729,BRCA1 dec exp MET over exp,no benefit,906,Rucaparib,672,26779812,,,
15,Preclinical,"In a preclinical study, decreasing Brca1 expression via shRNA knockdown sensitized triple-receptor negative breast cancer cells with low expression of Met to Rubraca (rucaparib) in culture (PMID: 26779812).",Actionable,6148,60081,triple-receptor negative breast cancer,DOID,22726,BRCA1 dec exp MET dec exp,sensitive,906,Rucaparib,672,26779812,,,
16,Preclinical - Cell line xenograft,"In a preclinical study, breast invasive ductal carcinoma cells harboring BRCA1 E23Vfs*17 (also referred to as BRCA1 185delAG) acquired resistance to Rubraca (rucaparib) both in culture and in cell line xenograft models through the expression of a RING-less Brca1 protein utilizing an in-frame translation start site downstream of the mutation (PMID: 27454289).",Actionable,8822,3008,invasive ductal carcinoma,DOID,26390,BRCA1 E23Vfs*17,resistant,906,Rucaparib,672,27454289,,,
17,Preclinical - Pdx & cell culture,"In a preclinical study, breast cancer cells harboring BRCA1 E23Vfs*17 (referred to as BRCA1 185delAG) demonstrated reduced sensitivity, developed resistance to Lynparza (olaparib) in culture and in patient-derived xenograft models due to the expression of a RING-less form of Brca1 (PMID: 27454287).",Actionable,8665,1612,breast cancer,DOID,26390,BRCA1 E23Vfs*17,decreased response,837,Olaparib,672,27454287,,,
18,Preclinical - Cell line xenograft,"In a preclinical study, breast invasive ductal carcinoma cells harboring BRCA1 E23Vfs*17 (also referred to as BRCA1 185delAG) acquired resistance to Platinol (cisplatin) both in culture and in cell line xenograft models through the expression of a RING-less Brca1 protein utilizing an in-frame translation start site downstream of the mutation (PMID: 27454289).",Actionable,8823,3008,invasive ductal carcinoma,DOID,26390,BRCA1 E23Vfs*17,resistant,700,Cisplatin,672,27454289,,,
19,Preclinical - Cell line xenograft,"In a preclinical study, E7449 inhibited tumor growth in a triple-negative breast cancer cell line xenograft model harboring a BRCA1 splice donor site mutation (PMID: 26513298).",Actionable,6539,60081,triple-receptor negative breast cancer,DOID,1282,BRCA1 inact mut,predicted â€“ sensitive,724,E7449,672,26513298,,,
20,Phase I,"In a Phase I clinical trial, Zejula (niraparib) demonstrated safety and efficacy in ovarian cancer patients with BRCA1 inactivating mutations (PMID: 23810788).",Actionable,1738,2394,ovarian cancer,DOID,1282,BRCA1 inact mut,sensitive,832,Niraparib,672,23810788,,,
21,Phase II,"In a Phase II clinical trial, the combination of Veliparib (ABT-888) and Cytoxan (cyclophosphamide) did not demonstrate improved response rate or progression-free survival over Cytoxan (cyclophosphamide) alone in ovarian cancer patients harboring deleterious mutations in BRCA1 or BRCA2 (PMID: 25589624).",Actionable,6848,2394,ovarian cancer,DOID,1282,BRCA1 inact mut,no benefit,4283,Veliparib + Cyclophosphamide,672,25589624,,,
22,Preclinical,"In a preclinical study, E7449 inhibited proliferation of a BRCA1-deficient cell line in culture, which demonstrated increased sensitivity compared to cells without DNA repair pathway mutations (PMID: 26513298).",Actionable,6505,10000003,Advanced Solid Tumor,JAX,1282,BRCA1 inact mut,sensitive,724,E7449,672,26513298,,,
23,Phase I,"In a Phase I trial, Talazoparib (BMN673) treatment demonstrated safety and preliminary efficacy in patients with advanced solid tumors harboring deleterious BRCA1/2 mutations (J Clin Oncol 31, 2013 (suppl; abstr 2580)).",Actionable,6846,10000003,Advanced Solid Tumor,JAX,1282,BRCA1 inact mut,predicted â€“ sensitive,682,Talazoparib,672,None,,,
24,Phase II,"In a Phase II trial, the combination of Veliparib (ABT-888), Paraplatin (carboplatin), and Taxol (paclitaxel) resulted in a higher objective response rate (77.8% vs 61.3%) compared to placebo plus Paraplatin (carboplatin) and Taxol (paclitaxel) in breast cancer patients harboring either BRCA1 or BRCA2 deleterious mutations (SABCS, 2016, Abstract # S2-05).",Actionable,9866,1612,breast cancer,DOID,1282,BRCA1 inact mut,predicted â€“ sensitive,5274,Carboplatin + Paclitaxel + Veliparib,672,None,,,
25,Clinical Study,"In a clinical study, an ovarian carcinoma patient harboring a BRCA1 W1782* germline mutation demonstrated stable disease when treated with Rubraca (rucaparib) (PMID: 28588062). ",Actionable,12056,4001,ovarian carcinoma,DOID,28325,BRCA1 W1782*,sensitive,906,Rucaparib,672,28588062,,,
26,Preclinical,"In a preclinical study, BRCA1 deficient cancer cell lines with DNA repair deficiency demonstrated high sensitivity to the PARP inhibitor, BMN673 (PMID: 23881923). ",Actionable,1178,10000003,Advanced Solid Tumor,JAX,2075,BRCA1 negative,sensitive,682,Talazoparib,672,23881923,,,
27,Preclinical,"In a preclinical study, Lynparza (olaparib) treatment resulted in prolonged overall survival in BRCA1 deficient transgenic mouse models of breast cancer (PMID: 27454287).",Actionable,8663,1612,breast cancer,DOID,1787,BRCA1 loss,sensitive,837,Olaparib,672,27454287,,,
28,Phase II,"In a Phase II trial, high dose Paraplatin (carboplatin) chemotherapy was more beneficial for breast cancer patients with BRCA1 loss than was conventional anthracycline-based chemotherapy (PMID: 21135055).",Actionable,1057,1612,breast cancer,DOID,1787,BRCA1 loss,sensitive,1092,Carboplatin,672,21135055,,,
29,Preclinical,"In a preclinical study, a breast cancer model lacking BRCA1 and TP53 demonstrated sensitivity to treatment with AZD2461, which resulted in decreased tumor volume (PMID: 27550455). ",Actionable,8945,1612,breast cancer,DOID,26544,BRCA1 loss TP53 loss,sensitive,2542,AZD2461,672,27550455,,,
30,Clinical Study,"In a clinical study, an ovarian carcinoma patient harboring a BRCA1 L631Qfs*4 germline mutation demonstrated a partial response when treated with Rubraca (rucaparib) (PMID: 28588062). ",Actionable,12061,4001,ovarian carcinoma,DOID,28326,BRCA1 L631Qfs*4,sensitive,906,Rucaparib,672,28588062,,,
31,Phase II,"In a Phase II trial, Paraplatin (carboplatin) and MK-1775 combination treatment resulted in partial response in an ovarian cancer patient harboring TP53 E298* and mutations in BRCA1 (PMID: 27998224). ",Actionable,11779,2394,ovarian cancer,DOID,28241,BRCA1 mut TP53 E298*,predicted â€“ sensitive,1194,MK-1775 + Carboplatin ,672,27998224,,,
32,Phase II,"In a Phase II clinical trial, treatment with Rubraca (rucaparib) was tolerated and demonstrated activity in ovarian cancer patients with germline BRCA1/2 mutations (PMID: 27002934).",Actionable,8863,2394,ovarian cancer,DOID,1205,BRCA1 mutant,predicted â€“ sensitive,906,Rucaparib,672,27002934,,,
33,FDA approved,"In a retrospective analysis of 2 Phase II trials that supported FDA approval, Rubraca (rucaparib) treatment resulted in an overall response (complete response + partial response) rate of 53.7% (36/67) in high-grade ovarian cancer patients harboring BRCA1 or BRCA2 mutations (2016 ESMO Congress; October 7-11, 2016; Copenhagen, Denmark. Abstract 8560).",Actionable,9161,2394,ovarian cancer,DOID,1205,BRCA1 mutant,predicted â€“ sensitive,906,Rucaparib,672,None,,,
34,FDA approved,"In a Phase III trial that supported FDA approval, maintenance Zejula (niraparib) therapy significantly improved median progression-free survival compared to placebo (21.0 vs. 5.5 months, HR=0.27) in patients with platinum-sensitive, recurrent ovarian cancer harboring germline BRCA mutations (PMID: 27717299).",Actionable,9004,2394,ovarian cancer,DOID,1205,BRCA1 mutant,sensitive,832,Niraparib,672,27717299,,,
35,Phase I,"In a Phase I trial, Veliparib (ABT-888), in combination with Platinol (cisplatin) and Navelbine (vinorelbine), resulted in a greater complete response (7%, 1/14), partial response (50%, 7/14), and 6-month progression free survival rate (71%, 10/14) in Erbb2 (Her2) negative breast cancer patients harboring germline BRCA1 or BRCA2 mutations compared to BRCA wild-type patients (PMID: 26801247).",Actionable,6874,60080,Her2-receptor negative breast cancer,DOID,1205,BRCA1 mutant,sensitive,4286,Cisplatin + Veliparib + Vinorelbine,672,26801247,,,
36,Phase I,"In a Phase I trial, Talazoparib (BMN-673) treatment in patients with triple-receptor negative breast cancer carrying a BRCA1 and/or BRCA2 mutation resulted in a lower clinical benefit rate (56% vs 89%) compared to treatment in non-triple-receptor negative breast cancer patients carrying a BRCA1/2 mutation (PMID: 28242752).",Actionable,11194,60081,triple-receptor negative breast cancer,DOID,1205,BRCA1 mutant,decreased response,682,Talazoparib,672,28242752,,,
37,Phase I,"In a Phase I trial, BGB-290 treatment resulted in improved objective response rate in ovarian cancer patients harboring germline BRCA1/2 mutations (58%, 7/12) compared to BRCA1/2 wild-type (25%, 2/8) patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 368PD; NCT02361723).",Actionable,11980,2394,ovarian cancer,DOID,1205,BRCA1 mutant,predicted â€“ sensitive,2947,BGB-290,672,None,,,
38,Preclinical,"In a preclinical study, Lynparza (olaparib) inhibited the growth of triple-receptor negative BRCA1-mutant breast cancer cell lines under hypoxic conditions (PMID: 25193512).",Actionable,2869,60081,triple-receptor negative breast cancer,DOID,1205,BRCA1 mutant,sensitive,837,Olaparib,672,25193512,,,
39,Phase II,"In a Phase II trial, Lynparza (olaparib) demonstrated safety and efficacy in breast cancer patients with BRCA1 mutations, with an objective response rate of 50% (9/18) in the maximum tolerated dose cohort and 19% (3/16) in the lower dose cohort (PMID: 20609467).",Actionable,1051,1612,breast cancer,DOID,1205,BRCA1 mutant,sensitive,837,Olaparib,672,20609467,,,
40,Phase I,"In a Phase I clinical trial, the combination of Veliparib (ABT-888) and Paraplatin (carboplatin) demonstrated preliminary efficacy in  metastatic breast cancer patients, with partial response in 25% (4/16) and stable disease in 62.5% (10/16) of patients with BRCA1/2 mutations or Fanconi Anemia pathway defects (J Clin Oncol 32:5s, 2014 (suppl; abstr 1074)).",Actionable,6852,1612,breast cancer,DOID,1205,BRCA1 mutant,predicted â€“ sensitive,2704,Veliparib + Carboplatin,672,None,,,
41,Phase I,"In a Phase I trial, Talazoparib (BMN673) treatment in breast cancer patients harboring germline deleterious BRCA1/2 mutations resulted in an objective response rate of 50% (7/14) including one patient with a complete response and six patients with a partial response and a median progression free survival of 34.6 weeks (PMID: 28242752). ",Actionable,11193,1612,breast cancer,DOID,1205,BRCA1 mutant,predicted â€“ sensitive,682,Talazoparib,672,28242752,,,
42,Phase I,"In a Phase I clinical trial, Talazoparib (BMN-673) was well-tolerated and demonstrated preliminary efficacy in patients with advanced solid tumors harboring deleterious BRCA1/2 mutations, including objective responses in 33% (2/6) of breast cancer patients carrying BRCA mutations (J Clin Oncol 31, 2013 (suppl; abstr 2580)).",Actionable,6858,1612,breast cancer,DOID,1205,BRCA1 mutant,predicted â€“ sensitive,682,Talazoparib,672,None,,,
43,Clinical Study,"In a clinical study, Xgeva (denosumab) inhibited cell proliferation in normal breast tissues of BRCA1 mutation carriers, provided a potential strategy to prevent breast cancer in this population (PMID: 27322743). ",Emerging,7478,1612,breast cancer,DOID,1205,BRCA1 mutant,not applicable,1198,Denosumab,672,27322743,,,
44,Preclinical - Cell culture,"In a preclinical study, AZD2461 inhibited cell growth of BRCA1 mutant breast cancer cells in culture (PMID: 27550455). ",Actionable,8943,1612,breast cancer,DOID,1205,BRCA1 mutant,sensitive,2542,AZD2461,672,27550455,,,
45,Phase II,"In a Phase II trial, Rubraca (rucaparib) treatment resulted in an objective response rate of 11% (2/19), disease control rate of 32% (6/19) in advanced pancreatic cancer patients with a known deleterious BRCA mutation, of whom 79% harbored a BRCA2 mutation (J Clin Oncol 34, 2016 (suppl; abstr 4110)).",Actionable,6745,1793,pancreatic cancer,DOID,1205,BRCA1 mutant,predicted â€“ sensitive,906,Rucaparib,672,None,,,
46,Phase I,"In a Phase I trial, ABT-767 treatment resulted in a response rate of 18% (n=79) in patients with high grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer or with solid tumors harboring germline BRCA1 or BRCA2 mutations, with an overall 6 month time to progression rate of 22% (Ann Oncol (2014) 25 (suppl 4): iv150). ",Actionable,6519,10000003,Advanced Solid Tumor,JAX,1205,BRCA1 mutant,predicted â€“ sensitive,4133,ABT-767,672,None,,,
47,Phase I,"In a Phase I clinical trial, Zejula (niraparib) was well-tolerated and demonstrated preliminary efficacy in advanced solid tumor patients, including partial responses in 50% (2/4) of breast cancer patients carrying BRCA1 or BRCA2 mutations (PMID: 23810788).",Actionable,6857,1612,breast cancer,DOID,1205,BRCA1 mutant,predicted â€“ sensitive,832,Niraparib,672,23810788,,,
48,FDA approved,"In a Phase II study that supported FDA approval, 40% (78/193) of patients with ovarian cancer harboring germline BRCA 1/2 mutations treated with Lynparza (olaparib) demonstrated stable disease at 8 weeks while a tumor response rate was observed in 31% (60/193) (PMID: 25366685).",Actionable,2145,2394,ovarian cancer,DOID,1205,BRCA1 mutant,sensitive,837,Olaparib,672,25366685,,,
49,Phase I,"In a Phase I trial, Talazoparib (BMN-673) treatment in ovarian cancer patients harboring germline deleterious BRCA1/2 mutations resulted in an objective response rate of 48%, including one complete response, and a clinical benefit rate of 76% at 24 weeks (PMID: 28242752). ",Actionable,11195,2394,ovarian cancer,DOID,1205,BRCA1 mutant,predicted â€“ sensitive,682,Talazoparib,672,28242752,,,
50,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Veliparib (ABT-888) and Paraplatin (carboplatin) induced DNA damage and decreased tumor growth in an intracranial human BRCA-mutant triple-negative breast cancer cell line xenograft model, but did not provide a significant survival benefit over Paraplatin (carboplatin) alone (PMID: 25824335).",Actionable,2193,60081,triple-receptor negative breast cancer,DOID,1205,BRCA1 mutant,sensitive,2704,Veliparib + Carboplatin,672,25824335,,,
51,Preclinical - Cell line xenograft,"In a preclinical study, BGB-290 inhibited PARylation and demonstrated anti-tumor activity in cell line xenograft models of breast cance harboring BRCA1 mutations (Cancer Res 2015; 75(15 Suppl): Abstract nr 1653).",Actionable,10817,1612,breast cancer,DOID,1205,BRCA1 mutant,sensitive,2947,BGB-290,672,None,,,
52,Phase I,"In a Phase I trial, Veliparib (ABT-888) and Camptosar (irinotecan) combination therapy resulted in partial response in 11% (1/9) and stable disease in 67% (6/9) of ovarian cancer patients harboring germline mutations in BRCA1 or BRCA2 (PMID: 26842236).",Actionable,7525,2394,ovarian cancer,DOID,1205,BRCA1 mutant,predicted â€“ sensitive,3314,Irinotecan + Veliparib,672,26842236,,,
53,Phase III,"In a Phase III trial, Lynparza (olaparib) treatment resulted in improved progression free survival (7.0 vs 4.2 months) and objective response rate (59.9%, 123/205 vs 28.8%, 26/288) compared to single agent chemotherapy in patients with Erbb2 (Her2)-negative breast cancer that also harbored germline BRCA mutations (J Clin Oncol 35, 2017 (suppl; abstr LBA4)).",Actionable,11131,60080,Her2-receptor negative breast cancer,DOID,27913,BRCA1 mut ERBB2 neg,predicted â€“ sensitive,837,Olaparib,672,None,,,
54,Phase I,"In a Phase I trial, VX-970 and Paraplatin (carboplatin) combination treatment resulted in partial response for 6 months in a PARP inhibitor-resistant ovarian cancer patient harboring a germline BRCA1 mutation and TP53 Y220C (J Clin Oncol 34, 2016 (suppl; abstr 2504)).",Actionable,6711,2394,ovarian cancer,DOID,23675,BRCA1 mut TP53 Y220C,sensitive,4253,Carboplatin + VX-970,672,None,,,
55,Preclinical,"In a preclinical study, mouse breast cancer models harboring BRCA1 C61G with conditional loss of Tp53 had a decreased response to Lynparza (olaparib) compared to models with conditional loss of Brca1 and Tp53 (PMID: 22172724).",Actionable,2016,1612,breast cancer,DOID,4728,BRCA1 C61G TP53 loss,decreased response,837,Olaparib,672,22172724,,,
56,Clinical Study,"In a clinical study, an ovarian carcinoma patient harboring a BRCA1 N682* germline mutation demonstrated a partial response when treated with Rubraca (rucaparib) (PMID: 28588062). ",Actionable,12062,4001,ovarian carcinoma,DOID,28327,BRCA1 N682*,sensitive,906,Rucaparib,672,28588062,,,
0,Preclinical,"In a preclinical study, BRCA2 deficient cancer cell lines with DNA repair deficiency demonstrated high sensitivity to the PARP inhibitor, BMN673 (PMID: 23881923). ",Actionable,1179,10000003,Advanced Solid Tumor,JAX,2076,BRCA2 negative,sensitive,682,Talazoparib,675,23881923,,,
1,Preclinical - Cell culture,"In a preclinical study, AZD6738 increased sensitivity to radiotherapy in a colorectal adenocarcinoma cell line harboring wild-type BRCA2 in culture, resulting in a greater decrease in cell survival compared to radiotherapy alone (PMID: 28062704). ",Actionable,10019,50861,colorectal adenocarcinoma,DOID,442,BRCA2 wild-type,sensitive,5346,AZD6738 + Radiotherapy,675,28062704,,,
2,Phase III,"In a Phase III trial that supported FDA approval, Zejula (niraparib) maintenance therapy improved median progression-free survival compared to placebo (9.3 vs. 3.9 months, HR=0.45) in platinum-sensitive, recurrent ovarian cancer patients without germline BRCA mutations, with and without homologous recombination deficiency (12.9 vs. 3.8 months, HR=0.38) (PMID: 27717299).",Actionable,9006,2394,ovarian cancer,DOID,22293,BRCA1 wild-type BRCA2 wild-type,predicted â€“ sensitive,832,Niraparib,675,27717299,,,
3,Preclinical,"In a preclinical study, triple-receptor negative breast cancer cells wild-type for BRCA1/2 demonstrated an increased sensitivity to Talazoparib (BMN673) when treatment was combined with KU-0063794, resulting in greater decreased cell proliferation and apoptosis in culture (PMID: 26546619). ",Actionable,6057,60081,triple-receptor negative breast cancer,DOID,22293,BRCA1 wild-type BRCA2 wild-type,sensitive,4013,KU-0063794 + Talazoparib,675,26546619,,,
4,Preclinical,"In a preclinical study, triple-receptor negative breast cancer cells wild-type for BRCA1/2 demonstrated an increased sensitivity to Lynparza (olaparib) when treatment was combined with Afinitor (everolimus), resulting in greater decreased cell proliferation and apoptosis in culture (PMID: 26546619). ",Actionable,6058,60081,triple-receptor negative breast cancer,DOID,22293,BRCA1 wild-type BRCA2 wild-type,sensitive,4014,Olaparib + Everolimus,675,26546619,,,
5,Preclinical,"In a preclinical study, triple-receptor negative breast cancer cells wild-type for BRCA1/2 demonstrated an increased sensitivity to Lynparza (olaparib) when treatment was combined with KU-0063794, resulting in greater decreased cell proliferation and apoptosis in culture (PMID: 26546619). ",Actionable,6059,60081,triple-receptor negative breast cancer,DOID,22293,BRCA1 wild-type BRCA2 wild-type,sensitive,4015,Olaparib + KU-0063794,675,26546619,,,
6,Preclinical,"In a preclinical study, triple-receptor negative breast cancer cells wild-type for BRCA1/2 demonstrated an increased sensitivity to Talazoparib (BMN673) when treatment was combined with Afinitor (everolimus), resulting in greater decreased cell proliferation and apoptosis in culture and reduced tumor volume in xenograft models (PMID: 26546619). ",Actionable,6056,60081,triple-receptor negative breast cancer,DOID,22293,BRCA1 wild-type BRCA2 wild-type,sensitive,4012,Everolimus + Talazoparib,675,26546619,,,
7,Phase I,"In a Phase I trial, VX-970 in combination with Platinol (cisplatin) resulted in an objective response rate of 38.9% (7/18, all partial responses) and a disease control rate of 72.2% (13/18) in patients with BRCA1/2 wild-type triple-receptor negative breast cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 242PD; NCT02157792).",Actionable,12060,60081,triple-receptor negative breast cancer,DOID,22293,BRCA1 wild-type BRCA2 wild-type,predicted â€“ sensitive,3109,Cisplatin + VX-970,675,None,,,
8,Preclinical,"In a preclinical study, YU238259 and Lynparza (olaparib) synergistically inhibited survival of colorectal cancer cell lines harboring BRCA2 loss in culture (PMID: 26116172).",Actionable,5537,9256,colorectal cancer,DOID,1788,BRCA2 loss,sensitive,3883,Olaparib + YU238259,675,26116172,,,
9,Phase II,"In a Phase II clinical trial, 100% (7/7) of metastatic castration-resistant prostate cancer patients with BRCA2 loss demonstrated response to Lynparza (olaparib) treatment (PMID: 26510020).",Actionable,3284,10283,prostate cancer,DOID,1788,BRCA2 loss,sensitive,837,Olaparib,675,26510020,,,
10,Preclinical - Cell line xenograft,"In a preclinical study, YU238259 induced cytotoxicity in a human BRCA2-deficient colorectal cancer cell line in culture and slowed tumor growth in xenograft models (PMID: 26116172).",Actionable,5530,9256,colorectal cancer,DOID,1788,BRCA2 loss,sensitive,3880,YU238259,675,26116172,,,
11,Preclinical,"In a preclinical study, YU238259 and Eposin (etoposide) synergistically inhibited survival of colorectal cancer cell lines harboring BRCA2 loss in culture (PMID: 26116172).",Actionable,5535,9256,colorectal cancer,DOID,1788,BRCA2 loss,sensitive,3881,Etoposide + YU238259,675,26116172,,,
12,Preclinical,"In a preclinical study, YU238259 and radiotherapy synergistically inhibited survival of colorectal cancer cell lines harboring BRCA2 loss in culture (PMID: 26116172).",Actionable,5536,9256,colorectal cancer,DOID,1788,BRCA2 loss,sensitive,3882,Radiotherapy + YU238259,675,26116172,,,
13,Preclinical,"In a preclinical study, YU238259 demonstrated increased cytotoxicity in BRCA2-deficient ovarian adenocarcinoma cell lines in culture (PMID: 26116172).",Actionable,5529,3713,ovary adenocarcinoma,DOID,1788,BRCA2 loss,sensitive,3880,YU238259,675,26116172,,,
14,Preclinical - Cell culture,"In a preclinical study, AZD6738 increased sensitivity to radiotherapy in a colorectal adenocarcinoma cell line deficient for BRCA2 in culture, resulting in a greater decrease in cell survival compared to radiotherapy alone (PMID: 28062704). ",Actionable,10020,50861,colorectal adenocarcinoma,DOID,1788,BRCA2 loss,sensitive,5346,AZD6738 + Radiotherapy,675,28062704,,,
15,Phase I,"In a Phase I trial, BGB-290 treatment resulted in improved objective response rate in ovarian cancer patients harboring germline BRCA1/2 mutations (58%, 7/12) compared to BRCA1/2 wild-type (25%, 2/8) patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 368PD; NCT02361723).",Actionable,11981,2394,ovarian cancer,DOID,1206,BRCA2 mutant,predicted â€“ sensitive,2947,BGB-290,675,None,,,
16,Phase I,"In a Phase I trial, Veliparib (ABT-888) in combination with Platinol (cisplatin) and Navelbine (vinorelbine) resulted in a greater complete response (7%, 1/14), partial response (50%, 7/14), and 6-month progression free survival rate (71%, 10/14) in Erbb2 (Her2) negative breast cancer patients harboring germline BRCA1 or BRCA2 mutations compared to BRCA wild-type patients (PMID: 26801247).",Actionable,6875,60080,Her2-receptor negative breast cancer,DOID,1206,BRCA2 mutant,predicted â€“ sensitive,4286,Cisplatin + Veliparib + Vinorelbine,675,26801247,,,
17,Preclinical - Pdx,"In a preclinical study, Lynparza (olaparib) decreased tumor growth in patient-derived xenografts carrying BRCA2 mutation (PMID: 21097693).",Actionable,1825,2394,ovarian cancer,DOID,1206,BRCA2 mutant,sensitive,837,Olaparib,675,21097693,,,
18,FDA approved,"In a Phase II study that supported FDA approval, 40% (78/193) of patients with ovarian cancer harboring germline BRCA 1/2 mutations treated with Lynparza (olaparib) demonstrated stable disease at 8 weeks while a tumor response rate was observed in 31% (60/193) (PMID: 25366685).",Actionable,2146,2394,ovarian cancer,DOID,1206,BRCA2 mutant,sensitive,837,Olaparib,675,25366685,,,
19,Phase III,"In a Phase III trial that supported FDA approval, maintenance Zejula (niraparib) therapy significantly improved median progression-free survival compared to placebo (21.0 vs. 5.5 months, HR=0.27) in patients with platinum-sensitive, recurrent ovarian cancer harboring germline BRCA mutations (PMID: 27717299).",Actionable,9005,2394,ovarian cancer,DOID,1206,BRCA2 mutant,sensitive,832,Niraparib,675,27717299,,,
20,Phase II,"In a Phase II clinical trial, treatment with Rubraca (rucaparib) was tolerated and demonstrated activity in ovarian cancer patients with germline BRCA1/2 mutations (PMID: 27002934).",Actionable,8867,2394,ovarian cancer,DOID,1206,BRCA2 mutant,predicted â€“ sensitive,906,Rucaparib,675,27002934,,,
21,FDA approved,"In a retrospective analysis of 2 Phase II trials that supported FDA approval, Rubraca (rucaparib) treatment resulted in an overall response (complete response + partial response) rate of 53.7% (36/67) in high-grade ovarian cancer patients harboring BRCA1 or BRCA2 mutations (2016 ESMO Congress; October 7-11, 2016; Copenhagen, Denmark. Abstract 8560).",Actionable,9160,2394,ovarian cancer,DOID,1206,BRCA2 mutant,predicted â€“ sensitive,906,Rucaparib,675,None,,,
22,Phase I,"In a Phase I trial, Talazoparib (BMN-673) treatment in patients with triple-receptor negative breast cancer carrying a BRCA1 and/or BRCA2 mutation resulted in a lower clinical benefit rate (56% vs 89%) compared to treatment in non-triple-receptor negative breast cancer patients carrying a BRCA1/2 mutation (PMID: 28242752).",Actionable,11201,60081,triple-receptor negative breast cancer,DOID,1206,BRCA2 mutant,decreased response,682,Talazoparib,675,28242752,,,
23,Phase I,"In a Phase I trial, Veliparib (ABT-888) and Camptosar (irinotecan) combination therapy resulted in partial response in 11% (1/9) and stable disease in 67% (6/9) of ovarian cancer patients harboring germline mutations in BRCA1 or BRCA2 (PMID: 26842236).",Actionable,7531,2394,ovarian cancer,DOID,1206,BRCA2 mutant,predicted â€“ sensitive,3314,Irinotecan + Veliparib,675,26842236,,,
24,Phase I,"In a Phase I trial, ABT-767 treatment resulted in a response rate of 18% (n=79) in patients with high grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer or with solid tumors harboring germline BRCA1 or BRCA2 mutations, with an overall 6 month time to progression rate of 22% (Ann Oncol (2014) 25 (suppl 4): iv150). ",Actionable,6520,10000003,Advanced Solid Tumor,JAX,1206,BRCA2 mutant,predicted â€“ sensitive,4133,ABT-767,675,None,,,
25,Phase I,"In a Phase I trial, Talazoparib (BMN-673) treatment in pancreatic cancer patients resulted in four patients with a clinical benefit including a partial response in one patient harboring a BRCA2 mutation (PMID: 28242752). ",Actionable,11197,1793,pancreatic cancer,DOID,1206,BRCA2 mutant,sensitive,682,Talazoparib,675,28242752,,,
26,Phase I,"In a Phase I clinical trial, the combination of Veliparib (ABT-888) and Paraplatin (carboplatin) demonstrated preliminary efficacy in  metastatic breast cancer patients, with partial response in 25% (4/16) and stable disease in 62.5% (10/16) of patients with BRCA1/2 mutations or Fanconi Anemia pathway defects (J Clin Oncol 32:5s, 2014 (suppl; abstr 1074)).",Actionable,6854,1612,breast cancer,DOID,1206,BRCA2 mutant,predicted â€“ sensitive,2704,Veliparib + Carboplatin,675,None,,,
27,Phase II,"In a Phase II trial, Rubraca (rucaparib) treatment resulted in an objective response rate of 11% (2/19), disease control rate of 32% (6/19) in advanced pancreatic cancer patients with a known deleterious BRCA mutation, of whom 79% harbored a BRCA2 mutation (J Clin Oncol 34, 2016 (suppl; abstr 4110)).",Actionable,6744,1793,pancreatic cancer,DOID,1206,BRCA2 mutant,predicted â€“ sensitive,906,Rucaparib,675,None,,,
28,Phase II,"In a Phase II clinical trial, Veliparib (ABT-888) demonstrated preliminary clinical activity in patients with BRCA2-mutant metastatic castration resistant prostate cancer, with an overall response rate of 66% (2/3) and clinical benefit rate of 100% (3/3) (J Clin Oncol 33, 2015 (suppl 7; abstr 170)).",Actionable,6855,10283,prostate cancer,DOID,1206,BRCA2 mutant,sensitive,954,Veliparib,675,None,,,
29,Phase I,"In a Phase I trial, Talazoparib (BMN-673) treatment in ovarian cancer patients harboring germline deleterious BRCA1/2 mutations resulted in an objective response rate of 48%, including one complete response, and a clinical benefit rate of 76% at 24 weeks (PMID: 28242752). ",Actionable,11202,2394,ovarian cancer,DOID,1206,BRCA2 mutant,predicted â€“ sensitive,682,Talazoparib,675,28242752,,,
30,Phase I,"In a Phase I trial, Talazoparib (BMN673) treatment in breast cancer patients harboring germline deleterious BRCA1/2 mutations resulted in an objective response rate of 50% (7/14) including one patient with a complete response and six patients with a partial response and a median progression free survival of 34.6 weeks (PMID: 28242752). ",Actionable,11200,1612,breast cancer,DOID,1206,BRCA2 mutant,predicted â€“ sensitive,682,Talazoparib,675,28242752,,,
31,Phase II,"In a Phase II clinical trial, Lynparza (olaparib) demonstrated safety and efficacy in breast cancer patients with BRCA2 mutations (PMID: 20609467).",Actionable,1055,1612,breast cancer,DOID,1206,BRCA2 mutant,sensitive,837,Olaparib,675,20609467,,,
32,Phase III,"In a Phase III trial, Lynparza (olaparib) treatment resulted in improved progression free survival (7.0 vs 4.2 months) and objective response rate (59.9%, 123/205 vs 28.8%, 26/288) compared to single agent chemotherapy in patients with Erbb2 (Her2)-negative breast cancer that also harbored germline BRCA mutations (J Clin Oncol 35, 2017 (suppl; abstr LBA4)).",Actionable,11132,60080,Her2-receptor negative breast cancer,DOID,27914,BRCA2 mut ERBB2 neg,predicted â€“ sensitive,837,Olaparib,675,None,,,
33,Preclinical,"In a preclinical study, colorectal adenocarcinoma cells with BRCA2 deletion demonstrated increased sensitivity to Ambochlorin (chlorambucil) compared to cells with intact BRCA2 in culture  (PMID: 25193512).",Actionable,3066,50861,colorectal adenocarcinoma,DOID,11671,BRCA2 del,sensitive,3035,Chlorambucil,675,25193512,,,
34,Preclinical - Cell line xenograft,"In a preclinical study, colorectal adenocarcinoma cells with BRCA2 deletion demonstrated increased sensitivity to Evofosfamide (TH-302) compared to cells with intact BRCA2 in culture and human cell line xenograft models (PMID: 25193512).",Actionable,3065,50861,colorectal adenocarcinoma,DOID,11671,BRCA2 del,sensitive,1317,Evofosfamide,675,25193512,,,
35,Preclinical - Cell line xenograft,"In a preclinical study, colorectal adenocarcinoma cells with BRCA2 deletion demonstrated increased sensitivity to PR-104 compared to cells with intact BRCA2 in culture and in cell line xenograft models (PMID: 25193512)",Actionable,3064,50861,colorectal adenocarcinoma,DOID,11671,BRCA2 del,sensitive,3029,PR-104,675,25193512,,,
36,Preclinical - Cell line xenograft,"In a preclinical study, Platinol (cisplatin) inhibited growth of a human colorectal adenocarcinoma cell line harboring BRCA2 deletion in culture, and inhibited tumor growth in xenograft models (PMID: 25193512).",Actionable,3063,50861,colorectal adenocarcinoma,DOID,11671,BRCA2 del,sensitive,700,Cisplatin,675,25193512,,,
37,Phase II,"In a Phase II clinical trial, the combination of Veliparib (ABT-888) and Cytoxan (cyclophosphamide) did not demonstrate improved response rate or progression-free survival over Cytoxan (cyclophosphamide) alone in ovarian cancer patients harboring deleterious mutations in BRCA1 or BRCA2 (PMID: 25589624).",Actionable,6849,2394,ovarian cancer,DOID,1283,BRCA2 inact mut,no benefit,4283,Veliparib + Cyclophosphamide,675,25589624,,,
38,Preclinical - Cell culture,"In a preclinical study, a BRCA2 deficient breast cancer cell line resistant to Lynparza (olaparib) demonstrated sensitivity to treatment with AZD2461 in culture, resulting in reduced cell viability (PMID: 27550455). ",Actionable,8944,1612,breast cancer,DOID,1283,BRCA2 inact mut,sensitive,2542,AZD2461,675,27550455,,,
39,Phase II,"In a Phase II trial, the combination of Veliparib (ABT-888), Paraplatin (carboplatin), and Taxol (paclitaxel) resulted in a higher objective response rate (77.8% vs 61.3%) compared to placebo plus Paraplatin (carboplatin) and Taxol (paclitaxel) in breast cancer patients harboring either BRCA1 or BRCA2 deleterious mutations (SABCS, 2016, Abstract # S2-05).",Actionable,9867,1612,breast cancer,DOID,1283,BRCA2 inact mut,predicted â€“ sensitive,5274,Carboplatin + Paclitaxel + Veliparib,675,None,,,
40,Preclinical,"In a preclinical study, E7449 inhibited proliferation of a BRCA2-deficient cell line in culture, which demonstrated increased sensitivity compared to cells without DNA repair mutations (PMID: 26513298).",Actionable,6506,10000003,Advanced Solid Tumor,JAX,1283,BRCA2 inact mut,sensitive,724,E7449,675,26513298,,,
41,Phase I,"In a Phase I trial, Talazoparib (BMN673) treatment demonstrated safety and preliminary efficacy in patients with advanced solid tumors harboring deleterious BRCA1/2 mutations, including one patient with prostate cancer (J Clin Oncol 31, 2013 (suppl; abstr 2580)).",Actionable,6860,10283,prostate cancer,DOID,1283,BRCA2 inact mut,predicted â€“ sensitive,682,Talazoparib,675,None,,,
42,Phase II,"In a Phase II clinical trial, Lynparza (olaparib) demonstrated safety and efficacy in breast cancer patients with BRCA2 inactivating mutations (PMID: 20609467).",Actionable,1054,1612,breast cancer,DOID,1283,BRCA2 inact mut,sensitive,837,Olaparib,675,20609467,,,
43,Phase I,"In a Phase I trial, Talazoparib (BMN673) treatment demonstrated safety and preliminary efficacy in patients with advanced solid tumors harboring deleterious BRCA1/2 mutations (J Clin Oncol 31, 2013 (suppl; abstr 2580)).",Actionable,6847,10000003,Advanced Solid Tumor,JAX,1283,BRCA2 inact mut,predicted â€“ sensitive,682,Talazoparib,675,None,,,
44,Preclinical,"In a preclinical study, decreasing Brca2 expression via shRNA knockdown sensitized triple-receptor negative breast cancer cells with low expression of Met to Rubraca (rucaparib) in culture (PMID: 26779812).",Actionable,6149,60081,triple-receptor negative breast cancer,DOID,22728,BRCA2 dec exp MET dec exp,sensitive,906,Rucaparib,675,26779812,,,
45,Preclinical,"In a preclinical study, decreasing Brca2 expression via shRNA knockdown did not sensitize triple-receptor negative breast cancer cells with Met over expression to Rubraca (rucaparib) in culture (PMID: 26779812).",Actionable,6151,60081,triple-receptor negative breast cancer,DOID,22730,BRCA2 dec exp MET over exp,no benefit,906,Rucaparib,675,26779812,,,
46,Preclinical - Cell culture,"In a preclinical study, knockdown of Brca2 with siRNA sensitized breast cancer cell lines to NU1025 in culture (PMID: 15829966).",Actionable,10847,1612,breast cancer,DOID,22727,BRCA2 dec exp,sensitive,2946,NU1025,675,15829966,,,
0,Clinical Study,"In a clinical study, Roferon-A (Alpha 2 Interferon) treatment resulted in hematologic response in 100% (31/31) and complete molecular response in 6% (2/31) of essential thrombocythemia (ET) patients harboring CALR mutations (PMID: 26486786).",Actionable,6433,4960,bone marrow cancer,DOID,23414,CALR mutant,predicted â€“ sensitive,1187,Alpha 2 Interferon,811,26486786,,,
1,Clinical Study,"CALR mutations are used in the diagnosis of myeloproliferative neoplasms, especially of essential thrombocythemia and primary myelofibrosis (PMID: 26697989, PMID: 26449662, PMID: 26071474, PMID: 25873496).",Diagnostic,6434,4960,bone marrow cancer,DOID,23414,CALR mutant,not applicable,1776,N/A,811,26697989,26449662,26071474,25873496
0,Preclinical - Cell line xenograft,"In a preclinical study, addition of Tarceva (erlotinib) overcame Gemzar (gemcitabine)-resistance in pancreatic ductal carcinoma cell lines with reduced Cbl expression via shRNA, resulted in decreased viability in cell culture and reduced tumor growth in cell line xenograft models (PMID: 25348515).",Emerging,6423,3587,pancreatic ductal carcinoma,DOID,23382,CBL dec exp,predicted â€“ sensitive,2381,Erlotinib + Gemcitabine,867,25348515,,,
1,Clinical Study,"In clinical analyses, mutations in CBL were associated with adverse prognosis in patients with chronic myelomonocytic leukemia (PMID: 26230957, PMID: 23690417, PMID: 19901108). ",Prognostic,3323,4972,myelodysplastic/myeloproliferative neoplasm,DOID,13184,CBL mutant,not applicable,1776,N/A,867,26230957,23690417,19901108,
2,Preclinical,"In a preclinical study, Quizartinib (AC220) reduced white blood cell counts and decreased myeloid cell invasion in a CBL mutant mouse model with myeloproliferative disorder (PMID: 22990016). ",Actionable,3331,4960,bone marrow cancer,DOID,13184,CBL mutant,sensitive,882,Quizartinib,867,22990016,,,
3,Preclinical,"In a preclinical study, Fasudil (HA-1077) selectively inhibited proliferation of CBL and CBLB double knockout hematopoietic stem/progenitor cells in mouse model of myeloproliferative disorder (PMID: 26177294).",Actionable,6425,4960,bone marrow cancer,DOID,23386,CBL del CBLB del,predicted â€“ sensitive,1777,Fasudil,867,26177294,,,
0,Preclinical,"In a preclinical study, Fasudil (HA-1077) selectively inhibited proliferation of CBL and CBLB double knockout hematopoietic stem/progenitor cells in mouse model of myeloproliferative disorder (PMID: 26177294).",Actionable,6425,4960,bone marrow cancer,DOID,23386,CBL del CBLB del,predicted â€“ sensitive,1777,Fasudil,868,26177294,,,
1,Preclinical,"In a preclinical study, gastric cancer cell lines with decreased Cblb expression level via shRNA knockdown demonstrated reduced sensitivity to Adrucil (fluorouracil) in cell culture (PMID: 24351824).",Actionable,6427,10534,stomach cancer,DOID,23411,CBLB dec exp,decreased response,1715,Fluorouracil,868,24351824,,,
0,Preclinical,"In a preclinical study, decreased Cblc expression through siRNA knockdown enhanced sensitivity to Lynparza (olaparib) in cultured osterosarcoma cell lines (PMID: 25883215).",Actionable,6429,3347,osteosarcoma,DOID,23413,CBLC dec exp,predicted â€“ sensitive,837,Olaparib,23624,25883215,,,
1,Preclinical,"In a preclinical study, decreased Cblc expression through siRNA knockdown enhanced sensitivity to Lynparza (olaparib) in cultured breast cancer cell lines (PMID: 25883215).",Actionable,6430,1612,breast cancer,DOID,23413,CBLC dec exp,predicted â€“ sensitive,837,Olaparib,23624,25883215,,,
2,Clinical Study,"In a clinical study, over expression of Cblc was identified as a promising diagnostic biomarker for non-small cell lung cancer (PMID: 17671213).",Emerging,6428,3908,non-small cell lung carcinoma,DOID,23412,CBLC over exp,not applicable,1776,N/A,23624,17671213,,,
0,Clinical Study,"Pathogenic germline CDH1 mutations are used in the diagnosis of hereditary diffuse gastric cancer (PMID: 26380059, PMID: 26182300).",Diagnostic,3819,10534,stomach cancer,DOID,16466,CDH1 mutant,not applicable,1776,N/A,999,26182300,26380059,, 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/26380059'}]
1,Clinical Study,"In a clinical case study, treatment with the combination of  Tykerb (lapatinib) and Xeloda (capecitabine) resulted in prolonged response and reduction in liver metastasis in a metastatic breast cancer patient harboring ERBB2 L869Q and CDH1 R63* mutations (PMID: 26487584).",Actionable,5027,1612,breast cancer,DOID,20031,CDH1 R63* ERBB2 L869Q,sensitive,1399,Lapatinib + Capecitabine,999,26487584,,,
2,Phase II,"In a Phase II clinical trial, patients with pancreatic ductal adenocarcinoma tumors expressing high levels of Cdh1 were more likely to respond to a combination therapy of Tarceva (erlotinib) and Selumetinib (AZD6244) (PMID: 26251290).",Actionable,3820,3498,pancreatic ductal adenocarcinoma,DOID,16477,CDH1 over exp,sensitive,3361,Erlotinib + Selumetinib,999,26251290,,,
3,Preclinical,"In a preclinical study, non-small cell lung carcinoma cells over expressing CDH1 were resistant to BI2536 in culture (PMID: 26597303). ",Actionable,6134,3908,non-small cell lung carcinoma,DOID,16477,CDH1 over exp,resistant,676,BI2536,999,26597303,,,
4,Preclinical,"In a preclinical study, non-small cell lung carcinoma cells over expressing CDH1 were resistant to volasertib in culture (PMID: 26597303). ",Actionable,6135,3908,non-small cell lung carcinoma,DOID,16477,CDH1 over exp,resistant,957,Volasertib,999,26597303,,,
0,Phase II,"In a Phase II trial, treatment with Ibrance (palbociclib) resulted in and stable disease in 50% (8/16) of non-small cell lung cancer patients with CDKN2A loss (J Clin Oncol 32:5s, 2014 (suppl; abstr 8077)).",Actionable,2935,3908,non-small cell lung carcinoma,DOID,1806,CDKN2A loss,sensitive,850,Palbociclib,1029,None,,,
1,Preclinical,"In a preclinical study, melanoma cell lines with CDKN2A loss demonstrated a greater sensitivity to Alvocidib (flavopiridol) as compared to melanoma cell lines positive for CDKN2A (PMID: 12777976).",Actionable,2268,1909,melanoma,DOID,1806,CDKN2A loss,sensitive,628,Alvocidib,1029,12777976,,,
2,Preclinical - Cell culture,"In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited growth of multiple cancer cell lines harboring CDKN2A loss and in Cdkn2a-depleted transformed cells in culture (PMID: 26140595).",Actionable,10252,10000003,Advanced Solid Tumor,JAX,1806,CDKN2A loss,predicted â€“ sensitive,5443,PF3644022 + PF-477736,1029,26140595,,,
3,Preclinical,"In a preclinical study, an orthotopic mouse model treated with ZK 304709 demonstrated an 80% tumor growth reduction in neuroendocrine tumor cells with CDKN2A loss (PMID: 18829975). ",Actionable,2270,169,neuroendocrine tumor,DOID,1806,CDKN2A loss,sensitive,2735,ZK304709,1029,18829975,,,
4,Preclinical - Cell culture,"In a preclinical study, Abemaciclib (LY2835219) inhibited growth of chordoma cell lines with CDKN2A loss and loss of p16 protein expression in culture (PMID: 26183925).",Actionable,7585,3302,chordoma,DOID,1806,CDKN2A loss,sensitive,802,Abemaciclib,1029,26183925,,,
5,Preclinical,"In a preclinical study, Ibrance (palbociclib) antagonized the efficacy of GSK461364 in pancreatic cancer cells with CDKN2A loss in culture (PMID: 25156567).",Actionable,1062,1793,pancreatic cancer,DOID,1806,CDKN2A loss,decreased response,1511,GSK461364 + PD0332991,1029,25156567,,,
6,Preclinical - Cell culture,"In a preclinical study, a melanoma cell line with CDKN2A loss demonstrated sensitivity to Mekinist (trametinib) in culture, resulting in inhibition of cell growth (PMID: 27488531). ",Actionable,8540,1909,melanoma,DOID,1806,CDKN2A loss,sensitive,2,Trametinib,1029,27488531,,,
7,Preclinical - Cell line xenograft,"In a preclinical study, Milciclib (PHA-848125AC) resulted in tumor regression in glioma cell line xenograft models with CDKN2A loss (PMID: 23347136).",Actionable,2269,3073,brain glioblastoma multiforme,DOID,1806,CDKN2A loss,sensitive,2654,PHA-848125AC,1029,23347136,,,
8,Preclinical,"In a preclinical study, Ibrance (palbociclib) antagonized the efficacy of ON-01910 in pancreatic cancer cell lines with CDKN2A loss in culture (PMID: 25156567).",Actionable,1063,1793,pancreatic cancer,DOID,1806,CDKN2A loss,decreased response,1512,ON-01910 + PD0332991,1029,25156567,,,
9,Preclinical,"In a preclinical study, renal cell carcinoma cell lines with CDKN2A loss were sensitive to Palbociclib (PD-0332991) (PMID: 23898052). ",Actionable,2267,4450,renal cell carcinoma,DOID,1806,CDKN2A loss,sensitive,850,Palbociclib,1029,23898052,,,
10,Preclinical - Cell culture,"In a preclinical study, Ibrance (palbociclib) inhibited expression of phosphorylated Rb and growth of chordoma cell lines with CDKN2A loss and loss of p16 protein expression in culture (PMID: 26183925).",Actionable,7583,3302,chordoma,DOID,1806,CDKN2A loss,sensitive,850,Palbociclib,1029,26183925,,,
11,Preclinical - Cell culture,"In a preclinical study, a melanoma cell line deficient for CDKN2A demonstrated resistance to treatment with Ibrance (palbociclib) in culture (PMID: 27488531). ",Actionable,8537,1909,melanoma,DOID,1806,CDKN2A loss,resistant,850,Palbociclib,1029,27488531,,,
12,Preclinical,"In a preclinical study, Ibrance (palbociclib) antagonized the efficacy of Gemzar (gemcitabine) in pancreatic cancer cells with CDKN2A loss in culture (PMID: 25156567).",Actionable,1061,1793,pancreatic cancer,DOID,1806,CDKN2A loss,decreased response,1510,PD0332991 + Gemcitabine,1029,25156567,,,
13,Preclinical,"In a preclinical study, Ibrance (palbociclib) antagonized the activity of HMN-214 in pancreatic cancer cell lines with CDKN2A loss in culture (PMID: 25156567).",Actionable,1064,1793,pancreatic cancer,DOID,1806,CDKN2A loss,decreased response,1514,HMN-214 + PD0332991,1029,25156567,,,
14,Phase I,"In a Phase I trial, a squamous non-small cell lung carcinoma patient with KRAS wild-type and loss of CDKN2A demonstrated a partial response when treated with Abemaciclib (LY2835219) (PMID: 27217383). ",Actionable,7431,3908,non-small cell lung carcinoma,DOID,25455,CDKN2A loss KRAS wild-type,sensitive,802,Abemaciclib,1029,27217383,,,
15,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Ibrance (palbociclib) and Mekinist (trametinib) induced tumor regression in a mouse melanoma model expressing NRAS Q61K and harboring CDKN2A loss (PMID: 22983396).",Actionable,2923,1909,melanoma,DOID,10733,NRAS Q61K CDKN2A loss,sensitive,1368,Palbociclib + Trametinib,1029,22983396,,,
16,Preclinical,"In a preclinical study, SBI-0640726 delayed tumor growth of melanomas in mice with a genetic background of NRAS Q61K and CDKN2A loss (PMID: 26603897).",Actionable,3791,1909,melanoma,DOID,10733,NRAS Q61K CDKN2A loss,sensitive,3306,SBI-0640756,1029,26603897,,,
17,Phase I,"In a Phase I trial, Abemaciclib (LY2835219) resulted in a partial response in a melanoma patient with CDKN2A loss and NRAS mutation (PMID: 27217383).",Actionable,2266,1909,melanoma,DOID,6894,CDKN2A loss NRAS mutant,sensitive,802,Abemaciclib,1029,None,27217383,,
18,Preclinical,"In a preclinical study, CDKN2A (p16) over expression was associated with decreased sensitivity to Ibrance (palbociclib) in a SMARCB1-negative malignant rhabdoid tumor cell line in culture (PMID: 21871868).",Actionable,5767,3672,rhabdoid cancer,DOID,21572,CDKN2A over exp SMARCB1 negative,decreased response,850,Palbociclib,1029,21871868,,,
19,Preclinical - Pdx & cell culture,"In a preclinical study, Ibrance (palbociclib) inhibited proliferation of patient-derived glioblastoma cells harboring homozygous deletion of CDKN2A in culture and prolonged survival in patient-derived xenograft models (PMID: 22711607).",Actionable,9368,3068,glioblastoma multiforme,DOID,6542,CDKN2A del,sensitive,850,Palbociclib,1029,22711607,,,
20,Preclinical - Cell line xenograft,"In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of CDKN2A-deleted lung cancer (PMID: 26140595).",Actionable,10260,1324,lung cancer,DOID,6542,CDKN2A del,predicted â€“ sensitive,5443,PF3644022 + PF-477736,1029,26140595,,,
21,Clinical Study,"In a clinical case study, a pancreatic ductal adenocarcinoma patient harboring EML4-ALK along with CDKN2A deletion, FGFR1 T141R, SMAD4 Q83*, and a TP53 splice site mutation, experienced disease progression after 2 months of Xalkori (crizotinib) treatment, then received Alecensa (alectinib) and remained on treatment for at least 3 months (PMID: 28476735).",Actionable,11544,3498,pancreatic ductal adenocarcinoma,DOID,28131,EML4-ALK CDKN2A del FGFR1 T141R SMAD4 Q83*,predicted â€“ sensitive,698,Alectinib,1029,28476735,,,
22,Clinical Study,"In a clinical case study, a pancreatic ductal adenocarcinoma patient harboring EML4-ALK along with CDKN2A deletion, FGFR1 T141R, SMAD4 Q83*, and a TP53 splice site mutation, experienced disease progression after 2 months of Xalkori (crizotinib) treatment, then received Alecensa (alectinib) and remained on treatment for at least 3 months (PMID: 28476735).",Actionable,11543,3498,pancreatic ductal adenocarcinoma,DOID,28131,EML4-ALK CDKN2A del FGFR1 T141R SMAD4 Q83*,resistant,706,Crizotinib,1029,28476735,,,
23,Preclinical - Patient cell culture,"In a preclinical study, patient-derived glioblastoma cells harboring RB1 truncation mutation and expressing Cdkn2a were resistant to Ibrance (palbociclib) in culture (PMID: 22711607).",Actionable,9364,3068,glioblastoma multiforme,DOID,26833,CDKN2A pos RB1 inact mut,resistant,850,Palbociclib,1029,22711607,,,
24,Preclinical - Cell line xenograft,"In a preclinical study, a gastric carcinoma cell line harboring CDKN2A R80* was sensitive to Ibrance (palbociclib) both in culture and in cell line xenograft models (PMID: 26380006, PMID: 20952405).",Actionable,3558,5517,stomach carcinoma,DOID,7936,CDKN2A R80*,sensitive,850,Palbociclib,1029,26380006,20952405,,
25,Clinical Study,"In a clinical study, a melanoma patient harboring a PDGFRA mutation, CDKN2A mutation, MET exon 14 splice site mutation, and SMAD4 Q249H demonstrated a 21 month overall survival when treated with a combination of Gleevec (imatinib), Paraplatin (carboplatin), and Taxol (paclitaxel) (PMID: 28514312).",Actionable,11053,1909,melanoma,DOID,27904,CDKN2A mut MET del exon14 PDGFRA mut SMAD4 Q249H,sensitive,5833,Imatinib + Carboplatin + Paclitaxel,1029,28514312,,,
26,Preclinical,"In a preclinical study, a breast cancer cell line harboring mutations in PIK3CA and CDKN2A demonstrated sensitivity to Sapanisertib (MLN0128) in culture (PMID: 25261369). ",Actionable,2105,1612,breast cancer,DOID,5388,PIK3CA mutant CDKN2A mutant,sensitive,1282,Sapanisertib,1029,25261369,,,
27,Preclinical,"In a preclinical study, human triple negative breast cancer cells harboring mutant BRAF, KRAS, and CDKN2A were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",Actionable,6690,60081,triple-receptor negative breast cancer,DOID,23670,BRAF mut KRAS mut CDKN2A mut,resistant,2,Trametinib,1029,26343583,,,
28,Preclinical,"In a preclinical study, human acute lymphoblastic leukemia cells harboring NRAS and CDKN2A mutations were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",Actionable,6683,9952,acute lymphocytic leukemia,DOID,23669,NRAS mut CDKN2A mut,resistant,2,Trametinib,1029,26343583,,,
0,Clinical Study,"In clinical analyses, mutations in GATA2 were associated with better overall survival in patients with cytogenetically normal acute myeloid leukemia (CN-AML) harboring biallelic CEBPA gene mutations (PMID: 22814295, PMID: 23521373, PMID: 25241285).",Prognostic,3612,9119,acute myeloid leukemia,DOID,22783,CEBPA mutant GATA2 mutant,not applicable,1776,N/A,1050,22814295,23521373,25241285,
1,Clinical Study,"In clinical analyses, biallelic CEBPA mutations were associated with favorable clinical outcome in patients with cytogenetically normal acute myeloid leukemia (PMID: 26601784, PMID: 19171880, PMID: 20038735, PMID: 22915647).",Prognostic,6167,9119,acute myeloid leukemia,DOID,13812,CEBPA mutant,not applicable,1776,N/A,1050,26601784,19171880,20038735,
0,Preclinical,"In a preclinical study, CSFR1 Y571D conferred sensitivity to Gleevec (imatinib) in myeloid cell lines in culture (PMID: 18971950).",Actionable,683,8692,myeloid leukemia,DOID,952,CSF1R Y571D,sensitive,770,Imatinib,1436,18971950,,,
1,Phase I,"In a Phase I trial, PLX3397 reduced tenosynovial giant cell tumor volume in patients with overexpression of Csf1r (PMID: 26222558).",Actionable,2791,314,tenosynovial giant cell tumor,DOID,10685,CSF1R over exp,sensitive,874,PLX3397,1436,26222558,,,
2,Preclinical,"In a preclinical study, a melanoma mouse model harboring BRAF V600E treated with Zelboraf (vemurafenib) demonstrated a greater drug induced sensitivity when treatment was combined with PLX3397, resulting in increased infiltration of lymphocytes via Csf1r inhibition and elevated antitumor activity (PMID: 25939769).",Actionable,6075,1909,melanoma,DOID,22385,BRAF V600E CSF1R positive,sensitive,1339,PLX3397 + Vemurafenib,1436,25939769,,,
3,Preclinical,"In a preclinical study, Nexavar (sorafenib) inhibited CSF1R phosphorylation and induced apoptosis in Hodgkin's lymphoma cells in culture (PMID: 21517818)",Actionable,2453,8567,Hodgkin's lymphoma,DOID,7709,CSF1R positive,sensitive,920,Sorafenib,1436,21517818,,,
4,Clinical Study,"In multiple clinical studies, elevated levels of CSF1R expression were associated with a worse survival in patients with Hodgkin's lymphoma (PMID: 24619759, PMID: 26066800, PMID: 22955918). ",Prognostic,6066,8567,Hodgkin's lymphoma,DOID,7709,CSF1R positive,not applicable,1776,N/A,1436,24619759,26066800,22955918,
0,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) reduces colony formation of cells expressing CSF3R T640N in culture (PMID: 26475333).",Actionable,4653,10000003,Advanced Solid Tumor,JAX,18726,CSF3R T640N,sensitive,907,Ruxolitinib,1441,26475333,,,
1,Clinical Study,"In clinical studies, high frequency of CSF3R mutations was identified in patients with chronic neutrophilic leukemia (PMID: 23656643, PMID: 24081659), suggesting that this may serve as a future diagnostic biomarker (PMID: 24441292).",Emerging,6483,4960,bone marrow cancer,DOID,23595,CSF3R mutant,not applicable,1776,N/A,1441,23656643,24081659,24441292,
2,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) reduces colony formation of cells expressing CSF3R T618I in culture (PMID: 26475333).",Actionable,4654,10000003,Advanced Solid Tumor,JAX,14885,CSF3R T618I,sensitive,907,Ruxolitinib,1441,26475333,,,
0,Clinical Study,"In a retrospective analysis, patients with desmoid fibromatosis harboring CTNNB1 T41A demonstrated a greater progression arrest rate at 6 months (70%) compared to patients with CTNNB1 wild-type (45%) when treated with Gleevec (imatinib) (PMID: 26861905). ",Actionable,4869,1115,sarcoma,DOID,3980,CTNNB1 T41A,sensitive,770,Imatinib,1499,26861905,,,
1,Clinical Study,"In a retrospective analysis, patients with desmoid fibromatosis harboring CTNNB1 activating mutations demonstrated a greater progression arrest rate at 6 months compared to patients with CTNNB1 wild-type when treated with Gleevec (imatinib) (PMID: 26861905).",Actionable,4868,1115,sarcoma,DOID,3638,CTNNB1 act mut,sensitive,770,Imatinib,1499,26861905,,,
2,Preclinical - Pdx,"In a preclinical study, the combination of NVP-TNKS656 and Triciribine (API-2) inhibited tumor growth in Triciribine (API-2)-resistant patient-derived xenograft (PDX) models of colon cancer with high nuclear CTNNB1 (Beta-catenin) levels (PMID: 26224873).",Actionable,10333,219,colon cancer,DOID,26160,CTNNB1 over exp,predicted â€“ sensitive,5469,NVP-TNKS656 + Triciribine,1499,26224873,,,
3,Preclinical,"In a preclinical study, human liver cancer cells harboring mutant NRAS and mutant CTNNB1 were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",Actionable,6696,3571,liver cancer,DOID,23671,CTNNB1 mut NRAS mut,resistant,2,Trametinib,1499,26343583,,,
4,Preclinical,"In a preclinical study, BC21 inhibited growth and viability of a colorectal cancer cell line with a CTNNB1 mutation and increased beta-catenin expression in culture (PMID: 22224445).",Actionable,3148,9256,colorectal cancer,DOID,11801,CTNNB1 mutant,sensitive,2410,BC21,1499,22224445,,,
5,Phase II,"In a retrospective study of a Phase II trial, Torisel (temsirolimus) treatment resulted in an increased progression-free survival (HR 0.46) but not response rate (response difference 0.00) in advanced endometrial cancer patients harboring CTNNB1 mutations (PMID: 27016228).",Actionable,6402,1380,endometrial cancer,DOID,11801,CTNNB1 mutant,predicted â€“ sensitive,936,Temsirolimus,1499,27016228,,,
6,Preclinical,"In a preclinical study, PMED-1 decreased Wnt expression and decreased proliferation of hepatocellular carcinoma cells with Ctnnb1 mutations (PMID: 2481996).",Actionable,3826,684,hepatocellular carcinoma,DOID,11801,CTNNB1 mutant,sensitive,3370,PMED-1,1499,24819961,,,
7,Phase I,"In a Phase I trial, CWP232291 reduced beta-catenin expression and demonstrated safety and preliminary efficacy in acute myeloid leukemia (J Clin Oncol (Meeting Abstracts) 2015 33: 7044)).",Actionable,3168,9119,acute myeloid leukemia,DOID,4007,CTNNB1 amp,predicted â€“ sensitive,3081,CWP232291,1499,None,,,
8,Preclinical - Pdx,"In a preclinical study, Vantictumab (OMP-18R5) inhibited tumor growth in patient-derived xenograft models of colon cancer with wild-type CTNNB1 (beta-catenin) and APC (PMID: 22753465).",Actionable,7164,219,colon cancer,DOID,24535,APC wild-type CTNNB1 wild-type,predicted â€“ sensitive,4397,Vantictumab,1499,22753465,,,
9,Clinical Study,"In a retrospective analysis, patients with desmoid fibromatosis harboring CTNNB1 S45F demonstrated a greater progression arrest rate at 6 months (85%) compared to patients with CTNNB1 wild-type (45%) when treated with Gleevec (imatinib) (PMID: 26861905). ",Actionable,4867,1115,sarcoma,DOID,4008,CTNNB1 S45F,sensitive,770,Imatinib,1499,26861905,,,
0,Clinical Study,"In a clinical study, acute myeloid leukemia patients harboring DNMT3A mutations demonstrated a greater complete response rate (60% vs 33%) compared to acute myeloid leukemia patients with wild-type DNMT3A when treated with hypomethylating agents such as Dacogen (decitabine) (PMID: 27418649).",Actionable,7518,9119,acute myeloid leukemia,DOID,3485,DNMT3A mut,predicted â€“ sensitive,650,Decitabine,1788,27418649,,,
1,Clinical Study,"In clinical analyses, mutations in DNMT3A were associated with poor prognosis and shorter overall survival in patients with acute myeloid leukemia (PMID: 22490330, PMID: 21881046, PMID: 21670448).",Prognostic,3571,9119,acute myeloid leukemia,DOID,3485,DNMT3A mut,not applicable,1776,N/A,1788,22490330,21881046,21670448,
2,Clinical Study,"In a retrospective analysis, of patients with acute myeloid leukemia, the combination of DNMT3A, FLT3, and NPM1 mutations was highly associated with decreased event free survival and overall survival, suggesting that this combination profile may serve as a future prognostic biomarker (PMID: 25281355).  ",Emerging,3573,9119,acute myeloid leukemia,DOID,13674,DNMT3A R882H FLT3 Y599_D600insSTDNEYFYVDFREYEY NPM1 W288fs,not applicable,1776,N/A,1788,25281355,,,
0,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing an EGFR D770delinsGY/EGFR C797S double mutation demonstrated resistance to dacomitinib in culture (PMID: 28363995).",Actionable,10510,10000003,Advanced Solid Tumor,JAX,27534,EGFR D770delinsGY EGFR C797S,resistant,714,Dacomitinib,1956,28363995,,,
1,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing an EGFR D770delinsGY/EGFR C797S double mutation demonstrated resistance to Gilotrif (afatinib) in culture (PMID: 28363995).",Actionable,10511,10000003,Advanced Solid Tumor,JAX,27534,EGFR D770delinsGY EGFR C797S,sensitive,623,Afatinib,1956,28363995,,,
2,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EGFR D770delinsGY demonstrated resistance to Nerlynx (neratinib) in culture (PMID: 28363995).",Actionable,12175,10000003,Advanced Solid Tumor,JAX,27528,EGFR D770delinsGY,resistant,828,Neratinib,1956,28363995,,,
3,Preclinical - Cell culture,"In a preclinical study, dacomitinib inhibited EGFR phosphorylation and growth of transformed cells expressing EGFR D770delinsGY in culture (PMID: 28363995).",Actionable,10498,10000003,Advanced Solid Tumor,JAX,27528,EGFR D770delinsGY,sensitive,714,Dacomitinib,1956,28363995,,,
4,Preclinical - Cell culture,"In a preclinical study, acquisition of EGFR T790M was associated with resistance to dacomitinib in transformed cells expressing EGFR D770delinsGY (PMID: 28363995).",Actionable,10509,10000003,Advanced Solid Tumor,JAX,27533,EGFR D770delinsGY EGFR T790M,resistant,714,Dacomitinib,1956,28363995,,,
5,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing an EGFR D770delinsGY/EGFR T790M double mutation demonstrated resistance to Gilotrif (afatinib) in culture (PMID: 28363995).",Actionable,10512,10000003,Advanced Solid Tumor,JAX,27533,EGFR D770delinsGY EGFR T790M,sensitive,623,Afatinib,1956,28363995,,,
6,Preclinical - Cell culture,"In a preclinical study, the addition of Mekinist (trametinib) to WZ4002 treatment did not significantly impact cell viability compared to WZ4002 alone, but delayed onset of drug resistance in a non-small cell lung cancer cell line harboring EGFR A750P and EGFR L747_E749del in culture (PMID: 26036643).",Actionable,9056,3908,non-small cell lung carcinoma,DOID,26702,EGFR A750P EGFR L747_E749del,sensitive,3351,WZ4002 + Trametinib,1956,26036643,,,
7,Clinical Study,"In an analysis of published clinical data, 14/18 (78%) non-small cell lung cancer patients harboring an EGFR G719X (X=A, C, or S) mutation were found to achieve disease control following treatment with EGFR tyrosine kinase inhibitors, Iressa (gefitinib) (PMID: 23344264).",Actionable,768,3908,non-small cell lung carcinoma,DOID,649,EGFR G719S,sensitive,751,Gefitinib,1956,23344264,,,
8,Preclinical,"In preclinical in vitro assays, EGFR G719S was demonstrated to stabilize the active conformation of Egfr and sensitize the protein to Iressa (gefitinib) (PMID: 17349580). ",Actionable,767,3908,non-small cell lung carcinoma,DOID,649,EGFR G719S,sensitive,751,Gefitinib,1956,17349580,,,
9,Preclinical,"In preclinical in vitro assays, EGFR G719S was demonstrated to stabilize the active conformation of Egfr and sensitize the protein to Gilotrif (afatinib) (PMID: 17349580). ",Actionable,765,3908,non-small cell lung carcinoma,DOID,649,EGFR G719S,sensitive,4,Erlotinib,1956,17349580,,,
10,Clinical Study,"In an analysis of published clinical data, 14/18 (78%) non-small cell lung cancer patients harboring an EGFR G719X (X=A, C, D, or S) mutation were found to achieve disease control following treatment with EGFR tyrosine kinase inhibitors, such as Tarceva (erlotinib) (PMID: 23344264).",Actionable,766,3908,non-small cell lung carcinoma,DOID,649,EGFR G719S,sensitive,4,Erlotinib,1956,23344264,,,
11,Phase III,"In Phase III clinical trials, patients with NSCLC tumors harboring an EGFR G719X (X=A, C, or S) mutation responded to EGFR tyrosine kinase inhibitors including dacomitinib (PMID: 24857124).",Actionable,764,3908,non-small cell lung carcinoma,DOID,649,EGFR G719S,sensitive,714,Dacomitinib,1956,24857124,,,
12,Phase III,"In Phase III trials, non-small cell lung carcinoma patients harboring EGFR G719X mutations (G719A, C, or S) demonstrated a response rate of 78% (14/18) following treatment with Gilotrif (afatinib) (PMID: 24790411).",Actionable,762,3908,non-small cell lung carcinoma,DOID,649,EGFR G719S,sensitive,623,Afatinib,1956,23344264,24790411,,
13,Preclinical,"In preclinical in vitro assays, EGFR G719S was demonstrated to stabilize the active conformation of Egfr and sensitize the protein to Gilotrif (afatinib) (PMID: 17349580). ",Actionable,1862,3908,non-small cell lung carcinoma,DOID,649,EGFR G719S,sensitive,623,Afatinib,1956,17349580,,,
14,Preclinical,"In a preclinical study, a colorectal cancer cell line harboring MAP2K1 mutations Q56P, H119Y, and D351G and an EGFR G719S mutation demonstrated some sensitivity to Mekinist (trametinib) in culture, resulting in decreased cell viability (PMID: 26582713). ",Actionable,6493,9256,colorectal cancer,DOID,23597,MAP2K1 Q56P MAP2K1 H119Y MAP2K1 D351G EGFR G719S,sensitive,2,Trametinib,1956,26582713,,,
15,Clinical Study,"In a clinical study, a patient with non-small cell lung carcinoma harboring EGFR K745_E746insIPVAIK demonstrated a partial response when treated with Gilotrif (afatinib) (PMID: 22190593). ",Actionable,10913,3908,non-small cell lung carcinoma,DOID,27853,EGFR K745_E746insIPVAIK,sensitive,623,Afatinib,1956,22190593,,,
16,Clinical Study,"In a prospective clinical study, Gilotrif (afatinib) treatment resulted in progressive disease in a non-small cell lung carcinoma patient carrying an EGFR R776H mutation (PMID: 26354527).",Actionable,3327,3908,non-small cell lung carcinoma,DOID,3302,EGFR R776H,no benefit,623,Afatinib,1956,26354527,,,
17,Phase II,"In a Phase II clinical trial, 74% (34/46) of patients with EGFR exon 19 or 21 mutant lung cancers had partial response (PFS average= 17 months) to first line treatment with dacomitinib (J Clin Oncol 30, 2012 (suppl; abstr 7530)).",Actionable,773,3908,non-small cell lung carcinoma,DOID,624,EGFR E746_A750del,sensitive,714,Dacomitinib,1956,None,,,
18,FDA approved,"In a Phase III trial that supported FDA approval, Tarceva (erlotinib) improved progression-free survival in non-small cell lung cancer patients harboring EGFR exon 19 deletions (HR= 0.27), such as EGFR E746_A750del (PMID: 24868098).",Actionable,344,3908,non-small cell lung carcinoma,DOID,624,EGFR E746_A750del,sensitive,4,Erlotinib,1956,None,24868098,,
19,FDA approved,"In a comparison of clinical outcomes, NSCLC patients with either EGFR exon 19 deletion or the L858R mutation responded to treatment with Iressa (gefitinib) or Tarceva (erlotinib) with similar effectiveness, with overall response rates > 75% (PMID: 24736073).",Actionable,774,3908,non-small cell lung carcinoma,DOID,624,EGFR E746_A750del,sensitive,751,Gefitinib,1956,24736073,,,
20,FDA approved,"In a Phase III trial, Gilotrif (afatinib) increased progression-free survival in non-small cell lung cancer (NSCLC) patients harboring EGFR exon 19 deletions, such as EGFR E746_A750del, which supported FDA approval for use in these patients (PMID: 23816960, FDA.gov). ",Actionable,772,3908,non-small cell lung carcinoma,DOID,624,EGFR E746_A750del,sensitive,623,Afatinib,1956,None,23816960,,
21,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Ganetespib and Tarceva (erlotinib) demonstrated improved antitumor activity compared to either agent alone in cell line xenograft models of non-small cell lung cancer harboring EGFR E746_A750del (PMID: 25077897).",Actionable,2292,3908,non-small cell lung carcinoma,DOID,624,EGFR E746_A750del,sensitive,2802,Erlotinib + Ganetespib,1956,25077897,,,
22,Clinical Study,"In a retrospective analysis, 5 patients with lung adenocarcinoma harboring EGFR E746_A750del were found to respond to Iressa (gefitinib) therapy, with 4 achieving partial response and 1 stable disease (PMID: 18981003).",Actionable,3046,3910,lung adenocarcinoma,DOID,624,EGFR E746_A750del,sensitive,751,Gefitinib,1956,18981003,,,
23,Preclinical - Cell line xenograft,"In a preclinical study, BGB-283 inhibited Egfr phosphorylation and cell proliferation in lung carcinoma cells harboring EGFR E746_A750del in culture, and resulted in tumor regression in cell line xenograft models (PMID: 26208524).",Actionable,8059,3905,lung carcinoma,DOID,624,EGFR E746_A750del,sensitive,4025,BGB-283,1956,26208524,,,
24,Preclinical,"In a preclinical study, non-small cell lung carcinoma cells harboring EGFR E746_A750del demonstrated resistance to growth inhibition by Tykerb (lapatinib) in cell culture (PMID: 18199554).",Actionable,3059,3908,non-small cell lung carcinoma,DOID,624,EGFR E746_A750del,resistant,787,Lapatinib,1956,18199554,,,
25,Preclinical,"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human non-small cell lung carcinoma cells harboring  EGFR E746_A750del in culture (PMID: 21325073, PMID: 16731747).",Actionable,3135,3908,non-small cell lung carcinoma,DOID,624,EGFR E746_A750del,sensitive,1040,PF-05212384,1956,21325073,16731747,,
26,Preclinical - Cell line xenograft,"In a preclinical study, the combination of WZ4002 and Mekinist (trametinib) inhibited tumor growth, and resulted in reduced tumor rebound compared to WZ4002 alone in non-small cell lung cancer cell line xenograft models harboring EGFR E746_A750del (PMID: 26036643).",Actionable,9055,3908,non-small cell lung carcinoma,DOID,624,EGFR E746_A750del,sensitive,3351,WZ4002 + Trametinib,1956,26036643,,,
27,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing EGFR E746_A750del in culture (PMID: 27780853).",Actionable,9253,10000003,Advanced Solid Tumor,JAX,624,EGFR E746_A750del,sensitive,634,AP26113,1956,27780853,,,
28,Preclinical - Cell line xenograft,"In a preclinical study, the combination of ER2 and Platinol (cisplatin) demonstrated synergy in inhibiting tumor growth in a non-small cell lung cancer cell line xenograft model harboring EGFR E746_A750del (PMID: 27040853).",Actionable,8041,3908,non-small cell lung carcinoma,DOID,624,EGFR E746_A750del,sensitive,4625,ER2 + Cisplatin,1956,27040853,,,
29,Preclinical - Cell line xenograft,"In a preclinical study, lung adenocarcinoma cells harboring EGFR E746_A750del demonstrated sensitivity to treatment with AC0010MA, which resulted in inhibition of both cell growth and Egfr phosphorylation in culture, and tumor regression in xenograft models (PMID: 27573423). ",Actionable,9114,3910,lung adenocarcinoma,DOID,624,EGFR E746_A750del,sensitive,2909,AC0010MA,1956,27573423,,,
30,Preclinical - Cell line xenograft,"In a preclinical study, treatment with ER2 resulted in decreased proliferation and increased apoptosis of non-small cell lung cancer (NSCLC) cells harboring EGFR E746_A750del in culture, and delayed tumor growth in NSCLC cell line xenograft models with EGFR E746_A750del (PMID: 27040853).",Actionable,5647,3908,non-small cell lung carcinoma,DOID,624,EGFR E746_A750del,sensitive,3916,ER2,1956,27040853,,,
31,Clinical Study,"In a retrospective analysis, 4 patients with lung adenocarcinoma harboring EGFR E746_A750del that had developed Iressa (gefitinib) resistance were found to have acquired EGFR T790M mutations (PMID: 18981003). ",Actionable,3048,3910,lung adenocarcinoma,DOID,11380,EGFR E746_A750del EGFR T790M,resistant,751,Gefitinib,1956,18981003,,,
32,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing EGFR E746_A750del and T790M in culture (PMID: 27780853).",Actionable,9254,10000003,Advanced Solid Tumor,JAX,11380,EGFR E746_A750del EGFR T790M,sensitive,634,AP26113,1956,27780853,,,
33,Preclinical - Cell line xenograft,"In a preclinical study, treatment with the combination of WZ4002 and Mekinist (trametinib)  inhibited tumor growth, and resulted in increased ERK inhibition and reduced tumor rebound compared to WZ4002 alone in non-small cell lung cancer cell line xenograft models harboring both EGFR E746_A750del and EGFR T790M (PMID: 26036643).",Actionable,9054,3908,non-small cell lung carcinoma,DOID,11380,EGFR E746_A750del EGFR T790M,sensitive,3351,WZ4002 + Trametinib,1956,26036643,,,
34,Clinical Study,"In a retrospective analysis, 3 of 4 patients with lung adenocarcinoma harboring EGFR E746_A750del and EGFR T790M were found to rapidly progress on Tarceva (erlotinib) therapy (PMID: 18981003). ",Actionable,3047,3910,lung adenocarcinoma,DOID,11380,EGFR E746_A750del EGFR T790M,resistant,4,Erlotinib,1956,18981003,,,
35,Preclinical,"In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR L718Q double mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).",Actionable,3076,10000003,Advanced Solid Tumor,JAX,11692,EGFR E746_A750del EGFR L718Q,resistant,1003,CO1686,1956,25948633,,,
36,Preclinical,"In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR E746_A750del/EGFR L718Q double mutation in culture (PMID: 25948633).",Actionable,3086,10000003,Advanced Solid Tumor,JAX,11692,EGFR E746_A750del EGFR L718Q,sensitive,660,Osimertinib,1956,25948633,,,
37,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited growth of transformed cells expressing an EGFR E746_A750del/EGFR L718Q double mutation in culture (PMID: 25948633).",Actionable,3099,10000003,Advanced Solid Tumor,JAX,11692,EGFR E746_A750del EGFR L718Q,sensitive,623,Afatinib,1956,25948633,,,
38,Preclinical - Cell line xenograft,"In a preclinical study, the addition of NPS-1034 to treatment with Iressa (gefitinib) overcame Iressa (gefitinib) resistance in a cell line xenograft model of non-small cell lung cancer reported to harbor EGFR E746_A750del (PMID: 23542356), which has acquired resistance to Iressa (gefitinib) due to MET amplification and over expression, resulting in tumor growth inhibition (PMID: 24165158).",Actionable,9655,3908,non-small cell lung carcinoma,DOID,26798,EGFR E746_A750del MET amp,sensitive,5116,Gefitinib + NPS-1034,1956,24165158,23542356,,
39,Preclinical - Cell line xenograft,"In a preclinical study, the combination of PHA-665752 and Iressa (gefitinib) overcame Iressa (gefitinib) resistance in a cell line xenograft model of non-small cell lung cancer reported to harbor EGFR E746_A750del (PMID: 23542356), which has acquired resistance to Iressa (gefitinib) due to MET amplification and over expression, resulting in tumor growth inhibition (PMID: 24165158).",Actionable,9656,3908,non-small cell lung carcinoma,DOID,26798,EGFR E746_A750del MET amp,sensitive,5094,Gefitinib + PHA-665752,1956,24165158,23542356,,
40,Preclinical - Pdx,"In a preclinical study, treatment with Capmatinib (INC280) plus Gilotrif (afatinib) resulted in improved survival with no evidence of tumor 300 days post-transplantation in patient-derived xenograft (PDX) models derived from the brain metastasis of a lung adenocarcinoma patient with EGFR E746_A750del (referred to as K745_A750delinsK) and high level MET amplification (PMID: 28961841).",Actionable,12150,3910,lung adenocarcinoma,DOID,26798,EGFR E746_A750del MET amp,sensitive,6313,Afatinib + Capmatinib,1956,28961841,,,
41,Preclinical - Pdx,"In a preclinical study, treatment with Capmatinib (INC280) resulted in improved survival in patient-derived xenograft (PDX) models derived from the brain metastasis of a lung adenocarcinoma patient with EGFR E746_A750del (referred to as K745_A750delinsK) and high level MET amplification (PMID: 28961841).",Actionable,12148,3910,lung adenocarcinoma,DOID,26798,EGFR E746_A750del MET amp,sensitive,1065,Capmatinib,1956,28961841,,,
42,Preclinical - Pdx,"In a preclinical study, treatment with Gilotrif (afatinib) did not demonstrate benefit in patient-derived xenograft (PDX) models derived from the brain metastasis of a lung adenocarcinoma patient with EGFR E746_A750del (referred to as K745_A750delinsK) and high level MET amplification, with all treated mice demonstrating progression (PMID: 28961841).",Actionable,12157,3910,lung adenocarcinoma,DOID,26798,EGFR E746_A750del MET amp,no benefit,623,Afatinib,1956,28961841,,,
43,Preclinical - Cell culture,"In a preclinical study, the combination of Rociletinib (CO-1686) and Xalkori (crizotinib) overcame resistance to Rociletinib (CO-1686) in non-small cell lung cancer cell line harboring EGFR E746_A750del and MET amplification in culture (PMID: 27283993).",Actionable,9248,3908,non-small cell lung carcinoma,DOID,26798,EGFR E746_A750del MET amp,sensitive,4962,CO1686 + Crizotinib,1956,27283993,,,
44,Preclinical - Cell line xenograft,"In a preclinical study, emergence of MET amplification was associated with resistance to Rociletinib (CO1686) in non-small cell lung cancer cell line xenograft models harboring EGFR E746_A750del (PMID: 27283993).",Actionable,9247,3908,non-small cell lung carcinoma,DOID,26798,EGFR E746_A750del MET amp,resistant,1003,CO1686,1956,27283993,,,
45,Clinical Study,"In a clinical case study, a patient with metastatic lung adenocarcinoma harboring EGFR E746_A750del (referred to as K745_A750delinsK) and T790M demonstrated an initial response, but subsequent progression, of the brain metastasis following Tagrisso (osimertinib) treatment, and analysis of the brain metastasis showed loss of EGFR T790M as well as acquisition of high-level MET amplification, and resistance to Tagrisso (osimertinib) was recapitulated in a patient-derived xenograft (PDX) model (PMID: 28961841)",Actionable,12147,3910,lung adenocarcinoma,DOID,26798,EGFR E746_A750del MET amp,resistant,660,Osimertinib,1956,28961841,,,
46,Preclinical - Cell culture,"In a preclinical study, acquired amplification of MET conferred resistance to Iressa (gefitinib) in a non-small cell lung cancer cell line harboring EGFR E746_A750del in culture (PMID: 27612490).",Actionable,9557,3908,non-small cell lung carcinoma,DOID,26798,EGFR E746_A750del MET amp,resistant,751,Gefitinib,1956,27612490,,,
47,Preclinical,"In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR C797S double mutation demonstrated resistance to AZD9291 in culture (PMID: 25948633).",Actionable,3090,10000003,Advanced Solid Tumor,JAX,11691,EGFR E746_A750del EGFR C797S,resistant,660,Osimertinib,1956,25948633,,,
48,Preclinical - Cell culture,"In a preclinical study, a non-small cell lung cancer cell line harboring EGFR DelE746_A750 and expressing EGFR DelE746_A750/C797S demonstrated resistance to growth inhibition by Rociletinib (CO1686) in culture (PMID: 25948633).",Actionable,10299,3908,non-small cell lung carcinoma,DOID,11691,EGFR E746_A750del EGFR C797S,resistant,1003,CO1686,1956,25948633,,,
49,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited growth of transformed cells expressing an EGFR E746_A750del/EGFR C797S double mutation in culture (PMID: 25948633).",Actionable,3102,10000003,Advanced Solid Tumor,JAX,11691,EGFR E746_A750del EGFR C797S,sensitive,623,Afatinib,1956,25948633,,,
50,Preclinical - Cell culture,"In a preclinical study, Iressa (gefitinib) inhibited growth of a non-small cell lung cancer cell line harboring EGFR E746_A750del and expressing EGFR E746_A750del/C797S in culture (PMID: 25948633).",Actionable,10302,3908,non-small cell lung carcinoma,DOID,11691,EGFR E746_A750del EGFR C797S,sensitive,751,Gefitinib,1956,25948633,,,
51,Preclinical,"In a preclinical study, cells expressing an EGFR E746_A750del/EGFR C797S double mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).",Actionable,3078,10000003,Advanced Solid Tumor,JAX,11691,EGFR E746_A750del EGFR C797S,resistant,1003,CO1686,1956,25948633,,,
52,Preclinical - Cell culture,"In a preclinical study, Gilotrif (afatinib) inhibited growth of a non-small cell lung cancer cell line harboring EGFR E746_A750del and expressing EGFR E746_A750del/C797S in culture (PMID: 25948633).",Actionable,10303,3908,non-small cell lung carcinoma,DOID,11691,EGFR E746_A750del EGFR C797S,sensitive,623,Afatinib,1956,25948633,,,
53,Preclinical - Cell culture,"In a preclinical study, a non-small cell lung cancer cell line harboring EGFR E746_A750del and expressing EGFR E746_A750del/C797S demonstrated resistance to growth inhibition by Tagrisso (osimertinib) in culture (PMID: 25948633).",Actionable,10301,3908,non-small cell lung carcinoma,DOID,11691,EGFR E746_A750del EGFR C797S,resistant,660,Osimertinib,1956,25948633,,,
54,Preclinical - Cell culture,"In a preclinical study, a non-small cell lung cancer cell line harboring EGFR E746_A750del and expressing EGFR E746_A750del/C797S demonstrated resistance to growth inhibition by WZ4002 in culture (PMID: 25948633).",Actionable,10300,3908,non-small cell lung carcinoma,DOID,11691,EGFR E746_A750del EGFR C797S,resistant,3075,WZ4002,1956,25948633,,,
55,Preclinical,"In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR T790M/EGFR Q791R triple mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).",Actionable,3094,10000003,Advanced Solid Tumor,JAX,11733,EGFR E746_A750del EGFR T790M EGFR Q791R,resistant,1003,CO1686,1956,25948633,,,
56,Preclinical,"In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR E746_A750del/EGFR T790M/EGFR Q791R triple mutation in culture (PMID: 25948633).",Actionable,3096,10000003,Advanced Solid Tumor,JAX,11733,EGFR E746_A750del EGFR T790M EGFR Q791R,sensitive,660,Osimertinib,1956,25948633,,,
57,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EGFR E746_A750del and EGFR L792F demonstrated decreased sensitivity to Gilotrif (afatinib) in culture compared to cells expressing E746_A750del alone (PMID: 27913578).",Actionable,9990,10000003,Advanced Solid Tumor,JAX,27220,EGFR E746_A750del EGFR L792F,decreased response,623,Afatinib,1956,27913578,,,
58,Preclinical,"In a preclinical study, the combination of Odomzo (sonidegib) and Iressa (gefitinib) decreased viability and migration of non-small cell lung cancer (NSCLC) cells harboring an EGFR E746_A750del mutation and SMO amplification in culture and inhibited tumor growth in NSCLC xenograft models with EGFR E746_A750del and SMO amplification (PMID: 26124204).",Actionable,2657,3908,non-small cell lung carcinoma,DOID,9076,EGFR E746_A750del SMO amp,sensitive,2986,Gefitinib + Sonidegib,1956,26124204,,,
59,Preclinical,"In a preclinical study, the combination of Odomzo (sonidegib) and PHA-665752 decreased viability and migration of non-small cell lung cancer (NSCLC) cells harboring EGFR E746_A750del and SMO amplification in culture, and resulted in complete response in 100% (8/8) of NSCLC xenograft models with EGFR E746_A750del and SMO amplification (PMID: 26124204).",Actionable,2658,3908,non-small cell lung carcinoma,DOID,9076,EGFR E746_A750del SMO amp,sensitive,2987,PHA-665752 + Sonidegib,1956,26124204,,,
60,Preclinical,"In a preclinical study, Odomzo (sonidegib) did not decrease viability or migration of non-small cell lung cancer cells harboring EGFR E746_A750del and amplification of SMO in culture (PMID: 26124204).",Actionable,2656,3908,non-small cell lung carcinoma,DOID,9076,EGFR E746_A750del SMO amp,no benefit,1428,Sonidegib,1956,26124204,,,
61,Preclinical,"In a preclinical study, amplification of SMO conferred acquired resistance to Iressa (gefitinib) in non-small cell lung cancer cells harboring EGFR E746_A750del in culture (PMID: 26124204).",Actionable,2547,3908,non-small cell lung carcinoma,DOID,9076,EGFR E746_A750del SMO amp,resistant,751,Gefitinib,1956,26124204,,,
62,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited growth of transformed cells expressing an EGFR E746_A750del/EGFR L844V double mutation in culture (PMID: 25948633).",Actionable,3101,10000003,Advanced Solid Tumor,JAX,11693,EGFR E746_A750del EGFR L844V,sensitive,623,Afatinib,1956,25948633,,,
63,Preclinical,"In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR L844V double mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).",Actionable,3077,10000003,Advanced Solid Tumor,JAX,11693,EGFR E746_A750del EGFR L844V,resistant,1003,CO1686,1956,25948633,,,
64,Preclinical,"In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR E746_A750del/EGFR L844V double mutation in culture (PMID: 25948633).",Actionable,3085,10000003,Advanced Solid Tumor,JAX,11693,EGFR E746_A750del EGFR L844V,sensitive,660,Osimertinib,1956,25948633,,,
65,Preclinical - Cell culture,"In a preclinical study, Erbitux (cetuximab) did not inhibit growth of transformed cells expressing a EGFR E746_A750del/T790M/C797S triple mutation in culture (PMID: 25948633).",Actionable,10305,10000003,Advanced Solid Tumor,JAX,11688,EGFR E746_A750del EGFR T790M EGFR C797S,no benefit,694,Cetuximab,1956,25948633,,,
66,Preclinical,"In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR T790M/EGFR L718Q triple mutation demonstrated resistance to AZD9291 in culture (PMID: 25948633).",Actionable,3093,10000003,Advanced Solid Tumor,JAX,11689,EGFR E746_A750del EGFR T790M EGFR L718Q,resistant,660,Osimertinib,1956,25948633,,,
67,Preclinical,"In a preclinical study, AZD9291 inhibited growth of non-small cell lung cancer cells harboring EGFR E746_A750del and EGFR T790M and ectopically expressing an EGFR E746_A750del/EGFR T790M/EGFR L718Q triple mutation in culture (PMID: 25948633).",Actionable,3108,3908,non-small cell lung carcinoma,DOID,11689,EGFR E746_A750del EGFR T790M EGFR L718Q,sensitive,660,Osimertinib,1956,25948633,,,
68,Preclinical,"In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR T790M/EGFR L718Q triple mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).",Actionable,3074,10000003,Advanced Solid Tumor,JAX,11689,EGFR E746_A750del EGFR T790M EGFR L718Q,resistant,1003,CO1686,1956,25948633,,,
69,Preclinical,"In a preclinical study, expression of an EGFR E746_A750del/EGFR T790M/EGFR L718Q triple mutation conferred resistance to Rociletinib (CO-1686) in non-small cell lung cancer cells harboring EGFR E746_A750del and EGFR T790M in culture (PMID: 25948633).",Actionable,3107,3908,non-small cell lung carcinoma,DOID,11689,EGFR E746_A750del EGFR T790M EGFR L718Q,resistant,1003,CO1686,1956,25948633,,,
70,Preclinical - Cell line xenograft,"In a preclinical study, ABT-414 demonstrated cytotoxicity against a lung adenocarcinoma cell line that harbored EGFR amplification and EGFR E746_A750del in culture and induced tumor regression in cell line xenograft models (PMID: 26846818).",Actionable,6932,3910,lung adenocarcinoma,DOID,24031,EGFR amp EGFR E746_A750del,sensitive,976,ABT-414,1956,26846818,,,
71,Preclinical,"In a preclinical study, expression of an EGFR E746_A750del/EGFR T790M/EGFR L844V triple mutation conferred resistance to Rociletinib (CO-1686) in non-small cell lung cancer cells harboring EGFR E746_A750del and EGFR T790M in culture (PMID: 25948633).",Actionable,3106,3908,non-small cell lung carcinoma,DOID,11690,EGFR E746_A750del EGFR T790M EGFR L844V,resistant,1003,CO1686,1956,25948633,,,
72,Preclinical,"In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR E746_A750del/EGFR T790M/EGFR L844V triple mutation in culture (PMID: 25948633).",Actionable,3088,10000003,Advanced Solid Tumor,JAX,11690,EGFR E746_A750del EGFR T790M EGFR L844V,sensitive,660,Osimertinib,1956,25948633,,,
73,Preclinical,"In a preclinical study, AZD9291 inhibited growth of non-small cell lung cancer cells harboring EGFR E746_A750del and EGFR T790M and ectopically expressing an EGFR E746_A750del/EGFR T790M/EGFR L844V triple mutation in culture (PMID: 25948633).",Actionable,3104,3908,non-small cell lung carcinoma,DOID,11690,EGFR E746_A750del EGFR T790M EGFR L844V,sensitive,660,Osimertinib,1956,25948633,,,
74,Preclinical,"In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR T790M/EGFR L844V triple mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).",Actionable,3083,10000003,Advanced Solid Tumor,JAX,11690,EGFR E746_A750del EGFR T790M EGFR L844V,resistant,1003,CO1686,1956,25948633,,,
75,Clinical Study,"In a retrospective clinical study, non-small lung cancer patients harboring EGFR S768I demonstrated a median progression-free survival of 2.7 months following treatment with EGFR tyrosine kinase inhibitors such as Tarceva (erlotinib), Iressa (gefitinib), or Icotinib, compared to 10.8 months in patients with EGFR L858R and EGFR exon 19 deletions  (PMID: 27468240).",Actionable,7802,3908,non-small cell lung carcinoma,DOID,3321,EGFR S768I,decreased response,751,Gefitinib,1956,27468240,,,
76,Preclinical - Cell culture,"In a preclinical study, non-small cell lung carcinoma cells expressing EGFR S768I had decreased sensitivity to Tarceva (erltonib) in cell culture (PMID: 19147750).",Actionable,1819,3908,non-small cell lung carcinoma,DOID,3321,EGFR S768I,decreased response,4,Erlotinib,1956,19147750,,,
77,Clinical Study,"In a retrospective clinical study, non-small lung cancer patients harboring EGFR S768I demonstrated a median progression-free survival of 2.7 months following treatment with EGFR tyrosine kinase inhibitors such as Tarceva (erlotinib), Iressa (gefitinib), or Icotinib, compared to 10.8 months in patients with EGFR L858R and EGFR exon 19 deletions (PMID: 27468240).",Actionable,7801,3908,non-small cell lung carcinoma,DOID,3321,EGFR S768I,decreased response,4,Erlotinib,1956,27468240,,,
78,Clinical Study,"In a retrospective analysis, non-small cell lung cancer patients harboring EGFR S768I demonstrated a response rate of 25% and disease control rate of 80%, and a median progression-free survival of 3.2 months following treatment with icotinib (J Clin Oncol 35, 2017 (suppl; abstr e14050)).",Actionable,11154,3908,non-small cell lung carcinoma,DOID,3321,EGFR S768I,decreased response,769,Icotinib,1956,None,,,
79,Clinical Study,"In a retrospective clinical study, non-small cell lung cancer patients harboring EGFR S768I demonstrated a median progression-free survival of 2.7 months following treatment with EGFR tyrosine kinase inhibitors such as Tarceva (erlotinib), Iressa (gefitinib), or icotinib, compared to 10.8 months in patients with EGFR L858R  and EGFR exon 19 deletions (PMID: 27468240).",Actionable,7803,3908,non-small cell lung carcinoma,DOID,3321,EGFR S768I,decreased response,769,Icotinib,1956,27468240,,,
80,Clinical Study,"In a prospective clinical study, Gilotrif (afatinib) treatment resulted in stable disease in a non-small cell lung carcinoma patient harboring EGFR S768I (PMID: 26354527).",Actionable,3367,3908,non-small cell lung carcinoma,DOID,3321,EGFR S768I,sensitive,623,Afatinib,1956,26354527,,,
81,Phase II,"In a post-hoc analysis of Gilotrif (afatinib) activity in Phase II and Phase III clinical trials, 100% (8/8) of non-small cell lung cancer patients harboring EGFR S768I mutations were found to have demonstrated an objective response, with a mean progression-free survival of 14.7 months (PMID: 26051236).",Actionable,3250,3908,non-small cell lung carcinoma,DOID,3321,EGFR S768I,sensitive,623,Afatinib,1956,26051236,,,
82,Preclinical,"In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) worked synergistically to inhibit survival of glioblastoma cell lines harboring mutations in EGFR (EGFRvIII, A289T) and PTEN (I253N, N69D) in culture (PMID: 26561558).",Actionable,6038,3068,glioblastoma multiforme,DOID,22288,EGFR act mut EGFR A289T PTEN I253N PTEN N69D,sensitive,4008,Gefitinib + Linsitinib,1956,26561558,,,
83,Preclinical,"In a preclinical study, Dacomitinib and BMS-754807 worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR (A289T, EGFRvIII) and PTEN (N69D, I253N) mutations in culture (PMID: 26561558).",Actionable,6046,3068,glioblastoma multiforme,DOID,22288,EGFR act mut EGFR A289T PTEN I253N PTEN N69D,sensitive,4009,BMS-754807 + Dacomitinib,1956,26561558,,,
84,Clinical Study,"In a clinical case study, a lung adenocarcinoma patient harboring a compound EGFR L833V/H835L mutation responded to treatment with Iressa (gefitinib), with disease progression after 34 weeks of treatment (PMID: 21422421).",Actionable,6890,3910,lung adenocarcinoma,DOID,23970,EGFR L833V EGFR H835L,sensitive,751,Gefitinib,1956,21422421,,,
85,Preclinical,"In a preclinical study, Tarceva (erlotinib) inhibited EGFR phosphorylation and cell proliferation in transformed cells expressing the kinase domain duplication mutant EGFR L698_S1037dup in culture (PMID: 26286086).",Actionable,4638,10000003,Advanced Solid Tumor,JAX,18657,EGFR L698_S1037dup,sensitive,4,Erlotinib,1956,26286086,,,
86,Preclinical,"In a preclinical study, Tagrisso (osimertinib) inhibited EGFR phosphorylation and cell proliferation in transformed cells expressing kinase domain duplication mutant EGFR L698_S1037dup in culture (PMID: 26286086).",Actionable,4639,10000003,Advanced Solid Tumor,JAX,18657,EGFR L698_S1037dup,sensitive,660,Osimertinib,1956,26286086,,,
87,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited EGFR phosphorylation and cell proliferation in transformed cells expressing kinase domain duplication mutant EGFR L698_S1037dup in culture (PMID: 26286086).",Actionable,4640,10000003,Advanced Solid Tumor,JAX,18657,EGFR L698_S1037dup,sensitive,623,Afatinib,1956,26286086,,,
88,Clinical Study,"In a clinical study, a patient with EGFR L698_S1037dup expressing lung adenocarcinoma had a partial response after two cycles of Gilotrif (afatinib) after failing first line chemotherapy (PMID: 26286086).",Actionable,4641,3910,lung adenocarcinoma,DOID,18657,EGFR L698_S1037dup,sensitive,623,Afatinib,1956,26286086,,,
89,Clinical Study,"In a clinical case study, a patient with EGFR L698_S1037dup expressing lung adenocarcinoma had a partial response after two cycles of Gilotrif (afatinib), but subsequently developed resistance to the therapy after amplification of EGFR (PMID: 26286086).",Actionable,4642,3910,lung adenocarcinoma,DOID,18658,EGFR amp EGFR L698_S1037dup,resistant,623,Afatinib,1956,26286086,,,
90,Preclinical,"In a preclinical study, Tarceva (erlotinib) decreased viability of transformed cells expressing EGFR T263P in culture (PMID: 17177598).",Actionable,6918,10000003,Advanced Solid Tumor,JAX,24028,EGFR T263P,sensitive,4,Erlotinib,1956,17177598,,,
91,Clinical Study,"In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L747_S752del had a partial response to Iressa (gefitinib) therapy (PMID: 18981003).",Actionable,3052,3910,lung adenocarcinoma,DOID,4963,EGFR L747_S752del,sensitive,751,Gefitinib,1956,18981003,,,
92,Clinical Study,"In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L747_S752del that developed Iressa (gefitinib) resistance was demonstrated to have acquired an EGFR T790M mutation (PMID: 18981003).",Actionable,3055,3910,lung adenocarcinoma,DOID,11381,EGFR L747_S752del EGFR T790M,resistant,751,Gefitinib,1956,18981003,,,
93,Clinical Study,"In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L747_S752del and EGFR T790M was found to rapidly progress on Tarceva (erlotinib) therapy (PMID: 18981003).",Actionable,3056,3910,lung adenocarcinoma,DOID,11381,EGFR L747_S752del EGFR T790M,resistant,4,Erlotinib,1956,18981003,,,
94,Preclinical,"In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR amplification, EGFRvIII, and PTEN R308C in culture (PMID: 26561558).",Actionable,6037,3068,glioblastoma multiforme,DOID,22287,EGFR amp EGFR act mut PTEN R308C,sensitive,4008,Gefitinib + Linsitinib,1956,26561558,,,
95,Preclinical,"In a preclinical study, Dacomitinib and BMS-754807 worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR amplification, EGFRvIII, and PTEN R308C in culture (PMID: 26561558).",Actionable,6045,3068,glioblastoma multiforme,DOID,22287,EGFR amp EGFR act mut PTEN R308C,sensitive,4009,BMS-754807 + Dacomitinib,1956,26561558,,,
96,Preclinical - Cell line xenograft,"In a preclinical study, ABT-414 induced cytoxicity in a glioblastoma cell line harboring amplified EGFR vIII (exon 2-7 deletion) in culture, and induced complete tumor regression in cell line xenograft models of glioblastoma harboring amplified EGFR vIII (PMID: 26846818).",Actionable,6981,3068,glioblastoma multiforme,DOID,24170,EGFR act mut EGFR amp,predicted â€“ sensitive,976,ABT-414,1956,26846818,,,
97,Preclinical - Cell line xenograft,"In a preclinical study, ABT-414 in combination with Temodar (temozolomide) and radiotherapy inhibited tumor growth and resulted in tumor growth delay in a glioblastoma multiforme cell line xenograft model harboring amplified EGFR vIII (exon 2-7 deletion), with increased efficacy compared to the combination of Temodar (temozolomide) and radiotherapy (PMID: 26846818).",Actionable,6994,3068,glioblastoma multiforme,DOID,24170,EGFR act mut EGFR amp,predicted â€“ sensitive,4346,ABT-414 + Temozolomide + Radiotherapy,1956,26846818,,,
98,Phase Ib/II,"In a Phase Ib/II clinical trial, the combination of AUY922 and Tarceva (erlotinib) demonstrated limited clinical benefit in patients with EGFR-mutant non-small cell carcinoma with acquired resistance to EGFR tyrosine kinase inhibitors, including patients with EGFR T790M, with 16% (4/25) patients achieving partial response (PMID: 25870087).",Actionable,3263,3908,non-small cell lung carcinoma,DOID,13014,EGFR act mut EGFR T790M,no benefit,2799,AUY922 + Erlotinib,1956,25870087,,,
99,Phase II,"In a Phase II trial, Avastin (bevacizumab) and Tarceva (erlotinib) combination treatment resulted in a median progression-free survival of 16.0 months and a 12 month progression-free survival of 68% (25/37) in treatment-naive lung adenocarcinoma patients harboring activating EGFR mutations (exon 19 deletion or L858R) and EGFR T790M (PMID: 28408243).",Actionable,10689,3910,lung adenocarcinoma,DOID,13014,EGFR act mut EGFR T790M,sensitive,1146,Bevacizumab + Erlotinib,1956,28408243,,,
100,Phase II,"In a Phase II trial, Avastin (bevacizumab) and Tarceva (erlotinib) combination treatment resulted in a median progression-free survival of 13.2 months and a 12 month progression-free survival of 55% (60/109) in treatment-naive lung adenocarcinoma patients harboring activating EGFR mutations (exon 19 deletion or L858R) (PMID: 28408243).",Actionable,10688,3910,lung adenocarcinoma,DOID,423,EGFR act mut,sensitive,1146,Bevacizumab + Erlotinib,1956,28408243,,,
101,Phase I,"In a Phase I trial, Glesatinib (MGCD265) and Tarceva (erlotinib) combination treatment resulted in partial response in a non-small cell lung carcinoma patient harboring an EGFR activating mutation (J Clin Oncol 30, 2012 (suppl; abstr e13602)).",Actionable,5291,3908,non-small cell lung carcinoma,DOID,423,EGFR act mut,predicted â€“ sensitive,1126,MGCD265 + Erlotinib,1956,None,,,
102,Phase II,"In a Phase II trial, Gilotrif (afatinib) treatment, when compared to Iressa (gefitinib), resulted in statistically significant improvement of progression free survival (11.0 vs 10.9 months, HR 0.74, p=0.0178), time-to-treatment failure (13.7 vs 11.5 months, HR 0.75, p=0.0136), and objective response rate (72.5% vs 56%, odd ratio 2.121, p=0.0018) (PMID: 28169392).",Actionable,10235,3908,non-small cell lung carcinoma,DOID,423,EGFR act mut,sensitive,623,Afatinib,1956,28169392,,,
103,Preclinical - Cell line xenograft,"In a preclinical study, Rociletinib (CO-1686) inhibited tumor growth in xenograft models of human non-small cell lung cancer cell lines harboring EGFR activating mutations (PMID: 24065731). ",Actionable,86,3908,non-small cell lung carcinoma,DOID,423,EGFR act mut,sensitive,1003,CO1686,1956,24065731,,,
104,Phase II,"In a Phase II study, XL647 demonstrated antitumor activity and increased progression-free survival in non-small cell lung cancer patients harboring EGFR activating mutations (PMID: 22722787).",Actionable,1310,3908,non-small cell lung carcinoma,DOID,423,EGFR act mut,sensitive,967,XL647,1956,22722787,,,
105,Preclinical,"In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFRvIII in culture (PMID: 26561558).",Actionable,6042,3068,glioblastoma multiforme,DOID,423,EGFR act mut,sensitive,4008,Gefitinib + Linsitinib,1956,26561558,,,
106,Preclinical - Cell culture,"In a preclinical study, AP32788 inhibited growth of transformed cell lines over expressing EGFR activating mutations in culture, regardless of the presence or absence of EGFR T790M (AACR, Cancer Res: April 2016; Volume 57, Abstract #2644).",Actionable,5912,10000003,Advanced Solid Tumor,JAX,423,EGFR act mut,sensitive,3981,AP32788,1956,None,,,
107,Preclinical,"In a preclinical study, Dacomitinib and BMS-754807 worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFRvIII in culture (PMID: 26561558).",Actionable,6043,3068,glioblastoma multiforme,DOID,423,EGFR act mut,sensitive,4009,BMS-754807 + Dacomitinib,1956,26561558,,,
108,Phase I,"In a Phase I trial, ABT-806 treatment in patients with advanced solid tumors that often express EGFR amplification or EGFR vIII was well-tolerated, demonstrated safety, and resulted in stable disease in two patients (PMID: 25895099). ",Actionable,6719,10000003,Advanced Solid Tumor,JAX,423,EGFR act mut,predicted â€“ sensitive,4256,ABT-806,1956,25895099,,,
109,Phase II,"In a Phase II trial, non-small cell lung cancer patients harboring EGFR activating mutations treated with Tarceva (erlotinib), in combination with MK-2206, demonstrated a 9% (4/45) response rate, which did not reach the primary endpoint rate of 20% or more, therefore, indicating no benefit (PMID: 26106072). ",Actionable,3298,3908,non-small cell lung carcinoma,DOID,423,EGFR act mut,no benefit,1097,Erlotinib + MK2206,1956,26106072,,,
110,Phase II,"In a Phase II clinical trial, progression-free survival at 4 months was 95.5% in patients with EGFR-mutant non-small cell lung cancer following treatment with dacomitinib, compared to 76.8% in the overall treatment population (PMID: 25456362).",Actionable,2423,3908,non-small cell lung carcinoma,DOID,423,EGFR act mut,sensitive,714,Dacomitinib,1956,25456362,,,
111,Phase III,"In a Phase III trial, dacomitinib demonstrated superior efficacy compared to Iressa (gefitinib) as first-line therapy in non-small cell lung cancer patients harboring activating mutations in EGFR, resulting in a median progression-free survival of 14.7 months, compared to 9.2 months with Iressa (gefitinib) (J Clin Oncol 35, 2017 (suppl; abstr LBA9007); NCT01774721).",Actionable,11670,3908,non-small cell lung carcinoma,DOID,423,EGFR act mut,sensitive,714,Dacomitinib,1956,None,,,
112,Phase I,"In a Phase I trial, ASP8273 demonstrated preliminary antitumor activity in non-small cell lung patients harboring EGFR activating mutations (J Clin Oncol 33, 2015 (suppl; abstr 8014).",Actionable,2425,3908,non-small cell lung carcinoma,DOID,423,EGFR act mut,sensitive,1082,ASP8273,1956,None,,,
113,Phase I,"In a Phase I trial, Nerlynx (neratinib) demonstrated limited clinical activity in EGFR-mutant non-small cell lung cancer patients with prior EGFR TKI therapy, with a response rate of 3.4% (3/88), stable disease as best response in 50% (44/88), and prolonged stable disease in 10%, (9/88) (PMID: 20479403).",Actionable,2563,3908,non-small cell lung carcinoma,DOID,423,EGFR act mut,decreased response,828,Neratinib,1956,20479403,,,
114,Preclinical - Cell line xenograft,"In a preclinical study, non-small cell lung cancer cell lines harboring activating EGFR mutations demonstrated sensitivity to the combination of amlexanox and Selumetinib (AZD6244), resulting in synergistic growth inhibition in culture and reduced tumor growth in xenograft models (PMID: 27287717).",Actionable,9781,3908,non-small cell lung carcinoma,DOID,423,EGFR act mut,sensitive,5229,Amlexanox + Selumetinib,1956,27287717,,,
115,Phase II,"In a Phase II trial, non-small cell lung cancer patients with EGFR mutations demonstrated a median progression-free survival of 10.8 months, overall survival of 31.0 months, an overall response rate of 66.2% (137/207), and a disease control rate of 82.6% (2 complete responses; 135 partial responses, and 34 stable disease) following treatment with Tarceva (erlotinib) (PMID: 26720423).",Actionable,5303,3908,non-small cell lung carcinoma,DOID,423,EGFR act mut,predicted â€“ sensitive,4,Erlotinib,1956,26720423,,,
116,Phase III,"In a Phase III trial, a trend toward disease free survival was observed in non-small cell lung cancer patients harboring EGFR activating mutations when treated with Tarceva (erlotinib) vs placebo in the adjuvant setting, but significance was not demonstrated due to study design (PMID: 26324372).",Actionable,4438,3908,non-small cell lung carcinoma,DOID,423,EGFR act mut,predicted â€“ sensitive,4,Erlotinib,1956,26324372,,,
117,Phase III,"In a Phase III trial, adjuvant Iressa (gefitinib) treatment resulted in prolonged disease-free survival (28.7 vs 18.0 months) compared to Navelbine (vinorelbine) and Platinol (cisplatin) combination in completely resected non-small cell lung cancer patients harboring EGFR-activating mutations (J Clin Oncol 35, 2017 (suppl; abstr 8500)).",Actionable,11141,3908,non-small cell lung carcinoma,DOID,423,EGFR act mut,sensitive,751,Gefitinib,1956,None,,,
118,Clinical Study,Iressa (gefitinib) has been recommended as a first-line treatment in patients with EGFR activating mutations (PMID: 22997455).,Actionable,356,3908,non-small cell lung carcinoma,DOID,423,EGFR act mut,sensitive,751,Gefitinib,1956,22997455,,,
119,Phase III,"In a Phase III clinical trial, Iressa (gefitinib) treatment resulted in an objective response rate of 71.2% (94/132) and increased progression-free survival in non-small cell lung cancer patients harboring EGFR activating mutations (PMID: 19692680).",Actionable,1873,3908,non-small cell lung carcinoma,DOID,423,EGFR act mut,sensitive,751,Gefitinib,1956,19692680,,,
120,Phase Ib/II,"In a Phase Ib/II clinical trial, the combination of AUY922 and Tarceva (erlotinib) demonstrated limited clinical benefit in patients with EGFR-mutant non-small cell carcinoma with acquired resistance to EGFR tyrosine kinase inhibitors, with 16% (4/25) patients achieving partial response (PMID: 25870087).",Actionable,3262,3908,non-small cell lung carcinoma,DOID,423,EGFR act mut,no benefit,2799,AUY922 + Erlotinib,1956,25870087,,,
121,Preclinical - Cell line xenograft,"In a preclinical study, Sapitinib (AZD8931) inhibited EGFR, ERBB2, and ERBB3 kinase activity, and inhibited growth in several non-small cell lung cancer cell lines and xenograft models, including those with EGFR activating mutations (PMID: 20145185).",Actionable,1702,3908,non-small cell lung carcinoma,DOID,423,EGFR act mut,sensitive,910,Sapitinib,1956,20145185,,,
122,Preclinical - Pdx,"In a preclinical study, ABT-414 induced tumor regression in a patient-derived xenograft model of glioblastoma multiforme harboring amplified wild-type EGFR and EGFR vIII (exon 2-7 deletion) (PMID: 26846818).",Actionable,6991,3068,glioblastoma multiforme,DOID,24172,EGFR amp EGFR wild-type EGFR act mut,predicted â€“ sensitive,976,ABT-414,1956,26846818,,,
123,Phase I,"In a Phase I trial, MM-151 treatment resulted in marked reduction of EGFR G465E in circulating cell-free tumor DNA and reduced tumor size in a colorectal cancer patient harboring both EGFR G465E and EGFR G465R (PMID: 26843189).",Actionable,6647,9256,colorectal cancer,DOID,23660,EGFR G465E EGFR G465R,sensitive,821,MM-151,1956,26843189,,,
124,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7641,9256,colorectal cancer,DOID,25926,BRAF V600E EGFR G465R,resistant,342,Vemurafenib,1956,27312529,,,
125,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Erbitux (cetuximab) in culture (PMID: 27312529).",Actionable,7639,9256,colorectal cancer,DOID,25926,BRAF V600E EGFR G465R,resistant,694,Cetuximab,1956,27312529,,,
126,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Vectibix (panitumumab) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).",Actionable,7643,9256,colorectal cancer,DOID,25926,BRAF V600E EGFR G465R,resistant,1717,Vemurafenib + Panitumumab,1956,27312529,,,
127,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Iressa (gefitinib) and Zelboraf (vemurafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7645,9256,colorectal cancer,DOID,25926,BRAF V600E EGFR G465R,sensitive,1709,Vemurafenib + Gefitinib,1956,27312529,,,
128,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7694,9256,colorectal cancer,DOID,25926,BRAF V600E EGFR G465R,sensitive,4542,Cetuximab + Dabrafenib + SCH772984,1956,27312529,,,
129,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Vectibix (panitumumab) in culture (PMID: 27312529).",Actionable,7640,9256,colorectal cancer,DOID,25926,BRAF V600E EGFR G465R,resistant,845,Panitumumab,1956,27312529,,,
130,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment in culture, likely due to the acquired secondary resistance mutation of EGFR G465R (PMID: 27312529).",Actionable,7627,9256,colorectal cancer,DOID,25926,BRAF V600E EGFR G465R,resistant,1711,Vemurafenib + Cetuximab,1956,27312529,,,
131,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) were resistant to Iressa (gefitinib) in culture (PMID: 27312529).",Actionable,7642,9256,colorectal cancer,DOID,25926,BRAF V600E EGFR G465R,resistant,751,Gefitinib,1956,27312529,,,
132,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired an EGFR G465R mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7692,9256,colorectal cancer,DOID,25926,BRAF V600E EGFR G465R,sensitive,4544,Dabrafenib + SCH772984,1956,27312529,,,
133,Phase I,"In a Phase I trial, MM-151 treatment resulted in reduction of EGFR S464L and stabilization of EGFR G465R in circulating cell-free tumor DNA and prolonged stable disease in a colorectal cancer patient harboring both EGFR G465R and EGFR S464L (PMID: 26843189).",Actionable,6648,9256,colorectal cancer,DOID,23659,EGFR G465R EGFR S464L,sensitive,821,MM-151,1956,26843189,,,
134,Preclinical,"In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR G465R in culture (PMID: 26843189).",Actionable,6635,9256,colorectal cancer,DOID,23654,EGFR G465R,sensitive,821,MM-151,1956,26843189,,,
135,Preclinical - Cell line xenograft,"In a preclinical study, SYM004 inhibited EGFR downstream signaling and proliferation of a colorectal cancer cell line harboring EGFR G465R in culture, and induced tumor regression in xenograft models (PMID: 26888827).",Actionable,9308,9256,colorectal cancer,DOID,23654,EGFR G465R,sensitive,931,SYM004,1956,26888827,,,
136,Clinical Study,"In a clinical study, a patient with Erbitux (cetuximab)-resistant metastatic colorectal cancer harboring EGFR G465R demonstrated stable disease for 15 weeks following treatment with SYM004 (PMID: 26888827). ",Actionable,9309,9256,colorectal cancer,DOID,23654,EGFR G465R,sensitive,931,SYM004,1956,26888827,,,
137,Preclinical,"In a preclinical study, colorectal cancer cell lines over expressing EGFR G465R were resistant to Vectibix (panitumumab)-induced growth inhibition in culture (PMID: 26843189).",Actionable,6636,9256,colorectal cancer,DOID,23654,EGFR G465R,resistant,845,Panitumumab,1956,26843189,,,
138,Preclinical,"In a preclinical study, colorectal cancer cell lines over expressing EGFR G465R were resistant to Erbitux (cetuximab)-induced growth inhibition in culture (PMID: 26843189).",Actionable,6637,9256,colorectal cancer,DOID,23654,EGFR G465R,resistant,694,Cetuximab,1956,26843189,,,
139,Clinical Study,"In a retrospective analysis, non-small cell lung cancer patients harboring EGFR G719 mutations demonstrated a response rate of 58% and disease control rate of 73.68%, and a median progression-free survival of 2.8 months following treatment with icotinib (J Clin Oncol 35, 2017 (suppl; abstr e14050)).",Actionable,11155,3908,non-small cell lung carcinoma,DOID,1207,EGFR G719X,decreased response,769,Icotinib,1956,None,,,
140,Clinical Study,"In a prospective clinical study, Gilotrif (afatinib) treatment resulted in partial response in 14% (1/7), stable disease in 43% (3/7), and progressive disease in 43% (3/7) of non-small cell lung carcinoma patients carrying an EGFR G719 mutation (PMID: 26354527).",Actionable,3361,3908,non-small cell lung carcinoma,DOID,1207,EGFR G719X,sensitive,623,Afatinib,1956,26354527,,,
141,Phase III,"In Phase III trials, non-small cell lung carcinoma patients harboring EGFR G719X mutations (G719A, C, or S) demonstrated a response rate of 78% (14/18) following treatment with Gilotrif (afatinib) (PMID: 24790411).",Actionable,1861,3908,non-small cell lung carcinoma,DOID,1207,EGFR G719X,sensitive,623,Afatinib,1956,24790411,,,
142,Phase II,"In a Phase II clinical trial, treatment with Nerlynx (neratinib) resulted in partial response in 75% (3/4) and stable disease in 25% (1/4) of non-small cell lung cancer patients harboring EGFR G719 mutations (PMID: 20479403).",Actionable,3729,3908,non-small cell lung carcinoma,DOID,1207,EGFR G719X,sensitive,828,Neratinib,1956,20479403,,,
143,Clinical Study,"In an analysis of published clinical data, 14/18 (78%) non-small cell lung cancer patients harboring an EGFR G719X (X=A, C, D, or S) mutation were found to achieve disease control following treatment with EGFR tyrosine kinase inhibitors, such as Iressa (gefitinib) (PMID: 23344264).",Actionable,751,3908,non-small cell lung carcinoma,DOID,1207,EGFR G719X,sensitive,751,Gefitinib,1956,23344264,,,
144,Clinical Study,"In an analysis of published clinical data, 14/18 (78%) non-small cell lung cancer patients harboring an EGFR G719X (X=A, C, D, or S) mutation were found to achieve disease control following treatment with EGFR tyrosine kinase inhibitors, such as Tarceva (erlotinib) (PMID: 23344264).",Actionable,750,3908,non-small cell lung carcinoma,DOID,1207,EGFR G719X,sensitive,4,Erlotinib,1956,23344264,,,
145,Preclinical,"In a preclinical study, transformed cells expressing an EGFR L858R/EGFR T790M/EGFR Q791R triple mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).",Actionable,3095,10000003,Advanced Solid Tumor,JAX,11732,EGFR L858R EGFR Q791R EGFR T790M,resistant,1003,CO1686,1956,25948633,,,
146,Preclinical,"In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR L858R/EGFR T790M/EGFR Q791R triple mutation in culture (PMID: 25948633).",Actionable,3097,10000003,Advanced Solid Tumor,JAX,11732,EGFR L858R EGFR Q791R EGFR T790M,sensitive,660,Osimertinib,1956,25948633,,,
147,Preclinical - Pdx,"In a preclinical study, treatment with Mekinist (trametinib) inhibited tumor growth and reduced ERK signaling in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).",Actionable,11661,4464,collecting duct carcinoma,DOID,28180,BRAF D594N BRAF G466A EGFR over exp MET over exp,sensitive,2,Trametinib,1956,28783719,,,
148,Preclinical - Pdx,"In a preclinical study, treatment with Capmatinib (INC280) inhibited tumor growth and reduced ERK signaling in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).",Actionable,11660,4464,collecting duct carcinoma,DOID,28180,BRAF D594N BRAF G466A EGFR over exp MET over exp,sensitive,1065,Capmatinib,1956,28783719,,,
149,Preclinical - Pdx,"In a preclinical study, the combination of Mekinist (trametinib) and Capmatinib (INC280) induced tumor regression in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).",Actionable,11662,4464,collecting duct carcinoma,DOID,28180,BRAF D594N BRAF G466A EGFR over exp MET over exp,sensitive,6103,INC280 + Trametinib,1956,28783719,,,
150,Preclinical - Cell line xenograft,"In a preclinical study, ABT-414 demonstrated cytoxicity against a lung squamous cell carcinoma cell line with EGFR over expression in culture and induced tumor regression in EGFR over expressing lung squamous cell carcinoma cell line xenograft models (PMID: 26846818).",Actionable,6934,3907,lung squamous cell carcinoma,DOID,2419,EGFR over exp,sensitive,976,ABT-414,1956,26846818,,,
151,Preclinical - Cell line xenograft,"In a preclinical study, BGB-283 inhibited Egfr phosphorylation in Egfr over expressing squamous cell carcinoma cells in culture, and inhibited tumor growth in cell line xenograft models (PMID: 26208524).",Actionable,8058,1749,squamous cell carcinoma,DOID,2419,EGFR over exp,sensitive,4025,BGB-283,1956,26208524,,,
152,Preclinical - Cell line xenograft,"In a preclinical study, TAK-285 inhibited growth of squamous cell carcinoma cells harboring EGFR over expression in culture and in cell line xenograft models (PMID: 23983820).",Actionable,7849,1749,squamous cell carcinoma,DOID,2419,EGFR over exp,sensitive,2135,TAK-285,1956,23983820,,,
153,Preclinical - Cell culture,"In a preclinical study, BGB-283 inhibited proliferation of Egfr over expressing lung cancer cells in culture (PMID: 26208524).",Actionable,8065,1324,lung cancer,DOID,2419,EGFR over exp,sensitive,4025,BGB-283,1956,26208524,,,
154,Preclinical,"In a preclinical study, treatment with GA201 resulted in inhibition of EGFR signaling and induced antibody-dependent cell-mediated cytotoxicity towards EGFR-over expressing squamous cell carcinoma cells in culture (PMID: 23209031).",Actionable,3780,1749,squamous cell carcinoma,DOID,2419,EGFR over exp,sensitive,3154,GA201,1956,23209031,,,
155,Preclinical - Cell culture,"In a preclinical study, head and neck squamous cell carcinoma cells harboring FGFR1 amplification and over expressing EGFR demonstrated sensitivity to the combination treatment of AZD4547 and Iressa (gefitinib) in culture, which also resulted in a synergistic effect (PMID: 26936917). ",Actionable,7833,5520,head and neck squamous cell carcinoma,DOID,26058,EGFR over exp FGFR1 amp,sensitive,4585,AZD4547 + Gefitinib,1956,26936917,,,
156,Preclinical - Cell culture,"In a preclinical study, head and neck squamous cell carcinoma cells with EGFR over expression and FGFR1 amplification demonstrated resistance to treatment with AZD4547 in culture (PMID: 26936917). ",Actionable,7830,5520,head and neck squamous cell carcinoma,DOID,26058,EGFR over exp FGFR1 amp,resistant,654,AZD4547,1956,26936917,,,
157,Preclinical - Cell culture,"In a preclinical study, the combination of Triciribine (API-2) and Mekinist (trametinib) worked synergistically to inhibit growth of a pancreatic adenocarcinoma cell line with wild-type KRAS that demonstrated high EGFR expression and activation in culture (PMID: 28957417).",Actionable,12146,4074,pancreatic adenocarcinoma,DOID,28493,EGFR over exp KRAS wild-type,sensitive,6312,Trametinib + Triciribine,1956,28957417,,,
158,Preclinical - Cell culture,"In a preclinical study, the combination of Gilotrif (afatinib) and Mekinist (trametinib) worked synergistically to inhibit growth of a pancreatic adenocarcinoma cell line with wild-type KRAS that demonstrated high EGFR expression and activation in culture (PMID: 28957417).",Actionable,12145,4074,pancreatic adenocarcinoma,DOID,28493,EGFR over exp KRAS wild-type,sensitive,4482,Afatinib + Trametinib,1956,28957417,,,
159,Preclinical - Cell culture,"In a preclinical study, over expression of wild type EGFR in colorectal cancer cells harboring BRAF V600E resulted in sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).",Actionable,7631,9256,colorectal cancer,DOID,25929,BRAF V600E EGFR over exp,resistant,3773,Selumetinib + Vemurafenib,1956,27312529,,,
160,Preclinical - Pdx & cell culture,"In a preclinical study, Sapitinib (AZD8931) demonstrated antitumor activity in patient-derived, EGFR over expressing inflammatory breast cancer cell lines expressing low level of Erb2 (Her2) protein in culture and in xenograft models (PMID: 24886365).",Actionable,964,6263,inflammatory breast carcinoma,DOID,23650,EGFR over exp ERBB2 dec exp,sensitive,910,Sapitinib,1956,24886365,,,
161,Preclinical - Pdx & cell culture,"In a preclinical study, combination of Sapatinib (AZD8931) and Taxol (paclitaxel) demonstrated enhanced antitumor activity in patient-derived, EGFR over expressing inflammatory breast cancer cell lines expressing low level of Erbb2 (Her2) protein in culture and in xenograft models (PMID: 24886365).",Actionable,965,6263,inflammatory breast carcinoma,DOID,23650,EGFR over exp ERBB2 dec exp,sensitive,1416,Sapitinib + Paclitaxel,1956,24886365,,,
162,Preclinical - Cell culture,"In a preclinical study, head and neck squamous cell carcinoma cells harboring FGFR2 amplification and over expressing EGFR demonstrated resistance to treatment with AZD4547 in culture (PMID: 26936917). ",Actionable,7832,5520,head and neck squamous cell carcinoma,DOID,26059,EGFR over exp FGFR2 amp,resistant,654,AZD4547,1956,26936917,,,
163,Preclinical - Cell culture,"In a preclinical study, head and neck squamous cell carcinoma cells harboring FGFR2 amplification and over expressing EGFR demonstrated sensitivity to the combination treatment of AZD4547 and Iressa (gefitinib) in culture, which also resulted in a moderate synergistic effect (PMID: 26936917). ",Actionable,7835,5520,head and neck squamous cell carcinoma,DOID,26059,EGFR over exp FGFR2 amp,sensitive,4585,AZD4547 + Gefitinib,1956,26936917,,,
164,Phase III,"In Phase III clinical trials, patients with NSCLC tumors harboring an EGFR G719X (X=A, C, or S) mutation responded to EGFR tyrosine kinase inhibitors including dacomitinib (PMID: 24857124).",Actionable,756,3908,non-small cell lung carcinoma,DOID,1046,EGFR G719C,sensitive,714,Dacomitinib,1956,24857124,,,
165,Clinical Study,"In an analysis of published clinical data, 14/18 (78%) non-small cell lung cancer patients harboring an EGFR G719X (X=A, C, D, or S) mutation were found to achieve disease control following treatment with EGFR tyrosine kinase inhibitors, such as Tarceva (erlotinib) (PMID: 23344264).",Actionable,758,3908,non-small cell lung carcinoma,DOID,1046,EGFR G719C,predicted â€“ sensitive,4,Erlotinib,1956,23344264,,,
166,Phase III,"In Phase III trials, non-small cell lung carcinoma patients harboring EGFR G719X mutations (G719A, C, or S) demonstrated a response rate of 78% (14/18) following treatment with Gilotrif (afatinib) (PMID: 24790411).",Actionable,753,3908,non-small cell lung carcinoma,DOID,1046,EGFR G719C,sensitive,623,Afatinib,1956,24790411,,,
167,Clinical Study,"In an analysis of published clinical data, 14/18 (78%) non-small cell lung cancer patients harboring an EGFR G719X (X=A, C, D, or S) mutation were found to achieve disease control following treatment with EGFR tyrosine kinase inhibitors, such as Iressa (gefitinib) (PMID: 23344264).",Actionable,760,3908,non-small cell lung carcinoma,DOID,1046,EGFR G719C,predicted â€“ sensitive,751,Gefitinib,1956,23344264,,,
168,Preclinical - Cell culture,"In a preclinical study, treatment with the combination of Selumetinib (AZD6244) and Tagrisso (osimertinib) resulted in increased inhibition of ERK phosphorylation and proliferation compared to either agent alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).",Actionable,11307,1324,lung cancer,DOID,27945,EGFR exon 19 del EGFR T790M,sensitive,2225,Osimertinib + Selumetinib,1956,28416483,,,
169,Preclinical - Cell line xenograft,"In a preclinical study, Tagrisso (osimertinib) and Sprycel (dasatinib) in combination resulted in increased PARP cleavage and inhibition of proliferation in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M compared to Tagrisso (osimertinib) alone, and inhibited tumor growth in xenograft models, with 3 out of 7 models demonstrating no tumor rebound after cessation of therapy (PMID: 28416483).",Actionable,11303,1324,lung cancer,DOID,27945,EGFR exon 19 del EGFR T790M,sensitive,4946,Dasatinib + Osimertinib,1956,28416483,,,
170,Preclinical - Cell culture,"In a preclinical study, treatment with the combination of TAK-632 and Tagrisso (osimertinib) resulted in increased inhibition of ERK phosphorylation and proliferation compared to either agent alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).",Actionable,11306,1324,lung cancer,DOID,27945,EGFR exon 19 del EGFR T790M,sensitive,5937,Osimertinib + TAK-632,1956,28416483,,,
171,Preclinical,"In a preclinical study, EGFR C797S conferred resistance to growth inhibition by Rociletinib (CO-1686) when expressed on the same allele as EGFR L858R and T790M in transformed cells in culture (PMID: 25939061).",Actionable,3697,10000003,Advanced Solid Tumor,JAX,14859,EGFR C797S EGFR L858R EGFR T790M,resistant,1003,CO1686,1956,25939061,,,
172,Preclinical,"In a preclinical study, expression of EGFR C797S on the same allele as both EGFR L858R and T790M in transformed cell lines resulted in resistance to growth inhibition by Tagrisso (osimertinib) in culture (PMID: 25939061).",Actionable,3696,10000003,Advanced Solid Tumor,JAX,14859,EGFR C797S EGFR L858R EGFR T790M,resistant,660,Osimertinib,1956,25939061,,,
173,Preclinical - Cell culture,"In a preclinical study, Erbitux (cetuximab) inhibited growth of transformed cells expressing a EGFR L858R/T790M/C797S triple mutation in culture (PMID: 25948633).",Actionable,10304,10000003,Advanced Solid Tumor,JAX,14859,EGFR C797S EGFR L858R EGFR T790M,sensitive,694,Cetuximab,1956,25948633,,,
174,Preclinical,"In a preclinical study, EAI045 and Erbitux (cetuximab) combination treatment induced tumor regression in an EGFR L858R/T790M/C797S-mutant-driven lung cancer mouse model (PMID: 27251290).",Actionable,7596,1324,lung cancer,DOID,14859,EGFR C797S EGFR L858R EGFR T790M,sensitive,4521,Cetuximab + EAI045,1956,27251290,,,
175,Preclinical - Cell culture,"In a preclinical study, EAI045 and Erbitux (cetuximab) synergistically inhibited proliferation of transformed cells over expressing EGFR that harbors concomitant C797S, L858R and T790M mutations in culture (PMID: 27251290).",Actionable,7597,10000003,Advanced Solid Tumor,JAX,14859,EGFR C797S EGFR L858R EGFR T790M,sensitive,4521,Cetuximab + EAI045,1956,27251290,,,
176,Preclinical,"In a preclinical study, the combination of Tagrisso (osimertinib) and Selumetinib increased Parp cleavage, and highly suppressed phosphorylated Erk in human non-small cell lung cancer cells harboring EGFR exon 19 deletion, EGFR T790M, and a gain in KRAS in culture (PMID: 25870145).",Actionable,4500,3908,non-small cell lung carcinoma,DOID,18232,EGFR exon 19 del EGFR T790M KRAS amp,sensitive,2225,Osimertinib + Selumetinib,1956,25870145,,,
177,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion, EGFR T790M and amplified KRAS were resistant to Tagrisso (osimertinib) treatment in culture (PMID: 25870145).",Actionable,4475,3908,non-small cell lung carcinoma,DOID,18232,EGFR exon 19 del EGFR T790M KRAS amp,resistant,660,Osimertinib,1956,25870145,,,
178,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Iressa (gefitinib) after the emergence of EGFR T790M and amplified KRAS in culture (PMID: 25870145).",Actionable,4474,3908,non-small cell lung carcinoma,DOID,18232,EGFR exon 19 del EGFR T790M KRAS amp,resistant,751,Gefitinib,1956,25870145,,,
179,Preclinical,"In a preclinical study, expression of EGFR T790M in MET-amplified lung adenocarcinoma cells resulted in resistance to Tagrisso (osimertinib) in culture, consistent with MET amplification identified in tumor samples of lung adenocarcinoma patients harboring EGFR T790M that developed resistance to Tagrisso (osimertinib) (PMID: 27252416).",Actionable,8802,3910,lung adenocarcinoma,DOID,26437,EGFR T790M MET amp,resistant,660,Osimertinib,1956,27252416,,,
180,Clinical Study,"In an analysis of EGFR T790M-positive non-small cell lung cancer patients, emergence of MET amplification was identified in 26% (28/43) of patients with acquired resistance to Rociletinib (CO1686), and patients with MET amplification prior to Rociletinib (CO1686) treatment demonstrated a decreased response compared to patients without MET amplification (PMID: 27283993).",Actionable,9246,3908,non-small cell lung carcinoma,DOID,26437,EGFR T790M MET amp,resistant,1003,CO1686,1956,27283993,,,
181,Preclinical,"In a preclinical study, expression of EGFR T790M in MET-amplified lung adenocarcinoma cells resulted in resistance to Rociletinib (CO-1686) in culture, consistent with MET amplification identified in tumor samples of lung adenocarcinoma patients harboring EGFR T790M that developed resistance to Rociletinib (CO-1686) (PMID: 27252416).",Actionable,8801,3910,lung adenocarcinoma,DOID,26437,EGFR T790M MET amp,resistant,1003,CO1686,1956,27252416,,,
182,Preclinical - Cell culture,"In a preclinical study, acquisition of EGFR T790M was associated with resistance to Gilotrif (afatinib) in transformed cells expressing EGFR G719A in culture (PMID: 27913578).",Actionable,9923,10000003,Advanced Solid Tumor,JAX,27160,EGFR G719A EGFR T790M,resistant,623,Afatinib,1956,27913578,,,
183,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture (PMID: 23629727).",Actionable,8186,3908,non-small cell lung carcinoma,DOID,26185,EGFR L858R EGFR T790M PIK3CA G118D,sensitive,4657,Pimasertib + Regorafenib,1956,23629727,,,
184,Preclinical - Cell line xenograft,"In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited Mapk and Akt signaling, resulted in growth inhibition of non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture and in cell line xenograft models (PMID: 23629727).",Actionable,8181,3908,non-small cell lung carcinoma,DOID,26185,EGFR L858R EGFR T790M PIK3CA G118D,sensitive,1659,Pimasertib + Sorafenib,1956,23629727,,,
185,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture (PMID: 23629727).",Actionable,8177,3908,non-small cell lung carcinoma,DOID,26185,EGFR L858R EGFR T790M PIK3CA G118D,sensitive,4656,Everolimus + Pimasertib,1956,23629727,,,
186,Preclinical - Cell culture,"In a preclinical study, non-small cell lung cancer cells harboring EGFR L858R, T790M, and PIK3CA G118D demonstrated decreased response to Pimasertib (MSC1936369B) in culture (PMID: 23629727).",Actionable,8172,3908,non-small cell lung carcinoma,DOID,26185,EGFR L858R EGFR T790M PIK3CA G118D,decreased response,871,Pimasertib,1956,23629727,,,
187,Preclinical - Cell line xenograft,"In a preclinical study, Pimasertib (MSC1936369B) and BEZ235 combination treatment inhibited tumor growth in non-small cell lung cancer cell line xenograft models harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture (PMID: 23629727).",Actionable,8187,3908,non-small cell lung carcinoma,DOID,26185,EGFR L858R EGFR T790M PIK3CA G118D,sensitive,1660,Pimasertib + BEZ235,1956,23629727,,,
188,Preclinical,"In a preclinical study, lung adenocarcinoma cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S in cis were resistant to Iressa (gefitinib) induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297).",Actionable,5758,3910,lung adenocarcinoma,DOID,14858,EGFR C797S EGFR del exon 19 EGFR T790M,resistant,751,Gefitinib,1956,25964297,,,
189,Preclinical,"In a preclinical study, lung adenocarcinoma cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S in cis were resistant to WZ4002 induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297).",Actionable,5759,3910,lung adenocarcinoma,DOID,14858,EGFR C797S EGFR del exon 19 EGFR T790M,resistant,3075,WZ4002,1956,25964297,,,
190,Phase I,"In a Phase I clinical trial, 40% (6/15) of non-small cell lung cancer patients harboring an EGFR exon 19 deletion and EGFR T790M  developed resistance to Tagrisso (osimertinib) due to acquired EGFR C797S mutations (PMID: 25939061).",Actionable,3692,3908,non-small cell lung carcinoma,DOID,14858,EGFR C797S EGFR del exon 19 EGFR T790M,resistant,660,Osimertinib,1956,25939061,,,
191,Preclinical,"In a preclinical study, Iressa (gefitinib) treatment resulted in partial inhibition of EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S when T790M and C797S were expressed in trans, but no EGFR inhibition when T790M and C797S were expressed in cis (PMID: 25964297).",Actionable,5754,10000003,Advanced Solid Tumor,JAX,14858,EGFR C797S EGFR del exon 19 EGFR T790M,conflicting,751,Gefitinib,1956,25964297,,,
192,Preclinical,"In a preclinical study, EGFR C797S conferred resistance to growth inhibition by Rociletinib (CO-1686) when expressed on the same allele as an EGFR exon 19 deletion mutation and T790M in transformed cells in culture (PMID: 25939061).",Actionable,3695,10000003,Advanced Solid Tumor,JAX,14858,EGFR C797S EGFR del exon 19 EGFR T790M,resistant,1003,CO1686,1956,25939061,,,
193,Preclinical,"In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 deletion, EGFR T790M and EGFR C797S were resistant to WZ4002 induced suppression of EGFR signaling and growth inhibition in culture, regardless of the allelic context of EGFR T790M and EGFR C797S (PMID: 25964297).",Actionable,5745,3908,non-small cell lung carcinoma,DOID,14858,EGFR C797S EGFR del exon 19 EGFR T790M,resistant,3075,WZ4002,1956,25964297,,,
194,Preclinical,"In a preclinical study, WZ4002 treatment resulted in partial inhibition of EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S when T790M and C797S were expressed in trans, but no EGFR inhibition when T790M and C797S were expressed in cis (PMID: 25964297).",Actionable,5755,10000003,Advanced Solid Tumor,JAX,14858,EGFR C797S EGFR del exon 19 EGFR T790M,conflicting,3075,WZ4002,1956,25964297,,,
195,Preclinical,"In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 deletion, EGFR T790M and EGFR C797S were resistant to Iressa (gefitinib) induced suppression of EGFR signaling and growth inhibition in culture, regardless of the allelic context of EGFR T790M and EGFR C797S (PMID: 25964297).",Actionable,5744,3908,non-small cell lung carcinoma,DOID,14858,EGFR C797S EGFR del exon 19 EGFR T790M,resistant,751,Gefitinib,1956,25964297,,,
196,Preclinical,"In a preclinical study, transformed human cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S in cis were resistant to Gilotrif (afatinib) induced suppression of EGFR signaling in culture (PMID: 25964297).",Actionable,5757,10000003,Advanced Solid Tumor,JAX,14858,EGFR C797S EGFR del exon 19 EGFR T790M,resistant,623,Afatinib,1956,25964297,,,
197,Preclinical,"In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 deletion, EGFR T790M and EGFR C797S in cis were resistant to Gilotrif (afatinib) induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297).",Actionable,5746,3908,non-small cell lung carcinoma,DOID,14858,EGFR C797S EGFR del exon 19 EGFR T790M,resistant,623,Afatinib,1956,25964297,,,
198,Preclinical,"In a preclinical study, expression of EGFR C797S on the same allele as an EGFR exon 19 deletion and EGFR T790M in transformed cell lines resulted in resistance to growth inhibition by Tagrisso (osimertinib) in culture (PMID: 25939061).",Actionable,3694,10000003,Advanced Solid Tumor,JAX,14858,EGFR C797S EGFR del exon 19 EGFR T790M,resistant,660,Osimertinib,1956,25939061,,,
199,Preclinical,"In a preclinical study, non-small cell lung carcinoma cells harboring EGFR exon 19 deletion, EGFR T790M and EGFR C797S were resistant to the combination of Iressa (gefitinib) and WZ4002 when T790M and C797S were in cis, but were sensitive when EGFR T790M and EGFR C797S were in trans (PMID: 25964297).",Actionable,5747,3908,non-small cell lung carcinoma,DOID,14858,EGFR C797S EGFR del exon 19 EGFR T790M,conflicting,3921,Gefitinib + WZ4002,1956,25964297,,,
200,Preclinical,"In a preclinical study, Iressa (gefitinib) and WZ4002 combination treatment resulted in complete inhibition of EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S when T790M and C797S were expressed in trans, but no EGFR inhibition when T790M and C797S were expressed in cis (PMID: 25964297).",Actionable,5756,10000003,Advanced Solid Tumor,JAX,14858,EGFR C797S EGFR del exon 19 EGFR T790M,conflicting,3921,Gefitinib + WZ4002,1956,25964297,,,
201,Preclinical,"In a preclinical study, lung adenocarcinoma cells over expressing EGFR exon 19 deletion, EGFR T790M and EGFR C797S in cis were resistant to Gilotrif (afatinib) induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297).",Actionable,5760,3910,lung adenocarcinoma,DOID,14858,EGFR C797S EGFR del exon 19 EGFR T790M,resistant,623,Afatinib,1956,25964297,,,
202,Clinical Study,"In a clinical case study, a lung adenocarcinoma patient harboring an EGFR exon 19 deletion and EGFR T790M developed resistance to Tagrisso (osimertinib), and was found to have acquired high level amplification of MET (PMID: 27393507).",Actionable,9236,3910,lung adenocarcinoma,DOID,18241,EGFR exon 19 del EGFR T790M MET amp,resistant,660,Osimertinib,1956,27393507,,,
203,Clinical Study,"In a clinical case study, a lung adenocarcinoma patient harboring an EGFR exon 19 deletion and EGFR T790M and resistance to Tagrisso (osimertinib) following acquired MET amplification, demonstrated some improvement in symptoms with treatment with Xalkori (crizotinib) (PMID: 27393507).",Actionable,9238,3910,lung adenocarcinoma,DOID,18241,EGFR exon 19 del EGFR T790M MET amp,predicted â€“ sensitive,706,Crizotinib,1956,27393507,,,
204,Preclinical,"In a preclinical study, transformed cells expressing an EGFR L858R/EGFR T790M/EGFR L718Q triple mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).",Actionable,3075,10000003,Advanced Solid Tumor,JAX,11729,EGFR L858R EGFR L718Q EGFR T790M,resistant,1003,CO1686,1956,25948633,,,
205,Preclinical,"In a preclinical study, transformed cells expressing an EGFR L858R/EGFR T790M/EGFR L718Q triple mutation demonstrated resistance to AZD9291 in culture (PMID: 25948633).",Actionable,3092,10000003,Advanced Solid Tumor,JAX,11729,EGFR L858R EGFR L718Q EGFR T790M,resistant,660,Osimertinib,1956,25948633,,,
206,Preclinical - Cell line xenograft,"In a preclinical study, non-small cell lung cancer cells harboring the double mutation, EGFR L858R and EGFR T790M, demonstrated sensitivity to treatment with AC0010MA, resulting in inhibition of both cell growth and Egfr phosphorylation in culture, and tumor regression in xenograft models (PMID: 27573423). ",Actionable,9113,3908,non-small cell lung carcinoma,DOID,2422,EGFR L858R EGFR T790M,sensitive,2909,AC0010MA,1956,27573423,,,
207,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing EGFR L858R and T790M in culture (PMID: 27780853).",Actionable,9234,10000003,Advanced Solid Tumor,JAX,2422,EGFR L858R EGFR T790M,sensitive,634,AP26113,1956,27780853,,,
208,Preclinical - Cell culture,"In a preclinical study, the addition of Selumetinib (AZD6244) to treatment with Tagrisso (osimertinib) resulted in increased inhibition of proliferation in lung cancer cell lines harboring EGFR L858R and T790M in culture (PMID: 28416483).",Actionable,11314,1324,lung cancer,DOID,2422,EGFR L858R EGFR T790M,sensitive,2225,Osimertinib + Selumetinib,1956,28416483,,,
209,Clinical Study,"In a clinical case study, Tagrisso (osimertinib) resulted in a partial response and stable disease of brain metastases in a NSCLC patient harboring EGFR L858R and a secondary resistance mutation, EGFR T790M, which occurred post Tarceva (erlotinib) therapy (PMID: 27435396).",Actionable,8972,3908,non-small cell lung carcinoma,DOID,2422,EGFR L858R EGFR T790M,sensitive,660,Osimertinib,1956,27435396,,,
210,Phase I,"In a Phase I trial, AZD9291 treatment resulted in a response rate of 57% (24/24) in patients harboring both EGFR L858R and T790M mutations (PMID: 25923549).",Actionable,2158,3908,non-small cell lung carcinoma,DOID,2422,EGFR L858R EGFR T790M,sensitive,660,Osimertinib,1956,25923549,,,
211,Preclinical,"In a preclinical study, non-small cell carcinoma cancer cell lines harboring EGFR L858R and T790M mutations demonstrated resistance to growth inhibition by Tykerb (lapatinib) in culture (PMID: 18199554).",Actionable,3054,3908,non-small cell lung carcinoma,DOID,2422,EGFR L858R EGFR T790M,resistant,787,Lapatinib,1956,18199554,,,
212,Clinical Study,"In a clinical study, acquired EGFR T790M mutations were detected in 47.6% (20/42) of lung adenocarcinoma patients with acquired resistance to Gilotrif (afatinib), with 10/20 of those patients harboring EGFR L858R as their primary EGFR mutation (PMID: 26862733).",Actionable,4911,3910,lung adenocarcinoma,DOID,2422,EGFR L858R EGFR T790M,resistant,623,Afatinib,1956,26862733,,,
213,Preclinical,"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human non-small cell lung carcinoma cells harboring EGFR L858R EGFR T790M in culture (PMID: 21325073, PMID: 19238632).",Actionable,3134,3908,non-small cell lung carcinoma,DOID,2422,EGFR L858R EGFR T790M,sensitive,1040,PF-05212384,1956,21325073,19238632,,
214,Phase Ib/II,"In a Phase Ib/II trial, treatment with Rociletinib (CO-1686) resulted in an objective response rate of 53.3% (8/15) in non-small cell lung cancer patients harboring both EGFR L858R and EGFR T790M (PMID: 25923550).",Actionable,3119,3908,non-small cell lung carcinoma,DOID,2422,EGFR L858R EGFR T790M,sensitive,1003,CO1686,1956,25923550,,,
215,Preclinical - Pdx,"In a preclinical study, Rociletinib (CO-1686) inhibited tumor growth in human non-small cell lung cancer cell line and patient-derived xenograft models of non-small cell lung cancer harboring both EGFR L858R and EGFR T790M (PMID: 24065731).",Actionable,9486,3908,non-small cell lung carcinoma,DOID,2422,EGFR L858R EGFR T790M,sensitive,1003,CO1686,1956,24065731,,,
216,Clinical Study,"In a clinical case report, a non-small cell lung cancer patient that progressed on Iressa (gefitinib) was demonstrated to harbor EGFR L858R and a secondary EGFR T790M mutation (PMID: 15737014).",Actionable,1705,3908,non-small cell lung carcinoma,DOID,2422,EGFR L858R EGFR T790M,resistant,751,Gefitinib,1956,15737014,,,
217,Clinical Study,"In a clinical study, EGFR T790M mutations were associated with acquired resistance to Iressa (gefitinib) in non-small cell lung cancer patients harboring EGFR L858R (PMID: 22263058).",Actionable,6668,3908,non-small cell lung carcinoma,DOID,2422,EGFR L858R EGFR T790M,resistant,751,Gefitinib,1956,22263058,,,
218,Preclinical - Cell line xenograft,"In a preclinical study, the addition of Ganetespib overcame resistance to Tarceva (erlotinib) in cell line xenograft models of non-small cell lung cancer harboring EGFR L858R and EGFR T790M (PMID: 25077897).",Actionable,2293,3908,non-small cell lung carcinoma,DOID,2422,EGFR L858R EGFR T790M,sensitive,2802,Erlotinib + Ganetespib,1956,25077897,,,
219,Preclinical,"In a preclinical study, EGFR T790M was detected in animal models of EGFR L858R-induced lung adenocarcinoma, which developed  after repeated Gilotrif (afatinib) and Erbitux (cetuximab) combination treatments and resulted in drug resistance (PMID: 26341921).",Actionable,6653,3910,lung adenocarcinoma,DOID,2422,EGFR L858R EGFR T790M,resistant,4190,Afatinib + Cetuximab,1956,26341921,,,
220,Preclinical,"In a preclinical study, addition of Rapamune (sirolimus) to Gilotrif (afatinib) and Erbitux (cetuximab) combination treatment restored sensitivity in transgenic animal models of lung adenocarcinoma driven by EGFR L858R and T790M that acquired resistance to the combination treatment, resulted in tumor shrinkage (PMID: 24813888).",Actionable,8526,3910,lung adenocarcinoma,DOID,2422,EGFR L858R EGFR T790M,sensitive,4764,Afatinib + Cetuximab + Sirolimus,1956,24813888,,,
221,Preclinical - Cell culture,"In a preclinical study, the addition of Sprycel (dasatinib) to treatment with Tagrisso (osimertinib) resulted in increased PARP cleavage and inhibition of proliferation in lung cancer cell lines harboring EGFR L858R and T790M in culture (PMID: 28416483).",Actionable,11313,1324,lung cancer,DOID,2422,EGFR L858R EGFR T790M,sensitive,4946,Dasatinib + Osimertinib,1956,28416483,,,
222,Preclinical - Cell culture,"In a preclinical study, a lung cancer cell line harboring EGFR L858R and T790M did not demonstrate sensitivity to AZD3759 in culture (PMID: 27928026).",Actionable,9569,1324,lung cancer,DOID,2422,EGFR L858R EGFR T790M,resistant,2912,AZD3759,1956,27928026,,,
223,Preclinical,"In a preclinical study, EGFR T790M was detected in animal models of EGFR L858R-induced lung adenocarcinoma, which occurred after repeated treatments with Tarceva (erlotinib) and resulted in drug resistance (PMID: 26341921).",Actionable,6652,3910,lung adenocarcinoma,DOID,2422,EGFR L858R EGFR T790M,resistant,4,Erlotinib,1956,26341921,,,
224,Preclinical,"In a preclinical study, the combination of Tagrisso (osimertinib) and Selumetinib inhibited growth of lung adenocarcinoma tumors driven by EGFR L858R and EGFR T790M that had developed resistance through continued exposure to Tagrisso (osimertinib) (PMID: 25870145).",Actionable,4501,3910,lung adenocarcinoma,DOID,2422,EGFR L858R EGFR T790M,sensitive,2225,Osimertinib + Selumetinib,1956,25870145,,,
225,Preclinical - Pdx & cell culture,"In a preclinical study, EGF816 inhibited proliferation of non-small cell lung cancer (NSCLC) cells harboring both EGFR L858R and EGFR T790M in culture, and induced tumor regression in NSCLC patient derived xenograft (PDX) models harboring both EGFR L858R and EGFR T790M (PMID: 26825170).",Actionable,5650,3908,non-small cell lung carcinoma,DOID,2422,EGFR L858R EGFR T790M,sensitive,1309,EGF816,1956,26825170,,,
226,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Ganetespib and Gilotrif (afatinib) demonstrated improved antitumor activity compared to either agent alone in  cell line xenograft models of non-small cell lung cancer harboring EGFR L858R and EGFR T790M (PMID: 25077897).",Actionable,2294,3908,non-small cell lung carcinoma,DOID,2422,EGFR L858R EGFR T790M,sensitive,2801,Afatinib + Ganetespib,1956,25077897,,,
227,Preclinical,"In a preclinical study, EAI045 and Erbitux (cetuximab) combination treatment induced tumor regression in an EGFR L858R/T790M-mutant-driven lung cancer mouse model (PMID: 27251290).",Actionable,7594,1324,lung cancer,DOID,2422,EGFR L858R EGFR T790M,sensitive,4521,Cetuximab + EAI045,1956,27251290,,,
228,Preclinical,"In a preclinical study, AV-412 inhibited EGFR signaling in a NSCLC cell line carrying the double EGFR mutant, L858R and T790M (PMID: 17888033).",Actionable,1380,3908,non-small cell lung carcinoma,DOID,2422,EGFR L858R EGFR T790M,sensitive,990,AV-412,1956,17888033,,,
229,Preclinical,"In a preclinical study, transformed cells expressing EGFR L858R and T790M demonstrated decreased sensitivity to EKI-285 (CL-387,785) in culture (PMID: 17085664).",Actionable,3001,10000003,Advanced Solid Tumor,JAX,2422,EGFR L858R EGFR T790M,decreased response,2911,EKI-285,1956,17085664,,,
230,Preclinical,"In a preclinical study, treatment with the combination of WZ4002 and Mekinist (trametinib) resulted in tumor regression, and decreased tumor rebound and increased survival compared to WZ4002 alone in non-small cell lung cancer mouse models expressing EGFR L858R and EGFR T790M (PMID: 26036643).",Actionable,9052,3908,non-small cell lung carcinoma,DOID,2422,EGFR L858R EGFR T790M,sensitive,3351,WZ4002 + Trametinib,1956,26036643,,,
231,Preclinical - Cell culture,"In a preclinical study, EAI045 inhibited proliferation of transformed cells over expressing EGFR that harbors both L858R and T790M in culture, although at a concentration much higher than the biochemical IC50 of the compound (PMID: 27251290).",Actionable,7580,10000003,Advanced Solid Tumor,JAX,2422,EGFR L858R EGFR T790M,sensitive,4520,EAI045,1956,27251290,,,
232,Preclinical - Cell culture,"In a preclinical study, EAI045 and Erbitux (cetuximab) synergistically inhibited proliferation of transformed cells over expressing EGFR that harbors both L858R and T790M in culture (PMID: 27251290).",Actionable,7590,10000003,Advanced Solid Tumor,JAX,2422,EGFR L858R EGFR T790M,sensitive,4521,Cetuximab + EAI045,1956,27251290,,,
233,Preclinical,"In a preclinical study, Gedatolisib (PKI-587) and Nerlynx (neratinib) in combination worked syngerstically to inhibit Akt phosphorylation in a human non-small cell lung cancer cell line harboring EGFR L858R and T790M in culture (PMID: 21325073).",Actionable,3898,3908,non-small cell lung carcinoma,DOID,2422,EGFR L858R EGFR T790M,sensitive,3379,Gedatolisib + Neratinib,1956,21325073,,,
234,Preclinical - Pdx,"In a preclinical study, JNJ-61186372 induced tumor regression in lung adenocaricnoma patient-derived xenograft (PDX) models harboring EGFR L858R and EGFR T790M, with response continuing up to 2 months post-treatment cessation (PMID: 27216193).",Actionable,7504,3910,lung adenocarcinoma,DOID,2422,EGFR L858R EGFR T790M,sensitive,4491,JNJ-61186372,1956,27216193,,,
235,Preclinical - Cell culture,"In a preclinical study, the addition of Buparlisib (BKM-120) to treatment with Tagrisso (osimertinib) resulted in increased inhibition of proliferation in lung cancer cell lines harboring EGFR L858R and T790M in culture (PMID: 28416483).",Actionable,11315,1324,lung cancer,DOID,2422,EGFR L858R EGFR T790M,sensitive,5935,BKM120 + Osimertinib,1956,28416483,,,
236,Preclinical,"In a preclinical study, transformed cells expressing EGFR L858R and T790M demonstrated decreased sensitivity to Nerlynx (neratinib) in culture (PMID: 17085664).",Actionable,2997,10000003,Advanced Solid Tumor,JAX,2422,EGFR L858R EGFR T790M,decreased response,828,Neratinib,1956,17085664,,,
237,Preclinical,"In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring both EGFR L858R and EGFR T790M mutations in culture (PMID: 26090892).",Actionable,3931,3908,non-small cell lung carcinoma,DOID,2422,EGFR L858R EGFR T790M,sensitive,2086,TAE226,1956,26090892,,,
238,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Tagrisso (osimertinib) and JNJ-61186372 inhibited tumor growth in non-small cell lung cancer cell line xenograft models harboring EGFR L858R and EGFR T790M, and resulted in durable response following treatment cessation (PMID: 27216193).",Actionable,7506,3908,non-small cell lung carcinoma,DOID,2422,EGFR L858R EGFR T790M,sensitive,4502,AZD9291 + JNJ-61186372,1956,27216193,,,
239,Preclinical - Cell culture,"In a preclinical study, EAI045 inhibited Egfr activation but not proliferation of non-small cell lung cancer cells harboring EGFR with both L858R and T790M mutations in culture (PMID: 27251290).",Actionable,7586,3908,non-small cell lung carcinoma,DOID,2422,EGFR L858R EGFR T790M,no benefit,4520,EAI045,1956,27251290,,,
240,Preclinical - Cell culture,"In a preclinical study, KEAP1 knockout resulted in decreased sensitivity to Gilotrif (afatinib) in a lung cancer cell line harboring EGFR L858R and T790M in culture (PMID: 28145866).",Actionable,11912,1324,lung cancer,DOID,2422,EGFR L858R EGFR T790M,decreased response,623,Afatinib,1956,28145866,,,
241,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion, EGFR T790M, and NRAS Q61K were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",Actionable,4494,3908,non-small cell lung carcinoma,DOID,18240,EGFR exon 19 del EGFR T790M NRAS Q61K,resistant,660,Osimertinib,1956,25870145,,,
242,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and NRAS Q61K were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",Actionable,4495,3908,non-small cell lung carcinoma,DOID,18261,EGFR L858R EGFR T790M NRAS Q61K,resistant,660,Osimertinib,1956,25870145,,,
243,Preclinical,"In a preclinical study, transformed cells expressing an EGFR L858R/EGFR T790M/EGFR L844V triple mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).",Actionable,3082,10000003,Advanced Solid Tumor,JAX,11730,EGFR L858R EGFR L844V EGFR T790M,resistant,1003,CO1686,1956,25948633,,,
244,Preclinical,"In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR L858R/EGFR T790M/EGFR L844V triple-mutation in culture (PMID: 25948633).",Actionable,3087,10000003,Advanced Solid Tumor,JAX,11730,EGFR L858R EGFR L844V EGFR T790M,sensitive,660,Osimertinib,1956,25948633,,,
245,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Gilotrif (afatinib) after the emergence of EGFR T790M in culture (PMID: 25870145).",Actionable,4479,3908,non-small cell lung carcinoma,DOID,5705,EGFR del exon 19 EGFR T790M,resistant,623,Afatinib,1956,25870145,,,
246,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion and EGFR T790M in culture (PMID: 25964297).",Actionable,5750,10000003,Advanced Solid Tumor,JAX,5705,EGFR del exon 19 EGFR T790M,sensitive,623,Afatinib,1956,25964297,,,
247,Preclinical,"In a preclinical study, WZ4002 inhibited EGFR signaling and cell growth in 1st generation TKI-resistant non-small cell lung carcinoma cells harboring EGFR exon 19 deletion and EGFR T790M in culture (PMID: 25964297).",Actionable,5732,3908,non-small cell lung carcinoma,DOID,5705,EGFR del exon 19 EGFR T790M,sensitive,3075,WZ4002,1956,25964297,,,
248,Preclinical,"In a preclinical study, WZ4002 inhibited EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion and EGFR T790M in culture (PMID: 25964297).",Actionable,5749,10000003,Advanced Solid Tumor,JAX,5705,EGFR del exon 19 EGFR T790M,sensitive,3075,WZ4002,1956,25964297,,,
249,Preclinical - Cell culture,"In a preclinical study, the combination of Tagrisso (osimertinib) with PF-573328 and Saracatinib (AZD0530) resulted in increased inhibition of AKT, FAK, and SFK phosphorylation and growth compared to Tagrisso (osimertinib) alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).",Actionable,11308,1324,lung cancer,DOID,5705,EGFR del exon 19 EGFR T790M,sensitive,5938,Osimertinib + PF-573328 + Saracatinib,1956,28416483,,,
250,Preclinical - Cell line xenograft,"In a preclinical study, TAE226 treatment inhibited cell proliferation and decreased xenograft tumor size of non-small cell lung carcinoma cell lines harboring both EGFR T790M and EGFR Exon 19 deletion mutations (PMID: 26090892).",Actionable,3929,3908,non-small cell lung carcinoma,DOID,5705,EGFR del exon 19 EGFR T790M,sensitive,2086,TAE226,1956,26090892,,,
251,Clinical Study,"In an analysis of lung adenocarcinoma patients treated with Gilotrif (afatinib), second-site EGFR T790M mutations were detected in 47.6% (20/42) of patients with acquired resistance, with 9/20 patients harboring primary EGFR exon 19 deletion mutations (PMID: 26862733).",Actionable,4912,3910,lung adenocarcinoma,DOID,5705,EGFR del exon 19 EGFR T790M,resistant,623,Afatinib,1956,26862733,,,
252,Clinical Study,"In a clinical case study, Tagrisso (osimertinib) resulted in a partial response and stable disease of brain metastases in a NSCLC patient harboring EGFR exon 19 deletion and a secondary resistance mutation, EGFR T790M, which occurred post Iressa (gefitinib) therapy (PMID: 27435396).",Actionable,8969,3908,non-small cell lung carcinoma,DOID,5705,EGFR del exon 19 EGFR T790M,sensitive,660,Osimertinib,1956,27435396,,,
253,Phase I,"In a Phase I trial, AZD9291 treatment resulted in a response rate of 64% (49/77) in NSCLC patients that harbored both EGFR exon 19 deletions and T790M mutations (PMID: 25923549).",Actionable,2157,3908,non-small cell lung carcinoma,DOID,5705,EGFR del exon 19 EGFR T790M,sensitive,660,Osimertinib,1956,25923549,,,
254,Preclinical,"In a preclinical study, EAI045 and Erbitux (cetuximab) combination treatment did not induced response in an EGFR exon 19 deletion/T790M-driven lung cancer mouse model (PMID: 27251290).",Actionable,7595,1324,lung cancer,DOID,5705,EGFR del exon 19 EGFR T790M,resistant,4521,Cetuximab + EAI045,1956,27251290,,,
255,Preclinical,"In a preclinical study, non-small cell lung cancercarcinoma cells harboring EGFR exon 19 deletion and EGFR T790M were resistant to Iressa (gefitinib) induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297).",Actionable,5731,3908,non-small cell lung carcinoma,DOID,5705,EGFR del exon 19 EGFR T790M,resistant,751,Gefitinib,1956,25964297,,,
256,Preclinical - Cell culture,"In a preclinical study, treatment with the combination of GSK2334470 and Tagrisso (osimertinib) resulted in increased inhibition of AKT phosphorylation and proliferation compared to Tagrisso (osimertinib) alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).",Actionable,11305,1324,lung cancer,DOID,5705,EGFR del exon 19 EGFR T790M,sensitive,5936,GSK2334470 + Osimertinib,1956,28416483,,,
257,Phase Ib/II,"In a Phase Ib/II trial, treatment with Rociletinib (CO-1686) resulted in an objective response rate of 64.3% (18/28) in non-small cell lung cancer patients harboring both EGFR exon 19 deletions and EGFR T790M (PMID: 25923550).",Actionable,3120,3908,non-small cell lung carcinoma,DOID,5705,EGFR del exon 19 EGFR T790M,sensitive,1003,CO1686,1956,25923550,,,
258,Preclinical - Cell culture,"In a preclinical study, EAI045 did not inhibit proliferation of transformed cells over expressing EGFR that harbors both exon 19 deletion and T790M in culture (PMID: 27251290).",Actionable,7582,10000003,Advanced Solid Tumor,JAX,5705,EGFR del exon 19 EGFR T790M,resistant,4520,EAI045,1956,27251290,,,
259,Preclinical - Cell culture,"In a preclinical study, treatment with the combination of Buparlisib (BKM120) and Tagrisso (osimertinib) resulted in increased inhibition of AKT phosphorylation and proliferation compared to Tagrisso (osimertinib) alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).",Actionable,11304,1324,lung cancer,DOID,5705,EGFR del exon 19 EGFR T790M,sensitive,5935,BKM120 + Osimertinib,1956,28416483,,,
260,Preclinical - Cell culture,"In a preclinical study, the combination of Tagrisso (osimertinib) with PF-573328 and Bosulif (bosutinib) resulted in increased inhibition of AKT, FAK, and SFK phosphorylation and growth compared to Tagrisso (osimertinib) alone in a lung cancer cell line harboring an EGFR exon 19 deletion and T790M in culture (PMID: 28416483).",Actionable,11309,1324,lung cancer,DOID,5705,EGFR del exon 19 EGFR T790M,sensitive,5939,Osimertinib + Bosutinib + PF-573328,1956,28416483,,,
261,Preclinical - Cell culture,"In a preclinical study, combination of EAI045 and Erbitux (cetuximab) did not inhibit proliferation of transformed cells over expressing EGFR that harbors both exon 19 deletion and T790M in culture (PMID: 27251290).",Actionable,7591,10000003,Advanced Solid Tumor,JAX,5705,EGFR del exon 19 EGFR T790M,resistant,4521,Cetuximab + EAI045,1956,27251290,,,
262,Preclinical,"In a preclinical study, transformed human cells over expressing EGFR exon 19 deletion and EGFR T790M were resistant to Iressa (gefitinib) induced suppression of EGFR signaling in culture (PMID: 25964297).",Actionable,5748,10000003,Advanced Solid Tumor,JAX,5705,EGFR del exon 19 EGFR T790M,resistant,751,Gefitinib,1956,25964297,,,
263,Preclinical - Cell culture,"In a preclinical study, BGB-283 inhibited proliferation of transformed cells over expressing both EGFR exon 19 deletion mutation and T790M in culture (PMID: 26208524).",Actionable,8062,10000003,Advanced Solid Tumor,JAX,5705,EGFR del exon 19 EGFR T790M,sensitive,4025,BGB-283,1956,26208524,,,
264,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing EGFR that harbors concomitant L858R, T790M and I941R mutations demonstrated increased sensitivity to EAI045 induced growth inhibition in culture (PMID: 27251290).",Actionable,7589,10000003,Advanced Solid Tumor,JAX,25912,EGFR I941R EGFR L858R EGFR T790M,sensitive,4520,EAI045,1956,27251290,,,
265,Clinical Study,"In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L747_T751delinsP and EGFR T790M was found to rapidly progress on Tarceva (erlotinib) therapy (PMID: 18981003).",Actionable,3053,3910,lung adenocarcinoma,DOID,11384,EGFR L747_T751delinsP EGFR T790M,resistant,4,Erlotinib,1956,18981003,,,
266,Clinical Study,"In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L747_T751delinsP that had developed Iressa (gefitinib) resistance was demonstrated to have acquired an EGFR T790M mutation (PMID: 18981003).",Actionable,3051,3910,lung adenocarcinoma,DOID,11384,EGFR L747_T751delinsP EGFR T790M,resistant,751,Gefitinib,1956,18981003,,,
267,Clinical Study,"In a retrospective study, Opdivo (nivolumab) treatment after disease progression during EGFR tyrosine kinase inhibitors resulted in longer median progression-free survival (2.1 vs 1.3 months, HR=0.48, p=0.099) in T790M-negative, EGFR mutant non-small cell lung cancer patients compared to T790M-positive patients (PMID: 28407039).",Actionable,11341,3908,non-small cell lung carcinoma,DOID,27962,EGFR T790M EGFR mut,decreased response,1312,Nivolumab,1956,28407039,,,
268,Preclinical,"In a preclinical study, over expression of Erbb2 (Her2) in lung adenocarcinoma cells harboring EGFR T790M resulted in resistance to Tagrisso (osimertinib) in culture, consistent with ERBB2 (HER2) amplification identified in tumor samples of lung adenocarcinoma patients harboring EGFR T790M that developed resistance to Tagrisso (osimertinib) (PMID: 27252416).",Actionable,8799,3910,lung adenocarcinoma,DOID,26436,EGFR T790M ERBB2 over exp,resistant,660,Osimertinib,1956,27252416,,,
269,Preclinical,"In a preclinical study, over expression of Erbb2 (Her2) in lung adenocarcinoma cells harboring EGFR T790M resulted in resistance to Rociletinib (CO-1686) in culture, consistent with ERBB2 (HER2) amplification identified in tumor samples of lung adenocarcinoma patients harboring EGFR T790M that developed resistance to Rociletinib (CO-1686) (PMID: 27252416).",Actionable,8800,3910,lung adenocarcinoma,DOID,26436,EGFR T790M ERBB2 over exp,resistant,1003,CO1686,1956,27252416,,,
270,Clinical Study,"In a prospective clinical study, Gilotrif (afatinib) treatment resulted in partial response in 15% (4/27), stable disease in 56% (15/27), and progressive disease in 30% (8/27) of non-small cell lung carcinoma patients carrying an EGFR T790M mutation (PMID: 26354527).",Actionable,3365,3908,non-small cell lung carcinoma,DOID,370,EGFR T790M,predicted â€“ resistant,623,Afatinib,1956,26354527,,,
271,Clinical Study,"In a clinical study, EGFR T790M mutations were associated with resistance to Iressa (gefitinib) in lung adenocarcinoma patients (PMID: 15737014).",Actionable,49,3910,lung adenocarcinoma,DOID,370,EGFR T790M,resistant,751,Gefitinib,1956,24410791,15737014,,
272,Phase I,"In a Phase I trial, ASP8273 treatment resulted in partial response in 38% (15/40) and stable disease in 28% (11/40) of non-small cell lung carcinoma patients harboring EGFR T790M, with a median progression free survival of 6.7 months (J Clin Oncol 34, 2016 (suppl; abstr 9050)).",Actionable,4350,3908,non-small cell lung carcinoma,DOID,370,EGFR T790M,sensitive,1082,ASP8273,1956,None,,,
273,Preclinical,"In a preclinical study, Selumetinib (AZD6244) mildly inhibited the growth of an Iressa (gefitinib)-resistant NSCLC cell line with an EGFR T790M mutation (PMID: 24939055). ",Actionable,982,3908,non-small cell lung carcinoma,DOID,370,EGFR T790M,decreased response,913,Selumetinib,1956,24939055,,,
274,Phase I,"In a Phase I study, EGF816 treatment resulted in an objective response rate of 44% (56/127), disease control rate of 91% (115/127), and an estimated progression free survival of 9.2 months in non-small cell lung carcinoma patients harboring EGFR T790M (J Clin Oncol 34, 2016 (suppl; abstr 9044)).",Actionable,6995,3908,non-small cell lung carcinoma,DOID,370,EGFR T790M,sensitive,1309,EGF816,1956,None,,,
275,Phase II,"In a Phase II trial, BI 1482694 (HM61713) treatment resulted in a disease control rate of 90% (64/71), and objective response with a median duration of 8.3 months in 56% (40/71) of patients with EGFR tyrosine kinase inhibitor-resistant non-small cell lung carcinoma harboring EGFR T790M (J Clin Oncol 34, 2016 (suppl; abstr 9055)).",Actionable,7049,3908,non-small cell lung carcinoma,DOID,370,EGFR T790M,sensitive,2137,HM61713,1956,None,,,
276,Clinical Study,"In a clinical study, 83% (5/6) of non-small cell lung cancer patients that had progressed on prior treatment with Iressa (gefinitib) with secondary EGFR T790M mutations had progressive disease as best response to treatment with Tarceva (erlotinib) (PMID: 18981003).",Actionable,43,3908,non-small cell lung carcinoma,DOID,370,EGFR T790M,resistant,4,Erlotinib,1956,24410791,18981003,,
277,Phase Ib/II,"In a Phase I/II trial, Brigatinib (AP26113) treatment did not result in objective response in EGFRT790M-positive non-small cell lung cancer patients resistant to one previous EGFR tyrosine kinase inhibitor (PMID: 27836716).",Actionable,9230,3908,non-small cell lung carcinoma,DOID,370,EGFR T790M,no benefit,634,AP26113,1956,27836716,,,
278,Preclinical,"In a preclinical study, AV-412 inhibited the kinase activity of EGFR T790M (PMID: 17888033).",Actionable,1379,10000003,Advanced Solid Tumor,JAX,370,EGFR T790M,sensitive,990,AV-412,1956,17888033,,,
279,Preclinical,"In a preclinical study, CUDC-101 inhibited the growth of lung cancer cells expressing EGFR T790M (PMID: 20388807).",Actionable,314,1324,lung cancer,DOID,370,EGFR T790M,sensitive,1005,CUDC-101,1956,20388807,,,
280,Preclinical - Cell line xenograft,"In a preclinical study, Selumetinib (AZD6244) in combination with BEZ235, synergistically inhibited proliferation of Iressa (gefitinib)-resistant NSCLC cells harboring EGFR T790M in culture and in cell line xenograft models (PMID: 24939055).",Actionable,987,3908,non-small cell lung carcinoma,DOID,370,EGFR T790M,sensitive,1420,Selumetinib + BEZ235,1956,24939055,,,
281,Preclinical,"In a preclinical study, BEZ235 suppressed the growth of an Iressa (gefitinib)-resistant NSCLC cell line with an EGFR T790M mutation (PMID: 24939055).",Actionable,986,3908,non-small cell lung carcinoma,DOID,370,EGFR T790M,sensitive,672,BEZ235,1956,24939055,,,
282,Clinical Study,"In a retrospective analysis, non-small cell lung cancer patients harboring EGFR T790M demonstrated a response rate of 4.76% and disease control rate of 47.62%, and a median progression-free survival of 1.6 months following treatment with icotinib (J Clin Oncol 35, 2017 (suppl; abstr e14050)).",Actionable,11157,3908,non-small cell lung carcinoma,DOID,370,EGFR T790M,decreased response,769,Icotinib,1956,None,,,
283,Clinical Study,"In a clinical study, two patients with non-small cell lung cancer harboring EGFR T790M demonstrated tumor reductions of 31% and 36% when treated with AC0010MA (PMID: 27573423). ",Actionable,9118,3908,non-small cell lung carcinoma,DOID,370,EGFR T790M,sensitive,2909,AC0010MA,1956,27573423,,,
284,Phase Ib/II,"In a Phase Ib/II trial, treatment with Rociletinib (CO-1686) resulted in a response rate of 59% (27/46) and a disease control rate of 93% (43/46) in non-small cell lung cancer patients harboring EGFR T790M (PMID: 25923550).",Actionable,3118,3908,non-small cell lung carcinoma,DOID,370,EGFR T790M,sensitive,1003,CO1686,1956,25923550,,,
285,Phase I,"In a Phase I trial, CO-1686 has demonstrated safety and efficacy in NSCLC patients carrying EGFR T790M mutations (J Clin Oncol 31, 2013 (suppl; abstr 2524)).",Actionable,46,3908,non-small cell lung carcinoma,DOID,370,EGFR T790M,sensitive,1003,CO1686,1956,None,,,
286,Phase I,"In a Phase I clinical trial, HMPL-813 (Epitinib) demonstrated safety and preliminary efficacy in patients with NSCLC, including a patient with EGFR T790M (J Clin Oncol 31, 2013 (suppl; abstr e19042).",Actionable,4877,3908,non-small cell lung carcinoma,DOID,370,EGFR T790M,predicted â€“ sensitive,3667,Epitinib,1956,None,,,
287,Preclinical - Cell line xenograft,"In a preclinical study, non-small cell lung cancer cell lines harboring activating EGFR mutations, including EGFR T790M, demonstrated sensitivity to the combination of amlexanox and Selumetinib (AZD6244), resulting in synergistic growth inhibition in culture and reduced tumor growth in xenograft models (PMID: 27287717).",Actionable,9782,3908,non-small cell lung carcinoma,DOID,370,EGFR T790M,sensitive,5229,Amlexanox + Selumetinib,1956,27287717,,,
288,Clinical Study,"In a clinical study, second-site EGFR T790M mutations were detected in 47.6% (20/42) of lung adenocarcinoma patients with acquired resistance to Gilotrif (afatinib) (PMID: 26862733).",Actionable,6669,3910,lung adenocarcinoma,DOID,370,EGFR T790M,resistant,623,Afatinib,1956,26862733,,,
289,Phase I,"In a Phase I trial, AZD9291 demonstrated efficacy in 50% (9/18) of NSCLC patients carrying EGFR T790M mutations (PMID: 24410791).",Actionable,45,3908,non-small cell lung carcinoma,DOID,370,EGFR T790M,sensitive,660,Osimertinib,1956,24410791,,,
290,FDA approved,"In a Phase I extension trial that supported FDA approval, treatment with Tagrisso (osimertinib) resulted in in an objective response rate of 58% (115/119) and disease control rate of 92%  in patients with EGFR-TKI resistant non-small cell lung cancer harboring EGFR T790M mutations (World Conf on Lung Cancer 2015. Abst MINI16.06).",Actionable,3623,3908,non-small cell lung carcinoma,DOID,370,EGFR T790M,sensitive,660,Osimertinib,1956,None,,,
291,Phase I,"In a Phase I trial, AZD9291 treatment resulted in an objective response rate of 61% (78/127) and a disease control rate of 95% (121/127) in NSCLC patients harboring EGFR T790M mutations (PMID: 25923549).",Actionable,2156,3908,non-small cell lung carcinoma,DOID,370,EGFR T790M,sensitive,660,Osimertinib,1956,25923549,,,
292,Phase III,"In a Phase III trial, treatment with Tagrisso (osimertinib) resulted in an improved median progression-free survival of 10.1 months vs. 4.4 months with platinum plus pemetrexed, and an objective response rate of 71% (95% CI, 65 to 76) compared to 31% (95% CI, 24 to 40) with platinum plus pemetrexed therapy in patients with EGFR T790M-positive non-small cell lung cancer (PMID: 27959700).",Actionable,9600,3908,non-small cell lung carcinoma,DOID,370,EGFR T790M,sensitive,660,Osimertinib,1956,27959700,,,
293,Clinical Study,"In a clinical case study, Tagrisso (osimertinib) treatment resulted in partial response for over 8 months in a patient with lung adenocarcinoma harboring EGFR G719A, L861Q, and T790M that has progressed while on Tarceva (erlotinib) treatment (PMID: 28343545).",Actionable,10488,3910,lung adenocarcinoma,DOID,27526,EGFR G719A EGFR L861Q EGFR T790M,predicted â€“ sensitive,660,Osimertinib,1956,28343545,,,
294,Clinical Study,"In a clinical case study, EGFR T790M was detected at the time of progression in a patient with lung adenocarcinoma harboring EGFR G719A and L861Q that was treated with Tarceva (erlotinib) (PMID: 28343545).",Actionable,10487,3910,lung adenocarcinoma,DOID,27526,EGFR G719A EGFR L861Q EGFR T790M,predicted â€“ resistant,4,Erlotinib,1956,28343545,,,
295,Clinical Study,"In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L858R and EGFR L747S had an initial partial response to Tarceva (erlotinib), but was found to progress after 6 months (PMID: 18981003).",Actionable,3058,3910,lung adenocarcinoma,DOID,11382,EGFR L858R EGFR L747S,decreased response,4,Erlotinib,1956,18981003,,,
296,Clinical Study,"In a retrospective analysis, a patient with lung adenocarcinoma harboring EGFR L858R that had developed Iressa (gefitinib) resistance was demonstrated to have acquired an EGFR L747S mutation (PMID: 18981003).",Actionable,3057,3910,lung adenocarcinoma,DOID,11382,EGFR L858R EGFR L747S,resistant,751,Gefitinib,1956,18981003,,,
297,Preclinical - Patient cell culture,"In a preclinical study, dacomitinib inhibited EGFR phosphorylation and growth of a patient-derived lung adenocarcinoma cell line harboring EGFR N771_H773dup (also referred to as H773_V774insNPH) in culture (PMID: 28363995).",Actionable,10519,3910,lung adenocarcinoma,DOID,13013,EGFR N771_H773dup,sensitive,714,Dacomitinib,1956,28363995,,,
298,Preclinical - Patient cell culture,"In a preclinical study, Gilotrif (afatinib) inhibited EGFR phosphorylation and growth of a patient-derived lung adenocarcinoma cell line harboring EGFR N771_H773dup (also referred to as H773_V774insNPH) in culture (PMID: 28363995).",Actionable,10522,3910,lung adenocarcinoma,DOID,13013,EGFR N771_H773dup,sensitive,623,Afatinib,1956,28363995,,,
299,Preclinical,"In a preclinical study, sinonasal squamous cell carcinoma cells harboring EGFR N771_H773dup demonstrated resistance to Tarceva (erlotinib) in culture (PMID: 25931286).",Actionable,3256,5520,head and neck squamous cell carcinoma,DOID,13013,EGFR N771_H773dup,resistant,4,Erlotinib,1956,25931286,,,
300,Preclinical,"In a preclinical study, sinonasal squamous cell carcinoma cells harboring EGFR N771_H773dup demonstrated resistance to Iressa (gefinitib) in culture (PMID: 25931286).",Actionable,3255,5520,head and neck squamous cell carcinoma,DOID,13013,EGFR N771_H773dup,resistant,751,Gefitinib,1956,25931286,,,
301,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited growth of sinonasal squamous cell carcinoma cells harboring EGFR N771_H773dup in culture (PMID: 25931286).",Actionable,3259,5520,head and neck squamous cell carcinoma,DOID,13013,EGFR N771_H773dup,sensitive,828,Neratinib,1956,25931286,,,
302,Preclinical,"In a preclinical study, cells expressing the double EGFR L858R/E844K mutation demonstrated decreased sensitivity to Tarceva (erlotinib) in culture compared to cells expressing EGFR L858R alone (PMID: 19015641).",Actionable,6888,10000003,Advanced Solid Tumor,JAX,23963,EGFR L858R EGFR E884K,decreased response,4,Erlotinib,1956,19015641,,,
303,Preclinical,"In a preclinical study, cells expressing the double EGFR L858R/E884K mutation demonstrated increased sensitivity to inhibition of Egfr phosphorylation by EKI-285 compared to cells expressing EGFR L858R alone (PMID: 20942962).",Actionable,6921,10000003,Advanced Solid Tumor,JAX,23963,EGFR L858R EGFR E884K,sensitive,2911,EKI-285,1956,20942962,,,
304,Preclinical,"In a preclinical study, cells expressing the double EGFR L858R/E884K mutation demonstrated increased sensitivity to inhibition by Iressa (gefitinib) compared to cells expressing EGFR L858R alone (PMID: 20942962).",Actionable,6920,10000003,Advanced Solid Tumor,JAX,23963,EGFR L858R EGFR E884K,sensitive,751,Gefitinib,1956,20942962,,,
305,Phase I,"In a Phase I trial, Capmatinib (INC280) treatment resulted in partial response in 29% (5/17) of EGFR wild-type, MET over-expressing non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9067)).",Actionable,7065,3908,non-small cell lung carcinoma,DOID,24382,EGFR wild-type MET over exp,sensitive,1065,Capmatinib,1956,None,,,
306,Preclinical - Cell line xenograft,"In a preclinical study, Ganetespib treatment resulted in decreased activation of MEK, AKT, and ERK and inhibited growth of a non-small cell lung cancer cell line with wild-type EGFR and BRAF G466V in culture, and inhibited tumor growth in xenograft models (PMID: 25077897).",Actionable,8231,3908,non-small cell lung carcinoma,DOID,26202,BRAF G466V EGFR wild-type,sensitive,745,Ganetespib,1956,25077897,,,
307,Preclinical,"In a preclinical study, the combination of K-756 and Iressa (gefitinib) worked synergistically to inhibit growth of non-small cell lung cancer cells with wild-type EGFR or EGFR exon 19 deletion in culture (PMID: 27196752).",Actionable,7255,3908,non-small cell lung carcinoma,DOID,343,EGFR wild-type,sensitive,4428,K-756 + Gefitinib,1956,27196752,,,
308,Preclinical - Pdx & cell culture,"In a preclinical study, Dacomitinib did not inhibit Egfr signaling or survival of patient-derived EGFR wild-type glioblastoma cells in culture and in intracranial xenograft models (PMID: 25939761).",Actionable,8044,3068,glioblastoma multiforme,DOID,343,EGFR wild-type,no benefit,714,Dacomitinib,1956,25939761,,,
309,Preclinical - Cell culture,"In a preclinical study, Tarceva (erlotinib) demonstrated decreased potency in inhibition of Egfr phosphorylation and resulted in decreased inhibition of downstream targets, including Stat5, in transformed cells expressing wild-type EGFR, compared to EGFR L858R expressing cells in culture (PMID: 25573954).",Actionable,4778,10000003,Advanced Solid Tumor,JAX,343,EGFR wild-type,decreased response,4,Erlotinib,1956,25573954,,,
310,Phase II,"In a Phase II trial, EGFR wild-type non-small cell lung cancer patients treated with Tarceva (erlotinib), in combination with MK-2206, demonstrated a clinical benefit as indicated by a disease control rate of 43% (15/43), thus, exceeding the primary endpoint rate of 20% (PMID: 26106072). ",Actionable,3299,3908,non-small cell lung carcinoma,DOID,343,EGFR wild-type,sensitive,1097,Erlotinib + MK2206,1956,26106072,,,
311,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) did not inhibit growth of lung carcinoma cells with activated wild-type EGFR signaling via EGF stimulation in culture (PMID: 27780853).",Actionable,9239,3905,lung carcinoma,DOID,343,EGFR wild-type,resistant,634,AP26113,1956,27780853,,,
312,Preclinical - Cell culture,"In a preclinical study, EAI045 did not inhibit proliferation of transformed cells harboring wild type EGFR in culture (PMID: 27251290).",Actionable,7584,10000003,Advanced Solid Tumor,JAX,343,EGFR wild-type,resistant,4520,EAI045,1956,27251290,,,
313,Phase II,"In a Phase II trial, treatment with Cometriq (cabozantinib) resulted in an improved median progression-free survival of 4.3 months, compared to 1.8 months with Tarceva (erlotinib), and an improved median overall survival of 9.2 months, versus 5.1 with Tarceva (erlotinib), in patients with EGFR wild-type non-small cell lung cancer (PMID: 27825638).",Actionable,9742,3908,non-small cell lung carcinoma,DOID,343,EGFR wild-type,unknown,998,cabozantinib,1956,27825638,,,
314,Preclinical - Cell line xenograft,"In a preclinical study, ER2 inhibited EGFR signaling and proliferation and induced apoptosis of EGFR wild-type non-small cell lung cancer cells in culture and delayed tumor growth in non-small cell lung cancer cell line xenograft models with wild-type EGFR (PMID: 27040853).",Actionable,5646,3908,non-small cell lung carcinoma,DOID,343,EGFR wild-type,sensitive,3916,ER2,1956,27040853,,,
315,Phase III,"In a Phase III trial, postoperative adjuvant Iressa (gefitinib) did not provide prolonged disease-free survival nor increased overall survival in NSCLC patients with wild-type EGFR (PMID: 23980091).",Actionable,9,3908,non-small cell lung carcinoma,DOID,343,EGFR wild-type,no benefit,751,Gefitinib,1956,23980091,,,
316,Phase III,"In Phase II and III clinical trials, Chinese patients with advanced NSCLC have shown Conmana (icotinib) to be safe and effective, with indication that patients with EGFR wild-type may receive some benefit  (PMID:23372346, PMID:2394835, PMID:24438614, PMID: 25261231).",Actionable,1217,3908,non-small cell lung carcinoma,DOID,343,EGFR wild-type,sensitive,769,Icotinib,1956,23372346,24438614,25261231,2394835
317,Preclinical - Cell culture,"In a preclinical study, Iressa (gefitinib) demonstrated decreased potency in inhibition of Egfr phosphorylation and inhibition of downstream targets, including Cbl, in EGFR wild-type expressing compared to EGFR L858R expressing transformed cells in culture (PMID: 25573954).",Actionable,4776,10000003,Advanced Solid Tumor,JAX,343,EGFR wild-type,decreased response,751,Gefitinib,1956,25573954,,,
318,Preclinical,"In a preclinical study, TAE226 treatment demonstrated reduced potency inhibiting proliferation of non-small cell lung carcinoma cell lines harboring wild-type EGFR in culture (PMID: 26090892).",Actionable,3938,3908,non-small cell lung carcinoma,DOID,343,EGFR wild-type,decreased response,2086,TAE226,1956,26090892,,,
319,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Tarceva (erlotinib) and Ganetespib led to tumor regression in cell line xenograft models of EGFR wild-type non-small cell lung cancer, and demonstrated improved efficacy over either agent alone (PMID: 25077897).",Actionable,8232,3908,non-small cell lung carcinoma,DOID,343,EGFR wild-type,sensitive,2802,Erlotinib + Ganetespib,1956,25077897,,,
320,Preclinical,"In a preclinical study, the combined treatment of DNA methyltransferase inhibitor decitabine and EGFR inhibitor gefitinib on EGFR wild-type colon cancer cell lines resulted in synergistic effects in inhibiting cell growth and migration (PMID: 24874286).",Actionable,1088,219,colon cancer,DOID,343,EGFR wild-type,sensitive,1531,Decitabine + Gefitinib,1956,24874286,,,
321,Preclinical - Cell line xenograft,"In a preclinical study, the combination of ER2 and Platinol (cisplatin) demonstrated synergy in inhibiting tumor growth in non-small cell lung cancer cell line xenograft models with wild-type EGFR (PMID: 27040853).",Actionable,8040,3908,non-small cell lung carcinoma,DOID,343,EGFR wild-type,sensitive,4625,ER2 + Cisplatin,1956,27040853,,,
322,Phase II,"In a Phase II clinical trial, Nexavar (sorafenib) demonstrated efficacy in NSCLC patients with wild-type EGFR (PMID: 24166906).",Actionable,1229,3908,non-small cell lung carcinoma,DOID,343,EGFR wild-type,sensitive,920,Sorafenib,1956,24166906,,,
323,Phase II,"In a Phase II trial, the combination of Cometriq (cabozantinib) and Tarceva (erlotinib) resulted in an improved median progression-free survival of 4.7 mo vs. 1.8 mo with Tarceva (erlotinib) alone, and an improved median overall survival of 13.3 months vs 5.1 mo with Tarceva (erlotinib) in patients with EGFR wild-type non-small cell lung cancer (PMID: 27825638).",Actionable,9741,3908,non-small cell lung carcinoma,DOID,343,EGFR wild-type,unknown,1255,Cabozantinib + Erlotinib,1956,27825638,,,
324,Preclinical - Cell line xenograft,"In a preclinical study, AC0010MA resulted in no antitumor activity when treating a squamous cell carcinoma cell line xenograft model harboring wild-type EGFR (PMID: 27573423).",Actionable,9117,1749,squamous cell carcinoma,DOID,343,EGFR wild-type,no benefit,2909,AC0010MA,1956,27573423,,,
325,Preclinical,"In a preclinical study, expression of EGFR T854A decreased sensitivity of transformed cells expressing EGFR L858R to Tarceva (erlotinib) in culture (PMID: 19010870).",Actionable,2226,10000003,Advanced Solid Tumor,JAX,6333,EGFR L858R EGFR T854A,decreased response,4,Erlotinib,1956,19010870,,,
326,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited growth of transformed cells expressing an EGFR L858R/EGFR L718Q double mutation in culture (PMID: 25948633).",Actionable,3100,10000003,Advanced Solid Tumor,JAX,11694,EGFR L858R EGFR L718Q,sensitive,623,Afatinib,1956,25948633,,,
327,Preclinical,"In a preclinical study, transformed cells expressing an EGFR L858R/EGFR L718Q double mutation demonstrated resistance to AZD9291 in culture (PMID: 25948633).",Actionable,3089,10000003,Advanced Solid Tumor,JAX,11694,EGFR L858R EGFR L718Q,resistant,660,Osimertinib,1956,25948633,,,
328,Preclinical,"In a preclinical study, transformed cells expressing an EGFR L858R/EGFR L718Q double mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).",Actionable,3079,10000003,Advanced Solid Tumor,JAX,11694,EGFR L858R EGFR L718Q,resistant,1003,CO1686,1956,25948633,,,
329,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited EGFR phosphorylation and growth of cells expressing EGFR L718Q in culture (PMID: 25948633).",Actionable,3068,10000003,Advanced Solid Tumor,JAX,11685,EGFR L718Q,sensitive,828,Neratinib,1956,25948633,,,
330,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited EGFR phosphorylation and growth of cells expressing EGFR L718Q in culture (PMID: 25948633).",Actionable,3067,10000003,Advanced Solid Tumor,JAX,11685,EGFR L718Q,sensitive,623,Afatinib,1956,25948633,,,
331,Preclinical,"In a preclinical study, EKI-285 inhibited EGFR phosphorylation and growth of cells expressing EGFR L718Q in culture (PMID: 25948633).",Actionable,3069,10000003,Advanced Solid Tumor,JAX,11685,EGFR L718Q,sensitive,2911,EKI-285,1956,25948633,,,
332,Preclinical,"In a preclinical study, transformed human cells harboring EGFR exon 19 deletion and EGFR C797S were resistant to WZ4002 induced suppression of EGFR signaling in culture (PMID: 25964297).",Actionable,5753,10000003,Advanced Solid Tumor,JAX,21570,EGFR C797S EGFR exon 19 del,resistant,3075,WZ4002,1956,25964297,,,
333,Preclinical,"In a preclinical study, lung adenocarcinoma cells over expressing EGFR exon 19 deletion and EGFR C797S were resistant to WZ4002 induced suppression of EGFR signaling and growth inhibition in culture (PMID: 25964297).",Actionable,5763,3910,lung adenocarcinoma,DOID,21570,EGFR C797S EGFR exon 19 del,resistant,3075,WZ4002,1956,25964297,,,
334,Preclinical,"In a preclinical study, Iressa (gefitinib) inhibited EGFR signaling and cell growth in lung adenocarcinoma cells over expressing EGFR exon 19 deletion and EGFR C797S in culture (PMID: 25964297).",Actionable,5762,3910,lung adenocarcinoma,DOID,21570,EGFR C797S EGFR exon 19 del,sensitive,623,Afatinib,1956,25964297,,,
335,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion and EGFR C797S in culture (PMID: 25964297).",Actionable,5752,10000003,Advanced Solid Tumor,JAX,21570,EGFR C797S EGFR exon 19 del,sensitive,623,Afatinib,1956,25964297,,,
336,Preclinical,"In a preclinical study, Iressa (gefitinib) inhibited EGFR signaling and cell growth in lung adenocarcinoma cells over expressing EGFR exon 19 deletion and EGFR C797S in culture (PMID: 25964297).",Actionable,5761,3910,lung adenocarcinoma,DOID,21570,EGFR C797S EGFR exon 19 del,sensitive,751,Gefitinib,1956,25964297,,,
337,Preclinical,"In a preclinical study, Iressa (gefitinib) inhibited EGFR signaling in transformed human cells over expressing EGFR exon 19 deletion and EGFR C797S in culture (PMID: 25964297).",Actionable,5751,10000003,Advanced Solid Tumor,JAX,21570,EGFR C797S EGFR exon 19 del,sensitive,751,Gefitinib,1956,25964297,,,
338,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Gilotrif (afatinib) after the emergence of amplified KRAS in culture (PMID: 25870145).",Actionable,4480,3908,non-small cell lung carcinoma,DOID,18233,EGFR exon 19 del KRAS amp,resistant,623,Afatinib,1956,25870145,,,
339,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and amplified KRAS were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",Actionable,4481,3908,non-small cell lung carcinoma,DOID,18233,EGFR exon 19 del KRAS amp,resistant,660,Osimertinib,1956,25870145,,,
340,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS E63K were resistant to Tagrisso (osimertinib) AZD9291 treatment in culture (PMID: 25870145).",Actionable,4478,3908,non-small cell lung carcinoma,DOID,18231,EGFR exon 19 del NRAS E63K,resistant,660,Osimertinib,1956,25870145,,,
341,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Iressa (gefitinib) after the emergence of NRAS E63K in culture (PMID: 25870145).",Actionable,4477,3908,non-small cell lung carcinoma,DOID,18231,EGFR exon 19 del NRAS E63K,resistant,751,Gefitinib,1956,25870145,,,
342,Preclinical,"In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS E63K in culture (PMID: 25870145).",Actionable,4476,3908,non-small cell lung carcinoma,DOID,18231,EGFR exon 19 del NRAS E63K,sensitive,913,Selumetinib,1956,25870145,,,
343,Clinical Study,"In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion, MET amplification, and MET D1228V demonstrated a strong response to the combination of Tarceva (erlotinib) and Cometriq (Cabometyx, cabozantinib), resulting in reduced tumor size (PMID: 27694386).",Actionable,9534,3910,lung adenocarcinoma,DOID,26887,EGFR exon 19 del MET amp MET D1228V,sensitive,1255,Cabozantinib + Erlotinib,1956,27694386,,,
344,Preclinical - Pdx & cell culture,"In a preclinical study, EGF816 inhibited proliferation of non-small cell lung cancer (NSCLC) cells harboring an exon 19 deletion in culture, and induced tumor regression in NSCLC patient derived xenograft (PDX) models harboring an exon 19 deletion (PMID: 26825170).",Actionable,5649,3908,non-small cell lung carcinoma,DOID,367,EGFR exon 19 del,sensitive,1309,EGF816,1956,26825170,,,
345,Preclinical,"In a preclinical study, the combination of K-756 and Iressa (gefitinib) worked synergistically to inhibit growth of non-small cell lung cancer cells with wild-type EGFR or EGFR exon 19 deletion in culture (PMID: 27196752).",Actionable,7253,3908,non-small cell lung carcinoma,DOID,367,EGFR exon 19 del,sensitive,4428,K-756 + Gefitinib,1956,27196752,,,
346,Preclinical - Pdx,"In a preclinical study, JNJ-61186372 induced tumor regression in lung adenocaricnoma patient-derived xenograft (PDX) models harboring an EGFR exon 19 deletion, with continued response following treatment cessation (PMID: 27216193).",Actionable,7505,3910,lung adenocarcinoma,DOID,367,EGFR exon 19 del,sensitive,4491,JNJ-61186372,1956,27216193,,,
347,Phase III,"In a meta-analysis of 12 Phase III trials investigating EGFR tyrosine kinase inhibitors in NSCLC patients with EFGR mutations (primarily exon 19 deletions or L858R) indicated TKIs, including icotinib, were superior to standard chemotherapy (PMID: 24533047).",Actionable,771,3908,non-small cell lung carcinoma,DOID,367,EGFR exon 19 del,sensitive,769,Icotinib,1956,24533047,,,
348,Preclinical - Cell line xenograft,"In a preclinical study, Rociletinib (CO-1686) did not result in tumor regression or a survival benefit when treating a NSCLC cell line xenograft model harboring an EGFR exon 19 deletion (PMID: 27435396). ",Actionable,8970,3908,non-small cell lung carcinoma,DOID,367,EGFR exon 19 del,no benefit,1003,CO1686,1956,27435396,,,
349,Guideline,Gilotrif (afatinib) is an active regimen in patients with metastatic NSCLC harboring sensitizing EGFR mutations (Guidelines).,Actionable,2014,3908,non-small cell lung carcinoma,DOID,367,EGFR exon 19 del,sensitive,623,Afatinib,1956,None,,,
350,FDA approved,"In a Phase III study that supported FDA approval, Gilotrif (afatinib) treatment resulted in increased progression-free survival in NSCLC patients with EGFR exon 19 deletions (PMID: 23816960, PMID: 23991291).",Actionable,33,3908,non-small cell lung carcinoma,DOID,367,EGFR exon 19 del,sensitive,623,Afatinib,1956,None,23991291,23816960,
351,Phase II,"In a Phase II trial, Gilotrif (afatinib) treatment resulted in improved progression-free survival (11.0 vs 10.9 months) and time-to-treatment failure (13.7 vs 11.5 months) compared to Iressa (gefitinib) in treatment-naive non-small cell lung carcinoma patients harboring EGFR exon 19 deletion or L858R (PMID: 27083334).",Actionable,6161,3908,non-small cell lung carcinoma,DOID,367,EGFR exon 19 del,sensitive,623,Afatinib,1956,27083334,,,
352,Preclinical - Cell line xenograft,"In a preclinical study, JNJ-61186372 inhibited tumor growth in non-small cell lung cancer cell line xenograft models harboring an EGFR exon 19 deletion, with increased efficacy following treatment cessation compared to Tarceva (erlotinib) (PMID: 27216193).",Actionable,7502,3908,non-small cell lung carcinoma,DOID,367,EGFR exon 19 del,sensitive,4491,JNJ-61186372,1956,27216193,,,
353,Preclinical - Cell line xenograft,"In a preclinical study, addition of Golvatinib (E7050) overcame Hgf-induced Iressa (gefitinib)-resistance in lung adenocarcinoma cell lines harboring EGFR exon 19 deletions in culture and in cell line xenograft models (PMID: 22789825).",Actionable,10759,3910,lung adenocarcinoma,DOID,367,EGFR exon 19 del,sensitive,5610,Gefitinib + Golvatinib,1956,22789825,,,
354,Preclinical - Cell culture,"In a preclinical study, the addition of Sprycel (dasatinib) to treatment with Tagrisso (osimertinib) resulted in increased PARP cleavage and inhibition of proliferation in lung cancer cell line harboring an EGFR exon 19 deletion in culture (PMID: 28416483).",Actionable,11318,1324,lung cancer,DOID,367,EGFR exon 19 del,sensitive,4946,Dasatinib + Osimertinib,1956,28416483,,,
355,Preclinical - Cell line xenograft,"In a preclinical study, AZD3759 inhibited EGFR activation and growth of a lung cancer cell line harboring an EGFR exon 19 deletion in culture and induced tumor regression in subcutaneous xenograft models, and inhibited tumor growth in brain and leptomeningeal xenograft models (PMID: 27928026).",Actionable,9568,1324,lung cancer,DOID,367,EGFR exon 19 del,sensitive,2912,AZD3759,1956,27928026,,,
356,FDA approved,"In a comparison of clinical outcomes, NSCLC patients with either EGFR exon 19 deletion or the L858R mutation responded to treatment with Iressa (gefitinib) or Tarceva (erlotinib) with similar effectiveness, with overall response rates > 75% (PMID: 24736073).",Actionable,770,3908,non-small cell lung carcinoma,DOID,367,EGFR exon 19 del,sensitive,751,Gefitinib,1956,24736073,,,
357,Phase III,"In a Phase III trial, treatment with dacomitinib as first-line therapy in patients with non-small cell lung cancer harboring an EGFR exon 19 deletion or EGFR L858R resulted in an improved median progression-free survival (mPFS) of 14.7 months compared to 9.2 months with Iressa (gefitinib), with a mPFS of 12.3 months with dacomitnib vs. 9.8 months with Iressa (gefitinib) among patients with EGFR exon 19 deletions (PMID: 28958502; NCT01777421).",Actionable,12177,3908,non-small cell lung carcinoma,DOID,367,EGFR exon 19 del,sensitive,714,Dacomitinib,1956,28958502,,,
358,Phase II,"In a Phase II clinical trial, 74% (34/46) of patients with EGFR exon 19 or 21 mutant lung cancers had partial response (PFS average= 17 months) to first line treatment with dacomitinib (J Clin Oncol 30, 2012 (suppl; abstr 7530); NCT00818441).",Actionable,769,3908,non-small cell lung carcinoma,DOID,367,EGFR exon 19 del,sensitive,714,Dacomitinib,1956,None,,,
359,Preclinical - Cell line xenograft,"In a preclinical study, a human NSCLC cell line xenograft model with brain metastases harboring an EGFR exon 19 deletion demonstrated tumor regression and improved survival benefit when treated with Tagrisso (osimertinib) (PMID: 27435396). ",Actionable,8968,3908,non-small cell lung carcinoma,DOID,367,EGFR exon 19 del,sensitive,660,Osimertinib,1956,27435396,,,
360,Phase I,"In a Phase I trial, non-small cell lung cancer patients harboring EGFR exon 19 deletions demonstrated a response rate of 30% (8/27) following treatment with Tagrisso (osimertinib) (PMID: 25923549).",Actionable,2159,3908,non-small cell lung carcinoma,DOID,367,EGFR exon 19 del,sensitive,660,Osimertinib,1956,25923549,,,
361,Preclinical - Cell culture,"In a preclinical study, the addition of Selumetinib (AZD6244) to treatment with Tagrisso (osimertinib) resulted in increased inhibition of proliferation in a lung cancer cell line harboring an EGFR exon 19 deletion in culture (PMID: 28416483).",Actionable,11317,1324,lung cancer,DOID,367,EGFR exon 19 del,sensitive,2225,Osimertinib + Selumetinib,1956,28416483,,,
362,Preclinical - Cell line xenograft,"In a preclinical study, TH-4000 induced tumor regression in erlotinib-resistant human cell line xenograft models of non-small cell lung cancer harboring EGFR exon 19 deletion mutations (J Clin Oncol 33, 2015 (suppl; abstr e13548)).",Actionable,2551,3908,non-small cell lung carcinoma,DOID,367,EGFR exon 19 del,sensitive,2910,TH-4000,1956,None,,,
363,Preclinical - Cell culture,"In a preclinical study, BGB-283 inhibited proliferation of transformed cells over expressing EGFR exon 19 deletion mutation in culture (PMID: 26208524).",Actionable,8060,10000003,Advanced Solid Tumor,JAX,367,EGFR exon 19 del,sensitive,4025,BGB-283,1956,26208524,,,
364,Guideline,"Tarceva (erlotinib) is an active regimen in patients with advanced, recurrent, or metastatic non-small cell lung cancer with sensitizing EGFR mutations (Guidelines).",Actionable,2010,3908,non-small cell lung carcinoma,DOID,367,EGFR exon 19 del,sensitive,4,Erlotinib,1956,None,,,
365,Phase II,"In a Phase II clinical trial, treatment with Tarceva (erlotinib) resulted in a median progression-free survival (PFS) of 10.8 months for the intent-to-treat population of non-small cell lung cancer patients with EGFR mutations, with a PFS of 11.0 months for patients harboring EGFR exon 19 deletions (PMID: 26720423).",Actionable,5304,3908,non-small cell lung carcinoma,DOID,367,EGFR exon 19 del,sensitive,4,Erlotinib,1956,26720423,,,
366,FDA approved,"In a Phase III trial that supported FDA approval, Tarceva (erlotinib) improved progression-free survival in non-small cell lung cancer patients harboring EGFR exon 19 deletions (HR= 0.27) (PMID: 24868098).",Actionable,724,3908,non-small cell lung carcinoma,DOID,367,EGFR exon 19 del,sensitive,4,Erlotinib,1956,None,24868098,,
367,Preclinical - Cell line xenograft,"In a preclinical study, TAE226 treatment inhibited cell proliferation and decreased xenograft tumor size of non-small cell lung carcinoma cell lines harboring EGFR Exon 19 deletion mutation (PMID: 26090892).",Actionable,3928,3908,non-small cell lung carcinoma,DOID,367,EGFR exon 19 del,sensitive,2086,TAE226,1956,26090892,,,
368,Clinical Study,"In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification was resistant to Gilotrif (afatinib) (PMID: 27694386). ",Actionable,9531,3910,lung adenocarcinoma,DOID,25627,EGFR exon 19 del MET amp,sensitive,623,Afatinib,1956,27694386,,,
369,Preclinical - Cell line xenograft,"In a preclinical study, JNJ-61186372 inhibited tumor growth in Tarceva (erlotinib)-resistant non-small cell lung cancer cell line xenograft models harboring an EGFR exon 19 deletion and MET amplification (PMID: 27216193).",Actionable,7503,3908,non-small cell lung carcinoma,DOID,25627,EGFR exon 19 del MET amp,sensitive,4491,JNJ-61186372,1956,27216193,,,
370,Clinical Study,"In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification was resistant to Tarceva (erlotinib) (PMID: 27694386). ",Actionable,9532,3910,lung adenocarcinoma,DOID,25627,EGFR exon 19 del MET amp,resistant,4,Erlotinib,1956,27694386,,,
371,Clinical Study,"In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification demonstrated a near complete response when treated with the combination of Savolitinib (AZD6094) and Tagrisso (osimertinib), however, after 36 weeks presented with progression (PMID: 27694386).",Actionable,9533,3910,lung adenocarcinoma,DOID,25627,EGFR exon 19 del MET amp,sensitive,2224,Osimertinib + Savolitinib,1956,27694386,,,
372,Preclinical,"In a preclinical study, amplification of MET conferred resistance to Iressa (gefitinib) in non-small cell lung cancer cells harboring an EGFR exon 19 deletion mutation in culture (PMID: 17463250).",Actionable,2471,3908,non-small cell lung carcinoma,DOID,8120,EGFR del exon19 MET amp,resistant,751,Gefitinib,1956,17463250,,,
373,Clinical Study,"In a clinical study, treatment with first-line tyrosine kinase inhibitors resulted in a median progression free survival of 4.2 months in non-small cell lung carcinoma patients harboring both TP53 exon 8 and EGFR mutations, compared to 16.8 months in patients harboring TP53 exon 8 wild-type and EGFR exon 19 deletion (J Clin Oncol 34, 2016 (suppl; abstr 9052)).",Actionable,7001,3908,non-small cell lung carcinoma,DOID,24186,EGFR exon 19 del TP53 wild-type,sensitive,1776,N/A,1956,None,,,
374,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to WZ4002 after the emergence of NRAS Q61K in culture (PMID: 25870145).",Actionable,4487,3908,non-small cell lung carcinoma,DOID,18236,EGFR exon 19 del NRAS Q61K,resistant,3075,WZ4002,1956,25870145,,,
375,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS Q61K were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",Actionable,4485,3908,non-small cell lung carcinoma,DOID,18236,EGFR exon 19 del NRAS Q61K,resistant,660,Osimertinib,1956,25870145,,,
376,Preclinical,"In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS Q61K in culture (PMID: 25870145).",Actionable,4486,3908,non-small cell lung carcinoma,DOID,18236,EGFR exon 19 del NRAS Q61K,sensitive,913,Selumetinib,1956,25870145,,,
377,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS G12R were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",Actionable,4491,3908,non-small cell lung carcinoma,DOID,18239,EGFR exon 19 del NRAS G12R,resistant,660,Osimertinib,1956,25870145,,,
378,Preclinical,"In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS G12R in culture (PMID: 25870145).",Actionable,4492,3908,non-small cell lung carcinoma,DOID,18239,EGFR exon 19 del NRAS G12R,sensitive,913,Selumetinib,1956,25870145,,,
379,Preclinical,"In a preclinical study, expression of KRAS G12S in lung adenocarcinoma cells harboring EGFR exon 19 deletion resulted in resistance to Tagrisso (osimertinib) in culture, consistent with KRAS G12S identified in tumor samples of a lung adenocarcinoma patient harboring EGFR exon 19 deletion who developed resistance to Tagrisso (osimertinib) (PMID: 27252416).",Actionable,8803,3910,lung adenocarcinoma,DOID,26445,EGFR exon 19 del KRAS G12S,resistant,660,Osimertinib,1956,27252416,,,
380,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS G12V were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",Actionable,4490,3908,non-small cell lung carcinoma,DOID,18238,EGFR exon 19 del NRAS G12V,resistant,660,Osimertinib,1956,25870145,,,
381,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and amplified NRAS were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",Actionable,4483,3908,non-small cell lung carcinoma,DOID,18234,EGFR exon 19 del NRAS amp,resistant,660,Osimertinib,1956,25870145,,,
382,Preclinical,"In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and amplified NRAS in culture (PMID: 25870145).  ",Actionable,4482,3908,non-small cell lung carcinoma,DOID,18234,EGFR exon 19 del NRAS amp,sensitive,913,Selumetinib,1956,25870145,,,
383,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Gilotrif (afatinib) after the emergence of amplified NRAS in culture (PMID: 25870145).",Actionable,4484,3908,non-small cell lung carcinoma,DOID,18234,EGFR exon 19 del NRAS amp,resistant,623,Afatinib,1956,25870145,,,
384,Clinical Study,"In a prospective clinical study, Gilotrif (afatinib) treatment resulted in partial response in 50% (1/2) and stable disease in 50% (1/2) of non-small cell lung carcinoma patients carrying an EGFR exon 19 deletion and insertion (PMID: 26354527).",Actionable,3363,3908,non-small cell lung carcinoma,DOID,13300,EGFR del exon 19 EGFR exon 19 ins,sensitive,623,Afatinib,1956,26354527,,,
385,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EGFR S768_D770dup (also referred to as D770_N771insSVD) demonstrated resistance to dacomitinib in culture (PMID: 28363995).",Actionable,10506,10000003,Advanced Solid Tumor,JAX,13009,EGFR S768_D770dup,resistant,714,Dacomitinib,1956,28363995,,,
386,Preclinical,"In a preclinical study, sinonasal squamous cell carcinoma cells harboring EGFR S768_D770dup demonstrated resistance to Iressa (gefinitib) in culture (PMID: 25931286).",Actionable,3254,5520,head and neck squamous cell carcinoma,DOID,13009,EGFR S768_D770dup,resistant,751,Gefitinib,1956,25931286,,,
387,Preclinical,"In a preclinical study, sinonasal squamous cell carcinoma cells harboring EGFR S768_D770dup demonstrated resistance to Tarceva (erlotinib) in culture (PMID: 25931286).",Actionable,3257,5520,head and neck squamous cell carcinoma,DOID,13009,EGFR S768_D770dup,resistant,4,Erlotinib,1956,25931286,,,
388,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited EGFR signaling and reduced growth of sinonasal squamous cell carcinoma cells harboring EGFR S768_D770dup in culture (PMID: 25931286).",Actionable,3258,5520,head and neck squamous cell carcinoma,DOID,13009,EGFR S768_D770dup,sensitive,828,Neratinib,1956,25931286,,,
389,Clinical Study,"In a prospective clinical study, Gilotrif (afatinib) treatment resulted in progressive disease in 50% (1/2) of non-small cell lung carcinoma patients carrying an EGFR A750V mutation (PMID: 26354527).",Actionable,3362,3908,non-small cell lung carcinoma,DOID,13299,EGFR A750V,no benefit,623,Afatinib,1956,26354527,,,
390,Preclinical - Cell line xenograft,"In a preclinical study, treatment with GA201 resulted in improved overall survival in KRAS wild-type colorectal cancer cell line xenograft models with low EGFR expression, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).",Actionable,3871,9256,colorectal cancer,DOID,16552,EGFR dec exp KRAS wild-type,sensitive,3154,GA201,1956,23209031,,,
391,Preclinical - Cell line xenograft,"In a preclinical study, treatment with the combination of GA201 and Camptosar (irinotecan) resulted in improved overall survival in KRAS wild-type colorectal cancer cell line xenograft models with low EGFR expression, when compared to either as a single agent (PMID: 23209031).",Actionable,3873,9256,colorectal cancer,DOID,16552,EGFR dec exp KRAS wild-type,sensitive,3373,GA201 + Irinotecan,1956,23209031,,,
392,Preclinical - Cell line xenograft,"In a preclinical study, the combination of ER2 and Platinol (cisplatin) demonstrated synergy in inhibiting tumor growth in a non-small cell lung cancer cell line xenograft model with low expression of wild-type EGFR, that also harbors a KRAS mutation (PMID: 27040853).",Actionable,8042,3908,non-small cell lung carcinoma,DOID,16550,EGFR dec exp KRAS mut,sensitive,4625,ER2 + Cisplatin,1956,27040853,,,
393,Preclinical,"In a preclinical study, treatment with GA201 resulted in improved overall survival in KRAS-mutant colorectal cancer cell line xenograft models with low EGFR expression, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).",Actionable,3867,9256,colorectal cancer,DOID,16550,EGFR dec exp KRAS mut,sensitive,3154,GA201,1956,23209031,,,
394,Preclinical - Cell line xenograft,"In a preclinical study, treatment with GA201 induced antibody-dependent cell-mediated cytotoxicity against KRAS-mutant lung adenocarcinoma with low EGFR expression in culture and improved overall survival in low EGFR expressing, KRAS-mutant lung adenocarcinoma cell line xenograft models, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).",Actionable,3866,3910,lung adenocarcinoma,DOID,16550,EGFR dec exp KRAS mut,sensitive,3154,GA201,1956,23209031,,,
395,Preclinical,"In a preclinical study, treatment with GA201 resulted in improved overall survival in KRAS-mutant non-small cell lung cancer cell line xenograft models with low EGFR expression, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).",Actionable,3865,3908,non-small cell lung carcinoma,DOID,16550,EGFR dec exp KRAS mut,sensitive,3154,GA201,1956,23209031,,,
396,Clinical Study,"In a retrospective analysis, non-small cell lung cancer patients harboring EGFR V769M demonstrated a response rate of 0% and disease control rate of 100%, and a median progression-free survival of 3.2 months following treatment with icotinib (J Clin Oncol 35, 2017 (suppl; abstr e14050)).",Actionable,11159,3908,non-small cell lung carcinoma,DOID,4978,EGFR V769M,decreased response,769,Icotinib,1956,None,,,
397,Preclinical - Cell line xenograft,"In a preclinical study, Tarceva (erlotinib) inhibited cell survival of a human glioblastoma multiforme cell line harboring an EGFR-SEPT14 fusion, and inhibited tumor growth in xenograft models (PMID: 23917401).",Actionable,8573,3068,glioblastoma multiforme,DOID,26359,EGFR-SEPT14,sensitive,4,Erlotinib,1956,23917401,,,
398,Preclinical - Cell line xenograft,"In a preclinical study, Tykerb (lapatinib) inhibited cell survival of a human glioblastoma multiforme cell line harboring an EGFR-SEPT14 fusion, and inhibited tumor growth in xenograft models (PMID: 23917401).",Actionable,8572,3068,glioblastoma multiforme,DOID,26359,EGFR-SEPT14,sensitive,787,Lapatinib,1956,23917401,,,
399,Clinical Study,"In a clinical case study, Tarceva (erlotinib) treatment resulted in partial response lasting for 18 months in a patient with lung adenocarcinoma harboring EGFR G719A and L861Q (PMID: 28343545).",Actionable,10486,3910,lung adenocarcinoma,DOID,27525,EGFR G719A EGFR L861Q,predicted â€“ sensitive,4,Erlotinib,1956,28343545,,,
400,Preclinical - Cell line xenograft,"In a preclinical study, Gilotrif (afatinib) treatment resulted in apoptotic induction in esophagus squamous carcinoma cells harboring EGFR L861Q in culture and inhibited tumor growth in cell line xenograft models (PMID: 27207775). ",Actionable,7882,3748,esophagus squamous cell carcinoma,DOID,1051,EGFR L861Q,sensitive,623,Afatinib,1956,27207775,,,
401,FDA approved,"A study cataloging tyrosine kinase inhibitor responses of NSCLC patients harboring EGFR mutations determined that EGFR L861Q responded to Iressa (gefitinib), but possibly not as favorably as EGFR L858R, exon 19 deletion, and G719X mutations (PMID: 23344264).",Actionable,784,3908,non-small cell lung carcinoma,DOID,1051,EGFR L861Q,sensitive,751,Gefitinib,1956,23344264,,,
402,Preclinical,"In a preclinical study, esophageal squamous cell carcinoma cells harboring EGFR L861Q demonstrated resistance to treatment with Erbitux (cetuximab) in a cell viability assay (PMID: 27207775). ",Actionable,7881,3748,esophagus squamous cell carcinoma,DOID,1051,EGFR L861Q,resistant,694,Cetuximab,1956,27207775,,,
403,Clinical Study,"In an analysis of published clinical data, non-small cell cancer patients harboring EGFR L861Q were demonstrated to respond to treatment with Tarceva (erlotinib), but possibly not as favorably as EGFR L858R, exon 19 deletion, and G719X mutations (PMID: 23344264).",Actionable,783,3908,non-small cell lung carcinoma,DOID,1051,EGFR L861Q,sensitive,4,Erlotinib,1956,23344264,,,
404,Clinical Study,"In a retrospective analysis, non-small cell lung cancer patients harboring EGFR L861Q demonstrated a response rate of 23.53% and disease control rate of 64.71%, and a median progression-free survival of 2.2 months following treatment with icotinib (J Clin Oncol 35, 2017 (suppl; abstr e14050)).",Actionable,11160,3908,non-small cell lung carcinoma,DOID,1051,EGFR L861Q,decreased response,769,Icotinib,1956,None,,,
405,Phase II,"In a post-hoc analysis of Gilotrif (afatinib) activity in Phase II and Phase III clinical trials, 56.3% (9/16) of non-small cell lung cancer patients harboring EGFR L861Q mutations were found to have demonstrated an objective response, with a mean progression-free survival of 8.2 months, and overall survival of 17.1 months (PMID: 26051236).",Actionable,3251,3908,non-small cell lung carcinoma,DOID,1051,EGFR L861Q,sensitive,623,Afatinib,1956,26051236,,,
406,Clinical Study,"In a prospective clinical study, Gilotrif (afatinib) treatment resulted in partial response in 33% (2/6), stable disease in 50% (3/6), and progressive disease in 17% (1/6) of non-small cell lung carcinoma patients harboring EGFR L861Q (PMID: 26354527).",Actionable,3329,3908,non-small cell lung carcinoma,DOID,1051,EGFR L861Q,sensitive,623,Afatinib,1956,26354527,,,
407,Preclinical - Cell culture,"In a preclinical study, esophagus squamous cell carcinoma cells harboring EGFR L861Q demonstrated resistance to treatment with Tarceva (erlotinib) in a cell viability assay (PMID: 27207775). ",Actionable,7879,3748,esophagus squamous cell carcinoma,DOID,1051,EGFR L861Q,resistant,4,Erlotinib,1956,27207775,,,
408,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EGFR Y764_V765insHH demonstrated resistance to dacomitinib in culture (PMID: 28363995).",Actionable,10508,10000003,Advanced Solid Tumor,JAX,27529,EGFR Y764_V765insHH,resistant,714,Dacomitinib,1956,28363995,,,
409,Preclinical - Cell culture,"In a preclinical study, the addition of Mekinist (trametinib) to WZ4002 treatment did not significantly impact cell viability compared to WZ4002 alone, but delayed onset of drug resistance in a non-small cell lung cancer cell line harboring EGFR L747_T751del and EGFR S752I in culture (PMID: 26036643).",Actionable,9057,3908,non-small cell lung carcinoma,DOID,26703,EGFR L747_T751del EGFR S752I,sensitive,3351,WZ4002 + Trametinib,1956,26036643,,,
410,Preclinical - Cell line xenograft,"In a preclinical study, S-222611 inhibited cell growth and resulted in anti-tumor activity of human breast cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299). ",Actionable,7722,1612,breast cancer,DOID,2242,EGFR pos ERBB2 pos,sensitive,1048,S-222611,1956,24837299,,,
411,Preclinical,"In a preclinical study, colorectal cancer cells positive for EGFR and ERBB2 (HER2) had decreased growth upon Gilotrif (afatinib) treatment (PMID: 21617858).",Actionable,1214,9256,colorectal cancer,DOID,2242,EGFR pos ERBB2 pos,sensitive,623,Afatinib,1956,21617858,,,
412,Preclinical - Cell line xenograft,"In a preclinical study, S-222611 inhibited cell growth, decreased phosphorylation of Egfr and Erbb2, and resulted in anti-tumor activity of human gastric cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299). ",Actionable,2842,10534,stomach cancer,DOID,2242,EGFR pos ERBB2 pos,sensitive,1048,S-222611,1956,24837299,,,
413,Preclinical - Cell line xenograft,"In a preclinical study, Gilotrif (afatinib) pre-treatment inhibited radiotherapy-induced activation of EGFR and ERBB2 (HER2) and downstream AKT and radiosensitized bladder cancer cell lines in culture, and Gilotrif (afatinib) in combination with radiotherapy led to improved tumor growth inhibition in bladder cancer cell line xenograft models compared to radiotherapy alone (PMID: 25589492).",Actionable,8342,11054,urinary bladder cancer,DOID,2242,EGFR pos ERBB2 pos,predicted â€“ sensitive,4711,Afatinib + Radiotherapy,1956,25589492,,,
414,Preclinical - Cell line xenograft,"In a preclinical study, S-222611 inhibited cell growth and resulted in anti-tumor activity of human lung cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299). ",Actionable,7723,1324,lung cancer,DOID,2242,EGFR pos ERBB2 pos,sensitive,1048,S-222611,1956,24837299,,,
415,Preclinical - Cell line xenograft,"In a preclinical study, S-222611 inhibited cell growth and resulted in anti-tumor activity of human colon cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299). ",Actionable,7724,219,colon cancer,DOID,2242,EGFR pos ERBB2 pos,sensitive,1048,S-222611,1956,24837299,,,
416,Preclinical - Cell line xenograft,"In a preclinical study, SYM004 demonstrated efficacy in cell line xenograft models of Erbitux (cetuximab)-resistant non-small cell lung cancer (PMID: 24204198).",Actionable,1231,3908,non-small cell lung carcinoma,DOID,1102,EGFR positive,predicted â€“ sensitive,931,SYM004,1956,24130052, 'url': 'http://www.ncbi.nlm.nih.gov/pubmed/24130052'},24204198,
417,Phase I,"In a Phase I clinical trial, AC480 (BMS-599626) treatment demonstrated preliminary clinical activity, resulting in stable disease as best response in 25% (11/44) of patients with advanced solid tumors, including patients expressing EGFR and/or ERBB2, with 2 patients achieving stable disease for greater than 6 months (PMID: 21576284).",Actionable,4371,10000003,Advanced Solid Tumor,JAX,1102,EGFR positive,predicted â€“ sensitive,977,AC480,1956,21576284,,,
418,Phase I,"In a Phase I study, 13% (5/39) of patients with metastatic colorectal cancer resistant to EGFR therapy had a partial response to SYM004 while 44% (17/39) demonstrated tumor regression (PMID: 25962717).",Actionable,2229,9256,colorectal cancer,DOID,1102,EGFR positive,sensitive,931,SYM004,1956,25962717,,,
419,Preclinical - Cell culture,"In a preclinical study, tumor cell lines expressing EGFR  demonstrated efficacy in culture when treated with the bispecific antibody, AFM24 (J Clin Oncol 35, 2017 (suppl; abstr e14001)).",Actionable,11075,10000003,Advanced Solid Tumor,JAX,1102,EGFR positive,sensitive,5856,AFM24,1956,None,,,
420,Phase II,"In a Phase II trial, addition of Nimotuzumab to Camptosar (irinotecan) improved median progression-free survival (118.5 vs 59.0 days), median overall survival (358.5 vs 229.5 days) and response rate (33.3% vs 0.0 %) compared to Camptosar alone in EGFR positive gastric cancer patients (PMID: 25185971).",Actionable,8760,10534,stomach cancer,DOID,1102,EGFR positive,predicted â€“ sensitive,4806,Irinotecan + Nimotuzumab,1956,25185971,,,
421,Phase I,"In a Phase I clinical trial, S-222611 demonstrated safety and some efficacy in patients with advanced solid tumors expressing EGFR or ERBB2 (HER2), with an overall clinical benefit rate of 27% (7/33) (PMID: 25434923).",Actionable,1148,10000003,Advanced Solid Tumor,JAX,1102,EGFR positive,predicted â€“ sensitive,1048,S-222611,1956,25434923,,,
422,Preclinical - Cell line xenograft,"In a preclinical study, GC1118 inhibited EGFR ligand binding and reduced ligand-induced downstream signaling and proliferation of colorectal cancer cell lines exposed to a variety of EGFR ligands in culture, and inhibited tumor growth in colorectal cancer cell line xenograft models expressing high-affinity EGFR ligands (PMID: 26586721).",Actionable,9299,9256,colorectal cancer,DOID,1102,EGFR positive,predicted â€“ sensitive,2913,GC1118,1956,26586721,,,
423,Phase I,"In a Phase I trial, ABBV-221 demonstrated safety and preliminary efficacy, resulting in stable disease in 38% (16/42) of patients with EGFR-dependent solid tumors (Journal of Clinical Oncology 35, no. 15_suppl (May 2017) 2510-2510; NCT02365662). ",Actionable,11803,10000003,Advanced Solid Tumor,JAX,1102,EGFR positive,predicted â€“ sensitive,2914,ABBV-221,1956,None,,,
424,Preclinical - Cell line xenograft,"In a preclinical study, S-222611 inhibited tumor growth of human kidney cancer cells expressing EGFR in cell line xenograft models (PMID: 24837299). ",Actionable,7725,263,kidney cancer,DOID,1102,EGFR positive,sensitive,1048,S-222611,1956,24837299,,,
425,Phase I,"In a Phase I clinical trial in patients with advanced solid tumors, MM-151 demonstrated safety and preliminary antitumor activity in patients with colorectal cancer (CRC), with 2 partial responses and 30% (8/26) of CRC patients demonstrating stable disease for greater than 4 months (J Clin Oncol 32:5s, 2014 (suppl; abstr 2518)).",Actionable,7048,9256,colorectal cancer,DOID,1102,EGFR positive,predicted â€“ sensitive,821,MM-151,1956,None,,,
426,Preclinical - Cell line xenograft,"In a preclinical study, SYM004 enhanced sensitivity to radiation therapy in non-small cell lung cancer cells in culture and in cell line xenografts (PMID: 24130052).",Actionable,6671,3908,non-small cell lung carcinoma,DOID,1102,EGFR positive,predicted â€“ sensitive,4231,SYM004 + Radiotherapy,1956,24130052,,,
427,Phase I,"In a Phase I trial, ABBV-221 demonstrated safety and preliminary efficacy, resulting in unconfirmed partial response in a patient with head and neck cancer that expressed high level of Egfr and its ligand (Journal of Clinical Oncology 35, no. 15_suppl (May 2017) 2510-2510; NCT02365662). ",Actionable,11804,11934,head and neck cancer,DOID,1102,EGFR positive,predicted â€“ sensitive,2914,ABBV-221,1956,None,,,
428,Phase III,"In a Phase III trial, no difference in disease free survival was observed in non-small cell lung cancer patients positive for Egfr treated with Tarceva (erlotinib) vs placebo in the adjuvant setting (PMID: 26324372).",Actionable,4437,3908,non-small cell lung carcinoma,DOID,1102,EGFR positive,no benefit,4,Erlotinib,1956,26324372,,,
429,Preclinical - Cell line xenograft,"In a preclinical study, EGFRBi-armed autologous activated T cells demonstrated efficacy in cultured cells and cell line mouse xenograft models of a variety of EGFR positive tumor types including pancreatic adenocarcinoma (PMID: 16397041).",Actionable,335,4074,pancreatic adenocarcinoma,DOID,1102,EGFR positive,sensitive,1012,EGFRBi-armed autologous activated T cells,1956,16397041,,,
430,Preclinical - Cell culture,"In a preclinical study, AVID100 demonstrated activity against several EGFR-positive tumor cell lines in culture (Eur J Cancer, Dec 2016, Vol 69, S147).",Actionable,10973,10000003,Advanced Solid Tumor,JAX,1102,EGFR positive,predicted â€“ sensitive,5755,AVID100,1956,None,,,
431,Preclinical - Cell culture,"In a preclinical study, EGFRBi-armed autologous activated T cells demonstrated efficacy in cultured cells of a variety of EGFR positive tumor types (PMID: 16397041).",Actionable,336,10000003,Advanced Solid Tumor,JAX,1102,EGFR positive,sensitive,1012,EGFRBi-armed autologous activated T cells,1956,16397041,,,
432,Phase I,"In a Phase I study, patients with advanced solid tumors that were positive for EGFR expression demonstrated no complete or partial responses when treated with Pelitinib (EKB-569) (PMID: 16710023). ",Actionable,23,10000003,Advanced Solid Tumor,JAX,1102,EGFR positive,no benefit,852,Pelitinib,1956,16710023,,,
433,Preclinical - Cell line xenograft,"In a preclinical study, treatment with GA201 resulted in improved overall survival in EGFR-positive pancreatic cancer cell line xenograft models harboring KRAS mutations, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).",Actionable,3869,1793,pancreatic cancer,DOID,16548,EGFR pos KRAS mut,sensitive,3154,GA201,1956,23209031,,,
434,Preclinical - Cell line xenograft,"In a preclinical study, treatment with GA201 resulted in increased tumor growth inhibition in EGFR-positive triple-negative breast cancer cell line xenograft models harboring KRAS mutations when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).",Actionable,3870,60081,triple-receptor negative breast cancer,DOID,16548,EGFR pos KRAS mut,sensitive,3154,GA201,1956,23209031,,,
435,Preclinical - Cell line xenograft,"In a preclinical study, treatment with GA201 resulted in improved overall survival in EGFR-positive renal cell carcinoma cell line xenograft models harboring KRAS mutations, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).",Actionable,3868,4450,renal cell carcinoma,DOID,16548,EGFR pos KRAS mut,sensitive,3154,GA201,1956,23209031,,,
436,Clinical Study,"In a retrospective analysis, non-small cell lung cancer patients harboring EGFR L833F demonstrated a response rate of 0% and disease control rate of 100%, and a median progression-free survival of 4.2 months following treatment with icotinib (J Clin Oncol 35, 2017 (suppl; abstr e14050)).",Actionable,11162,3908,non-small cell lung carcinoma,DOID,27921,EGFR L833F,decreased response,769,Icotinib,1956,None,,,
437,Clinical Study,"In a retrospective clinical study, non-small cell lung cancer patients with EGFR exon 20 insertions demonstrated inferior progression-free survival following treatment with first-generation EGFR tyrosine kinase inhibitors such as Iressa (gefitinib), Tarceva (erlotinib), or Icotinib compared to patients with EGFR L858R and exon 19 deletion mutations (1.9 months vs. 10.8 months) (PMID: 27468240).",Actionable,7799,3908,non-small cell lung carcinoma,DOID,4039,EGFR exon 20 ins,predicted â€“ resistant,4,Erlotinib,1956,27468240,,,
438,Clinical Study,"In a retrospective analysis, non-small cell lung cancer patients harboring EGFR exon 20 insertions displayed progressive disease following treatment with Tarceva (erlotinib), and resistance to Tarceva (erlotinib) was replicated in cell culture studies (PMID: 24353160).",Actionable,2568,3908,non-small cell lung carcinoma,DOID,4039,EGFR exon 20 ins,predicted â€“ resistant,4,Erlotinib,1956,24353160,,,
439,Preclinical - Pdx & cell culture,"In a preclinical study, AP32788 inhibited growth of transformed cell lines over expressing EGFR exon 20 insertions in culture, and induced tumor regression in PDX models (AACR, Cancer Res: April 2016; Volume 57, Abstract #2644).",Actionable,5915,10000003,Advanced Solid Tumor,JAX,4039,EGFR exon 20 ins,sensitive,3981,AP32788,1956,None,,,
440,Preclinical - Cell culture,"In a preclinical study, EGF816 inhibited growth of transformed cell lines expressing three different EGFR exon 20 insertions in culture (PMID: 26825170).",Actionable,5655,10000003,Advanced Solid Tumor,JAX,4039,EGFR exon 20 ins,predicted â€“ sensitive,1309,EGF816,1956,26825170,,,
441,Preclinical,"In a preclinical study, cells expressing an EGFR exon 20 insertion demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 24065731).",Actionable,2561,10000003,Advanced Solid Tumor,JAX,4039,EGFR exon 20 ins,resistant,1003,CO1686,1956,24065731,,,
442,Clinical Study,"In a retrospective study, non-small cell lung cancer patients with EGFR exon 20 insertions demonstrated inferior progression-free survival following treatment with first-generation EGFR tyrosine kinase inhibitors such as Iressa (gefitinib), Tarceva (erlotinib), or icotinib compared to patients with EGFR L858R or exon 19 deletion mutations (1.9 months vs. 10.8 months) (PMID: 27468240).",Actionable,7800,3908,non-small cell lung carcinoma,DOID,4039,EGFR exon 20 ins,decreased response,769,Icotinib,1956,27468240,,,
443,Clinical Study,"In a retrospective analysis, non-small cell lung cancer patients harboring EGFR exon 20 insertions demonstrated a response rate of 11.11%  and disease control rate of 44.44%, and a median progression-free survival of 1.9 months following treatment with icotinib (J Clin Oncol 35, 2017 (suppl; abstr e14050)). ",Actionable,11153,3908,non-small cell lung carcinoma,DOID,4039,EGFR exon 20 ins,decreased response,769,Icotinib,1956,None,,,
444,Phase II,"In a post-hoc analysis of Gilotrif (afatinib) activity in non-small cell lung cancer patients with uncommon EGFR mutations, Gilotrif (afatinib) was found to have limited clinical activity in patients harboring EGFR exon 20 insertions, with 8.7% (2/23) patients achieving partial response and a median progression-free survival of 2.7 months (PMID: 26051236).",Actionable,2612,3908,non-small cell lung carcinoma,DOID,4039,EGFR exon 20 ins,resistant,623,Afatinib,1956,26051236,,,
445,Clinical Study,"In a prospective clinical study, Gilotrif (afatinib) treatment resulted in partial response in 33% (1/3), stable disease in 33% (1/3), and progressive disease in 337% (1/3) in non-small cell lung carcinoma patients carrying an EGFR exon 20 insertion mutation (PMID: 26354527).",Actionable,3364,3908,non-small cell lung carcinoma,DOID,4039,EGFR exon 20 ins,resistant,623,Afatinib,1956,26354527,,,
446,Preclinical,"In a preclinical study, non-small cell carcinoma cell lines harboring EGFR exon 20 insertions demonstrated resistance to Gilotrif (afatinib) in cell culture (PMID: 24353160).",Actionable,2567,3908,non-small cell lung carcinoma,DOID,4039,EGFR exon 20 ins,resistant,623,Afatinib,1956,24353160,,,
447,Phase II,"In a Phase II trial, AUY922 demonstrated safety and preliminary efficacy in EGFR TKI-resistant non-small cell lung cancer patients harboring EGFR exon 20 insertions, with 10% (1/10) of patients achieving partial response and 30% of (3/10) patients achieving stable disease, and a median progression-free survival of 6.1 months (J Clin Oncol 33, 2015 (suppl; abstr 8015)).",Actionable,2559,3908,non-small cell lung carcinoma,DOID,4039,EGFR exon 20 ins,sensitive,647,AUY922,1956,None,,,
448,Preclinical,"In a preclinical study, transformed cells expressing an EGFR exon 20 insertion mutation had decreased response to Dacomitinib compared to other EGFR activating mutations, with inhibitory doses exceeding clinically attainable levels (PMID: 18089823, PMID: 21764376).",Actionable,2562,10000003,Advanced Solid Tumor,JAX,4039,EGFR exon 20 ins,resistant,714,Dacomitinib,1956,18089823,21764376,,
449,Preclinical,"In a preclinical study, cells expressing an EGFR exon 20 insertion mutation were resistant to AZD9291 in culture (PMID: 24893891).",Actionable,2564,10000003,Advanced Solid Tumor,JAX,4039,EGFR exon 20 ins,resistant,660,Osimertinib,1956,24893891,,,
450,Clinical Study,"In a retrospective clinical study, non-small cell lung cancer patients with EGFR exon 20 insertions demonstrated inferior progression-free survival following treatment with first-generation EGFR tyrosine kinase inhibitors such as Iressa (gefitinib), Tarceva (erlotinib), or Icotinib compared to patients with EGFR L858R and exon 19 deletion mutations (1.9 months vs. 10.8 months) (PMID: 27468240).",Actionable,7798,3908,non-small cell lung carcinoma,DOID,4039,EGFR exon 20 ins,resistant,751,Gefitinib,1956,27468240,,,
451,Clinical Study,"In a retrospective analysis, non-small cell lung cancer patients harboring EGFR exon 20 insertions displayed progressive disease following treatment with Iressa (gefitinib), and resistance to Iressa (gefitinib) was replicated in cell culture studies (PMID: 24353160).",Actionable,2569,3908,non-small cell lung carcinoma,DOID,4039,EGFR exon 20 ins,resistant,751,Gefitinib,1956,24353160,,,
452,Clinical Study,"In a retrospective analysis, non-small cell lung cancer patients harboring EGFR exon 20 insertions, such as EGFR H773_V774insH, displayed progressive disease following treatment with Iressa (gefitinib) (PMID: 24353160).",Actionable,793,3908,non-small cell lung carcinoma,DOID,1047,EGFR H773_V774insH,resistant,751,Gefitinib,1956,24353160,,,
453,Preclinical,"In a preclinical study, non-small cell carcinoma cell lines harboring EGFR exon 20 insertions, including EGFR H773_V774insH, demonstrated resistance to Gilotrif (afatinib) in cell culture (PMID: 24353160).",Actionable,795,3908,non-small cell lung carcinoma,DOID,1047,EGFR H773_V774insH,resistant,623,Afatinib,1956,24353160,,,
454,Clinical Study,"In a retrospective analysis, non-small cell lung cancer patients harboring EGFR exon 20 insertions, such as EGFR H773_V774insH, displayed progressive disease following treatment with Tarceva (erlotinib), and resistance to Tarceva (erlotinib) was replicated in cell culture studies (PMID: 24353160).",Actionable,794,3908,non-small cell lung carcinoma,DOID,1047,EGFR H773_V774insH,resistant,4,Erlotinib,1956,24353160,,,
455,Clinical Study,"In a retrospective analysis, non-small cell lung cancer patients harboring EGFR E709 mutations demonstrated a response rate of 66.66% and a median progression-free survival of 3.1 months following treatment with icotinib (J Clin Oncol 35, 2017 (suppl; abstr e14050)).",Actionable,11156,3908,non-small cell lung carcinoma,DOID,13298,EGFR E709X,decreased response,769,Icotinib,1956,None,,,
456,Clinical Study,"In a prospective clinical study, Gilotrif (afatinib) treatment resulted in partial response in 50% (2/4) and stable disease in 50% (2/4) of non-small cell lung carcinoma patients carrying an EGFR E709 mutation (PMID: 26354527).",Actionable,3360,3908,non-small cell lung carcinoma,DOID,13298,EGFR E709X,sensitive,623,Afatinib,1956,26354527,,,
457,Preclinical,"In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR G465E in culture (PMID: 26843189).",Actionable,6632,9256,colorectal cancer,DOID,23653,EGFR G465E,sensitive,821,MM-151,1956,26843189,,,
458,Preclinical,"In a preclinical study, colorectal cancer cell lines over expressing EGFR G465E were resistant to Erbitux (cetuximab)-induced growth inhibition in culture (PMID: 26843189).",Actionable,6634,9256,colorectal cancer,DOID,23653,EGFR G465E,resistant,694,Cetuximab,1956,26843189,,,
459,Preclinical,"In a preclinical study, colorectal cancer cell lines over expressing EGFR G465E were resistant to Vectibix (panitumumab)-induced growth inhibition in culture (PMID: 26843189).",Actionable,6633,9256,colorectal cancer,DOID,23653,EGFR G465E,resistant,845,Panitumumab,1956,26843189,,,
460,Preclinical - Cell culture,"In a preclinical study, the combination of Xalkori (crizotinib) and Tykerb (lapatinib) worked synergistically to inhibit growth of an esophageal adenocarcinoma cell line with EGFR and MET copy number gain in culture (PMID: 27595477).",Actionable,11557,4914,esophagus adenocarcinoma,DOID,17304,EGFR amp MET amp,sensitive,3440,Crizotinib + Lapatinib,1956,27595477,,,
461,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).",Actionable,7665,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,resistant,2618,SCH772984,1956,27312529,,,
462,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib) in culture (PMID: 27312529).",Actionable,7664,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,resistant,1066,Trametinib + Dabrafenib,1956,27312529,,,
463,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Selumetinib (AZD6244) in culture (PMID: 27312529).",Actionable,7637,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,resistant,913,Selumetinib,1956,27312529,,,
464,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).",Actionable,7666,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,sensitive,4542,Cetuximab + Dabrafenib + SCH772984,1956,27312529,,,
465,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Erbitux (cetuximab) in culture (PMID: 27312529).",Actionable,7635,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,resistant,694,Cetuximab,1956,27312529,,,
466,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment in culture (PMID: 27312529).",Actionable,7633,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,resistant,4536,Cetuximab + Selumetinib,1956,27312529,,,
467,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7636,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,resistant,342,Vemurafenib,1956,27312529,,,
468,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) in culture (PMID: 27312529).",Actionable,7663,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,resistant,1916,Cetuximab + Encorafenib,1956,27312529,,,
469,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Selumetinib (AZD6244), and Zelboraf (vemurafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).",Actionable,7634,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,sensitive,4540,Cetuximab + Selumetinib + Vemurafenib,1956,27312529,,,
470,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired EGFR amplification and subsequent resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment were resistant to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment in culture (PMID: 27312529).",Actionable,7632,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,resistant,1711,Vemurafenib + Cetuximab,1956,27312529,,,
471,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Zelboraf (vemurafenib) combination treatment in culture, likely due to the acquired EGFR amplification (PMID: 27312529).",Actionable,7621,9256,colorectal cancer,DOID,25921,BRAF V600E EGFR amp,resistant,3773,Selumetinib + Vemurafenib,1956,27312529,,,
472,Phase III,"In a Phase III study, response to Vectibix (pantitumumab) was associated with EGFR amplification in colorectal cancer patients (PMID: 17664472).",Actionable,2554,9256,colorectal cancer,DOID,447,EGFR amp,sensitive,845,Panitumumab,1956,17664472,,,
473,Phase Ib/II,"In a Phase I/II clinical trial, Torisel (temsirolimus) in combination with Tarceva (erlotinib) demostrated minimal efficacy at the maximum tolerated dosage in high-grade glioma patients, with no correlation between EGFR amplification and survival (PMID: 24470557).",Actionable,847,3070,malignant glioma,DOID,447,EGFR amp,no benefit,1340,Temsirolimus + Erlotinib,1956,24470557,,,
474,Preclinical - Cell line xenograft,"In a preclinical study, Gilotrif (afatinib) inhibited growth of head and neck squamous cell carcinoma (HNSCC) cell lines in culture, and inhibited tumor growth in HNSCC cell line xenograft models, with highest efficacy against EGFR-amplified cell lines (PMID: 25559287).",Actionable,6072,5520,head and neck squamous cell carcinoma,DOID,447,EGFR amp,sensitive,623,Afatinib,1956,25559287,,,
475,Preclinical,"In a preclinical study, ABT-414 demonstrated cytotoxicity against a EGFR-amplified triple-negative breast cancer cell line in culture (PMID: 26846818).",Actionable,6996,60081,triple-receptor negative breast cancer,DOID,447,EGFR amp,sensitive,976,ABT-414,1956,26846818,,,
476,Preclinical - Cell culture,"In a preclinical study, the combination of Tarceva (erlotinib) and PF-431396 resulted in a synergistic effect in a triple-receptor negative breast cancer cell line harboring EGFR amplification, demonstrating inhibition of cell growth in culture (PMID: 27793840). ",Actionable,10109,60081,triple-receptor negative breast cancer,DOID,447,EGFR amp,sensitive,5393,Erlotinib + PF-431396,1956,27793840,,,
477,Preclinical - Cell culture,"In a preclinical study, combination of an unspecified EGFR antibody, an unspecified Erbb3 (Her3) antibody, and an unspecified Igf-1r antibody resulted in potent inhibition of survival in Egfr amplified head and neck cancer cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767).",Actionable,7781,11934,head and neck cancer,DOID,447,EGFR amp,sensitive,4580,EGFR antibody + ERBB3 antibody + IGF-1R antibody,1956,27196767,,,
478,Preclinical - Cell culture,"In a preclinical study, esophagus squamous cell carcinoma cells harboring EGFR amplification demonstrated resistance to Tarceva (erlotinib) in a cell viability assay (PMID: 27207775). ",Actionable,7894,3748,esophagus squamous cell carcinoma,DOID,447,EGFR amp,resistant,4,Erlotinib,1956,27207775,,,
479,Preclinical - Cell culture,"In a preclinical study, head and neck squamous cell carcinoma cells harboring EGFR amplification demonstrated resistance to Erbitux (cetuximab) in a cell viability assay (PMID: 27207775).",Actionable,7897,5520,head and neck squamous cell carcinoma,DOID,447,EGFR amp,resistant,694,Cetuximab,1956,27207775,,,
480,Preclinical - Cell culture,"In a preclinical study, the combination of Iressa (gefitinib) and PF-573228 resulted in a synergistic effect in a triple-receptor negative breast cancer cell line harboring EGFR amplification, demonstrating decreased colony formation in culture (PMID: 27793840). ",Actionable,10100,60081,triple-receptor negative breast cancer,DOID,447,EGFR amp,sensitive,5389,Gefitinib + PF-573228,1956,27793840,,,
481,Preclinical - Pdx,"In preclinical studies, Erbitux (cetuximab) promoted tumor growth inhibition in several patient-derived xenograft models of gastric cancers with EGFR amplification (PMID: 24141978).",Actionable,140,3119,gastrointestinal system cancer,DOID,447,EGFR amp,sensitive,694,Cetuximab,1956,24141978,,,
482,Preclinical - Cell line xenograft,"In a preclinical study, SHP099 inhibited ERK activation and reduced proliferation of EGFR-amplified esophageal squamous cell carcinoma cells in culture, and inhibited tumor growth in EGFR-amplified esophageal squamous cell carcinoma cell line xenograft models (PMID: 27362227).",Actionable,7513,3748,esophagus squamous cell carcinoma,DOID,447,EGFR amp,sensitive,4504,SHP099,1956,27362227,,,
483,Preclinical - Cell culture,"In a preclinical study, esophagus squamous cell carcinoma cells harboring EGFR amplification demonstrated resistance to Erbitux (cetuximab) in a cell viability assay (PMID: 27207775). ",Actionable,7896,3748,esophagus squamous cell carcinoma,DOID,447,EGFR amp,resistant,694,Cetuximab,1956,27207775,,,
484,Phase I,"In a Phase I trial, ABT-414 displayed safety and preliminary efficacy in advanced solid tumor patients with EGFR amplification (J Clin Oncol 33, 2015 (suppl; abstr 2510)).",Actionable,3741,10000003,Advanced Solid Tumor,JAX,447,EGFR amp,sensitive,976,ABT-414,1956,None,,,
485,Preclinical - Cell culture,"In a preclinical study, esophagus squamous cell carcinoma cells harboring EGFR amplification demonstrated resistance to Gilotrif (afatinib) in a cell viability assay (PMID: 27207775). ",Actionable,7892,3748,esophagus squamous cell carcinoma,DOID,447,EGFR amp,resistant,623,Afatinib,1956,27207775,,,
486,Preclinical - Cell culture,"In a preclinical study, the combination of Iressa (gefitinib) and PF-431396 resulted in a synergistic effect in a triple-receptor negative breast cancer cell line harboring EGFR amplification, demonstrating a decrease in colony formation in culture (PMID: 27793840). ",Actionable,10104,60081,triple-receptor negative breast cancer,DOID,447,EGFR amp,sensitive,5391,Gefitinib + PF-431396,1956,27793840,,,
487,Preclinical - Pdx & cell culture,"In a preclinical study, Dacomitinib inhibited Egfr signaling and survival of patient-derived EGFR amplified glioblastoma cells in culture and in intracranial xenograft models (PMID: 25939761).",Actionable,8043,3068,glioblastoma multiforme,DOID,447,EGFR amp,sensitive,714,Dacomitinib,1956,25939761,,,
488,Preclinical - Cell line xenograft,"In a preclinical study, ABT-414 demonstrated cytoxicity against an EGFR-amplified head and neck squamous cell carcinoma (HNSCC) cell line in culture and induced tumor regression in EGFR-amplified HNSCC cell line xenograft models (PMID: 26846818).",Actionable,6933,5520,head and neck squamous cell carcinoma,DOID,447,EGFR amp,sensitive,976,ABT-414,1956,26846818,,,
489,Clinical Study,"In a clinical case study, a patient with esophageal adenocarcinoma progressed on AMG 337 therapy upon outgrowth of EGFR amplified tumor cells (PMID: 26432108).",Actionable,4101,4914,esophagus adenocarcinoma,DOID,447,EGFR amp,resistant,1064,AMG 337,1956,26432108,,,
490,Preclinical,"In a preclinical study, MM-151 antagonized EGFR activity and inhibited proliferation in several tumor cell lines in culture (PMID: 25911688).",Actionable,2553,10000003,Advanced Solid Tumor,JAX,447,EGFR amp,predicted â€“ sensitive,821,MM-151,1956,25911688,,,
491,Preclinical - Cell culture,"In a preclinical study, combination of two unspecified EGFR antibodies targeting nonoverlapping epitopes of Egfr resulted in Egfr degradation and inhibition of proliferation in Egfr amplified head and neck cancer cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767).",Actionable,7776,11934,head and neck cancer,DOID,447,EGFR amp,sensitive,4575,unspecified EGFR antibody,1956,27196767,,,
492,Preclinical - Cell culture,"In a preclinical study, Ganetespib inhibited growth of a non-small cell lung cancer cell line with EGFR amplification and overexpression in culture (PMID: 25077897).",Actionable,8230,3908,non-small cell lung carcinoma,DOID,447,EGFR amp,sensitive,745,Ganetespib,1956,25077897,,,
493,Phase II,"In a Phase II trial, Caprelsa (vandetinib), in combination with radiation therapy and Temodar (temozolomide), demonstrated no difference in PFS and OS in glioblastoma patients harboring EGFR amplification versus glioblastoma patients without EGFR amplification (PMID: 25910950). ",Actionable,3239,3068,glioblastoma multiforme,DOID,447,EGFR amp,no benefit,3094,Vandetanib + Temozolomide,1956,25910950,,,
494,Preclinical - Cell culture,"In a preclinical study, combination of an unspecified EGFR antibody and an unspecified Erbb3 (Her3) antibody resulted in inhibition of survival in Egfr amplified head and neck cancer cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767).",Actionable,7779,11934,head and neck cancer,DOID,447,EGFR amp,sensitive,4579,unspecified EGFR antibody + unspecified ERBB3 antibody,1956,27196767,,,
495,Phase II,"In a Phase II clinical trial, three urothelial carcinoma  patients with EGFR amplification in the absence of other ERBB family member alterations, received no benefit from Gilotrif (afatinib) therapy (PMID: 27044931).",Actionable,5941,11054,urinary bladder cancer,DOID,447,EGFR amp,no benefit,623,Afatinib,1956,27044931,,,
496,Phase I,"In a Phase I trial, ABT-414 displayed safety and preliminary efficacy in glioblastoma patients with EGFR amplification (J Clin Oncol 33, 2015 (suppl; abstr 2016)).",Actionable,3740,3068,glioblastoma multiforme,DOID,447,EGFR amp,sensitive,976,ABT-414,1956,None,,,
497,Phase I,"In a Phase I trial, ABT-414 treatment resulted in partial response in 5% (3/56), stable disease in 43% (24/56), and an estimated 6-month progression-free survival rate of 25.3% in patients with bevacizumab-naÃ¯ve, recurrent glioblastoma harboring EGFR amplification (Neuro Oncol (2016) 18 (suppl 6): vi2.).",Actionable,9358,3068,glioblastoma multiforme,DOID,447,EGFR amp,sensitive,976,ABT-414,1956,None,,,
498,Preclinical - Cell culture,"In a preclinical study, SHP099 inhibited ERK activation and reduced proliferation of an EGFR-amplified triple-negative breast cancer cell line in culture (PMID: 27362227).",Actionable,7514,60081,triple-receptor negative breast cancer,DOID,447,EGFR amp,sensitive,4504,SHP099,1956,27362227,,,
499,Phase I,"In a Phase I trial, ABT-806 treatment resulted in stable disease for more than 2.5 years in a penile cancer patient harboring EGFR amplification (PMID: 25895099).",Actionable,6891,11615,penile cancer,DOID,447,EGFR amp,sensitive,4256,ABT-806,1956,25895099,,,
500,Preclinical - Cell culture,"In a preclinical study, head and neck squamous cell carcinoma cells harboring EGFR amplification demonstrated resistance to  Tarceva (erlotinib) in a cell viability assay (PMID: 27207775). ",Actionable,7898,5520,head and neck squamous cell carcinoma,DOID,447,EGFR amp,resistant,4,Erlotinib,1956,27207775,,,
501,Preclinical - Cell culture,"In a preclinical study, combination of an unspecified EGFR antibody and an unspecified Igf-1r antibody resulted in growth inhibition in Egfr amplified head and neck cancer cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767).",Actionable,7780,11934,head and neck cancer,DOID,447,EGFR amp,sensitive,4578,unspecified EGFR antibody + unspecified IGF-1R antibody,1956,27196767,,,
502,Clinical Study,"In a clinical study, a colorectal cancer patient harboring EGFR amplification, BRAF V600E, and EGFR S492R demonstrated resistance to Erbitux (cetuximab) (PMID: 22270724). ",Actionable,3221,9256,colorectal cancer,DOID,12768,EGFR amp EGFR S492R BRAF V600E,resistant,694,Cetuximab,1956,22270724,,,
503,Preclinical - Cell culture,"In a preclinical study, a lung cancer cell line with co-amplification of FGFR1 and EGFR and harboring KRAS G13C demonstrated insensitivity to JNJ-42756493 (erdafitinib) in culture (PMID: 28341788).",Actionable,11185,1324,lung cancer,DOID,27923,EGFR amp FGFR1 amp KRAS G13C,resistant,1028,JNJ-42756493,1956,28341788,,,
504,Preclinical,"In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR amplification and EGFR G719A in culture (PMID: 26561558).",Actionable,6040,3068,glioblastoma multiforme,DOID,22289,EGFR amp EGFR G719A,sensitive,4008,Gefitinib + Linsitinib,1956,26561558,,,
505,Preclinical,"In a preclinical study, Dacomitinib and BMS-754807 worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR amplification and EGFR G719A in culture (PMID: 26561558).",Actionable,6044,3068,glioblastoma multiforme,DOID,22289,EGFR amp EGFR G719A,sensitive,4009,BMS-754807 + Dacomitinib,1956,26561558,,,
506,Preclinical,"In a preclinical study, Gleevec (imatinib) and Iressa (gefitinib) acted synergistically to decrease downstream signaling activity and inhibit cell growth of glioblastoma cell lines with EGFR and PDGFRA coamplification (PMID: 22323597). ",Actionable,1860,3068,glioblastoma multiforme,DOID,4004,PDGFRA amp EGFR amp,sensitive,2483,Gefitinib + Imatinib,1956,22323597,,,
507,Phase II,"In a Phase II clinical trial, two urothelial carcinoma patients with ERBB2 (HER2) and EGFR co-amplification had improved progression free survival when treated with Gilotrif (afatinib), and median PFS was 6.6 months for patients with ERBB2 or ERBB3 alterations relative to 1.4 months for patients lacking alterations (PMID: 27044931).",Actionable,5942,11054,urinary bladder cancer,DOID,22032,EGFR amp ERBB2 amp,sensitive,623,Afatinib,1956,27044931,,,
508,Clinical Study,"In a clinical study, a colorectal cancer patient harboring EGFR amplification and EGFR S492R demonstrated resistance to Erbitux (cetuximab) (PMID: 22270724).",Actionable,3220,9256,colorectal cancer,DOID,12767,EGFR amp EGFR S492R,resistant,694,Cetuximab,1956,22270724,,,
509,Clinical Study,"In a clinical study, a colorectal cancer patient harboring both EGFR amplification and EGFR S492R demonstrated a 50% tumor reduction when treated with Vectibix (panitumumab) (PMID: 22270724). ",Actionable,3219,9256,colorectal cancer,DOID,12767,EGFR amp EGFR S492R,sensitive,845,Panitumumab,1956,22270724,,,
510,Preclinical - Pdx & cell culture,"In a preclinical study, patient-derived EGFR amplified glioblastoma cells harboring PTEN loss demonstrated reduced sensitivity to Dacomitinib induced growth inhibition in culture and in xenograft models (PMID: 25939761).",Actionable,8045,3068,glioblastoma multiforme,DOID,26141,EGFR amp PTEN loss,decreased response,714,Dacomitinib,1956,25939761,,,
511,Preclinical - Cell culture,"In a preclinical study, lung cancer cell lines with co-amplification of FGFR1 and EGFR demonstrated insensitivity to JNJ-42756493 (erdafitinib) in culture (PMID: 28341788).",Actionable,11184,1324,lung cancer,DOID,27922,EGFR amp FGFR1 amp,resistant,1028,JNJ-42756493,1956,28341788,,,
512,Preclinical,"In a preclinical study, transformed cells expressing EGFR E709_T710delinsD demonstrated increased sensitivity to second-generation EGFR inhibitors including Gilotrif (afatinib) in culture, when compared to first and third-generation inhibitors (PMID: 26206867).",Actionable,3723,10000003,Advanced Solid Tumor,JAX,14932,EGFR E709_T710delinsD,sensitive,623,Afatinib,1956,26206867,,,
513,Preclinical,"In a preclinical study, transformed cells expressing EGFR E709_T710delinsD demonstrated decreased sensitivity to the first-generation EGFR inhibitor Iressa (gefitinib) in culture, when compared to second-generation inhibitors, with an IC90 concentration approximately two-times the estimated trough concentration at the recommended dose (PMID: 26206867).",Actionable,3727,10000003,Advanced Solid Tumor,JAX,14932,EGFR E709_T710delinsD,decreased response,751,Gefitinib,1956,26206867,,,
514,Phase I,"In a clinical case study, treatment with Gilotrif (afatinib) in a lung adenocarcinoma patient harboring EGFR E709_T710delinsD resulted in tumor shrinkage, while prior treatment with Tarceva (erlotinib) had achieved stable disease (PMID: 26206867).",Actionable,3728,3910,lung adenocarcinoma,DOID,14932,EGFR E709_T710delinsD,sensitive,623,Afatinib,1956,26206867,,,
515,Preclinical,"In a preclinical study, transformed cells expressing EGFR E709_T710delinsD demonstrated decreased sensitivity to third-generation EGFR inhibitors including Rociletinib (CO-1686) in culture, when compared to second-generation inhibitors (PMID: 26206867).",Actionable,3725,10000003,Advanced Solid Tumor,JAX,14932,EGFR E709_T710delinsD,decreased response,1003,CO1686,1956,26206867,,,
516,Preclinical,"In a preclinical study, transformed cells expressing EGFR E709_T710delinsD demonstrated increased sensitivity to second-generation EGFR inhibitors including Dacomitinib in culture, when compared to first and third-generation inhibitors (PMID: 26206867).",Actionable,3722,10000003,Advanced Solid Tumor,JAX,14932,EGFR E709_T710delinsD,sensitive,714,Dacomitinib,1956,26206867,,,
517,Preclinical,"In a preclinical study, transformed cells expressing EGFR E709_T710delinsD demonstrated decreased sensitivity to first-generation EGFR inhibitors including Tarceva (erlotinib) in culture, when compared to second-generation inhibitors (PMID: 26206867).",Actionable,3724,10000003,Advanced Solid Tumor,JAX,14932,EGFR E709_T710delinsD,decreased response,4,Erlotinib,1956,26206867,,,
518,Preclinical,"In a preclinical study, transformed cells expressing EGFR E709_T710delinsD demonstrated decreased sensitivity to third-generation EGFR inhibitors including Tagrisso (AZD9291) in culture, when compared to second-generation inhibitors (PMID: 26206867).",Actionable,3726,10000003,Advanced Solid Tumor,JAX,14932,EGFR E709_T710delinsD,decreased response,660,Osimertinib,1956,26206867,,,
519,Preclinical,"In a preclinical study, transformed cells expressing EGFR E709_T710delinsD demonstrated increased sensitivity to second-generation EGFR inhibitors including Nerlynx (neratinib) in culture, when compared to first and third-generation inhibitors (PMID: 26206867).",Actionable,3721,10000003,Advanced Solid Tumor,JAX,14932,EGFR E709_T710delinsD,sensitive,828,Neratinib,1956,26206867,,,
520,Preclinical - Cell culture,"In a preclinical study, dacomitinib inhibited growth of transformed cells expressing EGFR E709_T710delinsD and EGFR L792F in culture (PMID: 27913578).",Actionable,9926,10000003,Advanced Solid Tumor,JAX,27167,EGFR E709_T710delinsD EGFR L792F,sensitive,714,Dacomitinib,1956,27913578,,,
521,Preclinical - Cell culture,"In a preclinical study, acquisition of EGFR L792F was associated with resistance to Gilotrif in transformed cells expressing EGFR E709_T710delinsD in culture (PMID: 27913578).",Actionable,9925,10000003,Advanced Solid Tumor,JAX,27167,EGFR E709_T710delinsD EGFR L792F,resistant,623,Afatinib,1956,27913578,,,
522,Preclinical,"In a preclinical study, EKI-285 (CL-387,785) inhibited growth of transformed cells expressing EGFR L858R and EGFR D716Y in culture (PMID: 17085664).",Actionable,3000,10000003,Advanced Solid Tumor,JAX,6332,EGFR D761Y EGFR L858R,sensitive,2911,EKI-285,1956,17085664,,,
523,Preclinical,"In a preclinical study, transformed cells expressing EGFR L858R and D761Y demonstrated decreased sensitivity to Nerlynx (neratinib) in culture (PMID: 17085664).",Actionable,2996,10000003,Advanced Solid Tumor,JAX,6332,EGFR D761Y EGFR L858R,decreased response,828,Neratinib,1956,17085664,,,
524,Preclinical,"In a preclinical study, transformed cells expressing EGFR L858R and EGFR D761Y demonstrated decreased sensitivity to Iressa (gefitinib) in culture (PMID: 17085664).",Actionable,2225,10000003,Advanced Solid Tumor,JAX,6332,EGFR D761Y EGFR L858R,decreased response,751,Gefitinib,1956,17085664,,,
525,Clinical Study,"In a retrospective analysis, a patient with EGFR L858R-mutant non-small lung cancer that developed resistance to Iressa (gefitinib) was demonstrated to have acquired a secondary EGFR D761Y mutation (PMID: 17085664).",Actionable,3248,3908,non-small cell lung carcinoma,DOID,6332,EGFR D761Y EGFR L858R,resistant,751,Gefitinib,1956,17085664,,,
526,Preclinical,"In a preclinical study, Tarceva (erlotinib) decreased viability of transformed cells expressing EGFR A289V in culture (PMID: 17177598).",Actionable,6917,10000003,Advanced Solid Tumor,JAX,2929,EGFR A289V,sensitive,4,Erlotinib,1956,17177598,,,
527,Clinical Study,"In a prospective clinical study, Gilotrif (afatinib) treatment resulted in stable disease in a non-small cell lung carcinoma patient harboring EGFR V769L (PMID: 26354527).",Actionable,3366,3908,non-small cell lung carcinoma,DOID,3070,EGFR V769L,predicted â€“ sensitive,623,Afatinib,1956,26354527,,,
528,Preclinical,"In a preclinical study, KRAS G12V was detected in animal models of EGFR L858R-induced lung adenocarcinoma, which developed after repeated Gilotrif (afatinib) and Erbitux (cetuximab) combination treatments and resulted in drug resistance (PMID: 26341921).",Actionable,6656,3910,lung adenocarcinoma,DOID,23663,EGFR L858R KRAS G12V,resistant,4190,Afatinib + Cetuximab,1956,26341921,,,
529,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EGFR L858R and EGFR L792F demonstrated decreased sensitivity to Gilotrif (afatinib) in culture compared to cells expressing EGFR L858R alone (PMID: 27913578).",Actionable,9991,10000003,Advanced Solid Tumor,JAX,27221,EGFR L792F EGFR L858R,decreased response,623,Afatinib,1956,27913578,,,
530,Preclinical - Cell culture,"In a preclinical study, EAI045 inhibited proliferation of transformed cells over expressing EGFR L858R in culture, although at a concentration much higher than the biochemical IC50 of the compound (PMID: 27251290).",Actionable,7581,10000003,Advanced Solid Tumor,JAX,369,EGFR L858R,sensitive,4520,EAI045,1956,27251290,,,
531,Preclinical,"In a preclinical study, CO-1686 demonstrated efficacy in treating transgenic mouse models of lung adenocarcinoma expressing EGFR L858R (PMID: 24065731). ",Actionable,40,3910,lung adenocarcinoma,DOID,369,EGFR L858R,sensitive,1003,CO1686,1956,24065731,,,
532,Preclinical - Cell culture,"In a preclinical study, neither single agent or combination of Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 inhibited growth of transformed cells over expressing EGFR L858R in culture (PMID: 26140595).",Actionable,10251,10000003,Advanced Solid Tumor,JAX,369,EGFR L858R,no benefit,5443,PF3644022 + PF-477736,1956,26140595,,,
533,Preclinical - Cell culture,"In a preclinical study, Tarceva (erlotinib) inhibited Egfr phosphorylation and inhibited phosphorylation of downstream signaling molecules Cbl, Erk, Akt, phospholipase C gamma, Stat3, and Stat5 in EGFR L858R expressing transformed cells to a greater degree than EGFR wild-type expressing transformed cells in culture (PMID: 25573954).",Actionable,4779,10000003,Advanced Solid Tumor,JAX,369,EGFR L858R,sensitive,4,Erlotinib,1956,25573954,,,
534,Phase II,"In a Phase II clinical trial, 74% (34/46) of patients with EGFR exon 19 or 21 mutant lung cancers had partial response (PFS average= 17 months) to first line treatment with dacomitinib (J Clin Oncol 30, 2012 (suppl; abstr 7530); NCT00818441).",Actionable,780,3908,non-small cell lung carcinoma,DOID,369,EGFR L858R,sensitive,714,Dacomitinib,1956,None,,,
535,Phase III,"In a Phase III trial, treatment with dacomitinib as first-line therapy in patients with non-small cell lung cancer harboring an EGFR exon 19 deletion or EGFR L858R resulted in an improved median progression-free survival (mPFS) of 14.7 months compared to 9.2 months with Iressa (gefitinib), with a mPFS of 16.5 months with dacomitnib vs. 9.2 months with Iressa (gefitinib) among patients with EGFR L858R (PMID: 28958502; NCT01777421).",Actionable,12178,3908,non-small cell lung carcinoma,DOID,369,EGFR L858R,sensitive,714,Dacomitinib,1956,28958502,,,
536,Preclinical,"In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring EGFR L858R mutation in culture (PMID: 26090892).",Actionable,3930,3908,non-small cell lung carcinoma,DOID,369,EGFR L858R,sensitive,2086,TAE226,1956,26090892,,,
537,Phase III,"In a meta-analysis of 12 phase III trials investigating EGFR tyrosine kinase inhibitors in NSCLC patients with EFGR mutations (primarily exon 19 deletions or L858R) indicated TKIs, including icotinib, were superior to standard chemotherapy (PMID: 24533047).",Actionable,782,3908,non-small cell lung carcinoma,DOID,369,EGFR L858R,sensitive,769,Icotinib,1956,24533047,,,
538,Preclinical,"In a preclinical study, the combination of Tagrisso (osimertinib) and Selumetinib inhibited growth of lung adenocarcinoma tumors driven by EGFR L858R that had developed resistance through continued exposure to Tagrisso (osimertinib) (PMID: 25870145).",Actionable,4502,3910,lung adenocarcinoma,DOID,369,EGFR L858R,sensitive,2225,Osimertinib + Selumetinib,1956,25870145,,,
539,FDA approved,"In a Phase III trial that supported FDA approval, Iressa (gefitinib) treatment resulted in an objective response rate of 71.2% (94/132) and increased progression-free survival in non-small cell lung cancer patients harboring EGFR activating mutations including EGFR L858R (PMID: 19692680, NCT00322452).",Actionable,2420,3908,non-small cell lung carcinoma,DOID,369,EGFR L858R,sensitive,751,Gefitinib,1956,19692680,,,
540,Clinical Study,"A network meta-analysis of 12 Phase III trials investigating EGFR tyrosine kinase inhibitors in NSCLC patients with EGFR mutations (primarily exon 19 deletions or L858R) indicated TKIs, including Iressa (gefitinib), were superior to standard chemotherapy (PMID: 24533047).",Actionable,781,3908,non-small cell lung carcinoma,DOID,369,EGFR L858R,sensitive,751,Gefitinib,1956,24533047,,,
541,FDA approved,"In a Phase III trial that supported FDA approval, Tarceva (erlotinib) improved progression-free survival in non-small cell lung cancer patients harboring EGFR exon 21 (L858R) substitution mutations (HR= 0.52) (PMID: 24868098).",Actionable,211,3908,non-small cell lung carcinoma,DOID,369,EGFR L858R,sensitive,4,Erlotinib,1956,None,24868098,,
542,Phase II,"In a Phase II clinical trial, treatment with Tarceva (erlotinib) resulted in a median progression-free survival (PFS) of 10.8 months for the intent-to-treat population of non-small cell lung cancer patients with EGFR mutations, with a PFS of 9.2 months for patients harboring EGFR L858R (PMID: 26720423).",Actionable,5301,3908,non-small cell lung carcinoma,DOID,369,EGFR L858R,sensitive,4,Erlotinib,1956,26720423,,,
543,Preclinical - Cell culture,"In a preclinical study, the addition of Selumetinib (AZD6244) to treatment with Tagrisso (osimertinib) resulted in increased inhibition of proliferation in lung cancer cell lines harboring EGFR L858R in culture (PMID: 28416483).",Actionable,11311,1324,lung cancer,DOID,369,EGFR L858R,sensitive,2225,Osimertinib + Selumetinib,1956,28416483,,,
544,Preclinical - Cell culture,"In a preclinical study, Iressa (gefitinib) inhibited Egfr phosphorylation and inhibited phosphorylation of downstream signaling molecules Cbl, Erk, Akt, phospholipase C gamma, and Stat5 in EGFR L858R expressing transformed cells to a greater degree than EGFR wild-type expressing transformed cells in culture (PMID: 25573954).",Actionable,4777,10000003,Advanced Solid Tumor,JAX,369,EGFR L858R,sensitive,751,Gefitinib,1956,25573954,,,
545,Clinical Study,"In two clinical case studies, treatment with AZD3759 inhibited EGFR activity and demonstrated antitumor activity in patients harboring EGFR L858R, resulting in decreased CSF tumor cell number in the patient with leptomeningeal metastasis, and decreased brain tumor growth in the patient with brain metastasis (PMID: 27928026). ",Actionable,9567,1324,lung cancer,DOID,369,EGFR L858R,sensitive,2912,AZD3759,1956,27928026,,,
546,Preclinical - Cell line xenograft,"In a preclinical study, AZD3759 inhibited EGFR activation and growth of a lung cancer cell line harboring EGFR L858R in culture, and inhibited tumor growth in xenograft models (PMID: 27928026).",Actionable,9566,1324,lung cancer,DOID,369,EGFR L858R,sensitive,2912,AZD3759,1956,27928026,,,
547,Preclinical,"In a preclinical study, Gilotrif (afatinib) and Erbitux (cetuximab) combination treatment resulted in the least tumor recurrence after treatment cessation, and delayed development of treatment resistance compared to single drug treatment in animal models of EGFR L858R-induced lung adenocarcinoma (PMID: 26341921).",Actionable,6651,3910,lung adenocarcinoma,DOID,369,EGFR L858R,sensitive,4190,Afatinib + Cetuximab,1956,26341921,,,
548,Preclinical - Cell line xenograft,"In a preclinical study, EGF816 inhibited tumor growth and induced tumor regression in cell line xenograft models of non-small cell lung cancer harboring EGFR L858R (Cancer Res 2014;74(19 Suppl):Abstract nr 1733). ",Actionable,2424,3908,non-small cell lung carcinoma,DOID,369,EGFR L858R,sensitive,1309,EGF816,1956,None,,,
549,Preclinical,"In a preclinical study, Erbitux (cetuximab) inhibited tumor growth in mouse lung adenocarcinoma models expressing EGFR L858R (PMID: 24063894).",Actionable,3109,3910,lung adenocarcinoma,DOID,369,EGFR L858R,sensitive,694,Cetuximab,1956,24063894,,,
550,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing EGFR L858R in culture (PMID: 27780853).",Actionable,9233,10000003,Advanced Solid Tumor,JAX,369,EGFR L858R,sensitive,634,AP26113,1956,27780853,,,
551,Phase I,"In a Phase I trial, treatment with AZD9291 resulted in a response rate of 11% (2/19) in NSCLC patients harboring EGFR L858R without EGFR T790M (PMID: 25923549).",Actionable,2422,3908,non-small cell lung carcinoma,DOID,369,EGFR L858R,sensitive,660,Osimertinib,1956,25923549,,,
552,Preclinical,"In a preclinical study, EKI-285 (CL-387,785) inhibited growth of transformed cells expressing EGFR L858R in culture (PMID: 17085664).",Actionable,2999,10000003,Advanced Solid Tumor,JAX,369,EGFR L858R,sensitive,2911,EKI-285,1956,17085664,,,
553,Preclinical - Cell culture,"In a preclinical study, EAI045 inhibited Egfr activation but not proliferation of non-small cell lung cancer cells harboring EGFR L858R in culture (PMID: 27251290).",Actionable,7587,3908,non-small cell lung carcinoma,DOID,369,EGFR L858R,no benefit,4520,EAI045,1956,27251290,,,
554,Preclinical,"In a preclinical study, TAE226 treatment inhibited proliferation of transformed human cell lines harboring EGFR L858R mutation in culture (PMID: 26090892).",Actionable,3939,10000003,Advanced Solid Tumor,JAX,369,EGFR L858R,sensitive,2086,TAE226,1956,26090892,,,
555,Preclinical,"In a preclinical study, AV-412 inhibited the kinase activity of EGFR L858R (PMID: 17888033).",Actionable,1378,10000003,Advanced Solid Tumor,JAX,369,EGFR L858R,sensitive,990,AV-412,1956,17888033,,,
556,Preclinical - Cell culture,"In a preclinical study, the addition of Sprycel (dasatinib) to treatment with Tagrisso (osimertinib) resulted in increased PARP cleavage and inhibition of proliferation in lung cancer cell lines harboring EGFR L858R in culture (PMID: 28416483).",Actionable,11312,1324,lung cancer,DOID,369,EGFR L858R,sensitive,4600,Dasatinib + Selumetinib,1956,28416483,,,
557,Phase II,"In a Phase II trial, Gilotrif (afatinib) treatment resulted in improved progression-free survival (11.0 vs 10.9 months) and time-to-treatment failure (13.7 vs 11.5 months) compared to Iressa (gefitinib) in treatment-naive non-small cell lung carcinoma patients harboring EGFR exon 19 deletion or L858R (PMID: 27083334).",Actionable,6162,3908,non-small cell lung carcinoma,DOID,369,EGFR L858R,sensitive,623,Afatinib,1956,27083334,,,
558,FDA approved,"In a Phase III study that supported FDA approval, Gilotrif (afatinib) treatment resulted in increased progression-free survival in NSCLC patients with EGFR L858R mutations (PMID: 23816960, PMID: 23991291).",Actionable,39,3908,non-small cell lung carcinoma,DOID,369,EGFR L858R,sensitive,623,Afatinib,1956,None,23991291,23816960,
559,Guideline,Gilotrif (afatinib) is an active regimen in patients with metastatic NSCLC harboring sensitizing EGFR mutations (Guidelines).,Actionable,2015,3908,non-small cell lung carcinoma,DOID,369,EGFR L858R,sensitive,623,Afatinib,1956,None,,,
560,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited growth of transformed cells expressing EGFR L858R in culture (PMID: 17085664).",Actionable,2998,10000003,Advanced Solid Tumor,JAX,369,EGFR L858R,sensitive,828,Neratinib,1956,17085664,,,
561,Preclinical - Cell culture,"In a preclinical study, BGB-283 inhibited proliferation of transformed cells over expressing EGFR L858R in culture (PMID: 26208524).",Actionable,8061,10000003,Advanced Solid Tumor,JAX,369,EGFR L858R,sensitive,4025,BGB-283,1956,26208524,,,
562,Preclinical - Cell culture,"In a preclinical study, the addition of Buparlisib (BKM-120) to treatment with Tagrisso (osimertinib) resulted in increased inhibition of proliferation in lung cancer cell lines harboring EGFR L858R in culture (PMID: 28416483).",Actionable,11310,1324,lung cancer,DOID,369,EGFR L858R,sensitive,5935,BKM120 + Osimertinib,1956,28416483,,,
563,Preclinical - Pdx,"In a preclinical study, the combination of Rociletinib (CO-1686) and Xalkori (crizotinib) overcame resistance to Rociletinib (CO-1686) in a patient-derived xenograft model of non-small cell lung cancer harboring EGFR L858R and MET amplification, resulting in tumor growth inhibition (PMID: 27283993).",Actionable,9249,3908,non-small cell lung carcinoma,DOID,26799,EGFR L858R MET amp,sensitive,4962,CO1686 + Crizotinib,1956,27283993,,,
564,Preclinical,"In a preclinical study, KRAS G12D was detected in animal models of EGFR L858R-induced lung adenocarcinoma, which developed after repeated Gilotrif (afatinib) and Erbitux (cetuximab) combination treatments and resulted in drug resistance (PMID: 26341921).",Actionable,6654,3910,lung adenocarcinoma,DOID,23661,EGFR L858R KRAS G12D,resistant,4190,Afatinib + Cetuximab,1956,26341921,,,
565,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited growth of transformed cells expressing an EGFR L858R/EGFR L844V double mutation in culture (PMID: 25948633).",Actionable,3098,10000003,Advanced Solid Tumor,JAX,11695,EGFR L858R EGFR L844V,sensitive,623,Afatinib,1956,25948633,,,
566,Preclinical,"In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR L858R/EGFR L844V double mutation in culture (PMID: 25948633).",Actionable,3084,10000003,Advanced Solid Tumor,JAX,11695,EGFR L858R EGFR L844V,sensitive,660,Osimertinib,1956,25948633,,,
567,Preclinical,"In a preclinical study, transformed cells expressing an EGFR L858R/EGFR L844V double mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).",Actionable,3081,10000003,Advanced Solid Tumor,JAX,11695,EGFR L858R EGFR L844V,resistant,1003,CO1686,1956,25948633,,,
568,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited growth of transformed cells expressing an EGFR L858R/EGFR C797S double mutation in culture (PMID: 25948633).",Actionable,3103,10000003,Advanced Solid Tumor,JAX,11696,EGFR L858R EGFR C797S,sensitive,623,Afatinib,1956,25948633,,,
569,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EGFR L858R and EGFR C797S demonstrated sensitivity to Tarceva (erlotinib) in culture (PMID: 27913578).",Actionable,9989,10000003,Advanced Solid Tumor,JAX,11696,EGFR L858R EGFR C797S,sensitive,4,Erlotinib,1956,27913578,,,
570,Preclinical,"In a preclinical study, transformed cells expressing an EGFR L858R/EGFR C797S double mutation demonstrated resistance to AZD9291 in culture (PMID: 25948633).",Actionable,3091,10000003,Advanced Solid Tumor,JAX,11696,EGFR L858R EGFR C797S,resistant,660,Osimertinib,1956,25948633,,,
571,Preclinical,"In a preclinical study, transformed cells expressing an EGFR L858R/EGFR C797S double mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).",Actionable,3080,10000003,Advanced Solid Tumor,JAX,11696,EGFR L858R EGFR C797S,resistant,1003,CO1686,1956,25948633,,,
572,Preclinical,"In a preclinical study, KRAS G12R was detected in animal models of EGFR L858R-induced lung adenocarcinoma, which developed after repeated Gilotrif (afatinib) and Erbitux (cetuximab) combination treatments and resulted in drug resistance (PMID: 26341921).",Actionable,6655,3910,lung adenocarcinoma,DOID,23662,EGFR L858R KRAS G12R,resistant,4190,Afatinib + Cetuximab,1956,26341921,,,
573,Preclinical,"In a preclinical study, cells expressing EGFR E734Q demonstrated sensitivity to Tarceva (erlotinib) in culture (PMID: 20942962).",Actionable,2100,10000003,Advanced Solid Tumor,JAX,4960,EGFR E734Q,sensitive,4,Erlotinib,1956,20942962,,,
574,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EGFR A767_V769dup (also referred to as V769_D770insASV) demonstrated resistance to dacomitinib in culture (PMID: 28363995).",Actionable,10507,10000003,Advanced Solid Tumor,JAX,27532,EGFR A767_V769dup,resistant,714,Dacomitinib,1956,28363995,,,
575,Preclinical,"In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR I491M in culture (PMID: 26843189).",Actionable,6641,9256,colorectal cancer,DOID,23655,EGFR I491M,sensitive,821,MM-151,1956,26843189,,,
576,Preclinical,"In a preclinical study, colorectal cancer cell lines over expressing EGFR I491M were resistant to Vectibix (panitumumab)-induced growth inhibition in culture (PMID: 26843189).",Actionable,6642,9256,colorectal cancer,DOID,23655,EGFR I491M,resistant,845,Panitumumab,1956,26843189,,,
577,Preclinical,"In a preclinical study, colorectal cancer cell lines over expressing EGFR I491M were resistant to Erbitux (cetuximab)-induced growth inhibition in culture (PMID: 26843189).",Actionable,6643,9256,colorectal cancer,DOID,23655,EGFR I491M,resistant,694,Cetuximab,1956,26843189,,,
578,Preclinical - Cell culture,"In a preclinical study, SYM004 inhibited phosphorylation of EGFR in cells expressing EGFR R451C in culture (PMID: 26888827).",Actionable,9310,10000003,Advanced Solid Tumor,JAX,23657,EGFR R451C,predicted â€“ sensitive,931,SYM004,1956,26888827,,,
579,Preclinical,"In a preclinical study, Erbitux (cetuximab) inhibited survival of colorectal cancer cell lines over expressing EGFR R451C in culture (PMID: 26843189).",Actionable,6627,9256,colorectal cancer,DOID,23657,EGFR R451C,sensitive,694,Cetuximab,1956,26843189,,,
580,Preclinical,"In a preclinical study, Vectibix (panitumumab) inhibited survival of colorectal cancer cell lines over expressing EGFR R451C in culture (PMID: 26843189).",Actionable,6628,9256,colorectal cancer,DOID,23657,EGFR R451C,sensitive,845,Panitumumab,1956,26843189,,,
581,Preclinical,"In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR R451C in culture (PMID: 26843189).",Actionable,6626,9256,colorectal cancer,DOID,23657,EGFR R451C,sensitive,821,MM-151,1956,26843189,,,
582,Preclinical,"In a preclinical study, Vectibix (panitumumab) inhibited survival of colorectal cancer cell lines over expressing EGFR S492R in culture (PMID: 26843189).",Actionable,6645,9256,colorectal cancer,DOID,12766,EGFR S492R,sensitive,845,Panitumumab,1956,26843189,,,
583,Preclinical,"In a preclinical study, colorectal cancer cell lines over expressing EGFR S492R were resistant to Erbitux (cetuximab)-induced growth inhibition in culture (PMID: 26843189).",Actionable,6646,9256,colorectal cancer,DOID,12766,EGFR S492R,resistant,694,Cetuximab,1956,26843189,,,
584,Phase I,"In a Phase I study, a colorectal cancer patient harboring EGFR S492R demonstrated a partial response when treated with SYM004 (PMID: 25962717).",Actionable,3218,9256,colorectal cancer,DOID,12766,EGFR S492R,sensitive,931,SYM004,1956,25962717,,,
585,Preclinical,"In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR S492R in culture (PMID: 26843189).",Actionable,6644,9256,colorectal cancer,DOID,12766,EGFR S492R,sensitive,821,MM-151,1956,26843189,,,
586,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EGFR-RAD51 demonstrated sensitivity to treatment with Gilotrif (afatinib) in culture, resulting in decreased cell viability and inhibition of downstream MAPK and PI3K signaling (PMID: 27102076). ",Actionable,7540,10000003,Advanced Solid Tumor,JAX,25735,EGFR-RAD51,sensitive,623,Afatinib,1956,27102076,,,
587,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EGFR-RAD51 demonstrated sensitivity to treatment with Erbitux (cetuximab) in culture, resulting in decreased cell viability (PMID: 27102076). ",Actionable,7542,10000003,Advanced Solid Tumor,JAX,25735,EGFR-RAD51,sensitive,694,Cetuximab,1956,27102076,,,
588,Clinical Study,"In a clinical study, three patients with lung adenocarcinoma harboring EGFR-RAD51 demonstrated partial responses as indicated by tumor regression, when treated with Tarceva (erlotinib) (PMID: 27102076). ",Actionable,7538,3910,lung adenocarcinoma,DOID,25735,EGFR-RAD51,sensitive,4,Erlotinib,1956,27102076,,,
589,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EGFR-RAD51 demonstrated some sensitivity to treatment with Tagrisso (osimertinib) in culture, resulting in decreased cell viability (PMID: 27102076). ",Actionable,7541,10000003,Advanced Solid Tumor,JAX,25735,EGFR-RAD51,predicted â€“ sensitive,660,Osimertinib,1956,27102076,,,
590,Clinical Study,"In a clinical study, a patient with non-small cell lung carcinoma harboring EGFR I744_K745insKIPVAI demonstrated a partial response when treated with Tarceva (erlotinib) (PMID: 22190593). ",Actionable,10914,3908,non-small cell lung carcinoma,DOID,27852,EGFR I744_K745insKIPVAI,sensitive,4,Erlotinib,1956,22190593,,,
591,Clinical Study,"In a clinical study, two patients with non-small cell lung carcinoma each harboring EGFR I744_K745insKIPVAI demonstrated some efficacy when treated with Iressa (gefitinib), including a partial response and stable disease (PMID: 28089594). ",Actionable,10908,3908,non-small cell lung carcinoma,DOID,27852,EGFR I744_K745insKIPVAI,sensitive,751,Gefitinib,1956,28089594,,,
592,Clinical Study,"In a clinical study, a patient with non-small cell lung carcinoma harboring EGFR K745_E746insTPVAIK demonstrated a partial response when treated with Tarceva (erlotinib) (PMID: 22190593).",Actionable,10915,3908,non-small cell lung carcinoma,DOID,27854,EGFR K745_E746insTPVAIK,sensitive,4,Erlotinib,1956,22190593,,,
593,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring mutant EGFR and wild-type FGFR1 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366).",Actionable,3542,3908,non-small cell lung carcinoma,DOID,13351,EGFR mutant FGFR1 wild-type,resistant,877,Ponatinib,1956,22238366,,,
594,Clinical Study,"In a clinical study, treatment with first-line tyrosine kinase inhibitors resulted in a disease control rate (DCR) of 70% (26/37) in non-small cell lung carcinoma patients harboring both EGFR and TP53 mutations, compared to a DCR of 88% (76/86) in TP53 wild-type, EGFR mutated patients (J Clin Oncol 34, 2016 (suppl; abstr 9052)).",Actionable,6998,3908,non-small cell lung carcinoma,DOID,24178,EGFR mut TP53 mut,decreased response,1776,N/A,1956,None,,,
595,Clinical Study,"In a clinical study, treatment with first-line tyrosine kinase inhibitors resulted in a disease control rate (DCR) of 67% (8/13) in EGFR mutated, non-small cell lung carcinoma patients harboring nondisruptive TP53 mutations, compared to a DCR of 87% (21/24) in patients harboring disruptive TP53 mutations (J Clin Oncol 34, 2016 (suppl; abstr 9052)).",Actionable,7000,3908,non-small cell lung carcinoma,DOID,24180,EGFR mut TP53 inact mut,sensitive,1776,N/A,1956,None,,,
596,Clinical Study,"In a clinical study, treatment with first-line tyrosine kinase inhibitors resulted in a disease control rate (DCR) of 42% (5/12), median PFS and OS of 4.2 and 16.2 months in non-small cell lung carcinoma patients harboring both TP53 exon 8 and EGFR mutations, compared to 87% (97/111),  12.5 and 32.3 months in TP53 exon 8 wild-type patients (J Clin Oncol 34, 2016 (suppl; abstr 9052)).",Actionable,6999,3908,non-small cell lung carcinoma,DOID,24179,EGFR mut TP53 exon 8,decreased response,1776,N/A,1956,None,,,
597,Clinical Study,"In a prospective clinical study, Gilotrif (afatinib) treatment resulted in partial response in 22% (22/58), stable disease in 47% (27/58), and progressive disease in 31% (18/58) of non-small cell lung carcinoma patients carrying an EGFR mutation (PMID: 26354527).",Actionable,3358,3908,non-small cell lung carcinoma,DOID,1202,EGFR mutant,predicted â€“ sensitive,623,Afatinib,1956,26354527,,,
598,Phase II,"In a Phase II trial, Tykerb (lapatinib) demonstrated safety in patients with non-small cell lung cancer, but demonstrated minimal antitumor activity with no responses in patients harboring EGFR mutations (PMID: 20215545).",Actionable,2421,3908,non-small cell lung carcinoma,DOID,1202,EGFR mutant,no benefit,787,Lapatinib,1956,20215545,,,
599,Phase I,"In a Phase I study, Pelitinib (EKB-569) demonstrated efficacy in 2 patients with non-small cell lung cancer with EGFR mutations and acquired resistance to gefitinib (PMID: 16364494).",Actionable,22,3908,non-small cell lung carcinoma,DOID,1202,EGFR mutant,sensitive,852,Pelitinib,1956,16364494,,,
600,Clinical Study,"In a retrospective study, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Durvalumab (MEDI4736), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694).",Actionable,8428,3908,non-small cell lung carcinoma,DOID,1202,EGFR mutant,decreased response,1201,Atezolizumab,1956,27225694,,,
601,Preclinical - Cell culture,"In a preclinical study, NGI-1 inhibited EGFR phosphorylation and proliferation and induced cell cycle arrest in non-small cell lung cancer cell lines harboring kinase domain mutations in EGFR in culture (PMID: 27694802).",Actionable,9227,3908,non-small cell lung carcinoma,DOID,1202,EGFR mutant,predicted â€“ sensitive,4957,NGI-1,1956,27694802,,,
602,Phase I,"In a Phase I trial, ASP8273 treatment resulted in partial response in 36% (16/45) and stable disease in 27% (12/45) of non-small cell lung carcinoma patients harboring EGFR mutations, with a median progression free survival of 6.7 months (J Clin Oncol 34, 2016 (suppl; abstr 9050)).",Actionable,6997,3908,non-small cell lung carcinoma,DOID,1202,EGFR mutant,sensitive,1082,ASP8273,1956,None,,,
603,Preclinical - Cell line xenograft,"In a preclinical study, treatment with the combination of DS-1205b and Tagrisso (osimertinib) delayed the onset of therapeutic resistance compared to Tagrisso (osimertinib) alone in an EGFR-mutant non-small cell lung cancer cell line xenograft model (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #395P).",Actionable,12019,3908,non-small cell lung carcinoma,DOID,1202,EGFR mutant,predicted â€“ sensitive,6231,DS-1205b + Osimertinib,1956,None,,,
604,Preclinical - Cell culture,"In a preclinical study, combination of S63845 and Tarceva (erlotinib) resulted in potent cytotoxic effects in EGFR mutated non-small cell lung cancer cells in culture compared to the cytostatic effect of Tarceva (erlotinib) alone (PMID: 27760111).",Actionable,9038,3908,non-small cell lung carcinoma,DOID,1202,EGFR mutant,sensitive,4860,Erlotinib + S63845,1956,27760111,,,
605,Clinical Study,"In a clinical study, 87.5% (7/8) of solid tumor patients harboring EGFR alterations experienced disease progression within 2 months of anti-PD1/PD-L1 monotherapy, indicating a risk for hyperprogression on immunotherapy (PMID: 28351930).",Emerging,11638,10000003,Advanced Solid Tumor,JAX,1202,EGFR mutant,no benefit,1776,N/A,1956,28351930,,,
606,Phase II,"In a Phase IIa clinical trial, BMS-690514 demonstrated safety and preliminary anti-tumor activity in patients with non-small cell lung cancer, with patients harboring EGFR mutations achieving a disease control rate (DCR) of 70% (7/10), compared to a DCR of 29% (6/21) in EGFR-wild type patients (PMID: 23490650).",Actionable,4408,3908,non-small cell lung carcinoma,DOID,1202,EGFR mutant,predicted â€“ sensitive,685,BMS-690514,1956,23490650,,,
607,Preclinical - Cell line xenograft,"In a preclinical study, Rociletinib (CO-1686) induced tumor regression in EGFR-mutant human non-small cell lung cancer cell line xenograft models, while slightly inhibiting tumor growth in xenograft models of a wild-type EGFR human squamous carcinoma cell line (PMID: 24065731).",Actionable,308,1324,lung cancer,DOID,1202,EGFR mutant,sensitive,1003,CO1686,1956,24065731,,,
608,Clinical Study,"In a retrospective study, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Durvalumab (MEDI4736), or Tecentriq (atezolizumab)) resulted in lower objective response rate  (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694).",Actionable,8425,3908,non-small cell lung carcinoma,DOID,1202,EGFR mutant,decreased response,1312,Nivolumab,1956,27225694,,,
609,Phase I,"In a Phase I trial, AP26113 demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including NSCLC patients harboring EGFR mutations (J Clin Oncol 31, 2013 (suppl; abstr 8031)).",Actionable,2556,3908,non-small cell lung carcinoma,DOID,1202,EGFR mutant,sensitive,634,AP26113,1956,None,,,
610,Phase III,"In a Phase III trial, treatment with Nexavar (sorafenib) in non-small cell lung cancer patients harboring an EGFR mutation resulted in a greater overall survival and progression free survival when compared to placebo (PMID: 26743856). ",Actionable,7709,3908,non-small cell lung carcinoma,DOID,1202,EGFR mutant,sensitive,920,Sorafenib,1956,26743856,,,
611,Phase II,"In a Phase II trial, Poziotinib (HM781-36B) displayed modest efficacy in lung adenocarcinoma patients with mutant EGFR (J Clin Oncol 33, 2015 (suppl; abstr 8085).",Actionable,3260,3910,lung adenocarcinoma,DOID,1202,EGFR mutant,sensitive,1042,poziotinib,1956,None,,,
612,Clinical Study,"In a retrospective study, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Imfinzi (durvalumab), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694).",Actionable,8427,3908,non-small cell lung carcinoma,DOID,1202,EGFR mutant,decreased response,1356,Durvalumab,1956,27225694,,,
613,Clinical Study,"In a retrospective study, PD-1/PD-L1 inhibitors (Opdivo (nivolumab), Keytruda (pembrolizumab), Durvalumab (MEDI4736), or Tecentriq (atezolizumab)) resulted in lower objective response rate (3.6%, 1/28) in non-small cell lung cancer patients harboring EGFR mutations (22/28) or ALK rearrangement (6/28) compared to EGFR wild-type, ALK negative/unknown patients (23.3%, 7/30) (PMID: 27225694).",Actionable,8426,3908,non-small cell lung carcinoma,DOID,1202,EGFR mutant,decreased response,1447,Pembrolizumab,1956,27225694,,,
614,Preclinical - Cell line xenograft,"In a preclinical study, treatment with the combination of DS-1205b and Tarceva (erlotinib) delayed the onset of therapeutic resistance compared to Tarceva (erlotinib) alone in an EGFR-mutant non-small cell lung cancer cell line xenograft model, and overcame resistance to Tarceva (erlotinib) in a Tarceva (erlotinib)-resistant xenograft model (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #395P).",Actionable,12020,3908,non-small cell lung carcinoma,DOID,1202,EGFR mutant,predicted â€“ sensitive,6232,DS-1205b + Erlotinib,1956,None,,,
615,Clinical Study,"In a clinical study, lung adenocarcinoma patients with compound EGFR mutations had inferior overall survival when compared to patients with single EGFR mutations (PMID: 26785607), suggesting that the presence of compound EGFR mutations may be have prognostic significance in lung adenocarcinoma.",Emerging,6345,3910,lung adenocarcinoma,DOID,1202,EGFR mutant,not applicable,1776,N/A,1956,26785607,,,
616,Preclinical,"In a preclinical study, AEE788 inhibited the growth of cultured cells expressing the EGFR exon 19 variant, L747_P753delinsS (PMID: 19147750).",Actionable,1840,10000003,Advanced Solid Tumor,JAX,3680,EGFR L747_P753delinsS,sensitive,622,AEE788,1956,19147750,,,
617,Preclinical,"In a preclinical study, Iressa (gefitinib) inhibited the growth of cultured cells expressing the EGFR exon 19 variant, L747_P753delinsS (PMID: 19147750).",Actionable,1838,10000003,Advanced Solid Tumor,JAX,3680,EGFR L747_P753delinsS,sensitive,751,Gefitinib,1956,19147750,,,
618,Clinical Study,"In a prospective clinical study, Gilotrif (afatinib) treatment resulted in progressive disease in a non-small cell lung carcinoma patient carrying an EGFR A702S mutation (PMID: 26354527).",Actionable,3326,3908,non-small cell lung carcinoma,DOID,2932,EGFR A702S,no benefit,623,Afatinib,1956,26354527,,,
619,Preclinical - Pdx,"In a preclinical study, EGF816 inhibited tumor growth in patient-derived xenograft models of non-small cell lung cancer harboring EGFR H773_V774insNPH (PMID: 26825170).",Actionable,5654,3908,non-small cell lung carcinoma,DOID,3086,EGFR H773_V774insNPH,sensitive,1309,EGF816,1956,26825170,,,
620,Preclinical - Cell culture,"In a preclinical study, EGF816 inhibited growth of transformed cells expressing EGFR H773_V774insNPH in culture (PMID: 26825170).",Actionable,5653,10000003,Advanced Solid Tumor,JAX,3086,EGFR H773_V774insNPH,sensitive,1309,EGF816,1956,26825170,,,
621,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited EGFR phosphorylation and growth of cells expressing EGFR L844V in culture (PMID: 25948633).",Actionable,3071,10000003,Advanced Solid Tumor,JAX,11697,EGFR L844V,sensitive,623,Afatinib,1956,25948633,,,
622,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited EGFR phosphorylation and growth of cells expressing EGFR L844V in culture (PMID: 25948633).",Actionable,3070,10000003,Advanced Solid Tumor,JAX,11697,EGFR L844V,sensitive,828,Neratinib,1956,25948633,,,
623,Preclinical,"In a preclinical study, EKI-285 inhibited EGFR phosphorylation and growth of cells expressing EGFR L844V in culture (PMID: 25948633).",Actionable,3072,10000003,Advanced Solid Tumor,JAX,11697,EGFR L844V,sensitive,2911,EKI-285,1956,25948633,,,
624,Preclinical,"In a preclinical study, Tarceva (erlotinib) inhibited Egfr phosphorylation in cells expressing EGFR R831H in culture (PMID: 20942962).",Actionable,6923,10000003,Advanced Solid Tumor,JAX,24022,EGFR R831H,sensitive,4,Erlotinib,1956,20942962,,,
625,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR A763_Y764insFQEA mutations demonstrated sensitivity to Gilotrif (afatinib) in cell culture, in contrast to other EGFR exon 20 insertion mutations (PMID: 24353160).",Actionable,776,3908,non-small cell lung carcinoma,DOID,1052,EGFR A763_Y764insFQEA,sensitive,623,Afatinib,1956,24353160,,,
626,Clinical Study,"In a clinical study, a patient with non-small cell lung carcinoma harboring EGFR A763_Y764insFQEA demonstrated a partial response when treated with Iressa (gefitinib) (PMID: 28089594).",Actionable,10916,3908,non-small cell lung carcinoma,DOID,1052,EGFR A763_Y764insFQEA,sensitive,751,Gefitinib,1956,28089594,,,
627,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR A763_Y764insFQEA mutations demonstrated sensitivity to Iressa (gefitinib) in culture, in contrast to other Egfr exon 20 insertions, and consistent with clinical observations (PMID: 24353160).",Actionable,779,3908,non-small cell lung carcinoma,DOID,1052,EGFR A763_Y764insFQEA,sensitive,751,Gefitinib,1956,24353160,,,
628,Clinical Study,"In contrast to other known exon 20 insertions, EGFR A763_Y764insFQEA is sensitive to tyrosine kinase inhibitors, such as Tarceva (erlotinib), in cells, in animal models and in NSCLC patients (PMID: 24353160).",Actionable,778,3908,non-small cell lung carcinoma,DOID,1052,EGFR A763_Y764insFQEA,sensitive,4,Erlotinib,1956,24353160,,,
629,Clinical Study,"In a clinical study, a patient with non-small cell lung carcinoma harboring EGFR A763_Y764insFQEA demonstrated a partial response after treatment with Tarceva (erlotinib), however, another patient with the same mutation and tumor type demonstrated progressive disease when treated with Tarceva (erlotinib) (PMID: 28089594). ",Actionable,10909,3908,non-small cell lung carcinoma,DOID,1052,EGFR A763_Y764insFQEA,sensitive,4,Erlotinib,1956,28089594,,,
630,Preclinical - Cell culture,"In a preclinical study, AZD4547 treatment of head and neck squamous cell carcinoma cells over expressing FGFR1 and negative for EGFR resulted in decreased cell growth and reduced downstream signaling of Erk1/2 (PMID: 26936917).",Actionable,7828,5520,head and neck squamous cell carcinoma,DOID,26061,EGFR neg FGFR1 over exp,sensitive,654,AZD4547,1956,26936917,,,
631,Preclinical,"In a preclinical study, transformed cells expressing EGFR G719A demonstrated increased sensitivity to second-generation EGFR inhibitors including Nerlynx (neratinib) in culture, when compared to first and third-generation inhibitors (PMID: 26206867).",Actionable,3719,10000003,Advanced Solid Tumor,JAX,1044,EGFR G719A,sensitive,828,Neratinib,1956,26206867,,,
632,Preclinical,"In a preclinical study, transformed cells expressing EGFR G719A demonstrated increased sensitivity to second-generation EGFR inhibitors including Dacomitinib in culture, when compared to first and third-generation inhibitors (PMID: 26206867).",Actionable,3713,10000003,Advanced Solid Tumor,JAX,1044,EGFR G719A,sensitive,714,Dacomitinib,1956,26206867,,,
633,Clinical Study,"In an analysis of published clinical data, 7/11 non-small cell lung cancer patients harboring EGFR G719A were found to achieve disease control following treatment with EGFR tyrosine kinase inhibitors, such as Iressa (gefitinib) (PMID: 23344264).",Actionable,6667,3908,non-small cell lung carcinoma,DOID,1044,EGFR G719A,predicted â€“ sensitive,751,Gefitinib,1956,23344264,,,
634,Preclinical - Cell culture,"In a preclinical study, AP32788 inhibited growth of transformed cell lines over expressing EGFR G719A in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2644).",Actionable,5918,10000003,Advanced Solid Tumor,JAX,1044,EGFR G719A,sensitive,3981,AP32788,1956,None,,,
635,Phase III,"In Phase III trials, non-small cell lung carcinoma patients harboring EGFR G719X mutations (G719A, C, or S) demonstrated a response rate of 78% (14/18) following treatment with Gilotrif (afatinib) (PMID: 24790411).",Actionable,746,3908,non-small cell lung carcinoma,DOID,1044,EGFR G719A,sensitive,623,Afatinib,1956,24790411,,,
636,Preclinical,"In a preclinical study, transformed cells expressing EGFR G719A demonstrated increased sensitivity to second-generation EGFR inhibitors including Gilotrif (afatinib) in culture, when compared to first and third-generation inhibitors (PMID: 26206867).",Actionable,3715,10000003,Advanced Solid Tumor,JAX,1044,EGFR G719A,sensitive,623,Afatinib,1956,26206867,,,
637,Preclinical,"In a preclinical study, transformed cells expressing EGFR G719A demonstrated decreased sensitivity to first-generation EGFR inhibitors including Tarceva (erlotinib) in culture, when compared to second-generation inhibitors (PMID: 26206867).",Actionable,3716,10000003,Advanced Solid Tumor,JAX,1044,EGFR G719A,decreased response,4,Erlotinib,1956,26206867,,,
638,Preclinical,"In a preclinical study, transformed cells expressing EGFR G719A demonstrated decreased sensitivity to third-generation EGFR inhibitors including Tagrisso (AZD9291) in culture, when compared to second-generation inhibitors (PMID: 26206867).",Actionable,3717,10000003,Advanced Solid Tumor,JAX,1044,EGFR G719A,decreased response,660,Osimertinib,1956,26206867,,,
639,Preclinical,"In a preclinical study, transformed cells expressing EGFR G719A demonstrated decreased sensitivity to third-generation EGFR inhibitors including Rociletinib (CO-1686) in culture, when compared to second-generation inhibitors (PMID: 26206867).",Actionable,3718,10000003,Advanced Solid Tumor,JAX,1044,EGFR G719A,decreased response,1003,CO1686,1956,26206867,,,
640,Clinical Study,"In an analysis of published clinical data, 7/11 non-small cell lung cancer patients harboring EGFR G719A were found to achieve disease control following treatment with EGFR tyrosine kinase inhibitors, such as Tarceva (erlotinib) (PMID: 23344264).",Actionable,6666,3908,non-small cell lung carcinoma,DOID,1044,EGFR G719A,predicted â€“ sensitive,4,Erlotinib,1956,23344264,,,
641,Phase III,"In Phase III clinical trials, patients with NSCLC tumors harboring an EGFR G719X (X=A, C, or S) mutation responded to EGFR tyrosine kinase inhibitors including dacomitinib (PMID: 24857124).",Actionable,748,3908,non-small cell lung carcinoma,DOID,1044,EGFR G719A,sensitive,714,Dacomitinib,1956,24857124,,,
642,Preclinical,"In a preclinical study, transformed cells expressing EGFR G719A demonstrated decreased sensitivity to first-generation EGFR inhibitors including Iressa (gefitinib) in culture, when compared to second-generation inhibitors (PMID: 26206867).",Actionable,3714,10000003,Advanced Solid Tumor,JAX,1044,EGFR G719A,decreased response,751,Gefitinib,1956,26206867,,,
643,Preclinical - Cell culture,"In a preclinical study, EGF816 inhibited growth of transformed cells expressing EGFR D770_N771insSVD in culture (PMID: 26825170).",Actionable,5651,10000003,Advanced Solid Tumor,JAX,1049,EGFR D770_N771insSVD,sensitive,1309,EGF816,1956,26825170,,,
644,Preclinical,"In a preclinical study, transformed cells expressing EGFR D770_N771insSVD, demonstrated resistance to Gilotrif (afatinib) in cell culture (PMID: 24353160).",Actionable,787,10000003,Advanced Solid Tumor,JAX,1049,EGFR D770_N771insSVD,resistant,623,Afatinib,1956,24353160,,,
645,Phase I,"In a retrospective analysis, non-small cell lung cancer patients harboring EGFR exon 20 insertions, such as EGFR D770_N771insSVD, displayed progressive disease following treatment with Tarceva (erlotinib), and resistance to Tarceva (erlotinib) was replicated in cell culture studies (PMID: 24353160).",Actionable,786,3908,non-small cell lung carcinoma,DOID,1049,EGFR D770_N771insSVD,resistant,4,Erlotinib,1956,24353160,,,
646,Preclinical,"In a preclinical study, transformed cells expressing EGFR E709K demonstrated decreased sensitivity to first-generation EGFR inhibitors including Iressa (gefitinib) in culture, when compared to second-generation inhibitors (PMID: 26206867).",Actionable,3709,10000003,Advanced Solid Tumor,JAX,3079,EGFR E709K,decreased response,751,Gefitinib,1956,26206867,,,
647,Preclinical,"In a preclinical study, transformed cells expressing EGFR E709K demonstrated increased sensitivity to second-generation EGFR inhibitors including Gilotrif (afatinib) in culture, when compared to first and third-generation inhibitors (PMID: 26206867).",Actionable,3706,10000003,Advanced Solid Tumor,JAX,3079,EGFR E709K,sensitive,623,Afatinib,1956,26206867,,,
648,Preclinical,"In a preclinical study, transformed cells expressing EGFR E709K demonstrated increased sensitivity to second-generation EGFR inhibitors including Dacomitinib in culture, when compared to first and third-generation inhibitors (PMID: 26206867).",Actionable,3707,10000003,Advanced Solid Tumor,JAX,3079,EGFR E709K,sensitive,714,Dacomitinib,1956,26206867,,,
649,Preclinical,"In a preclinical study, transformed cells expressing EGFR E709K demonstrated increased sensitivity to second-generation EGFR inhibitors including Nerlynx (neratinib) in culture, when compared to first and third-generation inhibitors (PMID: 26206867).",Actionable,3708,10000003,Advanced Solid Tumor,JAX,3079,EGFR E709K,sensitive,828,Neratinib,1956,26206867,,,
650,Preclinical,"In a preclinical study, transformed cells expressing EGFR E709K demonstrated decreased sensitivity to first-generation EGFR inhibitors including Tarceva (erlotinib) in culture, when compared to second-generation inhibitors (PMID: 26206867).",Actionable,3710,10000003,Advanced Solid Tumor,JAX,3079,EGFR E709K,decreased response,4,Erlotinib,1956,26206867,,,
651,Preclinical,"In a preclinical study, transformed cells expressing EGFR E709K demonstrated decreased sensitivity to third-generation EGFR inhibitors including Rociletinib (CO-1686) in culture, when compared to second-generation inhibitors (PMID: 26206867).",Actionable,3712,10000003,Advanced Solid Tumor,JAX,3079,EGFR E709K,decreased response,1003,CO1686,1956,26206867,,,
652,Preclinical,"In a preclinical study, transformed cells expressing EGFR E709K demonstrated decreased sensitivity to third-generation EGFR inhibitors including Tagrisso (AZD9291) in culture, when compared to second-generation inhibitors (PMID: 26206867).",Actionable,3711,10000003,Advanced Solid Tumor,JAX,3079,EGFR E709K,decreased response,660,Osimertinib,1956,26206867,,,
653,Preclinical,"In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR S464L in culture (PMID: 26843189).",Actionable,6629,9256,colorectal cancer,DOID,23658,EGFR S464L,sensitive,821,MM-151,1956,26843189,,,
654,Preclinical,"In a preclinical study, colorectal cancer cell lines over expressing EGFR S464L were resistant to Erbitux (cetuximab)-induced growth inhibition in culture (PMID: 26843189).",Actionable,6631,9256,colorectal cancer,DOID,23658,EGFR S464L,resistant,694,Cetuximab,1956,26843189,,,
655,Preclinical,"In a preclinical study, colorectal cancer cell lines over expressing EGFR S464L were resistant to Vectibix (panitumumab)-induced growth inhibition in culture (PMID: 26843189).",Actionable,6630,9256,colorectal cancer,DOID,23658,EGFR S464L,resistant,845,Panitumumab,1956,26843189,,,
656,Preclinical,"In a preclinical study, Tarceva (erlotinib) inhibited Egfr phosphorylation in cells expressing EGFR E868G in culture (PMID: 20942962).",Actionable,6922,10000003,Advanced Solid Tumor,JAX,3115,EGFR E868G,sensitive,4,Erlotinib,1956,20942962,,,
657,Clinical Study,"In clinical case study, a patient with olfactory neuroblastoma harboring EGFR R521K, FGFR2 M186T, KDR Q472H, KDR V297I, and RET M1009T demonstrated sensitivity to the combination of Sutent (sunitinib) and Erbitux (cetuximab), resulting in a complete response (PMID: 27149458).",Actionable,7758,369,olfactory neuroblastoma,DOID,26023,EGFR R521K FGFR2 M186T KDR Q472H KDR V297I RET M1009T,sensitive,4568,Cetuximab + Sunitinib,1956,27149458,,,
658,Preclinical - Patient cell culture,"In a preclinical study, dacomitinib inhibited EGFR phosphorylation and growth of a patient-derived lung adenocarcinoma cell line harboring EGFR P772_H773insPNP in culture (PMID: 28363995).",Actionable,10520,3910,lung adenocarcinoma,DOID,27539,EGFR P772_H773insPNP,sensitive,714,Dacomitinib,1956,28363995,,,
659,Preclinical - Patient cell culture,"In a preclinical study, Gilotrif (afatinib) inhibited EGFR phosphorylation and growth of a patient-derived lung adenocarcinoma cell line harboring EGFR P772_H773insPNP in culture (PMID: 28363995).",Actionable,10521,3910,lung adenocarcinoma,DOID,27539,EGFR P772_H773insPNP,sensitive,623,Afatinib,1956,28363995,,,
660,Preclinical,"In a preclinical study, colorectal cancer cell lines over expressing EGFR K467T were resistant to Erbitux (cetuximab)-induced growth inhibition in culture (PMID: 26843189).",Actionable,6639,9256,colorectal cancer,DOID,23656,EGFR K467T,resistant,694,Cetuximab,1956,26843189,,,
661,Preclinical,"In a preclinical study, MM-151 inhibited survival of colorectal cancer cell lines over expressing EGFR K467T in culture (PMID: 26843189).",Actionable,6638,9256,colorectal cancer,DOID,23656,EGFR K467T,sensitive,821,MM-151,1956,26843189,,,
662,Preclinical,"In a preclinical study, Vectibix (panitumumab) inhibited survival of colorectal cancer cell lines over expressing EGFR K467T in culture (PMID: 26843189).",Actionable,6640,9256,colorectal cancer,DOID,23656,EGFR K467T,sensitive,845,Panitumumab,1956,26843189,,,
663,Preclinical - Cell culture,"In a preclinical study, SYM004 inhibited phosphorylation of EGFR in cells expressing EGFR K467T in culture (PMID: 26888827).",Actionable,9311,10000003,Advanced Solid Tumor,JAX,23656,EGFR K467T,predicted â€“ sensitive,931,SYM004,1956,26888827,,,
664,Clinical Study,"In a prospective clinical study, Gilotrif (afatinib) treatment resulted in partial response in 100% (2 of 2) of non-small cell lung carcinoma patients carrying EGFR L858M mutation (PMID: 26354527).",Actionable,3328,3908,non-small cell lung carcinoma,DOID,3104,EGFR L858M,sensitive,623,Afatinib,1956,26354527,,,
665,Clinical Study,"In a clinical study, a patient with lung adenocarcinoma harboring EGFR-PURB demonstrated a partial response when treated with Tarceva (erlotinib), resulting in a 48% decrease in lesion size and ongoing therapy for 20 months without indication of progression (PMID: 27102076). ",Actionable,7539,3910,lung adenocarcinoma,DOID,25738,EGFR-PURB,sensitive,4,Erlotinib,1956,27102076,,,
666,Preclinical,"In a preclinical study, Tarceva (erlotinib) decreased viability of transformed cells expressing EGFR R108K in culture (PMID: 17177598).",Actionable,6919,10000003,Advanced Solid Tumor,JAX,2925,EGFR R108K,sensitive,4,Erlotinib,1956,17177598,,,
667,Preclinical,"In a preclinical study, transformed cells expressing EGFR N826S demonstrated resistance to AEE788 in cell culture (PMID: 19147750).",Actionable,6894,10000003,Advanced Solid Tumor,JAX,23983,EGFR N826S,resistant,622,AEE788,1956,19147750,,,
668,Preclinical,"In a preclinical study, transformed cells expressing EGFR N826S demonstrated resistance to Tarceva (erlotinib) in cell culture (PMID: 19147750).",Actionable,6892,10000003,Advanced Solid Tumor,JAX,23983,EGFR N826S,resistant,4,Erlotinib,1956,19147750,,,
669,Preclinical,"In a preclinical study, transformed cells expressing EGFR N826S demonstrated resistance to Iressa (gefitinib) in cell culture (PMID: 19147750).",Actionable,6893,10000003,Advanced Solid Tumor,JAX,23983,EGFR N826S,resistant,751,Gefitinib,1956,19147750,,,
670,Preclinical - Cell culture,"In a preclinical study, Erbitux (cetuximab) did not efficiently inhibit Egfr phosphorylation in transformed cells over expressing T34_A289del in culture (PMID: 27216155). ",Actionable,7813,10000003,Advanced Solid Tumor,JAX,26048,EGFR T34_A289del,decreased response,694,Cetuximab,1956,27216155,,,
671,Preclinical - Cell culture,"In a preclinical study, Tarceva (erlotinib) inhibited Egfr phosphorylation and cell proliferation in neuroblastoma cells over expressing EGFR T34_A289del in culture (PMID: 27216155).",Actionable,7810,769,neuroblastoma,DOID,26048,EGFR T34_A289del,sensitive,4,Erlotinib,1956,27216155,,,
672,Preclinical - Cell culture,"In a preclinical study, Tarceva (erlotinib) inhibited Egfr phosphorylation and cell proliferation in transformed cells over expressing EGFR T34_A289del in culture (PMID: 27216155).",Actionable,7811,10000003,Advanced Solid Tumor,JAX,26048,EGFR T34_A289del,sensitive,4,Erlotinib,1956,27216155,,,
673,Preclinical - Cell culture,"In a preclinical study, neuroblastoma cells over expressing EGFR T34_A289del were resistant to Eposin (etoposide) in culture (PMID: 27216155).",Actionable,7812,769,neuroblastoma,DOID,26048,EGFR T34_A289del,resistant,1136,Etoposide,1956,27216155,,,
674,Phase I,"In a retrospective analysis, non-small cell lung cancer patients harboring EGFR exon 20 insertions, such as EGFR V769_D770insASV (also referred to as A767_V769dup), displayed progressive disease following treatment with Tarceva (erlotinib), and resistance to Tarceva (erlotinib) was replicated in cell culture studies (PMID: 24353160).",Actionable,791,3908,non-small cell lung carcinoma,DOID,1048,EGFR V769_D770insASV,resistant,4,Erlotinib,1956,24353160,,,
675,Clinical Study,"In a retrospective analysis, non-small cell lung cancer patients harboring EGFR exon 20 insertions, such as EGFR V769_D770insASV (also referred to as A767_V769dup), displayed progressive disease following treatment with Iressa (gefitinib), and resistance to Iressa (gefitinib) was replicated in cell culture studies (PMID: 24353160).",Actionable,792,3908,non-small cell lung carcinoma,DOID,1048,EGFR V769_D770insASV,resistant,751,Gefitinib,1956,24353160,,,
676,Preclinical,"In a preclinical study, transformed cells expressing EGFR exon 20 insertions, including EGFR V769_D770insASV (also known as A767_V769dupASV), demonstrated resistance to Gilotrif (afatinib) in cell culture (PMID: 24353160).",Actionable,790,10000003,Advanced Solid Tumor,JAX,1048,EGFR V769_D770insASV,resistant,623,Afatinib,1956,24353160,,,
677,Preclinical - Cell culture,"In a preclinical study, EGF816 inhibited growth of transformed cells expressing EGFR V769_D770insASV in culture (PMID: 26825170).",Actionable,5652,10000003,Advanced Solid Tumor,JAX,1048,EGFR V769_D770insASV,sensitive,1309,EGF816,1956,26825170,,,
678,Clinical Study,"In a retrospective analysis, 3 patients with lung adenocarcinoma harboring EGFR L747_T751delinsP were found to respond to Iressa (gefitinib) therapy (PMID: 18981003).",Actionable,3049,3910,lung adenocarcinoma,DOID,11383,EGFR L747_T751delinsP,sensitive,751,Gefitinib,1956,18981003,,,
0,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated a decreased response to treatment with Brigatinib (AP26113) in culture (PMID: 27432227).  ",Actionable,8639,10000003,Advanced Solid Tumor,JAX,26385,EML4-ALK ALK G1202del,decreased response,634,AP26113,27436,27432227,,,
1,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated a decreased response to treatment with Xalkori (crizotinib) in culture (PMID: 27432227).  ",Actionable,8636,10000003,Advanced Solid Tumor,JAX,26385,EML4-ALK ALK G1202del,decreased response,706,Crizotinib,27436,27432227,,,
2,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).  ",Actionable,8640,10000003,Advanced Solid Tumor,JAX,26385,EML4-ALK ALK G1202del,sensitive,869,PF-06463922,27436,27432227,,,
3,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated a decreased response to treatment with Alecensa (alectinib) in culture (PMID: 27432227).  ",Actionable,8638,10000003,Advanced Solid Tumor,JAX,26385,EML4-ALK ALK G1202del,decreased response,698,Alectinib,27436,27432227,,,
4,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated a decreased response to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).  ",Actionable,8637,10000003,Advanced Solid Tumor,JAX,26385,EML4-ALK ALK G1202del,decreased response,789,Ceritinib,27436,27432227,,,
5,Phase I,"In a Phase I clinical trial, a patient with EML4-ALK positive non-small lung cancer initially responded to Xalkori (crizotinib) but developed resistance with the emergence of a secondary ALK mutation C1156Y, and subsequently redeveloped sensitivity to Xalkori (crizotinib) upon the emergence of a second ALK mutation, L1198F arising from resistance to Lorlatinib (PF-06463922) (PMID: 26698910).",Actionable,5673,3908,non-small cell lung carcinoma,DOID,21372,EML4-ALK ALK C1156Y ALK L1198F,sensitive,706,Crizotinib,27436,26698910,,,
6,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).",Actionable,5684,10000003,Advanced Solid Tumor,JAX,21372,EML4-ALK ALK C1156Y ALK L1198F,resistant,698,Alectinib,27436,26698910,,,
7,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F were resistant to growth inhibition mediated by Brigatinib (AP26113) in culture (PMID: 26698910).",Actionable,5688,10000003,Advanced Solid Tumor,JAX,21372,EML4-ALK ALK C1156Y ALK L1198F,resistant,634,AP26113,27436,26698910,,,
8,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).",Actionable,5687,10000003,Advanced Solid Tumor,JAX,21372,EML4-ALK ALK C1156Y ALK L1198F,resistant,789,Ceritinib,27436,26698910,,,
9,Phase I,"In a Phase I clinical trial, a patient with EML4-ALK positive non-small lung cancer with a secondary Xalkori (critzotinib) resistance mutation C1156Y, responded to Lorlatinib (PF-06463922) but subsequently developed resistance upon the emergence of a second ALK mutation, L1198F (PMID: 26698910).",Actionable,5672,3908,non-small cell lung carcinoma,DOID,21372,EML4-ALK ALK C1156Y ALK L1198F,resistant,869,PF-06463922,27436,26698910,,,
10,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).",Actionable,5679,10000003,Advanced Solid Tumor,JAX,21372,EML4-ALK ALK C1156Y ALK L1198F,resistant,869,PF-06463922,27436,26698910,,,
11,Preclinical,"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y and ALK L1198F in culture (PMID: 26698910).",Actionable,5676,10000003,Advanced Solid Tumor,JAX,21372,EML4-ALK ALK C1156Y ALK L1198F,sensitive,706,Crizotinib,27436,26698910,,,
12,Preclinical,"In preclinical studies, Brigatinib (AP26113) inhibited the growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 27009859, PMID: 26698910).",Actionable,5388,10000003,Advanced Solid Tumor,JAX,5334,EML4-ALK ALK G1269A,sensitive,634,AP26113,27436,27009859,26698910,,
13,Preclinical,"In preclinical studies, Zykadia (ceritinib) inhibited growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 26698910, PMID: 27009859).",Actionable,5385,10000003,Advanced Solid Tumor,JAX,5334,EML4-ALK ALK G1269A,sensitive,789,Ceritinib,27436,27009859,26698910,,
14,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5387,10000003,Advanced Solid Tumor,JAX,5334,EML4-ALK ALK G1269A,resistant,643,ASP3026,27436,27009859,,,
15,Preclinical - Patient cell culture,"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and growth of non-small cell lung cancer (NSCLC) cells over expressing ALK G1269A in the context of EML4-ALK in culture and in cell line xenograft models, as well as inhibited  growth of patient derived NSCLC cells harboring EML4-ALK ALK G1269A in culture (PMID: 26144315). ",Actionable,3159,3908,non-small cell lung carcinoma,DOID,5334,EML4-ALK ALK G1269A,sensitive,869,PF-06463922,27436,26144315,,,
16,Preclinical,"In preclinical studies, human lung cancer cell lines expressing EML4-ALK G1269A demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 22235099, PMID: 23344087, PMID: 24675041).",Actionable,2054,3908,non-small cell lung carcinoma,DOID,5334,EML4-ALK ALK G1269A,resistant,706,Crizotinib,27436,23344087,22235099,24675041,
17,Preclinical,"In a preclinical study, human lung cancer cell lines harboring EML4-ALK with ALK G1269A demonstrated sensitivity to Zykadia (ceritinib) in culture (PMID: 24675041).",Actionable,2055,3908,non-small cell lung carcinoma,DOID,5334,EML4-ALK ALK G1269A,sensitive,789,Ceritinib,27436,24675041,,,
18,Preclinical,"In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 26698910).",Actionable,5721,10000003,Advanced Solid Tumor,JAX,5334,EML4-ALK ALK G1269A,sensitive,869,PF-06463922,27436,26698910,,,
19,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A demonstrated a decreased response when treated with Entrectinib (RXDX-101) (PMID: 26939704). ",Actionable,5640,10000003,Advanced Solid Tumor,JAX,5334,EML4-ALK ALK G1269A,decreased response,1455,Entrectinib,27436,26939704,,,
20,Preclinical,"In a preclinical study, Alecensa (alectinib) modestly inhibited growth of transformed cells expression EML4-ALK with ALK G1269A in culture (PMID: 26698910).",Actionable,5722,10000003,Advanced Solid Tumor,JAX,5334,EML4-ALK ALK G1269A,conflicting,698,Alectinib,27436,26698910,,,
21,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5386,10000003,Advanced Solid Tumor,JAX,5334,EML4-ALK ALK G1269A,conflicting,698,Alectinib,27436,27009859,,,
22,Preclinical,"In preclinical studies, transformed cells expressing EML4-ALK with ALK G1269A were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859, PMID: 26698910).",Actionable,5384,10000003,Advanced Solid Tumor,JAX,5334,EML4-ALK ALK G1269A,resistant,706,Crizotinib,27436,27009859,26698910,,
23,Preclinical,"In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 27009859).",Actionable,5389,10000003,Advanced Solid Tumor,JAX,5334,EML4-ALK ALK G1269A,sensitive,1586,AZD3463,27436,27009859,,,
24,Clinical Study,"In a clinical case study, a patient with EML4-ALK fusion positive non-small cell lung cancer with ALK G1269A had a partial response to Alecensa (alectinib) treatment (PMID: 26849637).",Actionable,4621,3908,non-small cell lung carcinoma,DOID,5334,EML4-ALK ALK G1269A,sensitive,698,Alectinib,27436,26849637,,,
25,Preclinical - Cell line xenograft,"In a preclinical study, Alecensa (alectinib) inhibited proliferation of a Xalkori (crizotinib)-resistant human non-small cell lung cancer (NSCLC) cell line harboring an EML-ALK fusion with ALK G1269A in culture and induced tumor regression in xenograft models (PMID: 26849637, PMID: 23344087).",Actionable,4462,3908,non-small cell lung carcinoma,DOID,5334,EML4-ALK ALK G1269A,sensitive,698,Alectinib,27436,23344087,26849637,,
26,Preclinical,"In a preclinical study, Xalkori (crizotinib) resistance was reduced in transformed cells expressing EML4-ALK with ALK L1196M with the addition of ALK L1198F in culture (PMID: 26698910).",Actionable,5703,10000003,Advanced Solid Tumor,JAX,21376,EML4-ALK ALK L1196M ALK L1198F,resistant,706,Crizotinib,27436,26698910,,,
27,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).",Actionable,5706,10000003,Advanced Solid Tumor,JAX,21376,EML4-ALK ALK L1196M ALK L1198F,resistant,869,PF-06463922,27436,26698910,,,
28,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).",Actionable,5704,10000003,Advanced Solid Tumor,JAX,21376,EML4-ALK ALK L1196M ALK L1198F,resistant,789,Ceritinib,27436,26698910,,,
29,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F were resistant to growth inhibition mediated by Brigatinib (AP26113) in culture (PMID: 26698910).",Actionable,5707,10000003,Advanced Solid Tumor,JAX,21376,EML4-ALK ALK L1196M ALK L1198F,resistant,634,AP26113,27436,26698910,,,
30,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).",Actionable,5705,10000003,Advanced Solid Tumor,JAX,21376,EML4-ALK ALK L1196M ALK L1198F,resistant,698,Alectinib,27436,26698910,,,
31,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK F1174V in the context of EML4-ALK in culture (PMID: 27780853).",Actionable,9261,10000003,Advanced Solid Tumor,JAX,26808,EML4-ALK ALK F1174V,sensitive,634,AP26113,27436,27780853,,,
32,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing ALK F1174V in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) in culture (PMID: 27780853).",Actionable,9267,10000003,Advanced Solid Tumor,JAX,26808,EML4-ALK ALK F1174V,decreased response,706,Crizotinib,27436,27780853,,,
33,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated a decreased response to treatment with Xalkori (crizotinib) in culture (PMID: 27432227). ",Actionable,8655,10000003,Advanced Solid Tumor,JAX,26388,EML4-ALK ALK D1203N ALK E1210K,decreased response,706,Crizotinib,27436,27432227,,,
34,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated a decreased response to treatment with Alecensa (alectinib) in culture (PMID: 27432227). ",Actionable,8657,10000003,Advanced Solid Tumor,JAX,26388,EML4-ALK ALK D1203N ALK E1210K,decreased response,698,Alectinib,27436,27432227,,,
35,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated a decreased response to treatment with Zykadia (ceritinib) in culture (PMID: 27432227). ",Actionable,8656,10000003,Advanced Solid Tumor,JAX,26388,EML4-ALK ALK D1203N ALK E1210K,decreased response,789,Ceritinib,27436,27432227,,,
36,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227). ",Actionable,8659,10000003,Advanced Solid Tumor,JAX,26388,EML4-ALK ALK D1203N ALK E1210K,sensitive,869,PF-06463922,27436,27432227,,,
37,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK E1210K demonstrated a decreased response to treatment with Brigatinib (AP26113) in culture (PMID: 27432227). ",Actionable,8658,10000003,Advanced Solid Tumor,JAX,26388,EML4-ALK ALK D1203N ALK E1210K,decreased response,634,AP26113,27436,27432227,,,
38,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910).",Actionable,5689,10000003,Advanced Solid Tumor,JAX,5336,EML4-ALK ALK C1156Y,sensitive,634,AP26113,27436,26698910,,,
39,Clinical Study,"In a clinical study, a patient with EML4-ALK positive non-small cell lung cancer with an ALK C1156Y secondary Xalkori (crizotinib) resistance mutation did not respond to Luminespib (AUY922) therapy (PMID: 26698910).",Actionable,5671,3908,non-small cell lung carcinoma,DOID,5336,EML4-ALK ALK C1156Y,resistant,647,AUY922,27436,26698910,,,
40,Preclinical,"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910).",Actionable,5682,10000003,Advanced Solid Tumor,JAX,5336,EML4-ALK ALK C1156Y,sensitive,698,Alectinib,27436,26698910,,,
41,Preclinical,"In a preclinical study, transformed human cells expressing EML4-ALK with ALK C1156Y were sensitive to Alecensa (alectinib) in culture (PMID: 21575866).",Actionable,2981,10000003,Advanced Solid Tumor,JAX,5336,EML4-ALK ALK C1156Y,sensitive,698,Alectinib,27436,21575866,,,
42,Preclinical - Cell line xenograft,"In a preclinical study, Zykadia (ceritinib) demonstrated tumor growth inhibition in xenograft models of a human non-small cell lung cancer cell line harboring EML4-ALK with ALK C1156Y when compared to Xalkori (crizotinib) (PMID: 24675041).",Actionable,2982,3908,non-small cell lung carcinoma,DOID,5336,EML4-ALK ALK C1156Y,conflicting,789,Ceritinib,27436,24675041,,,
43,Clinical Study,"In a clinical study, a patient with EML4-ALK positive non-small cell lung cancer with a secondary Xalkori (crizotinib) resistance mutation C1156Y, did not respond to Zykadia (ceritinib) therapy (PMID: 26698910).",Actionable,5720,3908,non-small cell lung carcinoma,DOID,5336,EML4-ALK ALK C1156Y,conflicting,789,Ceritinib,27436,26698910,,,
44,Preclinical,"In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910).",Actionable,5685,10000003,Advanced Solid Tumor,JAX,5336,EML4-ALK ALK C1156Y,sensitive,789,Ceritinib,27436,26698910,,,
45,Phase I,"In a Phase I clinical study, a patient with EML4-ALK positive non-small cell lung cancer with a secondary Xalkori (crizotinib) resistance mutation ALK C1156Y, was treated with Lorlatinib (PF-06463922) and displayed a 41% reduction in tumor growth after 5 weeks of treatment (PMID: 26698910).",Actionable,5669,3908,non-small cell lung carcinoma,DOID,5336,EML4-ALK ALK C1156Y,sensitive,869,PF-06463922,27436,26698910,,,
46,Preclinical,"In a preclinical study, Lorlatinib (PF-06463922) inhibited growth and ALK phosphorylation of transformed cells expressing EML4-ALK with ALK C1156Y in culture (PMID: 26698910).",Actionable,5677,10000003,Advanced Solid Tumor,JAX,5336,EML4-ALK ALK C1156Y,sensitive,869,PF-06463922,27436,26698910,,,
47,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y were sensitive to Entrectinib (RXDX-101), resulting in anti-proliferative activity (PMID: 26939704). ",Actionable,5637,10000003,Advanced Solid Tumor,JAX,5336,EML4-ALK ALK C1156Y,sensitive,1455,Entrectinib,27436,26939704,,,
48,Preclinical,"In a preclinical study, Ensartinib (X-396) inhibited growth and Alk phosphorylation in cells expressing the Xalkori (crizotinib) resistance mutation, EML4-ALK C1156Y (PMID: 21613408). ",Actionable,2093,10000003,Advanced Solid Tumor,JAX,5336,EML4-ALK ALK C1156Y,sensitive,961,X-396,27436,21613408,,,
49,Clinical Study,"In a clinical study, a patient with EML4-ALK positive non-small cell lung cancer developed resistance to Xalkori (crizotinib) with the emergence of ALK C1156Y, a secondary resistance mutation (PMID: 26698910).",Actionable,5668,3908,non-small cell lung carcinoma,DOID,5336,EML4-ALK ALK C1156Y,resistant,706,Crizotinib,27436,26698910,,,
50,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK ALK C1156Y were insensitive to Xalkori (crizotinib) as demonstrated by lack of growth inhibition and lack of kinase inhibition in culture (PMID: 21613408). ",Actionable,2092,10000003,Advanced Solid Tumor,JAX,5336,EML4-ALK ALK C1156Y,resistant,706,Crizotinib,27436,21613408,,,
51,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y were resistant to growth inhibition mediated by Xalkori (crizotinib) in culture (PMID: 26698910).",Actionable,5674,10000003,Advanced Solid Tumor,JAX,5336,EML4-ALK ALK C1156Y,resistant,706,Crizotinib,27436,26698910,,,
52,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated resistance to treatment with Alecensa (alectinib) in culture (PMID: 27432227).  ",Actionable,8628,10000003,Advanced Solid Tumor,JAX,26384,EML4-ALK ALK I1171N,resistant,698,Alectinib,27436,27432227,,,
53,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated a decreased response to treatment with Xalkori (crizotinib) in culture (PMID: 27432227).  ",Actionable,8626,10000003,Advanced Solid Tumor,JAX,26384,EML4-ALK ALK I1171N,decreased response,706,Crizotinib,27436,27432227,,,
54,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).  ",Actionable,8630,10000003,Advanced Solid Tumor,JAX,26384,EML4-ALK ALK I1171N,sensitive,869,PF-06463922,27436,27432227,,,
55,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated sensitivity to treatment with Brigatinib (AP26113) in culture (PMID: 27432227).  ",Actionable,8629,10000003,Advanced Solid Tumor,JAX,26384,EML4-ALK ALK I1171N,sensitive,634,AP26113,27436,27432227,,,
56,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).  ",Actionable,8627,10000003,Advanced Solid Tumor,JAX,26384,EML4-ALK ALK I1171N,sensitive,789,Ceritinib,27436,27432227,,,
57,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing ALK L1152P in the context of EML4-ALK demonstrated reduced sensitivity to Zykadia (ceritinib) in culture (PMID: 27780853).",Actionable,9269,10000003,Advanced Solid Tumor,JAX,26806,EML4-ALK ALK L1152P,decreased response,789,Ceritinib,27436,27780853,,,
58,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing ALK L1152P in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) in culture (PMID: 27780853).",Actionable,9265,10000003,Advanced Solid Tumor,JAX,26806,EML4-ALK ALK L1152P,decreased response,706,Crizotinib,27436,27780853,,,
59,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK L1152P in the context of EML4-ALK in culture (PMID: 27780853).",Actionable,9260,10000003,Advanced Solid Tumor,JAX,26806,EML4-ALK ALK L1152P,sensitive,634,AP26113,27436,27780853,,,
60,Preclinical,"In a preclinical study, TPX-0005 inhibited Alk and Src signaling, and cell proliferation in lung cancer cell lines harboring EML4-ALK and elevated Src activity in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).",Actionable,5831,1324,lung cancer,DOID,21947,EML4 - ALK SRC act mut,sensitive,3950,TPX-0005,27436,None,,,
61,Preclinical,"In a preclinical study, lung cancer cell lines harboring EML4-ALK and elevated Src activity were resistant to Zykadia (ceritinib) induced growth inhibition in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).",Actionable,5836,10000003,Advanced Solid Tumor,JAX,21947,EML4 - ALK SRC act mut,resistant,789,Ceritinib,27436,None,,,
62,Preclinical,"In a preclinical study, lung cancer cell lines harboring EML4-ALK and elevated Src activity were resistant to Xalkori (crizotinib) induced growth inhibition in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).",Actionable,5835,1324,lung cancer,DOID,21947,EML4 - ALK SRC act mut,resistant,706,Crizotinib,27436,None,,,
63,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated a decreased response to treatment with Brigatinib (AP26113) in culture (PMID: 27432227). ",Actionable,8653,10000003,Advanced Solid Tumor,JAX,26387,EML4-ALK ALK D1203N ALK F1174C,decreased response,634,AP26113,27436,27432227,,,
64,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated a decreased response to treatment with Alecensa (alectinib) in culture (PMID: 27432227). ",Actionable,8652,10000003,Advanced Solid Tumor,JAX,26387,EML4-ALK ALK D1203N ALK F1174C,decreased response,698,Alectinib,27436,27432227,,,
65,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated a decreased response to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227). ",Actionable,8654,10000003,Advanced Solid Tumor,JAX,26387,EML4-ALK ALK D1203N ALK F1174C,decreased response,869,PF-06463922,27436,27432227,,,
66,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated resistance to treatment with Xalkori (crizotinib) in culture (PMID: 27432227). ",Actionable,8651,10000003,Advanced Solid Tumor,JAX,26387,EML4-ALK ALK D1203N ALK F1174C,resistant,706,Crizotinib,27436,27432227,,,
67,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK, ALK D1203N, and ALK F1174C demonstrated resistance to treatment with Zykadia (ceritinib) in culture (PMID: 27432227). ",Actionable,8666,10000003,Advanced Solid Tumor,JAX,26387,EML4-ALK ALK D1203N ALK F1174C,resistant,789,Ceritinib,27436,27432227,,,
68,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).",Actionable,5715,10000003,Advanced Solid Tumor,JAX,21377,EML4-ALK ALK L1198F ALK G1202R,resistant,869,PF-06463922,27436,26698910,,,
69,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).",Actionable,5718,10000003,Advanced Solid Tumor,JAX,21377,EML4-ALK ALK L1198F ALK G1202R,resistant,789,Ceritinib,27436,26698910,,,
70,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).",Actionable,5716,10000003,Advanced Solid Tumor,JAX,21377,EML4-ALK ALK L1198F ALK G1202R,resistant,698,Alectinib,27436,26698910,,,
71,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Brigatinib (AP26113) in culture (PMID: 26698910).",Actionable,5717,10000003,Advanced Solid Tumor,JAX,21377,EML4-ALK ALK L1198F ALK G1202R,resistant,634,AP26113,27436,26698910,,,
72,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were re-sensitized to Xalkori (crizotinib) mediated growth inhibition with the introduction of an additional ALK mutation L1198F, in culture (PMID: 26698910).",Actionable,5714,10000003,Advanced Solid Tumor,JAX,21377,EML4-ALK ALK L1198F ALK G1202R,sensitive,706,Crizotinib,27436,26698910,,,
73,Preclinical,"In a preclinical study, transformed cell lines harboring EML4-ALK with ALK T1151M were resistant to ASP3026 in culture (PMID: 27009859).",Actionable,5377,10000003,Advanced Solid Tumor,JAX,20656,EML4-ALK ALK T1151M,resistant,643,ASP3026,27436,27009859,,,
74,Preclinical,"In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859).",Actionable,5375,10000003,Advanced Solid Tumor,JAX,20656,EML4-ALK ALK T1151M,sensitive,1586,AZD3463,27436,27009859,,,
75,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859).",Actionable,5374,10000003,Advanced Solid Tumor,JAX,20656,EML4-ALK ALK T1151M,sensitive,634,AP26113,27436,27009859,,,
76,Preclinical,"In a preclinical study, Xalkori (crizotinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859).",Actionable,5372,10000003,Advanced Solid Tumor,JAX,20656,EML4-ALK ALK T1151M,sensitive,706,Crizotinib,27436,27009859,,,
77,Preclinical,"In a preclinical study, transformed cell lines harboring EML4-ALK with ALK T1151M were resistant to Zykadia (ceritinib) in culture (PMID: 27009859).",Actionable,5376,10000003,Advanced Solid Tumor,JAX,20656,EML4-ALK ALK T1151M,resistant,789,Ceritinib,27436,27009859,,,
78,Preclinical,"In a preclinical study, Alecensa (alectinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859).",Actionable,5373,10000003,Advanced Solid Tumor,JAX,20656,EML4-ALK ALK T1151M,sensitive,698,Alectinib,27436,27009859,,,
79,Preclinical,"In preclinical studies, transformed cell lines expressing EML4-ALK L1152R demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 21791641).",Actionable,2144,10000003,Advanced Solid Tumor,JAX,5425,EML4-ALK ALK L1152R,resistant,706,Crizotinib,27436,21791641,,,
80,Preclinical - Cell culture,"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell proliferation of transformed cells over expressing ALK L1152R in the context of EML4-ALK in culture  (PMID: 26144315). ",Actionable,8295,10000003,Advanced Solid Tumor,JAX,5425,EML4-ALK ALK L1152R,sensitive,869,PF-06463922,27436,26144315,,,
81,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK L1152R in the context of EML4-ALK in culture (PMID: 27780853).",Actionable,9259,10000003,Advanced Solid Tumor,JAX,5425,EML4-ALK ALK L1152R,sensitive,634,AP26113,27436,27780853,,,
82,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing ALK L1152R in the context of EML4-ALK demonstrated reduced sensitivity to Zykadia (ceritinib) in culture (PMID: 27780853).",Actionable,9268,10000003,Advanced Solid Tumor,JAX,5425,EML4-ALK ALK L1152R,decreased response,789,Ceritinib,27436,27780853,,,
83,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1198F were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910), however, in another study, comparable cells demonstrated sensitivity in culture (PMID: 27432227).",Actionable,5683,10000003,Advanced Solid Tumor,JAX,21373,EML4-ALK ALK L1198F,conflicting,698,Alectinib,27436,26698910,27432227,,
84,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with L1198F were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).",Actionable,5686,10000003,Advanced Solid Tumor,JAX,21373,EML4-ALK ALK L1198F,resistant,789,Ceritinib,27436,26698910,,,
85,Preclinical,"In a preclinical study, Xalkori (crizotinib) enhanced growth inhibition of transformed cells expressing EML4-ALK with L1198F in culture (PMID: 26698910).",Actionable,5675,10000003,Advanced Solid Tumor,JAX,21373,EML4-ALK ALK L1198F,sensitive,706,Crizotinib,27436,26698910,,,
86,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing EML4-ALK with L1198F in culture (PMID: 26698910).",Actionable,5690,10000003,Advanced Solid Tumor,JAX,21373,EML4-ALK ALK L1198F,sensitive,634,AP26113,27436,26698910,,,
87,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with L1198F had reduced sensitivity to growth inhibition mediated by Lorlatinib (PF-06463922) in comparison to EML4-ALK wild type in culture (PMID: 26698910).",Actionable,5680,10000003,Advanced Solid Tumor,JAX,21373,EML4-ALK ALK L1198F,decreased response,869,PF-06463922,27436,26698910,,,
88,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Brigatinib (AP26113) in culture (PMID: 27432227).  ",Actionable,8644,10000003,Advanced Solid Tumor,JAX,26386,EML4-ALK ALK D1203N,sensitive,634,AP26113,27436,27432227,,,
89,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Alecensa (alectinib) in culture (PMID: 27432227).  ",Actionable,8643,10000003,Advanced Solid Tumor,JAX,26386,EML4-ALK ALK D1203N,sensitive,698,Alectinib,27436,27432227,,,
90,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).  ",Actionable,8642,10000003,Advanced Solid Tumor,JAX,26386,EML4-ALK ALK D1203N,sensitive,789,Ceritinib,27436,27432227,,,
91,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated a decreased response to treatment with Xalkori (crizotinib) in culture (PMID: 27432227).  ",Actionable,8641,10000003,Advanced Solid Tumor,JAX,26386,EML4-ALK ALK D1203N,decreased response,706,Crizotinib,27436,27432227,,,
92,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).  ",Actionable,8645,10000003,Advanced Solid Tumor,JAX,26386,EML4-ALK ALK D1203N,sensitive,869,PF-06463922,27436,27432227,,,
93,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing S1206Y in the context of EML4-ALK in culture (PMID: 27780853).",Actionable,9263,10000003,Advanced Solid Tumor,JAX,5338,EML4-ALK ALK S1206Y,sensitive,634,AP26113,27436,27780853,,,
94,Clinical Study,"In a clinical study, an ALK S1206Y secondary mutation in the context of EML4-ALK was associated with resistance to Xalkori (crizotinib) in a patient with non-small cell lung cancer, and resistance was replicated in cell culture studies (PMID: 22277784).",Actionable,1001,3908,non-small cell lung carcinoma,DOID,5338,EML4-ALK ALK S1206Y,resistant,706,Crizotinib,27436,22277784,,,
95,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK S1206Y demonstrated growth inhibition with Zykadia (ceritinib) treatment in culture (PMID: 24675041). ",Actionable,2099,10000003,Advanced Solid Tumor,JAX,5338,EML4-ALK ALK S1206Y,sensitive,789,Ceritinib,27436,24675041,,,
96,Preclinical - Cell culture,"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell proliferation of transformed cells over expressing ALK S1206Y in the context of EML4-ALK in culture  (PMID: 26144315). ",Actionable,8296,10000003,Advanced Solid Tumor,JAX,5338,EML4-ALK ALK S1206Y,sensitive,869,PF-06463922,27436,26144315,,,
97,Clinical Study,"In a clinical case study, a non-small cell lung cancer patient harboring EML4-ALK variant 3 that demonstrated resistance to treatment with Xalkori (crizotinib) after acquisition of ALK F1245C, achieved a complete radiographic response with no evidence of progression at 6 months following treatment with Zykadia (ceritinib) (PMID: 26775591).",Actionable,10734,3908,non-small cell lung carcinoma,DOID,27740,EML4-ALK ALK F1245C,sensitive,789,Ceritinib,27436,26775591,,,
98,Clinical Study,"In a clinical case study, a non-small cell lung cancer patient harboring EML4-ALK variant 3 demonstrated an initial response to treatment with Xalkori (crizotinib), but progressed after 27 months and was found to have acquired ALK F1245C (PMID: 26775591).",Actionable,10733,3908,non-small cell lung carcinoma,DOID,27740,EML4-ALK ALK F1245C,resistant,706,Crizotinib,27436,26775591,,,
99,Preclinical,"In a preclinical study, ASP3026 inhibited growth of a transformed cell line expressing EML4-ALK with ALK V1180L in culture (PMID: 25228534).",Actionable,3406,10000003,Advanced Solid Tumor,JAX,12072,EML4-ALK ALK V1180L,sensitive,643,ASP3026,27436,25228534,,,
100,Preclinical,"In a preclinical study, a transformed cell line expressing EML4-ALK with ALK V1180L was resistant to Alecensa (alectinib) treatment in culture (PMID: 25228534).",Actionable,3396,10000003,Advanced Solid Tumor,JAX,12072,EML4-ALK ALK V1180L,resistant,698,Alectinib,27436,25228534,,,
101,Preclinical,"In a preclinical study, a human non-small cell lung cancer cell line harboring EML4-ALK ALK V1180L was resistant to Xalkori (crizotinib) treatment in culture (PMID: 25228534).",Actionable,3393,3908,non-small cell lung carcinoma,DOID,12072,EML4-ALK ALK V1180L,resistant,706,Crizotinib,27436,25228534,,,
102,Preclinical,"In a preclinical study, TAE684 inhibited growth of a transformed cell line expressing EML4-ALK ALK V1180L in culture (PMID: 25228534).",Actionable,3398,10000003,Advanced Solid Tumor,JAX,12072,EML4-ALK ALK V1180L,sensitive,2386,TAE684,27436,25228534,,,
103,Preclinical - Cell culture,"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation, reduced proliferation, and induced apoptosis of non-small cell lung carcinoma cells harboring ALK V1180L in the context of EML4-ALK in culture (PMID: 26144315). ",Actionable,2648,3908,non-small cell lung carcinoma,DOID,12072,EML4-ALK ALK V1180L,sensitive,869,PF-06463922,27436,26144315,,,
104,Preclinical,"In a preclinical study, Zykadia (ceritinib) inhibited growth of a transformed cell line expressing EML4-ALK with ALK V1180L in culture (PMID: 25228534).",Actionable,3400,10000003,Advanced Solid Tumor,JAX,12072,EML4-ALK ALK V1180L,sensitive,789,Ceritinib,27436,25228534,,,
105,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited growth of a transformed cell line expressing EML4-ALK ALK V1180L in culture (PMID: 25228534).",Actionable,3403,10000003,Advanced Solid Tumor,JAX,12072,EML4-ALK ALK V1180L,sensitive,634,AP26113,27436,25228534,,,
106,Preclinical,"In a preclinical study, a human non-small cell lung cancer cell line harboring EML4-ALK with ALK V1180L was resistant to Alecensa (alectinib) treatment in culture (PMID: 25228534).",Actionable,3392,3908,non-small cell lung carcinoma,DOID,12072,EML4-ALK ALK V1180L,resistant,698,Alectinib,27436,25228534,,,
107,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK S1206F in the context of EML4-ALK in culture (PMID: 27780853).",Actionable,9262,10000003,Advanced Solid Tumor,JAX,26804,EML4-ALK ALK S1206F,sensitive,634,AP26113,27436,27780853,,,
108,Preclinical - Patient cell culture,"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell growth in patient derived non-small cell lung cancer cells harboring ALK I1171T in the context of EML4-ALK in culture (PMID: 26144315).",Actionable,3160,3908,non-small cell lung carcinoma,DOID,5340,EML4-ALK ALK I1171T,sensitive,869,PF-06463922,27436,26144315,,,
109,Preclinical,"In a preclinical study, a transformed cell line expressing EML4-ALK with ALK I1171T was resistant to ASP3026 treatment in culture (PMID: 25228534).",Actionable,3407,10000003,Advanced Solid Tumor,JAX,5340,EML4-ALK ALK I1171T,resistant,643,ASP3026,27436,25228534,,,
110,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171T demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).  ",Actionable,8633,10000003,Advanced Solid Tumor,JAX,5340,EML4-ALK ALK I1171T,sensitive,869,PF-06463922,27436,27432227,,,
111,Preclinical,"In a preclinical study, Zykadia (ceritinib) inhibited growth of a transformed cell line expressing EML4-ALK with ALK I1171T in culture (PMID: 25228534).",Actionable,2058,10000003,Advanced Solid Tumor,JAX,5340,EML4-ALK ALK I1171T,sensitive,789,Ceritinib,27436,25228534,,,
112,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited growth of a transformed cell line expressing EML4-ALK I1171T but to a lesser degree than EML4-ALK in culture (PMID: 25228534).",Actionable,3404,10000003,Advanced Solid Tumor,JAX,5340,EML4-ALK ALK I1171T,decreased response,634,AP26113,27436,25228534,,,
113,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171T demonstrated a decreased response to treatment with Xalkori (crizotinib) in culture (PMID: 27432227).  ",Actionable,8632,10000003,Advanced Solid Tumor,JAX,5340,EML4-ALK ALK I1171T,decreased response,706,Crizotinib,27436,27432227,,,
114,Preclinical,"In a preclinical study, a transformed cell line expressing EML4-ALK with ALK I1171T was resistant to Alecensa (alectinib) treatment in culture (PMID: 25228534), however, another study with comparable cells demonstrated sensitivity in culture (PMID: 27432227). ",Actionable,3397,10000003,Advanced Solid Tumor,JAX,5340,EML4-ALK ALK I1171T,conflicting,698,Alectinib,27436,25228534,27432227,,
115,Preclinical,"In a preclinical study, TAE684 inhibited growth of a transformed cell line expressing EML4-ALK ALK I1171T in culture (PMID: 25228534).",Actionable,3399,10000003,Advanced Solid Tumor,JAX,5340,EML4-ALK ALK I1171T,sensitive,2386,TAE684,27436,25228534,,,
116,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK T1151dup in the context of EML4-ALK in culture (PMID: 27780853).",Actionable,9258,10000003,Advanced Solid Tumor,JAX,26807,EML4-ALK ALK T1151dup,sensitive,634,AP26113,27436,27780853,,,
117,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing ALK T1151dup in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) in culture (PMID: 27780853).",Actionable,9264,10000003,Advanced Solid Tumor,JAX,26807,EML4-ALK ALK T1151dup,decreased response,706,Crizotinib,27436,27780853,,,
118,Preclinical - Cell line xenograft,"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and proliferation of non-small cell lung carcinoma cells over expressing ALK L1196M in the context of EML4-ALK in culture, and resulted in tumor regression in cell line xenograft models (PMID: 26144315). ",Actionable,2650,3908,non-small cell lung carcinoma,DOID,5335,EML4-ALK ALK L1196M,sensitive,869,PF-06463922,27436,26144315,,,
119,Preclinical - Cell line xenograft,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK L196M in the context of EML4-ALK in culture and reduced tumor growth in cell line xenograft models (PMID: 27780853).",Actionable,5702,10000003,Advanced Solid Tumor,JAX,5335,EML4-ALK ALK L1196M,sensitive,634,AP26113,27436,27780853,,,
120,Preclinical,"In preclinical studies, transformed cells expressing EML4-ALK ALK L1196M were insensitive to Xalkori (crizotinib) as demonstrated by lack of growth inhibition and Alk phosphorylation in culture (PMID: 21613408, PMID: 26698910). ",Actionable,2094,10000003,Advanced Solid Tumor,JAX,5335,EML4-ALK ALK L1196M,resistant,706,Crizotinib,27436,21613408,26698910,,
121,Preclinical,"In a preclinical study, Ensartinib (X-396) inhibited growth and Alk phosphorylation in cells expressing the Xalkori (crizotinib) resistance mutation, EML4-ALK ALK L1196M (PMID: 21613408).",Actionable,2095,10000003,Advanced Solid Tumor,JAX,5335,EML4-ALK ALK L1196M,sensitive,961,X-396,27436,21613408,,,
122,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M demonstrated decreased sensitivity to Alecensa (alectinib) compared to cells expressing EML4-ALK with wild-type ALK, in culture (PMID: 26698910).",Actionable,5701,10000003,Advanced Solid Tumor,JAX,5335,EML4-ALK ALK L1196M,conflicting,698,Alectinib,27436,26698910,,,
123,Preclinical - Cell line xenograft,"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing an EML4-ALK fusion and ALK L1196M in culture and in xenograft models (PMID: 21575866).",Actionable,10341,10000003,Advanced Solid Tumor,JAX,5335,EML4-ALK ALK L1196M,conflicting,698,Alectinib,27436,21575866,,,
124,Preclinical - Cell line xenograft,"In a preclinical study, Zykadia (ceritinib) inhibited cell survival and PI3K/AKT, MEK/ERK, and mTOR signaling in two human non-small cell lung carcinoma cell lines harboring the Xalkori (crizotinib) resistance mutation EML4-ALK ALK L1196M in culture and inhibited tumor growth in xenograft models of one of those cell lines (PMID: 24675041).",Actionable,2056,3908,non-small cell lung carcinoma,DOID,5335,EML4-ALK ALK L1196M,sensitive,789,Ceritinib,27436,24675041,,,
125,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910), however, in another study, comparable cells demonstrated sensitivity in culture (PMID: 27432227). ",Actionable,5708,10000003,Advanced Solid Tumor,JAX,5335,EML4-ALK ALK L1196M,conflicting,869,PF-06463922,27436,26698910,27432227,,
126,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK L1196M demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).  ",Actionable,8634,10000003,Advanced Solid Tumor,JAX,5335,EML4-ALK ALK L1196M,sensitive,789,Ceritinib,27436,27432227,,,
127,Preclinical - Cell culture,"In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing EML4-ALK with ALK L1196M in culture (PMID: 26698910)",Actionable,10342,10000003,Advanced Solid Tumor,JAX,5335,EML4-ALK ALK L1196M,sensitive,789,Ceritinib,27436,26698910,,,
128,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK L1196M were sensitive to Entrectinib (RXDX-101), resulting in anti-proliferative activity (PMID: 26939704).",Actionable,5638,10000003,Advanced Solid Tumor,JAX,5335,EML4-ALK ALK L1196M,sensitive,1455,Entrectinib,27436,26939704,,,
129,Preclinical - Cell culture,"In a preclinical study, TPX-0005 inhibited Alk activity and proliferation of transformed cells over expressing ALK L1196M in the context of EML4-ALK in culture (European Journal of Cancer , Volume 69, S32).",Actionable,10345,10000003,Advanced Solid Tumor,JAX,5335,EML4-ALK ALK L1196M,sensitive,3950,TPX-0005,27436,None,,,
130,Preclinical,"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK in culture (PMID: 26698910).",Actionable,5681,10000003,Advanced Solid Tumor,JAX,4138,EML4-ALK,sensitive,698,Alectinib,27436,26698910,,,
131,Preclinical,"In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing EML4-ALK in culture (PMID: 26698910).",Actionable,5678,10000003,Advanced Solid Tumor,JAX,4138,EML4-ALK,sensitive,869,PF-06463922,27436,26698910,,,
132,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of a transformed cell line expressing EML4-ALK in culture (PMID: 25228534).",Actionable,3402,10000003,Advanced Solid Tumor,JAX,4138,EML4-ALK,sensitive,634,AP26113,27436,25228534,,,
133,Preclinical - Cell culture,"In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of neuroblastoma cells harboring EML4-ALK in culture (PMID: 26554404).",Actionable,8378,769,neuroblastoma,DOID,4138,EML4-ALK,sensitive,869,PF-06463922,27436,26554404,,,
134,Preclinical - Cell culture,"In a preclinical study, Xalkori (crizotinib) did not inhibit growth of neuroblastoma cells over expressing EML4-ALK in culture (PMID: 26554404).",Actionable,8372,769,neuroblastoma,DOID,4138,EML4-ALK,resistant,706,Crizotinib,27436,26554404,,,
135,Preclinical,"In a preclinical study, non-small cell lung carcinoma cells harboring EML4-ALK were sensitive to Entrectinib (RXDX-101), resulting in inhibition of cell proliferation and complete tumor regression (PMID: 26939704).",Actionable,5636,3908,non-small cell lung carcinoma,DOID,4138,EML4-ALK,sensitive,1455,Entrectinib,27436,26939704,,,
136,Preclinical - Cell line xenograft,"In a preclinical study, combination of Gilotrif (afatinib) and Alecensa (alectinib) restored sensitivity to Alecensa (alectinib) in non-small cell lung cancer cells harboring EML4-ALK fusion that acquired resistance to Alecensa (alectinib) through up-regulating Egfr signaling in culture, inhibited tumor progression in cell line xenograft models (PMID: 26682573).",Actionable,9072,3908,non-small cell lung carcinoma,DOID,4138,EML4-ALK,sensitive,4873,Afatinib + Alectinib,27436,26682573,,,
137,Preclinical,"In a preclinical study, ASP3026 inhibited growth of a transformed cell line expressing EML4-ALK in culture (PMID: 25228534).",Actionable,3405,10000003,Advanced Solid Tumor,JAX,4138,EML4-ALK,sensitive,643,ASP3026,27436,25228534,,,
138,Preclinical,"In a preclinical study, Zykadia (ceritinib) inhibited growth of a transformed cell line expressing EML4-ALK in culture (PMID: 25228534).",Actionable,3401,10000003,Advanced Solid Tumor,JAX,4138,EML4-ALK,sensitive,789,Ceritinib,27436,25228534,,,
139,Preclinical - Cell line xenograft,"In a preclinical study, X-376 inhibited Alk signaling, resulted in growth inhibition in lung cancer cells harboring EML4-ALK fusion in culture and in cell line xenograft models (PMID: 21613408).",Actionable,10343,1324,lung cancer,DOID,4138,EML4-ALK,sensitive,2520,X-376,27436,21613408,,,
140,Preclinical - Cell line xenograft,"In a preclinical study, Alecensa (alectinib) inhibited Alk phosphorylation and growth of a human non-small cell lung cancer cell line harboring EML4-ALK in culture and in cell line xenografts (PMID: 21575866).",Actionable,6396,3908,non-small cell lung carcinoma,DOID,4138,EML4-ALK,sensitive,698,Alectinib,27436,21575866,,,
141,Preclinical,"In a preclinical study, Zykadia (ceritinib) inhibited phosphorylation of Alk and inhibited growth of human non-small cell lung cancer cell lines harboring EML4-ALK in culture (PMID: 25173427).",Actionable,6395,3908,non-small cell lung carcinoma,DOID,4138,EML4-ALK,sensitive,789,Ceritinib,27436,25173427,,,
142,Preclinical - Cell line xenograft,"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and proliferation of non-small cell lung carcinoma cells harboring EML4-ALK fusion, and reduced tumor size in intracranial cell line xenograft models (PMID: 26144315). ",Actionable,2651,3908,non-small cell lung carcinoma,DOID,4138,EML4-ALK,sensitive,869,PF-06463922,27436,26144315,,,
143,Preclinical,"In a preclinical study, transformed non-small cell lung cancer cells harboring EML4-ALK demonstrated enhanced growth inhibition to a combination treatment with Afinitor (sirolimus) and Ensartinib (X-396) (PMID: 21613408).",Actionable,2096,3908,non-small cell lung carcinoma,DOID,4138,EML4-ALK,sensitive,2592,Sirolimus + X-396,27436,21613408,,,
144,Preclinical - Cell line xenograft,"In a preclinical study, Brigatinib (AP26113) inhibited Alk phosphorylation and growth in non-small cell lung cancer cell lines harboring EML4-ALK in culture, and induced near complete tumor regression in cell line xenograft models (PMID: 27780853).",Actionable,9255,3908,non-small cell lung carcinoma,DOID,4138,EML4-ALK,sensitive,634,AP26113,27436,27780853,,,
145,Clinical Study,"In a clinical study, non-small cell lung carcinoma patients harboring an EML4-ALK fusion, in which exon 13 of EML4 is fused to exon 20 of ALK, demonstrated a significantly longer PFS compared to patients with an EML4-ALK fusion that includes either exon 20 or exon 6a/6b fused to ALK, when treated with Xalkori (crizotinib) (PMID: 27354483). ",Actionable,7510,3908,non-small cell lung carcinoma,DOID,4138,EML4-ALK,sensitive,706,Crizotinib,27436,27354483,,,
146,Phase I,"In a Phase I clinical trial, Xalkori (crizotinib) inhibited tumor growth by at least 30% from baseline in 90% (18/20) of patients with EML4-ALK positive non-small cell lung carcinoma (PMID: 20979469).",Actionable,6394,3908,non-small cell lung carcinoma,DOID,4138,EML4-ALK,sensitive,706,Crizotinib,27436,20979469,,,
147,Preclinical,"In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring EML4-ALK fusion in culture (PMID: 26090892).",Actionable,3932,3908,non-small cell lung carcinoma,DOID,4138,EML4-ALK,sensitive,2086,TAE226,27436,26090892,,,
148,Preclinical,"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK with ALK F1174L in culture (PMID: 27009859).",Actionable,5342,10000003,Advanced Solid Tumor,JAX,20658,EML4-ALK ALK F1174L,sensitive,698,Alectinib,27436,27009859,,,
149,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174L were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5340,10000003,Advanced Solid Tumor,JAX,20658,EML4-ALK ALK F1174L,resistant,789,Ceritinib,27436,27009859,,,
150,Preclinical,"In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK F1174L in culture (PMID: 27009859).",Actionable,5348,10000003,Advanced Solid Tumor,JAX,20658,EML4-ALK ALK F1174L,resistant,1586,AZD3463,27436,27009859,,,
151,Preclinical - Cell culture,"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing EML4-ALK with ALK F1174L in culture (PMID: 27009859).",Actionable,5338,10000003,Advanced Solid Tumor,JAX,20658,EML4-ALK ALK F1174L,conflicting,706,Crizotinib,27436,27009859,,,
152,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing ALK F1174L in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) in culture (PMID: 27780853).",Actionable,9266,10000003,Advanced Solid Tumor,JAX,20658,EML4-ALK ALK F1174L,conflicting,706,Crizotinib,27436,27780853,,,
153,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174L were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5345,10000003,Advanced Solid Tumor,JAX,20658,EML4-ALK ALK F1174L,resistant,643,ASP3026,27436,27009859,,,
154,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174L were resistant to Brigatinib (AP26113) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5343,10000003,Advanced Solid Tumor,JAX,20658,EML4-ALK ALK F1174L,resistant,634,AP26113,27436,27009859,,,
155,Preclinical - Cell culture,"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell proliferation of transformed cells over expressing ALK F1174L in the context of EML4-ALK in culture  (PMID: 26144315). ",Actionable,8297,10000003,Advanced Solid Tumor,JAX,20658,EML4-ALK ALK F1174L,sensitive,869,PF-06463922,27436,26144315,,,
156,Preclinical - Cell line xenograft,"In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation, reduced proliferation, and induced apoptosis in transformed cells over expressing ALK G1202R in the context of EML4-ALK in culture and in cell line xenograft models (PMID: 26144315). ",Actionable,2649,1324,lung cancer,DOID,5339,EML4-ALK ALK G1202R,conflicting,869,PF-06463922,27436,26144315,,,
157,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).",Actionable,8294,1324,lung cancer,DOID,5339,EML4-ALK ALK G1202R,conflicting,869,PF-06463922,27436,26698910,,,
158,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to RXDX-101 (PMID: 26939704). ",Actionable,5639,10000003,Advanced Solid Tumor,JAX,5339,EML4-ALK ALK G1202R,resistant,1455,Entrectinib,27436,26939704,,,
159,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Xalkori (crizotinib) in culture (PMID: 26698910).",Actionable,5709,10000003,Advanced Solid Tumor,JAX,5339,EML4-ALK ALK G1202R,resistant,706,Crizotinib,27436,26698910,,,
160,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).",Actionable,5711,10000003,Advanced Solid Tumor,JAX,5339,EML4-ALK ALK G1202R,resistant,789,Ceritinib,27436,26698910,,,
161,Preclinical - Cell line xenograft,"In a preclinical study, TPX-0005 inhibited Alk activity and proliferation of transformed cells over expressing ALK G1201R in the context of EML4-ALK in culture, resulted in tumor regression in cell line xenograft models (European Journal of Cancer , Volume 69, S32).",Actionable,10346,10000003,Advanced Solid Tumor,JAX,5339,EML4-ALK ALK G1202R,sensitive,3950,TPX-0005,27436,None,,,
162,Preclinical - Cell line xenograft,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ALK G1202R in the context of EML4-ALK in culture and reduced tumor growth in cell line xenograft models (PMID: 27780853).",Actionable,5713,10000003,Advanced Solid Tumor,JAX,5339,EML4-ALK ALK G1202R,sensitive,634,AP26113,27436,27780853,,,
163,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202R demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).  ",Actionable,8635,10000003,Advanced Solid Tumor,JAX,5339,EML4-ALK ALK G1202R,sensitive,869,PF-06463922,27436,27432227,,,
164,Clinical Study,"In a clinical study, an ALK G1202R secondary mutation in the context of EML4-ALK was associated with resistance to Xalkori (crizotinib) in a patient with non-small cell lung cancer, and resistance was replicated in cell culture studies (PMID: 22277784).",Actionable,1000,3908,non-small cell lung carcinoma,DOID,5339,EML4-ALK ALK G1202R,resistant,706,Crizotinib,27436,22277784,,,
165,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were insensitive to Zykadia (ceritinib) in culture (PMID: 24675041). ",Actionable,2097,3908,non-small cell lung carcinoma,DOID,5339,EML4-ALK ALK G1202R,resistant,789,Ceritinib,27436,24675041,,,
166,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).",Actionable,5710,10000003,Advanced Solid Tumor,JAX,5339,EML4-ALK ALK G1202R,resistant,698,Alectinib,27436,26698910,,,
167,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).  ",Actionable,8650,10000003,Advanced Solid Tumor,JAX,20889,EML4-ALK ALK E1210K,sensitive,869,PF-06463922,27436,27432227,,,
168,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Brigatinib (AP26113) in culture (PMID: 27432227).  ",Actionable,8649,10000003,Advanced Solid Tumor,JAX,20889,EML4-ALK ALK E1210K,sensitive,634,AP26113,27436,27432227,,,
169,Clinical Study,"In a clinical study, a lung cancer patient harboring EML4-ALK demonstrated progression when treated with Xalkori (crizotinib) due to the secondary acquired resistance mutation, ALK E1210K, however, in vitro transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Xalkori (crizotinib) in culture (PMID: 27432227).  ",Actionable,8646,10000003,Advanced Solid Tumor,JAX,20889,EML4-ALK ALK E1210K,conflicting,706,Crizotinib,27436,27432227,,,
170,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).  ",Actionable,8647,10000003,Advanced Solid Tumor,JAX,20889,EML4-ALK ALK E1210K,sensitive,789,Ceritinib,27436,27432227,,,
171,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Alecensa (alectinib) in culture (PMID: 27432227).  ",Actionable,8648,10000003,Advanced Solid Tumor,JAX,20889,EML4-ALK ALK E1210K,sensitive,698,Alectinib,27436,27432227,,,
172,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C demonstrated decreased sensitivity to Alecensa (alectinib) in culture compared to cells expressing EML4-ALK with wild-type ALK (PMID: 26698910), however, in another study, comparable cells demonstrated sensitivity in culture (PMID: 27432227). ",Actionable,5699,10000003,Advanced Solid Tumor,JAX,21374,EML4-ALK ALK F1174C,conflicting,698,Alectinib,27436,26698910,27432227,,
173,Preclinical,"In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing EML4-ALK with ALK F1174C in culture (PMID: 26698910).",Actionable,5693,10000003,Advanced Solid Tumor,JAX,21374,EML4-ALK ALK F1174C,sensitive,869,PF-06463922,27436,26698910,,,
174,Preclinical,"In a preclinical study, Brigatinib (AP26113) modestly inhibited growth of transformed cells expressing EML4-ALK with ALK F1174C in culture (PMID: 26698910).",Actionable,5695,10000003,Advanced Solid Tumor,JAX,21374,EML4-ALK ALK F1174C,decreased response,634,AP26113,27436,26698910,,,
175,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C were resistant to growth inhibition mediated by Xalkori (crizotinib) in culture (PMID: 26698910).",Actionable,5691,10000003,Advanced Solid Tumor,JAX,21374,EML4-ALK ALK F1174C,resistant,706,Crizotinib,27436,26698910,,,
176,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910), however, in another study, comparable cells demonstrated sensitivity in culture (PMID: 27432227).",Actionable,5697,10000003,Advanced Solid Tumor,JAX,21374,EML4-ALK ALK F1174C,conflicting,789,Ceritinib,27436,26698910,27432227,,
177,Clinical Study,"In a clinical case study, a pancreatic ductal adenocarcinoma patient harboring EML4-ALK along with CDKN2A deletion, FGFR1 T141R, SMAD4 Q83*, and a TP53 splice site mutation, experienced disease progression after 2 months of Xalkori (crizotinib) treatment, then received Alecensa (alectinib) and remained on treatment for at least 3 months (PMID: 28476735).",Actionable,11543,3498,pancreatic ductal adenocarcinoma,DOID,28131,EML4-ALK CDKN2A del FGFR1 T141R SMAD4 Q83*,resistant,706,Crizotinib,27436,28476735,,,
178,Clinical Study,"In a clinical case study, a pancreatic ductal adenocarcinoma patient harboring EML4-ALK along with CDKN2A deletion, FGFR1 T141R, SMAD4 Q83*, and a TP53 splice site mutation, experienced disease progression after 2 months of Xalkori (crizotinib) treatment, then received Alecensa (alectinib) and remained on treatment for at least 3 months (PMID: 28476735).",Actionable,11544,3498,pancreatic ductal adenocarcinoma,DOID,28131,EML4-ALK CDKN2A del FGFR1 T141R SMAD4 Q83*,predicted â€“ sensitive,698,Alectinib,27436,28476735,,,
179,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171S demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).  ",Actionable,8631,10000003,Advanced Solid Tumor,JAX,20653,EML4-ALK ALK I1171S,sensitive,869,PF-06463922,27436,27432227,,,
180,Clinical Study,"In a clinical study, a patient with EML4-ALK positive non-small cell lung cancer initially responded to Alecensa (alectinib) but progressed with the emergence of a secondary ALK I1171S mutation (PMID: 25393796).",Actionable,5391,3908,non-small cell lung carcinoma,DOID,20653,EML4-ALK ALK I1171S,resistant,698,Alectinib,27436,25393796,,,
181,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5325,10000003,Advanced Solid Tumor,JAX,20653,EML4-ALK ALK I1171S,resistant,706,Crizotinib,27436,27009859,,,
182,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Brigatinib (AP26113) mediated growth inhibition in culture (PMID: 27009859), however, another study with comparable cells demonstrated sensitivity (PMID: 27432227). ",Actionable,5331,10000003,Advanced Solid Tumor,JAX,20653,EML4-ALK ALK I1171S,resistant,634,AP26113,27436,27009859,27432227,,
183,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5330,10000003,Advanced Solid Tumor,JAX,20653,EML4-ALK ALK I1171S,resistant,698,Alectinib,27436,27009859,,,
184,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859), however, in another study comparable cells demonstrated sensitivity (PMID: (PMID: (PMID: 27432227).",Actionable,5328,10000003,Advanced Solid Tumor,JAX,20653,EML4-ALK ALK I1171S,conflicting,789,Ceritinib,27436,27009859,27432227,,
185,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to AZD3463 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5336,10000003,Advanced Solid Tumor,JAX,20653,EML4-ALK ALK I1171S,resistant,1586,AZD3463,27436,27009859,,,
186,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5333,10000003,Advanced Solid Tumor,JAX,20653,EML4-ALK ALK I1171S,resistant,643,ASP3026,27436,27009859,,,
187,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).",Actionable,5694,10000003,Advanced Solid Tumor,JAX,21375,EML4-ALK ALK F1174C ALK L1198F,resistant,869,PF-06463922,27436,26698910,,,
188,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F displayed enhanced resistance to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).",Actionable,5698,10000003,Advanced Solid Tumor,JAX,21375,EML4-ALK ALK F1174C ALK L1198F,resistant,789,Ceritinib,27436,26698910,,,
189,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C were re-sensitized to Xalkori (crizotinib) mediated growth inhibition with the introduction of an additional ALK mutation L1198F, in culture (PMID: 26698910).",Actionable,5692,10000003,Advanced Solid Tumor,JAX,21375,EML4-ALK ALK F1174C ALK L1198F,sensitive,706,Crizotinib,27436,26698910,,,
190,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F were resistant to growth inhibition mediated by Brigatinib (AP26113) in culture (PMID: 26698910).",Actionable,5696,10000003,Advanced Solid Tumor,JAX,21375,EML4-ALK ALK F1174C ALK L1198F,resistant,634,AP26113,27436,26698910,,,
191,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C and ALK L1198F displayed enhanced resistance to growth inhibition by Alecensa (alectinib) in culture (PMID: 26698910).",Actionable,5700,10000003,Advanced Solid Tumor,JAX,21375,EML4-ALK ALK F1174C ALK L1198F,resistant,698,Alectinib,27436,26698910,,,
192,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859).",Actionable,5363,10000003,Advanced Solid Tumor,JAX,20660,EML4-ALK ALK R1192P,sensitive,634,AP26113,27436,27009859,,,
193,Preclinical,"In a preclinical study, Xalkori (crizotinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859).",Actionable,5360,10000003,Advanced Solid Tumor,JAX,20660,EML4-ALK ALK R1192P,sensitive,706,Crizotinib,27436,27009859,,,
194,Preclinical,"In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859).",Actionable,5365,10000003,Advanced Solid Tumor,JAX,20660,EML4-ALK ALK R1192P,sensitive,1586,AZD3463,27436,27009859,,,
195,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK R1192P were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5364,10000003,Advanced Solid Tumor,JAX,20660,EML4-ALK ALK R1192P,resistant,643,ASP3026,27436,27009859,,,
196,Preclinical,"In a preclinical study, Alecensa (alectinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859).",Actionable,5362,10000003,Advanced Solid Tumor,JAX,20660,EML4-ALK ALK R1192P,sensitive,698,Alectinib,27436,27009859,,,
197,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK R1192P were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5361,10000003,Advanced Solid Tumor,JAX,20660,EML4-ALK ALK R1192P,resistant,789,Ceritinib,27436,27009859,,,
198,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A and ALK L1198F were resistant to growth inhibition mediated by Alecensa (alectinib) in culture (PMID: 26698910).",Actionable,5727,10000003,Advanced Solid Tumor,JAX,21453,EML4-ALK ALK L1198F ALK G1269A,resistant,698,Alectinib,27436,26698910,,,
199,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A and ALK L1198F were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).",Actionable,5726,10000003,Advanced Solid Tumor,JAX,21453,EML4-ALK ALK L1198F ALK G1269A,resistant,789,Ceritinib,27436,26698910,,,
200,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with G1269A were re-sensitized and modestly sensitive to Xalkori (crizotinib) with the introduction of an additional ALK mutation L1198F, in culture (PMID: 26698910).",Actionable,5723,10000003,Advanced Solid Tumor,JAX,21453,EML4-ALK ALK L1198F ALK G1269A,sensitive,706,Crizotinib,27436,26698910,,,
201,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing EML4-ALK with ALK G1269A and L1198F in culture (PMID: 26698910).",Actionable,5724,10000003,Advanced Solid Tumor,JAX,21453,EML4-ALK ALK L1198F ALK G1269A,sensitive,634,AP26113,27436,26698910,,,
202,Preclinical,"In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A and ALK L1198F were resistant to growth inhibition mediated by Lorlatinib (PF-06463922) in culture (PMID: 26698910).",Actionable,5725,10000003,Advanced Solid Tumor,JAX,21453,EML4-ALK ALK L1198F ALK G1269A,resistant,869,PF-06463922,27436,26698910,,,
0,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 D769Y reverted to normal morphology in culture upon Tykerb (lapatinib) treatment (PMID: 23220880).",Actionable,2025,1612,breast cancer,DOID,3129,ERBB2 D769Y,sensitive,787,Lapatinib,2064,23220880,,,
1,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) D769Y reverted to normal morphology in culture upon Nerlynx (neratinib) treatment (PMID: 23220880).",Actionable,2026,1612,breast cancer,DOID,3129,ERBB2 D769Y,sensitive,828,Neratinib,2064,23220880,,,
2,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 D769Y reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880).",Actionable,2027,1612,breast cancer,DOID,3129,ERBB2 D769Y,sensitive,947,Trastuzumab,2064,23220880,,,
3,Preclinical,"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) T733I in culture (PMID: 18413839).",Actionable,7319,10000003,Advanced Solid Tumor,JAX,24166,ERBB2 T733I,sensitive,967,XL647,2064,18413839,,,
4,Preclinical,"In a preclinical study, transformed cells expressing ERBB2 (HER2) T733I demonstrated resistance to treatment with Tykerb (lapatinib) (PMID: 18413839).",Actionable,6973,10000003,Advanced Solid Tumor,JAX,24166,ERBB2 T733I,resistant,787,Lapatinib,2064,18413839,,,
5,Preclinical,"In a preclinical study, xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y were resistant to Erbitux (cetuximab) (PMID: 26243863).",Actionable,7118,9256,colorectal cancer,DOID,3285,ERBB2 S310Y,resistant,694,Cetuximab,2064,26243863,,,
6,Preclinical,"In a preclinical study, Tykerb (lapatinib) delayed tumor growth in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y (PMID: 26243863).",Actionable,7122,9256,colorectal cancer,DOID,3285,ERBB2 S310Y,sensitive,787,Lapatinib,2064,26243863,,,
7,Preclinical,"In a preclinical study, Herceptin (trastuzumab) and Tykerb (lapatinib) combination treatment resulted in tumor regression in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y (PMID: 26243863).",Actionable,7124,9256,colorectal cancer,DOID,3285,ERBB2 S310Y,sensitive,1414,Trastuzumab + Lapatinib,2064,26243863,,,
8,Preclinical,"In a preclinical study, Herceptin (trastuzumab) and Nerlynx (neratinib) combination treatment resulted in tumor regression in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y (PMID: 26243863).",Actionable,7123,9256,colorectal cancer,DOID,3285,ERBB2 S310Y,sensitive,4359,Neratinib + Trastuzumab,2064,26243863,,,
9,Preclinical,"In a preclinical study, Herceptin (trastuzumab) delayed tumor growth in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y (PMID: 26243863).",Actionable,7120,9256,colorectal cancer,DOID,3285,ERBB2 S310Y,sensitive,947,Trastuzumab,2064,26243863,,,
10,Preclinical,"In a preclinical study, Nerlynx (neratinib) delayed tumor growth in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) S310Y (PMID: 26243863).",Actionable,7121,9256,colorectal cancer,DOID,3285,ERBB2 S310Y,sensitive,828,Neratinib,2064,26243863,,,
11,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA) and ERBB2 (HER2) C805S demonstrated resistance to Nerlynx (neratinib) in culture (PMID: 28363995).",Actionable,10513,10000003,Advanced Solid Tumor,JAX,27537,ERBB2 Y772_A775dup ERBB2 C805S,resistant,828,Neratinib,2064,28363995,,,
12,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing ERBB2 (HER2) C805S and ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA) demonstrated resistance to dacomitinib in culture (PMID: 28363995).",Actionable,10514,10000003,Advanced Solid Tumor,JAX,27537,ERBB2 Y772_A775dup ERBB2 C805S,resistant,714,Dacomitinib,2064,28363995,,,
13,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA) and ERBB2 (HER2) C805S demonstrated resistance to Gilotrif (afatinib) in culture (PMID: 28363995).",Actionable,10515,10000003,Advanced Solid Tumor,JAX,27537,ERBB2 Y772_A775dup ERBB2 C805S,resistant,623,Afatinib,2064,28363995,,,
14,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA) in culture (PMID: 26545934).",Actionable,6956,1324,lung cancer,DOID,3148,ERBB2 Y772_A775dup,sensitive,623,Afatinib,2064,26545934,,,
15,Preclinical,"In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA) did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934).",Actionable,6963,1324,lung cancer,DOID,3148,ERBB2 Y772_A775dup,no benefit,751,Gefitinib,2064,26545934,,,
16,Clinical Study,"In a clinical study, a lung adenocarcinoma patient harboring ERBB2 Y772_A775dup (also referred to as A775_G776insYVMA and E740_A741insAYVM) achieved a partial response for 5 months following treatment with pulse Gilotrif (afatinib), however, a second patient harboring ERBB2 Y772_A775dup treated with pulse Gilotrif (afatinib) demonstrated progressive disease (PMID: 26964772).",Actionable,7400,3910,lung adenocarcinoma,DOID,3148,ERBB2 Y772_A775dup,conflicting,623,Afatinib,2064,26964772,,,
17,Preclinical - Cell culture,"In a preclinical study, Nerlynx (neratinib) inhibited growth of transformed cells expressing ERBB2 (HER2) Y772_A775dup (also referred to as ERBB2 A775_G776insYVMA) in culture (PMID: 28363995).",Actionable,10528,10000003,Advanced Solid Tumor,JAX,3148,ERBB2 Y772_A775dup,sensitive,828,Neratinib,2064,28363995,,,
18,Preclinical,"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) E719G in culture (PMID: 18413839).",Actionable,7317,10000003,Advanced Solid Tumor,JAX,24159,ERBB2 E719G,sensitive,967,XL647,2064,18413839,,,
19,Preclinical,"In a preclinical study, transformed cells over expressing ERBB2 (HER2) E719G demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839).",Actionable,7311,10000003,Advanced Solid Tumor,JAX,24159,ERBB2 E719G,decreased response,787,Lapatinib,2064,18413839,,,
20,Preclinical,"In a preclinical study, Canertinib inhibited Erbb2 (Her2) phosphorylation and cell growth in transformed human cell lines expressing ERBB2 (HER2) G776_V777insYVMA (PMID: 16843263). ",Actionable,2906,10000003,Advanced Solid Tumor,JAX,3959,ERBB2 G776_V777insYVMA,sensitive,2136,Canertinib,2064,16843263,,,
21,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) S310F in culture (PMID: 26243863).",Actionable,7090,219,colon cancer,DOID,3284,ERBB2 S310F,sensitive,828,Neratinib,2064,26243863,,,
22,Preclinical,"In a preclinical study, bladder cancer cells over expressing ERBB2 (HER2) S310F demonstrated reduced sensitivity to Selumetinib (AZD6244) in culture (PMID: 24971884).",Actionable,7173,11054,urinary bladder cancer,DOID,3284,ERBB2 S310F,decreased response,913,Selumetinib,2064,24971884,,,
23,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited foci formation of bladder cancer cells over expressing ERBB2 (HER2) S310F in culture (PMID: 24971884).",Actionable,7171,11054,urinary bladder cancer,DOID,3284,ERBB2 S310F,sensitive,623,Afatinib,2064,24971884,,,
24,Preclinical,"In a preclinical study, Tykerb (lapatinib) inhibited foci formation of bladder cancer cells over expressing ERBB2 (HER2) S310F in culture (PMID: 24971884).",Actionable,7172,11054,urinary bladder cancer,DOID,3284,ERBB2 S310F,sensitive,787,Lapatinib,2064,24971884,,,
25,Preclinical,"In a preclinical study, Nerlynx (neratinib) decreased cell survival of transformed human cells expressing ERBB2 (HER2) S310F (PMID: 22908275). ",Actionable,2914,10000003,Advanced Solid Tumor,JAX,3284,ERBB2 S310F,sensitive,828,Neratinib,2064,22908275,,,
26,Preclinical,"In a preclinical study, Herceptin (trastuzumab) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) S310F in culture (PMID: 26243863).",Actionable,7086,219,colon cancer,DOID,3284,ERBB2 S310F,sensitive,947,Trastuzumab,2064,26243863,,,
27,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) S310F in culture (PMID: 26243863).",Actionable,7112,9256,colorectal cancer,DOID,3284,ERBB2 S310F,sensitive,623,Afatinib,2064,26243863,,,
28,Preclinical,"In a preclinical study, Tykerb (lapatinib) inhibited proliferation of transformed cells expressing ERBB2 S310F in culture (PMID: 22908275).",Actionable,2877,10000003,Advanced Solid Tumor,JAX,3284,ERBB2 S310F,sensitive,787,Lapatinib,2064,22908275,,,
29,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) S310F in culture (PMID: 26243863).",Actionable,7107,9256,colorectal cancer,DOID,3284,ERBB2 S310F,sensitive,828,Neratinib,2064,26243863,,,
30,Preclinical,"In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) S310F were resistant to Vectibix (panitumumab) in culture (PMID: 26243863).",Actionable,7103,9256,colorectal cancer,DOID,3284,ERBB2 S310F,resistant,845,Panitumumab,2064,26243863,,,
31,Preclinical,"In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) S310F were resistant to Erbitux (cetuximab) in culture (PMID: 26243863).",Actionable,7102,9256,colorectal cancer,DOID,3284,ERBB2 S310F,resistant,694,Cetuximab,2064,26243863,,,
32,Preclinical,"In a preclinical study, bladder cancer cells over expressing both ERBB2 (HER2) D277H and S310F demonstrated reduced sensitivity to Selumetinib (AZD6244) in culture (PMID: 24971884).",Actionable,7180,11054,urinary bladder cancer,DOID,24585,ERBB2 D277H ERBB2 S310F,decreased response,913,Selumetinib,2064,24971884,,,
33,Preclinical,"In a preclinical study, Tykerb (lapatinib) inhibited foci formation of bladder cancer cells over expressing both ERBB2 (HER2) D277H and S310F in culture (PMID: 24971884).",Actionable,7179,11054,urinary bladder cancer,DOID,24585,ERBB2 D277H ERBB2 S310F,sensitive,787,Lapatinib,2064,24971884,,,
34,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited foci formation of bladder cancer cells over expressing both ERBB2 (HER2) D277H and S310F in culture (PMID: 24971884).",Actionable,7178,11054,urinary bladder cancer,DOID,24585,ERBB2 D277H ERBB2 S310F,sensitive,623,Afatinib,2064,24971884,,,
35,Phase II,"In a Phase II trial, Nerlynx (neratinib) demonstrated activity in metastatic breast cancer patients harboring ERBB2 (HER2) mutations, resulting in a clinical benefit rate of 31% (5/16), with 1 complete response, 1 partial response, and 3 patients achieving stable disease for 24 weeks or more, which included a patient harboring ERBB2 (HER2) S310F and V842I (PMID: 28679771).",Actionable,11643,1612,breast cancer,DOID,28175,ERBB2 S310F ERBB2 V842I,predicted â€“ sensitive,828,Neratinib,2064,28679771,,,
36,Preclinical,"In a preclinical study, transformed cell lines expressing ERBB2 (HER2) H878Y demonstrated growth inhibition when treated with AEE788 in culture (PMID: 22046346).",Actionable,2031,10000003,Advanced Solid Tumor,JAX,3144,ERBB2 H878Y,sensitive,622,AEE788,2064,22046346,,,
37,Preclinical,"In a preclinical study, Tykerb (lapatinib) inhibited proliferation of  transformed cell lines expressing ERBB2 (HER2) H878Y in culture (PMID: 22046346).",Actionable,2032,10000003,Advanced Solid Tumor,JAX,3144,ERBB2 H878Y,sensitive,787,Lapatinib,2064,22046346,,,
38,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 V842I reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880).",Actionable,2053,1612,breast cancer,DOID,3235,ERBB2 V842I,sensitive,947,Trastuzumab,2064,23220880,,,
39,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) V842I demonstrated growth inhibition when treated with Nerlynx (neratinib) (PMID: 23220880).",Actionable,2052,1612,breast cancer,DOID,3235,ERBB2 V842I,sensitive,828,Neratinib,2064,23220880,,,
40,Preclinical,"In a preclinical study, transformed mouse colon epithelial cells over expressing ERBB2 (HER2) V842I were resistant to Herceptin (trastuzumab) in culture (PMID: 26243863).",Actionable,7093,219,colon cancer,DOID,3235,ERBB2 V842I,resistant,947,Trastuzumab,2064,26243863,,,
41,Preclinical,"In a preclinical study, colorectal cancer cell lines over expressing ERBB2 (HER2) V842I were resistant to Erbitux (cetuximab) in culture (PMID: 26243863).",Actionable,7094,9256,colorectal cancer,DOID,3235,ERBB2 V842I,resistant,694,Cetuximab,2064,26243863,,,
42,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 V842I demonstrated growth inhibition when treated with Tykerb (lapatinib) (PMID: 23220880).",Actionable,2051,1612,breast cancer,DOID,3235,ERBB2 V842I,sensitive,787,Lapatinib,2064,23220880,,,
43,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cell lines over expressing ERBB2 (HER2) V842I in culture (PMID: 26243863).",Actionable,7108,9256,colorectal cancer,DOID,3235,ERBB2 V842I,sensitive,828,Neratinib,2064,26243863,,,
44,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited growth of colorectal cancer cell lines over expressing ERBB2 (HER2) V842I in culture (PMID: 26243863).",Actionable,7113,9256,colorectal cancer,DOID,3235,ERBB2 V842I,sensitive,623,Afatinib,2064,26243863,,,
45,Preclinical,"In a preclinical study, colorectal cancer cell lines over expressing ERBB2 (HER2) V842I were resistant to Vectibix (panitumumab) in culture (PMID: 26243863).",Actionable,7095,9256,colorectal cancer,DOID,3235,ERBB2 V842I,resistant,845,Panitumumab,2064,26243863,,,
46,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) V842I in culture (PMID: 26243863).",Actionable,7091,219,colon cancer,DOID,3235,ERBB2 V842I,sensitive,828,Neratinib,2064,26243863,,,
47,Preclinical,"In a preclinical study, transformed cell lines expressing ERBB2 (HER2) L755P demonstrated resistance when treated with Tykerb (lapatinib) in culture (PMID: 22046346).",Actionable,2034,10000003,Advanced Solid Tumor,JAX,3150,ERBB2 L755P,resistant,787,Lapatinib,2064,22046346,,,
48,Preclinical,"In a preclinical study, transformed cell lines expressing ERBB2 (HER2) L755P demonstrated resistance when treated with AEE788 in culture (PMID: 22046346).",Actionable,2033,10000003,Advanced Solid Tumor,JAX,3150,ERBB2 L755P,resistant,622,AEE788,2064,22046346,,,
49,Preclinical,"In a preclinical study, WZ4002 inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) L755P in culture (PMID: 22046346).",Actionable,3034,10000003,Advanced Solid Tumor,JAX,3150,ERBB2 L755P,sensitive,3075,WZ4002,2064,22046346,,,
50,Preclinical,"In a preclinical study, EKI-285 (CL-387785) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) L755P in culture (PMID: 22046346).",Actionable,3033,10000003,Advanced Solid Tumor,JAX,3150,ERBB2 L755P,sensitive,2911,EKI-285,2064,22046346,,,
51,Preclinical,"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) V839G in culture (PMID: 18413839).",Actionable,7328,10000003,Advanced Solid Tumor,JAX,24614,ERBB2 V839G,sensitive,967,XL647,2064,18413839,,,
52,Preclinical - Cell culture,"In a preclinical study, Gilotrif (afatinib) inhibited ERBB2 (HER2) phosphorylation and growth of transformed breast epithelial cells expressing ERBB2 (HER2) L869R in culture (PMID: 28274957).",Actionable,11221,1612,breast cancer,DOID,18584,ERBB2 L869R,sensitive,623,Afatinib,2064,28274957,,,
53,Clinical Study,"In a clinical study, ERBB2 (HER2) L869R conferred resistant to ERBB2 (HER2)-directed therapy including Tarceva (erlotinib) and Tykerb (lapatinib) in a patient with lung adenocarcinoma (PMID: 27900369).",Actionable,10404,3910,lung adenocarcinoma,DOID,18584,ERBB2 L869R,resistant,4,Erlotinib,2064,27900369,,,
54,Preclinical - Cell line xenograft,"In a preclinical study, transformed breast cancer cells over expressing ERBB2 (HER2) L869R were resistant to Tykerb (lapatinib) in culture, formed tumors and metastasized readily in xenograft animal models (PMID: 27900369).",Actionable,10402,1612,breast cancer,DOID,18584,ERBB2 L869R,resistant,787,Lapatinib,2064,27900369,,,
55,Clinical Study,"In a clinical study, ERBB2 (HER2) L869R conferred resistant to ERBB2 (HER2)-directed therapy including Tarceva (erlotinib) and Tykerb (lapatinib) in a patient with lung adenocarcinoma (PMID: 27900369).",Actionable,10405,3910,lung adenocarcinoma,DOID,18584,ERBB2 L869R,resistant,787,Lapatinib,2064,27900369,,,
56,Preclinical - Cell culture,"In a preclinical study, transformed breast cancer cells over expressing ERBB2 (HER2) L869R were resistant to Tarceva (erlotinib) in culture (PMID: 27900369).",Actionable,10403,1612,breast cancer,DOID,18584,ERBB2 L869R,resistant,4,Erlotinib,2064,27900369,,,
57,Phase II,"In a Phase II trial, Nerlynx (neratinib) demonstrated activity in metastatic breast cancer patients harboring ERBB2 (HER2) mutations, resulting in a clinical benefit rate of 31% (5/16), with 1 complete response, 1 partial response, and 3 patients achieving stable disease for 24 weeks or more, which included a patient harboring ERBB2 (HER2) L869R (PMID: 28679771).",Actionable,11641,1612,breast cancer,DOID,18584,ERBB2 L869R,sensitive,828,Neratinib,2064,28679771,,,
58,Preclinical - Cell culture,"In a preclinical study, Nerlynx (neratinib) inhibited ERBB2 (HER2) phosphorylation and growth of transformed breast epithelial cells expressing ERBB2 (HER2) L869R in culture (PMID: 28274957).",Actionable,11220,1612,breast cancer,DOID,18584,ERBB2 L869R,sensitive,828,Neratinib,2064,28274957,,,
59,Preclinical,"In a preclinical study, breast cancer cells expressing ERBB2 T798M demonstrated resistance to CI-1040 (PMID: 23948973).",Actionable,963,1612,breast cancer,DOID,1572,ERBB2 T798M,resistant,699,CI-1040,2064,23948973,,,
60,Preclinical,"In a preclinical study, breast cancer cells expressing ERBB2 T798M were sensitive to the combination of Herceptin (trastuzumab) and XL147 (PMID: 23948973). ",Actionable,962,1612,breast cancer,DOID,1572,ERBB2 T798M,sensitive,1415,Trastuzumab + XL147,2064,23948973,,,
61,Preclinical,"In a preclinical study, transformed cell lines expressing ERBB2  (HER2) T798M demonstrated resistance when treated with Tykerb (lapatinib) in culture (PMID: 22046346).",Actionable,3030,10000003,Advanced Solid Tumor,JAX,1572,ERBB2 T798M,resistant,787,Lapatinib,2064,22046346,,,
62,Preclinical,"In a preclinical study, transformed cell lines expressing ERBB2 (HER2) T798M demonstrated resistance when treated with AEE788 in culture (PMID: 22046346).",Actionable,2046,10000003,Advanced Solid Tumor,JAX,1572,ERBB2 T798M,resistant,622,AEE788,2064,22046346,,,
63,Preclinical,"In a preclinical study, breast cancer cells expressing the ERBB2 (HER2) T798M mutant were resistant to Erbitux (cetuximab)(PMID: 23948973).",Actionable,959,1612,breast cancer,DOID,1572,ERBB2 T798M,resistant,694,Cetuximab,2064,23948973,,,
64,Preclinical,"In a preclinical study, breast cancer cell lines expressing ERBB2 (HER2) T798M demonstrated sensitivity to XL147 (SAR245408) in cell culture (PMID: 23948973).",Actionable,956,1612,breast cancer,DOID,1572,ERBB2 T798M,sensitive,1050,XL147,2064,23948973,,,
65,Preclinical - Cell line xenograft,"In a preclinical study, human breast cancer cell lines and cell line xenografts expressing ERBB2 T798M demonstrated sensitivity to the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) (PMID: 23948973).",Actionable,961,1612,breast cancer,DOID,1572,ERBB2 T798M,sensitive,1414,Trastuzumab + Lapatinib,2064,23948973,,,
66,Preclinical - Cell line xenograft,"In preclinical studies, the combination of Erbitux (cetuximab) and Tykerb (lapatinib) inhibited cell growth of a human breast cancer cell line harboring ERBB2 T798M and synergized to inhibit tumor growth in xenograft models (PMID: 23948973).",Actionable,960,1612,breast cancer,DOID,1572,ERBB2 T798M,sensitive,1672,Cetuximab + Lapatinib,2064,23948973,,,
67,Preclinical,"In a preclinical study, breast cancer cells expressing ERBB2(HER2) T798M were sensitive to Gilotrif (afatinib) (PMID: 23948973).",Actionable,957,1612,breast cancer,DOID,1572,ERBB2 T798M,sensitive,623,Afatinib,2064,23948973,,,
68,Preclinical,"In a preclinical study, ERBB2 (HER2)-receptor positive breast cancer cells expressing ERBB2 (HER2) T798M were resistant to Tykerb (lapatinib) in both culture and xenograft models (PMID: 23948973).",Actionable,953,60079,Her2-receptor positive breast cancer,DOID,1572,ERBB2 T798M,resistant,787,Lapatinib,2064,23948973,,,
69,Preclinical,"In a preclinical study, human breast cancer cells expressing the ERBB2 (HER2) T798M mutation demonstrated sensitivity to BKM120 (PMID: 23948973).",Actionable,955,1612,breast cancer,DOID,1572,ERBB2 T798M,sensitive,680,BKM120,2064,23948973,,,
70,Preclinical,"In a preclinical study, EKI-285 (CL-387785) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) T798M in culture (PMID: 22046346).",Actionable,3031,10000003,Advanced Solid Tumor,JAX,1572,ERBB2 T798M,sensitive,2911,EKI-285,2064,22046346,,,
71,Preclinical,"In a preclinical study, WZ4002 inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) T798M in culture (PMID: 22046346).",Actionable,3032,10000003,Advanced Solid Tumor,JAX,1572,ERBB2 T798M,sensitive,3075,WZ4002,2064,22046346,,,
72,Preclinical - Cell line xenograft,"In a preclinical study, a human ERBB2-amplified breast cancer cell line expressing ERBB2 (HER2) T798M was resistant to Herceptin (trastuzumab) in culture and in xenograft models (PMID: 23948973).",Actionable,954,1612,breast cancer,DOID,23649,ERBB2 amp ERBB2 T798M,resistant,947,Trastuzumab,2064,23948973,,,
73,Clinical Study,"In a clinical case study, treatment with the combination of  Tykerb (lapatinib) and Xeloda (capecitabine) resulted in prolonged response and reduction in liver metastasis in a metastatic breast cancer patient harboring ERBB2 L869Q and CDH1 R63* mutations (PMID: 26487584).",Actionable,5027,1612,breast cancer,DOID,20031,CDH1 R63* ERBB2 L869Q,sensitive,1399,Lapatinib + Capecitabine,2064,26487584,,,
74,Preclinical,"In a preclinical study, an ERBB2 (HER2) L726I mutation was detected in a murine breast cancer cell line that acquired resistance to Iressa (gefitinib) in culture (PMID: 17638894).",Actionable,7181,1612,breast cancer,DOID,24594,ERBB2 L726I,resistant,751,Gefitinib,2064,17638894,,,
75,Preclinical,"In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) G776delinsLC did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934).",Actionable,6966,1324,lung cancer,DOID,24128,ERBB2 G776delinsLC,no benefit,751,Gefitinib,2064,26545934,,,
76,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) G776delinsLC in culture (PMID: 26545934).",Actionable,6958,1324,lung cancer,DOID,24128,ERBB2 G776delinsLC,sensitive,623,Afatinib,2064,26545934,,,
77,Preclinical,"In a preclinical study, transformed cell lines expressing ERBB2 (HER2) V777L demonstrated growth inhibition when treated with AEE788 in culture (PMID: 22046346).",Actionable,2047,10000003,Advanced Solid Tumor,JAX,3234,ERBB2 V777L,sensitive,622,AEE788,2064,22046346,,,
78,Preclinical,"In a preclinical study, Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) V777L in culture (PMID: 22046346).",Actionable,3043,10000003,Advanced Solid Tumor,JAX,3234,ERBB2 V777L,sensitive,787,Lapatinib,2064,22046346,,,
79,Preclinical,"In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) V777L were resistant to Vectibix (panitumumab) in culture (PMID: 26243863).",Actionable,7099,9256,colorectal cancer,DOID,3234,ERBB2 V777L,resistant,845,Panitumumab,2064,26243863,,,
80,Preclinical - Cell line xenograft,"In a preclinical study, Herceptin (trastuzumab) and Nerlynx (neratinib) combination treatment inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) V777L in culture and suppressed tumor growth in cell line xenograft models (PMID: 26243863).",Actionable,7114,9256,colorectal cancer,DOID,3234,ERBB2 V777L,sensitive,4359,Neratinib + Trastuzumab,2064,26243863,,,
81,Preclinical,"In a preclinical study, transformed mouse colon epithelial cells over expressing ERBB2 (HER2) V777L were resistant to Herceptin (trastuzumab) in culture (PMID: 26243863).",Actionable,7092,219,colon cancer,DOID,3234,ERBB2 V777L,resistant,947,Trastuzumab,2064,26243863,,,
82,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) V777L in culture (PMID: 26243863).",Actionable,7110,9256,colorectal cancer,DOID,3234,ERBB2 V777L,sensitive,623,Afatinib,2064,26243863,,,
83,Preclinical - Cell line xenograft,"In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) V777L in culture and suppressed tumor growth in cell line xenograft models (PMID: 26243863).",Actionable,7105,9256,colorectal cancer,DOID,3234,ERBB2 V777L,sensitive,828,Neratinib,2064,26243863,,,
84,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 V777L demonstrated growth inhibition when treated with Tykerb (lapatinib) (PMID: 23220880).",Actionable,2048,1612,breast cancer,DOID,3234,ERBB2 V777L,sensitive,787,Lapatinib,2064,23220880,,,
85,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) V777L in culture (PMID: 26243863).",Actionable,7088,219,colon cancer,DOID,3234,ERBB2 V777L,sensitive,828,Neratinib,2064,26243863,,,
86,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 V777L reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880).",Actionable,2050,1612,breast cancer,DOID,3234,ERBB2 V777L,sensitive,947,Trastuzumab,2064,23220880,,,
87,Preclinical - Pdx,"In a preclinical study, human colorectal cancer cells over expressing ERBB2 (HER2) V777L were resistant to Erbitux (cetuximab) in culture and in patient-derived xenograft models (PMID: 26243863).",Actionable,7098,9256,colorectal cancer,DOID,3234,ERBB2 V777L,resistant,694,Cetuximab,2064,26243863,,,
88,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) V777L demonstrated growth inhibition when treated with Nerlynx (neratinib) (PMID: 23220880).",Actionable,2049,1612,breast cancer,DOID,3234,ERBB2 V777L,sensitive,828,Neratinib,2064,23220880,,,
89,Preclinical - Cell culture,"In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) L768S were sensitive to Nerlynx (neratinib) in culture, resulting in decreased colony formation (PMID: 27697991). ",Actionable,8751,1612,breast cancer,DOID,26427,ERBB2 L768S,sensitive,828,Neratinib,2064,27697991,,,
90,Preclinical - Cell culture,"In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) L768S were sensitive to Herceptin (trastuzumab) in culture, resulting in decreased colony formation (PMID: 27697991). ",Actionable,8748,1612,breast cancer,DOID,26427,ERBB2 L768S,sensitive,947,Trastuzumab,2064,27697991,,,
91,Preclinical - Cell culture,"In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) L768S were sensitive to Tykerb (lapatinib) in culture, resulting in decreased colony formation (PMID: 27697991). ",Actionable,8750,1612,breast cancer,DOID,26427,ERBB2 L768S,sensitive,787,Lapatinib,2064,27697991,,,
92,Preclinical - Cell culture,"In a preclinical study, dacomitinib inhibited growth of transformed cells expressing ERBB2 (HER2) G778_S779insCPG in culture (PMID: 28363995).",Actionable,10526,10000003,Advanced Solid Tumor,JAX,27531,ERBB2 G778_S779insCPG,sensitive,714,Dacomitinib,2064,28363995,,,
93,Preclinical,"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) P780L in culture (PMID: 18413839).",Actionable,7321,10000003,Advanced Solid Tumor,JAX,24176,ERBB2 P780L,sensitive,967,XL647,2064,18413839,,,
94,Preclinical,"In a preclinical study, transformed cells expressing ERBB2 (HER2) P780L demonstrated resistance to treatment with Tykerb (lapatinib) (PMID: 18413839).",Actionable,6992,10000003,Advanced Solid Tumor,JAX,24176,ERBB2 P780L,resistant,787,Lapatinib,2064,18413839,,,
95,Preclinical,"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) L915M in culture (PMID: 19718025).",Actionable,7329,10000003,Advanced Solid Tumor,JAX,24608,ERBB2 L915M,sensitive,967,XL647,2064,19718025,,,
96,Clinical Study,"In a clinical study, treatment with Herceptin (trastuzumab) in combination with chemotherapy resulted in an objective response rate of 67% (4/6) in non-small cell lung carcinoma patients harboring ERBB2 (HER2) mutations that progressed during previous therapies (PMID: 28167203). ",Actionable,10131,3908,non-small cell lung carcinoma,DOID,1216,ERBB2 mutant,predicted â€“ sensitive,947,Trastuzumab,2064,28167203,,,
97,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring an ERBB2 (HER2) mutation demonstrated sensitivity to AV-412, resulting in decreased phosphorylation of Erbb2, Akt, and Erk (PMID: 19459856). ",Actionable,2907,3908,non-small cell lung carcinoma,DOID,1216,ERBB2 mutant,sensitive,990,AV-412,2064,19459856,,,
98,Clinical Study,"In a clinical study, treatment with Gilotrif (afatinib) resulted in an objective response rate of 33% (2/6) in non-small cell lung carcinoma patients harboring ERBB2 (HER2) mutations that progressed during previous therapies (PMID: 28167203). ",Actionable,10130,3908,non-small cell lung carcinoma,DOID,1216,ERBB2 mutant,predicted â€“ sensitive,623,Afatinib,2064,28167203,,,
99,Phase I,"In a Phase I clinical trial, Nerlynx (neratinib) administered with Torisel (temsirolimus) was tolerable and demonstrated antitumor activity in ERBB2 (HER2)-mutant non-small-cell lung cancer (PMID: 24323026).",Actionable,427,1324,lung cancer,DOID,1216,ERBB2 mutant,sensitive,828,Neratinib,2064,24323026,,,
100,Phase II,"In a Phase II trial, Nerlynx (neratinib) treatment resulted in complete response in 12.5% (3/24) and partial response in 20.8% (5/24) of ERBB2 (HER2) mutant but not amplified breast cancer patients (Cancer Res 2017;77(4 Suppl):Abstract nr PD2-08).",Actionable,10950,60079,Her2-receptor positive breast cancer,DOID,1216,ERBB2 mutant,sensitive,828,Neratinib,2064,None,,,
101,Phase II,"In a Phase II trial, ERBB2 (HER2) mutations were only detected in  patients with muscle-invasive urothelial bladder cancer that responded to Nexavar (sorafenib), Platinol (cisplatin) and Gemzar (gemcitabine) combination therapy (J Clin Oncol 35, 2017 (suppl 6S; abstract 345)).",Actionable,10322,6477,invasive bladder transitional cell carcinoma,DOID,1216,ERBB2 mutant,predicted â€“ sensitive,5462,Cisplatin + Gemcitabine + Sorafenib,2064,None,,,
102,Phase II,"In a Phase II trial, treatment with Gilotrif (afatinib) resulted in objective response in 3 lung adenocarcinoma patients harboring ERBB2 (HER2) mutations (PMID: 22325357).",Actionable,2888,3910,lung adenocarcinoma,DOID,1216,ERBB2 mutant,sensitive,623,Afatinib,2064,22325357,,,
103,Phase I,"In a Phase I study, Nerlynx (neratinib) administered with temsirolimus was tolerable and demonstrated antitumor activity in ERBB2-mutant non-small-cell lung cancer (PMID:24323026).",Actionable,428,3908,non-small cell lung carcinoma,DOID,1216,ERBB2 mutant,sensitive,828,Neratinib,2064,24323026,,,
104,Phase II,"In a Phase II trial, Nerlynx (neratinib) demonstrated activity in metastatic breast cancer patients harboring ERBB2 (HER2) mutations, with treatment resulting in a clinical benefit rate of 31% (5/16; 1 complete response, 1 partial response, and 3 patients achieving stable disease for 24 weeks or more) and a median progression-free survival of 16 weeks (PMID: 28679771).",Actionable,11634,1612,breast cancer,DOID,1216,ERBB2 mutant,predicted â€“ sensitive,828,Neratinib,2064,28679771,,,
105,Phase II,"In a Phase II trial, Pyrotinib treatment in non-small cell lung cancer patients harboring an ERBB2 (HER2) mutation resulted in a partial response in 54.5% (6/11) of patients and stable disease in 27.3% (3/11) of patients, and a PFS of 6.2 months (Journal of Thoracic Oncology, Vol. 12, Issue 1, S359).",Actionable,9850,3908,non-small cell lung carcinoma,DOID,1216,ERBB2 mutant,sensitive,3082,Pyrotinib,2064,None,,,
106,Preclinical,"In a preclinical study, higher dose of Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) N862A in culture (PMID: 22046346).",Actionable,3038,10000003,Advanced Solid Tumor,JAX,11336,ERBB2 T862A,decreased response,787,Lapatinib,2064,22046346,,,
107,Preclinical,"In a preclinical study, AEE788 inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) T862A in culture (PMID: 22046346).",Actionable,3041,10000003,Advanced Solid Tumor,JAX,11336,ERBB2 T862A,sensitive,622,AEE788,2064,22046346,,,
108,Preclinical - Cell culture,"In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) V773L were sensitive to Nerlynx (nerlatinib) in culture, resulting in decreased colony formation (PMID: 27697991). ",Actionable,8754,1612,breast cancer,DOID,26428,ERBB2 V773L,sensitive,828,Neratinib,2064,27697991,,,
109,Preclinical - Cell culture,"In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) V773L were sensitive to Herceptin (trastuzumab) in culture, resulting in decreased colony formation (PMID: 27697991). ",Actionable,8752,1612,breast cancer,DOID,26428,ERBB2 V773L,sensitive,947,Trastuzumab,2064,27697991,,,
110,Preclinical - Cell culture,"In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) V773L were sensitive to Tykerb (lapatinib) in culture, resulting in decreased colony formation (PMID: 27697991). ",Actionable,8753,1612,breast cancer,DOID,26428,ERBB2 V773L,sensitive,787,Lapatinib,2064,27697991,,,
111,Preclinical - Pdx & cell culture,"In a preclinical study, Sapitinib (AZD8931) demonstrated antitumor activity in patient-derived, EGFR over expressing inflammatory breast cancer cell lines expressing low level of Erb2 (Her2) protein in culture and in xenograft models (PMID: 24886365).",Actionable,964,6263,inflammatory breast carcinoma,DOID,23650,EGFR over exp ERBB2 dec exp,sensitive,910,Sapitinib,2064,24886365,,,
112,Preclinical - Pdx & cell culture,"In a preclinical study, combination of Sapatinib (AZD8931) and Taxol (paclitaxel) demonstrated enhanced antitumor activity in patient-derived, EGFR over expressing inflammatory breast cancer cell lines expressing low level of Erbb2 (Her2) protein in culture and in xenograft models (PMID: 24886365).",Actionable,965,6263,inflammatory breast carcinoma,DOID,23650,EGFR over exp ERBB2 dec exp,sensitive,1416,Sapitinib + Paclitaxel,2064,24886365,,,
113,Preclinical,"In a preclinical study, bladder cancer cells over expressing ERBB2 (HER2) S653C demonstrated reduced sensitivity to Selumetinib (AZD6244) in culture (PMID: 24971884).",Actionable,7176,11054,urinary bladder cancer,DOID,24587,ERBB2 S653C,decreased response,913,Selumetinib,2064,24971884,,,
114,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited foci formation of bladder cancer cells over expressing ERBB2 (HER2) S653C in culture (PMID: 24971884).",Actionable,7174,11054,urinary bladder cancer,DOID,24587,ERBB2 S653C,sensitive,623,Afatinib,2064,24971884,,,
115,Preclinical,"In a preclinical study, Tykerb (lapatinib) inhibited foci formation of bladder cancer cells over expressing ERBB2 (HER2) S653C in culture (PMID: 24971884).",Actionable,7175,11054,urinary bladder cancer,DOID,24587,ERBB2 S653C,sensitive,787,Lapatinib,2064,24971884,,,
116,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) G309A demonstrated growth inhibition when treated with Nerlynx (neratinib) (PMID: 23220880).",Actionable,2029,1612,breast cancer,DOID,3131,ERBB2 G309A,sensitive,828,Neratinib,2064,23220880,,,
117,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 G309A demonstrated growth inhibition when treated with Tykerb (lapatinib) (PMID: 23220880).",Actionable,2028,1612,breast cancer,DOID,3131,ERBB2 G309A,sensitive,787,Lapatinib,2064,23220880,,,
118,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 G309A reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880).",Actionable,2030,1612,breast cancer,DOID,3131,ERBB2 G309A,sensitive,947,Trastuzumab,2064,23220880,,,
119,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) R678Q demonstrated growth inhibition when treated with Nerlynx (neratinib) (PMID: 23220880).",Actionable,2042,1612,breast cancer,DOID,3281,ERBB2 R678Q,sensitive,828,Neratinib,2064,23220880,,,
120,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 R678Q demonstrated growth inhibition when treated with Tykerb (lapatinib) (PMID: 23220880).",Actionable,2041,1612,breast cancer,DOID,3281,ERBB2 R678Q,sensitive,787,Lapatinib,2064,23220880,,,
121,Phase II,"In a Phase II trial, a lung adenocarcinoma patient harboring ERBB2 (HER2) M774delinsWLV demonstrated a partial response to treatment with dacomitinib (PMID: 25899785).",Actionable,10500,3910,lung adenocarcinoma,DOID,27530,ERBB2 M774delinsWLV,sensitive,714,Dacomitinib,2064,25899785,,,
122,Preclinical - Cell culture,"In a preclinical study, dacomitinib inhibited growth of transformed cells expressing ERBB2 (HER2) M774delinsWLV in culture (PMID: 28363995).",Actionable,10524,10000003,Advanced Solid Tumor,JAX,27530,ERBB2 M774delinsWLV,sensitive,714,Dacomitinib,2064,28363995,,,
123,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing ERBB2 (HER2) M774delinsWLV and ERBB2 (HER2) C805S demonstrated resistance to Gilotrif (afatinib) in culture (PMID: 28363995).",Actionable,10516,10000003,Advanced Solid Tumor,JAX,27538,ERBB2 M774delinsWLV ERBB2 C805S,resistant,623,Afatinib,2064,28363995,,,
124,Preclinical - Cell culture,"In a preclinical study, transformed cells co-expressing ERBB2 (HER2) M774delinsWLV and ERBB2 (HER2) C805S demonstrated resistance to Nerlynx (neratinib) in culture (PMID: 28363995).",Actionable,10517,10000003,Advanced Solid Tumor,JAX,27538,ERBB2 M774delinsWLV ERBB2 C805S,resistant,828,Neratinib,2064,28363995,,,
125,Preclinical - Cell culture,"In a preclinical study, acquisition of ERBB2 (HER2) C805S in transformed cells expressing ERBB2 (HER2) M774delinsWLV conferred resistance to dacomitinib in culture (PMID: 28363995).",Actionable,10518,10000003,Advanced Solid Tumor,JAX,27538,ERBB2 M774delinsWLV ERBB2 C805S,resistant,714,Dacomitinib,2064,28363995,,,
126,Preclinical,"In a preclinical study, the combination of 23814 and Tivozanib (AV-951) inhibited tumor growth in several transgenic mouse models of breast cancer expressing ERBB2 (HER2) V659E, including those with resistance to VEGFR inhibitors (PMID: 25995436).",Actionable,8843,1612,breast cancer,DOID,11379,ERBB2 V659E,sensitive,4824,23814 + Tivozanib,2064,25995436,,,
127,Preclinical,"In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) V659E did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934).",Actionable,6969,1324,lung cancer,DOID,11379,ERBB2 V659E,no benefit,751,Gefitinib,2064,26545934,,,
128,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) V659E in culture (PMID: 26545934).",Actionable,6971,1324,lung cancer,DOID,11379,ERBB2 V659E,sensitive,623,Afatinib,2064,26545934,,,
129,Preclinical,"In a preclinical study, colorectal cancer cells positive for EGFR and ERBB2 (HER2) had decreased growth upon Gilotrif (afatinib) treatment (PMID: 21617858).",Actionable,1214,9256,colorectal cancer,DOID,2242,EGFR pos ERBB2 pos,sensitive,623,Afatinib,2064,21617858,,,
130,Preclinical - Cell line xenograft,"In a preclinical study, Gilotrif (afatinib) pre-treatment inhibited radiotherapy-induced activation of EGFR and ERBB2 (HER2) and downstream AKT and radiosensitized bladder cancer cell lines in culture, and Gilotrif (afatinib) in combination with radiotherapy led to improved tumor growth inhibition in bladder cancer cell line xenograft models compared to radiotherapy alone (PMID: 25589492).",Actionable,8342,11054,urinary bladder cancer,DOID,2242,EGFR pos ERBB2 pos,predicted â€“ sensitive,4711,Afatinib + Radiotherapy,2064,25589492,,,
131,Preclinical - Cell line xenograft,"In a preclinical study, S-222611 inhibited cell growth, decreased phosphorylation of Egfr and Erbb2, and resulted in anti-tumor activity of human gastric cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299). ",Actionable,2842,10534,stomach cancer,DOID,2242,EGFR pos ERBB2 pos,sensitive,1048,S-222611,2064,24837299,,,
132,Preclinical - Cell line xenograft,"In a preclinical study, S-222611 inhibited cell growth and resulted in anti-tumor activity of human breast cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299). ",Actionable,7722,1612,breast cancer,DOID,2242,EGFR pos ERBB2 pos,sensitive,1048,S-222611,2064,24837299,,,
133,Preclinical - Cell line xenograft,"In a preclinical study, S-222611 inhibited cell growth and resulted in anti-tumor activity of human lung cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299). ",Actionable,7723,1324,lung cancer,DOID,2242,EGFR pos ERBB2 pos,sensitive,1048,S-222611,2064,24837299,,,
134,Preclinical - Cell line xenograft,"In a preclinical study, S-222611 inhibited cell growth and resulted in anti-tumor activity of human colon cancer cells expressing EGFR and ERBB2 (HER2) both in culture and in cell line xenograft models (PMID: 24837299). ",Actionable,7724,219,colon cancer,DOID,2242,EGFR pos ERBB2 pos,sensitive,1048,S-222611,2064,24837299,,,
135,Preclinical - Cell line xenograft,"In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of ERBB2 (HER2) positive breast cancer cells harboring PIK3CA K111N in culture, and induced tumor regression in cell line xenograft models (PMID: 26920887).",Actionable,7745,60079,Her2-receptor positive breast cancer,DOID,25948,ERBB2 pos PIK3CA K111N,sensitive,1402,trastuzumab emtansine,2064,26920887,,,
136,Clinical Study,"In a clinical study, a retrospective analysis of Herceptin (trastuzumab) treatment in ERBB2 (HER2) positive breast cancer patients demonstrated patients harboring a PIK3CA mutation trended towards a decreased response when compared to patients with wild-type PIK3CA (PMID: 27687302). ",Actionable,9164,60079,Her2-receptor positive breast cancer,DOID,25947,ERBB2 pos PIK3CA mut,decreased response,947,Trastuzumab,2064,27687302,,,
137,Phase III,"In a Phase III trial, Tykerb (lapatinib) and Xeloda (capecitabine) combination treatment resulted in decreased median progression free survival (4.3 vs. 6.4 months), median overall survival (17.3 vs. 27.8 months), and overall response rate(17.1% vs. 39.7%) in ERBB2 (HER2) positive breast cancer patients harboring PIK3CA mutations compared to PIK3CA wild type patients (PMID: 26920887). ",Actionable,7744,60079,Her2-receptor positive breast cancer,DOID,25947,ERBB2 pos PIK3CA mut,decreased response,1399,Lapatinib + Capecitabine,2064,26920887,,,
138,Clinical Study,"In a clinical study, a retrospective analysis of Tykerb (lapatinib) treatment in ERBB2 (HER2) positive breast cancer patients demonstrated patients harboring a PIK3CA mutation trended towards a decreased response when compared to patients with wild-type PIK3CA (PMID: 27687302). ",Actionable,9163,60079,Her2-receptor positive breast cancer,DOID,25947,ERBB2 pos PIK3CA mut,decreased response,787,Lapatinib,2064,27687302,,,
139,Preclinical - Cell line xenograft,"In a preclinical study, AT13148 inhibited tumor growth in a ERBB2 (HER2)-positive human breast cancer cell line xenograft model harboring mutant PIK3CA (PMID: 22781553).",Actionable,4784,60079,Her2-receptor positive breast cancer,DOID,25947,ERBB2 pos PIK3CA mut,sensitive,3653,AT13148,2064,22781553,,,
140,Preclinical,"In a preclinical study, circulating tumor cells (CTC) from patients with ERBB2 (HER2)-negative breast cancer were demonstrated to contain both ERBB2 (HER2)-positive and ERBB2 (HER2)-negative subpopulations, and the combination of RO4929097 and Taxol (paclitaxel) resulted in increased tumor growth inhibition in CTC-derived xenograft models compared to either agent alone  (PMID: 27556950).",Actionable,8862,60080,Her2-receptor negative breast cancer,DOID,26477,ERBB2 neg ERBB2 pos,sensitive,4840,RO4929097 + Paclitaxel,2064,27556950,,,
141,Preclinical,"In a preclinical study, circulating tumor cells (CTC) from patients with ERBB2 (HER2)-negative breast cancer were demonstrated to contain both ERBB2 (HER2)-positive and ERBB2 (HER2)-negative subpopulations, and the combination of LY411575 and Taxol (paclitaxel) resulted in increased tumor growth inhibition in CTC-derived xenograft models compared to either agent alone (PMID: 27556950).",Actionable,8861,60080,Her2-receptor negative breast cancer,DOID,26477,ERBB2 neg ERBB2 pos,sensitive,4841,LY411575 + Paclitaxel,2064,27556950,,,
142,Clinical Study,"In a retrospective analysis, ERBB2 (HER2)-positive breast cancer patients with PI3K pathway activation due to PTEN loss and/or PIK3CA activating mutation demonstrated a decreased median progression-free survival of 4.5 months, compared to 9.0 months for patients without PI3K pathway activation following treatment with a Herceptin (trastuzumab) containing regimen (PMID: 21676217).",Actionable,875,60079,Her2-receptor positive breast cancer,DOID,1409,ERBB2 pos PIK3CA act mut,decreased response,947,Trastuzumab,2064,21676217,,,
143,Clinical Study,"In a clinical study, ERBB2 (HER2)-positive breast cancer patients with PI3K pathway activation resulting from low PTEN expression and/or PIK3CA activating mutations demonstrated decreased progression-free survival following treatment with Herceptin (trastuzumab) compared to patients without PI3K pathway activation (PMID: 17936563).",Actionable,6664,60079,Her2-receptor positive breast cancer,DOID,1409,ERBB2 pos PIK3CA act mut,decreased response,947,Trastuzumab,2064,17936563,,,
144,Preclinical,"In a preclinical study, Taselisib (GDC-0032) inhibited growth of HER2 positive uterine cancer cell lines with PIK3CA mutations (PMID: 25172762).",Actionable,2850,363,uterine cancer,DOID,1409,ERBB2 pos PIK3CA act mut,sensitive,1016,GDC-0032,2064,25172762,,,
145,Phase I,"In a Phase I trial, the combination of Buparlisib (BKM120) and Herceptin (trastuzumab) was well tolerated and resulted in some preliminary efficacy in patients with ERBB2 (HER2)-positive breast cancer harboring PIK3CA activating mutations and/or PTEN mutations that had progressed on trastuzumab-based therapy (PMID: 24470511).",Actionable,286,60079,Her2-receptor positive breast cancer,DOID,1409,ERBB2 pos PIK3CA act mut,predicted â€“ sensitive,1417,BKM120 + Trastuzumab,2064,24470511,,,
146,Preclinical,"In a preclinical study, Ibrance (palbociclib) and Pictilisib (GDC-0941) worked synergistically to inhibit survival of ERBB2 (HER2)-positive breast cancer cell lines harboring PIK3CA mutations in culture (PMID: 27020857).",Actionable,5857,60079,Her2-receptor positive breast cancer,DOID,1409,ERBB2 pos PIK3CA act mut,sensitive,3956,Palbociclib + GDC-0941,2064,27020857,,,
147,Preclinical - Cell culture,"In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of ERBB2 (HER2) positive breast cancer cells harboring PIK3CA K111N in culture (PMID: 26920887).",Actionable,7746,60079,Her2-receptor positive breast cancer,DOID,25949,ERBB2 pos PIK3CA I391M,sensitive,1402,trastuzumab emtansine,2064,26920887,,,
148,Preclinical - Cell line xenograft,"In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of Herceptin (trastuzumab)-resistant ERBB2 (HER2) positive breast cancer cells harboring PIK3CA H1047R in culture, and induced tumor regression in cell line xenograft models (PMID: 26920887).",Actionable,7748,60079,Her2-receptor positive breast cancer,DOID,25951,ERBB2 pos PIK3CA H1047R,sensitive,1402,trastuzumab emtansine,2064,26920887,,,
149,Preclinical - Cell line xenograft,"In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of Herceptin (trastuzumab)-resistant ERBB2 (HER2) positive breast cancer cells harboring PIK3CA E545K in culture, and induced tumor regression in cell line xenograft models (PMID: 26920887).",Actionable,7749,60079,Her2-receptor positive breast cancer,DOID,20859,ERBB2 pos PIK3CA E545K,sensitive,1402,trastuzumab emtansine,2064,26920887,,,
150,Phase II,"In a Phase II trial, ERBB2-positive breast cancer patients harboring PIK3CA mutations demonstrated lower pathologic complete remission rate (12.5%) compared to those with wild-type PIK3CA (48.4%) after Herceptin (trastuzumab) and Tykerb (lapatinib) combination therapy (PMID: 26245675).",Actionable,5246,60079,Her2-receptor positive breast cancer,DOID,1669,PIK3CA mutant ERBB2 pos,decreased response,1414,Trastuzumab + Lapatinib,2064,26245675,,,
151,Clinical Study,"In a clinical study, a retrospective analysis of the combined treatment, Herceptin (trastuzumab) and Tykerb (lapatinib), in ERBB2 (HER2) positive breast cancer patients demonstrated patients harboring a PIK3CA mutation trended towards a decreased response when compared to patients with wild-type PIK3CA (PMID: 27687302). ",Actionable,9165,60079,Her2-receptor positive breast cancer,DOID,1669,PIK3CA mutant ERBB2 pos,decreased response,1414,Trastuzumab + Lapatinib,2064,27687302,,,
152,Phase I,"In a Phase I clinical trial, the combination of Buparlisib (BKM120) and Herceptin (trastuzumab) was well tolerated and resulted in some preliminary efficacy in patients with ERBB2 (HER2)-positive breast cancer harboring PIK3CA activating mutations and/or PTEN mutations that had progressed on Herceptin (trastuzumab)-based therapy (PMID: 24470511).",Actionable,4370,60079,Her2-receptor positive breast cancer,DOID,23651,ERBB2 pos PTEN mut,predicted â€“ sensitive,1417,BKM120 + Trastuzumab,2064,24470511,,,
153,Preclinical - Cell culture,"In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of ERBB2 (HER2) positive breast cancer cells harboring PIK3CA C420R in culture (PMID: 26920887).",Actionable,7747,60079,Her2-receptor positive breast cancer,DOID,25950,ERBB2 pos PIK3CA C420R,sensitive,1402,trastuzumab emtansine,2064,26920887,,,
154,Clinical Study,"In a clinical study, ERBB2 (HER2)-positive breast cancer patients with PI3K pathway activation resulting from low PTEN expression and/or PIK3CA activating mutations demonstrated decreased progression-free survival following treatment with Herceptin (trastuzumab) compared to patients without PI3K pathway activation (PMID: 17936563).",Actionable,6663,60079,Her2-receptor positive breast cancer,DOID,23664,ERBB2 pos PTEN dec exp,decreased response,947,Trastuzumab,2064,17936563,,,
155,Preclinical,"In a preclinical study, the combination of Herceptin (trastuzumab) and Eloxatin (oxaliplatin) resulted in growth inhibition of ERBB2 (HER2)-positive gastric cancer cells in culture (PMID: 24300914).",Actionable,947,10534,stomach cancer,DOID,1187,ERBB2 positive,sensitive,1412,Trastuzumab + Oxaliplatin,2064,24300914,,,
156,Preclinical - Cell culture,"In a preclinical study, SYD985 decreased survival of a ERBB2 (HER2)-positive ovarian carcinoma cell line in culture (PMID: 25589493).",Actionable,8248,4001,ovarian carcinoma,DOID,1187,ERBB2 positive,sensitive,4539,SYD985,2064,25589493,,,
157,Phase I,"In a Phase I trial, ZW25 treatment resulted in partial response in 28.6% (2/7) and stable disease in 28.6% (2/7) of patients with ERBB2 (HER2)-positive breast cancers (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 255P; NCT02892123).",Actionable,12051,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,predicted â€“ sensitive,6240,ZW25,2064,None,,,
158,Phase III,"In a Phase III trial, adjuvant Herceptin (trastuzumab), Perjeta (pertuzumab), plus chemotherapy resulted in improved invasive disease-free survival compared to Herceptin (trastuzumab) plus chemotherapy in patients with Erbb2 (Her2)-positive breast cancer (J Clin Oncol 35, 2017 (suppl; abstr LBA500)).",Actionable,11142,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,sensitive,1389,Trastuzumab + Pertuzumab,2064,None,,,
159,Phase I,"In a Phase I clinical trial, the combination of Buparlisib (BKM120) and Herceptin (trastuzumab) was well tolerated in patients with ERBB2 (HER2)-positive advanced or metastatic breast cancer that had progressed on Herceptin (trastuzumab) (PMID: 24470511).",Actionable,288,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,sensitive,1417,BKM120 + Trastuzumab,2064,24470511,,,
160,Phase I,"In a Phase I trial, treatment with Tucatinib (ARRY-380) resulted in a response rate of 14% (3/22; all partial responses (PR)) and a clinical benefit rate (PR plus stable disease for greater than or equal to 24 weeks) of 27% (6/22) in Erbb2 (Her2)-positive breast cancer patients (PMID: 28053022).",Actionable,2915,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,sensitive,639,Tucatinib,2064,28053022,,,
161,Preclinical - Pdx & cell culture,"In a preclinical study, DS-8201 inhibited growth of a ERBB2 (HER2)-positive gastric carcinoma cell line in culture and in xenograft models, and induced tumor regression in a patient-derived xenograft (PDX) model of ERBB2 (HER2)-positive gastric cancer (PMID: 27026201).",Actionable,8870,10534,stomach cancer,DOID,1187,ERBB2 positive,sensitive,4844,DS-8201a,2064,27026201,,,
162,FDA approved,"In a Phase III trial that supported FDA approval, treatment with Perjeta (pertuzumab), combined with Herceptin (trastuzumab) and docetaxel, improved median progression free survival to 18.5 months in patients with HER2-positive metastatic breast cancer (PMID: 23801166).",Actionable,2018,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,sensitive,1978,Pertuzumab + Trastuzumab + Docetaxel,2064,None,23801166,,
163,Phase III,"In a Phase III trial, ERBB2 (HER2) positive breast cancer patients with diabetes demonstrated a greater disease free survival and overall survival when treated with Glucophage (metformin) compared to ERBB2 (HER2) positive breast cancer patients with diabetes not treated with Glucophage (metformin) (PMID: 28375706).",Actionable,11061,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,predicted â€“ sensitive,1031,Metformin,2064,28375706,,,
164,Phase I,"In a Phase I trial, ZW25 treatment resulted in stable disease in 20% (1/5) of patients with ERBB2 (HER2)-positive gastric or esophageal cancers (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #255P; NCT02892123).",Actionable,12053,5041,esophageal cancer,DOID,1187,ERBB2 positive,predicted â€“ sensitive,6240,ZW25,2064,None,,,
165,Phase II,"In a Phase II trial, Sutent (sunitinib), in combination with Herceptin (trastuzumab), demonstrated safety and efficacy in ERBB2 (HER2) positive advanced breast cancer patients (PMID: 24606768).",Actionable,906,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,sensitive,1658,Sunitinib + Trastuzumab,2064,24606768,,,
166,Phase Ib/II,"In a Phase Ib trial, the combination of Tucatinib (ARRY-380) with other agents demonstrated clinical activity in central nervous system (CNS) metastases in patients with ERBB2 (HER2)-positive metastatic breast cancer, with 1/1 evaluable patient treated with Tucatinib (ARRY-380) and Capecitabine achieving CNS partial response (San Antonio Breast Cancer Symposium 2015, Abstract P4-14-19).",Actionable,3808,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,predicted â€“ sensitive,1577,ARRY-380 + Capecitabine,2064,None,,,
167,Preclinical - Cell culture,"In a preclinical study, SYD985 decreased survival of a ERBB2 (HER2)-positive gastric carcinoma cell line in culture (PMID: 25589493).",Actionable,8247,5517,stomach carcinoma,DOID,1187,ERBB2 positive,sensitive,4539,SYD985,2064,25589493,,,
168,Phase II,"In a Phase II trial, Tykerb (lapatinib) and Herceptin (trastuzumab) combination treatment resulted in complete response in the breast in 10.6% (7/66) and minimal residual disease in 16.7% (11/66) of ERBB2-positive breast cancer patients 11 days after receiving the treatment (European Breast Cancer Conference; Mar 2016; Abstract #6LBA).",Actionable,5079,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,sensitive,1414,Trastuzumab + Lapatinib,2064,None,,,
169,Clinical Study,"In a meta-analysis of six randomized clinical trials, Tykerb (lapatinib) and Herceptin (trastuzumab) combination treatment resulted in 13% absolute improvement in pathologic complete response rate in ERBB2 (HER2)-positive breast cancer patients compared to Herceptin (trastuzumab) single treatment (PMID: 27140927).",Actionable,8433,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,sensitive,1414,Trastuzumab + Lapatinib,2064,27140927,,,
170,Phase I,"In a Phase I trial, treatment with DS-8201a was well-tolerated and resulted in an overall response rate (ORR) of 38% (19/50) and disease control rate (DCR) of 90% (45/50) in patients with ERBB2 (HER2)-expressing solid tumors, and an ORR of 29% (4/14) and DCR of 93% (13/14) in patients with low ERBB2 (HER2) expression (J Clin Oncol 35, 2017 (suppl; abstr 108)).",Actionable,11103,10000003,Advanced Solid Tumor,JAX,1187,ERBB2 positive,predicted â€“ sensitive,4844,DS-8201a,2064,None,,,
171,Guideline,"Doxorubicin and cyclophosphamide (AC), followed by a one year treatment with Taxol (paclitaxel) and Herceptin (trastuzumab) is an active adjuvant regiment for patients with Her2-receptor positive breast cancer (Guidelines).",Actionable,2021,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,sensitive,1503,Paclitaxel + Trastuzumab + Doxorubicin + Cyclophosphamide,2064,None,,,
172,Phase III,"In a Phase III trial, the combination of Afinitor (everolimus), Herceptin (trastuzumab), and Navelbine (vinorelbine) increased progression-free survival in patients with Herceptin (trastuzumab)-resistant, ERBB2 (HER2)-positive, advanced breast cancer who had prior taxane treatment (PMID: 24742739). ",Actionable,945,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,sensitive,1411,Trastuzumab + Everolimus + Vinorelbine,2064,24742739,,,
173,Phase Ib/II,"In a Phase I/Ib clinical trial, vaccination with a HER2-peptide pulsed dendritic cell vaccine was well-tolerated and resulted in immune response in patients with ERBB2 (HER2)-positive ductal carcinoma in situ (DCIS), and resulted in pathologic complete response rate of 28% (12/42), compared to 8.3% (1/12) in patients with invasive breast cancer (PMID: 27965306).",Actionable,10237,60074,ductal carcinoma in situ,DOID,1187,ERBB2 positive,predicted â€“ sensitive,5222,HER2-pulsed DC1 vaccine,2064,27965306,,,
174,Preclinical - Pdx & cell culture,"In a preclinical study, SYD985 decreased survival of ERBB2 (HER2)-positive breast carcinoma cell lines in culture, and inhibited tumor growth and induced tumor remission in cell line and patient-derived xenograft models of ERBB2 (HER2)-positive breast carcinoma, including models with low ERBB2 (HER2) expression (PMID: 25589493).",Actionable,8251,3459,breast carcinoma,DOID,1187,ERBB2 positive,sensitive,4539,SYD985,2064,25589493,,,
175,Preclinical - Cell line xenograft,"In a preclinical study, Imbruvica (ibrutinib) inhibited Her family receptor signaling, resulted in apoptosis and growth inhibition in ERBB2 (HER2)-positive breast cancer cell lines in culture and in cell line xenograft models (PMID: 27256378).",Actionable,8229,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,predicted â€“ sensitive,768,Ibrutinib,2064,27256378,,,
176,Phase II,"In a Phase II trial, Neuvenge (lapuleucel-T) treatment did not result in statistically significant improvement of overall survival (37.0 vs 22.2 months, HR = 0.96) or disease recurrence-free survival (11.9 vs 10.1 months, HR = 0.99) compared to standard of care in ERBB2 (HER2) positive urothelial cancer patients (J Clin Oncol 34, 2016 (suppl; abstr 4513)).",Actionable,6974,2671,transitional cell carcinoma,DOID,1187,ERBB2 positive,no benefit,4344,lapuleucel-T,2064,None,,,
177,Preclinical - Cell line xenograft,"In a preclinical study, treatment with Hertuzumab-vc-MMAE decreased viability of ERBB2 (HER2)-positive ovarian cancer cell lines in culture and inhibited tumor growth in ERBB2 (HER2)-positive ovarian cancer cell line xenograft models (PMID: 27509865).",Actionable,7809,2394,ovarian cancer,DOID,1187,ERBB2 positive,sensitive,4583,Hertuzumab-vc-MMAE,2064,27509865,,,
178,Phase III,"In a Phase III trial, ABP 980 treatment demonstrated safety and efficacy similar to Herceptin (trastuzumab), with pathologic complete response rates of 48% and 40.5%, respectively, in patients with Erbb2 (Her2)-positive breast cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 151PD; NCT01901146).",Actionable,12067,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,predicted â€“ sensitive,6243,ABP 980,2064,None,,,
179,Preclinical,"In a preclinical study, the combination of Herceptin (trastuzumab) and Eloxatin (oxaliplatin) resulted in growth inhibition of ERBB2 (HER2)-positive breast cancer cells in culture (PMID: 24300914).",Actionable,946,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,sensitive,1412,Trastuzumab + Oxaliplatin,2064,24300914,,,
180,Preclinical - Cell line xenograft,"In a preclinical study, DS-8201a inhibited tumor growth in a pancreatic cancer cell line xenograft model with low ERBB2 (HER2) expression (PMID: 27026201).",Actionable,8873,1793,pancreatic cancer,DOID,1187,ERBB2 positive,sensitive,4844,DS-8201a,2064,27026201,,,
181,Phase II,"In a Phase II clinical trial, Nerlynx (neratinib) demonstrated safety and efficacy as a monotherapy in patients with ERBB2 (HER2)-positive breast cancer (PMID: 23953056).",Actionable,896,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,sensitive,828,Neratinib,2064,23953056,,,
182,FDA approved,"In a Phase III trial that supported FDA approval, ERBB2 (HER2)-positive breast cancer patients previously treated with Herceptin (trastuzumab) demonstrated a significantly greater two year invasive disease-free survival rate (93.9%) when treated with Nerlynx (neratinib) compared to the rate (91.6%) in those patients treated with placebo (PMID: 26874901; NCT00878709). ",Actionable,11507,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,sensitive,828,Neratinib,2064,26874901,,,
183,Phase II,"In Phase II clinical trials, the combination of Xeloda (capecitabine) and Herceptin (trastuzumab) demonstrated efficacy with a manageable toxicity profile in heavily pretreated patients with ERBB2 (HER2)-positive advanced breast cancer and earlier Herceptin (trastuzumab) exposure (PMID: 17679724). ",Actionable,938,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,sensitive,1409,Capecitabine + Trastuzumab,2064,17679724,,,
184,Phase III,"In a Phase III trial, MYL-1401O demonstrated safety and efficacy comparable to Herceptin (trastuzumab) when given in combination with Taxol (paclitaxel), resulted in an objective response rate of 69.6% in ERBB2 (HER2)-positive breast cancer patients (J Clin Oncol 34, 2016 (suppl; abstr LBA503)).",Actionable,6814,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,sensitive,4263,MYL-1401O + Paclitaxel,2064,None,,,
185,Phase I,"In a Phase I trial, Margetuximab (MGAH22) treatment resulted in tumor reduction in 78% (18/23) of patients with ERBB2 (HER2)-positive breast cancer (PMID: 28119295).",Actionable,897,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,predicted â€“ sensitive,808,MGAH22,2064,28119295,,,
186,Phase I,"In a Phase I expansion trial, 36% (5/14) of metastatic breast cancer patients positive for ERBB2 (HER2) demonstrated stable disease for up to 16 weeks when treated with Varlitinib (ARRY-334543) (Cancer Res May 1, 2009 69; 3603).",Actionable,2904,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,sensitive,1057,varlitinib,2064,None,,,
187,FDA approved,"In a Phase III trial, Kadclya (trastuzumab emtansine) demonstrated improved median progression free survival and overall survival compared to Tykerb (lapatinib) and Xeloda (capecitabine) combination treatment in patients with ERBB2 (HER2) positive breast cancer, regardless of the expression level of Erbb2 (Her2), Egfr, and Her3, or PIK3CA mutation status (PMID: 26920887). ",Actionable,7743,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,predicted â€“ sensitive,1402,trastuzumab emtansine,2064,26920887,,,
188,FDA approved,"In a Phase III trial that supported FDA approval, treatment with Kadclya (trastuzumab emtansine) improved median progression free survival in patients with metastatic ERBB2 (HER2) positive breast cancer (PMID: 24879797). ",Actionable,2017,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,predicted â€“ sensitive,1402,trastuzumab emtansine,2064,None,24879797,,
189,Preclinical,"In a preclinical study, withacnistin induced tumor regression in transgenic mouse models of Erbb2 (Her2)-driven breast cancer (PMID: 24983364).",Actionable,4927,1612,breast cancer,DOID,1187,ERBB2 positive,sensitive,3697,Withacnistin,2064,24983364,,,
190,Phase III,"In a Phase III trial, second-line treatment using Tykerb (lapatinib) with paclitaxel demonstrated some efficacy in patients with HER2-positive advanced gastric cancer (PMID: 24868024). ",Actionable,939,10534,stomach cancer,DOID,1187,ERBB2 positive,sensitive,1410,Lapatinib + Paclitaxel,2064,24868024,,,
191,Preclinical - Cell line xenograft,"In a preclinical study, SYD895 induced cell death in ERBB2 (HER2)-expressing primary uterine serous carcinoma (USC) cell lines in culture, including cell lines with both high and low levels of ERBB2 (HER2) expression, and inhibited tumor growth and improved survival in ERBB2 (HER2)-expressing USC primary cell line xenografts (PMID: 27256376).",Actionable,7638,5750,uterine corpus serous adenocarcinoma,DOID,1187,ERBB2 positive,sensitive,4539,SYD985,2064,27256376,,,
192,Phase II,"In a Phase II trial, Taxol (paclitaxel) and Herceptin (trastuzumab) treatment in combination with MM-111 did not improve progression free survival (9.6 weeks) and median overall survival (32.1 weeks) compared to without MM-111 (23.3 weeks, 56.1 weeks) in ERBB2 positive gastroesophageal junction cancer patients (J Clin Oncol 34, 2016 (suppl; abstr 4043)).",Actionable,6713,4944,gastroesophageal junction adenocarcinoma,DOID,1187,ERBB2 positive,no benefit,1892,Paclitaxel + Trastuzumab + MM-111,2064,None,,,
193,Phase Ib/II,"In a Phase Ib/II trial, Kadcyla (trastuzumab emtansine), Taxotere (docetaxel) and Perjeta (pertuzumab) combination treatment resulted in pathologic complete response in 60.3% (44/73) of patients with ERBB2 (HER2)-positive locally advanced breast cancer (PMID: 27052654).",Actionable,5819,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,sensitive,3931,Docetaxel + T-DM1 + Pertuzumab,2064,27052654,,,
194,Phase I,"In a Phase I trial, Margetuximab (MGAH22) treatment resulted in partial responses in 12% (7/60) and stable disease in 50% (30/60) of patients with ERBB2 (HER2)-positive breast or gastric cancer, or other carcinomas that overexpress Erbb2 (Her2) (PMID: 28119295).",Actionable,10448,10534,stomach cancer,DOID,1187,ERBB2 positive,predicted â€“ sensitive,808,MGAH22,2064,28119295,,,
195,Preclinical,"In a preclinical study, the combination of Tykerb (lapatinib) and Ibrance (palbociclib) worked additively to suppress growth of ERBB2 (HER2)-positive breast cancer cell lines in culture (PMID: 25221644). ",Actionable,2979,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,sensitive,3042,Lapatinib + Palbociclib,2064,25221644,,,
196,Preclinical,"In a preclinical study, CDX-3379 (KTN3379) inhibited tumor growth in xenograft models of ERBB2 (HER2)-positive breast cancer (PMID: 26880266).",Actionable,6441,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,sensitive,2054,CDX-3379,2064,26880266,,,
197,Phase Ib/II,"In a Phase I/II trial, treatment with ERBB2 (HER2)-specific CAR-T cells resulted in stable disease for 12 weeks to 14 months in 4/17 evaluable patients with ERBB2 (HER2)-positive sarcomas and a median overall survival of 10.3 months (PMID: 25800760; NCT00902044).",Actionable,11502,1115,sarcoma,DOID,1187,ERBB2 positive,predicted â€“ sensitive,6007,HER2 CAR-T cells,2064,25800760,,,
198,Phase I,"In a Phase I clinical trial, AC480 (BMS-599626) treatment demonstrated preliminary clinical activity, resulting in stable disease as best response in 25% (11/44) of patients with advanced solid tumors, including patients expressing EGFR and/or ERBB2, with 2 patients achieving stable disease for greater than 6 months (PMID: 21576284).",Actionable,2909,10000003,Advanced Solid Tumor,JAX,1187,ERBB2 positive,predicted â€“ sensitive,977,AC480,2064,21576284,,,
199,Phase II,"In a Phase II trial, Poziotinib (HM781-36B) treatment resulted in a median progression-free survival of 4.04 months, and a disease control rate of 75.49% (77/102; 20 partial responses) in heavily-treated Erbb2 (Her2)-positive breast cancer patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 237O; NCT02418689).",Actionable,12065,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,predicted â€“ sensitive,1042,poziotinib,2064,None,,,
200,Phase III,"In a Phase III trial, CT-P6 demonstrated equivalence to reference Herceptin (trastuzumab) in patients with ERBB2 (HER2)-positive breast cancer, with 46.8% (116/248) of patients treated with CT-P6 achieving pathologic complete response compared to 50.4% (129/256) with Herceptin (trastuzumab) treatment (PMID: 28592386).",Actionable,11356,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,sensitive,5954,CT-P6,2064,28592386,,,
201,Preclinical - Cell culture,"In a preclinical study, Hertuzumab-vc-MMAE decreased viability of ERBB2 (HER2)-positive breast cancer cell lines in culture (PMID: 27509865).",Actionable,7808,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,sensitive,4583,Hertuzumab-vc-MMAE,2064,27509865,,,
202,Phase I,"In a Phase I trial, glioblastoma patients positive for ERBB2 (HER2) demonstrated antitumor activity when treated with ERBB2 (HER2)-CAR-T cell therapy including one patient with a partial response and seven patients with stable disease ranging from 8 weeks to 29 months (PMID: 28426845). ",Actionable,11716,3068,glioblastoma multiforme,DOID,1187,ERBB2 positive,sensitive,6007,HER2 CAR-T cells,2064,28426845,,,
203,Phase II,"In a Phase II trial, Nerlynx (neratinib) plus Taxol (paclitaxel) demonstrated similar efficacy to Herceptin (trastuzumab) plus Taxol (paclitaxel), with an median progression-free survival of 12.9 months, however, potentially decreased CNS metastasis risk, with an incidence of 8.3% (20/242) compared to 17.3% (41/237) in the Herceptin (trastuzumab) plus Taxol (paclitaxel) group (PMID: 27078022).",Actionable,9585,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,sensitive,5101,Neratinib + Paclitaxel,2064,27078022,,,
204,Phase Ib/II,"In a Phase Ib trial, the combination of Tucatinib (ARRY-380), Herceptin (trastuzumab), and Capecitabine demonstrated clinical activity in CNS metastases in patients with ERBB2 (HER2)-positive metastatic breast cancer, with 50% (1/2) of evaluable patients achieving CNS partial response and 50% (1/2) achieving CNS stable disease (San Antonio Breast Cancer Symposium 2015, Abstract P4-14-19).",Actionable,3810,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,predicted â€“ sensitive,3340,ARRY-380 + Capecitabine + Trastuzumab,2064,None,,,
205,Phase III,"In a Phase III trial, Kadcyla (trastuzumab emtansine) did not demonstrated efficacy benefit over Taxol (paclitaxel) on median overall survival (7.9 vs 8.6 months) in patients with previously treated ERBB2 (HER2)-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (J Clin Oncol 34, 2016 (suppl 4S; abstr 5)).",Actionable,8740,4944,gastroesophageal junction adenocarcinoma,DOID,1187,ERBB2 positive,no benefit,1402,trastuzumab emtansine,2064,None,,,
206,Phase Ib/II,"In a Phase Ib/II trial, Kadcyla (trastuzumab emtansine) and Taxotere (docetaxel) combination treatment resulted in median progression-free survival of 13.8 months and objective response in 80.0% (20/25) of patients with ERBB2 (HER2)-positive metastatic breast cancer (PMID: 27052654).",Actionable,5818,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,sensitive,3930,Docetaxel + T-DM1,2064,27052654,,,
207,Preclinical - Pdx & cell culture,"In a preclinical study, XMT-1522 inhibited growth of Erbb2 (Her2)-positive breast cancer cells in culter, resulted in tumor regression in both cell line and patient-derived xenograft models (Cancer Res 2016;76(4 Suppl): Abstract nr P4-14-28).",Actionable,11055,1612,breast cancer,DOID,1187,ERBB2 positive,sensitive,5834,XMT-1522,2064,None,,,
208,Phase II,"In a Phase II clinical trial, the combination of TS-1 (S-1) and Herceptin (trastuzumab) demonstrated safety and efficacy in patients with ERBB2 (HER2)-positive metastatic breast cancer, with an overall response rate of 53.6% (15/28), and a clinical benefit rate of 75.0% (21/28)  (PMID: 24982373).",Actionable,937,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,sensitive,1408,Trastuzumab + TS-1,2064,24982373,,,
209,Phase I,"In a Phase I study, MM-302 demonstrated safety in patients with ERBB2 (HER2) positive breast cancer (Cancer Res 2012;72(24 Suppl):Abstract nr P5-18-09)",Actionable,899,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,sensitive,1401,MM-302,2064,None,,,
210,Phase Ib/II,"In a Phase Ib trial, the combination of Tucatinib (ARRY-380) and Trastuzumab emtansine (T-DM1) demonstrated clinical activity in CNS metastases in patients with ERBB2 (HER2)-positive metastatic breast cancer, with 12.5% (1/8) evaluable patients achieving CNS complete response, 25% (2/8) partial CNS response, and 62.5% (5/8) CNS stable disease (San Antonio Breast Cancer Symposium 2015, Abstract P4-14-19).",Actionable,3809,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,predicted â€“ sensitive,1573,ARRY-380 + Trastuzumab emtansine,2064,None,,,
211,Phase Ib/II,"In a Phase Ib clinical trial, treatment with the combination of Tucatinib (ARRY-380) and Trastuzumab emtansine (T-DM1) resulted in an overall response rate of 47% (15/52) and median progression-free survival of 6.5 months in patients with ERBB2 (HER2)-positive metastatic breast cancer, including patients with CNS metastasis (J Clin Oncol 34, 2016 (suppl; abstr 513)).",Actionable,7045,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,predicted â€“ sensitive,1573,ARRY-380 + Trastuzumab emtansine,2064,None,,,
212,Phase Ib/II,"In a Phase Ib clinical trial, treatment with the combination of Tucatinib (ARRY-380) and Trastuzumab emtansine (T-DM1) resulted in partial response in 33% (11/33) and stable disease in 48% (16/33) and a clinical benefit rate of 58% (19/33) in patients with ERBB2 (HER2)-positive metastatic breast cancer (San Antonio Breast Cancer Symposium 2015, Abstract P4-14-20).",Actionable,3806,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,predicted â€“ sensitive,1573,ARRY-380 + Trastuzumab emtansine,2064,None,,,
213,Phase I,"In a Phase I trial, combination treatment consisted of Entinostat, Tykerb (lapatinib) and Herceptin (trastuzumab) resulted in complete response in 9% (2/22), partial response in 14% (3/22), and stable disease in 27% (6/22) of ERBB2 (HER2) positive breast cancer patients (J Clin Oncol 34, 2016 (suppl; abstr 609)).",Actionable,6716,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,sensitive,1542,Entinostat + Lapatinib + Trastuzumab,2064,None,,,
214,Phase II,"In a Phase II trial, Nerlynx (neratinib) and Xeloda (capecitabine) combination therapy resulted in an overall 12-month survival rate of 63% (23/37) in patients with Erbb2 (Her2)-positive breast cancer brain metastases (J Clin Oncol 35, 2017 (suppl; abstr 1005)).",Actionable,11165,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,sensitive,1543,Capecitabine + Neratinib,2064,None,,,
215,Preclinical - Pdx,"In a preclinical study, ADCT-502 demonstrated anti-tumor activity in ERBB2 (HER2)-expressing breast cancer cell line and patient-derived xenograft (PDX) models, including PDX models expressing low levels of ERBB2 (HER2) (Eur J Cancer, 2016, Vol. 69, Supp1, S28).",Actionable,10927,1612,breast cancer,DOID,1187,ERBB2 positive,sensitive,5689,ADCT-502,2064,None,,,
216,Phase I,"In a Phase I trial, ZW25 treatment resulted in stable disease in 20% (1/5) of patients with ERBB2 (HER2)-positive gastric or esophageal cancers (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #255P; NCT02892123).",Actionable,12054,10534,stomach cancer,DOID,1187,ERBB2 positive,predicted â€“ sensitive,6240,ZW25,2064,None,,,
217,Phase I,"In a Phase I trial, Tykerb (lapatinib) and MK2206 combination treatment resulted in stable disease for more than 6 months in 40% (2/5) of patients with ERBB2 (HER2)-positive breast cancer (PMID: 27026198).",Actionable,6029,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,sensitive,4007,Lapatinib + MK2206,2064,27026198,,,
218,Preclinical - Pdx & cell culture,"In a preclinical study, DS-8201 inhibited growth of ERBB2 (HER2)-positive breast cancer cell lines in culture and xenograft models, and demonstrated antitumor activity in patient-derived xenograft (PDX) models of ERBB2 (HER2)-positive breast cancer, including models with low ERBB2 (HER2) expression (PMID: 27026201).",Actionable,8871,1612,breast cancer,DOID,1187,ERBB2 positive,sensitive,4844,DS-8201a,2064,27026201,,,
219,Preclinical - Cell culture,"In a preclinical study, Tucatinib (ARRY-380) inhibited tumor growth in a ERBB2 (HER2)-positive gastric carcinoma cell line xenograft model (Cancer Res April 15, 2012 72:852).",Actionable,2916,5517,stomach carcinoma,DOID,1187,ERBB2 positive,sensitive,639,Tucatinib,2064,None,,,
220,Phase III,"In a Phase III trial, SB3 treatment demonstrated safety, immunogenicity, and survival result similar to Herceptin (trastuzumab), resulted in event-free-survival rates of 92.2% and 91.6%, respectively, in patients with Erbb2 (Her2)-positive breast cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 153PD; NCT02149524).",Actionable,12066,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,predicted â€“ sensitive,6242,SB3,2064,None,,,
221,Phase Ib/II,"In a Phase Ib clinical trial, the combination of Tucatinib (ARRY-380) and Herceptin (trastuzumab) demonstrated clinical activity in central nervous system (CNS) metastases in patients with ERBB2 (HER2)-positive metastatic breast cancer, with 100% (3/3) patients achieving CNS stable disease as best response (San Antonio Breast Cancer Symposium 2015, Abstract P4-14-19).",Actionable,3807,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,predicted â€“ sensitive,1560,ARRY-380 + Trastuzumab,2064,None,,,
222,Preclinical - Cell line xenograft,"In a preclinical study, Trodusquemine (MSI-1436) inhibited tumor growth and metastasis in a ERBB2 (HER2)-positive human breast cancer cell line xenograft model (PMID: 24845231).",Actionable,4464,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,sensitive,3521,Trodusquemine,2064,24845231,,,
223,Phase I,"In a Phase I trial, Entinostat and Tykerb (lapatinib) combination treatment resulted in complete response in 7% (1/15) and stable disease in 27% (4/15) of ERBB2 (HER2) positive breast cancer patients (J Clin Oncol 34, 2016 (suppl; abstr 609)).",Actionable,6715,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,sensitive,4255,Entinostat + Lapatinib,2064,None,,,
224,Preclinical,"In a preclinical study, breast cancer cell lines with a PIK3CA activating mutation and/or ERBB2 (HER2)-over expression demonstrated increased sensitivity to inhibition of proliferation by Aliqopa (copanlisib) in culture, compared to ERBB2 (HER2)-negative and wild-type PIK3CA cell lines (PMID: 24170767).",Actionable,1373,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,sensitive,995,Copanlisib,2064,24170767,,,
225,Phase I,"In a Phase I trial, Pyrotinib treatment resulted in an objective response rate of 50% (18/36, all partial responses), and a clinical benefit rate of 61.1% (22/36), and a median progression-free survival of 35.4 weeks in patients with ERBB2 (HER2)-positive breast cancer (PMID: 28498781, NCT01937689).",Actionable,9851,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,sensitive,3082,Pyrotinib,2064,None,28498781,,
226,Phase I,"In a Phase I trial, treatment with DS-8201a resulted in a partial response in 40% (2/5) of evaluable patients with colorectal cancer and ERBB2 (HER2) expression (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 409P; NCT02564900).",Actionable,11991,9256,colorectal cancer,DOID,1187,ERBB2 positive,predicted â€“ sensitive,4844,DS-8201a,2064,None,,,
227,Phase II,"In Phase II clinical trials, ERBB2 (HER2) vaccines demonstrated safety and some efficacy in the adjuvant setting in ERBB2 (HER2)-positive breast cancer patients (PMID: 23585514).",Actionable,909,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,predicted â€“ sensitive,1404,HER2 Vaccine,2064,23585514,,,
228,Phase I,"In a Phase I trial, treatment with DS-8201a resulted in a partial response in 50% (2/4) of evaluable patients with salivary gland cancer and ERBB2 (HER2) expression (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 409P; NCT02564900).",Actionable,11992,8850,salivary gland cancer,DOID,1187,ERBB2 positive,predicted â€“ sensitive,4844,DS-8201a,2064,None,,,
229,FDA approved,"In a Phase III trial that supported FDA approval, treatment with the combination of Tykerb (lapatinib) and Femara (letrozole) resulted in an improved median progression-free survival of 8.2 months in patients with hormone receptor-positive/Erbb2 (Her2)-positive metastatic breast cancer, compared to 3.0 months with Femara (letrozole) and placebo (PMID: 19786658). ",Actionable,2019,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,sensitive,1497,Lapatinib + Letrozole,2064,None,19786658,,
230,Phase III,"In a Phase III trial, Kadcyla (trastuzumab emtansine) did not demonstrated efficacy benefit over Taxol (paclitaxel) on median overall survival (7.9 vs 8.6 months) in patients with previously treated ERBB2 (HER2)-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (J Clin Oncol 34, 2016 (suppl 4S; abstr 5)).",Actionable,8739,5635,gastric adenosquamous carcinoma,DOID,1187,ERBB2 positive,no benefit,1402,trastuzumab emtansine,2064,None,,,
231,Phase I,"In a Phase I trial, ZW25 treatment resulted in partial response in 14% (2/14) and stable disease in 21% (3/14) of patients with ERBB2 (HER2)-positive tumors, including breast, gastric, esophageal, colorectal, and adnexal cancers (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 255P; NCT02892123).",Actionable,12059,10000003,Advanced Solid Tumor,JAX,1187,ERBB2 positive,predicted â€“ sensitive,6240,ZW25,2064,None,,,
232,Preclinical - Patient cell culture,"In a preclinical study, ERBB2 (HER2)-specific cytotoxic T-cell lines generated from gastric cancer patients demonstrated activity against autologous ERBB2 (HER2)-expressing gastric cancer cells in culture (PMID: 9754653).",Actionable,928,10534,stomach cancer,DOID,1187,ERBB2 positive,sensitive,1404,HER2 Vaccine,2064,9754653,,,
233,Phase II,"In a Phase II clinical trial, treatment with Gilotrif (afatinib) resulted in a clinical benefit rate of 35% (9/26) in patients with ERBB2 (HER2)-positive inflammatory breast cancer, with 8 confirmed partial responses and 1 patient achieving stable disease for greater than 6 months (PMID: 27923043).",Actionable,9570,6263,inflammatory breast carcinoma,DOID,1187,ERBB2 positive,predicted â€“ sensitive,623,Afatinib,2064,27923043,,,
234,Phase I,"In a Phase I clinical trial, ERBB2 (HER2)-positive breast cancer patients treated with Gilotrif (afatinib), in combination with Herceptin (trastuzumab), demonstrated an overall objective response rate of 11% (2/18)  while 28% (5/18) attained a best response of stable disease (PMID: 25370464).",Actionable,2655,60079,Her2-receptor positive breast cancer,DOID,1187,ERBB2 positive,sensitive,1106,Afatinib + Trastuzumab,2064,25370464,,,
235,Phase I,"In a Phase I clinical trial, S-222611 demonstrated safety and some efficacy in patients with advanced solid tumors expressing EGFR or ERBB2 (HER2), with an overall clinical benefit rate of 27% (7/33) (PMID: 25434923).",Actionable,1215,10000003,Advanced Solid Tumor,JAX,1187,ERBB2 positive,predicted â€“ sensitive,1048,S-222611,2064,None,25434923,,
236,Phase I,"In a Phase I trial, ZW25 treatment resulted in disease progression in a patient with ERBB2 (HER2)-positive colorectal cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 255P; NCT02892123).",Actionable,12055,9256,colorectal cancer,DOID,1187,ERBB2 positive,no benefit,6240,ZW25,2064,None,,,
237,Preclinical - Cell culture,"In a preclinical study, DS-8201 inhibited growth of an ERBB2 (HER2)-positive breast adenocarcinoma cell line in culture (PMID: 27026201).",Actionable,8869,3458,breast adenocarcinoma,DOID,1187,ERBB2 positive,sensitive,4844,DS-8201a,2064,27026201,,,
238,Phase I,"In a retrospective analysis, ERBB2 (HER2)-positive breast cancer patients with PTEN loss demonstrated a decreased median progression-free survival of 6.0 months, compared to 9.0 months for patients without PI3K pathway activation following treatment with a Herceptin (trastuzumab) containing regimen (PMID: 21676217).",Actionable,874,60079,Her2-receptor positive breast cancer,DOID,1410,ERBB2 pos PTEN loss ,decreased response,947,Trastuzumab,2064,21676217,,,
239,Preclinical,"In a preclinical study, the combination of Ibrance (palbociclib) and Pictilisib (GDC-0941) did not improve growth inhibition compared to single drug treatment in ERBB2 (HER2)-positive breast cancer cell lines harboring PTEN loss in culture (PMID: 27020857).",Actionable,5862,60079,Her2-receptor positive breast cancer,DOID,1410,ERBB2 pos PTEN loss ,no benefit,3956,Palbociclib + GDC-0941,2064,27020857,,,
240,Phase II,"In a Phase II clinical trial, 30% (8/27) of patients with ERBB2 (HER2)-positive KRAS wild-type colorectal cancer achieved an objective response and 44% (12/27) of patients had stable disease when treated with the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) (PMID: 27108243).",Actionable,6482,9256,colorectal cancer,DOID,23355,ERBB2 positive KRAS wild-type,sensitive,1414,Trastuzumab + Lapatinib,2064,27108243,,,
241,Preclinical - Cell line xenograft,"In a preclinical study, Gilotrif (afatinib) induced tumor regression in a gastric cancer cell line xenograft model with HER2 (ERBB2) amplification and over expression (PMID: 23578997).",Actionable,2913,10534,stomach cancer,DOID,25933,ERBB2 amp ERBB2 over exp,sensitive,623,Afatinib,2064,23578997,,,
242,Preclinical - Cell line xenograft,"In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited tumor growth in human cell line xenograft models of gastric cancer with ERBB2 (HER2) amplification and over expression (PMID: 21458915).",Actionable,2928,10534,stomach cancer,DOID,25933,ERBB2 amp ERBB2 over exp,sensitive,1402,trastuzumab emtansine,2064,21458915,,,
243,Preclinical,"In a preclinical study, ADXS31-164 prevented development of spontaneous mammary tumors in Erbb2 (Her2)-over expressing transgenic animal models (PMID: 20725099).",Actionable,8169,60079,Her2-receptor positive breast cancer,DOID,1270,ERBB2 over exp,sensitive,4654,ADXS31-164,2064,20725099,,,
244,Preclinical - Cell culture,"In a preclinical study, Tucatinib (ARRY-380) inhibited proliferation of an ERBB2 (HER2) over expressing gastric cancer cell line in culture (Cancer Res April 15, 2010 70:3610).",Actionable,2889,10534,stomach cancer,DOID,1270,ERBB2 over exp,sensitive,639,Tucatinib,2064,None,,,
245,Preclinical - Cell culture,"In a preclinical study, Tykerb (lapatinib) inhibited growth of HER2-over expressing breast carcinoma cell lines in culture (PMID: 27450453).",Actionable,8531,60079,Her2-receptor positive breast cancer,DOID,1270,ERBB2 over exp,sensitive,787,Lapatinib,2064,27450453,,,
246,Preclinical - Cell line xenograft,"In a preclinical study, MM-111, in combination with Herceptin (trastuzumab) and Taxol (paclitaxel), resulted in a synergistic effect thereby inhibiting ErbB2 in ERBB2 (HER2) over expressing gastric cancer cell line xenograft models (J Clin Oncol 31, 2013 (suppl 4; abstr 48)).",Actionable,2925,10534,stomach cancer,DOID,1270,ERBB2 over exp,sensitive,1892,Paclitaxel + Trastuzumab + MM-111,2064,None,,,
247,Preclinical - Cell line xenograft,"In a preclinical study, combination of MM-302 and Herceptin (trastuzumab) synergistically inhibited tumor growth in cell line xenograft models of Erbb2 (Her2)-over expressing breast cancer (PMID: 26759238).",Actionable,10877,1612,breast cancer,DOID,1270,ERBB2 over exp,sensitive,1888,MM-302 + Trastuzumab,2064,26759238,,,
248,Preclinical,"In a preclinical study, CDX-3379 (KTN3379) inhibited tumor growth by 43% in N87 gastric cancer xenograft model, which has been demonstrated to have ERBB2 (HER2) amplification and overexpression (AACR; 2015. Abstract nr 1558, PMID: 18441328).",Actionable,2926,10534,stomach cancer,DOID,1270,ERBB2 over exp,sensitive,2054,CDX-3379,2064,18441328,None,,
249,Preclinical,"In a preclinical study, KU004 inhibited growth and induced apoptosis in breast cancer cell lines over expressing ERBB2 in culture (PMID: 26437915).",Actionable,3565,1612,breast cancer,DOID,1270,ERBB2 over exp,sensitive,3157,KU004,2064,26437915,,,
250,Phase I,"In a Phase I trial, a patient with perihilar cholangiocarcinoma over expressing ERBB2 achieved a partial response and progression-free survival for 4.5 months following treatment with ERBB2 (HER2)-specific CAR-T cells (PMID: 28710747, NCT01935843).",Actionable,11505,4947,cholangiocarcinoma,DOID,1270,ERBB2 over exp,predicted â€“ sensitive,6007,HER2 CAR-T cells,2064,28710747,,,
251,Preclinical - Cell line xenograft,"In a preclinical study, VS-5584 inhibited tumor growth in human gastric cancer cell line xenograft models overexpressing ERBB2 (HER2) (PMID: 23270925).",Actionable,2893,3717,gastric adenocarcinoma,DOID,1270,ERBB2 over exp,sensitive,960,VS-5584,2064,23270925,,,
252,Phase I,"In a Phase I trial, S-222611 resulted in a complete response in a gastric-esophageal junction cancer patient over expressing ERBB2 (HER2) and a partial response in a gastric cancer patient also over expressing ERBB2 (HER2) (J Clin Oncol 33, 2015 (suppl; abstr 2511)).",Actionable,2847,4944,gastroesophageal junction adenocarcinoma,DOID,1270,ERBB2 over exp,sensitive,1048,S-222611,2064,None,,,
253,Phase Ib/II,"In Phase I clinical trial, Margetuximab (MGAH22) displayed safety and had initial efficacy in patients with ERBB2 (HER2) positive breast cancer (J Clin Oncol 31, 2013 (suppl; abstr 3004)).",Actionable,2924,60079,Her2-receptor positive breast cancer,DOID,1270,ERBB2 over exp,predicted â€“ sensitive,808,MGAH22,2064,None,,,
254,Preclinical,"In a preclinical study, BMS-690514 inhibited tumor growth in a gastric cancer xenograft model with ERBB2 (HER2) amplification and overexpression (PMID: 21531814).",Actionable,2920,10534,stomach cancer,DOID,1270,ERBB2 over exp,sensitive,685,BMS-690514,2064,21531814,,,
255,Preclinical - Cell line xenograft,"In a preclinical study, Varlitinib (ARRY-334543) resulted in a 74%  tumor growth inhibition and tumor regression in 88% (7/8) of human cell line xenograft models of gastric cancer overexpressing ERBB2 (HER2) (Cancer Res January 15, 2009 69; 2150). ",Actionable,2903,10534,stomach cancer,DOID,1270,ERBB2 over exp,sensitive,1057,varlitinib,2064,None,,,
256,Phase I,"In a Phase I trial, Margetuximab (MGAH22) treatment resulted in partial responses in 12% (7/60) and stable disease in 50% (30/60) of patients with ERBB2 (HER2)-positive breast or gastric cancer, or other carcinomas that overexpress Erbb2 (Her2) (PMID: 28119295).",Actionable,10447,305,carcinoma,DOID,1270,ERBB2 over exp,predicted â€“ sensitive,808,MGAH22,2064,28119295,,,
257,Preclinical - Cell line xenograft,"In a preclinical study, AV-412 inhibited growth of ERBB2 (HER2)-over expressing breast cancer cell lines in culture, and inhibited tumor growth in a ERBB2 (HER2)-over expressing breast cancer cell line xenograft model (PMID: 17888033).",Actionable,1381,1612,breast cancer,DOID,1270,ERBB2 over exp,sensitive,990,AV-412,2064,17888033,,,
258,Phase I,"In a Phase I clinical trial, a breast cancer patient with ERBB2 (HER2) over expression that had progressed on Herceptin (trastuzumab) demonstrated stable disease for more than 12 weeks following treatment with CUDC-101 (PMID: 25107918). ",Actionable,2832,60079,Her2-receptor positive breast cancer,DOID,1270,ERBB2 over exp,sensitive,1005,CUDC-101,2064,25107918,,,
259,Preclinical,"In a preclinical study, ERBB2 (HER2) over expressing gastric cancer xenograft models demonstrated anti-tumor activity when treated with MM-302 (Cancer Res December 15, 2010 70; P3-14-09).",Actionable,2929,10534,stomach cancer,DOID,1270,ERBB2 over exp,predicted â€“ sensitive,1401,MM-302,2064,None,,,
260,Preclinical,"In a preclinical study, PF-05280014 inhibited growth of ERBB2 (HER2)-over expressing breast cancer cells with activity comparable to Herceptin (trastuzumab) in culture (PMID: 25001079).",Actionable,4620,60079,Her2-receptor positive breast cancer,DOID,1270,ERBB2 over exp,sensitive,3554,PF-05280014,2064,25001079,,,
261,Preclinical - Cell line xenograft,"In a preclinical study, TAK-285 inhibited growth of breast cancer cell line harboring ERBB2 (HER2) over expression in culture and in cell line xenograft models (PMID: 23983820).",Actionable,7848,60079,Her2-receptor positive breast cancer,DOID,1270,ERBB2 over exp,sensitive,2135,TAK-285,2064,23983820,,,
262,Phase I,"In a Phase I trial, treatment with ERBB2 (HER2)-specific CAR-T cells demonstrated safety and preliminary activity in patients with biliary tract or pancreatic carcinoma with ERBB2 (HER2) over expression, resulting in partial response in one of 11 patients and stable disease in 5, and a median progression free survival of 4.8 months (PMID: 28710747; NCT01935843).",Actionable,11504,4905,pancreatic carcinoma,DOID,1270,ERBB2 over exp,predicted â€“ sensitive,6007,HER2 CAR-T cells,2064,28710747,,,
263,Preclinical - Cell line xenograft,"In a preclinical study, Varlitinib (ARRY-334543), in combination with Herceptin (trastuzumab), resulted in a 91% tumor growth inhibition and tumor regression in human cell line xenograft models of gastric cancer overexpressing ERBB2 (HER2) (Cancer Res January 15, 2009 69; 2150).  ",Actionable,2852,10534,stomach cancer,DOID,1270,ERBB2 over exp,sensitive,3034,trastuzumab + varlitinib,2064,None,,,
264,Preclinical,"In a preclinical study, NAX014 induced cellular senescence, prevented tumor growth, and decreased tumor volume in a Her2 positive breast cancer mouse model (PMID: 26168818). ",Actionable,2647,60079,Her2-receptor positive breast cancer,DOID,1270,ERBB2 over exp,sensitive,2984,NAX014,2064,26168818,,,
265,Phase I,"In a Phase I trial, treatment with ERBB2 (HER2)-specific CAR-T cells demonstrated safety and preliminary activity in patients with biliary tract or pancreatic carcinoma with ERBB2 (HER2) over expression, resulting in partial response in one of 11 patients and stable disease in 5, and a median progression free survival of 4.8 months (PMID: 28710747; NCT01935843).",Actionable,11503,4607,biliary tract cancer,DOID,1270,ERBB2 over exp,predicted â€“ sensitive,6007,HER2 CAR-T cells,2064,28710747,,,
266,Preclinical,"In a preclinical study, KU004 inhibited growth and induced apoptosis in gastric cancer cell lines over expressing ERBB2 in culture and suppressed growth in a dose dependent manner in xenograft models (PMID: 26437915).",Actionable,3566,10534,stomach cancer,DOID,1270,ERBB2 over exp,sensitive,3157,KU004,2064,26437915,,,
267,Phase II,"In a Phase II trial, Dacomitinib resulted in a 7.4% (2/27) response rate and 40.7% (11/27) disease control rate when treating advanced gastric cancer patients with ERBB2 (HER2) over expression (J Clin Oncol 30, 2012 (suppl 4; abstr 54)).",Actionable,2917,10534,stomach cancer,DOID,1270,ERBB2 over exp,sensitive,714,Dacomitinib,2064,None,,,
268,Preclinical,"In a preclinical study, ERBB2 (HER2) over expressing gastric cancer cells were sensitive to Dacomitinib, resulting in inhibition of ERBB2 (HER2)/ERBB3 (HER3) heterodimers (PMID: 22135232).",Actionable,2934,10534,stomach cancer,DOID,1270,ERBB2 over exp,sensitive,714,Dacomitinib,2064,22135232,,,
269,Preclinical - Cell line xenograft,"In a preclinical study, ERBB2 (HER2) over expression was associated with resistance to Erbitux (cetuximab) treatment in a human cell line xenograft model of colorectal cancer (PMID: 26296355).",Actionable,11355,9256,colorectal cancer,DOID,1270,ERBB2 over exp,resistant,694,Cetuximab,2064,26296355,,,
270,Preclinical - Cell line xenograft,"In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited tumor growth in human cell line xenograft models of gastric cancer with ERBB2 (HER2) amplification and over expression (PMID: 21458915).",Actionable,2927,10534,stomach cancer,DOID,1270,ERBB2 over exp,sensitive,1402,trastuzumab emtansine,2064,21458915,,,
271,Preclinical,"In a preclinical study, the N87 gastric cancer cell line, which has been demonstrated to have ERBB2 (HER2) amplification and over expression, was sensitive to TAK-285, inhibiting phosphorylation of ERBB2 (HER2) and ERBB3 (HER3) (PMID: 25594012, PMID: 18441328).",Actionable,2977,10534,stomach cancer,DOID,1270,ERBB2 over exp,sensitive,2135,TAK-285,2064,18441328,25594012,,
272,Preclinical - Cell line xenograft,"In a preclinical study, TAK-285 inhibited tumor growth in gastric cancer cell line xenograft models over expressing ERBB2 (HER2)  (PMID: 23983820).",Actionable,2905,10534,stomach cancer,DOID,1270,ERBB2 over exp,sensitive,2135,TAK-285,2064,23983820,,,
273,Preclinical - Cell line xenograft,"In a preclinical study, combination of MM-302 and Herceptin (trastuzumab) resulted in improved tumor growth inhibition in cell line xenograft models of Erbb2 (Her2)-over expressing gastric cancer (PMID: 26759238).",Actionable,10878,10534,stomach cancer,DOID,1270,ERBB2 over exp,sensitive,1888,MM-302 + Trastuzumab,2064,26759238,,,
274,Preclinical - Cell line xenograft,"In a preclinical study, ERBB2 (HER2)-specific CAR-T cells induced cell death in ERBB2 (HER2)-over expressing gastric cancer cell lines in culture, and inhibited tumor growth and improved survival in a ERBB2 (HER2)-over expressing gastric cancer cell line xenograft model (PMID: 28284008).",Actionable,11506,10534,stomach cancer,DOID,1270,ERBB2 over exp,sensitive,6007,HER2 CAR-T cells,2064,28284008,,,
275,Preclinical,"In a preclinical study, Tykerb (lapatinib) inhibited growth of HER2-amplified and HER2-over expressing gastric cancer cell lines in culture (PMID: 18774637).",Actionable,2911,10534,stomach cancer,DOID,1270,ERBB2 over exp,sensitive,787,Lapatinib,2064,18774637,,,
276,Phase I,"In a Phase I trial, S-222611 resulted in a complete response in a gastric-esophageal junction cancer patient overexpressing ERBB2 (HER2) and a partial response in a gastric cancer patient also overexpressing ERBB2 (HER2) (J Clin Oncol 33, 2015 (suppl; abstr 2511)).",Actionable,2846,10534,stomach cancer,DOID,1270,ERBB2 over exp,sensitive,1048,S-222611,2064,None,,,
277,Preclinical,"In a preclinical study, over expression of Erbb2 (Her2) in lung adenocarcinoma cells harboring EGFR T790M resulted in resistance to Tagrisso (osimertinib) in culture, consistent with ERBB2 (HER2) amplification identified in tumor samples of lung adenocarcinoma patients harboring EGFR T790M that developed resistance to Tagrisso (osimertinib) (PMID: 27252416).",Actionable,8799,3910,lung adenocarcinoma,DOID,26436,EGFR T790M ERBB2 over exp,resistant,660,Osimertinib,2064,27252416,,,
278,Preclinical,"In a preclinical study, over expression of Erbb2 (Her2) in lung adenocarcinoma cells harboring EGFR T790M resulted in resistance to Rociletinib (CO-1686) in culture, consistent with ERBB2 (HER2) amplification identified in tumor samples of lung adenocarcinoma patients harboring EGFR T790M that developed resistance to Rociletinib (CO-1686) (PMID: 27252416).",Actionable,8800,3910,lung adenocarcinoma,DOID,26436,EGFR T790M ERBB2 over exp,resistant,1003,CO1686,2064,27252416,,,
279,Preclinical,"In a preclinical study, the combination of Herceptin (trastuzumab) and Buparlisib (BKM120) inhibited tumor growth in mouse ERBB2 (HER2)-over expressing breast cancer models expressing PIK3CA H1047R, with moderate efficacy over Buparlisib (BKM120) alone (PMID: 23940356).",Actionable,968,60079,Her2-receptor positive breast cancer,DOID,1575,ERBB2 over exp PIK3CA H1047R,sensitive,1417,BKM120 + Trastuzumab,2064,23940356,,,
280,Preclinical,"In a preclinical study, mouse breast cancer models over expressing ERBB2 (HER2) and expressing PIK3CA H1047R were resistant to Herceptin (trastuzumab) (PMID: 23940356).",Actionable,966,60079,Her2-receptor positive breast cancer,DOID,1575,ERBB2 over exp PIK3CA H1047R,resistant,947,Trastuzumab,2064,23940356,,,
281,Preclinical,"In a preclinical study, treatment with Buparlisib (BKM120) resulted in decreased tumor growth, but not tumor regression, in mouse models of ERBB2 (HER2)-over expressing breast cancer expressing PIK3CA H1047R (PMID: 23940356).",Actionable,967,60079,Her2-receptor positive breast cancer,DOID,1575,ERBB2 over exp PIK3CA H1047R,sensitive,1178,BKM120 + Bevacizumab,2064,23940356,,,
282,Preclinical,"In a preclinical study, a mouse breast cancer model with mammary ERBB2 (HER2) over-expression that also expressed the PIK3CA H1047R mutation showed resistance to the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) (PMID: 23940356).",Actionable,969,60079,Her2-receptor positive breast cancer,DOID,1575,ERBB2 over exp PIK3CA H1047R,resistant,1414,Trastuzumab + Lapatinib,2064,23940356,,,
283,Preclinical,"In a preclinical study, the combination of Buparlisib (BKM120), Herceptin (trastuzumab), and Tykerb (lapatinib) inhibited tumor growth in mouse models of ERBB2 (HER2)-over expressing breast cancer expressing PIK3CA H1047R, but efficacy was not significantly improved over Buparlisib (BKM120) alone (PMID: 23940356). ",Actionable,972,60079,Her2-receptor positive breast cancer,DOID,1575,ERBB2 over exp PIK3CA H1047R,no benefit,1419,BKM120 + Trastuzumab + Lapatinib,2064,23940356,,,
284,Preclinical,"In a preclinical study, a mouse breast cancer model with ERBB2 (HER2) over-expression that also expressed the PIK3CA H1047R mutation showed resistance to the combination of Heceptin (trastuzumab) and Perjeta (pertuzumab) (PMID: 23940356).",Actionable,970,60079,Her2-receptor positive breast cancer,DOID,1575,ERBB2 over exp PIK3CA H1047R,resistant,1389,Trastuzumab + Pertuzumab,2064,23940356,,,
285,Preclinical,"In a preclinical study, the combination of Buparlisib (BKM120), Herceptin (trastuzumab), and Perjeta (pertuzumab) inhibited tumor growth in mouse models of ERBB2 (HER2)-over expressing breast cancer expressing PIK3CA H1047R, with improved efficacy over Buparlisib (BKM120) alone (PMID: 23940356).",Actionable,971,60079,Her2-receptor positive breast cancer,DOID,1575,ERBB2 over exp PIK3CA H1047R,sensitive,1418,BKM120 + Trastuzumab + Pertuzumab,2064,23940356,,,
286,Preclinical - Pdx,"In a preclinical study, treatment with Tykerb (lapatinib) was not effective in inhibiting tumor growth in a patient-derived xenograft model of bladder cancer with ERBB2 (HER2) over expression, which also over expressed SRC and harbored PIK3CA H1047R (PMID: 26270481).",Actionable,7456,11054,urinary bladder cancer,DOID,25513,ERBB2 over exp PIK3CA H1047R SRC over exp,no benefit,787,Lapatinib,2064,26270481,,,
287,Preclinical - Pdx,"In a preclinical study, treatment with Iclusig (ponatinib) was not effective in inhibiting tumor growth in a patient-derived xenograft model of bladder cancer with SRC over expression, which also over expressed ERBB2 (HER2) and harbored PIK3CA H1047R (PMID: 26270481).",Actionable,7457,11054,urinary bladder cancer,DOID,25513,ERBB2 over exp PIK3CA H1047R SRC over exp,no benefit,877,Ponatinib,2064,26270481,,,
288,Preclinical - Cell line xenograft,"In a preclinical study, PKI-179 inhibited growth of breast cancer cells harboring PIK3CA mutations and ERBB2 (HER2) over expression in culture and cell line xenograft models (PMID: 20797855).",Actionable,2737,60079,Her2-receptor positive breast cancer,DOID,26179,ERBB2 over exp PIK3CA mut,sensitive,872,PKI-179,2064,20797855,,,
289,Preclinical - Cell line xenograft,"In a preclinical study, a breast cancer xenograft model with ERBB2 (HER2) over expression and harboring a PIK3CA mutation was sensitive to the combination treatment of ARQ092 and Herceptin (trastuzumab), demonstrating greater inhibition of tumor growth when compared to treatment with either agent alone (PMID: 26469692). ",Actionable,10286,1612,breast cancer,DOID,26179,ERBB2 over exp PIK3CA mut,sensitive,5454,ARQ092 + Trastuzumab,2064,26469692,,,
290,Preclinical - Cell line xenograft,"In a preclinical study, a breast cancer xenograft model with ERBB2 (HER2) over expression and harboring a PIK3CA mutation was sensitive to the combination treatment of ARQ092 and Taxol (paclitaxel), demonstrating greater inhibition of tumor growth when compared to treatment with either agent alone (PMID: 26469692). ",Actionable,10287,1612,breast cancer,DOID,26179,ERBB2 over exp PIK3CA mut,sensitive,5455,ARQ092 + Paclitaxel,2064,26469692,,,
291,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) G660D in culture (PMID: 26545934).",Actionable,6972,1324,lung cancer,DOID,24165,ERBB2 G660D,sensitive,623,Afatinib,2064,26545934,,,
292,Preclinical,"In a preclinical study, bronchial epithelial cells cells expressing ERBB2 (HER2) G660D did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934).",Actionable,6970,1324,lung cancer,DOID,24165,ERBB2 G660D,no benefit,751,Gefitinib,2064,26545934,,,
293,Preclinical,"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) S783P in culture (PMID: 18413839).",Actionable,7322,10000003,Advanced Solid Tumor,JAX,24612,ERBB2 S783P,sensitive,967,XL647,2064,18413839,,,
294,Preclinical,"In a preclinical study, transformed cells over expressing ERBB2 (HER2) S783P were resistant to Tykerb (lapatinib) in culture (PMID: 18413839).",Actionable,7309,10000003,Advanced Solid Tumor,JAX,24612,ERBB2 S783P,resistant,787,Lapatinib,2064,18413839,,,
295,Clinical Study,"In a clinical study, targeted therapy with Gilotrif (afatinib) or Herceptin (trastuzumab) resulted in an objective response rate of 44% (4/9) in non-small cell lung carcinoma patients harboring ERBB2 (HER2) mutations that progressed during previous therapies, all four responders harbored ERBB2 (HER2) exon 20 insertions (PMID: 28167203). ",Actionable,10132,3908,non-small cell lung carcinoma,DOID,22000,ERBB2 exon 20 ins,predicted â€“ sensitive,623,Afatinib,2064,28167203,,,
296,Clinical Study,"In a clinical study, targeted therapy with Gilotrif (afatinib) or Herceptin (trastuzumab) resulted in an objective response rate of 44% (4/9) in non-small cell lung carcinoma patients harboring ERBB2 (HER2) mutations that progressed during previous therapies, all four responders harbored ERBB2 (HER2) exon 20 insertions (PMID: 28167203). ",Actionable,10133,3908,non-small cell lung carcinoma,DOID,22000,ERBB2 exon 20 ins,predicted â€“ sensitive,947,Trastuzumab,2064,28167203,,,
297,Preclinical - Pdx & cell culture,"In a preclinical study, AP32788 inhibited growth of transformed cell lines over expressing ERBB2 (HER2) exon 20 insertions in culture, and induced tumor regression in PDX models (AACR, Cancer Res: April 2016; Volume 57, Abstract #2644).",Actionable,5916,10000003,Advanced Solid Tumor,JAX,22000,ERBB2 exon 20 ins,sensitive,3981,AP32788,2064,None,,,
298,Clinical Study,"In a clinical study, treatment with pulse Gilotrif (afatinib) resulted in an objective response rate of 33.3% (1/3) in lung adenocarcinoma patients with ERBB2 (HER2) exon 20 insertion mutations (PMID: 26964772).",Actionable,7399,3910,lung adenocarcinoma,DOID,22000,ERBB2 exon 20 ins,predicted â€“ sensitive,623,Afatinib,2064,26964772,,,
299,Preclinical,"In a preclinical study, transformed cells over expressing ERBB2 (HER2) T798I were resistant to Tykerb (lapatinib) in culture (PMID: 25238247).",Actionable,7330,10000003,Advanced Solid Tumor,JAX,24613,ERBB2 T798I,resistant,787,Lapatinib,2064,25238247,,,
300,Preclinical,"In a preclinical study, transformed lung cancer cells over expressing ERBB2 (HER2) T798I were resistant to Tykerb (lapatinib) in culture (PMID: 25238247).",Actionable,7333,1324,lung cancer,DOID,24613,ERBB2 T798I,resistant,787,Lapatinib,2064,25238247,,,
301,Preclinical,"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) T798I in culture (PMID: 18413839).",Actionable,7324,10000003,Advanced Solid Tumor,JAX,24613,ERBB2 T798I,sensitive,967,XL647,2064,18413839,,,
302,Preclinical,"In a preclinical study, AZD8055 inhibited tumor growth in a mouse model of spontaneous breast cancer harboring an ERBB2 (HER2) activating mutation and loss of STK11 (LKB1), which was enhanced by the addition of 2-DG (2-deoxyglucose) (PMID: 25436981).",Actionable,5405,1612,breast cancer,DOID,20860,ERBB2 act mut STK11 loss,sensitive,1519,AZD8055,2064,25436981,,,
303,Preclinical,"In a preclinical study, breast cancer cells with mutations in both ERBB2 (HER2) and PIK3CA were more sensitive to VS-5584 (PMID: 23270925). ",Actionable,2894,1612,breast cancer,DOID,10726,PIK3CA act mut ERBB2 act mut,sensitive,960,VS-5584,2064,23270925,,,
304,Preclinical,"In a preclinical study, transformed cells expressing ERBB2 (HER2) activation loop mutations demonstrated sensitivity to AEE788 in culture (PMID: 22046346).",Actionable,2890,10000003,Advanced Solid Tumor,JAX,1243,ERBB2 act mut,sensitive,622,AEE788,2064,22046346,,,
305,Phase I,"In a Phase I trial, Vistusertib (AZD2014) demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including a patient with ER-positive breast cancer harboring an ERBB2 activating mutation (PMID: 25805799). ",Actionable,4390,60075,estrogen-receptor positive breast cancer,DOID,1243,ERBB2 act mut,predicted â€“ sensitive,991,Vistusertib,2064,25805799,,,
306,Phase II,"In a Phase II clinical trial, Nerlynx (neratinib) treatment resulted in clinical benefit in 36% (5/14) of metastatic breast cancer patients harboring ERBB2 (HER2) activating mutations, with 1 complete response, 1 partial response, and 2 patients achieving stable disease for greater than 6 months, and a median progression-free survival of 5 months (J Clin Oncol 34, 2016 (suppl; abstr 516)).",Actionable,7046,1612,breast cancer,DOID,1243,ERBB2 act mut,sensitive,828,Neratinib,2064,None,,,
307,Preclinical - Cell culture,"In a preclinical study, AP32788 inhibited growth of transformed cell lines over expressing ERBB2 (HER2) G776V in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2644).",Actionable,5919,10000003,Advanced Solid Tumor,JAX,3960,ERBB2 G776V,sensitive,3981,AP32788,2064,None,,,
308,Preclinical,"In a preclinical study, AEE788 inhibited proliferation of transformed cell lines expressing wild-type ERBB2 (HER2) in culture (PMID: 22046346).",Actionable,3045,10000003,Advanced Solid Tumor,JAX,530,ERBB2 wild-type,sensitive,622,AEE788,2064,22046346,,,
309,Preclinical,"In a preclinical study, Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing wild-type ERBB2 (HER2) in culture (PMID: 22046346).",Actionable,3044,10000003,Advanced Solid Tumor,JAX,530,ERBB2 wild-type,sensitive,787,Lapatinib,2064,22046346,,,
310,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 R896C reverted to normal morphology in culture upon Tykerb (lapatinib) treatment (PMID: 23220880).",Actionable,2043,1612,breast cancer,DOID,3283,ERBB2 R896C,sensitive,787,Lapatinib,2064,23220880,,,
311,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 R896C reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880).",Actionable,2045,1612,breast cancer,DOID,3283,ERBB2 R896C,sensitive,947,Trastuzumab,2064,23220880,,,
312,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) R896C reverted to normal morphology in culture upon Nerlynx (neratinib) treatment (PMID: 23220880).",Actionable,2044,1612,breast cancer,DOID,3283,ERBB2 R896C,sensitive,828,Neratinib,2064,23220880,,,
313,Phase III,"In a Phase III trial, addition of Onartuzumab to mFOLFOX6 did not improve clinical outcome compared to mFOLFOX6 alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4012)).",Actionable,8746,3717,gastric adenocarcinoma,DOID,26426,ERBB2 neg MET pos,no benefit,838,Onartuzumab,2064,None,,,
314,Phase III,"In a Phase III trial, addition of Onartuzumab to the mFOLFOX6 chemotherapy did not improve overall survival (HR=0.82, p=0.24), progression free survival (HR=0.90, p=0.43), or objective response rate (46.1% vs 40.6%) compared to placebo in patients with Erbb2 (Her2)-negative, Met-positive gastroesophageal adenocarcinoma (PMID: 27918764).",Actionable,10905,4914,esophagus adenocarcinoma,DOID,26426,ERBB2 neg MET pos,no benefit,5676,Onartuzumab + mFOLFOX6,2064,27918764,,,
315,Phase III,"In a Phase III trial, addition of Onartuzumab to the mFOLFOX6 chemotherapy did not improve overall survival (HR=0.82, p=0.24), progression free survival (HR=0.90, p=0.43), or objective response rate (46.1% vs 40.6%) compared to placebo in patients with Erbb2 (Her2)-negative, Met-positive gastroesophageal adenocarcinoma (PMID: 27918764).",Actionable,10904,3717,gastric adenocarcinoma,DOID,26426,ERBB2 neg MET pos,no benefit,5676,Onartuzumab + mFOLFOX6,2064,27918764,,,
316,Phase III,"In a Phase III trial, addition of Onartuzumab to mFOLFOX6 did not improve clinical outcome compared to mFOLFOX6 alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4012)).",Actionable,8747,4944,gastroesophageal junction adenocarcinoma,DOID,26426,ERBB2 neg MET pos,no benefit,838,Onartuzumab,2064,None,,,
317,Phase III,"In a Phase III trial, addition of Rilotumumab to chemotherapy consisted of epirubicin, cisplatin and capecitabine (ECX) resulted in statistically significantly worse overall survival (9.6 vs 11.5 months) compared to ECX alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4000)).",Actionable,8744,4944,gastroesophageal junction adenocarcinoma,DOID,26426,ERBB2 neg MET pos,no benefit,629,AMG102,2064,None,,,
318,Phase III,"In a Phase III trial, addition of Rilotumumab to chemotherapy consisted of epirubicin, cisplatin and capecitabine (ECX) resulted in statistically significantly worse overall survival (9.6 vs 11.5 months) compared to ECX alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4000)).",Actionable,8745,3717,gastric adenocarcinoma,DOID,26426,ERBB2 neg MET pos,no benefit,629,AMG102,2064,None,,,
319,Phase III,"In a Phase III trial, Cyramze (ramucirumab) in combination with Taxotere (docetaxel) did not improve clinical outcomes in ERBB2 (HER2)-negative breast cancer patients (PMID: 25185099).",Actionable,1065,60080,Her2-receptor negative breast cancer,DOID,1184,ERBB2 neg,no benefit,1423,Ramucirumab + Docetaxel,2064,25185099,,,
320,Phase Ib/II,"In a Phase I/II trial, combination of Navelbine (vinorelbine) and Nexavar (sorafenib) resulted in a response rate of 30% (8/27), median progression free survival of 5.7 months, and a clinical benefit rate (absence of disease progression at 6 months) of 48% (13/27) in patients with ERBB2 (HER2)-negative metastatic breast cancer (PMID: 27992451).",Actionable,10434,60080,Her2-receptor negative breast cancer,DOID,1184,ERBB2 neg,predicted â€“ sensitive,2357,Sorafenib + Vinorelbine,2064,27992451,,,
321,Phase II,"In a Phase II trial, Seribantumab (MM-12) and Aromasin (exemestane) combination treatment resulted in a 74% decrease in risk of progression (HR 0.26) and a a 59% decrease in risk of death (HR 0.436) compared to exemestane alone in ERBB2-negative, hormone receptor positive breast cancer patients (AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer, May 2016, Abstract # A14).",Actionable,6540,60080,Her2-receptor negative breast cancer,DOID,1184,ERBB2 neg,predicted â€“ sensitive,4141,Exemestane + Seribantumab,2064,None,,,
322,Phase III,"In a Phase III trial, Lynparza (olaparib) treatment resulted in improved progression free survival (7.0 vs 4.2 months) and objective response rate (59.9%, 123/205 vs 28.8%, 26/288) compared to single agent chemotherapy in patients with Erbb2 (Her2)-negative breast cancer that also harbored germline BRCA mutations (J Clin Oncol 35, 2017 (suppl; abstr LBA4)).",Actionable,11131,60080,Her2-receptor negative breast cancer,DOID,27913,BRCA1 mut ERBB2 neg,predicted â€“ sensitive,837,Olaparib,2064,None,,,
323,Phase III,"In a Phase III trial, Lynparza (olaparib) treatment resulted in improved progression free survival (7.0 vs 4.2 months) and objective response rate (59.9%, 123/205 vs 28.8%, 26/288) compared to single agent chemotherapy in patients with Erbb2 (Her2)-negative breast cancer that also harbored germline BRCA mutations (J Clin Oncol 35, 2017 (suppl; abstr LBA4)).",Actionable,11132,60080,Her2-receptor negative breast cancer,DOID,27914,BRCA2 mut ERBB2 neg,predicted â€“ sensitive,837,Olaparib,2064,None,,,
324,Preclinical - Cell culture,"In a preclinical study, the combination of AZD-4547 and Tykerb (lapatinib) worked synergistically to inhibit growth of an esophageal adenocarcinoma cell line with ERBB2 (HER2) and FGFR2 amplification in culture (PMID: 27595477).",Actionable,11556,4914,esophagus adenocarcinoma,DOID,28144,ERBB2 amp FGFR2 amp,sensitive,6062,AZD4547 + Lapatinib,2064,27595477,,,
325,Preclinical - Cell line xenograft,"In a preclinical study, CH5132799 inhibited cell growth and Akt phosphorylation, and promoted apoptosis in a human breast cancer cell line harboring PIK3CA K111N and ERBB2 (HER2) amplification, and inhibited tumor growth in xenograft models (PMID: 21558396).",Actionable,2969,1612,breast cancer,DOID,10753,ERBB2 amp PIK3CA K111N,sensitive,2152,CH5132799,2064,21558396,,,
326,Preclinical,"In a preclinical study, knockdown of PTEN expression resulted in a decreased response to treatment with CDX-3379 (KTN3379) in ERBB2 (HER2)-amplified breast cancer cells in culture (PMID: 26880266).",Actionable,6465,60079,Her2-receptor positive breast cancer,DOID,23519,ERBB2 amp PTEN dec exp,decreased response,2054,CDX-3379,2064,26880266,,,
327,Preclinical,"In a preclinical study, CH5132799 inhibited proliferation of a breast cancer cell line harboring PIK3CA N345K and ERBB2 (HER2) amplification in culture (PMID: 21558396).",Actionable,2952,1612,breast cancer,DOID,10739,ERBB2 amp PIK3CA N345K,sensitive,2152,CH5132799,2064,21558396,,,
328,Preclinical,"In a preclinical study, colorectal cancer tumorgrafts with ERBB2 (HER2) amplification demonstrated resistance to Herceptin (trastuzumab) treatment in animal models (PMID: 26296355).",Actionable,3162,9256,colorectal cancer,DOID,531,ERBB2 amp,resistant,947,Trastuzumab,2064,26296355,,,
329,Preclinical,"In a preclinical study, SYD895 induced cell death in ERBB2 (HER2)-amplified primary uterine serous carcinoma (USC) cell lines in culture and inhibited tumor growth and improved survival in ERBB2 (HER2)-amplified USC primary cell line xenografts (PMID: 27256376).",Actionable,7644,5750,uterine corpus serous adenocarcinoma,DOID,531,ERBB2 amp,sensitive,4539,SYD985,2064,27256376,,,
330,Phase III,"In a Phase III clinical trial, the addition of Tykerb (lapatinib) to Xeloda (capecitabine) and Eloxatin (oxaliplatin) combination treatment did not significantly prolong overall survival compared to placebo, but did improve progression-free survival and response rate in gastric adenocarcinoma patients harboring ERBB2 amplification (PMID: 26628478).",Actionable,3800,3717,gastric adenocarcinoma,DOID,531,ERBB2 amp,no benefit,787,Lapatinib,2064,26628478,,,
331,Phase II,"In a Phase II clinical trial, patients with ERBB2 (HER2) amplified urothelial carcinoma had improved progression free survival when treated with Gilotrif (afatinib), and median PFS was 6.6 months for patients with ERBB2 or ERBB3 alterations relative to 1.4 months for patients lacking alterations (PMID: 27044931).",Actionable,5940,11054,urinary bladder cancer,DOID,531,ERBB2 amp,sensitive,623,Afatinib,2064,27044931,,,
332,Preclinical - Pdx,"In a preclinical study, Perjeta (pertuzumab) did not inhibit tumor growth in patient-derived xenograft (PDX) models of ERBB2 (HER2)-amplified colorectal cancer (PMID: 22586653).",Actionable,11360,9256,colorectal cancer,DOID,531,ERBB2 amp,no benefit,856,Pertuzumab,2064,22586653,,,
333,Preclinical,"In a preclinical study, the combination of Herceptin (trastuzumab) and CDX-3379 (KTN3379) inhibited tumor growth in xenograft models of ERBB2 (HER2)-amplified breast cancer, with increased efficacy compared to KTN3379 alone (PMID: 26880266).",Actionable,6443,60079,Her2-receptor positive breast cancer,DOID,531,ERBB2 amp,sensitive,2064,CDX-3379 + Trastuzumab,2064,26880266,,,
334,Preclinical - Cell culture,"In a preclinical study, MK-2206 and KRIBB11 synergistically inhibited growth of ERBB2 (HER2)-amplified breast cancer cell lines in culture (PMID: 28598816).",Actionable,11548,60079,Her2-receptor positive breast cancer,DOID,531,ERBB2 amp,predicted â€“ sensitive,6057,KRIBB11 + MK2206,2064,28598816,,,
335,Phase II,"In a Phase II trial, Gilotrif (afatinib), demonstrated safety and efficacy in various advanced solid tumor patients with ERBB2 (HER2) amplification (PMID: 23775486).",Actionable,903,10000003,Advanced Solid Tumor,JAX,531,ERBB2 amp,sensitive,623,Afatinib,2064,23775486,,,
336,Preclinical,"In a preclinical study, Poziotinib suppressed cell growth, decreased phosphorylation of downstream signaling molecules, and induced apoptosis of human gastric cancer cells harboring ERBB2 (HER2) amplification (PMID: 21306821). ",Actionable,2918,10534,stomach cancer,DOID,531,ERBB2 amp,sensitive,1042,poziotinib,2064,21306821,,,
337,Preclinical - Pdx,"In a preclinical study, treatment with Tykerb (lapatinib) resulted in initial disease stabilization with subsequent progression, in patient-derived colorectal cancer tumorgraft models with ERBB2 (HER2) amplification (PMID: 26296355).",Actionable,3164,9256,colorectal cancer,DOID,531,ERBB2 amp,decreased response,787,Lapatinib,2064,26296355,,,
338,Preclinical - Cell culture,"In a preclinical study, ERBB2 (HER2) amplified breast cancer cells treated with Tykerb (lapatinib) demonstrated decreased phosphorylation of Erbb2 (her2) and Akt, however, after 4-8 hours, Akt-driven Rictor showed upregulation, thereby resulting in a decreased treatment response (PMID: 27197158). ",Actionable,7814,1612,breast cancer,DOID,531,ERBB2 amp,decreased response,787,Lapatinib,2064,27197158,,,
339,Phase III,"In a Phase III clinical trial, the addition of Tykerb (lapatinib) to Xeloda (capecitabine) and Eloxatin (oxaliplatin) combination treatment did not significantly prolong overall survival compared to placebo, but did improve progression-free survival and response rate in gastroesophageal junction adenocarcinoma patients harboring ERBB2 amplification (PMID: 26628478).",Actionable,3802,4944,gastroesophageal junction adenocarcinoma,DOID,531,ERBB2 amp,no benefit,787,Lapatinib,2064,26628478,,,
340,Preclinical - Cell line xenograft,"In a preclinical study, breast cancer cell line xenograft models harboring ERBB2 (HER2) amplification were sensitive to the combination of Perjeta (pertuzumab) and Nerlynx (neratinib), resulting in a delay of brain lesion growth and improved survival (PMID: 28539475).",Actionable,11528,1612,breast cancer,DOID,531,ERBB2 amp,sensitive,6013,Neratinib + Pertuzumab,2064,28539475,,,
341,Preclinical - Cell line xenograft,"In a preclinical study, Herceptin (trastuzumab) inhibited tumor growth in human cell line xenograft models of gastric cancer with ERBB2 (HER2) amplification (PMID: 26296355).",Actionable,3163,10534,stomach cancer,DOID,531,ERBB2 amp,sensitive,947,Trastuzumab,2064,26296355,,,
342,Preclinical,"In a preclinical study, a lung squamous cell carcinoma cell line with ERBB2 (HER2) amplification demonstrated resistance to treatment with Iressa (gefitinib) in culture (PMID: 26545934).",Actionable,6962,3907,lung squamous cell carcinoma,DOID,531,ERBB2 amp,resistant,751,Gefitinib,2064,26545934,,,
343,Preclinical - Cell line xenograft,"In a preclinical study, breast cancer cell line xenograft models harboring ERBB2 (HER2) amplification were sensitive to the combination of Herceptin (trastuzumab) and LJM716, resulting in a delay of brain lesion growth and improved survival (PMID: 28539475).  ",Actionable,11525,1612,breast cancer,DOID,531,ERBB2 amp,sensitive,2037,LJM716 + Trastuzumab,2064,28539475,,,
344,Clinical Study,"In a clinical study, ERBB2 (HER2) amplification was associated with resistance to Erbitux (cetuximab) in colorectal cancer patients (PMID: 21900593).",Actionable,11354,9256,colorectal cancer,DOID,531,ERBB2 amp,resistant,694,Cetuximab,2064,21900593,,,
345,Preclinical - Cell culture,"In a preclinical study, a uterine serous carcinoma cell line harboring ERBB2 (HER2) amplification demonstrated sensitivity to treatment with Taselisib (GDC-0032) in culture, resulting in inhibition of cell growth (PMID: 26333383). ",Actionable,9061,5750,uterine corpus serous adenocarcinoma,DOID,531,ERBB2 amp,sensitive,1016,GDC-0032,2064,26333383,,,
346,Preclinical,"In preclinical studies, Tykerb (lapatinib) demonstrated antiproliferative activity in HER2-amplified gastric cancer in cell assays and in xenograft models (PMID: 20179222).",Actionable,926,10534,stomach cancer,DOID,531,ERBB2 amp,sensitive,787,Lapatinib,2064,20179222,,,
347,Clinical Study,"In a clinical case study, a patient with metastatic colorectal adenocarcinoma harboring ERBB2 (HER2) amplification demonstrated clinical benefit with stable disease in the primary tumor for 7 months following treatment with Kadcyla (trastuzumab emtansine) (PMID: 28040715).",Actionable,9714,50861,colorectal adenocarcinoma,DOID,531,ERBB2 amp,sensitive,1402,trastuzumab emtansine,2064,28040715,,,
348,Preclinical - Pdx,"In a preclinical study, the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) treatment induced tumor regression in patient-derived colorectal cancer tumorgraft models harboring ERBB2 (HER2) amplification (PMID: 26296355).",Actionable,3165,9256,colorectal cancer,DOID,531,ERBB2 amp,sensitive,1414,Trastuzumab + Lapatinib,2064,26296355,,,
349,Preclinical - Cell line xenograft,"In a preclinical study, breast cancer cell line xenograft models harboring ERBB2 (HER2) amplification were sensitive to the combination of Herceptin (trastuzumab) and Perjeta (pertuzumab), resulting in a delay of brain lesion growth and improved survival (PMID: 28539475).  ",Actionable,11526,1612,breast cancer,DOID,531,ERBB2 amp,sensitive,1389,Trastuzumab + Pertuzumab,2064,28539475,,,
350,Preclinical - Cell culture,"In a preclinical study, the combination of Taselisib (GDC-0032) and Nerlynx (neratinib) resulted in a synergistic effect, demonstrating greater cell growth inhibitory activity in uterine serous carcinoma cells harboring ERBB2 (HER2) amplification compared to either agent alone (PMID: 26333383). ",Actionable,9062,5750,uterine corpus serous adenocarcinoma,DOID,531,ERBB2 amp,sensitive,4871,GDC-0032 + Neratinib,2064,26333383,,,
351,Preclinical - Cell culture,"In a preclinical study, combination of S63845 and Tykerb (lapatinib) resulted in potent cytotoxic effects in ERBB2 (HER2)-amplified breast cancer cells in culture compared to the cytostatic effect of Tykerb (lapatinib) alone (PMID: 27760111).",Actionable,9037,1612,breast cancer,DOID,531,ERBB2 amp,sensitive,4859,Lapatinib + S63845,2064,27760111,,,
352,Preclinical - Cell culture,"In a preclinical study, ERBB2 (HER2) amplified breast cancer cells treated with Torkinib (PP242) demonstrated some efficacy in culture including reduced phosphorylation of S6 and Akt, apoptosis, and decreased cell growth (PMID: 27197158). ",Actionable,7821,1612,breast cancer,DOID,531,ERBB2 amp,sensitive,2240,Torkinib,2064,27197158,,,
353,Clinical Study,"In a clinical case study, a patient with duodenal adenocarcinoma harboring ERBB2 (HER2) amplification demonstrated a complete pathologic response after treatment with a combination of Herceptin (trastuzumab), Adrucil (fluorouracil), Wellcovorin (leucovorin), and Eloxatin (oxaliplatin) (PMID: 28784859).  ",Actionable,11715,10816,duodenum adenocarcinoma,DOID,531,ERBB2 amp,sensitive,3439,Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin,2064,28784859,,,
354,FDA approved,"In a Phase III clinical trial that supported FDA approval, gastric cancer patients with either ERBB2 (HER2) over expression or ERBB2 (HER2) amplification had increased overall survival when treated with Herceptin (trastuzumab), in combination with chemotherapy (PMID: 20728210).",Actionable,893,3717,gastric adenocarcinoma,DOID,531,ERBB2 amp,sensitive,947,Trastuzumab,2064,20728210,,,
355,Preclinical - Cell culture,"In a preclinical study, a uterine serous carcinoma cell line harboring ERBB2 (HER2) amplification demonstrated sensitivity to treatment with Nerlynx (neratinib) in culture, resulting in inhibition of cell growth (PMID: 26333383). ",Actionable,9059,5750,uterine corpus serous adenocarcinoma,DOID,531,ERBB2 amp,sensitive,828,Neratinib,2064,26333383,,,
356,Preclinical,"In a preclinical study, the combination of Ibrance (palbociclib) and Herceptin (trastuzumab) worked synergistically to inhibit growth of ERBB2 (HER2)-amplified breast cancer cells in culture (PMID: 19874578).",Actionable,2978,60079,Her2-receptor positive breast cancer,DOID,531,ERBB2 amp,sensitive,3041,Palbociclib + Trastuzumab,2064,19874578,,,
357,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited proliferation of breast cancer cell lines with ERBB2 (HER2) amplification in culture (PMID: 26545934).",Actionable,6947,1612,breast cancer,DOID,531,ERBB2 amp,sensitive,623,Afatinib,2064,26545934,,,
358,Preclinical - Cell line xenograft,"In a preclinical study, Debio 1347 did not inhibit tumor growth in cell line xenograft models of ERBB2 (HER2) amplified gastric carcinoma (PMID: 26438159).",Actionable,8494,5517,stomach carcinoma,DOID,531,ERBB2 amp,no benefit,1014,FF-284,2064,26438159,,,
359,Preclinical,"In a preclinical study, BMS-690514 inhibited tumor growth in a gastric cancer xenograft model with ERBB2 (HER2) amplification and overexpression (PMID: 21531814).",Actionable,2919,10534,stomach cancer,DOID,531,ERBB2 amp,sensitive,685,BMS-690514,2064,21531814,,,
360,Preclinical - Cell line xenograft,"In a preclinical study, Gilotrif (afatinib) inhibited proliferation and induced cell-cycle arrest and apoptosis of non-small cell lung cancer (NSCLC) cell lines with ERBB2 (HER2) amplification in culture, and inhibited tumor growth in ERBB2 (HER2)-amplified NSCLC cell line xenograft models (PMID: 26545934).",Actionable,6946,3908,non-small cell lung carcinoma,DOID,531,ERBB2 amp,sensitive,623,Afatinib,2064,26545934,,,
361,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) treatment induced tumor regression in ERBB2 (HER2)-amplified cell line xenograft models of gastric cancer (PMID: 26296355).",Actionable,3166,10534,stomach cancer,DOID,531,ERBB2 amp,sensitive,1414,Trastuzumab + Lapatinib,2064,26296355,,,
362,Preclinical - Cell culture,"In a preclinical study, esophageal cancer cells with ERBB2 (HER2) amplification demonstrated sensitivity to Imbruvica (ibrutinib), resulting in decreased survival in culture (PMID: 28830912).",Actionable,11801,5041,esophageal cancer,DOID,531,ERBB2 amp,sensitive,768,Ibrutinib,2064,28830912,,,
363,Phase I,"In a Phase I clinical trial, Nerlynx (neratinib) administered with Torisel (temsirolimus) was tolerable and demonstrated antitumor activity in ERBB2 (HER2)-amplified breast cancer resistant to (Herceptin) trastuzumab (PMID:24323026).",Actionable,426,1612,breast cancer,DOID,531,ERBB2 amp,predicted â€“ sensitive,1527,Temsirolimus + Neratinib,2064,24323026,,,
364,Preclinical - Pdx,"In a preclinical study, the combination of Perjeta (pertuzumab) and Tykerb (lapatinib) induced tumor regression in patient-derived xenograft (PDX) models of colorectal cancer with ERBB2 (HER2) amplification (PMID: 22586653).",Actionable,11359,9256,colorectal cancer,DOID,531,ERBB2 amp,sensitive,5958,Lapatinib + Pertuzumab,2064,22586653,,,
365,Preclinical,"In a preclinical study, dacomitinib was more effective in preventing proliferation in ERBB2 (HER2) amplified breast cancer cells than in wild-type ERBB2 (HER2) breast cancer cells (PMID: 22761403).",Actionable,907,1612,breast cancer,DOID,531,ERBB2 amp,sensitive,714,Dacomitinib,2064,22761403,,,
366,Clinical Study,"In a meta-analysis, breast cancer patients with >12 copies of ERBB2 (HER2) had a better response to Herceptin (trastuzumab) than patients with 6-12 copies of ERBB2 (HER2) (PMID: 24691421).",Actionable,892,60079,Her2-receptor positive breast cancer,DOID,531,ERBB2 amp,sensitive,947,Trastuzumab,2064,24691421,,,
367,Preclinical - Cell culture,"In a preclinical study, the combination therapy of Tykerb (lapatinib) and Torkinib (PP242) in ERBB2 (HER2) amplified breast cancer cells in culture blocked cell growth, inhibited phosphorylation of Akt and S6, and led to greater caspase activity when compared to each agent alone (PMID: 27197158).  ",Actionable,7822,1612,breast cancer,DOID,531,ERBB2 amp,sensitive,4584,Lapatinib + Torkinib,2064,27197158,,,
368,Preclinical - Cell line xenograft,"In a preclinical study, ABT-414 demonstrated cytoxicity against a EGFR-amplified vulvar epidermoid carcinoma cell line in culture and induced tumor regression in EGFR-amplified vulvar epidermoid carcinoma cell line xenograft models (PMID: 26846818).",Actionable,6979,2101,vulva squamous cell carcinoma,DOID,531,ERBB2 amp,sensitive,976,ABT-414,2064,26846818,,,
369,Preclinical,"In a preclinical study, dacomitinib demonstrated significant growth-inhibitory effects in HER2- amplified gastric cancer cells (PMID: 18606718).",Actionable,930,3119,gastrointestinal system cancer,DOID,531,ERBB2 amp,sensitive,714,Dacomitinib,2064,18606718,,,
370,Preclinical - Cell line xenograft,"In a preclinical study, breast cancer cell line xenograft models harboring ERBB2 (HER2) amplification were sensitive to the combination of LJM716 and Nerlynx (neratinib), resulting in a delay of brain lesion growth and improved survival (PMID: 28539475).  ",Actionable,11527,1612,breast cancer,DOID,531,ERBB2 amp,sensitive,6012,LJM716 + Neratinib,2064,28539475,,,
371,Preclinical - Pdx,"In a preclinical study, the combination of Erbitux (cetuximab) and Tykerb (lapatinib) induced tumor regression in patient-derived xenograft (PDX) models of colorectal cancer with ERBB2 (HER2) amplification (PMID: 22586653).",Actionable,11358,9256,colorectal cancer,DOID,531,ERBB2 amp,sensitive,1672,Cetuximab + Lapatinib,2064,22586653,,,
372,Preclinical - Cell culture,"In a preclinical study, BGB-283 inhibited proliferation of ERBB2 (HER2) amplified breast cancer cells in culture (PMID: 26208524).",Actionable,8064,60079,Her2-receptor positive breast cancer,DOID,531,ERBB2 amp,predicted â€“ sensitive,4025,BGB-283,2064,26208524,,,
373,Preclinical,"In a preclinical study, CDX-3379 (KTN3379) inhibited tumor growth in xenograft models of ERBB2 (HER2)-amplified breast cancer (PMID: 26880266).",Actionable,6442,60079,Her2-receptor positive breast cancer,DOID,531,ERBB2 amp,sensitive,2054,CDX-3379,2064,26880266,,,
374,Preclinical - Cell line xenograft,"In a preclinical study, a breast cancer cell line xenograft model harboring ERBB2 (HER2) amplification demonstrated tumor regression within the mammary fat pad when treated with Buparlisib (BKM120) (PMID: 28539475). ",Actionable,11513,1612,breast cancer,DOID,531,ERBB2 amp,sensitive,680,BKM120,2064,28539475,,,
375,FDA approved,"In a Phase III trial that supported FDA approval, gastric cancer patients with ERBB2 (HER2) amplification had increased overall survival when treated with Herceptin (trastuzumab), in combination with chemotherapy (PMID: 20728210).",Actionable,894,4944,gastroesophageal junction adenocarcinoma,DOID,531,ERBB2 amp,sensitive,947,Trastuzumab,2064,None,20728210,,
376,Preclinical,"In a preclinical study, CH5132799 inhibited proliferation of breast cancer cells with ERBB2 (HER2) amplification in culture (PMID: 21558396).",Actionable,2943,1612,breast cancer,DOID,531,ERBB2 amp,sensitive,2152,CH5132799,2064,21558396,,,
377,Phase III,"In a Phase III clinical trial, the addition of Tykerb (lapatinib) to Xeloda (capecitabine) and Eloxatin (oxaliplatin) combination treatment did not significantly prolong overall survival compared to placebo, but did improve progression-free survival and response rate in esophagus adenocarcinoma patients harboring ERBB2 amplification (PMID: 26628478).",Actionable,3801,4914,esophagus adenocarcinoma,DOID,531,ERBB2 amp,no benefit,787,Lapatinib,2064,26628478,,,
378,Phase II,"In a Phase II clinical trial, two urothelial carcinoma patients with ERBB2 (HER2) and EGFR co-amplification had improved progression free survival when treated with Gilotrif (afatinib), and median PFS was 6.6 months for patients with ERBB2 or ERBB3 alterations relative to 1.4 months for patients lacking alterations (PMID: 27044931).",Actionable,5942,11054,urinary bladder cancer,DOID,22032,EGFR amp ERBB2 amp,sensitive,623,Afatinib,2064,27044931,,,
379,Preclinical - Cell line xenograft,"In a preclinical study, CH5132799 inhibited cell growth and Akt phosphorylation, and promoted apoptosis in a human breast cancer cell line harboring PIK3CA H1047R and ERBB2 (HER2) amplification, and inhibited tumor growth in xenograft models (PMID: 21558396).",Actionable,2968,1612,breast cancer,DOID,10752,ERBB2 amp PIK3CA H1047R,sensitive,2152,CH5132799,2064,21558396,,,
380,Preclinical,"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human breast cancer cells harboring ERBB2 (HER2) amplification and PIK3CA H1047R in culture (PMID: 21325073, PMID: 17314276).",Actionable,3125,1612,breast cancer,DOID,10752,ERBB2 amp PIK3CA H1047R,sensitive,1040,PF-05212384,2064,21325073,17314276,,
381,Preclinical - Cell line xenograft,"In a preclinical study, CH5132799 inhibited cell growth in a human ovarian cancer cell line harboring PIK3CA H1047R and ERBB2 (HER2) amplification, and inhibited tumor growth in xenograft models (PMID: 21558396).",Actionable,2970,2394,ovarian cancer,DOID,10752,ERBB2 amp PIK3CA H1047R,sensitive,2152,CH5132799,2064,21558396,,,
382,Preclinical - Cell line xenograft,"In a preclinical study, the combination of CH5132799 and Herceptin (trastuzumab) inhibited tumor growth and overcame Herceptin (trastuzumab) insensitivity in xenograft models of a human breast cancer cell line harboring PIK3CA H1047R and ERBB2 (HER2) amplification (PMID: 21558396).",Actionable,2975,1612,breast cancer,DOID,10752,ERBB2 amp PIK3CA H1047R,sensitive,3039,CH5132799 + Trastuzumab,2064,21558396,,,
383,Preclinical,"In a preclinical study, CUDC-907 inhibited downstream signaling and growth of PIK3CA-mutant breast cancer cells with ERBB2 amplification in culture (PMID: 22693356).",Actionable,3016,1612,breast cancer,DOID,19124,ERBB2 amp PIK3CA mut,sensitive,709,CUDC-907,2064,22693356,,,
384,Preclinical - Cell line xenograft,"In a preclinical study, ERBB2 (HER2)-receptor positive breast cancer cell line xenograft models harboring amplification of ERBB2 (HER2) and a PIK3CA mutation demonstrated sensitivity to treatment with Ipatasertib (GDC-0068), resulting in inhibition of tumor growth (PMID: 24141624). ",Actionable,8966,60079,Her2-receptor positive breast cancer,DOID,19124,ERBB2 amp PIK3CA mut,sensitive,747,Ipatasertib,2064,24141624,,,
385,Preclinical - Cell line xenograft,"In a preclinical study, Aliqopa (copanlisib) promoted tumor regression in xenograft models of a human ERBB2 (HER2)-amplified breast cancer cell line harboring a PIK3CA activating mutation (PMID: 24170767).",Actionable,1374,60079,Her2-receptor positive breast cancer,DOID,19124,ERBB2 amp PIK3CA mut,sensitive,995,Copanlisib,2064,24170767,,,
386,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Nerlynx (neratinib) and Taselisib (GDC-0032), compared to either agent alone, resulted in greater inhibition of cell cycle activity in a uterine serous carcinoma cell line harboring ERBB2 (HER2) amplification and a PIK3CA mutation in culture, and in xenograft models, showed increased tumor growth inhibition and tumor regression (PMID: 26333383). ",Actionable,9067,5750,uterine corpus serous adenocarcinoma,DOID,19124,ERBB2 amp PIK3CA mut,sensitive,4871,GDC-0032 + Neratinib,2064,26333383,,,
387,Clinical Study,"In a clinical case study, a patient with gastric adenocarcinoma containing amplification of ERBB2 (HER2) and a TP53 R158H mutation progressed and developed metastases while being treated with AMG 337 (PMID: 26432108).",Actionable,4099,3717,gastric adenocarcinoma,DOID,17302,ERBB2 amp TP53 R158H,predicted â€“ resistant,1064,AMG 337,2064,26432108,,,
388,Preclinical,"In a preclinical study, Nerlynx (neratinib) treatment resulted in stable tumor size in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) L866M and ERBB2 (HER2) amplification (PMID: 26243863).",Actionable,7126,9256,colorectal cancer,DOID,24420,ERBB2 amp ERBB2 L866M,sensitive,828,Neratinib,2064,26243863,,,
389,Preclinical,"In a preclinical study, Herceptin (trastuzumab) had no effect on tumor growth in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) L866M and ERBB2 (HER2) amplification (PMID: 26243863).",Actionable,7125,9256,colorectal cancer,DOID,24420,ERBB2 amp ERBB2 L866M,resistant,947,Trastuzumab,2064,26243863,,,
390,Preclinical,"In a preclinical study, Herceptin (trastuzumab) and Nerlynx (neratinib) combination treatment resulted in sustained tumor regression in xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) L866M and ERBB2 (HER2) amplification (PMID: 26243863).",Actionable,7127,9256,colorectal cancer,DOID,24420,ERBB2 amp ERBB2 L866M,sensitive,4359,Neratinib + Trastuzumab,2064,26243863,,,
391,Preclinical,"In a preclinical study, xenograft models of patient derived colorectal cancer cells harboring ERBB2 (HER2) L866M and ERBB2 (HER2) amplification were resistant to Erbitux (cetuximab) (PMID: 26243863).",Actionable,7119,9256,colorectal cancer,DOID,24420,ERBB2 amp ERBB2 L866M,resistant,694,Cetuximab,2064,26243863,,,
392,Preclinical,"In a preclinical study, CH5132799 inhibited proliferation of a breast cancer cell line harboring PIK3CA C420R and ERBB2 (HER2) amplification (PMID: 21558396).",Actionable,2951,1612,breast cancer,DOID,10738,ERBB2 amp PIK3CA C420R,sensitive,2152,CH5132799,2064,21558396,,,
393,Preclinical - Cell line xenograft,"In a preclinical study, a breast cancer cell line xenograft model co-harboring ERBB2 (HER2) amplification and PIK3CA E545K demonstrated tumor regression within the mammary fat pad when treated with Buparlisib (BKM120) (PMID: 28539475). ",Actionable,11514,1612,breast cancer,DOID,11011,ERBB2 amp PIK3CA E545K,sensitive,680,BKM120,2064,28539475,,,
394,Preclinical,"In a preclinical study, CH5132799 inhibited proliferation of a breast cancer cell line harboring PIK3CA E545K and ERBB2 (HER2) amplification in culture (PMID: 21558396).",Actionable,3003,1612,breast cancer,DOID,11011,ERBB2 amp PIK3CA E545K,sensitive,2152,CH5132799,2064,21558396,,,
395,Preclinical,"In a preclinical study, gastric cancer cells with wild-type FGFR2  and ERBB2 (HER2) amplification were resistant to treatment with AZD4547 in culture (PMID: 22869148).",Actionable,2581,10534,stomach cancer,DOID,9482,FGFR2 wild-type ERBB2 amp,resistant,654,AZD4547,2064,22869148,,,
396,Preclinical - Cell culture,"In a preclinical study, the combination of Taselisib (GDC-0032) and Nerlynx (neratinib) delayed cell cycle activity in a uterine serous carcinoma cell line harboring PIK3CA wild-type and ERBB2 (HER2) amplification in culture (PMID: 26333383). ",Actionable,9065,5750,uterine corpus serous adenocarcinoma,DOID,26704,ERBB2 amp PIK3CA wild-type,sensitive,4871,GDC-0032 + Neratinib,2064,26333383,,,
397,Preclinical - Cell line xenograft,"In a preclinical study, Taselisib (GDC-0032) did not result in delay of cell cycle activity during treatment of a uterine serous carcinoma cell line harboring PIK3CA wild-type and ERBB2 (HER2) amplification in culture, however, did result in tumor growth inhibition in xenograft models (PMID: 26333383). ",Actionable,9063,5750,uterine corpus serous adenocarcinoma,DOID,26704,ERBB2 amp PIK3CA wild-type,sensitive,1016,GDC-0032,2064,26333383,,,
398,Preclinical - Cell line xenograft,"In a preclinical study, Nerlynx (neratinib) delayed cell cycle activity during treatment of a uterine serous carcinoma cell line harboring PIK3CA wild-type and ERBB2 (HER2) amplification in culture, and inhibited tumor growth in xenograft models (PMID: 26333383). ",Actionable,9064,5750,uterine corpus serous adenocarcinoma,DOID,26704,ERBB2 amp PIK3CA wild-type,sensitive,828,Neratinib,2064,26333383,,,
399,Preclinical - Cell line xenograft,"In a preclinical study, Gedatolisib (PKI-587) inhibited PI3K signaling, cell growth and induced apoptosis in human breast cancer cells harboring ERBB2 (HER2) amplification, PIK3CA E545K, and PIK3CA K567R in culture and in cell line xenografts (PMID: 21325073, PMID: 17314276).",Actionable,3124,60079,Her2-receptor positive breast cancer,DOID,11788,ERBB2 amp PIK3CA E545K PIK3CA K567R,sensitive,1040,PF-05212384,2064,21325073,17314276,,
400,Preclinical,"In a preclinical study, a human esophageal carcinoma cell line harboring amplification of ERBB2 and MET was resistant to Xalkori (crizotinib) in culture (PMID: 26432108).",Actionable,4089,1107,esophageal carcinoma,DOID,17215,ERBB2 amp MET amp,resistant,706,Crizotinib,2064,26432108,,,
401,Clinical Study,"In a clinical case study, a patient with ERBB2 (HER2) amplified gastric adenocarcinoma progressed rapidly when treated with Herceptin (trastuzumab) with Xeloda (capecitabine), Eloxatin (oxaliplatin), and Avastin (bevacizumab), and reprofiling of the tumor revealed co-amplification of MET (PMID: 26432108).",Actionable,4093,3717,gastric adenocarcinoma,DOID,17215,ERBB2 amp MET amp,resistant,3441,Bevacizumab + Capecitabine + Oxaliplatin + Trastuzumab,2064,26432108,,,
402,Preclinical - Cell culture,"In a preclinical study, the combination of Xalkori (crizotinib) and Tykerb (lapatinib) worked synergistically to inhibit growth of an esophageal adenocarcinoma cell line with ERBB2 (HER2) and MET amplification in culture (PMID: 27595477).",Actionable,11555,4914,esophagus adenocarcinoma,DOID,17215,ERBB2 amp MET amp,sensitive,3440,Crizotinib + Lapatinib,2064,27595477,,,
403,Clinical Study,"In a clinical case study, a patient with ERBB2 (HER2) and MET co-amplified gastric adenocarcinoma had near complete regression of the disease after 2 months of treatment with Herceptin (trastuzumab), Xalkori (crizotinib) and weekly Taxol (paclitaxel) (PMID: 26432108).",Actionable,4094,3717,gastric adenocarcinoma,DOID,17215,ERBB2 amp MET amp,sensitive,3442,Crizotinib + Trastuzumab + Paclitaxel,2064,26432108,,,
404,Preclinical,"In a preclinical study, a human esophageal carcinoma cell line harboring amplification of ERBB2 (HER2) and MET was sensitive to inhibition by Tykerb (lapatinib) and Xalkori (crizotinib) in culture (PMID: 26432108).",Actionable,4092,1107,esophageal carcinoma,DOID,17215,ERBB2 amp MET amp,sensitive,3440,Crizotinib + Lapatinib,2064,26432108,,,
405,Preclinical,"In a preclinical study, a human esophageal carcinoma cell line harboring amplification of ERBB2 and MET was resistant to Tykerb (lapatinib) in culture (PMID: 26432108).",Actionable,4090,1107,esophageal carcinoma,DOID,17215,ERBB2 amp MET amp,resistant,787,Lapatinib,2064,26432108,,,
406,Clinical Study,"In a clinical case study, a patient with ERBB2 (HER2) and MET amplified gastric adenocarcinoma was insensitive to AMG 337 therapy (PMID: 26432108).",Actionable,4084,3717,gastric adenocarcinoma,DOID,17215,ERBB2 amp MET amp,resistant,1064,AMG 337,2064,26432108,,,
407,Clinical Study,"In a clinical case study, a patient with ERBB2 (HER2) and MET amplified gastric adenocarcinoma was insensitive to treatment with Herceptin (trastuzumab) and FOLFOX (PMID: 26432108).",Actionable,4091,3717,gastric adenocarcinoma,DOID,17215,ERBB2 amp MET amp,resistant,3439,Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin,2064,26432108,,,
408,Preclinical,"In a preclinical study, breast cancer cells expressing ERBB2 (HER2) L755_T759del were resistant to treatment with Tykerb (lapatinib), resulting in decreased growth inhibition (PMID: 23220880). ",Actionable,6943,1612,breast cancer,DOID,24091,ERBB2 L755_T759del,resistant,787,Lapatinib,2064,23220880,,,
409,Preclinical,"In a preclinical study, breast cancer cells expressing ERBB2 (HER2) L755_T759del were sensitive to treatment with Nerlynx (neratinib) (PMID: 23220880). ",Actionable,6945,1612,breast cancer,DOID,24091,ERBB2 L755_T759del,sensitive,828,Neratinib,2064,23220880,,,
410,Preclinical,"In a preclinical study, breast cancer cells expressing ERBB2 (HER2) L755_T759del were sensitive to treatment with Iressa (gefitinib) (PMID: 23220880). ",Actionable,6944,1612,breast cancer,DOID,24091,ERBB2 L755_T759del,sensitive,751,Gefitinib,2064,23220880,,,
411,Preclinical,"In a preclinical study, AEE788 inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) V773A in culture (PMID: 22046346).",Actionable,3040,10000003,Advanced Solid Tumor,JAX,11339,ERBB2 V773A,sensitive,622,AEE788,2064,22046346,,,
412,Preclinical,"In a preclinical study, higher dose of Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) V773A in culture (PMID: 22046346).",Actionable,3039,10000003,Advanced Solid Tumor,JAX,11339,ERBB2 V773A,decreased response,787,Lapatinib,2064,22046346,,,
413,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) L866M in culture (PMID: 26243863).",Actionable,7111,9256,colorectal cancer,DOID,24403,ERBB2 L866M,sensitive,623,Afatinib,2064,26243863,,,
414,Preclinical,"In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) L866M were resistant to Erbitux (cetuximab) in culture (PMID: 26243863).",Actionable,7100,9256,colorectal cancer,DOID,24403,ERBB2 L866M,resistant,694,Cetuximab,2064,26243863,,,
415,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) L866M in culture (PMID: 26243863).",Actionable,7106,9256,colorectal cancer,DOID,24403,ERBB2 L866M,sensitive,828,Neratinib,2064,26243863,,,
416,Preclinical,"In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) L866M were resistant to Vectibix (panitumumab) in culture (PMID: 26243863).",Actionable,7101,9256,colorectal cancer,DOID,24403,ERBB2 L866M,resistant,845,Panitumumab,2064,26243863,,,
417,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) L866M in culture (PMID: 26243863).",Actionable,7089,219,colon cancer,DOID,24403,ERBB2 L866M,sensitive,828,Neratinib,2064,26243863,,,
418,Preclinical,"In a preclinical study, Herceptin (trastuzumab) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) L866M in culture (PMID: 26243863).",Actionable,7085,219,colon cancer,DOID,24403,ERBB2 L866M,sensitive,947,Trastuzumab,2064,26243863,,,
419,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) P780_Y781insGSP reverted to normal morphology in culture upon Nerlynx (neratinib) treatment (PMID: 23220880).",Actionable,2039,1612,breast cancer,DOID,3278,ERBB2 G778_P780dup,sensitive,828,Neratinib,2064,23220880,,,
420,Phase II,"In a Phase II trial, Nerlynx (neratinib) demonstrated activity in metastatic breast cancer patients harboring ERBB2 (HER2) mutations, resulting in a clinical benefit rate of 31% (5/16), which included patients with ERBB2 G778_P780dup (1 complete response (referred to as V777_G778insGSP) and 1 patient with stable disease for more than 24 weeks (referred to as P780_Y781insGSP) (PMID: 28679771).",Actionable,11645,1612,breast cancer,DOID,3278,ERBB2 G778_P780dup,sensitive,828,Neratinib,2064,28679771,,,
421,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) G778_P780dup (also referred to as P780_Y781insGSP) in culture (PMID: 26545934).",Actionable,6959,1324,lung cancer,DOID,3278,ERBB2 G778_P780dup,sensitive,623,Afatinib,2064,26545934,,,
422,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 P780_Y781insGSP demonstrated resistance when treated with Tykerb (lapatinib) (PMID: 23220880).",Actionable,2038,1612,breast cancer,DOID,3278,ERBB2 G778_P780dup,resistant,787,Lapatinib,2064,23220880,,,
423,Preclinical - Cell culture,"In a preclinical study, Nerlynx (neratinib) inhibited growth of transformed cells expressing ERBB2 (HER2) G778_P780dup (also referred to as P780_Y781insGSP) in culture (PMID: 28363995).",Actionable,10527,10000003,Advanced Solid Tumor,JAX,3278,ERBB2 G778_P780dup,sensitive,828,Neratinib,2064,28363995,,,
424,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 P780_Y781insGSP demonstrated resistance when treated with Herceptin (trastuzumab) (PMID: 23220880).",Actionable,2040,1612,breast cancer,DOID,3278,ERBB2 G778_P780dup,resistant,947,Trastuzumab,2064,23220880,,,
425,Preclinical - Cell culture,"In a preclinical study, dacomitinib inhibited growth of transformed cells expressing ERBB2 (HER2) G778_P780dup (also referred to as P780_Y781insGSP) in culture (PMID: 28363995).",Actionable,10525,10000003,Advanced Solid Tumor,JAX,3278,ERBB2 G778_P780dup,sensitive,714,Dacomitinib,2064,28363995,,,
426,Preclinical,"In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) G778_P780dup (also referred to as P780_Y781insGSP) did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934).",Actionable,6967,1324,lung cancer,DOID,3278,ERBB2 G778_P780dup,no benefit,751,Gefitinib,2064,26545934,,,
427,Phase II,"In a Phase II trial, two lung adenocarcinoma patients harboring ERBB2 (HER2) P780_Y781insGSP (also referred to as G778_780dup) demonstrated partial response to treatment with dacomitinib (PMID: 25899785).",Actionable,10501,3910,lung adenocarcinoma,DOID,3278,ERBB2 G778_P780dup,sensitive,714,Dacomitinib,2064,25899785,,,
428,Clinical Study,"In a clinical study, a lung adenocarcinoma patient harboring ERBB2 (HER2) G778_P780dup (also referred to as V747_G748insGSP and G748_P750dup), demonstrated a 13% regression of target lesions and stable disease for 11 months following treatment with pulse Gilotrif (afatinib) (PMID: 26964772).",Actionable,8055,3910,lung adenocarcinoma,DOID,3278,ERBB2 G778_P780dup,predicted â€“ sensitive,623,Afatinib,2064,26964772,,,
429,Clinical Study,"In a clinical study, a patient with metastatic lung adenocarcinoma harboring ERBB2 (HER2) G778_P780dup (also referred to as V777_G778insGSP) demonstrated tumor shrinkage and clinical response for 7 months following treatment with Gilotrif (afatinib) (PMID: 28363995).",Actionable,10523,3910,lung adenocarcinoma,DOID,3278,ERBB2 G778_P780dup,predicted â€“ sensitive,623,Afatinib,2064,28363995,,,
430,Preclinical,"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) Y803N in culture (PMID: 18413839).",Actionable,7325,10000003,Advanced Solid Tumor,JAX,24616,ERBB2 Y803N,sensitive,967,XL647,2064,18413839,,,
431,Preclinical,"In a preclinical study, transformed cells over expressing ERBB2 (HER2) Y803N demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839).",Actionable,7314,10000003,Advanced Solid Tumor,JAX,24616,ERBB2 Y803N,decreased response,787,Lapatinib,2064,18413839,,,
432,Clinical Study,"In a clinical case study, a rectal adenocarcinoma patient harboring APC Q1429fs, BRAF N581S, and ERBB2 L755S did not respond to Herceptin (trastuzumab) treatment in combination with Fluorouracil and Wellcovorin (leucovorin) (PMID: 27626067).",Actionable,9333,1996,rectum adenocarcinoma,DOID,26822,APC Q1429fs BRAF N581S ERBB2 L755S,no benefit,4970,Fluorouracil + Leucovorin + Trastuzumab,2064,27626067,,,
433,Preclinical,"In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) L755S were resistant to Erbitux (cetuximab) in culture (PMID: 26243863).",Actionable,7096,9256,colorectal cancer,DOID,3151,ERBB2 L755S,resistant,694,Cetuximab,2064,26243863,,,
434,Preclinical,"In a preclinical study, EKI-285 (CL-387785) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) L755S in culture (PMID: 22046346).",Actionable,3035,10000003,Advanced Solid Tumor,JAX,3151,ERBB2 L755S,sensitive,2911,EKI-285,2064,22046346,,,
435,Phase II,"In a Phase II trial, Nerlynx (neratinib) demonstrated activity in metastatic breast cancer patients harboring ERBB2 (HER2) mutations, resulting in a clinical benefit rate of 31% (5/16), with 1 complete response, 1 partial response in a patient with ERBB2 (HER2) L755S, and 3 patients achieving stable disease for 24 weeks or more (PMID: 28679771).",Actionable,11640,219,colon cancer,DOID,3151,ERBB2 L755S,sensitive,828,Neratinib,2064,28679771,,,
436,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) L755S in culture (PMID: 26243863).",Actionable,7087,219,colon cancer,DOID,3151,ERBB2 L755S,sensitive,828,Neratinib,2064,26243863,,,
437,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing ERBB2 L755S demonstrated resistance when treated with Tykerb (lapatinib) in culture (PMID: 22046346).",Actionable,2036,10000003,Advanced Solid Tumor,JAX,3151,ERBB2 L755S,resistant,787,Lapatinib,2064,22046346,23220880,,
438,Preclinical,"In a preclinical study, transformed cell lines expressing ERBB2 (HER2) L755S demonstrated resistance to AEE788 in culture, except at very high doses (PMID: 22046346).",Actionable,2035,10000003,Advanced Solid Tumor,JAX,3151,ERBB2 L755S,resistant,622,AEE788,2064,22046346,,,
439,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) L755S demonstrated growth inhibition when treated with Nerlynx (neratinib) (PMID: 23220880).",Actionable,2037,1612,breast cancer,DOID,3151,ERBB2 L755S,sensitive,828,Neratinib,2064,23220880,,,
440,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) L755S in culture (PMID: 26243863).",Actionable,7109,9256,colorectal cancer,DOID,3151,ERBB2 L755S,sensitive,623,Afatinib,2064,26243863,,,
441,Preclinical,"In a preclinical study, WZ4002 inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) L755S in culture (PMID: 22046346).",Actionable,3036,10000003,Advanced Solid Tumor,JAX,3151,ERBB2 L755S,sensitive,3075,WZ4002,2064,22046346,,,
442,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cells over expressing ERBB2 (HER2) L755S in culture (PMID: 26243863).",Actionable,7104,9256,colorectal cancer,DOID,3151,ERBB2 L755S,sensitive,828,Neratinib,2064,26243863,,,
443,Preclinical,"In a preclinical study, colorectal cancer cells over expressing ERBB2 (HER2) L755S were resistant to Vectibix (panitumumab) in culture (PMID: 26243863).",Actionable,7097,9256,colorectal cancer,DOID,3151,ERBB2 L755S,resistant,845,Panitumumab,2064,26243863,,,
444,Preclinical,"In a preclinical study, Herceptin (trastuzumab) inhibited colony formation in transformed mouse colon epithelial cells over expressing ERBB2 (HER2) L755S in culture (PMID: 26243863).",Actionable,7084,219,colon cancer,DOID,3151,ERBB2 L755S,sensitive,947,Trastuzumab,2064,26243863,,,
445,Preclinical,"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) L755S in culture (PMID: 18413839).",Actionable,7320,10000003,Advanced Solid Tumor,JAX,3151,ERBB2 L755S,sensitive,967,XL647,2064,18413839,,,
446,Preclinical,"In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) G776delinsVC did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934).",Actionable,6965,1324,lung cancer,DOID,24125,ERBB2 G776delinsVC,no benefit,751,Gefitinib,2064,26545934,,,
447,Preclinical,"In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) G776delinsVC in culture (PMID: 26545934).",Actionable,6957,1324,lung cancer,DOID,24125,ERBB2 G776delinsVC,sensitive,623,Afatinib,2064,26545934,,,
448,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring ERBB2 (HER2) G776delinsVC demonstrated resistance to treatment with Iressa (gefitinib) in culture (PMID: 26545934).",Actionable,6960,3908,non-small cell lung carcinoma,DOID,24125,ERBB2 G776delinsVC,resistant,751,Gefitinib,2064,26545934,,,
449,Preclinical - Cell line xenograft,"In a preclinical study, Gilotrif (afatinib) inhibited proliferation and induced cell-cycle arrest and apoptosis of a non-small cell lung cancer (NSCLC) cell line harboring ERBB2 (HER2) G776delinsVC in culture and inhibited tumor growth in NSCLC cell line xenografts carrying ERBB2 (HER2) G776delinsVC (PMID: 26545934).",Actionable,6948,3908,non-small cell lung carcinoma,DOID,24125,ERBB2 G776delinsVC,sensitive,623,Afatinib,2064,26545934,,,
450,Preclinical,"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) L726F in culture (PMID: 19718025).",Actionable,7318,10000003,Advanced Solid Tumor,JAX,24164,ERBB2 L726F,sensitive,967,XL647,2064,19718025,,,
451,Preclinical,"In a preclinical study, transformed cells over expressing ERBB2 (HER2) L726F demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839).",Actionable,7312,10000003,Advanced Solid Tumor,JAX,24164,ERBB2 L726F,decreased response,787,Lapatinib,2064,18413839,,,
452,Preclinical,"In a preclinical study, breast cancer cells expressing ERBB2 (HER2) L726F demonstrated resistance to Tykerb (lapatinib) in both culture and xenograft models (PMID: 25435280).",Actionable,6968,1612,breast cancer,DOID,24164,ERBB2 L726F,resistant,787,Lapatinib,2064,25435280,,,
453,Preclinical - Cell culture,"In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) K753 were sensitive to Nerlynx (neratinib) in culture, resulting in decreased colony formation (PMID: 27697991).",Actionable,8757,1612,breast cancer,DOID,26418,ERBB2 K753E,sensitive,828,Neratinib,2064,27697991,,,
454,Preclinical - Cell culture,"In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) K753E were resistant to Tykerb (lapatinib) in culture (PMID: 27697991).",Actionable,8756,1612,breast cancer,DOID,26418,ERBB2 K753E,resistant,787,Lapatinib,2064,27697991,,,
455,Preclinical - Cell culture,"In a preclinical study, transformed human breast cells expressing ERBB2 (HER2) K753E were resistant to Herceptin (trastuzumab) in culture (PMID: 27697991).",Actionable,8755,1612,breast cancer,DOID,26418,ERBB2 K753E,resistant,947,Trastuzumab,2064,27697991,,,
456,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 D769H demonstrated growth inhibition when treated with Tykerb (lapatinib) (PMID: 23220880).",Actionable,2022,1612,breast cancer,DOID,3128,ERBB2 D769H,sensitive,787,Lapatinib,2064,23220880,,,
457,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 D769H reverted to normal morphology in culture upon Herceptin (trastuzumab) treatment (PMID: 23220880).",Actionable,2024,1612,breast cancer,DOID,3128,ERBB2 D769H,sensitive,947,Trastuzumab,2064,23220880,,,
458,Preclinical,"In a preclinical study, transformed human breast cell lines expressing ERBB2 (HER2) D769H demonstrated growth inhibition when treated with Nerlynx (neratinib) (PMID: 23220880).",Actionable,2023,1612,breast cancer,DOID,3128,ERBB2 D769H,sensitive,828,Neratinib,2064,23220880,,,
459,Preclinical,"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) D821N in culture (PMID: 18413839).",Actionable,7327,10000003,Advanced Solid Tumor,JAX,24591,ERBB2 D821N,sensitive,967,XL647,2064,18413839,,,
460,Preclinical,"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) E812K in culture (PMID: 18413839).",Actionable,7326,10000003,Advanced Solid Tumor,JAX,24592,ERBB2 E812K,sensitive,967,XL647,2064,18413839,,,
461,Preclinical,"In a preclinical study, transformed cells over expressing ERBB2 (HER2) E812K demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839).",Actionable,7315,10000003,Advanced Solid Tumor,JAX,24592,ERBB2 E812K,decreased response,787,Lapatinib,2064,18413839,,,
462,Preclinical,"In a preclinical study, AEE788 inhibited proliferation of transformed cell lines expressing ERBB2(HER2) N857S in culture (PMID: 22046346).",Actionable,3042,10000003,Advanced Solid Tumor,JAX,11334,ERBB2 N857S,sensitive,622,AEE788,2064,22046346,,,
463,Preclinical,"In a preclinical study, higher dose of Tykerb (lapatinib) inhibited proliferation of transformed cell lines expressing ERBB2 (HER2) N857S in culture (PMID: 22046346).",Actionable,3037,10000003,Advanced Solid Tumor,JAX,11334,ERBB2 N857S,decreased response,787,Lapatinib,2064,22046346,,,
464,Preclinical,"In a preclinical study, transformed cells over expressing ERBB2 (HER2) E717K demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839).",Actionable,7310,10000003,Advanced Solid Tumor,JAX,24119,ERBB2 E717K,decreased response,787,Lapatinib,2064,18413839,,,
465,Preclinical,"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) E717K in culture (PMID: 18413839).",Actionable,7316,10000003,Advanced Solid Tumor,JAX,24119,ERBB2 E717K,sensitive,967,XL647,2064,18413839,,,
466,Clinical Study,"In a clinical study, the PIK3CA R425L mutation was identified as a potential resistance mechanism in a non-small cell lung carcinoma patient harboring ERBB2 (HER2) A775_G776insYVMA, that progressed during Herceptin (trastuzumab) treatment (PMID: 28167203). ",Actionable,10134,3908,non-small cell lung carcinoma,DOID,27298,ERBB2 A775_G776insYVMA PIK3CA R425L,predicted â€“ resistant,947,Trastuzumab,2064,28167203,,,
467,Preclinical,"In a preclinical study, transformed cells over expressing ERBB2 (HER2) L785F demonstrated reduced sensitivity to Tykerb (lapatinib) in culture (PMID: 18413839).",Actionable,7313,10000003,Advanced Solid Tumor,JAX,24607,ERBB2 L785F,decreased response,787,Lapatinib,2064,18413839,,,
468,Preclinical,"In a preclinical study, XL647 inhibited survival of transformed cells over expressing ERBB2 (HER2) L785F in culture (PMID: 18413839).",Actionable,7323,10000003,Advanced Solid Tumor,JAX,24607,ERBB2 L785F,sensitive,967,XL647,2064,18413839,,,
0,Preclinical,"In a preclinical study, Tykerb (lapatinib) inhibited survival and induced apoptosis in melanoma cells harboring ERBB4 E563K in culture (PMID: 19718025).",Actionable,7258,1909,melanoma,DOID,24621,ERBB4 E563K,sensitive,787,Lapatinib,2066,19718025,,,
1,Preclinical,"In a preclinical study, Tykerb (lapatinib) inhibited survival and induced apoptosis in melanoma cells harboring ERBB4 E317K in culture (PMID: 19718025).",Actionable,7254,1909,melanoma,DOID,24619,ERBB4 E317K,sensitive,787,Lapatinib,2066,19718025,,,
2,Preclinical - Cell culture,"In a preclinical study, head and neck squamous cell carcinoma cells harboring ERBB4 (HER4) G1109C demonstrated resistance to treatment with Erbitux (cetuximab) in a cell viability assay (PMID: 27207775). ",Actionable,7886,5520,head and neck squamous cell carcinoma,DOID,26082,ERBB4 G1109C,resistant,694,Cetuximab,2066,27207775,,,
3,Preclinical - Cell line xenograft,"In a preclinical study, Gilotrif (afatinib) treatment resulted in apoptotic induction in head and neck squamous cell carcinoma cells harboring ERBB4 (HER4) G1109C in culture and inhibited tumor growth in cell line xenograft models (PMID: 27207775). ",Actionable,7888,5520,head and neck squamous cell carcinoma,DOID,26082,ERBB4 G1109C,sensitive,623,Afatinib,2066,27207775,,,
4,Preclinical - Cell culture,"In a preclinical study, head and neck squamous cell carcinoma cells harboring ERBB4 (HER4) G1109C demonstrated resistance to treatment with Tarceva (erlotinib) in a cell viability assay (PMID: 27207775). ",Actionable,7885,5520,head and neck squamous cell carcinoma,DOID,26082,ERBB4 G1109C,resistant,4,Erlotinib,2066,27207775,,,
5,Preclinical,"In a preclinical study, Tykerb (lapatinib) inhibited survival and induced apoptosis in melanoma cells harboring ERBB4 E452K in culture (PMID: 19718025).",Actionable,7256,1909,melanoma,DOID,24620,ERBB4 E452K,sensitive,787,Lapatinib,2066,19718025,,,
6,Preclinical,"In a preclinical study, Tykerb (lapatinib) induced apoptosis in melanoma cells harboring ERBB4 R544W in culture (PMID: 19718025).",Actionable,7257,1909,melanoma,DOID,24624,ERBB4 R544W,sensitive,787,Lapatinib,2066,19718025,,,
7,Preclinical,"In a preclinical study, Tykerb (lapatinib) inhibited survival of melanoma cells harboring ERBB4 R393W in culture (PMID: 19718025). ",Actionable,7259,1909,melanoma,DOID,24809,ERBB4 R393W,sensitive,787,Lapatinib,2066,19718025,,,
0,Preclinical - Cell culture,"In a preclinical study, treatment with AZD4547 decreased Myc expression and inhibited growth of transformed cells expressing ETV6-FGFR1 (TEL-FGFR1) in culture (PMID: 27401245).",Actionable,10008,10000003,Advanced Solid Tumor,JAX,27222,ETV6-FGFR1,sensitive,654,AZD4547,2120,27401245,,,
1,Preclinical - Cell culture,"In a preclinical study, treatment with AZD4547 decreased Myc expression and inhibited growth of transformed cells expressing ETV6-FGFR4 (TEL-FGFR4) in culture (PMID: 27401245).",Actionable,10010,10000003,Advanced Solid Tumor,JAX,27224,ETV6-FGFR4,sensitive,654,AZD4547,2120,27401245,,,
2,Clinical Study,"In multiple clinical studies, the ETV6-RUNX1 fusion was associated with a favorable prognosis in acute lymphocytic leukemia patients (PMID: 8609706, PMID: 10086740, PMID: 11432885, Guidelines). ",Prognostic,6166,9952,acute lymphocytic leukemia,DOID,11683,ETV6-RUNX1,not applicable,1776,N/A,2120,8609706,10086740,11432885,None
3,Clinical Study,"ETV6-RUNX1 is used in the diagnosis of acute lymphocytic leukemia (PMID: 26711002, PMID: 15704129, PMID: 8609706, Guidelines).",Diagnostic,6165,9952,acute lymphocytic leukemia,DOID,11683,ETV6-RUNX1,not applicable,1776,N/A,2120,26711002,15704129,8609706,None
4,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing ETV6-ALK demonstrated sensitivity  to Entrectinib (RXDX-101) in culture (PMID: 26939704).",Actionable,5634,10000003,Advanced Solid Tumor,JAX,21319,ETV6-ALK,sensitive,1455,Entrectinib,2120,26939704,,,
5,Preclinical - Cell line xenograft,"In a preclinical study, transformed cells expressing ETV6-ROS1 were sensitive to Entrectinib (RXDX-101), resulting in inhibition of cell proliferation in culture and decreased tumor growth in xenograft models (PMID: 26939704).",Actionable,5632,10000003,Advanced Solid Tumor,JAX,21307,ETV6-ROS1,sensitive,1455,Entrectinib,2120,26939704,,,
6,Phase I,"In a Phase I clinical trial, treatment with Entrectinib (RXDX-101) resulted in a durable partial response in a patient with mammary analogue secretory carcinoma harboring ETV6-NTRK3 (PMID: 26884591).",Actionable,7378,8850,salivary gland cancer,DOID,2514,ETV6-NTRK3,sensitive,1455,Entrectinib,2120,26884591,,,
7,Preclinical,"In a preclinical study, transformed cells expressing ETV6-NTRK3 demonstrated sensitivity to Altiratinib (DCC-2701) in culture, resulting in inhibition of Ntrk3 phosphorylation and decreased cell proliferation (AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 790).",Actionable,7380,10000003,Advanced Solid Tumor,JAX,2514,ETV6-NTRK3,sensitive,1656,Altiratinib,2120,None,,,
8,Preclinical,"In a preclinical study, transformed cells expressing the fusion, ETV6-NTRK3, were treated with Lestaurtinib (CEP-701), which resulted in inhibition of ETV6-NTRK3 autophosphorylation and restoration of Tgf-b1 signaling (PMID: 16258068).",Actionable,3864,10000003,Advanced Solid Tumor,JAX,2514,ETV6-NTRK3,sensitive,793,Lestaurtinib,2120,16258068,,,
9,Preclinical,"In a preclinical study, the broad spectrum kinase inhibitor midostaurin inhibited growth of cells dependent on the fusion protein ETV6â€“NTRK3, reducing ETV6â€“NTRK3 kinase activity and downstream signaling and inducing apoptosis (PMID: 23131561).",Actionable,1567,162,cancer,DOID,2514,ETV6-NTRK3,sensitive,810,Midostaurin,2120,23131561,,,
10,Preclinical,"In a preclinical study, BMS-754807 inhibited growth of a breast cancer xenograft models expressing ETV6-NTRK3 (PMID: 21148487).",Actionable,2500,1612,breast cancer,DOID,2514,ETV6-NTRK3,sensitive,686,BMS-754807,2120,21148487,,,
11,Guideline,"ETV6-NTRK3 fusions are used in the diagnosis of congenital fibrosarcoma (Guidelines, PMID: 24517889, PMID: 9462753).",Diagnostic,3988,8418,congenital fibrosarcoma,DOID,2514,ETV6-NTRK3,not applicable,1776,N/A,2120,26606880,None,9462753,24517889
12,Clinical Study,"In a clinical case study, a patient with congenital fibrosarcoma harboring ETV6-NTRK3 demonstrated tumor regression by 90% when treated with LOXO-101 (PMID: 28578312). ",Actionable,11265,8418,congenital fibrosarcoma,DOID,2514,ETV6-NTRK3,sensitive,2650,LOXO-101,2120,28578312,,,
13,Phase I,"In a Phase I clinical trial, treatment with LOXO-101 resulted in a partial response in a pediatric patient with infantile fibrosarcoma harboring ETV6-NTRK3 (PMID: 27093299).",Actionable,7379,8418,congenital fibrosarcoma,DOID,2514,ETV6-NTRK3,sensitive,2650,LOXO-101,2120,27093299,,,
14,Preclinical,"In a preclinical study, LOXO-101 inhibited cell growth and downstream signaling in acute myeloid leukemia cells harboring ETV6-NTRK3 in culture and xenografts (PMID: 26216294).",Actionable,3246,9119,acute myeloid leukemia,DOID,2514,ETV6-NTRK3,sensitive,2650,LOXO-101,2120,26216294,,,
15,Preclinical - Cell line xenograft,"In a preclinical study, Xalkori (crizotinib) inhibited ETV6-NTRK3 activity, reduced cell growth in a human acute myeloid leukemia cell line harboring ETV6-NTRK3, and had anti-tumor activity in xenograft models (PMID: 23811600).",Actionable,1421,9119,acute myeloid leukemia,DOID,2514,ETV6-NTRK3,sensitive,706,Crizotinib,2120,23811600,,,
16,Preclinical,"In a preclinical study, transformed human cells expressing ETV6-NTRK3 were sensitive to BMS-536924, demonstrating a reduction in both cell survival and transformation activity in culture (PMID: 21804605).",Actionable,3975,10000003,Advanced Solid Tumor,JAX,2514,ETV6-NTRK3,sensitive,683,BMS-536924,2120,21804605,,,
17,Preclinical,"In a preclinical study, transformed cells expressing ETV6-NTRK3 were sensitive to Entrectinib (RXDX-101), resulting in inhibition of cell proliferation (PMID: 26939704).",Actionable,5631,10000003,Advanced Solid Tumor,JAX,2514,ETV6-NTRK3,sensitive,1455,Entrectinib,2120,26939704,,,
18,Preclinical - Cell culture,"In a preclinical study, HMPL-523 decreased viability of cells expressing ETV6-SYK in culture (Blood Dec 2016, 128 (22) 3970).",Actionable,9879,10000003,Advanced Solid Tumor,JAX,22332,ETV6-SYK,sensitive,5279,HMPL-523,2120,None,,,
19,Preclinical,"In a preclinical study, immune cells expressing ETV6-JAK2 with the R1127K mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",Actionable,5581,2531,hematologic cancer,DOID,21294,ETV6 - JAK2 JAK2 R1127K,resistant,2797,Pyridone 6,2120,22916261,,,
20,Preclinical,"In a preclinical study, immune cells expressing ETV6-JAK2 with the N909K mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",Actionable,2449,2531,hematologic cancer,DOID,7560,ETV6-JAK2 JAK2 N909K,resistant,2797,Pyridone 6,2120,22916261,,,
21,Preclinical,"In a preclinical study, immune cells expressing ETV6-JAK2 with the R975G mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",Actionable,2447,2531,hematologic cancer,DOID,7562,ETV6-JAK2 JAK2 R975G,resistant,2797,Pyridone 6,2120,22916261,,,
22,Preclinical,"In a preclinical study, immune cells expressing ETV6-JAK2 with the G935R mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",Actionable,5577,2531,hematologic cancer,DOID,21291,ETV6 - JAK2 JAK2 G935R,resistant,2797,Pyridone 6,2120,22916261,,,
23,Preclinical,"In a preclinical study, immune cells expressing ETV6-JAK2 with the P1057S mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",Actionable,5580,2531,hematologic cancer,DOID,21293,ETV6 - JAK2 JAK2 P1057S,resistant,2797,Pyridone 6,2120,22916261,,,
24,Preclinical,"In a preclinical study, immune cells expressing ETV6-JAK2 with the M929I mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",Actionable,5579,2531,hematologic cancer,DOID,21292,ETV6 - JAK2 JAK2 M929I,resistant,2797,Pyridone 6,2120,22916261,,,
25,Preclinical,"In a preclinical study, immune cells expressing ETV6-JAK2 with the G831R mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",Actionable,5576,2531,hematologic cancer,DOID,21289,ETV6 - JAK2 JAK2 G831R,resistant,2797,Pyridone 6,2120,22916261,,,
26,Preclinical,"In a preclinical study, immune cells expressing ETV6-JAK2 with the Y918H mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",Actionable,5582,2531,hematologic cancer,DOID,21295,ETV6 - JAK2 JAK2 Y918H,resistant,2797,Pyridone 6,2120,22916261,,,
27,Preclinical,"In a preclinical study, immune cells expressing ETV6-JAK2 with the V881A mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",Actionable,2448,2531,hematologic cancer,DOID,7564,ETV6-JAK2 JAK2 V881A,resistant,2797,Pyridone 6,2120,22916261,,,
28,Preclinical,"In a preclinical study, immune cells expressing ETV6-JAK2 with the E864K mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",Actionable,5575,2531,hematologic cancer,DOID,21290,ETV6 - JAK2 JAK2 E864K,resistant,2797,Pyridone 6,2120,22916261,,,
29,Clinical Study,"In multiple clinical studies, ETV6 inactivating germline mutations were shown to be a risk factor for the development of acute lymphocytic leukemia (PMID: 26522332, PMID: 26102509, PMID: 25807284). ",Risk Factor,8529,9952,acute lymphocytic leukemia,DOID,22787,ETV6 inact mut,not applicable,1776,N/A,2120,25807284,26102509,26522332,
30,Preclinical,"In a preclinical study, transformed cells expressing ETV6-NTRK2 were sensitive to Entrectinib (RXDX-101), resulting in inhibition of cell proliferation (PMID: 26939704).",Actionable,5630,10000003,Advanced Solid Tumor,JAX,21305,ETV6-NTRK2,sensitive,1455,Entrectinib,2120,26939704,,,
31,Clinical Study,"In multiple clinical studies, ETV6 mutations were associated with a shorter overall survival in patients with myelodysplastic syndrome (Guidelines, PMID: 21714648, PMID: 21877899, PMID: 26769228). ",Actionable,6163,50908,myelodysplastic syndrome,DOID,22742,ETV6 mutant,not applicable,1776,N/A,2120,21714648,21877899,26769228,None
32,Clinical Study,"In a clinical case report, a patient with ETV6-PDGFRA positive chronic eosinophilic leukemia experienced complete cytogenic remission after treatment with Gleevec (imatinib) (PMID: 17555450).",Actionable,4652,1036,chronic leukemia,DOID,18676,ETV6-PDGFRA,sensitive,770,Imatinib,2120,17555450,,,
33,Preclinical - Cell culture,"In a preclinical study, treatment with AZD4547 decreased Myc expression and inhibited growth of transformed cells expressing ETV6-FGFR3 (TEL-FGFR3) in culture (PMID: 27401245).",Actionable,10009,10000003,Advanced Solid Tumor,JAX,18674,ETV6-FGFR3,sensitive,654,AZD4547,2120,27401245,,,
0,Preclinical - Cell culture,"In a preclinical study, a diffuse large B-cell lymphoma cell line harboring EZH2 Y646S demonstrated sensitivity to EED226, resulting in inhibition of cell proliferation in culture (PMID: 28135235).",Actionable,11146,50745,diffuse large B-cell lymphoma,DOID,1176,EZH2 Y646S,sensitive,5886,EED226,2146,28135235,,,
1,Preclinical,"In a preclinical study, EPZ005687 promoted apoptosis in non-Hodgkin lymphoma cell lines expressing EZH2 Y641C (PMID: 23023262).",Actionable,2178,60060,non-Hodgkin lymphoma,DOID,675,EZH2 Y641C,sensitive,2663,EPZ005687,2146,23023262,,,
2,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing EZH2 carrying simultaneous A677G and Y111D mutations demonstrated reduced sensitivity to GSK126 in culture (PMID: 26360609).",Actionable,7819,10000003,Advanced Solid Tumor,JAX,26054,EZH2 Y111D EZH2 Y641F,decreased response,2925,GSK126,2146,26360609,,,
3,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing EZH2 carrying simultaneous Y641F and Y111D mutations demonstrated reduced sensitivity to Tazemetostat (EPZ-6438) in culture (PMID: 26360609).",Actionable,7820,10000003,Advanced Solid Tumor,JAX,26054,EZH2 Y111D EZH2 Y641F,decreased response,2683,Tazemetostat,2146,26360609,,,
4,Preclinical - Cell culture,"In a preclinical study, over expression of EZH2 Y111D in transformed cells harboring wild-type Ezh2 resulted in resistance to GSK126 treatment in culture (PMID: 26360609).",Actionable,7824,10000003,Advanced Solid Tumor,JAX,26049,EZH2 Y111D,resistant,2925,GSK126,2146,26360609,,,
5,Preclinical - Cell culture,"In a preclinical study, over expression of EZH2 Y111D in transformed cells harboring wild-type Ezh2 resulted in resistance to Tazemetostat (EPZ-6438) treatment in culture (PMID: 26360609).",Actionable,7825,10000003,Advanced Solid Tumor,JAX,26049,EZH2 Y111D,resistant,2683,Tazemetostat,2146,26360609,,,
6,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing EZH2 carrying simultaneous A677G and Y111D mutations were resistant to GSK126 in culture (PMID: 26360609).",Actionable,7818,10000003,Advanced Solid Tumor,JAX,26052,EZH2 A677G EZH2 Y111D,resistant,2925,GSK126,2146,26360609,,,
7,Preclinical - Cell culture,"In a preclinical study, EZH2 Y111D conferred resistance to Tazemetostat (EPZ-6438) when occurred in the same allele as EZH2 A677G in B-cell lymphoma cells in culture (PMID: 26360609).",Actionable,7815,707,B-cell lymphoma,DOID,26052,EZH2 A677G EZH2 Y111D,resistant,2683,Tazemetostat,2146,26360609,,,
8,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing EZH2 carrying simultaneous A677G and Y111D mutations were resistant to Tazemetostat (EPZ-6438) in culture (PMID: 26360609).",Actionable,7816,10000003,Advanced Solid Tumor,JAX,26052,EZH2 A677G EZH2 Y111D,resistant,2683,Tazemetostat,2146,26360609,,,
9,Preclinical - Cell culture,"In a preclinical study, EZH2 Y111D conferred resistance to GSK126 when occurred in the same allele as EZH2 A677G in B-cell lymphoma cells in culture (PMID: 26360609).",Actionable,7817,707,B-cell lymphoma,DOID,26052,EZH2 A677G EZH2 Y111D,resistant,2925,GSK126,2146,26360609,,,
10,Preclinical - Cell culture,"In a preclinical study, over expression of EZH2 Y111D in rhabdoid tumor cells harboring an SMARCB1 inactivating mutation resulted in resistance to Tazemetostat (EPZ-6438) treatment in culture (PMID: 26360609).",Actionable,7826,3672,rhabdoid cancer,DOID,26057,EZH2 Y111D SMARCB1 inact mut,resistant,2683,Tazemetostat,2146,26360609,,,
11,Preclinical - Cell culture,"In a preclinical study, a murine acute myeloid leukemia cell line expressing EZH2 T678_R679delinsKK were resistant to Tazemetostat (EPZ-6438) in culture (PMID: 28231254).",Actionable,11713,9119,acute myeloid leukemia,DOID,28195,EZH2 T678_R679delinsKK,resistant,2683,Tazemetostat,2146,28231254,,,
12,Preclinical - Cell culture,"In a preclinical study, diffuse large B-cell lymphoma cells co-expressing EZH2 F120L and EZH2 Y111N were resistant to EI1 in culture, demonstrating no inhibition of cell proliferation (PMID: 28135235). ",Actionable,11147,50745,diffuse large B-cell lymphoma,DOID,27920,EZH2 F120L EZH2 Y111N,resistant,2927,EI1,2146,28135235,,,
13,Preclinical - Cell culture,"In a preclinical study, diffuse large B-cell lymphoma cells co-expressing EZH2 F120L and EZH2 Y111N were sensitive to EED226, demonstrating inhibition of cell proliferation in culture (PMID: 28135235). ",Actionable,11149,50745,diffuse large B-cell lymphoma,DOID,27920,EZH2 F120L EZH2 Y111N,sensitive,5886,EED226,2146,28135235,,,
14,Preclinical - Cell culture,"In a preclinical study, a cancer cell line co-expressing EZH2 F120L and EZH2 Y111N was resistant to Tazemetostat (EPZ-6438) in culture, demonstrating no inhibition of cell proliferation (PMID: 28135235). ",Actionable,11148,10000003,Advanced Solid Tumor,JAX,27920,EZH2 F120L EZH2 Y111N,resistant,2683,Tazemetostat,2146,28135235,,,
15,Preclinical,"In a preclinical study, GSK126 inhibited H3K27 trimethylation in human melanoma cells harboring wild-type EZH2 in culture (PMID: 26936398).",Actionable,5616,1909,melanoma,DOID,535,EZH2 wild-type,predicted â€“ sensitive,2925,GSK126,2146,26936398,,,
16,Preclinical,"In a preclinical study, GSK126 inhibited H3K27 trimethylation and reversed transcriptional silencing in human melanoma cells harboring EZH2 Y641H in culture (PMID: 26936398).",Actionable,5613,1909,melanoma,DOID,674,EZH2 Y641H,predicted â€“ sensitive,2925,GSK126,2146,26936398,,,
17,Preclinical,"In a preclinical study, JQEZ5 inhibited proliferation of human EZH2 over expressing non-small cell lung cancer cells in culture and induced tumor regression in mouse models of EZH2-over expressing lung adenocarcinoma (PMID: 27312177).",Actionable,7042,3908,non-small cell lung carcinoma,DOID,24368,EZH2 over exp,sensitive,4354,JQEZ5,2146,27312177,,,
18,Preclinical,"In a preclinical study, DLBCL cells harboring EZH2 Y641S demonstrated sensitivity to ACY-957 in culture, resulting in increased levels of H3K27ac and cell cycle arrest (PMID: 25605023). ",Actionable,6552,50745,diffuse large B-cell lymphoma,DOID,673,EZH2 Y641S,sensitive,4144,ACY-957,2146,25605023,,,
19,Preclinical,"In a preclinical study, DLBCL cells harboring EZH2 Y641S demonstrated a decreased response to GSK126 in culture (PMID: 25605023). ",Actionable,6562,50745,diffuse large B-cell lymphoma,DOID,673,EZH2 Y641S,decreased response,2925,GSK126,2146,25605023,,,
20,Preclinical,"In a preclinical study, DZNeP enhanced the sensitivity of ACY-957 treatment in DLBCL cells harboring EZH2 Y641S in culture, resulting in increased cell death and elevated levels of H3K27ac (PMID: 25605023). ",Actionable,6561,50745,diffuse large B-cell lymphoma,DOID,673,EZH2 Y641S,sensitive,4147,ACY-957 + DZNeP,2146,25605023,,,
21,Preclinical,"In a preclinical study, DLBCL cells harboring EZH2 Y641S demonstrated sensitivity to Zolinza (vorinostat) in culture, resulting in increased levels of H3K27ac and cell cycle arrest (PMID: 25605023). ",Actionable,6557,50745,diffuse large B-cell lymphoma,DOID,673,EZH2 Y641S,sensitive,1077,Vorinostat,2146,25605023,,,
22,Preclinical,"In a preclinical study, DLBCL cells harboring EZH2 Y641S demonstrated a decreased response to DZNeP in culture (PMID: 25605023). ",Actionable,6564,50745,diffuse large B-cell lymphoma,DOID,673,EZH2 Y641S,decreased response,2702,DZNeP,2146,25605023,,,
23,Preclinical,"In a preclinical study, GSK126 enhanced the sensitivity of ACY-957 treatment in DLBCL cells harboring EZH2 Y641S in culture, resulting in increased cell death and elevated levels of H3K27ac (PMID: 25605023). ",Actionable,6559,50745,diffuse large B-cell lymphoma,DOID,673,EZH2 Y641S,sensitive,4148,ACY-957 + GSK126,2146,25605023,,,
24,Preclinical,"In a preclinical study, GSK126 reversed transcriptional silencing in human melanoma cells harboring wild-type EZH2 Y641S in culture (PMID: 26936398).",Actionable,5617,1909,melanoma,DOID,673,EZH2 Y641S,predicted â€“ sensitive,2925,GSK126,2146,26936398,,,
25,Preclinical,"In a preclinical study, DLBCL cells harboring EZH2 Y641N demonstrated sensitivity to Zolinza (vorinostat) in culture, resulting in increased levels of H3K27ac and cell cycle arrest (PMID: 25605023). ",Actionable,6554,50745,diffuse large B-cell lymphoma,DOID,672,EZH2 Y641N,sensitive,1077,Vorinostat,2146,25605023,,,
26,Preclinical - Cell culture,"In a preclinical study, a diffuse large B-cell lymphoma cell line harboring EZH2 Y641N demonstrated sensitivity to EED226, resulting in inhibition of cell proliferation in culture and delayed tumor growth and tumor regression in a cell line xenograft model (PMID: 28135235).",Actionable,11145,50745,diffuse large B-cell lymphoma,DOID,672,EZH2 Y641N,sensitive,5886,EED226,2146,28135235,,,
27,Preclinical,"In a preclinical study, GSK126 inhibited H3K27 trimethylation and reversed transcriptional silencing in human melanoma cells harboring EZH2 Y641N in culture (PMID: 26936398).",Actionable,5614,1909,melanoma,DOID,672,EZH2 Y641N,predicted â€“ sensitive,2925,GSK126,2146,26936398,,,
28,Preclinical,"In a preclinical study, DZNeP enhanced the sensitivity of ACY-957 treatment in DLBCL cells harboring EZH2 Y641N in culture, resulting in increased cell death and elevated levels of H3K27ac (PMID: 25605023). ",Actionable,6560,50745,diffuse large B-cell lymphoma,DOID,672,EZH2 Y641N,sensitive,4147,ACY-957 + DZNeP,2146,25605023,,,
29,Preclinical,"In a preclinical study, DLBCL cells harboring EZH2 Y641N demonstrated a decreased response to GSK126 in culture (PMID: 25605023). ",Actionable,6563,50745,diffuse large B-cell lymphoma,DOID,672,EZH2 Y641N,decreased response,2925,GSK126,2146,25605023,,,
30,Preclinical,"In a preclinical study, DLBCL cells harboring EZH2 Y641N treated with the combination of ACY-957 and Adriamycin (doxorubicin) resulted in a greater sensitivity to cell death compared to treatment with either agent alone (PMID: 25605023). ",Actionable,6625,50745,diffuse large B-cell lymphoma,DOID,672,EZH2 Y641N,sensitive,4187,ACY-957 + Doxorubicin,2146,25605023,,,
31,Preclinical,"In a preclinical study, UNC1999 treatment reduced H3K27me3 levels, decreased proliferation, and increased cell death in diffuse large B-cell lymphoma cells harboring an EZH2 Y641N mutation in cell culture (PMID: 23614352).",Actionable,1426,50745,diffuse large B-cell lymphoma,DOID,672,EZH2 Y641N,sensitive,1757,UNC1999,2146,23614352,,,
32,Preclinical,"In a preclinical study, DLBCL cells harboring EZH2 Y641N demonstrated sensitivity to ACY-957 in culture, resulting in increased levels of H3K27ac and cell cycle arrest (PMID: 25605023). ",Actionable,6551,50745,diffuse large B-cell lymphoma,DOID,672,EZH2 Y641N,sensitive,4144,ACY-957,2146,25605023,,,
33,Preclinical,"In a preclinical study, DLBCL cells harboring EZH2 Y641N demonstrated a decreased response to DZNeP in culture (PMID: 25605023). ",Actionable,6565,50745,diffuse large B-cell lymphoma,DOID,672,EZH2 Y641N,decreased response,2702,DZNeP,2146,25605023,,,
34,Preclinical,"In a preclinical study, GSK126 enhanced the sensitivity of ACY-957 treatment in DLBCL cells harboring EZH2 Y641N in culture, resulting in increased cell death and elevated levels of H3K27ac (PMID: 25605023). ",Actionable,6558,50745,diffuse large B-cell lymphoma,DOID,672,EZH2 Y641N,sensitive,4148,ACY-957 + GSK126,2146,25605023,,,
35,Preclinical - Cell culture,"In a preclinical study, the combination therapy of EED226 and EI1 synergistically inhibited cell proliferation of a diffuse large B-cell lymphoma harboring EZH2 Y641N (PMID: 28135235). ",Actionable,11151,50745,diffuse large B-cell lymphoma,DOID,672,EZH2 Y641N,sensitive,5887,EED226 + EI1,2146,28135235,,,
36,Preclinical - Cell line xenograft,"In a preclinical study, a diffuse large B-cell lymphoma cell line harboring an EZH2 mutation demonstrated sensitivity to A-395, showing inhibition of tumor growth, however, due to its chemical properties A-395 will not proceed to clinical development (PMID: 28135237). ",Actionable,11161,50745,diffuse large B-cell lymphoma,DOID,27863,EZH2 mutant,sensitive,5889,A-395,2146,28135237,,,
37,Preclinical,"In a preclinical study, GSK126 treatment inhibited cell growth via suppression of downstream tumor suppressor gene targets and induced apoptosis in melanoma cells harboring EZH2 Y646N in culture (PMID: 26304929). ",Actionable,4027,1909,melanoma,DOID,1175,EZH2 Y646N,sensitive,2925,GSK126,2146,26304929,,,
38,Preclinical - Cell culture,"In a preclinical study, a diffuse large B-cell lymphoma cell line harboring EZH2 Y646N demonstrated sensitivity to EED226, resulting in inhibition of cell proliferation in culture (PMID: 28135235).",Actionable,11144,50745,diffuse large B-cell lymphoma,DOID,1175,EZH2 Y646N,sensitive,5886,EED226,2146,28135235,,,
39,Phase I,"In a Phase I trial, Tazemetostat (EPZ-6438) treatment resulted in partial response for more than 16 weeks in a non-Hodgkin lymphoma patient harboring a EZH2 Y646H mutation (ASH 57th Annual Meeting and Exposition, Dec 2015, Abstract # 473).",Actionable,6950,60060,non-Hodgkin lymphoma,DOID,1174,EZH2 Y646H,sensitive,2683,Tazemetostat,2146,None,,,
40,Preclinical - Cell line xenograft,"In a preclinical study, the addition of DZNep increased sensitivity to Selumetinib (AZD6244) in EZH2-expressing lung adenocarcinoma cell lines harboring KRAS G12C, in culture and in xenograft models, resulting in decreased cell survival and tumor growth (PMID: 26676756).",Actionable,8498,3910,lung adenocarcinoma,DOID,26341,KRAS G12C EZH2 pos,sensitive,4746,DZNep + Selumetinib,2146,26676756,,,
41,Preclinical - Cell culture,"In a preclinical study, the addition of GSK343 did not increase sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12C in culture (PMID: 26676756).",Actionable,8512,3910,lung adenocarcinoma,DOID,26341,KRAS G12C EZH2 pos,no benefit,4751,GSK343 + MK2206,2146,26676756,,,
42,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep increased sensitivity to Selumetinib (AZD6244) in an EZH2-expressing pancreatic cancer cell line harboring KRAS G12C in culture (PMID: 26676756).",Actionable,8517,1793,pancreatic cancer,DOID,26341,KRAS G12C EZH2 pos,sensitive,4746,DZNep + Selumetinib,2146,26676756,,,
43,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing pancreatic cancer cell line harboring KRAS G12C in culture (PMID: 26676756).",Actionable,8521,1793,pancreatic cancer,DOID,26341,KRAS G12C EZH2 pos,sensitive,4747,DZNep + MK2206,2146,26676756,,,
44,Preclinical - Cell culture,"In a preclinical study, the addition of Tazemetostat (EPZ-6438) increased sensitivity to Selumetinib (AZD6244) in EZH2-expressing lung adenocarcinoma cell lines harboring KRAS G12C in culture (PMID: 26676756).",Actionable,8503,3910,lung adenocarcinoma,DOID,26341,KRAS G12C EZH2 pos,sensitive,4748,Selumetinib + Tazemetostat,2146,26676756,,,
45,Preclinical - Cell culture,"In a preclinical study, the addition of GSK343 increased sensitivity to Selumetinib (AZD6244) in EZH2-expressing lung adenocarcinoma cell lines harboring KRAS G12C in culture (PMID: 26676756).",Actionable,8502,3910,lung adenocarcinoma,DOID,26341,KRAS G12C EZH2 pos,sensitive,4750,GSK343 + Selumetinib,2146,26676756,,,
46,Preclinical - Cell culture,"In a preclinical study, the addition of Tazemetostat (EPZ-6438) did not increase sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12C in culture (PMID: 26676756).",Actionable,8513,3910,lung adenocarcinoma,DOID,26341,KRAS G12C EZH2 pos,no benefit,4749,MK2206 + Tazemetostat,2146,26676756,,,
47,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep did not increase sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12C (PMID: 26676756).",Actionable,8510,3910,lung adenocarcinoma,DOID,26341,KRAS G12C EZH2 pos,no benefit,4747,DZNep + MK2206,2146,26676756,,,
48,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing pancreatic cancer cell line harboring KRAS G12D in culture (PMID: 26676756).",Actionable,8516,1793,pancreatic cancer,DOID,26340,KRAS G12D EZH2 pos,no benefit,4746,DZNep + Selumetinib,2146,26676756,,,
49,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing pancreatic cancer cell line harboring KRAS G12D in culture (PMID: 26676756).",Actionable,8520,1793,pancreatic cancer,DOID,26340,KRAS G12D EZH2 pos,sensitive,4747,DZNep + MK2206,2146,26676756,,,
50,Preclinical - Cell culture,"In a preclinical study, the addition of GSK343 did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D (PMID: 26676756).",Actionable,8504,3910,lung adenocarcinoma,DOID,26340,KRAS G12D EZH2 pos,no benefit,4750,GSK343 + Selumetinib,2146,26676756,,,
51,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing colon cancer cell line harboring KRAS G12D in culture (PMID: 26676756).",Actionable,8519,219,colon cancer,DOID,26340,KRAS G12D EZH2 pos,sensitive,4747,DZNep + MK2206,2146,26676756,,,
52,Preclinical - Cell culture,"In a preclinical study, the addition of Tazemetostat (EPZ-6438) did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D (PMID: 26676756).",Actionable,8505,3910,lung adenocarcinoma,DOID,26340,KRAS G12D EZH2 pos,no benefit,4748,Selumetinib + Tazemetostat,2146,26676756,,,
53,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D (PMID: 26676756).",Actionable,8500,3910,lung adenocarcinoma,DOID,26340,KRAS G12D EZH2 pos,no benefit,4746,DZNep + Selumetinib,2146,26676756,,,
54,Preclinical - Cell culture,"In a preclinical study, the addition of GSK343 increased sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D in culture (PMID: 26676756).",Actionable,8507,3910,lung adenocarcinoma,DOID,26340,KRAS G12D EZH2 pos,sensitive,4751,GSK343 + MK2206,2146,26676756,,,
55,Preclinical - Cell culture,"In a preclinical study, the addition of Tazemetostat (EPZ-6438) increased sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D in culture (PMID: 26676756).",Actionable,8508,3910,lung adenocarcinoma,DOID,26340,KRAS G12D EZH2 pos,sensitive,4749,MK2206 + Tazemetostat,2146,26676756,,,
56,Preclinical - Cell line xenograft,"In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D in culture and in xenograft models, resulting in decreased cell survival and tumor growth (PMID: 26676756).",Actionable,8506,3910,lung adenocarcinoma,DOID,26340,KRAS G12D EZH2 pos,sensitive,4747,DZNep + MK2206,2146,26676756,,,
57,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing colon cancer cell line harboring KRAS G12D in culture (PMID: 26676756).",Actionable,8518,219,colon cancer,DOID,26340,KRAS G12D EZH2 pos,no benefit,4746,DZNep + Selumetinib,2146,26676756,,,
58,Phase I,"In a Phase I trial, Tazemetostat (EPZ-6438) treatment resulted in a total response rate of 80% (4/5, 3 complete and partial response, 1 stable disease) in follicular lymphoma patients harboring wild-type EZH2 or a EZH2 Y646H mutation (ASH 57th Annual Meeting and Exposition, Dec 2015, Abstract # 473).",Actionable,6952,50873,follicular lymphoma,DOID,24158,EZH2 positive,sensitive,2683,Tazemetostat,2146,None,,,
59,Phase I,"In a Phase I trial, Tazemetostat (EPZ-6438) treatment resulted in a total response rate (complete response and partial response) of 60% (9/15) in non-Hodgkin lymphoma patients harboring wild-type EZH2 or a EZH2 Y646H mutation (ASH 57th Annual Meeting and Exposition, Dec 2015, Abstract # 473).",Actionable,6949,60060,non-Hodgkin lymphoma,DOID,24158,EZH2 positive,sensitive,2683,Tazemetostat,2146,None,,,
60,Phase I,"In a Phase I trial, Tazemetostat (EPZ-6438) treatment resulted in a total response rate (complete response and partial response) of 56% (5/9) in diffuse large B-cell lymphoma patients harboring wild-type EZH2 or a EZH2 Y646H mutation (ASH 57th Annual Meeting and Exposition, Dec 2015, Abstract # 473).",Actionable,6951,50745,diffuse large B-cell lymphoma,DOID,24158,EZH2 positive,sensitive,2683,Tazemetostat,2146,None,,,
61,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12V (PMID: 26676756).",Actionable,8501,3910,lung adenocarcinoma,DOID,26342,KRAS G12V EZH2 pos,no benefit,4746,DZNep + Selumetinib,2146,26676756,,,
62,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep did not increase sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12V (PMID: 26676756).",Actionable,8509,3910,lung adenocarcinoma,DOID,26342,KRAS G12V EZH2 pos,no benefit,4747,DZNep + MK2206,2146,26676756,,,
63,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep increased sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12S in culture (PMID: 26676756).",Actionable,8499,3910,lung adenocarcinoma,DOID,26343,KRAS G12S EZH2 pos,sensitive,4746,DZNep + Selumetinib,2146,26676756,,,
64,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12S in culture (PMID: 26676756)",Actionable,8511,3910,lung adenocarcinoma,DOID,26343,KRAS G12S EZH2 pos,sensitive,4747,DZNep + MK2206,2146,26676756,,,
65,Preclinical,"In a preclinical study, treatment with EPZ-6438 inhibited proliferation and promoted cell death in lymphoma cells expressing EZH2 Y646F (PMID: 24563539). ",Actionable,2187,60058,lymphoma,DOID,1173,EZH2 Y646F,sensitive,2683,Tazemetostat,2146,24563539,,,
66,Preclinical - Cell culture,"In a preclinical study, a diffuse large B-cell lymphoma cell line harboring EZH2 Y646F demonstrated sensitivity to EED226, resulting in inhibition of cell proliferation in culture (PMID: 28135235). ",Actionable,11143,50745,diffuse large B-cell lymphoma,DOID,1173,EZH2 Y646F,sensitive,5886,EED226,2146,28135235,,,
0,Preclinical,"In a preclinical study, homozygous deletion of FBXW7 is conferred resistance to gamma secretase inhibitor, MRK-003, by activation of the NOTCH pathway and stablization of MYC as demonstrated in T cell acute lymphoblastic leukemia (T-ALL) cell lines (PMID: 17646409).",Actionable,719,5602,T-cell adult acute lymphocytic leukemia,DOID,1039,FBXW7 del,resistant,1084,MRK-003,55294,17646409,,,
1,Preclinical,"In a preclinical study, FBXW7 R465C conferred resistance to gamma secretase inhibitor, MRK-003, by activation of the NOTCH pathway and stablization of MYC as demonstrated in T cell acute lymphoblastic leukemia (T-ALL) cell lines (PMID: 17646409).",Actionable,722,5602,T-cell adult acute lymphocytic leukemia,DOID,813,FBXW7 R465C,resistant,1084,MRK-003,55294,17646409,,,
2,Clinical Study,"In a clinical case report, a patient with lung adenocarcinoma harboring FBXW7 R465H demonstrated tumor shrinkage when treated with Torisel (temsirolimus) (PMID: 24360397).",Actionable,2504,3910,lung adenocarcinoma,DOID,1038,FBXW7 R465H,sensitive,936,Temsirolimus,55294,24360397,,,
3,Preclinical,"In a preclinical study, FBXW7 R465H conferred resistance to gamma secretase inhibitor, MRK-003, by activation of the NOTCH pathway and stablization of MYC as demonstrated in T cell acute lymphoblastic leukemia (T-ALL) cell lines (PMID: 17646409).",Actionable,718,5602,T-cell adult acute lymphocytic leukemia,DOID,1038,FBXW7 R465H,resistant,1084,MRK-003,55294,17646409,,,
4,Preclinical,"In a preclinical study, FBXW7 R479Q conferred resistance to gamma secretase inhibitor, MRK-003, by activation of the NOTCH pathway and stablization of MYC as demonstrated in T cell acute lymphoblastic leukemia (T-ALL) cell lines (PMID: 17646409).",Actionable,721,5602,T-cell adult acute lymphocytic leukemia,DOID,1041,FBXW7 R479Q,resistant,1084,MRK-003,55294,17646409,,,
5,Preclinical - Cell culture,"In a preclinical study, colorectal cell lines with FBXW7 R505C demonstrated acquired resistance in regorafenib (PMID: 27399335).",Actionable,11965,9256,colorectal cancer,DOID,1040,FBXW7 R505C,resistant,890,Regorafenib,55294,27399335,,,
6,Preclinical,"In a preclinical study, FBXW7 R505C conferred resistance to gamma secretase inhibitor, MRK-300, by activation of the NOTCH pathway and stablization of MYC as demonstrated in T cell acute lymphoblastic leukemia (T-ALL) cell lines (PMID: 17646409).",Actionable,720,5602,T-cell adult acute lymphocytic leukemia,DOID,1040,FBXW7 R505C,resistant,1084,MRK-003,55294,17646409,,,
7,Preclinical,"In a preclinical study, Zolinza (vorinostat) inhibited growth of a head and neck squamous cell carcinoma cell line harboring FBXW7 R505C in culture (PMID: 23274910). ",Actionable,3375,5520,head and neck squamous cell carcinoma,DOID,1040,FBXW7 R505C,sensitive,1077,Vorinostat,55294,23274910,,,
8,Preclinical,"In a preclinical study, Rapamune (sirolimus) inhibited epithelial-mesenchymal transition, motility, and invasiveness in colon cancer cells lacking FBXW7 in culture (PMID: 23558291)",Actionable,1304,219,colon cancer,DOID,2397,FBXW7 loss,sensitive,917,Sirolimus,55294,23558291,,,
9,Preclinical - Cell line xenograft,"In a preclinical study, breast cancer cells harboring a FBXW7 mutation demonstrated sensitivity to Rapamune (sirolimus) in culture and in cell line xenograft models (PMID: 18787170).",Actionable,2073,1612,breast cancer,DOID,5029,FBXW7 inact mut,sensitive,917,Sirolimus,55294,18787170,,,
10,Preclinical,"In a preclinical study, Beleodaq (belinostat) inhibited human cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910).",Actionable,3388,10000003,Advanced Solid Tumor,JAX,5029,FBXW7 inact mut,sensitive,1078,Belinostat,55294,23274910,,,
11,Preclinical,"In a preclinical study, AR-42 inhibited human hematologic cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910).",Actionable,3391,2531,hematologic cancer,DOID,5029,FBXW7 inact mut,sensitive,987,AR-42,55294,23274910,,,
12,Preclinical,"In a preclinical study, human cancer cell lines harboring FBXW7 inactivating mutations were resistant to docetaxel in culture (PMID: 23274910). ",Actionable,3387,10000003,Advanced Solid Tumor,JAX,5029,FBXW7 inact mut,resistant,720,Docetaxel,55294,23274910,,,
13,Preclinical,"In a preclinical study, entinostat (MS-275) inhibited cancer cells from advanced solid tumors and hematological cells harboring FBXW7 inactivating mutations in culture (PMID: 23274910).",Actionable,3754,2531,hematologic cancer,DOID,5029,FBXW7 inact mut,sensitive,1541,Entinostat,55294,23274910,,,
14,Preclinical,"In a preclinical study, Beleodaq (belinostat) inhibited human hematologic cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910).",Actionable,3389,2531,hematologic cancer,DOID,5029,FBXW7 inact mut,sensitive,1078,Belinostat,55294,23274910,,,
15,Phase I,"In a Phase I study, Rapamune (sirolimus) resulted in prolonged stable disease in a patient with hepatocellular fibrolamellar carcinoma harboring a FBXW7 mutation (PMID: 24586741).",Actionable,2072,5015,fibrolamellar carcinoma,DOID,5029,FBXW7 inact mut,sensitive,917,Sirolimus,55294,24586741,,,
16,Preclinical,"In a preclinical study, entinostat (MS-275) inhibited cancer cells from advanced solid tumors and hematological cells harboring FBXW7 inactivating mutations in culture (PMID: 23274910).",Actionable,3386,10000003,Advanced Solid Tumor,JAX,5029,FBXW7 inact mut,sensitive,1541,Entinostat,55294,23274910,,,
17,Preclinical,"In a preclinical study, AR-42 inhibited human cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910).",Actionable,3390,10000003,Advanced Solid Tumor,JAX,5029,FBXW7 inact mut,sensitive,987,AR-42,55294,23274910,,,
18,Preclinical,"In a preclinical study, FBXW7 R505L may conferred resistance to gamma secretase inhibitor, MRK-003, by activation of the NOTCH pathway and stablization of MYC as demonstrated in T cell acute lymphoblastic leukemia (T-ALL) cell lines (PMID: 17646409).",Actionable,723,5602,T-cell adult acute lymphocytic leukemia,DOID,839,FBXW7 R505L,resistant,1084,MRK-003,55294,17646409,,,
0,Preclinical - Cell line xenograft,"In a preclinical study, a variety of cancer cell lines harboring mutations in FGFR1, FGFR2, and/or FGFR3 demonstrated sensitivity to INCB054828 in culture and in cell line xenograft models, resulting in inhibition of tumor growth (Cancer Res 2015;75(15 Suppl):Abstract nr 771).",Actionable,7177,10000003,Advanced Solid Tumor,JAX,1221,FGFR1 mutant,sensitive,4173,INCB054828,2260,None,,,
1,Preclinical - Cell culture,"In a preclinical study, an estrogen-receptor positive breast cancer cell line harboring an FGFR1 amplification demonstrated resistance to Alpelisib (BYL719) in culture (PMID: 27126994). ",Actionable,9707,60075,estrogen-receptor positive breast cancer,DOID,812,FGFR1 amp,resistant,691,BYL719,2260,27126994,,,
2,Preclinical,"In a preclinical study, Ofev (nintedanib) inhibited the growth of ER-positive breast cancer cells harboring FGFR1 amplification in culture (PMID: 22238366).",Actionable,3531,60075,estrogen-receptor positive breast cancer,DOID,812,FGFR1 amp,sensitive,831,Nintedanib,2260,22238366,,,
3,Preclinical - Cell line xenograft,"In a preclinical study, JNJ-42756493 (erdafitinib) inhibited FGFR downstream signaling and proliferation of several lung cancer cell lines with FGFR1 amplification in culture, and inhibited tumor growth in an FGFR1-amplified lung cancer cell line xenograft model (PMID: 28341788).",Actionable,11179,1324,lung cancer,DOID,812,FGFR1 amp,predicted â€“ sensitive,1028,JNJ-42756493,2260,28341788,,,
4,Preclinical - Cell line xenograft,"In a preclinical study, GSK3052230 (FP-1039) treatment inhibited growth of FGFR1 amplified lung small cell carcinoma cell lines in culture and in cell line xenograft models (PMID: 23536011).",Actionable,11477,5409,lung small cell carcinoma,DOID,812,FGFR1 amp,sensitive,2899,GSK3052230,2260,23536011,,,
5,Preclinical - Cell line xenograft,"In a preclinical study, addition of GSK3052230 (FP-1039) to Platinol (cisplatin) and Vepesid (etoposide) resulted in improved tumor growth inhibition in cell line xenograft models of FGFR1 amplified lung small cell carcinoma (PMID: 23536011).",Actionable,11479,5409,lung small cell carcinoma,DOID,812,FGFR1 amp,sensitive,6002,Cisplatin + Etoposide + GSK3052230,2260,23536011,,,
6,Preclinical,"In a preclinical study, AZD4547 inhibited proliferation of a small cell lung cancer cell line harboring FGFR1 amplification in culture (PMID: 23082000).",Actionable,6866,5409,lung small cell carcinoma,DOID,812,FGFR1 amp,sensitive,654,AZD4547,2260,23082000,,,
7,Preclinical,"In a preclinical study, Dovitinib (TKI258) inhibited cell proliferation in estrogen receptor (ER)-positive breast cancer cells harboring FGFR1 amplification in culture (PMID: 22238366).",Actionable,3529,60075,estrogen-receptor positive breast cancer,DOID,812,FGFR1 amp,sensitive,721,Dovitinib,2260,22238366,,,
8,Preclinical - Cell culture,"In a preclinical study, BGJ398 inhibited survival of FGFR1 amplified synovial sarcoma cells in culture (PMID: 27535980).",Actionable,8025,5485,synovial sarcoma,DOID,812,FGFR1 amp,sensitive,674,BGJ398,2260,27535980,,,
9,Preclinical,"In a preclinical study, Cediranib (AZD-2171) inhibited growth of estrogen receptor (ER)-positive breast cancer cells with FGFR1 amplification in culture (PMID: 22238366).",Actionable,3530,60075,estrogen-receptor positive breast cancer,DOID,812,FGFR1 amp,sensitive,1001,Cediranib,2260,22238366,,,
10,Preclinical - Pdx,"In a preclinical study, PRN1371 treatment resulted in tumor growth inhibition in patient-derived xenograft models of FGFR1-amplified non-small cell lung cancer (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).",Actionable,8409,3908,non-small cell lung carcinoma,DOID,812,FGFR1 amp,sensitive,3583,PRN1371,2260,None,,,
11,Preclinical - Cell line xenograft,"In a preclinical study, GSK3052230 (FP-1039) treatment resulted in greater tumor growth inhibition (56% vs 22%) in cell line xenograft models of FGFR1 amplified lung cancer compared to FGFR1 non-amplified models (PMID: 23536011).",Actionable,11476,1324,lung cancer,DOID,812,FGFR1 amp,sensitive,2899,GSK3052230,2260,23536011,,,
12,Preclinical - Cell culture,"In a preclinical study, PD173074 inhibited survival of FGFR1 amplified synovial sarcoma cells in culture (PMID: 27535980).",Actionable,8023,5485,synovial sarcoma,DOID,812,FGFR1 amp,sensitive,2948,PD173074,2260,27535980,,,
13,Preclinical - Cell culture,"In a preclinical study, FGFR1 amplified non-small cell lung carcinoma cells were not sensitive to RO5126766 in culture (PMID: 26438159).",Actionable,8469,3908,non-small cell lung carcinoma,DOID,812,FGFR1 amp,no benefit,2011,RO5126766,2260,26438159,,,
14,Preclinical - Cell culture,"In a preclinical study, a small cell lung cancer cell line harboring FGFR1 amplification demonstrated sensitivity to E7090, resulting in decreased cell viability in culture and antitumor activity in xenograft models (PMID: 27535969). ",Actionable,9140,5409,lung small cell carcinoma,DOID,812,FGFR1 amp,sensitive,4911,E7090,2260,27535969,,,
15,Preclinical - Cell culture,"In a preclinical study, an estrogen-receptor positive breast cancer cell line harboring FGFR1 amplification (PMID: 7506125) demonstrated sensitivity to E7090 in culture, resulting in decreased cell viability (PMID: 27535969). ",Actionable,9127,60075,estrogen-receptor positive breast cancer,DOID,812,FGFR1 amp,sensitive,4911,E7090,2260,27535969,7506125,,
16,Preclinical,"In a preclinical study, AZD4547 inhibited proliferation of a large cell lung cancer cell line harboring FGFR1 amplification in culture and induced tumor regression in xenograft models (PMID: 23082000).",Actionable,6865,4556,lung large cell carcinoma,DOID,812,FGFR1 amp,sensitive,654,AZD4547,2260,23082000,,,
17,Preclinical - Cell culture,"In a preclinical study, the combination of AZD4547 and Buparlisib (BKM120) induced apoptosis in a squamous cell lung cancer cell line with amplification of FGFR1 in culture (PMID: 28108151).",Actionable,11212,3907,lung squamous cell carcinoma,DOID,812,FGFR1 amp,sensitive,5898,AZD4547 + BKM120,2260,28108151,,,
18,Preclinical - Cell culture,"In a preclinical study, FGFR1 amplified non-small cell lung carcinoma cells were not sensitive to RO4987655 in culture (PMID: 26438159).",Actionable,8451,3908,non-small cell lung carcinoma,DOID,812,FGFR1 amp,no benefit,903,RO4987655,2260,26438159,,,
19,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited Fgfr phosphorylation and cell proliferation in ER-positive breast cancer cells harboring FGFR1 amplification in culture (PMID: 22238366).",Actionable,3528,1612,breast cancer,DOID,812,FGFR1 amp,sensitive,877,Ponatinib,2260,22238366,,,
20,Preclinical - Cell culture,"In a preclinical study, FGFR1 amplified lung small cell carcinoma cells were not sensitive to RO5126766 in culture (PMID: 26438159).",Actionable,8467,5409,lung small cell carcinoma,DOID,812,FGFR1 amp,no benefit,2011,RO5126766,2260,26438159,,,
21,Preclinical - Cell line xenograft,"In a preclinical study, a non-small cell lung cancer cell line, harboring FGFR1 amplification, treated with E7090 demonstrated decreased cell viability in culture and antitumor activity in xenograft models (PMID: 27535969). ",Actionable,9130,3908,non-small cell lung carcinoma,DOID,812,FGFR1 amp,sensitive,4911,E7090,2260,27535969,,,
22,Preclinical,"In a preclinical study, Debio 1347 inhibited proliferation of non-small cell lung cancer cell lines harboring FGFR1 amplification in culture (PMID: 25169980).",Actionable,4067,3908,non-small cell lung carcinoma,DOID,812,FGFR1 amp,sensitive,1014,FF-284,2260,25169980,,,
23,Preclinical - Cell line xenograft,"In a preclinical study, GSK3052230 (FP-1039) treatment inhibited growth of FGFR1 amplified non-small cell lung carcinoma cell lines in culture and in cell line xenograft models (PMID: 23536011).",Actionable,11478,3908,non-small cell lung carcinoma,DOID,812,FGFR1 amp,sensitive,2899,GSK3052230,2260,23536011,,,
24,Preclinical - Cell culture,"In a preclinical study, NGI-1 inhibited FGFR1 phosphorylation and proliferation of a FGFR1-amplified cell line dependent on FGFR1 signaling in culture, however, did not inhibit proliferation of an FGFR1-amplified cell line not dependent on FGFR1 signaling (PMID: 27694802).",Actionable,9229,3908,non-small cell lung carcinoma,DOID,812,FGFR1 amp,predicted â€“ sensitive,4957,NGI-1,2260,27694802,,,
25,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited growth of squamous cell lung cancer cell lines harboring FGFR1 amplification (PMID: 22238366).",Actionable,648,3907,lung squamous cell carcinoma,DOID,812,FGFR1 amp,sensitive,877,Ponatinib,2260,22238366,,,
26,Preclinical - Cell culture,"In a preclinical study, AZD4547 inhibited survival of FGFR1 amplified synovial sarcoma cells in culture (PMID: 27535980).",Actionable,8024,5485,synovial sarcoma,DOID,812,FGFR1 amp,sensitive,654,AZD4547,2260,27535980,,,
27,Phase I,"In a Phase I trial, patients with lung squamous cell carcinoma harboring an FGFR1 amplification demonstrated a disease control rate of 50% (18/36) when treated with BGJ398, resulting in 14 patients with stable disease and 4 patients with a partial response (PMID: 27870574). ",Actionable,9731,3907,lung squamous cell carcinoma,DOID,812,FGFR1 amp,sensitive,674,BGJ398,2260,27870574,,,
28,Preclinical - Cell culture,"In a preclinical study, FGFR1 amplified lung small cell carcinoma cells were not sensitive to RO4987655 in culture (PMID: 26438159).",Actionable,8449,5409,lung small cell carcinoma,DOID,812,FGFR1 amp,no benefit,903,RO4987655,2260,26438159,,,
29,Preclinical,"In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of lung cancer cells with FGFR1 amplification in culture (PMID: 22238366).",Actionable,3541,1324,lung cancer,DOID,812,FGFR1 amp,no benefit,996,Brivanib,2260,22238366,,,
30,Phase II,"In a Phase II clinical trial, treatment with AZD4547 resulted in a response rate of 12.5% (1/8) in patients with FGFR1-amplified breast cancer, and did not meet the predetermined criteria for efficacy (PMID: 27179038).",Actionable,7571,1612,breast cancer,DOID,812,FGFR1 amp,no benefit,654,AZD4547,2260,27179038,,,
31,Phase I,"In a Phase I trial, Dovitinib (TKI258) promoted 6-month stable disease in Erbb2 (Her2)-positive breast cancer patients with FGFR1 amplification (PMID: 23658459).",Actionable,1043,60079,Her2-receptor positive breast cancer,DOID,812,FGFR1 amp,sensitive,721,Dovitinib,2260,23658459,,,
32,Preclinical - Cell culture,"In a preclinical study, the combination of AZD4547 and Buparlisib (BKM120) worked synergistically to induce apoptosis and inhibit growth of a urothelial cell carcinoma cell line with FGFR1 amplification in culture, with increased efficacy over either agent alone (PMID: 28108151).",Actionable,11213,2671,transitional cell carcinoma,DOID,812,FGFR1 amp,sensitive,5898,AZD4547 + BKM120,2260,28108151,,,
33,Preclinical,"In a preclinical study, AZD4547 inhibited proliferation of lung cancer cell lines harboring FGFR1 amplification in culture and induced tumor regression in xenograft models (PMID: 23082000).",Actionable,6791,1324,lung cancer,DOID,812,FGFR1 amp,sensitive,654,AZD4547,2260,23082000,,,
34,Preclinical - Cell culture,"In a preclinical study, FGFR1 amplified lung squamous cell carcinoma cells were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).",Actionable,8482,3907,lung squamous cell carcinoma,DOID,812,FGFR1 amp,no benefit,913,Selumetinib,2260,26438159,,,
35,Phase II,"In a Phase II clinical trial, dovitinib treatment resulted in a objective response rate of 11.5% (3/26, all partial responses) and disease control rate of 50% (13/26), and a median progression-free survival of 2.9 months in lung squamous cell carcinoma patients with FGFR1 amplification, and FGFR1 amplification was not determined to be a predictive biomarker for sensitivity (PMID: 27315356).",Actionable,7244,3907,lung squamous cell carcinoma,DOID,812,FGFR1 amp,no benefit,721,Dovitinib,2260,27315356,,,
36,Preclinical - Cell culture,"In a preclinical study, FGFR1 amplified lung squamous cell carcinoma cells were not sensitive to RO4987655 in culture (PMID: 26438159).",Actionable,8450,3907,lung squamous cell carcinoma,DOID,812,FGFR1 amp,no benefit,903,RO4987655,2260,26438159,,,
37,Preclinical - Cell culture,"In a preclinical study, an estrogen-receptor positive breast cancer cell line harboring FGFR1 amplification demonstrated sensitivity to treatment with Lucitanib (E-3810) in culture (PMID: 27126994). ",Actionable,9708,60075,estrogen-receptor positive breast cancer,DOID,812,FGFR1 amp,sensitive,1029,Lucitanib,2260,27126994,,,
38,Phase I,"In a Phase I trial, 28% (9/32) of breast cancer patients harboring FGFR1 amplification demonstrated stable disease when treated with BGJ398 (PMID: 27870574). ",Actionable,9735,1612,breast cancer,DOID,812,FGFR1 amp,sensitive,674,BGJ398,2260,27870574,,,
39,Preclinical - Cell culture,"In a preclinical study, FGFR1 amplified lung small cell carcinoma cells were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).",Actionable,8481,5409,lung small cell carcinoma,DOID,812,FGFR1 amp,no benefit,913,Selumetinib,2260,26438159,,,
40,Phase I,"In a Phase Ib trial, AZD4547 demonstrated limited efficacy in patients with squamous cell lung cancer with FGFR1 amplification, resulting in an overall response rate of 8% (1/15) and a median overall survival of 4.9 months (PMID: 28615371; NCT00979134).",Actionable,12086,3907,lung squamous cell carcinoma,DOID,812,FGFR1 amp,no benefit,654,AZD4547,2260,28615371,,,
41,Preclinical - Pdx,"In a preclinical study, AZD4547 inhibited FGFR1 signaling and resulted in tumor regression in patient-derived xenograft models of non-small cell lung carcinoma harboring FGFR1 amplification, wild-type for EGFR, K-Ras and negative for EML4-ALK fusion (PMID: 23082000).",Actionable,6868,3908,non-small cell lung carcinoma,DOID,812,FGFR1 amp,sensitive,654,AZD4547,2260,23082000,,,
42,Preclinical - Cell culture,"In a preclinical study, the combination of AZD4547 and Buparlisib (BKM120) induced apoptosis in a small cell lung cancer cell line with amplification of FGFR1 in culture (PMID: 28108151).",Actionable,11211,5409,lung small cell carcinoma,DOID,812,FGFR1 amp,sensitive,5898,AZD4547 + BKM120,2260,28108151,,,
43,Preclinical,"In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of estrogen receptor (ER)-positive breast cancer cells with FGFR2 amplification in culture (PMID: 22238366).",Actionable,3532,60075,estrogen-receptor positive breast cancer,DOID,812,FGFR1 amp,no benefit,996,Brivanib,2260,22238366,,,
44,Preclinical - Cell culture,"In a preclinical study, FGFR1 amplified lung squamous cell carcinoma cells were not sensitive to RO5126766 in culture (PMID: 26438159).",Actionable,8468,3907,lung squamous cell carcinoma,DOID,812,FGFR1 amp,no benefit,2011,RO5126766,2260,26438159,,,
45,Phase I,"In a Phase I trial, ARQ 087 treatment resulted stable disease for greater than 22 months in an adrenocortical carcinoma patient harboring FGFR1 amplification (J Clin Oncol 33, 2015 (suppl; abstr 2545)).",Actionable,3992,3948,adrenocortical carcinoma,DOID,812,FGFR1 amp,sensitive,2900,ARQ 087,2260,None,,,
46,Preclinical - Cell culture,"In a preclinical study, FGFR1 amplified non-small cell lung carcinoma cells were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).",Actionable,8483,3908,non-small cell lung carcinoma,DOID,812,FGFR1 amp,no benefit,913,Selumetinib,2260,26438159,,,
47,Preclinical,"In a preclinical study, Debio 1347 inhibited proliferation of small cell lung cancer cell lines harboring FGFR1 amplification in culture (PMID: 25169980).",Actionable,4069,5409,lung small cell carcinoma,DOID,812,FGFR1 amp,sensitive,1014,FF-284,2260,25169980,,,
48,Preclinical - Cell culture,"In a preclinical study, a lung cancer cell line with co-amplification of FGFR1 and EGFR and harboring KRAS G13C demonstrated insensitivity to JNJ-42756493 (erdafitinib) in culture (PMID: 28341788).",Actionable,11185,1324,lung cancer,DOID,27923,EGFR amp FGFR1 amp KRAS G13C,resistant,1028,JNJ-42756493,2260,28341788,,,
49,Preclinical - Cell culture,"In a preclinical study, lung cancer cell lines with co-amplification of FGFR1 and EGFR demonstrated insensitivity to JNJ-42756493 (erdafitinib) in culture (PMID: 28341788).",Actionable,11184,1324,lung cancer,DOID,27922,EGFR amp FGFR1 amp,resistant,1028,JNJ-42756493,2260,28341788,,,
50,Preclinical - Cell culture,"In a preclinical study, a lung cancer cell line harboring FGFR1 amplification and KRAS G13C demonstrated insensitivity to JNJ-42756493 (erdafitinib) in culture (PMID: 28341788).",Actionable,11186,1324,lung cancer,DOID,27924,FGFR1 amp KRAS G12V,resistant,1028,JNJ-42756493,2260,28341788,,,
51,Preclinical - Cell line xenograft,"In a preclinical study, a breast cancer cell line, harboring FGFR1 amplification and FGFR2 amplification, treated with E7090 demonstrated decreased cell viability in culture and antitumor activity in xenograft models (PMID: 27535969). ",Actionable,9126,1612,breast cancer,DOID,26745,FGFR1 amp FGFR2 amp,sensitive,4911,E7090,2260,27535969,,,
52,Preclinical - Cell culture,"In a preclinical study, a lung cancer cell line with co-amplification of FGFR1 and KRAS demonstrated insensitivity to JNJ-42756493 (erdafitinib) in culture (PMID: 28341788).",Actionable,11187,1324,lung cancer,DOID,27925,FGFR1 amp KRAS amp,resistant,1028,JNJ-42756493,2260,28341788,,,
53,Preclinical - Cell culture,"In a preclinical study, head and neck squamous cell carcinoma cells harboring FGFR1 amplification and over expressing EGFR demonstrated sensitivity to the combination treatment of AZD4547 and Iressa (gefitinib) in culture, which also resulted in a synergistic effect (PMID: 26936917). ",Actionable,7833,5520,head and neck squamous cell carcinoma,DOID,26058,EGFR over exp FGFR1 amp,sensitive,4585,AZD4547 + Gefitinib,2260,26936917,,,
54,Preclinical - Cell culture,"In a preclinical study, head and neck squamous cell carcinoma cells with EGFR over expression and FGFR1 amplification demonstrated resistance to treatment with AZD4547 in culture (PMID: 26936917). ",Actionable,7830,5520,head and neck squamous cell carcinoma,DOID,26058,EGFR over exp FGFR1 amp,resistant,654,AZD4547,2260,26936917,,,
55,Preclinical,"In a preclinical study, transformed cells expressing constitutively active FGFR1 demonstrated reduced sensitivity to Ofev (Nintedanib) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366).",Actionable,3488,10000003,Advanced Solid Tumor,JAX,1218,FGFR1 act mut,decreased response,831,Nintedanib,2260,22238366,,,
56,Preclinical,"In a preclinical study, FIIN-01 inhibited Fgfr1 activation-induced proliferation and transformation of human breast epithelial cell lines in culture (PMID: 20338520).",Actionable,4021,1612,breast cancer,DOID,1218,FGFR1 act mut,sensitive,2507,FIIN-01,2260,20338520,,,
57,Preclinical,"In a preclinical study, Brivanib (BMS-540215) did not inhibit receptor phosphorylation and cell proliferation in transformed cells expressing constitutively active FGFR1 in culture (PMID: 22238366).",Actionable,3493,10000003,Advanced Solid Tumor,JAX,1218,FGFR1 act mut,no benefit,996,Brivanib,2260,22238366,,,
58,Phase I,"In a Phase I trial, Debio 1347 (CH5183284) dosing regimen has been determined in solid tumor patients with activating FGFR1 alterations (JCO, Vol 33, No 15_suppl (May 20 Supplement), 2015: 2540).",Actionable,1248,10000003,Advanced Solid Tumor,JAX,1218,FGFR1 act mut,sensitive,1014,FF-284,2260,None,,,
59,Preclinical,"In a preclinical study, Dovitinib (TKI258) inhibited receptor phosphorylation and cell proliferation in transformed cells expressing constitutively active FGFR1 in culture (PMID: 22238366).",Actionable,3472,10000003,Advanced Solid Tumor,JAX,1218,FGFR1 act mut,sensitive,721,Dovitinib,2260,22238366,,,
60,Phase I,"In a Phase I trial, JNJ-42756493 treatment resulted in stable disease in 70% (16/23) and partial response in 22% (5/23) of patients with advanced solid tumors harboring FGFR 1-4 activating mutations (including amplifications, mutations and translocations), while no antitumor activity was observed in patients with unknown or no known changes in FGFR (PMID: 26324363).",Actionable,3998,10000003,Advanced Solid Tumor,JAX,1218,FGFR1 act mut,sensitive,1028,JNJ-42756493,2260,26324363,,,
61,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited receptor phosphorylation and cell growth in transformed cells expressing constitutively active FGFR1 in culture (PMID: 22238366).",Actionable,3469,10000003,Advanced Solid Tumor,JAX,1218,FGFR1 act mut,sensitive,877,Ponatinib,2260,22238366,,,
62,Preclinical,"In a preclinical study, transformed cells expressing constitutively active FGFR1 demonstrated reduced sensitivity to inhibition of receptor phosphorylation and cell proliferation by Cediranib (AZD-2171) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366).",Actionable,3476,10000003,Advanced Solid Tumor,JAX,1218,FGFR1 act mut,decreased response,1001,Cediranib,2260,22238366,,,
63,Preclinical - Cell culture,"In a preclinical study, PHA-665752 treatment did not result in decreased colony formation or reduced phosphorylation levels of FGFR1 and FGFR2 in hepatocellular carcinoma cells in culture (PMID: 26351320).",Actionable,9053,684,hepatocellular carcinoma,DOID,26701,FGFR1 pos FGFR2 pos,no benefit,2162,PHA-665752,2260,26351320,,,
64,Preclinical - Cell culture,"In a preclinical study, hepatocellular carcinoma cell lines treated with AZD4547 demonstrated decreased phosphorylation of FGFR1 and FGFR2, reduced colony formation, and evidence of apoptotic activity in culture (PMID: 26351320). ",Actionable,9051,684,hepatocellular carcinoma,DOID,26701,FGFR1 pos FGFR2 pos,sensitive,654,AZD4547,2260,26351320,,,
65,Preclinical - Cell culture,"In a preclinical study, synovial sarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to PD173074 in culture (PMID: 27535980).",Actionable,8031,5485,synovial sarcoma,DOID,26138,FGFR1 positive,decreased response,2948,PD173074,2260,27535980,,,
66,Preclinical - Cell culture,"In a preclinical study, leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to AZD4547 in culture (PMID: 27535980).",Actionable,8032,1967,leiomyosarcoma,DOID,26138,FGFR1 positive,decreased response,654,AZD4547,2260,27535980,,,
67,Preclinical - Cell culture,"In a preclinical study, synovial sarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to BGJ398 in culture (PMID: 27535980).",Actionable,8037,5485,synovial sarcoma,DOID,26138,FGFR1 positive,decreased response,674,BGJ398,2260,27535980,,,
68,Phase I,"In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including long lasting stable disease with resolution of edema in a patient with FGFR1-positive hemangioendothelioma (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741).",Actionable,12005,255,hemangioma,DOID,26138,FGFR1 positive,predicted â€“ sensitive,2030,Rogaratinib,2260,None,,,
69,Preclinical - Cell culture,"In a preclinical study, AZD4547 and Rapamune (sirolimus) synergistically inhibited survival of FGFR1-dependent lung adenocarcinoma cells in culture (PMID: 26359452).",Actionable,9349,3910,lung adenocarcinoma,DOID,26138,FGFR1 positive,sensitive,4985,AZD4547 + Sirolimus,2260,26359452,,,
70,Preclinical - Cell culture,"In a preclinical study, AZD4547 and AZD8055 synergistically inhibited survival of FGFR1-dependent lung large cell carcinoma cells in culture (PMID: 26359452).",Actionable,9345,4556,lung large cell carcinoma,DOID,26138,FGFR1 positive,sensitive,4983,AZD4547 + AZD8055,2260,26359452,,,
71,Preclinical - Cell culture,"In a preclinical study, AZD4547 and Vistusertib (AZD2014) synergistically inhibited survival of FGFR1-dependent head and neck squamous cell carcinoma cells in culture (PMID: 26359452).",Actionable,9348,5520,head and neck squamous cell carcinoma,DOID,26138,FGFR1 positive,sensitive,4984,AZD4547 + Vistusertib,2260,26359452,,,
72,Preclinical - Cell culture,"In a preclinical study, synovial sarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to AZD4547 in culture (PMID: 27535980).",Actionable,8034,5485,synovial sarcoma,DOID,26138,FGFR1 positive,decreased response,654,AZD4547,2260,27535980,,,
73,Preclinical - Cell culture,"In a preclinical study, AZD4547 and Rapamune (sirolimus) synergistically inhibited survival of FGFR1-dependent lung large cell carcinoma cells in culture (PMID: 26359452).",Actionable,9351,4556,lung large cell carcinoma,DOID,26138,FGFR1 positive,sensitive,4985,AZD4547 + Sirolimus,2260,26359452,,,
74,Preclinical - Cell culture,"In a preclinical study, uterine leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to PD173074 in culture (PMID: 27535980).",Actionable,8030,5289,uterus leiomyosarcoma,DOID,26138,FGFR1 positive,decreased response,2948,PD173074,2260,27535980,,,
75,Preclinical - Cell culture,"In a preclinical study, leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to BGJ398 in culture (PMID: 27535980).",Actionable,8035,1967,leiomyosarcoma,DOID,26138,FGFR1 positive,decreased response,674,BGJ398,2260,27535980,,,
76,Preclinical - Cell culture,"In a preclinical study, uterine leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to BGJ398 in culture (PMID: 27535980).",Actionable,8036,5289,uterus leiomyosarcoma,DOID,26138,FGFR1 positive,decreased response,674,BGJ398,2260,27535980,,,
77,Preclinical - Cell line xenograft,"In a preclinical study, AZD4547 and Vistusertib (AZD2014) synergistically inhibited survival of FGFR1-dependent lung adenocarcinoma cells in culture and in cell line xenograft models (PMID: 26359452).",Actionable,9347,3910,lung adenocarcinoma,DOID,26138,FGFR1 positive,sensitive,4984,AZD4547 + Vistusertib,2260,26359452,,,
78,Preclinical - Cell culture,"In a preclinical study, AZD4547 and AZD8055 synergistically inhibited survival of FGFR1-dependent lung adenocarcinoma cells in culture (PMID: 26359452).",Actionable,9344,3910,lung adenocarcinoma,DOID,26138,FGFR1 positive,sensitive,4983,AZD4547 + AZD8055,2260,26359452,,,
79,Preclinical - Cell culture,"In a preclinical study, leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to PD173074 in culture (PMID: 27535980).",Actionable,8029,1967,leiomyosarcoma,DOID,26138,FGFR1 positive,decreased response,2948,PD173074,2260,27535980,,,
80,Preclinical - Cell line xenograft,"In a preclinical study, AZD4547 and Vistusertib (AZD2014) synergistically inhibited survival of FGFR1-dependent lung large cell carcinoma cells in culture and in cell line xenograft models (PMID: 26359452).",Actionable,9346,4556,lung large cell carcinoma,DOID,26138,FGFR1 positive,sensitive,4984,AZD4547 + Vistusertib,2260,26359452,,,
81,Phase I,"In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including a partial remission in a patient with FGFR1-positive adenoid cystic carcinoma of the tongue (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741).",Actionable,12000,4866,salivary gland adenoid cystic carcinoma,DOID,26138,FGFR1 positive,predicted â€“ sensitive,2030,Rogaratinib,2260,None,,,
82,Preclinical - Cell culture,"In a preclinical study, uterine leiomyosarcoma cells with moderate Fgfr1 expression level demonstrated decreased response to AZD4547 in culture (PMID: 27535980).",Actionable,8033,5289,uterus leiomyosarcoma,DOID,26138,FGFR1 positive,decreased response,654,AZD4547,2260,27535980,,,
83,Preclinical,"In a preclinical study, FIIN-01 inhibited Fgfr1 autophosphorylation in a human transformed embryonic kidney cell line harboring FGFR1 V561M mutation in culture (PMID: 20338520).",Actionable,4026,10000003,Advanced Solid Tumor,JAX,17133,FGFR1 V561M,sensitive,2507,FIIN-01,2260,20338520,,,
84,Preclinical,"In a preclinical study, knocking down of Fgfr1 through shRNA did not sensitize KRAS wild-type lung cancer cells to Mekinist (trametinib) induced growth inhibition in culture  (PMID: 27338794).",Actionable,7364,1324,lung cancer,DOID,25310,FGFR1 dec exp KRAS wild-type,no benefit,2,Trametinib,2260,27338794,,,
85,Preclinical - Cell culture,"In a preclinical study, Mekinist (trametinib) treatment demonstrated enhanced growth inhibition of KRAS mutant pancreatic cancer cells with decreased Fgfr1 expression through shRNA knockdown in culture (PMID: 27338794).",Actionable,7365,1793,pancreatic cancer,DOID,25304,FGFR1 dec exp KRAS mut,sensitive,2,Trametinib,2260,27338794,,,
86,Preclinical - Cell line xenograft,"In a preclinical study, Mekinist (trametinib) treatment demonstrated enhanced growth inhibition in KRAS mutant lung cancer cells with decreased Fgfr1 expression through shRNA knockdown in culture, and tumor regression in xenograft models (PMID: 27338794).",Actionable,7360,1324,lung cancer,DOID,25304,FGFR1 dec exp KRAS mut,sensitive,2,Trametinib,2260,27338794,,,
87,Preclinical - Cell culture,"In a preclinical study, knocking down of Fgfr1 through shRNA did not sensitize KRAS mutant colorectal cancer cells to Mekinist (trametinib) induced growth inhibition in culture (PMID: 27338794).",Actionable,7366,9256,colorectal cancer,DOID,25304,FGFR1 dec exp KRAS mut,no benefit,2,Trametinib,2260,27338794,,,
88,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring mutant EGFR and wild-type FGFR1 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366).",Actionable,3542,3908,non-small cell lung carcinoma,DOID,13351,EGFR mutant FGFR1 wild-type,resistant,877,Ponatinib,2260,22238366,,,
89,Preclinical,"In a preclinical study, ER-positive breast cancer cells with wild-type FGFR1 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366).",Actionable,3537,1612,breast cancer,DOID,542,FGFR1 wild-type,resistant,877,Ponatinib,2260,22238366,,,
90,Preclinical,"In a preclinical study, FGFR1 non-amplified lung cancer cell lines demonstrated reduced sensitivity to AZD4547 induced growth inhibition in culture and in xenograft models (PMID: 23082000).",Actionable,6867,1324,lung cancer,DOID,542,FGFR1 wild-type,decreased response,654,AZD4547,2260,23082000,,,
91,Preclinical,"In a preclinical study, primary cells from 8p11 myeloproliferative syndrome patients harboring FGFR1 rearrangement were sensitive to Dovitinib (TKI258)-induced growth inhibition in culture (PMID: 17698633).",Actionable,4039,2226,myeloproliferative neoplasm,DOID,1276,FGFR1 rearrange,sensitive,721,Dovitinib,2260,17698633,,,
92,Preclinical - Cell culture,"In a preclinical study, AZD4547 inhibited survival of small cell lung cancer cells harboring FGFR1 translocation in culture (PMID: 27550940).",Actionable,9121,5409,lung small cell carcinoma,DOID,1276,FGFR1 rearrange,sensitive,654,AZD4547,2260,27550940,,,
93,Preclinical - Cell line xenograft,"In a preclinical study, AZD4547 inhibited survival of leukemia cells harboring FGFR1 translocation in culture and in cell line xenograft models (PMID: 27550940).",Actionable,9120,1240,leukemia,DOID,1276,FGFR1 rearrange,sensitive,654,AZD4547,2260,27550940,,,
94,Preclinical,"In a preclinical study, Dovitinib (TKI258) inhibited Erk, Stat5 signaling and survival of transformed cell lines overexpressing FGFR1 fusion proteins (ZMYM2-FGFR1 or BCR-FGFR1) in culture (PMID: 17698633).",Actionable,4037,10000003,Advanced Solid Tumor,JAX,14910,FGFR1 fusion,sensitive,721,Dovitinib,2260,17698633,,,
95,Preclinical,"In a preclinical study, Dovitinib (TKI258) increased apoptosis and inhibited survival of acute myelogenous leukemia cell lines harboring FGFR1OP2-FGFR1 fusion in culture (PMID: 17698633).",Actionable,4038,9119,acute myeloid leukemia,DOID,14910,FGFR1 fusion,sensitive,721,Dovitinib,2260,17698633,,,
96,Clinical Study,"In a clinical case study, a pancreatic ductal adenocarcinoma patient harboring EML4-ALK along with CDKN2A deletion, FGFR1 T141R, SMAD4 Q83*, and a TP53 splice site mutation, experienced disease progression after 2 months of Xalkori (crizotinib) treatment, then received Alecensa (alectinib) and remained on treatment for at least 3 months (PMID: 28476735).",Actionable,11543,3498,pancreatic ductal adenocarcinoma,DOID,28131,EML4-ALK CDKN2A del FGFR1 T141R SMAD4 Q83*,resistant,706,Crizotinib,2260,28476735,,,
97,Clinical Study,"In a clinical case study, a pancreatic ductal adenocarcinoma patient harboring EML4-ALK along with CDKN2A deletion, FGFR1 T141R, SMAD4 Q83*, and a TP53 splice site mutation, experienced disease progression after 2 months of Xalkori (crizotinib) treatment, then received Alecensa (alectinib) and remained on treatment for at least 3 months (PMID: 28476735).",Actionable,11544,3498,pancreatic ductal adenocarcinoma,DOID,28131,EML4-ALK CDKN2A del FGFR1 T141R SMAD4 Q83*,predicted â€“ sensitive,698,Alectinib,2260,28476735,,,
98,Preclinical - Cell culture,"In a preclinical study, AZD4547 inhibited Fgfr1 kinase activity and cell growth in transformed cells expressing the FGFR1-TACC1 fusion in culture (PMID: 22837387).",Actionable,2707,3070,malignant glioma,DOID,10477,FGFR1-TACC1,sensitive,654,AZD4547,2260,22837387,,,
99,Preclinical - Cell culture,"In a preclinical study, BJG398 inhibited Fgfr1 kinase activity and cell growth in transformed cells expressing the FGFR1-TACC1 fusion in culture (PMID: 22837387).",Actionable,2708,3070,malignant glioma,DOID,10477,FGFR1-TACC1,sensitive,674,BGJ398,2260,22837387,,,
100,Preclinical - Cell culture,"In a preclinical study, PD173074 inhibited Fgfr1 kinase activity and cell growth in transformed cells expressing the FGFR1-TACC1 fusion in culture (PMID: 22837387).",Actionable,2705,3070,malignant glioma,DOID,10477,FGFR1-TACC1,sensitive,2948,PD173074,2260,22837387,,,
101,Preclinical - Cell culture,"In a preclinical study, an estrogen-receptor positive breast cancer cell line over expressing FGFR1 and expressing a PIK3CA mutation demonstrated sensitivity to the combination of Alpelisib (BYL719) and Lucitanib (E-3810) in culture (PMID: 27126994). ",Actionable,9709,60075,estrogen-receptor positive breast cancer,DOID,26996,FGFR1 over exp PIK3CA mut,sensitive,5164,Alpelisib + Lucitanib,2260,27126994,,,
102,Phase II,"In a clinical analysis of a Phase II trial, high Fgfr1 expression level was associated with decreased progression free survival in renal cell carcinoma patients treated with Nexavar (sorafenib) (PMID: 25900027).",Emerging,7206,4450,renal cell carcinoma,DOID,4208,FGFR1 over exp,not applicable,920,Sorafenib,2260,25900027,,,
103,Preclinical - Cell culture,"In a preclinical study, AZD4547 inhibited survival of FGFR1 over expressing uterus leiomyosarcoma cells in culture (PMID: 27535980).",Actionable,8027,5289,uterus leiomyosarcoma,DOID,4208,FGFR1 over exp,sensitive,654,AZD4547,2260,27535980,,,
104,Preclinical,"In a preclinical study, BGJ398 inhibited cell growth and induced apoptosis in HNSCC cells over expressing Fgfr1 in culture and in xenograft models (PMID: 26015511). ",Actionable,3249,5520,head and neck squamous cell carcinoma,DOID,4208,FGFR1 over exp,sensitive,674,BGJ398,2260,26015511,,,
105,Preclinical,"In a preclinical study, Lenvima (lenvatinib) inhibited FGFR1 phosphorylation and signaling in thyroid cancer cells overexpressing FGFR1 (PMID: 25295214).",Actionable,1893,1781,thyroid cancer,DOID,4208,FGFR1 over exp,sensitive,792,Lenvatinib,2260,25295214,,,
106,Preclinical - Cell culture,"In a preclinical study, PD173074 inhibited survival of FGFR1 over expressing uterus leiomyosarcoma cells in culture (PMID: 27535980).",Actionable,8026,5289,uterus leiomyosarcoma,DOID,4208,FGFR1 over exp,sensitive,2948,PD173074,2260,27535980,,,
107,Preclinical - Cell culture,"In a preclinical study, PD173074 inhibited survival of FGFR1 over expressing uterus leiomyosarcoma cells in culture (PMID: 27535980).",Actionable,8028,5289,uterus leiomyosarcoma,DOID,4208,FGFR1 over exp,sensitive,674,BGJ398,2260,27535980,,,
108,Preclinical,"In a preclinical study, Iclusig (ponatinib) blocked proliferation of Ewingâ€™s sarcoma cells over expressing Fgfr1 (PMID: 26179511).",Actionable,2566,4232,extraosseous Ewing's sarcoma,DOID,4208,FGFR1 over exp,sensitive,877,Ponatinib,2260,26179511,26175911,,
109,Preclinical - Cell culture,"In a preclinical study, AZD4547 treatment of head and neck squamous cell carcinoma cells over expressing FGFR1 and negative for EGFR resulted in decreased cell growth and reduced downstream signaling of Erk1/2 (PMID: 26936917).",Actionable,7828,5520,head and neck squamous cell carcinoma,DOID,26061,EGFR neg FGFR1 over exp,sensitive,654,AZD4547,2260,26936917,,,
0,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 V565I were resistant to treatment with Dovitinib (TKI258) (PMID: 23908597).",Actionable,2587,10000003,Advanced Solid Tumor,JAX,9491,FGFR2 V565I,resistant,721,Dovitinib,2263,23908597,,,
1,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 V565I were resistant to treatment with PD173074 (PMID: 23908597).",Actionable,3281,10000003,Advanced Solid Tumor,JAX,9491,FGFR2 V565I,resistant,2948,PD173074,2263,23908597,,,
2,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 V565I were resistant to treatment with Iclusig (ponatinib) (PMID: 23908597).",Actionable,2601,10000003,Advanced Solid Tumor,JAX,9491,FGFR2 V565I,resistant,877,Ponatinib,2263,23908597,,,
3,Clinical Study,"In a clinical study, FGFR2 mutations E565A, K659M, N549H, N549K and V564F were identified in the cell-free DNA of a cholangiocarcinoma patient harboring FGFR2-ZMYM4 fusion after the patient progressed while on BGJ398 treatment (PMID: 28034880).  ",Actionable,10147,4947,cholangiocarcinoma,DOID,27311,FGFR2 E565A FGFR2 K659M FGFR2 N549H FGFR2 N549K FGFR2 V564F FGFR2-ZMYM4,predicted â€“ resistant,674,BGJ398,2263,28034880,,,
4,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited downstream phosphorylation of Akt and Erk1/2 in cells expressing Fgfr2 S267_D273dup (PMID: 26048680).",Actionable,2677,10000003,Advanced Solid Tumor,JAX,9977,FGFR2 S267_D273dup,sensitive,877,Ponatinib,2263,26048680,,,
5,Preclinical,"In a preclinical study, BGJ398 prevented oncogenic transformation of cells expressing FGFR2 S267_D273dup (PMID: 26048680).",Actionable,2674,10000003,Advanced Solid Tumor,JAX,9977,FGFR2 S267_D273dup,sensitive,674,BGJ398,2263,26048680,,,
6,Preclinical - Cell culture,"In a preclinical study, hepatocellular carcinoma cell lines treated with AZD4547 demonstrated decreased phosphorylation of FGFR1 and FGFR2, reduced colony formation, and evidence of apoptotic activity in culture (PMID: 26351320). ",Actionable,9051,684,hepatocellular carcinoma,DOID,26701,FGFR1 pos FGFR2 pos,sensitive,654,AZD4547,2263,26351320,,,
7,Preclinical - Cell culture,"In a preclinical study, PHA-665752 treatment did not result in decreased colony formation or reduced phosphorylation levels of FGFR1 and FGFR2 in hepatocellular carcinoma cells in culture (PMID: 26351320).",Actionable,9053,684,hepatocellular carcinoma,DOID,26701,FGFR1 pos FGFR2 pos,no benefit,2162,PHA-665752,2263,26351320,,,
8,Phase I,"In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including long lasting stable disease in a patient with FGFR2-positive breast cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741).",Actionable,12002,1612,breast cancer,DOID,9798,FGFR2 positive,predicted â€“ sensitive,2030,Rogaratinib,2263,None,,,
9,Preclinical - Pdx & cell culture,"In a preclinical study, BAY1187982 inhibited survival of gastric cancer cell lines with elevated Fgfr2 expression level in culture, and suppressed tumor growth in cell line or patient-derived xenograft models (PMID: 27543601).",Actionable,9094,10534,stomach cancer,DOID,9798,FGFR2 positive,sensitive,2931,BAY1187982,2263,27543601,,,
10,Preclinical - Pdx & cell culture,"In a preclinical study, BAY1187982 inhibited survival of Fgfr2 positive breast cancer cell lines in culture, and suppressed tumor growth in both cell line and patient-derived xenograft models (PMID: 27543601).",Actionable,9097,1612,breast cancer,DOID,9798,FGFR2 positive,sensitive,2931,BAY1187982,2263,27543601,,,
11,Preclinical - Pdx & cell culture,"In a preclinical study, sensitivity to BAY1187982 positively correlated with Fgfr2 expression level in a variety of cancer cell lines in culture, and in cell line or patient-derived xenograft models (PMID: 27543601).",Actionable,9093,10000003,Advanced Solid Tumor,JAX,9798,FGFR2 positive,sensitive,2931,BAY1187982,2263,27543601,,,
12,Preclinical,"In a preclinical study, a mouse breast carcinoma cell line xenograft model demonstrated inhibition of tumor growth when treated with E7090, a result of decreased FGFR2 and FGFR3 activity (PMID: 27535969). ",Actionable,9142,3459,breast carcinoma,DOID,26749,FGFR2 pos FGFR3 pos,sensitive,4911,E7090,2263,27535969,,,
13,Preclinical - Cell culture,"In a preclinical study, PRN1371 inhibited Fgfr2 activity in transformed cells over expressing FGFR2 K660N in culture (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).",Actionable,8400,10000003,Advanced Solid Tumor,JAX,26311,FGFR2 K660N,sensitive,3583,PRN1371,2263,None,,,
14,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited Fgfr2 phosphorylation and proliferation in transformed cells expressing FGFR2 I548V (PMID: 23908597).",Actionable,2605,10000003,Advanced Solid Tumor,JAX,9490,FGFR2 I548V,sensitive,877,Ponatinib,2263,23908597,,,
15,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 I548V demonstrated a decreased response to treatment with Dovitinib (TKI258) (PMID: 23908597).",Actionable,2591,10000003,Advanced Solid Tumor,JAX,9490,FGFR2 I548V,decreased response,721,Dovitinib,2263,23908597,,,
16,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 I548V demonstrated a decreased response to treatment with PD173074 (PMID: 23908597).",Actionable,2598,10000003,Advanced Solid Tumor,JAX,9490,FGFR2 I548V,decreased response,2948,PD173074,2263,23908597,,,
17,Preclinical - Cell culture,"In a preclinical study, Debio 1347 did not inhibit Fgfr2 phosphorylation in transformed cells over expressing FGFR2 V564L in culture (PMID: 25169980).",Actionable,10190,10000003,Advanced Solid Tumor,JAX,27307,FGFR2 V564L,resistant,1014,FF-284,2263,25169980,,,
18,Preclinical - Cell line xenograft,"In a preclinical study, S-49076 inhibited Met activation, resulting in growth inhibition of gastric carcinoma cells harboring FGFR2 activating mutations in culture and in cell line xenograft models (PMID: 23804704).",Actionable,1771,5517,stomach carcinoma,DOID,1219,FGFR2 act mut,sensitive,2158,S-49076,2263,23804704,,,
19,Preclinical,"In a preclinical study, transformed cells expressing constitutively active FGFR2 demonstrated reduced sensitivity to inhibition of receptor phosphorylation and cell proliferation by Brivanib (BMS-540215) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366).",Actionable,3492,10000003,Advanced Solid Tumor,JAX,1219,FGFR2 act mut,decreased response,996,Brivanib,2263,22238366,,,
20,Preclinical,"In a preclinical study, Dovitinib (TKI258) inhibited receptor phosphorylation and cell proliferation in transformed cells expressing constitutively active FGFR2 in culture (PMID: 22238366).",Actionable,3473,10000003,Advanced Solid Tumor,JAX,1219,FGFR2 act mut,sensitive,721,Dovitinib,2263,22238366,,,
21,Preclinical,"In a preclinical study, transformed cells expressing constitutively active FGFR2 demonstrated reduced sensitivity to inhibition of receptor phosphorylation and cell proliferation by Cediranib (AZD-2171) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366).",Actionable,3477,10000003,Advanced Solid Tumor,JAX,1219,FGFR2 act mut,decreased response,1001,Cediranib,2263,22238366,,,
22,Phase I,"In a Phase I trial, Debio 1347 (CH5183284) dosing regimen has been determined in solid tumor patients with activating FGFR2 alterations (JCO, Vol 33, No 15_suppl (May 20 Supplement), 2015: 2540).",Actionable,347,10000003,Advanced Solid Tumor,JAX,1219,FGFR2 act mut,sensitive,1014,FF-284,2263,None,,,
23,Preclinical,"In a preclinical study, transformed cells expressing constitutively active FGFR2 demonstrated reduced sensitivity to Ofev (Nintedanib) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366).",Actionable,3489,10000003,Advanced Solid Tumor,JAX,1219,FGFR2 act mut,decreased response,831,Nintedanib,2263,22238366,,,
24,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited receptor phosphorylation and cell growth in transformed cells expressing constitutively active FGFR2 in culture (PMID: 22238366).",Actionable,3470,10000003,Advanced Solid Tumor,JAX,1219,FGFR2 act mut,sensitive,877,Ponatinib,2263,22238366,,,
25,Preclinical - Cell line xenograft,"In a preclinical study, both cell lines and cell line xenograft models of endometrial cancer with FGFR2 activating mutations showed greater sensitivity to Dovitinib (TKI258) as compared to FGFR2 wild-type (PMID: 23443805). ",Actionable,328,1380,endometrial cancer,DOID,1219,FGFR2 act mut,sensitive,721,Dovitinib,2263,23443805,,,
26,Phase I,"In a Phase I trial, JNJ-42756493 treatment resulted in stable disease in 70% (16/23) and partial response in 22% (5/23) of patients with advanced solid tumors harboring FGFR 1-4 activating mutations (including amplifications, mutations and translocations), while no antitumor activity was observed in patients with unknown or no known changes in FGFR (PMID: 26324363).",Actionable,3999,10000003,Advanced Solid Tumor,JAX,1219,FGFR2 act mut,sensitive,1028,JNJ-42756493,2263,26324363,,,
27,Preclinical - Patient cell culture,"In a preclincal study, BGJ398 demonstrated enhanced inhibition of the survival in patient-derived ovarian cancer cells harboring FGFR2 - FAM76A in culture (PMID: 24563622).",Actionable,7543,2394,ovarian cancer,DOID,25826,FGFR2-FAM76A,sensitive,674,BGJ398,2263,24563622,,,
28,Preclinical - Pdx,"In a preclinical study, PRN1371 treatment resulted in tumor regression in patient-derived xenograft models of liver cancer harboring FGFR2-CCDC6 fusion (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).",Actionable,8413,3571,liver cancer,DOID,17514,FGFR2-CCDC6,sensitive,3583,PRN1371,2263,None,,,
29,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited downstream phosphorylation of Akt and Erk1/2 in cells expressing Fgfr2 W290_I291delinsC (PMID: 26048680).",Actionable,2678,10000003,Advanced Solid Tumor,JAX,9978,FGFR2 W290_I291delinsC,sensitive,877,Ponatinib,2263,26048680,,,
30,Preclinical,"In a preclinical study, BGJ398 prevented oncogenic transformation of cells expressing FGFR2 W290_I291delinsC (PMID: 26048680).",Actionable,2675,10000003,Advanced Solid Tumor,JAX,9978,FGFR2 W290_I291delinsC,sensitive,674,BGJ398,2263,26048680,,,
31,Preclinical - Pdx & cell culture,"In a preclinical study, AZD4547 inhibited proliferation of endometrial cells and delayed tumor growth in cell-line derived xenografts harboring the Fgfr2 double mutant, K310R, N550K (PMID: 26294741).",Actionable,8851,1380,endometrial cancer,DOID,26470,FGFR2 K310R FGFR2 N550K,sensitive,654,AZD4547,2263,26294741,,,
32,Preclinical - Cell culture,"In a preclinical study, the combination of BGJ398 and Buparlisib (BKM120) resulted in a synergistic effect, demonstrating inhibition of cell proliferation, decreased colony formation, and cell death in an endometrial cancer cell line harboring FGFR2 N550K, PIK3CA I20M and P539R, and PTEN R130Q and T321fs*23 in culture (PMID: 28119489). ",Actionable,10778,1380,endometrial cancer,DOID,27771,FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs*23,sensitive,5612,BGJ398 + BKM120,2263,28119489,,,
33,Preclinical - Cell culture,"In a preclinical study, the combination of BGJ398 and Alpelisib (BYL719) resulted in a synergistic effect, demonstrating inhibition of cell proliferation and induced cell death in an endometrial cancer cell line harboring FGFR2 N550K, PIK3CA I20M and P539R, and PTEN R130Q and T321fs*23 in culture (PMID: 28119489). ",Actionable,10780,1380,endometrial cancer,DOID,27771,FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs*23,sensitive,1293,BGJ398 + BYL719,2263,28119489,,,
34,Preclinical - Cell culture,"In a preclinical study, the combination of BGJ398 and Pictilisib (GDC-0941) resulted in a synergistic effect, demonstrating inhibition of cell proliferation, decreased colony formation, and cell death in an endometrial cancer cell line harboring FGFR2 N550K, PIK3CA I20M and P539R, and PTEN R130Q and T321fs*23 in culture (PMID: 28119489). ",Actionable,10777,1380,endometrial cancer,DOID,27771,FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs*23,sensitive,5613,BGJ398 + GDC-0941,2263,28119489,,,
35,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 N550K were resistant to treatment with Dovitinib (TKI258) (PMID: 23908597).",Actionable,2584,10000003,Advanced Solid Tumor,JAX,3428,FGFR2 N550K,resistant,721,Dovitinib,2263,23908597,,,
36,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited Fgfr2 phosphorylation and proliferation in transformed cells expressing FGFR2 N550K (PMID: 23908597).",Actionable,2607,10000003,Advanced Solid Tumor,JAX,3428,FGFR2 N550K,sensitive,877,Ponatinib,2263,23908597,,,
37,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 N550K were resistant to PD173074 (PMID: 23908597). ",Actionable,3280,10000003,Advanced Solid Tumor,JAX,3428,FGFR2 N550K,resistant,2948,PD173074,2263,23908597,,,
38,Preclinical - Cell culture,"In a preclinical study, endometrial cells harboring Fgfr2 N550K were less sensitive to the anti-proliferative effects of AZD4547 than the Fgfr2 double mutant, K310R, N550K (PMID: 26294741).",Actionable,8852,1380,endometrial cancer,DOID,3428,FGFR2 N550K,decreased response,654,AZD4547,2263,26294741,,,
39,Preclinical - Cell culture,"In a preclinical study, PRN1371 inhibited Fgfr2 activity in transformed cells over expressing FGFR2 N550K in culture (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).",Actionable,8401,10000003,Advanced Solid Tumor,JAX,3428,FGFR2 N550K,sensitive,3583,PRN1371,2263,None,,,
40,Preclinical,"In a preclinical study, an endometrial cancer cell line harboring FGFR2 C383R and expressing FGFR2 N550K demonstrated resistance when treated with PD173074 (PMID: 23908597). ",Actionable,3288,1380,endometrial cancer,DOID,13108,FGFR2 C383R FGFR2 N550K,resistant,2948,PD173074,2263,23908597,,,
41,Phase I,"In a Phase I trial, a patient with cholangiocarcinoma harboring an FGFR2 mutation demonstrated a decreased tumor burden when treated with BGJ398 (PMID: 27870574). ",Actionable,9738,4947,cholangiocarcinoma,DOID,1185,FGFR2 mutant,sensitive,674,BGJ398,2263,27870574,,,
42,Preclinical - Cell culture,"In a preclinical study, PRN1371 inhibited proliferation of endometrial cancer cells harboring FGFR2 mutations in culture (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).",Actionable,8406,1380,endometrial cancer,DOID,1185,FGFR2 mutant,sensitive,3583,PRN1371,2263,None,,,
43,Preclinical,"In a preclinical study, BGJ398 inhibited the growth of FGFR2-mutated endometrial cancer cells in vitro and in xenograft models (PMID: 23443805).",Actionable,1274,1380,endometrial cancer,DOID,1185,FGFR2 mutant,sensitive,674,BGJ398,2263,23443805,,,
44,Preclinical - Cell culture,"In a preclinical study, a variety of cancer cell lines harboring mutations in FGFR1, FGFR2, and/or FGFR3 demonstrated sensitivity to INCB054828 in culture and in cell line xenograft models, resulting in inhibition of tumor growth (Cancer Res 2015;75(15 Suppl):Abstract nr 771).",Actionable,8390,10000003,Advanced Solid Tumor,JAX,1185,FGFR2 mutant,sensitive,4173,INCB054828,2263,None,,,
45,Preclinical,"In a preclinical study, treatment with PD173074 prevented transformation of cells expressing FGFR2-BICC1 in culture (PMID: 24122810).",Actionable,4216,10000003,Advanced Solid Tumor,JAX,17509,FGFR2-BICC1,sensitive,2948,PD173074,2263,24122810,,,
46,Preclinical,"In a preclinical study, treatment with BGJ398 prevented transformation of cells expressing FGFR2-BICC1 in culture (PMID: 24122810).",Actionable,4215,10000003,Advanced Solid Tumor,JAX,17509,FGFR2-BICC1,sensitive,674,BGJ398,2263,24122810,,,
47,Clinical Study,"In a clinical study, FGFR2 V564F was identified in the cell-free DNA of a cholangiocarcinoma patient harboring FGFR2-BICC1 fusion after the patient progressed while on BGJ398 treatment (PMID: 28034880).  ",Actionable,10149,4947,cholangiocarcinoma,DOID,27313,FGFR2 V564F FGFR2-BICC1,predicted â€“ resistant,674,BGJ398,2263,28034880,,,
48,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited downstream phosphorylation of Akt and Erk1/2 in cells expressing the fusion, FGFR2 - TACC3 (PMID: 26048680).",Actionable,2679,10000003,Advanced Solid Tumor,JAX,9979,FGFR2 - TACC3,sensitive,877,Ponatinib,2263,26048680,,,
49,Preclinical,"In a preclinical study, BGJ398 prevented oncogenic transformation of cells expressing FGFR2 - TACC3 (PMID: 26048680).",Actionable,2676,10000003,Advanced Solid Tumor,JAX,9979,FGFR2 - TACC3,sensitive,674,BGJ398,2263,26048680,,,
50,Clinical Study,"In a clinical study, FGFR2 mutations E565A, K641R, L617V, N549H and V564F were identified in the cell-free DNA of a cholangiocarcinoma patient harboring FGFR2-OPTN fusion after the patient progressed while on BGJ398 treatment (PMID: 28034880).  ",Actionable,10148,4947,cholangiocarcinoma,DOID,27312,FGR2 E565A FGFR2 K641R FGFR2 L617V FGFR2 N549H FGFR2 V564F FGFR2-OPTN,predicted â€“ resistant,674,BGJ398,2263,28034880,,,
51,Phase I,"In a Phase I trial, Dovitinib (TKI258) displayed safety and preliminary efficacy resulting in tumor regression of 28.2% and 18.5% in two patients with FGFR2 amplified Erbb2 (Her2)-receptor positive breast cancer (PMID: 23658459).",Actionable,1748,60079,Her2-receptor positive breast cancer,DOID,3147,FGFR2 amp,sensitive,721,Dovitinib,2263,23658459,,,
52,Preclinical - Cell culture,"In a preclinical study, FGFR2 amplified colorectal adenocarcinoma cells were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).",Actionable,8484,50861,colorectal adenocarcinoma,DOID,3147,FGFR2 amp,no benefit,913,Selumetinib,2263,26438159,,,
53,Preclinical - Cell line xenograft,"In a preclinical study, PRN1371 inhibited proliferation of FGFR2 amplified gastric cancer cells in culture and tumor growth in cell line xenograft models (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).",Actionable,8404,10534,stomach cancer,DOID,3147,FGFR2 amp,sensitive,3583,PRN1371,2263,None,,,
54,Preclinical - Cell line xenograft,"In a preclinical study, Debio 1347 inhibited proliferation of FGFR-amplified gastric cancer cells in culture and inhibited tumor growth in cell line xenograft models of gastric cancer harboring FGFR2 amplification (PMID: 25169980).",Actionable,4053,10534,stomach cancer,DOID,3147,FGFR2 amp,sensitive,1014,FF-284,2263,25169980,,,
55,Preclinical - Cell culture,"In a preclinical study, FGFR2 amplified gastric carcinoma cell lines were not sensitive to RO4987655 in culture (PMID: 26438159).",Actionable,8453,5517,stomach carcinoma,DOID,3147,FGFR2 amp,no benefit,903,RO4987655,2263,26438159,,,
56,Preclinical - Cell culture,"In a preclinical study, FGFR2 amplified gastric carcinoma cell lines were not sensitive to RO5126766 in culture (PMID: 26438159).",Actionable,8471,5517,stomach carcinoma,DOID,3147,FGFR2 amp,no benefit,2011,RO5126766,2263,26438159,,,
57,Preclinical - Cell culture,"In a preclinical study, FGFR2 amplified colorectal adenocarcinoma cells demonstrated decreased response to RO4987655 in culture (PMID: 26438159).",Actionable,8452,50861,colorectal adenocarcinoma,DOID,3147,FGFR2 amp,decreased response,903,RO4987655,2263,26438159,,,
58,Preclinical - Cell line xenograft,"In a preclinical study, JNJ-42756493 (erdafitinib) inhibited tumor growth in an FGFR2-amplified colorectal cancer cell line xenograft model (PMID: 28341788).",Actionable,11182,9256,colorectal cancer,DOID,3147,FGFR2 amp,sensitive,1028,JNJ-42756493,2263,28341788,,,
59,Preclinical - Cell culture,"In a preclinical study, treatment with M-COPA resulted in decreased Fgfr2 cell surface expression and phosphorylation and reduced growth of an FGFR2-amplified signet cell gastric cancer cell line in culture (PMID: 27197184).",Actionable,7605,8025,gastric signet ring cell adenocarcinoma,DOID,3147,FGFR2 amp,sensitive,4522,M-COPA,2263,27197184,,,
60,Preclinical - Cell line xenograft,"In a preclinical study, Debio 1347 inhibited tumor growth in cell line xenograft models of FGFR2 amplified gastric carcinoma (PMID: 26438159).",Actionable,8496,5517,stomach carcinoma,DOID,3147,FGFR2 amp,sensitive,1014,FF-284,2263,26438159,,,
61,Preclinical,"In a preclinical study, Dovitinib (TKI258) increased apoptosis, inhibited cell proliferation and migration of myxoid liposarcoma cell lines harbors FGFR2 amplification in culture (PMID: 26036639).",Actionable,4036,5363,myxoid liposarcoma,DOID,3147,FGFR2 amp,sensitive,721,Dovitinib,2263,26036639,,,
62,Preclinical,"In a preclinical study, Dovitinib (TKI258) inhibited cell proliferation in gastric cancer cell lines harboring FGFR2 amplification in culture (PMID: 22238366).",Actionable,3522,10534,stomach cancer,DOID,3147,FGFR2 amp,sensitive,721,Dovitinib,2263,22238366,,,
63,Preclinical,"In a preclinical study, Debio 1347 inhibited proliferation of colorectal cancer cell lines harboring FGFR2 amplification in culture (PMID: 25169980).",Actionable,4071,9256,colorectal cancer,DOID,3147,FGFR2 amp,sensitive,1014,FF-284,2263,25169980,,,
64,Preclinical - Cell line xenograft,"In a preclinical study, Iclusig (ponatinib) inhibited proliferation of FGFR2-amplified gastric cancer cells in culture, and inhibited tumor growth in FGFR2-amplified gastric cancer cell line xenograft models (PMID: 22238366).",Actionable,3521,10534,stomach cancer,DOID,3147,FGFR2 amp,sensitive,877,Ponatinib,2263,22238366,,,
65,Preclinical,"In a preclinical study, Ofev (nintedanib) inhibited growth of colon cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).",Actionable,3546,219,colon cancer,DOID,3147,FGFR2 amp,sensitive,831,Nintedanib,2263,22238366,,,
66,Preclinical,"In a preclinical study, BGJ398 and Yondelis (trabectedin) worked synergistically to increase apoptosis, inhibit cell proliferation and migration of myxoid liposarcoma cell lines harboring FGFR2 amplification in culture (PMID: 26036639).",Actionable,4047,5363,myxoid liposarcoma,DOID,3147,FGFR2 amp,sensitive,3423,BGJ398 + Trabectedin,2263,26036639,,,
67,Preclinical - Pdx & cell culture,"In a preclinical study, Dovitinib (TKI258) inhibited cell growth of an FGFR2 amplified breast cancer cell line in culture and prevented tumor growth and induced tumor regression in FGFR2 amplified breast cancer patient derived xenograft (PDX) models (PMID: 23658459).",Actionable,1747,1612,breast cancer,DOID,3147,FGFR2 amp,sensitive,721,Dovitinib,2263,23658459,,,
68,Preclinical,"In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of colon cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).",Actionable,3547,219,colon cancer,DOID,3147,FGFR2 amp,no benefit,996,Brivanib,2263,22238366,,,
69,Preclinical - Cell line xenograft,"In a preclinical study, JNJ-42756493 (erdafitinib) inhibited proliferation of a gastric cancer cell line with FGFR2 amplification in culture, and inhibited tumor growth in xenograft models (PMID: 28341788).",Actionable,11178,10534,stomach cancer,DOID,3147,FGFR2 amp,sensitive,1028,JNJ-42756493,2263,28341788,,,
70,Preclinical - Pdx,"In a preclinical study, BAY1187982 inhibited tumor growth in patient-derived xenograft models of FGFR2 amplified ovarian cancer (PMID: 27543601).",Actionable,9095,2394,ovarian cancer,DOID,3147,FGFR2 amp,sensitive,2931,BAY1187982,2263,27543601,,,
71,Preclinical - Pdx,"In a preclinical study, PRN1371 treatment resulted in tumor growth inhibition in patient-derived xenograft models of FGFR2-amplified non-small cell lung cancer (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).",Actionable,8410,3908,non-small cell lung carcinoma,DOID,3147,FGFR2 amp,sensitive,3583,PRN1371,2263,None,,,
72,Preclinical,"In a preclinical study, Dovitinib (TKI258) inhibited cell proliferation in colon cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).",Actionable,3544,219,colon cancer,DOID,3147,FGFR2 amp,sensitive,721,Dovitinib,2263,22238366,,,
73,Phase I,"In a Phase I trial, a breast cancer patient harboring an FGFR2 amplification demonstrated stable disease when treated with BGJ398 (PMID: 27870574). ",Actionable,9736,1612,breast cancer,DOID,3147,FGFR2 amp,sensitive,674,BGJ398,2263,27870574,,,
74,Preclinical,"In a preclinical study, FIIN-01 inhibited Fgfr2-dependent cell proliferation of gastric cancer cell lines harboring FGFR2 amplification (PMID: 20338520).",Actionable,4022,10534,stomach cancer,DOID,3147,FGFR2 amp,sensitive,2507,FIIN-01,2263,20338520,,,
75,Phase II,"In a Phase II clinical trial, treatment with AZD4547 resulted in a 33% (3/9) response rate in patients with FGFR2-amplified gastroesophageal cancer, and high-level amplification was associated with clinical response (PMID: 27179038).",Actionable,7569,10534,stomach cancer,DOID,3147,FGFR2 amp,sensitive,654,AZD4547,2263,27179038,,,
76,Preclinical,"In a preclinical study, AZD4547 inhibited FGFR signaling, and decreased proliferation and induced cell-cycle arrest in gastric cancer cells with amplification and over expression of FGFR2 in culture (PMID: 22869148).",Actionable,2580,10534,stomach cancer,DOID,3147,FGFR2 amp,sensitive,654,AZD4547,2263,22869148,,,
77,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited Fgfr phosphorylation and cell proliferation in colon cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).",Actionable,3543,219,colon cancer,DOID,3147,FGFR2 amp,sensitive,877,Ponatinib,2263,22238366,,,
78,Preclinical,"In a preclinical study, Debio 1347 inhibited proliferation of breast cancer cell lines harboring FGFR2 amplification in culture (PMID: 25169980).",Actionable,4070,1612,breast cancer,DOID,3147,FGFR2 amp,sensitive,1014,FF-284,2263,25169980,,,
79,Preclinical - Cell line xenograft,"In a preclinical study, a gastric cancer cell line harboring FGFR2 amplification demonstrated decreased cell viability in culture and antitumor activity in xenograft models when treated with E7090 (PMID: 27535969). ",Actionable,9132,10534,stomach cancer,DOID,3147,FGFR2 amp,sensitive,4911,E7090,2263,27535969,,,
80,Preclinical,"In a preclinical study, BGJ398 increased apoptosis, and inhibited cell proliferation and migration of myxoid liposarcoma cell lines harboring FGFR2 amplification  in culture (PMID: 26036639).",Actionable,4042,5363,myxoid liposarcoma,DOID,3147,FGFR2 amp,sensitive,674,BGJ398,2263,26036639,,,
81,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited Fgfr phosphorylation and cell proliferation in ER-negative breast cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).",Actionable,3533,1612,breast cancer,DOID,3147,FGFR2 amp,sensitive,877,Ponatinib,2263,22238366,,,
82,Preclinical,"In a preclinical study, Selumetinib (AZD-6244) did not inhibit growth of gastric cancer cells with FGFR2 amplification in culture (PMID: 19755509).",Actionable,4032,10534,stomach cancer,DOID,3147,FGFR2 amp,resistant,913,Selumetinib,2263,19755509,,,
83,Preclinical,"In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of gastric cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).",Actionable,3525,10534,stomach cancer,DOID,3147,FGFR2 amp,no benefit,996,Brivanib,2263,22238366,,,
84,Preclinical - Cell line xenograft,"In a preclinical study, PRN1109 treatment resulted in tumor regression in gastric cancer cell line xenograft models harboring FGFR2 amplification (Eu J Cancer 2014 Vol 50, Suppl 6:157).",Actionable,4627,10534,stomach cancer,DOID,3147,FGFR2 amp,predicted â€“ sensitive,4645,PRN1109,2263,None,,,
85,Preclinical,"In a preclinical study, Cediranib (AZD-2171) inhibited growth of colon cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).",Actionable,3545,219,colon cancer,DOID,3147,FGFR2 amp,sensitive,1001,Cediranib,2263,22238366,,,
86,Preclinical - Cell culture,"In a preclinical study, BGJ398 reduced Myc expression, induced cell-cycle arrest, and inhibited growth of a colon cancer cell line with FGFR2 amplification in culture (PMID: 27401245).",Actionable,10025,219,colon cancer,DOID,3147,FGFR2 amp,sensitive,674,BGJ398,2263,27401245,,,
87,Preclinical,"In a preclinical study, PD173074 increased apoptosis, inhibited cell proliferation and migration of myxoid liposarcoma cell lines harboring FGFR2 amplification  in culture (PMID: 26036639).",Actionable,4041,5363,myxoid liposarcoma,DOID,3147,FGFR2 amp,sensitive,2948,PD173074,2263,26036639,,,
88,Preclinical,"In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of estrogen receptor (ER)-negative breast cancer cells with FGFR2 amplification in culture (PMID: 22238366).",Actionable,3535,60076,estrogen-receptor negative breast cancer,DOID,3147,FGFR2 amp,no benefit,996,Brivanib,2263,22238366,,,
89,Preclinical,"In a preclinical study, BGJ398 inhibited proliferation of gastric cancer cell lines harboring FGFR2 amplification in culture (PMID: 26036639).",Actionable,4045,10534,stomach cancer,DOID,3147,FGFR2 amp,sensitive,674,BGJ398,2263,26036639,,,
90,Preclinical - Cell culture,"In a preclinical study, AZD4547 inhibited survival of FGFR2 amplified colon cancer cells in culture (PMID: 27550940).",Actionable,9115,219,colon cancer,DOID,3147,FGFR2 amp,sensitive,654,AZD4547,2263,27550940,,,
91,Preclinical - Cell culture,"In a preclinical study, RO5126766 inhibited proliferation of FGFR2 amplified colorectal adenocarcinoma cells in culture (PMID: 26438159).",Actionable,8470,50861,colorectal adenocarcinoma,DOID,3147,FGFR2 amp,predicted â€“ sensitive,2011,RO5126766,2263,26438159,,,
92,Preclinical,"In a preclinical study, Cediranib (AZD-2171) inhibited growth of gastric cancer cells harboring FGFR2 amplification in culture (PMID: 22238366).",Actionable,3523,10534,stomach cancer,DOID,3147,FGFR2 amp,sensitive,1001,Cediranib,2263,22238366,,,
93,Preclinical,"In a preclinical study, Dovitinib (TKI258) and Yondelis (trabectedin) worked synergistically to increase apoptosis, inhibit cell proliferation and migration of myxoid liposarcoma cell lines harbors FGFR2 amplification in culture (PMID: 26036639).",Actionable,4040,5363,myxoid liposarcoma,DOID,3147,FGFR2 amp,sensitive,3421,Dovitinib + Trabectedin,2263,26036639,,,
94,Preclinical,"In a preclinical study, PD173034 and Yondelis (trabectedin) worked synergistically to increase apoptosis, inhibit cell proliferation and migration of myxoid liposarcoma cell lines harboring FGFR2 amplification in culture (PMID: 26036639).",Actionable,4046,5363,myxoid liposarcoma,DOID,3147,FGFR2 amp,sensitive,3422,PD173074 + Trabectedin,2263,26036639,,,
95,Phase I,"In a Phase I trial, TAS-120 treatment resulted in clinical response in a gastric cancer patient harboring FGFR2 amplification (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 372PD).",Actionable,11984,10534,stomach cancer,DOID,3147,FGFR2 amp,predicted â€“ sensitive,1053,TAS-120,2263,None,,,
96,Preclinical - Cell culture,"In a preclinical study, AZD4547 inhibited survival of FGFR2 amplified breast cancer cells in culture (PMID: 27550940).",Actionable,9116,1612,breast cancer,DOID,3147,FGFR2 amp,sensitive,654,AZD4547,2263,27550940,,,
97,Preclinical - Cell culture,"In a preclinical study, FGFR2-amplified gastric cancer cell lines demonstrated sensitivity to PD173074 in culture, with cell lines with high-level FGFR2 amplification displaying higher sensitivity compared to cell lines with low-level amplification (PMID: 27179038).",Actionable,7570,10534,stomach cancer,DOID,3147,FGFR2 amp,sensitive,2948,PD173074,2263,27179038,,,
98,Preclinical - Cell culture,"In a preclinical study, PD173074 inhibited proliferation of a gastric cancer cell line harboring FGFR2 amplification in culture (PMID: 26036639).",Actionable,4043,10534,stomach cancer,DOID,3147,FGFR2 amp,sensitive,2948,PD173074,2263,26036639,,,
99,Preclinical - Cell line xenograft,"In a preclinical study, AZD4547 inhibited survival of FGFR2 amplified endometrial cancer cells in cell line xenograft models (PMID: 27550940).",Actionable,9119,1380,endometrial cancer,DOID,3147,FGFR2 amp,sensitive,654,AZD4547,2263,27550940,,,
100,Preclinical - Pdx,"In a preclinical study, PRN1371 treatment resulted in tumor growth inhibition in patient-derived xenograft models of FGFR2-amplified breast cancer harboring FGFR2-GAB2 fusion (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).",Actionable,8414,1612,breast cancer,DOID,26313,FGFR2 amp FGFR2 fusion,sensitive,3583,PRN1371,2263,None,,,
101,Preclinical - Cell culture,"In a preclinical study, head and neck squamous cell carcinoma cells harboring FGFR2 amplification and over expressing EGFR demonstrated resistance to treatment with AZD4547 in culture (PMID: 26936917). ",Actionable,7832,5520,head and neck squamous cell carcinoma,DOID,26059,EGFR over exp FGFR2 amp,resistant,654,AZD4547,2263,26936917,,,
102,Preclinical - Cell culture,"In a preclinical study, head and neck squamous cell carcinoma cells harboring FGFR2 amplification and over expressing EGFR demonstrated sensitivity to the combination treatment of AZD4547 and Iressa (gefitinib) in culture, which also resulted in a moderate synergistic effect (PMID: 26936917). ",Actionable,7835,5520,head and neck squamous cell carcinoma,DOID,26059,EGFR over exp FGFR2 amp,sensitive,4585,AZD4547 + Gefitinib,2263,26936917,,,
103,Preclinical - Cell culture,"In a preclinical study, the combination of AZD-4547 and Tykerb (lapatinib) worked synergistically to inhibit growth of an esophageal adenocarcinoma cell line with ERBB2 (HER2) and FGFR2 amplification in culture (PMID: 27595477).",Actionable,11556,4914,esophagus adenocarcinoma,DOID,28144,ERBB2 amp FGFR2 amp,sensitive,6062,AZD4547 + Lapatinib,2263,27595477,,,
104,Preclinical - Cell line xenograft,"In a preclinical study, a breast cancer cell line, harboring FGFR1 amplification and FGFR2 amplification, treated with E7090 demonstrated decreased cell viability in culture and antitumor activity in xenograft models (PMID: 27535969). ",Actionable,9126,1612,breast cancer,DOID,26745,FGFR1 amp FGFR2 amp,sensitive,4911,E7090,2263,27535969,,,
105,Preclinical - Pdx,"In a preclinical study, AZD4547 decreased Myc expression and inhibited tumor growth in patient-derived xenograft (PDX) models of gastric cancer with FGFR2 amplification and over expression (PMID: 27401245).",Actionable,10029,10534,stomach cancer,DOID,27227,FGFR2 amp FGFR2 over exp,sensitive,654,AZD4547,2263,27401245,,,
106,Preclinical - Pdx,"In a preclinical study, BGJ398 decreased Myc expression and inhibited tumor growth in patient-derived xenograft (PDX) models of gastric cancer with FGFR2 amplification and over expression (PMID: 27401245).",Actionable,10028,10534,stomach cancer,DOID,27227,FGFR2 amp FGFR2 over exp,sensitive,674,BGJ398,2263,27401245,,,
107,Clinical Study,"In a clinical study, FGFR2 V564F was identified in the cell-free DNA of 3 cholangiocarcinoma patients harboring FGFR2 fusion after the patients progressed while on BGJ398 treatment (PMID: 28034880).  ",Actionable,10150,4947,cholangiocarcinoma,DOID,27314,FGFR2 fusion FGFR2 V564F,predicted â€“ resistant,674,BGJ398,2263,28034880,,,
108,Phase I,"In a Phase I trial, JNJ-42756493 treatment resulted tumor shrinkage and no disease progression for 10 months in an adrenal carcinoma patient harboring FGFR3 - TACC3 and FGFR2 - CCDC6 fusions (PMID: 26324363).",Actionable,4007,3950,adrenal carcinoma,DOID,17093,FGFR2 fusion FGFR3 - TACC3,sensitive,1028,JNJ-42756493,2263,26324363,,,
109,Phase I,"In a Phase I trial, JNJ-42756493 treatment resulted in partial response in an endometrial cancer patient harboring FGFR2 - BICC1 and FGFR2 - OFD1 fusions (PMID: 26324363).",Actionable,4006,1380,endometrial cancer,DOID,2969,FGFR2 fusion,sensitive,1028,JNJ-42756493,2263,26324363,,,
110,Phase I,"In a Phase I clinical trial, ARQ 087 treatment resulted in stable disease for greater than 24 weeks and 26% tumor reduction in one, and a partial response in a second, of two intrahepatic cholangiocarcinoma patients harboring FGFR2 fusions (J Clin Oncol 33, 2015 (suppl; abstr 2545)).",Actionable,3993,4928,intrahepatic cholangiocarcinoma,DOID,2969,FGFR2 fusion,sensitive,2900,ARQ 087,2263,None,,,
111,Phase I,"In a Phase I trial, two patients with cholangiocarcinoma harboring FGFR2 fusions demonstrated a decreased tumor burden when treated with BGJ398 (PMID: 27870574). ",Actionable,9737,4947,cholangiocarcinoma,DOID,2969,FGFR2 fusion,sensitive,674,BGJ398,2263,27870574,,,
112,Phase I,"In a Phase I trial, JNJ-42756493 treatment resulted in partial response for more than 12 months in a urothelial cancer patient harboring FGFR2 - BICC1 and FGFR2 - CASP7 fusions (PMID: 26324363).",Actionable,4003,3996,urinary system cancer,DOID,2969,FGFR2 fusion,sensitive,1028,JNJ-42756493,2263,26324363,,,
113,Phase I,"In a Phase I trial, TAS-120 treatment resulted in stable disease over 24 weeks in two biliary tract cancer patients harboring FGFR2 fusions (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 372PD).",Actionable,11986,4607,biliary tract cancer,DOID,2969,FGFR2 fusion,predicted â€“ sensitive,1053,TAS-120,2263,None,,,
114,Preclinical,"In a preclinical study, treatment with BGJ398 prevented transformation of cells expressing FGFR2-AHCYL1 in culture (PMID: 24122810).",Actionable,4213,10000003,Advanced Solid Tumor,JAX,17510,FGFR2-AHCYL1,sensitive,674,BGJ398,2263,24122810,,,
115,Preclinical,"In a preclinical study, treatment with PD173074 prevented transformation of cells expressing FGFR2-AHCYL1 in culture (PMID: 24122810).",Actionable,4214,10000003,Advanced Solid Tumor,JAX,17510,FGFR2-AHCYL1,sensitive,2948,PD173074,2263,24122810,,,
116,Preclinical,"In a preclinical study, Debio 1347 inhibited proliferation of endometrial cancer cells harboring FGFR2 N549K mutation in culture (PMID: 25169980).",Actionable,4054,1380,endometrial cancer,DOID,547,FGFR2 N549K,sensitive,1014,FF-284,2263,25169980,,,
117,Preclinical,"In a preclinical study, Dovitinib (TKI258) did not potently inhibit proliferation of endometrial cancer cell lines harboring FGFR2 N549K in cell culture (PMID: 22238366).",Actionable,3497,1380,endometrial cancer,DOID,547,FGFR2 N549K,decreased response,721,Dovitinib,2263,22238366,,,
118,Preclinical,"In a preclinical study, Cediranib (AZD-2171) inhibited growth of endometrial cancer cells harboring FGFR2 N549K in cell culture (PMID: 22238366).",Actionable,3498,1380,endometrial cancer,DOID,547,FGFR2 N549K,sensitive,1001,Cediranib,2263,22238366,,,
119,Preclinical - Cell culture,"In a preclinical study, endometrial carcinoma cells harboring FGFR2 N549K were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).",Actionable,8486,2871,endometrial carcinoma,DOID,547,FGFR2 N549K,no benefit,913,Selumetinib,2263,26438159,,,
120,Preclinical - Cell line xenograft,"In a preclinical study, Iclusig (ponatinib) inhibited growth of endometrial cancer cells harboring FGFR2 N549K in culture and in cell line xenograft models (PMID: 22238366).",Actionable,3496,1380,endometrial cancer,DOID,547,FGFR2 N549K,sensitive,877,Ponatinib,2263,22238366,,,
121,Preclinical - Cell culture,"In a preclinical study, endometrial carcinoma cells harboring FGFR2 N549K were not sensitive to RO4987655 in culture (PMID: 26438159).",Actionable,8456,2871,endometrial carcinoma,DOID,547,FGFR2 N549K,no benefit,903,RO4987655,2263,26438159,,,
122,Preclinical,"In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of endometrial cancer cells harboring FGFR2 N549K in cell culture (PMID: 22238366).",Actionable,3500,1380,endometrial cancer,DOID,547,FGFR2 N549K,no benefit,996,Brivanib,2263,22238366,,,
123,Preclinical,"In a preclinical study, FIIN-01 inhibited proliferation of endometrial carcinoma cell lines harboring FGFR2 N549K mutation in culture (PMID: 20338520).",Actionable,4023,2871,endometrial carcinoma,DOID,547,FGFR2 N549K,sensitive,2507,FIIN-01,2263,20338520,,,
124,Preclinical - Cell culture,"In a preclinical study, endometrial carcinoma cells harboring FGFR2 N549K were not sensitive to RO5126766 in culture (PMID: 26438159).",Actionable,8472,2871,endometrial carcinoma,DOID,547,FGFR2 N549K,no benefit,2011,RO5126766,2263,26438159,,,
125,Preclinical,"In a preclinical study, Ofev (Nintedanib) did not inhibit growth of endometrial cancer cells harboring FGFR2 N549K in cell culture (PMID: 22238366).",Actionable,3499,1380,endometrial cancer,DOID,547,FGFR2 N549K,resistant,831,Nintedanib,2263,22238366,,,
126,Preclinical - Cell culture,"In a preclinical study, endometrial carcinoma cells harboring both FGFR2 K310R and N549K were not sensitive to RO4987655 in culture (PMID: 26438159).",Actionable,8457,2871,endometrial carcinoma,DOID,17132,FGFR2 K310R FGFR2 N549K,no benefit,903,RO4987655,2263,26438159,,,
127,Preclinical,"In a preclinical study, Debio 1347 inhibited proliferation of endometrial cancer cells harboring FGFR2 K310R and FGFR2 N549K mutations in culture (PMID: 25169980).",Actionable,4057,1380,endometrial cancer,DOID,17132,FGFR2 K310R FGFR2 N549K,sensitive,1014,FF-284,2263,25169980,,,
128,Preclinical - Cell culture,"In a preclinical study, endometrial carcinoma cells harboring both FGFR2 K310R and N549K were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).",Actionable,8487,2871,endometrial carcinoma,DOID,17132,FGFR2 K310R FGFR2 N549K,no benefit,913,Selumetinib,2263,26438159,,,
129,Preclinical - Cell culture,"In a preclinical study, endometrial carcinoma cells harboring both FGFR2 K310R and N549K were not sensitive to RO5126766 in culture (PMID: 26438159).",Actionable,8473,2871,endometrial carcinoma,DOID,17132,FGFR2 K310R FGFR2 N549K,no benefit,2011,RO5126766,2263,26438159,,,
130,Preclinical,"In a preclinical study, FIIN-01 inhibited proliferation of endometrial carcinoma cell lines harboring FGFR2 N549K and FGFR2 K310R mutations in culture (PMID: 20338520).",Actionable,4024,2871,endometrial carcinoma,DOID,17132,FGFR2 K310R FGFR2 N549K,sensitive,2507,FIIN-01,2263,20338520,,,
131,Preclinical - Cell line xenograft,"In a preclinical study, BAY1187982 inhibited survival of colorectal cancer cells with over expressing Fgfr2 in culture, and suppressed tumor growth in cell line xenograft models (PMID: 27543601).",Actionable,9096,9256,colorectal cancer,DOID,8808,FGFR2 over exp,sensitive,2931,BAY1187982,2263,27543601,,,
132,Preclinical - Cell culture,"In a preclinical study, endometrial cells with Fgfr2 overexpression were resistant to the anti-proliferative effects of AZD4547 (PMID: 26294741).",Actionable,8854,1380,endometrial cancer,DOID,8808,FGFR2 over exp,resistant,654,AZD4547,2263,26294741,,,
133,Preclinical,"In a preclinical study, AZD4547 inhibited downstream Erk phosphorylation and proliferation of breast cancer cells over expressing FGFR2 in culture (PMID: 22869148).",Actionable,2579,1612,breast cancer,DOID,8808,FGFR2 over exp,sensitive,654,AZD4547,2263,22869148,,,
134,Preclinical,"In a preclinical study, AZ8010 inhibited downstream Erk phosphorylation and proliferation of breast cancer cells over expressing FGFR2 in culture (PMID: 22869148).",Actionable,2577,1612,breast cancer,DOID,8808,FGFR2 over exp,sensitive,2955,AZ8010,2263,22869148,,,
135,Preclinical,"In a preclinical study, PD173074 inhibited proliferation of breast cancer cells over expressing FGFR2 in culture (PMID: 22869148).",Actionable,3279,1612,breast cancer,DOID,8808,FGFR2 over exp,sensitive,2948,PD173074,2263,22869148,,,
136,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 N550H demonstrated a decreased response to treatment with Dovitinib (TKI258) (PMID: 23908597).",Actionable,2586,10000003,Advanced Solid Tumor,JAX,3427,FGFR2 N550H,decreased response,721,Dovitinib,2263,23908597,,,
137,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 N550H were resistant to treatment with PD173074 (PMID: 23908597).",Actionable,2594,10000003,Advanced Solid Tumor,JAX,3427,FGFR2 N550H,resistant,2948,PD173074,2263,23908597,,,
138,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited Fgfr2 phosphorylation and proliferation in transformed cells expressing FGFR2 N550H (PMID: 23908597).",Actionable,2606,10000003,Advanced Solid Tumor,JAX,3427,FGFR2 N550H,sensitive,877,Ponatinib,2263,23908597,,,
139,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 K660E demonstrated a decreased response when treated with PD173074 (PMID: 23908597).",Actionable,3283,10000003,Advanced Solid Tumor,JAX,3413,FGFR2 K660E,decreased response,2948,PD173074,2263,23908597,,,
140,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 K660E were resistant to treatment with Dovitinib (TKI258) (PMID: 23908597).",Actionable,2590,10000003,Advanced Solid Tumor,JAX,3413,FGFR2 K660E,resistant,721,Dovitinib,2263,23908597,,,
141,Preclinical - Cell culture,"In a preclinical study, PRN1371 inhibited Fgfr2 activity in transformed cells over expressing FGFR K660E in culture (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).",Actionable,8399,10000003,Advanced Solid Tumor,JAX,3413,FGFR2 K660E,sensitive,3583,PRN1371,2263,None,,,
142,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 K660E demonstrated a decreased response to treatment with Iclusig (ponatinib) (PMID: 23908597).",Actionable,2603,10000003,Advanced Solid Tumor,JAX,3413,FGFR2 K660E,decreased response,877,Ponatinib,2263,23908597,,,
143,Preclinical - Cell culture,"In a preclinical study, endometrial carcinoma cells harboring FGFR2 S252W demonstrated decreased response to RO4987655 in culture (PMID: 26438159).",Actionable,8455,2871,endometrial carcinoma,DOID,3430,FGFR2 S252W,decreased response,903,RO4987655,2263,26438159,,,
144,Preclinical,"In a preclinical study, Ofev (Nintedanib) inhibited cell proliferation in endometrial cancer cells harboring FGFR2 S252W mutation in culture (PMID: 22238366).",Actionable,3505,1380,endometrial cancer,DOID,3430,FGFR2 S252W,sensitive,831,Nintedanib,2263,22238366,,,
145,Preclinical,"In a preclinical study, Brivanib (BMS-540215) inhibited growth of endometrial cancer cells harboring FGFR2 S252W in culture (PMID: 22238366).",Actionable,3504,1380,endometrial cancer,DOID,3430,FGFR2 S252W,sensitive,996,Brivanib,2263,22238366,,,
146,Preclinical,"In a preclinical study, Cediranib (AZD-2171) inhibited growth of endometrial cancer cells harboring FGFR2 S252W in culture (PMID: 22238366).",Actionable,3503,1380,endometrial cancer,DOID,3430,FGFR2 S252W,sensitive,1001,Cediranib,2263,22238366,,,
147,Preclinical - Cell culture,"In a preclinical study, RO5126766 inhibited proliferation of endometrial carcinoma cells harboring FGFR2 S252W in culture (PMID: 26438159).",Actionable,8497,2871,endometrial carcinoma,DOID,3430,FGFR2 S252W,sensitive,2011,RO5126766,2263,26438159,,,
148,Preclinical,"In a preclinical study, Dovitinib (TKI258) did not potently inhibit cell proliferation in endometrial cancer cells harboring FGFR2 S252W mutation in culture (PMID: 22238366).",Actionable,3755,1380,endometrial cancer,DOID,3430,FGFR2 S252W,decreased response,721,Dovitinib,2263,22238366,,,
149,Preclinical - Cell culture,"In a preclinical study, endometrial carcinoma cells harboring FGFR2 S252W demonstrated decreased sensitivity to Selumetinib (AZD-6244) in culture (PMID: 26438159).",Actionable,8485,2871,endometrial carcinoma,DOID,3430,FGFR2 S252W,decreased response,913,Selumetinib,2263,26438159,,,
150,Preclinical - Cell line xenograft,"In a preclinical study, Debio 1347 inhibited proliferation of endometrial cancer cells harboring an FGFR2 S252W mutation in culture and inhibited tumor growth in FGFR2 S252W-positive endometrial cancer cell line xenograft models (PMID: 25169980).",Actionable,4059,1380,endometrial cancer,DOID,3430,FGFR2 S252W,sensitive,1014,FF-284,2263,25169980,,,
151,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 S252W were sensitive to Dovitinib (TKI258) (PMID: 23908597). ",Actionable,3275,10000003,Advanced Solid Tumor,JAX,3430,FGFR2 S252W,sensitive,721,Dovitinib,2263,23908597,,,
152,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited Fgfr2 phosphorylation and cell proliferation in endometrial cancer cells harboring FGFR2 S252W in culture (PMID: 22238366).",Actionable,3501,1380,endometrial cancer,DOID,3430,FGFR2 S252W,sensitive,877,Ponatinib,2263,22238366,,,
153,Preclinical - Cell culture,"In a preclinical study, an endometrial cancer cell line harboring FGFR2 S252W (PMID: 18552176) demonstrated sensitivity to E7090 in culture, resulting in decreased cell viability (PMID: 27535969). ",Actionable,9137,1380,endometrial cancer,DOID,3430,FGFR2 S252W,sensitive,4911,E7090,2263,18552176,27535969,,
154,Preclinical - Cell line xenograft,"In a preclinical study, GSK3052230 (FP-1039) treatment resulted in greater tumor growth inhibition (95% vs 30%) in cell line xenograft models of endometrial carcinoma harboring FGFR2 S252W compared to FGFR2 wild-type models (PMID: 23536011).",Actionable,11475,2871,endometrial carcinoma,DOID,3430,FGFR2 S252W,sensitive,2899,GSK3052230,2263,23536011,,,
155,Preclinical - Cell culture,"In a preclinical study, endometrial cells harboring Fgfr2 S252W were less sensitive to the anti-proliferative effects of AZD4547 than the Fgfr2 double mutant, K310R, N550K (PMID: 26294741).",Actionable,8853,1380,endometrial cancer,DOID,3430,FGFR2 S252W,decreased response,654,AZD4547,2263,26294741,,,
156,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 M538I demonstrated a decreased response to treatment with Dovitinib (TKI258) (PMID: 23908597).",Actionable,2592,10000003,Advanced Solid Tumor,JAX,9489,FGFR2 M538I,decreased response,721,Dovitinib,2263,23908597,,,
157,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 M538I demonstrated a decreased response to treatment with PD173074 (PMID: 23908597).",Actionable,2597,10000003,Advanced Solid Tumor,JAX,9489,FGFR2 M538I,decreased response,2948,PD173074,2263,23908597,,,
158,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 M538I demonstrated a decreased response to treatment with Iclusig (ponatinib) (PMID: 23908597).",Actionable,2602,10000003,Advanced Solid Tumor,JAX,9489,FGFR2 M538I,decreased response,877,Ponatinib,2263,23908597,,,
159,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited Fgfr2 phosphorylation and proliferation in transformed cells expressing FGFR2 M536I (PMID: 23908597).",Actionable,2604,10000003,Advanced Solid Tumor,JAX,9488,FGFR2 M536I,sensitive,877,Ponatinib,2263,23908597,,,
160,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 M536I demonstrated a decreased response to treatment with Dovitinib (TKI258) (PMID: 23908597).",Actionable,2593,10000003,Advanced Solid Tumor,JAX,9488,FGFR2 M536I,decreased response,721,Dovitinib,2263,23908597,,,
161,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 M536I demonstrated a decreased response to treatment with PD173074 (PMID: 23908597).",Actionable,2596,10000003,Advanced Solid Tumor,JAX,9488,FGFR2 M536I,decreased response,2948,PD173074,2263,23908597,,,
162,Clinical Study,"In clinical case study, a patient with olfactory neuroblastoma harboring EGFR R521K, FGFR2 M186T, KDR Q472H, KDR V297I, and RET M1009T demonstrated sensitivity to the combination of Sutent (sunitinib) and Erbitux (cetuximab), resulting in a complete response (PMID: 27149458).",Actionable,7758,369,olfactory neuroblastoma,DOID,26023,EGFR R521K FGFR2 M186T KDR Q472H KDR V297I RET M1009T,sensitive,4568,Cetuximab + Sunitinib,2263,27149458,,,
163,Preclinical,"In a preclinical study, AZ12576089 (AZ6089) inhibited FGF2-induced ERK1/2 phosphorylation and cell proliferation in transformed fibroblasts in culture (PMID: 22869148).",Actionable,3995,10000003,Advanced Solid Tumor,JAX,543,FGFR2 wild-type,predicted â€“ sensitive,2956,AZ6089,2263,22869148,,,
164,Preclinical,"In a preclinical study, an endometrial carcinoma cell line harboring wild-type FGFR2 was resistant to FIIN-01-induced growth inhibition in culture (PMID: 20338520).",Actionable,4025,2871,endometrial carcinoma,DOID,543,FGFR2 wild-type,resistant,2507,FIIN-01,2263,20338520,,,
165,Preclinical,"In a preclinical study, ER-negative breast cancer cells with wild-type FGFR2 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366).",Actionable,3536,1612,breast cancer,DOID,543,FGFR2 wild-type,resistant,877,Ponatinib,2263,22238366,,,
166,Preclinical,"In a preclinical study, colon cancer cells with wild-type FGFR2 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366).",Actionable,3548,219,colon cancer,DOID,543,FGFR2 wild-type,resistant,877,Ponatinib,2263,22238366,,,
167,Preclinical,"In a preclinical study, endometrial cancer cells with wild-type FGFR2 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366).",Actionable,3506,1380,endometrial cancer,DOID,543,FGFR2 wild-type,resistant,877,Ponatinib,2263,22238366,,,
168,Preclinical,"In a preclinical study, gastric cancer cells with wild-type FGFR2 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366).",Actionable,3520,10534,stomach cancer,DOID,543,FGFR2 wild-type,resistant,877,Ponatinib,2263,22238366,,,
169,Preclinical - Cell culture,"In a preclinical study, endometrial cells with Fgfr2 wild-type were resistant to the anti-proliferative effects of AZD4547 (PMID: 26294741).",Actionable,8855,1380,endometrial cancer,DOID,543,FGFR2 wild-type,resistant,654,AZD4547,2263,26294741,,,
170,Preclinical - Cell culture,"In a preclinical study, PRN1371 inhibited Fgfr2 activity in transformed cells over expressing wild-type Fgfr2 in culture (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).",Actionable,8398,10000003,Advanced Solid Tumor,JAX,543,FGFR2 wild-type,sensitive,3583,PRN1371,2263,None,,,
171,Preclinical,"In a preclinical study, gastric cancer cells with wild-type FGFR2  and ERBB2 (HER2) amplification were resistant to treatment with AZD4547 in culture (PMID: 22869148).",Actionable,2581,10534,stomach cancer,DOID,9482,FGFR2 wild-type ERBB2 amp,resistant,654,AZD4547,2263,22869148,,,
172,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 N550S demonstrated a decreased response to treatment with Dovitinib (TKI258) (PMID: 23908597).",Actionable,2585,10000003,Advanced Solid Tumor,JAX,9483,FGFR2 N550S,decreased response,721,Dovitinib,2263,23908597,,,
173,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited Fgfr2 phosphorylation and proliferation in transformed cells expressing FGFR2 N550S (PMID: 23908597).",Actionable,2608,10000003,Advanced Solid Tumor,JAX,9483,FGFR2 N550S,sensitive,877,Ponatinib,2263,23908597,,,
174,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 N550S demonstrated a decreased response to treatment with PD173074 (PMID: 23908597).",Actionable,2599,10000003,Advanced Solid Tumor,JAX,9483,FGFR2 N550S,decreased response,2948,PD173074,2263,23908597,,,
175,Preclinical - Cell line xenograft,"In a preclinical study, transformed cells over expressing FGFR2 V564F were resistant to AZD4547 in culture and in cell line xenograft models (PMID: 25169980).",Actionable,10185,10000003,Advanced Solid Tumor,JAX,27305,FGFR2 V564F,resistant,654,AZD4547,2263,25169980,,,
176,Preclinical - Cell line xenograft,"In a preclinical study, Debio 1347 inhibited proliferation of transformed cells over expressing FGFR2 V564F in culture and inhibited tumor growth in cell line xenograft models (PMID: 25169980).",Actionable,10184,10000003,Advanced Solid Tumor,JAX,27305,FGFR2 V564F,sensitive,1014,FF-284,2263,25169980,,,
177,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FGFR2 V564F were resistant to BGJ398 in culture (PMID: 28034880).",Actionable,10183,10000003,Advanced Solid Tumor,JAX,27305,FGFR2 V564F,resistant,674,BGJ398,2263,28034880,,,
178,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 L618M demonstrated a decreased response to treatment with Dovitinib (TKI258) (PMID: 23908597).",Actionable,2589,10000003,Advanced Solid Tumor,JAX,9492,FGFR2 L618M,decreased response,721,Dovitinib,2263,23908597,,,
179,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 L618M demonstrated a decreased response to treatment with PD173074 (PMID: 23908597).",Actionable,2600,10000003,Advanced Solid Tumor,JAX,9492,FGFR2 L618M,decreased response,2948,PD173074,2263,23908597,,,
180,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 L618M were sensitive to treatment with Iclusig (ponatinib) (PMID: 23908597).",Actionable,3282,10000003,Advanced Solid Tumor,JAX,9492,FGFR2 L618M,sensitive,877,Ponatinib,2263,23908597,,,
181,Preclinical - Cell culture,"In a preclinical study, Debio 1347 did not inhibit Fgfr2 phosphorylation in transformed cells over expressing FGFR2 V564I in culture (PMID: 25169980).",Actionable,10188,10000003,Advanced Solid Tumor,JAX,27306,FGFR2 V564I,resistant,1014,FF-284,2263,25169980,,,
182,Preclinical,"In a preclinical study, knocking down of Fgfr2 through shRNA did not sensitize KRAS mutant lung cancer cells to Mekinist (trametinib) induced growth inhibition in culture (PMID: 27338794).",Actionable,7362,1324,lung cancer,DOID,25308,FGFR2 dec exp KRAS mut,no benefit,2,Trametinib,2263,27338794,,,
183,Preclinical - Cell culture,"In a preclinical study, BAY1187982 did not inhibit growth of breast cancer cells with very low Fgfr2 expression level in culture (PMID: 27543601).",Actionable,9098,1612,breast cancer,DOID,25307,FGFR2 dec exp,resistant,2931,BAY1187982,2263,27543601,,,
184,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited Fgfr2 phosphorylation and proliferation in transformed cells expressing FGFR2 E566G (PMID: 23908597).",Actionable,2609,10000003,Advanced Solid Tumor,JAX,9485,FGFR2 E566G,sensitive,877,Ponatinib,2263,23908597,,,
185,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 E566G were resistant to treatment with PD173074 (PMID: 23908597).",Actionable,2595,10000003,Advanced Solid Tumor,JAX,9485,FGFR2 E566G,resistant,2948,PD173074,2263,23908597,,,
186,Preclinical,"In a preclinical study, transformed cells expressing FGFR2 E566G were resistant to treatment with Dovitinib (TKI258) (PMID: 23908597).",Actionable,2588,10000003,Advanced Solid Tumor,JAX,9485,FGFR2 E566G,resistant,721,Dovitinib,2263,23908597,,,
0,Preclinical,"In a preclinical study, urothelial cancer cells with low expression of wild-type FGFR3 that harbored HRAS G12V demonstrated resistance to PD173074 in culture (PMID: 22869148).",Actionable,3278,2671,transitional cell carcinoma,DOID,13021,FGFR3 wild-type FGFR3 dec exp HRAS G12V,resistant,2948,PD173074,2261,22869148,,,
1,Preclinical,"In a preclinical study, urothelial cancer cells with low expression of wild-type FGFR3 that harbored HRAS G12V demonstrated resistance to AZD4547 in culture (PMID: 22869148).",Actionable,2576,2671,transitional cell carcinoma,DOID,13021,FGFR3 wild-type FGFR3 dec exp HRAS G12V,resistant,654,AZD4547,2261,22869148,,,
2,Preclinical,"In a preclinical study, urothelial cancer cells with low expression of wild-type FGFR3 that harbored HRAS G12V demonstrated resistance to AZ8010 in culture (PMID: 22869148).",Actionable,2575,2671,transitional cell carcinoma,DOID,13021,FGFR3 wild-type FGFR3 dec exp HRAS G12V,decreased response,2955,AZ8010,2261,22869148,,,
3,Preclinical,"In a preclinical study, knocking down of Fgfr3 through shRNA did not sensitize KRAS mutant lung cancer cells to Mekinist (trametinib) induced growth inhibition in culture  (PMID: 27338794).",Actionable,7363,1324,lung cancer,DOID,25309,FGFR3 dec exp KRAS mut,no benefit,2,Trametinib,2261,27338794,,,
4,Phase II,"In a Phase II trial, Dovitinib (TKI258) treatment resulted in complete response for 6 months in 33% (1/3) of non-muscle invasive bladder cancer patients harboring both FGFR3 mutations and FGFR3 over expression (J Clin Oncol 34, 2016 (suppl; abstr 4526)).",Actionable,6980,11054,urinary bladder cancer,DOID,24169,FGFR3 mut FGFR3 over exp,sensitive,721,Dovitinib,2261,None,,,
5,Preclinical - Cell culture,"In a preclinical study, AZD4547 inhibited survival of bladder cancer cells harboring FGFR3 mutation in culture (PMID: 27550940).",Actionable,9123,11054,urinary bladder cancer,DOID,1222,FGFR3 mutant,sensitive,654,AZD4547,2261,27550940,,,
6,Preclinical - Cell line xenograft,"In a preclinical study, a variety of cancer cell lines harboring mutations in FGFR1, FGFR2, and/or FGFR3 demonstrated sensitivity to INCB054828 in culture and in cell line xenograft models, resulting in inhibition of tumor growth (Cancer Res 2015;75(15 Suppl):Abstract nr 771).",Actionable,8391,10000003,Advanced Solid Tumor,JAX,1222,FGFR3 mutant,sensitive,4173,INCB054828,2261,None,,,
7,Preclinical,"In a preclinical study, tumor cell lines with FGFR3 mutations demonstrated sensitivity to BGJ398 in culture (PMID: 23002168).",Actionable,1118,10000003,Advanced Solid Tumor,JAX,1222,FGFR3 mutant,sensitive,674,BGJ398,2261,23002168,,,
8,Phase II,"In a Phase II trial, Dovitinib (TKI258) treatment resulted in complete response in 33% (1/3) of patients with BCG-unresponsive, nonâ€“muscle-invasive, urothelial carcinoma of the bladder harboring FGFR3 mutations (PMID: 27932416).",Actionable,11227,4006,bladder urothelial carcinoma,DOID,1222,FGFR3 mutant,sensitive,721,Dovitinib,2261,27932416,,,
9,Phase I,"In a Phase I trial, JNJ-42756493 treatment resulted in 25% tumor shrinkage at week 8 in an urothelial cancer patient harboring FGFR3 mutations (PMID: 26324363).",Actionable,4008,3996,urinary system cancer,DOID,1222,FGFR3 mutant,sensitive,1028,JNJ-42756493,2261,26324363,,,
10,Phase I,"In a Phase I trial, patients with urinary bladder urothelial carcinoma demonstrated a disease control rate of 75% (6/8) when treated with BGJ398, resulting in 3 patients with a partial response and 3 with stable disease (PMID: 27870574). ",Actionable,9734,4006,bladder urothelial carcinoma,DOID,1222,FGFR3 mutant,sensitive,674,BGJ398,2261,27870574,,,
11,Phase I,"In a Phase I trial, BGJ398 treatment resulted in complete response in 4% (1/25) and partial response in 32% (8/25) of urothelial carcinoma patients harboring FGFR3 mutations or fusions (J Clin Oncol 34, 2016 (suppl; abstr 4517)).",Actionable,6976,2671,transitional cell carcinoma,DOID,1222,FGFR3 mutant,sensitive,674,BGJ398,2261,None,,,
12,Preclinical - Cell line xenograft,"In a preclinical study, R3Mab decreased wild-type FGFR3 activation, thereby inhibited cell proliferation of FGFR3 wild-type human bladder cancer cells in culture and in cell line xenograft models (PMID: 19381019).",Actionable,1035,4007,bladder carcinoma,DOID,544,FGFR3 wild-type,sensitive,1465,R3Mab,2261,19381019,,,
13,Preclinical - Cell culture,"In a preclinical study, SU5402 inhibited proliferation of myeloma cells expressing wild-type FGFR3 in culture (PMID: 23597562).",Actionable,7843,70004,myeloid neoplasm,DOID,544,FGFR3 wild-type,sensitive,3305,SU5402,2261,23597562,,,
14,Preclinical,"In a preclinical study, SSR128129E inhibited proliferation of myeloma cells expressing wild-type FGFR3 in culture (PMID: 23597562).",Actionable,4015,70004,myeloid neoplasm,DOID,544,FGFR3 wild-type,sensitive,2508,SSR128129E,2261,23597562,,,
15,Preclinical,"In a preclinical study, bladder cancer cells with wild-type FGFR3 were resistant to growth inhibition by Iclusig (ponatinib) in cell culture (PMID: 22238366).",Actionable,3518,11054,urinary bladder cancer,DOID,544,FGFR3 wild-type,resistant,877,Ponatinib,2261,22238366,,,
16,Preclinical - Cell culture,"In a preclinical study, Iclusig (ponatinib) inhibited proliferation of transformed cells over expressing FGFR3 V555M in culture (PMID: 28034880).",Actionable,10160,10000003,Advanced Solid Tumor,JAX,25236,FGFR3 V555M,sensitive,877,Ponatinib,2261,28034880,,,
17,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FGFR3 V555M were resistant to AZD4547 in culture (PMID: 28034880).",Actionable,10169,10000003,Advanced Solid Tumor,JAX,25236,FGFR3 V555M,resistant,654,AZD4547,2261,28034880,,,
18,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FGFR3 V555M were resistant to BGJ398 in culture (PMID: 28034880).",Actionable,10155,10000003,Advanced Solid Tumor,JAX,25236,FGFR3 V555M,resistant,674,BGJ398,2261,28034880,,,
19,Preclinical - Cell culture,"In a preclinical study, Dovitinib (TKI258) inhibited proliferation of transformed cells over expressing FGFR3 V555M in culture (PMID: 28034880).",Actionable,10166,10000003,Advanced Solid Tumor,JAX,25236,FGFR3 V555M,sensitive,721,Dovitinib,2261,28034880,,,
20,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FGFR3 V555M demonstrated reduced sensitivity to Debio 1347 in culture (PMID: 28034880).",Actionable,10171,10000003,Advanced Solid Tumor,JAX,25236,FGFR3 V555M,decreased response,1014,FF-284,2261,28034880,,,
21,Preclinical - Cell culture,"In a preclinical study, LY2874455 inhibited proliferation of transformed cells over expressing FGFR3 V555M in culture (PMID: 28034880).",Actionable,10180,10000003,Advanced Solid Tumor,JAX,25236,FGFR3 V555M,sensitive,2032,LY2874455,2261,28034880,,,
22,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FGFR3 V555M demonstrated reduced sensitivity to FIIN-2 in culture (PMID: 28034880).",Actionable,10177,10000003,Advanced Solid Tumor,JAX,25236,FGFR3 V555M,decreased response,5421,FIIN-2,2261,28034880,,,
23,Phase I,"In a Phase I trial, Debio 1347 (CH5183284) dosing regimen has been determined in solid tumor patients with activating FGFR3 alterations (JCO, Vol 33, No 15_suppl (May 20 Supplement), 2015: 2540).",Actionable,1249,10000003,Advanced Solid Tumor,JAX,1217,FGFR3 act mut,sensitive,1014,FF-284,2261,None,,,
24,Preclinical,"In a preclinical study, transformed cells expressing constitutively active FGFR3 demonstrated reduced sensitivity to Ofev (Nintedanib) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366).",Actionable,3490,10000003,Advanced Solid Tumor,JAX,1217,FGFR3 act mut,decreased response,831,Nintedanib,2261,22238366,,,
25,Preclinical,"In a preclinical study, S-49076 inhibited autophosphorylation of FGFR3 and downstream signaling in bladder cancer cells over expressing constitutively active FGFR3 in culture (PMID: 23804704).",Actionable,4014,11054,urinary bladder cancer,DOID,1217,FGFR3 act mut,predicted â€“ sensitive,2158,S-49076,2261,23804704,,,
26,Preclinical,"In a preclinical study, Brivanib (BMS-540215) did not inhibit receptor phosphorylation and cell proliferation in transformed cells expressing constitutively active FGFR3 in culture (PMID: 22238366).",Actionable,3494,10000003,Advanced Solid Tumor,JAX,1217,FGFR3 act mut,no benefit,996,Brivanib,2261,22238366,,,
27,Preclinical,"In a preclinical study, Dovitinib (TKI258) inhibited receptor phosphorylation and cell proliferation in transformed cells expressing constitutively active FGFR3 in culture (PMID: 22238366).",Actionable,3474,10000003,Advanced Solid Tumor,JAX,1217,FGFR3 act mut,sensitive,721,Dovitinib,2261,22238366,,,
28,Phase I,"In a Phase I trial, JNJ-42756493 treatment resulted in stable disease in 70% (16/23) and partial response in 22% (5/23) of patients with advanced solid tumors harboring FGFR 1-4 activating mutations (including amplifications, mutations and translocations), while no antitumor activity was observed in patients with unknown or no known changes in FGFR (PMID: 26324363).",Actionable,4000,10000003,Advanced Solid Tumor,JAX,1217,FGFR3 act mut,sensitive,1028,JNJ-42756493,2261,26324363,,,
29,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited receptor phosphorylation and cell growth in transformed cells expressing constitutively active FGFR3 in culture (PMID: 22238366).",Actionable,3471,10000003,Advanced Solid Tumor,JAX,1217,FGFR3 act mut,sensitive,877,Ponatinib,2261,22238366,,,
30,Preclinical,"In a preclinical study, transformed cells expressing constitutively active FGFR3 demonstrated reduced sensitivity to inhibition of receptor phosphorylation and cell proliferation by Cediranib (AZD-2171) in culture, when compared to other tyrosine kinase inhibitors (PMID: 22238366).",Actionable,3478,10000003,Advanced Solid Tumor,JAX,1217,FGFR3 act mut,decreased response,1001,Cediranib,2261,22238366,,,
31,Preclinical - Cell culture,"In a preclinical study, Iclusig (ponatinib) inhibited proliferation of transformed cells over expressing FGFR3 N540K in culture (PMID: 28034880).",Actionable,10161,10000003,Advanced Solid Tumor,JAX,25257,FGFR3 N540K,sensitive,877,Ponatinib,2261,28034880,,,
32,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FGFR3 N540K demonstrated reduced sensitivity to LY2874455 in culture (PMID: 28034880).",Actionable,10182,10000003,Advanced Solid Tumor,JAX,25257,FGFR3 N540K,decreased response,2032,LY2874455,2261,28034880,,,
33,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FGFR3 N540K were reistant to growth inhibition by AZD4547 in culture (PMID: 26992226).",Actionable,7575,10000003,Advanced Solid Tumor,JAX,25257,FGFR3 N540K,resistant,654,AZD4547,2261,26992226,,,
34,Preclinical - Cell culture,"In a preclinical study, Dovitinib (TKI258) inhibited proliferation of transformed cells over expressing FGFR3 N540K in culture (PMID: 28034880).",Actionable,10165,10000003,Advanced Solid Tumor,JAX,25257,FGFR3 N540K,sensitive,721,Dovitinib,2261,28034880,,,
35,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FGFR3 N540K demonstrated reduced sensitivity to FIIN-2 in culture (PMID: 28034880).",Actionable,10178,10000003,Advanced Solid Tumor,JAX,25257,FGFR3 N540K,decreased response,5421,FIIN-2,2261,28034880,,,
36,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FGFR3 N540K demonstrated reduced sensitivity to Debio 1347 in culture (PMID: 28034880).",Actionable,10172,10000003,Advanced Solid Tumor,JAX,25257,FGFR3 N540K,decreased response,1014,FF-284,2261,28034880,,,
37,Preclinical - Cell culture,"In a preclinicl study, JNJ-42756493 inhibited proliferation of transformed cells over expressing FGFR3 K560E in culture (PMID: 26992226). ",Actionable,7577,10000003,Advanced Solid Tumor,JAX,25257,FGFR3 N540K,sensitive,1028,JNJ-42756493,2261,26992226,,,
38,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FGFR3 N540K were resistant to BGJ398 in culture (PMID: 28034880).",Actionable,10153,10000003,Advanced Solid Tumor,JAX,25257,FGFR3 N540K,resistant,674,BGJ398,2261,28034880,,,
39,Preclinical - Cell culture,"In a preclinical study, Debio 1347 inhibited proliferation of a bladder cancer cell line harboring an FGFR3-BAIAP2L1 fusion in culture (PMID: 25169980).",Actionable,4061,11054,urinary bladder cancer,DOID,15037,FGFR3-BAIAP2L1,sensitive,1014,FF-284,2261,25169980,,,
40,Preclinical - Cell line xenograft,"In a preclinical study, Debio 1347 decreased phosphorylation of ERK and FRS and inhibited proliferation of a bladder cancer cell line harboring FGFR3-BAIAP2L1 in culture, and inhibited tumor growth in bladder cancer cell line xenograft models with FGFR3-BAIAP2L1 (PMID: 25589496)",Actionable,8348,11054,urinary bladder cancer,DOID,15037,FGFR3-BAIAP2L1,sensitive,1014,FF-284,2261,25589496,,,
41,Preclinical - Cell culture,"In a preclinical study, BGJ398 inhibited proliferation of a bladder cancer cell line harboring FGFR3-BAIAP2L1 in culture (PMID: 25589496).",Actionable,8351,11054,urinary bladder cancer,DOID,15037,FGFR3-BAIAP2L1,sensitive,674,BGJ398,2261,25589496,,,
42,Preclinical - Cell culture,"In a preclinical study, Cediranib (AZD-2171) inhibited proliferation of a bladder cancer cell line harboring FGFR3-BAIAP2L1 in culture (PMID: 25589496).",Actionable,8352,11054,urinary bladder cancer,DOID,15037,FGFR3-BAIAP2L1,sensitive,1001,Cediranib,2261,25589496,,,
43,Preclinical - Cell culture,"In a preclinical study, PD173074 inhibited proliferation of a bladder cancer cell line harboring FGFR3-BAIAP2L1 in culture (PMID: 25589496).",Actionable,8349,11054,urinary bladder cancer,DOID,15037,FGFR3-BAIAP2L1,sensitive,2948,PD173074,2261,25589496,,,
44,Preclinical - Cell culture,"In a preclinical study, AZD4547 inhibited proliferation of a bladder cancer cell line harboring FGFR3-BAIAP2L1 in culture (PMID: 25589496).",Actionable,8350,11054,urinary bladder cancer,DOID,15037,FGFR3-BAIAP2L1,sensitive,654,AZD4547,2261,25589496,,,
45,Preclinical - Cell culture,"In a preclinical study, ASP5878 treatment inhibited proliferation of a bladder cancer cell line harboring an FGFR3-BAIAP2L1 fusion in culture (Mol Cancer Ther December 2015 14; A170).",Actionable,4635,11054,urinary bladder cancer,DOID,15037,FGFR3-BAIAP2L1,sensitive,3584,ASP5878,2261,None,,,
46,Preclinical - Cell culture,"In a preclinical study, Dovitinib (TKI258) inhibited proliferation of a bladder cancer cell line harboring FGFR3-BAIAP2L1 in culture (PMID: 25589496).",Actionable,8353,11054,urinary bladder cancer,DOID,15037,FGFR3-BAIAP2L1,sensitive,721,Dovitinib,2261,25589496,,,
47,Preclinical,"In a preclinical study, a mouse breast carcinoma cell line xenograft model demonstrated inhibition of tumor growth when treated with E7090, a result of decreased FGFR2 and FGFR3 activity (PMID: 27535969). ",Actionable,9142,3459,breast carcinoma,DOID,26749,FGFR2 pos FGFR3 pos,sensitive,4911,E7090,2261,27535969,,,
48,Phase I,"In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including a partial remission in a patient with FGFR3-positive head and neck squamous cell carcinoma (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741).",Actionable,11999,5520,head and neck squamous cell carcinoma,DOID,9322,FGFR3 positive,predicted â€“ sensitive,2030,Rogaratinib,2261,None,,,
49,Phase I,"In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including long lasting stable disease in a patient with FGFR3-positive lung squamous cell carcinoma (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741).",Actionable,12006,3907,lung squamous cell carcinoma,DOID,9322,FGFR3 positive,predicted â€“ sensitive,2030,Rogaratinib,2261,None,,,
50,Phase I,"In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including long lasting stable disease in a patient with FGFR3-positive gastric cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741).",Actionable,12004,10534,stomach cancer,DOID,9322,FGFR3 positive,predicted â€“ sensitive,2030,Rogaratinib,2261,None,,,
51,Phase I,"In a Phase I trial, sensitivity to treatment with Rogaratinib (BAY 1163877) was demonstrated in patients with a variety of FGFR-expressing solid tumor types, including long lasting stable disease in a patient with FGFR3-positive lung adenocarcinoma (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #379P; NCT01976741).",Actionable,12001,3910,lung adenocarcinoma,DOID,9322,FGFR3 positive,predicted â€“ sensitive,2030,Rogaratinib,2261,None,,,
52,Preclinical - Cell culture,"In a preclinical study, a head and neck squamous cell carcinoma cell line expressing FGFR3 S131L demonstrated decreased sensitivity to BGJ398 compared to cells expressing wild-type FGFR3 in culture (PMID: 27053219).",Actionable,9034,5520,head and neck squamous cell carcinoma,DOID,26695,FGFR3 S131L,decreased response,674,BGJ398,2261,27053219,,,
53,Preclinical - Cell culture,"In a preclinical study, LY2874455 inhibited proliferation of transformed cells over expressing FGFR3 K650E in culture (PMID: 28034880).",Actionable,10181,10000003,Advanced Solid Tumor,JAX,2183,FGFR3 K650E,sensitive,2032,LY2874455,2261,28034880,,,
54,Preclinical - Cell culture,"In a preclinical study, SU5402 inhibited proliferation of myeloma cells expressing FGFR3 K650E in culture (PMID: 23597562).",Actionable,7844,70004,myeloid neoplasm,DOID,2183,FGFR3 K650E,sensitive,3305,SU5402,2261,23597562,,,
55,Preclinical,"In a preclinical study, Debio 1347 inhibited proliferation of myeloma cell lines harboring FGFR3 K650E in culture (PMID: 25169980).",Actionable,4064,70004,myeloid neoplasm,DOID,2183,FGFR3 K650E,sensitive,1014,FF-284,2261,25169980,,,
56,Preclinical - Cell culture,"In a preclinical study, FIIN-2 inhibited proliferation of transformed cells over expressing FGFR3 K650E in culture (PMID: 28034880).",Actionable,10176,10000003,Advanced Solid Tumor,JAX,2183,FGFR3 K650E,sensitive,5421,FIIN-2,2261,28034880,,,
57,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FGFR3 K650E demonstrated reduced sensitivity to growth inhibition by AZD4547 in culture (PMID: 26992226).",Actionable,7574,10000003,Advanced Solid Tumor,JAX,2183,FGFR3 K650E,decreased response,654,AZD4547,2261,26992226,,,
58,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FGFR3 K650E demonstrated reduced sensitivity to BGJ398 in culture (PMID: 28034880).",Actionable,10152,10000003,Advanced Solid Tumor,JAX,2183,FGFR3 K650E,decreased response,674,BGJ398,2261,28034880,,,
59,Preclinical,"In a preclinical study, SSR128129E did not inhibit proliferation of myeloma cells expressing FGFR3 K650E in culture (PMID: 23597562).",Actionable,4016,70004,myeloid neoplasm,DOID,2183,FGFR3 K650E,no benefit,2508,SSR128129E,2261,23597562,,,
60,Preclinical - Cell culture,"In a preclinical study, Iclusig (ponatinib) inhibited proliferation of transformed cells over expressing FGFR3 K650E in culture (PMID: 28034880).",Actionable,10163,10000003,Advanced Solid Tumor,JAX,2183,FGFR3 K650E,sensitive,877,Ponatinib,2261,28034880,,,
61,Preclinical,"In a preclinical study, PD98059 inhibited FGFR3 K650E-induced transformation of cells in culture (PMID: 14534538).",Actionable,3997,10000003,Advanced Solid Tumor,JAX,2183,FGFR3 K650E,sensitive,2617,PD98059,2261,14534538,,,
62,Preclinical - Cell culture,"In a preclinical study, Debio 1347 inhibited proliferation of transformed cells over expressing FGFR3 K650E in culture (PMID: 28034880).",Actionable,10173,10000003,Advanced Solid Tumor,JAX,2183,FGFR3 K650E,sensitive,1014,FF-284,2261,28034880,,,
63,Preclinical - Cell culture,"In a preclinicl study, JNJ-42756493 inhibited proliferation of transformed cells over expressing FGFR3 K560E in culture (PMID: 26992226). ",Actionable,7576,10000003,Advanced Solid Tumor,JAX,2183,FGFR3 K650E,sensitive,1028,JNJ-42756493,2261,26992226,,,
64,Preclinical - Cell culture,"In a preclinical study, Dovitinib (TKI258) inhibited proliferation of transformed cells over expressing FGFR3 K650E in culture (PMID: 28034880).",Actionable,10164,10000003,Advanced Solid Tumor,JAX,2183,FGFR3 K650E,sensitive,721,Dovitinib,2261,28034880,,,
65,Preclinical,"In a preclinical study, PD173074 inhibited Fgfr3 signaling, induced cell-cycle arrest, and decreased proliferation of multiple myeloma cells harboring HRAS H117E and over expression of FGFR3 K650E in culture (PMID: 22869148).",Actionable,2578,9538,multiple myeloma,DOID,13017,FGFR3 K650E FGFR3 over exp HRAS K117E,sensitive,2948,PD173074,2261,22869148,,,
66,Preclinical,"In a preclinical study, AZ8010 inhibited Fgfr3 signaling and decreased proliferation of myeloma cells with HRAS K117E and overexpression of FGFR3 K650E in culture (PMID: 22869148).",Actionable,2571,70004,myeloid neoplasm,DOID,13017,FGFR3 K650E FGFR3 over exp HRAS K117E,sensitive,2955,AZ8010,2261,22869148,,,
67,Preclinical,"In a preclinical study, R3Mab prevented constitutive cell proliferation induced by FGFR3 R248C in cultured cells (PMID: 19381019).",Actionable,1030,10000003,Advanced Solid Tumor,JAX,1737,FGFR3 R248C,sensitive,1465,R3Mab,2261,19381019,,,
68,Preclinical - Cell culture,"In a preclinical study, FIIN-2 inhibited proliferation of transformed cells over expressing FGFR3 L608V in culture (PMID: 28034880).",Actionable,10175,10000003,Advanced Solid Tumor,JAX,27303,FGFR3 L608V,sensitive,5421,FIIN-2,2261,28034880,,,
69,Preclinical - Cell culture,"In a preclinical study, Dovitinib (TKI258) inhibited proliferation of transformed cells over expressing FGFR3 L608V in culture (PMID: 28034880).",Actionable,10167,10000003,Advanced Solid Tumor,JAX,27303,FGFR3 L608V,sensitive,721,Dovitinib,2261,28034880,,,
70,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FGFR3 L608V demonstrated reduced sensitivity to Debio 1347 in culture (PMID: 28034880).",Actionable,10170,10000003,Advanced Solid Tumor,JAX,27303,FGFR3 L608V,decreased response,1014,FF-284,2261,28034880,,,
71,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FGFR3 L608V demonstrated reduced sensitivity to AZD4547 in culture (PMID: 28034880).",Actionable,10168,10000003,Advanced Solid Tumor,JAX,27303,FGFR3 L608V,decreased response,654,AZD4547,2261,28034880,,,
72,Preclinical - Cell culture,"In a preclinical study, Iclusig (ponatinib) inhibited proliferation of transformed cells over expressing FGFR3 L608V in culture (PMID: 28034880).",Actionable,10159,10000003,Advanced Solid Tumor,JAX,27303,FGFR3 L608V,sensitive,877,Ponatinib,2261,28034880,,,
73,Preclinical - Cell culture,"In a preclinical study, LY2874455 inhibited proliferation of transformed cells over expressing FGFR3 L608V in culture (PMID: 28034880).",Actionable,10179,10000003,Advanced Solid Tumor,JAX,27303,FGFR3 L608V,sensitive,2032,LY2874455,2261,28034880,,,
74,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FGFR3 L608V demonstrated reduced sensitivity to BGJ398 in culture (PMID: 28034880).",Actionable,10151,10000003,Advanced Solid Tumor,JAX,27303,FGFR3 L608V,decreased response,674,BGJ398,2261,28034880,,,
75,Preclinical - Cell culture,"In a preclinical study, BGJ398 decreased Myc expression, induced cell cycle arrest, and inhibited growth of a urinary tract cancer cell line harboring FGFR3 amplification in culture (PMID: 27401245).",Actionable,10026,3996,urinary system cancer,DOID,3329,FGFR3 amp,sensitive,674,BGJ398,2261,27401245,,,
76,Phase I,"In a Phase I trial, BGJ398 demonstrated safety and preliminary efficacy in patients with select solid tumors harboring FGFR alterations (Cancer Res October 1, 2014 74:CT326).",Actionable,2482,10000003,Advanced Solid Tumor,JAX,3329,FGFR3 amp,predicted â€“ sensitive,674,BGJ398,2261,None,,,
77,Preclinical - Cell culture,"In a preclinical study, AZD4547 decreased Myc expression, induced cell cycle arrest, and inhibited growth of a urinary tract cancer cell line harboring FGFR3 amplification in culture (PMID: 27401245).",Actionable,10012,3996,urinary system cancer,DOID,3329,FGFR3 amp,sensitive,654,AZD4547,2261,27401245,,,
78,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited growth of several tumor cell lines with FGFR alterations in culture (Cancer Res April 15, 2011 71:3560).",Actionable,2480,10000003,Advanced Solid Tumor,JAX,3329,FGFR3 amp,predicted â€“ sensitive,877,Ponatinib,2261,None,,,
79,Phase I,"In a Phase I trial, ARQ 087 demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including tumors with FGFR pathway alterations (J Clin Oncol 33, 2015 (suppl; abstr 2545)).",Actionable,7760,10000003,Advanced Solid Tumor,JAX,3329,FGFR3 amp,predicted â€“ sensitive,2900,ARQ 087,2261,None,,,
80,Preclinical - Pdx,"In a preclinical study, PRN1371 treatment had no effect on tumor growth in patient-derived xenograft models of FGFR3-amplified non-small cell lung cancer (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).",Actionable,8411,3908,non-small cell lung carcinoma,DOID,3329,FGFR3 amp,no benefit,3583,PRN1371,2261,None,,,
81,Phase I,"In a Phase I trial, JNJ-42756493 treatment resulted in partial response in a glioblastoma patient harboring FGFR3 - TACC3 fusion (PMID: 26324363).",Actionable,4004,3068,glioblastoma multiforme,DOID,10071,FGFR3-TACC3,sensitive,1028,JNJ-42756493,2261,26324363,,,
82,Phase I,"In a Phase I trial, JNJ-42756493 treatment resulted in tumor reduction and stable disease in 2 glioblastoma multiforme patients harboring FGFR3 - TACC3 fusion (PMID: 25609060).",Actionable,4005,3068,glioblastoma multiforme,DOID,10071,FGFR3-TACC3,sensitive,1028,JNJ-42756493,2261,25609060,,,
83,Phase I,"In a Phase Ib trial, BGJ398 and Alpelisib (BYL719) combination treatment resulted in partial response and a complete shrinkage of target lesions lasting 4 months in one urothelial carcinoma patient harboring a FGFR3-TACC3 fusion (J Clin Oncol 34, 2016 (suppl; abstr 2500)).",Actionable,6546,2671,transitional cell carcinoma,DOID,10071,FGFR3-TACC3,predicted â€“ sensitive,1293,BGJ398 + BYL719,2261,None,,,
84,Preclinical,"In a preclinical study, SU5402 induced cell-cycle arrest and inhibited proliferation of bladder cancer cells that have been demonstrated to harbor FGFR3-TACC3 in culture (PMID: 21119661, PMID: 23175443).",Actionable,4068,11054,urinary bladder cancer,DOID,10071,FGFR3-TACC3,sensitive,3305,SU5402,2261,23175443,21119661,,
85,Preclinical - Cell culture,"In a preclinicl study, AZD4547 inhibited proliferation of transformed cells over expressing FGFR3-TACC3 in culture (PMID: 26992226). ",Actionable,7579,10000003,Advanced Solid Tumor,JAX,10071,FGFR3-TACC3,sensitive,654,AZD4547,2261,26992226,,,
86,Preclinical,"In a preclinical study, S-49076 inhibited autophosphorylation of FGFR3 and downstream signaling in bladder cancer cells that have been demonstrated to harbor FGFR3-TACC3 in culture (PMID: 23804704, PMID: 23175443).",Actionable,4056,11054,urinary bladder cancer,DOID,10071,FGFR3-TACC3,predicted â€“ sensitive,2158,S-49076,2261,23804704,23175443,,
87,Preclinical - Cell line xenograft,"In a preclinical study, urinary bladder cancer cells harboring FGFR3-TACC3 demonstrated sensitivity to E7090 in culture, resulting in decreased cell viability, and antitumor activity in xenograft models (PMID: 27535969). ",Actionable,9138,11054,urinary bladder cancer,DOID,10071,FGFR3-TACC3,sensitive,4911,E7090,2261,23175443,27535969,,
88,Preclinical - Cell line xenograft,"In a preclinical study, the combination of AZD4547 and Buparlisib (BKM120) worked synergistically to induce apoptosis and inhibit growth of a urothelial cell carcinoma cell line harboring FGFR3-TACC3 in culture, and inhibited tumor growth in xenograft models, with increased efficacy over either agent alone (PMID: 28108151).",Actionable,11210,2671,transitional cell carcinoma,DOID,10071,FGFR3-TACC3,sensitive,5898,AZD4547 + BKM120,2261,28108151,,,
89,Preclinical,"In a preclinical study, Iclusig (ponatanib) inhibited growth and FGFR3 phosphorylation in cells expressing FGFR3-TACC3 fusion in culture (PMID: 25294908).",Actionable,2702,3910,lung adenocarcinoma,DOID,10071,FGFR3-TACC3,sensitive,877,Ponatinib,2261,25294908,,,
90,Preclinical - Cell culture,"In a preclinical study, BJG398 inhibited Fgfr3 kinase activity in transformed astrocytes expressing the FGFR3-TACC3 fusion in culture (PMID: 22837387).",Actionable,2709,3070,malignant glioma,DOID,10071,FGFR3-TACC3,sensitive,674,BGJ398,2261,22837387,,,
91,Preclinical - Cell line xenograft,"In a preclinical study, Debio 1347 inhibited proliferation of bladder cancer cell lines harboring an FGFR3-TACC3 fusion in culture and inhibited tumor growth in FGFR3-TACC3-positive bladder cancer cell line xenograft models (PMID: 25169980).",Actionable,4060,11054,urinary bladder cancer,DOID,10071,FGFR3-TACC3,sensitive,1014,FF-284,2261,25169980,,,
92,Preclinical,"In a preclinical study, bladder cancer cells harboring FGFR3-TACC were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).",Actionable,4034,11054,urinary bladder cancer,DOID,10071,FGFR3-TACC3,no benefit,913,Selumetinib,2261,26438159,,,
93,Preclinical,"In a preclinical study, JNJ-42756493 inhibited proliferation of glioma cells harboring FGFR3 - TACC3 fusion in culture and xenograft tumor growth in animal models (PMID: 25609060).",Actionable,4009,3070,malignant glioma,DOID,10071,FGFR3-TACC3,sensitive,1028,JNJ-42756493,2261,25609060,,,
94,Preclinical - Pdx,"In a preclinical study, JNJ-42756493 (erdafitinib) inhibited pERK signaling and tumor growth in a patient-derived xenograft (PDX) model of non-small cell lung cancer harboring FGFR3-TACC3 (PMID: 28341788).",Actionable,11177,3908,non-small cell lung carcinoma,DOID,10071,FGFR3-TACC3,sensitive,1028,JNJ-42756493,2261,28341788,,,
95,Preclinical,"In a preclinical study, U0126 inhibited downstream signaling and growth of glioblastoma cells expressing the FGFR3-TACC3 fusion in culture (PMID: 23298836).",Actionable,2712,3068,glioblastoma multiforme,DOID,10071,FGFR3-TACC3,sensitive,2427,U0126,2261,23298836,,,
96,Phase I,"In a Phase I clinical trial, JNJ-42756493 treatment resulted in partial response in 2 urothelial cancer patients harboring FGFR3-TACC3 (PMID: 26324363).",Actionable,4002,3996,urinary system cancer,DOID,10071,FGFR3-TACC3,sensitive,1028,JNJ-42756493,2261,26324363,,,
97,Preclinical - Cell culture,"In a preclinical study, bladder transitional cell papilloma cells harboring FGFR3-TACC3 were not sensitive to RO5126766 in culture (PMID: 26438159).",Actionable,8476,6933,bladder transitional cell papilloma,DOID,10071,FGFR3-TACC3,no benefit,2011,RO5126766,2261,26438159,,,
98,Preclinical - Cell line xenograft,"In a preclinical study, R3Mab inhibited FGFR3 signaling and tumor growth in bladder cancer cell line xenograft models harboring FGFR3-TACC3 (PMID: 25326231).",Actionable,4010,11054,urinary bladder cancer,DOID,10071,FGFR3-TACC3,sensitive,1465,R3Mab,2261,25326231,,,
99,Preclinical,"In a preclinical study, AZ12908010 (AZ8010) induced cell cycle arrest and inhibited proliferation of urothelial cancer cell lines that have been demonstrated to harbor FGFR3-TACC3 in culture (PMID: 22869148, PMID: 23175443).",Actionable,4075,11054,urinary bladder cancer,DOID,10071,FGFR3-TACC3,sensitive,2955,AZ8010,2261,22869148,23175443,,
100,Preclinical,"In a preclinical study, bladder cancer cells harboring FGFR3-TACC3 demonstrated sensitivity to Votrient (pazopanib) in culture (PMID: 23558953).",Actionable,4050,11054,urinary bladder cancer,DOID,10071,FGFR3-TACC3,sensitive,848,Pazopanib,2261,23558953,,,
101,Preclinical - Pdx,"In a preclinical study, PRN1371 treatment resulted in tumor regression in patient-derived xenograft models of anaplastic oligodendroglioma harboring FGFR3-TACC3 fusion (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).",Actionable,8412,3181,oligodendroglioma,DOID,10071,FGFR3-TACC3,sensitive,3583,PRN1371,2261,None,,,
102,Preclinical - Cell line xenograft,"In a preclinical study, PD173074 inhibited Fgfr3 kinase activity and growth in transformed astrocytes expressing the FGFR3-TACC3 fusion in culture and in cell line xenograft models (PMID: 22837387).",Actionable,2704,3070,malignant glioma,DOID,10071,FGFR3-TACC3,sensitive,2948,PD173074,2261,22837387,,,
103,Preclinical - Cell line xenograft,"In a preclinical study, PRN1109 treatment resulted in tumor regression in bladder cancer cell line xenograft models harboring FGFR3-TACC3 fusion (Eu J Cancer 2014 Vol 50, Suppl 6:157).",Actionable,4626,11054,urinary bladder cancer,DOID,10071,FGFR3-TACC3,sensitive,4645,PRN1109,2261,None,,,
104,Preclinical - Cell line xenograft,"In a preclinical study, ASP5878 treatment inhibited proliferation of bladder cancer cell lines harboring a FGFR3-TACC3 fusion in culture, and resulted in tumor regression in a FGFR3-TACC3 positive bladder cancer cell line xenograft model (Mol Cancer Ther December 2015 14; A170).",Actionable,4634,11054,urinary bladder cancer,DOID,10071,FGFR3-TACC3,sensitive,3584,ASP5878,2261,None,,,
105,Preclinical,"In a preclinical study, BGJ398 inhibited growth and FGFR3 phosphorylation in cells expressing FGFR3-TACC3 fusion in culture (PMID: 25294908).",Actionable,2703,3910,lung adenocarcinoma,DOID,10071,FGFR3-TACC3,sensitive,674,BGJ398,2261,25294908,,,
106,Preclinical,"In a preclinical study, FIIN-1 inhibited growth of the RT4 bladder cancer cell line, which has been demonstrated to harbor an FGFR3-TACC3 fusion, in culture (PMID: 20338520, PMID: 23175443).",Actionable,4078,11054,urinary bladder cancer,DOID,10071,FGFR3-TACC3,sensitive,2507,FIIN-01,2261,20338520,23175443,,
107,Preclinical - Cell culture,"In a preclinicl study, JNJ-42756493 inhibited proliferation of transformed cells over expressing FGFR3-TACC3 in culture (PMID: 26992226). ",Actionable,7578,10000003,Advanced Solid Tumor,JAX,10071,FGFR3-TACC3,sensitive,1028,JNJ-42756493,2261,26992226,,,
108,Preclinical - Cell line xenograft,"In a preclinical study, PRN1371 inhibited proliferation of bladder transitional cell carcinoma cell lines harboring FGFR3-TACC3 fusion in culture and tumor growth in cell line xenograft models (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).",Actionable,8405,4006,bladder urothelial carcinoma,DOID,10071,FGFR3-TACC3,sensitive,3583,PRN1371,2261,None,,,
109,Preclinical - Cell culture,"In a preclinical study, bladder transitional cell papilloma cells harboring FGFR3-TACC3 were not sensitive to RO4987655 in culture (PMID: 26438159).",Actionable,8477,6933,bladder transitional cell papilloma,DOID,10071,FGFR3-TACC3,no benefit,903,RO4987655,2261,26438159,,,
110,Preclinical,"In a preclinical study, LY2874455 induced tumor regression in bladder cancer xenograft models that have been demonstrated to harbor an FGFR3-TACC3 fusion (PMID: 21900693, PMID: 23175443). ",Actionable,4052,11054,urinary bladder cancer,DOID,10071,FGFR3-TACC3,sensitive,2032,LY2874455,2261,21900693,23175443,,
111,Preclinical - Cell culture,"In a preclinical study, AZD4547 inhibited Fgfr3 kinase activity in transformed astrocytes expressing the FGFR3-TACC3 fusion in culture (PMID: 22837387).",Actionable,2706,3070,malignant glioma,DOID,10071,FGFR3-TACC3,sensitive,654,AZD4547,2261,22837387,,,
112,Preclinical,"In a preclinical study, Dovitinib (TKI258) inhibited growth of bladder cancer cell lines that have been demonstrated to harbor FGFR3-TACC3 in culture (PMID: 24325461, PMID: 23175443).",Actionable,4076,11054,urinary bladder cancer,DOID,10071,FGFR3-TACC3,sensitive,721,Dovitinib,2261,23175443,24325461,,
113,Phase I,"In a Phase I trial, JNJ-42756493 treatment resulted tumor shrinkage and no disease progression for 10 months in an adrenal carcinoma patient harboring FGFR3 - TACC3 and FGFR2 - CCDC6 fusions (PMID: 26324363).",Actionable,4007,3950,adrenal carcinoma,DOID,17093,FGFR2 fusion FGFR3 - TACC3,sensitive,1028,JNJ-42756493,2261,26324363,,,
114,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FGFR3 V555L demonstrated reduced sensitivity to BGJ398 in culture (PMID: 28034880).",Actionable,10154,10000003,Advanced Solid Tumor,JAX,27304,FGFR3 V555L,decreased response,674,BGJ398,2261,28034880,,,
115,Preclinical,"In a preclinical study, Cediranib (AZD-2171) inhibited growth of bladder cancer cells harboring FGFR3 S249C mutation in culture (PMID: 22238366).",Actionable,3514,11054,urinary bladder cancer,DOID,1736,FGFR3 S249C,sensitive,1001,Cediranib,2261,22238366,,,
116,Preclinical - Cell culture,"In a preclinical study, renal pelvis transitional cell carcinoma cells harboring FGFR3 S249C were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).",Actionable,8489,5974,renal pelvis transitional cell carcinoma,DOID,1736,FGFR3 S249C,no benefit,913,Selumetinib,2261,26438159,,,
117,Preclinical - Cell line xenograft,"In a preclinical study, Iclusig (ponatinib) inhibited growth of bladder cancer cells harboring FGFR3 S249C in culture and in cell line xenograft models (PMID: 22238366).",Actionable,3512,11054,urinary bladder cancer,DOID,1736,FGFR3 S249C,sensitive,877,Ponatinib,2261,22238366,,,
118,Preclinical - Cell line xenograft,"In a preclinical study, AZD4547 decreased Myc expression and inhibited growth of a urinary tract cancer cell line harboring FGFR3 S249C in culture and in xenograft models (PMID: 27401245).",Actionable,10011,3996,urinary system cancer,DOID,1736,FGFR3 S249C,sensitive,654,AZD4547,2261,27401245,,,
119,Preclinical,"In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of bladder cancer cells harboring FGFR3 S249C in culture (PMID: 22238366).",Actionable,3517,11054,urinary bladder cancer,DOID,1736,FGFR3 S249C,no benefit,996,Brivanib,2261,22238366,,,
120,Phase II,"In a Phase II trial, Dovitinib (TKI258) treatment resulted in complete response in a patient with BCG-unresponsive, nonâ€“muscle-invasive, urothelial carcinoma of the bladder harboring FGFR3 S249C (PMID: 27932416).",Actionable,11228,4006,bladder urothelial carcinoma,DOID,1736,FGFR3 S249C,sensitive,721,Dovitinib,2261,27932416,,,
121,Preclinical,"In a preclinical study, bladder cancer cells harboring FGFR3 S249C were resistant to Ofev (Nintedanib) induced inhibition of cell proliferation in culture (PMID: 22238366).",Actionable,3516,11054,urinary bladder cancer,DOID,1736,FGFR3 S249C,resistant,831,Nintedanib,2261,22238366,,,
122,Preclinical,"In a preclinical study, Dovitinib (TKI258) inhibited cell proliferation in bladder cancer cells harboring FGFR3 S249C mutation in culture (PMID: 22238366).",Actionable,3513,11054,urinary bladder cancer,DOID,1736,FGFR3 S249C,sensitive,721,Dovitinib,2261,22238366,,,
123,Preclinical - Cell culture,"In a preclinical study, renal pelvis transitional cell carcinoma cells harboring FGFR3 S249C were not sensitive to RO5126766 in culture (PMID: 26438159).",Actionable,8475,5974,renal pelvis transitional cell carcinoma,DOID,1736,FGFR3 S249C,no benefit,2011,RO5126766,2261,26438159,,,
124,Preclinical - Cell culture,"In a preclinical study, BGJ398 decreased Myc expression, induced cell cycle arrest, and inhibited growth of a urinary tract cancer cell line harboring FGFR3 S249C in culture (PMID: 27401245).",Actionable,10027,3996,urinary system cancer,DOID,1736,FGFR3 S249C,sensitive,674,BGJ398,2261,27401245,,,
125,Preclinical - Cell line xenograft,"In a preclinical study, R3Mab decreased activation of FGFR3 S249C, thereby inhibited cell proliferation of human bladder cancer cells in culture and in cell line xenograft models (PMID: 19381019).",Actionable,1036,4007,bladder carcinoma,DOID,1736,FGFR3 S249C,sensitive,1465,R3Mab,2261,19381019,,,
126,Preclinical - Cell culture,"In a preclinical study, R3Mab inhibited proliferation of transformed cells over expressing FGFR3 S249C in culture (PMID: 19381019).",Actionable,1031,10000003,Advanced Solid Tumor,JAX,1736,FGFR3 S249C,sensitive,1465,R3Mab,2261,19381019,,,
127,Preclinical - Cell line xenograft,"In a preclinical study, Debio 1347 inhibited proliferation of bladder cancer cells harboring FGFR3 S249C in culture and inhibited tumor growth in FGFR3 S249C-positive bladder cancer cell line xenograft models (PMID: 25169980).",Actionable,4062,11054,urinary bladder cancer,DOID,1736,FGFR3 S249C,sensitive,1014,FF-284,2261,25169980,,,
128,Preclinical - Cell culture,"In a preclinical study, renal pelvis transitional cell carcinoma cells harboring FGFR3 S249C were not sensitive to RO4987655 in culture (PMID: 26438159).",Actionable,8460,5974,renal pelvis transitional cell carcinoma,DOID,1736,FGFR3 S249C,no benefit,903,RO4987655,2261,26438159,,,
129,Preclinical - Cell line xenograft,"In a preclinical study, ASP5878 treatment inhibited proliferation of a bladder cancer cell line harboring FGFR3 S249C in culture, and resulted in tumor regression in xenograft models (Mol Cancer Ther December 2015 14; A170).",Actionable,4633,11054,urinary bladder cancer,DOID,1736,FGFR3 S249C,sensitive,3584,ASP5878,2261,None,,,
130,Preclinical,"In a preclinical study, PD173074 inhibited growth of urothelial carcinoma (UC) cells expressing high levels of FGFR3 S249C, but had reduced efficacy against UC cells with low levels of FGFR3 S249C expression (PMID: 22869148).",Actionable,2583,2671,transitional cell carcinoma,DOID,13018,FGFR3 S249C FGFR3 over exp,sensitive,2948,PD173074,2261,22869148,,,
131,Preclinical - Cell culture,"In a preclinical study, BGJ398 inhibited proliferation of a head and neck squamous cell carcinoma cell line expressing FGFR3 D788N in culture, however, cells expressing FGFR3 D788N did not demonstrate increased sensitivity to BGJ398 compared to cells expressing wild-type FGFR3 (PMID: 27053219).",Actionable,9032,5520,head and neck squamous cell carcinoma,DOID,26694,FGFR3 D788N,no benefit,674,BGJ398,2261,27053219,,,
132,Preclinical,"In a preclinical study, R3Mab prevented ligand-dependent cell proliferation induced by FGFR3 G372C in cultured cells (PMID: 19381019).",Actionable,1032,10000003,Advanced Solid Tumor,JAX,1738,FGFR3 G372C,sensitive,1465,R3Mab,2261,19381019,,,
133,Preclinical,"In a preclinical study, Debio 1347 inhibited proliferation of myeloma cell lines harboring FGFR3 F386L in culture (PMID: 25169980).",Actionable,4066,70004,myeloid neoplasm,DOID,5005,FGFR3 F386L,sensitive,1014,FF-284,2261,25169980,,,
134,Preclinical,"In a preclinical study, R3Mab prevented ligand-dependent cell proliferation induced by FGFR3 K652E in cultured cells (PMID: 19381019).",Actionable,1034,10000003,Advanced Solid Tumor,JAX,817,FGFR3 K652E,sensitive,1465,R3Mab,2261,19381019,,,
135,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited Fgfr phosphorylation and cell proliferation in bladder cancer cells harboring FGFR3 Y375C in culture (PMID: 22238366).",Actionable,3507,11054,urinary bladder cancer,DOID,1735,FGFR3 Y375C,sensitive,877,Ponatinib,2261,22238366,,,
136,Preclinical,"In a preclinical study, Dovitinib (TKI258) inhibited cell proliferation in bladder cancer cells harboring FGFR3 Y375C in culture (PMID: 22238366).",Actionable,3508,11054,urinary bladder cancer,DOID,1735,FGFR3 Y375C,sensitive,721,Dovitinib,2261,22238366,,,
137,Preclinical,"In a preclinical study, Brivanib (BMS-540215) did not inhibit growth of bladder cancer cells harboring FGFR3 Y375C in culture (PMID: 22238366).",Actionable,3511,11054,urinary bladder cancer,DOID,1735,FGFR3 Y375C,no benefit,996,Brivanib,2261,22238366,,,
138,Preclinical,"In a preclinical study, bladder cancer cells harboring FGFR3 Y375C were resistant to growth inhibition by Ofev (Nintedanib) in culture (PMID: 22238366).",Actionable,3510,11054,urinary bladder cancer,DOID,1735,FGFR3 Y375C,resistant,831,Nintedanib,2261,22238366,,,
139,Preclinical,"In a preclinical study, bladder cancer cells harboring an FGFR3 Y375C mutation were resistant to growth inhibition by Cediranib (AZD-2171) in culture (PMID: 22238366).",Actionable,3509,11054,urinary bladder cancer,DOID,1735,FGFR3 Y375C,resistant,1001,Cediranib,2261,22238366,,,
140,Preclinical,"In a preclinical study, R3Mab prevented ligand-dependent cell proliferation induced by FGFR3 Y375C in cultured cells (PMID: 19381019).",Actionable,1033,10000003,Advanced Solid Tumor,JAX,1735,FGFR3 Y375C,sensitive,1465,R3Mab,2261,19381019,,,
141,Preclinical,"In a preclinical study, multiple myeloma cells over expressing FGFR3 G384D had reduced sensitivity to PD173074 in culture, compared to cells with ligand-independent activation of FGFR3 (PMID: 22869148).",Actionable,3274,9538,multiple myeloma,DOID,13019,FGFR3 G384D FGFR3 over exp,decreased response,2948,PD173074,2261,22869148,,,
142,Preclinical,"In a preclinical study, multiple myeloma cells over expressing FGFR3 G384D had reduced sensitivity to AZD4547 in culture, compared to cells with ligand-independent activation of FGFR3 (PMID: 22869148).",Actionable,3276,9538,multiple myeloma,DOID,13019,FGFR3 G384D FGFR3 over exp,decreased response,654,AZD4547,2261,22869148,,,
143,Preclinical,"In a preclinical study, multiple myeloma cells over expressing FGFR3 G384D had reduced sensitivity to AZ8010 in culture, compared to cells with ligand-independent activation of FGFR3 (PMID: 22869148).",Actionable,3277,9538,multiple myeloma,DOID,13019,FGFR3 G384D FGFR3 over exp,decreased response,2955,AZ8010,2261,22869148,,,
144,Preclinical,"In a preclinical study, PD173074 inhibited Fgfr3 signaling and decreased proliferation and survival of multiple myeloma cells over expressing FGFR3 Y373C in culture (PMID: 22869148).",Actionable,2582,9538,multiple myeloma,DOID,13015,FGFR3 Y373C FGFR3 over exp,sensitive,2948,PD173074,2261,22869148,,,
145,Preclinical,"In a preclinical study, AZ8010 inhibited Fgfr3 signaling, induced cell-cycle arrest, and decreased proliferation of multiple myeloma cells over expressing FGFR3 Y373C in culture (PMID: 22869148).",Actionable,2570,9538,multiple myeloma,DOID,13015,FGFR3 Y373C FGFR3 over exp,sensitive,2955,AZ8010,2261,22869148,,,
146,Preclinical - Cell culture,"In a preclinical study, myeloma cells harboring FGFR3 Y373C were not sensitive to RO4987655 in culture (PMID: 26438159).",Actionable,8458,70004,myeloid neoplasm,DOID,3514,FGFR3 Y373C,no benefit,903,RO4987655,2261,26438159,,,
147,Preclinical,"In a preclinical study, Debio 1347 inhibited proliferation of myeloma cell lines harboring FGFR3 Y373C in culture (PMID: 25169980).",Actionable,4063,70004,myeloid neoplasm,DOID,3514,FGFR3 Y373C,sensitive,1014,FF-284,2261,25169980,,,
148,Preclinical - Cell culture,"In a preclinical study, myeloma cells harboring FGFR3 Y373C were not sensitive to Selumetinib (AZD-6244) in culture (PMID: 26438159).",Actionable,8488,70004,myeloid neoplasm,DOID,3514,FGFR3 Y373C,no benefit,913,Selumetinib,2261,26438159,,,
149,Preclinical - Cell culture,"In a preclinical study, myeloma cells harboring FGFR3 Y373C were not sensitive to RO5126766 in culture (PMID: 26438159).",Actionable,8474,70004,myeloid neoplasm,DOID,3514,FGFR3 Y373C,no benefit,2011,RO5126766,2261,26438159,,,
150,Preclinical - Cell culture,"In a preclinical study, a multiple myeloma cell line harboring FGFR3 Y373C (PMID: 19901323) demonstrated sensitivity to E7090 in culture, resulting in decreased cell viability (PMID: 27535969). ",Actionable,9136,9538,multiple myeloma,DOID,3514,FGFR3 Y373C,sensitive,4911,E7090,2261,27535969,19901323,,
151,Preclinical,"In a preclinical study, the combined therapy of AZD5363 and AZD4547 resulted in tumor regression in urinary bladder cancer xenograft models simultaneously harboring the mutations, AKT1 E17K and FGFR3 Y373C (PMID: 26351323). ",Actionable,3811,11054,urinary bladder cancer,DOID,14066,AKT1 E17K FGFR3 Y373C,sensitive,3346,AZD5363 + AZD4547,2261,26351323,,,
152,Preclinical - Cell culture,"In a preclinical study, BGJ398 inhibited proliferation of a head and neck squamous cell carcinoma cell line expressing FGFR3 D764N in culture, however, cells expressing FGFR3 D764N did not demonstrate increased sensitivity to BGJ398 compared to cells expressing wild-type FGFR3 (PMID: 27053219).",Actionable,9033,5520,head and neck squamous cell carcinoma,DOID,26696,FGFR3 D764N,no benefit,674,BGJ398,2261,27053219,,,
153,Preclinical - Pdx,"In a preclinical study, treatment with BGJ398 led to improved progression-free survival in a patient-derived xenograft (PDX) model of  bladder cancer with FGFR3 over expression (PMID: 26270481).",Actionable,7433,11054,urinary bladder cancer,DOID,8807,FGFR3 over exp,sensitive,674,BGJ398,2261,26270481,,,
154,Preclinical,"In a preclinical study, LY2874455 induced tumor regression in FGFR3-over expressing bladder and multiple myeloma xenograft models (PMID: 21900693). ",Actionable,3996,10000003,Advanced Solid Tumor,JAX,8807,FGFR3 over exp,sensitive,2032,LY2874455,2261,21900693,,,
155,Preclinical,"In a preclinical study, Rogaratinib (BAY 1163877) inhibited tumor growth in a head and neck squamous cell carcinoma xenograft model with FGFR3 overexpression (Cancer Res August 1, 2015 75:772).",Actionable,4077,5520,head and neck squamous cell carcinoma,DOID,8807,FGFR3 over exp,sensitive,2030,Rogaratinib,2261,None,,,
156,Preclinical - Cell culture,"In a preclinical study, PRN1371 inhibited Fgfr3 activity in transformed cells over expressing wild-type FGFR3 in culture (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).",Actionable,8402,10000003,Advanced Solid Tumor,JAX,8807,FGFR3 over exp,sensitive,3583,PRN1371,2261,None,,,
157,Preclinical,"In a preclinical study, AZD4547 inhibited proliferation of urothelial cancer cells with over expression of FGFR3 in culture (PMID: 22869148).",Actionable,3272,2671,transitional cell carcinoma,DOID,8807,FGFR3 over exp,sensitive,654,AZD4547,2261,22869148,,,
158,Preclinical - Pdx,"In a preclinical study, the combination of BEZ235 and Nexavar (sorafenib) resulted in improved progression-free survival in an FGFR3-over expressing patient-derived xenograft (PDX) model of bladder cancer with secondary resistance to BGJ398 due to reactivation of downstream signaling, as evidenced by increased activation of Akt and Erk (PMID: 26270481).",Actionable,7445,11054,urinary bladder cancer,DOID,8807,FGFR3 over exp,sensitive,1067,Sorafenib + BEZ235,2261,26270481,,,
159,Preclinical,"In a preclinical study, AZ8010 inhibited proliferation of urothelial cancer cells with over expression of FGFR3 in culture (PMID: 22869148).",Actionable,3273,2671,transitional cell carcinoma,DOID,8807,FGFR3 over exp,sensitive,2955,AZ8010,2261,22869148,,,
160,Phase II,"In a Phase II trial, Dovitinib (TKI258) treatment resulted in complete response for 6 months in 8% (1/13) of non-muscle invasive bladder cancer patients over expressing FGFR3 (J Clin Oncol 34, 2016 (suppl; abstr 4526)).",Actionable,6982,11054,urinary bladder cancer,DOID,8807,FGFR3 over exp,sensitive,721,Dovitinib,2261,None,,,
161,Preclinical,"In a preclinical study, U0126 inhibited downstream signaling and growth of glioblastoma cells over-expressing Fgfr3 in culture (PMID: 23298836).",Actionable,2713,3068,glioblastoma multiforme,DOID,8807,FGFR3 over exp,sensitive,2427,U0126,2261,23298836,,,
162,Preclinical,"In a preclinical study, SU5402 inhibited growth of bladder cancer cells over expressing wild-type FGFR3 in culture (PMID: 21119661).",Actionable,4018,11054,urinary bladder cancer,DOID,8807,FGFR3 over exp,sensitive,3305,SU5402,2261,21119661,,,
163,Phase I,"In a Phase I trial, MFGR1877S demonstrated safety and resulted in stable disease in 42% (6/14) of multiple myeloma patients overexpressing FGFR3 (Blood (ASH Annual Meeting Abstracts) 2012 120: Abstract 4029).",Actionable,2550,9538,multiple myeloma,DOID,8807,FGFR3 over exp,sensitive,2936,MFGR1877S,2261,None,,,
164,Preclinical - Cell culture,"In a preclinical study, PRN1371 inhibited Fgfr3 activity in transformed cells over expressing FGFR3 K650M in culture (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).",Actionable,8403,10000003,Advanced Solid Tumor,JAX,2184,FGFR3 K650M,sensitive,3583,PRN1371,2261,None,,,
165,Phase I,"In a Phase I trial, BGJ398 treatment resulted in complete response in 4% (1/25) and partial response in 32% (8/25) of urothelial carcinoma patients harboring FGFR3 mutations or fusions (J Clin Oncol 34, 2016 (suppl; abstr 4517)).",Actionable,6977,2671,transitional cell carcinoma,DOID,14903,FGFR3 fusion,sensitive,674,BGJ398,2261,None,,,
166,Preclinical - Cell culture,"In a preclinical study, AZD4547 inhibited survival of bladder cancer cells harboring FGFR3 fusion in culture (PMID: 27550940).",Actionable,9124,11054,urinary bladder cancer,DOID,14903,FGFR3 fusion,sensitive,654,AZD4547,2261,27550940,,,
167,Preclinical - Cell line xenograft,"In a preclinical study, TAS-120 demonstrated growth inhibition and reduced FGFR phosphorylation in human cancer cell lines and xenograft models harboring FGFR mutations (Mol Cancer Ther 2013;12(11 Suppl):A270).",Actionable,4020,10000003,Advanced Solid Tumor,JAX,14903,FGFR3 fusion,predicted â€“ sensitive,1053,TAS-120,2261,None,,,
168,Preclinical - Cell line xenograft,"In a preclinical study, AZD4547 inhibited survival of myeloma cells harboring FGFR3 translocation in culture and in cell line xenograft models (PMID: 27550940).",Actionable,9122,70004,myeloid neoplasm,DOID,1318,FGFR3 rearrange,sensitive,654,AZD4547,2261,27550940,,,
169,Preclinical - Cell culture,"In a preclinical study, PRN1371 inhibited proliferation of myeloma cells harboring FGFR3 rearrangements in culture (AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1249).",Actionable,8408,70004,myeloid neoplasm,DOID,1318,FGFR3 rearrange,sensitive,3583,PRN1371,2261,None,,,
0,Preclinical,"In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D839A were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4831,10000003,Advanced Solid Tumor,JAX,19296,FLT3 exon 14 ins FLT3 D839A,resistant,874,PLX3397,2322,25847190,,,
1,Preclinical,"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D835A mutation were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4830,10000003,Advanced Solid Tumor,JAX,19297,FLT3 exon 14 ins FLT3 F691L FLT3 D839A,resistant,874,PLX3397,2322,25847190,,,
2,Preclinical,"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D835N mutation were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4828,10000003,Advanced Solid Tumor,JAX,19282,FLT3 exon 14 ins FLT3 F691L FLT3 D835N,resistant,874,PLX3397,2322,25847190,,,
3,Preclinical,"In a preclinical study, transformed cells expressing FLT3-ITD  along with FLT3 D835N were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4827,10000003,Advanced Solid Tumor,JAX,19281,FLT3 exon 14 ins FLT3 D835N,resistant,874,PLX3397,2322,25847190,,,
4,Preclinical,"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/N676S mutation were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4804,10000003,Advanced Solid Tumor,JAX,19314,FLT3 exon 14 ins FLT3 N676S FLT3 F691L,resistant,874,PLX3397,2322,25847190,,,
5,Preclinical,"In a preclinical study, transformed cells expressing FLT3-ITD with FLT3 N676S were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4803,10000003,Advanced Solid Tumor,JAX,19313,FLT3 exon 14 ins FLT3 N676S,resistant,874,PLX3397,2322,25847190,,,
6,Preclinical,"In a preclinical study, FLT3 Y842C conferred resistance to PLX3397 when expressed in a compound mutation with FLT3-ITD in cell culture (PMID: 25847190).",Actionable,2403,10000003,Advanced Solid Tumor,JAX,19136,FLT3 exon 14 ins FLT3 Y842C,resistant,874,PLX3397,2322,25847190,,,
7,Preclinical - Cell culture,"In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing both FLT3 internal tandem duplication (ITD) and Y842C in culture (PMID: 27158668).",Actionable,9437,10000003,Advanced Solid Tumor,JAX,19136,FLT3 exon 14 ins FLT3 Y842C,sensitive,5016,MRX-2843,2322,27158668,,,
8,Preclinical,"In a preclinical study, E6201 inhibited proliferation and induced apoptosis in FLT3 inhibitor-resistant leukemia cell lines harboring FLT3 Y842C in addition to FLT3 internal tandem duplications (ITD) in culture (PMID: 26822154).",Actionable,6463,1240,leukemia,DOID,19136,FLT3 exon 14 ins FLT3 Y842C,sensitive,1011,E6201,2322,26822154,,,
9,Preclinical,"In a preclinical study, E6201 inhibited proliferation and induced apoptosis in FLT3 inhibitor-resistant leukemia cell lines harboring FLT3 N676D and Y842C in addition to FLT3 internal tandem duplications (ITD) in culture (PMID: 26822154).",Actionable,6464,1240,leukemia,DOID,23516,FLT3 ITD FLT3 N676D FLT3 Y842C,sensitive,1011,E6201,2322,26822154,,,
10,Preclinical,"In a preclinical study, primary AML blasts expressing FLT3 Y842C were resistant to Gleevec (imatinib) as demonstrated by constitutively phosphorylated FLT3 and STAT-5 (PMID: 15345593).",Actionable,2324,9119,acute myeloid leukemia,DOID,6801,FLT3 Y842C,resistant,770,Imatinib,2322,15345593,,,
11,Preclinical - Cell culture,"In a preclinical study, Rydapt (midostaurin) induced cell death and inhibited FLT3 activation and downstream STAT5 activation in primary acute myeloid leukemic blasts harboring FLT3 Y842C in culture (PMID: 15345593).",Actionable,2323,9119,acute myeloid leukemia,DOID,6801,FLT3 Y842C,sensitive,810,Midostaurin,2322,15345593,,,
12,Preclinical,"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/Y842C mutation were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4838,10000003,Advanced Solid Tumor,JAX,19286,FLT3 exon 14 ins FLT3 F691L FLT3 Y842C,resistant,874,PLX3397,2322,25847190,,,
13,Clinical Study,"In a clinical study, a patient with FLT3-ITD positive leukemia initially responded to PLX3397 therapy, but experienced relapse after emergence of FLT3 D835Y on the same allele as the FLT3-ITD mutation (PMID: 25847190).",Actionable,4846,1240,leukemia,DOID,19130,FLT3 exon 14 ins FLT3 D835Y,resistant,874,PLX3397,2322,25847190,,,
14,Preclinical,"In a preclinical study, FLT3 D835Y conferred resistance to PLX3397 when expressed in a compound mutation with FLT3-ITD in cell culture (PMID: 25847190).",Actionable,4793,10000003,Advanced Solid Tumor,JAX,19130,FLT3 exon 14 ins FLT3 D835Y,resistant,874,PLX3397,2322,25847190,,,
15,Preclinical - Cell culture,"In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing both FLT3 internal tandem duplication (ITD) and D835Y in culture (PMID: 27158668).",Actionable,9433,10000003,Advanced Solid Tumor,JAX,19130,FLT3 exon 14 ins FLT3 D835Y,sensitive,5016,MRX-2843,2322,27158668,,,
16,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing FLT3 ITD and D835Y in culture (PMID: 27780853).",Actionable,9232,10000003,Advanced Solid Tumor,JAX,19130,FLT3 exon 14 ins FLT3 D835Y,sensitive,634,AP26113,2322,27780853,,,
17,Preclinical - Cell line xenograft,"In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant acute myeloid leukemia cells harboring FLT3 internal tandem duplication (ITD) and D835Y in culture, and prolonged survival in cell line xenograft models (PMID: 27158668).",Actionable,9430,9119,acute myeloid leukemia,DOID,19130,FLT3 exon 14 ins FLT3 D835Y,sensitive,5016,MRX-2843,2322,27158668,,,
18,Preclinical,"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D835Y mutation were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4829,10000003,Advanced Solid Tumor,JAX,19343,FLT3 exon 14 ins FLT3 F691L FLT3 D835Y,resistant,874,PLX3397,2322,25847190,,,
19,Preclinical - Cell culture,"In a preclinical study, treatment with Rydapt (midostaurin) inhibited FLT3 phosphorylation and resulted in decreased proliferation and viability of transformed cells expressing FLT3 D835Y in culture (PMID: 12124173).",Actionable,1752,10000003,Advanced Solid Tumor,JAX,3153,FLT3 D835Y,sensitive,810,Midostaurin,2322,12124173,,,
20,Preclinical,"In a preclinical study, E6201 inhibited proliferation and induced apoptosis in FLT3 inhibitor-resistant leukemia cell lines over expressing FLT3 D835Y in culture (PMID: 26822154).",Actionable,6460,1240,leukemia,DOID,3153,FLT3 D835Y,sensitive,1011,E6201,2322,26822154,,,
21,Preclinical - Cell culture,"In a preclinical study, E6201 induced apoptosis in blast samples derived from acute myeloid leukemia patients harboring FLT3 D835Y in culture (PMID: 26822154).",Actionable,7426,9119,acute myeloid leukemia,DOID,3153,FLT3 D835Y,sensitive,1011,E6201,2322,26822154,,,
22,Clinical Study,"In a clinical case study, a patient with acute promyelocytic leukemia harboring FLT3 D835Y demonstrated a complete molecular remission after treatment with Trisenox (arsenic trioxide) and Vesanoid (tretinoin) combined with Cytosar-U (cytarabine) and Methotrexate (PMID: 27626069).",Actionable,11375,60318,acute promyelocytic leukemia,DOID,3153,FLT3 D835Y,sensitive,5965,Arsenic trioxide + Cytarabine + Methotrexate + Tretinoin,2322,27626069,,,
23,Preclinical,"In a preclinical study, transformed cells expressing FLT3 D835Y were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,5035,10000003,Advanced Solid Tumor,JAX,3153,FLT3 D835Y,resistant,874,PLX3397,2322,25847190,,,
24,Clinical Study,"In a clinical case study, a patient with acute promyelocytic leukemia developed meningeal relapse after maintenance therapy with Vesanoid (tretinoid), which was found to be due to a FLT3 D835Y variant (PMID: 27626069). ",Actionable,11376,60318,acute promyelocytic leukemia,DOID,3153,FLT3 D835Y,resistant,1877,Tretinoin  ,2322,27626069,,,
25,Preclinical - Cell culture,"In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing FLT3 D835Y in culture (PMID: 27158668).",Actionable,9434,10000003,Advanced Solid Tumor,JAX,3153,FLT3 D835Y,sensitive,5016,MRX-2843,2322,27158668,,,
26,Preclinical,"In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D835E were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4809,10000003,Advanced Solid Tumor,JAX,19277,FLT3 exon 14 ins FLT3 D835E,resistant,874,PLX3397,2322,25847190,,,
27,Preclinical,"In a preclinical study, transformed cells expressing FLT3 ITD with R834Q and F691L were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4810,10000003,Advanced Solid Tumor,JAX,19278,FLT3 exon 14 ins FLT3 F691L FLT3 D835E,resistant,874,PLX3397,2322,25847190,,,
28,Preclinical,"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691Q/G846R mutation were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4845,10000003,Advanced Solid Tumor,JAX,19306,FLT3 exon 14 ins FLT3 F691L FLT3 G846R,resistant,874,PLX3397,2322,25847190,,,
29,Preclinical,"In a preclinical study, transformed cells expressing a compound FLT3-ITD /F691L/D839G mutation were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4832,10000003,Advanced Solid Tumor,JAX,19283,FLT3 exon 14 ins FLT3 F691L FLT3 D839G,resistant,874,PLX3397,2322,25847190,,,
30,Preclinical,"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/Y842H mutation were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4839,10000003,Advanced Solid Tumor,JAX,19287,FLT3 exon 14 ins FLT3 F691L FLT3 Y842H,resistant,874,PLX3397,2322,25847190,,,
31,Preclinical,"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D698N mutation were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4806,10000003,Advanced Solid Tumor,JAX,19294,FLT3 exon 14 ins FLT3 F691L FLT3 D698N,resistant,874,PLX3397,2322,25847190,,,
32,Preclinical,"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D835G mutation were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4812,10000003,Advanced Solid Tumor,JAX,19292,FLT3 exon 14 ins FLT3 F691L FLT3 D835G,resistant,874,PLX3397,2322,25847190,,,
33,Preclinical,"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/Y842S mutation were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4841,10000003,Advanced Solid Tumor,JAX,19324,FLT3 exon 14 ins FLT3 F691L FLT3 Y842S,resistant,874,PLX3397,2322,25847190,,,
34,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FLT3 ITD and F691L were resistant to Quizartinib (AC220) in culture (PMID: 23392356).",Actionable,9286,10000003,Advanced Solid Tumor,JAX,19129,FLT3 exon 14 ins FLT3 F691L,resistant,882,Quizartinib,2322,23392356,,,
35,Preclinical,"In a preclinical study, E6201 inhibited proliferation and induced apoptosis in FLT3 inhibitor-resistant leukemia cell lines harboring FLT3 F691L in addition to FLT3 internal tandem duplications (ITD) in culture (PMID: 26822154).",Actionable,6462,1240,leukemia,DOID,19129,FLT3 exon 14 ins FLT3 F691L,sensitive,1011,E6201,2322,26822154,,,
36,Preclinical - Cell culture,"In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing both FLT3 internal tandem duplication (ITD) and F691L in culture (PMID: 27158668).",Actionable,9432,10000003,Advanced Solid Tumor,JAX,19129,FLT3 exon 14 ins FLT3 F691L,sensitive,5016,MRX-2843,2322,27158668,,,
37,Preclinical - Cell line xenograft,"In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant acute myeloid leukemia cells harboring FLT3 internal tandem duplication (ITD) and F691L in culture, and prolonged survival in cell line xenograft models (PMID: 27158668).",Actionable,9431,9119,acute myeloid leukemia,DOID,19129,FLT3 exon 14 ins FLT3 F691L,sensitive,5016,MRX-2843,2322,27158668,,,
38,Preclinical,"In a preclinical study, PLX3397 inhibited growth of transformed cells expressing a compound FLT3 F691L/FLT3-ITD mutation in culture (PMID: 25847190).",Actionable,4789,10000003,Advanced Solid Tumor,JAX,19129,FLT3 exon 14 ins FLT3 F691L,sensitive,874,PLX3397,2322,25847190,,,
39,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing FLT3 ITD and F691L in culture (PMID: 27780853).",Actionable,9251,10000003,Advanced Solid Tumor,JAX,19129,FLT3 exon 14 ins FLT3 F691L,sensitive,634,AP26113,2322,27780853,,,
40,Preclinical,"In a preclinical study, PLX3397 inhibited proliferation of human leukemia cells harboring both FLT3-ITD and FLT3 F691L in culture (PMID: 25847190).",Actionable,4790,1240,leukemia,DOID,19129,FLT3 exon 14 ins FLT3 F691L,sensitive,874,PLX3397,2322,25847190,,,
41,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FLT3 ITD and F691L were resistant to Nexavar (sorafenib) in culture (PMID: 23392356).",Actionable,9279,10000003,Advanced Solid Tumor,JAX,19129,FLT3 exon 14 ins FLT3 F691L,resistant,920,Sorafenib,2322,23392356,,,
42,Preclinical,"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691Q/R834Q mutation were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4808,10000003,Advanced Solid Tumor,JAX,19276,FLT3 exon 14 ins FLT3 F691L FLT3 R834Q,resistant,874,PLX3397,2322,25847190,,,
43,Preclinical,"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D835H mutation were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4825,10000003,Advanced Solid Tumor,JAX,19280,FLT3 exon 14 ins FLT3 F691L FLT3 D835H,resistant,874,PLX3397,2322,25847190,,,
44,Preclinical,"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/M664I mutation were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4802,10000003,Advanced Solid Tumor,JAX,19311,FLT3 exon 14 ins FLT3 M664I FLT3 F691L,resistant,874,PLX3397,2322,25847190,,,
45,Preclinical,"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/N841K mutation were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4837,10000003,Advanced Solid Tumor,JAX,19317,FLT3 exon 14 ins FLT3 F691L FLT3 N841K,resistant,874,PLX3397,2322,25847190,,,
46,Preclinical,"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/R845G mutation were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4843,10000003,Advanced Solid Tumor,JAX,19320,FLT3 exon 14 ins FLT3 F691L FLT3 R845G,resistant,874,PLX3397,2322,25847190,,,
47,Preclinical,"In a preclinical study, transformed cells expressing a compound FLT3-ITD/F691L/D839N were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4835,10000003,Advanced Solid Tumor,JAX,19302,FLT3 exon 14 ins FLT3 F691L FLT3 D839N,resistant,874,PLX3397,2322,25847190,,,
48,Clinical Study,"In a clinical case report, Nexavar (sorafenib) treatment targeting FLT3 amplification in a rectal adenocarcinoma patient who had progressed on all standard therapies resulted in rapid clinical improvement (PMID: 25848357).",Actionable,6018,9256,colorectal cancer,DOID,5008,FLT3 amp,sensitive,920,Sorafenib,2322,25848357,,,
49,Preclinical - Cell culture,"In a preclinical study, Tandutinib (CT53518) inhibited phosphorylation of FLT3 and activation of ERK and STAT5, and reduced growth of transformed cells expressing FLT3 I836del in culture (PMID: 15256420).",Actionable,12171,162,cancer,DOID,6640,FLT3 I836del,sensitive,933,Tandutinib,2322,15256420,,,
50,Preclinical - Cell culture,"In a preclinical study, Rydapt (midostaurin) inhibited phosphorylation of FLT3, ERK, and STAT5, and growth of transformed cells expressing FLT3 I836del in culture (PMID: 17827387).",Actionable,12172,162,cancer,DOID,6640,FLT3 I836del,sensitive,810,Midostaurin,2322,17827387,,,
51,Preclinical,"In a preclinical study, transformed cells expressing FLT3-ITD with FLT3 Y842S were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4840,10000003,Advanced Solid Tumor,JAX,19323,FLT3 exon 14 ins FLT3 Y842S,resistant,874,PLX3397,2322,25847190,,,
52,Preclinical,"In a preclinical study, FLT3 D835H conferred resistance to PLX3397 in transformed cells when expressed as a compound mutation with FLT3-ITD in culture (PMID: 25847190).",Actionable,4826,10000003,Advanced Solid Tumor,JAX,19279,FLT3 exon 14 ins FLT3 D835H,resistant,874,PLX3397,2322,25847190,,,
53,Clinical Study,"In a clinical study, a patient with FLT3-ITD positive leukemia initially responded to PLX3397, but experienced relapse after emergence of a FLT3 D835H mutation on the same allele as the FLT3-ITD mutation (PMID: 25847190).",Actionable,4850,1240,leukemia,DOID,19279,FLT3 exon 14 ins FLT3 D835H,resistant,874,PLX3397,2322,25847190,,,
54,Preclinical,"In a preclinical study, Crenolanib (CP-868596) inhibited Flt3 phosphorylation and induced apoptosis in leukemia cells expressing FLT3 D835H (PMID: 24623852).",Actionable,2295,9119,acute myeloid leukemia,DOID,3155,FLT3 D835H,sensitive,705,Crenolanib,2322,24623852,,,
55,Preclinical,"In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 N841K were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4836,10000003,Advanced Solid Tumor,JAX,19316,FLT3 exon 14 ins FLT3 N841K,resistant,874,PLX3397,2322,25847190,,,
56,Clinical Study,"In multiple clinical studies, the combination of an NPM1 mutation and FLT3 wild-type in acute myeloid leukemia (AML) patients was associated with a favorable prognosis compared to AML patients harboring an NPM1 mutation and FLT3 internal tandem duplication (PMID: 19047294, PMID: 24573385, PMID: 25713434). ",Prognostic,6501,9119,acute myeloid leukemia,DOID,23600,NPM1 mutant FLT3 wild-type,not applicable,1776,N/A,2322,19047294,24573385,25713434,
57,Phase Ib/II,"In a Phase Ib clinical trial, Rydapt (midostaurin) treatment after Daunorubicin and Cytosar-U (cytarabine) induction resulted in  complete remission in 74% (20 of 27) of acute myeloid leukemia patients carrying wild-type FLT3 (PMID: 22627678).",Actionable,3409,9119,acute myeloid leukemia,DOID,545,FLT3 wild-type,sensitive,3137,Cytarabine + Daunorubicin + Midostaurin,2322,22627678,,,
58,Preclinical,"In a preclinical study, Ibrance (palbociclib) following TCS-359 treatment enhanced growth inhibition of FLT3 wild-type acute myeloid leukemia cell lines in culture (PMID: 27099147).",Actionable,6580,9119,acute myeloid leukemia,DOID,545,FLT3 wild-type,sensitive,4160,Palbociclib + TCS 359,2322,27099147,,,
59,Preclinical - Cell culture,"In a preclinical study, Rydapt (midostaurin) inhibited FLT3 phosphorylation in transformed cells expressing wild-type FLT3 in culture (PMID: 12124173).",Actionable,3271,10000003,Advanced Solid Tumor,JAX,545,FLT3 wild-type,sensitive,810,Midostaurin,2322,12124173,,,
60,Preclinical,"In a preclinical study, TCS-359 inhibited growth of FLT3 wild-type acute myeloid leukemia cell lines in culture (PMID: 27099147).",Actionable,6582,9119,acute myeloid leukemia,DOID,545,FLT3 wild-type,sensitive,2615,TCS 359,2322,27099147,,,
61,Preclinical,"In a preclinical study, Ibrance (palbociclib) inhibited growth of human FLT3 wild-type human leukemia cells in culture (PMID: 27099147).",Actionable,6578,9119,acute myeloid leukemia,DOID,545,FLT3 wild-type,sensitive,850,Palbociclib,2322,27099147,,,
62,Preclinical - Cell culture,"In a preclinical study, Rydapt (midostaurin) inhibited FLT3-induced phosphorylation of ERK1/2 and reduced growth of transformed cells expressing FLT3 V592G in culture (PMID: 18068628).",Actionable,2284,10000003,Advanced Solid Tumor,JAX,6924,FLT3 V592G,sensitive,810,Midostaurin,2322,18068628,,,
63,Preclinical - Cell line xenograft,"In a preclinical study, VS-5584 inhibited PI3K/mTOR signaling and cell proliferation in a FLT3-ITD positive human acute myeloid leukemia cell line in culture, and inhibited tumor growth in xenograft models (PMID: 23270925).",Actionable,8849,9119,acute myeloid leukemia,DOID,2774,FLT3 act mut,sensitive,960,VS-5584,2322,23270925,,,
64,Preclinical,"In a preclinical study, TCS-359 inhibited growth of FLT3-ITD positive acute myeloid leukemia cell lines in culture (PMID: 27099147).",Actionable,6581,9119,acute myeloid leukemia,DOID,2774,FLT3 act mut,sensitive,2615,TCS 359,2322,27099147,,,
65,Preclinical,"In a preclinical study, Ibrance (palbociclib) following TCS-359 treatment enhanced growth inhibition of FLT3-ITD positive acute myeloid leukemia cell lines in culture (PMID: 27099147).",Actionable,6579,9119,acute myeloid leukemia,DOID,2774,FLT3 act mut,sensitive,4160,Palbociclib + TCS 359,2322,27099147,,,
66,Preclinical,"In a preclinical study, Ibrance (palbociclib) blocked growth, induced apoptosis, and inhibited STAT activation in human FLT3-ITD positive human acute myeloid leukemia cells in culture (PMID: 27099147).",Actionable,6576,9119,acute myeloid leukemia,DOID,2774,FLT3 act mut,sensitive,850,Palbociclib,2322,27099147,,,
67,Preclinical,"In a preclinical study, Ibrance (palbociclib) and tandutinib (MLN518) were synergistic towards growth inhibition of FLT3-ITD positive acute myeloid leukemia cell lines in culture (PMID: 27099147).",Actionable,6584,9119,acute myeloid leukemia,DOID,2774,FLT3 act mut,sensitive,4162,Palbociclib + Tandutinib,2322,27099147,,,
68,Phase Ib/II,"In a Phase Ib/II trial, 59% (13/22) of acute myeloid leukemia patients harboring FLT3 activating mutations achieved complete remission following treatment with Sutent (sunitinib) in combination with Cytarabine and Daunorubicin (PMID: 25818407).",Actionable,2531,9119,acute myeloid leukemia,DOID,2774,FLT3 act mut,sensitive,2923,Sunitinib + Cytarabine + Daunorubicin,2322,25818407,,,
69,Phase II,"In a Phase II trial, relapsed or refractory acute myeloid leukemia patients harboring FLT3 activating mutations without a history of FLT3 therapy demonstrated a significantly greater overall survival and event free survival compared to those that had prior FLT3 therapy when treated with Crenolanib (ASH meeting, Dec 2014, abstract #389).",Actionable,3584,9119,acute myeloid leukemia,DOID,2774,FLT3 act mut,sensitive,705,Crenolanib,2322,None,,,
70,Preclinical,"In a preclinical study, Ibrance (palbociclib) and SGI-1776 were synergistic towards growth inhibition of FLT3-ITD positive acute myeloid leukemia cell lines in culture (PMID: 27099147).",Actionable,6585,9119,acute myeloid leukemia,DOID,2774,FLT3 act mut,sensitive,4184,Palbociclib + SGI-1776,2322,27099147,,,
71,Preclinical,"In a preclinical study, Ibrance (palbociclib) and Quizartinib (AC220) were synergistic towards growth inhibition of FLT3-ITD positive acute myeloid leukemia cell lines in culture (PMID: 27099147).",Actionable,6583,9119,acute myeloid leukemia,DOID,2774,FLT3 act mut,sensitive,4161,Palbociclib + Quizartinib,2322,27099147,,,
72,Preclinical - Cell line xenograft,"In a preclinical study, PLX3397 inhibited FLT3 autophosphorylation in leukemia cells overexpressing FLT3 or harboring FLT3 activating mutations, and inhibited growth of leukemia cells harboring FLT3-ITD mutations in culture and in cell line xenograft models (ASH Annual Meeting Abstracts 2011 118: 3632).",Actionable,2532,1240,leukemia,DOID,2774,FLT3 act mut,sensitive,874,PLX3397,2322,None,,,
73,Preclinical,"In a preclinical study, transformed cells expressing FLT3-ITD with FLT3 G846R were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4844,10000003,Advanced Solid Tumor,JAX,19304,FLT3 exon 14 ins FLT3 G846R,resistant,874,PLX3397,2322,25847190,,,
74,Clinical Study,"In a clinical study, a leukemia patient with FLT3-ITD positive leukemia initially responded to PLX3397, but experienced relapse after emergence of a compound FLT3 M837G/S838R/D839H mutation on the FLT3-ITD allele (PMID: 25847190).",Actionable,4847,1240,leukemia,DOID,19288,FLT3 exon 14 ins FLT3 M837G FLT3 S838R FLT3 D839H,resistant,874,PLX3397,2322,25847190,,,
75,Preclinical,"In a preclinical study, transformed cells expressing FLT3-ITD  along with FLT3 D839N were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4834,10000003,Advanced Solid Tumor,JAX,19301,FLT3 exon 14 ins FLT3 D839N,resistant,874,PLX3397,2322,25847190,,,
76,Preclinical,"In a preclinical study, tandutinib (CT53518) inhibited proliferation of cells expressing FLT3 E612_F613insGYVDFREYEYDLKWEFRPRENLEF in culture (PMID: 12124172).",Actionable,1038,9119,acute myeloid leukemia,DOID,1758,FLT3 E612_F613insGYVDFREYEYDLKWEFRPRENLEF,sensitive,933,Tandutinib,2322,12124172,,,
77,Preclinical,"In a preclinical study, FLT3 D835G conferred resistance to PLX3397 when expressed in a compound mutation with FLT3-ITD in cell culture (PMID: 25847190).",Actionable,5034,10000003,Advanced Solid Tumor,JAX,19284,FLT3 exon 14 ins FLT3 D839G,resistant,874,PLX3397,2322,25847190,,,
78,Preclinical,"In a preclinical study, transformed cells expressing FLT3-ITD with FLT3 R845G were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4842,10000003,Advanced Solid Tumor,JAX,19319,FLT3 exon 14 ins FLT3 R845G,resistant,874,PLX3397,2322,25847190,,,
79,Preclinical - Cell culture,"In a preclinical study, E6201 induced apoptosis in blast samples derived from acute myeloid leukemia patients harboring FLT3 D835G in culture (PMID: 26822154).",Actionable,7427,9119,acute myeloid leukemia,DOID,19290,FLT3 D835G,sensitive,1011,E6201,2322,26822154,,,
80,Preclinical,"In a preclinical study, E6201 inhibited proliferation and induced apoptosis in FLT3 inhibitor-resistant leukemia cell lines over expressing FLT3 D835G in culture (PMID: 26822154).",Actionable,6458,1240,leukemia,DOID,19290,FLT3 D835G,sensitive,1011,E6201,2322,26822154,,,
81,Preclinical,"In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D835G were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4811,10000003,Advanced Solid Tumor,JAX,19291,FLT3 exon 14 ins FLT3 D835G,resistant,874,PLX3397,2322,25847190,,,
82,Preclinical,"In a preclinical study, tandutinib (CT53518) inhibited proliferation of cells expressing FLT3 L611_E612insCSSDNEYFYVDFREYEYDLKWEFPRENL in culture (PMID: 12124172).",Actionable,1040,9119,acute myeloid leukemia,DOID,1757,FLT3 L611_E612insCSSDNEYFYVDFREYEYDLKWEFPRENL,sensitive,933,Tandutinib,2322,12124172,,,
83,Preclinical,"In a preclinical study, transformed cells expressing FLT3-ITD with FLT3 M664I displayed reduced sensitivity to PLX3397 relative to cells expressing FLT3-ITD in culture (PMID: 25847190).",Actionable,4801,10000003,Advanced Solid Tumor,JAX,19310,FLT3 exon 14 ins FLT3 M664I,decreased response,874,PLX3397,2322,25847190,,,
84,Phase I,"In a Phase I trial, two acute myeloid leukemia patients co-harboring a FLT3-ITD mutation and NPM1 mutation demonstrated anti-leukemia activity when treated with ENMD-2076 (PMID: 27406088). ",Actionable,8008,9119,acute myeloid leukemia,DOID,26135,FLT3 exon 14 ins NPM1 mutant,sensitive,727,ENMD-2076,2322,27406088,,,
85,Preclinical,"In a preclinical study, MI-503 inhibited growth of murine leukemia cells expressing an NPM1 mutation and FLT3 internal tandem duplication in culture, and improved survival in mouse models (PMID: 27535106).",Actionable,11489,1240,leukemia,DOID,26135,FLT3 exon 14 ins NPM1 mutant,predicted â€“ sensitive,6006,MI-503,2322,27535106,,,
86,Preclinical,"In a preclinical study, EPZ004777 inhibited growth and induced differentiation of murine leukemia cells expressing an NPM1 mutation and FLT3 internal tandem duplication in culture, and improved survival in mouse models (PMID: 27535106).",Actionable,11490,1240,leukemia,DOID,26135,FLT3 exon 14 ins NPM1 mutant,predicted â€“ sensitive,1744,EPZ004777,2322,27535106,,,
87,Clinical Study,"In a clinical study, a patient with FLT3-ITD positive leukemia initially responded to PLX3397, but experienced relapse after emergence of a FLT3 S652G mutation on the same allele as FLT3-ITD (PMID: 25847190).",Actionable,4849,1240,leukemia,DOID,19366,FLT3 exon 14 ins FLT3 S652G,resistant,874,PLX3397,2322,25847190,,,
88,Preclinical - Cell culture,"In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing both FLT3 internal tandem duplication (ITD) and D835F in culture (PMID: 27158668).",Actionable,9438,10000003,Advanced Solid Tumor,JAX,19133,FLT3 exon 14 ins FLT3 D835F,sensitive,5016,MRX-2843,2322,27158668,,,
89,Preclinical,"In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D835F were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4795,10000003,Advanced Solid Tumor,JAX,19133,FLT3 exon 14 ins FLT3 D835F,resistant,874,PLX3397,2322,25847190,,,
90,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FLT3 ITD and N676D were resistant to Rydapt (midostaurin) in culture (PMID: 23392356).",Actionable,9274,10000003,Advanced Solid Tumor,JAX,26809,FLT3 exon 14 ins FLT3 N676D,resistant,810,Midostaurin,2322,23392356,,,
91,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FLT3 ITD and N676D demonstrated reduced sensitivity to Quizartinib (AC220) in culture (PMID: 23392356).",Actionable,9282,10000003,Advanced Solid Tumor,JAX,26809,FLT3 exon 14 ins FLT3 N676D,decreased response,882,Quizartinib,2322,23392356,,,
92,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FLT3 ITD and Y842H demonstrated reduced sensitivity to Nexavar (sorafenib) in culture (PMID: 23392356).",Actionable,9281,10000003,Advanced Solid Tumor,JAX,19135,FLT3 exon 14 ins FLT3 Y842H,decreased response,920,Sorafenib,2322,23392356,,,
93,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FLT3 ITD and Y842H demonstrated reduced sensitivity to Quizartinib (AC220) in culture (PMID: 23392356).",Actionable,9283,10000003,Advanced Solid Tumor,JAX,19135,FLT3 exon 14 ins FLT3 Y842H,decreased response,882,Quizartinib,2322,23392356,,,
94,Preclinical - Cell culture,"In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing both FLT3 internal tandem duplication (ITD) and Y842H in culture (PMID: 27158668).",Actionable,9436,10000003,Advanced Solid Tumor,JAX,19135,FLT3 exon 14 ins FLT3 Y842H,sensitive,5016,MRX-2843,2322,27158668,,,
95,Preclinical,"In a preclinical study, transformed cells expressing FLT3-ITD with FLT3 Y842H were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4796,10000003,Advanced Solid Tumor,JAX,19135,FLT3 exon 14 ins FLT3 Y842H,resistant,874,PLX3397,2322,25847190,,,
96,Preclinical,"In a preclinical study, transformed cells expressing FLT3-ITD with FLT3 R834Q were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4807,10000003,Advanced Solid Tumor,JAX,19275,FLT3 exon 14 ins FLT3 R834Q,resistant,874,PLX3397,2322,25847190,,,
97,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FLT3 ITD and A848P demonstrated reduced sensitivity to Quizartinib (AC220) in culture (PMID: 23392356).",Actionable,9284,10000003,Advanced Solid Tumor,JAX,26811,FLT3 exon 14 ins FLT3 A848P,decreased response,882,Quizartinib,2322,23392356,,,
98,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FLT3 ITD and A848P demonstrated reduced sensitivity to Nexavar (sorafenib) in culture (PMID: 23392356).",Actionable,9280,10000003,Advanced Solid Tumor,JAX,26811,FLT3 exon 14 ins FLT3 A848P,decreased response,920,Sorafenib,2322,23392356,,,
99,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FLT3 ITD and A848P were resistant to Sutent (sunitinib) in culture (PMID: 23392356).",Actionable,9277,10000003,Advanced Solid Tumor,JAX,26811,FLT3 exon 14 ins FLT3 A848P,resistant,930,Sunitinib,2322,23392356,,,
100,Preclinical - Cell culture,"In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing both FLT3 internal tandem duplication (ITD) and D835V in culture (PMID: 27158668).",Actionable,9439,10000003,Advanced Solid Tumor,JAX,19131,FLT3 exon 14 ins FLT3 D835V,sensitive,5016,MRX-2843,2322,27158668,,,
101,Preclinical,"In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D835V were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4794,10000003,Advanced Solid Tumor,JAX,19131,FLT3 exon 14 ins FLT3 D835V,resistant,874,PLX3397,2322,25847190,,,
102,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FLT3 ITD and F691I were resistant to Quizartinib (AC220) in culture (PMID: 23392356).",Actionable,9285,10000003,Advanced Solid Tumor,JAX,26802,FLT3 exon 14 ins FLT3 F691I,resistant,882,Quizartinib,2322,23392356,,,
103,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FLT3 ITD and F691I demonstrated reduced response to Sutent (sunitinib) in culture (PMID: 23392356).",Actionable,9276,10000003,Advanced Solid Tumor,JAX,26802,FLT3 exon 14 ins FLT3 F691I,decreased response,930,Sunitinib,2322,23392356,,,
104,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing FLT3 ITD and F691I demonstrated reduced sensitivity to Brigatinib (AP26113) in culture (PMID: 27780853).",Actionable,9252,10000003,Advanced Solid Tumor,JAX,26802,FLT3 exon 14 ins FLT3 F691I,decreased response,634,AP26113,2322,27780853,,,
105,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FLT3 ITD and F691I were resistant to Rydapt (midostaurin) in culture (PMID: 23392356).",Actionable,9275,10000003,Advanced Solid Tumor,JAX,26802,FLT3 exon 14 ins FLT3 F691I,resistant,810,Midostaurin,2322,23392356,,,
106,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing FLT3 ITD and F691I were resistant to Nexavar (sorafenib) in culture (PMID: 23392356).",Actionable,9278,10000003,Advanced Solid Tumor,JAX,26802,FLT3 exon 14 ins FLT3 F691I,resistant,920,Sorafenib,2322,23392356,,,
107,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing FLT3 ITD in culture (PMID: 27780853).",Actionable,9231,10000003,Advanced Solid Tumor,JAX,19128,FLT3 exon 14 ins,sensitive,634,AP26113,2322,27780853,,,
108,Preclinical - Pdx,"In a preclinical study, treatment with SHP099 resulted in reduction of CD45-positive leukemic cells and decreased splenomegaly in a human primary tumor-derived xenograft model of acute myeloid leukemia harboring a FLT3-ITD mutation (PMID: 27362227). ",Actionable,7519,9119,acute myeloid leukemia,DOID,19128,FLT3 exon 14 ins,predicted â€“ sensitive,4504,SHP099,2322,27362227,,,
109,Preclinical - Cell culture,"In a preclinical study, Altiratinib (DCC-0701) inhibited proliferation of an acute myeloid leukemia cell harboring a FLT3-ITD mutation in culture (PMID: 26285778).",Actionable,10068,9119,acute myeloid leukemia,DOID,19128,FLT3 exon 14 ins,sensitive,1656,Altiratinib,2322,26285778,,,
110,Phase Ib/II,"In a Phase I/II trial, treatment with Gilteritinib (ASP2215) at a dose of 80mg/day or higher resulted in an overall response rate of 55% (77/141) in patients with relapsed or refractory acute myeloid leukemia harboring FLT3 internal tandem duplication mutations (PMID: 28645776; NCT02014558).",Actionable,11484,9119,acute myeloid leukemia,DOID,19128,FLT3 exon 14 ins,sensitive,2865,Gilteritinib,2322,28645776,,,
111,Preclinical,"In a preclinical study, PLX3397 inhibited proliferation of transformed cells expressing FLT3-ITD in culture (PMID: 25847190).",Actionable,4788,10000003,Advanced Solid Tumor,JAX,19128,FLT3 exon 14 ins,sensitive,874,PLX3397,2322,25847190,,,
112,Phase I,"In a Phase I trial, acute myeloid leukemia patients harboring a FLT3 internal tandem duplication did not benefit from treatment with Rebastinib (DCC-2036) (PMID: 27927766). ",Actionable,10755,9119,acute myeloid leukemia,DOID,19128,FLT3 exon 14 ins,no benefit,1045,rebastinib,2322,27927766,,,
113,Preclinical - Cell line xenograft,"In a preclinical study, MRX-2843 inhibited Flt3 activation, resulted in growth inhibition in acute myeloid leukemia cell lines harboring FLT3 internal tandem duplication (ITD) in culture and in cell line xenograft models, and prolonged survival in patient-derived xenograft models (PMID: 27158668).",Actionable,9429,9119,acute myeloid leukemia,DOID,19128,FLT3 exon 14 ins,sensitive,5016,MRX-2843,2322,27158668,,,
114,Phase I,"In a Phase I trial, acute myeloid leukemia (AML) pediatric patients harboring a FLT3-ITD mutation demonstrated a greater sensitivity to treatment with Quizartinib (AC220) when compared to AML patients with wild-type FLT3, resulting in three complete responses, four with stable disease, and a lower bone marrow blast cell count (PMID: 26920889).",Actionable,7770,9119,acute myeloid leukemia,DOID,19128,FLT3 exon 14 ins,sensitive,882,Quizartinib,2322,26920889,,,
115,Phase I,"In a Phase I trial, an acute myeloid leukemia patient with a FLT3-ITD mutation demonstrated anti-leukemia activity when treated with ENMD-2076 (PMID: 27406088). ",Actionable,8007,9119,acute myeloid leukemia,DOID,19128,FLT3 exon 14 ins,sensitive,727,ENMD-2076,2322,27406088,,,
116,Phase III,"In a Phase III trial that supported FDA approval, treatment with Rydapt (midostaurin), combined with Cytosar-U (cytarabine) and Daunorubicin, improved overall survival (74.7 mo vs 25.6 mo) in patients with FLT3-mutant or FLT3-ITD acute myeloid leukemia compared to Cytosar-U (cytarabine) and Daunorubicin with placebo (PMID: 28644114). ",Actionable,11372,9119,acute myeloid leukemia,DOID,19128,FLT3 exon 14 ins,sensitive,3137,Cytarabine + Daunorubicin + Midostaurin,2322,28644114,,,
117,Preclinical - Patient cell culture,"In a preclinical study, Iclusig (ponatinib) inhibited viability of patient derived acute myeloid leukemia cells harboring FLT3 ITD mutations in culture, and inhibited growth of tumors in cell line xenograft models (PMID: 21482694).",Actionable,2530,9119,acute myeloid leukemia,DOID,19128,FLT3 exon 14 ins,sensitive,877,Ponatinib,2322,21482694,,,
118,Phase I,"In a Phase I trial, Iclusig (ponatinib) resulted in a 25% (3/12) overall response rate, indicated as partial remission or better, in acute myeloid leukemia patients harboring FLT3-ITD (PMID: 23691988).",Actionable,12174,9119,acute myeloid leukemia,DOID,19128,FLT3 exon 14 ins,sensitive,877,Ponatinib,2322,23691988,,,
119,Preclinical - Cell culture,"In a preclinical study, E6201 induced apoptosis in blast samples derived from acute myeloid leukemia patients harboring FLT3 internal tandem duplications (ITD) in culture (PMID: 26822154).",Actionable,7429,9119,acute myeloid leukemia,DOID,19128,FLT3 exon 14 ins,sensitive,1011,E6201,2322,26822154,,,
120,Preclinical - Cell line xenograft,"In a preclinical study, PLX3397 inhibited proliferation of human leukemia cells harboring FLT3-ITD in culture and in cell line xenograft models (PMID: 25847190).",Actionable,4791,1240,leukemia,DOID,19128,FLT3 exon 14 ins,sensitive,874,PLX3397,2322,25847190,,,
121,Preclinical - Cell line xenograft,"In a preclinical study, E6201 induced growth inhibition and apoptosis in leukemia cell lines harboring FLT3 internal tandem duplications (ITD) and reduced tumor burden in xenograft models (PMID: 26822154).",Actionable,6457,1240,leukemia,DOID,19128,FLT3 exon 14 ins,sensitive,1011,E6201,2322,26822154,,,
122,Phase I,"In a Phase I trial, Crenolanib treatment resulted in an overall survival (OS) of 238 days in AML patients harboring FLT3 exon 14 insertions (ITD) that received no prior therapy, and an OS of 158 days in those progressed on TKIs (J Clin Oncol 34, 2016 (suppl; abstr 7008)).",Actionable,6885,9119,acute myeloid leukemia,DOID,19128,FLT3 exon 14 ins,sensitive,705,Crenolanib,2322,None,,,
123,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing a FLT3-ITD mutation were sensitive to Cometriq (cabozantinib) in culture (PMID: 21926191).",Actionable,3574,10000003,Advanced Solid Tumor,JAX,19128,FLT3 exon 14 ins,predicted â€“ sensitive,998,cabozantinib,2322,21926191,,,
124,Preclinical - Cell culture,"In a preclinical study, Rydapt (midostaurin) demonstrated efficacy in inhibiting proliferation and viability of transformed cells expressing a FLT3-ITD mutation in culture (PMID: 12124173).",Actionable,3270,10000003,Advanced Solid Tumor,JAX,19128,FLT3 exon 14 ins,sensitive,810,Midostaurin,2322,12124173,,,
125,Preclinical,"In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D839H were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4833,10000003,Advanced Solid Tumor,JAX,19285,FLT3 exon 14 ins FLT3 D839H,resistant,874,PLX3397,2322,25847190,,,
126,Preclinical,"In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D698N were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4805,10000003,Advanced Solid Tumor,JAX,19293,FLT3 exon 14 ins FLT3 D698N,resistant,874,PLX3397,2322,25847190,,,
127,Phase I,"In a Phase I trial, Crenolanib treatment resulted in an overall survival (OS) of 128 days in AML patients harboring both FLT3 D835X and exon 14 insertion (ITD) that received no prior therapy, and an OS of 63 days in those progressed on TKIs (J Clin Oncol 34, 2016 (suppl; abstr 7008)).",Actionable,6886,9119,acute myeloid leukemia,DOID,23954,FLT3 D835X FLT3 exon 14 ins,sensitive,705,Crenolanib,2322,None,,,
128,Preclinical,"In a preclinical study, tandutinib (CT53518) inhibited proliferation of cells expressing FLT3 E598_Y599insGLVQVTGSSDNEYFYVDFREYE in culture (PMID: 12124172).",Actionable,1037,9119,acute myeloid leukemia,DOID,1755,FLT3 E598_Y599insGLVQVTGSSDNEYFYVDFREYE,sensitive,933,Tandutinib,2322,12124172,,,
129,Clinical Study,"In a retrospective analysis, of patients with acute myeloid leukemia, the combination of DNMT3A, FLT3, and NPM1 mutations was highly associated with decreased event free survival and overall survival, suggesting that this combination profile may serve as a future prognostic biomarker (PMID: 25281355).  ",Emerging,3573,9119,acute myeloid leukemia,DOID,13674,DNMT3A R882H FLT3 Y599_D600insSTDNEYFYVDFREYEY NPM1 W288fs,not applicable,1776,N/A,2322,25281355,,,
130,Preclinical,"In a preclinical study, acute myeloid leukemia cells harboring a FLT3-ITD secondary resistance mutation demonstrated sensitivity to FLX925 (Cancer Res, August 1, 2015 75; 787).",Actionable,3590,9119,acute myeloid leukemia,DOID,13493,FLT3 Y599_D600insSTDNEYFYVDFREYEY,predicted â€“ sensitive,2529,FLX925  ,2322,None,,,
131,Phase I,"In a Phase I clinical trial, patients with refractory or relapsed acute myeloid leukemia positive for FLT3-ITD demonstrated a 53% (9/17) response rate compared to a 14% (5/37) response rate in those patients negative for FLT3-ITD when treated with Quizartinib (AC220) (PMID: 24002496). ",Actionable,3596,9119,acute myeloid leukemia,DOID,13493,FLT3 Y599_D600insSTDNEYFYVDFREYEY,predicted â€“ sensitive,882,Quizartinib,2322,24002496,,,
132,Preclinical - Cell line xenograft,"In a preclinical study, acute myeloid leukemia cells harboring a FLT3-ITD mutation treated with Pacritinib resulted in apoptosis and inhibition of cell proliferation in culture and in cell line xenograft models demonstrated tumor growth inhibition and tumor regression (PMID: 22829080). ",Actionable,3594,9119,acute myeloid leukemia,DOID,13493,FLT3 Y599_D600insSTDNEYFYVDFREYEY,predicted â€“ sensitive,2006,Pacritinib,2322,22829080,,,
133,Preclinical - Cell line xenograft,"In a preclinical study, E6201 induced cell death, inhibited cell growth, and decreased tumor burden in acute myeloid leukemia cells harboring FLT3-ITD mutations in culture and in cell line xenograft models (Blood Nov 2013, 122 (21) 2683). ",Actionable,3588,9119,acute myeloid leukemia,DOID,13493,FLT3 Y599_D600insSTDNEYFYVDFREYEY,predicted â€“ sensitive,1011,E6201,2322,None,,,
134,Phase II,"In a Phase II trial, 93% (40/43) of acute myeloid leukemia patients harbored a FLT3-ITD and of the 37 patients that were evaluable, the combination therapy, Nexavar (sorafenib) and Vidaza (azacitidine), resulted in a 46% (17/37) response rate, which included 10 CRi, 6 CR, and 1 PR (PMID: 23613521).  ",Actionable,3578,9119,acute myeloid leukemia,DOID,13493,FLT3 Y599_D600insSTDNEYFYVDFREYEY,predicted â€“ sensitive,1633,Sorafenib + Azacitidine,2322,23613521,,,
135,Preclinical,"In a preclinical study, the combination of Enasidenib (AG-221) and Quizartinib (AC220) stimulated leukemic cell differentiation and reduced leukemic cell self-renewal in an acute myeloid leukemia mouse model simultaneously expressing IDH2 R140Q and a FLT3-ITD mutation (Blood Dec 2014, 124 (21) 437). ",Actionable,3593,9119,acute myeloid leukemia,DOID,13759,IDH2 R140W FLT3 Y599_D600insSTDNEYFYVDFREYEY,predicted â€“ sensitive,3172,Enasidenib + Quizartinib,2322,None,,,
136,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing FLT3 S451F demonstrated decreased sensitivity to inhibition of FLT3 phosphorylation and growth by Rydapt (midostaurin) in culture, when compared to cells expressing other FLT3 activating mutations (PMID: 18068628).",Actionable,2283,10000003,Advanced Solid Tumor,JAX,6896,FLT3 S451F,decreased response,810,Midostaurin,2322,18068628,,,
137,Preclinical,"In a preclinical study, PD98059 inhibited ERK1/2 phosphorylation and reduced cell growth in transformed cells expressing FLT3 R834Q (PMID: 18068628).",Actionable,2286,10000003,Advanced Solid Tumor,JAX,6799,FLT3 R834Q,sensitive,2617,PD98059,2322,18068628,,,
138,Preclinical - Cell culture,"In a preclinical study, Rydapt (midostaurin) inhibited FLT3-induced phosphorylation of ERK1/2 and reduced growth of transformed cells expressing FLT3 R834Q in culture (PMID: 18068628).",Actionable,2285,10000003,Advanced Solid Tumor,JAX,6799,FLT3 R834Q,sensitive,810,Midostaurin,2322,18068628,,,
139,Preclinical - Cell culture,"In a preclinical study, Rydapt (midostaurin) inhibited FLT3 phosphorylation of ERK1/2 and reduced cell growth in transformed cells expressing FLT3 Y572C in culture (PMID: 18068628).",Actionable,2282,10000003,Advanced Solid Tumor,JAX,6805,FLT3 Y572C,sensitive,810,Midostaurin,2322,18068628,,,
140,Preclinical,"In a preclinical study, tandutinib (CT53518) inhibited proliferation of cells expressing FLT3 Y599_D600insGLYVDFREYEY in culture (PMID: 12124172).",Actionable,1041,9119,acute myeloid leukemia,DOID,1739,FLT3 Y599_D600insGLYVDFREYEY,sensitive,933,Tandutinib,2322,12124172,,,
141,Phase I,"In a Phase I trial, Crenolanib treatment resulted in an overall survival (OS) of 185 days in AML patients harboring FLT3 D835X that received no prior therapy (J Clin Oncol 34, 2016 (suppl; abstr 7008)).",Actionable,6884,9119,acute myeloid leukemia,DOID,5329,FLT3 D835X,sensitive,705,Crenolanib,2322,None,,,
142,Preclinical,"In a preclinical study, tandutinib (CT53518) inhibited cell proliferation in cell culture and in mouse models carrying FLT3 L601_K602insREYEYDL (PMID: 12124172).",Actionable,1039,9119,acute myeloid leukemia,DOID,1756,FLT3 L601_K602insREYEYDL,sensitive,933,Tandutinib,2322,12124172,,,
143,Preclinical,"In a preclinical study, UNC2025 inhibited FLT3 activation and growth of acute myeloid leukemia cells harboring a FLT3-ITD mutation in culture (PMID: 25068800).",Actionable,3751,9119,acute myeloid leukemia,DOID,1227,FLT3 mutant,sensitive,3291,UNC2025,2322,25068800,,,
144,Phase Ib/II,"In a Phase Ib/II trial, acute myeloid leukemia patients harboring a FLT3 mutation demonstrated an improved remission duration when treated with the combination therapy, Rydapt (midostaurin) and Vidaza (azacitidine) (PMID: 25530214).",Actionable,3591,9119,acute myeloid leukemia,DOID,1227,FLT3 mutant,sensitive,2471,Azacitidine + Midostaurin,2322,25530214,,,
145,Preclinical,"In a preclinical study, acute myeloid leukemia cell lines harboring FLT3 mutations demonstrated increased sensitivity to E6201 induced growth inhibition and apoptosis in culture compared to FLT3 wild-type cells (PMID: 26822154).",Actionable,6455,9119,acute myeloid leukemia,DOID,1227,FLT3 mutant,sensitive,1011,E6201,2322,26822154,,,
146,Phase Ib/II,"In a Phase I/II trial, treatment with Gilteritinib (ASP2215) resulted in an overall response rate of 49% (93/191) in patients with relapsed or refractory acute myeloid leukemia harboring FLT3 mutations, compared to 12% (7/58) in patients with wild-type FLT3 (PMID: 28645776; NCT02014558).",Actionable,3583,9119,acute myeloid leukemia,DOID,1227,FLT3 mutant,predicted â€“ sensitive,2865,Gilteritinib,2322,None,28645776,,
147,Preclinical - Cell line xenograft,"In a preclinical study, TG02 inhibited growth of FLT3-mutated acute myeloid leukemia cells in culture, resulted in complete tumor regression in cell line xenograft animal models (PMID: 21860433).",Actionable,11216,9119,acute myeloid leukemia,DOID,1227,FLT3 mutant,sensitive,5836,TG02,2322,21860433,,,
148,Phase Ib/II,"In a Phase Ib clinical trial, Rydapt (midostaurin) treatment after Daunorubicin and Cytosar-U (cytarabine) induction resulted in complete remission in 92% (12/13) of acute myeloid leukemia patients carrying FLT3 mutations, although overall survival rate was similar to patients with wild-type FLT3 (PMID: 22627678).",Actionable,3408,9119,acute myeloid leukemia,DOID,1227,FLT3 mutant,sensitive,3137,Cytarabine + Daunorubicin + Midostaurin,2322,22627678,,,
149,FDA approved,"In a Phase III trial that supported FDA approval, treatment with Rydapt (midostaurin), combined with Cytosar-U (cytarabine) and Daunorubicin, improved overall survival (74.7 mo vs 25.6 mo) in patients with FLT3-mutant or FLT3-ITD acute myeloid leukemia compared to Cytosar-U (cytarabine) and Daunorubicin with placebo (PMID: 28644114). ",Actionable,10716,9119,acute myeloid leukemia,DOID,1227,FLT3 mutant,sensitive,3137,Cytarabine + Daunorubicin + Midostaurin,2322,None,28644114,,
150,Phase I,"In a Phase I trial, Crenolanib treatment resulted in complete response (CR) in 39% (7/18), partial response (PR) in 11% (2/18), and an overall survival (OS) of 234 days in AML patients harboring FLT3 mutations (D835X, ITD, or both) that received no prior therapy, and CR in 17% (6/36), PR in 14% (5/36), and OS of 94 days in those progressed on TKIs (J Clin Oncol 34, 2016 (suppl; abstr 7008)).",Actionable,6883,9119,acute myeloid leukemia,DOID,1227,FLT3 mutant,sensitive,705,Crenolanib,2322,None,,,
151,Preclinical - Cell culture,"In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing FLT3 D835V in culture (PMID: 27158668).",Actionable,9435,10000003,Advanced Solid Tumor,JAX,3154,FLT3 D835V,sensitive,5016,MRX-2843,2322,27158668,,,
152,Preclinical,"In a preclinical study, transformed cells expressing FLT3 D835V were resistant to PLX3397 in culture (PMID: 25847190).",Actionable,4792,10000003,Advanced Solid Tumor,JAX,3154,FLT3 D835V,resistant,874,PLX3397,2322,25847190,,,
0,Preclinical,"FOXL2 C134W mutations are used in the diagnosis of adult granulosa cell tumors of the ovary (PMID: 26791928, PMID: 22240241).",Diagnostic,5775,2999,granulosa cell tumor,DOID,3836,FOXL2 C134W,not applicable,1776,N/A,668,26791928,22240241,,
0,Clinical Study,"GATA1 mutations are used in the diagnosis of Down Syndrome related acute megakaryoblastic leukemia (PMID: 25266042, PMID: 14636651, PMID: 12586620). ",Diagnostic,6078,8761,megakaryocytic leukemia,DOID,22437,GATA1 mutant,not applicable,1776,N/A,2623,25266042,14636651,12586620,
1,Preclinical - Cell culture,"In a preclinical study, high expression of GATA1 was associated with decreased sensitivity to Cytosar-U (cytarabine) in an non-Down Syndrome megakaryocytic leukemia cell line in culture (PMID: 23874683).",Actionable,1428,8761,megakaryocytic leukemia,DOID,2519,GATA1 over exp,decreased response,712,Cytarabine,2623,23874683,,,
2,Preclinical - Cell culture,"In a preclinical study, high expression of GATA1 was associated with decreased sensitivity to Cerubidine (daunorubicin) in a non-Down Syndrome megakaryocytic leukemia cell line in culture (PMID: 23874683).",Actionable,1429,8761,megakaryocytic leukemia,DOID,2519,GATA1 over exp,decreased response,1006,Daunorubicin,2623,23874683,,,
0,Clinical Study,"In clinical analyses, mutations in GATA2 were associated with better overall survival in patients with cytogenetically normal acute myeloid leukemia (CN-AML) harboring biallelic CEBPA gene mutations (PMID: 22814295, PMID: 23521373, PMID: 25241285).",Prognostic,3612,9119,acute myeloid leukemia,DOID,22783,CEBPA mutant GATA2 mutant,not applicable,1776,N/A,2624,22814295,23521373,25241285,
1,Clinical Study,"In multiple clinical studies, GATA2 germline mutations were shown to be a risk factor for the development of acute myeloid leukemia following myelodysplastic syndrome (PMID: 21892162, PMID: 22271902, PMID: 22147895, PMID: 22533337). ",Prognostic,6221,9119,acute myeloid leukemia,DOID,11068,GATA2 mutant,not applicable,1776,N/A,2624,21892162,22271902,22147895,22533337
2,Preclinical,"In a preclinical study, the combination of bortezomib and fasudil blocked GATA2 downstream signals in KRAS activated NSCLC cells, resulting in reduced tumor burden, size and number in treated mice (PMID: 22541434).  ",Actionable,1462,3908,non-small cell lung carcinoma,DOID,2563,KRAS mut + GATA2 wild-type,sensitive,1778,bortezomib + fasudil,2624,22541434,,,
0,Preclinical - Pdx & cell culture,"In a preclinical study, treatment with the combination of Sotrastaurin (AEB071) and Afinitor (everolimus) inhibited tumor growth in patient-derived xenograft (PDX) models of uveal melanoma harboring GNA11 mutations, including tumor regression, and inhibited growth of GNA11-mutant uveal melanoma cell lines in culture (PMID: 27507190).",Actionable,10694,6039,uveal melanoma,DOID,24999,GNA11 mutant,predicted â€“ sensitive,1951,AEB071 + Everolimus,2767,27507190,,,
1,Preclinical - Pdx & cell culture,"In a preclinical study, treatment with the combination of Sotrastaurin (AEB071) and CGM097 resulted in tumor regression or stasis in patient-derived xenograft (PDX) models of uveal melanoma harboring GNA11 mutations, and induced apoptosis and inhibited growth of GNA11-mutant uveal melanoma cell lines in culture (PMID: 27507190).",Actionable,10692,6039,uveal melanoma,DOID,24999,GNA11 mutant,predicted â€“ sensitive,5587,AEB071 + CGM097,2767,27507190,,,
2,Preclinical - Pdx & cell culture,"In a preclinical study, the combination of Binimetinib (MEK162) and Sotrastaurin (AEB071) inhibited tumor growth in patient-derived xenograft (PDX) models of uveal melanoma harboring GNA11 mutations, and inhibited growth of GNA11-mutant uveal melanoma cell lines in culture (PMID: 27507190).",Actionable,10696,6039,uveal melanoma,DOID,24999,GNA11 mutant,predicted â€“ sensitive,1114,MEK162 + AEB071,2767,27507190,,,
3,Preclinical - Cell culture,"In a preclinical study, uveal melanoma cell lines harboring GNA11 Q209L demonstrated increased sensitivity to growth inhibition by Mekinist (trametinib) in culture, compared to cells with wild-type GNA11 (PMID: 22733540).",Actionable,10641,6039,uveal melanoma,DOID,550,GNA11 Q209L,sensitive,2,Trametinib,2767,22733540,,,
4,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Binimetinib (MEK162) and Sotrastaurin (AEB071) synergized to inhibit growth in a human uveal melanoma cancer cell line harboring a GNA11 Q209L mutation in culture and in xenograft models, and demonstrated improved efficacy over either agent alone (PMID: 24141786).",Actionable,1045,6039,uveal melanoma,DOID,550,GNA11 Q209L,sensitive,1114,MEK162 + AEB071,2767,24141786,,,
5,Preclinical - Cell culture,"In a preclinical study, TAK-733 inhibited growth of uveal melanoma cell lines harboring GNA11 Q209L in culture (PMID: 22515704).",Actionable,10624,6039,uveal melanoma,DOID,550,GNA11 Q209L,sensitive,932,TAK-733,2767,22515704,,,
0,Preclinical - Pdx & cell culture,"In a preclinical study, treatment with the combination of Sotrastaurin (AEB071) and Afinitor (everolimus) inhibited tumor growth in patient-derived xenograft (PDX) models of uveal melanoma harboring GNAQ mutations, including tumor regression or stasis, and inhibited growth of GNAQ-mutant uveal melanoma cell lines in culture (PMID: 27507190).",Actionable,10693,6039,uveal melanoma,DOID,25000,GNAQ mutant,predicted â€“ sensitive,1951,AEB071 + Everolimus,2776,27507190,,,
1,Preclinical - Pdx & cell culture,"In a preclinical study, treatment with the combination of Sotrastaurin (AEB071) and CGM097 resulted in tumor regression or stasis in patient-derived xenograft (PDX) models of uveal melanoma harboring GNAQ mutations, and induced apoptosis and inhibited growth of GNAQ-mutant uveal melanoma cell lines in culture (PMID: 27507190).",Actionable,10691,6039,uveal melanoma,DOID,25000,GNAQ mutant,predicted â€“ sensitive,5587,AEB071 + CGM097,2776,27507190,,,
2,Preclinical - Pdx & cell culture,"In a preclinical study, the combination of Binimetinib (MEK162) and Sotrastaurin (AEB071) inhibited tumor growth in patient-derived xenograft (PDX) models of uveal melanoma harboring GNAQ mutations, and inhibited growth of GNAQ-mutant uveal melanoma cell lines in culture (PMID: 27507190).",Actionable,10695,6039,uveal melanoma,DOID,25000,GNAQ mutant,predicted â€“ sensitive,1114,MEK162 + AEB071,2776,27507190,,,
3,Phase I,"In a Phase I clinical trial, Refametinib (BAY 86-9766) demonstrated preliminary clinical activity in patients with several tumor types, including prolonged stable disease in an ocular melanoma patient harboring GNAQ Q209L and PTEN R173S (PMID: 23434733).",Actionable,10644,1752,ocular melanoma,DOID,27655,GNAQ Q209L PTEN R173S,predicted â€“ sensitive,888,Refametinib,2776,23434733,,,
4,Preclinical - Cell culture,"In a preclinical study, uveal melanoma cell lines harboring GNAQ Q209L demonstrated increased sensitivity to growth inhibition by Mekinist (trametinib) in culture, compared to cells with wild-type GNAQ (PMID: 22733540).",Actionable,10640,6039,uveal melanoma,DOID,561,GNAQ Q209L,sensitive,2,Trametinib,2776,22733540,,,
5,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) induced cell-cycle arrest and decreased viability of uveal melanoma cells harboring GNAQ Q209L in culture (PMID: 22550165).",Actionable,10645,6039,uveal melanoma,DOID,561,GNAQ Q209L,sensitive,913,Selumetinib,2776,22550165,,,
6,Preclinical - Cell culture,"In a preclinical study, Sotrastaurin (AEB071), in combination with PD-0325901, worked synergisitically to inhibit MAPK pathway activation and proliferation of a uveal melanoma cell line harboring GNAQ Q209L (PMID: 24141786).",Actionable,1783,6039,uveal melanoma,DOID,561,GNAQ Q209L,sensitive,2275,AEB071 + PD-0325901,2776,24141786,,,
7,Preclinical - Cell culture,"In a preclinical study, treatment with U0126 resulted in reduced cell numbers in uveal melanoma cell lines harboring GNAQ Q209L in culture (PMID: 19078957).",Actionable,10647,6039,uveal melanoma,DOID,561,GNAQ Q209L,sensitive,2427,U0126,2776,19078957,,,
8,Preclinical - Cell line xenograft,"In a preclinical study, human uveal melanoma cell lines harboring GNAQ Q209L demonstrated sensitivity to Sotrastaurin (AEB071) in culture, and Sotrastaurin (AEB071) decreased tumor growth in uveal melanoma cell line xenograft models harboring GNAQ Q209L (PMID: 24141786).",Actionable,10583,6039,uveal melanoma,DOID,561,GNAQ Q209L,sensitive,621,AEB071,2776,24141786,,,
9,Preclinical - Cell culture,"In a preclinical study, TAK-733 inhibited growth of a uveal melanoma cell line harboring GNAQ Q209L in culture (PMID: 22515704).",Actionable,10622,6039,uveal melanoma,DOID,561,GNAQ Q209L,sensitive,932,TAK-733,2776,22515704,,,
10,Preclinical - Cell culture,"In a preclinical study, treatment with the combination of Mekinist (trametinib) and GSK2126458 induced apoptosis in uveal melanoma cell lines harboring GNAQ Q209L in culture (PMID: 22733540).",Actionable,10642,6039,uveal melanoma,DOID,561,GNAQ Q209L,sensitive,3027,GSK2126458 + Trametinib,2776,22733540,,,
11,Preclinical - Cell line xenograft,"In a preclinical study, NAV-2729 inhibited signaling downstream of GNAQ Q209L in melanoma cells in culture, and inhibited initiation and growth of tumors in a uveal melanoma cell line xenograft model harboring GNAQ Q209L (PMID: 27265506).",Actionable,10591,6039,uveal melanoma,DOID,561,GNAQ Q209L,sensitive,5564,NAV-2729,2776,27265506,,,
12,Preclinical - Cell line xenograft,"In a preclinical study, Visudyne (verteporfin) inhibited tumor formation in a uveal melanoma cell line xenograft model harboring GNAQ Q209L (PMID: 27308390).",Actionable,10632,6039,uveal melanoma,DOID,561,GNAQ Q209L,sensitive,3319,Verteporfin,2776,27308390,,,
13,Preclinical - Cell culture,"In a preclinical study, Enzastaurin (LY317615) increased cell-cycle arrest and apoptosis and decreased viability of uveal melanoma cell lines harboring GNAQ Q209L in culture (PMID: 22253748).",Actionable,1266,6039,uveal melanoma,DOID,561,GNAQ Q209L,sensitive,1682,Enzastaurin,2776,22253748,,,
14,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) induced cell-cycle arrest and decreased viability of uveal melanoma cells harboring GNAQ Q209P in culture (PMID: 22550165).",Actionable,10646,6039,uveal melanoma,DOID,560,GNAQ Q209P,sensitive,913,Selumetinib,2776,22550165,,,
15,Preclinical - Cell culture,"In a preclinical study, Sotrastaurin (AEB071) induced cell-cycle arrest and apoptosis, and decreased viability of a uveal melanoma cell line harboring GNAQ Q209P in culture (PMID: 22653968).",Actionable,10595,6039,uveal melanoma,DOID,560,GNAQ Q209P,sensitive,621,AEB071,2776,22653968,,,
16,Preclinical - Cell culture,"In a preclinical study, TAK-733 inhibited growth of uveal melanoma cell lines harboring GNAQ Q209P in culture (PMID: 22515704). ",Actionable,10623,6039,uveal melanoma,DOID,560,GNAQ Q209P,sensitive,932,TAK-733,2776,22515704,,,
17,Preclinical - Cell culture,"In a preclinical study, Enzastaurin (LY317615) increased cell-cycle arrest and apoptosis and decreased viability of a uveal melanoma cell line harboring GNAQ Q209P in culture (PMID: 22253748).",Actionable,10603,6039,uveal melanoma,DOID,560,GNAQ Q209P,sensitive,1682,Enzastaurin,2776,22253748,,,
0,Clinical Study,"Inactivating mutations in HNF1A (TCF1) are used in the diagnosis of the HCA-H subtype of hepatocellular adenoma (PMID: 25076298, PMID: 26961851, PMID: 25434466).",Diagnostic,3989,50868,hepatocellular adenoma,DOID,16436,HNF1A inact mut,not applicable,1776,N/A,6927,25076298,26961851,25434466,
0,Preclinical,"In a preclinical study, BEZ235 inhibited growth of thyroid cancer cells harboring an HRAS pathway activating mutation in cell culture (PMID: 21831957).",Actionable,1700,1781,thyroid cancer,DOID,2870,HRAS inact mut,sensitive,672,BEZ235,3265,21831957,,,
1,Preclinical - Cell culture,"In a preclinical study, human solid tumor cell lines harboring HRAS mutations demonstrated increased sensitivity to growth inhibition by  Selumetinib (AZD6244) in culture compared to cell lines with wild-type HRAS (PMID: 26544513).",Actionable,9456,10000003,Advanced Solid Tumor,JAX,1208,HRAS mutant,predicted â€“ sensitive,913,Selumetinib,3265,26544513,,,
2,Phase Ib/II,"In a Phase Ib study,  Alpelisib (BYL719) in combination with Binimetinib (MEK162) demonstrated preliminary safety and efficacy in patients with RAS-mutant advanced solid tumors, including patients with ovarian cancer (J Clin Oncol 32:5s, 2014 (suppl; abstr 9051).",Actionable,1689,2394,ovarian cancer,DOID,1208,HRAS mutant,predicted â€“ sensitive,1311,BYL719 + MEK162,3265,None,,,
3,Preclinical,"In a preclinical study, mouse models of bladder cancer harboring an HRAS mutation were sensitive to Glucophage (metformin), resulting in tumor growth reduction and prevention of hyperplasia regression (PMID: 26921394).",Actionable,5174,11054,urinary bladder cancer,DOID,1208,HRAS mutant,sensitive,1031,Metformin,3265,26951660,26921394,,
4,Preclinical,"In a preclinical study, human urinary transitional cell carcinoma cells harboring mutant HRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",Actionable,6737,2671,transitional cell carcinoma,DOID,1208,HRAS mutant,resistant,2,Trametinib,3265,26343583,,,
5,Preclinical - Cell culture,"In a preclinical study, Binimetinib (MEK162) inhibited growth and induced apoptosis in human solid tumor cell lines harboring HRAS mutations in culture (PMID: 26544513).",Actionable,9457,10000003,Advanced Solid Tumor,JAX,1208,HRAS mutant,predicted â€“ sensitive,807,Binimetinib,3265,26544513,,,
6,Phase III,"In a Phase III trial, Cometriq (cabozantinib) treatment resulted in improved progression free survival (47 vs 8 weeks) compared to placebo in thyroid medullary carcinoma patients harboring RAS mutations (PMID: 27525386).",Actionable,10387,3973,thyroid medullary carcinoma,DOID,1208,HRAS mutant,sensitive,998,cabozantinib,3265,27525386,,,
7,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited growth of human endometrial cancer cells harboring mutant HRAS in culture (PMID: 26343583).",Actionable,6692,1380,endometrial cancer,DOID,1208,HRAS mutant,sensitive,2,Trametinib,3265,26343583,,,
8,Preclinical - Cell culture,"In a preclinical study, human solid tumor cell lines harboring HRAS mutations demonstrated increased sensitivity to growth inhibition by Afinitor (everolimus) in culture compared to cell lines with wild-type HRAS (PMID: 26544513).",Actionable,9466,10000003,Advanced Solid Tumor,JAX,1208,HRAS mutant,predicted â€“ sensitive,735,Everolimus,3265,26544513,,,
9,Preclinical - Cell line xenograft,"In a preclinical study, Mekinist (trametinib) inhibited growth of Sprycel (dasatinib)-resistant thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M in culture and in cell line xenograft models (PMID: 27222538).",Actionable,7855,1781,thyroid cancer,DOID,26068,HRAS G13R KRAS G12R SRC T341M,sensitive,2,Trametinib,3265,27222538,,,
10,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) and SCH772984 synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture (PMID: 27222538).",Actionable,7870,1781,thyroid cancer,DOID,26068,HRAS G13R KRAS G12R SRC T341M,sensitive,4601,Dasatinib + SCH772984,3265,27222538,,,
11,Preclinical - Cell line xenograft,"In a preclinical study, Sprycel (dasatinib) and Mekinist (trametinib) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture, and resulted in sustained tumor suppression and prolonged survival in cell line xenograft models (PMID: 27222538).",Actionable,7867,1781,thyroid cancer,DOID,26068,HRAS G13R KRAS G12R SRC T341M,sensitive,4599,Dasatinib + Trametinib,3265,27222538,,,
12,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) inhibited growth of Sprycel (dasatinib)-resistant thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture (PMID: 27222538).",Actionable,7860,1781,thyroid cancer,DOID,26068,HRAS G13R KRAS G12R SRC T341M,sensitive,913,Selumetinib,3265,27222538,,,
13,Preclinical - Cell line xenograft,"In a preclinical study, thyroid cancer cell lines harboring HRAS G13R and KRAS G12R with an acquired SRC T341M mutation demonstrated resistance to Sprycel (dasatinib) in culture and in cell line xenograft models (PMID: 27222538).",Actionable,7839,1781,thyroid cancer,DOID,26068,HRAS G13R KRAS G12R SRC T341M,resistant,717,Dasatinib,3265,27222538,,,
14,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) and Selumetinib (AZD6244) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture (PMID: 27222538).",Actionable,7868,1781,thyroid cancer,DOID,26068,HRAS G13R KRAS G12R SRC T341M,sensitive,4600,Dasatinib + Selumetinib,3265,27222538,,,
15,Preclinical - Cell culture,"In a preclinical study, MK2206 inhibited AKT activation, proliferation, and growth of thyroid cancer cell lines with  PI3K/AKT pathway alterations in culture, including an anaplastic thyroid cancer cell line harboring HRAS G13R (PMID: 21289267).",Actionable,8217,1781,thyroid cancer,DOID,3556,HRAS G13R,sensitive,816,MK2206,3265,21289267,,,
16,Preclinical - Cell culture,"In a preclinical study, Mekinist (trametinib) reduced ERK signaling and inhibited proliferation of a melanoma cell line harboring BRAF G466E and HRAS Q61K in culture (PMID: 28783719).",Actionable,11656,1909,melanoma,DOID,28179,BRAF G466E HRAS Q61K,sensitive,2,Trametinib,3265,28783719,,,
17,Preclinical - Cell culture,"In a preclinical study, the combination of Binimetinib (MEK162) and Afinitor (everolimus) worked synergistically to inhibit growth of transformed cells expressing HRAS Q61L in culture (PMID: 26544513).",Actionable,9481,10000003,Advanced Solid Tumor,JAX,3563,HRAS Q61L,sensitive,5022,Binimetinib + Everolimus,3265,26544513,,,
18,Preclinical - Cell line xenograft,"In a preclinical study, Selumetinib (AZD6244) inhibited growth of a lung squamous cell carcinoma cell line harboring HRAS Q61L in culture, and inhibited tumor growth in xenograft models (PMID: 26544513).",Actionable,9458,3907,lung squamous cell carcinoma,DOID,3563,HRAS Q61L,sensitive,913,Selumetinib,3265,26544513,,,
19,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Selumetinib (AZD6244) and Afinitor (everolimus) inhibited growth of a lung squamous cell carcinoma cell line harboring HRAS Q61L in culture, and inhibited tumor growth in xenograft models, with increased efficacy compared to either agent alone (PMID: 26544513).",Actionable,9462,3907,lung squamous cell carcinoma,DOID,3563,HRAS Q61L,sensitive,4901,Everolimus + Selumetinib,3265,26544513,,,
20,Preclinical - Cell culture,"In a preclinical study, the combination of Binimetinib (MEK162) and AZD8055 reduced phosphorylation of ERK and S6 and worked synergistically to inhibit growth of a lung squamous cell carcinoma cell line harboring HRAS Q61L in culture (PMID: 26544513).",Actionable,9467,3907,lung squamous cell carcinoma,DOID,3563,HRAS Q61L,sensitive,5023,AZD8055 + Binimetinib,3265,26544513,,,
21,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing HRAS Q61L demonstrated sensitivity to growth inhibition by Afinitor (everolimus) in culture (PMID: 26544513).",Actionable,9474,10000003,Advanced Solid Tumor,JAX,3563,HRAS Q61L,sensitive,735,Everolimus,3265,26544513,,,
22,Preclinical - Cell line xenograft,"In a preclinical study, PLX7904 did not stimulate growth of Zelboraf (vemurafenib)-induced cutaneous squamous cell carcinoma cells harboring HRAS Q61L in culture or in cell line xenograft models (PMID: 26466569).",Actionable,7902,3151,skin squamous cell carcinoma,DOID,3563,HRAS Q61L,no benefit,4606,PLX7904,3265,26466569,,,
23,Preclinical - Cell culture,"In a preclinical study, the combination of Binimetinib (MEK162) and Afinitor (everolimus) reduced phosphorylation of ERK and S6 and worked synergistically to inhibit growth of a lung squamous cell carcinoma cell line harboring HRAS Q61L in culture (PMID: 26544513).",Actionable,9463,3907,lung squamous cell carcinoma,DOID,3563,HRAS Q61L,sensitive,5022,Binimetinib + Everolimus,3265,26544513,,,
24,Preclinical - Cell culture,"In a preclinical study, BKM120 did not inhibit growth of a lung squamous cell carcinoma cell line harboring HRAS Q61L in culture (PMID: 26544513)",Actionable,9459,3907,lung squamous cell carcinoma,DOID,3563,HRAS Q61L,no benefit,680,BKM120,3265,26544513,,,
25,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing HRAS Q61L demonstrated sensitivity to growth inhibition by Binimetinib (MEK162) in culture (PMID: 26544513). ",Actionable,9478,10000003,Advanced Solid Tumor,JAX,3563,HRAS Q61L,sensitive,807,Binimetinib,3265,26544513,,,
26,Preclinical - Cell culture,"In a preclinical study, bladder carcinoma cells expressing HRAS Q61L demonstrated sensitivity to NS1, resulting in inhibition of Mapk signaling and cell proliferation in culture (PMID: 27820802). ",Actionable,9780,4007,bladder carcinoma,DOID,3563,HRAS Q61L,sensitive,5228,NS1,3265,27820802,,,
27,Preclinical - Cell line xenograft,"In a preclinical study, Rapamune (sirolimus) worked synergistically with Mekinist (trametinib) to inhibit proliferation of head and neck squamous carcinoma cell lines harboring HRAS Q61L in culture and to reduce tumor growth in cell line xenograft models (PMID: 26882569).",Actionable,4687,5520,head and neck squamous cell carcinoma,DOID,3563,HRAS Q61L,sensitive,3596,Sirolimus + Trametinib,3265,26882569,,,
28,Preclinical - Cell culture,"In a preclinical study, the combination of Binimetinib (MEK162) and Afinitor (everolimus) worked synergistically to inhibit growth of transformed cells expressing HRAS G12V in culture (PMID: 26544513).",Actionable,9480,10000003,Advanced Solid Tumor,JAX,2794,HRAS G12V,sensitive,5022,Binimetinib + Everolimus,3265,26544513,,,
29,Preclinical,"In a preclinical study, tumor cells expressing HRAS G12V demonstrated resistance to treatment with Erbitux (cetuximab) (PMID: 22797062).",Actionable,1692,10000003,Advanced Solid Tumor,JAX,2794,HRAS G12V,resistant,694,Cetuximab,3265,22797062,,,
30,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing HRAS G12V demonstrated sensitivity to growth inhibition by Afinitor (everolimus) in culture (PMID: 26544513).",Actionable,9476,10000003,Advanced Solid Tumor,JAX,2794,HRAS G12V,sensitive,735,Everolimus,3265,26544513,,,
31,Preclinical - Cell line xenograft,"In a preclinical study, SF1126 inhibited Akt activation, proliferation, and migration of transgenic mouse glioma cells expressing HRAS G12V in culture, and suppressed tumor growth in xenograft models (PMID: 25425962).",Actionable,5211,3070,malignant glioma,DOID,2794,HRAS G12V,sensitive,915,SF1126,3265,25425962,,,
32,Preclinical - Cell culture,"In a preclinical study, Estybon (rigosertib) inhibited oncogenic transformation in fibroblast cells over-expressing HRAS G12V in culture (PMID: 27104980).",Actionable,8554,10000003,Advanced Solid Tumor,JAX,2794,HRAS G12V,sensitive,1046,rigosertib,3265,27104980,,,
33,Preclinical - Cell culture,"In a preclinical study, the combination of Binimetinib (MEK162) and Afinitor (everolimus) reduced phosphorylation of ERK and S6 and worked synergistically to inhibit growth of a bladder cell line harboring HRAS G12V in culture (PMID: 26544513).",Actionable,9464,11054,urinary bladder cancer,DOID,2794,HRAS G12V,sensitive,5022,Binimetinib + Everolimus,3265,26544513,,,
34,Preclinical,"In a preclinical study, tumor cells expressing HRAS G12V demonstrated resistance to treatment with Vectibix (panitumumab) (PMID: 22797062).",Actionable,1693,10000003,Advanced Solid Tumor,JAX,2794,HRAS G12V,resistant,845,Panitumumab,3265,22797062,,,
35,Preclinical - Cell culture,"In a preclinical study, the combination of Selumetinib (AZD6244) and Afinitor (everolimus) reduced phosphorylation of ERK and S6 and worked synergistically to inhibit growth of a bladder cancer cell line harboring HRAS G12V in culture (PMID: 26544513).",Actionable,9465,11054,urinary bladder cancer,DOID,2794,HRAS G12V,sensitive,4901,Everolimus + Selumetinib,3265,26544513,,,
36,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing HRAS G12V demonstrated sensitivity to growth inhibition by Binimetinib (MEK162) in culture (PMID: 26544513).",Actionable,9479,10000003,Advanced Solid Tumor,JAX,2794,HRAS G12V,sensitive,807,Binimetinib,3265,26544513,,,
37,Preclinical,In a preclinical study CI-1040 (PD-184352) inhibited melanoma progression in a transgenic zebrafish model of melanoma expressing HRAS G12V (PMID: 26267534).,Actionable,5784,1909,melanoma,DOID,2794,HRAS G12V,sensitive,699,CI-1040,3265,26267534,,,
38,Preclinical - Cell line xenograft,"In a preclinical study, Pz-1 reduced tumor growth in xenograft models of transformed cells over expressing HRAS G12V in a dose-dependent manner (PMID: 26126987).",Actionable,6193,10000003,Advanced Solid Tumor,JAX,2794,HRAS G12V,sensitive,4089,Pz-1,3265,26126987,,,
39,Preclinical,"In a preclinical study, urothelial cancer cells with low expression of wild-type FGFR3 that harbored HRAS G12V demonstrated resistance to PD173074 in culture (PMID: 22869148).",Actionable,3278,2671,transitional cell carcinoma,DOID,13021,FGFR3 wild-type FGFR3 dec exp HRAS G12V,resistant,2948,PD173074,3265,22869148,,,
40,Preclinical,"In a preclinical study, urothelial cancer cells with low expression of wild-type FGFR3 that harbored HRAS G12V demonstrated resistance to AZD4547 in culture (PMID: 22869148).",Actionable,2576,2671,transitional cell carcinoma,DOID,13021,FGFR3 wild-type FGFR3 dec exp HRAS G12V,resistant,654,AZD4547,3265,22869148,,,
41,Preclinical,"In a preclinical study, urothelial cancer cells with low expression of wild-type FGFR3 that harbored HRAS G12V demonstrated resistance to AZ8010 in culture (PMID: 22869148).",Actionable,2575,2671,transitional cell carcinoma,DOID,13021,FGFR3 wild-type FGFR3 dec exp HRAS G12V,decreased response,2955,AZ8010,3265,22869148,,,
42,Preclinical,"In a preclinical study, the farnesyltransferase inhibitor FTI-277 sensitized Hras transformed rat fibroblasts to radiation therapy (PMID: 8620483).",Actionable,1299,162,cancer,DOID,575,HRAS wild-type,predicted â€“ sensitive,1683,FTI-277,3265,8620483,,,
43,Preclinical,"In a preclinical study, E6201 inhibited proliferation of several melanoma cell lines in culture and hypersensitivity was associated with wild-type HRAS (PMID: 23039341).",Actionable,5626,1909,melanoma,DOID,575,HRAS wild-type,sensitive,1011,E6201,3265,23039341,,,
44,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) and Selumetinib (AZD6244) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture (PMID: 27222538).",Actionable,7865,1781,thyroid cancer,DOID,26080,HRAS G12R KRAS G13R,sensitive,4600,Dasatinib + Selumetinib,3265,27222538,,,
45,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) inhibited growth of thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture (PMID: 27222538).",Actionable,7858,1781,thyroid cancer,DOID,26080,HRAS G12R KRAS G13R,sensitive,913,Selumetinib,3265,27222538,,,
46,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) and Mekinist (trametinib) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture (PMID: 27222538).",Actionable,7864,1781,thyroid cancer,DOID,26080,HRAS G12R KRAS G13R,sensitive,4599,Dasatinib + Trametinib,3265,27222538,,,
47,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) and SCH772984 synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture (PMID: 27222538).",Actionable,7866,1781,thyroid cancer,DOID,26080,HRAS G12R KRAS G13R,sensitive,4601,Dasatinib + SCH772984,3265,27222538,,,
48,Preclinical - Cell line xenograft,"In a preclinical study, Mekinist (trametinib) inhibited growth of thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture and in cell line xenograft models (PMID: 27222538).",Actionable,7854,1781,thyroid cancer,DOID,26080,HRAS G12R KRAS G13R,sensitive,2,Trametinib,3265,27222538,,,
49,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing HRAS Q61R demonstrated sensitivity to growth inhibition by Binimetinib (MEK162) in culture (PMID: 26544513). ",Actionable,9477,10000003,Advanced Solid Tumor,JAX,3564,HRAS Q61R,sensitive,807,Binimetinib,3265,26544513,,,
50,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing HRAS Q61R demonstrated sensitivity to growth inhibition by Afinitor (everolimus) in culture (PMID: 26544513).",Actionable,9475,10000003,Advanced Solid Tumor,JAX,3564,HRAS Q61R,sensitive,735,Everolimus,3265,26544513,,,
51,Preclinical,"In a preclinical study, PD173074 inhibited Fgfr3 signaling, induced cell-cycle arrest, and decreased proliferation of multiple myeloma cells harboring HRAS H117E and over expression of FGFR3 K650E in culture (PMID: 22869148).",Actionable,2578,9538,multiple myeloma,DOID,13017,FGFR3 K650E FGFR3 over exp HRAS K117E,sensitive,2948,PD173074,3265,22869148,,,
52,Preclinical,"In a preclinical study, AZ8010 inhibited Fgfr3 signaling and decreased proliferation of myeloma cells with HRAS K117E and overexpression of FGFR3 K650E in culture (PMID: 22869148).",Actionable,2571,70004,myeloid neoplasm,DOID,13017,FGFR3 K650E FGFR3 over exp HRAS K117E,sensitive,2955,AZ8010,3265,22869148,,,
0,Preclinical,"In a preclinical study, BAY 1436032 inhibited growth of transformed cell lines over expressing IDH1 R132X in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2645).",Actionable,5927,10000003,Advanced Solid Tumor,JAX,10006,IDH1 R132X,sensitive,3987,BAY 1436032,3417,None,,,
1,Phase I,"In a Phase I trial, IDH305 treatment resulted in objective response in 33% (7/21) of acute myeloid leukemia patients harboring IDH1 R132 mutations, including complete remission in 3 (14%) and partial remission in 4 (19%) patients (Blood 2016 128 (22):1073).",Actionable,10000,9119,acute myeloid leukemia,DOID,10006,IDH1 R132X,sensitive,2981,IDH305,3417,None,,,
2,Phase I,"In a Phase I trial, IDH305 demonstrated safety and preliminary efficacy in patients with advanced solid tumors harboring IDH1 R132 mutations (Blood 2016 128 (22):1073).",Actionable,4403,10000003,Advanced Solid Tumor,JAX,10006,IDH1 R132X,predicted â€“ sensitive,2981,IDH305,3417,None,,,
3,Phase I,"In a Phase I trial, IDH305 demonstrated safety and preliminary efficacy in patients with glioms harboring IDH1 R132 mutations (Blood 2016 128 (22):1073).",Actionable,9999,3070,malignant glioma,DOID,10006,IDH1 R132X,predicted â€“ sensitive,2981,IDH305,3417,None,,,
4,Preclinical,"In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH1 R132S demonstrated increased sensitivity to Saracatinib (AZD0530) induced growth inhibition compared to IDH1 wild-type cells in culture (PMID: 27231123).",Actionable,7348,4928,intrahepatic cholangiocarcinoma,DOID,5018,IDH1 R132S,sensitive,912,Saracatinib,3417,27231123,,,
5,Preclinical - Patient cell culture,"In a preclinical study, BAY1436032 decreased (R)-2-hydroxyglutarate (R-2HG) levels, and inhibited growth and increased differentiation of patient-derived acute myeloid leukemia cells harboring IDH1 R132S in culture (PMID: 28232670).",Actionable,10940,9119,acute myeloid leukemia,DOID,5018,IDH1 R132S,sensitive,5698,BAY1436032,3417,28232670,,,
6,Preclinical,"In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH1 R132S demonstrated increased sensitivity to Sprycel (dasatinib) induced growth inhibition compared to IDH1 wild-type cells in culture (PMID: 27231123).",Actionable,7347,4928,intrahepatic cholangiocarcinoma,DOID,5018,IDH1 R132S,sensitive,717,Dasatinib,3417,27231123,,,
7,Preclinical,"In a preclinical study, colorectal cancer cells expressing IDH1 R132H were resistant to radiotherapy when treated with AGI-5198 (PMID: 26363012).",Actionable,5556,9256,colorectal cancer,DOID,1253,IDH1 R132H,resistant,3895,AGI-5198 + Radiotherapy,3417,26363012,,,
8,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing IDH1 R132H demonstrated increased sensitivity to Zejula (niraparib)-induced growth inhibition in culture (PMID: 28148839).",Actionable,9946,10000003,Advanced Solid Tumor,JAX,1253,IDH1 R132H,sensitive,832,Niraparib,3417,28148839,,,
9,Phase II,"In a Phase II trial, Caprelsa (vandetinib), in combination with Temodar (temozolomide) and radiation therapy, demonstrated a significant increase in PFS and OS in glioblastoma patients harboring IDH1 R132H compared to glioblastoma patients without IDH1 R132H (PMID: 25910950). ",Actionable,3237,3068,glioblastoma multiforme,DOID,1253,IDH1 R132H,sensitive,3094,Vandetanib + Temozolomide,3417,25910950,,,
10,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing IDH1 R132H demonstrated increased sensitivity to Rubraca (rucaparib)-induced growth inhibition in culture (PMID: 28148839).",Actionable,9948,10000003,Advanced Solid Tumor,JAX,1253,IDH1 R132H,sensitive,906,Rucaparib,3417,28148839,,,
11,Preclinical - Cell line xenograft,"In a preclinical study, AGI-5198 inhibited growth of a glioma cell line harboring IDH1 R132H in culture and in xenograft models (PMID: 23558169).",Actionable,2071,3070,malignant glioma,DOID,1253,IDH1 R132H,sensitive,2569,AGI-5198,3417,23558169,,,
12,Preclinical,"In a preclinical study, colorectal carcinoma cells expressing IDH1 R132H were sensitive to Glucophage (metformin), resulting in decreased cell proliferation in culture (PMID: 26363012). ",Actionable,5180,9256,colorectal cancer,DOID,1253,IDH1 R132H,sensitive,1031,Metformin,3417,26363012,,,
13,Preclinical,"In a preclinical study, long-term treatment with Vidaza (azacitidine) resulted in increased cellular differentiation, decreased proliferation, and tumor regression in a patient-derived xenograft (PDX) model of anaplastic astrocytoma harboring IDH1 R132H (PMID: 24077805).",Actionable,849,3078,grade III astrocytoma,DOID,1253,IDH1 R132H,sensitive,651,Azacitidine,3417,24077805,,,
14,Preclinical - Patient cell culture,"In a preclinical study, patient-derived glioma cells harboring IDH1 R132H demonstrated increased sensitivity to Talazoparib (BMN-673)-induced growth inhibition in culture (PMID: 28148839).",Actionable,9939,3070,malignant glioma,DOID,1253,IDH1 R132H,sensitive,682,Talazoparib,3417,28148839,,,
15,Preclinical,"In a preclinical study, colorectal cancer cells harboring IDH1 R132H demonstrated increased cell proliferation when treated with a combination of Glucophage (metformin) and AGI-5198 (PMID: 26363012). ",Actionable,5230,9256,colorectal cancer,DOID,1253,IDH1 R132H,resistant,3784,Metformin + AGI-5198,3417,26363012,,,
16,Preclinical - Pdx & cell culture,"In a preclinical study, Dacogen (decitabine) decreased colony formation and tumor growth in patient derived xenograft (PDX) models of patient derived oligodendroglioma cells with IDH1 R132H mutations and co-deletion of 1p and 19q (PMID: 24077826).",Actionable,846,3181,oligodendroglioma,DOID,1253,IDH1 R132H,sensitive,650,Decitabine,3417,24077826,,,
17,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing IDH1 R132H demonstrated increased sensitivity to Lynparza (olaparib)-induced growth inhibition in culture (PMID: 28148839).",Actionable,9943,10000003,Advanced Solid Tumor,JAX,1253,IDH1 R132H,sensitive,837,Olaparib,3417,28148839,,,
18,Preclinical - Cell culture,"In a preclinical study, colon carcinoma cells over expressing IDH1 R132H demonstrated increased sensitivity to Lynparza (olaparib)-induced growth inhibition in culture (PMID: 28148839).",Actionable,9942,1520,colon carcinoma,DOID,1253,IDH1 R132H,sensitive,837,Olaparib,3417,28148839,,,
19,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing IDH1 R132H demonstrated increased sensitivity to VX-970-induced growth inhibition in culture (PMID: 28148839).",Actionable,9941,10000003,Advanced Solid Tumor,JAX,1253,IDH1 R132H,sensitive,2879,VX-970,3417,28148839,,,
20,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing IDH1 R132H demonstrated increased sensitivity to Talazoparib (BMN-673)-induced growth inhibition in culture (PMID: 28148839).",Actionable,9938,10000003,Advanced Solid Tumor,JAX,1253,IDH1 R132H,sensitive,682,Talazoparib,3417,28148839,,,
21,Preclinical - Cell culture,"In a preclinical study, Talazoparib (BMN-673) and Cisplatin synergistically inhibited growth of transformed cells over expressing IDH1 R132H in culture (PMID: 28148839).",Actionable,9949,10000003,Advanced Solid Tumor,JAX,1253,IDH1 R132H,sensitive,5324,Cisplatin + Talazoparib,3417,28148839,,,
22,Preclinical - Cell culture,"In a preclinical study, colon carcinoma cells over expressing IDH1 R132H demonstrated increased sensitivity to Talazoparib (BMN-673)-induced growth inhibition in culture (PMID: 28148839).",Actionable,9937,1520,colon carcinoma,DOID,1253,IDH1 R132H,sensitive,682,Talazoparib,3417,28148839,,,
23,Preclinical - Patient cell culture,"In a preclinical study, BAY1436032 decreased (R)-2-hydroxyglutarate (R-2HG) levels, and inhibited growth and increased differentiation of patient-derived acute myeloid leukemia cells harboring IDH1 R132H in culture (PMID: 28232670).",Actionable,10936,9119,acute myeloid leukemia,DOID,1253,IDH1 R132H,sensitive,5698,BAY1436032,3417,28232670,,,
24,Preclinical - Cell culture,"In a preclinical study, AGI-5198 reverted the sensitivity of transformed cells over expressing IDH1 R132H to Talazoparib (BMN-673)-induced growth inhibition in culture (PMID: 28148839).",Actionable,9950,10000003,Advanced Solid Tumor,JAX,1253,IDH1 R132H,decreased response,5325,AGI-5198 + Talazoparib,3417,28148839,,,
25,Preclinical - Cell culture,"In a preclinical study, a glioma cell line expressing IDH1 R132H demonstrated increased sensitivity to growth inhibition by BPTES compared to a cell line expressing wild-type IDH1 in culture (PMID: 21045145).",Actionable,9755,3070,malignant glioma,DOID,1253,IDH1 R132H,sensitive,5194,BPTES,3417,21045145,,,
26,Preclinical - Patient cell culture,"In a preclinical study, BAY1436032 decreased (R)-2-hydroxyglutarate (R-2HG) levels, and inhibited growth and increased differentiation of patient-derived acute myeloid leukemia cells harboring IDH1 R132L in culture (PMID: 28232670).",Actionable,10937,9119,acute myeloid leukemia,DOID,5017,IDH1 R132L,sensitive,5698,BAY1436032,3417,28232670,,,
27,Preclinical - Pdx & cell culture,"In a preclinical study, BAY1436032 decreased R-2HG levels and inhibited growth of primary acute myeloid leukemia (AML) cells harboring IDH1 R132C in culture, and decreased blast number and increased survival of two AML patient-derived xenograft (PDX) models, one which harbored additional alterations in FLT3, NPM1, and NRAS and one which harbored a KMT2A (MLL) alteration (PMID: 28232670).",Actionable,10939,9119,acute myeloid leukemia,DOID,1252,IDH1 R132C,sensitive,5698,BAY1436032,3417,28232670,,,
28,Preclinical - Cell line xenograft,"In a preclinical study, Lynparza (olaparib) treatment delayed tumor growth in cell line xenograft models of sarcoma harboring IDH1 R132C (PMID: 28148839).",Actionable,9945,1115,sarcoma,DOID,1252,IDH1 R132C,sensitive,837,Olaparib,3417,28148839,,,
29,Preclinical,"In a preclinical study, Sprycel (dasatinib)  inhibited growth of intrahepatic cholangiocarcinoma cells harboring IDH1 R132C in culture, and suppressed tumor growth in PDX models (PMID: 27231123).",Actionable,7350,4928,intrahepatic cholangiocarcinoma,DOID,1252,IDH1 R132C,sensitive,717,Dasatinib,3417,27231123,,,
30,Preclinical,"In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH1 R132C demonstrated increased sensitivity to Saracatinib (AZD0530) induced growth inhibition compared to IDH1 wild-type cells in culture (PMID: 27231123).",Actionable,7349,4928,intrahepatic cholangiocarcinoma,DOID,1252,IDH1 R132C,sensitive,912,Saracatinib,3417,27231123,,,
31,Preclinical - Cell culture,"In a preclinical study, AGI-5198 reverted the sensitivity of sarcoma cells harboring IDH1 R132C to Talazoparib (BMN-673)-induced growth inhibition in culture (PMID: 28148839).",Actionable,9951,1115,sarcoma,DOID,1252,IDH1 R132C,decreased response,5325,AGI-5198 + Talazoparib,3417,28148839,,,
32,Preclinical - Cell culture,"In a preclinical study, AGI-5198 reverted the sensitivity of sarcoma cells harboring IDH1 R132C to Lynparza (olaparib)-induced growth inhibition in culture (PMID: 28148839).",Actionable,9952,1115,sarcoma,DOID,1252,IDH1 R132C,decreased response,5326,AGI-5198 + Olaparib,3417,28148839,,,
33,Preclinical - Patient cell culture,"In a preclinical study, patient-derived glioma cells harboring IDH1 R132C demonstrated increased sensitivity to Talazoparib (BMN-673)-induced growth inhibition in culture (PMID: 28148839).",Actionable,9940,3070,malignant glioma,DOID,1252,IDH1 R132C,sensitive,682,Talazoparib,3417,28148839,,,
34,Preclinical,"In a preclinical study, AGI-5198 inhibited growth and promoted differentiation in glioma cells expressing IDH1 R132C (PMID: 23558169).",Actionable,2070,3070,malignant glioma,DOID,1252,IDH1 R132C,sensitive,2569,AGI-5198,3417,23558169,,,
35,Preclinical,"In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH1 R132S acquired resistance to Sprycel (dasatinib) after over expressing SRC T341I in culture (PMID: 27231123).",Actionable,7355,4928,intrahepatic cholangiocarcinoma,DOID,25297,IDH1 R132C SRC T341I,resistant,717,Dasatinib,3417,27231123,,,
36,Preclinical - Patient cell culture,"In a preclinical study, BAY1436032 decreased (R)-2-hydroxyglutarate (R-2HG) levels and increased differentiation of patient-derived acute myeloid leukemia cells harboring IDH1 R132G in culture (PMID: 28232670).",Actionable,10944,9119,acute myeloid leukemia,DOID,1256,IDH1 R132G,sensitive,5698,BAY1436032,3417,28232670,,,
37,Phase I,"In a Phase I trial, Gemzar (gemcitabine) plus radiation therapy resulted in median overall survival of 73.5 months in 7 high-grade glioma patients with IDH mutated, non-codeleted tumors with ATRX loss (PMID: 26853339).",Actionable,6205,3070,malignant glioma,DOID,22833,ATRX loss IDH1 mutant,predicted â€“ sensitive,4093,Gemcitabine + Radiotherapy,3417,26853339,,,
38,Clinical Study,"In two meta-analyses, IDH1 mutations were associated with a worse overall survival in patients with acute myeloid leukemia (PMID: 22616558, PMID: 23226625).",Prognostic,6076,9119,acute myeloid leukemia,DOID,1781,IDH1 mutant,not applicable,1776,N/A,3417,22616558,23226625,,
39,Preclinical,"In a preclinical study, BAY 1436032 inhibited growth of transformed cell lines over expressing mutant IDH1 in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2645).",Actionable,5926,10000003,Advanced Solid Tumor,JAX,1781,IDH1 mutant,sensitive,3987,BAY 1436032,3417,None,,,
40,Phase I,"In a Phase I clinical trial, treatment with AG-120 reduced R-2-hydroxy-glutarate (2-HG) levels and resulted in partial responses in 41% (7/17) and complete remission in 23% (4/17) of patients with acute myeloid leukemia with IDH1 mutations (PMID: 25583779).",Actionable,2228,9119,acute myeloid leukemia,DOID,1781,IDH1 mutant,sensitive,1491,AG-120,3417,25583779,,,
41,Phase I,"In a Phase I trial, AG-120 demonstrated safety and preliminary efficacy in IDH1 mutant glioma patients ( Neuro Oncol (2016) 18 (suppl 6): vi12.).",Actionable,9361,3070,malignant glioma,DOID,1781,IDH1 mutant,sensitive,1491,AG-120,3417,None,,,
42,Phase II,"In a retrospective analysis of a Phase II trial, IDH1 mutation correlated with favorable overall survival in recurrent glioblastoma patients treated with a combination of  Avastin (bevacizumab) and Lomustine (PMID: 26762204).",Actionable,4332,3068,glioblastoma multiforme,DOID,1781,IDH1 mutant,predicted â€“ sensitive,2118,Bevacizumab + Lomustine,3417,26762204,,,
43,Phase I,"AG-881 is currently in clinical trials in patients with IDH1 mutations and advanced solid tumors (clinicaltrials.gov, Aug 2017). ",Actionable,9225,10000003,Advanced Solid Tumor,JAX,1781,IDH1 mutant,not applicable,2995,AG-881,3417,None,,,
44,Preclinical,"In a preclinical study, lung adenocarcinoma cells harboring IDH1 mutations were resistant to Sprycel (dasatinib) in culture (PMID: 27231123).",Actionable,7352,3910,lung adenocarcinoma,DOID,1781,IDH1 mutant,resistant,717,Dasatinib,3417,27231123,,,
45,Clinical Study,"In multiple clinical studies, including two meta-analyses, IDH1 mutations were associated with a greater overall survival and progression free survival in patients with glioblastoma (PMID: 23904262, PMID: 26945349, PMID: 20560678). ",Prognostic,6031,3068,glioblastoma multiforme,DOID,1781,IDH1 mutant,not applicable,1776,N/A,3417,23904262,26945349,20560678,
46,Preclinical,"In a preclinical study, chondrosarcoma cells harboring IDH1 mutations were resistant to Sprycel (dasatinib) in culture (PMID: 27231123).",Actionable,7351,3371,chondrosarcoma,DOID,1781,IDH1 mutant,resistant,717,Dasatinib,3417,27231123,,,
47,Phase II,"In a Phase II trial, 33% (4/12) of acute myeloid leukemia patients harboring either IDH1 or IDH2 mutations responded to treatment with Venclexta (venetoclax), demonstrating a complete response or complete response with incomplete blood count recovery (PMID: 27520294).",Actionable,8019,9119,acute myeloid leukemia,DOID,1781,IDH1 mutant,predicted â€“ sensitive,1562,Venetoclax,3417,27520294,,,
48,Clinical Study,"In multiple clinical studies, including two meta-analyses, IDH1 mutations were associated with improved overall survival and progression free survival in patients with gliomas (PMID: 23817809, PMID: 26220714, PMID: 23894344). ",Prognostic,6030,3070,malignant glioma,DOID,1781,IDH1 mutant,not applicable,1776,N/A,3417,23817809,26220714,23894344,
49,Clinical Study,"IDH1 mutations are used in the diagnosis of various subtypes of gliomas (PMID: 23041832, PMID: 19755387, PMID: 19915484). ",Diagnostic,6033,3070,malignant glioma,DOID,1781,IDH1 mutant,not applicable,1776,N/A,3417,23041832,19755387,19915484,
50,Phase I,"The Phase I trial of AG-881 in patients with IDH1 mutations and hematological cancers is active and no longer recruiting patients and there are no other trials for AG-881 (clinicaltrials.gov, Aug 2017). ",Actionable,9226,2531,hematologic cancer,DOID,1781,IDH1 mutant,not applicable,2995,AG-881,3417,None,,,
0,Preclinical,"In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH2 R172K and KRAS G12D demonstrated increased sensitivity to Sprycel (dasatinib) induced growth inhibition in culture and in xenograft models (PMID: 27231123).",Actionable,7353,4928,intrahepatic cholangiocarcinoma,DOID,25295,IDH2 R172K KRAS G12D,sensitive,717,Dasatinib,3418,27231123,,,
1,Preclinical,"In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH2 R172K and KRAS G12D demonstrated increased sensitivity to Saracatinib (AZD0530) induced growth inhibition in culture (PMID: 27231123).",Actionable,7354,4928,intrahepatic cholangiocarcinoma,DOID,25295,IDH2 R172K KRAS G12D,sensitive,912,Saracatinib,3418,27231123,,,
2,Preclinical - Cell culture,"In a preclinical study, Enasidenib (AG-221) decreased 2-hydroxyglutarate (2HG) levels in a glioblastoma cell line expressing IDH2 R172K in culture (PMID: 28193778).",Actionable,10741,3068,glioblastoma multiforme,DOID,1255,IDH2 R172K,predicted â€“ sensitive,2982,Enasidenib,3418,28193778,,,
3,Preclinical - Patient cell culture,"In a preclinical study, Enasidenib (AG-221) decreased 2-hydroxyglutarate (2HG) levels and induced differentiation of leukemic blasts from acute myeloid leukemia (AML) patients harboring IDH2 R172K in culture (PMID: 28193778).",Actionable,10739,9119,acute myeloid leukemia,DOID,1255,IDH2 R172K,sensitive,2982,Enasidenib,3418,28193778,,,
4,Preclinical - Cell culture,"In a preclinical study, Enasidenib (AG-221) decreased 2-hydroxyglutarate (2HG) levels in a colorectal carcinoma cell line expressing IDH2 R172K in culture (PMID: 28193778).",Actionable,10742,9256,colorectal cancer,DOID,1255,IDH2 R172K,predicted â€“ sensitive,2982,Enasidenib,3418,28193778,,,
5,Phase II,"In a Phase II trial, an acute myeloid leukemia patient harboring IDH2 D76fs demonstrated sensitivity to treatment with Venclexta (venetoclax), achieving a complete response with incomplete blood count recovery after 24 weeks (PMID: 27520294). ",Actionable,8021,9119,acute myeloid leukemia,DOID,26136,IDH2 D76fs,sensitive,1562,Venetoclax,3418,27520294,,,
6,Preclinical - Cell line xenograft,"In a preclinical study, Enasidenib (AG-221) decreased 2-hydroxyglutarate (2HG) levels in a glioblastoma cell line expressing IDH2 R140Q in culture and in xenograft models (PMID: 28193778).",Actionable,10740,3068,glioblastoma multiforme,DOID,1254,IDH2 R140Q,predicted â€“ sensitive,2982,Enasidenib,3418,28193778,,,
7,Preclinical - Pdx & cell culture,"In a preclinical study, Enasidenib (AG-221) treatment reduced 2-hydroxyglutarate (2HG) levels and induced differentiation of leukemic blasts from acute myeloid leukemia (AML) patients harboring IDH2 R140Q in culture, and decreased 2HG levels and blast percentage and improved survival relative to Cytosar-U (cytarabine) treatment in IDH2 R140Q-mutant primary AML xenograft models (PMID: 28193778).",Actionable,10738,9119,acute myeloid leukemia,DOID,1254,IDH2 R140Q,sensitive,2982,Enasidenib,3418,28193778,,,
8,Preclinical,"In a preclinical study, treatment with AGI-6780 resulted in the differentiation of erythroleukemia and AML cell lines expressing IDH2 R140Q (PMID: 23558173).",Actionable,1138,9119,acute myeloid leukemia,DOID,1254,IDH2 R140Q,sensitive,1585,AGI-6780,3418,23558173,,,
9,Phase I,"In a Phase I study, Enasidenib (AG-221) demonstrated safety and efficacy in patients with hematological cancer harboring IDH2 mutations and included 8 CR, 1 CRp, 3 CRi, and 8 PR (ASH Meeting, Dec 2014, abstract #115).",Actionable,3581,2531,hematologic cancer,DOID,5912,IDH2 mutant,sensitive,2982,Enasidenib,3418,None,,,
10,Phase I,"The Phase I trial of AG-881 in patients with IDH2 mutations and hematological cancers is active and no longer recruiting patients and there are no other trials for AG-881 (clinicaltrials.gov, Aug 2017). ",Actionable,4400,2531,hematologic cancer,DOID,5912,IDH2 mutant,not applicable,2995,AG-881,3418,None,,,
11,Phase II,"In a Phase II trial, 33% (4/12) of acute myeloid leukemia patients harboring either IDH1 or IDH2 mutations responded to treatment with Venclexta (venetoclax), demonstrating a complete response or complete response with incomplete blood count recovery (PMID: 27520294).",Actionable,8020,9119,acute myeloid leukemia,DOID,5912,IDH2 mutant,predicted â€“ sensitive,1562,Venetoclax,3418,27520294,,,
12,FDA approved,"In a Phase I/II trial that supported FDA approval, Idhifa (enasidenib) treatment resulted in an overall response rate of 40.3% (71/176), with a complete remission rate of 19.3% (34/176), and stable disease in 48.3% (85/176) of acute myeloid leukemia patients harboring IDH2 mutations (PMID: 28588020; NCT01915498).",Actionable,11292,9119,acute myeloid leukemia,DOID,5912,IDH2 mutant,sensitive,2982,Enasidenib,3418,28588020,,,
13,Phase I,"AG-881 is currently in clinical trials in patients with IDH2 mutations and advanced solid tumors (clinicaltrials.gov, Aug 2017). ",Actionable,4402,10000003,Advanced Solid Tumor,JAX,5912,IDH2 mutant,not applicable,2995,AG-881,3418,None,,,
14,Preclinical,"In a preclinical study, the combination of Enasidenib (AG-221) and Quizartinib (AC220) stimulated leukemic cell differentiation and reduced leukemic cell self-renewal in an acute myeloid leukemia mouse model simultaneously expressing IDH2 R140Q and a FLT3-ITD mutation (Blood Dec 2014, 124 (21) 437). ",Actionable,3593,9119,acute myeloid leukemia,DOID,13759,IDH2 R140W FLT3 Y599_D600insSTDNEYFYVDFREYEY,predicted â€“ sensitive,3172,Enasidenib + Quizartinib,3418,None,,,
0,Clinical Study,"In multiple clinical studies, including a meta-analysis, IKZF1 deletion was associated with a worse event-free survival and overall survival in patients with acute lymphocytic leukemia (PMID: 25335741, PMID: 26194343, PMID: 27067989).",Prognostic,6168,9952,acute lymphocytic leukemia,DOID,22784,IKZF1 del,not applicable,1776,N/A,10320,25335741,26194343,27067989,
1,Preclinical,"In a preclinical study, Revlimid (lenalidomide) treatment resulted in IKZF1 degradation and decreased proliferation of multiple myeloma cells in culture (PMID: 24292625). ",Actionable,1492,9538,multiple myeloma,DOID,2606,IKZF1 wild-type,sensitive,1164,lenalidomide,10320,24292625,,,
0,Preclinical,"In a preclinical study, immune cells expressing ETV6-JAK2 with the Y918H mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",Actionable,5582,2531,hematologic cancer,DOID,21295,ETV6 - JAK2 JAK2 Y918H,resistant,2797,Pyridone 6,3717,22916261,,,
1,Preclinical,"In a preclinical study, immune cells expressing ETV6-JAK2 with the P1057S mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",Actionable,5580,2531,hematologic cancer,DOID,21293,ETV6 - JAK2 JAK2 P1057S,resistant,2797,Pyridone 6,3717,22916261,,,
2,Preclinical,"In a preclinical study, immune cells expressing ETV6-JAK2 with the G831R mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",Actionable,5576,2531,hematologic cancer,DOID,21289,ETV6 - JAK2 JAK2 G831R,resistant,2797,Pyridone 6,3717,22916261,,,
3,Clinical Study,"In a clinical study, a melanoma patient treated with Keytruda (pembrolizumab) initially demonstrated a partial response, however, post 734 days developed disease progression due to a splice site mutation in JAK2, which resulted in an intron inclusion and an early stop codon (PMID: 27433843). ",Actionable,7476,1909,melanoma,DOID,25521,JAK2 inact mut,predicted â€“ resistant,1447,Pembrolizumab,3717,27433843,,,
4,Preclinical,"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 G935R double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 22271575).",Actionable,2409,2531,hematologic cancer,DOID,7466,JAK2 V617F JAK2 G935R,resistant,907,Ruxolitinib,3717,22271575,,,
5,Preclinical - Cell culture,"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 G935R double mutation demonstrated resistance to NVP-BSK805 in culture (PMID: 22271575).",Actionable,2411,2531,hematologic cancer,DOID,7466,JAK2 V617F JAK2 G935R,resistant,2785,NVP-BSK805,3717,22271575,,,
6,Preclinical,"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 G935R double mutation demonstrated resistance to NVP-BVB808 in culture (PMID: 22271575).",Actionable,2412,2531,hematologic cancer,DOID,7466,JAK2 V617F JAK2 G935R,resistant,2834,NVP-BVB808,3717,22271575,,,
7,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) worked synergistically with SGI-1776 to inhibit proliferation of myeloproliferative cancer cell lines harboring JAK2 V617F in culture (PMID: 26472029).",Actionable,4583,4960,bone marrow cancer,DOID,591,JAK2 V617F,sensitive,3549,Ruxolitinib + SGI-1776,3717,26472029,,,
8,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) worked synergistically with AZD1208 to inhibit proliferation of myeloproliferative cancer cell lines harboring JAK2 V617F  in culture (PMID: 26472029).",Actionable,4584,4960,bone marrow cancer,DOID,591,JAK2 V617F,sensitive,3550,AZD1208 + Ruxolitinib,3717,26472029,,,
9,Preclinical,"In a preclinical study, acute myeloid leukemia cells harboring JAK2 V617F demonstrated sensitivity to A-1155463 in culture (PMID: 25787766).",Actionable,2087,9119,acute myeloid leukemia,DOID,591,JAK2 V617F,sensitive,2576,A-1155463,3717,25787766,,,
10,Preclinical,"In a preclinical study, myeloproliferative cancer cell lines harboring JAK2 V617F demonstrated reduced sensitivity to SGI-1776 induced growth inhibition in culture (PMID: 26472029).",Actionable,4581,4960,bone marrow cancer,DOID,591,JAK2 V617F,decreased response,3533,SGI-1776,3717,26472029,,,
11,Preclinical,"In a preclinical study, RP6530 worked synergistically with Jakafi (ruxolitinib) to inhibit proliferation of Jakafi (ruxolitinib)-resistant erythroleukemia cell lines carrying JAK2 V617F mutation ( Cancer Res August 1, 2015 75; 2704 ).",Actionable,5167,9119,acute myeloid leukemia,DOID,591,JAK2 V617F,sensitive,3765,RP6530 + Ruxolitinib,3717,None,,,
12,Preclinical - Cell culture,"In a preclinical study, transformed mouse myeloid cells over expressing JAK2 V617F were resistant to Gleevec (imatinib) in culture (PMID: 21224473).",Actionable,7413,8692,myeloid leukemia,DOID,591,JAK2 V617F,resistant,770,Imatinib,3717,21224473,,,
13,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and Pictilisib (GDC-0941) synergistically inhibited growth of transformed cell lines over expressing JAK2 V617F in cell culture (PMID: 24251790).",Actionable,5797,10000003,Advanced Solid Tumor,JAX,591,JAK2 V617F,sensitive,3927,GDC-0941 + Ruxolitinib,3717,24251790,,,
14,Preclinical - Cell culture,"In a preclinical study, SHP099 inhibited proliferation of a hematopoietic cancer cell line harboring JAK2 V617F in culture (PMID: 27362227).",Actionable,7516,2531,hematologic cancer,DOID,591,JAK2 V617F,sensitive,4504,SHP099,3717,27362227,,,
15,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and BEZ235 synergistically inhibited growth of transformed cell lines over expressing JAK2 V617F in cell culture (PMID: 24251790).",Actionable,5803,10000003,Advanced Solid Tumor,JAX,591,JAK2 V617F,sensitive,3928,BEZ235 + Ruxolitinib,3717,24251790,,,
16,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and ZSTK474 synergistically inhibited growth of transformed cell lines over expressing JAK2 V617F in cell culture (PMID: 24251790).",Actionable,5790,10000003,Advanced Solid Tumor,JAX,591,JAK2 V617F,sensitive,3926,Ruxolitinib + ZSTK474,3717,24251790,,,
17,Preclinical,"In a preclinical study, myeloproliferative cancer cell lines harboring JAK2 V617F demonstrated reduced sensitivity to AZD1208 induced growth inhibition in culture (PMID: 26472029).",Actionable,4582,4960,bone marrow cancer,DOID,591,JAK2 V617F,decreased response,3224,AZD1208,3717,26472029,,,
18,Preclinical,"In a preclinical study, CHZ868 inhibited proliferation of myeloproliferative neoplasm cells harboring JAK2 V617F , including cells with decreased response to Type I JAK inhibitors following chronic exposure, and decreased mutant allele burden in a mouse polycythemia vera model expressing JAK2 V617F (PMID: 26175413).",Actionable,6061,4960,bone marrow cancer,DOID,591,JAK2 V617F,sensitive,4016,CHZ868,3717,26175413,,,
19,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and TGX-221 synergistically inhibited growth of transformed cell lines over expressing JAK2 V617F in cell culture (PMID: 24251790).",Actionable,5808,10000003,Advanced Solid Tumor,JAX,591,JAK2 V617F,sensitive,3929,Ruxolitinib + TGX-221,3717,24251790,,,
20,Preclinical,"In a preclinical study, Go 6976 inhibited proliferation of cultured acute myeloid leukemia cells expressing the JAK2 V617F mutation (PMID: 16956345).",Actionable,1810,9119,acute myeloid leukemia,DOID,591,JAK2 V617F,sensitive,2343,Go 6976,3717,16956345,,,
21,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and ZSTK474 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790).",Actionable,5788,10000003,Advanced Solid Tumor,JAX,21621,JAK2 V617F MPL wild-type,sensitive,3926,Ruxolitinib + ZSTK474,3717,24251790,,,
22,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and Pictilisib (GDC-0941) synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790).",Actionable,5794,10000003,Advanced Solid Tumor,JAX,21621,JAK2 V617F MPL wild-type,sensitive,3927,GDC-0941 + Ruxolitinib,3717,24251790,,,
23,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and BEZ235 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790).",Actionable,5800,10000003,Advanced Solid Tumor,JAX,21621,JAK2 V617F MPL wild-type,sensitive,3928,BEZ235 + Ruxolitinib,3717,24251790,,,
24,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and TGX-221 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790).",Actionable,5806,10000003,Advanced Solid Tumor,JAX,21621,JAK2 V617F MPL wild-type,sensitive,3929,Ruxolitinib + TGX-221,3717,24251790,,,
25,Preclinical,"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 E985K double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 21926964).",Actionable,2408,2531,hematologic cancer,DOID,7465,JAK2 V617F JAK2 E985K,resistant,907,Ruxolitinib,3717,21926964,,,
26,Preclinical,"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 M929I double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 21926964).",Actionable,2426,2531,hematologic cancer,DOID,7535,JAK2 V617F JAK2 M929I,resistant,907,Ruxolitinib,3717,21926964,,,
27,Preclinical,"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 R938L double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 21926964).",Actionable,2427,2531,hematologic cancer,DOID,7555,JAK2 V617F JAK2 R938L,resistant,907,Ruxolitinib,3717,21926964,,,
28,Preclinical - Cell culture,"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 R938L double mutation demonstrated resistance to fedratinib (SAR302503) in culture (PMID: 21926964).",Actionable,2430,2531,hematologic cancer,DOID,7555,JAK2 V617F JAK2 R938L,resistant,911,SAR302503,3717,21926964,,,
29,Preclinical,"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 R938L double mutation demonstrated resistance to AZD1480 in culture (PMID: 21926964).",Actionable,2431,2531,hematologic cancer,DOID,7555,JAK2 V617F JAK2 R938L,resistant,652,AZD1480,3717,21926964,,,
30,Preclinical,"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 R938L double mutation demonstrated resistance to Momelotinib (CYT387) in culture (PMID: 21926964).",Actionable,2428,2531,hematologic cancer,DOID,7555,JAK2 V617F JAK2 R938L,resistant,823,Momelotinib,3717,21926964,,,
31,Preclinical,"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 R938L double mutation demonstrated resistance to lestauranib in culture (PMID: 21926964).",Actionable,2429,2531,hematologic cancer,DOID,7555,JAK2 V617F JAK2 R938L,resistant,793,Lestaurtinib,3717,21926964,,,
32,Preclinical,"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 I960V double mutation demonstrated resistance to AZD1480 in culture (PMID: 21926964).",Actionable,2418,2531,hematologic cancer,DOID,7470,JAK2 V617F JAK2 I960V,resistant,652,AZD1480,3717,21926964,,,
33,Preclinical,"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 I960V double mutation demonstrated resistance to Lestauranib in culture (PMID: 21926964).",Actionable,2416,2531,hematologic cancer,DOID,7470,JAK2 V617F JAK2 I960V,resistant,793,Lestaurtinib,3717,21926964,,,
34,Preclinical - Cell culture,"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 I960V double mutation demonstrated resistance to Fedratinib (SAR302503) in culture (PMID: 21926964).",Actionable,2417,2531,hematologic cancer,DOID,7470,JAK2 V617F JAK2 I960V,resistant,911,SAR302503,3717,21926964,,,
35,Preclinical,"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 I960V double mutation demonstrated resistance to Momelotinib in culture (PMID: 21926964).",Actionable,2419,2531,hematologic cancer,DOID,7470,JAK2 V617F JAK2 I960V,resistant,823,Momelotinib,3717,21926964,,,
36,Preclinical,"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 I960V double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 21926964).",Actionable,2415,2531,hematologic cancer,DOID,7470,JAK2 V617F JAK2 I960V,resistant,907,Ruxolitinib,3717,21926964,,,
37,Preclinical - Cell culture,"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 E864K double mutation demonstrated resistance to NVP-BSK805 in culture (PMID: 22271575).",Actionable,2404,2531,hematologic cancer,DOID,7462,JAK2 V617F JAK2 E864K,resistant,2785,NVP-BSK805,3717,22271575,,,
38,Preclinical,"In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 E864K double mutation demonstrated resistance to NVP-BVB808 in culture (PMID: 22271575).",Actionable,2405,2531,hematologic cancer,DOID,7462,JAK2 V617F JAK2 E864K,resistant,2834,NVP-BVB808,3717,22271575,,,
39,Preclinical,"In a preclinical study, cells harboring the JAK2 V617F/Y931C double mutation displayed resistance to ATP-competetive JAK inhibitors, such as  Jakafi (Ruxolitinib) (PMID: 21393331).",Actionable,1162,162,cancer,DOID,2065,JAK2 V617F JAK2 Y931C,resistant,907,Ruxolitinib,3717,21393331,,,
40,Preclinical,"In a preclinical study, cells expressing the JAK2 R683G/G935R double mutation demonstrated resistance to Jakafi (Ruxolitinib) in culture (PMID: 22271575).",Actionable,2410,162,cancer,DOID,7468,JAK2 R683G JAK2 G935R,resistant,907,Ruxolitinib,3717,22271575,,,
41,Preclinical,"In a preclinical study, cells expressing the JAK2 R683G/G935R double mutation demonstrated resistance to NVP-BVB808 in culture (PMID: 22271575).",Actionable,2414,162,cancer,DOID,7468,JAK2 R683G JAK2 G935R,resistant,2834,NVP-BVB808,3717,22271575,,,
42,Preclinical - Cell culture,"In a preclinical study, cells expressing the JAK2 R683G/G935R double mutation demonstrated resistance to NVP-BSK805 in culture (PMID: 22271575).",Actionable,2413,162,cancer,DOID,7468,JAK2 R683G JAK2 G935R,resistant,2785,NVP-BSK805,3717,22271575,,,
43,Preclinical,"In a preclinical study, cells expressing the JAK2 R683G/E864K double mutation demonstrated resistance to NVP-BVB808 in culture (PMID: 22271575).",Actionable,2407,162,cancer,DOID,7464,JAK2 R683G JAK2 E864K,resistant,2834,NVP-BVB808,3717,22271575,,,
44,Preclinical - Cell culture,"In a preclinical study, cells expressing the JAK2 R683G/E864K double mutation demonstrated resistance to NVP-BSK805 in culture (PMID: 22271575).",Actionable,2406,162,cancer,DOID,7464,JAK2 R683G JAK2 E864K,resistant,2785,NVP-BSK805,3717,22271575,,,
45,Preclinical,"In a preclinical study, immune cells expressing ETV6-JAK2 with the R975G mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",Actionable,2447,2531,hematologic cancer,DOID,7562,ETV6-JAK2 JAK2 R975G,resistant,2797,Pyridone 6,3717,22916261,,,
46,Preclinical,"In a preclinical study, cells harboring JAK2 Y931C displayed resistance to ATP-competetive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331).",Actionable,1161,162,cancer,DOID,2064,JAK2 Y931C,resistant,907,Ruxolitinib,3717,21393331,,,
47,Preclinical,"In a preclinical study, immune cells expressing ETV6-JAK2 with the V881A mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",Actionable,2448,2531,hematologic cancer,DOID,7564,ETV6-JAK2 JAK2 V881A,resistant,2797,Pyridone 6,3717,22916261,,,
48,Preclinical,"In a preclinical study, immune cells expressing ETV6-JAK2 with the G935R mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",Actionable,5577,2531,hematologic cancer,DOID,21291,ETV6 - JAK2 JAK2 G935R,resistant,2797,Pyridone 6,3717,22916261,,,
49,Preclinical,"In a preclinical study, immune cells expressing ETV6-JAK2 with the E864K mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",Actionable,5575,2531,hematologic cancer,DOID,21290,ETV6 - JAK2 JAK2 E864K,resistant,2797,Pyridone 6,3717,22916261,,,
50,Preclinical,"In a preclinical study, immune cells expressing ETV6-JAK2 with the N909K mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",Actionable,2449,2531,hematologic cancer,DOID,7560,ETV6-JAK2 JAK2 N909K,resistant,2797,Pyridone 6,3717,22916261,,,
51,Preclinical,"In a preclinical study, immune cells expressing ETV6-JAK2 with the M929I mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",Actionable,5579,2531,hematologic cancer,DOID,21292,ETV6 - JAK2 JAK2 M929I,resistant,2797,Pyridone 6,3717,22916261,,,
52,Preclinical,"In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to AZ960 in culture (PMID: 24398328).",Actionable,5587,2531,hematologic cancer,DOID,13666,JAK2 R867Q,decreased response,2786,AZ960,3717,24398328,,,
53,Preclinical - Cell culture,"In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to Fedratinib (SAR302503) in culture (PMID: 24398328).",Actionable,5585,2531,hematologic cancer,DOID,13666,JAK2 R867Q,decreased response,911,SAR302503,3717,24398328,,,
54,Preclinical,"In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to Momelotinib (CYT387) in culture (PMID: 24398328).",Actionable,5588,2531,hematologic cancer,DOID,13666,JAK2 R867Q,decreased response,823,Momelotinib,3717,24398328,,,
55,Preclinical,"In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to Jakafi (ruxolitinib) in culture (PMID: 24398328).",Actionable,5586,2531,hematologic cancer,DOID,13666,JAK2 R867Q,decreased response,907,Ruxolitinib,3717,24398328,,,
56,Preclinical,"In a preclinical study, immune cells expressing JAK2 R867Q demonstrated decreased response to AUY922 in culture (PMID: 24398328).",Actionable,5589,2531,hematologic cancer,DOID,13666,JAK2 R867Q,decreased response,647,AUY922,3717,24398328,,,
57,Preclinical - Pdx,"In a preclinical study, NVP-BSK805 with Abraxane (paclitaxel) inhibited tumor growth in triple-negative breast cancer patient-derived xenograft models with JAK2 amplification (PMID: 27075627).",Actionable,5947,60081,triple-receptor negative breast cancer,DOID,22035,JAK2 amp,sensitive,3991,NVP-BSK805 + paclitaxel,3717,27075627,,,
58,Preclinical - Pdx,"In a preclinical study, NVP-BSK805 inhibited tumor growth in triple-negative breast cancer patient-derived xenograft models harboring JAK2 amplification (PMID: 27075627).",Actionable,5948,60081,triple-receptor negative breast cancer,DOID,22035,JAK2 amp,sensitive,2785,NVP-BSK805,3717,27075627,,,
59,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and ZSTK474 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and Jak2 in cell culture (PMID: 24251790).",Actionable,5787,10000003,Advanced Solid Tumor,JAX,21624,JAK2 over exp MPL over exp,sensitive,3926,Ruxolitinib + ZSTK474,3717,24251790,,,
60,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and BEZ235 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and Jak2 in cell culture (PMID: 24251790).",Actionable,5799,10000003,Advanced Solid Tumor,JAX,21624,JAK2 over exp MPL over exp,sensitive,3928,BEZ235 + Ruxolitinib,3717,24251790,,,
61,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and TGX-221 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and Jak2 in cell culture (PMID: 24251790).",Actionable,5805,10000003,Advanced Solid Tumor,JAX,21624,JAK2 over exp MPL over exp,sensitive,3929,Ruxolitinib + TGX-221,3717,24251790,,,
62,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and Pictilisib (GDC-0941) synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and Jak2 in cell culture (PMID: 24251790).",Actionable,5793,10000003,Advanced Solid Tumor,JAX,21624,JAK2 over exp MPL over exp,sensitive,3927,GDC-0941 + Ruxolitinib,3717,24251790,,,
63,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and BEZ235 synergistically inhibited growth of transformed cell lines over expressing wild-type Jak2 in cell culture (PMID: 24251790).",Actionable,5802,10000003,Advanced Solid Tumor,JAX,21622,JAK2 over exp,sensitive,3928,BEZ235 + Ruxolitinib,3717,24251790,,,
64,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and ZSTK474 synergistically inhibited growth of transformed cell lines over expressing wild-type Jak2 in cell culture (PMID: 24251790).",Actionable,5791,10000003,Advanced Solid Tumor,JAX,21622,JAK2 over exp,sensitive,3926,Ruxolitinib + ZSTK474,3717,24251790,,,
65,Preclinical - Pdx,"In a preclinical study, NVP-BSK805 with Abraxane (paclitaxel) inhibited tumor growth in patient-derived xenograft models of triple-negative breast cancer with JAK2 overexpression (PMID: 27075627).",Actionable,5946,60081,triple-receptor negative breast cancer,DOID,21622,JAK2 over exp,sensitive,3991,NVP-BSK805 + paclitaxel,3717,27075627,,,
66,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and Pictilisib (GDC-0941) synergistically inhibited growth of transformed cell lines over expressing wild-type Jak2 in cell culture (PMID: 24251790).",Actionable,5796,10000003,Advanced Solid Tumor,JAX,21622,JAK2 over exp,sensitive,3927,GDC-0941 + Ruxolitinib,3717,24251790,,,
67,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and TGX-221 synergistically inhibited growth of transformed cell lines over expressing wild-type Jak2 in cell culture (PMID: 24251790).",Actionable,5809,10000003,Advanced Solid Tumor,JAX,21622,JAK2 over exp,sensitive,3929,Ruxolitinib + TGX-221,3717,24251790,,,
68,Preclinical,"In a preclinical study, immune cells expressing ETV6-JAK2 with the R1127K mutation demonstrated resistance to Pyridone 6 (CMP6) in culture (PMID: 22916261).",Actionable,5581,2531,hematologic cancer,DOID,21294,ETV6 - JAK2 JAK2 R1127K,resistant,2797,Pyridone 6,3717,22916261,,,
0,Preclinical - Cell culture,"In a preclinical study, JANEX-1 (WHI-P131) inhibited proliferation of transformed cells expressing JAK3 I87T in culture (PMID: 18397343).",Actionable,11807,10000003,Advanced Solid Tumor,JAX,2192,JAK3 I87T,sensitive,2808,JANEX-1,3718,18397343,,,
1,Preclinical - Cell culture,"In a preclinical study, transformed human cells expressing JAK3 E183G in culture demonstrated decreased cell survival, increased G1 arrest, elevated apoptotic activity, and reduced phosphorylation of Stat5a when treated with Xeljanz (tofacitinib) (PMID: 21821710).",Actionable,10921,10000003,Advanced Solid Tumor,JAX,27858,JAK3 E183G,sensitive,941,Tofacitinib,3718,21821710,,,
2,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing JAK3 V674A demonstrated reduced sensitivity to NIBR3049 in culture (PMID: 26446793).",Actionable,7406,10000003,Advanced Solid Tumor,JAX,7054,JAK3 V674A,decreased response,2809,NIBR3049,3718,26446793,,,
3,Preclinical - Cell culture,"In a preclinical study, Jakafi (ruxolitinib) inhibited Jak3-Stat signaling and cell proliferation in transformed cells over expressing JAK3 V674A in culture (PMID: 26446793).",Actionable,7401,10000003,Advanced Solid Tumor,JAX,7054,JAK3 V674A,sensitive,907,Ruxolitinib,3718,26446793,,,
4,Preclinical - Cell culture,"In a preclinical study, Xeljanz (tofacitinib) inhibited Jak3-Stat signaling and cell proliferation in transformed cells over expressing JAK3 V674A in culture (PMID: 26446793).",Actionable,7407,10000003,Advanced Solid Tumor,JAX,7054,JAK3 V674A,sensitive,941,Tofacitinib,3718,26446793,,,
5,Preclinical,"In a preclinical study, Xeljanz (tofacitinib) treatment converted cells expressing JAK3 V221I from factor-independent to factor-dependent growth in cell culture (PMID: 25146434).",Actionable,1638,10000003,Advanced Solid Tumor,JAX,2791,JAK3 V722I,sensitive,941,Tofacitinib,3718,25146434,,,
6,Preclinical - Cell culture,"In a preclinical study, NIBR3049 inhibited Jak3-Stat signaling and cell proliferation in transformed cells over expressing both JAK3 L857P and Y100A in culture (PMID: 26446793). ",Actionable,7405,10000003,Advanced Solid Tumor,JAX,25374,JAK3 L857P JAK3 Y100A,sensitive,2809,NIBR3049,3718,26446793,,,
7,Preclinical - Cell culture,"In a preclinical study, Xeljanz (tofacitinib) inhibited Jak3-Stat signaling and cell proliferation in transformed cells over expressing both JAK3 L857P and Y100A in culture (PMID: 26446793).",Actionable,7409,10000003,Advanced Solid Tumor,JAX,25374,JAK3 L857P JAK3 Y100A,sensitive,941,Tofacitinib,3718,26446793,,,
8,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing both JAK3 L857P and JAK3 Y100A demonstrated reduced sensitivity to Jakafi (ruxolitinib) in culture (PMID: 26446793).",Actionable,7403,10000003,Advanced Solid Tumor,JAX,25374,JAK3 L857P JAK3 Y100A,decreased response,907,Ruxolitinib,3718,26446793,,,
9,Preclinical,"In a preclinical study, Xeljanz (tofacitinib), a pan-JAK inhibitor, reduced cell viability and increased apoptosis in a JAK3 A572V mutant natural killer/T-cell lymphoma cell line (PMID: 22705984). ",Actionable,1087,50743,mature T-cell and NK-cell lymphoma,DOID,2168,JAK3 A572V,sensitive,941,Tofacitinib,3718,22705984,,,
10,Preclinical - Cell culture,"In a preclinical study, transformed human cells expressing JAK3 A572V in culture demonstrated decreased cell survival, increased G1 arrest, elevated apoptotic activity, and reduced phosphorylation of Stat5a when treated with Xeljanz (tofacitinib) (PMID: 21821710).",Actionable,10922,10000003,Advanced Solid Tumor,JAX,2168,JAK3 A572V,sensitive,941,Tofacitinib,3718,21821710,,,
11,Preclinical - Cell culture,"In a preclinical study, transformed human cells expressing JAK3 R172Q in culture demonstrated decreased cell survival, reduced phosphorylation of Stat5a, and G1 arrest when treated with Xeljanz (tofacitinib) (PMID: 21821710). ",Actionable,10919,10000003,Advanced Solid Tumor,JAX,27856,JAK3 R172Q,sensitive,941,Tofacitinib,3718,21821710,,,
12,Preclinical - Cell culture,"In a preclinical study, Xeljanz (tofacitinib) inhibited Jak3-Stat signaling and cell proliferation in transformed cells over expressing JAK3 L857P in culture (PMID: 26446793). ",Actionable,7408,10000003,Advanced Solid Tumor,JAX,25367,JAK3 L857P,sensitive,941,Tofacitinib,3718,26446793,,,
13,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing JAK3 L857P demonstrated reduced sensitivity to Jakafi (ruxolitinib) in culture (PMID: 26446793).",Actionable,7402,10000003,Advanced Solid Tumor,JAX,25367,JAK3 L857P,decreased response,907,Ruxolitinib,3718,26446793,,,
14,Preclinical - Cell culture,"In a preclinical study, NIBR3049 inhibited Jak3-Stat signaling and cell proliferation in transformed cells over expressing JAK3 L857P in culture (PMID: 26446793).",Actionable,7404,10000003,Advanced Solid Tumor,JAX,25367,JAK3 L857P,sensitive,2809,NIBR3049,3718,26446793,,,
15,Preclinical - Cell culture,"In a preclinical study, transformed human cells expressing JAK3 L156P in culture demonstrated decreased cell survival, increased G1 arrest, and reduced phosphorylation of Stat5a when treated with Xeljanz (tofacitinib) (PMID: 21821710).",Actionable,10920,10000003,Advanced Solid Tumor,JAX,27857,JAK3 L156P,sensitive,941,Tofacitinib,3718,21821710,,,
0,Preclinical - Cell line xenograft,"In a preclinical study, GSK343 inhibited proliferation of KDM6A null urothelial bladder carcinoma cell lines in culture and delayed tumor onset, improved survival in cell line xenograft models (PMID: 28228601).",Actionable,10232,4006,bladder urothelial carcinoma,DOID,27321,KDM6A loss,sensitive,2701,GSK343,7403,28228601,,,
0,Clinical Study,"In clinical case study, a patient with olfactory neuroblastoma harboring EGFR R521K, FGFR2 M186T, KDR Q472H, KDR V297I, and RET M1009T demonstrated sensitivity to the combination of Sutent (sunitinib) and Erbitux (cetuximab), resulting in a complete response (PMID: 27149458).",Actionable,7758,369,olfactory neuroblastoma,DOID,26023,EGFR R521K FGFR2 M186T KDR Q472H KDR V297I RET M1009T,sensitive,4568,Cetuximab + Sunitinib,3791,27149458,,,
1,Preclinical,"In a preclinical study, Anti-VEGFR2 CAR CD8 lymphocytes increased survival of melanoma mouse models (PMID: 23633494).",Actionable,1314,1909,melanoma,DOID,366,KDR wild-type,predicted â€“ sensitive,984,Anti-VEGFR2 CAR CD8 lymphocytes,3791,23633494,,,
2,Phase I,"In a Phase I trial, VEGFR2-169, in combination with Gemzar (gemcitabine), achieved a disease control rate of 67% (12/18) and an improved overall survival time to 8.7 months in pancreatic cancer patients expressing the HLA-A*2402 version of the KDR (VEGFR2) wild-type allele (PMID: 19930156).",Actionable,2555,1793,pancreatic cancer,DOID,366,KDR wild-type,sensitive,2938,VEGFR2-169 + Gemcitabine,3791,19930156,,,
3,Preclinical,"In a preclinical study, Anti-VEGFR2 CAR CD8 lymphocytes, displayed efficacy in inhibiting cell and tumor growth in a variety of solid tumor cell lines and mouse tumor models (PMID: 20978347).",Actionable,1007,10000003,Advanced Solid Tumor,JAX,366,KDR wild-type,predicted â€“ sensitive,984,Anti-VEGFR2 CAR CD8 lymphocytes,3791,20978347,,,
4,Preclinical,"In a preclinical study, Pz-1 inhibited Kdr2 phosphorylation in transformed cells expressing KDR wild-type (PMID: 26126987).",Actionable,6192,10000003,Advanced Solid Tumor,JAX,366,KDR wild-type,predicted â€“ sensitive,4089,Pz-1,3791,26126987,,,
5,Phase I,"In a Phase I trial, Cyramza (ramucirumab), an inhibitor of KDR (VEGFR2), demonstrated safety and efficacy (partial response or stable disease) in patients with advanced solid tumors (PMID: 20048182).",Actionable,1283,10000003,Advanced Solid Tumor,JAX,366,KDR wild-type,predicted â€“ sensitive,886,Ramucirumab,3791,20048182,,,
6,Preclinical,"In a preclinical study, upregulation of Kdr (Vegfr2) was identified in tumors acquired resistance to Sutent (sunitinib) in allograft models of breast cancer (PMID: 28011623). ",Actionable,10041,1612,breast cancer,DOID,20512,KDR over exp,predicted â€“ resistant,930,Sunitinib,3791,28011623,,,
7,Preclinical,"In a preclinical study, cells expressing KDR A1065T were sensitive to Sutent (sunitinib) in culture (PMID: 19723655).",Actionable,1572,10000003,Advanced Solid Tumor,JAX,14289,KDR A1065T,sensitive,930,Sunitinib,3791,19723655,,,
8,Preclinical - Cell culture,"In a preclinical study, cells expressing KDR D717V were sensitive to Sutent (sunitinib) in culture (PMID: 19723655).",Actionable,1573,10000003,Advanced Solid Tumor,JAX,2698,KDR D717V,sensitive,930,Sunitinib,3791,19723655,,,
9,Clinical Study,"In a clinical case study, Stivarga (regorafenib) treatment resulted in durable partial response in a colorectal cancer patient harboring KDR R961W and mutations in APC and KRAS (PMID: 27004155).",Actionable,5559,9256,colorectal cancer,DOID,21268,APC mutant KRAS mutant KDR R961W,sensitive,890,Regorafenib,3791,27004155,,,
10,Phase I,"In a Phase I trial, Lucitanib (E-3810) demonstrated safety and efficacy in patients with FGF-aberrant or angiogenesis-sensitive advanced solid tumors (PMID: 25193991). ",Actionable,1023,10000003,Advanced Solid Tumor,JAX,635,KDR act mut,predicted â€“ sensitive,1029,Lucitanib,3791,25193991,,,
11,Preclinical,"In a preclinical study, Nexavar (sorafenib) demonstrated efficacy in cells expressing KDR activating mutations (PMID: 19723655). ",Actionable,1434,10000003,Advanced Solid Tumor,JAX,635,KDR act mut,sensitive,920,Sorafenib,3791,19723655,,,
12,Phase II,"In a Phase II clinical trial of patients with metastatic urothelial cancer, Sutent (sunitinib) demonstrated limited antitumor activity, warranting further investigation of VEGF pathways as a therapeutic target (PMID: 20142593).",Actionable,974,4006,bladder urothelial carcinoma,DOID,635,KDR act mut,predicted â€“ sensitive,930,Sunitinib,3791,20142593,,,
13,Preclinical,"In a preclinical study, cells expressing KDR activating mutations were sensitive to Sutent (sunitinib) in cell culture (PMID: 19723655).",Actionable,1571,10000003,Advanced Solid Tumor,JAX,635,KDR act mut,sensitive,930,Sunitinib,3791,19723655,,,
14,Preclinical,"In a preclinical study, pancreatic islet endothelial cells were sensitive to TAS-115, resulting in decreased phosphorylation of Vegfr2, and inhibition of cell growth and angiogenesis in culture and mouse models (PMID: 24140932). ",Actionable,5899,1793,pancreatic cancer,DOID,21996,KDR positive,sensitive,3976,TAS-115,3791,24140932,,,
15,Preclinical - Cell line xenograft,"In a preclinical study, Motesanib (AMG 706) inhibited KDR (VEGFR2) phosphorylation, but had minimal activity against RET in a medullary thyroid carcinoma (MTC) cell line harboring RET C634W in culture, however, inhibited both RET and KDR (VEGFR2) phosphorylation and decreased tumor angiogenesis and growth in MTC cell line xenograft models with RET C634W (PMID: 21422803).",Actionable,8334,3973,thyroid medullary carcinoma,DOID,26230,KDR pos RET C634W,predicted â€“ sensitive,824,Motesanib,3791,21422803,,,
16,Phase III,"In a retrospective analysis of a Phase III trial, treatment with Caprelsa (vandetanib) did not correlate with an improved PFS, OS, or objective response rate in non-small cell lung carcinoma patients harboring a KDR amplification nor did it inhibit cell proliferation of the KDR amplified archived tumor cells in culture (PMID: 26578684). ",Actionable,6035,3908,non-small cell lung carcinoma,DOID,3601,KDR amp,no benefit,953,Vandetanib,3791,26578684,,,
17,Preclinical,"In a preclinical study, human melanoma cells harboring KDR (VEGFR2) Q472H demonstrated increased sensitivity to treatment with a VEGFR2 (KDR) function-blocking antibody compared to cells with wild-type KDR (VEGFR), resulting in decreased proliferation and invasion in culture (PMID: 26631613).",Actionable,5324,1909,melanoma,DOID,641,KDR Q472H,sensitive,3842,unspecified VEGFR2 antibody,3791,26631613,,,
0,Phase III,"In a Phase III trial, gastrointestinal stromal tumor patients harboring KIT exon 11 deletions or indels demonstrated improved improved recurrence-free survival (RFS) with 3-year adjuvant Gleevec (imatinib) treatment (5-year RFS, 70%), compared to patients receiving 1-year treatment (5-year RFS, 41.3%) (PMID: 28334365).",Actionable,10902,9253,gastrointestinal stromal tumor,DOID,27851,KIT exon 11 del,predicted â€“ sensitive,770,Imatinib,3815,28334365,,,
1,Preclinical - Pdx & cell culture,"In a preclinical study, a patient derived GIST cell line harboring KIT V560_L576del demonstrated sensitivity to Iclusig (ponatinib) in both culture and PDX models, resulting in phosphorylation inhibition of Akt, Kit, and Erk (PMID: 25239608). ",Actionable,6796,9253,gastrointestinal stromal tumor,DOID,3291,KIT V560_L576del,sensitive,877,Ponatinib,3815,25239608,,,
2,Preclinical - Pdx & cell culture,"In a preclinical study, a patient derived GIST cell line harboring KIT V560_L576del demonstrated sensitivity to Gleevec (imatinib) in both culture and PDX models, resulting in phosphorylation inhibition of Akt, Kit, and Erk (PMID: 25239608). ",Actionable,6797,9253,gastrointestinal stromal tumor,DOID,3291,KIT V560_L576del,sensitive,770,Imatinib,3815,25239608,,,
3,Preclinical,"In a preclinical study, a patient derived GIST cell line co-harboring KIT V560_L576del and KIT V654A demonstrated sensitivity to treatment with Sutent (sunitinib) (PMID: 25239608). ",Actionable,6800,9253,gastrointestinal stromal tumor,DOID,23691,KIT V560_L576del KIT V654A,sensitive,930,Sunitinib,3815,25239608,,,
4,Phase II,"In a Phase II clinical trial, Sprycel (dasatinib) demonstrated preliminary activity in patients with Gleevec (imatinib)-resistant gastrointestinal stromal tumor (GIST), including patients harboring KIT exon 11 mutations, with a partial response rate of 32% (15/47),  median progression-free survival of 2.0 months, and overall survival of 19 months (J Clin Oncol 29: 2011 (suppl; abstr 10006)).",Actionable,8611,9253,gastrointestinal stromal tumor,DOID,19852,KIT exon 11,predicted â€“ sensitive,717,Dasatinib,3815,None,,,
5,Clinical Study,"In a clinical case report, Gleevec (imatinib mesylate) treatment resulted in partial response in a patient with metastasized anal melanoma harboring a 21 base-pair duplication in exon 11 of KIT, reduced pulmonary metastasis by 60% (PMID: 20372153). ",Actionable,8613,1909,melanoma,DOID,19852,KIT exon 11,predicted â€“ sensitive,770,Imatinib,3815,20372153,,,
6,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Gleevec (imatinib) and MK2206 increased growth inhibition and decreased viability of gastrointestinal stromal tumor (GIST) cell lines harboring KIT exon 11 mutations in culture, and improved survival and inhibited tumor growth in a KIT exon 11-mutant GIST cell line xenograft model, with increased efficacy compared to either agent alone (PMID: 27370604).",Actionable,9688,9253,gastrointestinal stromal tumor,DOID,19852,KIT exon 11,sensitive,5163,Imatinib + MK2206,3815,27370604,,,
7,Phase III,"In a Phase III trial, a 24 month progression free survival was observed in 69.6% of advanced GIST patients harboring KIT exon 11 mutations when treated with Tasigna (nilotinib) (J Clin Oncol May 2013 vol. 31 no. 15_suppl 10501).",Actionable,8612,9253,gastrointestinal stromal tumor,DOID,19852,KIT exon 11,sensitive,829,Nilotinib,3815,None,,,
8,Phase II,"In a Phase II clinical trial, treatment with Stivarga (regorafenib) resulted in a clinical benefit rate of 76% (25/33), a median progression-free survival (PFS) of 13.2 months, and a median overall survival of 25 months in patients with gastrointestinal stromal tumors, with patients with KIT exon 11 mutations demonstrating the longest PFS of 13.4 months (PMID: 27371698).",Actionable,8574,9253,gastrointestinal stromal tumor,DOID,19852,KIT exon 11,sensitive,890,Regorafenib,3815,27371698,,,
9,Preclinical - Cell culture,"In a preclinical study, treatment with the combination of XAV939 and Gleevec (imatinib) resulted in decreased viability of gastrointestinal stromal tumor (GIST) cell lines harboring KIT exon 11 mutations compared to Gleevec (imatinib) alone, in culture (PMID: 28611108).",Actionable,11960,9253,gastrointestinal stromal tumor,DOID,19852,KIT exon 11,sensitive,6214,Imatinib + XAV939,3815,28611108,,,
10,Phase III,"In a Phase III trial, Gleevec (imatinib) treatment resulted in longer overall survival (OS) (66 vs 40 months) in gastrointestinal stromal tumor (GIST) patients harboring KIT exon 11 mutations compared to KIT and PDGFRA wild-type patients, while subtypes of KIT exon  11 mutations (deletion, insertation/duplication, point mutation) did not affect OS outcome (PMID: 28196207; NCT00009906).",Actionable,11705,9253,gastrointestinal stromal tumor,DOID,19852,KIT exon 11,sensitive,770,Imatinib,3815,28196207,,,
11,Phase III,"In a Phase III trial, a long-term analysis of gastrointestinal stromal tumor (GIST) patients treated with Gleevec (imatinib) demonstrated patients harboring KIT exon 11 mutations had a median progression-free survival of 39.4 months, and median overall survival was not reached, with 69.1% of patients with KIT exon 11 mutations alive at 5 years (PMID: 26687836; NCT00367861).",Actionable,8571,9253,gastrointestinal stromal tumor,DOID,19852,KIT exon 11,sensitive,770,Imatinib,3815,26687836,,,
12,Phase II,"In a Phase II trial, Iclusig (ponatinib) treatment resulted in partial response in 7% (2/27), stable disease in 59% (16/27), a median progression free survival of 4.3 months and a median overall survival of 15.0 months in gastrointestinal stromal tumor patients harboring KIT exon 11 mutations after prior tyrosine kinase inhibitor treatment failure (J Clin Oncol 33, 2015 (suppl; abstr 10535)).",Actionable,8608,9253,gastrointestinal stromal tumor,DOID,19852,KIT exon 11,predicted â€“ sensitive,877,Ponatinib,3815,None,,,
13,Clinical Study,"In a retrospective analysis, GIST patients with KIT exon 11 mutations showed decreased benefit compared to patients with exon 9 mutations, with median PFS of 7.0 months with exon 11 mutations vs. 12.3 months with exon 9 mutations, and an ORR of 6% (9/143) vs. 19% (8/42) following treatment with Sutent (sunitinib) (PMID: 26772734).",Actionable,5010,9253,gastrointestinal stromal tumor,DOID,19852,KIT exon 11,decreased response,930,Sunitinib,3815,26772734,,,
14,Phase II,"In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41), which included a partial response of 38.5% (10/26) and a progression free survival of 5.4 months in melanoma patients harboring KIT exon 11 mutations (PMID: 28327988). ",Actionable,11229,1909,melanoma,DOID,19852,KIT exon 11,sensitive,829,Nilotinib,3815,28327988,,,
15,Phase II,"In a Phase II trial, Tasigna (nilotinib) treatment resulted in complete response in 5% (1/19) and partial response in 21% (4/19) of melanoma patients harboring KIT exon 11 or exon 13 mutations (PMID: 28843487; NCT01168050).",Actionable,11854,1909,melanoma,DOID,19852,KIT exon 11,sensitive,829,Nilotinib,3815,28843487,,,
16,Preclinical - Cell culture,"In a preclinical study, treatment with the combination of PKF118-310 and Gleevec (imatinib) resulted in decreased viability of gastrointestinal stromal tumor (GIST) cell lines harboring KIT exon 11 mutations compared to Gleevec (imatinib) alone, in culture (PMID: 28611108).",Actionable,11959,9253,gastrointestinal stromal tumor,DOID,19852,KIT exon 11,sensitive,6216,Imatinib + PKF118-310,3815,28611108,,,
17,Preclinical - Cell line xenograft,"In a preclinical study, DCC-2618 inhibited Kit phosphorylation and tumor growth in a gastrointestinal stromal tumor cell line xenograft model harboring a KIT exon 11 deletion mutation (Cancer Res 2015;75(15 Suppl):Abstract nr 2690).",Actionable,8602,9253,gastrointestinal stromal tumor,DOID,19852,KIT exon 11,predicted â€“ sensitive,4316,DCC-2618,3815,None,,,
18,Preclinical - Cell culture,"In a preclinical study, the combination of Gleevec (imatinib) and MK2206 demonstrated synergy in inhibiting growth of a Gleevec (imatinib)-resistant gastrointestinal stromal tumor cell line harboring a KIT exon 11 deletion mutation and KIT V654A in culture (PMID: 27370604).",Actionable,9690,9253,gastrointestinal stromal tumor,DOID,26979,KIT exon 11 KIT V654A,sensitive,5163,Imatinib + MK2206,3815,27370604,,,
19,Preclinical - Cell culture,"In a preclinical study, the combination of Gleevec (imatinib) and MK2206 demonstrated synergy in inhibiting growth of a Gleevec (imatinib)-resistant gastrointestinal stromal tumor cell line harboring a KIT exon 11 mutation and KIT A829P in culture (PMID: 27370604).",Actionable,9689,9253,gastrointestinal stromal tumor,DOID,26978,KIT exon 11 KIT A829P,sensitive,5163,Imatinib + MK2206,3815,27370604,,,
20,Phase I,"In a Phase I trial, BLU-285 demonstrated preliminary antitumor activity in gastrointestinal stromal tumor patients harboring KIT mutations, with reduced tumor burden in 38% (5/13) of patients, including 1 partial response and 4 stable diseases, and 3 of the 5 responding patients harbored KIT exon 17 mutations (EORTC-NCI-AACR 2016, Abs 6LBA). ",Actionable,9776,9253,gastrointestinal stromal tumor,DOID,27079,KIT exon 17,sensitive,2941,BLU-285,3815,None,,,
21,Preclinical - Pdx,"In a preclinical study, Cometriq (Cabometyx, cabozantinib) slowed tumor growth and decreased mitotic activity in a gastrointestinal stromal tumor patient derived xenograft (PDX) model harboring KIT mutations, P577del, W557Lfs*5, and D820G (PMID: 27777285).  ",Actionable,9596,9253,gastrointestinal stromal tumor,DOID,26916,KIT P577del KIT W557Lfs*5 KIT D820G,sensitive,998,cabozantinib,3815,27777285,,,
22,Preclinical - Pdx,"In a preclinical study, a gastrointestinal stromal tumor patient derived xenograft (PDX) model harboring KIT mutations, P577del, W557Lfs*5, and D820G, demonstrated resistance to treatment with Gleevec (imatinib) (PMID: 27777285). ",Actionable,9593,9253,gastrointestinal stromal tumor,DOID,26916,KIT P577del KIT W557Lfs*5 KIT D820G,resistant,770,Imatinib,3815,27777285,,,
23,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D820G were resistant to Gleevec (imatinib) in an in vitro kinase assay (PMID: 25239608).",Actionable,6908,10000003,Advanced Solid Tumor,JAX,24008,KIT W557_K558del KIT D820G,resistant,770,Imatinib,3815,25239608,,,
24,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D820G were resistant to Stivarga (regorafenib) in an in vitro kinase assay (PMID: 25239608).",Actionable,6913,10000003,Advanced Solid Tumor,JAX,24008,KIT W557_K558del KIT D820G,resistant,890,Regorafenib,3815,25239608,,,
25,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D820G were sensitive to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).",Actionable,6898,10000003,Advanced Solid Tumor,JAX,24008,KIT W557_K558del KIT D820G,sensitive,877,Ponatinib,3815,25239608,,,
26,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D820G were resistant to Sutent (sunitinib) in an in vitro kinase assay (PMID: 25239608).",Actionable,6903,10000003,Advanced Solid Tumor,JAX,24008,KIT W557_K558del KIT D820G,resistant,930,Sunitinib,3815,25239608,,,
27,Preclinical - Pdx,"In a preclinical study, a gastrointestinal stromal tumor patient derived xenograft (PDX) model harboring KIT A502_Y503dup demonstrated resistance to treatment with Gleevec (imatinib), resulting in increased tumor volume (PMID: 27777285). ",Actionable,9592,9253,gastrointestinal stromal tumor,DOID,10919,KIT A502_Y503dup,resistant,770,Imatinib,3815,27777285,,,
28,Preclinical - Pdx,"In a preclinical study, Cometriq (Cabometyx, cabozantinib) resulted in decreased tumor volume and reduced mitotic activity in a gastrointestinal stromal tumor patient derived xenograft (PDX) model harboring KIT A502_Y503dup (PMID: 27777285).  ",Actionable,9595,9253,gastrointestinal stromal tumor,DOID,10919,KIT A502_Y503dup,sensitive,998,cabozantinib,3815,27777285,,,
29,Preclinical,"In a preclinical study, a gastrointestinal stromal tumor cell line harboring KIT V560D and KIT D820A demonstrated resistance to Sutent (sunitinib) in culture (PMID: 18955458).",Actionable,2681,9253,gastrointestinal stromal tumor,DOID,10025,KIT D820A KIT V560D,resistant,930,Sunitinib,3815,18955458,,,
30,Preclinical,"In a preclinical study, a gastrointestinal stromal tumor cell line harboring KIT V560D and KIT D820A demonstrated resistance to Gleevec (imatinib) in culture (PMID: 16954519).",Actionable,2680,9253,gastrointestinal stromal tumor,DOID,10025,KIT D820A KIT V560D,resistant,770,Imatinib,3815,16954519,,,
31,Preclinical - Cell culture,"In a preclinical study, Motesanib (AMG 706) inhibited KIT phosphorylation and growth of cells expressing KIT V560D in culture (PMID: 20633291).",Actionable,11824,10000003,Advanced Solid Tumor,JAX,1698,KIT V560D,sensitive,824,Motesanib,3815,20633291,,,
32,Preclinical,"In a preclinical study, transformed cells expressing KIT V560D demonstrated sensitivity to treatment with Sutent (sunitinib) in culture, resulting in reduced cell viability (PMID: 25239608). ",Actionable,6759,10000003,Advanced Solid Tumor,JAX,1698,KIT V560D,sensitive,930,Sunitinib,3815,25239608,,,
33,Preclinical,"In a preclinical study, transformed cells expressing KIT V560D demonstrated sensitivity to treatment with Iclusig (ponatinib) in culture, resulting in reduced cell viability (PMID: 25239608). ",Actionable,6758,10000003,Advanced Solid Tumor,JAX,1698,KIT V560D,sensitive,877,Ponatinib,3815,25239608,,,
34,Phase II,"In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41) including a melanoma patient harboring KIT V560D demonstrating a partial response and progression free survival of 8.6 months and overall survival of 23.5 months (PMID: 28327988). ",Actionable,11236,1909,melanoma,DOID,1698,KIT V560D,sensitive,829,Nilotinib,3815,28327988,,,
35,Preclinical,"In a preclinical study, transformed cells expressing KIT V560D were sensitive to Nexavar (sorafenib) in culture (PMID: 22665524).",Actionable,2535,10000003,Advanced Solid Tumor,JAX,1698,KIT V560D,sensitive,920,Sorafenib,3815,22665524,,,
36,Preclinical,"In a preclinical study, transformed cells expressing KIT V560D demonstrated sensitivity to treatment with Stivarga (regorafineb) in culture, resulting in reduced cell viability (PMID: 25239608). ",Actionable,6761,10000003,Advanced Solid Tumor,JAX,1698,KIT V560D,sensitive,890,Regorafenib,3815,25239608,,,
37,Preclinical,"In a preclinical study, transformed cells expressing KIT V560D were sensitive to Sprycel (dasatinib) in culture (PMID: 16397263).",Actionable,2538,10000003,Advanced Solid Tumor,JAX,1698,KIT V560D,sensitive,717,Dasatinib,3815,16397263,,,
38,Preclinical,"In a preclinical study, transformed cells expressing KIT V560D demonstrated sensitivity to treatment with Gleevec (imatinib) in culture, resulting in reduced cell viability (PMID: 25239608). ",Actionable,6760,10000003,Advanced Solid Tumor,JAX,1698,KIT V560D,sensitive,770,Imatinib,3815,25239608,,,
39,Preclinical - Cell culture,"In a preclinical study, Motesanib (AMG 706) inhibited KIT phosphorylation and growth of cells expressing a KIT V560D/V654A double mutation in culture (PMID: 20633291).",Actionable,11833,10000003,Advanced Solid Tumor,JAX,28309,KIT V560D KIT V654A,sensitive,824,Motesanib,3815,20633291,,,
40,Preclinical - Cell culture,"In a preclinical study, Motesanib (AMG 706) inhibited KIT phosphorylation and growth of cells expressing a KIT V560D/T670I double mutation in culture (PMID: 20633291).",Actionable,11834,10000003,Advanced Solid Tumor,JAX,28308,KIT T670I KIT V560D,sensitive,824,Motesanib,3815,20633291,,,
41,Clinical Study,"In a clinical case study, a GIST patient harboring KIT S476I and MET R988C demonstrated sensitivity to the combination treatment, Nexavar (sorafenib) and Avastin (bevacizumab), resulting in stable disease for 6 months (PMID: 25363205). ",Actionable,7766,9253,gastrointestinal stromal tumor,DOID,26035,KIT S476I MET R988C,sensitive,4517,Bevacizumab + Sorafenib,3815,25363205,,,
42,Preclinical - Patient cell culture,"In a preclinical study, treatment with Tasigna (nilotinib) decreased proliferation of patient-derived neoplastic mast cells harboring KIT S476I in culture (PMID: 25209843).",Actionable,11811,9254,mast-cell leukemia,DOID,1637,KIT S476I,predicted â€“ sensitive,829,Nilotinib,3815,25209843,,,
43,Preclinical - Patient cell culture,"In a preclinical study, treatment with Rydapt (midostaurin) decreased proliferation of patient-derived neoplastic mast cells harboring KIT S476I in culture (PMID: 25209843).",Actionable,11810,9254,mast-cell leukemia,DOID,1637,KIT S476I,predicted â€“ sensitive,810,Midostaurin,3815,25209843,,,
44,Clinical Study,"In a clinical study, a GIST patient harboring KIT M552_K558del, resistant to multiple tyrosine kinase inhibitors, demonstrated resistance to Iclusig (ponatinib) treatment as indicated by disease progression after 4 weeks of treatment (PMID: 25239608). ",Actionable,6810,9253,gastrointestinal stromal tumor,DOID,23707,KIT M552_K558del,resistant,877,Ponatinib,3815,25239608,,,
45,Phase II,"In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41) including a melanoma patient harboring KIT W557R demonstrating a partial response and progression free survival of 35.4 months and overall survival of 35.4 months (PMID: 28327988). ",Actionable,11238,1909,melanoma,DOID,995,KIT W557R,sensitive,829,Nilotinib,3815,28327988,,,
46,Phase II,"In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41) including a melanoma patient co-harboring KIT L576P and KIT W557R demonstrating a partial response and a progression free survival of 5.3 months and overall survival of 14.7 months when treated with Tasigna (nilotinib) (PMID: 28327988). ",Actionable,11232,1909,melanoma,DOID,27931,KIT L576P KIT W557R,sensitive,829,Nilotinib,3815,28327988,,,
47,Preclinical - Cell culture,"In a preclinical study, an acute myeloid leukemia cell line harboring KIT wild-type was sensitive to BPR1J373 in culture, demonstrating apoptotic induction and inhibition of cell proliferation (PMID: 27512117). ",Actionable,8706,9119,acute myeloid leukemia,DOID,582,KIT wild-type,sensitive,4798,BPR1J373,3815,27512117,,,
48,Preclinical,"In a preclinical study, cells expressing KIT V560G demonstrated sensitivity to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).  ",Actionable,6752,10000003,Advanced Solid Tumor,JAX,1675,KIT V560G,sensitive,877,Ponatinib,3815,25239608,,,
49,Preclinical,"In a preclinical study, transformed cells expressing KIT V560G demonstrated inhibition of cell proliferation and tumor regression both in culture and in vivo when treated with Tasigna (nilotinib) (PMID: 20442311). ",Actionable,2540,10000003,Advanced Solid Tumor,JAX,1675,KIT V560G,sensitive,829,Nilotinib,3815,20442311,,,
50,Preclinical,"In a preclinical study, KIT D816V conferred resistance to Quizartinib in a mast cell line harboring both KIT V560G and KIT D816V in culture (PMID: 23497317).",Actionable,3600,3664,mast cell neoplasm,DOID,13758,KIT D816V KIT V560G,resistant,882,Quizartinib,3815,23497317,,,
51,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited growth of a human mast cell line harboring both KIT V560G and KIT D816V in culture (PMID: 24552773).",Actionable,3592,9254,mast-cell leukemia,DOID,13758,KIT D816V KIT V560G,sensitive,877,Ponatinib,3815,24552773,,,
52,Preclinical - Cell culture,"In a preclinical study, a mast-cell leukemia cell line simultaneously harboring KIT D816V and KIT V560G was sensitive to BPR1J373 in culture, demonstrating inhibition of Kit phosphorylation and apoptotic activity (PMID: 27512117). ",Actionable,8709,9254,mast-cell leukemia,DOID,13758,KIT D816V KIT V560G,sensitive,4798,BPR1J373,3815,27512117,,,
53,Preclinical,"In a preclinical study, Sprycel (dasatinib) inhibited growth and induced apoptosis in a mast-cell leukemia cell line harboring both KIT V560G and KIT D816V in culture (PMID: 18024392).",Actionable,3562,9254,mast-cell leukemia,DOID,13758,KIT D816V KIT V560G,sensitive,717,Dasatinib,3815,18024392,,,
54,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D820A were resistant to Sutent (sunitinib) in an in vitro kinase assay (PMID: 25239608).",Actionable,6902,10000003,Advanced Solid Tumor,JAX,24007,KIT W557_K558del KIT D820A,resistant,930,Sunitinib,3815,25239608,,,
55,Preclinical,"In a preclinical study, transformed cells co-expressing W557_K558del and KIT D820A were resistant to Gleevec (imatinib) in an in vitro kinase assay (PMID: 25239608).",Actionable,6907,10000003,Advanced Solid Tumor,JAX,24007,KIT W557_K558del KIT D820A,resistant,770,Imatinib,3815,25239608,,,
56,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D820A were sensitive to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).",Actionable,6897,10000003,Advanced Solid Tumor,JAX,24007,KIT W557_K558del KIT D820A,sensitive,877,Ponatinib,3815,25239608,,,
57,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D820A were resistant to Stivarga (regorafenib) in an in vitro kinase assay (PMID: 25239608).",Actionable,6912,10000003,Advanced Solid Tumor,JAX,24007,KIT W557_K558del KIT D820A,resistant,890,Regorafenib,3815,25239608,,,
58,Clinical Study,"In a clinical case report, Gleevec (imatinib) in conjunction with third-line chemotherapy resulted in a complete response in a patient with stage IV chemoresistant pure seminoma with KIT over expression (PMID: 18751412).",Actionable,673,4440,seminoma,DOID,852,KIT over exp,sensitive,770,Imatinib,3815,18751412,,,
59,Clinical Study,"In a clinical case report, a patient with metastatic thymic carcinoma harboring KIT V560del with KIT over expression initially demonstrated stable disease and reduction in metastatic lesions following treatment with Gleevec (imatinib), but progressed after 6 months (PMID: 15201427).",Actionable,6748,3284,thymic carcinoma,DOID,23682,KIT V560del KIT over exp,sensitive,770,Imatinib,3815,15201427,,,
60,Phase I,"In a Phase I trial, DCC-2618 demonstrated preliminary safety and efficacy in patients with advanced solid tumors, including a partial response in a glioblastoma multiforme patient harboring KIT and PDGFRA amplification (EORTC-NCI-AACR 2016, Abs 7LBA).",Actionable,9778,3068,glioblastoma multiforme,DOID,27080,KIT amp PDGFRA amp,sensitive,4316,DCC-2618,3815,None,,,
61,Preclinical - Cell culture,"In a preclinical study, Motesanib (AMG 706) inhibited KIT phosphorylation and growth of cells expressing KIT Y823D in culture (PMID: 20633291).",Actionable,11829,10000003,Advanced Solid Tumor,JAX,1652,KIT Y823D,sensitive,824,Motesanib,3815,20633291,,,
62,Preclinical - Pdx,"In a preclinical study, DCC-2618 induced tumor regression in a patient-derived xenograft (PDX) model of gastrointestinal stromal tumor harboring KIT W557_K558del and KIT Y823D (Cancer Res 2015;75(15 Suppl):Abstract nr 2690).",Actionable,8605,9253,gastrointestinal stromal tumor,DOID,23695,KIT W557_K558del KIT Y823D,sensitive,4316,DCC-2618,3815,None,,,
63,Preclinical - Pdx & cell culture,"In a preclinical study, a patient derived GIST cell line co-harboring KIT W557_K558del and KIT Y823D demonstrated sensitivity to Iclusig (ponatinib) in a PDX model, resulting in complete tumor regression (PMID: 25239608). ",Actionable,6807,9253,gastrointestinal stromal tumor,DOID,23695,KIT W557_K558del KIT Y823D,sensitive,877,Ponatinib,3815,25239608,,,
64,Preclinical,"In a preclinical study, a patient derived GIST cell line co-harboring KIT V560_Y578del and KIT A829P demonstrated a decreased response to treatment with Sutent (sunitinib) (PMID: 25239608). ",Actionable,6804,9253,gastrointestinal stromal tumor,DOID,23694,KIT V560_Y578del KIT A829P,decreased response,930,Sunitinib,3815,25239608,,,
65,Preclinical,"In a preclinical study, a patient derived GIST cell line co-harboring KIT V560_Y578del and KIT D816E demonstrated a decreased response to treatment with Sutent (sunitinib) (PMID: 25239608). ",Actionable,6803,9253,gastrointestinal stromal tumor,DOID,23693,KIT V560_Y578del KIT D816E,decreased response,930,Sunitinib,3815,25239608,,,
66,Preclinical - Cell culture,"In a preclinical study, BGJ398 and Gleevec (imatinib mesylate) combination treatment demonstrated enhanced antiproliferative activity in gastrointestinal stromal tumor cells harboring KIT V560_Y578del in culture (PMID: 25673643).",Actionable,7786,9253,gastrointestinal stromal tumor,DOID,23687,KIT V560_Y578del,sensitive,2284,BGJ398 + Imatinib,3815,25673643,,,
67,Preclinical,"In a preclinical study, a patient derived GIST cell line harboring KIT V560_Y578del demonstrated sensitivity to Gleevec (imatinib) in culture (PMID: 25239608). ",Actionable,6799,9253,gastrointestinal stromal tumor,DOID,23687,KIT V560_Y578del,sensitive,770,Imatinib,3815,25239608,,,
68,Preclinical - Patient cell culture,"In a preclinical study, a patient-derived gastrointestinal stromal tumor (GIST) cell line harboring KIT V560_Y578del demonstrated sensitivity to Iclusig (ponatinib) in culture (PMID: 25239608). ",Actionable,6798,9253,gastrointestinal stromal tumor,DOID,23687,KIT V560_Y578del,sensitive,877,Ponatinib,3815,25239608,,,
69,Preclinical,"In a preclinical study, a patient derived GIST cell line co-harboring KIT V560_Y578del and KIT T670I demonstrated sensitivity to treatment with Iclusig (ponatinib) (PMID: 25239608). ",Actionable,6801,9253,gastrointestinal stromal tumor,DOID,23692,KIT V560_Y578del KIT T670I,sensitive,877,Ponatinib,3815,25239608,,,
70,Preclinical,"In a preclinical study, a patient derived GIST cell line co-harboring KIT V560_Y578del and KIT T670I demonstrated sensitivity to treatment with Sutent (sunitinib) (PMID: 25239608). ",Actionable,6802,9253,gastrointestinal stromal tumor,DOID,23692,KIT V560_Y578del KIT T670I,sensitive,930,Sunitinib,3815,25239608,,,
71,Preclinical,"In a preclinical study, cells expressing KIT V654A demonstrated some sensitivity to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).  ",Actionable,6757,10000003,Advanced Solid Tumor,JAX,1659,KIT V654A,sensitive,877,Ponatinib,3815,25239608,,,
72,Preclinical,"In a preclinical study, cells expressing KIT V654A demonstrated resistance to Gleevec (imatinib) in culture (PMID: 16751810). ",Actionable,6742,10000003,Advanced Solid Tumor,JAX,1659,KIT V654A,resistant,770,Imatinib,3815,16751810,,,
73,Preclinical - Cell culture,"In a preclinical study, Tasigna (nilotinib) inhibited proliferation of transformed cells expressing a KIT V560del/V654A double mutation in culture (PMID: 17699867).",Actionable,11842,10000003,Advanced Solid Tumor,JAX,28310,KIT V560del KIT V654A,sensitive,829,Nilotinib,3815,17699867,,,
74,Preclinical - Cell line xenograft,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT V654A demonstrated sensitivity to treatment with Sutent (sunitinib) in both culture and cell line xenograft models, resulting in reduced cell viability, decreased tumor volume, and tumor regression (PMID: 25239608). ",Actionable,6784,10000003,Advanced Solid Tumor,JAX,23688,KIT W557_K558del KIT V654A,sensitive,930,Sunitinib,3815,25239608,,,
75,Preclinical - Cell line xenograft,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT V654A demonstrated no response to treatment with Gleevec (imatinib) in both culture and xenograft models (PMID: 25239608). ",Actionable,6785,10000003,Advanced Solid Tumor,JAX,23688,KIT W557_K558del KIT V654A,no benefit,770,Imatinib,3815,25239608,,,
76,Preclinical - Cell line xenograft,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT V654A demonstrated sensitivity to treatment with Iclusig (ponatinib) in both culture and cell line xenograft models, resulting in reduced cell viability and decreased tumor volume (PMID: 25239608). ",Actionable,6783,10000003,Advanced Solid Tumor,JAX,23688,KIT W557_K558del KIT V654A,sensitive,877,Ponatinib,3815,25239608,,,
77,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT V654A demonstrated resistance to treatment with Stivarga (regorafenib) in culture (PMID: 25239608). ",Actionable,6786,10000003,Advanced Solid Tumor,JAX,23688,KIT W557_K558del KIT V654A,resistant,890,Regorafenib,3815,25239608,,,
78,Phase I,"In Phase I trials, KIT M541L has been associated with response to Gleevec (imatinib) in chronic eosinophilic leukemia, NOS (PMID: 25015329) and mastocytosis (PMID: 18795925).",Actionable,1074,1036,chronic leukemia,DOID,1113,KIT M541L,sensitive,770,Imatinib,3815,18795925,25015329,,
79,Clinical Study,"In a clinical case report, a patient with advanced thymic carcinoma harboring KIT P577_D579del demonstrated response to treatment with Nexavar (sorafenib), with a decrease in tumor size (PMID: 20970876).",Actionable,6749,3284,thymic carcinoma,DOID,23683,KIT P577_D579del,sensitive,920,Sorafenib,3815,20970876,,,
80,Clinical Study,"In a clinical case report, a patient with thymic carcinoma harboring KIT D579del achieved disease stabilization following treatment with Gleevec (imatinib) (PMID: 24419427).",Actionable,6746,3284,thymic carcinoma,DOID,1700,KIT D579del,sensitive,770,Imatinib,3815,24419427,,,
81,Preclinical,"In a preclinical study, Gleevec (imatinib mesylate) inhibited Kit phosphorylation efficiently in transformed human cells over expressing KIT W557G in culture (PMID: 23567324).",Actionable,6878,10000003,Advanced Solid Tumor,JAX,1639,KIT W557G,sensitive,770,Imatinib,3815,23567324,,,
82,Preclinical - Cell culture,"In a preclinical study, Motesanib (AMG 706) inhibited KIT phosphorylation and growth of cells expressing KIT M552_V559del in culture (PMID: 20633291).",Actionable,11827,10000003,Advanced Solid Tumor,JAX,28307,KIT M552_V559del,sensitive,824,Motesanib,3815,20633291,,,
83,Preclinical,"In a preclinical study, Gleevec (imatinib) inhibited growth of transformed cell lines over expressing KIT V560del in culture (PMID: 19861435).",Actionable,4366,10000003,Advanced Solid Tumor,JAX,3289,KIT V560del,sensitive,770,Imatinib,3815,19861435,,,
84,Preclinical,"In a preclinical study, Sutent (sunitinib) inhibited growth of transformed cell lines over expressing KIT V560del in culture (PMID: 19861435).",Actionable,4367,10000003,Advanced Solid Tumor,JAX,3289,KIT V560del,sensitive,930,Sunitinib,3815,19861435,,,
85,Clinical Study,"In a clinical case study, Gleevec (imatinib) treatment in a patient with metastatic melanoma resulted in regression of the lung metastasis, which harbored KIT V559A, however, neither the primary tumor or lymph node metastasis responded, which had wild-type KIT (PMID: 19812602).",Actionable,11823,1909,melanoma,DOID,1640,KIT V559A,predicted â€“ sensitive,770,Imatinib,3815,19812602,,,
86,Phase II,"In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41) including a melanoma patient harboring KIT V559A demonstrating a partial response and progression free survival of 19.4 months and overall survival of 32.9 months (PMID: 28327988). ",Actionable,11235,1909,melanoma,DOID,1640,KIT V559A,sensitive,829,Nilotinib,3815,28327988,,,
87,Guideline,Gleevec (imatinib) is an active regimen for melanoma patients with wild-type BRAF and a c-KIT positive mutation (Guidelines). ,Actionable,1938,1909,melanoma,DOID,4361,BRAF wild-type KIT positive,sensitive,770,Imatinib,3815,None,,,
88,FDA approved,"In a Phase II trial that supported FDA approval, treatment with Gleevec (imatinib) resulted in a 38% overall response rate in patients with c-KIT positive GIST (PMID: 12374669). ",Actionable,716,9253,gastrointestinal stromal tumor,DOID,851,KIT positive,sensitive,770,Imatinib,3815,None,12374669,,
89,Preclinical,"In a preclinical study, a prostate neuroendocrine tumor mouse model expressing Kit did not respond to Gleevec (imatinib), a result of impaired signaling of the Kit pathway (PMID: 27980106). ",Actionable,9913,2992,prostate neuroendocrine neoplasm,DOID,851,KIT positive,no benefit,770,Imatinib,3815,27980106,,,
90,Phase II,"In a small Phase II study, 18 patients with KIT-positive refractory germ cell tumors treated with Gleevec (imatinib) experienced no significant antitumor activity (PMID: 16462496).",Actionable,672,2994,germ cell cancer,DOID,851,KIT positive,resistant,770,Imatinib,3815,16462496,,,
91,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) inhibited growth and induced apoptosis of transformed cells expressing KIT N822I in culture (PMID: 21689725).",Actionable,11819,10000003,Advanced Solid Tumor,JAX,1651,KIT N822I,sensitive,717,Dasatinib,3815,21689725,,,
92,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing KIT N822I demonstrated resistance to Gleevec (imatinib) in culture (PMID: 21689725).",Actionable,11818,10000003,Advanced Solid Tumor,JAX,1651,KIT N822I,resistant,770,Imatinib,3815,21689725,,,
93,Clinical Study,"In a clinical study, a GIST patient harboring KIT K558_V560del and KIT W557C, resistant to Gleevec (imatinib), Sutent (sunitinib), and Stivarga (regorafenib), demonstrated sensitivity when treated with Iclusig (ponatinib), which resulted in a radiologic response and stabilization for six months (PMID: 25239608). ",Actionable,6808,9253,gastrointestinal stromal tumor,DOID,23705,KIT K558_V560del KIT W557C,sensitive,877,Ponatinib,3815,25239608,,,
94,Preclinical,"In a preclinical study, Gleevec (imatinib mesylate) inhibited Kit phosphorylation efficiently in transformed human cells over expressing both KIT W557C and KIT Y578C in culture (PMID: 23567324).",Actionable,6880,10000003,Advanced Solid Tumor,JAX,23934,KIT W557C KIT Y578C,sensitive,770,Imatinib,3815,23567324,,,
95,Preclinical - Pdx,"In a preclinical study, Nexavar (sorafenib) inhibited Erk signaling, induced apoptosis, resulted in tumor growth inhibition in patient derived xenograft models of gastrointestinal stromal tumor harboring KIT P551_V555delinsTL (PMID: 19139124).",Actionable,8618,9253,gastrointestinal stromal tumor,DOID,26378,KIT P551_V555delinsTL,sensitive,920,Sorafenib,3815,19139124,,,
96,Clinical Study,"In a retrospective analysis, GIST patients with KIT exon 9 mutations showed improved progression-free survival (PFS), overall survival, and objective response rate (ORR) compared to patients with exon 11 mutations, with a median PFS of 12.3 months vs. 7.0 months, and an ORR of 19% (8/42) vs. 6% (9/143) following treatment with Sutent (sunitinib) (PMID: 26772734).",Actionable,5009,9253,gastrointestinal stromal tumor,DOID,19853,KIT exon 9,predicted â€“ sensitive,930,Sunitinib,3815,26772734,,,
97,Preclinical,"In a preclinical study, transformed cells expressing a KIT exon 9 mutation demonstrated sensitivity to treatment with Iclusig (ponatinib) in culture, resulting in reduced cell viability (PMID: 25239608). ",Actionable,6762,10000003,Advanced Solid Tumor,JAX,19853,KIT exon 9,sensitive,877,Ponatinib,3815,25239608,,,
98,Preclinical,"In a preclinical study, Gleevec (imatinib) had no effect on transformed cells expressing a KIT exon 9 mutation in culture (PMID: 25239608). ",Actionable,6764,10000003,Advanced Solid Tumor,JAX,19853,KIT exon 9,resistant,770,Imatinib,3815,25239608,,,
99,Preclinical,"In a preclinical study, Stivarga (regorafineb) had no effect on transformed cells expressing a KIT exon 9 mutation in culture (PMID: 25239608). ",Actionable,6765,10000003,Advanced Solid Tumor,JAX,19853,KIT exon 9,resistant,890,Regorafenib,3815,25239608,,,
100,Preclinical,"In a preclinical study, transformed cells expressing a KIT exon 9 mutation demonstrated sensitivity to treatment with Sutent (sunitinib) in culture, resulting in reduced cell viability (PMID: 25239608). ",Actionable,6763,10000003,Advanced Solid Tumor,JAX,19853,KIT exon 9,sensitive,930,Sunitinib,3815,25239608,,,
101,Preclinical,"In a preclinical study, Sutent (sunitinib) inhibited growth of transformed cell lines overexpressing KIT H697Y in culture (PMID: 19861435).",Actionable,4364,10000003,Advanced Solid Tumor,JAX,1656,KIT H697Y,sensitive,930,Sunitinib,3815,19861435,,,
102,Preclinical,"In a preclinical study, transformed cell lines overexpressing KIT H697Y demonstrated reduced sensitivity to Gleevec (imatinib mesylate)-induced growth inhibition in culture (PMID: 19861435).",Actionable,4365,10000003,Advanced Solid Tumor,JAX,1656,KIT H697Y,decreased response,770,Imatinib,3815,19861435,,,
103,Clinical Study,"In a clinical study, a GIST patient harboring KIT P551_W557delinsL, resistant to Gleevec (imatinib), Sutent (sunitinib), and Stivarga (regorafenib), demonstrated sensitivity to Iclusig (ponatinib) treatment, which resulted in tumor regression and stable disease (PMID: 25239608). ",Actionable,6809,9253,gastrointestinal stromal tumor,DOID,23708,KIT P551_W557delinsL,sensitive,877,Ponatinib,3815,25239608,,,
104,Preclinical - Cell culture,"In a preclinical study, DCC-2618 inhibited proliferation of a mouse mastocytosis cell line expressing KIT K816Y in culture (Cancer Res 2015;75(15 Suppl):Abstract nr 2690).",Actionable,8604,3664,mast cell neoplasm,DOID,1649,KIT D816Y,sensitive,4316,DCC-2618,3815,None,,,
105,Preclinical,"In a preclinical study, melanoma cells expressing KIT A829P demonstrated resistance to treatment with Gleevec (imatinib mesylate) (PMID: 23582185, PMID: 25594040).",Actionable,1811,1909,melanoma,DOID,1653,KIT A829P,resistant,770,Imatinib,3815,23582185,25594040,,
106,Preclinical,"In a preclinical study, cells expressing KIT A829P demonstrated sensitivity to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).  ",Actionable,6756,10000003,Advanced Solid Tumor,JAX,1653,KIT A829P,sensitive,877,Ponatinib,3815,25239608,,,
107,Preclinical,"In a preclinical study, melanoma cells expressing KIT A829P demonstrated resistance to treatment with Sutent (sunitinib) (PMID: 23582185, PMID: 25594040).",Actionable,1812,1909,melanoma,DOID,1653,KIT A829P,resistant,930,Sunitinib,3815,23582185,25594040,,
108,Preclinical,"In a preclinical study, Sprycel (dasatinib) demonstrated efficacy by inhibiting proliferation of cultured melanoma cells expressing KIT A829P (PMID: 23582185, PMID: 25594040). ",Actionable,1814,1909,melanoma,DOID,1653,KIT A829P,sensitive,717,Dasatinib,3815,23582185,25594040,,
109,Preclinical,"In a preclinical study, Tasigna (nilotinib) demonstrated efficacy by inhibiting proliferation of cultured melanoma cells expressing KIT A829P (PMID: 23582185, PMID: 25594040).",Actionable,1813,1909,melanoma,DOID,1653,KIT A829P,sensitive,829,Nilotinib,3815,23582185,25594040,,
110,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT A829P were resistant to Sutent (sunitinb) in an in vitro kinase assay (PMID: 25239608).",Actionable,6905,10000003,Advanced Solid Tumor,JAX,24011,KIT W557_K558del KIT A829P,resistant,930,Sunitinib,3815,25239608,,,
111,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT A829P were resistant to Stivarga (regorafenib) in an in vitro kinase assay (PMID: 25239608).",Actionable,6915,10000003,Advanced Solid Tumor,JAX,24011,KIT W557_K558del KIT A829P,resistant,890,Regorafenib,3815,25239608,,,
112,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT A829P were resistant to Gleevec (imatinib) in an in vitro kinase assay (PMID: 25239608).",Actionable,6910,10000003,Advanced Solid Tumor,JAX,24011,KIT W557_K558del KIT A829P,resistant,770,Imatinib,3815,25239608,,,
113,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT A829P were sensitive to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).",Actionable,6900,10000003,Advanced Solid Tumor,JAX,24011,KIT W557_K558del KIT A829P,sensitive,877,Ponatinib,3815,25239608,,,
114,Preclinical,"In a preclinical study, transformed cells expressing K558delinsNP demonstrated sensitivity to treatment with Stivarga (regorafenib) in culture, resulting in reduced cell viability (PMID: 25239608). ",Actionable,6782,10000003,Advanced Solid Tumor,JAX,23686,KIT K558delinsNP,sensitive,890,Regorafenib,3815,25239608,,,
115,Preclinical,"In a preclinical study, transformed cells expressing KIT K558delinsNP demonstrated sensitivity to treatment with Gleevec (imatinib) in culture, resulting in reduced cell viability (PMID: 25239608). ",Actionable,6781,10000003,Advanced Solid Tumor,JAX,23686,KIT K558delinsNP,sensitive,770,Imatinib,3815,25239608,,,
116,Preclinical,"In a preclinical study, transformed cells expressing K558delinsNP demonstrated sensitivity to treatment with Sutent (sunitinib) in culture, resulting in reduced cell viability (PMID: 25239608). ",Actionable,6780,10000003,Advanced Solid Tumor,JAX,23686,KIT K558delinsNP,sensitive,930,Sunitinib,3815,25239608,,,
117,Preclinical,"In a preclinical study, transformed cells expressing KIT K558delinsNP demonstrated sensitivity to treatment with Iclusig (ponatinib) in culture, resulting in reduced cell viability (PMID: 25239608). ",Actionable,6779,10000003,Advanced Solid Tumor,JAX,23686,KIT K558delinsNP,sensitive,877,Ponatinib,3815,25239608,,,
118,Clinical Study,"In a clinical case report, Nexavar (sorafenib) treatment resulted in stable disease in a patient with anal melanoma and pulmonary metastases harboring KIT D820Y (PMID: 20372153). ",Actionable,8616,1909,melanoma,DOID,1650,KIT D820Y,predicted â€“ sensitive,920,Sorafenib,3815,20372153,,,
119,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) inhibited proliferation of transformed cells expressing a KIT V559D/D820Y double mutation in culture (PMID: 17699867).",Actionable,11845,10000003,Advanced Solid Tumor,JAX,28311,KIT D820Y KIT V559D,sensitive,717,Dasatinib,3815,17699867,,,
120,Preclinical - Cell culture,"In a preclinical study, Nexavar (sorafenib) inhibited proliferation of transformed cells expressing a KIT V559D/D820Y double mutation in culture (PMID: 17699867).",Actionable,11846,10000003,Advanced Solid Tumor,JAX,28311,KIT D820Y KIT V559D,sensitive,920,Sorafenib,3815,17699867,,,
121,Preclinical - Cell culture,"In a preclinical study, Tasigna (nilotinib) inhibited proliferation of transformed cells expressing a KIT V559D/D820Y double mutation in culture, with increased potency compared to Sprycel (dasatinib) or Nexavar (sorafenib) (PMID: 17699867).",Actionable,11843,10000003,Advanced Solid Tumor,JAX,28311,KIT D820Y KIT V559D,sensitive,829,Nilotinib,3815,17699867,,,
122,Preclinical - Cell line xenograft,"In a preclinical study, an acute myeloid leukemia cell line harboring KIT N822K demonstrated sensitivity to treatment with BPR1J373, showing inhibition of Kit phosphorylation and apoptotic induction in culture, and tumor regression in xenograft models (PMID: 27512117).",Actionable,8696,9119,acute myeloid leukemia,DOID,3607,KIT N822K,sensitive,4798,BPR1J373,3815,27512117,,,
123,Clinical Study,"In a clinical case study, KIT N822K was identified in the tumor of a gastrointestinal stromal tumor patient that was resistant to Gleevec (imatinib mesylate) treatment. (PMID: 26316776).",Actionable,6806,9253,gastrointestinal stromal tumor,DOID,3607,KIT N822K,resistant,770,Imatinib,3815,26316776,,,
124,Preclinical - Cell culture,"In a preclinical study, Iclusig (ponatinib) inhibited Kit signaling and viability in leukemia cells harboring KIT N822K in culture (PMID: 21482694).",Actionable,8003,1240,leukemia,DOID,3607,KIT N822K,sensitive,877,Ponatinib,3815,21482694,,,
125,Preclinical - Pdx,"In a preclinical study, DCC-2618 induced tumor regression in a patient-derived xenograft (PDX) model of acute myeloid leukemia harboring KIT N822K (Cancer Res 2015;75(15 Suppl):Abstract nr 2690).",Actionable,8606,9119,acute myeloid leukemia,DOID,3607,KIT N822K,sensitive,4316,DCC-2618,3815,None,,,
126,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT N822K were resistant to Stivarga (regorafenib) in an in vitro kinase assay (PMID: 25239608).",Actionable,6914,10000003,Advanced Solid Tumor,JAX,24010,KIT W557_K558del KIT N822K,resistant,890,Regorafenib,3815,25239608,,,
127,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT N822K were resistant to Sutent (sunitinb) in an in vitro kinase assay (PMID: 25239608).",Actionable,6904,10000003,Advanced Solid Tumor,JAX,24010,KIT W557_K558del KIT N822K,resistant,930,Sunitinib,3815,25239608,,,
128,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT N822K were resistant to Gleevec (imatinib) in an in vitro kinase assay (PMID: 25239608).",Actionable,6909,10000003,Advanced Solid Tumor,JAX,24010,KIT W557_K558del KIT N822K,resistant,770,Imatinib,3815,25239608,,,
129,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT N822K were sensitive to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).",Actionable,6899,10000003,Advanced Solid Tumor,JAX,24010,KIT W557_K558del KIT N822K,sensitive,877,Ponatinib,3815,25239608,,,
130,Preclinical,"In a preclinical study, Gleevec (imatinib mesylate) inhibited Kit phosphorylation efficiently in transformed human cells over expressing KIT Y578C in culture (PMID: 23567324).",Actionable,6879,10000003,Advanced Solid Tumor,JAX,1661,KIT Y578C,sensitive,770,Imatinib,3815,23567324,,,
131,Preclinical - Cell culture,"In a preclinical study, the combination of Gleevec (imatinib) and MK2206 demonstrated synergy in inhibiting growth of a gastrointestinal stromal tumor cell line harboring a KIT exon 13 mutation in culture (PMID: 27370604).",Actionable,9691,9253,gastrointestinal stromal tumor,DOID,26977,KIT exon 13,sensitive,5163,Imatinib + MK2206,3815,27370604,,,
132,Phase II,"In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41), which included a partial response in 7.7% (1/13) of melanoma patients harboring KIT exon 13 mutations (PMID: 28327988). ",Actionable,11230,1909,melanoma,DOID,26977,KIT exon 13,sensitive,829,Nilotinib,3815,28327988,,,
133,Phase II,"In a Phase II trial, Tasigna (nilotinib) treatment resulted in complete response in 5% (1/19) and partial response in 21% (4/19) of melanoma patients harboring KIT exon 11 or exon 13 mutations (PMID: 28843487; NCT01168050).",Actionable,11855,1909,melanoma,DOID,26977,KIT exon 13,sensitive,829,Nilotinib,3815,28843487,,,
134,Preclinical,"In a preclinical study, melanoma cells expressing KIT T670I demonstrated resistance to treatment with Gleevec (imatinib mesylate) (PMID: 23582185, PMID: 25594040). ",Actionable,1815,1909,melanoma,DOID,1657,KIT T670I,resistant,770,Imatinib,3815,23582185,25594040,,
135,Preclinical,"In a preclinical study, cells expressing KIT T670I demonstrated sensitivity to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).  ",Actionable,6753,10000003,Advanced Solid Tumor,JAX,1657,KIT T670I,sensitive,877,Ponatinib,3815,25239608,,,
136,Preclinical,"In a preclinical study, Sutent (sunitinib) demonstrated efficacy by inhibiting proliferation of cultured melanoma cells expressing KIT T670I (PMID: 23582185, PMID: 25594040). ",Actionable,1818,1909,melanoma,DOID,1657,KIT T670I,sensitive,930,Sunitinib,3815,23582185,25594040,,
137,Preclinical,"In a preclinical study, melanoma cells expressing KIT T670I demonstrated resistance to treatment with Sprycel (dasatinib) (PMID: 23582185, PMID: 25594040). ",Actionable,1817,1909,melanoma,DOID,1657,KIT T670I,resistant,717,Dasatinib,3815,23582185,25594040,,
138,Clinical Study,"In a clinical case report, a patient with a gastrointestinal stromal tumor developed disease progression while being treated with Gleevec (imatinib), demonstrating a KIT T670I mutation in the progressive lesion (PMID: 15236194).",Actionable,6739,9253,gastrointestinal stromal tumor,DOID,1657,KIT T670I,resistant,770,Imatinib,3815,15236194,,,
139,Preclinical,"In a preclinical study, melanoma cells expressing KIT T670I demonstrated resistance to treatment with Tasigna (nilotinib) (PMID: 23582185, PMID: 25594040). ",Actionable,1816,1909,melanoma,DOID,1657,KIT T670I,resistant,829,Nilotinib,3815,23582185,25594040,,
140,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT T670I demonstrated resistance to treatment with Stivarga (regorafenib) in culture (PMID: 25239608). ",Actionable,6790,10000003,Advanced Solid Tumor,JAX,23689,KIT W557_K558del KIT T670I,resistant,890,Regorafenib,3815,25239608,,,
141,Preclinical - Cell line xenograft,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT T670I demonstrated no response to treatment with Gleevec (imatinib) in both culture and xenograft models (PMID: 25239608). ",Actionable,6789,10000003,Advanced Solid Tumor,JAX,23689,KIT W557_K558del KIT T670I,no benefit,770,Imatinib,3815,25239608,,,
142,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT T670I demonstrated sensitivity to treatment with Iclusig (ponatinib) in both culture and cell line xenograft models, resulting in reduced cell viability and decreased tumor volume (PMID: 25239608). ",Actionable,6787,10000003,Advanced Solid Tumor,JAX,23689,KIT W557_K558del KIT T670I,sensitive,877,Ponatinib,3815,25239608,,,
143,Preclinical - Cell line xenograft,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT T670I demonstrated sensitivity to treatment with Sutent (sunitinib) in both culture and cell line xenograft models, resulting in reduced cell viability, decreased tumor volume, and tumor regression (PMID: 25239608). ",Actionable,6788,10000003,Advanced Solid Tumor,JAX,23689,KIT W557_K558del KIT T670I,sensitive,930,Sunitinib,3815,25239608,,,
144,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing a KIT W557_K558del/T670I double mutation demonstrated resistance to Sprycel (dasatinib) in culture (PMID: 17699867).",Actionable,11839,10000003,Advanced Solid Tumor,JAX,23689,KIT W557_K558del KIT T670I,resistant,717,Dasatinib,3815,17699867,,,
145,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing a KIT W557_K558del/T670I double mutation demonstrated resistance to Tasigna (nilotinib) in culture (PMID: 17699867).",Actionable,11840,10000003,Advanced Solid Tumor,JAX,23689,KIT W557_K558del KIT T670I,resistant,829,Nilotinib,3815,17699867,,,
146,Preclinical - Cell culture,"In a preclinical study, Nexavar (sorafenib) inhibited proliferation and induced apoptosis of transformed cells expressing a KIT W557_K558del/T670I double mutation in culture (PMID: 17699867).",Actionable,11841,10000003,Advanced Solid Tumor,JAX,23689,KIT W557_K558del KIT T670I,sensitive,920,Sorafenib,3815,17699867,,,
147,Clinical Study,"In a case report study, a patient with mucosal melanoma harboring KIT C443S demonstrated a substantial response to Gleevec (imatinib) in the first two weeks and then developed progression at 15 weeks (PMID: 25003536). ",Actionable,6518,50929,mucosal melanoma,DOID,5733,KIT C443S,sensitive,770,Imatinib,3815,25003536,,,
148,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) decreased KIT signaling, and inhibited growth and induced apoptosis of transformed cells expressing KIT V559D in culture (PMID: 21689725).",Actionable,11820,10000003,Advanced Solid Tumor,JAX,1641,KIT V559D,sensitive,717,Dasatinib,3815,21689725,,,
149,Preclinical,"In a preclinical study, cells expressing KIT V559D demonstrated sensitivity to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).  ",Actionable,6751,10000003,Advanced Solid Tumor,JAX,1641,KIT V559D,sensitive,877,Ponatinib,3815,25239608,,,
150,Preclinical - Cell culture,"In a preclinical study, Gleevec (imatinib) decreased KIT signaling, and inhibited growth and induced apoptosis of transformed cells expressing KIT V559D in culture (PMID: 21689725).",Actionable,11821,10000003,Advanced Solid Tumor,JAX,1641,KIT V559D,sensitive,770,Imatinib,3815,21689725,,,
151,Phase II,"In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41) including a melanoma patient harboring KIT V559D demonstrating a partial response and progression free survival of 28.3 months and overall survival of 28.3 months (PMID: 28327988). ",Actionable,11234,1909,melanoma,DOID,1641,KIT V559D,sensitive,829,Nilotinib,3815,28327988,,,
152,Clinical Study,"In a clinical case report, a patient with metastatic thymic carcinoma harboring KIT Y553N demonstrated improved clinical performance and reduction in metastatic lesions following treatment with Gleevec (imatinib) (PMID: 21969494).",Actionable,6747,3284,thymic carcinoma,DOID,3216,KIT Y553N,sensitive,770,Imatinib,3815,21969494,,,
153,Preclinical,"In a preclinical study, Cometriq (cabozantinib) decreased cell viability in imatinib-sensitive and resistant gastrointestinal stromal tumor (GIST) cell lines harboring KIT activating mutations in culture, and induced tumor regression in KIT-mutant GIST mouse models (PMID: 25836719).",Actionable,2537,9253,gastrointestinal stromal tumor,DOID,1668,KIT act mut,sensitive,998,cabozantinib,3815,25836719,,,
154,Preclinical - Cell line xenograft,"In a preclinical study, PLX3397 inhibited growth of gastrointestinal stromal tumor cell lines harboring KIT activating mutations in culture and in cell line xenograft models (PMID: 24583793).",Actionable,2543,9253,gastrointestinal stromal tumor,DOID,1668,KIT act mut,sensitive,874,PLX3397,3815,24583793,,,
155,Preclinical,"In a preclinical study, PLX9486 inhibited KIT mutations, including exon 17 mutations, and demonstrated in vivo and in vitro activity against tumors harboring KIT exon 17 mutations (Cancer Res February 1, 2016 76; IA32).",Actionable,6392,10000003,Advanced Solid Tumor,JAX,1668,KIT act mut,sensitive,2602,PLX9486,3815,None,,,
156,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) inhibited growth and induced apoptosis of transformed cells expressing KIT W557_K558del in culture (PMID: 17699867).",Actionable,11838,10000003,Advanced Solid Tumor,JAX,1706,KIT W557_K558del,sensitive,717,Dasatinib,3815,17699867,,,
157,Preclinical - Cell line xenograft,"In a preclinical study, transformed cells expressing KIT W557_K558del demonstrated sensitivity to treatment with Iclusig (ponatinib) in both culture and cell line xenograft models, resulting in reduced cell viability and near complete tumor regression (PMID: 25239608). ",Actionable,6766,10000003,Advanced Solid Tumor,JAX,1706,KIT W557_K558del,sensitive,877,Ponatinib,3815,25239608,,,
158,Preclinical - Cell culture,"In a preclinical study, Tasigna (nilotinib) inhibited growth of transformed cells expressing KIT W557_K558del in culture (PMID: 17699867).",Actionable,11837,10000003,Advanced Solid Tumor,JAX,1706,KIT W557_K558del,sensitive,829,Nilotinib,3815,17699867,,,
159,Preclinical,"In a preclinical study, transformed cells expressing KIT W557_K558del demonstrated sensitivity to treatment with Stivarga (regorafineb) in culture, resulting in reduced cell viability (PMID: 25239608). ",Actionable,6769,10000003,Advanced Solid Tumor,JAX,1706,KIT W557_K558del,sensitive,890,Regorafenib,3815,25239608,,,
160,Preclinical,"In a preclinical study, transformed cells expressing KIT W557_K558del demonstrated sensitivity to treatment with Gleevec (imatinib) in culture, resulting in reduced cell viability (PMID: 25239608). ",Actionable,6768,10000003,Advanced Solid Tumor,JAX,1706,KIT W557_K558del,sensitive,770,Imatinib,3815,25239608,,,
161,Preclinical - Cell culture,"In a preclinical study, PD-0325901 treatment inhibited Erk phosphorylation and decreased expression of ETV1 and CXCR4 in gastrointestinal stromal tumor cells harboring KIT W557_K558del (PMID: 26936919). ",Actionable,7522,9253,gastrointestinal stromal tumor,DOID,1706,KIT W557_K558del,sensitive,849,PD-0325901,3815,26936919,,,
162,Preclinical,"In a preclinical study, transformed cells expressing W557_K558del demonstrated sensitivity to treatment with Sutent (sunitinib) in culture, resulting in reduced cell viability (PMID: 25239608). ",Actionable,6767,10000003,Advanced Solid Tumor,JAX,1706,KIT W557_K558del,sensitive,930,Sunitinib,3815,25239608,,,
163,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816G were resistant to Sutent (sunitinib) in an in vitro kinase assay (PMID: 25239608).",Actionable,6901,10000003,Advanced Solid Tumor,JAX,24005,KIT W557_K558del KIT D816G,resistant,930,Sunitinib,3815,25239608,,,
164,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816G were sensitive to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).",Actionable,6896,10000003,Advanced Solid Tumor,JAX,24005,KIT W557_K558del KIT D816G,resistant,877,Ponatinib,3815,25239608,,,
165,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816G were resistant to Stivarga (regorafenib) in an in vitro kinase assay (PMID: 25239608).",Actionable,6911,10000003,Advanced Solid Tumor,JAX,24005,KIT W557_K558del KIT D816G,resistant,890,Regorafenib,3815,25239608,,,
166,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816G were resistant to Gleevec (imatinib) in an in vitro kinase assay (PMID: 25239608).",Actionable,6906,10000003,Advanced Solid Tumor,JAX,24005,KIT W557_K558del KIT D816G,resistant,770,Imatinib,3815,25239608,,,
167,Preclinical - Cell line xenograft,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816H demonstrated a decreased response to treatment with Gleevec (imatinib) in both culture and xenograft models, resulting in only a slight decrease in tumor volume (PMID: 25239608). ",Actionable,6794,10000003,Advanced Solid Tumor,JAX,23690,KIT W557_K558del KIT D816H,decreased response,770,Imatinib,3815,25239608,,,
168,Preclinical - Cell line xenograft,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816H demonstrated sensitivity to treatment with Iclusig (ponatinib) in both culture and cell line xenograft models, resulting in reduced cell viability and tumor regression (PMID: 25239608). ",Actionable,6792,10000003,Advanced Solid Tumor,JAX,23690,KIT W557_K558del KIT D816H,sensitive,877,Ponatinib,3815,25239608,,,
169,Preclinical,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816H demonstrated a decreased response to treatment with Stivarga (regorafenib) in culture (PMID: 25239608). ",Actionable,6795,10000003,Advanced Solid Tumor,JAX,23690,KIT W557_K558del KIT D816H,decreased response,890,Regorafenib,3815,25239608,,,
170,Preclinical - Cell line xenograft,"In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT D816H demonstrated a decreased response to treatment with Sutent (sunitinib) in both culture and cell line xenograft models, resulting in only a slight decrease in tumor volume (PMID: 25239608). ",Actionable,6793,10000003,Advanced Solid Tumor,JAX,23690,KIT W557_K558del KIT D816H,decreased response,930,Sunitinib,3815,25239608,,,
171,Preclinical,"In a preclinical study, transformed cells expressing KIT K550_W557del demonstrated sensitivity to treatment with Iclusig (ponatinib) in culture, resulting in reduced cell viability (PMID: 25239608). ",Actionable,6770,10000003,Advanced Solid Tumor,JAX,23684,KIT K550_W557del,sensitive,877,Ponatinib,3815,25239608,,,
172,Preclinical,"In a preclinical study, transformed cells expressing KIT K550_W557del demonstrated sensitivity to treatment with Sutent (sunitinib) in culture, resulting in reduced cell viability (PMID: 25239608). ",Actionable,6771,10000003,Advanced Solid Tumor,JAX,23684,KIT K550_W557del,sensitive,930,Sunitinib,3815,25239608,,,
173,Preclinical,"In a preclinical study, transformed cells expressing KIT K550_W557del demonstrated sensitivity to treatment with Stivarga (regorafenib) in culture, resulting in reduced cell viability (PMID: 25239608). ",Actionable,6773,10000003,Advanced Solid Tumor,JAX,23684,KIT K550_W557del,sensitive,890,Regorafenib,3815,25239608,,,
174,Preclinical,"In a preclinical study, transformed cells expressing KIT K550_W557del demonstrated sensitivity to treatment with Gleevec (imatinib) in culture, resulting in reduced cell viability (PMID: 25239608). ",Actionable,6772,10000003,Advanced Solid Tumor,JAX,23684,KIT K550_W557del,sensitive,770,Imatinib,3815,25239608,,,
175,Preclinical - Pdx,"In a preclinical study, Gleevec (imatinib) treatment resulted in tumor regression and decreased mitotic activity in gastrointestinal stromal tumor patient derived xenograft (PDX) models harboring KIT K558_G565delinsR (PMID: 27777285). ",Actionable,9591,9253,gastrointestinal stromal tumor,DOID,26913,KIT K558_G565delinsR,sensitive,770,Imatinib,3815,27777285,,,
176,Preclinical - Pdx,"In a preclinical study, Cometriq (Cabometyx, cabozantinib) resulted in tumor regression, decreased mitotic activity, and increased apoptotic activity in a gastrointestinal stromal tumor patient derived xenograft (PDX) model harboring KIT K558_G565delins (PMID: 27777285).  ",Actionable,9594,9253,gastrointestinal stromal tumor,DOID,26913,KIT K558_G565delinsR,sensitive,998,cabozantinib,3815,27777285,,,
177,Clinical Study,"In a clinical case report, Gleevec (imatinib mesylate) treatment resulted in partial response in a patient with recurrent vulval melanoma harboring KIT K642E, reduced tumor mass by 35% (PMID: 20372153). ",Actionable,8614,2093,vulvar melanoma,DOID,1660,KIT K642E,predicted â€“ sensitive,770,Imatinib,3815,20372153,,,
178,Phase II,"In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41) including a melanoma patient harboring KIT K642E demonstrating a partial response and a progression free survival of 5.8 months and overall survival of 18.6 months (PMID: 28327988). ",Actionable,11233,1909,melanoma,DOID,1660,KIT K642E,sensitive,829,Nilotinib,3815,28327988,,,
179,Preclinical - Cell culture,"In a preclinical study, Stivarga (regorafenib) inhibited proliferation of gastrointestinal stromal tumor cells harboring KIT K642E in culture (PMID: 21170960).",Actionable,538,9253,gastrointestinal stromal tumor,DOID,1660,KIT K642E,sensitive,890,Regorafenib,3815,21170960,,,
180,Preclinical,"In a preclinical study, a patient derived GIST cell line harboring KIT K642E demonstrated sensitivity to Iclusig (ponatinib) in culture (PMID: 25239608). ",Actionable,6805,9253,gastrointestinal stromal tumor,DOID,1660,KIT K642E,sensitive,877,Ponatinib,3815,25239608,,,
181,Preclinical - Cell culture,"In a preclinical study, BGJ398 and Gleevec (imatinib mesylate) combination treatment demonstrated enhanced antiproliferative activity in gastrointestinal stromal tumor cells harboring KIT K642E in culture (PMID: 25673643).",Actionable,7785,9253,gastrointestinal stromal tumor,DOID,1660,KIT K642E,sensitive,2284,BGJ398 + Imatinib,3815,25673643,,,
182,Preclinical,"In a preclinical study, KIT N505I induced phosphorylation of KIT, ERK, and AKT, and was inhibited by Nexavar (sorafenib) in cell culture of melanocytes, demonstrating sensitivity of N505I to sorafenib (PMID: 24317392).",Actionable,990,1909,melanoma,DOID,1642,KIT N505I,sensitive,920,Sorafenib,3815,24317392,,,
183,Preclinical,"In a preclinical study, Gleevec (imatinib) decreased phosphorylation of KIT, AKT, and ERK in melanocytes expressing KIT N505I in culture (PMID: 24317392).",Actionable,991,1909,melanoma,DOID,1642,KIT N505I,predicted â€“ sensitive,770,Imatinib,3815,24317392,,,
184,Clinical Study,"In clinical analyses, coincident KIT mutations were associated with higher relapse rate and decreased overall survival in acute myeloid leukemia patients with RUNX1-RUNX1T1 fusions (PMID: 18648004, PMID: 16384925, PMID: 25111512).",Prognostic,6080,9119,acute myeloid leukemia,DOID,22438,RUNX1-RUNX1T1 KIT mut,not applicable,1776,N/A,3815,18648004,25111512,16384925,
185,Phase I,"In a Phase I trial, DCC-2618 demonstrated preliminary safety and efficacy in patients with advanced solid tumors, including KIT-mutant gastrointestinal stromal tumor (GIST), with 1 patient harboring KIT exon 11 and 17 mutations demonstrating a partial response, and 7/7 KIT-mutant GIST patients demonstrating a partial metabolic response (EORTC-NCI-AACR 2016, Abs 7LBA).",Actionable,9777,9253,gastrointestinal stromal tumor,DOID,1214,KIT mutant,predicted â€“ sensitive,4316,DCC-2618,3815,None,,,
186,Phase II,"In a Phase II trial, Tasigna (nilotinib) treatment resulted in complete response in 4% (1/25), durable partial response in 16% (4/25), and stable disease in 56% (14/25) of melanoma patients harboring KIT mutations (PMID: 28843487; NCT01168050).",Actionable,11853,1909,melanoma,DOID,1214,KIT mutant,sensitive,829,Nilotinib,3815,28843487,,,
187,Phase II,"In a Phase II trial, Tasigna (nilotinib) treatment in patients with melanoma harboring KIT mutations resulted in an overall response rate of 26.2% (11/42), which included 11 patients with a partial response, a median duration of response of 7.1 months, and an overall survival of 18 months (PMID: 28327988; NCT01028222). ",Actionable,3305,1909,melanoma,DOID,1214,KIT mutant,sensitive,829,Nilotinib,3815,28327988,,,
188,Preclinical - Pdx,"In a preclinical study, BGJ398 and Gleevec (imatinib mesylate) combination treatment demonstrated enhanced antitumor activity in patient derived xenograft models of gastrointestinal stromal tumor harboring KIT mutations (PMID: 25673643).",Actionable,7788,9253,gastrointestinal stromal tumor,DOID,1214,KIT mutant,sensitive,2284,BGJ398 + Imatinib,3815,25673643,,,
189,Clinical Study,"KIT mutations are used in the diagnosis of gastrointestinal stromal tumors (PMID: 25193432, PMID: 26276366, PMID: 25729899).",Diagnostic,3968,9253,gastrointestinal stromal tumor,DOID,1214,KIT mutant,not applicable,1776,N/A,3815,25729899,25193432,26276366,
190,Clinical Study,"In a clinical study, a melanoma patient harboring KIT D816V and NRAS Q61R demonstrated progressive disease when treated with a combination of Mekinist (trametinib) and Keytruda (pembrolizumab) (PMID: 28514312). ",Actionable,11050,1909,melanoma,DOID,27900,KIT D816V NRAS Q61R,no benefit,1450,Pembrolizumab + Trametinib,3815,28514312,,,
191,Preclinical,"In a preclinical study, Iclusig (ponatinib) did not inhibit growth of transformed cells expressing KIT D816V in culture (PMID: 22301675).",Actionable,3560,10000003,Advanced Solid Tumor,JAX,1643,KIT D816V,resistant,877,Ponatinib,3815,22301675,,,
192,Preclinical,"In a preclinical study, transformed cells expressing KIT D816V demonstrated resistance to Quizartinib in culture (PMID: 23497317).",Actionable,3601,10000003,Advanced Solid Tumor,JAX,1643,KIT D816V,resistant,882,Quizartinib,3815,23497317,,,
193,Preclinical,"In a preclinical study, a mouse myeloid cell line expressing KIT D816V demonstrated resistance to Gleevec (imatinib) in culture (PMID: 12481435).",Actionable,3580,2531,hematologic cancer,DOID,1643,KIT D816V,resistant,770,Imatinib,3815,12481435,,,
194,Preclinical,"In a preclinical study, transformed hematopoietic cells expressing KIT D816V demonstrated resistance to Nexavar (sorafenib) in culture (PMID: 17229632).",Actionable,3561,2531,hematologic cancer,DOID,1643,KIT D816V,resistant,920,Sorafenib,3815,17229632,,,
195,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing KIT D816V were sensitive to BPR1J373, demonstrating inhibition of Kit phosphorylation (PMID: 27512117).",Actionable,8707,10000003,Advanced Solid Tumor,JAX,1643,KIT D816V,predicted â€“ sensitive,4798,BPR1J373,3815,27512117,,,
196,Preclinical,"In a preclinical study, transformed cells expressing KIT D816V demonstrated resistance to Gleevec (imatinib mesylate) in culture (PMID: 15790786).",Actionable,3579,10000003,Advanced Solid Tumor,JAX,1643,KIT D816V,resistant,770,Imatinib,3815,15790786,,,
197,Preclinical,"In a preclinical study, Tasigna (nilotinib) decreased viability of cells expressing KIT D816V in culture, but did not inhibit KIT phosphorylation or growth of KIT D816V-expressing tumors in mouse models (PMID: 20442311).",Actionable,3577,10000003,Advanced Solid Tumor,JAX,1643,KIT D816V,decreased response,829,Nilotinib,3815,20442311,,,
198,Preclinical,"In a preclinical study, transformed cells expressing KIT D816V demonstrated resistance to Cometriq (cabozantinib) in culture (PMID: 24205792).",Actionable,3585,10000003,Advanced Solid Tumor,JAX,1643,KIT D816V,resistant,998,cabozantinib,3815,24205792,,,
199,Clinical Study,"In a clinical case study, a patient with acute myeloid leukemia harboring KIT D816V achieved long-term remission and loss of KIT D816V following treatment with the combination of Sprycel (dasatinib) and Cytosar-U (cytarabine) (PMID: 18986703).",Actionable,3613,9119,acute myeloid leukemia,DOID,1643,KIT D816V,sensitive,3174,Dasatinib + Cytarabine,3815,18986703,,,
200,FDA approved,Gleevec (imatinib) is not indicated for patients with aggressive systemic mastocytosis harboring KIT D816V (FDA.gov).,Actionable,1979,10000005,Indication other than cancer,JAX,1643,KIT D816V,resistant,770,Imatinib,3815,None,,,
201,Preclinical,"In a preclinical study, KIT D816V mutations demonstrated resistance to Sutent (sunitinib) in a biochemical assay (PMID: 19164557).",Actionable,3575,10000003,Advanced Solid Tumor,JAX,1643,KIT D816V,resistant,930,Sunitinib,3815,19164557,,,
202,Preclinical,"In a preclinical study, cells expressing KIT D820E demonstrated sensitivity to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).  ",Actionable,6755,10000003,Advanced Solid Tumor,JAX,4900,KIT D820E,sensitive,877,Ponatinib,3815,25239608,,,
203,Clinical Study,"In a clinical case report, a patient with metastatic thymic carcinoma harboring KIT D820E demonstrated a partial response to treatment with Nexavar (sorafenib) (PMID: 19461405).",Actionable,6750,3284,thymic carcinoma,DOID,4900,KIT D820E,sensitive,920,Sorafenib,3815,19461405,,,
204,Preclinical,"In a preclinical study, Gleevec (imatinib mesylate) inhibited Kit phosphorylation in transformed cells over expressing KIT T417_D419delinsI in culture (PMID: 16015387). ",Actionable,6775,10000003,Advanced Solid Tumor,JAX,23697,KIT T417_D419delinsI,sensitive,770,Imatinib,3815,16015387,,,
205,Preclinical - Pdx,"In a preclinical study, Nexavar (sorafenib) inhibited Erk signaling, induced apoptosis, resulted in tumor growth inhibition in patient derived xenograft models of gastrointestinal stromal tumor harboring KIT P551_V555del (PMID: 19139124).",Actionable,8617,9253,gastrointestinal stromal tumor,DOID,1702,KIT P551_V555del,sensitive,920,Sorafenib,3815,19139124,,,
206,Clinical Study,"In two clinical case studies, patients with Gleevec (imatinib)-melanoma that harboring KIT L576P demonstrated initial clinical benefit following treatment with Sprycel (dasatinib), however progressed after 3-4 months of treatment (PMID: 19671763).",Actionable,8609,1909,melanoma,DOID,1670,KIT L576P,sensitive,717,Dasatinib,3815,19671763,,,
207,Phase II,"In a Phase II trial, Tasigna (nilotinib) resulted in an overall response rate of 26.2% (11/41) including three melanoma patients harboring KIT L576P demonstrating a partial response (PMID: 28327988). ",Actionable,11231,1909,melanoma,DOID,1670,KIT L576P,sensitive,829,Nilotinib,3815,28327988,,,
208,Clinical Study,"In a clinical case report, Gleevec (imatinib mesylate) treatment resulted in initial tumor reduction followed by disease progression in a patient with metastasized labial melanoma harboring KIT L576P (PMID: 20372153). ",Actionable,8615,1909,melanoma,DOID,1670,KIT L576P,no benefit,770,Imatinib,3815,20372153,,,
209,Clinical Study,"In a clinical case study, a melanoma patient harboring KIT L576P demonstrated sensitivity to the combination treatment of Nexavar (sorafenib) and Avastin (bevacizumab), resulting in a partial response for 8 months (PMID: 25363205). ",Actionable,7765,1909,melanoma,DOID,1670,KIT L576P,sensitive,4517,Bevacizumab + Sorafenib,3815,25363205,,,
210,Preclinical,"In a preclinical study, the combination of G007-LK and Gleevec (imatinib) demonstrated increased anti-tumor activity compared to either agent alone in a mouse model of gastrointestinal stromal tumor expressing Kit V558del (corresponding to human V559del) (PMID: 28611108).",Actionable,11962,9253,gastrointestinal stromal tumor,DOID,1699,KIT V559del,sensitive,6215,G007-LK + Imatinib,3815,28611108,,,
211,Preclinical,"In a preclinical study, KIT D816H demonstrated resistance to Stivarga (regorafenib) in an in vitro assay, and conferred secondary resistance to Stivarga (regorafenib) in transformed cells expressing other KIT mutations (PMID: 25239608).",Actionable,3589,10000003,Advanced Solid Tumor,JAX,1646,KIT D816H,resistant,890,Regorafenib,3815,25239608,,,
212,Preclinical,"In a preclinical study, cells expressing KIT D816H demonstrated sensitivity to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).  ",Actionable,6754,10000003,Advanced Solid Tumor,JAX,1646,KIT D816H,sensitive,877,Ponatinib,3815,25239608,,,
0,Preclinical,"In a preclinical study, transformed cells expressing the fusion, KMT2A-MLLT10, demonstrated sensitivity to EPZ004777 in culture and in mouse models, resulting in cell cycle arrest, increased apoptotic activity, and inhibition of cell proliferation (PMID: 23138183). ",Actionable,6224,1240,leukemia,DOID,22961,KMT2A-MLLT10,sensitive,1744,EPZ004777,4297,23138183,,,
1,Preclinical - Patient cell culture,"In a preclinical study, I-BET151 and SGC0946 synergistically inhibited proliferation of patient-derived acute myeloid leukemia cells harboring KMT2A-MLLT10 in culture (PMID: 27294782).",Actionable,11381,9119,acute myeloid leukemia,DOID,22961,KMT2A-MLLT10,sensitive,5966,I-BET151 + SGC0946,4297,27294782,,,
2,Preclinical,"In a preclinical study, AZD0156 treatment resulted in growth inhibition of tumor cells and prolonged survival in animal models of acute myeloid leukemia harboring KMT2A-MLLT1 fusion and NRAS G12D (PMID: 27625305).",Actionable,12168,9119,acute myeloid leukemia,DOID,20552,KMT2A-MLLT1 NRAS G12D,predicted â€“ sensitive,3557,AZD0156,4297,27625305,,,
3,Preclinical,"In a preclinical study, AZ20 treatment resulted in growth inhibition of tumor cells and prolonged survival in animal models of acute myeloid leukemia harboring KMT2A-MLLT1 fusion and NRAS G12D (PMID: 27625305).",Actionable,12169,9119,acute myeloid leukemia,DOID,20552,KMT2A-MLLT1 NRAS G12D,predicted â€“ sensitive,2880,AZ20,4297,27625305,,,
4,Preclinical,"In a preclinical study, acute myeloid leukemia cells co-harboring KMT2A-MLLT1 and NRAS G12D demonstrated a decrease in tumor burden, reduced colony formation, and an increase in cell death when treated with Dinaciclib in both culture and mouse models (PMID: 26627013).",Actionable,5311,9119,acute myeloid leukemia,DOID,20552,KMT2A-MLLT1 NRAS G12D,sensitive,719,Dinaciclib,4297,26627013,,,
5,Preclinical - Cell culture,"In a preclinical study, MI-503 inhibited growth of an acute myeloid leukemia cell line harboring KMT2A-MLLT1 (MLL-ENL) in culture (PMID: 25817203).",Actionable,11493,9119,acute myeloid leukemia,DOID,20541,KMT2A-MLLT1,sensitive,6006,MI-503,4297,25817203,,,
6,Preclinical - Patient cell culture,"In a preclinical study, I-BET151 and SGC0946 synergistically inhibited proliferation of patient-derived acute myeloid leukemia cells harboring KMT2A fusions in culture (PMID: 27294782).",Actionable,11382,9119,acute myeloid leukemia,DOID,27975,KMT2A fusion,sensitive,5966,I-BET151 + SGC0946,4297,27294782,,,
7,Preclinical - Cell culture,"In a preclinical study, MI-503 inhibited growth of several acute myeloid leukemia (AML) cell lines and primary AML samples harboring KMT2A (MLL) fusions in culture (PMID: 25817203).",Actionable,11496,9119,acute myeloid leukemia,DOID,27975,KMT2A fusion,predicted â€“ sensitive,6006,MI-503,4297,25817203,,,
8,Preclinical,"In a preclinical study, a transgenic leukemic mouse model harboring KMT2A-MLLT3 demonstrated sensitivity to IRAK1/4, resulting in delayed progression and improved survival (PMID: 28065413). ",Actionable,9763,1240,leukemia,DOID,20485,KMT2A-MLLT3,sensitive,5196,IRAK1/4,4297,28065413,,,
9,Preclinical - Patient cell culture,"In a preclinical study, MI-503 inhibited growth of an acute myeloid leukemia (AML) cell line and primary AML samples harboring KMT2A-MLLT3 (MLL-AF9) in culture (PMID: 25817203).",Actionable,11491,9119,acute myeloid leukemia,DOID,20485,KMT2A-MLLT3,sensitive,6006,MI-503,4297,25817203,,,
10,Preclinical,"In a preclinical study, treatment with Dinaciclib resulted in induced cell death of acute myeloid leukemia cells harboring KMT2A-MLLT3 in culture (PMID: 26627013).",Actionable,5312,9119,acute myeloid leukemia,DOID,20485,KMT2A-MLLT3,sensitive,719,Dinaciclib,4297,26627013,,,
11,Preclinical,"In a preclinical study, MI-503 reduced progression and improved survival of a mouse leukemia model expressing KMT2A-MLLT3 (MLL-AF9) (PMID: 25817203).",Actionable,11497,1240,leukemia,DOID,20485,KMT2A-MLLT3,sensitive,6006,MI-503,4297,25817203,,,
12,Preclinical - Patient cell culture,"In a preclinical study, I-BET151 and SGC0946 synergistically inhibited proliferation of patient-derived acute myeloid leukemia cells harboring KMT2A-MLLT3 in culture, and prolonged survival in animal models of mouse KMT2A-MLLT3-positive leukemia (PMID: 27294782).",Actionable,11378,9119,acute myeloid leukemia,DOID,20485,KMT2A-MLLT3,sensitive,5966,I-BET151 + SGC0946,4297,27294782,,,
13,Preclinical - Cell line xenograft,"In a preclinical study, AZD5153 inhibited proliferation of acute myeloid leukemia cells harboring KMT2A-AFF1 (MLL-AF4) in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 27573426).",Actionable,9134,9119,acute myeloid leukemia,DOID,20536,KMT2A-AFF1,predicted â€“ sensitive,4910,AZD5153,4297,27573426,,,
14,Preclinical - Cell culture,"In a preclinical study, I-BET151 and SGC0946 synergistically inhibited proliferation of leukemia cells harboring KMT2A-AFF1 in culture (PMID: 27294782).",Actionable,11377,1240,leukemia,DOID,20536,KMT2A-AFF1,sensitive,5966,I-BET151 + SGC0946,4297,27294782,,,
15,Preclinical - Cell culture,"In a preclinical study, leukemia cells harboring KMT2A-AFF1 demonstrated sensitivity to IRAK1/4 in culture, resulting in decreased cell proliferation (PMID: 28065413). ",Actionable,9762,1240,leukemia,DOID,20536,KMT2A-AFF1,sensitive,5196,IRAK1/4,4297,28065413,,,
16,Preclinical - Cell line xenograft,"In a preclinical study, AZD5153 inhibited proliferation of acute lymphocytic leukemia cells harboring KMT2A-AFF1 (MLL-AF4) in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 27573426).",Actionable,9128,9952,acute lymphocytic leukemia,DOID,20536,KMT2A-AFF1,predicted â€“ sensitive,4910,AZD5153,4297,27573426,,,
17,Preclinical - Cell line xenograft,"In a preclinical study, MI-503 reduced expression of KMT2A (MLL) fusion target genes, inhibited growth of an acute myeloid leukemia (AML) cell lines harboring KMT2A-AFF1 (MLL-AF4) in culture, and inhibited tumor growth and progression in an AML cell line xenograft model harboring KMT2A-AFF1 (MLL-AF4) (PMID: 25817203).",Actionable,11492,9119,acute myeloid leukemia,DOID,20536,KMT2A-AFF1,sensitive,6006,MI-503,4297,25817203,,,
18,Preclinical,"In a preclinical study, treatment with Dinaciclib resulted in induced cell death of acute myeloid leukemia cells harboring KMT2A-AFF1 in culture (PMID: 26627013).",Actionable,5313,9119,acute myeloid leukemia,DOID,20536,KMT2A-AFF1,sensitive,719,Dinaciclib,4297,26627013,,,
19,Preclinical - Patient cell culture,"In a preclinical study, I-BET151 and SGC0946 synergistically inhibited proliferation of patient-derived acute myeloid leukemia cells harboring KMT2A-SEPT6 in culture (PMID: 27294782).",Actionable,11379,9119,acute myeloid leukemia,DOID,27973,KMT2A-SEPT6,sensitive,5966,I-BET151 + SGC0946,4297,27294782,,,
20,Preclinical - Cell line xenograft,"In a preclinical study, Istodax (romidepsin) enhanced the effects of Cytosar-U (cytarabine) in acute lymphocytic leukemia cell lines harboring a KMT2A rearrangement in culture, and in cell line xenograft models, demonstrating decreased leukemic cells by 73% (PMID: 27443263). ",Actionable,9495,9952,acute lymphocytic leukemia,DOID,14079,KMT2A rearrange,sensitive,5035,Cytarabine + Romidepsin,4297,27443263,,,
21,Preclinical,"In a preclinical study, I-CBP112 sensitized leukemia cells harboring KMT2A fusions to JQ1, resulting in decreased cell growth in culture (PMID: 26552700).",Actionable,3776,1240,leukemia,DOID,14079,KMT2A rearrange,predicted â€“ sensitive,3298,I-CBP112 + JQ1,4297,26552700,,,
22,Preclinical - Cell culture,"In a preclinical study, Mocetinostat (MGCD0103) enhanced the effects of Cytosar-U (cytarabine) in acute lymphoblastic leukemia cell lines harboring a KMT2A rearrangement in culture, resulting in cell death (PMID: 27443263). ",Actionable,9492,9952,acute lymphocytic leukemia,DOID,14079,KMT2A rearrange,sensitive,5037,Cytarabine + Mocetinostat,4297,27443263,,,
23,Preclinical - Cell line xenograft,"In a preclinical study, Istodax (romidepsin) resulted in minimal activity in acute lymphocytic leukemia cell lines harboring a KMT2A rearrangement in culture, and in cell line xenograft models, demonstrating decreased leukemic cells by 16% (PMID: 27443263). ",Actionable,9497,9952,acute lymphocytic leukemia,DOID,14079,KMT2A rearrange,decreased response,1075,romidepsin,4297,27443263,,,
24,Clinical Study,"In multiple clinical studies, KMT2A rearrangements, specifically partial tandem duplications, were associated with a poor overall survival in acute myeloid leukemia patients (PMID: 24487413, PMID: 22915647, PMID: 22417203, PMID: 21881046). ",Prognostic,6222,9119,acute myeloid leukemia,DOID,14079,KMT2A rearrange,not applicable,1776,N/A,4297,22915647,21881046,24487413,22417203
25,Preclinical - Cell culture,"In a preclinical study, Dacinostat (LAQ824) enhanced the effects of Cytosar-U (cytarabine) in acute lymphoblastic leukemia cell lines harboring a KMT2A rearrangement in culture, resulting in cell death (PMID: 27443263). ",Actionable,9493,9952,acute lymphocytic leukemia,DOID,14079,KMT2A rearrange,sensitive,5038,Cytarabine + Dacinostat,4297,27443263,,,
26,Preclinical,"In a preclinical study, I-CBP112 sensitized leukemia cells harboring KMT2A fusions to Doxorubicin, leading to decreased cell growth in culture (PMID: 26552700).",Actionable,3775,1240,leukemia,DOID,14079,KMT2A rearrange,predicted â€“ sensitive,3299,I-CBP112 + Doxorubicin,4297,26552700,,,
27,Preclinical - Cell line xenograft,"In a preclinical study, Cytosar-U (cytarabine) decreased leukemic cells by 66% in acute lymphocytic leukemia cell line xenograft models harboring a KMT2A rearrangement (PMID: 27443263). ",Actionable,9498,9952,acute lymphocytic leukemia,DOID,14079,KMT2A rearrange,sensitive,712,Cytarabine,4297,27443263,,,
28,Preclinical - Cell culture,"In a preclinical study, Farydak (panobinostat) enhanced the effects of Cytosar-U (cytarabine) in acute lymphoblastic leukemia cells harboring a KMT2A rearrangement in culture, resulting in cell death (PMID: 27443263). ",Actionable,9491,9952,acute lymphocytic leukemia,DOID,14079,KMT2A rearrange,sensitive,5036,Cytarabine + Panobinostat,4297,27443263,,,
29,Preclinical - Patient cell culture,"In a preclinical study, I-BET151 and SGC0946 synergistically inhibited proliferation of patient-derived acute myeloid leukemia cells harboring KMT2A-ELL in culture (PMID: 27294782).",Actionable,11380,9119,acute myeloid leukemia,DOID,27964,KMT2A-ELL,sensitive,5966,I-BET151 + SGC0946,4297,27294782,,,
30,Preclinical - Cell line xenograft,"In a preclinical study, treatment with AMI-408 decreased growth of leukemia cells expressing KMT2A-GAS7 (MLL-GAS7) in culture, and increased survival in xenograft models (PMID:26766589).",Actionable,10326,1240,leukemia,DOID,27356,KMT2A-GAS7,sensitive,5463,AMI-408,4297,26766589,,,
31,Preclinical - Patient cell culture,"In a preclinical study, MI-503 inhibited growth of a primary acute myeloid sample harboring KMT2A-EP300 in culture (PMID: 25817203).",Actionable,11494,9119,acute myeloid leukemia,DOID,25868,KMT2A - EP300,sensitive,6006,MI-503,4297,25817203,,,
0,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep increased sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12S in culture (PMID: 26676756).",Actionable,8499,3910,lung adenocarcinoma,DOID,26343,KRAS G12S EZH2 pos,sensitive,4746,DZNep + Selumetinib,3845,26676756,,,
1,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12S in culture (PMID: 26676756)",Actionable,8511,3910,lung adenocarcinoma,DOID,26343,KRAS G12S EZH2 pos,sensitive,4747,DZNep + MK2206,3845,26676756,,,
2,Preclinical - Cell culture,"In a preclinical study, the combination of APS-2-49 and Binimetinib (MEK162) worked synergistically to decrease viability of a lung cancer cell line harboring KRAS G12S in culture (PMID: 27556948).",Actionable,8015,1324,lung cancer,DOID,1128,KRAS G12S,sensitive,4621,APS-2-79 + Binimetinib,3845,27556948,,,
3,Preclinical,"In a preclinical study, a colorectal cancer cell line harboring the KRAS G12S mutation showed resistance to Sutent (sunitinib) treatment (PMID: 23455880).",Actionable,817,9256,colorectal cancer,DOID,1128,KRAS G12S,resistant,930,Sunitinib,3845,23455880,,,
4,Preclinical,"In a preclinical study, a lung adenocarcinoma cell line harboring KRAS G12S demonstrated a decreased response when treated with Mekinist (trametinib) in culture (PMID: 26582713). ",Actionable,6450,1324,lung cancer,DOID,1128,KRAS G12S,decreased response,2,Trametinib,3845,26582713,,,
5,Preclinical,"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human non-small cell lung carcinoma cells harboring KRAS G12S in culture (PMID: 21325073, PMID: 23012248).",Actionable,3133,3908,non-small cell lung carcinoma,DOID,1128,KRAS G12S,sensitive,1040,PF-05212384,3845,21325073,23012248,,
6,Preclinical - Cell culture,"In a preclinical study, the combination of APS-2-49 and Selumetinib (AZD6244) worked synergistically to decrease viability of a lung cancer cell line harboring KRAS G12S in culture (PMID: 27556948).",Actionable,8017,1324,lung cancer,DOID,1128,KRAS G12S,sensitive,4622,APS-2-79 + Selumetinib,3845,27556948,,,
7,Preclinical,"In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring KRAS G12S mutation in culture (PMID: 26090892).",Actionable,3935,3908,non-small cell lung carcinoma,DOID,1128,KRAS G12S,sensitive,2086,TAE226,3845,26090892,,,
8,Preclinical,"In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Mekinist (trametinib) on human non-small cell lung cancer cells harboring KRAS G12S in culture (PMID: 25665005).",Actionable,4535,3908,non-small cell lung carcinoma,DOID,1128,KRAS G12S,sensitive,1386,Trametinib + Navitoclax,3845,25665005,,,
9,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring KRAS G12S in culture (PMID: 23629727).",Actionable,8179,3908,non-small cell lung carcinoma,DOID,1128,KRAS G12S,sensitive,1659,Pimasertib + Sorafenib,3845,23629727,,,
10,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring KRAS G12S in culture (PMID: 23629727).",Actionable,8184,3908,non-small cell lung carcinoma,DOID,1128,KRAS G12S,sensitive,4657,Pimasertib + Regorafenib,3845,23629727,,,
11,Preclinical,"In a preclinical study, TW-37 enhanced the inhibitory effect of Mekinist (trametinib) on human non-small cell lung cancer cells harboring KRAS G12S in culture (PMID: 25665005).",Actionable,4537,3908,non-small cell lung carcinoma,DOID,1128,KRAS G12S,sensitive,3532,Trametinib + TW-37,3845,25665005,,,
12,Preclinical,"In a preclinical study, a lung cancer cell line harboring KRAS G12S demonstrated a decreased response when treated with PD-0325901 in culture (PMID: 26582713). ",Actionable,6452,1324,lung cancer,DOID,1128,KRAS G12S,decreased response,849,PD-0325901,3845,26582713,,,
13,Preclinical - Cell culture,"In a preclinical study, AZD4785 inhibited Kras expression, resulted in growth inhibition in 3-D cultures of lung carcinoma cells harboring KRAS G12S (PMID: 28615361).",Actionable,11320,3905,lung carcinoma,DOID,1128,KRAS G12S,sensitive,5914,AZD4785,3845,28615361,,,
14,Preclinical - Cell line xenograft,"In a preclinical study, Estybon (rigosertib) inhibited Mek/Erk signaling and tumor growth in cell line xenograft models of lung cancer harboring KRAS G12S (PMID: 27104980).",Actionable,8561,1324,lung cancer,DOID,1128,KRAS G12S,sensitive,1046,rigosertib,3845,27104980,,,
15,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of non-small cell lung cancer cells harboring KRAS G12S in culture (PMID: 23629727).",Actionable,8175,3908,non-small cell lung carcinoma,DOID,1128,KRAS G12S,sensitive,4656,Everolimus + Pimasertib,3845,23629727,,,
16,Preclinical - Cell culture,"In a preclinical study, the combination of APS-2-49 and PD-0325901 worked synergistically to decrease viability of a lung cancer cell line harboring KRAS G12S in culture (PMID: 27556948).",Actionable,8016,1324,lung cancer,DOID,1128,KRAS G12S,sensitive,4623,APS-2-79 + PD-0325901,3845,27556948,,,
17,Preclinical - Cell culture,"In a preclinical study, Binimetinib (MEK162) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G12S mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).",Actionable,8987,3910,lung adenocarcinoma,DOID,1128,KRAS G12S,decreased response,807,Binimetinib,3845,27422710,,,
18,Preclinical - Cell culture,"In a preclinical study, the combination of APS-2-49 and Mekinist (trametinib) worked synergistically to decrease viability of a lung cancer cell line harboring KRAS G12S in culture (PMID: 27556948).",Actionable,8012,1324,lung cancer,DOID,1128,KRAS G12S,sensitive,4620,APS-2-79 + Trametinib,3845,27556948,,,
19,Preclinical,"In a preclinical study, pancreatic cell lines with KRAS codon 12 mutations had increased sensitivity to Binimetinib (MEK162) (PMID: 25167228).",Actionable,1445,1793,pancreatic cancer,DOID,1128,KRAS G12S,sensitive,807,Binimetinib,3845,25167228,,,
20,Preclinical,"In a preclinical study, a lung adenocarcinoma cell line harboring KRAS G12S demonstrated a decreased response when treated with Refametinib (BAY86-9766) in culture (PMID: 26582713). ",Actionable,6451,1324,lung cancer,DOID,1128,KRAS G12S,decreased response,888,Refametinib,3845,26582713,,,
21,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G12S mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).",Actionable,8995,3910,lung adenocarcinoma,DOID,1128,KRAS G12S,decreased response,913,Selumetinib,3845,27422710,,,
22,Preclinical - Cell line xenograft,"In a preclinical study, XL147 inhibited tumor growth in xenograft models of a human non-small cell lung cancer cell line harboring KRAS G12S and an STK11(LKB) inactivating mutation (PMID: 25637314).",Actionable,6336,3908,non-small cell lung carcinoma,DOID,23102,KRAS G12S STK11 inact mut,sensitive,1050,XL147,3845,25637314,,,
23,Preclinical,"In a preclinical study, expression of KRAS G12S in lung adenocarcinoma cells harboring EGFR exon 19 deletion resulted in resistance to Tagrisso (osimertinib) in culture, consistent with KRAS G12S identified in tumor samples of a lung adenocarcinoma patient harboring EGFR exon 19 deletion who developed resistance to Tagrisso (osimertinib) (PMID: 27252416).",Actionable,8803,3910,lung adenocarcinoma,DOID,26445,EGFR exon 19 del KRAS G12S,resistant,660,Osimertinib,3845,27252416,,,
24,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS amplification and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to combination therapy consisting of Tafinlar (dabrafenib) and SCH772984 in culture (PMID: 27312529).",Actionable,7686,9256,colorectal cancer,DOID,25925,BRAF V600E KRAS amp,resistant,4544,Dabrafenib + SCH772984,3845,27312529,,,
25,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment in culture, likely due to the acquired KRAS amplification (PMID: 27312529).",Actionable,7625,9256,colorectal cancer,DOID,25925,BRAF V600E KRAS amp,resistant,4525,Cetuximab + Dabrafenib,3845,27312529,,,
26,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS amplification and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7684,9256,colorectal cancer,DOID,25925,BRAF V600E KRAS amp,resistant,1711,Vemurafenib + Cetuximab,3845,27312529,,,
27,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS amplification and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) in culture (PMID: 27312529).",Actionable,7683,9256,colorectal cancer,DOID,25925,BRAF V600E KRAS amp,resistant,1916,Cetuximab + Encorafenib,3845,27312529,,,
28,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS amplification and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).",Actionable,7685,9256,colorectal cancer,DOID,25925,BRAF V600E KRAS amp,resistant,2618,SCH772984,3845,27312529,,,
29,Preclinical - Cell culture,"In a preclinical study, a lung cancer cell line with co-amplification of FGFR1 and KRAS demonstrated insensitivity to JNJ-42756493 (erdafitinib) in culture (PMID: 28341788).",Actionable,11187,1324,lung cancer,DOID,27925,FGFR1 amp KRAS amp,resistant,1028,JNJ-42756493,3845,28341788,,,
30,Preclinical,"In a preclinical study, the combination of Tagrisso (osimertinib) and Selumetinib increased Parp cleavage, and highly suppressed phosphorylated Erk in human non-small cell lung cancer cells harboring EGFR exon 19 deletion, EGFR T790M, and a gain in KRAS in culture (PMID: 25870145).",Actionable,4500,3908,non-small cell lung carcinoma,DOID,18232,EGFR exon 19 del EGFR T790M KRAS amp,sensitive,2225,Osimertinib + Selumetinib,3845,25870145,,,
31,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion, EGFR T790M and amplified KRAS were resistant to Tagrisso (osimertinib) treatment in culture (PMID: 25870145).",Actionable,4475,3908,non-small cell lung carcinoma,DOID,18232,EGFR exon 19 del EGFR T790M KRAS amp,resistant,660,Osimertinib,3845,25870145,,,
32,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Iressa (gefitinib) after the emergence of EGFR T790M and amplified KRAS in culture (PMID: 25870145).",Actionable,4474,3908,non-small cell lung carcinoma,DOID,18232,EGFR exon 19 del EGFR T790M KRAS amp,resistant,751,Gefitinib,3845,25870145,,,
33,Preclinical,"In a preclinical study, the combination of BEZ235 and the MEK1 inhibitor PD98509 worked synergistically or additively to inhibit growth of endometrial cancer cells with amplification of PIK3CA and KRAS in culture (PMID: 22662154).",Actionable,2142,1380,endometrial cancer,DOID,5417,PIK3CA amp KRAS amp,sensitive,2619,BEZ235 + PD98509,3845,22662154,,,
34,Phase III,"In retrospective study of a Phase III trial, melanoma patients harboring KRAS amplification treated with a combination of Paraplatin (carboplatin), Taxol (paclitaxel), and Nexavar (sorafenib) demonstrated a greater overall survival when compared to Paraplatin (carboplatin) and Taxol (paclitaxel) without Nexavar (sorafenib) (PMID: 26307133).",Actionable,4086,1909,melanoma,DOID,1413,KRAS amp,sensitive,3428,Sorafenib + Carboplatin + Paclitaxel,3845,26307133,,,
35,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and amplified KRAS were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",Actionable,4481,3908,non-small cell lung carcinoma,DOID,18233,EGFR exon 19 del KRAS amp,resistant,660,Osimertinib,3845,25870145,,,
36,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Gilotrif (afatinib) after the emergence of amplified KRAS in culture (PMID: 25870145).",Actionable,4480,3908,non-small cell lung carcinoma,DOID,18233,EGFR exon 19 del KRAS amp,resistant,623,Afatinib,3845,25870145,,,
37,Preclinical - Pdx,"In a preclinical study, combination of Sprycel (dasatinib) and Demcizumab (OMP-21M18) treatment resulted in durable tumor inhibition in patient-derived animal models of lung adenocarcinoma harboring KRAS G12F and PIK3CA H1047R (PMID: 26855149).",Actionable,10884,3910,lung adenocarcinoma,DOID,27820,KRAS G12F PIK3CA H1047R,sensitive,5671,Dasatinib + Demcizumab,3845,26855149,,,
38,Clinical Study,"In a retrospective study, Erbitux (cetuximab) treatment, alone or in combination, resulted in disease regression or stable disease in 88% (7/8) KRAS/BRAF-wild type colorectal carcinoma patients harboring a PIK3CA mutation (PMID: 25714871).",Actionable,3671,9256,colorectal cancer,DOID,14283,BRAF wild-type KRAS wild-type PIK3CA mutant,sensitive,694,Cetuximab,3845,25714871,,,
39,Phase II,"In a Phase II clinical trial, 30% (8/27) of patients with ERBB2 (HER2)-positive KRAS wild-type colorectal cancer achieved an objective response and 44% (12/27) of patients had stable disease when treated with the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) (PMID: 27108243).",Actionable,6482,9256,colorectal cancer,DOID,23355,ERBB2 positive KRAS wild-type,sensitive,1414,Trastuzumab + Lapatinib,3845,27108243,,,
40,Phase III,"In a Phase III trial, Avastin (bevacizumab) and Xeloda (capecitabine) maintenance treatment resulted in better time to first progression (HR = 0.27), time to second progression (HR = 0.42) and overall survival (HR = 0.64) in KRAS wild-type colorectal cancer patients compared to patients harboring KRAS mutations (HR = 0.40, 0.75, 1.07 respectively) (J Clin Oncol 34, 2016 (suppl; abstr 3525)).",Actionable,6954,9256,colorectal cancer,DOID,496,KRAS wild-type,predicted â€“ sensitive,2097,Bevacizumab + Capecitabine,3845,None,,,
41,Phase Ib/II,"In a Phase Ib/II clinical trial, BBI608 and Vectibix (panitumumab) combination therapy resulted in PR in 22.2% (2/9), SD in 22.2% (2/9), and median PFS of 9 weeks in colorectal cancer patients carrying wild-type Kras naive for anti-EGFR therapy; compared to SD in 53.3% (8/15), and median PFS of 16.4 weeks in patients failed anti-EGFR treatment (J Clin Oncol 33, 2015 (suppl; abstr 3617)). ",Actionable,5442,9256,colorectal cancer,DOID,496,KRAS wild-type,predicted â€“ sensitive,2092,BBI608 + Panitumumab,3845,None,,,
42,Preclinical,"In a preclinical study, treatment with GA201 induced antibody-dependent cell-mediated cytotoxicity against KRAS wild-type gastric adenocarcinoma in culture, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).",Actionable,3872,3717,gastric adenocarcinoma,DOID,496,KRAS wild-type,sensitive,3154,GA201,3845,23209031,,,
43,Phase III,"In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI improved progression-free survival and median overall survival in patients with RAS wild-type colorectal cancer compared to FOLFIRI treatment alone (PMID: 26341920).",Actionable,3268,9256,colorectal cancer,DOID,496,KRAS wild-type,sensitive,3102,Panitumumab + Oxaliplatin + Fluorouracil + Irinotecan,3845,26341920,,,
44,Phase III,"In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI improved progression-free survival and median overall survival in patients with KRAS exon 2 wild-type colorectal cancer compared to FOLFIRI treatment alone, with an overall response rate of 35% (105/297) with the combination versus 10% (28/285) with FOLFIRI alone (PMID: 26341920).",Actionable,3264,9256,colorectal cancer,DOID,496,KRAS wild-type,sensitive,3102,Panitumumab + Oxaliplatin + Fluorouracil + Irinotecan,3845,26341920,,,
45,Guideline,Vectibix (panitumumab) has demonstrated clinical efficacy only in colorectal cancer patients with wild-type KRAS (PMID: 18316791).  ,Actionable,578,10000003,Advanced Solid Tumor,JAX,496,KRAS wild-type,sensitive,845,Panitumumab,3845,18316791,,,
46,Preclinical - Cell line xenograft,"In a preclinical study, Glucophage (metformin) did not induce growth inhibition or apoptosis in a KRAS wild-type squamous cell carcinoma cell line in culture and did not inhibit tumor growth in xenograft models (PMID: 23877793).",Actionable,3222,1749,squamous cell carcinoma,DOID,496,KRAS wild-type,no benefit,1031,Metformin,3845,23877793,,,
47,Phase III,"In a Phase III trial, Nexavar (sorafenib) treatment in KRAS wild-type non-small cell lung carcinoma patients did not meet its primary endpoint when compared to placebo, resulting in a similar overall survival, however, did meet its secondary endpoint, showing a longer progression free survival (PMID: 26743856).",Actionable,7711,3908,non-small cell lung carcinoma,DOID,496,KRAS wild-type,no benefit,920,Sorafenib,3845,26743856,,,
48,Phase II,"In a Phase II clinical trial, the combination of Portrazza (necitumumab) and FOLFOX in colorectal cancer patients resulted in an objective response rate (ORR) of 63.6% (28/44) in the overall intent-to-treat population, with KRAS wild-type patients achieving an ORR of 87.5% (14/16), including complete response in 25% (4/16), and partial response in 62.5% (10/16) of patients (PMID: 26766738). ",Actionable,4368,9256,colorectal cancer,DOID,496,KRAS wild-type,predicted â€“ sensitive,3498,Necitumumab + FOLFOX,3845,26766738,,,
49,Phase I,"In a Phase I trial, Erbitux (cetuximab) and Revlimid (lenalidomide) combination therapy resulted in partial response in 5% (1/19) and stable disease in 32% (6/19) of KRAS wild-type colorectal cancer patients, and induced Revlimid (lenalidomide) dose-dependent increase of antibody-dependent cellular cytotoxicity (PMID: 27458141).",Actionable,8150,9256,colorectal cancer,DOID,496,KRAS wild-type,predicted â€“ sensitive,4647,Cetuximab + lenalidomide,3845,27458141,,,
50,Phase III,"In a post-hoc analysis of a Phase III trial, colorectal cancer patients with KRAS wild-type demonstrated a greater overall survival (8.1 mo) upon treatment with Vectibix (panitumumab) compared to overall survival (4.4 mo) of patients with KRAS mutations randomized to best supportive care only (PMID: 23625191).",Actionable,5505,9256,colorectal cancer,DOID,496,KRAS wild-type,sensitive,845,Panitumumab,3845,23625191,,,
51,Phase III,"In a Phase III trial, Vectibix (panitumumab) treatment resulted in better overall survival (HR = 0.65) compared to Erbitux (cetuximab) in colorectal cancer patients harboring KRAS with wild-type exon 2 who received prior Avastin (bevacizumab) treatment (J Clin Oncol 34, 2016 (suppl; abstr 3538)).",Actionable,6955,9256,colorectal cancer,DOID,496,KRAS wild-type,sensitive,845,Panitumumab,3845,None,,,
52,FDA approved,Vectibix (panitumumab) has demonstrated clinical efficacy only in colorectal cancer patients with wild-type KRAS (PMID: 18316791).  ,Actionable,582,9256,colorectal cancer,DOID,496,KRAS wild-type,sensitive,845,Panitumumab,3845,18316791,,,
53,Phase III,"In a Phase III trial, the combination of Erbitux (cetuximab) and FOLFIRI demonstrated a significant clinical benefit in OS, PFS, and objective response compared to FOLFIRI alone in colorectal cancer patients with RAS wild-type status (PMID: 25605843). ",Actionable,3356,9256,colorectal cancer,DOID,496,KRAS wild-type,predicted â€“ sensitive,2180,Cetuximab + FOLFIRI,3845,25605843,,,
54,Phase III,"In a Phase III trial, addition of Erbitux (cetuximab) or Avastin (bevacizumab) to chemotherapy (FOLFIRI or mFOLFOX6) resulted in similar median overall survival (30.0 vs 29.0 months, HR=0.88, p=0.08) and median progression-free survival (10.5 vs 10.6 months, HR=0.95, p?=?0.45) in KRAS wild-type colorectal cancer patients (PMID: 28632865).",Actionable,11285,9256,colorectal cancer,DOID,496,KRAS wild-type,predicted â€“ sensitive,694,Cetuximab,3845,28632865,,,
55,Phase Ib/II,"In a Phase Ib/II trial, the combination of Erbitux (cetuximab), Sprycel (dasatinib), and FOLFOX demonstrated minimal clinical benefit in patients with metastatic colorectal adenocarcinoma, with an overall response rate of 20% (6/30) in the Phase Ib portion, and 13% (3/24) in KRAS codon 12/13 wild-type patients in the Phase II portion (PMID: 28280091; NCT00501410).",Actionable,11609,50861,colorectal adenocarcinoma,DOID,496,KRAS wild-type,no benefit,6074,Cetuximab + Dasatinib + FOLFOX,3845,28280091,,,
56,Phase Ib/II,"In a Phase Ib trial, Cometriq (cabozantinib) and Vectibix (panitumumab) combination treatment resulted in a median progression free survival of 3.7 months, median overall survival of 7.5 months, and partial response in 14% (2/14) of KRAS wild-type colorectal patients (J Clin Oncol 34, 2016 (suppl; abstr 3548)). ",Actionable,6964,9256,colorectal cancer,DOID,496,KRAS wild-type,sensitive,1985,Panitumumab + cabozantinib,3845,None,,,
57,Phase Ib/II,"In a Phase Ib/II trial, the combination of HGF inhibitor, rilotumumab, with Vectibix (panitumumab) demonstrated efficacy in previously treated patients with wild-type KRAS metastatic colorectal cancer (PMID: 24919569).",Actionable,1454,9256,colorectal cancer,DOID,496,KRAS wild-type,sensitive,1775,Rilotumumab + Panitumumab,3845,24919569,,,
58,Phase I,"In a Phase I trial, Tarceva (erlotinib) treatment resulted in a greater survival benefit in non-small cell lung cancer patients with wild-type KRAS compared to treatment in those patients harboring KRAS mutations (PMID: 18626007).",Actionable,7859,3908,non-small cell lung carcinoma,DOID,496,KRAS wild-type,sensitive,4,Erlotinib,3845,18626007,,,
59,Phase I,"In a Phase I trial, GDC-0632 treatment resulted in stable disease for more than 5 months in 13% (6/45) of patients with advanced solid tumors and 1 partial response in a squamous cell vaginal carcinoma patient carrying wild-type KRAS (Mol Cancer Ther 2013;12(11 Suppl):B75).",Actionable,4013,138,vaginal squamous tumor,DOID,496,KRAS wild-type,sensitive,748,GDC-0623,3845,None,,,
60,Phase Ib/II,"In a Phase I/II trial, Refametinib (BAY86-9766) and Gemzar (gemcitabine) combination treatment resulted in improved overall response rate, disease control rate, progression-free survival, and overall survival (48% vs. 28%, 81% vs. 69%, 8.8 vs. 5.3 months,18.2 vs. 6.6 months, respectively) in pancreatic cancer patients without detectable KRAS mutations in circulating tumor DNA (PMID: 27975152).",Actionable,10503,1793,pancreatic cancer,DOID,496,KRAS wild-type,predicted â€“ sensitive,5545,Gemcitabine + Refametinib,3845,27975152,,,
61,Preclinical - Cell culture,"In a preclinical study, KRAS wild-type lung carcinoma cell lines demonstrated decreased respond to AZD4785 compared to KRAS mutant cell lines in culture (PMID: 28615361).",Actionable,11329,3905,lung carcinoma,DOID,496,KRAS wild-type,decreased response,5914,AZD4785,3845,28615361,,,
62,Clinical Study,"In a systematic review of 2,266 colorectal cancer patients, treatment with Avastin (bevacizumab) increased progression-free survival in patients harboring wild-type KRAS but not in patients with mutant KRAS (PMID: 23828442).",Actionable,1282,9256,colorectal cancer,DOID,496,KRAS wild-type,sensitive,667,Bevacizumab,3845,23828442,,,
63,Phase III,"In a Phase III trial, addition of Erbitux (cetuximab) or Avastin (bevacizumab) to chemotherapy (FOLFIRI or mFOLFOX6) resulted in similar median overall survival (30.0 vs 29.0 months, HR=0.88, p=0.08) and median progression-free survival (10.5 vs 10.6 months, HR=0.95, p?=?0.45) in KRAS wild-type colorectal cancer patients (PMID: 28632865).",Actionable,11286,9256,colorectal cancer,DOID,496,KRAS wild-type,sensitive,667,Bevacizumab,3845,28632865,,,
64,Preclinical - Pdx,"In a preclinical study, AZD4785 inhibited Kras expression in tumors, but had no effect on tumor growth in patient-derived xenograft models of KRAS wild-type non-small cell lung carcinoma (PMID: 28615361).",Actionable,11333,3908,non-small cell lung carcinoma,DOID,496,KRAS wild-type,decreased response,5914,AZD4785,3845,28615361,,,
65,Preclinical,"In a preclinical study, Mekinist (trametinib) and Iclusig (ponatinib) combination treatment was less efficient at inhibiting proliferation of KRAS wild-type lung cancer cells in culture (PMID: 27338794). ",Actionable,7369,1324,lung cancer,DOID,496,KRAS wild-type,decreased response,4477,Ponatinib + Trametinib,3845,27338794,,,
66,Phase II,"In a Phase II clinical trial, a PFS difference was not observed between KRAS wild-type biliary tract cancer patients when treated with a combination of Vectibix (panitumumab), Gemzar (gemcitabine), and Eloxatin (oxaliplatin) versus Gemzar (gemcitabine) and Eloxatin (oxaliplatin) only (PMID: 26540314). ",Actionable,3686,4607,biliary tract cancer,DOID,496,KRAS wild-type,predicted â€“ sensitive,3226,Panitumumab + Gemcitabine + Oxaliplatin,3845,26540314,,,
67,Preclinical - Cell culture,"In a preclinical study, KRAS wild-type pancreatic cancer cells were less sensitive to Aphanin induced growth inhibition and apoptosis in culture (PMID: 27333990).",Actionable,9100,1793,pancreatic cancer,DOID,496,KRAS wild-type,decreased response,4900,Aphanin,3845,27333990,,,
68,Phase I,"In a Phase I trial, Erbitux (cetuximab) and Revlimid (lenalidomide) combination therapy resulted in stable disease in 67% (2/3) of KRAS wild-type head and neck squamous cell cancer patients, and induced Revlimid (lenalidomide) dose-dependent increase of antibody-dependent cellular cytotoxicity (PMID: 27458141).",Actionable,8151,5520,head and neck squamous cell carcinoma,DOID,496,KRAS wild-type,predicted â€“ sensitive,4647,Cetuximab + lenalidomide,3845,27458141,,,
69,Preclinical - Cell culture,"In a preclinical study, KRAS wild-type colorectal cancer cell lines demonstrated decreased respond to AZD4785 compared to KRAS mutant cell lines in culture (PMID: 28615361).",Actionable,11331,9256,colorectal cancer,DOID,496,KRAS wild-type,decreased response,5914,AZD4785,3845,28615361,,,
70,FDA approved,Clinical efficacy of Erbitux (cetuximab) has only been demonstrated in patients with wild-type KRAS (PMID: 19064407).  ,Actionable,577,10000003,Advanced Solid Tumor,JAX,496,KRAS wild-type,sensitive,694,Cetuximab,3845,19064407,,,
71,Phase I,"In a Phase I trial, GDC-0632 treatment resulted in stable disease for more than 5 months in 13% (6/45) of patients with advanced solid tumors and 1 partial response in a squamous cell vaginal carcinoma patient carrying wild-type KRAS (Mol Cancer Ther 2013;12(11 Suppl):B75).",Actionable,4012,10000003,Advanced Solid Tumor,JAX,496,KRAS wild-type,sensitive,748,GDC-0623,3845,None,,,
72,Preclinical - Cell line xenograft,"In a preclinical study, treatment with the combination of GA201 and Camptosar (irinotecan) resulted in improved overall survival in KRAS wild-type colorectal cancer cell line xenograft models with low EGFR expression, when compared to either as a single agent (PMID: 23209031).",Actionable,3873,9256,colorectal cancer,DOID,16552,EGFR dec exp KRAS wild-type,sensitive,3373,GA201 + Irinotecan,3845,23209031,,,
73,Preclinical - Cell line xenograft,"In a preclinical study, treatment with GA201 resulted in improved overall survival in KRAS wild-type colorectal cancer cell line xenograft models with low EGFR expression, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).",Actionable,3871,9256,colorectal cancer,DOID,16552,EGFR dec exp KRAS wild-type,sensitive,3154,GA201,3845,23209031,,,
74,Preclinical - Pdx,"In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib)  combination treatment did not result in enhanced antitumor activity compared to Ibrance (palbociclib) alone in PDX models of KRAS wild-type colorectal cancer harboring BRAF V600E (PMID: 26369631).",Actionable,5623,9256,colorectal cancer,DOID,21304,BRAF V600E KRAS wild-type,no benefit,1368,Palbociclib + Trametinib,3845,26369631,,,
75,Clinical Study,"In a retrospective study, 100% (2/2) colorectal carcinoma patients harboring an AKT1 E17K mutation and wild-type KRAS/BRAF demonstrated resistance to Erbitux (cetuximab) in combination with Camptosar (irinotecan) (PMID: 25714871).",Actionable,3614,9256,colorectal cancer,DOID,13841,AKT1 E17K KRAS wild-type BRAF wild-type,resistant,1874,Cetuximab + Irinotecan,3845,25714871,,,
76,Preclinical - Pdx,"In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib)  combination treatment did not result in enhanced antitumor activity compared to Ibrance (palbociclib) alone in PDX models of KRAS wild-type colorectal cancer harboring PIK3CA H1047R (PMID: 26369631).",Actionable,5622,9256,colorectal cancer,DOID,21303,KRAS wild-type PIK3CA H1047R,no benefit,1368,Palbociclib + Trametinib,3845,26369631,,,
77,Phase I,"In a Phase I trial, a squamous non-small cell lung carcinoma patient with KRAS wild-type and loss of CDKN2A demonstrated a partial response when treated with Abemaciclib (LY2835219) (PMID: 27217383). ",Actionable,7431,3908,non-small cell lung carcinoma,DOID,25455,CDKN2A loss KRAS wild-type,sensitive,802,Abemaciclib,3845,27217383,,,
78,Preclinical - Pdx,"In a preclinical study, LSN3074753 demonstrated limited efficacy in BRAF and KRAS wild-type patient-derived xenograft models of colorectal cancer, resulted in a disease control rate of 3.8% (1/26) (PMID: 28611205).",Actionable,12189,9256,colorectal cancer,DOID,28546,BRAF wild-type KRAS wild-type,decreased response,6337,LSN3074753,3845,28611205,,,
79,Preclinical,"In a preclinical study, knocking down of Fgfr1 through shRNA did not sensitize KRAS wild-type lung cancer cells to Mekinist (trametinib) induced growth inhibition in culture  (PMID: 27338794).",Actionable,7364,1324,lung cancer,DOID,25310,FGFR1 dec exp KRAS wild-type,no benefit,2,Trametinib,3845,27338794,,,
80,Preclinical,"In a preclinical study, Erbitux (cetuximab) inhibited growth of human colorectal cancer cells wild-type for BRAF, KRAS, NRAS and PIK3CA in culture (PMID: 25838391).",Actionable,4934,9256,colorectal cancer,DOID,19839,BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type,sensitive,694,Cetuximab,3845,25838391,,,
81,Preclinical,"In a preclinical study, colorectal cancer cell lines with wild-type BRAF, KRAS, NRAS and PIK3CA were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).",Actionable,4944,9256,colorectal cancer,DOID,19839,BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type,resistant,890,Regorafenib,3845,25838391,,,
82,Phase II,"In a Phase II trial, Erbitux (cetuximab) in combination with FOLFOX resulted in improved median progression-free survival (6.9 months) comparing to FOLFOX alone (5.3 months) in BRAF, KRAS, NRAS, and PIK3CA wild-type colorectal cancer patients (hazard ratio =0.56) (PMID: 27002107).",Actionable,5563,9256,colorectal cancer,DOID,19839,BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type,predicted â€“ sensitive,2182,Cetuximab + FOLFOX,3845,27002107,,,
83,Preclinical - Cell culture,"In a preclinical study, the combination of Gilotrif (afatinib) and Mekinist (trametinib) worked synergistically to inhibit growth of a pancreatic adenocarcinoma cell line with wild-type KRAS that demonstrated high EGFR expression and activation in culture (PMID: 28957417).",Actionable,12145,4074,pancreatic adenocarcinoma,DOID,28493,EGFR over exp KRAS wild-type,sensitive,4482,Afatinib + Trametinib,3845,28957417,,,
84,Preclinical - Cell culture,"In a preclinical study, the combination of Triciribine (API-2) and Mekinist (trametinib) worked synergistically to inhibit growth of a pancreatic adenocarcinoma cell line with wild-type KRAS that demonstrated high EGFR expression and activation in culture (PMID: 28957417).",Actionable,12146,4074,pancreatic adenocarcinoma,DOID,28493,EGFR over exp KRAS wild-type,sensitive,6312,Trametinib + Triciribine,3845,28957417,,,
85,Preclinical - Cell culture,"In a preclinical study, lung cancer cell lines harboring activating KRAS mutations demonstrated increased sensitivity to Dinaciclib (SCH 727965) in culture (PMID: 27550941).",Actionable,9139,1324,lung cancer,DOID,16855,KRAS act mut,predicted â€“ sensitive,719,Dinaciclib,3845,27550941,,,
86,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) and AZ628 synergistically inhibited Mapk signaling and cell proliferation in colorectal cancer cell lines harboring KRAS activating mutations in culture (PMID: 26351322).",Actionable,8679,9256,colorectal cancer,DOID,16855,KRAS act mut,sensitive,4791,AZ628 + Selumetinib,3845,26351322,,,
87,Preclinical - Cell culture,"In a preclinical study, inhibition of Erk signaling by VX-11e did not sensitize colorectal cancer cell lines harboring KRAS or BRAF activating mutations to Venclexta (venetoclax) in culture (PMID: 27974663).",Actionable,10076,9256,colorectal cancer,DOID,16855,KRAS act mut,no benefit,5375,Venetoclax + VX-11e,3845,27974663,,,
88,Preclinical - Cell culture,"In a preclinical study, inhibition of Erk signaling by VX-11e sensitized colorectal cancer cell lines harboring KRAS or BRAF activating mutations to WEHI-539 in culture (PMID: 27974663).",Actionable,10074,9256,colorectal cancer,DOID,16855,KRAS act mut,predicted â€“ sensitive,5374,VX-11e + WEHI-539,3845,27974663,,,
89,Preclinical,"In a preclinical study, the combination of BEZ235 and the MEK1 inhibitor PD98509 worked synergistically or additively to inhibit growth of endometrial cancer cells harboring PIK3CA G1049R, KRAS G12D, and amplification of PIK3CA in culture (PMID: 22662154).",Actionable,2143,1380,endometrial cancer,DOID,5398,PIK3CA G1049R KRAS G12D PIK3CA amp,sensitive,2619,BEZ235 + PD98509,3845,22662154,,,
90,Preclinical - Cell line xenograft,"In a preclinical study, Glucophage (metformin) inhibited cell proliferation and induced apoptosis in a PTEN-expressing human endometrial cancer cell line harboring KRAS G12D in culture and decreased tumor growth in xenograft models (PMID: 24077915).",Actionable,590,1380,endometrial cancer,DOID,26548,PTEN pos KRAS G12D,sensitive,1031,Metformin,3845,24077915,,,
91,Preclinical,"In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH2 R172K and KRAS G12D demonstrated increased sensitivity to Saracatinib (AZD0530) induced growth inhibition in culture (PMID: 27231123).",Actionable,7354,4928,intrahepatic cholangiocarcinoma,DOID,25295,IDH2 R172K KRAS G12D,sensitive,912,Saracatinib,3845,27231123,,,
92,Preclinical,"In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH2 R172K and KRAS G12D demonstrated increased sensitivity to Sprycel (dasatinib) induced growth inhibition in culture and in xenograft models (PMID: 27231123).",Actionable,7353,4928,intrahepatic cholangiocarcinoma,DOID,25295,IDH2 R172K KRAS G12D,sensitive,717,Dasatinib,3845,27231123,,,
93,Preclinical,"In a preclinical study, KRAS G12D was detected in animal models of EGFR L858R-induced lung adenocarcinoma, which developed after repeated Gilotrif (afatinib) and Erbitux (cetuximab) combination treatments and resulted in drug resistance (PMID: 26341921).",Actionable,6654,3910,lung adenocarcinoma,DOID,23661,EGFR L858R KRAS G12D,resistant,4190,Afatinib + Cetuximab,3845,26341921,,,
94,Preclinical,"In a preclinical study, AZD5363 inhibited proliferation of the AGS gastric cancer cell line, which has been reported to harbor KRAS G12D and PIK3CA E453K mutations (PMID: 24088382, PMID: 19755509).",Actionable,2860,10534,stomach cancer,DOID,10717,KRAS G12D PIK3CA E453K,sensitive,655,AZD5363,3845,24088382,,,
95,Preclinical,"In a preclinical study, a human gastric cancer cell line with high levels of MET expression and expressing KRAS G12D was resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 26432108).",Actionable,4082,10534,stomach cancer,DOID,17217,KRAS G12D MET over exp,resistant,706,Crizotinib,3845,26432108,,,
96,Clinical Study,"In a clinical case study, a patient with colorectal cancer harboring KRAS G12D and PIK3CA Q546R demonstrated sensitivity to treatment with the combination of Nexavar (sorafenib) and Avastin (bevacizumab), resulting in stable disease for more than 6 months (PMID: 25363205). ",Actionable,7768,9256,colorectal cancer,DOID,27864,KRAS G12D PIK3CA Q546R,sensitive,4517,Bevacizumab + Sorafenib,3845,25363205,,,
97,Preclinical,"In a preclinical study, SRA737 (CCT245737) resulted in some decreased tumor volume in a pancreatic ductal adenocarcinoma transgenic mouse model harboring KRAS G12D and TP53 R175H when compared to control (PMID: 27167172). ",Actionable,9550,3498,pancreatic ductal adenocarcinoma,DOID,18195,KRAS G12D TP53 R175H,sensitive,5069,SRA737,3845,27167172,,,
98,Preclinical,"In a preclinical study, the combination of pimasertib and Gemzar (gemcitabine) inhibited tumor growth in a syngeneic mouse model of pancreatic cancer expressing KRAS G12D and TP53 R175H (PMID: 26228206).",Actionable,4467,1793,pancreatic cancer,DOID,18195,KRAS G12D TP53 R175H,sensitive,3526,Pimasertib + Gemcitabine,3845,26228206,,,
99,Preclinical,"In a preclinical study, Rapamune (sirolimus) treatment in transgenic animal models of pancreatic ductal adenocarcinoma harboring KRAS G12D and TP53 R175H resulted in proliferation of tumor cells in interior, hypovascularized tumor regions, but inhibited proliferation in outer, vascularized tumor regions, despite inhibition of mTORC signaling in both regions (PMID: 26144316).",Actionable,8856,3498,pancreatic ductal adenocarcinoma,DOID,18195,KRAS G12D TP53 R175H,conflicting,917,Sirolimus,3845,26144316,,,
100,Preclinical,"In a preclinical study, PI-3065 treatment prolonged survival and decreased metastasis in allograft animal models of pancreatic ductal adenocarcinoma harboring KRAS G12D and TP53 R175H through upregulation of host anti-tumor immune response(PMID: 24919154).",Actionable,5164,3498,pancreatic ductal adenocarcinoma,DOID,18195,KRAS G12D TP53 R175H,not applicable,2965,PI-3065,3845,24919154,,,
101,Preclinical,"In a preclinical study, Gemzar (gemcitabine) resulted in enhanced antitumor efficacy, including decreased tumor volume, when combined with SRA737 (CCT245737) in a pancreatic ductal adenocarcinoma transgenic mouse model harboring KRAS G12D and TP53 R175H (PMID: 27167172). ",Actionable,9549,3498,pancreatic ductal adenocarcinoma,DOID,18195,KRAS G12D TP53 R175H,sensitive,5070,Gemcitabine + SRA737,3845,27167172,,,
102,Preclinical - Pdx,"In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib)  combination treatment resulted in partial tumor regression in PDX models of colorectal cancer cells harboring KRAS G12D and PIK3CA Q546L (PMID: 26369631).",Actionable,5619,9256,colorectal cancer,DOID,21301,KRAS G12D PIK3CA Q546L,sensitive,1368,Palbociclib + Trametinib,3845,26369631,,,
103,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063).",Actionable,8702,9256,colorectal cancer,DOID,26376,KRAS G12D PIK3CA H1047R TP53 wild-type,decreased response,913,Selumetinib,3845,26272063,,,
104,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment did not improve tumor growth stabilization compared to single agent in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063).",Actionable,8601,9256,colorectal cancer,DOID,26376,KRAS G12D PIK3CA H1047R TP53 wild-type,no benefit,1420,Selumetinib + BEZ235,3845,26272063,,,
105,Preclinical - Pdx,"In a preclinical study, BEZ235 inhibited tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063).",Actionable,8703,9256,colorectal cancer,DOID,26376,KRAS G12D PIK3CA H1047R TP53 wild-type,predicted â€“ sensitive,672,BEZ235,3845,26272063,,,
106,Preclinical,"In a preclinical study, Sapanisertib (MLN0128) inhibited lung tumor growth in mouse models with KRAS G12D and inactivation of STK11 (LKB1), and demonstrated limited efficacy in tumors with KRAS G12D and wild-type STK11 (PMID: 26574479).",Actionable,5409,1324,lung cancer,DOID,20862,KRAS G12D STK11 inact mut,sensitive,1282,Sapanisertib,3845,26574479,,,
107,Preclinical,"In a preclinical study, BEZ235 did not induce tumor shrinkage in mouse lung cancer models carrying KRAS G12D (PMID: 19029981).",Actionable,1290,1324,lung cancer,DOID,746,KRAS G12D,no benefit,672,BEZ235,3845,19029981,,,
108,Preclinical - Cell line xenograft,"In a preclinical study, Pictilisib (GDC-0941) demonstrated limited efficacy as a single agent in a pancreatic cell line xenograft model harboring KRAS G12D (PMID: 22952903).",Actionable,2764,1793,pancreatic cancer,DOID,746,KRAS G12D,decreased response,749,GDC-0941,3845,22952903,,,
109,Preclinical,"In a preclinical study, the treatment of KRAS G12D mutant mouse lung cancer with PX-866, a PI3K inhibitor, resulted in inhibition of tumor growth (PMID: 18493606). ",Actionable,980,3910,lung adenocarcinoma,DOID,746,KRAS G12D,sensitive,881,PX-866,3845,18493606,,,
110,Preclinical,"In a preclinical study, the combination of Buparlisib (BKM120) and Tyrphostin B42 (AG-490) worked synergistically to inhibit proliferation and induce apoptosis in gastric cancer cell lines harboring KRAS G12D in culture (PMID: 22159814).",Actionable,2739,10534,stomach cancer,DOID,746,KRAS G12D,sensitive,3019,BKM120 + AG490,3845,22159814,,,
111,Preclinical,"In a preclinical study, UC-857993 did not inhibit growth of pancreatic cancer cells harboring KRAS G12D in culture (PMID: 25825487).",Actionable,2464,1793,pancreatic cancer,DOID,746,KRAS G12D,resistant,2861,UC-857993,3845,25825487,,,
112,Preclinical,"In a preclinical study, a colorectal cancer cell line harboring the KRAS G12D mutation showed resistance to Sutent (sunitinib) treatment (PMID: 23455880).",Actionable,803,9256,colorectal cancer,DOID,746,KRAS G12D,resistant,930,Sunitinib,3845,23455880,,,
113,Preclinical,"In a preclinical study, the treatment of a mouse model lung adenocarcinoma harboring the KRAS G12D mutant with selumetinib, a MEK inhibitor, resulted in modest tumor regression (PMID: 19029981).",Actionable,978,3910,lung adenocarcinoma,DOID,746,KRAS G12D,decreased response,913,Selumetinib,3845,19029981,,,
114,Clinical Study,"In a clinical case study, a patient with metastatic colorectal cancer harboring KRAS G12D demonstrated regression of metastatic lung lesions and a partial response for 9 months following infusion of autologous tumor-infiltrating lymphocytes containing cytotoxic T-cells that specifically recognize KRAS G12D (PMID: 27959684).",Actionable,9636,9256,colorectal cancer,DOID,746,KRAS G12D,sensitive,5112,KRAS mutant-specific TIL,3845,27959684,,,
115,Preclinical,"In a preclinical study, PD-0325901 inhibited growth of lung adenocarcinomas in mouse models expressing Kras G12D (PMID: 22684718).",Actionable,2733,3910,lung adenocarcinoma,DOID,746,KRAS G12D,sensitive,849,PD-0325901,3845,22684718,,,
116,Preclinical,"In a preclinical study, LY294002 reduced phosphorylation of Akt in pancreatic epithelial cells expressing Kras G12D (PMID: 22871572). ",Actionable,2730,10000003,Advanced Solid Tumor,JAX,746,KRAS G12D,sensitive,1062,LY294002,3845,22871572,,,
117,Preclinical - Cell culture,"In a preclinical study, AUY922 inhibited growth of a colon cancer cell line harboring KRAS G12D in culture (PMID: 26832792).",Actionable,9211,219,colon cancer,DOID,746,KRAS G12D,sensitive,647,AUY922,3845,26832792,,,
118,Preclinical - Cell culture,"In a preclinical study, AZD4785 inhibited Kras expression, resulted in growth inhibition in 3-D cultures of pancreatic cancer cells harboring KRAS G12D (PMID: 28615361).",Actionable,11327,1793,pancreatic cancer,DOID,746,KRAS G12D,sensitive,5914,AZD4785,3845,28615361,,,
119,Preclinical,"In a preclinical study, BEZ235 in combination with Selumetinib (AZD6244) induced tumor shrinkage in mouse lung cancer models carrying KRAS G12D (PMID: 19029981).",Actionable,1291,1324,lung cancer,DOID,746,KRAS G12D,sensitive,1420,Selumetinib + BEZ235,3845,19029981,,,
120,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Pictilisib (GDC-0941) and Selumetinib (AZD6244) worked synergistically to induce tumor regression in a pancreatic cancer cell line xenograft model harboring KRAS G12D (PMID: 22952903).",Actionable,2763,1793,pancreatic cancer,DOID,746,KRAS G12D,sensitive,3024,GDC-0941 + Selumetinib,3845,22952903,,,
121,Preclinical - Pdx,"In a preclinical study, LSN3074753 resulted in tumor regression in a patient-derived xenograft model of colorectal cancer harboring KRAS G12D, but relapse upon discontinuation of treatment (PMID: 28611205).",Actionable,12193,9256,colorectal cancer,DOID,746,KRAS G12D,predicted â€“ sensitive,6337,LSN3074753,3845,28611205,,,
122,Preclinical,"In a preclinical study, SH-1242 inhibited lung tumor growth in a KRAS G12D-expressing transgenic mouse model that forms spontaneous lung tumors (PMID: 26645561).",Actionable,4618,1324,lung cancer,DOID,746,KRAS G12D,sensitive,3552,SH-1242,3845,26645561,,,
123,Preclinical,"In a preclinical study, Herceptin (trastuzumab) and Nerlynx (neratinib) combination treatment resulted in continued tumor growth in xenograft models of patient derived colorectal cancer cells harboring KRAS G12D (PMID: 26243863).",Actionable,7129,9256,colorectal cancer,DOID,746,KRAS G12D,resistant,4359,Neratinib + Trastuzumab,3845,26243863,,,
124,Preclinical,"In a preclinical study, Pictilisib (GDC-0941) demonstrated efficacy in a mouse model of chronic myelomonocytic leukemia expressing KRAS G12D (ASH Annual Meeting Abstracts 2012 120: 2862).",Actionable,2759,4972,myelodysplastic/myeloproliferative neoplasm,DOID,746,KRAS G12D,sensitive,749,GDC-0941,3845,None,,,
125,Preclinical,"In a preclinical study, the combination of Mekinist (trametinib) and Iclusig (ponatinib) induced cell death in tumors and prolonged survival in an animal model of pancreatic cancer harboring KRAS G12D (PMID: 27338794).",Actionable,7377,1793,pancreatic cancer,DOID,746,KRAS G12D,sensitive,4477,Ponatinib + Trametinib,3845,27338794,,,
126,Preclinical,"In a preclinical study, Estybon (rigosertib) inhibited tumorigenesis in transgenic animal model of pancreatic cancer driven by KRAS G12D (PMID: 27104980).",Actionable,8562,1793,pancreatic cancer,DOID,746,KRAS G12D,sensitive,1046,rigosertib,3845,27104980,,,
127,Preclinical,"In a preclinical study, AZD8055 worked synergistically with MK-1775 to inhibit proliferation and promote apoptosis in transformed cells expressing KRAS G12D in culture (PMID: 24791855).",Actionable,2711,10000003,Advanced Solid Tumor,JAX,746,KRAS G12D,sensitive,3017,AZD8055 + MK-1775,3845,24791855,,,
128,Preclinical - Cell culture,"In a preclinical study, Aphanin inhibited proliferation and induced apoptosis in pancreatic cancer cells harboring KRAS G12D in culture (PMID: 27333990).",Actionable,9099,1793,pancreatic cancer,DOID,746,KRAS G12D,predicted â€“ sensitive,4900,Aphanin,3845,27333990,,,
129,Guideline,"Vectibix (panitumumab) is not indicated for use in colorectal cancer patients with KRAS exon 2 mutations (Guidelines).",Actionable,1527,9256,colorectal cancer,DOID,746,KRAS G12D,resistant,845,Panitumumab,3845,None,,,
130,FDA approved,Patients with metastatic colorectal cancer harboring KRAS mutations in codons 12 or 13 showed resistance to Vectibix (panitumumab) (PMID: 18316791).,Actionable,583,9256,colorectal cancer,DOID,746,KRAS G12D,resistant,845,Panitumumab,3845,18316791,,,
131,Preclinical - Pdx,"In a preclinical study, LSN3074753 and Erbitux (cetuximab) worked synergistically, resulting in tumor regression in patient-derived xenograft models of colorectal cancer harboring KRAS G12D (PMID: 28611205).",Actionable,12196,9256,colorectal cancer,DOID,746,KRAS G12D,sensitive,6338,Cetuximab + LSN3074753,3845,28611205,,,
132,Clinical Study,"In a clinical case report, treatment with Reolysin (pelareorep) in combination with Gemzar (gemcitabine) resulted in stable disease in a patient with pancreatic cancer harboring KRAS G12D (PMID: 26156229).",Actionable,2747,1793,pancreatic cancer,DOID,746,KRAS G12D,sensitive,3020,Reolysin + Gemcitabine,3845,26156229,,,
133,Preclinical,"In a preclinical study, a mouse lung adenocarcinoma model harboring the KRAS G12D mutation treated with a combination of the MEK inhibitor selumetinib (AZD6244) and the PI3K inhibitor BEZ235 resulted in significant tumor regression (PMID: 19029981).",Actionable,979,3910,lung adenocarcinoma,DOID,746,KRAS G12D,sensitive,1420,Selumetinib + BEZ235,3845,19029981,,,
134,Preclinical - Pdx,"In a preclinical study, TAK-733 induce tumor regression in patient derived xenografts of cholangiocarcinoma with Kras G12D mutations (AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2523).",Actionable,2771,4947,cholangiocarcinoma,DOID,746,KRAS G12D,sensitive,932,TAK-733,3845,None,,,
135,Preclinical,"In a preclinical study, UC-773587 did not inhibit growth of pancreatic cancer cells harboring KRAS G12D in culture (PMID: 25825487).",Actionable,2463,1793,pancreatic cancer,DOID,746,KRAS G12D,resistant,2860,UC-773587,3845,25825487,,,
136,Guideline,Ertibux (cetuximab) is not indicated for use in colorectal cancer patients with KRAS exon 2 mutations (Guidelines).,Actionable,1524,9256,colorectal cancer,DOID,746,KRAS G12D,resistant,694,Cetuximab,3845,None,,,
137,Clinical Study,"In a clinical study, KRAS mutations in codon 12 or 13 were associated with resistance to Erbitux (cetuximab) in colorectal cancer patients (PMID: 18202412).",Actionable,575,9256,colorectal cancer,DOID,746,KRAS G12D,resistant,694,Cetuximab,3845,18202412,,,
138,FDA approved,Colorectal cancer patients with KRAS mutations in exon 12 or 13 are resistant to Vectibix (panitumumab) (PMID: 18316791).,Actionable,579,10000003,Advanced Solid Tumor,JAX,746,KRAS G12D,predicted â€“ resistant,845,Panitumumab,3845,18316791,,,
139,Preclinical,"In a preclinical study, Nerlynx (neratinib) treatment resulted in continued tumor growth in xenograft models of patient derived colorectal cancer cells harboring KRAS G12D (PMID: 26243863).",Actionable,7128,9256,colorectal cancer,DOID,746,KRAS G12D,resistant,828,Neratinib,3845,26243863,,,
140,Preclinical,"In a preclinical study, Aliqopa (copanlisib) and Refametinib (BAY86-9766) worked synergistically to inhibit proliferation and increase apoptosis of biliary tract cancer cells harboring KRAS G12D in culture (Cancer Res April 15, 2012 72:869).",Actionable,2721,4607,biliary tract cancer,DOID,746,KRAS G12D,sensitive,3018,Copanlisib + Refametinib,3845,None,,,
141,Preclinical,"In a preclinical study, combination of BEZ235 and Binimetinib (MEK162) increased survival compared to single agent in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation and KRAS G12D (PMID: 26206338).",Actionable,9201,9256,colorectal cancer,DOID,26772,APC inact mut KRAS G12D PTEN inact mut,sensitive,4932,BEZ235 + Binimetinib,3845,26206338,,,
142,Preclinical,"In a preclinical study, Binimetinib (MEK162) increased both apoptosis and proliferation in tumors, resulted in no improvement in survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation and KRAS G12D (PMID: 26206338).",Actionable,9194,9256,colorectal cancer,DOID,26772,APC inact mut KRAS G12D PTEN inact mut,no benefit,807,Binimetinib,3845,26206338,,,
143,Preclinical,"In a preclinical study, BEZ235 inhibited mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation, and KRAS G12D (PMID: 26206338).",Actionable,9191,9256,colorectal cancer,DOID,26772,APC inact mut KRAS G12D PTEN inact mut,sensitive,672,BEZ235,3845,26206338,,,
144,Preclinical - Pdx,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment resulted in tumor growth stabilization in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D, PIK3CA E545K and H1047L (PMID: 26272063).",Actionable,8581,9256,colorectal cancer,DOID,26369,KRAS G12D PIK3CA E545K PIK3CA H1047L TP53 wild-type,sensitive,4771,MLN0128 + PD-0325901,3845,26272063,,,
145,Preclinical,"In a preclinical study, a KRAS G12D driven lung adenocarcinoma mouse model with homozygous deletion of ATM was sensitive to VX-970, demonstrating decreased tumor volume and greater overall survival compared to control treated models (PMID: 28363999). ",Actionable,11388,3910,lung adenocarcinoma,DOID,27978,ATM del KRAS G12D,sensitive,2879,VX-970,3845,28363999,,,
146,Preclinical,"In a preclinical study, a KRAS G12D driven lung adenocarcinoma mouse model with homozygous deletion of ATM was sensitive to Lynparza (olaparib), demonstrating reduced tumor volume and greater overall survival when compared to models treated with control (PMID: 28363999).",Actionable,11387,3910,lung adenocarcinoma,DOID,27978,ATM del KRAS G12D,sensitive,837,Olaparib,3845,28363999,,,
147,Preclinical,"In a preclinical study, CH5132799 inhibited proliferation of endometrial cancer cells harboring PIK3CA G1049R and KRAS G12D mutations in culture (PMID: 21558396).",Actionable,2954,1380,endometrial cancer,DOID,10740,KRAS G12D PIK3CA G1049R,sensitive,2152,CH5132799,3845,21558396,,,
148,Preclinical - Pdx,"In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R, and TP53 R248W did not respond to Selumetinib (AZD6244) treatment (PMID: 26272063).",Actionable,8695,9256,colorectal cancer,DOID,26372,KRAS G12D PIK3CA H1047R TP53 R248W,resistant,913,Selumetinib,3845,26272063,,,
149,Preclinical - Pdx,"In a preclinical study, BEZ235 stabilized tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R, and TP53 R248W (PMID: 26272063).",Actionable,8697,9256,colorectal cancer,DOID,26372,KRAS G12D PIK3CA H1047R TP53 R248W,predicted â€“ sensitive,672,BEZ235,3845,26272063,,,
150,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment did not improve tumor growth stabilization compared to single agent in patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R and TP53 R248W (PMID: 26272063).",Actionable,8596,9256,colorectal cancer,DOID,26372,KRAS G12D PIK3CA H1047R TP53 R248W,no benefit,1420,Selumetinib + BEZ235,3845,26272063,,,
151,Clinical Study,"In a clinical case study, a patient with a MET amplified esophageal carcinoma that initially responded to AMG 337, developed resistance upon emergence of KRAS G12D (PMID: 26432108). ",Actionable,4081,1107,esophageal carcinoma,DOID,17216,KRAS G12D MET amp,resistant,1064,AMG 337,3845,26432108,,,
152,Phase I,"In a Phase I study, a patient with pancreatic adenocarcinoma harboring PTEN loss and KRAS G12D was treated with MK-2206 and demonstrated a 23% reduction in tumor size (PMID: 22025163).",Actionable,2147,4074,pancreatic adenocarcinoma,DOID,5589,PTEN loss KRAS G12D,sensitive,816,MK2206,3845,22025163,,,
153,Preclinical - Pdx,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12D, decreased PTEN expression, and TP53 R306* (PMID: 26272063).",Actionable,8576,9256,colorectal cancer,DOID,26365,KRAS G12D PTEN dec exp TP53 R306*,no benefit,4771,MLN0128 + PD-0325901,3845,26272063,,,
154,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing pancreatic cancer cell line harboring KRAS G12D in culture (PMID: 26676756).",Actionable,8516,1793,pancreatic cancer,DOID,26340,KRAS G12D EZH2 pos,no benefit,4746,DZNep + Selumetinib,3845,26676756,,,
155,Preclinical - Cell line xenograft,"In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D in culture and in xenograft models, resulting in decreased cell survival and tumor growth (PMID: 26676756).",Actionable,8506,3910,lung adenocarcinoma,DOID,26340,KRAS G12D EZH2 pos,sensitive,4747,DZNep + MK2206,3845,26676756,,,
156,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing colon cancer cell line harboring KRAS G12D in culture (PMID: 26676756).",Actionable,8519,219,colon cancer,DOID,26340,KRAS G12D EZH2 pos,sensitive,4747,DZNep + MK2206,3845,26676756,,,
157,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing pancreatic cancer cell line harboring KRAS G12D in culture (PMID: 26676756).",Actionable,8520,1793,pancreatic cancer,DOID,26340,KRAS G12D EZH2 pos,sensitive,4747,DZNep + MK2206,3845,26676756,,,
158,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing colon cancer cell line harboring KRAS G12D in culture (PMID: 26676756).",Actionable,8518,219,colon cancer,DOID,26340,KRAS G12D EZH2 pos,no benefit,4746,DZNep + Selumetinib,3845,26676756,,,
159,Preclinical - Cell culture,"In a preclinical study, the addition of Tazemetostat (EPZ-6438) increased sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D in culture (PMID: 26676756).",Actionable,8508,3910,lung adenocarcinoma,DOID,26340,KRAS G12D EZH2 pos,sensitive,4749,MK2206 + Tazemetostat,3845,26676756,,,
160,Preclinical - Cell culture,"In a preclinical study, the addition of GSK343 increased sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D in culture (PMID: 26676756).",Actionable,8507,3910,lung adenocarcinoma,DOID,26340,KRAS G12D EZH2 pos,sensitive,4751,GSK343 + MK2206,3845,26676756,,,
161,Preclinical - Cell culture,"In a preclinical study, the addition of GSK343 did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D (PMID: 26676756).",Actionable,8504,3910,lung adenocarcinoma,DOID,26340,KRAS G12D EZH2 pos,no benefit,4750,GSK343 + Selumetinib,3845,26676756,,,
162,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D (PMID: 26676756).",Actionable,8500,3910,lung adenocarcinoma,DOID,26340,KRAS G12D EZH2 pos,no benefit,4746,DZNep + Selumetinib,3845,26676756,,,
163,Preclinical - Cell culture,"In a preclinical study, the addition of Tazemetostat (EPZ-6438) did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12D (PMID: 26676756).",Actionable,8505,3910,lung adenocarcinoma,DOID,26340,KRAS G12D EZH2 pos,no benefit,4748,Selumetinib + Tazemetostat,3845,26676756,,,
164,Preclinical - Cell line xenograft,"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type pancreatic cancer cells harboring KRAS G12D in cell line xenograft models (PMID: 19276360).",Actionable,7887,1793,pancreatic cancer,DOID,26084,BRAF wild-type KRAS G12D,resistant,1095,GDC0879,3845,19276360,,,
165,Preclinical,"In a preclinical study,  MK-1775 and Platinol (cisplatin) combination treatment resulted in improved survival in transgenic animal models of non-small cell lung carcinoma harboring KRAS G12D and STK11 loss compared to Platinol (cisplatin) alone (PMID: 28652249).",Actionable,11860,3908,non-small cell lung carcinoma,DOID,28318,KRAS G12D STK11 loss,predicted â€“ sensitive,1725,MK-1775 + Cisplatin,3845,28652249,,,
166,Preclinical - Pdx,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PTEN loss, and TP53 V216M (PMID: 26272063).",Actionable,8575,9256,colorectal cancer,DOID,26364,KRAS G12D PTEN loss TP53 V216M,no benefit,4771,MLN0128 + PD-0325901,3845,26272063,,,
167,Preclinical - Pdx,"In a preclinical study, treatment with Selumetinib (AZD6244) slowed growth of tumors in patient-derived xenograft models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, PTEN R130G (PMID: 26232337).",Actionable,9374,1380,endometrial cancer,DOID,26839,KRAS G12D PIK3CA H1047R PTEN R130G,sensitive,913,Selumetinib,3845,26232337,,,
168,Preclinical - Pdx,"In a preclinical study, treatment with BEZ235 slowed growth of tumors in patient-derived xenograft models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, PTEN R130G (PMID: 26232337).",Actionable,9375,1380,endometrial cancer,DOID,26839,KRAS G12D PIK3CA H1047R PTEN R130G,sensitive,672,BEZ235,3845,26232337,,,
169,Preclinical - Pdx,"In a preclinical study, treatment with the combination of Selumetinib (AZD6244) and BEZ235 resulted in stable disease in patient-derived xenograft (PDX) models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, and PTEN R130G, and demonstrated improved efficacy over either agent alone (PMID: 26232337).",Actionable,9373,1380,endometrial cancer,DOID,26839,KRAS G12D PIK3CA H1047R PTEN R130G,sensitive,1420,Selumetinib + BEZ235,3845,26232337,,,
170,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a KRAS G12D mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7690,9256,colorectal cancer,DOID,25922,BRAF V600E KRAS G12D,sensitive,4541,Cetuximab + Dabrafenib + Trametinib,3845,27312529,,,
171,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a KRAS G12D mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7691,9256,colorectal cancer,DOID,25922,BRAF V600E KRAS G12D,sensitive,4543,Cetuximab + SCH772984,3845,27312529,,,
172,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G12D mutation and subsequent resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) in culture (PMID: 27312529).",Actionable,7689,9256,colorectal cancer,DOID,25922,BRAF V600E KRAS G12D,resistant,1917,LGX818 + Cetuximab + BYL719,3845,27312529,,,
173,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Zelboraf (vemurafenib) combination treatment in culture, likely due to the acquisition of KRAS G12D (PMID: 27312529).",Actionable,7626,9256,colorectal cancer,DOID,25922,BRAF V600E KRAS G12D,resistant,1711,Vemurafenib + Cetuximab,3845,27312529,,,
174,Preclinical,"In a preclinical study, combination of BEZ235 and Binimetinib (MEK162) resulted in reduced tumor growth and additive effect on survival compared to single agent in transgenic animal models of colorectal cancer driven by APC inactivation and KRAS G12D (PMID: 26206338).",Actionable,9200,9256,colorectal cancer,DOID,26771,APC inact mut KRAS G12D,sensitive,4932,BEZ235 + Binimetinib,3845,26206338,,,
175,Preclinical,"In a preclinical study, BEZ235 inhibited  PI3K/mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC inactivation and KRAS G12D (PMID: 26206338).",Actionable,9190,9256,colorectal cancer,DOID,26771,APC inact mut KRAS G12D,sensitive,672,BEZ235,3845,26206338,,,
176,Preclinical,"In a preclinical study, Binimetinib (MEK162) increased apoptosis in tumors and improved survival in transgenic animal models of colorectal cancer driven by APC inactivation and KRAS G12D (PMID: 26206338).",Actionable,9193,9256,colorectal cancer,DOID,26771,APC inact mut KRAS G12D,sensitive,807,Binimetinib,3845,26206338,,,
177,Preclinical - Pdx,"In a preclinical study, combination of Sprycel (dasatinib) and Demcizumab (OMP-21M18) treatment resulted in durable tumor inhibition in patient-derived animal models of lung adenocarcinoma harboring KRAS G12D and TP53 S127Y (PMID: 26855149).",Actionable,10885,3910,lung adenocarcinoma,DOID,27819,KRAS G12D TP53 S127Y,sensitive,5671,Dasatinib + Demcizumab,3845,26855149,,,
178,Clinical Study,"In a clinical study, a colorectal cancer patient harboring a PIK3CA mutation and KRAS mutations at codons 12 and 13 demonstrated stable disease when treated with a combination of Torisel (temsirolimus) and Avastin (bevacizumab) (PMID: 21216929). ",Actionable,3378,9256,colorectal cancer,DOID,13305,PIK3CA mutant KRAS G12X KRAS G13X,sensitive,3133,Temsirolimus + Bevacizumab,3845,21216929,,,
179,Guideline,Ertibux (cetuximab) is not indicated for use in colorectal cancer patients with KRAS exon 2 mutations (Guidelines).,Actionable,1560,9256,colorectal cancer,DOID,1193,KRAS G13X,resistant,694,Cetuximab,3845,None,,,
180,Phase III,"In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI did not have improved clinical benefit compared to FOLFIRI alone in patients with KRAS exon 2 mutant colorectal cancer (PMID: 26341920).",Actionable,3266,9256,colorectal cancer,DOID,1193,KRAS G13X,no benefit,3102,Panitumumab + Oxaliplatin + Fluorouracil + Irinotecan,3845,26341920,,,
181,Guideline,Vectibix (panitumumab) is not indicated for use in colorectal cancer patients with KRAS exon 2 mutations (Guidelines).,Actionable,1558,9256,colorectal cancer,DOID,1193,KRAS G13X,resistant,845,Panitumumab,3845,None,,,
182,FDA approved,"In clinical studies, lung adenocarcinoma patients with KRAS codon 12 or 13 mutations lack sensitivity to Iressa (gefitinib) (PMID: 15696205).",Actionable,1301,3910,lung adenocarcinoma,DOID,1193,KRAS G13X,resistant,751,Gefitinib,3845,15696205,,,
183,Preclinical,"In a preclinical study, sensitivity to Eloxatin (oxaliplatin) was increased in colorectal tumor cell lines carrying KRAS codon 12 or 13 mutations (PMID: 23209813). ",Actionable,1440,9256,colorectal cancer,DOID,1193,KRAS G13X,sensitive,1104,Oxaliplatin,3845,23209813,,,
184,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G12R mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).",Actionable,8997,3910,lung adenocarcinoma,DOID,1732,KRAS G12R,decreased response,913,Selumetinib,3845,27422710,,,
185,Preclinical,"In a preclinical study,  colorectal cancer cells harboring a KRAS G12R mutation demonstrated resistance to Sutent (sunitinib) treatment (PMID: 23455880).",Actionable,1017,9256,colorectal cancer,DOID,1732,KRAS G12R,resistant,930,Sunitinib,3845,23455880,,,
186,Preclinical - Cell line xenograft,"In a preclinical study, combination of Mekinist (trametinib) and Votrient (pazopanib) significantly delayed tumor progression in cell line xenograft models of thyroid cancer harboring KRAS G12R (PMID: 26324075).",Actionable,9960,1781,thyroid cancer,DOID,1732,KRAS G12R,sensitive,1310,Pazopanib + Trametinib,3845,26324075,,,
187,Preclinical - Cell line xenograft,"In a preclinical study, Mekinist (trametinib) inhibited Erk activation and growth of thyroid cancer cells harboring KRAS G12R in culture, and reduced tumor size in cell line xenograft models (PMID: 26324075).",Actionable,9958,1781,thyroid cancer,DOID,1732,KRAS G12R,sensitive,2,Trametinib,3845,26324075,,,
188,Preclinical - Cell culture,"In a preclinical study, Binimetinib (MEK162) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G12R mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).",Actionable,8989,3910,lung adenocarcinoma,DOID,1732,KRAS G12R,decreased response,807,Binimetinib,3845,27422710,,,
189,Preclinical - Cell line xenograft,"In a preclinical study, Votrient (pazopanib) inhibited Erk activation and growth of thyroid cancer cells harboring KRAS G12R in culture, and reduced tumor size in cell line xenograft models (PMID: 26324075).",Actionable,9959,1781,thyroid cancer,DOID,1732,KRAS G12R,sensitive,848,Pazopanib,3845,26324075,,,
190,Preclinical - Pdx,"In a preclinical study, combination of Sprycel (dasatinib) and Demcizumab (OMP-21M18) treatment resulted in durable tumor inhibition in patient-derived animal models of lung adenocarcinoma harboring KRAS G12R and TP53 R248L (PMID: 26855149).",Actionable,10886,3910,lung adenocarcinoma,DOID,27821,KRAS G12R TP53 R248L,sensitive,5671,Dasatinib + Demcizumab,3845,26855149,,,
191,Preclinical - Cell line xenograft,"In a preclinical study, thyroid cancer cell lines harboring HRAS G13R and KRAS G12R with an acquired SRC T341M mutation demonstrated resistance to Sprycel (dasatinib) in culture and in cell line xenograft models (PMID: 27222538).",Actionable,7839,1781,thyroid cancer,DOID,26068,HRAS G13R KRAS G12R SRC T341M,resistant,717,Dasatinib,3845,27222538,,,
192,Preclinical - Cell line xenograft,"In a preclinical study, Mekinist (trametinib) inhibited growth of Sprycel (dasatinib)-resistant thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M in culture and in cell line xenograft models (PMID: 27222538).",Actionable,7855,1781,thyroid cancer,DOID,26068,HRAS G13R KRAS G12R SRC T341M,sensitive,2,Trametinib,3845,27222538,,,
193,Preclinical - Cell line xenograft,"In a preclinical study, Sprycel (dasatinib) and Mekinist (trametinib) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture, and resulted in sustained tumor suppression and prolonged survival in cell line xenograft models (PMID: 27222538).",Actionable,7867,1781,thyroid cancer,DOID,26068,HRAS G13R KRAS G12R SRC T341M,sensitive,4599,Dasatinib + Trametinib,3845,27222538,,,
194,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) and SCH772984 synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture (PMID: 27222538).",Actionable,7870,1781,thyroid cancer,DOID,26068,HRAS G13R KRAS G12R SRC T341M,sensitive,4601,Dasatinib + SCH772984,3845,27222538,,,
195,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) and Selumetinib (AZD6244) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture (PMID: 27222538).",Actionable,7868,1781,thyroid cancer,DOID,26068,HRAS G13R KRAS G12R SRC T341M,sensitive,4600,Dasatinib + Selumetinib,3845,27222538,,,
196,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) inhibited growth of Sprycel (dasatinib)-resistant thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture (PMID: 27222538).",Actionable,7860,1781,thyroid cancer,DOID,26068,HRAS G13R KRAS G12R SRC T341M,sensitive,913,Selumetinib,3845,27222538,,,
197,Preclinical,"In a preclinical study, KRAS G12R was detected in animal models of EGFR L858R-induced lung adenocarcinoma, which developed after repeated Gilotrif (afatinib) and Erbitux (cetuximab) combination treatments and resulted in drug resistance (PMID: 26341921).",Actionable,6655,3910,lung adenocarcinoma,DOID,23662,EGFR L858R KRAS G12R,resistant,4190,Afatinib + Cetuximab,3845,26341921,,,
198,Preclinical,"In a preclinical study, human colorectal cancer cell lines harboring KRAS G13D, PIK3CA E545K and PIK3CA D549N were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).",Actionable,4943,9256,colorectal cancer,DOID,11790,KRAS G13D PIK3CA E545K PIK3CA D549N,resistant,890,Regorafenib,3845,25838391,,,
199,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis of human colorectal cancer cell lines harboring KRAS G13D, PIK3CA E545K, and PIK3CA D549N in culture and reduced tumor growth in cell line xenograft models (PMID: 25838391).",Actionable,4946,9256,colorectal cancer,DOID,11790,KRAS G13D PIK3CA E545K PIK3CA D549N,sensitive,1305,Regorafenib + Cetuximab,3845,25838391,,,
200,Preclinical,"In a preclinical study, human colon cancer cells harboring KRAS G13D, PIK3CA E545K, and PIK3CA D549N had a decreased response to Gedatolisib (PKI-587) in culture (PMID: 21325073, PMID: 24042735).",Actionable,3132,219,colon cancer,DOID,11790,KRAS G13D PIK3CA E545K PIK3CA D549N,decreased response,1040,PF-05212384,3845,21325073,24042735,,
201,Preclinical - Cell line xenograft,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring KRAS G13D and PIK3CA H1047R in culture and in cell line xenograft models (PMID: 26272063).",Actionable,8567,9256,colorectal cancer,DOID,26360,KRAS G13D PIK3CA H1047R TP53 wild-type,sensitive,4771,MLN0128 + PD-0325901,3845,26272063,,,
202,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7673,9256,colorectal cancer,DOID,25923,BRAF V600E KRAS G13D,resistant,1711,Vemurafenib + Cetuximab,3845,27312529,,,
203,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Selumetinib (AZD6244) in culture (PMID: 27312529).",Actionable,7675,9256,colorectal cancer,DOID,25923,BRAF V600E KRAS G13D,resistant,4536,Cetuximab + Selumetinib,3845,27312529,,,
204,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment in culture, likely due to the acquisition of KRAS G13D (PMID: 27312529).",Actionable,7622,9256,colorectal cancer,DOID,25923,BRAF V600E KRAS G13D,resistant,1916,Cetuximab + Encorafenib,3845,27312529,,,
205,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) in culture (PMID: 27312529).",Actionable,7677,9256,colorectal cancer,DOID,25923,BRAF V600E KRAS G13D,resistant,4541,Cetuximab + Dabrafenib + Trametinib,3845,27312529,,,
206,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib) in culture (PMID: 27312529).",Actionable,7676,9256,colorectal cancer,DOID,25923,BRAF V600E KRAS G13D,resistant,1066,Trametinib + Dabrafenib,3845,27312529,,,
207,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).",Actionable,7678,9256,colorectal cancer,DOID,25923,BRAF V600E KRAS G13D,resistant,2618,SCH772984,3845,27312529,,,
208,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and SCH772984 in culture (PMID: 27312529).",Actionable,7679,9256,colorectal cancer,DOID,25923,BRAF V600E KRAS G13D,resistant,4543,Cetuximab + SCH772984,3845,27312529,,,
209,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Tafinlar (dabrafenib) in culture (PMID: 27312529).",Actionable,7668,9256,colorectal cancer,DOID,25923,BRAF V600E KRAS G13D,resistant,4525,Cetuximab + Dabrafenib,3845,27312529,,,
210,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS G13D mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) in culture (PMID: 27312529).",Actionable,7674,9256,colorectal cancer,DOID,25923,BRAF V600E KRAS G13D,resistant,1917,LGX818 + Cetuximab + BYL719,3845,27312529,,,
211,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring KRAS G13D, PIK3CA D549N, and PIK3CA E545K in culture (PMID: 23629727).",Actionable,8207,9256,colorectal cancer,DOID,26186,KRAS G13D PIK3CA D549N PIK3CA E545K,sensitive,4657,Pimasertib + Regorafenib,3845,23629727,,,
212,Preclinical - Cell line xenograft,"In a preclinical study, Pimasertib (MSC1936369B) and BEZ235 combination treatment inhibited tumor growth in colorectal cancer cell line xenograft models harboring KRAS G13D, PIK3CA D549N, and PIK3CA E545K (PMID: 23629727).",Actionable,8208,9256,colorectal cancer,DOID,26186,KRAS G13D PIK3CA D549N PIK3CA E545K,sensitive,1660,Pimasertib + BEZ235,3845,23629727,,,
213,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of colorectal cancer cells harboring KRAS G13D, PIK3CA D549N, and PIK3CA E545K in culture (PMID: 23629727).",Actionable,8197,9256,colorectal cancer,DOID,26186,KRAS G13D PIK3CA D549N PIK3CA E545K,sensitive,4656,Everolimus + Pimasertib,3845,23629727,,,
214,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring KRAS G13D, PIK3CA D549N and PIK3CA E545K demonstrated decreased response to Pimasertib (MSC1936369B) in culture (PMID: 23629727).",Actionable,8192,9256,colorectal cancer,DOID,26186,KRAS G13D PIK3CA D549N PIK3CA E545K,decreased response,871,Pimasertib,3845,23629727,,,
215,Preclinical - Cell line xenograft,"In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited Mapk and Akt signaling, resulted in growth inhibition of colorectal cancer cells harboring KRAS G13D, PIK3CA D549N, and PIK3CA E545K in culture and in cell line xenograft models (PMID: 23629727).",Actionable,8201,9256,colorectal cancer,DOID,26186,KRAS G13D PIK3CA D549N PIK3CA E545K,sensitive,1659,Pimasertib + Sorafenib,3845,23629727,,,
216,Preclinical,"In a preclinical study, AT-7867 inhibited proliferation of cultured HCT-116 colon cancer cells, which have been reported to harbor KRAS G13D and PIK3CA H1047R mutations (PMID: 20423992, PMID: 24978597).",Actionable,2859,219,colon cancer,DOID,10711,KRAS G13D PIK3CA H1047R,sensitive,2447,AT-7867,3845,24978597,20423992,,
217,Preclinical - Cell line xenograft,"In a preclinical study, Gedatolisib (PKI-587) and Camptostar (irinotecan) synergistically suppressed the growth of a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R (PMID: 24042735) in xenograft models (PMID: 21325073).",Actionable,3901,219,colon cancer,DOID,10711,KRAS G13D PIK3CA H1047R,sensitive,3396,Gedatolisib + Irinotecan,3845,21325073,24042735,,
218,Preclinical,"In a preclinical study, Gedatolisib (PKI-587) and Camptothecin in combination synergistictically enhanced Parp cleavage in a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R in culture (PMID: 21325073, PMID: 24042735). ",Actionable,3903,219,colon cancer,DOID,10711,KRAS G13D PIK3CA H1047R,sensitive,3398,Gedatolisib + Camptothecin,3845,24042735,25688157,,
219,Preclinical,"In a preclinical study, CC-223 inhibited proliferation of HCT-116 colon cancer cells, which have been reported to harbor KRAS G13D and PIK3CA H1047R mutations, in culture (PMID: 25855786, PMID: 24978597).",Actionable,2876,219,colon cancer,DOID,10711,KRAS G13D PIK3CA H1047R,sensitive,693,CC-223,3845,24978597,25855786,,
220,Preclinical,"In a preclinical study, Camptostar (irinotecan) suppressed the growth of a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R in xenograft models (PMID: 21325073, PMID: 16707468).",Actionable,3902,219,colon cancer,DOID,10711,KRAS G13D PIK3CA H1047R,sensitive,1074,Irinotecan,3845,21325073,16707468,,
221,Preclinical,"In a preclinical study, human colorectal cancer cells harboring KRAS G13D and PIK3CA H1047R were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).",Actionable,4942,9256,colorectal cancer,DOID,10711,KRAS G13D PIK3CA H1047R,resistant,890,Regorafenib,3845,25838391,,,
222,Preclinical - Cell culture,"In a preclinical study, Alpelisib (BYL719) decreased viability of a colorectal cancer cell line harboring KRAS G13D and PIK3CA H1047R in culture (PMID: 27602501).",Actionable,12024,9256,colorectal cancer,DOID,10711,KRAS G13D PIK3CA H1047R,sensitive,691,BYL719,3845,27602501,,,
223,Preclinical - Cell line xenograft,"In a preclinical study, CH5132799 inhibited tumor growth in xenograft models of a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R mutations (PMID: 21558396).",Actionable,2836,219,colon cancer,DOID,10711,KRAS G13D PIK3CA H1047R,sensitive,2152,CH5132799,3845,21558396,,,
224,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Gedatolisib (PF-05212384) and PD-0325901 inhibited tumor growth in colon cancer cell line xenograft models harboring KRAS G13D and PIK3CA H1047R (PMID: 21325073).",Actionable,2856,219,colon cancer,DOID,10711,KRAS G13D PIK3CA H1047R,sensitive,3025,PD-0325901 + Gedatolisib,3845,21325073,,,
225,Preclinical,"In a preclinical study, CUDC-907 induced caspase activation in a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R in culture (PMID: 20570890, PMID: 22693356). ",Actionable,3010,219,colon cancer,DOID,10711,KRAS G13D PIK3CA H1047R,sensitive,709,CUDC-907,3845,20570890,22693356,,
226,Preclinical,"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human colon cancer cells harboring KRAS G13D and PIK3CA H1047R in culture (PMID: 21325073, PMID: 24042735).",Actionable,3131,219,colon cancer,DOID,10711,KRAS G13D PIK3CA H1047R,sensitive,1040,PF-05212384,3845,21325073,24042735,,
227,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis of human colorectal cancer cell lines harboring KRAS G13D and PIK3CA H1047R in culture, and reduced tumor growth in cell line xenograft models (PMID: 25838391).",Actionable,4947,9256,colorectal cancer,DOID,10711,KRAS G13D PIK3CA H1047R,sensitive,1305,Regorafenib + Cetuximab,3845,25838391,,,
228,Preclinical,"In a preclinical study, human colorectal cancer cells harboring KRAS G13D were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).",Actionable,4938,9256,colorectal cancer,DOID,811,KRAS G13D,resistant,890,Regorafenib,3845,25838391,,,
229,Preclinical,"In a preclinical studu, BKM120 alone failed to induce tumor regression in mouse xenograft models of Kras G13D mutant colorectal cancer (PMID: 24576621).",Actionable,684,219,colon cancer,DOID,811,KRAS G13D,no benefit,680,BKM120,3845,24576621,,,
230,Preclinical - Cell line xenograft,"In a preclinical study, AZD4785 inhibited Kras expression, resulted in growth inhibition in 3-D cultures of non-small cell lung carcinoma cells harboring KRAS G13D, and anti-tumor activity in cell line xenograft models (PMID: 28615361).",Actionable,11326,3908,non-small cell lung carcinoma,DOID,811,KRAS G13D,sensitive,5914,AZD4785,3845,28615361,,,
231,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring KRAS G13D in culture (PMID: 23629727).",Actionable,8205,9256,colorectal cancer,DOID,811,KRAS G13D,sensitive,4657,Pimasertib + Regorafenib,3845,23629727,,,
232,Preclinical,"In a preclinical study, LY3009120 inhibited growth of, and blocked MAPK signaling in human colorectal cancer cells harboring KRAS G13D in culture (PMID: 26343583).",Actionable,6590,9256,colorectal cancer,DOID,811,KRAS G13D,sensitive,3268,LY3009120,3845,26343583,,,
233,Preclinical,"In a preclinical study, a colorectal cancer cell line harboring the KRAS G13D mutation showed resistance to Sutent (sunitinib) treatment (PMID: 23455880).",Actionable,805,9256,colorectal cancer,DOID,811,KRAS G13D,resistant,930,Sunitinib,3845,23455880,,,
234,Preclinical,"In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis in human colorectal cancer cell lines harboring KRAS G13D in culture (PMID: 25838391).",Actionable,4952,9256,colorectal cancer,DOID,811,KRAS G13D,sensitive,1305,Regorafenib + Cetuximab,3845,25838391,,,
235,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring KRAS G13D demonstrated decreased response to Pimasertib (MSC1936369B) in culture (PMID: 23629727).",Actionable,8190,9256,colorectal cancer,DOID,811,KRAS G13D,decreased response,871,Pimasertib,3845,23629727,,,
236,Preclinical,"In a preclinical study, colorectal cancer cells harboring KRAS G13D were less sensitive to Nerlynx (neratinib) induced growth inhibition in culture (PMID: 26243863).",Actionable,7116,9256,colorectal cancer,DOID,811,KRAS G13D,decreased response,828,Neratinib,3845,26243863,,,
237,Preclinical - Cell line xenograft,"In a preclinical study, Estybon (rigosertib) inhibited Mek/Erk signaling and tumor growth in cell line xenograft models of colorectal cancer harboring KRAS G13D (PMID: 27104980).",Actionable,8560,9256,colorectal cancer,DOID,811,KRAS G13D,sensitive,1046,rigosertib,3845,27104980,,,
238,Preclinical - Cell line xenograft,"In a preclinical study, GDC-0623 demonstrated efficacy against both KRAS-mutant and BRAF-mutant cancer models in cell based assays and cell line xenografts (PMID: 23934108).",Actionable,565,10000003,Advanced Solid Tumor,JAX,811,KRAS G13D,sensitive,748,GDC-0623,3845,23934108,,,
239,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD-6244) inhibited proliferation of colorectal adenocarcinoma cells harboring KRAS G13D in culture (PMID: 26438159).",Actionable,8493,50861,colorectal adenocarcinoma,DOID,811,KRAS G13D,predicted â€“ sensitive,913,Selumetinib,3845,26438159,,,
240,Preclinical - Cell culture,"In a preclinical study, RO4987655 inhibited proliferation of colorectal adenocarcinoma cells harboring KRAS G13D in culture (PMID: 26438159).",Actionable,8463,50861,colorectal adenocarcinoma,DOID,811,KRAS G13D,sensitive,903,RO4987655,3845,26438159,,,
241,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of colorectal cancer cells harboring KRAS G13D in culture (PMID: 23629727).",Actionable,8195,9256,colorectal cancer,DOID,811,KRAS G13D,sensitive,4656,Everolimus + Pimasertib,3845,23629727,,,
242,Preclinical - Cell line xenograft,"In a preclinical study, Cobimetinib (GDC-0973) inhibited tumor growth in xenograft models of human colorectal cancer cell lines harboring KRAS G13D (PMID: 23934108).",Actionable,1342,9256,colorectal cancer,DOID,811,KRAS G13D,sensitive,1004,Cobimetinib,3845,23934108,,,
243,Preclinical - Cell line xenograft,"In a preclinical study, 3144 inhibited growth of a breast cancer cell line harboring KRAS G13D in culture and reduced tumor growth in xenograft models (PMID: 28235199).",Actionable,10840,1612,breast cancer,DOID,811,KRAS G13D,sensitive,5658,3144,3845,28235199,,,
244,Preclinical - Pdx & cell culture,"In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib) synergistically inhibited growth of colorectal cancer cells harboring KRAS G13D in culture and resulted in partial tumor regression in patient-derived xenograft models (PMID: 26369631). ",Actionable,5615,9256,colorectal cancer,DOID,811,KRAS G13D,sensitive,1368,Palbociclib + Trametinib,3845,26369631,,,
245,Guideline,Colorectal cancer patients with KRAS mutations in exon 2 or 3 are resistant to Vectibix (panitumumab) (PMID: 18316791).,Actionable,581,10000003,Advanced Solid Tumor,JAX,811,KRAS G13D,resistant,845,Panitumumab,3845,18316791,,,
246,Preclinical,"In a preclinical study, sensitivity to Eloxatin (oxaliplatin) was increased in colon tumor cell lines carrying KRAS G13D (PMID: 23209813). ",Actionable,1437,9256,colorectal cancer,DOID,811,KRAS G13D,sensitive,1104,Oxaliplatin,3845,23209813,,,
247,Guideline,"Ertibux (cetuximab) is not indicated for use in colorectal cancer patients with KRAS exon 2 mutations (Guidelines).",Actionable,1525,9256,colorectal cancer,DOID,811,KRAS G13D,resistant,694,Cetuximab,3845,None,,,
248,Clinical Study,"In a clinical study, KRAS mutations in codon 12 or 13 were associated with resistance to Erbitux (cetuximab) in colorectal cancer patients (PMID: 18202412).",Actionable,574,9256,colorectal cancer,DOID,811,KRAS G13D,resistant,694,Cetuximab,3845,18202412,,,
249,Preclinical - Cell culture,"In a preclinical study, the combination of APS-2-49 and Mekinist (trametinib) worked synergistically to decrease viability of a colon cancer cell line harboring KRAS G13D in culture (PMID: 27556948).",Actionable,8014,219,colon cancer,DOID,811,KRAS G13D,sensitive,4620,APS-2-79 + Trametinib,3845,27556948,,,
250,Guideline,"Vectibix (panitumumab) is not indicated for use in colorectal cancer patients with KRAS exon 2 mutations (Guidelines).",Actionable,1528,9256,colorectal cancer,DOID,811,KRAS G13D,resistant,845,Panitumumab,3845,None,None,,
251,FDA approved,Patients with metastatic colorectal cancer harboring KRAS mutations in codons 12 or 13 showed resistance to Vectibix (panitumumab) (PMID: 18316791).,Actionable,585,9256,colorectal cancer,DOID,811,KRAS G13D,resistant,845,Panitumumab,3845,18316791,,,
252,Preclinical - Cell culture,"In a preclinical study, RO5126766 inhibited proliferation of colorectal adenocarcinoma cells harboring KRAS G13D in culture (PMID: 26438159).",Actionable,8480,50861,colorectal adenocarcinoma,DOID,811,KRAS G13D,sensitive,2011,RO5126766,3845,26438159,,,
253,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring KRAS G13D in culture (PMID: 23629727).",Actionable,8200,9256,colorectal cancer,DOID,811,KRAS G13D,sensitive,1659,Pimasertib + Sorafenib,3845,23629727,,,
254,Preclinical - Cell line xenograft,"In a preclinical study, a colon cancer cell line harboring KRAS G13D demonstrated increased sensitivity to AUY922 compared to cell lines with wild-type KRAS, resulting in decreased viability and increased apoptosis in culture and reduced tumor growth in xenograft models (PMID: 26832792). ",Actionable,5519,219,colon cancer,DOID,811,KRAS G13D,sensitive,647,AUY922,3845,26832792,,,
255,Preclinical - Cell line xenograft,"In a preclinical study, Stivarga (regorafenib) inhibited proliferation of breast cancer cells harboring BRAF G464V and KRAS G13D in culture and inhibited angiogenesis and tumor growth in cell line xenograft models (PMID: 21170960).",Actionable,1075,1612,breast cancer,DOID,10754,BRAF G464V KRAS G13D,sensitive,890,Regorafenib,3845,21170960,,,
256,Preclinical,"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human breast cancer cells harboring BRAF G464V and KRAS G13D in culture (PMID: 21325073, PMID: 17314276).",Actionable,3129,1612,breast cancer,DOID,10754,BRAF G464V KRAS G13D,sensitive,1040,PF-05212384,3845,21325073,17314276,,
257,Preclinical - Cell line xenograft,"In a preclinical study, CH5132799 demonstrated decreased response to tumor growth inhibition in xenograft models of human breast cancer cell lines harboring KRAS G13D and BRAF G464V (PMID: 21558396).",Actionable,2973,1612,breast cancer,DOID,10754,BRAF G464V KRAS G13D,decreased response,2152,CH5132799,3845,21558396,,,
258,Preclinical - Cell line xenograft,"In a preclinical study, DHM25 increased cell death and decreased migration of a triple-negative breast cancer cell line harboring KRAS G13D and BRAF G464V in culture, and reduced tumor growth and lung metastasis in xenograft models (PMID: 26237138).",Actionable,10363,60081,triple-receptor negative breast cancer,DOID,10754,BRAF G464V KRAS G13D,sensitive,5494,DHM25,3845,26237138,,,
259,Preclinical - Cell line xenograft,"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type colon cancer cells harboring KRAS G13D in culture ann in cell line xenograft models (PMID: 19276360).",Actionable,7883,219,colon cancer,DOID,26083,BRAF wild-type KRAS G13D,resistant,1095,GDC0879,3845,19276360,,,
260,Preclinical - Cell culture,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, but did not induce apoptosis in colorectal cancer cells harboring KRAS G13D, PIK3CA E545K, and TP53 S241F in culture (PMID: 26272063).",Actionable,8564,9256,colorectal cancer,DOID,26357,KRAS G13D PIK3CA E545k TP53 S241F,sensitive,4771,MLN0128 + PD-0325901,3845,26272063,,,
261,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Pictilisib (GDC-0941) and Cobimetinib (GDC-0973) inhibited tumor growth in a colorectal adenocarcinoma xenograft model harboring KRAS G13D and PIK3CA E545K mutations, and demonstrated improved efficacy over either agent alone (PMID: 22084396).",Actionable,2854,50861,colorectal adenocarcinoma,DOID,10712,KRAS G13D PIK3CA E545K,sensitive,1702,GDC-0941 + cobimetinib,3845,22084396,,,
262,Preclinical - Cell line xenograft,"In a preclinical study, expression of KRAS G13D in an endometrial cancer cell line harboring PIK3CA E545K conferred resistance to Afinitor (everolimus) in xenograft models (PMID: 20664172). ",Actionable,9329,1380,endometrial cancer,DOID,10712,KRAS G13D PIK3CA E545K,resistant,735,Everolimus,3845,20664172,,,
263,Preclinical - Cell culture,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, but did not induce apoptosis in colorectal cancer cells harboring KRAS Q61L, PIK3CA E542K, and TP53 T118Qfs*5 in culture (PMID: 26272063).",Actionable,8566,9256,colorectal cancer,DOID,26412,KRAS Q61L PIK3CA E542K TP53 T118Qfs*5,sensitive,4771,MLN0128 + PD-0325901,3845,26272063,,,
264,Phase I,"In a Phase I trial, the combination of Erbitux (cetuximab) and Selumetinib (AZD6244) demonstrated safety, but minimal efficacy, in patients with metastatic colorectal cancer harboring KRAS exon 2 mutations, with no responses and 36% (5/14) of patients achieving stable disease (PMID: 26666244).",Actionable,10476,9256,colorectal cancer,DOID,27386,KRAS exon 2,no benefit,4536,Cetuximab + Selumetinib,3845,26666244,,,
265,Phase II,"In a Phase II study, Selumetinib (AZD6244), in combination with Camptosar (irinotecan), resulted in a partial response in 9.7% (3/31) and stable disease in 51.6% (16/31) of colorectal cancer patients with KRAS exon 2 mutations (PMID: 25322874).",Actionable,2432,9256,colorectal cancer,DOID,27386,KRAS exon 2,predicted â€“ sensitive,2835,Irinotecan + Selumetinib,3845,25322874,,,
266,Preclinical - Cell culture,"In a preclinical study, Binimetinib (MEK162) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS Q61K mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).",Actionable,8991,3910,lung adenocarcinoma,DOID,1864,KRAS Q61K,decreased response,807,Binimetinib,3845,27422710,,,
267,Preclinical - Cell line xenograft,"In a preclinical study, the combination of XL147 and Paraplatin (carboplatin) inhibited tumor growth and angiogenesis in xenograft models of a human non-small cell lung cancer cell line harboring KRAS Q61K, with increased efficacy compared to either agent alone (PMID: 25637314).",Actionable,6337,3908,non-small cell lung carcinoma,DOID,1864,KRAS Q61K,sensitive,4116,XL147 + Carboplatin,3845,25637314,,,
268,Preclinical - Cell line xenograft,"In a preclinical study, XL147 inhibited tumor growth and vascularization in xenograft models of a human non-small cell lung cancer cell line harboring KRAS Q61K (PMID: 25637314).",Actionable,6330,3908,non-small cell lung carcinoma,DOID,1864,KRAS Q61K,sensitive,1050,XL147,3845,25637314,,,
269,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS Q61K mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).",Actionable,8999,3910,lung adenocarcinoma,DOID,1864,KRAS Q61K,decreased response,913,Selumetinib,3845,27422710,,,
270,Preclinical - Cell line xenograft,"In a preclinical study, BI-847325 inhibited MEK phosphorylation and proliferation and disrupted cell cycle progression in a non-small cell lung cancer cell line harboring KRAS Q61K in culture, and induced tumor stasis or regression in KRAS Q61K mutant non-small cell lung cancer cell line xenograft models (PMID: 27496137).",Actionable,8788,3908,non-small cell lung carcinoma,DOID,1864,KRAS Q61K,sensitive,1059,BI-847325,3845,27496137,,,
271,Preclinical - Cell line xenograft,"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type non-small cell lung cancer cells harboring KRAS Q61K in culture and in cell line xenograft models (PMID: 19276360).",Actionable,7884,3908,non-small cell lung carcinoma,DOID,26085,BRAF wild-type KRAS Q61K,resistant,1095,GDC0879,3845,19276360,,,
272,Clinical Study,"In a clinical case study, a patient with a carcinoma of unknown primary harboring MET amplification and KRAS G12V demonstrated a durable response following treatment with Xalkori (crizotinib) (PMID: 25232318).",Actionable,7753,305,carcinoma,DOID,25979,KRAS G12V MET amp,predicted â€“ sensitive,706,Crizotinib,3845,25232318,,,
273,Preclinical - Pdx,"In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K, and TP53 R273* did not respond to Selumetinib (AZD6244) treatment (PMID: 26272063).",Actionable,8698,9256,colorectal cancer,DOID,26374,KRAS G12V PIK3CA E545K TP53 R273*,resistant,913,Selumetinib,3845,26272063,,,
274,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment did not improve tumor growth stabilization compared to single agent in patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K and TP53 R273* (PMID: 26272063).",Actionable,8597,9256,colorectal cancer,DOID,26374,KRAS G12V PIK3CA E545K TP53 R273*,no benefit,1420,Selumetinib + BEZ235,3845,26272063,,,
275,Preclinical - Pdx,"In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K, and TP53 R273* did not respond to BEZ235 treatment (PMID: 26272063).",Actionable,8699,9256,colorectal cancer,DOID,26374,KRAS G12V PIK3CA E545K TP53 R273*,resistant,672,BEZ235,3845,26272063,,,
276,Preclinical - Pdx,"In a preclinical study, BEZ235 delayed tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA Q546K, and TP53 R282W (PMID: 26272063).",Actionable,8701,9256,colorectal cancer,DOID,26375,KRAS G12V PIK3CA Q546K TP53 R282W,decreased response,672,BEZ235,3845,26272063,,,
277,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) inhibited tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA Q546K, and TP53 R282W (PMID: 26272063).",Actionable,8700,9256,colorectal cancer,DOID,26375,KRAS G12V PIK3CA Q546K TP53 R282W,predicted â€“ sensitive,913,Selumetinib,3845,26272063,,,
278,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment resulted in enhanced tumor growth stabilization compared to single agent in patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA Q546K and TP53 R282W (PMID: 26272063).",Actionable,8600,9256,colorectal cancer,DOID,26375,KRAS G12V PIK3CA Q546K TP53 R282W,sensitive,1420,Selumetinib + BEZ235,3845,26272063,,,
279,Preclinical - Cell culture,"In a preclinical study, BRAF mutant melanoma cells over-expressing KRAS G12V were resistant to Selumetinib (AZD6244) and AZ628 combination treatment in culture (PMID: 26351322).",Actionable,8682,1909,melanoma,DOID,26406,BRAF mut KRAS G12V,resistant,4791,AZ628 + Selumetinib,3845,26351322,,,
280,Preclinical,"In a preclinical study, KRAS G12V was detected in animal models of EGFR L858R-induced lung adenocarcinoma, which developed after repeated Gilotrif (afatinib) and Erbitux (cetuximab) combination treatments and resulted in drug resistance (PMID: 26341921).",Actionable,6656,3910,lung adenocarcinoma,DOID,23663,EGFR L858R KRAS G12V,resistant,4190,Afatinib + Cetuximab,3845,26341921,,,
281,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep did not increase sensitivity to Selumetinib (AZD6244) in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12V (PMID: 26676756).",Actionable,8501,3910,lung adenocarcinoma,DOID,26342,KRAS G12V EZH2 pos,no benefit,4746,DZNep + Selumetinib,3845,26676756,,,
282,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep did not increase sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12V (PMID: 26676756).",Actionable,8509,3910,lung adenocarcinoma,DOID,26342,KRAS G12V EZH2 pos,no benefit,4747,DZNep + MK2206,3845,26676756,,,
283,Preclinical - Pdx,"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type non-small cell lung cancer cells harboring KRAS G12V in patient-derived xenograft models (PMID: 19276360).",Actionable,7895,3908,non-small cell lung carcinoma,DOID,26087,BRAF wild-type KRAS G12V,resistant,1095,GDC0879,3845,19276360,,,
284,Preclinical - Cell culture,"In a preclinical study, BAY1125976 inhibited proliferation of a prostate cancer cell line harboring KRAS G12V and PTEN K6fs*4 in culture (PMID: 27699769).",Actionable,8821,10283,prostate cancer,DOID,26456,KRAS G12V PTEN K6fs*4,sensitive,994,BAY1125976,3845,27699769,,,
285,Preclinical,"In a preclinical study, 7RH treatment had no effect on tumor cell apoptosis in KRAS G12V-driven animal models of lung cancer with TP53 knockout background (PMID: 26855149).",Actionable,10882,1324,lung cancer,DOID,27818,KRAS G12V TP53 del,resistant,5669,7RH,3845,26855149,,,
286,Preclinical,"In a preclinical study, 7RH and LY411575 combination treatment induced apoptosis in KRAS G12V-driven animal models of lung cancer with TP53 knockout background (PMID: 26855149).",Actionable,10883,1324,lung cancer,DOID,27818,KRAS G12V TP53 del,sensitive,5670,7RH + LY411575,3845,26855149,,,
287,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment resulted in enhanced tumor growth stabilization compared to single agent in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12V and PIK3CA E545K (PMID: 26272063).",Actionable,8603,9256,colorectal cancer,DOID,26377,KRAS G12V PIK3CA E545K TP53 wild-type,sensitive,1420,Selumetinib + BEZ235,3845,26272063,,,
288,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12V and PIK3CA E545K (PMID: 26272063).",Actionable,8705,9256,colorectal cancer,DOID,26377,KRAS G12V PIK3CA E545K TP53 wild-type,decreased response,913,Selumetinib,3845,26272063,,,
289,Preclinical - Pdx,"In a preclinical study, BEZ235 delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12V and PIK3CA E545K (PMID: 26272063).",Actionable,8704,9256,colorectal cancer,DOID,26377,KRAS G12V PIK3CA E545K TP53 wild-type,decreased response,672,BEZ235,3845,26272063,,,
290,Preclinical,"In a preclinical study, endometrial cancer cells harboring PIK3CA R88Q. PTEN mutations, and KRAS G12V demonstrated decreased sensitivity to BEZ235 compared with cells without KRAS mutations in culture (PMID: 22662154).",Actionable,2141,1380,endometrial cancer,DOID,5418,PIK3CA R88Q PTEN mut KRAS G12V,decreased response,672,BEZ235,3845,22662154,,,
291,Preclinical,"In a preclinical study, endometrial cancer cells harboring PIK3CA R88Q. PTEN mutations, and KRAS G12V demonstrated decreased sensitivity to Afinitor (everolimus) compared with cells without KRAS mutations in culture (PMID: 22662154).",Actionable,2140,1380,endometrial cancer,DOID,5418,PIK3CA R88Q PTEN mut KRAS G12V,decreased response,735,Everolimus,3845,22662154,,,
292,Preclinical - Pdx,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K, and TP53 R335fs (PMID: 26272063).",Actionable,8578,9256,colorectal cancer,DOID,26368,KRAS G12V PIK3CA E545K TP53 R335fs,no benefit,4771,MLN0128 + PD-0325901,3845,26272063,,,
293,Preclinical - Cell culture,"In a preclinical study, Aurora Kinase Inhibitor II (AI II) decreased viability of transformed lung cells expressing KRAS G12V  in culture (PMID: 26842935).",Actionable,9791,1324,lung cancer,DOID,1127,KRAS G12V,sensitive,5230,Aurora Kinase Inhibitor II,3845,26842935,,,
294,Preclinical,"In a preclinical study, 7RH and LY411575 combination treatment resulted in additive effect on apoptosis in KRAS G12V-driven animal models of lung cancer (PMID: 26855149).",Actionable,10881,1324,lung cancer,DOID,1127,KRAS G12V,sensitive,5670,7RH + LY411575,3845,26855149,,,
295,Preclinical,"In a preclinical study, a colorectal cancer cell line harboring the KRAS G12V mutation showed resistance to Sutent (sunitinib) treatment (PMID: 23455880).",Actionable,818,9256,colorectal cancer,DOID,1127,KRAS G12V,resistant,930,Sunitinib,3845,23455880,,,
296,Preclinical,"In a preclinical study, human colorectal cancer cells harboring KRAS G12V were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).",Actionable,4939,9256,colorectal cancer,DOID,1127,KRAS G12V,resistant,890,Regorafenib,3845,25838391,,,
297,Preclinical,"In a preclinical study, sensitivity to Eloxatin (oxaliplatin) was increased in colorectal tumor cell lines carrying KRAS G12V (PMID: 23209813). ",Actionable,1438,9256,colorectal cancer,DOID,1127,KRAS G12V,sensitive,1104,Oxaliplatin,3845,23209813,,,
298,Preclinical - Cell culture,"In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited growth of transformed cells over expressing KRAS G12V in culture, while single agent inhibition had no effect (PMID: 26140595).",Actionable,10249,10000003,Advanced Solid Tumor,JAX,1127,KRAS G12V,predicted â€“ sensitive,5443,PF3644022 + PF-477736,3845,26140595,,,
299,Phase I,"In a Phase I study, NSCLC patients harboring KRAS G12C or G12V mutations demonstrated a trend towards better overall survival, progression free survival, and objective response rate compared to NSCLC patients with other KRAS mutations when treated with the combination therapy, Selumetinib (AZD6244) and Taxotere (docetaxel) (PMID: 26125448). ",Actionable,2619,3908,non-small cell lung carcinoma,DOID,1127,KRAS G12V,predicted â€“ sensitive,1117,Selumetinib + Docetaxel,3845,26125448,,,
300,Preclinical - Cell culture,"In a preclinical study, 3144 inhibited growth of a colorectal cancer cell line harboring KRAS G12V in culture (PMID: 28235199).",Actionable,10841,9256,colorectal cancer,DOID,1127,KRAS G12V,sensitive,5658,3144,3845,28235199,,,
301,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G12V mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).",Actionable,8994,3910,lung adenocarcinoma,DOID,1127,KRAS G12V,decreased response,913,Selumetinib,3845,27422710,,,
302,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) inhibited proliferation of non-small cell lung cancer cells harboring KRAS G12V in culture (PMID: 23629727).",Actionable,8148,3908,non-small cell lung carcinoma,DOID,1127,KRAS G12V,sensitive,871,Pimasertib,3845,23629727,,,
303,Clinical Study,"In a clinical case study, treatment with Selumetinib (AZD6244)  resulted in lack of tumor progression for greater than 7 years in patient with low grade serous ovarian carcinoma harboring KRAS G12V (PMID: 27231576). ",Actionable,7751,50933,ovarian serous carcinoma,DOID,1127,KRAS G12V,sensitive,913,Selumetinib,3845,27231576,,,
304,Preclinical,"In a preclinical study, human colorectal cancer cells harboring KRAS G12V were resistant to Erbitux (cetuximab) in culture (PMID: 25838391).",Actionable,4937,9256,colorectal cancer,DOID,1127,KRAS G12V,resistant,694,Cetuximab,3845,25838391,,,
305,Preclinical - Cell culture,"In a preclinical study, Binimetinib (MEK162) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G12V mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).",Actionable,8986,3910,lung adenocarcinoma,DOID,1127,KRAS G12V,decreased response,807,Binimetinib,3845,27422710,,,
306,Preclinical - Cell culture,"In a preclinical study, AUY922 inhibited growth of colon cancer cell lines harboring KRAS G12V in culture (PMID: 26832792).",Actionable,9210,219,colon cancer,DOID,1127,KRAS G12V,sensitive,647,AUY922,3845,26832792,,,
307,Preclinical,"In a preclinical study, colorectal cancer cells harboring KRAS G12V were less sensitive to Nerlynx (neratinib) induced growth inhibition in culture (PMID: 26243863).",Actionable,7115,9256,colorectal cancer,DOID,1127,KRAS G12V,decreased response,828,Neratinib,3845,26243863,,,
308,Preclinical - Cell line xenograft,"In a preclinical study, Rapamune (sirolimus) worked synergistically with Mekinist (trametinib) to inhibit proliferation of head and neck squamous carcinoma cell lines overexpressing KRAS G12V in culture and to reduce tumor growth in cell line xenograft models (PMID: 26882569).",Actionable,4689,5520,head and neck squamous cell carcinoma,DOID,1127,KRAS G12V,sensitive,3596,Sirolimus + Trametinib,3845,26882569,,,
309,Preclinical - Cell culture,"In a preclinical study, a colon cancer cell line harboring KRAS G12V demonstrated sensitivity to AZ-TAK1 in culture, resulting in inhibition of cell growth (PMID: 27655129). ",Actionable,10060,219,colon cancer,DOID,1127,KRAS G12V,sensitive,5359,AZ-TAK1,3845,27655129,,,
310,Preclinical - Cell culture,"In a preclinical study, Alpelisib (BYL719) decreased viability of a colorectal cancer cell line harboring KRAS G12V in culture (PMID: 27602501).",Actionable,12023,9256,colorectal cancer,DOID,1127,KRAS G12V,sensitive,691,BYL719,3845,27602501,,,
311,Preclinical - Cell culture,"In a preclinical study, AZD4785 inhibited Kras expression, resulted in growth inhibition in 3-D cultures of colorectal cancer cell lines harboring KRAS G12V (PMID: 28615361).",Actionable,11325,9256,colorectal cancer,DOID,1127,KRAS G12V,sensitive,5914,AZD4785,3845,28615361,,,
312,Preclinical,"In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis of human colorectal cancer cell lines harboring KRAS G12V in culture (PMID: 25838391).",Actionable,4951,9256,colorectal cancer,DOID,1127,KRAS G12V,sensitive,1305,Regorafenib + Cetuximab,3845,25838391,,,
313,Preclinical - Pdx,"In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib)  combination treatment resulted in partial tumor regression in PDX models of PIK3CA wild-type colorectal cancer cells harboring KRAS G12V (PMID: 26369631).",Actionable,5618,9256,colorectal cancer,DOID,21300,KRAS G12V PIK3CA wild-type,sensitive,1368,Palbociclib + Trametinib,3845,26369631,,,
314,Preclinical - Cell culture,"In a preclinical study, a lung cancer cell line harboring FGFR1 amplification and KRAS G13C demonstrated insensitivity to JNJ-42756493 (erdafitinib) in culture (PMID: 28341788).",Actionable,11186,1324,lung cancer,DOID,27924,FGFR1 amp KRAS G12V,resistant,1028,JNJ-42756493,3845,28341788,,,
315,Guideline,Ertibux (cetuximab) is not indicated for use in colorectal cancer patients with KRAS exon 4 mutations (Guidelines).,Actionable,3836,9256,colorectal cancer,DOID,1870,KRAS A146P,resistant,694,Cetuximab,3845,None,,,
316,Guideline,Vectibix (panitumumab) is not indicated for use in colorectal cancer patients with KRAS exon 4 mutations (Guidelines).,Actionable,3841,9256,colorectal cancer,DOID,1870,KRAS A146P,resistant,845,Panitumumab,3845,None,,,
317,Preclinical - Cell culture,"In a preclinical study,  non-small cell lung carcinoma cells harboring KRAS mutation, STK11 and TP53 loss demonstrated increased sensitivity to MK-1775 and Platinol (cisplatin) combination treatment in culture compared to isogenic cell lines expressing wild-type Tp53 or Stk11 (PMID: 28652249).",Actionable,11859,3908,non-small cell lung carcinoma,DOID,28317,KRAS mut STK11 loss TP53 loss,predicted â€“ sensitive,1725,MK-1775 + Cisplatin,3845,28652249,,,
318,Preclinical,"In a preclinical study, human triple negative breast cancer cells harboring mutant BRAF, KRAS, and CDKN2A were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",Actionable,6690,60081,triple-receptor negative breast cancer,DOID,23670,BRAF mut KRAS mut CDKN2A mut,resistant,2,Trametinib,3845,26343583,,,
319,Preclinical,"In a preclinical study, Buparlisib (BKM120) inhibited proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA H1047R in culture (PMID: 26715098).",Actionable,4571,219,colon cancer,DOID,18592,KRAS mutant PIK3CA H1047R,sensitive,680,BKM120,3845,26715098,,,
320,Preclinical,"In a preclinical study, Buparlisib (BKM120) worked synergistically with Erbitux (cetuximab) to inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA H1047R in culture (PMID: 26715098).",Actionable,4573,219,colon cancer,DOID,18592,KRAS mutant PIK3CA H1047R,sensitive,3548,BKM120 + Cetuximab,3845,26715098,,,
321,Preclinical,"In a preclinical study, Erbitux (cetuximab) did not inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA H1047R in culture (PMID: 26715098).",Actionable,4572,219,colon cancer,DOID,18592,KRAS mutant PIK3CA H1047R,no benefit,694,Cetuximab,3845,26715098,,,
322,Preclinical,"In a preclinical study, knocking down of Fgfr3 through shRNA did not sensitize KRAS mutant lung cancer cells to Mekinist (trametinib) induced growth inhibition in culture  (PMID: 27338794).",Actionable,7363,1324,lung cancer,DOID,25309,FGFR3 dec exp KRAS mut,no benefit,2,Trametinib,3845,27338794,,,
323,Preclinical - Cell culture,"In a preclinical study, treatment with BI-847325 inhibited growth of a BRAF-mutant melanoma cell line with BRAF-inhibitor resistance due to a KRAS mutation in culture (PMID: 25873592).",Actionable,7831,1909,melanoma,DOID,26062,BRAF mut KRAS mut,predicted â€“ sensitive,1059,BI-847325,3845,25873592,,,
324,Preclinical,"In a preclinical study, CUDC-907 inhibited growth and induced apoptosis in a human colon cancer cell line harboring PIK3CA and KRAS mutations (PMID: 22693356).",Actionable,2840,219,colon cancer,DOID,1630,KRAS mut PIK3CA mut,sensitive,709,CUDC-907,3845,22693356,,,
325,Preclinical - Cell line xenograft,"In a preclinical study, treatment with Aliqopa (copanlisib) inhibited tumor growth in xenograft models of a human colon cancer cell line harboring PIK3CA and KRAS mutations (PMID: 24170767).",Actionable,2722,219,colon cancer,DOID,1630,KRAS mut PIK3CA mut,sensitive,995,Copanlisib,3845,24170767,,,
326,Preclinical - Cell line xenograft,"In a preclincal study, GDC-0980 delayed tumor growth in colon cancer cell line xenograft models harboring KRAS and PIKC3A mutations (PMID: 21998291).",Actionable,2855,219,colon cancer,DOID,1630,KRAS mut PIK3CA mut,sensitive,750,GDC-0980,3845,21998291,,,
327,Preclinical,"In a preclinical study, Selumetinib (AZD6244) mildly inhibited the growth of an Iressa (gefitinib)-resistant NSCLC cell line with KRAS and PIK3CA mutations (PMID: 24939055).",Actionable,983,3908,non-small cell lung carcinoma,DOID,1630,KRAS mut PIK3CA mut,decreased response,913,Selumetinib,3845,24939055,,,
328,Preclinical - Cell line xenograft,"In a preclinical study, Selumetinib (AZD6244) in combination with BEZ235, synergistically prevented proliferation of an Iressa (gefitinib)-resistant NSCLC cell line harboring KRAS and PIK3CA mutations in culture and in cell line xenograft models (PMID: 24939055).",Actionable,989,3908,non-small cell lung carcinoma,DOID,1630,KRAS mut PIK3CA mut,sensitive,1420,Selumetinib + BEZ235,3845,24939055,,,
329,Phase I,"In a Phase I trial, a colorectal cancer patient co-harboring a PIK3CA mutation and KRAS mutation progressed on treatment with Taselisib (GDC-0032) (PMID: 28331003). ",Actionable,11446,9256,colorectal cancer,DOID,1630,KRAS mut PIK3CA mut,no benefit,1016,GDC-0032,3845,28331003,,,
330,Preclinical - Cell culture,"In a preclinical study, a colorectal cancer cell line co-harboring a KRAS mutation and PIK3CA mutation was sensitive to XL765 (SAR245409), demonstrating inhibition of cell proliferation in culture (PMID: 24634413). ",Actionable,10707,9256,colorectal cancer,DOID,1630,KRAS mut PIK3CA mut,sensitive,1051,SAR245409,3845,24634413,,,
331,Phase II,"In a Phase II trial, one patient with Kras and Pikc3a mutant non-squamous NSCLC had a partial response to Buparlisib (BKM120) however, stage 2 of the study was not initiated due to failure of meeting overall stage 1 response endpoints (PMID: 26098748).",Actionable,9817,3908,non-small cell lung carcinoma,DOID,1630,KRAS mut PIK3CA mut,sensitive,680,BKM120,3845,26098748,,,
332,Preclinical - Cell line xenograft,"In a preclinical study, PF-04691502 inhibited tumor growth in non-small cell lung cancer cell line xenograft models harboring both PIK3CA and KRAS mutations (PMID: 21750219).",Actionable,8388,3908,non-small cell lung carcinoma,DOID,1630,KRAS mut PIK3CA mut,sensitive,865,PF-04691502,3845,21750219,,,
333,Preclinical,"In a preclinical study, human solid tumor cell lines harboring coincident PIK3CA and KRAS mutations demonstrated sensitivity to CH5132799 in culture (PMID: 21558396).",Actionable,2835,10000003,Advanced Solid Tumor,JAX,1630,KRAS mut PIK3CA mut,sensitive,2152,CH5132799,3845,21558396,,,
334,Preclinical,"In a preclinical study, human cancer cells with PIK3CA mutations demonstrated sensitivity to Afinitor (everolimus), but a coincident KRAS mutation led to Afinitor (everolimus) resistance  (PMID: 20664172).",Actionable,145,10000003,Advanced Solid Tumor,JAX,1630,KRAS mut PIK3CA mut,resistant,735,Everolimus,3845,20664174,20664172,,
335,Phase I,"In a Phase I trial, Taselisib (GDC-0032) demonstrated activity in patients with PIK3CA-mutant advanced solid tumors, but preliminary data analysis suggested the presence of a KRAS mutation was associated with lack of response (Cancer Res October 1, 2014 74:915).",Actionable,2851,10000003,Advanced Solid Tumor,JAX,1630,KRAS mut PIK3CA mut,decreased response,1016,GDC-0032,3845,None,,,
336,Preclinical,"In a preclinical study, BEZ235 inhibited the growth of an Iressa (gefitinib)-resistant NSCLC cell line with KRAS and PIK3CA mutations (PMID: 24939055).",Actionable,984,3908,non-small cell lung carcinoma,DOID,1630,KRAS mut PIK3CA mut,sensitive,672,BEZ235,3845,24939055,,,
337,Preclinical - Cell line xenograft,"In a preclinical study, Navitoclax (ABT-263) improved the therapeutic effects of the combination of CGM097 and Mekinist (trametinib) in colorectal cancer cells, resulting in greater apoptotic activity and growth inhibition in culture, and tumor regression in xenograft models (PMID: 27659046). ",Actionable,9931,9256,colorectal cancer,DOID,1630,KRAS mut PIK3CA mut,sensitive,5315,ABT-263 + CGM097 + Trametinib,3845,27659046,,,
338,Preclinical,"In a preclinical study, Deguelin inhibited growth of the AGS gastric cancer cell line, which has been reported to harbor PIK3CA and KRAS mutations, in culture (PMID: 20811676, PMID: 24978597).",Actionable,2844,10534,stomach cancer,DOID,1630,KRAS mut PIK3CA mut,predicted â€“ sensitive,1867,Deguelin,3845,24978597,20811676,,
339,Preclinical,"In a preclinical study, a colon cancer cell line harboring PIK3CA and KRAS mutations demonstrated sensitivity to AT13148 in culture (PMID: 22781553).",Actionable,2779,219,colon cancer,DOID,1630,KRAS mut PIK3CA mut,sensitive,3653,AT13148,3845,22781553,,,
340,Preclinical,"In a preclinical study, Alpelisib (BYL719) inhibited growth in multiple tumor cell lines expressing PIK3CA mutations, and concurrent KRAS mutations was not associated with resistance (PMID: 24608574).",Actionable,2874,10000003,Advanced Solid Tumor,JAX,1630,KRAS mut PIK3CA mut,sensitive,691,BYL719,3845,24608574,,,
341,Preclinical - Cell line xenograft,"In a preclinical study, the combination of CGM097 and Mekinist (trametinib) treatment compared to treatment with either agent alone in a colorectal cancer cell line resulted in a greater decrease in colony formation in culture, and improved stable disease in xenograft models (PMID: 27659046). ",Actionable,9930,9256,colorectal cancer,DOID,1630,KRAS mut PIK3CA mut,sensitive,5314,CGM097 + Trametinib,3845,27659046,,,
342,Preclinical,"In a preclinical study, the combination of AZD8055 and Selumetinib (AZD6244) inhibited tumor growth in a colorectal cancer xenograft model harboring PIK3CA and KRAS mutations and had increased efficacy compared to either agent alone (PMID: 22271687).",Actionable,2795,9256,colorectal cancer,DOID,1630,KRAS mut PIK3CA mut,sensitive,2561,AZD8055 + Selumetinib,3845,22271687,,,
343,Preclinical,"In a preclinical study, colon cancer cells harboring KRAS and PIK3CA mutations demonstrated resistance to BEZ235 in culture and xenograft models (PMID: 23475782).",Actionable,2724,9256,colorectal cancer,DOID,1630,KRAS mut PIK3CA mut,resistant,672,BEZ235,3845,23475782,,,
344,Preclinical,"In a preclinical study, A-443654 inhibited proliferation of colon cancer cell lines that have been reported to harbor KRAS and PIK3CA mutations in culture (PMID: 24569089, PMID: 24978597).",Actionable,2864,219,colon cancer,DOID,1630,KRAS mut PIK3CA mut,sensitive,2448,A-443654,3845,24978597,24569089,,
345,Preclinical,"In a preclinical study, BKM120 suppressed growth of a gastric cancer cell line harboring PIK3CA and KRAS mutations in culture (PMID: 22159814).",Actionable,2799,10534,stomach cancer,DOID,1630,KRAS mut PIK3CA mut,sensitive,680,BKM120,3845,22159814,,,
346,Preclinical - Cell line xenograft,"In a preclinical study, a non-small cell lung carcinoma cell line harboring a KRAS mutation and STK11 inactivating mutation was sensitive to XL765 (SAR245409), demonstrating inhibition of cell proliferation in culture, and inhibition of tumor growth in cell line xenograft models (PMID: 24634413). ",Actionable,10705,3908,non-small cell lung carcinoma,DOID,20861,KRAS mut STK11 inact mut,sensitive,1051,SAR245409,3845,24634413,,,
347,Preclinical - Cell culture,"In a preclinical study, MK-1775 combined with radiation therapy demonstrated enhanced growth inhibition in non-small cell lung carcinoma cell lines harboring KRAS mutations and STK11 inactivating mutations compared to cells expressing wild-type STK11 in culture (PMID: 28652249).",Actionable,11858,3908,non-small cell lung carcinoma,DOID,20861,KRAS mut STK11 inact mut,predicted â€“ sensitive,4186,MK-1775 + Radiotherapy,3845,28652249,,,
348,Preclinical - Cell culture,"In a preclinical study, MK-1775 and Platinol (cisplatin) combination treatment demonstrated enhanced growth inhibition in non-small cell lung carcinoma cell lines harboring KRAS mutations and STK11 inactivating mutations compared to cells expressing wild-type STK11 in culture (PMID: 28652249).",Actionable,11857,3908,non-small cell lung carcinoma,DOID,20861,KRAS mut STK11 inact mut,predicted â€“ sensitive,1725,MK-1775 + Cisplatin,3845,28652249,,,
349,Preclinical,"In a preclinical study, Sapanisertib (MLN0128) in combination with phenformin induced apoptosis and energetic stress in human lung adenocarcinoma cell lines with concurrent KRAS and STK11 (LKB1) mutations in culture, with higher levels than either therapy as a single agent (PMID: 26574479).",Actionable,5408,3910,lung adenocarcinoma,DOID,20861,KRAS mut STK11 inact mut,sensitive,3861,MLN0128 + Phenformin,3845,26574479,,,
350,Preclinical - Cell culture,"In a preclinical study, non-small cell lung carcinoma cell lines harboring KRAS mutations and STK11 inactivating mutations demonstrated increased sensitivity to MK-1775 compared to cells expressing wild-type STK11 in culture (PMID: 28652249).",Actionable,11856,3908,non-small cell lung carcinoma,DOID,20861,KRAS mut STK11 inact mut,predicted â€“ sensitive,822,MK-1775,3845,28652249,,,
351,Preclinical,"In a preclinical study, Buparlisib (BKM120) worked synergistically with Erbitux (cetuximab) to inhibit proliferation of colon cancer cell lines harboring mutant KRAS and wild-type PIK3CA in culture and tumor growth in xenograft models (PMID: 26715098).",Actionable,4570,219,colon cancer,DOID,18590,KRAS mutant PIK3CA wild-type,sensitive,3548,BKM120 + Cetuximab,3845,26715098,,,
352,Preclinical,"In a preclinical study, Buparlisib (BKM120) inhibited proliferation of colon cancer cell lines harboring mutant KRAS and wild-type PIK3CA in culture and reduced tumor growth in xenograft models (PMID: 26715098).",Actionable,4568,219,colon cancer,DOID,18590,KRAS mutant PIK3CA wild-type,sensitive,680,BKM120,3845,26715098,,,
353,Preclinical - Pdx & cell culture,"In a preclinical study, colorectal cancer cell lines harboring mutations in KRAS or NRAS with wild-type PIK3CA demonstrated a trend toward increased sensitivity to TAK-733 in culture, and colorectal cancer patient-derived xenograft (PDX) models with KRAS or BRAF mutations and wild-type PIK3CA demonstrated a trend toward greater tumor growth inhibition (PMID: 26439693).",Actionable,10766,9256,colorectal cancer,DOID,18590,KRAS mutant PIK3CA wild-type,predicted â€“ sensitive,932,TAK-733,3845,26439693,,,
354,Preclinical,"In a preclinical study, knocking down of Fgfr2 through shRNA did not sensitize KRAS mutant lung cancer cells to Mekinist (trametinib) induced growth inhibition in culture (PMID: 27338794).",Actionable,7362,1324,lung cancer,DOID,25308,FGFR2 dec exp KRAS mut,no benefit,2,Trametinib,3845,27338794,,,
355,Preclinical - Cell line xenograft,"In a preclinical study, Mekinist (trametinib) treatment demonstrated enhanced growth inhibition in KRAS mutant lung cancer cells with decreased Fgfr1 expression through shRNA knockdown in culture, and tumor regression in xenograft models (PMID: 27338794).",Actionable,7360,1324,lung cancer,DOID,25304,FGFR1 dec exp KRAS mut,sensitive,2,Trametinib,3845,27338794,,,
356,Preclinical - Cell culture,"In a preclinical study, Mekinist (trametinib) treatment demonstrated enhanced growth inhibition of KRAS mutant pancreatic cancer cells with decreased Fgfr1 expression through shRNA knockdown in culture (PMID: 27338794).",Actionable,7365,1793,pancreatic cancer,DOID,25304,FGFR1 dec exp KRAS mut,sensitive,2,Trametinib,3845,27338794,,,
357,Preclinical - Cell culture,"In a preclinical study, knocking down of Fgfr1 through shRNA did not sensitize KRAS mutant colorectal cancer cells to Mekinist (trametinib) induced growth inhibition in culture (PMID: 27338794).",Actionable,7366,9256,colorectal cancer,DOID,25304,FGFR1 dec exp KRAS mut,no benefit,2,Trametinib,3845,27338794,,,
358,Phase I,"In a clinical study, a retrospective analysis of a Phase I trial demonstrated four non-small cell lung carcinoma (NSCLC) patients co-harboring  a TP53 mutation and KRAS mutation had greater progression free survival compared to NSCLC patients harboring a single TP53 mutation or single KRAS mutation when treated with Keytruda (pembrolizumab) (PMID: 28039262). ",Actionable,11296,3908,non-small cell lung carcinoma,DOID,25456,KRAS mutant TP53 mutant,predicted â€“ sensitive,1447,Pembrolizumab,3845,28039262,,,
359,Preclinical - Cell culture,"In a preclinical study, the combination of Navitoclax (ABT-263), Mekinist (trametinib), Alpelisib (BYL719), and Tarceva (erlotinib) resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a KRAS mutation and TP53 mutation compared to the double or triple combinations of the therapies (PMID: 27659046). ",Actionable,9932,9256,colorectal cancer,DOID,25456,KRAS mutant TP53 mutant,sensitive,5316,ABT-263 + Alpelisib + Erlotinib + Trametinib,3845,27659046,,,
360,Phase I,"In a Phase I trial, a colorectal cancer patient co-harboring a KRAS mutation and TP53 mutation demonstrated sensitivity when treated with Abemaciclib (LY2835219), which resulted in stable disease (PMID: 27217383). ",Actionable,7460,9256,colorectal cancer,DOID,25456,KRAS mutant TP53 mutant,sensitive,802,Abemaciclib,3845,27217383,,,
361,Preclinical - Cell culture,"In a preclinical study, DEL-22379 inhibited growth of KRAS-mutant melanoma cells over expressing BRAF V600E in culture (PMID: 26267534).",Actionable,5815,9256,colorectal cancer,DOID,21629,BRAF V600E KRAS mutant,sensitive,3769,DEL-22379,3845,26267534,,,
362,Preclinical,"In a preclinical study, over expression of BRAF V600E in KRAS-mutant colorectal cancer cells resulted in resistance to growth inhibition by PD-0325901 in cell culture (PMID: 26267534).",Actionable,5813,9256,colorectal cancer,DOID,21629,BRAF V600E KRAS mutant,resistant,849,PD-0325901,3845,26267534,,,
363,Preclinical - Cell line xenograft,"In a preclinical study, treatment with GA201 induced antibody-dependent cell-mediated cytotoxicity against KRAS-mutant lung adenocarcinoma with low EGFR expression in culture and improved overall survival in low EGFR expressing, KRAS-mutant lung adenocarcinoma cell line xenograft models, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).",Actionable,3866,3910,lung adenocarcinoma,DOID,16550,EGFR dec exp KRAS mut,sensitive,3154,GA201,3845,23209031,,,
364,Preclinical,"In a preclinical study, treatment with GA201 resulted in improved overall survival in KRAS-mutant colorectal cancer cell line xenograft models with low EGFR expression, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).",Actionable,3867,9256,colorectal cancer,DOID,16550,EGFR dec exp KRAS mut,sensitive,3154,GA201,3845,23209031,,,
365,Preclinical - Cell line xenograft,"In a preclinical study, the combination of ER2 and Platinol (cisplatin) demonstrated synergy in inhibiting tumor growth in a non-small cell lung cancer cell line xenograft model with low expression of wild-type EGFR, that also harbors a KRAS mutation (PMID: 27040853).",Actionable,8042,3908,non-small cell lung carcinoma,DOID,16550,EGFR dec exp KRAS mut,sensitive,4625,ER2 + Cisplatin,3845,27040853,,,
366,Preclinical,"In a preclinical study, treatment with GA201 resulted in improved overall survival in KRAS-mutant non-small cell lung cancer cell line xenograft models with low EGFR expression, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).",Actionable,3865,3908,non-small cell lung carcinoma,DOID,16550,EGFR dec exp KRAS mut,sensitive,3154,GA201,3845,23209031,,,
367,Clinical Study,"In a clinical case study, Stivarga (regorafenib) treatment resulted in durable partial response in a colorectal cancer patient harboring KDR R961W and mutations in APC and KRAS (PMID: 27004155).",Actionable,5559,9256,colorectal cancer,DOID,21268,APC mutant KRAS mutant KDR R961W,sensitive,890,Regorafenib,3845,27004155,,,
368,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9394,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,sensitive,4601,Dasatinib + SCH772984,3845,26725216,,,
369,Preclinical - Pdx & cell culture,"In a preclinical study, AZD8186 and SCH772984 synergistically inhibited growth of both established and patient-derived, SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9369,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,sensitive,4986,AZD8186 + SCH772984,3845,26725216,,,
370,Preclinical - Cell culture,"In a preclinical study, Rydapt (midostaurin) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9393,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,sensitive,5008,Midostaurin + SCH772984,3845,26725216,,,
371,Phase Ib/II,"In a Phase Ib/II trial, the combination of Sprycel (dasatinib) and FOLFOX demonstrated minimal clinical benefit in patients with metastatic colorectal adenocarcinoma harboring KRAS codon 12/13 mutations, with no responses and a median time to treatment failure of 2.0 months (PMID: 28280091; NCT00501410).",Actionable,11610,50861,colorectal adenocarcinoma,DOID,448,KRAS mutant,no benefit,6075,Dasatinib + FOLFOX,3845,28280091,,,
372,Preclinical,"In a preclinical study, BI-847325 promoted tumor regression in mutant KRAS pancreatic adenocarcinoma models (Cancer Res 2012;72(8 Suppl):Abstract nr 1919).",Actionable,1287,4074,pancreatic adenocarcinoma,DOID,448,KRAS mutant,sensitive,1059,BI-847325,3845,None,,,
373,Preclinical - Cell culture,"In a preclinical study, the addition of combination PD-0325901 to treatment with Gedatolisib (PF-05212384) and PD-0325901 inhibited Gedatolisib (PF-05212384)-enhanced ERK activation, and the combination resulted in decreased proliferation of pancreatic ductal adenocarcinoma cell lines harboring KRAS mutations in culture (PMID: 25673820).",Actionable,2765,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,sensitive,3025,PD-0325901 + Gedatolisib,3845,25673820,,,
374,Preclinical,"In a preclinical study, the addition of PD-0325901 to treatment with GDC-0980 and inhibited GDC-0980-enhanced ERK activation, and the combination resulted in decreased proliferation of pancreatic cancer cells harboring KRAS mutations in culture (PMID: 25673820).",Actionable,2766,1793,pancreatic cancer,DOID,448,KRAS mutant,sensitive,3026,GDC-0980 + PD-0325901,3845,25673820,,,
375,Preclinical - Cell culture,"In a preclinical study, Navitoclax (ABT-263)  and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9384,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,sensitive,4998,Navitoclax + SCH772984,3845,26725216,,,
376,Phase I,"In a Phase I trial, of eight patients with colorectal cancer, three patients harbored a KRAS mutation and demonstrated stable disease when treated with Mekinist (trametinib) (PMID: 22805291). ",Actionable,1435,9256,colorectal cancer,DOID,448,KRAS mutant,sensitive,2,Trametinib,3845,22805291,,,
377,Preclinical - Cell culture,"In a preclinical study, AZD8055 and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9380,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,sensitive,4994,AZD8055 + SCH772984,3845,26725216,,,
378,Phase I,"In a Phase I trial, Binimetinib (MEK162) treatment resulted in an estimated progression free survival (PFS) of 1.5 months and overall survival (OS) of 4.7 months when dosed at 45mg, and PFS of 3.5 months and OS of 9.1 months when dosed at 60mg, in colorectal cancer patients harboring KRAS mutations (PMID: 28152546).",Actionable,10458,9256,colorectal cancer,DOID,448,KRAS mutant,predicted â€“ sensitive,807,Binimetinib,3845,28152546,,,
379,Clinical Study,"In a clinical study, KRAS mutations were associated with resistance to Afinitor (everolimus) in patients with advanced solid tumors (PMID: 20664172).",Actionable,1436,10000003,Advanced Solid Tumor,JAX,448,KRAS mutant,resistant,735,Everolimus,3845,20664172,,,
380,Preclinical - Cell culture,"In a preclinical study, Ipatasertib (GDC-0068) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9379,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,sensitive,5004,GDC-0941 + SCH772984,3845,26725216,,,
381,Phase I,"In a Phase I trial, BI-847325 demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including patients harboring KRAS mutations (Mol Cancer Ther 2013;12(11 Suppl):B281).",Actionable,2725,10000003,Advanced Solid Tumor,JAX,448,KRAS mutant,sensitive,1059,BI-847325,3845,None,,,
382,Phase I,"In a Phase I trial, a patient with colon cancer harboring a KRAS mutation demonstrated stable disease when treated with OPB-111077 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B118).",Actionable,10963,219,colon cancer,DOID,448,KRAS mutant,predicted â€“ sensitive,5739,OPB-111077,3845,None,,,
383,Preclinical - Pdx,"In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of KRAS-mutant pancreatic cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",Actionable,11968,1793,pancreatic cancer,DOID,448,KRAS mutant,predicted â€“ sensitive,5747,KO-947,3845,None,,,
384,Preclinical,"In a preclinical study, Mekinist (trametinib) and Iclusig (ponatinib) synergistically inhibited proliferation of KRAS mutant pancreatic cancer cells in culture (PMID: 27338794).",Actionable,7368,1793,pancreatic cancer,DOID,448,KRAS mutant,sensitive,4477,Ponatinib + Trametinib,3845,27338794,,,
385,Phase Ib/II,"In a Phase Ib/II clinical trial, treatment with Mekinist (trametinib) resulted in an overall response rate of 28% in RAS-mutant leukemia patients, with 12% (7/57) of patients achieving complete remission (ASH 2015 Annual Meeting, Abst 677).",Actionable,3563,1240,leukemia,DOID,448,KRAS mutant,predicted â€“ sensitive,2,Trametinib,3845,None,,,
386,Phase I,"In a Phase I trial, two non-small cell lung carcinoma patients harboring a KRAS mutation demonstrated a partial response when treated with Mekinist (trametinib) (PMID: 22805291). ",Actionable,11974,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,sensitive,2,Trametinib,3845,22805291,,,
387,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited growth of non-small cell cancer cell lines harboring mutant KRAS in culture (PMID: 26343583).",Actionable,6700,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,sensitive,2,Trametinib,3845,26343583,,,
388,Preclinical - Cell culture,"In a preclinical study, the combination of Mekinist (trametinib) and AZD4547 synergistically inhibited proliferation of KRAS mutant lung cancer cells in culture (PMID: 27338794).",Actionable,7372,1324,lung cancer,DOID,448,KRAS mutant,sensitive,4478,AZD4547 + Trametinib,3845,27338794,,,
389,Preclinical - Cell culture,"In a preclinical study, Linsitinib (OSI-906) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9388,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,sensitive,5002,Linsitinib + SCH772984,3845,26725216,,,
390,Preclinical,"In a preclinical study, human multiple myeloma cells harboring mutant KRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",Actionable,6688,9538,multiple myeloma,DOID,448,KRAS mutant,resistant,2,Trametinib,3845,26343583,,,
391,Phase I,"In a Phase I trial, BGB-283 demonstrated safety and preliminary efficacy, resulted in partial response in 14% (4/29), and prolonged stable disease in 48% (14/29) of advanced solid tumor patients harboring mutations in KRAS, NRAS, and/or BRAF (AACR Annual Meeting, Apr 2016, abstract # CT005).",Actionable,7226,10000003,Advanced Solid Tumor,JAX,448,KRAS mutant,predicted â€“ sensitive,4025,BGB-283,3845,None,,,
392,Preclinical - Cell culture,"In a preclinical study, BMS-754807 and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9392,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,sensitive,5007,BMS-754807 + SCH772984,3845,26725216,,,
393,Preclinical - Cell culture,"In a preclinical study, the combination of Tarceva (erlotinib) and IRX4204 inhibited proliferation of non-small cell lung cancer cell lines in culture, including cell lines harboring KRAS mutations, and resulted in increased inhibition of proliferation and Src, p-AKT, and ribosomal S6 compared to either agent alone (J Clin Oncol 35, 2017 (suppl; abstr e14095)).",Actionable,11171,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,predicted â€“ sensitive,5135,Erlotinib + IRX4204,3845,None,,,
394,Preclinical - Cell culture,"In a preclinical study, MK2206 and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9383,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,sensitive,4997,MK2206 + SCH772984,3845,26725216,,,
395,Phase II,"In a Phase II study, Estybon (rigosertib) in combination with, gemcitabine, did not demonstrate increased efficacy over gemcitabine alone and there was no correlation of reponse with Kras mutational status in pancreatic patients (PMID: 26091808).",Actionable,2748,1793,pancreatic cancer,DOID,448,KRAS mutant,no benefit,3021,Rigosertib + Gemcitabine,3845,26091808,,,
396,Preclinical - Pdx,"In a preclinical study, the combination of Dinaciclib (SCH 727965) and MK-2206 inhibited tumor growth and metastasis in KRAS-mutant patient-derived xenograft models of pancreatic ductal adenocarcinoma, with some models achieving complete response (PMID: 25931518).",Actionable,8377,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,sensitive,2193,Dinaciclib + MK2206,3845,25931518,,,
397,Preclinical,"In a preclinical study, the combination of Buparlisib (BKM120) and Tyrphostin B42 (AG-490) worked synergistically to inhibit proliferation and induce apoptosis in gastric cancer cell lines harboring KRAS mutations in culture (PMID: 22159814).",Actionable,2738,10534,stomach cancer,DOID,448,KRAS mutant,sensitive,3019,BKM120 + AG490,3845,22159814,,,
398,Preclinical,"In a preclinical study, tumor cell lines harboring KRAS mutations were resistant to AZD8835 induced growth inhibition in culture (PMID: 26839307).",Actionable,5098,10000003,Advanced Solid Tumor,JAX,448,KRAS mutant,resistant,2013,AZD8835,3845,26839307,,,
399,Preclinical - Pdx,"In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of KRAS-mutant gastric carcinoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",Actionable,11971,5517,stomach carcinoma,DOID,448,KRAS mutant,predicted â€“ sensitive,5747,KO-947,3845,None,,,
400,Phase I,"In a Phase I/Ib trial, treatment with the combination of Mekinist (trametinib) and Taxotere (docetaxel) resulted in an overall response rate (ORR) of 24% (6/25, all partial responses), and stable disease in 36% (9/25) in the subset of patients with KRAS-mutant non-small cell lung cancer, compared to an ORR of 18% (4/22) in patients with wild-type or unknown KRAS status (PMID: 27876675).",Actionable,10762,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,predicted â€“ sensitive,1264,Docetaxel + Trametinib,3845,27876675,,,
401,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited growth of squamous cell lung carcinoma cells harboring mutant KRAS in culture (PMID: 26343583).",Actionable,6701,3907,lung squamous cell carcinoma,DOID,448,KRAS mutant,sensitive,2,Trametinib,3845,26343583,,,
402,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited growth of a majority (12/17) lung adenocarcinoma cell lines harboring mutant KRAS in culture (PMID: 26343583).",Actionable,6698,3910,lung adenocarcinoma,DOID,448,KRAS mutant,sensitive,2,Trametinib,3845,26343583,,,
403,Phase II,"In a Phase II trial, Tarceva (erlotinib) and MK2206 combination treatment resulted in comparable 8-week disease control rate in KRAS wild-type (57%, 16/28) and KRAS mutated (25%, 2/8) patients with advanced non-small cell lung carcinoma (PMID: 27480147).",Actionable,7740,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,no benefit,1097,Erlotinib + MK2206,3845,27480147,,,
404,Preclinical,"In a preclinical study, human endometrial cancer cells harboring mutant KRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",Actionable,6693,1380,endometrial cancer,DOID,448,KRAS mutant,resistant,2,Trametinib,3845,26343583,,,
405,Phase I,"In a Phase Ib trial, Tecentriq (atezolizumab) and Cotellic (cobimetinib) combination treatment resulted in partial response in 17% (4/23) and stable disease in 22% (5/23) of colorectal cancer patients harboring KRAS mutations (Ann Oncol (2016) 27 (suppl 2): ii140).",Actionable,7233,9256,colorectal cancer,DOID,448,KRAS mutant,predicted â€“ sensitive,1343,Atezolizumab + Cobimetinib,3845,None,,,
406,Phase I,"In a Phase I clinical trial, GI-4000 was well-tolerated and led to some RAS-directed immune response in patients with RAS-mutant pancreatic cancer (PMID: 25585100).",Actionable,358,1793,pancreatic cancer,DOID,448,KRAS mutant,predicted â€“ sensitive,1018,GI-4000,3845,24372276,25585100,,
407,Phase I,"In a clinical study, a retrospective analysis of a Phase I trial demonstrated non-small cell lung carcinoma (NSCLC) patients harboring either a TP53 mutation (n=15) or KRAS mutation (n=8) had greater progression free survival compared to NSCLC patients harboring wild-type TP53 or KRAS (n=15) (14.5mo vs 14.7mo vs 3.5mo, respectively) when treated with Keytruda (pembrolizumab) (PMID: 28039262). ",Actionable,11295,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,predicted â€“ sensitive,1447,Pembrolizumab,3845,28039262,,,
408,Preclinical,"In a preclinical study, MLN1117 (INK1117) did not inhibit tumor growth in xenograft models harboring mutations in KRAS (American Association for Cancer Research; 2011:Abstract nr 4501).",Actionable,1685,10000003,Advanced Solid Tumor,JAX,448,KRAS mutant,no benefit,1033,MLN1117,3845,None,,,
409,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS mutations due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).",Actionable,9001,3910,lung adenocarcinoma,DOID,448,KRAS mutant,decreased response,913,Selumetinib,3845,27422710,,,
410,Preclinical - Cell line xenograft,"In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of KRAS mutant lung cancer (PMID: 26140595).",Actionable,10255,1324,lung cancer,DOID,448,KRAS mutant,predicted â€“ sensitive,5443,PF3644022 + PF-477736,3845,26140595,,,
411,Clinical Study,"In a clinical study, KRAS mutations were associated with resistance to Tarceva (erlotinib) in patients with lung adenocarcinoma (PMID: 15696205).",Actionable,141,3910,lung adenocarcinoma,DOID,448,KRAS mutant,resistant,4,Erlotinib,3845,15696205,,,
412,Phase III,"In a Phase III trial supporting FDA approval, Stivarga (regorafenib) treatment resulted in a median progression free survival (PFS) of 2.3 months in metastatic colorectal cancer patients harboring KRAS mutations, and a median PFS of 2.1 months in KRAS wild-type patients (J Clin Oncol 34, 2016 (suppl 4S; abstr 735)).",Actionable,6004,9256,colorectal cancer,DOID,448,KRAS mutant,predicted â€“ sensitive,890,Regorafenib,3845,None,,,
413,Preclinical - Pdx,"In a preclinical study, XMT-1536 induced tumor regression in patient-derived-xenograft models of of non-small cell lung cancer harboring KRAS mutations (Proceedings of AACR, Vol 57, Apr 2016, Abstract # 1194).",Actionable,6211,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,predicted â€“ sensitive,4094,XMT-1536,3845,None,,,
414,Preclinical,"In a preclinical study, gastric cancer xenograft models harboring KRAS mutations demonstrated decreased sensitivity to BAY1082439 in culture (AACR; 2015. Abstract nr 2674).",Actionable,2719,10534,stomach cancer,DOID,448,KRAS mutant,decreased response,666,BAY1082439,3845,None,,,
415,Preclinical,"In a preclinical study, AT13148 inhibited tumor growth in a human lung adenocarcinoma cell line xenograft model harboring mutant KRAS (PMID: 22781553).",Actionable,4787,3910,lung adenocarcinoma,DOID,448,KRAS mutant,sensitive,3653,AT13148,3845,22781553,,,
416,Phase I,"In a Phase I trial, none of 30 colorectal cancer patients with KRAS mutations achieved favorable response after treatment with RO4987655 (PMID: 24947927).",Actionable,2751,9256,colorectal cancer,DOID,448,KRAS mutant,no benefit,903,RO4987655,3845,24947927,,,
417,Preclinical,"In a preclinical study, Mekinist (trametinib) and Iressa (gefitinib) did not demonstrate synergy at inhibiting proliferation of KRAS mutant lung cancer cells in culture (PMID: 27338794).",Actionable,7375,1324,lung cancer,DOID,448,KRAS mutant,no benefit,4481,Gefitinib + Trametinib,3845,27338794,,,
418,Preclinical - Cell line xenograft,"In a preclinical study, CI-1040 inhibited growth of a human ovarian cancer cell line harboring a KRAS mutation in culture, and inhibited tumor growth in xenograft models (PMID: 19018267).",Actionable,2741,2394,ovarian cancer,DOID,448,KRAS mutant,sensitive,699,CI-1040,3845,19018267,,,
419,Preclinical - Cell culture,"In a preclinical study, the combination of AZ-TAK1 and Selumetinib (AZD6244) resulted in an additive effect in colon cancer cells harboring KRAS mutant in culture, demonstrating a 90% growth reduction (PMID: 27655129). ",Actionable,10059,219,colon cancer,DOID,448,KRAS mutant,sensitive,5360,AZ-TAK1 + Selumetinib,3845,27655129,,,
420,Preclinical,"In a preclinical study, Mekinist (trametinib) and Xalkori (crizotinib) did not demonstrate synergy at inhibiting proliferation of KRAS mutant lung cancer cells in culture (PMID: 27338794).",Actionable,7374,1324,lung cancer,DOID,448,KRAS mutant,no benefit,4480,Crizotinib + Trametinib,3845,27338794,,,
421,Preclinical - Cell culture,"In a preclinical study, Ralimetinib (LY2228820) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9386,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,sensitive,5000,Ralimetinib + SCH772984,3845,26725216,,,
422,Preclinical - Patient cell culture,"In a preclinical study, AZD8186 and BVD-523 synergistically inhibited growth of both established and patient-derived, SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture, and inhibited tumor growth in cell line xenograft models (PMID: 26725216).",Actionable,9370,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,sensitive,4987,AZD8186 + BVD-523,3845,26725216,,,
423,Preclinical - Cell line xenograft,"In a preclinical study, OSI-027 inhibited tumor growth in ovarian cancer cell line xenograft models harboring KRAS mutations (PMID: 21673091).",Actionable,8732,2394,ovarian cancer,DOID,448,KRAS mutant,sensitive,841,OSI-027,3845,21673091,,,
424,Phase I,"In a Phase I trial, the combination of Ipatasertib (GDC-0068) and Cobimetinib (GDC-0973) demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including patients harboring KRAS mutations (Cancer Res, October 1, 2014 74; CT328).",Actionable,2746,10000003,Advanced Solid Tumor,JAX,448,KRAS mutant,predicted â€“ sensitive,1160,Cobimetinib + GDC-0068,3845,None,,,
425,Preclinical - Pdx,"In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib)  combination treatment resulted in objective response in PDX models of colorectal cancer cells  harboring KRAS mutations (PMID: 26369631).",Actionable,5621,9256,colorectal cancer,DOID,448,KRAS mutant,sensitive,1368,Palbociclib + Trametinib,3845,26369631,,,
426,Preclinical - Cell culture,"In a preclinical study, Danusertib (PHA-739358) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9385,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,sensitive,4999,Danusertib + SCH772984,3845,26725216,,,
427,Preclinical - Cell line xenograft,"In a preclinical study, Panulisib (P7170) demonstrated inhibition of tumor growth in cell line xenograft models of non-small cell lung cancer harboring KRAS mutations (Cancer Res 2012, 72(8 Suppl), Abstract  #3759).",Actionable,2732,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,sensitive,857,P7170,3845,None,,,
428,Preclinical - Cell culture,"In a preclinical study, Gedatolisib (PF-05212384) inhibited growth of several human solid tumor cell lines in culture, including cell lines harboring KRAS mutations (PMID: 21325073).",Actionable,9539,10000003,Advanced Solid Tumor,JAX,448,KRAS mutant,predicted â€“ sensitive,1040,PF-05212384,3845,21325073,,,
429,Phase III,"In a post-hoc analysis of a Phase III trial, KRAS mutations in colon adenocarcinoma patients with microsatellite stable tumors were associated with a shorter disease-free survival and overall survival compared to those patients with microsatellite instability tumors, suggesting that KRAS mutations may serve as a future prognostic biomarker in this patient population (PMID: 26768652). ",Emerging,6440,234,colon adenocarcinoma,DOID,448,KRAS mutant,not applicable,1776,N/A,3845,26768652,,,
430,Preclinical - Pdx,"In a preclinical study, SCH772984 inhibited tumor growth in both cell line and patient-derived xenograft models of KRAS mutant pancreatic ductal adenocarcinoma through down-regulation of Myc protein level (PMID: 26725216).",Actionable,9371,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,sensitive,2618,SCH772984,3845,26725216,,,
431,Preclinical,"In a preclinical study, treatment with the combination of MK2206 and Istodax (romidepsin) resulted in greater cell death in tumor cell lines harboring Kras mutations compared to cell lines with wild-type Kras (Cancer Res April 15, 2012 72:4708)",Actionable,2491,10000003,Advanced Solid Tumor,JAX,448,KRAS mutant,sensitive,2875,MK2206 + Romidepsin,3845,None,,,
432,Phase II,"In a Phase II clinical trial, the combination of Portrazza (necitumumab) and FOLFOX in colorectal cancer patients resulted in an objective response rate (ORR) of 63.6% (28/44) in the overall intent-to-treat population, with an ORR of 56.5% (5/9; all partial responses), and stable disease in 44.4% (4/9) of KRAS-mutant patients (PMID: 26766738). ",Actionable,4369,9256,colorectal cancer,DOID,448,KRAS mutant,predicted â€“ sensitive,3498,Necitumumab + FOLFOX,3845,26766738,,,
433,Phase II,"In a Phase II trial, Refametinib (BAY86-9766), in combination with Nexavar (sorafenib), demonstrated more clinical benefit in hepatocellular carcinoma patients with mutant Kras than in patients with wild-type Kras (PMID: 25294897).",Actionable,2436,684,hepatocellular carcinoma,DOID,448,KRAS mutant,sensitive,2221,Refametinib + Sorafenib,3845,25294897,,,
434,Phase III,"In a retrospective analysis of a Phase III trial, the combination of Erbitux (cetuximab) and FOLFIRI did not demonstrate an improved clinical benefit compared to FOLFIRI alone in colorectal cancer patients with RAS mutations (PMID: 25605843). ",Actionable,3354,9256,colorectal cancer,DOID,448,KRAS mutant,no benefit,2180,Cetuximab + FOLFIRI,3845,25605843,,,
435,Preclinical,"In a preclinical study, Mekinist (trametinib) and Iclusig (ponatinib) combination treatment was less efficient at inhibiting proliferation of KRAS mutant colon cancer cells in culture (PMID: 27338794).",Actionable,7370,219,colon cancer,DOID,448,KRAS mutant,decreased response,4477,Ponatinib + Trametinib,3845,27338794,,,
436,Preclinical - Cell culture,"In a preclinical study, PF-04691502 and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9390,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,sensitive,5005,PF-04691502 + SCH772984,3845,26725216,,,
437,Phase II,"In a retrospective study of a Phase II trial, mutation status of KRAS was not associated with progression-free survival or response rate in advanced endometrial cancer patients treated with Torisel (temsirolimus) (PMID: 27016228).",Actionable,6405,1380,endometrial cancer,DOID,448,KRAS mutant,no benefit,936,Temsirolimus,3845,27016228,,,
438,Preclinical - Cell culture,"In a preclinical study, Binimetinib (MEK162) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS mutations due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).",Actionable,8993,3910,lung adenocarcinoma,DOID,448,KRAS mutant,decreased response,807,Binimetinib,3845,27422710,,,
439,Phase III,"In a Phase II trial, Selumetinib (AZD6244) in combination with Taxotere (docetaxel) did not significantly improve median progression-free survival (3.9 vs 2.8 months), median overall survival (8.7 vs 7.9 months), and overall response rate (20.1% vs 13.7%) compared to placebo in KRAS-mutant non-small cell lung cancer patients (PMID: 28492898).",Actionable,9320,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,no benefit,1117,Selumetinib + Docetaxel,3845,28492898,,,
440,Phase II,"In a Phase II trial, Selumetinib (AZD6244) in combination with Taxotere (docetaxel) improved progression-free survival in KRAS-mutant non-small cell lung cancer patients (PMID: 23200175).",Actionable,150,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,no benefit,1117,Selumetinib + Docetaxel,3845,23200175,,,
441,FDA approved,Vectibix (panitumumab) has demonstrated clinical efficacy only in colorectal cancer patients with wild-type KRAS (PMID: 19064407).,Actionable,148,9256,colorectal cancer,DOID,448,KRAS mutant,resistant,845,Panitumumab,3845,19064407,,,
442,Guideline,"Vectibix (panitumumab) is not indicated for use in patients with KRAS-mutant colorectal cancer (Guidelines).",Actionable,1529,9256,colorectal cancer,DOID,448,KRAS mutant,resistant,845,Panitumumab,3845,None,,,
443,Guideline,"Ertibux (cetuximab) is not indicated for use in patients with KRAS-mutant colorectal cancer (Guidelines).",Actionable,1526,9256,colorectal cancer,DOID,448,KRAS mutant,resistant,694,Cetuximab,3845,None,,,
444,Clinical Study,"In a clinical case report, an acquired KRAS mutation was associated with resistance to Erbitux (cetuximab) in a patient with metastatic colorectal cancer (PMID: 24304820).",Actionable,6670,9256,colorectal cancer,DOID,448,KRAS mutant,resistant,694,Cetuximab,3845,24304820,,,
445,Clinical Study,"In a clinical study, KRAS mutations were associated with resistance to Erbitux (cetuximab) in patients with colorectal cancer (PMID: 18202412).",Actionable,707,9256,colorectal cancer,DOID,448,KRAS mutant,resistant,694,Cetuximab,3845,18202412,,,
446,Preclinical - Cell culture,"In a preclinical study, Ridaforolimus (MK-8669) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9377,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,sensitive,4991,Ridaforolimus + SCH772984,3845,26725216,,,
447,Preclinical - Cell line xenograft,"In a preclinical study, Pictilisib (GDC-0941) demonstrated limited efficacy as a single agent in pancreatic cell line xenograft models harboring KRAS mutations (PMID: 22952903).",Actionable,2761,1793,pancreatic cancer,DOID,448,KRAS mutant,decreased response,749,GDC-0941,3845,22952903,,,
448,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Pictilisib (GDC-0941) and Selumetinib (AZD6244) worked synergistically to induce tumor regression in pancreatic cancer cell line xenograft models harboring KRAS mutations (PMID: 22952903).",Actionable,2762,1793,pancreatic cancer,DOID,448,KRAS mutant,sensitive,3024,GDC-0941 + Selumetinib,3845,22952903,,,
449,Preclinical - Pdx,"In a preclinical study, KO-947 resulted in tumor regression in patient derived xenograft (PDX) models harboring either a BRAF mutation, NRAS mutation, or KRAS mutation (EJC Dec 2016, 69:1; S126).",Actionable,10967,10000003,Advanced Solid Tumor,JAX,448,KRAS mutant,predicted â€“ sensitive,5747,KO-947,3845,None,,,
450,Phase I,"In a Phase I trial, BGB-283 resulted in partial response in 1 endometrial cancer patient harboring harboring KRAS mutation, who remained on treatment for over 456 days (AACR Annual Meeting, Apr 2016, abstract # CT005).",Actionable,7230,1380,endometrial cancer,DOID,448,KRAS mutant,predicted â€“ sensitive,4025,BGB-283,3845,None,,,
451,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring a KRAS mutation demonstrated growth inhibition, cell membrane dysruption, induction of apoptosis, and G2/M arrest in culture when treated with Reolysin (pelareorep) (PMID: 24798549). ",Actionable,10892,9256,colorectal cancer,DOID,448,KRAS mutant,sensitive,893,Reolysin,3845,24798549,,,
452,Phase II,"In a Phase II trial, Nexavar (sorafenib) treatment resulted in comparable 8-week disease control rate in KRAS wild-type (47%, 20/43) and KRAS mutated (44%, 8/18) patients with advanced non-small cell lung carcinoma (PMID: 27480147).",Actionable,7742,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,sensitive,920,Sorafenib,3845,27480147,,,
453,Phase III,"In a Phase III trial, treatment with Nexavar (sorafenib) resulted in a longer progression free survival in patients with KRAS-mutant non-small cell lung cancer when compared to placebo, however, overall survival was similar between the two arms (PMID: 26743856).",Actionable,7714,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,sensitive,920,Sorafenib,3845,26743856,,,
454,Phase II,"In a Phase II trial, treatment with Nexavar (sorafenib) resulted in partial response in 8.8% (5/57) and stable disease in 43.8% (25/57) of patients with KRAS-mutant non-small cell lung cancer (PMID: 23224737).",Actionable,2489,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,sensitive,920,Sorafenib,3845,23224737,,,
455,Preclinical,"In a preclinical study, MLN2480 inhibited growth of RAS mutant melanoma and colorectal cancer cell lines in culture (Mol Cancer Ther November 2013 12; C146).",Actionable,1577,1909,melanoma,DOID,448,KRAS mutant,predicted â€“ sensitive,1034,MLN2480,3845,None,,,
456,Preclinical - Cell culture,"In a preclinical study, Nerlynx (neratinib) and Selumetinib (AZD6244) synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9398,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,sensitive,5011,Neratinib + Selumetinib,3845,26725216,,,
457,Preclinical - Cell line xenograft,"In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of KRAS mutant pancreatic cancer (PMID: 26140595).",Actionable,10257,1793,pancreatic cancer,DOID,448,KRAS mutant,predicted â€“ sensitive,5443,PF3644022 + PF-477736,3845,26140595,,,
458,Preclinical,"In a preclinical study, Mekinist (trametinib) and Iclusig (ponatinib) synergistically inhibited proliferation of KRAS mutant lung cancer cells in culture and induced tumor regression in xenograft models (PMID: 27338794).",Actionable,7367,1324,lung cancer,DOID,448,KRAS mutant,sensitive,4477,Ponatinib + Trametinib,3845,27338794,,,
459,Preclinical - Cell culture,"In a preclinical study, AZD8186 and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9378,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,sensitive,4992,Everolimus + SCH772984,3845,26725216,,,
460,Preclinical - Pdx & cell culture,"In a preclinical study, the small-molecule activators of PP2A (SMAP) DT-061 inhibited Mapk signaling, resulted in growth inhibition and apoptosis in KRAS mutant lung cancer cell lines in culture, and in both cell line and patient-derived xenograft models (PMID: 28504649).",Actionable,11389,1324,lung cancer,DOID,448,KRAS mutant,predicted â€“ sensitive,5969,DT-061,3845,28504649,,,
461,Preclinical - Cell culture,"In a preclinical study, the combination of APS-2-49 and Mekinist (trametinib) worked synergistically to decrease viability of several KRAS mutant cancer cell lines in culture (PMID: 27556948).",Actionable,8018,10000003,Advanced Solid Tumor,JAX,448,KRAS mutant,predicted â€“ sensitive,4620,APS-2-79 + Trametinib,3845,27556948,,,
462,Phase I,"In a Phase I trial, a pancreatic cancer patient harboring a KRAS mutation demonstrated a partial response when treated with Mekinist (trametinib) (PMID: 22805291). ",Actionable,11970,1793,pancreatic cancer,DOID,448,KRAS mutant,predicted â€“ sensitive,2,Trametinib,3845,22805291,,,
463,Phase Ib/II,"In a Phase Ib trial, XL765 (SAR245409) in combination with, Pimasertib (MSC1936369B), demonstrated safety and preliminary efficacy in Kras mutant colorectal patients (Cancer Res 2013;73(8 Suppl):Abstract nr LB-147).",Actionable,2755,9256,colorectal cancer,DOID,448,KRAS mutant,sensitive,3023,SAR245409 + Pimasertib,3845,None,,,
464,Preclinical - Pdx,"In a preclinical study, LSN3074753 resulted in a disease control rate of 11.4% (5/44) in KRAS mutant patient-derived xenograft models of colorectal cancer (PMID: 28611205).",Actionable,12190,9256,colorectal cancer,DOID,448,KRAS mutant,predicted â€“ sensitive,6337,LSN3074753,3845,28611205,,,
465,Phase I,"In a Phase I/Ib trial, treatment with the combination of Mekinist (trametinib) and Alimta (pemetrexed) resulted in an overall response rate (ORR) of 17% (4/23, all partial responses), and stable disease in 48% (11/23) in the subset of patients with KRAS-mutant non-small cell lung cancer, compared to an ORR of 11% (2/19) in patients with wild-type or unknown KRAS status (PMID: 27876675).",Actionable,10765,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,predicted â€“ sensitive,1266,Pemetrexed + GSK1120212,3845,27876675,,,
466,Preclinical - Patient cell culture,"In a preclinical study, primary tumor cells isolated from lung adenocarcinoma patients harboring KRAS mutations demonstrated increased sensitivity to Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 combination treatment in culture compared to cells lacking KRAS or BRAF mutations (PMID: 26140595).",Actionable,10262,3910,lung adenocarcinoma,DOID,448,KRAS mutant,predicted â€“ sensitive,5443,PF3644022 + PF-477736,3845,26140595,,,
467,Preclinical - Cell culture,"In a preclinical study, Saracatinib (AZD0530) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9391,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,sensitive,5006,Saracatinib + SCH772984,3845,26725216,,,
468,Preclinical,"In a preclinical study, non-small cell lung carcinoma cells harboring a KRAS mutation were more sensitive to BI2536 than cells wild-type for KRAS (PMID: 26597303). ",Actionable,6129,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,sensitive,676,BI2536,3845,26597303,,,
469,Phase I,"In a Phase I trial, TVB-2640 treatment resulted in stable disease for more than 17 weeks in 100% (3/3) of patients with non-small cell lung carcinoma harboring KRAS mutations (J Clin Oncol 34, 2016 (suppl; abstr 2512)).",Actionable,6550,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,predicted â€“ sensitive,3611,TVB-2640,3845,None,,,
470,Preclinical - Cell line xenograft,"In a preclinical study, colon cancer cell lines with KRAS codon 12 or 13 mutations demonstrated increased sensitivity to treatment with AUY922 in culture and in xenograft models (PMID: 26832792).",Actionable,9209,219,colon cancer,DOID,448,KRAS mutant,predicted â€“ sensitive,647,AUY922,3845,26832792,,,
471,Preclinical,"In a preclinical study, colorectal cancer cell lines harboring KRAS mutations demonstrated resistance to SHP099 in culture (PMID: 27362227). ",Actionable,7520,9256,colorectal cancer,DOID,448,KRAS mutant,predicted â€“ resistant,4504,SHP099,3845,27362227,,,
472,Phase I,"In a Phase I trial, Ixabepilone and Sutent (sunitinib) combination therapy resulted in an overall clinical benefit rate (complete response, partial response, or stable disease) of 53% (9/17) in colorectal cancer patients,  most of whom harbored KRAS mutations (PMID: 26864210).",Actionable,7528,9256,colorectal cancer,DOID,448,KRAS mutant,predicted â€“ sensitive,4505,Ixabepilone + Sunitinib,3845,26864210,,,
473,Preclinical - Cell culture,"In a preclinical study, Aurora Kinase Inhibitor II (AI II) induced apoptosis and inhibited growth of KRAS-mutant non-small cell lung cancer cell lines in culture (PMID: 26842935).",Actionable,9783,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,sensitive,5230,Aurora Kinase Inhibitor II,3845,26842935,,,
474,Preclinical - Cell line xenograft,"In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited growth of various cancer cell lines harboring KRAS mutations in culture and in cell line xenograft models (PMID: 26140595).",Actionable,10253,10000003,Advanced Solid Tumor,JAX,448,KRAS mutant,predicted â€“ sensitive,5443,PF3644022 + PF-477736,3845,26140595,,,
475,Preclinical,"In a preclinical study, a human gastric cancer cell line harboring a KRAS mutation demonstrated resistance to Poziotinib (PMID: 21306821). ",Actionable,2839,10534,stomach cancer,DOID,448,KRAS mutant,resistant,1042,poziotinib,3845,21306821,,,
476,Phase I,"In a Phase I trial, Mekinist (trametinib) reduced tumor formation in 36% (8/22) of solid tumor patients harboring KRAS mutations (PMID: 22805291).",Actionable,1627,10000003,Advanced Solid Tumor,JAX,448,KRAS mutant,sensitive,2,Trametinib,3845,22805291,,,
477,Preclinical - Cell line xenograft,"In a preclinical study, GDC-0623 demonstrated efficacy in several human tumor cell line xenograft models harboring KRAS mutations (PMID: 23934108).",Actionable,2757,10000003,Advanced Solid Tumor,JAX,448,KRAS mutant,sensitive,748,GDC-0623,3845,23934108,,,
478,Phase I,"In a Phase Ia trial, CC-90003 treatment did not result in any objective responses and demonstrated toxicity in advanced solid tumor patients harboring KRAS, NRAS, or BRAF mutations (J Clin Oncol 35, 2017 (suppl; abstr 2577)).",Actionable,11065,10000003,Advanced Solid Tumor,JAX,448,KRAS mutant,no benefit,2874,CC-90003,3845,None,,,
479,Preclinical - Cell line xenograft,"In a preclinical study, PF-04691502 resulted in tumor regression in KRAS-mutant non-small cell lung cancer cell line xenograft models (PMID: 21750219).",Actionable,8389,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,predicted â€“ sensitive,865,PF-04691502,3845,21750219,,,
480,Preclinical - Cell culture,"In a preclinical study, colon cancer cells harboring KRAS mutations were resistant to GDC0879 induced growth inhibition in culture (PMID: 19276360).",Actionable,7877,219,colon cancer,DOID,448,KRAS mutant,resistant,1095,GDC0879,3845,19276360,,,
481,Preclinical,"In a preclinical study, human tumor cell lines harboring KRAS mutations did not demonstrate sensitivity to CH5132799 in culture (PMID: 22159814).",Actionable,2740,10000003,Advanced Solid Tumor,JAX,448,KRAS mutant,no benefit,2152,CH5132799,3845,22159814,,,
482,Preclinical - Cell culture,"In a preclinical study, Vistusertib (AZD2014) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9382,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,sensitive,4996,SCH772984 + Vistusertib,3845,26725216,,,
483,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing a KRAS mutation demonstrated sensitivity to NS1 in culture, resulting in decreased Mapk and Akt signaling and inhibition of cell transformation (PMID: 27820802). ",Actionable,9784,10000003,Advanced Solid Tumor,JAX,448,KRAS mutant,sensitive,5228,NS1,3845,27820802,,,
484,Phase I,"In a Phase I trial, treatment with Abemaciclib (LY2835219) in non-small cell lung carcinoma patients harboring a KRAS mutation resulted in a disease control rate of 55% (16/29) and a median PFS of 2.8 months (LY2835219) (PMID: 27217383). ",Actionable,7430,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,sensitive,802,Abemaciclib,3845,27217383,,,
485,Phase II,"In a Phase II clinical trial, salirasib showed no benefit in KRAS-mutant lung adenocarcinoma patients (PMID: 21847063).",Actionable,149,3910,lung adenocarcinoma,DOID,448,KRAS mutant,no benefit,909,Salirasib,3845,21847063,,,
486,Preclinical - Cell culture,"In a preclinical study, the addition of PD-0325901 to treatment with BEZ235 inhibited BEZ235-enhanced ERK activation, and the combination resulted in increased inhibition of cell proliferation in KRAS-mutant pancreatic ductal adenocarcinoma cell lines in culture compared to either agent alone (PMID: 25673820).",Actionable,9687,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,predicted â€“ sensitive,5162,BEZ235 + PD-0325901,3845,25673820,,,
487,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited growth of a majority (4/5) of human pancreatic adenocarcinoma cell lines harboring mutant KRAS in culture (PMID: 26343583).",Actionable,6732,4074,pancreatic adenocarcinoma,DOID,448,KRAS mutant,sensitive,2,Trametinib,3845,26343583,,,
488,Preclinical - Pdx,"In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of KRAS-mutant colorectal cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",Actionable,11969,9256,colorectal cancer,DOID,448,KRAS mutant,predicted â€“ sensitive,5747,KO-947,3845,None,,,
489,Preclinical,"In a preclinical study, colorectal cancer cells harboring KRAS mutations demonstrated sensitivity to CI-1040 in culture (PMID: 19372556).",Actionable,2743,9256,colorectal cancer,DOID,448,KRAS mutant,sensitive,699,CI-1040,3845,19372556,,,
490,Phase III,"In a Phase III trial, Cyramza (ramucirumab) followed by FOLFIRI was equally efficacious in metastatic colorectal carcinoma patients with Kras exon 2 mutations as patients with wild-type Kras (PMID: 25877855).",Actionable,2446,9256,colorectal cancer,DOID,448,KRAS mutant,sensitive,2633,Ramucirumab + FOLFIRI,3845,25877855,,,
491,Phase II,"In a Phase II trial, Tarceva (erlotinib) treatment resulted in comparable 8-week disease control rate in KRAS wild-type (36%, 5/14) and KRAS mutated (20%, 1/5) patients with advanced non-small cell lung carcinoma (PMID: 27480147).",Actionable,7739,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,no benefit,4,Erlotinib,3845,27480147,,,
492,Preclinical - Cell culture,"In a preclinical study, Torisel (temsirolimus) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9376,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,sensitive,4988,SCH772984 + Temsirolimus,3845,26725216,,,
493,Preclinical - Cell line xenograft,"In a preclinical study, Glucophage (metformin) inhibited tumor growth in a variety of KRAS-mutant cancer cell line xenograft models (PMID: 23877793).",Actionable,589,10000003,Advanced Solid Tumor,JAX,448,KRAS mutant,sensitive,1031,Metformin,3845,23877793,,,
494,Preclinical,"In a preclinical study, SH-1242 inhibited growth of non-small cell lung cancer cells expressing mutant KRAS in culture (PMID: 26645561).",Actionable,4617,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,sensitive,3552,SH-1242,3845,26645561,,,
495,Preclinical - Cell line xenograft,"In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of KRAS mutant colon cancer (PMID: 26140595).",Actionable,10258,219,colon cancer,DOID,448,KRAS mutant,predicted â€“ sensitive,5443,PF3644022 + PF-477736,3845,26140595,,,
496,Phase III,"In a Phase III trial, Cometriq (cabozantinib) treatment resulted in improved progression free survival (47 vs 8 weeks) compared to placebo in thyroid medullary carcinoma patients harboring RAS mutations (PMID: 27525386).",Actionable,10388,3973,thyroid medullary carcinoma,DOID,448,KRAS mutant,sensitive,998,cabozantinib,3845,27525386,,,
497,Preclinical - Cell line xenograft,"In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 synergistically inhibited tumor growth in cell line xenograft models of KRAS mutant bladder cancer (PMID: 26140595).",Actionable,10256,11054,urinary bladder cancer,DOID,448,KRAS mutant,predicted â€“ sensitive,5443,PF3644022 + PF-477736,3845,26140595,,,
498,Preclinical - Pdx,"In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of KRAS-mutant melanoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",Actionable,11967,1909,melanoma,DOID,448,KRAS mutant,predicted â€“ sensitive,5747,KO-947,3845,None,,,
499,Preclinical,"In a preclinical study, human pancreatic ductal carcinoma cell lines harboring mutant KRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",Actionable,6733,3587,pancreatic ductal carcinoma,DOID,448,KRAS mutant,resistant,2,Trametinib,3845,26343583,,,
500,Preclinical,"In a preclinical study, gastric cancer cell lines with Kras mutations were sensitive to Selumetinib (AZD6244) (PMID: 24935174).",Actionable,2768,3717,gastric adenocarcinoma,DOID,448,KRAS mutant,sensitive,913,Selumetinib,3845,24935174,,,
501,Preclinical,"In a preclinical study, Mekinist (trametinib) and Gilotrif (afatinib) did not demonstrate synergy at inhibiting proliferation of KRAS mutant lung cancer cells in culture (PMID: 27338794).",Actionable,7376,1324,lung cancer,DOID,448,KRAS mutant,no benefit,4482,Afatinib + Trametinib,3845,27338794,,,
502,Preclinical - Cell line xenograft,"In a preclinical study, AZD4785 inhibited Kras expression, resulted in growth inhibition in 3-D cultures of lung carcinoma cell lines harboring KRAS mutations, and anti-tumor activity in cell line xenograft models (PMID: 28615361).",Actionable,11328,3905,lung carcinoma,DOID,448,KRAS mutant,sensitive,5914,AZD4785,3845,28615361,,,
503,Phase I,"In a Phase I trial, 11% (2/11) of NSCLC patients with Kras mutations achieved partial response after treatment with RO4987655 (PMID: 24947927).",Actionable,2750,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,sensitive,903,RO4987655,3845,24947927,,,
504,Phase III,"In a Phase III trial, the combination therapy of Tarceva (erlotinib), Paraplatin (carboplatin), and Taxol (paclitaxel) resulted in a worse overall response rate (8%) compared to Paraplatin (carboplatin) and Taxol (paclitaxel) without Tarceva (erlotinib) (23%) in non-small cell lung cancer patients harboring KRAS mutations (PMID: 16043828).",Actionable,7857,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,no benefit,4581,Carboplatin + Erlotinib + Paclitaxel,3845,16043828,,,
505,Preclinical,"In a preclinical study, BEZ235 inhibited growth of colorectal cancer cells harboring KRAS mutations in culture and in xenograft models (PMID: 23475782).",Actionable,2723,9256,colorectal cancer,DOID,448,KRAS mutant,sensitive,672,BEZ235,3845,23475782,,,
506,Preclinical - Pdx,"In a preclinical study, LSN3074753 and Erbitux (cetuximab) synergistically inhibited tumor growth in patient-derived xenograft models of colorectal cancer harboring KRAS mutations, resulted in a disease control rate of 41.7% (5/12) (PMID: 28611205).",Actionable,12195,9256,colorectal cancer,DOID,448,KRAS mutant,sensitive,6338,Cetuximab + LSN3074753,3845,28611205,,,
507,Phase I,"In a Phase I clinical trial, Alpelisib (BYL719), in combination with Binimetinib (MEK162), demonstrated safety and preliminary efficacy in patients with KRAS-mutant advanced solid tumors, including patients with ovarian cancer (J Clin Oncol 32:5s, 2014 (suppl; abstr 9051).",Actionable,1655,2394,ovarian cancer,DOID,448,KRAS mutant,sensitive,1311,BYL719 + MEK162,3845,None,,,
508,Preclinical - Cell culture,"In a preclinical study, OSI-027 and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9381,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,sensitive,4995,OSI-027 + SCH772984,3845,26725216,,,
509,Preclinical - Cell line xenograft,"In a preclinical study, CUDC-907 induced apoptosis and cell cycle arrest in several human solid tumor and hematological cancer cell lines in culture and inhibited tumor growth in tumor cell line xenograft models, including those harboring KRAS mutations (PMID: 22693356).",Actionable,1690,10000003,Advanced Solid Tumor,JAX,448,KRAS mutant,sensitive,709,CUDC-907,3845,22693356,,,
510,Preclinical - Cell culture,"In a preclinical study, Farydak (panobinostat) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9387,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,sensitive,5001,Panobinostat + SCH772984,3845,26725216,,,
511,Phase I,"In a Phase I trial, BGB-283 resulted in partial response in 1 non-small cell lung carcinoma patient harboring KRAS mutation, who remained on treatment for over 572 days (AACR Annual Meeting, Apr 2016, abstract # CT005).",Actionable,7232,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,predicted â€“ sensitive,4025,BGB-283,3845,None,,,
512,Phase II,"In a Phase II clinical trial, GI-4000 was well-tolerated and resulted in some immune response to KRAS in lung adenocarcinoma patients carrying KRAS mutations (PMID: 25044103).",Actionable,359,3910,lung adenocarcinoma,DOID,448,KRAS mutant,sensitive,1018,GI-4000,3845,24372276,25044103,,
513,Preclinical - Cell culture,"In a preclinical study, Saracatinib (AZD0530) and Selumetinib (AZD6244) synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9397,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,sensitive,5010,Saracatinib + Selumetinib,3845,26725216,,,
514,Clinical Study,"In a systematic review of 2,266 colorectal cancer patients, treatment with Avastin (bevacizumab) increased progression-free survival in patients harboring wild-type KRAS but not in patients with mutant KRAS (PMID: 23828442).",Actionable,800,9256,colorectal cancer,DOID,448,KRAS mutant,decreased response,667,Bevacizumab,3845,23828442,,,
515,Phase III,"In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI did not have improved clinical benefit compared to FOLFIRI alone in colorectal cancer patients with KRAS mutations (PMID: 26341920).",Actionable,3267,9256,colorectal cancer,DOID,448,KRAS mutant,no benefit,3102,Panitumumab + Oxaliplatin + Fluorouracil + Irinotecan,3845,26341920,,,
516,Preclinical - Pdx,"In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of KRAS-mutant non-small cell lung cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",Actionable,11696,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,predicted â€“ sensitive,5747,KO-947,3845,None,,,
517,Preclinical - Cell culture,"In a preclinical study, Tasigna (nilotinib) and SCH772984 synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9389,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,sensitive,5003,Nilotinib + SCH772984,3845,26725216,,,
518,Preclinical,"In a preclinical study, DEL-22379 induced tumor regression in colorectal cancer xenograft models harboring mutant KRAS (PMID: 26267534).",Actionable,5781,9256,colorectal cancer,DOID,448,KRAS mutant,sensitive,3769,DEL-22379,3845,26267534,,,
519,Preclinical - Cell culture,"In a preclinical study, Pictilisib (GDC-0941) and Selumetinib (AZD6244) synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9396,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,sensitive,3024,GDC-0941 + Selumetinib,3845,26725216,,,
520,Preclinical - Cell culture,"In a preclinical study, the combination of Reolysin (pelareorep) and Camptosar (irinotecan) resulted in a synergistic effect, demonstrating increased apoptotic activity and growth inhibition in colorectal cancer cells harboring a KRAS mutation in culture compared to either agent alone (PMID: 24798549). ",Actionable,10893,9256,colorectal cancer,DOID,448,KRAS mutant,sensitive,5674,Irinotecan + Reolysin,3845,24798549,,,
521,Preclinical - Pdx,"In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of KRAS-mutant cervical carcinoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",Actionable,11973,2893,cervix carcinoma,DOID,448,KRAS mutant,predicted â€“ sensitive,5747,KO-947,3845,None,,,
522,Preclinical,"In a preclinical study, the effect of Mekinist (trametinib) on human gastric adenocarcinoma cell lines harboring mutant KRAS is conflicting as cell lines were both sensitive and insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",Actionable,6735,3717,gastric adenocarcinoma,DOID,448,KRAS mutant,conflicting,2,Trametinib,3845,26343583,,,
523,Preclinical - Cell culture,"In a preclinical study, Ipatasertib (GDC-0068) and Selumetinib (AZD6244) synergistically inhibited growth of SCH772984-sensitive, KRAS mutant pancreatic ductal adenocarcinoma cell lines in culture (PMID: 26725216).",Actionable,9395,3498,pancreatic ductal adenocarcinoma,DOID,448,KRAS mutant,sensitive,5009,Ipatasertib + Selumetinib,3845,26725216,,,
524,Preclinical - Cell culture,"In a preclinical study, non-small cell lung cancer cells harboring KRAS mutations were resistant to GDC0879 induced growth inhibition in culture (PMID: 19276360).",Actionable,7878,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,resistant,1095,GDC0879,3845,19276360,,,
525,Preclinical - Cell culture,"In a preclinical study, KPT-185 resulted in greater apoptotic activity and decreased cell viability in non-small cell lung cancer (NSCLC) cell lines harboring KRAS mutations compared to NSCLC cell lines with wild-type KRAS, suggesting a synthetic lethal effect via XPO1 inhibition (PMID: 27680702).",Actionable,8804,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,sensitive,4814,KPT-185,3845,27680702,,,
526,Preclinical - Patient cell culture,"In a preclinical study, Chk1 inhibitor PF-477736 and MK2 inhibitor PF3644022 combination treatment resulted in significant apoptosis in primary tumor cells isolated from pancreas adenocarcinoma patients harboring KRAS mutations in culture (PMID: 26140595).",Actionable,10263,4074,pancreatic adenocarcinoma,DOID,448,KRAS mutant,predicted â€“ sensitive,5443,PF3644022 + PF-477736,3845,26140595,,,
527,Phase Ib/II,"In a Phase Ib study, Alpelisib (BYL719) in combination with Binimetinib (MEK162) demonstrated preliminary safety and efficacy in patients with KRAS-mutant advanced solid tumors, including patients with ovarian cancer (J Clin Oncol 32:5s, 2014 (suppl; abstr 9051).",Actionable,1695,10000003,Advanced Solid Tumor,JAX,448,KRAS mutant,sensitive,1311,BYL719 + MEK162,3845,None,,,
528,Phase I,"In a Phase I trial, TVB-2640 and Taxol (paclitaxel) combination treatment resulted in partial response in 33% (1/3) and stable disease for more than 21 weeks in 67% (2/3) of patients with non-small cell lung carcinoma harboring KRAS mutations (J Clin Oncol 34, 2016 (suppl; abstr 2512)).",Actionable,6549,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,predicted â€“ sensitive,3743,Paclitaxel + TVB-2640,3845,None,,,
529,Preclinical,"In a preclinical study, non-small cell lung carcinoma cells harboring a KRAS mutation were more sensitive to volasertib than cells wild-type for KRAS (PMID: 26597303). ",Actionable,6132,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,sensitive,957,Volasertib,3845,26597303,,,
530,Preclinical - Cell culture,"In a preclinical study, the combination of Mekinist (trametinib) and BGJ398 synergistically inhibited proliferation of KRAS mutant lung cancer cells in culture (PMID: 27338794).",Actionable,7373,1324,lung cancer,DOID,448,KRAS mutant,sensitive,4479,BGJ398 + Trametinib,3845,27338794,,,
531,Phase II,"In a Phase II trial, Selumetinib (AZD6244) and MK2206 combination treatment resulted in comparable 8-week disease control rate in KRAS wild-type (49%, 24/49) and KRAS mutated (62%, 13/21) patients with advanced non-small cell lung carcinoma (PMID: 27480147).",Actionable,7741,3908,non-small cell lung carcinoma,DOID,448,KRAS mutant,no benefit,1098,MK2206 + Selumetinib,3845,27480147,,,
532,Preclinical - Cell culture,"In a preclinical study, a colon cancer cell line harboring a KRAS mutation demonstrated sensitivity to AZ-TAK1 in culture, resulting in a 50% cell growth reduction (PMID: 27655129). ",Actionable,10058,219,colon cancer,DOID,448,KRAS mutant,sensitive,5359,AZ-TAK1,3845,27655129,,,
533,Preclinical - Cell line xenograft,"In a preclinical study, PKI-402 inhibited growth of a non-small cell lung cancer cell line harboring both KRAS and STK11 mutations in culture and in cell line xenograft models (PMID: 20371716).",Actionable,5398,3908,non-small cell lung carcinoma,DOID,20858,KRAS mut STK11 mut,sensitive,3857,PKI-402,3845,20371716,,,
534,Preclinical - Cell line xenograft,"In a preclinical study, treatment with GA201 resulted in improved overall survival in EGFR-positive pancreatic cancer cell line xenograft models harboring KRAS mutations, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).",Actionable,3869,1793,pancreatic cancer,DOID,16548,EGFR pos KRAS mut,sensitive,3154,GA201,3845,23209031,,,
535,Preclinical - Cell line xenograft,"In a preclinical study, treatment with GA201 resulted in increased tumor growth inhibition in EGFR-positive triple-negative breast cancer cell line xenograft models harboring KRAS mutations when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).",Actionable,3870,60081,triple-receptor negative breast cancer,DOID,16548,EGFR pos KRAS mut,sensitive,3154,GA201,3845,23209031,,,
536,Preclinical - Cell line xenograft,"In a preclinical study, treatment with GA201 resulted in improved overall survival in EGFR-positive renal cell carcinoma cell line xenograft models harboring KRAS mutations, when compared to Erbitux (cetuximab) or vehicle control (PMID: 23209031).",Actionable,3868,4450,renal cell carcinoma,DOID,16548,EGFR pos KRAS mut,sensitive,3154,GA201,3845,23209031,,,
537,Preclinical - Cell culture,"In a preclinical study, the combination of Navitoclax (ABT-263), Alpelisib (BYL719), Mekinist (trametinib), and CGM097 resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a KRAS mutation and wild-type TP53 in culture compared to the double or triple combinations of the therapies (PMID: 27659046). ",Actionable,9935,9256,colorectal cancer,DOID,2521,KRAS mut + TP53 wild-type,sensitive,5319,ABT-263 + Alpelisib + CGM097 + Trametinib,3845,27659046,,,
538,Preclinical,"In a preclinical study, Eloxatin (oxaliplatin), in combination with ABT-737, was only effective in tumor cell lines carrying KRAS mutants and wild-type TP53 (PMID: 21468686).",Actionable,1443,10000003,Advanced Solid Tumor,JAX,2521,KRAS mut + TP53 wild-type,sensitive,1773,Oxaliplatin + ABT-737,3845,21468686,,,
539,Preclinical - Cell line xenograft,"In a preclinical study, AMG 232 induced activation of Tp53 target genes and inhibited growth of a colorectal cancer (CRC) cell line with wild-type TP53, that also harbored a KRAS mutation, in culture and inhibited tumor growth in a TP53 wild-type KRAS-mutant CRC cell line xenograft model (PMID: 25567130).",Actionable,8094,9256,colorectal cancer,DOID,2521,KRAS mut + TP53 wild-type,sensitive,1452,AMG 232,3845,25567130,,,
540,Preclinical - Cell line xenograft,"In a preclinical study, the combination of AMG 232 and Camptosaur (irinotecan) inhibited tumor growth in a TP53 wild-type colorectal cancer cell line xenograft model, which also harbors a KRAS mutation, with increased efficacy over either agent alone (PMID: 25567130).",Actionable,8140,9256,colorectal cancer,DOID,2521,KRAS mut + TP53 wild-type,sensitive,4639,AMG 232 + Irinotecan,3845,25567130,,,
541,Preclinical,"In a preclinical study, the combination of bortezomib and fasudil blocked GATA2 downstream signals in KRAS activated NSCLC cells, resulting in reduced tumor burden, size and number in treated mice (PMID: 22541434).  ",Actionable,1462,3908,non-small cell lung carcinoma,DOID,2563,KRAS mut + GATA2 wild-type,sensitive,1778,bortezomib + fasudil,3845,22541434,,,
542,Phase II,"In a Phase II trial, Paraplatin (carboplatin) and MK-1775 combination treatment resulted in partial response in an ovarian cancer patient harboring TP53 G105C, V157fs and mutations in Kras (PMID: 27998224). ",Actionable,11778,2394,ovarian cancer,DOID,28237,KRAS mut TP53 G105C TP53 V157fs,predicted â€“ sensitive,1194,MK-1775 + Carboplatin ,3845,27998224,,,
543,Preclinical,"In a preclinical study, colon cancer cell lines harboring mutant KRAS and PIK3CA E545K demonstrated reduced sensitivity to Buparlisib (BKM120) induced growth inhibition in culture (PMID: 26715098).",Actionable,4574,219,colon cancer,DOID,18591,KRAS mutant PIK3CA E545K,decreased response,680,BKM120,3845,26715098,,,
544,Preclinical,"In a preclinical study, Erbitux (cetuximab) did not inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA E545K in culture (PMID: 26715098).",Actionable,4575,219,colon cancer,DOID,18591,KRAS mutant PIK3CA E545K,no benefit,694,Cetuximab,3845,26715098,,,
545,Preclinical,"In a preclinical study, Buparlisib (BKM120) worked synergistically with Erbitux (cetuximab) to inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA E545K in culture (PMID: 26715098).",Actionable,4576,219,colon cancer,DOID,18591,KRAS mutant PIK3CA E545K,sensitive,3548,BKM120 + Cetuximab,3845,26715098,,,
546,Clinical Study,"In a clinical study, the combination of Torisel (temsirolimus) plus Avastin (bevacizumab) and Doxil (pegylated liposomal-doxorubicin) resulted in a partial response in a patient with ovarian carcinoma harboring both a PIK3CA mutation and a KRAS Q61 mutation (PMID: 21216929).",Actionable,3383,4001,ovarian carcinoma,DOID,13307,PIK3CA mutant KRAS Q61X,sensitive,1121,Bevacizumab + Temsirolimus + Doxil,3845,21216929,,,
547,Guideline,Vectibix (panitumumab) is not indicated for use in colorectal cancer patients with KRAS exon 3 mutations (Guidelines).,Actionable,3843,9256,colorectal cancer,DOID,1194,KRAS Q61X,resistant,845,Panitumumab,3845,None,,,
548,Guideline,Ertibux (cetuximab) is not indicated for use in colorectal cancer patients with KRAS exon 3 mutations (Guidelines).,Actionable,3834,9256,colorectal cancer,DOID,1194,KRAS Q61X,resistant,694,Cetuximab,3845,None,,,
549,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) and Selumetinib (AZD6244) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture (PMID: 27222538).",Actionable,7865,1781,thyroid cancer,DOID,26080,HRAS G12R KRAS G13R,sensitive,4600,Dasatinib + Selumetinib,3845,27222538,,,
550,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) inhibited growth of thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture (PMID: 27222538).",Actionable,7858,1781,thyroid cancer,DOID,26080,HRAS G12R KRAS G13R,sensitive,913,Selumetinib,3845,27222538,,,
551,Preclinical - Cell line xenograft,"In a preclinical study, Mekinist (trametinib) inhibited growth of thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture and in cell line xenograft models (PMID: 27222538).",Actionable,7854,1781,thyroid cancer,DOID,26080,HRAS G12R KRAS G13R,sensitive,2,Trametinib,3845,27222538,,,
552,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) and SCH772984 synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture (PMID: 27222538).",Actionable,7866,1781,thyroid cancer,DOID,26080,HRAS G12R KRAS G13R,sensitive,4601,Dasatinib + SCH772984,3845,27222538,,,
553,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) and Mekinist (trametinib) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R and HRAS G12R in culture (PMID: 27222538).",Actionable,7864,1781,thyroid cancer,DOID,26080,HRAS G12R KRAS G13R,sensitive,4599,Dasatinib + Trametinib,3845,27222538,,,
554,Preclinical - Cell culture,"In a preclinical study, a lung cancer cell line with co-amplification of FGFR1 and EGFR and harboring KRAS G13C demonstrated insensitivity to JNJ-42756493 (erdafitinib) in culture (PMID: 28341788).",Actionable,11185,1324,lung cancer,DOID,27923,EGFR amp FGFR1 amp KRAS G13C,resistant,1028,JNJ-42756493,3845,28341788,,,
555,Preclinical - Cell line xenograft,"In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring KRAS G13C, PIK3CA H1047Y, PTEN G143fs*4, and PTEN K267fs*9 was sensitive to treatment with DS-7423, demonstrating inhibition of cell proliferation in culture and tumor growth inhibition in xenograft models (PMID: 24504419). ",Actionable,10541,5304,ovarian clear cell adenocarcinoma,DOID,27593,KRAS G13C PIK3CA H1047Y PTEN G143fs*4 PTEN K267fs*9,sensitive,722,DS-7423,3845,24504419,,,
556,Preclinical - Cell culture,"In a preclinical study, Binimetinib (MEK162) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G13C mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).",Actionable,8990,3910,lung adenocarcinoma,DOID,1438,KRAS G13C,decreased response,807,Binimetinib,3845,27422710,,,
557,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G13C mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).",Actionable,8998,3910,lung adenocarcinoma,DOID,1438,KRAS G13C,decreased response,913,Selumetinib,3845,27422710,,,
558,Guideline,Ertibux (cetuximab) is not indicated for use in colorectal cancer patients with KRAS exon 3 mutations (Guidelines).,Actionable,3833,9256,colorectal cancer,DOID,3416,KRAS A59G,resistant,694,Cetuximab,3845,None,,,
559,Guideline,Vectibix (panitumumab) is not indicated for use in colorectal cancer patients with KRAS exon 3 mutations (Guidelines).,Actionable,3844,9256,colorectal cancer,DOID,3416,KRAS A59G,resistant,845,Panitumumab,3845,None,,,
560,Preclinical - Cell culture,"In a preclinical study, the addition of Tazemetostat (EPZ-6438) increased sensitivity to Selumetinib (AZD6244) in EZH2-expressing lung adenocarcinoma cell lines harboring KRAS G12C in culture (PMID: 26676756).",Actionable,8503,3910,lung adenocarcinoma,DOID,26341,KRAS G12C EZH2 pos,sensitive,4748,Selumetinib + Tazemetostat,3845,26676756,,,
561,Preclinical - Cell culture,"In a preclinical study, the addition of GSK343 increased sensitivity to Selumetinib (AZD6244) in EZH2-expressing lung adenocarcinoma cell lines harboring KRAS G12C in culture (PMID: 26676756).",Actionable,8502,3910,lung adenocarcinoma,DOID,26341,KRAS G12C EZH2 pos,sensitive,4750,GSK343 + Selumetinib,3845,26676756,,,
562,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep increased sensitivity to Selumetinib (AZD6244) in an EZH2-expressing pancreatic cancer cell line harboring KRAS G12C in culture (PMID: 26676756).",Actionable,8517,1793,pancreatic cancer,DOID,26341,KRAS G12C EZH2 pos,sensitive,4746,DZNep + Selumetinib,3845,26676756,,,
563,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep did not increase sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12C (PMID: 26676756).",Actionable,8510,3910,lung adenocarcinoma,DOID,26341,KRAS G12C EZH2 pos,no benefit,4747,DZNep + MK2206,3845,26676756,,,
564,Preclinical - Cell culture,"In a preclinical study, the addition of Tazemetostat (EPZ-6438) did not increase sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12C in culture (PMID: 26676756).",Actionable,8513,3910,lung adenocarcinoma,DOID,26341,KRAS G12C EZH2 pos,no benefit,4749,MK2206 + Tazemetostat,3845,26676756,,,
565,Preclinical - Cell culture,"In a preclinical study, the addition of DZNep increased sensitivity to MK2206 in an EZH2-expressing pancreatic cancer cell line harboring KRAS G12C in culture (PMID: 26676756).",Actionable,8521,1793,pancreatic cancer,DOID,26341,KRAS G12C EZH2 pos,sensitive,4747,DZNep + MK2206,3845,26676756,,,
566,Preclinical - Cell line xenograft,"In a preclinical study, the addition of DZNep increased sensitivity to Selumetinib (AZD6244) in EZH2-expressing lung adenocarcinoma cell lines harboring KRAS G12C, in culture and in xenograft models, resulting in decreased cell survival and tumor growth (PMID: 26676756).",Actionable,8498,3910,lung adenocarcinoma,DOID,26341,KRAS G12C EZH2 pos,sensitive,4746,DZNep + Selumetinib,3845,26676756,,,
567,Preclinical - Cell culture,"In a preclinical study, the addition of GSK343 did not increase sensitivity to MK2206 in an EZH2-expressing lung adenocarcinoma cell line harboring KRAS G12C in culture (PMID: 26676756).",Actionable,8512,3910,lung adenocarcinoma,DOID,26341,KRAS G12C EZH2 pos,no benefit,4751,GSK343 + MK2206,3845,26676756,,,
568,Preclinical - Pdx,"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type non-small cell lung cancer cells harboring KRAS G12C in patient-derived xenograft models (PMID: 19276360).",Actionable,7893,3908,non-small cell lung carcinoma,DOID,26088,BRAF wild-type KRAS G12C,resistant,1095,GDC0879,3845,19276360,,,
569,Preclinical - Pdx,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12C, PIK3CA H1047R, and TP53 R248W (PMID: 26272063).",Actionable,8577,9256,colorectal cancer,DOID,26366,KRAS G12C PIK3CA H1047R TP53 R248W,no benefit,4771,MLN0128 + PD-0325901,3845,26272063,,,
570,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G12C mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).",Actionable,8996,3910,lung adenocarcinoma,DOID,1042,KRAS G12C,decreased response,913,Selumetinib,3845,27422710,,,
571,Preclinical,"In a preclinical study, Mekinist (trametinib) and SCH772984 combination treatment demonstrated enhanced growth inhibition and sustained inhibition of Erk signaling in lung cancer cells harboring KRAS G12C in culture (PMID: 27338794).",Actionable,7356,1324,lung cancer,DOID,1042,KRAS G12C,sensitive,4476,SCH772984 + Trametinib,3845,27338794,,,
572,Preclinical,"In a preclinical study, SML-10-70-1 inhibited proliferation and Erk/Akt signaling in cells expressing KRAS G12C (PMID: 24259466).",Actionable,2770,10000003,Advanced Solid Tumor,JAX,1042,KRAS G12C,sensitive,2227,SML-10-70-1 ,3845,24259466,,,
573,Preclinical - Cell line xenograft,"In a preclinical study, GDC-0623 induced tumor regression in pancreatic cancer cell line xenograft models harboring KRAS G12C (PMID: 23934108).",Actionable,2758,1793,pancreatic cancer,DOID,1042,KRAS G12C,sensitive,748,GDC-0623,3845,23934108,,,
574,Preclinical - Cell culture,"In a preclinical study, a pancreatic adenocarcinoma cell line harboring KRAS G12C demonstrated sensitivity to growth inhibition by MEK inhibitors, including Refametinib (BAY86-9766), in culture (PMID: 28957417).",Actionable,12138,4074,pancreatic adenocarcinoma,DOID,1042,KRAS G12C,sensitive,888,Refametinib,3845,28957417,,,
575,Preclinical - Cell line xenograft,"In a preclinical study, Cobimetinib (GDC-0973) inhibited tumor growth in xenograft models of a human non-small cell lung cancer cell line harboring KRAS G12C (PMID: 23934108).",Actionable,1446,3908,non-small cell lung carcinoma,DOID,1042,KRAS G12C,sensitive,1004,Cobimetinib,3845,23934108,,,
576,Preclinical - Pdx,"In a preclinical study, AZD4785 inhibited Kras expression and downstream signaling, resulted in tumor growth inhibition in patient-derived xenograft models of lung cancer harboring KRAS G12C (PMID: 28615361).",Actionable,11332,1324,lung cancer,DOID,1042,KRAS G12C,sensitive,5914,AZD4785,3845,28615361,,,
577,Preclinical,"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human pancreatic cancer cell lines harboring KRAS G12C in culture (PMID: 21325073, PMID: 12068308).",Actionable,3137,1793,pancreatic cancer,DOID,1042,KRAS G12C,sensitive,1040,PF-05212384,3845,21325073,12068308,,
578,Preclinical,"In a preclinical study, CID1067700 inhibited growth and increased apoptosis of non-small cell lung cancer cells that harbor KRAS G12C in culture (PMID: 26247207, PMID: 19477428).",Actionable,3568,3908,non-small cell lung carcinoma,DOID,1042,KRAS G12C,sensitive,3158,CID1067700,3845,26247207,19477428,,
579,Preclinical - Cell culture,"In a preclinical study, a pancreatic adenocarcinoma cell line harboring KRAS G12C demonstrated sensitivity to growth inhibition by MEK inhibitors, including Mekinist (trametinib), in culture (PMID: 28957417).",Actionable,12143,4074,pancreatic adenocarcinoma,DOID,1042,KRAS G12C,sensitive,2,Trametinib,3845,28957417,,,
580,Preclinical,"In a preclinical study, Navitoclax (ABT-263) enhanced the inhibitory effect of Mekinist (trametinib) on human non-small cell lung cancer cells harboring KRAS G12C in culture (PMID: 25665005).",Actionable,4536,3908,non-small cell lung carcinoma,DOID,1042,KRAS G12C,sensitive,1386,Trametinib + Navitoclax,3845,25665005,,,
581,Preclinical - Cell culture,"In a preclinical study, a pancreatic adenocarcinoma cell line harboring KRAS G12C demonstrated sensitivity to growth inhibition by MEK inhibitors, including PD-0325901, in culture (PMID: 28957417).",Actionable,12136,4074,pancreatic adenocarcinoma,DOID,1042,KRAS G12C,sensitive,849,PD-0325901,3845,28957417,,,
582,Phase II,"In a Phase II trial, treatment with Nexavar (sorafenib) resulted in partial response (PR) in 8.8% (5/57) and stable disease (SD) in 43.8% (25/57) of patients with KRAS-mutant non-small cell lung cancer, including SD in 12 patients and PR in 3 patients with KRAS G12C (PMID: 23224737).",Actionable,2490,3908,non-small cell lung carcinoma,DOID,1042,KRAS G12C,sensitive,920,Sorafenib,3845,23224737,,,
583,Preclinical,"In a preclinical study, TW-37 enhanced the inhibitory effect of Mekinist (trametinib) on human lung cells harboring KRAS G12C in culture (PMID: 25665005).",Actionable,4538,3908,non-small cell lung carcinoma,DOID,1042,KRAS G12C,sensitive,3532,Trametinib + TW-37,3845,25665005,,,
584,Phase I,"In a Phase I/Ib trial, the subgroup of non-small cell lung cancer patients harboring KRAS G12C demonstrated a disease control rate (DCR) of 80% (8/10; 4 partial responses, 4 stable disease) following treatment with the combination of Mekinist (trametinib) and Taxotere (docetaxel), compared to a DCR of 60% (15/25) in the overall KRAS-mutant population (PMID: 27876675).",Actionable,10763,3908,non-small cell lung carcinoma,DOID,1042,KRAS G12C,predicted â€“ sensitive,1264,Docetaxel + Trametinib,3845,27876675,,,
585,Preclinical - Cell culture,"In a preclinical study, the combination of Erbitux (cetuximab) and Mekinist (trametinib) decreased viability of colorectal cancer cells harboring KRAS G12C in culture (PMID: 28179366).",Actionable,10313,9256,colorectal cancer,DOID,1042,KRAS G12C,sensitive,3505,Cetuximab + Trametinib,3845,28179366,,,
586,Preclinical - Cell line xenograft,"In a preclinical study, BI-847325 induced sustained tumor regression in pancreatic adenocarcinoma cell line xenograft models harboring KRAS G12C (PMID: 27496137).",Actionable,8789,4074,pancreatic adenocarcinoma,DOID,1042,KRAS G12C,sensitive,1059,BI-847325,3845,27496137,,,
587,Phase I,"In a Phase I study, NSCLC patients harboring KRAS G12C or G12V mutations demonstrated a trend towards better overall survival, progression free survival, and objective response rate compared to NSCLC patients with other KRAS mutations when treated with the combination therapy, Selumetinib (AZD6244) and Taxotere (docetaxel) (PMID: 26125448). ",Actionable,2618,3908,non-small cell lung carcinoma,DOID,1042,KRAS G12C,predicted â€“ sensitive,1117,Selumetinib + Docetaxel,3845,26125448,,,
588,Preclinical - Cell culture,"In a preclinical study, a pancreatic adenocarcinoma cell line harboring KRAS G12C demonstrated sensitivity to growth inhibition by Selumetinib (AZD6244) in culture (PMID: 28957417).",Actionable,12135,4074,pancreatic adenocarcinoma,DOID,1042,KRAS G12C,sensitive,913,Selumetinib,3845,28957417,,,
589,Preclinical - Cell line xenograft,"In a preclinical study, Cobimetinib (GDC-0973) inhibited tumor growth in xenograft models of a human pancreatic cancer cell line harboring KRAS G12C (PMID: 23934108).",Actionable,1447,1793,pancreatic cancer,DOID,1042,KRAS G12C,sensitive,1004,Cobimetinib,3845,23934108,,,
590,Preclinical - Cell line xenograft,"In a preclinical study, AZD4785 inhibited Kras expression, resulted in growth inhibition in 3-D cultures of non-small cell lung carcinoma cell lines harboring KRAS G12C, and anti-tumor activity in cell line xenograft models (PMID: 28615361).",Actionable,11323,3908,non-small cell lung carcinoma,DOID,1042,KRAS G12C,sensitive,5914,AZD4785,3845,28615361,,,
591,Guideline,Vectibix (panitumumab) is not indicated for use in colorectal cancer patients with KRAS exon 2 mutations (Guidelines).,Actionable,1531,9256,colorectal cancer,DOID,1042,KRAS G12C,resistant,845,Panitumumab,3845,None,None,,
592,Preclinical - Cell culture,"In a preclinical study, ARS-853 treatment in culture resulted in decreased cell proliferation and apoptotic induction in non-small cell lung carcinoma cells harboring KRAS G12C (PMID: 26841430).",Actionable,7869,3908,non-small cell lung carcinoma,DOID,1042,KRAS G12C,sensitive,3553,ARS-853,3845,26841430,,,
593,Preclinical - Cell culture,"In a preclinical study, Binimetinib (MEK162) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS G12C mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).",Actionable,8988,3910,lung adenocarcinoma,DOID,1042,KRAS G12C,decreased response,807,Binimetinib,3845,27422710,,,
594,Clinical Study,"In a clinical study, KRAS mutations in codon 12 or 13 were associated with resistance to Erbitux (cetuximab) in colorectal cancer patients (PMID: 18202412).",Actionable,742,9256,colorectal cancer,DOID,1042,KRAS G12C,resistant,694,Cetuximab,3845,18202412,,,
595,Guideline,Ertibux (cetuximab) is not indicated for use in colorectal cancer patients with KRAS exon 2 mutations (Guidelines).,Actionable,1530,9256,colorectal cancer,DOID,1042,KRAS G12C,resistant,694,Cetuximab,3845,None,,,
596,Preclinical,"In a preclinical study, a colorectal cancer cell line harboring the KRAS G12C mutation showed resistance to Sutent (sunitinib) treatment (PMID: 23455880).",Actionable,802,9256,colorectal cancer,DOID,1042,KRAS G12C,resistant,930,Sunitinib,3845,23455880,,,
597,Preclinical,"In a preclinical study, ARS-853 inhibited growth of several human tumor cell lines harboring KRAS G12C in 3-dimensional culture conditions (PMID: 26739882).",Actionable,4619,10000003,Advanced Solid Tumor,JAX,1042,KRAS G12C,sensitive,3553,ARS-853,3845,26739882,,,
598,Preclinical,"In a preclinical study, Mekinist (trametinib) treatment demonstrated enhanced growth inhibition and sustained inhibition of Erk signaling in lung cancer cells harboring KRAS G12C with decreased Braf expression through shRNA knockdown in culture (PMID: 27338794).",Actionable,7359,1324,lung cancer,DOID,25302,BRAF dec exp KRAS G12C,sensitive,2,Trametinib,3845,27338794,,,
599,Guideline,Vectibix (panitumumab) is not indicated for use in colorectal cancer patients with KRAS exon 4 mutations (Guidelines).,Actionable,3842,9256,colorectal cancer,DOID,1868,KRAS K117N,resistant,845,Panitumumab,3845,None,,,
600,Guideline,Ertibux (cetuximab) is not indicated for use in colorectal cancer patients with KRAS exon 4 mutations (Guidelines).,Actionable,3835,9256,colorectal cancer,DOID,1868,KRAS K117N,resistant,694,Cetuximab,3845,None,,,
601,Preclinical - Pdx,"In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib)  combination treatment resulted in partial tumor regression in PDX models of colorectal cancer cells harboring KRAS Q61H and PIK3CA E542K (PMID: 26369631).",Actionable,5620,9256,colorectal cancer,DOID,21302,KRAS Q61H PIK3CA E542K,sensitive,1368,Palbociclib + Trametinib,3845,26369631,,,
602,Clinical Study,"In a clinical case study, a patient with ovarian carcinoma harboring KRAS Q61H demonstrated sensitivity to treatment with the combination of Nexavar (sorafenib) and Avastin (bevacizumab), resulting in 62% tumor regression (PMID: 25363205). ",Actionable,7767,4001,ovarian carcinoma,DOID,1862,KRAS Q61H,sensitive,4517,Bevacizumab + Sorafenib,3845,25363205,,,
603,Preclinical,"In a preclinical study, CUDC-907 inhibited growth and repressed RAF-MEK-MAPK signaling as indicated by reduced phosphorylation of Craf, Mek, and Mapk in a human non-small cell lung cancer cell line harboring KRAS Q61H in culture (PMID: 19165201, PMID: 22693356).",Actionable,3013,3908,non-small cell lung carcinoma,DOID,1862,KRAS Q61H,sensitive,709,CUDC-907,3845,22693356,19165201,,
604,Preclinical - Cell culture,"In a preclinical study, AZD4785 inhibited Kras expression, resulted in growth inhibition in 3-D cultures of non-small cell lung carcinoma cell lines harboring KRAS Q61H (PMID: 28615361).",Actionable,11324,3908,non-small cell lung carcinoma,DOID,1862,KRAS Q61H,sensitive,5914,AZD4785,3845,28615361,,,
605,Preclinical - Cell culture,"In a preclinical study, Binimetinib (MEK162) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS Q61H mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).",Actionable,8992,3910,lung adenocarcinoma,DOID,1862,KRAS Q61H,decreased response,807,Binimetinib,3845,27422710,,,
606,Preclinical,"In a preclinical study, a human non-small cell lung cancer cell line harboring KRAS Q61H (PMID: 19165201) were insensitive to pictilisib (GDC-0941) growth inhibition in culture (PMID: 22693356).",Actionable,3008,3908,non-small cell lung carcinoma,DOID,1862,KRAS Q61H,resistant,749,GDC-0941,3845,22693356,19165201,,
607,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) only moderately inhibited survival of lung adenocarcinoma cells harboring KRAS Q61H mutation due to the adaptive activation of Met, Egfr, and Akt signaling in cells (PMID: 27422710).",Actionable,9000,3910,lung adenocarcinoma,DOID,1862,KRAS Q61H,decreased response,913,Selumetinib,3845,27422710,,,
608,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring KRAS Q61H and PIK3CA E545K in culture (PMID: 23629727).",Actionable,8185,3908,non-small cell lung carcinoma,DOID,26184,KRAS Q61H PIK3CA E545K,sensitive,4657,Pimasertib + Regorafenib,3845,23629727,,,
609,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring KRAS Q61H and PIK3CA E545K in culture (PMID: 23629727).",Actionable,8180,3908,non-small cell lung carcinoma,DOID,26184,KRAS Q61H PIK3CA E545K,sensitive,1659,Pimasertib + Sorafenib,3845,23629727,,,
610,Preclinical - Cell culture,"In a preclinical study, non-small cell lung cancer cells harboring KRAS Q61H and PIK3CA E545K demonstrated decreased response to Pimasertib (MSC1936369B) in culture (PMID: 23629727).",Actionable,8171,3908,non-small cell lung carcinoma,DOID,26184,KRAS Q61H PIK3CA E545K,decreased response,871,Pimasertib,3845,23629727,,,
611,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of non-small cell lung cancer cells harboring KRAS Q61H and PIK3CA E545K in culture (PMID: 23629727).",Actionable,8176,3908,non-small cell lung carcinoma,DOID,26184,KRAS Q61H PIK3CA E545K,sensitive,4656,Everolimus + Pimasertib,3845,23629727,,,
612,Preclinical,"In a preclinical study, treatment with Refametanib (BAY86-9766) had no effect on a lung adenocarcinoma cell line co-harboring MAP2K1 Y134C and KRAS Q61H in culture (PMID: 26582713). ",Actionable,6449,3910,lung adenocarcinoma,DOID,23451,MAP2K1 Y134C KRAS Q61H,no benefit,888,Refametinib,3845,26582713,,,
613,Preclinical,"In a preclinical study, treatment with Mekinist (trametinib) had no effect on a lung adenocarcinoma cell line co-harboring MAP2K1 Y134C and KRAS Q61H in culture (PMID: 26582713). ",Actionable,6448,3910,lung adenocarcinoma,DOID,23451,MAP2K1 Y134C KRAS Q61H,no benefit,2,Trametinib,3845,26582713,,,
614,Guideline,Vectibix (panitumumab) is not indicated for use in colorectal cancer patients with KRAS exon 4 mutations (Guidelines).,Actionable,3839,9256,colorectal cancer,DOID,1869,KRAS A146V,resistant,845,Panitumumab,3845,None,,,
615,Guideline,Ertibux (cetuximab) is not indicated for use in colorectal cancer patients with KRAS exon 4 mutations (Guidelines).,Actionable,3838,9256,colorectal cancer,DOID,1869,KRAS A146V,resistant,694,Cetuximab,3845,None,,,
616,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS A146V and A146T mutations and subsequent resistance to Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) in culture (PMID: 27312529).",Actionable,7695,9256,colorectal cancer,DOID,25927,BRAF V600E KRAS A146T KRAS A146V,resistant,1916,Cetuximab + Encorafenib,3845,27312529,,,
617,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS A146V and A146T mutations and subsequent resistance to Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7698,9256,colorectal cancer,DOID,25927,BRAF V600E KRAS A146T KRAS A146V,resistant,1711,Vemurafenib + Cetuximab,3845,27312529,,,
618,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS A146V and A146T mutations and subsequent resistance to Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Tafinlar (dabrafenib) in culture (PMID: 27312529).",Actionable,7697,9256,colorectal cancer,DOID,25927,BRAF V600E KRAS A146T KRAS A146V,resistant,4525,Cetuximab + Dabrafenib,3845,27312529,,,
619,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired KRAS A146V and A146T mutations and subsequent resistance to Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Selumetinib (AZD6244) in culture (PMID: 27312529).",Actionable,7699,9256,colorectal cancer,DOID,25927,BRAF V600E KRAS A146T KRAS A146V,resistant,4536,Cetuximab + Selumetinib,3845,27312529,,,
620,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to combination treatment consisting of Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) in culture, likely due to the acquisition of KRAS A146V and A146T secondary resistance mutations (PMID: 27312529).",Actionable,7628,9256,colorectal cancer,DOID,25927,BRAF V600E KRAS A146T KRAS A146V,resistant,1917,LGX818 + Cetuximab + BYL719,3845,27312529,,,
621,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS A146T mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) in culture (PMID: 27312529).",Actionable,7680,9256,colorectal cancer,DOID,25924,BRAF V600E KRAS A146T,resistant,1711,Vemurafenib + Cetuximab,3845,27312529,,,
622,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a KRAS A146T mutation and subsequent resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818), and Alpelisib (BYL719) in culture (PMID: 27312529).",Actionable,7687,9256,colorectal cancer,DOID,25924,BRAF V600E KRAS A146T,resistant,1917,LGX818 + Cetuximab + BYL719,3845,27312529,,,
623,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Tafinlar (dabrafenib) combination treatment in culture, likely due to the acquired secondary resistance mutation KRAS A146T (PMID: 27312529).",Actionable,7624,9256,colorectal cancer,DOID,25924,BRAF V600E KRAS A146T,resistant,4525,Cetuximab + Dabrafenib,3845,27312529,,,
624,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) inhibited survival of colorectal cancer cell lines harboring BRAF V600E that acquired a KRAS A146T mutation and subsequent resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment in culture (PMID: 27312529).",Actionable,7682,9256,colorectal cancer,DOID,25924,BRAF V600E KRAS A146T,sensitive,4541,Cetuximab + Dabrafenib + Trametinib,3845,27312529,,,
625,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Erbitux (cetuximab) and Encorafenib (LGX818) combination treatment in culture, likely due to the acquired secondary resistance mutation KRAS A146T (PMID: 27312529).",Actionable,7623,9256,colorectal cancer,DOID,25924,BRAF V600E KRAS A146T,resistant,1916,Cetuximab + Encorafenib,3845,27312529,,,
626,Preclinical - Cell line xenograft,"In a preclinical study, PD-0325901 inhibited growth of colorectal cancer cell lines harboring KRAS A146T in culture and in cell line xenograft models (PMID: 20570890).",Actionable,1708,9256,colorectal cancer,DOID,1441,KRAS A146T,sensitive,849,PD-0325901,3845,20570890,,,
627,Guideline,Ertibux (cetuximab) is not indicated for use in colorectal cancer patients with KRAS exon 4 mutations (Guidelines).,Actionable,3837,9256,colorectal cancer,DOID,1441,KRAS A146T,resistant,694,Cetuximab,3845,None,,,
628,Preclinical - Cell line xenograft,"In preclinical studies, Erbitux (cetuximab) decreased pERK and cyclin D1 expression, induced p27, and inhibited cell growth in several human colorectal cancer cell line harboring KRAS A146T in culture; it decreased pERK and cyclin D1 expression, induced p27, and inhbited tumor growth in one colorectal cancer cell line harboring KRAS A146T in xenograft models (PMID: 24141978).",Actionable,1709,9256,colorectal cancer,DOID,1441,KRAS A146T,resistant,694,Cetuximab,3845,20570890,,,
629,Guideline,Vectibix (panitumumab) is not indicated for use in colorectal cancer patients with KRAS exon 4 mutations (Guidelines).,Actionable,3840,9256,colorectal cancer,DOID,1441,KRAS A146T,resistant,845,Panitumumab,3845,None,,,
630,Clinical Study,"In a clinical case study, a colon cancer patient harboring KRAS A59T demonstrated sensitivity to the combination treatment of Vectibix (panitumumab) and FOLFIRI, which resulted in an objective response of a 36% decrease according to RECIST (PMID: 28404754). ",Actionable,10670,219,colon cancer,DOID,862,KRAS A59T,sensitive,5573,Panitumumab + FOLFIRI,3845,28404754,,,
631,Clinical Study,"In a clinical study, the combination of XL147 plus Paraplatin (carboplatin) and Taxol (paclitaxel) resulted in progressive disease in a patient with colorectal cancer harboring a PIK3CA H1047 mutation and KRAS G12 mutation (PMID: 21216929). ",Actionable,3385,9256,colorectal cancer,DOID,13308,PIK3CA H1047X KRAS G12X,resistant,3135,XL147 + Carboplatin + Paclitaxel,3845,21216929,,,
632,FDA approved,Lung adenocarcinoma patients with KRAS codon 12 or 13 mutations lack sensitivity to Iressa (gefitinib) (PMID: 15696205).,Actionable,146,3910,lung adenocarcinoma,DOID,1192,KRAS G12X,resistant,751,Gefitinib,3845,15696205,,,
633,Phase III,"In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI did not have improved clinical benefit compared to FOLFIRI alone in patients with KRAS exon 2 mutant colorectal cancer (PMID: 26341920).",Actionable,3265,9256,colorectal cancer,DOID,1192,KRAS G12X,no benefit,3102,Panitumumab + Oxaliplatin + Fluorouracil + Irinotecan,3845,26341920,,,
634,Preclinical,"In a preclinical study, sensitivity to Eloxatin (oxaliplatin) was increased in colorectal tumor cell lines carrying KRAS codon 12 or 13 mutations (PMID: 23209813). ",Actionable,1439,50861,colorectal adenocarcinoma,DOID,1192,KRAS G12X,sensitive,1104,Oxaliplatin,3845,23209813,,,
635,Guideline,Ertibux (cetuximab) is not indicated for use in colorectal cancer patients with KRAS exon 2 mutations (Guidelines).,Actionable,1559,9256,colorectal cancer,DOID,1192,KRAS G12X,resistant,694,Cetuximab,3845,None,,,
636,Preclinical - Cell line xenograft,"In a preclinical study, Cobimetinib (GDC-0973) inhibited tumor growth in xenograft models of a human non-small cell lung cancer cell line harboring a KRAS codon 12 mutation (PMID: 23934108).",Actionable,1449,3908,non-small cell lung carcinoma,DOID,1192,KRAS G12X,sensitive,1004,Cobimetinib,3845,23934108,,,
637,Preclinical,"In a preclinical study, pancreatic cell lines with KRAS codon 12 mutations had increased sensitivity to Binimetinib (MEK162) (PMID: 25167228).",Actionable,1444,1793,pancreatic cancer,DOID,1192,KRAS G12X,sensitive,807,Binimetinib,3845,25167228,,,
638,Preclinical,"In a preclinical study, a pancreatic cancer cell line harboring a KRAS codon 12 mutation demonstrated resistance to PHT-427, resulting in increased Akt activity (PMID: 20197390, PMID: 20418756).",Actionable,4824,1793,pancreatic cancer,DOID,1192,KRAS G12X,resistant,3148,PHT-427,3845,20418756,20197390,,
639,Guideline,Vectibix (panitumumab) is not indicated for use in colorectal cancer patients with KRAS exon 2 mutations (Guidelines).,Actionable,1557,9256,colorectal cancer,DOID,1192,KRAS G12X,resistant,845,Panitumumab,3845,None,,,
640,Preclinical - Cell line xenograft,"In a preclinical study, Cobimetinib (GDC-0973) inhibited tumor growth in xenograft models of a human pancreatic cancer cell line harboring a KRAS codon 12 mutation (PMID: 23934108).",Actionable,1448,1793,pancreatic cancer,DOID,1192,KRAS G12X,sensitive,1004,Cobimetinib,3845,23934108,,,
641,Preclinical,"In a preclinical study, transformed cell lines with various KRAS codon 12 mutations displayed differential inhibition by PD-0325901 (PMID: 26037647).",Actionable,2442,10000003,Advanced Solid Tumor,JAX,1192,KRAS G12X,sensitive,849,PD-0325901,3845,23934108,26037647,,
642,Clinical Study,"In a clinical study, two colorectal cancer patients harboring both a PIK3CA E545 and KRAS G12 mutation demonstrated stable disease when treated with Torisel (temsirolimus) (PMID: 21216929). ",Actionable,3312,9256,colorectal cancer,DOID,13163,PIK3CA E545X KRAS G12X,sensitive,936,Temsirolimus,3845,21216929,,,
643,Preclinical,"In a preclinical study, CUDC-907 induced caspase activation and apoptosis in a human multiple myeloma cell line harboring KRAS G12A in culture (PMID: 19490892, PMID: 22693356).",Actionable,3011,9538,multiple myeloma,DOID,2381,KRAS G12A,sensitive,709,CUDC-907,3845,22693356,19490892,,
644,Preclinical,"In a preclinical study, Farydak (panobinostat) induced caspase activation and apoptosis in a human multiple myeloma cell line harboring KRAS G12A in culture (PMD: 19490892, PMID: 22693356).",Actionable,3012,9538,multiple myeloma,DOID,2381,KRAS G12A,sensitive,1080,Panobinostat,3845,22693356,19490892,,
645,Preclinical,"In a preclinical study, colorectal cancer cells harboring KRAS G12A were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).",Actionable,4941,9256,colorectal cancer,DOID,2381,KRAS G12A,resistant,890,Regorafenib,3845,25838391,,,
646,Preclinical,"In a preclinical study, Erbitux (cetuximab) inhibited growth of human colorectal cancer cells harboring KRAS G12A in culture (PMID: 25838391).",Actionable,4935,9256,colorectal cancer,DOID,2381,KRAS G12A,sensitive,694,Cetuximab,3845,25838391,,,
647,Preclinical - Cell culture,"In a preclinical study, a MET-amplified lung cancer cell line harboring KRAS G12A was not sensitive to growth inhibition by AMG 337 in culture (PMID: 27196782).",Actionable,9029,1324,lung cancer,DOID,25935,KRAS G12A MET amp,resistant,1064,AMG 337,3845,27196782,,,
648,Preclinical - Cell culture,"In a preclinical study, MET amplified lung cancer cells harboring KRAS G12A were insensitive to SAR125844-mediated growth inhibition in culture (PMID: 25504634).",Actionable,7733,1324,lung cancer,DOID,25935,KRAS G12A MET amp,resistant,2159,SAR125844,3845,25504634,,,
0,Clinical Study,"In a clinical case study, a patient with colorectal cancer developed liver metastases harboring MAP2K1 K57T that were insensitive to Erbitux (cetuximab) treatment and the mutation was confirmed to cause resistance in human colorectal cancer cell lines in culture (PMID: 26644315).",Actionable,4421,9256,colorectal cancer,DOID,3890,MAP2K1 K57T,resistant,694,Cetuximab,5604,26644315,,,
1,Preclinical,"In a preclinical study, a colorectal cancer cell line expressing MAP2K1 K57T was resistant to Vectibix (panitumumab) in culture (PMID: 26644315).",Actionable,4422,9256,colorectal cancer,DOID,3890,MAP2K1 K57T,resistant,845,Panitumumab,5604,26644315,,,
2,Preclinical,"In a preclinical study, Erbitux (cetuximab) and Mekinist (trametinib) inhibited colorectal cancer cell lines expressing MAP2K1 K57T in culture (PMID: 26644315).",Actionable,4425,9256,colorectal cancer,DOID,3890,MAP2K1 K57T,sensitive,3505,Cetuximab + Trametinib,5604,26644315,,,
3,Clinical Study,"In a clinical case study, a combination of Vectibix (panitumumab) and Mekinist (trametinib) caused tumor regression in a patientâ€™s colorectal cancer metastases harboring MAP2K1 K57T after being identified pre-clinically as a combination likely to inhibit MAP2K1 K57T expressing colorectal cancer (PMID: 26644315).",Actionable,4428,9256,colorectal cancer,DOID,3890,MAP2K1 K57T,sensitive,1991,Panitumumab + Trametinib,5604,26644315,,,
4,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Tafinlar (dabrafenib) and Mekinist (trametinib) in culture (PMID: 27312529).",Actionable,7702,9256,colorectal cancer,DOID,21654,BRAF V600E MAP2K1 V211D,resistant,1066,Trametinib + Dabrafenib,5604,27312529,,,
5,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) in culture (PMID: 27312529).",Actionable,7700,9256,colorectal cancer,DOID,21654,BRAF V600E MAP2K1 V211D,resistant,1916,Cetuximab + Encorafenib,5604,27312529,,,
6,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K V211D demonstrated resistance to growth inhibition by CI-1040 in cell culture (PMID: 19915144).",Actionable,5820,1909,melanoma,DOID,21654,BRAF V600E MAP2K1 V211D,resistant,699,CI-1040,5604,19915144,,,
7,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 V211D demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",Actionable,12152,1909,melanoma,DOID,21654,BRAF V600E MAP2K1 V211D,resistant,2,Trametinib,5604,28655712,,,
8,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Selumetinib (AZD6244) and Erbitux (cetuximab) combination treatment in culture, likely due to the acquired secondary resistant mutation of MAP2K1 V211D (PMID: 27312529).",Actionable,7629,9256,colorectal cancer,DOID,21654,BRAF V600E MAP2K1 V211D,resistant,4536,Cetuximab + Selumetinib,5604,27312529,,,
9,Preclinical - Cell culture,"In a preclinical study, BVD-523 (Ulixertinib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 V211D in culture (PMID: 28655712). ",Actionable,12158,1909,melanoma,DOID,21654,BRAF V600E MAP2K1 V211D,sensitive,997,BVD-523,5604,28655712,,,
10,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) in culture (PMID: 27312529).",Actionable,7703,9256,colorectal cancer,DOID,21654,BRAF V600E MAP2K1 V211D,resistant,4541,Cetuximab + Dabrafenib + Trametinib,5604,27312529,,,
11,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 V211D in culture (PMID: 28655712).",Actionable,12155,1909,melanoma,DOID,21654,BRAF V600E MAP2K1 V211D,sensitive,342,Vemurafenib,5604,28655712,,,
12,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K V211D demonstrated resistance to growth inhibition by Selumetinib (AZD6244) in cell culture (PMID: 19915144).",Actionable,5821,1909,melanoma,DOID,21654,BRAF V600E MAP2K1 V211D,resistant,913,Selumetinib,5604,19915144,,,
13,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 V211D mutation and subsequent resistance to Erbitux (cetuximab) and Selumetinib (AZD6244) combination treatment were resistant to SCH772984 in culture (PMID: 27312529).",Actionable,7704,9256,colorectal cancer,DOID,21654,BRAF V600E MAP2K1 V211D,resistant,2618,SCH772984,5604,27312529,,,
14,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 V60E demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).",Actionable,7002,1909,melanoma,DOID,24281,BRAF V600E MAP2K1 V60E,sensitive,4351,VRT11E,5604,24265153,,,
15,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 V60E demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).",Actionable,7056,1909,melanoma,DOID,24281,BRAF V600E MAP2K1 V60E,resistant,3,Dabrafenib,5604,24265153,,,
16,Preclinical,"In a preclinical study, a melanoma cell line expressing MAP2K1 V60E demonstrated resistance to Tafinlar (dabrafenib) in culture (PMID: 24265153).",Actionable,6825,1909,melanoma,DOID,23745,MAP2K1 V60E,resistant,3,Dabrafenib,5604,24265153,,,
17,Preclinical,"In a preclinical study, a melanoma cell line expressing MAP2K1 V60E demonstrated resistance to Mekinist (trametinib) in culture (PMID: 24265153).",Actionable,6824,1909,melanoma,DOID,23745,MAP2K1 V60E,resistant,2,Trametinib,5604,24265153,,,
18,Clinical Study,"In a clinical study, a melanoma patient harboring a BRAF V600 mutation developed resistant mutations, MAP2K1 V60E, NRAS T58I, and NRAS Q61R, after 18 weeks of treatment with Zelboraf (vemurafenib) (PMID: 24265153).",Actionable,7068,1909,melanoma,DOID,24385,BRAF V600X MAP2K1 V60E NRAS T58I NRAS Q61R,resistant,342,Vemurafenib,5604,24265153,,,
19,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 I111N demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",Actionable,12149,1909,melanoma,DOID,28495,BRAF V600E MAP2K1 I111N,resistant,2,Trametinib,5604,28655712,,,
20,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 I111N  in culture (PMID: 28655712).",Actionable,12153,1909,melanoma,DOID,28495,BRAF V600E MAP2K1 I111N,sensitive,342,Vemurafenib,5604,28655712,,,
21,Preclinical,"In a preclinical study, Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del in culture, compared to either agent alone (PMID: 22389471).",Actionable,5983,1909,melanoma,DOID,22045,BRAF V600E MAP2K1 K59del,sensitive,4004,Dabrafenib + GSK2126458,5604,22389471,,,
22,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to growth inhibition by Mekinist (trametinib) in culture (PMID: 22389471).",Actionable,5964,1909,melanoma,DOID,22045,BRAF V600E MAP2K1 K59del,resistant,2,Trametinib,5604,22389471,,,
23,Preclinical,"In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E harboring MAP2K1 K59del in culture (PMID: 22389471).",Actionable,5980,1909,melanoma,DOID,22045,BRAF V600E MAP2K1 K59del,sensitive,1066,Trametinib + Dabrafenib,5604,22389471,,,
24,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).",Actionable,5957,1909,melanoma,DOID,22045,BRAF V600E MAP2K1 K59del,resistant,342,Vemurafenib,5604,22389471,,,
25,Preclinical,"In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del in culture, compared to either agent alone (PMID: 22389471).",Actionable,5984,1909,melanoma,DOID,22045,BRAF V600E MAP2K1 K59del,sensitive,3027,GSK2126458 + Trametinib,5604,22389471,,,
26,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5969,1909,melanoma,DOID,22045,BRAF V600E MAP2K1 K59del,decreased response,763,GSK2126458,5604,22389471,,,
27,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E and MAP2K1 K59del were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).",Actionable,5953,1909,melanoma,DOID,22045,BRAF V600E MAP2K1 K59del,resistant,3,Dabrafenib,5604,22389471,,,
28,Preclinical,"In a preclinical study, treatment with Mekinist (trametinib) had no effect on a lung adenocarcinoma cell line co-harboring MAP2K1 Y134C and KRAS Q61H in culture (PMID: 26582713). ",Actionable,6448,3910,lung adenocarcinoma,DOID,23451,MAP2K1 Y134C KRAS Q61H,no benefit,2,Trametinib,5604,26582713,,,
29,Preclinical,"In a preclinical study, treatment with Refametanib (BAY86-9766) had no effect on a lung adenocarcinoma cell line co-harboring MAP2K1 Y134C and KRAS Q61H in culture (PMID: 26582713). ",Actionable,6449,3910,lung adenocarcinoma,DOID,23451,MAP2K1 Y134C KRAS Q61H,no benefit,888,Refametinib,5604,26582713,,,
30,Preclinical,"In a preclinical study, MAP2K1 (MEK1) K57E mutations restored extracellular signalâ€“regulated kinase (ERK) activation in the presence of Tafinlar (dabrafenib) in cultured melanoma cell lines (PMID:24463458).",Actionable,666,1909,melanoma,DOID,846,MAP2K1 K57E,resistant,3,Dabrafenib,5604,24463458,,,
31,Preclinical - Cell culture,"In a preclinical study, expression of MAP2K1 K57E in a melanoma cell line harboring BRAF V600E conferred resistance to Tafinlar (dabrafenib) in culture (PMID: 25370473).",Actionable,7592,1909,melanoma,DOID,25914,BRAF V600E MAP2K1 K57E,resistant,3,Dabrafenib,5604,25370473,,,
32,Preclinical - Cell culture,"In a preclinical study, CI-1040 (PD184352) did not inhibit kinase activity of Map2k1 L115P expressed in transformed human kidney cells (PMID: 12370306).",Actionable,10420,10000003,Advanced Solid Tumor,JAX,21626,MAP2K1 L115P,resistant,699,CI-1040,5604,12370306,,,
33,Preclinical - Cell culture,"In a preclinical study, CI-1040 (PD184352) did not inhibit proliferation of melanoma cells expressing Map2k1 L115P (PMID: 19915144).",Actionable,10421,1909,melanoma,DOID,21626,MAP2K1 L115P,resistant,699,CI-1040,5604,19915144,,,
34,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) did not inhibit proliferation of melanoma cells expressing Map2k1 L115P (PMID: 19915144).",Actionable,10422,1909,melanoma,DOID,21626,MAP2K1 L115P,resistant,913,Selumetinib,5604,19915144,,,
35,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Encorafenib (LGX818) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",Actionable,7654,9256,colorectal cancer,DOID,21627,BRAF V600E MAP2K1 L115P,sensitive,1916,Cetuximab + Encorafenib,5604,27312529,,,
36,Preclinical - Cell culture,"In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 L115P in culture (PMID: 28655712).",Actionable,12154,1909,melanoma,DOID,21627,BRAF V600E MAP2K1 L115P,sensitive,342,Vemurafenib,5604,28655712,,,
37,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Tafinlar (dabrafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",Actionable,7655,9256,colorectal cancer,DOID,21627,BRAF V600E MAP2K1 L115P,sensitive,4525,Cetuximab + Dabrafenib,5604,27312529,,,
38,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",Actionable,7660,9256,colorectal cancer,DOID,21627,BRAF V600E MAP2K1 L115P,sensitive,4543,Cetuximab + SCH772984,5604,27312529,,,
39,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and Mekinist (trametinib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",Actionable,7658,9256,colorectal cancer,DOID,21627,BRAF V600E MAP2K1 L115P,sensitive,4541,Cetuximab + Dabrafenib + Trametinib,5604,27312529,,,
40,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab) and Zelboraf (vemurafenib) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",Actionable,7656,9256,colorectal cancer,DOID,21627,BRAF V600E MAP2K1 L115P,sensitive,1711,Vemurafenib + Cetuximab,5604,27312529,,,
41,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Tafinlar (dabrafenib) and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",Actionable,7661,9256,colorectal cancer,DOID,21627,BRAF V600E MAP2K1 L115P,sensitive,4544,Dabrafenib + SCH772984,5604,27312529,,,
42,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Encorafenib (LGX818) and Alpelisib (BYL719) inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",Actionable,7657,9256,colorectal cancer,DOID,21627,BRAF V600E MAP2K1 L115P,sensitive,1917,LGX818 + Cetuximab + BYL719,5604,27312529,,,
43,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring BRAF V600E developed sustained activation of Mapk signaling and resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture, likely due to the acquired secondary resistance mutation MAP2K1 L115P (PMID: 27312529).",Actionable,7620,9256,colorectal cancer,DOID,21627,BRAF V600E MAP2K1 L115P,resistant,1066,Trametinib + Dabrafenib,5604,27312529,,,
44,Preclinical - Cell culture,"In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 L115P in culture (PMID: 26267534).",Actionable,5817,1909,melanoma,DOID,21627,BRAF V600E MAP2K1 L115P,sensitive,3769,DEL-22379,5604,26267534,,,
45,Preclinical - Cell culture,"In a preclinical study, combination therapy consisting of Erbitux (cetuximab), Tafinlar (dabrafenib), and SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",Actionable,7662,9256,colorectal cancer,DOID,21627,BRAF V600E MAP2K1 L115P,sensitive,4542,Cetuximab + Dabrafenib + SCH772984,5604,27312529,,,
46,Preclinical,"In a preclinical study, over expression of MAPK21 L115P in melanoma cells harboring BRAF V600E resulted in insensitivity to growth inhibition by PD-0325901 in cell culture (PMID: 26267534).",Actionable,5812,1909,melanoma,DOID,21627,BRAF V600E MAP2K1 L115P,resistant,849,PD-0325901,5604,26267534,,,
47,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 L115P demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",Actionable,12151,1909,melanoma,DOID,21627,BRAF V600E MAP2K1 L115P,resistant,2,Trametinib,5604,28655712,,,
48,Preclinical - Cell culture,"In a preclinical study, SCH772984 inhibited survival of colorectal cancer cells harboring BRAF V600E that acquired a MAP2K1 L115P mutation and subsequent resistance to Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment in culture (PMID: 27312529).",Actionable,7659,9256,colorectal cancer,DOID,21627,BRAF V600E MAP2K1 L115P,sensitive,2618,SCH772984,5604,27312529,,,
49,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 E203K demonstrated resistance to treatment with Zelboraf (vemurafenib) in culture (PMID: 28655712).",Actionable,12161,1909,melanoma,DOID,28497,BRAF V600E MAP2K1 E203K,resistant,342,Vemurafenib,5604,28655712,,,
50,Preclinical - Cell culture,"In a preclinical study, BVD-523 (ulixertinib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 E203K in culture (PMID: 28655712). ",Actionable,12166,1909,melanoma,DOID,28497,BRAF V600E MAP2K1 E203K,sensitive,997,BVD-523,5604,28655712,,,
51,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 E203K demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",Actionable,12160,1909,melanoma,DOID,28497,BRAF V600E MAP2K1 E203K,resistant,2,Trametinib,5604,28655712,,,
52,Preclinical,"In a preclinical study, Vectibix (panitumumab) and Mekinist (trametinib) inhibited colorectal cancer cell lines expressing MAP2K1 K57N in culture (PMID: 26644315).",Actionable,4427,9256,colorectal cancer,DOID,504,MAP2K1 K57N,sensitive,1991,Panitumumab + Trametinib,5604,26644315,,,
53,Clinical Study,"In a clinical study, a patient with refractory Erdheimâ€“Chester disease harboring a MAP2K1 K57N mutation had a sustained clinical response to Mekinist (trametinib) for over 6 months (PMID: 26566875).",Actionable,6025,60073,lymphatic system cancer,DOID,504,MAP2K1 K57N,sensitive,2,Trametinib,5604,26566875,,,
54,Preclinical,"In a preclinical study, Erbitux (cetuximab) and Mekinist (trametinib) inhibited colorectal cancer cell lines expressing MAP2K1 K57N in culture (PMID: 26644315).",Actionable,4426,9256,colorectal cancer,DOID,504,MAP2K1 K57N,sensitive,3505,Cetuximab + Trametinib,5604,26644315,,,
55,Preclinical,"In a preclinical study, colorectal cancer cell lines expressing MAP2K1 K57N were insensitive to Vectibix (panitumumab) in culture (PMID: 26644315).",Actionable,4424,9256,colorectal cancer,DOID,504,MAP2K1 K57N,resistant,845,Panitumumab,5604,26644315,,,
56,Preclinical,"In a preclinical study, colorectal cancer cell lines expressing MAP2K1 K57N were insensitive to Erbitux (cetuximab) in culture (PMID: 26644315).",Actionable,4423,9256,colorectal cancer,DOID,504,MAP2K1 K57N,resistant,694,Cetuximab,5604,26644315,,,
57,Preclinical,"In a preclinical study, selumetinib (AZD6244) inhibited phosphorylation of ERK in cells expressing MAP2K1 K57N and inhibited MAP2K1 K57N-dependent growth in cell culture (PMID: 18632602).",Actionable,182,3910,lung adenocarcinoma,DOID,504,MAP2K1 K57N,sensitive,913,Selumetinib,5604,18632602,,,
58,Preclinical - Patient cell culture,"In a preclinical study, NSCLC patient derived cells harboring an ALK rearrangement demonstrated resistance to Zykadia (ceritinib) due to the acquired mutation MAP2K1 K57N, however, sensitivity was restored to Zykadia (ceritinib) with the addition of AZD6244, resulting in decreased cell survival in culture and reduced tumor volume in xenograft models (PMID: 25394791).",Actionable,8661,3908,non-small cell lung carcinoma,DOID,26393,ALK rearrange MAP2K1 K57N,sensitive,4786,Ceritinib + Selumetinib,5604,25394791,,,
59,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated resistance to treatment with Mekinist (trametinib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).",Actionable,7059,1909,melanoma,DOID,24283,BRAF V600E MAP2K1 G128V,resistant,2,Trametinib,5604,24265153,,,
60,Preclinical,"In a preclinical study, MAP2K1 G128V conferred resistance to the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF V600E-mutant melanoma cells in culture (PMID: 24265154).",Actionable,7033,1909,melanoma,DOID,24283,BRAF V600E MAP2K1 G128V,resistant,1066,Trametinib + Dabrafenib,5604,24265154,,,
61,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).",Actionable,7005,1909,melanoma,DOID,24283,BRAF V600E MAP2K1 G128V,sensitive,4351,VRT11E,5604,24265153,,,
62,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 G128V demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).",Actionable,7058,1909,melanoma,DOID,24283,BRAF V600E MAP2K1 G128V,resistant,3,Dabrafenib,5604,24265153,,,
63,Preclinical - Cell culture,"In a preclinical study, CI-1040 (PD184352) did not inhibit proliferation of melanoma cells expressing Map2k1 I103N (PMID: 19915144). ",Actionable,10427,1909,melanoma,DOID,21625,MAP2K1 I103N,resistant,699,CI-1040,5604,19915144,,,
64,Preclinical - Cell culture,"In a preclinical study, CI-1040 (PD184352) partially inhibited kinase activity of Map2k1 I103N expressed in transformed human kidney cells (PMID: 12370306).",Actionable,10425,10000003,Advanced Solid Tumor,JAX,21625,MAP2K1 I103N,decreased response,699,CI-1040,5604,12370306,,,
65,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) did not inhibit proliferation of melanoma cells expressing Map2k1 I103N (PMID: 19915144). ",Actionable,10426,1909,melanoma,DOID,21625,MAP2K1 I103N,resistant,913,Selumetinib,5604,19915144,,,
66,Preclinical - Cell culture,"In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I103N in culture (PMID: 26267534).",Actionable,5816,1909,melanoma,DOID,21628,BRAF V600E MAP2K1 I103N,sensitive,3769,DEL-22379,5604,26267534,,,
67,Preclinical,"In a preclinical study, over expression of MAPK21 I103N in melanoma cells harboring BRAF V600E resulted in insensitivity to growth inhibition by PD-0325901 in cell culture (PMID: 26267534).",Actionable,5811,1909,melanoma,DOID,21628,BRAF V600E MAP2K1 I103N,resistant,849,PD-0325901,5604,26267534,,,
68,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S were resistant Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).",Actionable,5954,1909,melanoma,DOID,22046,BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S,resistant,3,Dabrafenib,5604,22389471,,,
69,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, A146T and MAP2K1 P387S were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).",Actionable,5958,1909,melanoma,DOID,22046,BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S,resistant,342,Vemurafenib,5604,22389471,,,
70,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5968,1909,melanoma,DOID,22046,BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S,decreased response,763,GSK2126458,5604,22389471,,,
71,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S were resistant to growth inhibition by Mekinist (trametinib) in culture (PMID: 22389471).",Actionable,5963,1909,melanoma,DOID,22046,BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S,resistant,2,Trametinib,5604,22389471,,,
72,Preclinical,"In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).",Actionable,5994,1909,melanoma,DOID,22046,BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S,sensitive,3027,GSK2126458 + Trametinib,5604,22389471,,,
73,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5966,1909,melanoma,DOID,22037,BRAF V600E NRAS A146T MAP2K1 P387S,decreased response,763,GSK2126458,5604,22389471,,,
74,Preclinical,"In a preclinical study, Talfinlar (dabrafenib) in combination with Omipalisib (GSK2126458) did not improve the response to human melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S in culture (PMID: 22389471).",Actionable,5989,1909,melanoma,DOID,22037,BRAF V600E NRAS A146T MAP2K1 P387S,no benefit,4004,Dabrafenib + GSK2126458,5604,22389471,,,
75,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were >20-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E and also had reduced sensitivity in comparison to cell lines harboring BRAF V600E and NRAS A146T in culture (PMID: 22389471).",Actionable,5960,1909,melanoma,DOID,22037,BRAF V600E NRAS A146T MAP2K1 P387S,decreased response,2,Trametinib,5604,22389471,,,
76,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).",Actionable,5950,1909,melanoma,DOID,22037,BRAF V600E NRAS A146T MAP2K1 P387S,resistant,3,Dabrafenib,5604,22389471,,,
77,Preclinical,"In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).",Actionable,5992,1909,melanoma,DOID,22037,BRAF V600E NRAS A146T MAP2K1 P387S,sensitive,3027,GSK2126458 + Trametinib,5604,22389471,,,
78,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).",Actionable,5956,1909,melanoma,DOID,22037,BRAF V600E NRAS A146T MAP2K1 P387S,resistant,342,Vemurafenib,5604,22389471,,,
79,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were >20-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5962,1909,melanoma,DOID,22043,BRAF V600E NRAS Q61K MAP2K1 P387S,decreased response,2,Trametinib,5604,22389471,,,
80,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were resistant to growth inhibition by Zelboraf (vemurafenib) in culture (PMID: 22389471).",Actionable,5961,1909,melanoma,DOID,22043,BRAF V600E NRAS Q61K MAP2K1 P387S,resistant,342,Vemurafenib,5604,22389471,,,
81,Preclinical,"In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E, NRAS Q61K, and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).",Actionable,5993,1909,melanoma,DOID,22043,BRAF V600E NRAS Q61K MAP2K1 P387S,sensitive,3027,GSK2126458 + Trametinib,5604,22389471,,,
82,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).",Actionable,5952,1909,melanoma,DOID,22043,BRAF V600E NRAS Q61K MAP2K1 P387S,resistant,3,Dabrafenib,5604,22389471,,,
83,Preclinical,"In a preclinical study, the response of human melanoma cell lines harboring BRAF V600E, NRAS Q61K, and MAP2K1 P387S to Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) was conflicting as one cell line with this mutation profile responded to the combination and another cell line with the mutation profile did not (PMID: 22389471).",Actionable,5990,1909,melanoma,DOID,22043,BRAF V600E NRAS Q61K MAP2K1 P387S,conflicting,4004,Dabrafenib + GSK2126458,5604,22389471,,,
84,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5967,1909,melanoma,DOID,22043,BRAF V600E NRAS Q61K MAP2K1 P387S,decreased response,763,GSK2126458,5604,22389471,,,
85,Clinical Study,"In a clinical case study, a patient harboring BRAF V600E demonstrated an initial response to treatment with Zelboraf (vemurafenib), but progressed following emergence of a MAP2K1 C121S mutation (PMID: 21383288).",Actionable,7037,1909,melanoma,DOID,17135,BRAF V600E MAP2K1 C121S,decreased response,342,Vemurafenib,5604,21383288,,,
86,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E mutation and overexpressing MAP2K1 C121S were less sensitive than those overexpressing wild-type MAP2K1 to Zelboraf (vemurafenib)-induced inhibition of Mapk pathway activation and cell proliferation in culture (PMID: 24448821).",Actionable,4030,1909,melanoma,DOID,17135,BRAF V600E MAP2K1 C121S,decreased response,342,Vemurafenib,5604,24448821,,,
87,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 C121S demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 28655712).",Actionable,12159,1909,melanoma,DOID,17135,BRAF V600E MAP2K1 C121S,resistant,2,Trametinib,5604,28655712,,,
88,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E mutation and overexpressing MAP2K1 C121S were less sensitive than those overexpressing wild-type MAP2K1 to Selumetinib (AZD6244)-induced inhibition of Mapk pathway activation and cell proliferation in culture (PMID: 24448821).",Actionable,4031,1909,melanoma,DOID,17135,BRAF V600E MAP2K1 C121S,decreased response,913,Selumetinib,5604,24448821,,,
89,Preclinical,"In a preclinical study, expression of MAP2K1 C121S conferred resistance to PLX4720 in melanoma cells harboring BRAF V600E in culture (PMID: 21383288).",Actionable,7038,1909,melanoma,DOID,17135,BRAF V600E MAP2K1 C121S,resistant,1060,PLX4720,5604,21383288,,,
90,Preclinical,"In a preclinical study, E6201 inhibited Mapk pathway activation and proliferation of melanoma cell line harboring BRAF V600E mutation and overexpressing MAP2K1 C121S in culture (PMID: 24448821).",Actionable,4029,1909,melanoma,DOID,17135,BRAF V600E MAP2K1 C121S,sensitive,1011,E6201,5604,24448821,,,
91,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 C121S demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).",Actionable,7003,1909,melanoma,DOID,17135,BRAF V600E MAP2K1 C121S,sensitive,4351,VRT11E,5604,24265153,,,
92,Preclinical,"In a preclinical study, MAP2K1 C121S conferred resistance to the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) in BRAF V600E-mutant melanoma cells in culture (PMID: 24265154).",Actionable,7032,1909,melanoma,DOID,17135,BRAF V600E MAP2K1 C121S,resistant,1066,Trametinib + Dabrafenib,5604,24265154,,,
93,Preclinical - Cell culture,"In a preclinical study, expression of MAP2K1 C121S conferred resistance to Erbitux (cetuximab) in colorectal cancer cells in culture (PMID: 28179366).",Actionable,10310,9256,colorectal cancer,DOID,17134,MAP2K1 C121S,resistant,694,Cetuximab,5604,28179366,,,
94,Preclinical - Cell culture,"In a preclinical study, the combination of Erbitux (cetuximab) and Mekinist (trametinib) decreased viability of colorectal cancer cells harboring MAP2K1 C121S in culture (PMID: 28179366).",Actionable,10312,9256,colorectal cancer,DOID,17134,MAP2K1 C121S,sensitive,3505,Cetuximab + Trametinib,5604,28179366,,,
95,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated resistance to treatment with Mekinist (trametinib) in culture (PMID: 24265153).",Actionable,7061,1909,melanoma,DOID,24282,BRAF V600E MAP2K1 P124S,resistant,2,Trametinib,5604,24265153,,,
96,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and MAP2K1 P124S demonstrated decreased sensitivity to Selumetinib (AZD6244) compared to cells harboring BRAF V600E alone in culture (PMID: 22197931).",Actionable,7035,1909,melanoma,DOID,24282,BRAF V600E MAP2K1 P124S,decreased response,913,Selumetinib,5604,22197931,,,
97,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).",Actionable,7004,1909,melanoma,DOID,24282,BRAF V600E MAP2K1 P124S,sensitive,4351,VRT11E,5604,24265153,,,
98,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124S demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture (PMID: 24265153).",Actionable,7057,1909,melanoma,DOID,24282,BRAF V600E MAP2K1 P124S,resistant,3,Dabrafenib,5604,24265153,,,
99,Preclinical,"In a preclinical study, a colorectal cancer cell line harboring MAP2K1 F53L demonstrated sensitivity to Mekinist (trametinib) in culture, resulting in decreased cell viability (PMID: 26582713). ",Actionable,6453,9256,colorectal cancer,DOID,21379,MAP2K1 F53L,sensitive,2,Trametinib,5604,26582713,,,
100,Preclinical - Cell culture,"In a preclinical study, expression of MAP2K1 F53L conferred resistance to Erbitux (cetuximab) in colorectal cancer cells in culture (PMID: 28179366).",Actionable,10309,9256,colorectal cancer,DOID,21379,MAP2K1 F53L,resistant,694,Cetuximab,5604,28179366,,,
101,Preclinical - Cell culture,"In a preclinical study, the combination of Erbitux (cetuximab) and Mekinist (trametinib) decreased viability of colorectal cancer cells harboring MAP2K1 F53L in culture (PMID: 28179366).",Actionable,10311,9256,colorectal cancer,DOID,21379,MAP2K1 F53L,sensitive,3505,Cetuximab + Trametinib,5604,28179366,,,
102,Preclinical,"In a preclinical study, melanoma cells harboring BRAF V600E treated with Selumetinib (AZD6244) in culture demonstrated resistance, which was a result of the resistance mutation, MAP2K1 H119P (PMID: 19915144).",Actionable,6895,1909,melanoma,DOID,23996,BRAF V600E MAP2K1 H119P,resistant,913,Selumetinib,5604,19915144,,,
103,Preclinical - Cell culture,"In a preclinical study, CI-1040 (PD184352) partially inhibited kinase activity of Map2k1 L115A expressed in transformed human kidney cells (PMID: 12370306).",Actionable,10423,10000003,Advanced Solid Tumor,JAX,27458,MAP2K1 L115A,decreased response,699,CI-1040,5604,12370306,,,
104,Preclinical - Cell culture,"In a preclinical study, VX-11e inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q in culture (PMID: 25370473).",Actionable,7601,1909,melanoma,DOID,25913,BRAF V600K MAP2K1 P124Q,sensitive,2804,VX-11e,5604,25370473,,,
105,Preclinical - Cell culture,"In a preclinical study, Mekinist (trametinib) inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q in culture (PMID: 25370473).",Actionable,7602,1909,melanoma,DOID,25913,BRAF V600K MAP2K1 P124Q,sensitive,2,Trametinib,5604,25370473,,,
106,Preclinical - Cell culture,"In a preclinical study, a melanoma cell line harboring BRAF V600K and MAP2K1 P124Q demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 25370473).",Actionable,7598,1909,melanoma,DOID,25913,BRAF V600K MAP2K1 P124Q,decreased response,3,Dabrafenib,5604,25370473,,,
107,Preclinical - Cell culture,"In a preclinical study, a melanoma cell line harboring BRAF V600E and expressing MAP2K1 P124Q demonstrated decreased sensitivity to Tafinlar (dabrafenib) in cell culture (PMID: 25370473).",Actionable,7593,1909,melanoma,DOID,25915,BRAF V600E MAP2K1 P124Q,decreased response,3,Dabrafenib,5604,25370473,,,
108,Preclinical,"In a preclinical study, a colorectal cancer cell line harboring MAP2K1 mutations Q56P, H119Y, and D351G and an EGFR G719S mutation demonstrated some sensitivity to Mekinist (trametinib) in culture, resulting in decreased cell viability (PMID: 26582713). ",Actionable,6493,9256,colorectal cancer,DOID,23597,MAP2K1 Q56P MAP2K1 H119Y MAP2K1 D351G EGFR G719S,sensitive,2,Trametinib,5604,26582713,,,
109,Preclinical,"In a preclinical study, selumetinib (AZD6244) inhibited growth of a gastric cancer cell line that requires MAP2K1 Q56P and inhibited phosphorylation of ERK in these cells (PMID: 22327936).",Actionable,502,10534,stomach cancer,DOID,584,MAP2K1 Q56P,sensitive,913,Selumetinib,5604,22327936,,,
110,Preclinical,"In a preclinical study, a lung adenocarcinoma cell line harboring MAP2K1 Q56P demonstrated sensitivity to Mekinist (trametinib), resulting in decreased cell viability (PMID: 26582713). ",Actionable,6444,3910,lung adenocarcinoma,DOID,584,MAP2K1 Q56P,sensitive,2,Trametinib,5604,26582713,,,
111,Preclinical,"In a preclinical study, a lung adenocarcinoma cell line harboring MAP2K1 Q56P demonstrated sensitivity to Selumetinib (AZD6244), resulting in decreased cell viability (PMID: 26582713). ",Actionable,6445,3910,lung adenocarcinoma,DOID,584,MAP2K1 Q56P,sensitive,913,Selumetinib,5604,26582713,,,
112,Preclinical,"In a preclinical study, a lung adenocarcinoma cell line harboring MAP2K1 Q56P demonstrated sensitivity to Refametinib (BAY86-9766), resulting in decreased cell viability (PMID: 26582713). ",Actionable,6446,3910,lung adenocarcinoma,DOID,584,MAP2K1 Q56P,sensitive,888,Refametinib,5604,26582713,,,
113,Clinical Study,"In a clinical study, a patient with refractory Erdheimâ€“Chester disease harboring a MAP2K1 Q56P mutation had a reduction of lymphatic infiltrates to background within a month of receiving Cotellic (cobimetinib) therapy (PMID: 26566875).",Actionable,6026,60073,lymphatic system cancer,DOID,584,MAP2K1 Q56P,sensitive,1004,Cobimetinib,5604,26566875,,,
114,Preclinical,"In a preclinical study, a gastric cancer cell line harboring MAP2K1 Q56P demonstrated sensitivity to Mekinist (trametinib), resulting in decreased cell viability (PMID: 26582713). ",Actionable,6492,10534,stomach cancer,DOID,584,MAP2K1 Q56P,sensitive,2,Trametinib,5604,26582713,,,
115,Preclinical,"In a preclinical study, a lung adenocarcinoma cell line harboring MAP2K1 Q56P demonstrated sensitivity to PD-0325901, resulting in decreased cell viability (PMID: 26582713). ",Actionable,6447,3910,lung adenocarcinoma,DOID,584,MAP2K1 Q56P,sensitive,849,PD-0325901,5604,26582713,,,
116,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E expressing MAP2K1 Q56P displayed reduced sensitivity to Mekinist (trametinib) mediated growth inhibition and retained MEK and ERK signaling (PMID: 22389471).",Actionable,5976,1909,melanoma,DOID,22096,BRAF V600E MAP2K1 Q56P,decreased response,2,Trametinib,5604,22389471,,,
117,Preclinical,"In a preclinical study, the combination of Talfinlar (dabrafenib)    and Mekinist (trametinib) resulted in improved growth inhibition in melanoma cells harboring BRAF V600E and expressing MAP2K1 Q56P in culture (PMID: 22389471).",Actionable,5982,1909,melanoma,DOID,22096,BRAF V600E MAP2K1 Q56P,sensitive,1066,Trametinib + Dabrafenib,5604,22389471,,,
118,Preclinical - Cell culture,"In a preclinical study, BVD-523 (ulixertinib) inhibited proliferation of melanoma cells harboring BRAF V600E and expressing MAP2K1 Q56P in culture (PMID: 28655712). ",Actionable,12165,1909,melanoma,DOID,22096,BRAF V600E MAP2K1 Q56P,sensitive,997,BVD-523,5604,28655712,,,
119,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E expressing MAP2K1 Q56P were resistant to Tafinlar (dabrafenib) mediated growth inhibition and retained MEK and ERK signaling in culture (PMID: 22389471).",Actionable,5975,1909,melanoma,DOID,22096,BRAF V600E MAP2K1 Q56P,resistant,3,Dabrafenib,5604,22389471,,,
120,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 Q56P demonstrated resistance to treatment with Zelboraf (vemurafenib) in culture (PMID: 28655712). ",Actionable,12164,1909,melanoma,DOID,22096,BRAF V600E MAP2K1 Q56P,resistant,342,Vemurafenib,5604,28655712,,,
121,Preclinical,"In a preclinical study, melanoma cells harboring the MAP2K1 Q56P mutation in the presence of BRAF V600E were resistant to the B-RAF inhibitor PLX4720 in culture (PMID: 19915144).",Actionable,505,1909,melanoma,DOID,520,MAP2K1 Q56P BRAF V600E,resistant,1060,PLX4720,5604,19915144,,,
122,Preclinical,"In a preclinical study, melanoma cells harboring the MAP2K1 Q56P mutation in the presence of BRAF V600E were resistant to the MEK inhibitor selumetinib (AZD6244) cell culture.",Actionable,183,1909,melanoma,DOID,520,MAP2K1 Q56P BRAF V600E,resistant,913,Selumetinib,5604,19915144,,,
123,Preclinical,"In a preclinical study, combined treatment with selumetinib and PLX4720 strongly suppressed the emergence of resistant MAP2K1 mutations in BRAF V600E cells in culture (PMID: 19915144).",Actionable,506,1909,melanoma,DOID,520,MAP2K1 Q56P BRAF V600E,sensitive,1061,Selumetinib + PLX4720,5604,19915144,,,
124,Preclinical - Cell culture,"In a preclinical study, Mekinist (trametinib) inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124L in culture (PMID: 25370473).",Actionable,7603,1909,melanoma,DOID,25916,BRAF V600K MAP2K1 P124L,sensitive,2,Trametinib,5604,25370473,,,
125,Preclinical - Cell culture,"In a preclinical study, a melanoma cell line harboring BRAF V600K and MAP2K1 P124L demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 25370473).",Actionable,7599,1909,melanoma,DOID,25916,BRAF V600K MAP2K1 P124L,decreased response,3,Dabrafenib,5604,25370473,,,
126,Preclinical,"In a preclinical study, VX-11e inhibited ERK signaling and reduced growth of a melanoma cell line harboring BRAF V600K and MAP2K1 P124L in culture (PMID: 25370473).",Actionable,7600,1909,melanoma,DOID,25916,BRAF V600K MAP2K1 P124L,sensitive,2804,VX-11e,5604,25370473,,,
127,Preclinical,"In a preclinical study, transformed human melanoma cells expressing MAP2K1 P124L demonstrated resistance to the MEK inhibitor, Selumetinib (AZD6244) (PMID: 19915144).",Actionable,1859,1909,melanoma,DOID,3892,MAP2K1 P124L,resistant,913,Selumetinib,5604,19915144,,,
128,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124L demonstrated a decreased response to treatment with Zelboraf (vemurafenib) in culture (PMID: 28655712).",Actionable,12163,1909,melanoma,DOID,28498,BRAF V600E MAP2K1 P124L,decreased response,342,Vemurafenib,5604,28655712,,,
129,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K1 P124L demonstrated a decreased response to treatment with Mekinist (trametinib) in culture (PMID: 28655712). ",Actionable,12162,1909,melanoma,DOID,28498,BRAF V600E MAP2K1 P124L,decreased response,2,Trametinib,5604,28655712,,,
130,Preclinical - Cell line xenograft,"In a preclinical study, a colorectal cancer cell line harboring MAP2K1 F129L demonstrated sensitivity to treatment with RO4927350 in culture and in cell line xenograft models, demonstrating inhibition of tumor growth (PMID: 21705440).",Actionable,7719,9256,colorectal cancer,DOID,21391,MAP2K1 F129L,sensitive,4552,RO4927350,5604,21705440,,,
131,Preclinical - Cell culture,"In a preclinical study, CI-1040 (PD184352) inhibited kinase activity of Map2k1 F53S expressed in transformed human kidney cells (PMID: 12370306).",Actionable,10424,10000003,Advanced Solid Tumor,JAX,23728,MAP2K1 F53S,sensitive,699,CI-1040,5604,12370306,,,
132,Phase I,"LXH 254 is currently in clinical trials in patients with MAPK pathway alterations and advanced solid tumors (clinicaltrials.gov, Sep 2017). ",Actionable,9587,10000003,Advanced Solid Tumor,JAX,1238,MAP2K1 mutant,not applicable,4442,LXH 254,5604,None,,,
0,Preclinical - Cell culture,"In a preclinical study, transformed human cells expressing MET D1228V were sensitive to Glesatinib (MGCD265) in culture, resulting in suppression of Met phosphorylation (PMID: 27694386).",Actionable,9519,10000003,Advanced Solid Tumor,JAX,26872,MET D1228V,sensitive,809,MGCD265,4233,27694386,,,
1,Preclinical - Cell culture,"In a preclinical study, transformed human cells expressing MET D1228V were sensitive to Cometriq (Cabometyx, cabozantinib) in culture, resulting in suppression of Met phosphorylation (PMID: 27694386).",Actionable,9518,10000003,Advanced Solid Tumor,JAX,26872,MET D1228V,sensitive,998,cabozantinib,4233,27694386,,,
2,Preclinical - Cell culture,"In a preclinical study, transformed human cells expressing MET D1228V demonstrated resistance to treatment with Savolitinib (AZD6094) in culture, resulting in sustained Met phosphorylation (PMID: 27694386).",Actionable,9515,10000003,Advanced Solid Tumor,JAX,26872,MET D1228V,resistant,2161,Savolitinib,4233,27694386,,,
3,Preclinical - Cell culture,"In a preclinical study, transformed human cells expressing MET D1228V were sensitive to Merestinib (LY2801653) in culture, resulting in suppression of Met phosphorylation (PMID: 27694386).",Actionable,9520,10000003,Advanced Solid Tumor,JAX,26872,MET D1228V,sensitive,1030,LY2801653,4233,27694386,,,
4,Preclinical - Cell culture,"In a preclinical study, transformed human cells expressing MET D1228V demonstrated resistance to treatment with Capmatinib (INC280) in culture, resulting in sustained Met phosphorylation (PMID: 27694386). ",Actionable,9517,10000003,Advanced Solid Tumor,JAX,26872,MET D1228V,resistant,1065,Capmatinib,4233,27694386,,,
5,Preclinical - Cell culture,"In a preclinical study, transformed human cells expressing MET D1228V demonstrated resistance to treatment with Xalkori (crizotinib) in culture, resulting in sustained Met phosphorylation (PMID: 27694386).",Actionable,9516,10000003,Advanced Solid Tumor,JAX,26872,MET D1228V,resistant,706,Crizotinib,4233,27694386,,,
6,Clinical Study,"In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion, MET amplification, and MET D1228V demonstrated a strong response to the combination of Tarceva (erlotinib) and Cometriq (Cabometyx, cabozantinib), resulting in reduced tumor size (PMID: 27694386).",Actionable,9534,3910,lung adenocarcinoma,DOID,26887,EGFR exon 19 del MET amp MET D1228V,sensitive,1255,Cabozantinib + Erlotinib,4233,27694386,,,
7,Preclinical,"In a preclinical study, SU11274 induced apoptosis of cells expressing MET E168D, which demonstrated increased sensitivity compared to cells expressing wild-type MET (PMID: 19723643).",Actionable,4759,10000003,Advanced Solid Tumor,JAX,3122,MET E168D,sensitive,1089,SU11274,4233,19723643,,,
8,Preclinical - Cell culture,"In a preclinical study, Altiratinib (DCC-2701) inhibited MET activity, including MET activating mutations, and inhibited proliferation of MET-driven tumor cell lines in culture (PMID: 26285778).",Actionable,9535,10000003,Advanced Solid Tumor,JAX,2096,MET act mut,sensitive,1656,Altiratinib,4233,26285778,,,
9,Phase I,"In a Phase I clinical trial, Xalkori (crizotinib) was generally well-tolerated and demonstrated preliminary efficacy in patients with non-small cell lung cancer harboring MET exon 14 alterations, with anti-tumor activity demonstrated in 10/15 evaluable patients (J Clin Oncol 34, 2016 (suppl; abstr 108)).",Actionable,6822,3908,non-small cell lung carcinoma,DOID,2096,MET act mut,predicted â€“ sensitive,706,Crizotinib,4233,None,,,
10,Preclinical,"In a preclinical study, Emibetuzumab (LY2875358) treatment inhibited MET activation and proliferation of tumor cells with constitutive MET activation in culture, and inhibited tumor growth in xenograft models (PMID: 25231402).",Actionable,1696,10000003,Advanced Solid Tumor,JAX,2096,MET act mut,sensitive,803,Emibetuzumab,4233,25231402,,,
11,Preclinical - Cell line xenograft,"In a preclinical study, Merestinib (LY2801653) demonstrated anti-tumor activity in cell line xenograft models of glioma with autocrine activation of Met signaling (PMID: 23275061).",Actionable,9980,3070,malignant glioma,DOID,2096,MET act mut,sensitive,1030,LY2801653,4233,23275061,,,
12,Preclinical,"In a preclinical study, Tepotinib (MSC2156119J) inhibited tumor growth in hepatocellular cancer (HCC) mouse xenograft models with MET overexpression or activation (Cancer Res April 15, 2013; 73(8 Supplement): 925)",Actionable,3792,684,hepatocellular carcinoma,DOID,2096,MET act mut,sensitive,1398,MSC2156119J,4233,None,,,
13,Preclinical,"In a preclinical study, BMS-777607 (ASLAN002) demonstrated efficacy in blocking Met phosphorylation and inhibiting cell proliferation and metastasis in cultured cells and murine models with activating Met mutations (PMID: 22286523).",Actionable,1757,1115,sarcoma,DOID,2096,MET act mut,sensitive,687,BMS-777607,4233,22286523,,,
14,Preclinical,"In a preclinical study, cells harboring MET activating mutations demonstrated sensitivity to treatment with Glesatinib (MGCD265) in cell-based assays (AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3609).",Actionable,9538,10000003,Advanced Solid Tumor,JAX,2096,MET act mut,sensitive,809,MGCD265,4233,None,,,
15,Phase II,"In a Phase II trial, treatment with Savolitinib (AZD6094) resulted in an overall response rate (ORR) of 18% (8/44, all partial responses) in the subgroup of patients with MET-driven papillary renal cell carcinoma (PRCC), which included patients with MET kinase domain mutations, compared to an ORR of 0% (0/46) in patients with MET-independent PRCC (PMID: 28644771; NCT02127710).",Actionable,11440,4465,papillary renal cell carcinoma,DOID,2096,MET act mut,predicted â€“ sensitive,2161,Savolitinib,4233,28644771,,,
16,Preclinical - Cell line xenograft,"In a preclinical study, S-49076 inhibited Met activation, resulting in growth inhibition of gastric carcinoma cells harboring MET activating mutations in culture and in cell line xenograft models (PMID: 23804704).",Actionable,1770,5517,stomach carcinoma,DOID,2096,MET act mut,sensitive,2158,S-49076,4233,23804704,,,
17,Preclinical - Cell line xenograft,"In a preclinical study, acquired MET Y1230C and MET Y1230H mutations were associated with secondary resistance to Xalkori (crizotinib) in a MET-over expressing gastric cancer cell line xenograft model, and cells derived from this model demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 21266357).",Actionable,10119,10534,stomach cancer,DOID,27263,MET over exp MET Y1230C MET Y1230H,resistant,706,Crizotinib,4233,21266357,,,
18,Preclinical - Cell line xenograft,"In a preclinical study, MET Y1230H was associated with resistance to PHA-665752 in a gastric cancer cell line with MET over expression in culture (PMID: 21266357).",Actionable,10117,10534,stomach cancer,DOID,27261,MET over exp MET Y1230H,resistant,2162,PHA-665752,4233,21266357,,,
19,Preclinical - Cell culture,"In a preclinical study, a gastric adenocarcinoma cell line (PMID: 15494073) co-harboring MET Y1230H and MET F1200L was sensitive to treatment with Glesatinib (MGCD265), demonstrating cell growth inhibition in culture (PMID: 28765324). ",Actionable,11771,10534,stomach cancer,DOID,28234,MET F1200L MET Y1230H,sensitive,809,MGCD265,4233,28765324,15494073,,
20,Preclinical - Cell culture,"In a preclinical study, a gastric adenocarcinoma cell line (PMID: 15494073) treated with Xalkori (crizotinib) in culture for several months developed resistance and was found to co-harbor MET Y1230H and MET F1200L(PMID: 28765324). ",Actionable,11768,10534,stomach cancer,DOID,28234,MET F1200L MET Y1230H,resistant,706,Crizotinib,4233,28765324,15494073,,
21,Preclinical - Cell culture,"In a preclinical study, a gastric adenocarcinoma cell line (PMID: 15494073) co-harboring MET Y1230H and MET F1200L demonstrated resistance when treated with Capmatinib (INC280) in culture (PMID: 28765324). ",Actionable,11769,10534,stomach cancer,DOID,28234,MET F1200L MET Y1230H,resistant,1065,Capmatinib,4233,28765324,15494073,,
22,Clinical Study,"In a clinical case study, a patient with lung adenocarcinoma harboring MET del exon14 responded to Xalkori (crizotinib), demonstrating a near complete response at 3 months, however, after 9 months progression ensued and a re-biospy identified MET del exon14, MET amplification, MET D1228N, MET Y1230H, MET Y1230S, and MET G1163R (PMID: 28522754). ",Actionable,11740,3910,lung adenocarcinoma,DOID,28219,MET amp MET del exon14 MET D1228N MET G1163R MET Y1230H MET Y1230S,resistant,706,Crizotinib,4233,28522754,,,
23,Clinical Study,"In a clinical case study, a lung adenocarcinoma patient harboring MET del exon14 and MET amplification demonstrated resistance to Xalkori (crizotinib), and the patient was found to have acquired MET Y1230H, MET D1228N, MET Y1230S, and MET G1163R (PMID: 28765324). ",Actionable,11788,3910,lung adenocarcinoma,DOID,28219,MET amp MET del exon14 MET D1228N MET G1163R MET Y1230H MET Y1230S,resistant,706,Crizotinib,4233,28765324,,,
24,Preclinical,"In a preclinical study, Altiratinib (DCC-2701) inhibited activity of MET Y1230H in an in vitro kinase assay (PMID: 26285778).",Actionable,10073,10000003,Advanced Solid Tumor,JAX,26643,MET Y1230H,predicted â€“ sensitive,1656,Altiratinib,4233,26285778,,,
25,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing mouse MET Y1228H (corresponds to MET Y1230H in humans) were resistant to treatment with Savolitinib (AZD6094), demonstrating sustained cell growth in culture (PMID: 28396313). ",Actionable,11732,10000003,Advanced Solid Tumor,JAX,26643,MET Y1230H,predicted â€“ resistant,2161,Savolitinib,4233,28396313,,,
26,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing mouse MET Y1228H (corresponds to Y1230H in humans) were sensitive to treatment with BMS-777607 (ASLAN002), demonstrating inhibition of cell growth in culture (PMID: 28396313). ",Actionable,11734,10000003,Advanced Solid Tumor,JAX,26643,MET Y1230H,predicted â€“ sensitive,687,BMS-777607,4233,28396313,,,
27,Preclinical,"In a preclinical study, transformed cells expressing mouse MET Y1228H (corresponds to MET Y1230H in humans) were sensitive to treatment with Cometriq (Cabometyx, cabozantinib), demonstrating inhibition of cell growth in culture and tumor growth inhibition in mouse models (PMID: 28396313). ",Actionable,11728,10000003,Advanced Solid Tumor,JAX,26643,MET Y1230H,predicted â€“ sensitive,998,cabozantinib,4233,28396313,,,
28,Preclinical,"In a preclinical study, transformed cells expressing mouse MET Y1228H (corresponds to MET Y1230H in humans) were resistant to treatment with Capmatinib (INC280), demonstrating sustained cell growth in culture and minimal tumor growth inhibition in mouse models (PMID: 28396313). ",Actionable,11726,10000003,Advanced Solid Tumor,JAX,26643,MET Y1230H,predicted â€“ resistant,1065,Capmatinib,4233,28396313,,,
29,Preclinical,"In a preclinical study, transformed cells expressing mouse MET Y1228H (corresponds to MET Y1230H in humans) were resistant to treatment with Xalkori (crizotinib) demonstrating sustained cell growth in culture and minimal tumor growth inhibition in mouse models (PMID: 28396313). ",Actionable,11727,10000003,Advanced Solid Tumor,JAX,26643,MET Y1230H,predicted â€“ resistant,706,Crizotinib,4233,28396313,,,
30,Phase III,"In a Phase III trial, addition of Onartuzumab to mFOLFOX6 did not improve clinical outcome compared to mFOLFOX6 alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4012)).",Actionable,8747,4944,gastroesophageal junction adenocarcinoma,DOID,26426,ERBB2 neg MET pos,no benefit,838,Onartuzumab,4233,None,,,
31,Phase III,"In a Phase III trial, addition of Rilotumumab to chemotherapy consisted of epirubicin, cisplatin and capecitabine (ECX) resulted in statistically significantly worse overall survival (9.6 vs 11.5 months) compared to ECX alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4000)).",Actionable,8744,4944,gastroesophageal junction adenocarcinoma,DOID,26426,ERBB2 neg MET pos,no benefit,629,AMG102,4233,None,,,
32,Phase III,"In a Phase III trial, addition of Onartuzumab to the mFOLFOX6 chemotherapy did not improve overall survival (HR=0.82, p=0.24), progression free survival (HR=0.90, p=0.43), or objective response rate (46.1% vs 40.6%) compared to placebo in patients with Erbb2 (Her2)-negative, Met-positive gastroesophageal adenocarcinoma (PMID: 27918764).",Actionable,10904,3717,gastric adenocarcinoma,DOID,26426,ERBB2 neg MET pos,no benefit,5676,Onartuzumab + mFOLFOX6,4233,27918764,,,
33,Phase III,"In a Phase III trial, addition of Onartuzumab to the mFOLFOX6 chemotherapy did not improve overall survival (HR=0.82, p=0.24), progression free survival (HR=0.90, p=0.43), or objective response rate (46.1% vs 40.6%) compared to placebo in patients with Erbb2 (Her2)-negative, Met-positive gastroesophageal adenocarcinoma (PMID: 27918764).",Actionable,10905,4914,esophagus adenocarcinoma,DOID,26426,ERBB2 neg MET pos,no benefit,5676,Onartuzumab + mFOLFOX6,4233,27918764,,,
34,Phase III,"In a Phase III trial, addition of Onartuzumab to mFOLFOX6 did not improve clinical outcome compared to mFOLFOX6 alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4012)).",Actionable,8746,3717,gastric adenocarcinoma,DOID,26426,ERBB2 neg MET pos,no benefit,838,Onartuzumab,4233,None,,,
35,Phase III,"In a Phase III trial, addition of Rilotumumab to chemotherapy consisted of epirubicin, cisplatin and capecitabine (ECX) resulted in statistically significantly worse overall survival (9.6 vs 11.5 months) compared to ECX alone in MET-positive, ERBB2 (HER2)-positive gastric/gastroesophageal junction adenocarcinoma patients (J Clin Oncol 33, 2015 (suppl; abstr 4000)).",Actionable,8745,3717,gastric adenocarcinoma,DOID,26426,ERBB2 neg MET pos,no benefit,629,AMG102,4233,None,,,
36,Preclinical - Cell line xenograft,"In a preclinical study, Cometriq (cabozantinib) inhibited Met activity, cell growth, and invasive cellular characteristics in a human MET positive TNBC cell line in culture, and reduced tumor volume in xenograft models (PMID: 26432786).",Actionable,6225,60081,triple-receptor negative breast cancer,DOID,1240,MET positive,sensitive,998,cabozantinib,4233,26432786,,,
37,Phase I,"In a Phase I trial, Capmatinib (INC280) treatment resulted in partial response in 19% (5/26) of MET-positive non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9067)).",Actionable,7063,3908,non-small cell lung carcinoma,DOID,1240,MET positive,sensitive,1065,Capmatinib,4233,None,,,
38,Phase I,"In a Phase I trial, Emibetuzumab (LY2875358) and Tarceva (erlotinib) combination treatment resulted in durable partial response in 15% (2/13) of Met-positive patients with non-small cell lung carcinoma (J Clin Oncol 31, 2013 (suppl; abstr 8093)).",Actionable,9972,3908,non-small cell lung carcinoma,DOID,1240,MET positive,sensitive,1179,Emibetuzumab + Erlotinib,4233,None,,,
39,Phase I,"In a Phase I trial, Emibetuzumab (LY2875358) and Tarceva (erlotinib) combination treatment resulted in durable partial response in 14.3% (2/14) of patients with non-small cell lung carcinoma, with both responders being Met positive (PMID: 27803065).",Actionable,10639,3908,non-small cell lung carcinoma,DOID,1240,MET positive,sensitive,1179,Emibetuzumab + Erlotinib,4233,27803065,,,
40,Phase I,"In a Phase I trial, INCB028060 demonstrated safety and preliminary efficacy in patients with advanced solid tumors, as indicated by decreased whole blood Met phosphorylation level (J Clin Oncol 29: 2011 (suppl; abstr 3091)).",Actionable,9984,10000003,Advanced Solid Tumor,JAX,1240,MET positive,sensitive,776,INCB028060,4233,None,,,
41,Phase I,"In a Phase I trial, Emibetuzumab (LY2875358) treatment resulted in durable partial response in 4% (1/23) of Met-positive patients with advanced solid tumors (J Clin Oncol 31, 2013 (suppl; abstr 8093)).",Actionable,9971,10000003,Advanced Solid Tumor,JAX,1240,MET positive,sensitive,803,Emibetuzumab,4233,None,,,
42,Phase III,"In a Phase II clinical trial, Onartuzumab (RO5490258), in combination with Tarceva (erlotinib) demonstrated efficacy in patients with Met-positive NSCLC (PMID: 24101053). However, a subsequent Phase III clinical trial has been unable to confirm this efficacy (J Clin Oncol 32:5s, 2014 (suppl; abstr 8000)).",Actionable,1769,3908,non-small cell lung carcinoma,DOID,1240,MET positive,conflicting,1280,Onartuzumab + Erlotinib,4233,24101053,,,
43,Preclinical - Cell line xenograft,"In a preclinical study, Altiratinib (DCC-2701) inhibited MET activation, decreased viability and migration of c-MET positive ovarian cancer cells in culture, and reduced tumor growth in ovarian cancer cell line xenograft models (PMID: 24362531).",Actionable,1644,2394,ovarian cancer,DOID,1240,MET positive,predicted â€“ sensitive,1656,Altiratinib,4233,24362531,,,
44,Phase I,"In a Phase I clinical trial, ABBV-399 was well-tolerated and demonstrated preliminary efficacy in patients with MET-positive non-small cell lung cancer, with 30% (3/10) of patients demonstrating a partial response (J Clin Oncol 34, 2016 (suppl; abstr 2510)).",Actionable,9983,3908,non-small cell lung carcinoma,DOID,1240,MET positive,sensitive,1363,ABBV-399,4233,None,,,
45,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Altiratinib (DCC-2701) and Avastin (bevacizumab) inhibited tumor growth and invasiveness, decreased blood vessel formation, and prolonged survival in cell line xenograft models of MET-expressing glioblastoma (PMID: 26965451).",Actionable,7040,3068,glioblastoma multiforme,DOID,1240,MET positive,sensitive,4353,Altiratinib + Bevacizumab,4233,26965451,,,
46,Phase I,"In a Phase I trial, Ficlatuzumab treatment resulted in stable disease in 57% (12/21) of patients with advanced solid tumors and a decrease in phosphorylated Met in one patient with multiple myeloma (PMID: 24901237).",Actionable,9975,9538,multiple myeloma,DOID,1240,MET positive,predicted â€“ sensitive,740,Ficlatuzumab,4233,24901237,,,
47,Phase II,"In a Phase II trial, higher baseline soluble Met level correlated with longer overall survival in cholangiocarcinoma patients treated with Cometriq (cabozantinib) (PMID: 28192597).",Emerging,10414,4947,cholangiocarcinoma,DOID,1240,MET positive,predicted â€“ sensitive,998,cabozantinib,4233,28192597,,,
48,Preclinical - Cell line xenograft,"In a preclinical study, Altiratinib (DCC-2701) inhibited viability of several MET-expressing glioblastoma cell lines in culture and inhibited tumor growth in cell line xenograft models (PMID: 26965451).",Actionable,7041,3068,glioblastoma multiforme,DOID,1240,MET positive,predicted â€“ sensitive,1656,Altiratinib,4233,26965451,,,
49,Phase I,"In a Phase I trial, ARGX-111 demonstrated safety and resulted in some efficacy in patients with advanced solid tumors expressing MET, including a decrease in circulating tumor cells positive for MET (Journal of Clinical Oncology 33, no. 15_suppl, May 2015, 2580-2580).",Actionable,9969,10000003,Advanced Solid Tumor,JAX,1240,MET positive,sensitive,2157,ARGX-111,4233,None,,,
50,Preclinical,"In a preclinical study, a cell line expressing MET M1268T demonstrated sensitivity to SU11274 treatment (PMID: 15064724).",Actionable,809,162,cancer,DOID,965,MET M1268T,sensitive,1089,SU11274,4233,15064724,,,
51,Preclinical,"In preclinical studies, cell lines transformed by MET M1268T were sensitive to K252a treatment in both culture and mouse model experiments (PMID: 12118367).",Actionable,808,162,cancer,DOID,965,MET M1268T,sensitive,1088,K252a,4233,12118367,,,
52,Preclinical,"In a preclinical study, a cell line expressing MET H1112L demonstrated sensitivity to SU11274 treatment (PMID: 19783361).",Actionable,816,162,cancer,DOID,1126,MET H1112L,sensitive,1089,SU11274,4233,19783361,,,
53,Preclinical,"In a preclinical study, Altiratinib (DCC-2701) inhibited activity of MET Y1230D in an in vitro kinase assay (PMID: 26285778).",Actionable,10078,10000003,Advanced Solid Tumor,JAX,27241,MET Y1230D,predicted â€“ sensitive,1656,Altiratinib,4233,26285778,,,
54,Preclinical,"In a preclinical study, decreasing Brca2 expression via shRNA knockdown did not sensitize triple-receptor negative breast cancer cells with Met over expression to Rubraca (rucaparib) in culture (PMID: 26779812).",Actionable,6151,60081,triple-receptor negative breast cancer,DOID,22730,BRCA2 dec exp MET over exp,no benefit,906,Rucaparib,4233,26779812,,,
55,Preclinical - Cell culture,"In a preclinical study, shRNA knock-down of Tp53 in Met over-expressing gastric carcinoma cells enhanced sensitivity to the combination of EMD 1214063 and radiation in culture (PMID: 26358474).",Actionable,9470,5517,stomach carcinoma,DOID,26857,MET over exp TP53 dec exp,sensitive,5024,EMD 1214063 + Radiotherapy,4233,26358474,,,
56,Preclinical - Cell line xenograft,"In a preclinical study, an acquired MET Y1230C mutation was associated with resistance to PHA-665752 in a MET-over expressing gastric cancer cell line xenograft model, and cells derived from this xenograft model demonstrated sustained MET activation following treatment with PHA-665752 in culture (PMID: 21266357).",Actionable,10118,10534,stomach cancer,DOID,27262,MET over exp MET Y1230C,resistant,2162,PHA-665752,4233,21266357,,,
57,Preclinical - Pdx,"In a preclinical study, the combination of Mekinist (trametinib) and Capmatinib (INC280) induced tumor regression in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).",Actionable,11662,4464,collecting duct carcinoma,DOID,28180,BRAF D594N BRAF G466A EGFR over exp MET over exp,sensitive,6103,INC280 + Trametinib,4233,28783719,,,
58,Preclinical - Pdx,"In a preclinical study, treatment with Mekinist (trametinib) inhibited tumor growth and reduced ERK signaling in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).",Actionable,11661,4464,collecting duct carcinoma,DOID,28180,BRAF D594N BRAF G466A EGFR over exp MET over exp,sensitive,2,Trametinib,4233,28783719,,,
59,Preclinical - Pdx,"In a preclinical study, treatment with Capmatinib (INC280) inhibited tumor growth and reduced ERK signaling in a patient-derived xenograft (PDX) model derived from the ovarian metastasis of a patient with collecting duct carcinoma, which harbored BRAF D594N and BRAF G466A and had high levels of MET and EGFR expression (PMID: 28783719).",Actionable,11660,4464,collecting duct carcinoma,DOID,28180,BRAF D594N BRAF G466A EGFR over exp MET over exp,sensitive,1065,Capmatinib,4233,28783719,,,
60,Preclinical,"In a preclinical study, a human gastric cancer cell line with high levels of MET expression and expressing KRAS G12D was resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 26432108).",Actionable,4082,10534,stomach cancer,DOID,17217,KRAS G12D MET over exp,resistant,706,Crizotinib,4233,26432108,,,
61,Phase I,"In a Phase I trial, Capmatinib (INC280) treatment resulted in partial response in 29% (5/17) of EGFR wild-type, MET over-expressing non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9067)).",Actionable,7065,3908,non-small cell lung carcinoma,DOID,24382,EGFR wild-type MET over exp,sensitive,1065,Capmatinib,4233,None,,,
62,Preclinical,"In a preclinical study, decreasing Brca1 expression via shRNA knockdown did not sensitize triple-receptor negative breast cancer cells with Met over expression to Rubraca (rucaparib) in culture (PMID: 26779812).",Actionable,6150,60081,triple-receptor negative breast cancer,DOID,22729,BRCA1 dec exp MET over exp,no benefit,906,Rucaparib,4233,26779812,,,
63,Preclinical - Cell culture,"In a preclinical study, the addition of JNJ-38877605 to Erbitux (cetuximab) treatment overcame Erbitux (cetuximab) resistance in colorectal cancer cell lines over expressing MET in culture (PMID: 23729478).",Actionable,11352,9256,colorectal cancer,DOID,5392,MET over exp,sensitive,5951,Cetuximab + JNJ 38877605,4233,23729478,,,
64,Preclinical,"In a preclinical study, Xalkori (crizotinib) inhibited growth of a human gastric cancer cell line with high levels of MET expression in culture (PMID: 26432108).",Actionable,4083,10534,stomach cancer,DOID,5392,MET over exp,sensitive,706,Crizotinib,4233,26432108,,,
65,Phase II,"In a Phase II trial, a cholangiocarcinoma patient with high Met expression in tumor stayed on Cometriq (cabozantinib) treatment for 278 days (PMID: 28192597).",Actionable,10413,4947,cholangiocarcinoma,DOID,5392,MET over exp,predicted â€“ sensitive,998,cabozantinib,4233,28192597,,,
66,Preclinical - Cell line xenograft,"In a preclinical study, LY2801653 blocked tumor growth in a gastric cancer cell line xenograft model over expressing Met (PMID: 23275061).  ",Actionable,9536,10534,stomach cancer,DOID,5392,MET over exp,sensitive,1030,LY2801653,4233,23275061,,,
67,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Xalkori (crizotinib) and Rubraca (rucaparib) synergized to inhibit growth of Met-over expressing human triple-receptor negative breast cancer cell lines in culture, and reduced tumor growth in xenograft models (PMID: 26779812).",Actionable,6146,60081,triple-receptor negative breast cancer,DOID,5392,MET over exp,sensitive,4070,Crizotinib + Rucaparib,4233,26779812,,,
68,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Xalkori (crizotinib) and Rubraca (rucaparib) synergized to inhibit growth of a Met-over expressing human lung cancer cell line in culture, and reduced tumor growth in xenograft models (PMID: 26779812).",Actionable,6160,1324,lung cancer,DOID,5392,MET over exp,sensitive,4070,Crizotinib + Rucaparib,4233,26779812,,,
69,Preclinical,"In a preclinical study, Foretinib (GSK1363089) and Rubraca (rucaparib) combination treatment resulted in enhanced growth inhibition in Met-over expressing triple-receptor negative breast cancer cells in culture (PMID: 26779812).",Actionable,6147,60081,triple-receptor negative breast cancer,DOID,5392,MET over exp,sensitive,4071,Foretinib + Rucaparib,4233,26779812,,,
70,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Xalkori (crizotinib) and Rubraca (rucaparib) synergized to inhibit growth of a Met-over expressing human breast cancer cell line in culture, and reduced tumor growth in xenograft models (PMID: 26779812).",Actionable,6159,1612,breast cancer,DOID,5392,MET over exp,sensitive,4070,Crizotinib + Rucaparib,4233,26779812,,,
71,Preclinical - Cell culture,"In a preclinical study, EMD 1214063 inhibited Met phosphorylation and cell viability of Met over-expressing gasric carcinoma cell lines in culture, regardless of their TP53 status (PMID: 26358474).",Actionable,9468,5517,stomach carcinoma,DOID,5392,MET over exp,sensitive,726,EMD 1214063,4233,26358474,,,
72,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited growth of small cell lung carcinoma lines over-expressing MET (PMID: 25122427).",Actionable,2987,5409,lung small cell carcinoma,DOID,5392,MET over exp,sensitive,877,Ponatinib,4233,25122427,,,
73,Preclinical - Cell line xenograft,"In a preclinical study, Altiratinib (DCC-2701) inhibited Met phosphorylation and viability of several Met over expressing glioblastoma cell lines in culture and inhibited tumor growth in cell line xenograft models (PMID: 26965451).",Actionable,7039,3068,glioblastoma multiforme,DOID,5392,MET over exp,predicted â€“ sensitive,1656,Altiratinib,4233,26965451,,,
74,Preclinical - Cell culture,"In a preclinical study, treatment with ABBV-399 resulted in complete response in a MET-over expressing papillary lung adenocarcinoma cell line xenograft model (PMID: 27573171).",Actionable,9978,5588,lung papillary adenocarcinoma,DOID,5392,MET over exp,sensitive,1363,ABBV-399,4233,27573171,,,
75,Preclinical - Cell culture,"In a preclinical study, EMD 1214063 inhibited Met phosphorylation and cell viability of Met over-expressing lung squamous cell carcinoma cells in culture (PMID: 26358474).",Actionable,9469,3907,lung squamous cell carcinoma,DOID,5392,MET over exp,sensitive,726,EMD 1214063,4233,26358474,,,
76,Phase I,"In a Phase I trial, the combination of ABBV-399 and Tarceva (erlotinib) resulted in a partial response in 31% (4/13) of non-small cell lung carcinoma patients and disease control at 12 weeks in 61.5% (8/13) of patients (J Clin Oncol 35, 2017 (suppl; abstr 2509)). ",Actionable,11070,3908,non-small cell lung carcinoma,DOID,5392,MET over exp,sensitive,1364,ABBV-399 + Erlotinib,4233,None,,,
77,Preclinical - Cell culture,"In a preclinical study, the addition of JNJ-38877605 to Vectibix (panitumumab) treatment overcame Vectibix (panitumumab) resistance in colorectal cancer cell lines over expressing MET in culture (PMID: 23729478).",Actionable,11353,9256,colorectal cancer,DOID,5392,MET over exp,sensitive,5952,JNJ 38877605 + Panitumumab,4233,23729478,,,
78,Preclinical - Pdx,"In a preclinical study, Tepotinib (MSC2156119J) treatment resulted in tumor regression in patient-derived xenograft models of hepatocellular cancer with high Met expression level (PMID: 25256830).",Actionable,869,684,hepatocellular carcinoma,DOID,5392,MET over exp,sensitive,1398,MSC2156119J,4233,25256830,,,
79,Preclinical - Cell line xenograft,"In a preclinical study, Merestinib (LY2801653) demonstrated anti-tumor activity in cell line xenograft models of lung adenocarcinoma with Met over expression (PMID: 23275061).",Actionable,9981,3910,lung adenocarcinoma,DOID,5392,MET over exp,sensitive,1030,LY2801653,4233,23275061,,,
80,Preclinical - Cell culture,"In a preclinical study, over expression of MET conferred resistance to Erbitux (cetuximab) in colorectal cancer cell lines in culture (PMID: 23729478).",Actionable,11347,9256,colorectal cancer,DOID,5392,MET over exp,resistant,694,Cetuximab,4233,23729478,,,
81,Preclinical - Pdx,"In a preclinical study, ABBV-399 demonstrated efficacy in MET-expressing lung adenocarcinoma patient-derived xenograft (PDX) models, with the PDX model with higher MET expression levels showing improved tumor growth delay (PMID: 27573171).",Actionable,9982,3910,lung adenocarcinoma,DOID,5392,MET over exp,predicted â€“ sensitive,1363,ABBV-399,4233,27573171,,,
82,Preclinical,"In a preclinical study, XL147 inhibited migration and growth of mouse melanoma cells with MET over expression in culture (PMID: 25637314).",Actionable,6303,1909,melanoma,DOID,5392,MET over exp,sensitive,1050,XL147,4233,25637314,,,
83,Preclinical,"In a preclinical study, KRC-00509 induced cell-cycle arrest and inhibited growth of Met-over expressing gastric cancer cell lines in culture, and did not inhibit growth of cell lines with low Met expression (PMID: 26801760).",Actionable,5500,10534,stomach cancer,DOID,5392,MET over exp,sensitive,3872,KRC-00509,4233,26801760,,,
84,Preclinical,"In a preclinical study, triple-receptor negative breast cancer cell lines over expressing Met demonstrated decreased sensitivity to Rubraca (rucaparib) induced growth and colony formation inhibition in culture (PMID: 26779812).",Actionable,6145,60081,triple-receptor negative breast cancer,DOID,5392,MET over exp,decreased response,906,Rucaparib,4233,26779812,,,
85,Preclinical - Cell line xenograft,"In a preclinical study, Foretinib (GSK1363089) and Veliparib (ABT-888) worked synergistically to inhibit growth of Met-over expressing triple-receptor negative breast cancer cells in culture, and reduced tumor growth in xenograft models (PMID: 26779812).",Actionable,6158,60081,triple-receptor negative breast cancer,DOID,5392,MET over exp,sensitive,4072,Foretinib + Veliparib,4233,26779812,,,
86,Preclinical - Cell culture,"In a preclinical study, ABBV-399 inhibited growth of MET over expressing non-small cell lung cancer cell lines in culture (PMID: 27573171).",Actionable,10001,3908,non-small cell lung carcinoma,DOID,5392,MET over exp,sensitive,1363,ABBV-399,4233,27573171,,,
87,Phase I,"In a Phase I trial, ABBV-399 resulted in a partial response in 19% (3/16) of patients with non-small cell lung carcinoma while 37.5% (6/16) of patients experienced disease control at 12 weeks (J Clin Oncol 35, 2017 (suppl; abstr 2509)). ",Actionable,11069,3908,non-small cell lung carcinoma,DOID,5392,MET over exp,sensitive,1363,ABBV-399,4233,None,,,
88,Preclinical,"In a preclinical study, KRC-00715 induced cell-cycle arrest and inhibited growth of Met-over expressing gastric cancer cell lines in culture and in xenograft models, and did not inhibit growth of cell lines with low Met expression (PMID: 26801760).",Actionable,5498,10534,stomach cancer,DOID,5392,MET over exp,sensitive,3871,KRC-00715,4233,26801760,,,
89,Preclinical - Cell culture,"In a preclinical study, over expression of MET conferred resistance to Vectibix (panitumumab) in colorectal cancer cell lines in culture (PMID: 23729478).",Actionable,11348,9256,colorectal cancer,DOID,5392,MET over exp,resistant,845,Panitumumab,4233,23729478,,,
90,Preclinical - Cell culture,"In a preclinical study, Altiratinib (DCC-2701) inhibited Met phosphorylation and proliferation of a non-small cell lung cancer cell line with MET amplification and overexpression in culture (PMID: 26285778).",Actionable,10063,3908,non-small cell lung carcinoma,DOID,1066,MET amp over exp,sensitive,1656,Altiratinib,4233,26285778,,,
91,Preclinical - Cell line xenograft,"In a preclinical study, Altiratinib (DCC-0701) inhibited Met phosphorylation and proliferation of a gastric cancer cell line with MET amplification and over expression in culture, and inhibited tumor growth and induced tumor regression in xenograft models (PMID: 26285778).",Actionable,10067,10534,stomach cancer,DOID,1066,MET amp over exp,sensitive,1656,Altiratinib,4233,26285778,,,
92,Preclinical,"In preclinical studies, a MET amplified, gastric carcinoma cell over expressing Met was sensitive to K252a treatment in both culture and mouse model experiments (PMID: 12118367).",Actionable,799,5517,stomach carcinoma,DOID,1066,MET amp over exp,sensitive,1088,K252a,4233,12118367,,,
93,Preclinical,"In a preclinical study, a cell line expressing MET H1112Y demonstrated sensitivity to SU11274 treatment (PMID: 19783361).",Actionable,810,162,cancer,DOID,1120,MET H1112Y,sensitive,1089,SU11274,4233,15064724,,,
94,Preclinical,"In a preclinical study, a cell line expressing MET Y1248H showed resistance to SU11274 treatment (PMID: 15064724).",Actionable,812,162,cancer,DOID,1122,MET Y1248H,resistant,1089,SU11274,4233,15064724,,,
95,Preclinical,"In a preclinical study, a cell line expressing MET L1213V showed resistance to SU11274 treatment (PMID: 15064724).",Actionable,811,162,cancer,DOID,1121,MET L1213V,resistant,1089,SU11274,4233,15064724,,,
96,Preclinical,"In a preclinical study, MET T1010I showed sensitivity to Xalkori (crizotinib) in cell culture (PMID: 17483355).",Actionable,878,10000003,Advanced Solid Tumor,JAX,1408,MET T1010I,sensitive,706,Crizotinib,4233,17483355,,,
97,Preclinical,"In a preclinical study, Altiratinib (DCC-2701) inhibited activity of MET D1228H in an in vitro kinase assay (PMID: 26285778).",Actionable,10071,10000003,Advanced Solid Tumor,JAX,26646,MET D1228H,predicted â€“ sensitive,1656,Altiratinib,4233,26285778,,,
98,Preclinical,"In a preclinical study, a cell line expressing MET V1238I demonstrated sensitivity to SU11274 treatment (PMID: 19783361).",Actionable,814,162,cancer,DOID,1124,MET V1238I,sensitive,1089,SU11274,4233,19783361,,,
99,Preclinical,"In a preclinical study, Cometriq (cabozantinib) treatment had no effect on the cellular outgrowth or tumor volume of a TNBC cell line negative for MET expression in culture (PMID: 26432786). ",Actionable,6226,60081,triple-receptor negative breast cancer,DOID,22988,MET negative,no benefit,998,cabozantinib,4233,26432786,,,
100,Clinical Study,"In a clinical case study, a patient with ovarian cancer harboring MET N375S demonstrated sensitivity to the combination treatment, Nexavar (sorafenib) and Avastin (bevacizumab), resulting in stable disease for greater than six months (PMID: 25363205). ",Actionable,7769,4001,ovarian carcinoma,DOID,3165,MET N375S,sensitive,4517,Bevacizumab + Sorafenib,4233,25363205,,,
101,Clinical Study,"In a clinical study, a patient with oral cavity cancer harboring MET N375S demonstrated progressive disease and overall survival of five weeks when treated with Xalkori (crizotinib) (PMID: 28514312). ",Actionable,11049,8618,oral cavity cancer,DOID,3165,MET N375S,no benefit,706,Crizotinib,4233,28514312,,,
102,Preclinical,"In a preclinical study, cells expressing MET N375S had decreased sensitivity to SU11274 in culture compared to cells expressing wild-type MET (PMID: 19723643).",Actionable,2622,10000003,Advanced Solid Tumor,JAX,3165,MET N375S,decreased response,1089,SU11274,4233,19723643,,,
103,Phase I,"In a Phase I trial, Capmatinib (INC280) treatment resulted in partial response in 100% (2/2) of non-small cell lung carcinoma patients harboring MET exon 14 mutations (J Clin Oncol 34, 2016 (suppl; abstr 9067)).",Actionable,7064,3908,non-small cell lung carcinoma,DOID,24383,MET exon 14,sensitive,1065,Capmatinib,4233,None,,,
104,Preclinical - Cell line xenograft,"In a preclinical study, transformed cells expressing MET del exon14 and MET Y1230C were sensitive to Glesatinib (MGCD265) treatment, demonstrating cell growth inhibition in culture and 52% tumor regression in xenograft models (PMID: 28765324).",Actionable,11781,10000003,Advanced Solid Tumor,JAX,28240,MET del exon14 MET Y1230C,sensitive,809,MGCD265,4233,28765324,,,
105,Preclinical - Cell culture,"In a preclinical study, a Capmatinib (INC280)-resistant gastric cancer cell line (PMID: 15494073) harboring MET Y1230C also demonstrated resistance when treated with Xalkori (crizotinib) (PMID: 28765324). ",Actionable,11761,10534,stomach cancer,DOID,26644,MET Y1230C,resistant,706,Crizotinib,4233,28765324,15494073,,
106,Preclinical - Cell line xenograft,"In a preclinical study, a transformed cell line expressing MET Y1230C was sensitive to Glesatinib (MGCD265), demonstrating inhibition of cell growth in culture and 88% tumor regression in xenograft models (PMID: 28765324). ",Actionable,11785,10000003,Advanced Solid Tumor,JAX,26644,MET Y1230C,sensitive,809,MGCD265,4233,28765324,,,
107,Preclinical,"In a preclinical study, Altiratinib (DCC-2701) inhibited activity of MET Y1230C in an in vitro kinase assay (PMID: 26285778).",Actionable,10080,10000003,Advanced Solid Tumor,JAX,26644,MET Y1230C,predicted â€“ sensitive,1656,Altiratinib,4233,26285778,,,
108,Preclinical - Cell culture,"In a preclinical study, a gastric adenocarcinoma cell line (PMID: 15494073) treated with Capmatinib (INC280) in culture for several months developed resistance and was found to harbor MET Y1230C (PMID: 28765324). ",Actionable,11760,10534,stomach cancer,DOID,26644,MET Y1230C,resistant,1065,Capmatinib,4233,28765324,15494073,,
109,Preclinical - Cell culture,"In a preclinical study, Merestinib (LY2801653) inhibited growth of transformed cells over expressing MET Y1230C in culture (PMID: 23275061).",Actionable,9976,10000003,Advanced Solid Tumor,JAX,26644,MET Y1230C,sensitive,1030,LY2801653,4233,23275061,,,
110,Preclinical - Cell culture,"In a preclinical study, a gastric adenocarcinoma cell line (PMID: 15494073) harboring MET Y1230C was sensitive to treatment with Glesatinib (MGCD265), demonstrating cell growth inhibition in culture (PMID: 28765324). ",Actionable,11770,10534,stomach cancer,DOID,26644,MET Y1230C,sensitive,809,MGCD265,4233,28765324,15494073,,
111,Clinical Study,"In a clinical case study, a patient with a MET amplified esophageal carcinoma that initially responded to AMG 337, developed resistance upon emergence of KRAS G12D (PMID: 26432108). ",Actionable,4081,1107,esophageal carcinoma,DOID,17216,KRAS G12D MET amp,resistant,1064,AMG 337,4233,26432108,,,
112,Preclinical - Pdx,"In a preclinical study, the combination of Rociletinib (CO-1686) and Xalkori (crizotinib) overcame resistance to Rociletinib (CO-1686) in a patient-derived xenograft model of non-small cell lung cancer harboring EGFR L858R and MET amplification, resulting in tumor growth inhibition (PMID: 27283993).",Actionable,9249,3908,non-small cell lung carcinoma,DOID,26799,EGFR L858R MET amp,sensitive,4962,CO1686 + Crizotinib,4233,27283993,,,
113,Preclinical,"In a preclinical study, Xalkori (crizotinib) treatment resulted in complete tumor regression in transplant models of TP53-null-luminal breast cancer harboring MET amplification (PMID: 27149990).",Actionable,11535,1612,breast cancer,DOID,28118,MET amp TP53 del,sensitive,706,Crizotinib,4233,27149990,,,
114,Preclinical - Cell line xenograft,"In a preclinical study, JNJ-61186372 inhibited tumor growth in Tarceva (erlotinib)-resistant non-small cell lung cancer cell line xenograft models harboring an EGFR exon 19 deletion and MET amplification (PMID: 27216193).",Actionable,7503,3908,non-small cell lung carcinoma,DOID,25627,EGFR exon 19 del MET amp,sensitive,4491,JNJ-61186372,4233,27216193,,,
115,Clinical Study,"In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification demonstrated a near complete response when treated with the combination of Savolitinib (AZD6094) and Tagrisso (osimertinib), however, after 36 weeks presented with progression (PMID: 27694386).",Actionable,9533,3910,lung adenocarcinoma,DOID,25627,EGFR exon 19 del MET amp,sensitive,2224,Osimertinib + Savolitinib,4233,27694386,,,
116,Clinical Study,"In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification was resistant to Gilotrif (afatinib) (PMID: 27694386). ",Actionable,9531,3910,lung adenocarcinoma,DOID,25627,EGFR exon 19 del MET amp,sensitive,623,Afatinib,4233,27694386,,,
117,Clinical Study,"In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification was resistant to Tarceva (erlotinib) (PMID: 27694386). ",Actionable,9532,3910,lung adenocarcinoma,DOID,25627,EGFR exon 19 del MET amp,resistant,4,Erlotinib,4233,27694386,,,
118,Preclinical - Pdx,"In a preclinical study, Xalkori (crizotinib) inhibited tumor grow in patient-derived xenograft models of MET amplified liver cancer (PMID: 26483207).",Actionable,9179,3571,liver cancer,DOID,1629,MET amp,sensitive,706,Crizotinib,4233,26483207,,,
119,Preclinical,"In a preclinical study, Emibetuzumab (LY2875358) treatment inhibited MET activation and proliferation of tumor cells with MET amplification in culture, and inhibited growth in MET-amplified tumor xenograft models (PMID: 25231402). ",Actionable,1650,10000003,Advanced Solid Tumor,JAX,1629,MET amp,sensitive,803,Emibetuzumab,4233,25231402,,,
120,Preclinical - Pdx,"In a preclinical study, Xalkori (crizotinib) inhibited tumor grow in patient-derived xenograft models of MET amplified non-small cell lung cancer (PMID: 26483207).",Actionable,9178,3908,non-small cell lung carcinoma,DOID,1629,MET amp,sensitive,706,Crizotinib,4233,26483207,,,
121,Preclinical - Pdx & cell culture,"In a preclinical study, AMG 337 inhibited Met phosphorylation and growth of hepatocellular carcinoma (HCC) cell lines with MET amplification in culture, and inhibited tumor growth in MET-amplified HCC patient-derived xenograft models (PMID: 27196749).",Actionable,6929,684,hepatocellular carcinoma,DOID,1629,MET amp,sensitive,1064,AMG 337,4233,27196749,,,
122,Preclinical,"In a preclinical study, Selumetinib (AZD6244) suppressed the growth of an Iressa (gefitinib)-resistant NSCLC cell line with MET amplification (PMID: 24939055).",Actionable,981,3908,non-small cell lung carcinoma,DOID,1629,MET amp,sensitive,913,Selumetinib,4233,24939055,,,
123,Preclinical - Cell line xenograft,"In a preclinical study, AMG 337 inhibited growth of gastric cancer cell lines in culture, and inhibited growth and induced regression of tumors in MET-amplified gastric cancer cell line xenograft models (PMID: 27196782).",Actionable,9027,10534,stomach cancer,DOID,1629,MET amp,sensitive,1064,AMG 337,4233,27196782,,,
124,Preclinical - Cell culture,"In a preclinical study, SGX523 inhibited survival of MET-amplified non-small cell lung cancer cells in culture (PMID: 26483207).",Actionable,9172,3908,non-small cell lung carcinoma,DOID,1629,MET amp,sensitive,916,SGX523,4233,26483207,,,
125,Preclinical - Cell line xenograft,"In a preclinical study, Golvatinib (E7050) inhibited Met and Kdr (Vegfr2) phosphorylation, resulted in growth inhibition of lung cancer cells in culture and tumor regression in cell line xenograft models (PMID: 19832844).",Actionable,10757,1324,lung cancer,DOID,1629,MET amp,sensitive,1019,Golvatinib,4233,19832844,,,
126,Clinical Study,"In a clinical case study, a patient with MET amplified esophageal adenocarcinoma had a partial response to AMG 337 therapy after 2 months of treatment (PMID: 26432108).",Actionable,4100,4914,esophagus adenocarcinoma,DOID,1629,MET amp,sensitive,1064,AMG 337,4233,26432108,,,
127,Clinical Study,"In a retrospective study, advanced solid tumor patients harboring MET amplification only achieved stable disease in 29% (2/7) of the population, while MET-nonamplified patients achieved partial response in 10% (14/134) and stable disease in 36% (48/134) of the population, when treated with Met inhibitors including AMG 337 and EMD 1204831 (PMID: 25326232).",Actionable,5557,10000003,Advanced Solid Tumor,JAX,1629,MET amp,decreased response,1064,AMG 337,4233,25326232,,,
128,Preclinical - Cell line xenograft,"In a preclinical study, M-COPA reduced Met cell surface expression and downstream signaling and decreased growth of MET-amplified gastric cancer cell lines in culture, and demonstrated antitumor activity in MET-amplified gastric cancer cell line xenograft models (PMID: 27197184).",Actionable,7604,10534,stomach cancer,DOID,1629,MET amp,sensitive,4522,M-COPA,4233,27197184,,,
129,Phase I,"In a Phase I trial, a gastric cancer patient harboring MET amplification was sensitive to treatment with ARGX-111, demonstrating stable disease, a metabolic response, and a decrease in circulating tumor cells (Journal of Clinical Oncology 33, no. 15_suppl (May 2015) 2580-2580).",Actionable,9970,10534,stomach cancer,DOID,1629,MET amp,sensitive,2157,ARGX-111,4233,None,,,
130,Preclinical,"In a preclinical study, BEZ235 suppressed the growth of an Iressa (gefitinib)-resistant NSCLC cell line with MET amplification (PMID: 24939055).",Actionable,985,3908,non-small cell lung carcinoma,DOID,1629,MET amp,sensitive,672,BEZ235,4233,24939055,,,
131,Clinical Study,"In clinical case studies, patients with MET amplified esophageal cancer responded to AMG 337 therapy (PMID: 26432108).",Actionable,4080,5041,esophageal cancer,DOID,1629,MET amp,sensitive,1064,AMG 337,4233,26432108,,,
132,Phase I,"In a Phase I study, Tepotinib (MSC2156119J) demonstrated safety and preliminary efficacy in advanced solid tumor patients with MET amplification (JCO, Vol 33, No 15_suppl (May 20 Supplement), 2015: 2591).",Actionable,3178,10000003,Advanced Solid Tumor,JAX,1629,MET amp,sensitive,1398,MSC2156119J,4233,None,,,
133,Clinical Study,"In a retrospective study, advanced solid tumor patients harboring MET amplification demonstrated worse overall survival (7.23 months) comparing to patients without MET amplification (8.62 months) (PMID: 25326232), suggesting that this may serve as a future prognostic biomarker.",Emerging,5555,10000003,Advanced Solid Tumor,JAX,1629,MET amp,not applicable,1776,N/A,4233,25326232,,,
134,Preclinical - Cell line xenograft,"In a preclinical study, EMD 1214063 induced tumor regression in mouse cell line xenograft models of gastric carcinoma harboring MET amplification (PMID: 23553846).",Actionable,7727,5517,stomach carcinoma,DOID,1629,MET amp,sensitive,726,EMD 1214063,4233,23553846,,,
135,Preclinical - Cell line xenograft,"In a preclinical study, disruption of multiple kinases with Hsp90 inhibitor Alvespimycin inhibited survival of MET amplified non-small cell lung cancer cells that acquired resistance to SGX532 through activation of multiple kinase signaling pathways in culture and in cell line xenograft models (PMID: 26483207).",Actionable,9176,3908,non-small cell lung carcinoma,DOID,1629,MET amp,predicted â€“ sensitive,627,Alvespimycin,4233,26483207,,,
136,Preclinical - Cell line xenograft,"In a preclinical study, SGX523 inhibited Met signaling and proliferation of MET amplified gastric cancer cells in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 19934279).",Actionable,9171,10534,stomach cancer,DOID,1629,MET amp,sensitive,916,SGX523,4233,19934279,,,
137,Preclinical - Cell line xenograft,"In a preclinical study, ABBV-399 inhibited growth of MET-amplified gastric cancer cell in culture, and induced tumor regression in a MET-amplified gastric cancer cell line xenograft model (PMID: 27573171).",Actionable,9979,10534,stomach cancer,DOID,1629,MET amp,sensitive,1363,ABBV-399,4233,27573171,,,
138,Preclinical - Cell line xenograft,"In a preclinical study, Golvatinib (E7050) inhibited Met and Kdr (Vegfr2) phosphorylation, resulted in growth inhibition of gastric cancer cell lines in culture and in cell line xenograft models (PMID: 19832844).",Actionable,10756,10534,stomach cancer,DOID,1629,MET amp,sensitive,1019,Golvatinib,4233,19832844,,,
139,Preclinical - Cell culture,"In a preclinical study, KTN0073-IgG2 inhibited MET phosphorylation and induced MET degradation, and inhibited proliferation of a MET-amplified non-small cell lung cancer cell line in culture (PMID: 27550450).",Actionable,8712,3908,non-small cell lung carcinoma,DOID,1629,MET amp,sensitive,4799,KTN0073-IgG2,4233,27550450,,,
140,Preclinical - Cell culture,"In a preclinical study, the multitarget kinase inhibitor Sprycel (dasatinib) inhibited survival of MET amplified non-small cell lung cancer cells that acquired resistance to SGX532 through activation of multiple kinase signaling pathways in culture (PMID: 26483207).",Actionable,9173,3908,non-small cell lung carcinoma,DOID,1629,MET amp,predicted â€“ sensitive,717,Dasatinib,4233,26483207,,,
141,Preclinical - Cell culture,"In a preclinical study, the multitarget kinase inhibitor PP-121 inhibited survival of MET amplified non-small cell lung cancer cells that acquired resistance to SGX532 through activation of multiple kinase signaling pathways in culture (PMID: 26483207).",Actionable,9174,3908,non-small cell lung carcinoma,DOID,1629,MET amp,predicted â€“ sensitive,2251,PP-121,4233,26483207,,,
142,Clinical Study,"In a clinical study, MET amplification was associated with resistance to Erbitux (cetuximab) in 2 colorectal cancer patients, and in patient-derived xenograft (PDX) models (PMID: 23729478).",Actionable,11344,9256,colorectal cancer,DOID,1629,MET amp,resistant,694,Cetuximab,4233,23729478,,,
143,Preclinical - Cell line xenograft,"In a preclinical study, Debio 1347 did not inhibit tumor growth in cell line xenograft models of MET amplified gastric cancer (PMID: 26438159).",Actionable,8495,10534,stomach cancer,DOID,1629,MET amp,no benefit,1014,FF-284,4233,26438159,,,
144,Preclinical - Cell culture,"In a preclinical study, SAR125844 inhibited Met signaling, leading to growth inhibition of MET amplified lung cancer cells in culture (PMID: 25504634).",Actionable,7731,1324,lung cancer,DOID,1629,MET amp,sensitive,2159,SAR125844,4233,25504634,,,
145,Phase I,"In a Phase I clinical trial, SAR125844 demonstrated safety and preliminary evidence of efficacy in patients with advanced solid tumors, including one patient with Met amplified lung adenocarcinoma (J Clin Oncol 32:5s, 2014 (suppl; abstr 2506)).",Actionable,1774,10000003,Advanced Solid Tumor,JAX,1629,MET amp,predicted â€“ sensitive,2159,SAR125844,4233,None,,,
146,Preclinical - Cell line xenograft,"In a preclinical study, KTN0073-IgG2 inhibited MET phosphorylation and induced MET degradation, and inhibited growth of a MET-amplified gastric cancer cell line in culture and in xenograft models (PMID: 27550450).",Actionable,8708,10534,stomach cancer,DOID,1629,MET amp,sensitive,4799,KTN0073-IgG2,4233,27550450,,,
147,Preclinical - Cell line xenograft,"In a preclinical study, Selumetinib (AZD6244) in combination with BEZ235, synergistically inhibited proliferation of an Iressa (gefitinib)-resistant NSCLC cell line harboring MET amplification in culture and in cell line xenograft models (PMID: 24939055).",Actionable,988,3908,non-small cell lung carcinoma,DOID,1629,MET amp,sensitive,1420,Selumetinib + BEZ235,4233,24939055,,,
148,Preclinical,"In a preclinical study, TAE226 treatment inhibited proliferation of gastric cancer cell lines harboring MET amplification in culture (PMID: 26090892).",Actionable,3937,10534,stomach cancer,DOID,1629,MET amp,sensitive,2086,TAE226,4233,26090892,,,
149,Preclinical,"In a preclinical study, MET amplified gastric cancer cell lines were sensitive to TAS-115, resulting in suppression of cell proliferation in culture (PMID: 24140932). ",Actionable,5898,10534,stomach cancer,DOID,1629,MET amp,sensitive,3976,TAS-115,4233,24140932,,,
150,Preclinical - Cell line xenograft,"In a preclinical study, SAR125844 inhibited Met signaling leading to growth inhibition of MET amplified gastric cancer cell lines  in culture and in xenograft models (PMID: 25504634).",Actionable,1773,10534,stomach cancer,DOID,1629,MET amp,sensitive,2159,SAR125844,4233,25504634,,,
151,Phase I,"In a Phase I trial, INC280 displayed safety and preliminary efficacy in patients with MET dependent solid tumors (J Clin Oncol 32:5s, 2014 (suppl; abstr 2520)).",Actionable,1634,10000003,Advanced Solid Tumor,JAX,1629,MET amp,predicted â€“ sensitive,1065,Capmatinib,4233,None,,,
152,Preclinical - Cell culture,"In a preclinical study, AMG 337 inhibited growth of MET-amplified lung cancer cell lines in culture (PMID: 27196782).",Actionable,9028,1324,lung cancer,DOID,1629,MET amp,sensitive,1064,AMG 337,4233,27196782,,,
153,Clinical Study,"In a retrospective study, advanced solid tumor patients harboring MET amplification only achieved stable disease in 29% (2/7) of the population, while MET-nonamplified patients achieved partial response in 10% (14/134) and stable disease in 36% (48/134) of the population, when treated with Met inhibitors including AMG 337 and EMD 1204831 (PMID: 25326232).",Actionable,5558,10000003,Advanced Solid Tumor,JAX,1629,MET amp,decreased response,725,EMD 1204831,4233,25326232,,,
154,Phase I,"In a Phase I trial, Capmatinib (INC280) treatment resulted in partial response in 63% (5/8) of MET amplified non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9067)).",Actionable,7066,3908,non-small cell lung carcinoma,DOID,1629,MET amp,sensitive,1065,Capmatinib,4233,None,,,
155,Preclinical - Pdx,"In a preclinical study, JNJ-38877605 inhibited tumor growth in colorectal cancer patient-derived xenograft models with MET amplification (PMID: 23729478).",Actionable,11345,9256,colorectal cancer,DOID,1629,MET amp,sensitive,783,JNJ 38877605,4233,23729478,,,
156,Phase II,"In a Phase II trial, treatment with Savolitinib (AZD6094) resulted in an overall response rate (ORR) of 18% (8/44, all partial responses) in the subgroup of patients with MET-driven papillary renal cell carcinoma (PRCC), which included patients with MET amplification, compared to an ORR of 0% (0/46) in patients with MET-independent PRCC (PMID: 28644771; NCT02127710).",Actionable,11441,4465,papillary renal cell carcinoma,DOID,1629,MET amp,sensitive,2161,Savolitinib,4233,28644771,,,
157,Preclinical - Pdx,"In a preclinical study, Savolitinib (AZD6094) demonstrated antitumor activity in patient-derived papillary renal cell carcinoma xenograft models harboring MET amplification (PMID: 25779944). ",Actionable,2460,4465,papillary renal cell carcinoma,DOID,1629,MET amp,sensitive,2161,Savolitinib,4233,25779944,,,
158,Phase I,"In a Phase I trial, ABT-700 demonstrated safety and preliminary efficacy in patients with MET-amplified advanced solid tumors, including a patient with ovarian cancer (J Clin Oncol 32:5s, 2014 (suppl; abstr 2507)).",Actionable,1698,10000003,Advanced Solid Tumor,JAX,1629,MET amp,sensitive,1063,ABT-700,4233,None,,,
159,Preclinical - Cell culture,"In a preclinical study, disruption of multiple kinases with Hsp90 inhibitor Ganetespib inhibited survival of MET amplified non-small cell lung cancer cells that acquired resistance to SGX532 through activation of multiple kinase signaling pathways in culture (PMID: 26483207).",Actionable,9175,3908,non-small cell lung carcinoma,DOID,1629,MET amp,predicted â€“ sensitive,745,Ganetespib,4233,26483207,,,
160,Preclinical - Cell line xenograft,"In a preclinical study, EMD 1214063 induced tumor regression in mouse cell line xenograft models of non-small cell lung carcinoma harboring MET amplification (PMID: 23553846).",Actionable,7728,3908,non-small cell lung carcinoma,DOID,1629,MET amp,sensitive,726,EMD 1214063,4233,23553846,,,
161,Preclinical - Pdx & cell culture,"In a preclinical study, Sym015 inhibited growth of cancer cell lines with MET amplification in culture, and inhibited tumor growth in MET-amplified patient-derived xenograft (PDX) models (Cancer Res July 15 2016 (76) (14 Supplement) 1219).",Actionable,9967,10000003,Advanced Solid Tumor,JAX,1629,MET amp,sensitive,4322,SYM015,4233,None,,,
162,Preclinical,"In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring MET amplification in culture (PMID: 26090892).",Actionable,3936,3908,non-small cell lung carcinoma,DOID,1629,MET amp,sensitive,2086,TAE226,4233,26090892,,,
163,Preclinical - Pdx,"In a preclinical study, treatment with Gilotrif (afatinib) did not demonstrate benefit in patient-derived xenograft (PDX) models derived from the brain metastasis of a lung adenocarcinoma patient with EGFR E746_A750del (referred to as K745_A750delinsK) and high level MET amplification, with all treated mice demonstrating progression (PMID: 28961841).",Actionable,12157,3910,lung adenocarcinoma,DOID,26798,EGFR E746_A750del MET amp,no benefit,623,Afatinib,4233,28961841,,,
164,Preclinical - Cell line xenograft,"In a preclinical study, the addition of NPS-1034 to treatment with Iressa (gefitinib) overcame Iressa (gefitinib) resistance in a cell line xenograft model of non-small cell lung cancer reported to harbor EGFR E746_A750del (PMID: 23542356), which has acquired resistance to Iressa (gefitinib) due to MET amplification and over expression, resulting in tumor growth inhibition (PMID: 24165158).",Actionable,9655,3908,non-small cell lung carcinoma,DOID,26798,EGFR E746_A750del MET amp,sensitive,5116,Gefitinib + NPS-1034,4233,24165158,23542356,,
165,Preclinical - Pdx,"In a preclinical study, treatment with Capmatinib (INC280) resulted in improved survival in patient-derived xenograft (PDX) models derived from the brain metastasis of a lung adenocarcinoma patient with EGFR E746_A750del (referred to as K745_A750delinsK) and high level MET amplification (PMID: 28961841).",Actionable,12148,3910,lung adenocarcinoma,DOID,26798,EGFR E746_A750del MET amp,sensitive,1065,Capmatinib,4233,28961841,,,
166,Clinical Study,"In a clinical case study, a patient with metastatic lung adenocarcinoma harboring EGFR E746_A750del (referred to as K745_A750delinsK) and T790M demonstrated an initial response, but subsequent progression, of the brain metastasis following Tagrisso (osimertinib) treatment, and analysis of the brain metastasis showed loss of EGFR T790M as well as acquisition of high-level MET amplification, and resistance to Tagrisso (osimertinib) was recapitulated in a patient-derived xenograft (PDX) model (PMID: 28961841)",Actionable,12147,3910,lung adenocarcinoma,DOID,26798,EGFR E746_A750del MET amp,resistant,660,Osimertinib,4233,28961841,,,
167,Preclinical - Pdx,"In a preclinical study, treatment with Capmatinib (INC280) plus Gilotrif (afatinib) resulted in improved survival with no evidence of tumor 300 days post-transplantation in patient-derived xenograft (PDX) models derived from the brain metastasis of a lung adenocarcinoma patient with EGFR E746_A750del (referred to as K745_A750delinsK) and high level MET amplification (PMID: 28961841).",Actionable,12150,3910,lung adenocarcinoma,DOID,26798,EGFR E746_A750del MET amp,sensitive,6313,Afatinib + Capmatinib,4233,28961841,,,
168,Preclinical - Cell culture,"In a preclinical study, acquired amplification of MET conferred resistance to Iressa (gefitinib) in a non-small cell lung cancer cell line harboring EGFR E746_A750del in culture (PMID: 27612490).",Actionable,9557,3908,non-small cell lung carcinoma,DOID,26798,EGFR E746_A750del MET amp,resistant,751,Gefitinib,4233,27612490,,,
169,Preclinical - Cell line xenograft,"In a preclinical study, emergence of MET amplification was associated with resistance to Rociletinib (CO1686) in non-small cell lung cancer cell line xenograft models harboring EGFR E746_A750del (PMID: 27283993).",Actionable,9247,3908,non-small cell lung carcinoma,DOID,26798,EGFR E746_A750del MET amp,resistant,1003,CO1686,4233,27283993,,,
170,Preclinical - Cell culture,"In a preclinical study, the combination of Rociletinib (CO-1686) and Xalkori (crizotinib) overcame resistance to Rociletinib (CO-1686) in non-small cell lung cancer cell line harboring EGFR E746_A750del and MET amplification in culture (PMID: 27283993).",Actionable,9248,3908,non-small cell lung carcinoma,DOID,26798,EGFR E746_A750del MET amp,sensitive,4962,CO1686 + Crizotinib,4233,27283993,,,
171,Preclinical - Cell line xenograft,"In a preclinical study, the combination of PHA-665752 and Iressa (gefitinib) overcame Iressa (gefitinib) resistance in a cell line xenograft model of non-small cell lung cancer reported to harbor EGFR E746_A750del (PMID: 23542356), which has acquired resistance to Iressa (gefitinib) due to MET amplification and over expression, resulting in tumor growth inhibition (PMID: 24165158).",Actionable,9656,3908,non-small cell lung carcinoma,DOID,26798,EGFR E746_A750del MET amp,sensitive,5094,Gefitinib + PHA-665752,4233,24165158,23542356,,
172,Preclinical - Cell culture,"In a preclinical study, the combination of Xalkori (crizotinib) and Tykerb (lapatinib) worked synergistically to inhibit growth of an esophageal adenocarcinoma cell line with EGFR and MET copy number gain in culture (PMID: 27595477).",Actionable,11557,4914,esophagus adenocarcinoma,DOID,17304,EGFR amp MET amp,sensitive,3440,Crizotinib + Lapatinib,4233,27595477,,,
173,Preclinical,"In a preclinical study, a human esophageal carcinoma cell line harboring amplification of ERBB2 (HER2) and MET was sensitive to inhibition by Tykerb (lapatinib) and Xalkori (crizotinib) in culture (PMID: 26432108).",Actionable,4092,1107,esophageal carcinoma,DOID,17215,ERBB2 amp MET amp,sensitive,3440,Crizotinib + Lapatinib,4233,26432108,,,
174,Preclinical - Cell culture,"In a preclinical study, the combination of Xalkori (crizotinib) and Tykerb (lapatinib) worked synergistically to inhibit growth of an esophageal adenocarcinoma cell line with ERBB2 (HER2) and MET amplification in culture (PMID: 27595477).",Actionable,11555,4914,esophagus adenocarcinoma,DOID,17215,ERBB2 amp MET amp,sensitive,3440,Crizotinib + Lapatinib,4233,27595477,,,
175,Clinical Study,"In a clinical case study, a patient with ERBB2 (HER2) and MET co-amplified gastric adenocarcinoma had near complete regression of the disease after 2 months of treatment with Herceptin (trastuzumab), Xalkori (crizotinib) and weekly Taxol (paclitaxel) (PMID: 26432108).",Actionable,4094,3717,gastric adenocarcinoma,DOID,17215,ERBB2 amp MET amp,sensitive,3442,Crizotinib + Trastuzumab + Paclitaxel,4233,26432108,,,
176,Preclinical,"In a preclinical study, a human esophageal carcinoma cell line harboring amplification of ERBB2 and MET was resistant to Tykerb (lapatinib) in culture (PMID: 26432108).",Actionable,4090,1107,esophageal carcinoma,DOID,17215,ERBB2 amp MET amp,resistant,787,Lapatinib,4233,26432108,,,
177,Clinical Study,"In a clinical case study, a patient with ERBB2 (HER2) and MET amplified gastric adenocarcinoma was insensitive to treatment with Herceptin (trastuzumab) and FOLFOX (PMID: 26432108).",Actionable,4091,3717,gastric adenocarcinoma,DOID,17215,ERBB2 amp MET amp,resistant,3439,Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin,4233,26432108,,,
178,Clinical Study,"In a clinical case study, a patient with ERBB2 (HER2) and MET amplified gastric adenocarcinoma was insensitive to AMG 337 therapy (PMID: 26432108).",Actionable,4084,3717,gastric adenocarcinoma,DOID,17215,ERBB2 amp MET amp,resistant,1064,AMG 337,4233,26432108,,,
179,Preclinical,"In a preclinical study, a human esophageal carcinoma cell line harboring amplification of ERBB2 and MET was resistant to Xalkori (crizotinib) in culture (PMID: 26432108).",Actionable,4089,1107,esophageal carcinoma,DOID,17215,ERBB2 amp MET amp,resistant,706,Crizotinib,4233,26432108,,,
180,Clinical Study,"In a clinical case study, a patient with ERBB2 (HER2) amplified gastric adenocarcinoma progressed rapidly when treated with Herceptin (trastuzumab) with Xeloda (capecitabine), Eloxatin (oxaliplatin), and Avastin (bevacizumab), and reprofiling of the tumor revealed co-amplification of MET (PMID: 26432108).",Actionable,4093,3717,gastric adenocarcinoma,DOID,17215,ERBB2 amp MET amp,resistant,3441,Bevacizumab + Capecitabine + Oxaliplatin + Trastuzumab,4233,26432108,,,
181,Clinical Study,"In a clinical case study, a lung adenocarcinoma patient harboring an EGFR exon 19 deletion and EGFR T790M and resistance to Tagrisso (osimertinib) following acquired MET amplification, demonstrated some improvement in symptoms with treatment with Xalkori (crizotinib) (PMID: 27393507).",Actionable,9238,3910,lung adenocarcinoma,DOID,18241,EGFR exon 19 del EGFR T790M MET amp,predicted â€“ sensitive,706,Crizotinib,4233,27393507,,,
182,Clinical Study,"In a clinical case study, a lung adenocarcinoma patient harboring an EGFR exon 19 deletion and EGFR T790M developed resistance to Tagrisso (osimertinib), and was found to have acquired high level amplification of MET (PMID: 27393507).",Actionable,9236,3910,lung adenocarcinoma,DOID,18241,EGFR exon 19 del EGFR T790M MET amp,resistant,660,Osimertinib,4233,27393507,,,
183,Preclinical,"In a preclinical study, amplification of MET conferred resistance to Iressa (gefitinib) in non-small cell lung cancer cells harboring an EGFR exon 19 deletion mutation in culture (PMID: 17463250).",Actionable,2471,3908,non-small cell lung carcinoma,DOID,8120,EGFR del exon19 MET amp,resistant,751,Gefitinib,4233,17463250,,,
184,Clinical Study,"In a clinical case study, a patient with a carcinoma of unknown primary harboring MET amplification and KRAS G12V demonstrated a durable response following treatment with Xalkori (crizotinib) (PMID: 25232318).",Actionable,7753,305,carcinoma,DOID,25979,KRAS G12V MET amp,predicted â€“ sensitive,706,Crizotinib,4233,25232318,,,
185,Preclinical,"In a preclinical study, expression of EGFR T790M in MET-amplified lung adenocarcinoma cells resulted in resistance to Rociletinib (CO-1686) in culture, consistent with MET amplification identified in tumor samples of lung adenocarcinoma patients harboring EGFR T790M that developed resistance to Rociletinib (CO-1686) (PMID: 27252416).",Actionable,8801,3910,lung adenocarcinoma,DOID,26437,EGFR T790M MET amp,resistant,1003,CO1686,4233,27252416,,,
186,Preclinical,"In a preclinical study, expression of EGFR T790M in MET-amplified lung adenocarcinoma cells resulted in resistance to Tagrisso (osimertinib) in culture, consistent with MET amplification identified in tumor samples of lung adenocarcinoma patients harboring EGFR T790M that developed resistance to Tagrisso (osimertinib) (PMID: 27252416).",Actionable,8802,3910,lung adenocarcinoma,DOID,26437,EGFR T790M MET amp,resistant,660,Osimertinib,4233,27252416,,,
187,Clinical Study,"In an analysis of EGFR T790M-positive non-small cell lung cancer patients, emergence of MET amplification was identified in 26% (28/43) of patients with acquired resistance to Rociletinib (CO1686), and patients with MET amplification prior to Rociletinib (CO1686) treatment demonstrated a decreased response compared to patients without MET amplification (PMID: 27283993).",Actionable,9246,3908,non-small cell lung carcinoma,DOID,26437,EGFR T790M MET amp,resistant,1003,CO1686,4233,27283993,,,
188,Clinical Study,"In a clinical case study, a lung adenocarcinoma patient previously harboring MET amp, MET del exon14, MET D1228N, MET Y1230H, MET Y1230S, and MET G1163R demonstrated a decrease in lesion size when treated with Glesatinib (MGCD265), however, progression ensued and plasma testing indicated the patient lost Y1230H and Y1230S, but acquired MET L1195V (PMID: 28765324). ",Actionable,11787,3910,lung adenocarcinoma,DOID,28246,MET amp MET del exon14 MET D1228N MET G1163R MET L1195V,resistant,809,MGCD265,4233,28765324,,,
189,Preclinical - Pdx,"In a preclinical study, a lung cancer patient-derived xenograft (PDX) model harboring MET amplification and MET del exon14 demonstrated tumor regression when treated with Glesatinib (MGCD265) (PMID: 28765324). ",Actionable,11767,1324,lung cancer,DOID,28229,MET amp MET del exon14,sensitive,809,MGCD265,4233,28765324,,,
190,Clinical Study,"In a clinical case study, a lung adenocarcinoma patient co-harboring MET del exon14 and MET amp was sensitive to Xalkori (crizotinib), demonstrating a partial response for 8 months (PMID: 28765324). ",Actionable,11786,3910,lung adenocarcinoma,DOID,28229,MET amp MET del exon14,sensitive,706,Crizotinib,4233,28765324,,,
191,Preclinical - Cell culture,"In a preclinical study, a MET-amplified lung cancer cell line harboring KRAS G12A was not sensitive to growth inhibition by AMG 337 in culture (PMID: 27196782).",Actionable,9029,1324,lung cancer,DOID,25935,KRAS G12A MET amp,resistant,1064,AMG 337,4233,27196782,,,
192,Preclinical - Cell culture,"In a preclinical study, MET amplified lung cancer cells harboring KRAS G12A were insensitive to SAR125844-mediated growth inhibition in culture (PMID: 25504634).",Actionable,7733,1324,lung cancer,DOID,25935,KRAS G12A MET amp,resistant,2159,SAR125844,4233,25504634,,,
193,Preclinical - Cell line xenograft,"In a preclinical study, transformed cells expressing MET del exon14 and MET D1228N were sensitive to Glesatinib (MGCD265) treatment, demonstrating cell growth inhibition in culture and 21% tumor regression in xenograft models (PMID: 28765324).",Actionable,11775,10000003,Advanced Solid Tumor,JAX,27264,MET del exon14 MET D1228N,sensitive,809,MGCD265,4233,28765324,,,
194,Clinical Study,"In a clinical case study, a patient with squamous cell lung cancer harboring a MET exon 14 skipping mutation was determined to have acquired MET D1228N after progression on Xalkori (crizotinib) therapy (PMID: 27343442).",Actionable,10126,3907,lung squamous cell carcinoma,DOID,27264,MET del exon14 MET D1228N,predicted â€“ resistant,706,Crizotinib,4233,27343442,,,
195,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing MET del exon14 were sensitive to Capmatinib (INC280) treatment in culture, demonstrating inhibition of spheroid growth (PMID: 28765324). ",Actionable,11773,10000003,Advanced Solid Tumor,JAX,26413,MET del exon14,sensitive,1065,Capmatinib,4233,28765324,,,
196,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing MET del exon14 were sensitive to Xalkori (crizotinib) treatment in culture, demonstrating inhibition of spheroid growth (PMID: 28765324). ",Actionable,11774,10000003,Advanced Solid Tumor,JAX,26413,MET del exon14,sensitive,706,Crizotinib,4233,28765324,,,
197,Clinical Study,"In a clinical study, three patients with lung adenocarcinoma harboring MET del exon14 demonstrated partial responses when treated with Xalkori (crizotinib) (PMID: 25971939).",Actionable,9565,3910,lung adenocarcinoma,DOID,26413,MET del exon14,sensitive,706,Crizotinib,4233,25971939,,,
198,Clinical Study,"In a clinical study, a patient with lung adenocarcinoma harboring MET del exon14 demonstrated a 66% reduction in target lesion size and maintained a partial response for 7 months when treated with Glesatinib (MGCD265) (PMID: 28765324). ",Actionable,11759,3910,lung adenocarcinoma,DOID,26413,MET del exon14,sensitive,809,MGCD265,4233,28765324,,,
199,Preclinical - Pdx & cell culture,"In a preclinical study, Sym015 inhibited growth of cancer cell lines harboring MET exon 14 deletion in culture, and inhibited tumor growth in patient-derived xenograft (PDX) models with MET exon 14 deletion (Cancer Res July 15 2016 (76) (14 Supplement) 1219).",Actionable,9968,10000003,Advanced Solid Tumor,JAX,26413,MET del exon14,sensitive,4322,SYM015,4233,None,,,
200,Preclinical - Cell culture,"In a preclinical study, KTN0073-IgG1 inhibited growth of a non-small cell lung cancer cell line harboring deletion of MET exon 14 in culture (PMID: 27550450).",Actionable,8737,3908,non-small cell lung carcinoma,DOID,26413,MET del exon14,sensitive,4802,KTN0073-IgG1,4233,27550450,,,
201,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing MET del exon14 were sensitive to Glesatinib (MGCD265) treatment in culture, demonstrating inhibition of spheroid growth (PMID: 28765324). ",Actionable,11772,10000003,Advanced Solid Tumor,JAX,26413,MET del exon14,sensitive,809,MGCD265,4233,28765324,,,
202,Clinical Study,"In a clinical case study, Capmatinib (INC280) treatment resulted in a decreased tumor volume of 61% in a patient with lung squamous cell carcinoma harboring MET del exon14 (PMID: 25971938).",Actionable,9563,3907,lung squamous cell carcinoma,DOID,26413,MET del exon14,sensitive,1065,Capmatinib,4233,25971938,,,
203,Clinical Study,"In a clinical study, a patient with lung adenocarcinoma harboring MET del exon14 demonstrated a complete response via PERCIST criteria when treated with Cometriq (Cabometyx, cabozantinib) (PMID: 25971939).",Actionable,9564,3910,lung adenocarcinoma,DOID,26413,MET del exon14,sensitive,998,cabozantinib,4233,25971939,,,
204,Preclinical - Cell line xenograft,"In a preclinical study, Onartuzumab inhibited tumor growth and decreased MET expression in a non-small cell lung cancer xenograft model harboring MET exon 14 deletion (PMID: 23882082).",Actionable,9973,3908,non-small cell lung carcinoma,DOID,26413,MET del exon14,sensitive,838,Onartuzumab,4233,23882082,,,
205,Clinical Study,"In a clinical case study, Capmatinib (INC280) treatment resulted in decreased tumor volume by 53% in a patient with large cell lung carcinoma harboring MET del exon14 and TP53 N30fs*14 (PMID: 25971938).",Actionable,9562,4556,lung large cell carcinoma,DOID,26905,MET del exon14 TP53 N30fs*14,sensitive,1065,Capmatinib,4233,25971938,,,
206,Clinical Study,"In a clinical case study, Xalkori (crizotinib) treatment resulted in a decrease in tumor volume by more than 60% in a patient with histiocytic sarcoma harboring MET del exon14 and TP53 R175H (PMID: 25971938).",Actionable,9561,5621,histiocytic and dendritic cell cancer,DOID,26903,MET del exon14 TP53 R175H,sensitive,706,Crizotinib,4233,25971938,,,
207,Clinical Study,"In a clinical study, a melanoma patient harboring a PDGFRA mutation, CDKN2A mutation, MET exon 14 splice site mutation, and SMAD4 Q249H demonstrated a 21 month overall survival when treated with a combination of Gleevec (imatinib), Paraplatin (carboplatin), and Taxol (paclitaxel) (PMID: 28514312).",Actionable,11053,1909,melanoma,DOID,27904,CDKN2A mut MET del exon14 PDGFRA mut SMAD4 Q249H,sensitive,5833,Imatinib + Carboplatin + Paclitaxel,4233,28514312,,,
208,Preclinical,"In a preclinical study, decreasing Brca2 expression via shRNA knockdown sensitized triple-receptor negative breast cancer cells with low expression of Met to Rubraca (rucaparib) in culture (PMID: 26779812).",Actionable,6149,60081,triple-receptor negative breast cancer,DOID,22728,BRCA2 dec exp MET dec exp,sensitive,906,Rucaparib,4233,26779812,,,
209,Preclinical,"In a preclinical study, triple-receptor negative breast cancer cell lines with decreased Met expression via shRNA knockdown demonstrated increased sensitivity to Veliparib (ABT-888) induced growth and colony formation inhibition in culture (PMID: 26779812).",Actionable,6143,60081,triple-receptor negative breast cancer,DOID,22706,MET dec exp,sensitive,954,Veliparib,4233,26779812,,,
210,Preclinical,"In a preclinical study, triple-receptor negative breast cancer cell lines with decreased Met expression via shRNA knockdown demonstrated increased sensitivity to Lynparza (olaparib) induced growth and colony formation inhibition in culture (PMID: 26779812).",Actionable,6142,60081,triple-receptor negative breast cancer,DOID,22706,MET dec exp,sensitive,837,Olaparib,4233,26779812,,,
211,Preclinical,"In a preclinical study, triple-receptor negative breast cancer cell lines with decreased Met expression via shRNA knockdown demonstrated increased sensitivity to Rubraca (rucaparib) induced growth and colony formation inhibition in culture (PMID: 26779812).",Actionable,6144,60081,triple-receptor negative breast cancer,DOID,22706,MET dec exp,sensitive,906,Rucaparib,4233,26779812,,,
212,Preclinical,"In a preclinical study, decreasing Brca1 expression via shRNA knockdown sensitized triple-receptor negative breast cancer cells with low expression of Met to Rubraca (rucaparib) in culture (PMID: 26779812).",Actionable,6148,60081,triple-receptor negative breast cancer,DOID,22726,BRCA1 dec exp MET dec exp,sensitive,906,Rucaparib,4233,26779812,,,
213,Preclinical,"In a preclinical study, Amuvatinib (MP470) demonstrated efficacy in reducing Met phosphorylation and inducing apoptosis in cultured myeloma cells (PMID: 24326130).",Actionable,1756,70004,myeloid neoplasm,DOID,587,MET wild-type,sensitive,632,Amuvatinib,4233,24326130,,,
214,Preclinical,"In a preclinical study, BMS-777607 (ASLAN002) demonstrated efficacy in inhibiting migration and invasion of cultured prostate cancer cells expressing wild-type Met (PMID: 20515943).",Actionable,1758,10283,prostate cancer,DOID,587,MET wild-type,sensitive,687,BMS-777607,4233,20515943,,,
215,Preclinical - Pdx & cell culture,"In a preclinical study, LY2801653 inhibited phosphorylation of Met, resulting in inhibition of cholangiocarcinoma proliferation in cell culture and growth of tumors in Pdx models (PMID: 26757360).",Actionable,9581,4947,cholangiocarcinoma,DOID,587,MET wild-type,sensitive,1030,LY2801653,4233,26757360,,,
216,Preclinical,"In a preclinical study, Altiratinib (DCC-2701) inhibited activity of MET M1250T in an in vitro kinase assay (PMID: 26285778).",Actionable,10079,10000003,Advanced Solid Tumor,JAX,24002,MET M1250T,predicted â€“ sensitive,1656,Altiratinib,4233,26285778,,,
217,Preclinical,"In a preclinical study, Altiratinib (DCC-2701) inhibited activity of MET D1228N in an in vitro kinase assay (PMID: 26285778).",Actionable,10072,10000003,Advanced Solid Tumor,JAX,26645,MET D1228N,predicted â€“ sensitive,1656,Altiratinib,4233,26285778,,,
218,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing mouse MET D1226N (corresponds to MET D1228N in humans) were resistant to treatment with Savolitinib (AZD6094), demonstrating sustained cell growth in culture (PMID: 28396313). ",Actionable,11733,10000003,Advanced Solid Tumor,JAX,26645,MET D1228N,predicted â€“ resistant,2161,Savolitinib,4233,28396313,,,
219,Preclinical - Cell culture,"In a preclinical study, Merestinib (LY2801653) inhibited growth of transformed cells over expressing MET D1228N in culture (PMID: 23275061).",Actionable,9977,10000003,Advanced Solid Tumor,JAX,26645,MET D1228N,sensitive,1030,LY2801653,4233,23275061,,,
220,Preclinical,"In a preclinical study, transformed cells expressing mouse MET D1226N (corresponds to MET D1228N in humans) were resistant to treatment with Capmatinib (INC280), demonstrating sustained cell growth in culture and minimal tumor growth inhibition in mouse models (PMID: 28396313). ",Actionable,11730,10000003,Advanced Solid Tumor,JAX,26645,MET D1228N,predicted â€“ resistant,1065,Capmatinib,4233,28396313,,,
221,Preclinical,"In a preclinical study, transformed cells expressing mouse MET D1226N (corresponds to MET D1228N in humans) were resistant to treatment with Xalkori (crizotinib), demonstrating sustained cell growth in culture and minimal tumor growth inhibition in mouse models (PMID: 28396313). ",Actionable,11731,10000003,Advanced Solid Tumor,JAX,26645,MET D1228N,predicted â€“ resistant,706,Crizotinib,4233,28396313,,,
222,Preclinical,"In a preclinical study, transformed cells expressing mouse MET D1226N (corresponds to MET D1228N in humans) were sensitive to treatment with Cometriq (Cabometyx, cabozantinib), demonstrating inhibition of cell growth in culture and tumor growth inhibition in mouse models (PMID: 28396313). ",Actionable,11729,10000003,Advanced Solid Tumor,JAX,26645,MET D1228N,predicted â€“ sensitive,998,cabozantinib,4233,28396313,,,
223,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing mouse MET D1226N (corresponds to D1228N in humans) were sensitive to treatment with BMS-777607 (ASLAN002), demonstrating inhibition of cell growth in culture (PMID: 28396313). ",Actionable,11735,10000003,Advanced Solid Tumor,JAX,26645,MET D1228N,predicted â€“ sensitive,687,BMS-777607,4233,28396313,,,
224,Clinical Study,"In a clinical case study, a GIST patient harboring KIT S476I and MET R988C demonstrated sensitivity to the combination treatment, Nexavar (sorafenib) and Avastin (bevacizumab), resulting in stable disease for 6 months (PMID: 25363205). ",Actionable,7766,9253,gastrointestinal stromal tumor,DOID,26035,KIT S476I MET R988C,sensitive,4517,Bevacizumab + Sorafenib,4233,25363205,,,
225,Preclinical,"In a preclinical study, cultured cells with MET R998C mutations demonstrated sensitivity to Xalkori (crizotinib, PF-2341066) (PMID: 17483355).",Actionable,559,10000003,Advanced Solid Tumor,JAX,810,MET R988C,sensitive,706,Crizotinib,4233,17483355,,,
226,Preclinical,"In a preclinical study, a cell line expressing MET V1110I demonstrated sensitivity to SU11274 treatment (PMID: 19783361).",Actionable,813,162,cancer,DOID,1123,MET V1110I,sensitive,1089,SU11274,4233,19783361,,,
227,Preclinical,"In a preclinical study, a cell line expressing MET V1206I demonstrated sensitivity to SU11274 treatment (PMID: 19783361).",Actionable,815,162,cancer,DOID,1125,MET V1206L,sensitive,1089,SU11274,4233,19783361,,,
0,Preclinical - Cell culture,"In a preclinical study, MLH1 deficient colon cancer cell lines were sensitive to KU60648 in culture, demonstrating decreased cell viability and reduced colony formation (PMID: 28224663). ",Actionable,11383,219,colon cancer,DOID,25004,MLH1 loss,sensitive,5967,KU60648,4292,28224663,,,
1,Preclinical,"In a preclinical study, MLH1 inactivation through hypermethylation was associated with high microsatellite instability (MSI-H) colorectal carcinoma by whole genome sequencing of tumor samples (PMID: 22810696), suggesting it may be a potential biomarker.",Emerging,5782,9256,colorectal cancer,DOID,16867,MLH1 inact mut,not applicable,1776,N/A,4292,22810696,,,
2,Phase I,"Clinical trials are currently enrolling patients with mutations in MLH1 (clinicaltrials.gov, Oct 2017).",Actionable,5783,10000003,Advanced Solid Tumor,JAX,17286,MLH1 mutant,not applicable,1776,N/A,4292,None,,,
0,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and Pictilisib (GDC-0941) synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790).",Actionable,5794,10000003,Advanced Solid Tumor,JAX,21621,JAK2 V617F MPL wild-type,sensitive,3927,GDC-0941 + Ruxolitinib,4352,24251790,,,
1,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and BEZ235 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790).",Actionable,5800,10000003,Advanced Solid Tumor,JAX,21621,JAK2 V617F MPL wild-type,sensitive,3928,BEZ235 + Ruxolitinib,4352,24251790,,,
2,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and TGX-221 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790).",Actionable,5806,10000003,Advanced Solid Tumor,JAX,21621,JAK2 V617F MPL wild-type,sensitive,3929,Ruxolitinib + TGX-221,4352,24251790,,,
3,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and ZSTK474 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and JAK2 V617F in cell culture (PMID: 24251790).",Actionable,5788,10000003,Advanced Solid Tumor,JAX,21621,JAK2 V617F MPL wild-type,sensitive,3926,Ruxolitinib + ZSTK474,4352,24251790,,,
4,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and BEZ235 synergistically inhibited growth of transformed cell lines over expressing MPL W515L in cell culture (PMID: 24251790).",Actionable,5801,10000003,Advanced Solid Tumor,JAX,589,MPL W515L,sensitive,3928,BEZ235 + Ruxolitinib,4352,24251790,,,
5,Phase II,"In a phase II study of patients with myelofibrosis, 2/2 patients with MPL W515L/K had tumor response to everolimus, with one patient displaying clinical benefit (PMID: 21725052).",Actionable,1099,4971,myelofibrosis,DOID,589,MPL W515L,sensitive,735,Everolimus,4352,21725052,,,
6,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and ZSTK474 synergistically inhibited growth of transformed cell lines over expressing MPL W515L in cell culture (PMID: 24251790).",Actionable,5789,10000003,Advanced Solid Tumor,JAX,589,MPL W515L,sensitive,3926,Ruxolitinib + ZSTK474,4352,24251790,,,
7,Preclinical,"In a preclinical study, MK2206 treatment reduced disease burden in MPL W515L transduced mouse models of myelofibrosis (PMID: 23748344).",Actionable,5814,4971,myelofibrosis,DOID,589,MPL W515L,sensitive,816,MK2206,4352,23748344,,,
8,Preclinical,"In a preclinical study, CHZ868 demonstrated efficacy in a mouse model of MPL W515L induced myelofibrosis (PMID: 26175413). ",Actionable,6062,4971,myelofibrosis,DOID,589,MPL W515L,sensitive,4016,CHZ868,4352,26175413,,,
9,Preclinical,"In a preclinical study, CHZ868 inhibited proliferation of bone marrow cell lines expressing MPL W515L in culture, including cells with decreased response to Type I JAK inhibitors due to chronic exposure (PMID: 26175413).",Actionable,6063,2531,hematologic cancer,DOID,589,MPL W515L,sensitive,4016,CHZ868,4352,26175413,,,
10,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and TGX-221 synergistically inhibited growth of transformed cell lines over expressing MPL W515L in cell culture (PMID: 24251790).",Actionable,5807,10000003,Advanced Solid Tumor,JAX,589,MPL W515L,sensitive,3929,Ruxolitinib + TGX-221,4352,24251790,,,
11,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and Pictilisib (GDC-0941) synergistically inhibited growth of transformed cell lines over expressing MPL W515L in cell culture (PMID: 24251790).",Actionable,5795,10000003,Advanced Solid Tumor,JAX,589,MPL W515L,sensitive,3927,GDC-0941 + Ruxolitinib,4352,24251790,,,
12,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and BEZ235 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and Jak2 in cell culture (PMID: 24251790).",Actionable,5799,10000003,Advanced Solid Tumor,JAX,21624,JAK2 over exp MPL over exp,sensitive,3928,BEZ235 + Ruxolitinib,4352,24251790,,,
13,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and Pictilisib (GDC-0941) synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and Jak2 in cell culture (PMID: 24251790).",Actionable,5793,10000003,Advanced Solid Tumor,JAX,21624,JAK2 over exp MPL over exp,sensitive,3927,GDC-0941 + Ruxolitinib,4352,24251790,,,
14,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and TGX-221 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and Jak2 in cell culture (PMID: 24251790).",Actionable,5805,10000003,Advanced Solid Tumor,JAX,21624,JAK2 over exp MPL over exp,sensitive,3929,Ruxolitinib + TGX-221,4352,24251790,,,
15,Preclinical,"In a preclinical study, Jakafi (ruxolitinib) and ZSTK474 synergistically inhibited growth of transformed cell lines over expressing wild-type Mpl and Jak2 in cell culture (PMID: 24251790).",Actionable,5787,10000003,Advanced Solid Tumor,JAX,21624,JAK2 over exp MPL over exp,sensitive,3926,Ruxolitinib + ZSTK474,4352,24251790,,,
16,Phase II,"In a phase II study of patients with myelofibrosis, 2/2 patients with MPL W515L/K had tumor response to everolimus, with one patient displaying clinical benefit (PMID: 21725052).",Actionable,1100,4971,myelofibrosis,DOID,590,MPL W515K,sensitive,735,Everolimus,4352,21725052,,,
0,Preclinical,"In a preclinical study, glioblastoma cells harboring a MSH6 T1219I mutation were resistant to Temodar (temozolomide) in cell culture (PMID: 19584161).",Actionable,1545,3068,glioblastoma multiforme,DOID,2665,MSH6 T1219I,resistant,1141,Temozolomide,2956,19584161,,,
1,Preclinical - Cell culture,"In a preclinical study, MSH6 deficient colon cancer cells did not respond to treatment with KU60648 in culture (PMID: 28224663). ",Actionable,11384,219,colon cancer,DOID,7744,MSH6 loss,no benefit,5967,KU60648,2956,28224663,,,
2,Preclinical,"Preclinical shRNA mediated-inhibition of PTEN-induced putative kinase 1 (PINK1) in colon carcinoma cells with MSH6 loss resulted in synthetic lethality, suggesting PINK1 may be a promising therapeutic target for MSH6 deficient cancer cells (PMID: 21242281). ",Emerging,2456,1520,colon carcinoma,DOID,7744,MSH6 loss,not applicable,1776,N/A,2956,21242281,,,
3,Clinical Study,"Germline mutations in MSH6 are associated with microsatellite instability in colorectal cancer (CRC), and are diagnostic for Lynch syndrome (hereditary nonpolyposis colorectal cancer) in colorectal cancer patients (PMID: 26582061; PMID: 19125127).",Actionable,6034,9256,colorectal cancer,DOID,17288,MSH6 mutant,not applicable,1776,N/A,2956,26582061,19125127,,
4,Phase I,"Clinical trials are currently enrolling patients with mutations in MSH6 (clinicaltrials.gov, Oct 2017).",Actionable,5458,10000003,Advanced Solid Tumor,JAX,17288,MSH6 mutant,not applicable,1776,N/A,2956,None,,,
0,Preclinical,"In a preclinical study, STS2825 demonstrated effective inhibition of MYD88 homodimerization and signalling in cultured cells and is currently being evaluated in preclinical studies of B cell lymphoma  (Blood Lymph Canc 2013; 3: 53-61). ",Actionable,1115,50745,diffuse large B-cell lymphoma,DOID,593,MYD88 wild-type,predicted â€“ sensitive,1563,ST2825,4615,None,,,
1,Clinical Study,"MYD88 mutations are used in the diagnosis of lymphoplasmacytic lymphoma (Guidelines, PMID: 22944768).",Diagnostic,3967,50747,lymphoplasmacytic lymphoma,DOID,1917,MYD88 mutant,not applicable,1776,N/A,4615,26230596,22944768,None,
2,Preclinical - Cell culture,"In a preclinical study, a diffuse large B-cell lymphoma cell line harboring MYD88 L256P demonstrated sensitivity to Zolinza (vorinostat) in culture, resulting in increased apoptosis (PMID: 27733371).",Actionable,10340,50745,diffuse large B-cell lymphoma,DOID,6507,MYD88 L265P,sensitive,1077,Vorinostat,4615,27733371,,,
3,Phase I,"In a Phase I trial, two patients with primary central nervous system lymphoma each harboring MYD88 L265P demonstrated a complete response when treated with Imbruvica (ibrutinib) (PMID: 28619981). ",Actionable,12106,3234,central nervous system lymphoma,DOID,6507,MYD88 L265P,sensitive,768,Ibrutinib,4615,28619981,,,
4,Preclinical - Cell line xenograft,"In a preclinical study, treatment with IMO-8400 resulted in decreased survival of B-cell lymphoma cell lines harboring MYD88 L265P in culture, and decreased tumor growth in a MYD88 L265P-positive B-cell lymphoma cell line xenograft models (Cancer Res October 1, 2014 74:2570).",Actionable,2469,707,B-cell lymphoma,DOID,6507,MYD88 L265P,sensitive,2866,IMO-8400,4615,None,,,
5,Clinical Study,"In multiple clinical studies, MYD88 L265P was associated with a worse overall survival in patients with diffuse large B-cell lymphoma when compared to MYD88 wild-type (PMID: 24903481, PMID: 25055137, PMID: 26792260). ",Prognostic,6344,50745,diffuse large B-cell lymphoma,DOID,6507,MYD88 L265P,not applicable,1776,N/A,4615,24903481,25055137,26792260,
6,Preclinical - Pdx,"In a preclinical study, a non-Hodgkin lymphoma (NHL) patient derived xenograft (PDX) model harboring both CD79B Y197N and MYD88 L265P demonstrated sensitivity to Ibruvica (ibrutinib) while an NHL patient derived xenograft (PDX) model harboring only MYD88 L265P did not respond to Ibruvica (ibrutinib) (ASH 57th Annual Meeting, 2015, abstract #2759). ",Actionable,3704,60060,non-Hodgkin lymphoma,DOID,6507,MYD88 L265P,no benefit,768,Ibrutinib,4615,None,,,
7,Preclinical - Cell line xenograft,"In a preclinical study, eFT508 demonstrated anti-tumor activity in two diffuse large B-cell lymphoma cell line xenograft models, both harboring MYD88 activating mutations (Blood Dec 2015, 126 (23) 1554).",Actionable,6009,50745,diffuse large B-cell lymphoma,DOID,22222,MYD88 act mut,predicted â€“ sensitive,4005,eFT508,4615,None,,,
0,Preclinical - Pdx,"In a preclinical study, xenograft models of patient-derived acute lymphocytic leukemia cells harboring NOTCH1 activating muatations demonstrated better response to Brontictuzumab (OMP-52M51) compared to NOTCH1 wild-type models (PMID: 23774673).",Actionable,7156,9952,acute lymphocytic leukemia,DOID,2334,NOTCH1 act mut,sensitive,839,Brontictuzumab,4851,23774673,,,
1,Preclinical - Pdx,"In a preclinical study, the combination of Kisqali (ribociclib) and Adexone (dexamethasone) resulted in reduced leukemia burden and a greater survival benefit in a NOTCH1 activated T-cell acute lymphoblastic leukemia patient derived xenograft (PDX) model when compared to control or either agent alone (PMID: 28151717). ",Actionable,10054,5602,T-cell adult acute lymphocytic leukemia,DOID,2334,NOTCH1 act mut,predicted â€“ sensitive,5355,Ribociclib + Dexamethasone,4851,28151717,,,
2,Preclinical - Pdx,"In a preclinical study, Brontictuzumab (OMP-52M51) inhibited tumor growth and reduced cancer stem cells in xenograft models of tumor derived from a breast cancer patient harboring activating NOTCH1 mutations (Cancer Res 2013;73(8 Suppl):Abstract nr 3728).",Actionable,7154,1612,breast cancer,DOID,2334,NOTCH1 act mut,sensitive,839,Brontictuzumab,4851,None,,,
3,Preclinical - Cell culture,"In a preclinical study, the gamma secretase inhibitor PF-03084014 reduced Notch1 cleavage, decreased activation of Notch targets, and increased apoptosis in colorectal cancer cell lines exhibiting increased Notch activation (PMID: 23868008).",Actionable,1263,9256,colorectal cancer,DOID,2334,NOTCH1 act mut,sensitive,859,PF-03084014,4851,23868008,,,
4,Preclinical,"In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 A1707T in culture (PMID: 25104330).",Actionable,4328,3347,osteosarcoma,DOID,6144,NOTCH1 A1707T,sensitive,1084,MRK-003,4851,25104330,,,
5,Preclinical,"In a preclinical study, transformed cells expressing NOTCH1 A1707T demonstrated sensitivity to MRK-003 in culture (PMID: 25104330).",Actionable,2984,10000003,Advanced Solid Tumor,JAX,6144,NOTCH1 A1707T,sensitive,1084,MRK-003,4851,25104330,,,
6,Preclinical,"In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 I1680S in culture (PMID: 25104330).",Actionable,4321,3347,osteosarcoma,DOID,17691,NOTCH1 I1680S,sensitive,1084,MRK-003,4851,25104330,,,
7,Preclinical,"In a preclinical study, LGK974 inhibited growth of head and neck squamous cell carcinoma cells harboring NOTCH1 C478F in culture and xenograft models (PMID: 24277854).",Actionable,2689,5520,head and neck squamous cell carcinoma,DOID,10166,NOTCH1 C478F,sensitive,1937,LGK974,4851,24277854,,,
8,Preclinical - Cell culture,"In a preclinical study, a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 demonstrated sensitivity to treatment with Kisqali (ribociclib) in culture, resulting in inhibition of cell growth (PMID: 28151717). ",Actionable,10032,5602,T-cell adult acute lymphocytic leukemia,DOID,27229,NOTCH1 wild-type RB1 wild-type,sensitive,790,Ribociclib,4851,28151717,,,
9,Preclinical - Cell culture,"In a preclinical study, the combination of Kisqali (ribociclib) and JQ1 resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717). ",Actionable,10051,5602,T-cell adult acute lymphocytic leukemia,DOID,27229,NOTCH1 wild-type RB1 wild-type,sensitive,5357,Ribociclib + JQ1,4851,28151717,,,
10,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Kisqali (ribociclib) and Adexone (dexamethasone) in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and NOTCH1 resulted in decreased cell viability and reduced phosphorylation of Rb1 in culture, however, survival did not differ between xenograft models treated with the combination or Kisqali (ribociclib) alone (PMID: 28151717). ",Actionable,10044,5602,T-cell adult acute lymphocytic leukemia,DOID,27229,NOTCH1 wild-type RB1 wild-type,conflicting,5355,Ribociclib + Dexamethasone,4851,28151717,,,
11,Preclinical - Cell culture,"In a preclinical study, the addition of Kisqali (ribociclib) to Methotrexate resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717). ",Actionable,10034,5602,T-cell adult acute lymphocytic leukemia,DOID,27229,NOTCH1 wild-type RB1 wild-type,decreased response,5352,Ribociclib + Methotrexate,4851,28151717,,,
12,Preclinical - Cell culture,"In a preclinical study, the addition of Kisqali (ribociclib) to Purixan (mercaptopurine) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717). ",Actionable,10036,5602,T-cell adult acute lymphocytic leukemia,DOID,27229,NOTCH1 wild-type RB1 wild-type,decreased response,5353,Ribociclib + Mercaptopurine,4851,28151717,,,
13,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Kisqali (ribociclib) and Afinitor (everolimus) treatment in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 resulted in decreased Rb1 phosphorylation and a greater inhibition of cell growth compared to either agent alone in culture, and prolonged survival in cell-line xenograft models (PMID: 28151717). ",Actionable,10049,5602,T-cell adult acute lymphocytic leukemia,DOID,27229,NOTCH1 wild-type RB1 wild-type,sensitive,5073,Ribociclib + Everolimus,4851,28151717,,,
14,Preclinical - Cell culture,"In a preclinical study, the combination of Kisqali (ribociclib) and Omnipred (prednisolone) resulted in a synergistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717). ",Actionable,10047,5602,T-cell adult acute lymphocytic leukemia,DOID,27229,NOTCH1 wild-type RB1 wild-type,sensitive,5356,Ribociclib + Prednisolone,4851,28151717,,,
15,Preclinical - Cell culture,"In a preclinical study, the addition of Kisqali (ribociclib) to Elspar (asparaginase) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717). ",Actionable,10042,5602,T-cell adult acute lymphocytic leukemia,DOID,27229,NOTCH1 wild-type RB1 wild-type,decreased response,5354,Ribociclib + Asparaginase,4851,28151717,,,
16,Preclinical - Cell culture,"In a preclinical study, the combination of Kisqali (ribociclib) and Velcade (bortezomib) resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717). ",Actionable,10053,5602,T-cell adult acute lymphocytic leukemia,DOID,27229,NOTCH1 wild-type RB1 wild-type,sensitive,5358,Ribociclib + Bortezomib,4851,28151717,,,
17,Preclinical - Cell culture,"In a preclinical study, a T-cell acute lymphoblastic leukemia cell line harboring wild-type NOTCH1 and loss of RB1 demonstrated resistance to Kisqali (ribociclib) in culture, resulting in limited inhibition of cell growth (PMID: 28151717). ",Actionable,10045,5602,T-cell adult acute lymphocytic leukemia,DOID,27230,NOTCH1 wild-type RB1 loss,resistant,790,Ribociclib,4851,28151717,,,
18,Preclinical,"In a preclinical study, triple receptor-negative breast cancer xenograft models harboring wild-type NOTCH1 demonstrated reduced sensitivity to MRK-003 induced tumor growth inhibition (PMID: 25104330).",Actionable,4317,60081,triple-receptor negative breast cancer,DOID,597,NOTCH1 wild-type,decreased response,1084,MRK-003,4851,25104330,,,
19,Preclinical,"In a preclinical study, the combination of MRK-003 and Taxol (paclitaxel) did not potentiate the anti-tumor effects compared to single agent therapy in triple receptor-negative breast cancer xenograft models harboring wild-type NOTCH1 (PMID: 25104330).",Actionable,4319,60081,triple-receptor negative breast cancer,DOID,597,NOTCH1 wild-type,no benefit,3491,MRK-003 + Paclitaxel,4851,25104330,,,
20,Preclinical,"In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 A1552G in culture (PMID: 25104330).",Actionable,4323,3347,osteosarcoma,DOID,17693,NOTCH1 A1552G,sensitive,1084,MRK-003,4851,25104330,,,
21,Preclinical,"In a preclinical study, LY3039478 inhibited Notch1 cleavage and downstream gene expression, demonstrated anti-tumor activity in xenograft models of lung cancer (AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1131).",Actionable,7134,1324,lung cancer,DOID,5943,NOTCH1 positive,sensitive,2958,LY3039478,4851,None,,,
22,Phase I,"In a Phase I trial, addition of RO4929097 to Temodar (temozolomide) and radiation therapy inhibited Notch signaling and cell proliferation in patient tumor samples, resulted in a median overall survival of 21 months and a median progression free survival of 13 months in glioblastoma patients (PMID: 27154916).",Actionable,8728,3068,glioblastoma multiforme,DOID,5943,NOTCH1 positive,sensitive,4803,Radiotherapy + RO4929097 + Temozolomide,4851,27154916,,,
23,Preclinical,"In a preclinical study, LY3039478 inhibited Notch1 cleavage and downstream gene expression, demonstrated anti-tumor activity in xenograft models of colon cancer (AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1131).",Actionable,7133,219,colon cancer,DOID,5943,NOTCH1 positive,sensitive,2958,LY3039478,4851,None,,,
24,Preclinical - Cell line xenograft,"In a preclinical study, PF-03084014 and Taxotere (docetaxel) in combination inhibited growth of Notch1-expressing Taxotere (docetaxel)-resistant prostate cancer cell lines in culture, and inhibited both soft tissue and bony tumor growth in Taxotere (docetaxel)-resistant prostate cancer cell line xenograft models, with increased efficacy over either agent alone (PMID: 26202948).",Actionable,9081,10283,prostate cancer,DOID,5943,NOTCH1 positive,predicted â€“ sensitive,1115,PF-03084014 + Docetaxel,4851,26202948,,,
25,Preclinical,"In a preclinical study, LY3039478 inhibited Notch1 cleavage and downstream gene expression, demonstrated anti-tumor activity in xenograft models of ovarian cancer (AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1131).",Actionable,7135,2394,ovarian cancer,DOID,5943,NOTCH1 positive,sensitive,2958,LY3039478,4851,None,,,
26,Preclinical,"In a preclinical study, LY3039478 inhibited Notch1 cleavage and downstream gene expression, demonstrated anti-tumor activity in xenograft models of glioblastoma (AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1131).",Actionable,7138,3068,glioblastoma multiforme,DOID,5943,NOTCH1 positive,sensitive,2958,LY3039478,4851,None,,,
27,Preclinical,"In a preclinical study, LY3039478 inhibited Notch1 cleavage and downstream gene expression, demonstrated anti-tumor activity in xenograft models of breast cancer (AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1131).",Actionable,7137,1612,breast cancer,DOID,5943,NOTCH1 positive,sensitive,2958,LY3039478,4851,None,,,
28,Preclinical,"In a preclinical study, LY3039478 inhibited Notch1 cleavage and downstream gene expression, demonstrated anti-tumor activity in xenograft models of gastric cancer (AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1131).",Actionable,7136,10534,stomach cancer,DOID,5943,NOTCH1 positive,sensitive,2958,LY3039478,4851,None,,,
29,Preclinical,"In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 E1567K in culture (PMID: 25104330).",Actionable,4322,3347,osteosarcoma,DOID,17692,NOTCH1 E1567K,sensitive,1084,MRK-003,4851,25104330,,,
30,Preclinical,"In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 V1575A in culture (PMID: 25104330).",Actionable,4326,3347,osteosarcoma,DOID,17697,NOTCH1 V1575A,sensitive,1084,MRK-003,4851,25104330,,,
31,Preclinical,"In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 R1683W in culture (PMID: 25104330).",Actionable,4329,3347,osteosarcoma,DOID,17699,NOTCH1 R1683W,sensitive,1084,MRK-003,4851,25104330,,,
32,Preclinical,"In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 V1599M in culture (PMID: 25104330).",Actionable,4327,3347,osteosarcoma,DOID,17698,NOTCH1 V1599M,sensitive,1084,MRK-003,4851,25104330,,,
33,Preclinical,"In a preclinical study, MRK-003 inhibited growth of triple receptor-negative breast cancer cells harboring NOTCH1 rearrangement in culture and reduced tumor growth in xenograft models (PMID: 25104330).",Actionable,4289,60081,triple-receptor negative breast cancer,DOID,17701,NOTCH1 rearrange,sensitive,1084,MRK-003,4851,25104330,,,
34,Preclinical,"In a preclinical study, SCH772984 did not potentiate the growth inhibition effect of MRK-003 in triple receptor-negative breast cancer cells harboring NOTCH1 rearrangement in culture (PMID: 25104330).",Actionable,4315,60081,triple-receptor negative breast cancer,DOID,17701,NOTCH1 rearrange,no benefit,3492,MRK-003 + SCH772984,4851,25104330,,,
35,Preclinical,"In a preclinical study, MRK-003 and Taxol (paclitaxel) worked synergistically to inhibit tumor growth in triple receptor-negative breast cancer xenograft models harboring NOTCH1 rearrangement, resulting in tumor regression (PMID: 25104330).",Actionable,4318,60081,triple-receptor negative breast cancer,DOID,17701,NOTCH1 rearrange,sensitive,3491,MRK-003 + Paclitaxel,4851,25104330,,,
36,Phase I,"In a Phase I trial, Brontictuzumab (OMP-52M51) treatment resulted in stable disease in 43% (3/7) of advanced solid tumor patients with elevated levels of Notch1 intracellular domain (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr C42).",Actionable,7155,10000003,Advanced Solid Tumor,JAX,4730,NOTCH1 over exp,sensitive,839,Brontictuzumab,4851,None,,,
37,Preclinical,"In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 A1570G in culture (PMID: 25104330).",Actionable,4325,3347,osteosarcoma,DOID,17695,NOTCH1 A1570G,sensitive,1084,MRK-003,4851,25104330,,,
38,Preclinical,"In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 V1676I in culture (PMID: 25104330).",Actionable,4330,3347,osteosarcoma,DOID,879,NOTCH1 V1676I,sensitive,1084,MRK-003,4851,25104330,,,
39,Preclinical,"In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 A1552V in culture (PMID: 25104330).",Actionable,4324,3347,osteosarcoma,DOID,17694,NOTCH1 A1552V,sensitive,1084,MRK-003,4851,25104330,,,
40,Preclinical - Pdx,"In a preclinical study, PF-03084014 treatment resulted in tumor regression in patient derived xenograft animal models of triple receptor negative breast cancer harboring NOTCH1 S2449fs (PMID: 25564152).",Actionable,3666,60081,triple-receptor negative breast cancer,DOID,15929,NOTCH1 S2449fs,sensitive,859,PF-03084014,4851,25564152,,,
41,Preclinical - Cell culture,"In a preclinical study, a T-cell acute lymphoblastic leukemia cell line co-harboring wild-type RB1 and a NOTCH1 mutation demonstrated sensitivity to treatment with Kisqali (ribociclib) in culture, resulting in inhibition of cell growth (PMID: 28151717). ",Actionable,10031,5602,T-cell adult acute lymphocytic leukemia,DOID,27228,NOTCH1 mut RB1 wild-type,sensitive,790,Ribociclib,4851,28151717,,,
42,Preclinical - Cell culture,"In a preclinical study, the addition of Kisqali (ribociclib) to Methotrexate resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717). ",Actionable,10033,5602,T-cell adult acute lymphocytic leukemia,DOID,27228,NOTCH1 mut RB1 wild-type,decreased response,5352,Ribociclib + Methotrexate,4851,28151717,,,
43,Preclinical - Cell culture,"In a preclinical study, the combination of Kisqali (ribociclib) and Afinitor (everolimus) treatment in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation resulted in decreased Rb1 phosphorylation and a greater inhibition of cell growth compared to either agent alone in culture (PMID: 28151717). ",Actionable,10048,5602,T-cell adult acute lymphocytic leukemia,DOID,27228,NOTCH1 mut RB1 wild-type,sensitive,5073,Ribociclib + Everolimus,4851,28151717,,,
44,Preclinical - Cell culture,"In a preclinical study, the combination of Kisqali (ribociclib) and Velcade (bortezomib) resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717). ",Actionable,10052,5602,T-cell adult acute lymphocytic leukemia,DOID,27228,NOTCH1 mut RB1 wild-type,sensitive,5358,Ribociclib + Bortezomib,4851,28151717,,,
45,Preclinical - Cell culture,"In a preclinical study, the combination of Kisqali (ribociclib) and Omnipred (prednisolone) resulted in a synergistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717). ",Actionable,10046,5602,T-cell adult acute lymphocytic leukemia,DOID,27228,NOTCH1 mut RB1 wild-type,sensitive,5356,Ribociclib + Prednisolone,4851,28151717,,,
46,Preclinical - Cell culture,"In a preclinical study, the addition of Kisqali (ribociclib) to Elspar (asparaginase) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717). ",Actionable,10037,5602,T-cell adult acute lymphocytic leukemia,DOID,27228,NOTCH1 mut RB1 wild-type,decreased response,5354,Ribociclib + Asparaginase,4851,28151717,,,
47,Preclinical - Cell culture,"In a preclinical study, the addition of Kisqali (ribociclib) to Purixan (mercaptopurine) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717). ",Actionable,10035,5602,T-cell adult acute lymphocytic leukemia,DOID,27228,NOTCH1 mut RB1 wild-type,decreased response,5353,Ribociclib + Mercaptopurine,4851,28151717,,,
48,Preclinical - Cell culture,"In a preclinical study, the combination of Kisqali (ribociclib) and JQ1 resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717). ",Actionable,10050,5602,T-cell adult acute lymphocytic leukemia,DOID,27228,NOTCH1 mut RB1 wild-type,sensitive,5357,Ribociclib + JQ1,4851,28151717,,,
49,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Kisqali (ribociclib) and Adexone (dexamethasone) treatment in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation resulted in decreased cell viability and reduced phosphorylation of Rb1 in culture, and a greater survival benefit in xenograft models when compared to Kisqali (ribociclib) alone (PMID: 28151717). ",Actionable,10043,5602,T-cell adult acute lymphocytic leukemia,DOID,27228,NOTCH1 mut RB1 wild-type,sensitive,5355,Ribociclib + Dexamethasone,4851,28151717,,,
50,Preclinical - Pdx,"In a preclinical study, PF-03084014 treatment resulted in tumor regression in patient-derived xenograft models of triple receptor negative breast cancer harboring NOTCH1 mutations (PMID: 25564152).",Actionable,3668,60081,triple-receptor negative breast cancer,DOID,14278,NOTCH1 mutant,sensitive,859,PF-03084014,4851,25564152,,,
0,Preclinical,"In a preclinical study, MI-503 inhibited growth of murine leukemia cells expressing an NPM1 mutation and FLT3 internal tandem duplication in culture, and improved survival in mouse models (PMID: 27535106).",Actionable,11489,1240,leukemia,DOID,26135,FLT3 exon 14 ins NPM1 mutant,predicted â€“ sensitive,6006,MI-503,4869,27535106,,,
1,Phase I,"In a Phase I trial, two acute myeloid leukemia patients co-harboring a FLT3-ITD mutation and NPM1 mutation demonstrated anti-leukemia activity when treated with ENMD-2076 (PMID: 27406088). ",Actionable,8008,9119,acute myeloid leukemia,DOID,26135,FLT3 exon 14 ins NPM1 mutant,sensitive,727,ENMD-2076,4869,27406088,,,
2,Preclinical,"In a preclinical study, EPZ004777 inhibited growth and induced differentiation of murine leukemia cells expressing an NPM1 mutation and FLT3 internal tandem duplication in culture, and improved survival in mouse models (PMID: 27535106).",Actionable,11490,1240,leukemia,DOID,26135,FLT3 exon 14 ins NPM1 mutant,predicted â€“ sensitive,1744,EPZ004777,4869,27535106,,,
3,Clinical Study,"In multiple clinical studies, the combination of an NPM1 mutation and FLT3 wild-type in acute myeloid leukemia (AML) patients was associated with a favorable prognosis compared to AML patients harboring an NPM1 mutation and FLT3 internal tandem duplication (PMID: 19047294, PMID: 24573385, PMID: 25713434). ",Prognostic,6501,9119,acute myeloid leukemia,DOID,23600,NPM1 mutant FLT3 wild-type,not applicable,1776,N/A,4869,19047294,24573385,25713434,
4,Preclinical - Patient cell culture,"In a preclinical study, EPZ004777 decreased HOX gene expression, and reduced proliferation and increased differentiation of a human acute myeloid leukemia (AML) cell line and primary AML samples harboring NPM1 mutations in culture (PMID: 27535106).",Actionable,11486,9119,acute myeloid leukemia,DOID,8907,NPM1 mutant,predicted â€“ sensitive,1744,EPZ004777,4869,27535106,,,
5,Preclinical,"In a preclinical study, acute myeloid leukemia cells harboring a NPM1 mutation were sensitive to NSC348884 as demonstrated by induced apoptosis (PMID: 21719597). ",Actionable,2521,9119,acute myeloid leukemia,DOID,8907,NPM1 mutant,sensitive,2905,NSC348884,4869,21719597,,,
6,Clinical Study,"In clinical analyses, mutations in NPM1 were associated with favorable prognosis in acute myeloid leukemia patients with normal karyotype in the absence of a FLT3 ITD mutation (PMID: 26239249, PMID: 26586702, PMID: 26676635, PMID: 16109776). ",Prognostic,5660,9119,acute myeloid leukemia,DOID,8907,NPM1 mutant,not applicable,1776,N/A,4869,16109776,26676635,26586702,26239249
7,Preclinical,"In  preclinical study, treatment with EPZ004777 resulted in reduced proliferation and increased differentiation of murine leukemia cells expressing an NPM1 mutation, and improved survival in NPM1-mutant murine leukemia models (PMID: 27535106).",Actionable,11487,1240,leukemia,DOID,8907,NPM1 mutant,predicted â€“ sensitive,1744,EPZ004777,4869,27535106,,,
8,Phase I,"In a Phase I trial, three acute myeloid leukemia patient harboring an NPM1 mutation demonstrated anti-leukemia activity when treated with ENMD-2076 (PMID: 27406088). ",Actionable,8009,9119,acute myeloid leukemia,DOID,8907,NPM1 mutant,sensitive,727,ENMD-2076,4869,27406088,,,
9,Preclinical - Cell line xenograft,"In a preclinical study, MI-503 inhibited growth of an acute myeloid leukemia cell line and primary AML samples harboring NPM1 mutations in culture, and reduced tumor burden and improved survival in an NPM1-mutant AML cell line xenograft model (PMID: 27535106).",Actionable,11488,9119,acute myeloid leukemia,DOID,8907,NPM1 mutant,predicted â€“ sensitive,6006,MI-503,4869,27535106,,,
10,Clinical Study,"In a retrospective analysis, of patients with acute myeloid leukemia, the combination of DNMT3A, FLT3, and NPM1 mutations was highly associated with decreased event free survival and overall survival, suggesting that this combination profile may serve as a future prognostic biomarker (PMID: 25281355).  ",Emerging,3573,9119,acute myeloid leukemia,DOID,13674,DNMT3A R882H FLT3 Y599_D600insSTDNEYFYVDFREYEY NPM1 W288fs,not applicable,1776,N/A,4869,25281355,,,
11,Preclinical - Cell culture,"In a preclinical study, Ixazomib (MLN9708) and Zolinza (vorinostat) synergistically induced apoptosis in NPMc+ (due to NPM1 exon 12 mutations) acute myeloid leukemia cells in culture (PMID: 26634271).",Actionable,10911,9119,acute myeloid leukemia,DOID,2682,NPM1 exon12,sensitive,1360,Ixazomib + Vorinostat,4869,26634271,,,
12,Preclinical,"In preclinical studies, deguelin treatment of an AML cell line harboring NPM1 exon12 mutation resulted in reduced levels of mutant Npm1 protein and induced differentiation of the cells (PMID: 25242579, PMID: 25348016).",Actionable,1561,9119,acute myeloid leukemia,DOID,2682,NPM1 exon12,sensitive,1867,Deguelin,4869,25242579,,,25348016
13,Clinical Study,"In a clinical study, Ixazomib (MLN9708) treatment resulted in significantly reduced peripheral blast cells in a NPMc+ (due to NPM1 exon 12 mutations) acute myeloid leukemia (AML) patient, and demonstrated selective toxicity towards NPMc+ AML cell lines in culture (PMID: 26634271).",Actionable,10910,9119,acute myeloid leukemia,DOID,2682,NPM1 exon12,predicted â€“ sensitive,1359,Ixazomib,4869,26634271,,,
14,Preclinical,"In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK demonstrated a decreased response compared to parental cell lines harboring NPM1-ALK when treated with Alecensa (alectinib) in culture (PMID: 25421750).",Actionable,3427,50744,anaplastic large cell lymphoma,DOID,13319,NPM1-ALK amp,decreased response,698,Alectinib,4869,25421750,,,
15,Preclinical,"In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK were resistant to ASP3026 treatment in culture (PMID: 25421750).",Actionable,3431,50744,anaplastic large cell lymphoma,DOID,13319,NPM1-ALK amp,resistant,643,ASP3026,4869,25421750,,,
16,Preclinical,"In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK were resistant to Xalkori (crizotinib) treatment in culture (PMID: 25421750).",Actionable,3425,50744,anaplastic large cell lymphoma,DOID,13319,NPM1-ALK amp,resistant,706,Crizotinib,4869,25421750,,,
17,Preclinical,"In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK were resistant to Brigatinib (AP26113) in culture (PMID: 25421750).",Actionable,3432,50744,anaplastic large cell lymphoma,DOID,13319,NPM1-ALK amp,resistant,634,AP26113,4869,25421750,,,
18,Preclinical,"In a preclinical study, anaplastic large cell lymphoma cell lines harboring an amplification of NPM1-ALK were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750).",Actionable,3426,50744,anaplastic large cell lymphoma,DOID,13319,NPM1-ALK amp,resistant,789,Ceritinib,4869,25421750,,,
19,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited the growth of transformed cells expressing NPM1-ALK with ALK F1174L in culture (PMID: 27009859).",Actionable,5344,10000003,Advanced Solid Tumor,JAX,20659,NPM1-ALK ALK F1174L,sensitive,634,AP26113,4869,27009859,,,
20,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK F1174L were resistant to Zykadia (ceritinib) in culture (PMID: 27009859).",Actionable,5352,50744,anaplastic large cell lymphoma,DOID,20659,NPM1-ALK ALK F1174L,resistant,789,Ceritinib,4869,27009859,,,
21,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5341,10000003,Advanced Solid Tumor,JAX,20659,NPM1-ALK ALK F1174L,resistant,698,Alectinib,4869,27009859,,,
22,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5346,10000003,Advanced Solid Tumor,JAX,20659,NPM1-ALK ALK F1174L,resistant,643,ASP3026,4869,27009859,,,
23,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to AZD3463 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5347,10000003,Advanced Solid Tumor,JAX,20659,NPM1-ALK ALK F1174L,resistant,1586,AZD3463,4869,27009859,,,
24,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5339,10000003,Advanced Solid Tumor,JAX,20659,NPM1-ALK ALK F1174L,resistant,789,Ceritinib,4869,27009859,,,
25,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174L were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5337,10000003,Advanced Solid Tumor,JAX,20659,NPM1-ALK ALK F1174L,resistant,706,Crizotinib,4869,27009859,,,
26,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK with ALK E1210K were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).",Actionable,5415,50744,anaplastic large cell lymphoma,DOID,20888,NPM1-ALK ALK E1210K,resistant,643,ASP3026,4869,25749034,,,
27,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with E1210K were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).",Actionable,5490,10000003,Advanced Solid Tumor,JAX,20888,NPM1-ALK ALK E1210K,resistant,789,Ceritinib,4869,25749034,,,
28,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to Alecensa (alectinib) in culture (PMID: 25749034).",Actionable,5439,10000003,Advanced Solid Tumor,JAX,20888,NPM1-ALK ALK E1210K,resistant,698,Alectinib,4869,25749034,,,
29,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to Brigatinib (AP26113) in culture (PMID: 25749034).",Actionable,5431,10000003,Advanced Solid Tumor,JAX,20888,NPM1-ALK ALK E1210K,resistant,634,AP26113,4869,25749034,,,
30,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).",Actionable,5501,10000003,Advanced Solid Tumor,JAX,20888,NPM1-ALK ALK E1210K,resistant,869,PF-06463922,4869,25749034,,,
31,Preclinical,"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK E1210K in culture (PMID: 25749034).",Actionable,5483,10000003,Advanced Solid Tumor,JAX,20888,NPM1-ALK ALK E1210K,sensitive,706,Crizotinib,4869,25749034,,,
32,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK E1210K were resistant to ASP3026 in culture (PMID: 25749034).",Actionable,5422,10000003,Advanced Solid Tumor,JAX,20888,NPM1-ALK ALK E1210K,resistant,643,ASP3026,4869,25749034,,,
33,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to Brigatinib (AP26113) treatment in culture (PMID: 25421750).",Actionable,3444,10000003,Advanced Solid Tumor,JAX,13325,NPM1-ALK ALK L1198F,resistant,634,AP26113,4869,25421750,,,
34,Preclinical,"In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1198F in culture (PMID: 25421750).",Actionable,3457,10000003,Advanced Solid Tumor,JAX,13325,NPM1-ALK ALK L1198F,sensitive,706,Crizotinib,4869,25421750,,,
35,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750).",Actionable,3481,10000003,Advanced Solid Tumor,JAX,13325,NPM1-ALK ALK L1198F,resistant,789,Ceritinib,4869,25421750,,,
36,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).",Actionable,3462,10000003,Advanced Solid Tumor,JAX,13325,NPM1-ALK ALK L1198F,resistant,698,Alectinib,4869,25421750,,,
37,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1198F were resistant to ASP3026 treatment in culture (PMID: 25421750).",Actionable,3555,10000003,Advanced Solid Tumor,JAX,13325,NPM1-ALK ALK L1198F,resistant,643,ASP3026,4869,25421750,,,
38,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Alecensa (alectinib) in culture (PMID: 25749034).",Actionable,5436,10000003,Advanced Solid Tumor,JAX,20881,NPM1-ALK ALK C1156F,resistant,698,Alectinib,4869,25749034,,,
39,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).",Actionable,5495,10000003,Advanced Solid Tumor,JAX,20881,NPM1-ALK ALK C1156F,resistant,869,PF-06463922,4869,25749034,,,
40,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Brigatinib (AP26113) in culture (PMID: 25749034).",Actionable,5427,10000003,Advanced Solid Tumor,JAX,20881,NPM1-ALK ALK C1156F,resistant,634,AP26113,4869,25749034,,,
41,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to ASP3026 in culture (PMID: 25749034).",Actionable,5421,10000003,Advanced Solid Tumor,JAX,20881,NPM1-ALK ALK C1156F,resistant,643,ASP3026,4869,25749034,,,
42,Preclinical,"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK C1156F in culture (PMID: 25749034).",Actionable,5480,10000003,Advanced Solid Tumor,JAX,20881,NPM1-ALK ALK C1156F,sensitive,706,Crizotinib,4869,25749034,,,
43,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).",Actionable,5486,10000003,Advanced Solid Tumor,JAX,20881,NPM1-ALK ALK C1156F,resistant,789,Ceritinib,4869,25749034,,,
44,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK C1156F were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).",Actionable,5416,50744,anaplastic large cell lymphoma,DOID,20881,NPM1-ALK ALK C1156F,resistant,643,ASP3026,4869,25749034,,,
45,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK with ALK F1174I were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).",Actionable,5392,50744,anaplastic large cell lymphoma,DOID,20772,NPM1-ALK ALK F1174I,resistant,643,ASP3026,4869,25749034,,,
46,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).",Actionable,5435,10000003,Advanced Solid Tumor,JAX,20772,NPM1-ALK ALK F1174I,sensitive,634,AP26113,4869,25749034,,,
47,Preclinical,"In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).",Actionable,5484,10000003,Advanced Solid Tumor,JAX,20772,NPM1-ALK ALK F1174I,sensitive,789,Ceritinib,4869,25749034,,,
48,Preclinical,"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).",Actionable,5481,10000003,Advanced Solid Tumor,JAX,20772,NPM1-ALK ALK F1174I,sensitive,706,Crizotinib,4869,25749034,,,
49,Preclinical,"In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).",Actionable,5493,10000003,Advanced Solid Tumor,JAX,20772,NPM1-ALK ALK F1174I,sensitive,869,PF-06463922,4869,25749034,,,
50,Preclinical,"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174I in culture (PMID: 25749034).",Actionable,5433,10000003,Advanced Solid Tumor,JAX,20772,NPM1-ALK ALK F1174I,sensitive,698,Alectinib,4869,25749034,,,
51,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174I were resistant to ASP3026 relative to wild type NPM1-ALK in culture (PMID: 25749034).",Actionable,5424,10000003,Advanced Solid Tumor,JAX,20772,NPM1-ALK ALK F1174I,resistant,643,ASP3026,4869,25749034,,,
52,Preclinical,"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3465,10000003,Advanced Solid Tumor,JAX,13321,NPM1-ALK ALK F1174V,decreased response,698,Alectinib,4869,25421750,,,
53,Preclinical,"In a preclinical trial, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V in culture (PMID: 25421750).",Actionable,3484,10000003,Advanced Solid Tumor,JAX,13321,NPM1-ALK ALK F1174V,sensitive,789,Ceritinib,4869,25421750,,,
54,Preclinical,"In a preclinical trial, ASP3026 inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3557,10000003,Advanced Solid Tumor,JAX,13321,NPM1-ALK ALK F1174V,decreased response,643,ASP3026,4869,25421750,,,
55,Preclinical,"In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V in culture (PMID: 25421750).",Actionable,3456,10000003,Advanced Solid Tumor,JAX,13321,NPM1-ALK ALK F1174V,sensitive,706,Crizotinib,4869,25421750,,,
56,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V in culture (PMID: 25421750).",Actionable,3443,10000003,Advanced Solid Tumor,JAX,13321,NPM1-ALK ALK F1174V,sensitive,634,AP26113,4869,25421750,,,
57,Preclinical,"In a preclinical study, ASP3026 inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S in culture (PMID: 25421750).",Actionable,3549,10000003,Advanced Solid Tumor,JAX,13329,NPM1-ALK ALK P1139S,sensitive,643,ASP3026,4869,25421750,,,
58,Preclinical,"In a preclinical trial, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S in culture (PMID: 25421750).",Actionable,3464,10000003,Advanced Solid Tumor,JAX,13329,NPM1-ALK ALK P1139S,sensitive,698,Alectinib,4869,25421750,,,
59,Preclinical,"In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S in culture (PMID: 25421750).",Actionable,3455,10000003,Advanced Solid Tumor,JAX,13329,NPM1-ALK ALK P1139S,sensitive,706,Crizotinib,4869,25421750,,,
60,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing NPM1-ALK P1139S in culture (PMID: 25421750).",Actionable,3446,10000003,Advanced Solid Tumor,JAX,13329,NPM1-ALK ALK P1139S,sensitive,634,AP26113,4869,25421750,,,
61,Preclinical,"In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK P1139S to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3486,10000003,Advanced Solid Tumor,JAX,13329,NPM1-ALK ALK P1139S,decreased response,789,Ceritinib,4869,25421750,,,
62,Preclinical,"In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3454,10000003,Advanced Solid Tumor,JAX,13320,NPM1-ALK ALK L1196M,decreased response,706,Crizotinib,4869,25421750,,,
63,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M in culture (PMID: 25421750).",Actionable,3437,10000003,Advanced Solid Tumor,JAX,13320,NPM1-ALK ALK L1196M,sensitive,634,AP26113,4869,25421750,,,
64,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with  ALK L1196M were resistant to ASP3026 treatment in culture (PMID: 25421750).",Actionable,3554,10000003,Advanced Solid Tumor,JAX,13320,NPM1-ALK ALK L1196M,resistant,643,ASP3026,4869,25421750,,,
65,Preclinical,"In a preclinical trial, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M in culture (PMID: 25421750).",Actionable,3485,10000003,Advanced Solid Tumor,JAX,13320,NPM1-ALK ALK L1196M,sensitive,789,Ceritinib,4869,25421750,,,
66,Preclinical,"In a preclinical trial, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3466,10000003,Advanced Solid Tumor,JAX,13320,NPM1-ALK ALK L1196M,decreased response,698,Alectinib,4869,25421750,,,
67,Preclinical,"In a preclinical study, ASP3026 inhibited growth of transformed cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3450,10000003,Advanced Solid Tumor,JAX,11406,NPM1-ALK,sensitive,643,ASP3026,4869,25421750,,,
68,Preclinical,"In a preclinical study, Alecensa (alectinib) inhibited growth of an anaplastic large cell lymphoma cell line harboring NPM1-ALK in culture (PMID: 25421750).",Actionable,3428,50744,anaplastic large cell lymphoma,DOID,11406,NPM1-ALK,sensitive,698,Alectinib,4869,25421750,,,
69,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3445,10000003,Advanced Solid Tumor,JAX,11406,NPM1-ALK,sensitive,634,AP26113,4869,25421750,,,
70,Preclinical,"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3447,10000003,Advanced Solid Tumor,JAX,11406,NPM1-ALK,sensitive,706,Crizotinib,4869,25421750,,,
71,Preclinical,"In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3449,10000003,Advanced Solid Tumor,JAX,11406,NPM1-ALK,sensitive,789,Ceritinib,4869,25421750,,,
72,Preclinical,"In a preclinical study, TAE684 inhibited proliferation of transformed cells expressing NPM1-ALK in culture (PMID: 20207848). ",Actionable,3112,10000003,Advanced Solid Tumor,JAX,11406,NPM1-ALK,sensitive,2386,TAE684,4869,20207848,,,
73,Preclinical,"In a preclinical study, anaplastic large cell lymphoma cells harboring NPM1-ALK were sensitive to Entrectinib (RXDX-101) in culture and in mouse models, resulting in inhibition of NPM1-ALK autophosphorylation and near complete tumor regression (PMID: 26939704).",Actionable,5635,50744,anaplastic large cell lymphoma,DOID,11406,NPM1-ALK,sensitive,1455,Entrectinib,4869,26939704,,,
74,Preclinical,"In a preclinical study, ASP3026 inhibited growth of an anaplastic large cell lymphoma cell line harboring NPM1-ALK in culture (PMID: 25421750).",Actionable,3429,50744,anaplastic large cell lymphoma,DOID,11406,NPM1-ALK,sensitive,643,ASP3026,4869,25421750,,,
75,Preclinical - Cell line xenograft,"In a preclinical study, Xalkori (crizotinib) inhibited cell growth, Alk phosphorylation, downstream signaling and induced apoptosis in human anaplastic large cell lymphoma cell lines harboring a NPM1-ALK fusion in culture and in xenograft models (PMID: 18089725).",Actionable,3110,50744,anaplastic large cell lymphoma,DOID,11406,NPM1-ALK,sensitive,706,Crizotinib,4869,18089725,,,
76,Preclinical,"In a preclinical study, Zykadia (ceritinib) inhibited growth of an anaplastic large cell lymphoma cell line harboring NPM1-ALK in culture (PMID: 25421750).",Actionable,3430,50744,anaplastic large cell lymphoma,DOID,11406,NPM1-ALK,sensitive,789,Ceritinib,4869,25421750,,,
77,Preclinical - Cell line xenograft,"In a preclinical study, Brigatinib (AP26113) inhibited Alk phosphorylation and growth in anaplastic large cell lymphoma cell lines harboring NPM1-ALK in culture, and induced near complete tumor regression in cell line xenograft models (PMID: 27780853).",Actionable,3433,50744,anaplastic large cell lymphoma,DOID,11406,NPM1-ALK,sensitive,634,AP26113,4869,27780853,,,
78,Preclinical,"In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing NPM1-ALK in culture (PMID: 25749034).",Actionable,5492,10000003,Advanced Solid Tumor,JAX,11406,NPM1-ALK,sensitive,869,PF-06463922,4869,25749034,,,
79,Preclinical,"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3448,10000003,Advanced Solid Tumor,JAX,11406,NPM1-ALK,sensitive,698,Alectinib,4869,25421750,,,
80,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK C1156Y were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).",Actionable,5410,50744,anaplastic large cell lymphoma,DOID,20770,NPM1-ALK ALK C1156Y,resistant,643,ASP3026,4869,25749034,,,
81,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited the growth of transformed cells expressing NPM1-ALK with ALK G1269A in culture (PMID: 27009859).",Actionable,5381,10000003,Advanced Solid Tumor,JAX,20662,NPM1-ALK ALK G1269A,sensitive,634,AP26113,4869,27009859,,,
82,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1269A were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5378,10000003,Advanced Solid Tumor,JAX,20662,NPM1-ALK ALK G1269A,resistant,706,Crizotinib,4869,27009859,,,
83,Preclinical,"In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing NPM1-ALK with ALK G1269A in culture (PMID: 27009859).",Actionable,5383,10000003,Advanced Solid Tumor,JAX,20662,NPM1-ALK ALK G1269A,sensitive,1586,AZD3463,4869,27009859,,,
84,Preclinical,"In a preclinical study, ASP3026 inhibited the growth of transformed cells expressing NPM1-ALK with ALK G1269A in culture (PMID: 27009859).",Actionable,5382,10000003,Advanced Solid Tumor,JAX,20662,NPM1-ALK ALK G1269A,sensitive,643,ASP3026,4869,27009859,,,
85,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK G1269A were resistant to Xalkori (crizotinib) in culture (PMID: 27009859).",Actionable,5351,50744,anaplastic large cell lymphoma,DOID,20662,NPM1-ALK ALK G1269A,resistant,706,Crizotinib,4869,27009859,,,
86,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1269A were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5380,10000003,Advanced Solid Tumor,JAX,20662,NPM1-ALK ALK G1269A,resistant,698,Alectinib,4869,27009859,,,
87,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1269A were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5379,10000003,Advanced Solid Tumor,JAX,20662,NPM1-ALK ALK G1269A,resistant,789,Ceritinib,4869,27009859,,,
88,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to Brigatinib (AP26113) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5369,10000003,Advanced Solid Tumor,JAX,20657,NPM1-ALK ALK T1151M,resistant,634,AP26113,4869,27009859,,,
89,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5368,10000003,Advanced Solid Tumor,JAX,20657,NPM1-ALK ALK T1151M,resistant,698,Alectinib,4869,27009859,,,
90,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to AZD3463 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5371,10000003,Advanced Solid Tumor,JAX,20657,NPM1-ALK ALK T1151M,resistant,1586,AZD3463,4869,27009859,,,
91,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK T1151M were resistant to Zykadia (ceritinib) in culture (PMID: 27009859).",Actionable,5353,50744,anaplastic large cell lymphoma,DOID,20657,NPM1-ALK ALK T1151M,resistant,789,Ceritinib,4869,27009859,,,
92,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5366,10000003,Advanced Solid Tumor,JAX,20657,NPM1-ALK ALK T1151M,resistant,706,Crizotinib,4869,27009859,,,
93,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5367,10000003,Advanced Solid Tumor,JAX,20657,NPM1-ALK ALK T1151M,resistant,789,Ceritinib,4869,27009859,,,
94,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK T1151M were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5370,10000003,Advanced Solid Tumor,JAX,20657,NPM1-ALK ALK T1151M,resistant,643,ASP3026,4869,27009859,,,
95,Preclinical,"In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3483,10000003,Advanced Solid Tumor,JAX,13342,NPM1-ALK ALK L1196M ALK D1203N,decreased response,789,Ceritinib,4869,25421750,,,
96,Preclinical,"In a preclinical trial, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3467,10000003,Advanced Solid Tumor,JAX,13342,NPM1-ALK ALK L1196M ALK D1203N,decreased response,698,Alectinib,4869,25421750,,,
97,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N were resistant to Brigatinib (AP26113) treatment in culture (PMID: 25421750).",Actionable,3442,10000003,Advanced Solid Tumor,JAX,13342,NPM1-ALK ALK L1196M ALK D1203N,resistant,634,AP26113,4869,25421750,,,
98,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N were resistant to Xalkori (crizotinib) treatment in culture (PMID: 25421750).",Actionable,3452,10000003,Advanced Solid Tumor,JAX,13342,NPM1-ALK ALK L1196M ALK D1203N,resistant,706,Crizotinib,4869,25421750,,,
99,Preclinical,"In a preclinical study, ASP3026 inhibited growth of transformed cells expressing NPM1-ALK with ALK L1196M and ALK D1203N in culture (PMID: 25421750).",Actionable,3550,10000003,Advanced Solid Tumor,JAX,13342,NPM1-ALK ALK L1196M ALK D1203N,sensitive,643,ASP3026,4869,25421750,,,
100,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).",Actionable,3459,10000003,Advanced Solid Tumor,JAX,13326,NPM1-ALK ALK L1122V,resistant,698,Alectinib,4869,25421750,,,
101,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V were resistant to Brigatinib (AP26113) treatment in culture (PMID: 25421750).",Actionable,3441,10000003,Advanced Solid Tumor,JAX,13326,NPM1-ALK ALK L1122V,resistant,634,AP26113,4869,25421750,,,
102,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V were resistant to ASP3026 treatment in culture (PMID: 25421750).",Actionable,3551,10000003,Advanced Solid Tumor,JAX,13326,NPM1-ALK ALK L1122V,resistant,643,ASP3026,4869,25421750,,,
103,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750).",Actionable,3480,10000003,Advanced Solid Tumor,JAX,13326,NPM1-ALK ALK L1122V,resistant,789,Ceritinib,4869,25421750,,,
104,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK N1178H were resistant to Brigatinib (AP26113) in culture (PMID: 25749034).",Actionable,5430,10000003,Advanced Solid Tumor,JAX,20899,NPM1-ALK ALK N1178H,resistant,634,AP26113,4869,25749034,,,
105,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK N1178H were resistant to ASP3026 in culture (PMID: 25749034).",Actionable,5425,10000003,Advanced Solid Tumor,JAX,20899,NPM1-ALK ALK N1178H,decreased response,643,ASP3026,4869,25749034,,,
106,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK N1178H were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).",Actionable,5417,50744,anaplastic large cell lymphoma,DOID,20899,NPM1-ALK ALK N1178H,resistant,643,ASP3026,4869,25749034,,,
107,Preclinical,"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK N1178H in culture (PMID: 25749034).",Actionable,5482,10000003,Advanced Solid Tumor,JAX,20899,NPM1-ALK ALK N1178H,sensitive,706,Crizotinib,4869,25749034,,,
108,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK N1178H were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).",Actionable,5499,10000003,Advanced Solid Tumor,JAX,20899,NPM1-ALK ALK N1178H,resistant,869,PF-06463922,4869,25749034,,,
109,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK N1178H were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).",Actionable,5489,10000003,Advanced Solid Tumor,JAX,20899,NPM1-ALK ALK N1178H,resistant,789,Ceritinib,4869,25749034,,,
110,Preclinical,"In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK N1178H in culture (PMID: 25749034).",Actionable,5434,10000003,Advanced Solid Tumor,JAX,20899,NPM1-ALK ALK N1178H,sensitive,698,Alectinib,4869,25749034,,,
111,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to Alecensa (alectinib) in culture (PMID: 25749034).",Actionable,5441,10000003,Advanced Solid Tumor,JAX,20894,NPM1-ALK ALK G1128S,resistant,698,Alectinib,4869,25749034,,,
112,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing NPM1-ALK with ALK G1128S in culture (PMID: 25749034).",Actionable,5426,10000003,Advanced Solid Tumor,JAX,20894,NPM1-ALK ALK G1128S,sensitive,634,AP26113,4869,25749034,,,
113,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).",Actionable,5485,10000003,Advanced Solid Tumor,JAX,20894,NPM1-ALK ALK G1128S,resistant,789,Ceritinib,4869,25749034,,,
114,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK G1128S were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).",Actionable,5413,50744,anaplastic large cell lymphoma,DOID,20894,NPM1-ALK ALK G1128S,resistant,643,ASP3026,4869,25749034,,,
115,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to Xalkori (critzotinb) in culture (PMID: 25749034).",Actionable,5476,10000003,Advanced Solid Tumor,JAX,20894,NPM1-ALK ALK G1128S,resistant,706,Crizotinib,4869,25749034,,,
116,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to ASP3026 in culture (PMID: 25749034).",Actionable,5420,10000003,Advanced Solid Tumor,JAX,20894,NPM1-ALK ALK G1128S,resistant,643,ASP3026,4869,25749034,,,
117,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK G1128S were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).",Actionable,5494,10000003,Advanced Solid Tumor,JAX,20894,NPM1-ALK ALK G1128S,resistant,869,PF-06463922,4869,25749034,,,
118,Preclinical,"In a preclinical study, anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Brigatinib (AP26113) in culture (PMID: 25421750).",Actionable,3435,50744,anaplastic large cell lymphoma,DOID,13328,NPM1-ALK ALK L1122V ALK L1196M,resistant,634,AP26113,4869,25421750,,,
119,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).",Actionable,3460,10000003,Advanced Solid Tumor,JAX,13328,NPM1-ALK ALK L1122V ALK L1196M,resistant,698,Alectinib,4869,25421750,,,
120,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Xalkori (crizotinib) treatment in culture (PMID: 25421750).",Actionable,3451,10000003,Advanced Solid Tumor,JAX,13328,NPM1-ALK ALK L1122V ALK L1196M,resistant,706,Crizotinib,4869,25421750,,,
121,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to ASP3026 treatment in culture (PMID: 25421750).",Actionable,3552,10000003,Advanced Solid Tumor,JAX,13328,NPM1-ALK ALK L1122V ALK L1196M,resistant,643,ASP3026,4869,25421750,,,
122,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK L1122V and ALK L1196M were resistant to Brigatinib (AP26113) treatment in culture (PMID: 25421750).",Actionable,3440,10000003,Advanced Solid Tumor,JAX,13328,NPM1-ALK ALK L1122V ALK L1196M,resistant,634,AP26113,4869,25421750,,,
123,Preclinical,"In a preclinical study, anaplastic large cell lymphoma cell lines harboring NPM1-ALK ALK S1206C were resistant to brigatinib (AP26113) in culture (PMID: 25421750).",Actionable,3436,50744,anaplastic large cell lymphoma,DOID,13332,NPM1-ALK ALK S1206C,resistant,634,AP26113,4869,25421750,,,
124,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK S1206C were resistant to Brigatinib (AP26113) treatment in culture (PMID: 25421750).",Actionable,3439,10000003,Advanced Solid Tumor,JAX,13332,NPM1-ALK ALK S1206C,resistant,634,AP26113,4869,25421750,,,
125,Preclinical,"In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK S1206C to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3487,10000003,Advanced Solid Tumor,JAX,13332,NPM1-ALK ALK S1206C,decreased response,789,Ceritinib,4869,25421750,,,
126,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK S1206C were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).",Actionable,3463,10000003,Advanced Solid Tumor,JAX,13332,NPM1-ALK ALK S1206C,resistant,698,Alectinib,4869,25421750,,,
127,Preclinical,"In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK ALK S1206C to a lesser degree than cells expressing NPM1-ALK in culture (PMID: 25421750).",Actionable,3453,10000003,Advanced Solid Tumor,JAX,13332,NPM1-ALK ALK S1206C,decreased response,706,Crizotinib,4869,25421750,,,
128,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK and ALK S1206C were resistant to ASP3026 treatment in culture (PMID: 25421750).",Actionable,3556,10000003,Advanced Solid Tumor,JAX,13332,NPM1-ALK ALK S1206C,resistant,643,ASP3026,4869,25421750,,,
129,Preclinical,"In a preclinical study, ASP3026 inhibited growth of human anaplastic large cell lymphoma cell lines harboring NPM1-ALK containing the crizotinib-resistant mutation ALK L1196Q in culture (PMID: 25749034).",Actionable,5503,50744,anaplastic large cell lymphoma,DOID,20952,NPM1-ALK ALK L1196Q,sensitive,643,ASP3026,4869,25749034,,,
130,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK containing ALK L1196Q were resistant to Xalkori (crizotinib) in culture (PMID: 25749034).",Actionable,5504,50744,anaplastic large cell lymphoma,DOID,20952,NPM1-ALK ALK L1196Q,resistant,706,Crizotinib,4869,25749034,,,
131,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Brigatinib (AP26113) in culture (PMID: 25749034).",Actionable,5428,10000003,Advanced Solid Tumor,JAX,20769,NPM1-ALK ALK I1171N,resistant,634,AP26113,4869,25749034,,,
132,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).",Actionable,5487,10000003,Advanced Solid Tumor,JAX,20769,NPM1-ALK ALK I1171N,resistant,789,Ceritinib,4869,25749034,,,
133,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK I1171N were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).",Actionable,5412,50744,anaplastic large cell lymphoma,DOID,20769,NPM1-ALK ALK I1171N,resistant,643,ASP3026,4869,25749034,,,
134,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Xalkori (critzotinb) in culture (PMID: 25749034).",Actionable,5477,10000003,Advanced Solid Tumor,JAX,20769,NPM1-ALK ALK I1171N,resistant,706,Crizotinib,4869,25749034,,,
135,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to ASP3026 in culture (PMID: 25749034).",Actionable,5418,10000003,Advanced Solid Tumor,JAX,20769,NPM1-ALK ALK I1171N,resistant,643,ASP3026,4869,25749034,,,
136,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Alecensa (alectinib) in culture (PMID: 25749034).",Actionable,5437,10000003,Advanced Solid Tumor,JAX,20769,NPM1-ALK ALK I1171N,resistant,698,Alectinib,4869,25749034,,,
137,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171N were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).",Actionable,5496,10000003,Advanced Solid Tumor,JAX,20769,NPM1-ALK ALK I1171N,resistant,869,PF-06463922,4869,25749034,,,
138,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited the growth of transformed cells expressing NPM1-ALK with ALK R1192P in culture (PMID: 27009859).",Actionable,5357,10000003,Advanced Solid Tumor,JAX,20661,NPM1-ALK ALK R1192P,sensitive,634,AP26113,4869,27009859,,,
139,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK R1192P were resistant to Xalkori (crizotinib) in culture (PMID: 27009859).",Actionable,5350,50744,anaplastic large cell lymphoma,DOID,20661,NPM1-ALK ALK R1192P,resistant,706,Crizotinib,4869,27009859,,,
140,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5355,10000003,Advanced Solid Tumor,JAX,20661,NPM1-ALK ALK R1192P,resistant,789,Ceritinib,4869,27009859,,,
141,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P had a reduced response to AZD3463 mediated growth inhibition in culture relative to NPM1-ALK (PMID: 27009859).",Actionable,5359,10000003,Advanced Solid Tumor,JAX,20661,NPM1-ALK ALK R1192P,decreased response,1586,AZD3463,4869,27009859,,,
142,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to Xalkori (Crizotinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5354,10000003,Advanced Solid Tumor,JAX,20661,NPM1-ALK ALK R1192P,resistant,706,Crizotinib,4869,27009859,,,
143,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5356,10000003,Advanced Solid Tumor,JAX,20661,NPM1-ALK ALK R1192P,resistant,698,Alectinib,4869,27009859,,,
144,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK R1192P were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5358,10000003,Advanced Solid Tumor,JAX,20661,NPM1-ALK ALK R1192P,resistant,643,ASP3026,4869,27009859,,,
145,Preclinical,"In a preclinical study, Brigatinib (AP26113) inhibited the growth of transformed cells expressing NPM1-ALK with ALK I1171S in culture (PMID: 27009859).",Actionable,5332,10000003,Advanced Solid Tumor,JAX,20654,NPM1-ALK ALK I1171S,sensitive,634,AP26113,4869,27009859,,,
146,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171S were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).",Actionable,5334,10000003,Advanced Solid Tumor,JAX,20654,NPM1-ALK ALK I1171S,resistant,643,ASP3026,4869,27009859,,,
147,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171S were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5327,10000003,Advanced Solid Tumor,JAX,20654,NPM1-ALK ALK I1171S,resistant,789,Ceritinib,4869,27009859,,,
148,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171S were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5329,10000003,Advanced Solid Tumor,JAX,20654,NPM1-ALK ALK I1171S,resistant,698,Alectinib,4869,27009859,,,
149,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171S were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).",Actionable,5326,10000003,Advanced Solid Tumor,JAX,20654,NPM1-ALK ALK I1171S,resistant,706,Crizotinib,4869,27009859,,,
150,Preclinical,"In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing NPM1-ALK with ALK I1171S in culture (PMID: 27009859).",Actionable,5335,10000003,Advanced Solid Tumor,JAX,20654,NPM1-ALK ALK I1171S,sensitive,1586,AZD3463,4869,27009859,,,
151,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK I1161S were resistant to Xalkori (crizotinib) in culture (PMID: 27009859).",Actionable,5349,50744,anaplastic large cell lymphoma,DOID,20654,NPM1-ALK ALK I1171S,resistant,706,Crizotinib,4869,27009859,,,
152,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK I1171T were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).",Actionable,5411,50744,anaplastic large cell lymphoma,DOID,5337,NPM1-ALK ALK I1171T,resistant,643,ASP3026,4869,25749034,,,
153,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Xalkori (critzotinb) in culture (PMID: 25749034).",Actionable,5478,10000003,Advanced Solid Tumor,JAX,5337,NPM1-ALK ALK I1171T,resistant,706,Crizotinib,4869,25749034,,,
154,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).",Actionable,5488,10000003,Advanced Solid Tumor,JAX,5337,NPM1-ALK ALK I1171T,resistant,789,Ceritinib,4869,25749034,,,
155,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Brigatinib (AP26113) in culture (PMID: 25749034).",Actionable,5429,10000003,Advanced Solid Tumor,JAX,5337,NPM1-ALK ALK I1171T,resistant,634,AP26113,4869,25749034,,,
156,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to ASP3026 in culture (PMID: 25749034).",Actionable,5419,10000003,Advanced Solid Tumor,JAX,5337,NPM1-ALK ALK I1171T,resistant,643,ASP3026,4869,25749034,,,
157,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).",Actionable,5497,10000003,Advanced Solid Tumor,JAX,5337,NPM1-ALK ALK I1171T,resistant,869,PF-06463922,4869,25749034,,,
158,Preclinical,"In a preclinical study, an anaplastic large-cell lymphoma cell line expressing NPM-ALK I1171T demonstrated resistance to Xalkori (crizotinib) in culture (PMID: 24509625).",Actionable,2057,50744,anaplastic large cell lymphoma,DOID,5337,NPM1-ALK ALK I1171T,resistant,706,Crizotinib,4869,24509625,,,
159,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK I1171T were resistant to Alecensa (alectinib) in culture (PMID: 25749034).",Actionable,5438,10000003,Advanced Solid Tumor,JAX,5337,NPM1-ALK ALK I1171T,resistant,698,Alectinib,4869,25749034,,,
160,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with C1156F and D1203N were resistant to Zykadia (ceritinib) in culture (PMID: 25749034).",Actionable,5491,10000003,Advanced Solid Tumor,JAX,20896,NPM1-ALK ALK C1156F ALK D1203N,resistant,789,Ceritinib,4869,25749034,,,
161,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and ALK D1203N were resistant to Lorlatinib (PF-06463922) in culture (PMID: 25749034).",Actionable,5502,10000003,Advanced Solid Tumor,JAX,20896,NPM1-ALK ALK C1156F ALK D1203N,resistant,869,PF-06463922,4869,25749034,,,
162,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and ALK D1203N were resistant to ASP3026 in culture (PMID: 25749034).",Actionable,5423,10000003,Advanced Solid Tumor,JAX,20896,NPM1-ALK ALK C1156F ALK D1203N,resistant,643,ASP3026,4869,25749034,,,
163,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and D1203N were resistant to Xalkori (critzotinb) in culture (PMID: 25749034).",Actionable,5479,10000003,Advanced Solid Tumor,JAX,20896,NPM1-ALK ALK C1156F ALK D1203N,resistant,706,Crizotinib,4869,25749034,,,
164,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and D1203N were resistant to Brigatinib (AP26113) in culture (PMID: 25749034).",Actionable,5432,10000003,Advanced Solid Tumor,JAX,20896,NPM1-ALK ALK C1156F ALK D1203N,resistant,634,AP26113,4869,25749034,,,
165,Preclinical,"In a preclinical study, human anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK with ALK C1156F and D1203N were resistant to ASP3026 mediated growth inhibition in culture (PMID: 25749034).",Actionable,5414,50744,anaplastic large cell lymphoma,DOID,20896,NPM1-ALK ALK C1156F ALK D1203N,resistant,643,ASP3026,4869,25749034,,,
166,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK C1156F and D1203N were resistant to Alecensa (alectinib) in culture (PMID: 25749034).",Actionable,5440,10000003,Advanced Solid Tumor,JAX,20896,NPM1-ALK ALK C1156F ALK D1203N,resistant,698,Alectinib,4869,25749034,,,
167,Preclinical,"In a preclinical study, anaplastic large cell lymphoma cell lines harboring NPM1-ALK with ALK F1174V and ALK L1198F were resistant to Brigatinib (AP26113) in culture (PMID: 25421750).",Actionable,3434,50744,anaplastic large cell lymphoma,DOID,13333,NPM1-ALK ALK F1174V ALK L1198F,resistant,634,AP26113,4869,25421750,,,
168,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK1198F were resistant to Brigatinib (AP26113) treatment in culture (PMID: 25421750).",Actionable,3438,10000003,Advanced Solid Tumor,JAX,13333,NPM1-ALK ALK F1174V ALK L1198F,resistant,634,AP26113,4869,25421750,,,
169,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F were resistant to Alecensa (alectinib) treatment in culture (PMID: 25421750).",Actionable,3461,10000003,Advanced Solid Tumor,JAX,13333,NPM1-ALK ALK F1174V ALK L1198F,resistant,698,Alectinib,4869,25421750,,,
170,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F were resistant to ASP3026 treatment in culture (PMID: 25421750).",Actionable,3553,10000003,Advanced Solid Tumor,JAX,13333,NPM1-ALK ALK F1174V ALK L1198F,resistant,643,ASP3026,4869,25421750,,,
171,Preclinical,"In a preclinical trial, Xalkori (crizotinib) inhibited growth of transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F in culture (PMID: 25421750).",Actionable,3458,10000003,Advanced Solid Tumor,JAX,13333,NPM1-ALK ALK F1174V ALK L1198F,sensitive,706,Crizotinib,4869,25421750,,,
172,Preclinical,"In a preclinical study, transformed cells expressing NPM1-ALK with ALK F1174V and ALK L1198F were resistant to Zykadia (ceritinib) treatment in culture (PMID: 25421750).",Actionable,3482,10000003,Advanced Solid Tumor,JAX,13333,NPM1-ALK ALK F1174V ALK L1198F,resistant,789,Ceritinib,4869,25421750,,,
0,Preclinical,"In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).",Actionable,5994,1909,melanoma,DOID,22046,BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S,sensitive,3027,GSK2126458 + Trametinib,4893,22389471,,,
1,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, A146T and MAP2K1 P387S were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).",Actionable,5958,1909,melanoma,DOID,22046,BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S,resistant,342,Vemurafenib,4893,22389471,,,
2,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S were resistant Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).",Actionable,5954,1909,melanoma,DOID,22046,BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S,resistant,3,Dabrafenib,4893,22389471,,,
3,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5968,1909,melanoma,DOID,22046,BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S,decreased response,763,GSK2126458,4893,22389471,,,
4,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS Q61K, NRAS A146T and MAP2K1 P387S were resistant to growth inhibition by Mekinist (trametinib) in culture (PMID: 22389471).",Actionable,5963,1909,melanoma,DOID,22046,BRAF V600E NRAS Q61K NRAS A146T MAP2K1 P387S,resistant,2,Trametinib,4893,22389471,,,
5,Preclinical,"In a preclinical study, human melanoma cells harboring BRAF G469R and NRAS G61K were insensitive to Zelboraf (vemurafenib) in culture (PMID: 26343583).",Actionable,6612,1909,melanoma,DOID,23638,BRAF G469R NRAS Q61K,resistant,342,Vemurafenib,4893,26343583,,,
6,Preclinical,"In a preclinical study, Selumetinib (AZD6244) modestly inhibited proliferation of human melanoma cells harboring BRAF G469R and NRAS Q61K in culture (PMID: 26343583).",Actionable,6603,1909,melanoma,DOID,23638,BRAF G469R NRAS Q61K,decreased response,913,Selumetinib,4893,26343583,,,
7,Preclinical,"In a preclinical study, LY3009120 inhibited soft agar growth of human melanoma cancer cells harboring BRAF G469R and NRAS Q61K in culture (PMID: 26343583).",Actionable,6592,1909,melanoma,DOID,23638,BRAF G469R NRAS Q61K,sensitive,3268,LY3009120,4893,26343583,,,
8,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Ibrance (palbociclib) and Mekinist (trametinib) induced tumor regression in a mouse melanoma model expressing NRAS Q61K and harboring CDKN2A loss (PMID: 22983396).",Actionable,2923,1909,melanoma,DOID,10733,NRAS Q61K CDKN2A loss,sensitive,1368,Palbociclib + Trametinib,4893,22983396,,,
9,Preclinical,"In a preclinical study, SBI-0640726 delayed tumor growth of melanomas in mice with a genetic background of NRAS Q61K and CDKN2A loss (PMID: 26603897).",Actionable,3791,1909,melanoma,DOID,10733,NRAS Q61K CDKN2A loss,sensitive,3306,SBI-0640756,4893,26603897,,,
10,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and NRAS Q61K were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",Actionable,4495,3908,non-small cell lung carcinoma,DOID,18261,EGFR L858R EGFR T790M NRAS Q61K,resistant,660,Osimertinib,4893,25870145,,,
11,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to WZ4002 after the emergence of NRAS Q61K in culture (PMID: 25870145).",Actionable,4487,3908,non-small cell lung carcinoma,DOID,18236,EGFR exon 19 del NRAS Q61K,resistant,3075,WZ4002,4893,25870145,,,
12,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS Q61K were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",Actionable,4485,3908,non-small cell lung carcinoma,DOID,18236,EGFR exon 19 del NRAS Q61K,resistant,660,Osimertinib,4893,25870145,,,
13,Preclinical,"In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS Q61K in culture (PMID: 25870145).",Actionable,4486,3908,non-small cell lung carcinoma,DOID,18236,EGFR exon 19 del NRAS Q61K,sensitive,913,Selumetinib,4893,25870145,,,
14,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600K and NRAS Q61K were resistant to Tafinlar (dabrafenib) growth inhibition in culture (PMID: 22389471).",Actionable,5971,1909,melanoma,DOID,22095,BRAF V600K NRAS Q61K,resistant,3,Dabrafenib,4893,22389471,,,
15,Preclinical,"In a preclinical study, Omipalisib (GSK2126458) inhibited the growth of melanoma cell lines harboring BRAF V600K in culture (PMID: 22389471).",Actionable,5974,1909,melanoma,DOID,22095,BRAF V600K NRAS Q61K,sensitive,763,GSK2126458,4893,22389471,,,
16,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600K and NRAS Q61K were 3-7 fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600K in culture (PMID: 22389471).",Actionable,5972,1909,melanoma,DOID,22095,BRAF V600K NRAS Q61K,decreased response,2,Trametinib,4893,22389471,,,
17,Preclinical,"In a preclinical study, Tafinlar (dabrafenib) in combination with Mekinist (trametinib) inhibited growth of melanoma cell lines harboring BRAF V600K and NRAS Q61K in culture (PMID: 22389471).",Actionable,5981,1909,melanoma,DOID,22095,BRAF V600K NRAS Q61K,sensitive,1066,Trametinib + Dabrafenib,4893,22389471,,,
18,Preclinical,"In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600K and NRAS Q61K in culture, compared to either agent alone (PMID: 22389471).",Actionable,5995,1909,melanoma,DOID,22095,BRAF V600K NRAS Q61K,sensitive,3027,GSK2126458 + Trametinib,4893,22389471,,,
19,Preclinical,"In a preclinical study, Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600K and NRAS Q61K in culture (PMID: 22389471).",Actionable,5996,1909,melanoma,DOID,22095,BRAF V600K NRAS Q61K,sensitive,4004,Dabrafenib + GSK2126458,4893,22389471,,,
20,Preclinical - Cell culture,"In a preclinical study, non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909).",Actionable,7956,3908,non-small cell lung carcinoma,DOID,26095,BRAF L597V NRAS Q61K,decreased response,342,Vemurafenib,4893,27523909,,,
21,Preclinical - Cell culture,"In a preclinical study, TAK-632 inhibited proliferation of non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K in culture (PMID: 27523909).",Actionable,7939,3908,non-small cell lung carcinoma,DOID,26095,BRAF L597V NRAS Q61K,sensitive,3300,TAK-632,4893,27523909,,,
22,Preclinical - Cell culture,"In a preclinical study, AZ628 inhibited proliferation of non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K in culture (PMID: 27523909).",Actionable,7909,3908,non-small cell lung carcinoma,DOID,26095,BRAF L597V NRAS Q61K,sensitive,1093,AZ628,4893,27523909,,,
23,Preclinical - Cell culture,"In a preclinical study, non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61L demonstrated decreased sensitivity to PLX7904 in culture (PMID: 27523909).",Actionable,7949,3908,non-small cell lung carcinoma,DOID,26095,BRAF L597V NRAS Q61K,decreased response,4606,PLX7904,4893,27523909,,,
24,Preclinical - Cell culture,"In a preclinical study, non-small cell lung cancer cells harboring both BRAF L597V and NRAS Q61K demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 27523909).",Actionable,7964,3908,non-small cell lung carcinoma,DOID,26095,BRAF L597V NRAS Q61K,decreased response,3,Dabrafenib,4893,27523909,,,
25,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion, EGFR T790M, and NRAS Q61K were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",Actionable,4494,3908,non-small cell lung carcinoma,DOID,18240,EGFR exon 19 del EGFR T790M NRAS Q61K,resistant,660,Osimertinib,4893,25870145,,,
26,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were >20-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5962,1909,melanoma,DOID,22043,BRAF V600E NRAS Q61K MAP2K1 P387S,decreased response,2,Trametinib,4893,22389471,,,
27,Preclinical,"In a preclinical study, the response of human melanoma cell lines harboring BRAF V600E, NRAS Q61K, and MAP2K1 P387S to Tafinlar (dabrafenib) in combination with Omipalisib (GSK2126458) was conflicting as one cell line with this mutation profile responded to the combination and another cell line with the mutation profile did not (PMID: 22389471).",Actionable,5990,1909,melanoma,DOID,22043,BRAF V600E NRAS Q61K MAP2K1 P387S,conflicting,4004,Dabrafenib + GSK2126458,4893,22389471,,,
28,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were resistant to growth inhibition by Zelboraf (vemurafenib) in culture (PMID: 22389471).",Actionable,5961,1909,melanoma,DOID,22043,BRAF V600E NRAS Q61K MAP2K1 P387S,resistant,342,Vemurafenib,4893,22389471,,,
29,Preclinical,"In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E, NRAS Q61K, and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).",Actionable,5993,1909,melanoma,DOID,22043,BRAF V600E NRAS Q61K MAP2K1 P387S,sensitive,3027,GSK2126458 + Trametinib,4893,22389471,,,
30,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).",Actionable,5952,1909,melanoma,DOID,22043,BRAF V600E NRAS Q61K MAP2K1 P387S,resistant,3,Dabrafenib,4893,22389471,,,
31,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS Q61K and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5967,1909,melanoma,DOID,22043,BRAF V600E NRAS Q61K MAP2K1 P387S,decreased response,763,GSK2126458,4893,22389471,,,
32,Preclinical,"In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of human melanoma cells harboring BRAF V600E and NRAS A146T and NRAS Q61K in culture (PMID: 22389471).",Actionable,5979,1909,melanoma,DOID,22097,BRAF V600E NRAS Q61K NRAS A146T,sensitive,1066,Trametinib + Dabrafenib,4893,22389471,,,
33,Clinical Study,"In a clinical study, a melanoma patient harboring a BRAF V600 mutation developed resistant mutations, BRAF amplification and NRAS Q61K, during treatment with Zelboraf (vemurafenib) (PMID: 24265153).",Actionable,7070,1909,melanoma,DOID,24387,BRAF amp BRAF V600X NRAS Q61K,resistant,342,Vemurafenib,4893,24265153,,,
34,Preclinical - Cell culture,"In a preclinical study, Mekinist (trametinib) growth of a non-small cell lung cancer cell line harboring BRAF G466V and expressing NRAS Q61K in culture (PMID: 28783719).",Actionable,11667,3908,non-small cell lung carcinoma,DOID,28181,BRAF G466V NRAS Q61K,sensitive,2,Trametinib,4893,28783719,,,
35,Preclinical,"In a preclinical study, human melanoma cell lines harboring NRAS Q61K were insensitive to Zelboraf (vemurafenib) in culture (PMID: 26343583).",Actionable,6609,1909,melanoma,DOID,646,NRAS Q61K,resistant,342,Vemurafenib,4893,26343583,,,
36,Phase II,"In a Phase II trial, Binimetinib (MEK162) treatment resulted in partial response in 20% (6/30), and stable disease in 43% (13/30) of melanoma patients harboring NRAS mutations, including Q61L (1/30), Q61K (9/30), and Q61R (15/30) (PMID: 23414587).",Actionable,10897,1909,melanoma,DOID,646,NRAS Q61K,sensitive,807,Binimetinib,4893,23414587,,,
37,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of non-small cell lung cancer cells harboring NRAS Q61K in culture (PMID: 23629727).",Actionable,8174,3908,non-small cell lung carcinoma,DOID,646,NRAS Q61K,sensitive,4656,Everolimus + Pimasertib,4893,23629727,,,
38,Preclinical,"In a preclinical study, Selumetinib (AZD6244) inhibited proliferation of human melanoma cell lines harboring NRAS Q61K in culture (PMID: 26343583).",Actionable,6601,1909,melanoma,DOID,646,NRAS Q61K,sensitive,913,Selumetinib,4893,26343583,,,
39,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring NRAS Q61K in culture (PMID: 23629727).",Actionable,8183,3908,non-small cell lung carcinoma,DOID,646,NRAS Q61K,sensitive,4657,Pimasertib + Regorafenib,4893,23629727,,,
40,Preclinical,"In a preclinical study, LY3009120 inhibited soft agar growth of human melanoma cancer cells harboring NRAS Q61K in culture (PMID: 26343583).",Actionable,6591,1909,melanoma,DOID,646,NRAS Q61K,sensitive,3268,LY3009120,4893,26343583,,,
41,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) inhibited proliferation of non-small cell lung cancer cells harboring NRAS Q61K in culture (PMID: 23629727).",Actionable,8147,3908,non-small cell lung carcinoma,DOID,646,NRAS Q61K,sensitive,871,Pimasertib,4893,23629727,,,
42,Preclinical,"In a preclinical study, human non-small cell lung cancer cells harboring NRAS Q61K had a decreased response to Gedatolisib (PKI-587) in culture (PMID: 21325073, PMID: 12068308).",Actionable,3136,3908,non-small cell lung carcinoma,DOID,646,NRAS Q61K,decreased response,1040,PF-05212384,4893,21325073,12068308,,
43,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring NRAS Q61K in culture (PMID: 23629727).",Actionable,8178,3908,non-small cell lung carcinoma,DOID,646,NRAS Q61K,sensitive,1659,Pimasertib + Sorafenib,4893,23629727,,,
44,Preclinical,"In a preclinical study, Talfinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of melanoma cell lines harboring BRAF V600E and NRAS Q61K in culture, compared to either agent alone (PMID: 22389471).",Actionable,5978,1909,melanoma,DOID,6906,BRAF V600E NRAS Q61K,sensitive,1066,Trametinib + Dabrafenib,4893,22389471,,,
45,Preclinical,"In a preclinical study, treatment with XL888 resulted in increased apoptosis and decreased growth of Zelboraf (vemurafenib)-resistant melanoma cells harboring BRAF V600E along with NRAS Q61K in cell culture (PMID: 22351686).",Actionable,2275,1909,melanoma,DOID,6906,BRAF V600E NRAS Q61K,sensitive,970,XL888,4893,22351686,,,
46,Preclinical,"In a preclinical study, a NRAS Q61K mutation conferred resistance to Zelboraf (vemurafenib) in melanoma cells harboring BRAF V600E in culture (PMID: 21107323).",Actionable,2279,1909,melanoma,DOID,6906,BRAF V600E NRAS Q61K,resistant,342,Vemurafenib,4893,21107323,,,
47,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E expressing NRAS Q61K were resistant to Tafinlar (dabrafenib) mediated growth inhibition and retained MEK and ERK signaling (PMID: 22389471).",Actionable,5949,1909,melanoma,DOID,6906,BRAF V600E NRAS Q61K,resistant,3,Dabrafenib,4893,22389471,,,
48,Preclinical - Pdx,"In a preclinical study, GDC0879 failed to inhibit growth of BRAF wild-type melanoma cells harboring NRAS Q61K in patient-derived xenograft models (PMID: 19276360).",Actionable,7889,1909,melanoma,DOID,26086,BRAF wild-type NRAS Q61K,resistant,1095,GDC0879,4893,19276360,,,
49,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring NRAS G12V demonstrated resistance to Erbitux (cetuximab) in culture (PMID: 28179366).",Actionable,10315,9256,colorectal cancer,DOID,3354,NRAS G12V,resistant,694,Cetuximab,4893,28179366,,,
50,Preclinical - Cell culture,"In a preclinical study, the combination of Erbitux (cetuximab) and Mekinist (trametinib) decreased viability of colorectal cancer cells harboring NRAS G12V in culture (PMID: 28179366).",Actionable,10314,9256,colorectal cancer,DOID,3354,NRAS G12V,sensitive,3505,Cetuximab + Trametinib,4893,28179366,,,
51,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS G12V were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",Actionable,4490,3908,non-small cell lung carcinoma,DOID,18238,EGFR exon 19 del NRAS G12V,resistant,660,Osimertinib,4893,25870145,,,
52,Preclinical,"In a preclinical study, expression of NRAS G12V in melanoma cells harboring BRAF V600E conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 26267534).",Actionable,5785,1909,melanoma,DOID,21619,BRAF V600E NRAS G12V,resistant,342,Vemurafenib,4893,26267534,,,
53,Preclinical - Cell culture,"In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and over expressing NRAS G12V in culture (PMID: 26267534).",Actionable,5786,1909,melanoma,DOID,21619,BRAF V600E NRAS G12V,sensitive,3769,DEL-22379,4893,26267534,,,
54,Guideline,Vectibix (panitumumab) is not indicated for use in colorectal cancer patients with NRAS exon 2 mutations (Guidelines).,Actionable,3851,9256,colorectal cancer,DOID,1197,NRAS G13X,resistant,845,Panitumumab,4893,None,,,
55,Guideline,Erbitux (cetuximab) is not indicated for use in colorectal cancer patients with NRAS exon 2 mutations (Guidelines).,Actionable,3846,9256,colorectal cancer,DOID,1197,NRAS G13X,resistant,694,Cetuximab,4893,None,,,
56,Preclinical - Cell line xenograft,"In a preclinical study, PLX4720 did not inhibit growth of melanoma cells harboring NRAS Q61L in culture or in cell line xenograft models (PMID: 25500121, PMID: 23431193).",Actionable,3317,1909,melanoma,DOID,3375,NRAS Q61L,resistant,1060,PLX4720,4893,25500121,23431193,,
57,Preclinical - Cell line xenograft,"In a preclinical study, CCT241161 inhibited MEK and ERK activation and growth of a melanoma cell line harboring NRAS Q61L in culture, and inhibited tumor growth in a NRAS Q61L-mutant melanoma cell line xenograft model (PMID: 25500121, PMID: 23431193).",Actionable,3315,1909,melanoma,DOID,3375,NRAS Q61L,sensitive,3106,CCT241161,4893,25500121,23431193,,
58,Preclinical,"In a preclinical study, human melanoma cells harboring NRAS Q61L were insensitive to Zelboraf (vemurafenib) in culture (PMID: 26343583).",Actionable,6611,1909,melanoma,DOID,3375,NRAS Q61L,resistant,342,Vemurafenib,4893,26343583,,,
59,Preclinical - Cell line xenograft,"In a preclinical study, CCT196969 inhibited MEK and ERK activation and growth of a melanoma cell line harboring NRAS Q61L in culture, and inhibited tumor growth in a NRAS Q61L-mutant melanoma cell line xenograft model (PMID: 25500121, PMID: 23431193).",Actionable,3316,1909,melanoma,DOID,3375,NRAS Q61L,sensitive,3105,CCT196969,4893,25500121,23431193,,
60,Phase II,"In a Phase II trial, Binimetinib (MEK162) treatment resulted in partial response in 20% (6/30), and stable disease in 43% (13/30) of melanoma patients harboring NRAS mutations, including Q61L (1/30), Q61K (9/30), and Q61R (15/30) (PMID: 23414587).",Actionable,10896,1909,melanoma,DOID,3375,NRAS Q61L,sensitive,807,Binimetinib,4893,23414587,,,
61,Preclinical,"In a preclinical study, Selumetinib (AZD6244) modestly inhibited proliferation of human melanoma cells harboring NRAS Q61L in culture (PMID: 26343583).",Actionable,6604,1909,melanoma,DOID,3375,NRAS Q61L,decreased response,913,Selumetinib,4893,26343583,,,
62,Preclinical,"In a preclinical study, LY3009120 modestly inhibited soft agar growth of human melanoma cancer cells harboring NRAS Q61L in culture (PMID: 26343583).",Actionable,6594,1909,melanoma,DOID,3375,NRAS Q61L,decreased response,3268,LY3009120,4893,26343583,,,
63,Preclinical,"In a preclinical study, human acute lymphoblastic leukemia cells harboring NRAS and CDKN2A mutations were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",Actionable,6683,9952,acute lymphocytic leukemia,DOID,23669,NRAS mut CDKN2A mut,resistant,2,Trametinib,4893,26343583,,,
64,Preclinical - Pdx,"In a preclinical study, LSN3074753 and Erbitux (cetuximab) worked synergistically, resulting in tumor regression in a patient-derived xenograft model of colorectal cancer harboring BRAF G596V and NRAS G13R (PMID: 28611205).",Actionable,12197,9256,colorectal cancer,DOID,28547,BRAF G596V NRAS G13R,sensitive,6338,Cetuximab + LSN3074753,4893,28611205,,,
65,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring both BRAF D594G and NRAS G12D demonstrated decreased sensitivity to Zelboraf (vemurafenib) in culture (PMID: 27523909).",Actionable,7957,1909,melanoma,DOID,26096,BRAF D594G NRAS G12D,decreased response,342,Vemurafenib,4893,27523909,,,
66,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring both BRAF D594G and NRAS G12D demonstrated decreased sensitivity to Tafinlar (dabrafenib) in culture (PMID: 27523909).",Actionable,7965,1909,melanoma,DOID,26096,BRAF D594G NRAS G12D,decreased response,3,Dabrafenib,4893,27523909,,,
67,Preclinical - Cell culture,"In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring both BRAF D594G and NRAS G12D in culture (PMID: 27523909).",Actionable,7911,1909,melanoma,DOID,26096,BRAF D594G NRAS G12D,sensitive,1093,AZ628,4893,27523909,,,
68,Preclinical - Cell culture,"In a preclinical study, melanoma cells harboring both BRAF D594G and NRAS G12D demonstrated decreased sensitivity to PLX7904 in culture (PMID: 27523909).",Actionable,7951,1909,melanoma,DOID,26096,BRAF D594G NRAS G12D,decreased response,4606,PLX7904,4893,27523909,,,
69,Preclinical - Cell culture,"In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring both BRAF D594G and NRAS G12D in culture (PMID: 27523909).",Actionable,7941,1909,melanoma,DOID,26096,BRAF D594G NRAS G12D,sensitive,3300,TAK-632,4893,27523909,,,
70,Preclinical,"In a preclinical study, Binimetinib (MEK162) inhibited growth of acute myeloid leukemia cells that have been demonstrated to harbor NRAS G12D in culture and decreased disease burden in xenograft models with NRAS G12D (PMID: 24569456, PMID: 11238126).",Actionable,3595,9119,acute myeloid leukemia,DOID,2899,NRAS G12D,sensitive,807,Binimetinib,4893,24569456,11238126,,
71,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Binimetinib (MEK162) and Alpelisib (BYL719) inhibited proliferation in a human acute myeloid leukemia (AML) cell line harboring NRAS G12D in culture, and decreased disease burden in xenograft models (PMID: 24569456).",Actionable,3597,9119,acute myeloid leukemia,DOID,2899,NRAS G12D,sensitive,1311,BYL719 + MEK162,4893,24569456,,,
72,Preclinical - Cell culture,"In a preclinical study, N-Arachidonoyl Dopamine (NADA) disrupted NRAS protein membrane localization and decreased NRAS downstream signaling, and inhibited proliferation and induced cell death in transformed cells expressing NRAS G12D in culture (PMID: 27760835).",Actionable,9740,10000003,Advanced Solid Tumor,JAX,2899,NRAS G12D,sensitive,5185,N-Arachidonoyl Dopamine ,4893,27760835,,,
73,Preclinical,"In a preclinical study, AZD0156 treatment resulted in growth inhibition of tumor cells and prolonged survival in animal models of acute myeloid leukemia harboring KMT2A-MLLT1 fusion and NRAS G12D (PMID: 27625305).",Actionable,12168,9119,acute myeloid leukemia,DOID,20552,KMT2A-MLLT1 NRAS G12D,predicted â€“ sensitive,3557,AZD0156,4893,27625305,,,
74,Preclinical,"In a preclinical study, AZ20 treatment resulted in growth inhibition of tumor cells and prolonged survival in animal models of acute myeloid leukemia harboring KMT2A-MLLT1 fusion and NRAS G12D (PMID: 27625305).",Actionable,12169,9119,acute myeloid leukemia,DOID,20552,KMT2A-MLLT1 NRAS G12D,predicted â€“ sensitive,2880,AZ20,4893,27625305,,,
75,Preclinical,"In a preclinical study, acute myeloid leukemia cells co-harboring KMT2A-MLLT1 and NRAS G12D demonstrated a decrease in tumor burden, reduced colony formation, and an increase in cell death when treated with Dinaciclib in both culture and mouse models (PMID: 26627013).",Actionable,5311,9119,acute myeloid leukemia,DOID,20552,KMT2A-MLLT1 NRAS G12D,sensitive,719,Dinaciclib,4893,26627013,,,
76,Preclinical - Cell line xenograft,"In a preclinical study, BAY1125976 inhibited proliferation of a prostate cancer cell line harboring AKT E17K and NRAS G12D in culture, and demonstrated antitumor activity in xenograft models (PMID: 27699769).",Actionable,8810,10283,prostate cancer,DOID,26446,AKT1 E17K NRAS G12D,sensitive,994,BAY1125976,4893,27699769,,,
77,Preclinical,"In a preclinical study, LY3009120 modestly inhibited soft agar growth of human melanoma cancer cells harboring NRAS R167L, BRAF K601E, and BRAF A665V in culture (PMID: 26343583).",Actionable,6597,1909,melanoma,DOID,23641,NRAS R167L BRAF K601E BRAF A665V,decreased response,3268,LY3009120,4893,26343583,,,
78,Preclinical,"In a preclinical study, human melanoma cells harboring BRAF K601E, BRAF A665V, and NRAS R167L were insensitive to Selumetinib (AZD6244) in culture (PMID: 26343583).",Actionable,6605,1909,melanoma,DOID,23641,NRAS R167L BRAF K601E BRAF A665V,resistant,913,Selumetinib,4893,26343583,,,
79,Preclinical,"In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS G12R in culture (PMID: 25870145).",Actionable,4492,3908,non-small cell lung carcinoma,DOID,18239,EGFR exon 19 del NRAS G12R,sensitive,913,Selumetinib,4893,25870145,,,
80,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS G12R were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",Actionable,4491,3908,non-small cell lung carcinoma,DOID,18239,EGFR exon 19 del NRAS G12R,resistant,660,Osimertinib,4893,25870145,,,
81,Preclinical - Pdx & cell culture,"In a preclinical study, 3144 inhibited growth of patient-derived T-cell acute lymphocytic leukemia cells harboring NRAS G13V in culture, and reduced tumor burden in xenograft models (PMID: 28235199).",Actionable,10842,50523,adult T-cell leukemia,DOID,3366,NRAS G13V,sensitive,5658,3144,4893,28235199,,,
82,Preclinical,"In a preclinical study, human melanoma cells harboring NRAS G13D were insensitive to Zelboraf (vemurafenib) in culture (PMID: 26343583).",Actionable,6610,1909,melanoma,DOID,3361,NRAS G13D,resistant,342,Vemurafenib,4893,26343583,,,
83,Preclinical,"In a preclinical study, LY3009120 inhibited soft agar growth of human melanoma cancer cells harboring NRAS G13D in culture (PMID: 26343583).",Actionable,6593,1909,melanoma,DOID,3361,NRAS G13D,sensitive,3268,LY3009120,4893,26343583,,,
84,Preclinical - Cell culture,"In a preclinical study, 3144 inhibited growth of patient-derived T-cell acute lymphocytic leukemia cells harboring NRAS G13D in culture (PMID: 28235199).",Actionable,10843,50523,adult T-cell leukemia,DOID,3361,NRAS G13D,sensitive,5658,3144,4893,28235199,,,
85,Preclinical,"In a preclinical study, Selumetinib (AZD6244) inhibited proliferation of human melanoma cells harboring NRAS G13D in culture (PMID: 26343583).",Actionable,6602,1909,melanoma,DOID,3361,NRAS G13D,sensitive,913,Selumetinib,4893,26343583,,,
86,Preclinical,"In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS E63K in culture (PMID: 25870145).",Actionable,4476,3908,non-small cell lung carcinoma,DOID,18231,EGFR exon 19 del NRAS E63K,sensitive,913,Selumetinib,4893,25870145,,,
87,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS E63K were resistant to Tagrisso (osimertinib) AZD9291 treatment in culture (PMID: 25870145).",Actionable,4478,3908,non-small cell lung carcinoma,DOID,18231,EGFR exon 19 del NRAS E63K,resistant,660,Osimertinib,4893,25870145,,,
88,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Iressa (gefitinib) after the emergence of NRAS E63K in culture (PMID: 25870145).",Actionable,4477,3908,non-small cell lung carcinoma,DOID,18231,EGFR exon 19 del NRAS E63K,resistant,751,Gefitinib,4893,25870145,,,
89,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5966,1909,melanoma,DOID,22037,BRAF V600E NRAS A146T MAP2K1 P387S,decreased response,763,GSK2126458,4893,22389471,,,
90,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 22389471).",Actionable,5950,1909,melanoma,DOID,22037,BRAF V600E NRAS A146T MAP2K1 P387S,resistant,3,Dabrafenib,4893,22389471,,,
91,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were >20-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E and also had reduced sensitivity in comparison to cell lines harboring BRAF V600E and NRAS A146T in culture (PMID: 22389471).",Actionable,5960,1909,melanoma,DOID,22037,BRAF V600E NRAS A146T MAP2K1 P387S,decreased response,2,Trametinib,4893,22389471,,,
92,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).",Actionable,5956,1909,melanoma,DOID,22037,BRAF V600E NRAS A146T MAP2K1 P387S,resistant,342,Vemurafenib,4893,22389471,,,
93,Preclinical,"In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S in culture, compared to either agent alone (PMID: 22389471).",Actionable,5992,1909,melanoma,DOID,22037,BRAF V600E NRAS A146T MAP2K1 P387S,sensitive,3027,GSK2126458 + Trametinib,4893,22389471,,,
94,Preclinical,"In a preclinical study, Talfinlar (dabrafenib) in combination with Omipalisib (GSK2126458) did not improve the response to human melanoma cell lines harboring BRAF V600E, NRAS A146T and MAP2K1 P387S in culture (PMID: 22389471).",Actionable,5989,1909,melanoma,DOID,22037,BRAF V600E NRAS A146T MAP2K1 P387S,no benefit,4004,Dabrafenib + GSK2126458,4893,22389471,,,
95,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E and NRAS A146T had reduced sensitivity to Omipalisib (GSK2126458) in comparison to parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5965,1909,melanoma,DOID,22042,BRAF V600E NRAS A146T,decreased response,763,GSK2126458,4893,22389471,,,
96,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E and NRAS A146T were resistant to Zelboraf (vemurafenib) growth inhibition in culture (PMID: 22389471).",Actionable,5955,1909,melanoma,DOID,22042,BRAF V600E NRAS A146T,resistant,342,Vemurafenib,4893,22389471,,,
97,Preclinical,"In a preclinical study, human melanoma cell lines harboring BRAF V600E and NRAS A146T were resistant to Tafinlar (dabrafenib) growth inhibition in culture (PMID: 22389471).",Actionable,5951,1909,melanoma,DOID,22042,BRAF V600E NRAS A146T,resistant,3,Dabrafenib,4893,22389471,,,
98,Preclinical,"In a preclinical study, Tafinlar (dabrafenib) in combination with Mekinist (trametinib) resulted in improved growth inhibition of melanoma cell lines harboring BRAF V600E and NRAS A146T in culture, compared to either agent alone (PMID: 22389471).",Actionable,5977,1909,melanoma,DOID,22042,BRAF V600E NRAS A146T,sensitive,1066,Trametinib + Dabrafenib,4893,22389471,,,
99,Preclinical,"In a preclinical study, Mekinist (trametinib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition in melanoma cell lines harboring BRAF V600E and NRAS A146T in culture, compared to either agent alone (PMID: 22389471).",Actionable,5991,1909,melanoma,DOID,22042,BRAF V600E NRAS A146T,sensitive,3027,GSK2126458 + Trametinib,4893,22389471,,,
100,Preclinical,"In a preclinical study, melanoma cell lines harboring BRAF V600E and NRAS A146T were >10-fold less sensitive to growth inhibition by Mekinist (trametinib) than parental cell lines harboring BRAF V600E in culture (PMID: 22389471).",Actionable,5959,1909,melanoma,DOID,22042,BRAF V600E NRAS A146T,decreased response,2,Trametinib,4893,22389471,,,
101,Preclinical,"In a preclinical study, Talfinlar (dabrafenib) in combination with Omipalisib (GSK2126458) resulted in improved growth inhibition of human melanoma cell lines harboring BRAF V600E and NRAS A146T in culture, compared to either agent alone (PMID: 22389471).",Actionable,5988,1909,melanoma,DOID,22042,BRAF V600E NRAS A146T,sensitive,4004,Dabrafenib + GSK2126458,4893,22389471,,,
102,Guideline,Vectibix (panitumumab) is not indicated for use in colorectal cancer patients with NRAS exon 4 mutations (Guidelines).,Actionable,3849,9256,colorectal cancer,DOID,3351,NRAS A146T,resistant,845,Panitumumab,4893,None,,,
103,Guideline,Erbitux (cetuximab) is not indicated for use in colorectal cancer patients with NRAS exon 4 mutations (Guidelines).,Actionable,3848,9256,colorectal cancer,DOID,3351,NRAS A146T,resistant,694,Cetuximab,4893,None,,,
104,Preclinical - Cell culture,"In a preclinical study, BAY1125976 inhibited Akt activation and downstream signaling in bladder cancer cell lines carrying both Akt1 E17K and Nras Q61R mutations (AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3685).",Actionable,3830,4007,bladder carcinoma,DOID,16525,AKT1 E17K NRAS Q61R,sensitive,994,BAY1125976,4893,None,,,
105,Phase II,"In a Phase II trial, Binimetinib (MEK162) treatment resulted in partial response in 20% (6/30), and stable disease in 43% (13/30) of melanoma patients harboring NRAS mutations, including Q61L (1/30), Q61K (9/30), and Q61R (15/30) (PMID: 23414587).",Actionable,10898,1909,melanoma,DOID,3043,NRAS Q61R,sensitive,807,Binimetinib,4893,23414587,,,
106,Preclinical - Cell culture,"In a preclinical study, MK2206 inhibited AKT activation, proliferation, and growth of thyroid cancer cell lines with  PI3K/AKT pathway alterations in culture, including an anaplastic thyroid cancer cell line harboring NRAS Q61R (PMID: 21289267).",Actionable,8218,1781,thyroid cancer,DOID,3043,NRAS Q61R,sensitive,816,MK2206,4893,21289267,,,
107,Clinical Study,"In a clinical study, a melanoma patient harboring KIT D816V and NRAS Q61R demonstrated progressive disease when treated with a combination of Mekinist (trametinib) and Keytruda (pembrolizumab) (PMID: 28514312). ",Actionable,11050,1909,melanoma,DOID,27900,KIT D816V NRAS Q61R,no benefit,1450,Pembrolizumab + Trametinib,4893,28514312,,,
108,Clinical Study,"In a clinical study, a melanoma patient harboring an ATM mutation and NRAS Q61R demonstrated a partial response and 16 month progression free survival when treated with Binimetinib (MEK162) (PMID: 28514312). ",Actionable,11054,1909,melanoma,DOID,27905,ATM mut NRAS Q61R,sensitive,807,Binimetinib,4893,28514312,,,
109,Clinical Study,"In a clinical study, a melanoma patient harboring a BRAF V600 mutation developed resistant mutations, MAP2K1 V60E, NRAS T58I, and NRAS Q61R, after 18 weeks of treatment with Zelboraf (vemurafenib) (PMID: 24265153).",Actionable,7068,1909,melanoma,DOID,24385,BRAF V600X MAP2K1 V60E NRAS T58I NRAS Q61R,resistant,342,Vemurafenib,4893,24265153,,,
110,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Gilotrif (afatinib) after the emergence of amplified NRAS in culture (PMID: 25870145).",Actionable,4484,3908,non-small cell lung carcinoma,DOID,18234,EGFR exon 19 del NRAS amp,resistant,623,Afatinib,4893,25870145,,,
111,Preclinical,"In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and amplified NRAS were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).",Actionable,4483,3908,non-small cell lung carcinoma,DOID,18234,EGFR exon 19 del NRAS amp,resistant,660,Osimertinib,4893,25870145,,,
112,Preclinical,"In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and amplified NRAS in culture (PMID: 25870145).  ",Actionable,4482,3908,non-small cell lung carcinoma,DOID,18234,EGFR exon 19 del NRAS amp,sensitive,913,Selumetinib,4893,25870145,,,
113,Guideline,Vectibix (panitumumab) is not indicated for use in colorectal cancer patients with NRAS exon 2 mutations (Guidelines).,Actionable,3852,9256,colorectal cancer,DOID,1196,NRAS G12X,resistant,845,Panitumumab,4893,None,,,
114,Guideline,Erbitux (cetuximab) is not indicated for use in colorectal cancer patients with NRAS exon 2 mutations (Guidelines).,Actionable,3845,9256,colorectal cancer,DOID,1196,NRAS G12X,resistant,694,Cetuximab,4893,None,,,
115,Guideline,Erbitux (cetuximab) is not indicated for use in colorectal cancer patients with NRAS exon 3 mutations (Guidelines).,Actionable,3847,9256,colorectal cancer,DOID,1198,NRAS Q61X,resistant,694,Cetuximab,4893,None,,,
116,Guideline,Vectibix (panitumumab) is not indicated for use in colorectal cancer patients with NRAS exon 3 mutations (Guidelines).,Actionable,3850,9256,colorectal cancer,DOID,1198,NRAS Q61X,resistant,845,Panitumumab,4893,None,,,
117,Phase I,"In a Phase I trial, Abemaciclib (LY2835219) resulted in a partial response in a melanoma patient with CDKN2A loss and NRAS mutation (PMID: 27217383).",Actionable,2266,1909,melanoma,DOID,6894,CDKN2A loss NRAS mutant,sensitive,802,Abemaciclib,4893,None,27217383,,
118,Preclinical,"In a preclinical study, human liver cancer cells harboring mutant NRAS and mutant CTNNB1 were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",Actionable,6696,3571,liver cancer,DOID,23671,CTNNB1 mut NRAS mut,resistant,2,Trametinib,4893,26343583,,,
119,Preclinical - Cell culture,"In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in NRAS mutated melanoma cell lines resulted in decreased response to Mekinist (trametinib) in culture (PMID: 27500726).",Actionable,7794,1909,melanoma,DOID,26045,NRAS mut STAG2 dec exp,decreased response,2,Trametinib,4893,27500726,,,
120,Preclinical - Cell culture,"In a preclinical study, treatment with BI-847325 inhibited growth of a BRAF-mutant melanoma cell line with BRAF-inhibitor resistance due to an NRAS mutation in culture (PMID: 25873592).",Actionable,7829,1909,melanoma,DOID,14782,BRAF mut NRAS mut,predicted â€“ sensitive,1059,BI-847325,4893,25873592,,,
121,Phase I,"In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 50% (1/2) of melanoma patients harboring both BRAF and NRAS mutations (PMID: 26169970).",Actionable,3688,1909,melanoma,DOID,14782,BRAF mut NRAS mut,sensitive,792,Lenvatinib,4893,26169970,,,
122,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cell lines harboring mutations in KRAS or NRAS and with wild-type PIK3CA demonstrated a trend toward increased sensitivity to TAK-733 in culture (PMID: 26439693).",Actionable,10774,9256,colorectal cancer,DOID,27788,NRAS mut PIK3CA wild-type,predicted â€“ sensitive,932,TAK-733,4893,26439693,,,
123,Phase I,"In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 83% (5/6) of melanoma patients harboring NRAS mutations and wild-type BRAF (PMID: 26169970).",Actionable,3797,1909,melanoma,DOID,1299,BRAF wild-type NRAS mutant,sensitive,792,Lenvatinib,4893,26169970,,,
124,Preclinical - Cell line xenograft,"In a preclinical study, the combination treatment of PD-0325901 and Ibrance (palbociclib) resulted in tumor regression in 33% (2/6) of melanoma xenograft models harboring an NRAS mutation (PMID: 27488531). ",Actionable,8553,1909,melanoma,DOID,3,NRAS mutant,sensitive,1823,PD-0325901 + Palbociclib,4893,27488531,,,
125,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited growth of liver cancer cell lines harboring mutant NRAS in culture (PMID: 26343583).",Actionable,6695,3571,liver cancer,DOID,3,NRAS mutant,sensitive,2,Trametinib,4893,26343583,,,
126,Preclinical,"In a preclinical study, human melanoma cell lines harboring a mutation in NRAS were resistant to Zelboraf (vemurafenib) mediated growth inhibition in culture (PMID: 26343583).",Actionable,6615,1909,melanoma,DOID,3,NRAS mutant,resistant,342,Vemurafenib,4893,26343583,,,
127,Preclinical,"In a preclinical study, human non-Hodgkin lymphoma cells harboring mutant NRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",Actionable,6689,60060,non-Hodgkin lymphoma,DOID,3,NRAS mutant,resistant,2,Trametinib,4893,26343583,,,
128,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited growth of human acute myeloid leukemia cell lines harboring mutant NRAS in culture (PMID: 26343583).",Actionable,6684,9119,acute myeloid leukemia,DOID,3,NRAS mutant,sensitive,2,Trametinib,4893,26343583,,,
129,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited growth of human multiple myeloma cells harboring mutant NRAS in culture (PMID: 26343583).",Actionable,6686,9538,multiple myeloma,DOID,3,NRAS mutant,sensitive,2,Trametinib,4893,26343583,,,
130,Preclinical,"In a preclinical study, Tubastatin A inhibited proliferation of NRAS mutant melanoma cell lines in culture (PMID: 25957812).",Actionable,4763,1909,melanoma,DOID,3,NRAS mutant,sensitive,3635,Tubastatin A,4893,25957812,,,
131,Preclinical,"In a preclinical study, obatoclax decreased proliferation in human tumor cell lines with NRAS mutation in culture (PMID: 22460902).",Actionable,1824,10000003,Advanced Solid Tumor,JAX,3,NRAS mutant,sensitive,834,Obatoclax,4893,22460902,,,
132,Preclinical,"In a preclinical study, CCT241161 inhibited growth of melanoma cells harboring NRAS mutations in culture (PMID: 25500121).",Actionable,3319,1909,melanoma,DOID,3,NRAS mutant,sensitive,3106,CCT241161,4893,25500121,,,
133,Phase II,"In a Phase II trial, Binimetinib (MEK162) treatment resulted in partial response in 20% (6/30), and stable disease in 43% (13/30) of melanoma patients harboring NRAS mutations, including Q61L (1/30), Q61K (9/30), and Q61R (15/30) (PMID: 23414587). ",Actionable,709,1909,melanoma,DOID,3,NRAS mutant,conflicting,807,Binimetinib,4893,23414587,,,
134,Phase III,"In a Phase III clinical trial, treatment with Binimetinib (MEK162) improved median progression-free survival compared to treatment with Deticene (dacarbazine) (2.8 mo. vs. 1.5 mo.), but did not improve overall survival in patients with NRAS-mutant melanoma (PMID: 28284557).",Actionable,10334,1909,melanoma,DOID,3,NRAS mutant,conflicting,807,Binimetinib,4893,28284557,,,
135,Phase I,"In a Phase I trial, Mekinist (trametinib) treatment resulted in stable disease in 29% (2/7) of patients with NRAS mutated melanoma (PMID: 22805292).",Actionable,10895,1909,melanoma,DOID,3,NRAS mutant,predicted â€“ sensitive,2,Trametinib,4893,22805292,,,
136,Preclinical - Pdx,"In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of NRAS-mutant colorectal cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",Actionable,11700,9256,colorectal cancer,DOID,3,NRAS mutant,predicted â€“ sensitive,5747,KO-947,4893,None,,,
137,Preclinical,"In a preclinical study, BI-69A11 inhibited proliferation and transformation of human melanoma cell lines harboring NRAS mutation in culture (PMID: 26603897).",Actionable,3786,1909,melanoma,DOID,3,NRAS mutant,sensitive,3308,BI-69A11,4893,26603897,,,
138,Phase I,"In a Phase I trial, Binimetinib (MEK162) treatment resulted in partial response in a biliary tract cancer patient harboring NRAS mutation (PMID: 28152546)",Actionable,10460,4607,biliary tract cancer,DOID,3,NRAS mutant,predicted â€“ sensitive,807,Binimetinib,4893,28152546,,,
139,Phase I,"In a Phase I study, selumetinib demonstrated an increase in iodine uptake and retention in a subgroup of patients with thyroid cancer that was refractory to radioiodine; including patients with BRAF and NRAS mutations disease (PMID: 23406027).",Actionable,1280,1781,thyroid cancer,DOID,3,NRAS mutant,sensitive,913,Selumetinib,4893,23406027,,,
140,Guideline,Vectibix (panitumumab) is not indicated for use in patients with NRAS-mutant colorectal cancer (Guidelines). ,Actionable,1961,9256,colorectal cancer,DOID,3,NRAS mutant,resistant,845,Panitumumab,4893,None,,,
141,Preclinical - Cell line xenograft,"In a preclinical study, AZD5153 inhibited proliferation of acute myeloid leukemia cells harboring NRAS mutation in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 27573426).",Actionable,9133,9119,acute myeloid leukemia,DOID,3,NRAS mutant,predicted â€“ sensitive,4910,AZD5153,4893,27573426,,,
142,Preclinical - Pdx,"In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of NRAS-mutant gastric carcinoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",Actionable,11702,5517,stomach carcinoma,DOID,3,NRAS mutant,predicted â€“ sensitive,5747,KO-947,4893,None,,,
143,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited growth of human autonomic ganglia cancer cells harboring mutant NRAS in culture (PMID: 26343583).",Actionable,6682,2621,autonomic nervous system neoplasm,DOID,3,NRAS mutant,sensitive,2,Trametinib,4893,26343583,,,
144,Phase Ib/II,"In a Phase Ib/II clinical trial, treatment with Mekinist (trametinib) resulted in an overall response rate of 28% in RAS-mutant leukemia patients, with 12% (7/57) of patients achieving complete remission (ASH 2015 Annual Meeting, Abst 677).",Actionable,3586,1240,leukemia,DOID,3,NRAS mutant,predicted â€“ sensitive,2,Trametinib,4893,None,,,
145,Preclinical,"In a preclinical study, human urinary tract transitional cell carcinoma cells harboring mutant NRAS were moderately sensitive to Mekinist (trametinib) growth inhibition in culture (PMID: 26343583).",Actionable,6736,2671,transitional cell carcinoma,DOID,3,NRAS mutant,decreased response,2,Trametinib,4893,26343583,,,
146,Preclinical - Pdx,"In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of NRAS-mutant pancreatic cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",Actionable,11698,1793,pancreatic cancer,DOID,3,NRAS mutant,predicted â€“ sensitive,5747,KO-947,4893,None,,,
147,Phase III,"In a Phase III trial, Binimetinib (MEK162) treatment resulted in improved progression free survival (2.8 months), objective response rate (15%, 40/269) and disease control rate (58%, 156/269) compared to Deticene (dacarbazine) (1.5 months, 7%, 25%, respectively) in NRAS-mutant cutaneous melanoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9500)).",Actionable,6819,8923,skin melanoma,DOID,3,NRAS mutant,sensitive,807,Binimetinib,4893,None,,,
148,Preclinical - Cell line xenograft,"In a preclinical study, Ibrance (palbociclib) treatment resulted in stable tumor growth in melanoma cell line xenograft models harboring an NRAS mutation, however, growth later ensued and thus, demonstrated a lack of benefit (PMID: 27488531). ",Actionable,8552,1909,melanoma,DOID,3,NRAS mutant,no benefit,850,Palbociclib,4893,27488531,,,
149,Phase III,"In a retrospective analysis of a Phase III trial, the combination of Erbitux (cetuximab) and FOLFIRI did not demonstrate an improved clinical benefit compared to FOLFIRI alone in colorectal cancer patients with RAS mutations (PMID: 25605843). ",Actionable,3355,9256,colorectal cancer,DOID,3,NRAS mutant,no benefit,2180,Cetuximab + FOLFIRI,4893,25605843,,,
150,Preclinical,"In a preclinical study, hematopoietic cancer cell lines harboring NRAS mutations demonstrated resistance to SHP099 in cell culture (PMID: 27362227).",Actionable,7529,2531,hematologic cancer,DOID,3,NRAS mutant,predicted â€“ resistant,4504,SHP099,4893,27362227,,,
151,Preclinical - Pdx,"In a preclinical study, KO-947 resulted in tumor regression in patient derived xenograft (PDX) models harboring either a BRAF mutation, NRAS mutation, or KRAS mutation (EJC Dec 2016, 69:1; S126).",Actionable,10966,10000003,Advanced Solid Tumor,JAX,3,NRAS mutant,predicted â€“ sensitive,5747,KO-947,4893,None,,,
152,Preclinical - Pdx,"In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of NRAS-mutant cervical carcinoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",Actionable,11704,2893,cervix carcinoma,DOID,3,NRAS mutant,predicted â€“ sensitive,5747,KO-947,4893,None,,,
153,Preclinical - Pdx,"In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of NRAS-mutant non-small cell lung cancer (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",Actionable,11966,3908,non-small cell lung carcinoma,DOID,3,NRAS mutant,predicted â€“ sensitive,5747,KO-947,4893,None,,,
154,Preclinical - Pdx,"In a preclinical study, KO-947 inhibited Erk signaling and induced tumor regression in patient-derived xenograft models of NRAS-mutant melanoma (Cancer Res 2017;77(13 Suppl):Abstract nr 5168).",Actionable,11694,1909,melanoma,DOID,3,NRAS mutant,predicted â€“ sensitive,5747,KO-947,4893,None,,,
155,Preclinical - Cell line xenograft,"In a preclinical study, Buparlisib (BKM120) treatment in human melanoma cell line xenograft models with brain metastases and harboring an NRAS mutation resulted in inhibition of brain tumor growth and an improved survival benefit (PMID: 27307593). ",Actionable,10125,1909,melanoma,DOID,3,NRAS mutant,sensitive,680,BKM120,4893,27307593,,,
156,Guideline,Erbitux (cetuximab) is not indicated for use in patients with NRAS-mutant colorectal cancer (Guidelines). ,Actionable,1960,9256,colorectal cancer,DOID,3,NRAS mutant,resistant,694,Cetuximab,4893,None,,,
157,Preclinical,"In a preclinical study, CCT196969 inhibited growth of melanoma cells harboring NRAS mutations in culture (PMID: 25500121).",Actionable,3318,1909,melanoma,DOID,3,NRAS mutant,sensitive,3105,CCT196969,4893,25500121,,,
158,Preclinical - Cell culture,"In a preclinical study, combination of S63845 and Mekinist (trametinib) resulted in potent cytotoxic effects in NRAS-mutated melanoma cells in culture compared to the cytostatic effect of Mekinist (trametinib) alone (PMID: 27760111).",Actionable,9040,1909,melanoma,DOID,3,NRAS mutant,sensitive,4864,S63845 + Trametinib,4893,27760111,,,
159,Preclinical,"In a preclinical study, LY3009120 inhibited growth of NRAS mutant human melanoma cell lines in culture (PMID: 26343583).",Actionable,6616,1909,melanoma,DOID,3,NRAS mutant,sensitive,3268,LY3009120,4893,26343583,,,
160,Phase I,"In a Phase I trial, BGB-283 demonstrated safety and preliminary efficacy, resulted in partial response in 14% (4/29), and prolonged stable disease in 48% (14/29) of advanced solid tumor patients harboring mutations in KRAS, NRAS, and/or BRAF (AACR Annual Meeting, Apr 2016, abstract # CT005).",Actionable,7227,10000003,Advanced Solid Tumor,JAX,3,NRAS mutant,predicted â€“ sensitive,4025,BGB-283,4893,None,,,
161,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited growth of human central nervous system cancer cells harboring mutant NRAS in culture (PMID: 26343583).",Actionable,6691,3620,central nervous system cancer,DOID,3,NRAS mutant,sensitive,2,Trametinib,4893,26343583,,,
162,Preclinical,"In a preclinical study, SBI-0640756 inhibited proliferation and transformation of human melanoma cell lines harboring NRAS mutation in culture (PMID: 26603897).",Actionable,3787,1909,melanoma,DOID,3,NRAS mutant,sensitive,3306,SBI-0640756,4893,26603897,,,
163,Preclinical,"In a preclinical study, human sarcoma cells harboring mutant NRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",Actionable,6734,1115,sarcoma,DOID,3,NRAS mutant,resistant,2,Trametinib,4893,26343583,,,
164,Preclinical,"In a preclinical study, human lung adenocarcinoma cell lines harboring mutant NRAS were insensitive to Mekinist (trametinib) in culture (PMID: 26343583).",Actionable,6699,3910,lung adenocarcinoma,DOID,3,NRAS mutant,resistant,2,Trametinib,4893,26343583,,,
165,Phase Ib/II,"In a Phase Ib trial, the combination of Binimetinib (MEK162) and Kisqali (ribociclib) resulted in a median progression-free survival of 6.7 months, a partial response in 25% (4/16), and stable disease in 44% (7/16) of NRAS mutant melanoma patients (J Clin Oncol 35, 2017 (suppl; abstr 9519)). ",Actionable,11414,1909,melanoma,DOID,3,NRAS mutant,sensitive,5,Binimetinib + Ribociclib,4893,None,,,
166,Phase Ib/II,"In a Phase Ib/II trial, the combination of Binimetinib (MEK162) and Kisqali (ribociclib) resulted in a partial response in 43% (6/14) and stable disease in 43% (6/14) of NRAS mutant melanoma patients (J Clin Oncol 32:5s, 2014 (Suppl;abstr 9009)). ",Actionable,2265,1909,melanoma,DOID,3,NRAS mutant,sensitive,5,Binimetinib + Ribociclib,4893,None,,,
167,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited growth of human lymphoma cells harboring mutant NRAS in culture (PMID: 26343583).",Actionable,6685,60058,lymphoma,DOID,3,NRAS mutant,sensitive,2,Trametinib,4893,26343583,,,
168,Phase I,"In a Phase Ia trial, CC-90003 treatment did not result in any objective responses and demonstrated toxicity in advanced solid tumor patients harboring KRAS, NRAS, or BRAF mutations (J Clin Oncol 35, 2017 (suppl; abstr 2577)).",Actionable,11067,10000003,Advanced Solid Tumor,JAX,3,NRAS mutant,no benefit,2874,CC-90003,4893,None,,,
169,Preclinical,"In a preclinical study, LY3009120 inhibited proliferation of human NRAS mutant acute myeloid leukemia cell lines in culture (PMID: 26343583).",Actionable,6600,9119,acute myeloid leukemia,DOID,3,NRAS mutant,sensitive,3268,LY3009120,4893,26343583,,,
170,Preclinical - Cell culture,"In a preclinical study, colon cancer cells harboring NRAS mutations were resistant to GDC0879 induced growth inhibition in culture (PMID: 19276360).",Actionable,7880,219,colon cancer,DOID,3,NRAS mutant,resistant,1095,GDC0879,4893,19276360,,,
171,Preclinical,"In a preclinical study, MK-1775 showed efficacy in NRAS mutant melanoma and in mutant KRAS colorectal, pancreatic, and lung cancers (PMID:24791855).",Actionable,689,1909,melanoma,DOID,3,NRAS mutant,sensitive,822,MK-1775,4893,24791855,,,
172,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing an NRAS mutation did not respond to treatment with NS1 in culture, resulting in sustained downstream signaling and cell transformation (PMID: 27820802). ",Actionable,9785,10000003,Advanced Solid Tumor,JAX,3,NRAS mutant,no benefit,5228,NS1,4893,27820802,,,
173,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited growth of ovarian cancer cells harboring mutant NRAS in culture (PMID: 26343583).",Actionable,6702,2394,ovarian cancer,DOID,3,NRAS mutant,sensitive,2,Trametinib,4893,26343583,,,
174,Preclinical - Cell culture,"In a preclinical study, the combination of Binimetinib (MEK162) and Buparlisib (BKM120) resulted in improved cell growth inhibition compared to either agent alone in a metastatic melanoma cell line harboring an NRAS mutation (PMID: 27307593). ",Actionable,10121,1909,melanoma,DOID,3,NRAS mutant,sensitive,5400,Binimetinib + BKM120,4893,27307593,,,
175,Preclinical,"In a preclinical study, SBI-0640726 inhibited proliferation and transformation of human melanoma cell lines harboring NRAS mutation in culture (PMID: 26603897).",Actionable,3788,1909,melanoma,DOID,3,NRAS mutant,sensitive,3307,SBI-0640726,4893,26603897,,,
176,Preclinical - Cell line xenograft,"In a preclinical study, PD-0325901 treatment resulted in stable tumor growth in melanoma cell line xenograft models harboring an NRAS mutation, however, growth later ensued and thus, demonstrates a lack of benefit (PMID: 27488531). ",Actionable,8551,1909,melanoma,DOID,3,NRAS mutant,no benefit,849,PD-0325901,4893,27488531,,,
177,Preclinical - Cell culture,"In a preclinical study, an NRAS wild-type melanoma cell line demonstrated minimal sensitivity when treated with the combination of Ibrance (palbociclib) and Mekinist (trametinib) in culture (PMID: 27488531). ",Actionable,8545,1909,melanoma,DOID,481,NRAS wild-type,decreased response,1368,Palbociclib + Trametinib,4893,27488531,,,
178,Phase III,"In a Phase III trial, the combination of Erbitux (cetuximab) and FOLFIRI demonstrated a significant clinical benefit in OS, PFS, and objective response compared to FOLFIRI alone in colorectal cancer patients with RAS wild-type status (PMID: 25605843). ",Actionable,3357,9256,colorectal cancer,DOID,481,NRAS wild-type,predicted â€“ sensitive,2180,Cetuximab + FOLFIRI,4893,25605843,,,
179,Phase III,"In a Phase III clinical trial, the combination of Vectibix (panitumumab) and FOLFIRI improved progression-free survival and median overall survival in patients with RAS wild-type colorectal cancer compared to FOLFIRI treatment alone (PMID: 26341920).",Actionable,3269,9256,colorectal cancer,DOID,481,NRAS wild-type,predicted â€“ sensitive,845,Panitumumab,4893,26341920,,,
180,Preclinical,"In a preclinical study, E6201 inhibited proliferation of several melanoma cell lines in culture and hypersensitivity was associated with wild-type NRAS (PMID: 23039341).",Actionable,5625,1909,melanoma,DOID,481,NRAS wild-type,sensitive,1011,E6201,4893,23039341,,,
181,Preclinical - Cell culture,"In a preclinical study, NRAS wild-type melanoma cells demonstrated decreased cell viability when treated with Ibrance (palbociclib) in culture (PMID: 27488531). ",Actionable,8535,1909,melanoma,DOID,481,NRAS wild-type,sensitive,850,Palbociclib,4893,27488531,,,
182,Preclinical - Cell culture,"In a preclinical study, an NRAS wild-type melanoma cell line demonstrated inhibition of cell growth when treated with Mekinist (trametinib) in culture (PMID: 27488531). ",Actionable,8538,1909,melanoma,DOID,481,NRAS wild-type,sensitive,2,Trametinib,4893,27488531,,,
183,Phase I,"In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 44% (4/9) and partial response in 22% (2/9) of melanoma patients carrying wild-type BRAF and NRAS (PMID: 26169970).",Actionable,3798,1909,melanoma,DOID,15933,BRAF wild-type NRAS wild-type,sensitive,792,Lenvatinib,4893,26169970,,,
184,Preclinical - Cell culture,"In a preclinical study, BRAF and NRAS wild-type melanoma cells were resistant to Zelboraf (vemurafenib) in culture (PMID: 27523909).",Actionable,7960,1909,melanoma,DOID,15933,BRAF wild-type NRAS wild-type,resistant,342,Vemurafenib,4893,27523909,,,
185,Preclinical - Cell culture,"In a preclinical study, TAK-632 inhibited proliferation of BRAF and NRAS wild-type melanoma cells in culture (PMID: 27523909).",Actionable,7945,1909,melanoma,DOID,15933,BRAF wild-type NRAS wild-type,sensitive,3300,TAK-632,4893,27523909,,,
186,Preclinical - Cell culture,"In a preclinical study, the combination of Binimetinib (MEK162) and Buparlisib (BKM120) resulted in improved cell growth inhibition compared to either agent alone in a metastatic melanoma cell line with wild-type BRAF and wild-type NRAS in culture (PMID: 27307593). ",Actionable,10122,1909,melanoma,DOID,15933,BRAF wild-type NRAS wild-type,sensitive,5400,Binimetinib + BKM120,4893,27307593,,,
187,Preclinical - Cell culture,"In a preclinical study, BRAF and NRAS wild-type melanoma cells were resistant to PLX7904 in culture (PMID: 27523909).",Actionable,7952,1909,melanoma,DOID,15933,BRAF wild-type NRAS wild-type,resistant,4606,PLX7904,4893,27523909,,,
188,Preclinical - Cell culture,"In a preclinical study, AZ628 inhibited proliferation of BRAF and NRAS wild-type melanoma cells in culture (PMID: 27523909).",Actionable,7935,1909,melanoma,DOID,15933,BRAF wild-type NRAS wild-type,sensitive,1093,AZ628,4893,27523909,,,
189,Phase I,"In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 100% (5/5) of melanoma patients harboring BRAF mutations and wild-type NRAS (PMID: 26169970).",Actionable,3796,1909,melanoma,DOID,15931,BRAF mut NRAS wild-type,sensitive,792,Lenvatinib,4893,26169970,,,
190,Preclinical,"In a preclinical study, Erbitux (cetuximab) inhibited growth of human colorectal cancer cells wild-type for BRAF, KRAS, NRAS and PIK3CA in culture (PMID: 25838391).",Actionable,4934,9256,colorectal cancer,DOID,19839,BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type,sensitive,694,Cetuximab,4893,25838391,,,
191,Phase II,"In a Phase II trial, Erbitux (cetuximab) in combination with FOLFOX resulted in improved median progression-free survival (6.9 months) comparing to FOLFOX alone (5.3 months) in BRAF, KRAS, NRAS, and PIK3CA wild-type colorectal cancer patients (hazard ratio =0.56) (PMID: 27002107).",Actionable,5563,9256,colorectal cancer,DOID,19839,BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type,predicted â€“ sensitive,2182,Cetuximab + FOLFOX,4893,27002107,,,
192,Preclinical,"In a preclinical study, colorectal cancer cell lines with wild-type BRAF, KRAS, NRAS and PIK3CA were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).",Actionable,4944,9256,colorectal cancer,DOID,19839,BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type,resistant,890,Regorafenib,4893,25838391,,,
0,Preclinical,"In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation and decreased proliferation in transformed human cells expressing PDGFRA G853D in culture (PMID: 24132921).",Actionable,1826,10000003,Advanced Solid Tumor,JAX,3615,PDGFRA G853D,sensitive,770,Imatinib,5156,24132921,,,
1,Preclinical,"In a preclinical study, crenolanib inhibited Pdgfra phosphorylation and decreased proliferation in transformed human cells expressing PDGFRA G853D in culture (PMID: 24132921).",Actionable,1827,10000003,Advanced Solid Tumor,JAX,3615,PDGFRA G853D,sensitive,705,Crenolanib,5156,24132921,,,
2,Preclinical - Cell culture,"In a preclinical study, Gleevec (imatinib) inhibited growth of transformed mouse myeloid cells over expressing PDGFRA Y849S in culture (PMID: 21224473).",Actionable,7417,8692,myeloid leukemia,DOID,24650,PDGFRA Y849S,sensitive,770,Imatinib,5156,21224473,,,
3,Preclinical - Cell culture,"In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation and cell proliferation in transformed cells over expressing PDGFRA Y849S in culture (PMID: 21224473).",Actionable,7420,10000003,Advanced Solid Tumor,JAX,24650,PDGFRA Y849S,sensitive,770,Imatinib,5156,21224473,,,
4,Phase I,"In a Phase I trial, Vistusertib (AZD2014) demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including a patient with pancreatic cancer harboring a PDGFRA activating mutation (PMID: 25805799). ",Actionable,2368,1793,pancreatic cancer,DOID,2881,PDGFRA act mut,predicted â€“ sensitive,991,Vistusertib,5156,25805799,,,
5,Preclinical,"In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation in cells expressing PDGFRA H845Y in culture (PMID: 24132921).",Actionable,1848,10000003,Advanced Solid Tumor,JAX,3745,PDGFRA H845Y,sensitive,770,Imatinib,5156,24132921,,,
6,Preclinical,"In a preclinical study, crenolanib inhibited Pdgfra phosphorylation in cells expressing PDGFRA H845Y in culture (PMID: 24132921).",Actionable,1847,10000003,Advanced Solid Tumor,JAX,3745,PDGFRA H845Y,sensitive,705,Crenolanib,5156,24132921,,,
7,Preclinical - Cell line xenograft,"In a preclinical study, Gleevec (imatinib) inhibited growth of transformed mouse myeloid cells over expressing PDGFRA R748G in culture and prolonged survival in xenograft models (PMID: 21224473).",Actionable,7418,8692,myeloid leukemia,DOID,24649,PDGFRA R748G,sensitive,770,Imatinib,5156,21224473,,,
8,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing PDGFRA D842_I843delinsIM were resistant to inhibition of Pdgfra phosphorylation by Gleevec (imatinib) in culture (PMID: 21224473).",Actionable,7422,10000003,Advanced Solid Tumor,JAX,24640,PDGFRA D842_I843delinsIM,resistant,770,Imatinib,5156,21224473,,,
9,Preclinical - Cell culture,"In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation in transformed cells over expressing PDGFRA S566_E571delinsR in culture (PMID: 21224473).",Actionable,7425,10000003,Advanced Solid Tumor,JAX,24637,PDGFRA S566_E571delinsR,sensitive,770,Imatinib,5156,21224473,,,
10,Preclinical,"In a preclinical study, cells expressing PDGFRA V561D demonstrated sensitivity to Gleevec (imatinib) in cell culture (PMID: 15928335).",Actionable,191,10000003,Advanced Solid Tumor,JAX,603,PDGFRA V561D,sensitive,770,Imatinib,5156,15928335,,,
11,Preclinical - Cell culture,"In a preclinical study, PDGFRA D842V conferred resistance to inhibition of PDGFRA phosphorylation by Sutent (sunitinib) in cells expressing PDGFRA V561D in culture (PMID: 18955458).",Actionable,8936,10000003,Advanced Solid Tumor,JAX,26542,PDGFRA D842V PDGFRA V561D,resistant,930,Sunitinib,5156,18955458,,,
12,Preclinical,"In a preclinical study, crenolanib decreased Pdgfra phosphorylation in cells expressing PDGFRA N659K in culture (PMID: 22745105).",Actionable,1831,10000003,Advanced Solid Tumor,JAX,3648,PDGFRA N659K,sensitive,705,Crenolanib,5156,22745105,,,
13,Preclinical,"In a preclinical study, Gleevec (imatinib) decreased Pdgfra phosphorylation in cells expressing PDGFRA N659K in culture (PMID: 22745105).",Actionable,1830,10000003,Advanced Solid Tumor,JAX,3648,PDGFRA N659K,sensitive,770,Imatinib,5156,22745105,,,
14,Preclinical,"In a preclinical study, Gleevec (imatinib) decreased phosphorylation of Pdgfra in cell lines expressing PDGFRA I843del mutation in culture (PMID: 14645423).",Actionable,1829,10000003,Advanced Solid Tumor,JAX,3643,PDGFRA I843del,sensitive,770,Imatinib,5156,14645423,,,
15,Preclinical,"In a preclinical study, crenolanib inhibited Pdgfra phosphorylation and decreased proliferation in cells expressing PDGFRA V658A in culture (PMID: 24132921).",Actionable,1843,10000003,Advanced Solid Tumor,JAX,3699,PDGFRA V658A,sensitive,705,Crenolanib,5156,24132921,,,
16,Preclinical,"In a preclinical study, crenolanib inhibited Pdgfra phosphorylation and decreased proliferation in transformed human cells expressing PDGFRA V658A in culture (PMID: 24132921).",Actionable,7190,10000003,Advanced Solid Tumor,JAX,3699,PDGFRA V658A,sensitive,770,Imatinib,5156,24132921,,,
17,Preclinical,"In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation and decreased proliferation in transformed human cells expressing PDGFRA D842Y in culture (PMID: 24132921).",Actionable,7188,10000003,Advanced Solid Tumor,JAX,3676,PDGFRA D842Y,sensitive,770,Imatinib,5156,24132921,,,
18,Preclinical,"In a preclinical study, Crenolanib inhibited Pdgfra phosphorylation and decreased proliferation in transformed human cells expressing PDGFRA D842Y in culture (PMID: 24132921).",Actionable,7189,10000003,Advanced Solid Tumor,JAX,3676,PDGFRA D842Y,sensitive,705,Crenolanib,5156,24132921,,,
19,Preclinical,"In a preclinical study, mice injected with transformed cells harboring PDGFRA H650Q developed leukemia-like disease that is sensitive to Gleevec (imatinib) (PMID: 21224473).",Actionable,727,1240,leukemia,DOID,980,PDGFRA H650Q,sensitive,770,Imatinib,5156,21224473,,,
20,Preclinical - Cell culture,"In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation in transformed cells over expressing PDGFRA V561_I562insER in culture (PMID: 21224473).",Actionable,7424,10000003,Advanced Solid Tumor,JAX,24633,PDGFRA V561_I562insER,sensitive,770,Imatinib,5156,21224473,,,
21,Phase I,"In a Phase I trial, BLU-285 demonstrated preliminary antitumor activity in gastrointestinal stromal tumor patients harboring PDGFRA D842 mutations, with partial responses in 50% (6/12) and stable disease in 50% (6/12) of patients (EORTC-NCI-AACR 2016, Abs 6LBA).",Actionable,9775,9253,gastrointestinal stromal tumor,DOID,27078,PDGFRA D842X,sensitive,2941,BLU-285,5156,None,,,
22,Preclinical,"In a preclinical study, crenolanib inhibited Pdgfra phosphorylation and decreased proliferation in cells expressing PDGFRA P577S in culture (PMID: 24132921).",Actionable,1833,10000003,Advanced Solid Tumor,JAX,3650,PDGFRA P577S,sensitive,705,Crenolanib,5156,24132921,,,
23,Preclinical,"In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation and decreased proliferation in cells expressing PDGFRA P577S in culture (PMID: 24132921).",Actionable,1832,10000003,Advanced Solid Tumor,JAX,3650,PDGFRA P577S,sensitive,770,Imatinib,5156,24132921,,,
24,Phase I,"In a Phase I retrospective study, treatment with Gleevec (imatinib) demonstrated a prolonged response in a patient with a gastrointestinal stromal tumor harboring a PDGFRA L221F mutation (PMID: 22718859).",Actionable,676,9253,gastrointestinal stromal tumor,DOID,863,PDGFRA L221F,sensitive,770,Imatinib,5156,22718859,,,
25,Clinical Study,"In a clinical study, a melanoma patient harboring a PDGFRA mutation, CDKN2A mutation, MET exon 14 splice site mutation, and SMAD4 Q249H demonstrated a 21 month overall survival when treated with a combination of Gleevec (imatinib), Paraplatin (carboplatin), and Taxol (paclitaxel) (PMID: 28514312).",Actionable,11053,1909,melanoma,DOID,27904,CDKN2A mut MET del exon14 PDGFRA mut SMAD4 Q249H,sensitive,5833,Imatinib + Carboplatin + Paclitaxel,5156,28514312,,,
26,Clinical Study,"PDGFRA mutations are used in the diagnosis of gastrointestinal stromal tumors (PMID: 26276366, PMID: 25729899).",Diagnostic,3969,9253,gastrointestinal stromal tumor,DOID,1215,PDGFRA mutant,not applicable,1776,N/A,5156,25729899,26276366,,
27,Preclinical - Cell culture,"In a preclinical study, transformed cells over expressing PDGFRA R841_D842delinsKI were resistant to inhibition of Pdgfra phosphorylation by Gleevec (imatinib) in culture (PMID: 21224473).",Actionable,7423,10000003,Advanced Solid Tumor,JAX,24639,PDGFRA R841_D842delinsKI,resistant,770,Imatinib,5156,21224473,,,
28,Preclinical - Cell culture,"In a preclinical study, transformed mouse myeloid cells over expressing PDGFRA N659S demonstrated reduced sensitivity to Gleevec (imatinib) in culture (PMID: 21224473).",Actionable,7415,8692,myeloid leukemia,DOID,24648,PDGFRA N659S,decreased response,770,Imatinib,5156,21224473,,,
29,FDA approved,Gleevec (imatinib) is FDA approved for myelodysplastic/myeloproliferative cancers that are associated with PDGFR rearrangements (FDA.gov). ,Actionable,1974,4972,myelodysplastic/myeloproliferative neoplasm,DOID,1320,PDGFRA rearrange,sensitive,770,Imatinib,5156,None,,,
30,Preclinical - Cell culture,"In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation and cell proliferation in transformed cells over expressing PDGFRA D846Y in culture (PMID: 21224473).",Actionable,7421,10000003,Advanced Solid Tumor,JAX,3677,PDGFRA D846Y,sensitive,770,Imatinib,5156,21224473,,,
31,Preclinical,"In a preclinical study, crenolanib inhibited Pdgfra phosphorylation and decreased proliferation in cells expressing PDGFRA R841K in culture (PMID: 24132921).",Actionable,1842,10000003,Advanced Solid Tumor,JAX,3696,PDGFRA R841K,sensitive,705,Crenolanib,5156,24132921,,,
32,Preclinical,"In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation and decreased proliferation in cells expressing PDGFRA R841K in culture (PMID: 24132921).",Actionable,1841,10000003,Advanced Solid Tumor,JAX,3696,PDGFRA R841K,sensitive,770,Imatinib,5156,24132921,,,
33,Phase I,"In a Phase I trial, DCC-2618 demonstrated preliminary safety and efficacy in patients with advanced solid tumors, including a partial response in a glioblastoma multiforme patient harboring KIT and PDGFRA amplification (EORTC-NCI-AACR 2016, Abs 7LBA).",Actionable,9778,3068,glioblastoma multiforme,DOID,27080,KIT amp PDGFRA amp,sensitive,4316,DCC-2618,5156,None,,,
34,Preclinical,"In a preclinical study, Gleevec (imatinib) and Iressa (gefitinib) acted synergistically to decrease downstream signaling activity and inhibit cell growth of glioblastoma cell lines with EGFR and PDGFRA coamplification (PMID: 22323597). ",Actionable,1860,3068,glioblastoma multiforme,DOID,4004,PDGFRA amp EGFR amp,sensitive,2483,Gefitinib + Imatinib,5156,22323597,,,
35,Preclinical,"In a preclinical study, Gleevec (imatinib) inhibited growth of lung squamous cell cancer cells with PDGFRA amplification in culture (PMID: 22328973).",Actionable,5090,3907,lung squamous cell carcinoma,DOID,1417,PDGFRA amp,sensitive,770,Imatinib,5156,22328973,,,
36,Preclinical,"In a preclinical study, a malignant peripheral nerve sheath tumor cell line harboring a PDGFRA amplification demonstrated cell growth inhibition when treated with Gleevec (imatinib) (PMID: 16357008). ",Actionable,1897,5940,malignant peripheral nerve sheath tumor,DOID,1417,PDGFRA amp,sensitive,770,Imatinib,5156,16357008,,,
37,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited growth of lung squamous cell cancer cells with PDGFRA amplification in culture (PMID: 22328973).",Actionable,5094,5409,lung small cell carcinoma,DOID,1417,PDGFRA amp,sensitive,877,Ponatinib,5156,22328973,,,
38,Preclinical,"In a preclinical study, Sutent (sunitinib) decreased cell proliferation and inhibited downstream signaling in a NSCLC cell line harboring a PDGFRA amplification (PMID: 19366796). ",Actionable,1898,3908,non-small cell lung carcinoma,DOID,1417,PDGFRA amp,sensitive,930,Sunitinib,5156,19366796,,,
39,Preclinical - Cell line xenograft,"In a preclinical study, Sprycel (dasatinib) inhibited growth of a lung squamous cell cancer (SCC) cell line with amplification of PDGFRA in culture, and inhibited tumor growth in PDGFRA-amplified lung SCC xenograft models (PMID: 22328973).",Actionable,5082,3907,lung squamous cell carcinoma,DOID,1417,PDGFRA amp,sensitive,717,Dasatinib,5156,22328973,,,
40,Preclinical - Cell culture,"In a preclinical study, transformed cells expressing PDGFRA D842V demonstrated resistance to growth inhibition by Tasigna (nilotinib) in culture (PMID: 18794084).",Actionable,8848,10000003,Advanced Solid Tumor,JAX,604,PDGFRA D842V,resistant,829,Nilotinib,5156,18794084,,,
41,Clinical Study,"In a clinical study, Stivarga (regorafenib) treatment resulted in partial response in 11% (2/18) of patients and stable disease in 39% (7/18) of gastrointestinal stromal tumor patients, including prolonged stable disease for 12 months in a patient harboring PDGFRA D842V (PMID: 25905001).",Actionable,8923,9253,gastrointestinal stromal tumor,DOID,604,PDGFRA D842V,predicted â€“ sensitive,890,Regorafenib,5156,25905001,,,
42,Phase Ib/II,"In a Phase I/II trial, treatment with Crenolanib (CP-868596) resulted in a clinical benefit rate of 31% (5/16) in gastronintestinal stromal tumor patients harboring PDGFRA D842V, with partial response in 2/16 and stable disease in 3/16 patients (J Clin Oncol 34, 2016 (suppl; abstr 11010)).",Actionable,8922,9253,gastrointestinal stromal tumor,DOID,604,PDGFRA D842V,sensitive,705,Crenolanib,5156,None,,,
43,Preclinical,"In a preclinical study, expression of PDGFRA D842V conferred resistance to Gleevec (imatinib) in cell culture (PMID: 15928335).",Actionable,834,10000003,Advanced Solid Tumor,JAX,604,PDGFRA D842V,resistant,770,Imatinib,5156,15928335,,,
44,Preclinical - Cell culture,"In a preclinical study, Crenolanib inhibited Pdgfra phosphorylation and proliferation of transformed cells expressing PDGFRA D842V in culture (PMID: 22745105).",Actionable,8847,10000003,Advanced Solid Tumor,JAX,604,PDGFRA D842V,sensitive,705,Crenolanib,5156,22745105,,,
45,Preclinical - Cell culture,"In a preclinical study, cells expressing PDGFRA D842V demonstrated resistance to inhibition of PDGFRA phosphorylation by Sutent (sunitinib) in culture (PMID: 18955458).",Actionable,8935,10000003,Advanced Solid Tumor,JAX,604,PDGFRA D842V,resistant,930,Sunitinib,5156,18955458,,,
46,Preclinical - Cell culture,"In a preclinical study, Gleevec (imatinib) inhibited Pdgfra phosphorylation in transformed cells over expressing PDGFRA H845_N848delinsP in culture (PMID: 21224473).",Actionable,7419,10000003,Advanced Solid Tumor,JAX,24642,PDGFRA H845_N848delinsP,sensitive,770,Imatinib,5156,21224473,,,
0,Preclinical - Pdx,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment resulted in tumor growth stabilization in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D, PIK3CA E545K and H1047L (PMID: 26272063).",Actionable,8581,9256,colorectal cancer,DOID,26369,KRAS G12D PIK3CA E545K PIK3CA H1047L TP53 wild-type,sensitive,4771,MLN0128 + PD-0325901,5290,26272063,,,
1,Preclinical,"In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047L in culture (PMID: 26627007).",Actionable,4243,1612,breast cancer,DOID,3636,PIK3CA H1047L,sensitive,787,Lapatinib,5290,26627007,,,
2,Preclinical,"In a preclinical study, MK2206 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047L in culture (PMID: 26627007).",Actionable,4236,1612,breast cancer,DOID,3636,PIK3CA H1047L,sensitive,816,MK2206,5290,26627007,,,
3,Preclinical - Cell culture,"In a preclinical study, Alpelisib (BYL719) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047L in culture (PMID: 26627007).",Actionable,4229,1612,breast cancer,DOID,3636,PIK3CA H1047L,sensitive,691,BYL719,5290,26627007,,,
4,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047L in culture (PMID: 26627007).",Actionable,4250,1612,breast cancer,DOID,3636,PIK3CA H1047L,sensitive,828,Neratinib,5290,26627007,,,
5,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047L in culture (PMID: 26627007).",Actionable,4257,1612,breast cancer,DOID,3636,PIK3CA H1047L,sensitive,2,Trametinib,5290,26627007,,,
6,Preclinical,"In a preclinical study, BEZ235 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047L in culture (PMID: 26627007).",Actionable,4222,1612,breast cancer,DOID,3636,PIK3CA H1047L,sensitive,672,BEZ235,5290,26627007,,,
7,Clinical Study,"In a clinical study, the PIK3CA R425L mutation was identified as a potential resistance mechanism in a non-small cell lung carcinoma patient harboring ERBB2 (HER2) A775_G776insYVMA, that progressed during Herceptin (trastuzumab) treatment (PMID: 28167203). ",Actionable,10134,3908,non-small cell lung carcinoma,DOID,27298,ERBB2 A775_G776insYVMA PIK3CA R425L,predicted â€“ resistant,947,Trastuzumab,5290,28167203,,,
8,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited growth of colorectal cancer cells harboring both BRAF G596R and PIK3CA E545K in culture (PMID: 26243863).",Actionable,7117,9256,colorectal cancer,DOID,24419,BRAF G596R PIK3CA E545K,sensitive,828,Neratinib,5290,26243863,,,
9,Preclinical - Cell culture,"In a preclinical study, non-small cell lung cancer cells harboring KRAS Q61H and PIK3CA E545K demonstrated decreased response to Pimasertib (MSC1936369B) in culture (PMID: 23629727).",Actionable,8171,3908,non-small cell lung carcinoma,DOID,26184,KRAS Q61H PIK3CA E545K,decreased response,871,Pimasertib,5290,23629727,,,
10,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring KRAS Q61H and PIK3CA E545K in culture (PMID: 23629727).",Actionable,8180,3908,non-small cell lung carcinoma,DOID,26184,KRAS Q61H PIK3CA E545K,sensitive,1659,Pimasertib + Sorafenib,5290,23629727,,,
11,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of non-small cell lung cancer cells harboring KRAS Q61H and PIK3CA E545K in culture (PMID: 23629727).",Actionable,8176,3908,non-small cell lung carcinoma,DOID,26184,KRAS Q61H PIK3CA E545K,sensitive,4656,Everolimus + Pimasertib,5290,23629727,,,
12,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring KRAS Q61H and PIK3CA E545K in culture (PMID: 23629727).",Actionable,8185,3908,non-small cell lung carcinoma,DOID,26184,KRAS Q61H PIK3CA E545K,sensitive,4657,Pimasertib + Regorafenib,5290,23629727,,,
13,Preclinical - Cell line xenograft,"In a preclinical study, Gedatolisib (PKI-587) inhibited PI3K signaling, cell growth and induced apoptosis in human breast cancer cells harboring ERBB2 (HER2) amplification, PIK3CA E545K, and PIK3CA K567R in culture and in cell line xenografts (PMID: 21325073, PMID: 17314276).",Actionable,3124,60079,Her2-receptor positive breast cancer,DOID,11788,ERBB2 amp PIK3CA E545K PIK3CA K567R,sensitive,1040,PF-05212384,5290,21325073,17314276,,
14,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment did not improve tumor growth stabilization compared to single agent in patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K and TP53 R273* (PMID: 26272063).",Actionable,8597,9256,colorectal cancer,DOID,26374,KRAS G12V PIK3CA E545K TP53 R273*,no benefit,1420,Selumetinib + BEZ235,5290,26272063,,,
15,Preclinical - Pdx,"In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K, and TP53 R273* did not respond to BEZ235 treatment (PMID: 26272063).",Actionable,8699,9256,colorectal cancer,DOID,26374,KRAS G12V PIK3CA E545K TP53 R273*,resistant,672,BEZ235,5290,26272063,,,
16,Preclinical - Pdx,"In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K, and TP53 R273* did not respond to Selumetinib (AZD6244) treatment (PMID: 26272063).",Actionable,8698,9256,colorectal cancer,DOID,26374,KRAS G12V PIK3CA E545K TP53 R273*,resistant,913,Selumetinib,5290,26272063,,,
17,Preclinical - Cell culture,"In a preclinical study, Akt1 over expression in breast cancer cells harboring PIK3CA E545K resulted in resistance to Pictilisib (GDC-0941) in culture (PMID: 27604488).",Actionable,8896,1612,breast cancer,DOID,26498,AKT1 over exp PIK3CA E545K,resistant,749,GDC-0941,5290,27604488,,,
18,Preclinical - Cell culture,"In a preclinical study, treatment with ARQ092 resulted in growth inhibition in hormone receptor positive breast cancer cells harboring PIK3CA E545K in culture (PMID: 26469692).",Actionable,10269,1612,breast cancer,DOID,2421,PIK3CA E545K,sensitive,635,ARQ092,5290,26469692,,,
19,Preclinical,"In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E545K in culture (PMID: 26627007).",Actionable,4241,1612,breast cancer,DOID,2421,PIK3CA E545K,sensitive,787,Lapatinib,5290,26627007,,,
20,Preclinical - Cell line xenograft,"In a preclinical study, XL147 inhibited PI3K signaling and proliferation of a human breast carcinoma cell line harboring PIK3CA E545K in culture and inhibited tumor growth in xenograft models (PMID: 25637314).",Actionable,6309,3459,breast carcinoma,DOID,2421,PIK3CA E545K,sensitive,1050,XL147,5290,25637314,,,
21,Preclinical,"In a preclinical study, CH5132799 inhibited proliferation of breast cancer cells expressing PIK3CA E545K (PMID: 21558396).",Actionable,2949,1612,breast cancer,DOID,2421,PIK3CA E545K,sensitive,2152,CH5132799,5290,21558396,,,
22,Preclinical - Pdx,"In a preclinical study, Aliqopa (copanlisib), in combination with Taxol (paclitaxel), induced tumor regression in PIK3CA E545K-mutant patient-derived non-small cell lung cancer xenografts (PMID: 24170767).",Actionable,1375,3908,non-small cell lung carcinoma,DOID,2421,PIK3CA E545K,sensitive,1276,Copanlisib + Paclitaxel,5290,24170767,,,
23,Preclinical,"In a preclinical study, WYE-125132 inhibited proliferation of breast cancer cells with a PIK3CA E545K mutation (PMID: 20068177).",Actionable,2899,1612,breast cancer,DOID,2421,PIK3CA E545K,sensitive,2242,WYE-125132,5290,20068177,,,
24,Preclinical,"In a preclinical study, LY294002 inhibited cell proliferation of esophagus squamous cell carcinoma cells expressing PIK3CA E545K (PMID: 18262558). ",Actionable,2780,3748,esophagus squamous cell carcinoma,DOID,2421,PIK3CA E545K,sensitive,1062,LY294002,5290,18262558,,,
25,Phase II,"In a Phase II trial, treatment with Torisel (temsirolimus) resulted in disease stabilization in 57.6% (19/33) and tumor shrinkage in 39.4% (13/33) of patients with head and neck squamous cell carcinoma (PMID: 25527417).",Actionable,2481,5520,head and neck squamous cell carcinoma,DOID,2421,PIK3CA E545K,sensitive,936,Temsirolimus,5290,25527417,,,
26,Preclinical,"In a preclinical study, breast cancer cell lines harboring a PIK3CA E545K mutation had increased sensitivity to Afinitor (everolimus) in culture (PMID: 20664172).",Actionable,1390,1612,breast cancer,DOID,2421,PIK3CA E545K,sensitive,735,Everolimus,5290,20664172,,,
27,Preclinical - Cell culture,"In a preclinical study, DHM25 increased cell death in a breast cancer cell line harboring PIK3CA E545K in culture (PMID: 26237138).",Actionable,10357,1612,breast cancer,DOID,2421,PIK3CA E545K,sensitive,5494,DHM25,5290,26237138,,,
28,Preclinical,"In a preclinical study, CH5132799 inhibited proliferation of ovarian cancer cells harboring PIK3CA E545K in culture (PMID: 21558396).",Actionable,2950,2394,ovarian cancer,DOID,2421,PIK3CA E545K,sensitive,2152,CH5132799,5290,21558396,,,
29,Preclinical,"In a preclinical study, MK2206 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E545K in culture (PMID: 26627007).",Actionable,4234,1612,breast cancer,DOID,2421,PIK3CA E545K,sensitive,816,MK2206,5290,26627007,,,
30,Preclinical - Cell culture,"In a preclinical study, Estybon (rigosertib) inhibited oncogenic transformation in fibroblast cells over-expressing PIK3CA E545K in culture (PMID: 27104980).",Actionable,8555,10000003,Advanced Solid Tumor,JAX,2421,PIK3CA E545K,sensitive,1046,rigosertib,5290,27104980,,,
31,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E545K in culture (PMID: 26627007).",Actionable,4248,1612,breast cancer,DOID,2421,PIK3CA E545K,sensitive,828,Neratinib,5290,26627007,,,
32,Clinical Study,"In a retrospective study, treatment with the combination of Erbitux (cetuximab) and Camptosar (irinotecan) resulted in stable disease in 50% (1/2) and 14 months without evidence of disease in 50% (1/2) of colorectal carcinoma patients harboring a PIK3CA E545K mutation (PMID: 25714871).",Actionable,3759,9256,colorectal cancer,DOID,2421,PIK3CA E545K,sensitive,1874,Cetuximab + Irinotecan,5290,25714871,,,
33,Preclinical - Cell culture,"In a preclinical study, a breast cancer cell line harboring PIK3CA E545K was sensitive to ARQ 751 in culture, demonstrating inhibition of cell growth (PMID: 26469692). ",Actionable,10274,1612,breast cancer,DOID,2421,PIK3CA E545K,sensitive,4331,ARQ 751,5290,26469692,,,
34,Phase II,"In a Phase II trial, a patient with head and neck squamous cell carcinoma harboring PIK3CA E545K demonstrated a partial response when treated with the combination of Torisel (temsirolimus), Paraplatin (carboplatin), and Taxol (paclitaxel) (PMID: 28961834). ",Actionable,12182,5520,head and neck squamous cell carcinoma,DOID,2421,PIK3CA E545K,predicted â€“ sensitive,6333,Carboplatin + Paclitaxel + Temsirolimus,5290,28961834,,,
35,Preclinical,"In a preclinical study, PW12 inhibited proliferation of cervical cancer cells with a PIK3CA E545K mutation (PMID: 22391131).",Actionable,2828,4362,cervical cancer,DOID,2421,PIK3CA E545K,sensitive,2961,PW12,5290,22391131,,,
36,Phase I,"In a Phase I trial, Apitolisib (GDC-0980) resulted in a partial response in two patients, one with head and neck squamous cell carcinoma and another with ovarian cancer, both harboring PIK3CA E545K (PMID: 26787751). ",Actionable,6086,10000003,Advanced Solid Tumor,JAX,2421,PIK3CA E545K,sensitive,750,GDC-0980,5290,26787751,,,
37,Preclinical,"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human breast cancer cells harboring PIK3CA E545K in culture (PMID: 21325073, PMID: 17314276).",Actionable,3128,1612,breast cancer,DOID,2421,PIK3CA E545K,sensitive,1040,PF-05212384,5290,21325073,17314276,,
38,Preclinical - Cell culture,"In a preclinical study, inhibition of Pi3k signaling by BEZ235 did not sensitize breast cancer cell lines harboring PIK3CA E545K to Venclexta (venetoclax) in culture (PMID: 27974663).",Actionable,10083,1612,breast cancer,DOID,2421,PIK3CA E545K,no benefit,5376,BEZ235 + Venetoclax,5290,27974663,,,
39,Preclinical,"In a preclinical study, BEZ235 decreased cell proliferation in colorectal cancer cells harboring a PIK3CA E545K mutation in cell culture (PMID: 21966435).",Actionable,1393,9256,colorectal cancer,DOID,2421,PIK3CA E545K,sensitive,672,BEZ235,5290,21966435,,,
40,Preclinical - Cell culture,"In a preclinical study, Alpelisib (BYL719) induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing PIK3CA E545K in culture (PMID: 26013318).",Actionable,7974,3907,lung squamous cell carcinoma,DOID,2421,PIK3CA E545K,sensitive,691,BYL719,5290,26013318,,,
41,Preclinical,"In a preclinical study, gastric cancer cells harboring PI3KCA E545K mutations were sensitive to the AKT inhibitor AZD5363 (PMID: 24088382).",Actionable,1388,3119,gastrointestinal system cancer,DOID,2421,PIK3CA E545K,sensitive,655,AZD5363,5290,24088382,,,
42,Preclinical - Cell culture,"In a preclinical study, Alpelisib (BYL719) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E545K in culture (PMID: 26627007).",Actionable,4227,1612,breast cancer,DOID,2421,PIK3CA E545K,sensitive,691,BYL719,5290,26627007,,,
43,Preclinical,"In a preclinical study, BEZ235 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E545K in culture (PMID: 26627007).",Actionable,4220,1612,breast cancer,DOID,2421,PIK3CA E545K,sensitive,672,BEZ235,5290,26627007,,,
44,Preclinical - Cell line xenograft,"In a preclinical study, BAY1125976 inhibited proliferation of a breast cancer cell line harboring PIK3CA E545K in culture, and inhibited AKT signaling and tumor growth in xenograft models (PMID: 27699769).",Actionable,8815,1612,breast cancer,DOID,2421,PIK3CA E545K,sensitive,994,BAY1125976,5290,27699769,,,
45,Preclinical - Cell culture,"In a preclinical study, expression of PIK3CA E545K in a thyroid cancer cell line resulted in increased sensitivity to MK2206 in culture (PMID: 21289267).",Actionable,8221,1781,thyroid cancer,DOID,2421,PIK3CA E545K,sensitive,816,MK2206,5290,21289267,,,
46,Preclinical - Cell culture,"In a preclinical study, Buparlisib (BKM120) induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing PIK3CA E545K in culture (PMID: 26013318).",Actionable,7968,3907,lung squamous cell carcinoma,DOID,2421,PIK3CA E545K,sensitive,680,BKM120,5290,26013318,,,
47,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E545K in culture (PMID: 26627007).",Actionable,4255,1612,breast cancer,DOID,2421,PIK3CA E545K,sensitive,2,Trametinib,5290,26627007,,,
48,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited survival of transformed cell lines overexpressing PIK3CA E545K in culture (PMID: 26627007).",Actionable,4265,10000003,Advanced Solid Tumor,JAX,2421,PIK3CA E545K,sensitive,2,Trametinib,5290,26627007,,,
49,Preclinical,"In a preclinical study, cancer cell lines harboring PIK3CA E545K did not demonstrate sensitivity to A66 in culture, in contrast with cells harboring PIK3CA H1047R (PMID: 21668414).",Actionable,2775,10000003,Advanced Solid Tumor,JAX,2421,PIK3CA E545K,resistant,617,A66,5290,21668414,,,
50,Preclinical,"In a preclinical study, LY3023414 inhibited tumor growth in a transgenic animal model of leukemia driven by PIK3CA E545K (PMID: 27439478).",Actionable,8942,1240,leukemia,DOID,2421,PIK3CA E545K,sensitive,1069,LY3023414,5290,27439478,,,
51,Preclinical - Pdx,"In a preclinical study, Alpelisib (BYL719) inhibited PIK3CA E545K and showed anti-tumor activity in patient-derived xenograft models harboring a PIK3CA E545K mutation (PMID: 24608574).",Actionable,1395,10000003,Advanced Solid Tumor,JAX,2421,PIK3CA E545K,sensitive,691,BYL719,5290,24608574,,,
52,Preclinical,"In a preclinical study, AZD8835 inhibited proliferation of estrogen receptor (ER)-positive breast cancer cells harboring PIK3CA E545K in culture and suppressed tumor growth in xenograft models (PMID: 26839307).",Actionable,5109,60075,estrogen-receptor positive breast cancer,DOID,2421,PIK3CA E545K,sensitive,2013,AZD8835,5290,26839307,,,
53,Phase I,"In a Phase I trial, a colon cancer patient harboring PIK3CA E545K was sensitive to LY2780301, demonstrating stable disease for approximately 125 days (PMID: 25902900).",Actionable,10298,219,colon cancer,DOID,2421,PIK3CA E545K,sensitive,800,LY2780301,5290,25902900,,,
54,Preclinical,"In a preclinical study, Rapamune (sirolimus) demonstrated efficacy in inhibiting transformation of cultured cells containing PIK3CA E545K mutations (PMID: 15647370).",Actionable,1387,10000003,Advanced Solid Tumor,JAX,2421,PIK3CA E545K,sensitive,917,Sirolimus,5290,15647370,,,
55,Preclinical - Cell line xenograft,"In a preclinical study, a breast cancer cell line harboring PIK3CA E545K was sensitive to XL765 (SAR245409), demonstrating inhibition of cell proliferation and colony formation in culture, and inhibition of tumor growth in cell line xenograft models (PMID: 24634413).",Actionable,10702,1612,breast cancer,DOID,2421,PIK3CA E545K,sensitive,1051,SAR245409,5290,24634413,,,
56,Preclinical - Cell line xenograft,"In a preclinical study, treatment with PKI-402 resulted in decreased Akt phosphorylation and tumor regression in ERBB2 (HER2)-positive breast cancer cell line xenograft models harboring PIK3CA E545K (PMID: 20371716).",Actionable,5399,1612,breast cancer,DOID,2421,PIK3CA E545K,sensitive,3857,PKI-402,5290,20371716,,,
57,Preclinical - Cell culture,"In a preclinical study, inhibition of Pi3k signaling by BEZ235 sensitized breast cancer cell lines harboring PIK3CA E545K to WEHI-539 in culture (PMID: 27974663).",Actionable,10086,1612,breast cancer,DOID,2421,PIK3CA E545K,predicted â€“ sensitive,5377,BEZ235 + WEHI-539,5290,27974663,,,
58,Preclinical - Pdx,"In a preclinical study, head and neck squamous cell carcinoma patient-derived xenograft models harboring a PIK3CA E545K mutation demonstrated increased sensitivity to Estybon (rigosertib) (PMID: 23873848).",Actionable,1407,5520,head and neck squamous cell carcinoma,DOID,2421,PIK3CA E545K,sensitive,1046,rigosertib,5290,23873848,,,
59,Preclinical - Cell culture,"In a preclinical study, BEZ235 induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing PIK3CA E545K in culture (PMID: 26013318).",Actionable,7971,3907,lung squamous cell carcinoma,DOID,2421,PIK3CA E545K,sensitive,672,BEZ235,5290,26013318,,,
60,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells over expressing PIK3CA E545K were resistant to Erbitux (cetuximab) and Fluorouracil combination treatment in culture (PMID: 28424201).",Actionable,11722,9256,colorectal cancer,DOID,2421,PIK3CA E545K,resistant,2000,Fluorouracil + Cetuximab,5290,28424201,,,
61,Preclinical - Cell line xenograft,"In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of Herceptin (trastuzumab)-resistant ERBB2 (HER2) positive breast cancer cells harboring PIK3CA E545K in culture, and induced tumor regression in cell line xenograft models (PMID: 26920887).",Actionable,7749,60079,Her2-receptor positive breast cancer,DOID,20859,ERBB2 pos PIK3CA E545K,sensitive,1402,trastuzumab emtansine,5290,26920887,,,
62,Preclinical - Pdx,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K, and TP53 R335fs (PMID: 26272063).",Actionable,8578,9256,colorectal cancer,DOID,26368,KRAS G12V PIK3CA E545K TP53 R335fs,no benefit,4771,MLN0128 + PD-0325901,5290,26272063,,,
63,Preclinical,"In a preclinical study, CH5132799 inhibited proliferation of a breast cancer cell line harboring PIK3CA E545K and ERBB2 (HER2) amplification in culture (PMID: 21558396).",Actionable,3003,1612,breast cancer,DOID,11011,ERBB2 amp PIK3CA E545K,sensitive,2152,CH5132799,5290,21558396,,,
64,Preclinical - Cell line xenograft,"In a preclinical study, a breast cancer cell line xenograft model co-harboring ERBB2 (HER2) amplification and PIK3CA E545K demonstrated tumor regression within the mammary fat pad when treated with Buparlisib (BKM120) (PMID: 28539475). ",Actionable,11514,1612,breast cancer,DOID,11011,ERBB2 amp PIK3CA E545K,sensitive,680,BKM120,5290,28539475,,,
65,Preclinical - Cell line xenograft,"In a preclinical study, expression of KRAS G13D in an endometrial cancer cell line harboring PIK3CA E545K conferred resistance to Afinitor (everolimus) in xenograft models (PMID: 20664172). ",Actionable,9329,1380,endometrial cancer,DOID,10712,KRAS G13D PIK3CA E545K,resistant,735,Everolimus,5290,20664172,,,
66,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Pictilisib (GDC-0941) and Cobimetinib (GDC-0973) inhibited tumor growth in a colorectal adenocarcinoma xenograft model harboring KRAS G13D and PIK3CA E545K mutations, and demonstrated improved efficacy over either agent alone (PMID: 22084396).",Actionable,2854,50861,colorectal adenocarcinoma,DOID,10712,KRAS G13D PIK3CA E545K,sensitive,1702,GDC-0941 + cobimetinib,5290,22084396,,,
67,Preclinical - Cell culture,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, but did not induce apoptosis in colorectal cancer cells harboring KRAS G13D, PIK3CA E545K, and TP53 S241F in culture (PMID: 26272063).",Actionable,8564,9256,colorectal cancer,DOID,26357,KRAS G13D PIK3CA E545k TP53 S241F,sensitive,4771,MLN0128 + PD-0325901,5290,26272063,,,
68,Preclinical,"In a preclinical study, Erbitux (cetuximab) did not inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA E545K in culture (PMID: 26715098).",Actionable,4575,219,colon cancer,DOID,18591,KRAS mutant PIK3CA E545K,no benefit,694,Cetuximab,5290,26715098,,,
69,Preclinical,"In a preclinical study, Buparlisib (BKM120) worked synergistically with Erbitux (cetuximab) to inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA E545K in culture (PMID: 26715098).",Actionable,4576,219,colon cancer,DOID,18591,KRAS mutant PIK3CA E545K,sensitive,3548,BKM120 + Cetuximab,5290,26715098,,,
70,Preclinical,"In a preclinical study, colon cancer cell lines harboring mutant KRAS and PIK3CA E545K demonstrated reduced sensitivity to Buparlisib (BKM120) induced growth inhibition in culture (PMID: 26715098).",Actionable,4574,219,colon cancer,DOID,18591,KRAS mutant PIK3CA E545K,decreased response,680,BKM120,5290,26715098,,,
71,Preclinical - Cell line xenograft,"In a preclinical study, Pimasertib (MSC1936369B) and BEZ235 combination treatment inhibited tumor growth in colorectal cancer cell line xenograft models harboring KRAS G13D, PIK3CA D549N, and PIK3CA E545K (PMID: 23629727).",Actionable,8208,9256,colorectal cancer,DOID,26186,KRAS G13D PIK3CA D549N PIK3CA E545K,sensitive,1660,Pimasertib + BEZ235,5290,23629727,,,
72,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of colorectal cancer cells harboring KRAS G13D, PIK3CA D549N, and PIK3CA E545K in culture (PMID: 23629727).",Actionable,8197,9256,colorectal cancer,DOID,26186,KRAS G13D PIK3CA D549N PIK3CA E545K,sensitive,4656,Everolimus + Pimasertib,5290,23629727,,,
73,Preclinical - Cell line xenograft,"In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited Mapk and Akt signaling, resulted in growth inhibition of colorectal cancer cells harboring KRAS G13D, PIK3CA D549N, and PIK3CA E545K in culture and in cell line xenograft models (PMID: 23629727).",Actionable,8201,9256,colorectal cancer,DOID,26186,KRAS G13D PIK3CA D549N PIK3CA E545K,sensitive,1659,Pimasertib + Sorafenib,5290,23629727,,,
74,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells harboring KRAS G13D, PIK3CA D549N and PIK3CA E545K demonstrated decreased response to Pimasertib (MSC1936369B) in culture (PMID: 23629727).",Actionable,8192,9256,colorectal cancer,DOID,26186,KRAS G13D PIK3CA D549N PIK3CA E545K,decreased response,871,Pimasertib,5290,23629727,,,
75,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring KRAS G13D, PIK3CA D549N, and PIK3CA E545K in culture (PMID: 23629727).",Actionable,8207,9256,colorectal cancer,DOID,26186,KRAS G13D PIK3CA D549N PIK3CA E545K,sensitive,4657,Pimasertib + Regorafenib,5290,23629727,,,
76,Preclinical - Pdx,"In a preclinical study, BEZ235 delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12V and PIK3CA E545K (PMID: 26272063).",Actionable,8704,9256,colorectal cancer,DOID,26377,KRAS G12V PIK3CA E545K TP53 wild-type,decreased response,672,BEZ235,5290,26272063,,,
77,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment resulted in enhanced tumor growth stabilization compared to single agent in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12V and PIK3CA E545K (PMID: 26272063).",Actionable,8603,9256,colorectal cancer,DOID,26377,KRAS G12V PIK3CA E545K TP53 wild-type,sensitive,1420,Selumetinib + BEZ235,5290,26272063,,,
78,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12V and PIK3CA E545K (PMID: 26272063).",Actionable,8705,9256,colorectal cancer,DOID,26377,KRAS G12V PIK3CA E545K TP53 wild-type,decreased response,913,Selumetinib,5290,26272063,,,
79,Preclinical,"In a preclinical study, human colon cancer cells harboring KRAS G13D, PIK3CA E545K, and PIK3CA D549N had a decreased response to Gedatolisib (PKI-587) in culture (PMID: 21325073, PMID: 24042735).",Actionable,3132,219,colon cancer,DOID,11790,KRAS G13D PIK3CA E545K PIK3CA D549N,decreased response,1040,PF-05212384,5290,21325073,24042735,,
80,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis of human colorectal cancer cell lines harboring KRAS G13D, PIK3CA E545K, and PIK3CA D549N in culture and reduced tumor growth in cell line xenograft models (PMID: 25838391).",Actionable,4946,9256,colorectal cancer,DOID,11790,KRAS G13D PIK3CA E545K PIK3CA D549N,sensitive,1305,Regorafenib + Cetuximab,5290,25838391,,,
81,Preclinical,"In a preclinical study, human colorectal cancer cell lines harboring KRAS G13D, PIK3CA E545K and PIK3CA D549N were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).",Actionable,4943,9256,colorectal cancer,DOID,11790,KRAS G13D PIK3CA E545K PIK3CA D549N,resistant,890,Regorafenib,5290,25838391,,,
82,Phase I,"In a Phase I clinical trial, an endometrial carcinoma patient harboring PIK3CA T1052K, R88L, and E453del, as well as a PTEN mutation and loss of PTEN protein expression demonstrated a complete response to treatment with Aliqopa (copanlisib) (PMID: 27672108). ",Actionable,9350,2871,endometrial carcinoma,DOID,26828, PIK3CA E453del PIK3CA T1025K PIK3CA R88L PTEN mut PTEN loss,sensitive,995,Copanlisib,5290,27672108,,,
83,Preclinical - Cell culture,"In a preclinical study, PF-4989216 inhibited proliferation of small cell lung carcinoma cells harboring PIK3CA T1025A in culture (PMID: 24240111).",Actionable,8282,5409,lung small cell carcinoma,DOID,3719,PIK3CA T1025A,sensitive,867,PF-4989216,5290,24240111,,,
84,Preclinical - Cell culture,"In a preclinical study, small cell lung carcinoma cells harboring PIK3CA D1029Y and PTEN inactivating mutation were resistant to PF-4989216 induced growth inhibition in culture (PMID: 24240111).",Actionable,5214,5409,lung small cell carcinoma,DOID,26219,PIK3CA D1029Y PTEN inact mut,resistant,867,PF-4989216,5290,24240111,,,
85,Preclinical - Cell line xenograft,"In a preclinical study, PF-4989216 inhibited proliferation of small cell lung carcinoma cells harboring PIK3CA H1047R, PIK3CA K111R, and wild-type PTEN in culture, and suppressed tumor growth in cell line xenograft models (PMID: 24240111).",Actionable,5218,5409,lung small cell carcinoma,DOID,20308,PIK3CA H1047R PIK3CA K111R PTEN wild-type,sensitive,867,PF-4989216,5290,24240111,,,
86,Preclinical - Cell line xenograft,"In a preclinical study, CH5132799 inhibited cell growth in a human endometrial cancer cell line harboring a PIK3CA H1047Y mutation, and inhibited tumor growth in xenograft models (PMID: 21558396).",Actionable,2947,1380,endometrial cancer,DOID,3652,PIK3CA H1047Y,sensitive,2152,CH5132799,5290,21558396,,,
87,Preclinical,"In a preclinical study, glioblastoma cell lines harboring PIK3CA H1047Y demonstrated increased sensitivity to YM-204 induced growth inhibition (PMID: 24718026).",Actionable,5181,3068,glioblastoma multiforme,DOID,3652,PIK3CA H1047Y,sensitive,2967,YM-024,5290,24718026,,,
88,Preclinical - Cell line xenograft,"In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring KRAS G13C, PIK3CA H1047Y, PTEN G143fs*4, and PTEN K267fs*9 was sensitive to treatment with DS-7423, demonstrating inhibition of cell proliferation in culture and tumor growth inhibition in xenograft models (PMID: 24504419). ",Actionable,10541,5304,ovarian clear cell adenocarcinoma,DOID,27593,KRAS G13C PIK3CA H1047Y PTEN G143fs*4 PTEN K267fs*9,sensitive,722,DS-7423,5290,24504419,,,
89,Preclinical - Cell line xenograft,"In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of ERBB2 (HER2) positive breast cancer cells harboring PIK3CA K111N in culture, and induced tumor regression in cell line xenograft models (PMID: 26920887).",Actionable,7745,60079,Her2-receptor positive breast cancer,DOID,25948,ERBB2 pos PIK3CA K111N,sensitive,1402,trastuzumab emtansine,5290,26920887,,,
90,Preclinical - Cell line xenograft,"In a preclinical study, CH5132799 inhibited cell growth and Akt phosphorylation, and promoted apoptosis in a human breast cancer cell line harboring PIK3CA K111N and ERBB2 (HER2) amplification, and inhibited tumor growth in xenograft models (PMID: 21558396).",Actionable,2969,1612,breast cancer,DOID,10753,ERBB2 amp PIK3CA K111N,sensitive,2152,CH5132799,5290,21558396,,,
91,Preclinical - Cell culture,"In a preclinical study, hormone receptor positive breast cancer cells harboring PIK3CA K111N were sensitive to ARQ092 in culture, demonstrating inhibition of cell growth (PMID: 26469692). ",Actionable,10270,1612,breast cancer,DOID,3658,PIK3CA K111N,sensitive,635,ARQ092,5290,26469692,,,
92,Preclinical - Cell culture,"In a preclinical study, BAY1125976 inhibited proliferation of a breast cancer cell line harboring PIK3CA K111N in culture (PMID: 27699769).",Actionable,8813,1612,breast cancer,DOID,3658,PIK3CA K111N,sensitive,994,BAY1125976,5290,27699769,,,
93,Preclinical,"In a preclinical study, AZD8835 inhibited proliferation of estrogen receptor (ER)-positive breast cancer cells harboring PIK3CA K111N in culture and induced tumor regression in xenograft models (PMID: 26839307).",Actionable,5110,60075,estrogen-receptor positive breast cancer,DOID,3658,PIK3CA K111N,sensitive,2013,AZD8835,5290,26839307,,,
94,Preclinical - Cell culture,"In a preclinical study, a breast cancer cell line harboring PIK3CA K111N was sensitive to ARQ 751 in culture, demonstrating inhibition of cell growth (PMID: 26469692). ",Actionable,10275,1612,breast cancer,DOID,3658,PIK3CA K111N,sensitive,4331,ARQ 751,5290,26469692,,,
95,Preclinical - Cell culture,"In a preclinical study, DHM25 increased cell death in a breast cancer cell line harboring PIK3CA K111N in culture (PMID: 26237138).",Actionable,10362,1612,breast cancer,DOID,3658,PIK3CA K111N,sensitive,5494,DHM25,5290,26237138,,,
96,Preclinical - Cell culture,"In a preclinical study, PF-04691502 inhibited Akt phosphorylation and proliferation of breast cancer cells harboring both PIK3CA P539R and H1047R in culture (PMID: 21750219).",Actionable,2621,1612,breast cancer,DOID,9797,PIK3CA P539R PIK3CA H1047R,sensitive,865,PF-04691502,5290,21750219,,,
97,Preclinical - Cell culture,"In a preclinical study, breast cancer cells harboring PIK3CA P539R and H1047R were sensitive to ARQ092 in culture, demonstrating inhibition of cell growth (PMID: 26469692). ",Actionable,10273,1612,breast cancer,DOID,9797,PIK3CA P539R PIK3CA H1047R,sensitive,635,ARQ092,5290,26469692,,,
98,Preclinical - Cell culture,"In a preclinical study, a breast cancer cell line harboring PIK3CA P539R and PH1047R was sensitive to ARQ 751 in culture, demonstrating inhibition of cell growth (PMID: 26469692). ",Actionable,10276,1612,breast cancer,DOID,9797,PIK3CA P539R PIK3CA H1047R,sensitive,4331,ARQ 751,5290,26469692,,,
99,Preclinical - Cell culture,"In a preclinical study, BAY1125976 inhibited proliferation of a breast cancer cell line harboring PIK3CA P539R in culture (PMID: 27699769).",Actionable,8820,1612,breast cancer,DOID,2913,PIK3CA P539R,sensitive,994,BAY1125976,5290,27699769,,,
100,Preclinical - Cell culture,"In a preclinical study, the combination of BGJ398 and Buparlisib (BKM120) resulted in a synergistic effect, demonstrating inhibition of cell proliferation, decreased colony formation, and cell death in an endometrial cancer cell line harboring FGFR2 N550K, PIK3CA I20M and P539R, and PTEN R130Q and T321fs*23 in culture (PMID: 28119489). ",Actionable,10778,1380,endometrial cancer,DOID,27771,FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs*23,sensitive,5612,BGJ398 + BKM120,5290,28119489,,,
101,Preclinical - Cell culture,"In a preclinical study, the combination of BGJ398 and Alpelisib (BYL719) resulted in a synergistic effect, demonstrating inhibition of cell proliferation and induced cell death in an endometrial cancer cell line harboring FGFR2 N550K, PIK3CA I20M and P539R, and PTEN R130Q and T321fs*23 in culture (PMID: 28119489). ",Actionable,10780,1380,endometrial cancer,DOID,27771,FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs*23,sensitive,1293,BGJ398 + BYL719,5290,28119489,,,
102,Preclinical - Cell culture,"In a preclinical study, the combination of BGJ398 and Pictilisib (GDC-0941) resulted in a synergistic effect, demonstrating inhibition of cell proliferation, decreased colony formation, and cell death in an endometrial cancer cell line harboring FGFR2 N550K, PIK3CA I20M and P539R, and PTEN R130Q and T321fs*23 in culture (PMID: 28119489). ",Actionable,10777,1380,endometrial cancer,DOID,27771,FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs*23,sensitive,5613,BGJ398 + GDC-0941,5290,28119489,,,
103,Clinical Study,"In a clinical study, PIK3CA K944N was identified as a potential mechanism for acquired Erbitux (cetuximab) resistance in colorectal cancer patients, which is supported by cell culture studies demonstrating resistance to Erbitux (cetuximab) and Fluorouracil combination treatment in colorectal cancer cells over expressing PIK3CA K944N (PMID: 28424201).",Actionable,11717,9256,colorectal cancer,DOID,28196,PIK3CA K944N,resistant,2000,Fluorouracil + Cetuximab,5290,28424201,,,
104,Preclinical,"In a preclinical study, BEZ235 inhibited proliferation of endometrial cancer cells harboring PIK3CA E365K and PTEN mutations in culture (PMID: 22662154).",Actionable,2139,7519,endocervical carcinoma,DOID,5401,PIK3CA E365K PTEN mut,sensitive,672,BEZ235,5290,22662154,,,
105,Preclinical,"In a preclinical study, BEZ235 inhibited proliferation of endometrial cancer cells harboring PIK3CA E365K and PTEN mutations in culture (PMID: 22662154).",Actionable,2113,1380,endometrial cancer,DOID,5401,PIK3CA E365K PTEN mut,sensitive,672,BEZ235,5290,22662154,,,
106,Clinical Study,"In a clinical study, PIK3CA F930S was identified as a potential mechanism for acquired Erbitux (cetuximab) resistance in colorectal cancer patients, which is consistent with cell culture studies demonstrating moderate resistance to Erbitux (cetuximab) and Fluorouracil combination treatment in colorectal cancer cells over expressing PIK3CA F930S (PMID: 28424201).",Actionable,11724,9256,colorectal cancer,DOID,28200,PIK3CA F930S,resistant,2000,Fluorouracil + Cetuximab,5290,28424201,,,
107,Phase II,"In a Phase II study, MK2206 increased stable disease to 12 months in a nasopharyngeal carcinoma patient with Pik3ca amplification (PMID: 26084990).",Actionable,2478,9261,nasopharynx carcinoma,DOID,1191,PIK3CA amp,sensitive,816,MK2206,5290,26084990,,,
108,Preclinical - Cell line xenograft,"In a preclinical study, Taselisib (GDC-0032) enhanced the effects of radiation induced apoptosis in HNSCC cell lines and cell line xenograft models with PIK3CA amplification (PMID: 26589432).",Actionable,3914,5520,head and neck squamous cell carcinoma,DOID,1191,PIK3CA amp,sensitive,3967,GDC-0032 + Radiotherapy,5290,26589432,,,
109,Preclinical,"In a preclinical study, Panulisib (P7170) downregulated mTOR pathway signaling in ovarian cancer cells with amplified PIK3CA (PMID: 25700704).",Actionable,2819,2394,ovarian cancer,DOID,1191,PIK3CA amp,sensitive,857,P7170,5290,25700704,,,
110,Preclinical - Cell culture,"In a preclinical study, Linsitinib (OSI-906) enhanced sensitivity of PIK3CA amplified triple-receptor negative breast cancer cells to Pictilisib (GDC-0941) in culture (PMID: 27196766).",Actionable,8345,60081,triple-receptor negative breast cancer,DOID,1191,PIK3CA amp,sensitive,4713,GDC-0941 + Linsitinib,5290,27196766,,,
111,Preclinical - Cell culture,"In a preclinical study, small cell lung carcinoma cells harboring amplification of wild-type PIK3CA were resistant to PF-4989216 induced growth inhibition in culture (PMID: 24240111).",Actionable,8287,5409,lung small cell carcinoma,DOID,1191,PIK3CA amp,resistant,867,PF-4989216,5290,24240111,,,
112,Preclinical - Cell culture,"In a preclinical study, BEZ235 resulted in antiproliferative activity in head and neck squamous cell carcinoma cells harboring PIK3CA amplification in culture (PMID: 28446642). ",Actionable,11510,5520,head and neck squamous cell carcinoma,DOID,1191,PIK3CA amp,sensitive,672,BEZ235,5290,28446642,,,
113,Preclinical - Cell line xenograft,"In a preclinical study, XL147 inhibited PI3K signaling and proliferation of a PIK3CA amplified human ovarian cancer cell line in culture, and inhibited tumor growth in xenograft models (PMID: 25637314).",Actionable,6312,2394,ovarian cancer,DOID,1191,PIK3CA amp,sensitive,1050,XL147,5290,25637314,,,
114,Preclinical - Cell culture,"In a preclinical study, NVP-AEW541 enhanced sensitivity of PIK3CA amplified triple-receptor negative breast cancer cells to Pictilisib (GDC-0941) in culture (PMID: 27196766).",Actionable,8346,60081,triple-receptor negative breast cancer,DOID,1191,PIK3CA amp,sensitive,4046,GDC-0941 + NVP-AEW541,5290,27196766,,,
115,Preclinical - Cell line xenograft,"In a preclinical study, an ovarian cancer cell line harboring PIK3CA E545K was sensitive to XL765 (SAR245409), demonstrating inhibition of cell proliferation in culture, and inhibition of tumor growth in cell line xenograft models (PMID: 24634413).",Actionable,10703,2394,ovarian cancer,DOID,1191,PIK3CA amp,sensitive,1051,SAR245409,5290,24634413,,,
116,Preclinical - Cell culture,"In a preclinical study, treatment with AZD8055 resulted in antiproliferative activity in head and neck squamous cell carcinoma cells harboring PIK3CA amplification in culture (PMID: 28446642). ",Actionable,11508,5520,head and neck squamous cell carcinoma,DOID,1191,PIK3CA amp,predicted â€“ sensitive,1519,AZD8055,5290,28446642,,,
117,Preclinical,"In a preclinical study, the combination of BEZ235 and the MEK1 inhibitor PD98509 worked synergistically or additively to inhibit growth of endometrial cancer cells harboring PIK3CA G1049R, KRAS G12D, and amplification of PIK3CA in culture (PMID: 22662154).",Actionable,2143,1380,endometrial cancer,DOID,5398,PIK3CA G1049R KRAS G12D PIK3CA amp,sensitive,2619,BEZ235 + PD98509,5290,22662154,,,
118,Preclinical,"In a preclinical study, the combination of BEZ235 and the MEK1 inhibitor PD98509 worked synergistically or additively to inhibit growth of endometrial cancer cells with amplification of PIK3CA and KRAS in culture (PMID: 22662154).",Actionable,2142,1380,endometrial cancer,DOID,5417,PIK3CA amp KRAS amp,sensitive,2619,BEZ235 + PD98509,5290,22662154,,,
119,Preclinical,"In a preclinical study, MK2206 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007).",Actionable,4238,1612,breast cancer,DOID,3668,PIK3CA N345K,sensitive,816,MK2206,5290,26627007,,,
120,Preclinical - Cell culture,"In a preclinical study, Alpelisib (BYL719) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007).",Actionable,4231,1612,breast cancer,DOID,3668,PIK3CA N345K,sensitive,691,BYL719,5290,26627007,,,
121,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007).",Actionable,4252,1612,breast cancer,DOID,3668,PIK3CA N345K,sensitive,828,Neratinib,5290,26627007,,,
122,Preclinical,"In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007).",Actionable,4245,1612,breast cancer,DOID,3668,PIK3CA N345K,sensitive,787,Lapatinib,5290,26627007,,,
123,Preclinical,"In a preclinical study, BEZ235 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007).",Actionable,4224,1612,breast cancer,DOID,3668,PIK3CA N345K,sensitive,672,BEZ235,5290,26627007,,,
124,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited survival of transformed cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007).",Actionable,4262,10000003,Advanced Solid Tumor,JAX,3668,PIK3CA N345K,sensitive,2,Trametinib,5290,26627007,,,
125,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007).",Actionable,4259,1612,breast cancer,DOID,3668,PIK3CA N345K,sensitive,2,Trametinib,5290,26627007,,,
126,Preclinical,"In a preclinical study, CH5132799 inhibited proliferation of a breast cancer cell line harboring PIK3CA N345K and ERBB2 (HER2) amplification in culture (PMID: 21558396).",Actionable,2952,1612,breast cancer,DOID,10739,ERBB2 amp PIK3CA N345K,sensitive,2152,CH5132799,5290,21558396,,,
127,Preclinical,"In a preclinical study, BEZ235 inhibited proliferation of endometrial cancer cells harboring PIK3CA R88Q and PTEN mutations in culture (PMID: 22662154).",Actionable,2109,1380,endometrial cancer,DOID,5393,PIK3CA R88Q PTEN mut,sensitive,672,BEZ235,5290,22662154,,,
128,Preclinical,"In a preclinical study, Afinitor (everolimus) inhibited proliferation of endometrial cancer cells harboring PIK3CA R88Q and PTEN mutations in culture (PMID: 22662154).",Actionable,2110,1380,endometrial cancer,DOID,5393,PIK3CA R88Q PTEN mut,sensitive,735,Everolimus,5290,22662154,,,
129,Preclinical,"In a preclinical study, endometrial cancer cells harboring PIK3CA R88Q. PTEN mutations, and KRAS G12V demonstrated decreased sensitivity to BEZ235 compared with cells without KRAS mutations in culture (PMID: 22662154).",Actionable,2141,1380,endometrial cancer,DOID,5418,PIK3CA R88Q PTEN mut KRAS G12V,decreased response,672,BEZ235,5290,22662154,,,
130,Preclinical,"In a preclinical study, endometrial cancer cells harboring PIK3CA R88Q. PTEN mutations, and KRAS G12V demonstrated decreased sensitivity to Afinitor (everolimus) compared with cells without KRAS mutations in culture (PMID: 22662154).",Actionable,2140,1380,endometrial cancer,DOID,5418,PIK3CA R88Q PTEN mut KRAS G12V,decreased response,735,Everolimus,5290,22662154,,,
131,Phase I,"In a Phase I trial, treatment with Apitolisib (GDC-0980) resulted in a partial response in a patient with malignant pleural mesothelioma harboring PIK3CA R88Q (PMID: 26787751). ",Actionable,6084,7474,malignant pleural mesothelioma,DOID,3041,PIK3CA R88Q,sensitive,750,GDC-0980,5290,26787751,,,
132,Clinical Study,"In a retrospective study, treatment with the combination of Erbitux (cetuximab), Adrucil (fluorouracil), Camptosar (irinotecan), and Floxuridine resulted in at least 24 months without evidence of disease in a colorectal carcinoma patient harboring a PIK3CA R88Q mutation (PMID: 25714871).",Actionable,3756,9256,colorectal cancer,DOID,3041,PIK3CA R88Q,sensitive,3292,Cetuximab + Fluorouracil + Irinotecan + Floxuridine,5290,25714871,,,
133,Preclinical,"In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007).",Actionable,4246,1612,breast cancer,DOID,2914,PIK3CA Q546K,sensitive,787,Lapatinib,5290,26627007,,,
134,Preclinical,"In a preclinical study, MK2206 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007).",Actionable,4239,1612,breast cancer,DOID,2914,PIK3CA Q546K,sensitive,816,MK2206,5290,26627007,,,
135,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007).",Actionable,4253,1612,breast cancer,DOID,2914,PIK3CA Q546K,sensitive,828,Neratinib,5290,26627007,,,
136,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007).",Actionable,4260,1612,breast cancer,DOID,2914,PIK3CA Q546K,sensitive,2,Trametinib,5290,26627007,,,
137,Preclinical - Cell culture,"In a preclinical study, Alpelisib (BYL719) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007).",Actionable,4232,1612,breast cancer,DOID,2914,PIK3CA Q546K,sensitive,691,BYL719,5290,26627007,,,
138,Preclinical,"In a preclinical study, BEZ235 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007).",Actionable,4225,1612,breast cancer,DOID,2914,PIK3CA Q546K,sensitive,672,BEZ235,5290,26627007,,,
139,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited survival of transformed cell lines overexpressing PIK3CA Q546K in culture (PMID: 26627007).",Actionable,4261,10000003,Advanced Solid Tumor,JAX,2914,PIK3CA Q546K,sensitive,2,Trametinib,5290,26627007,,,
140,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) inhibited tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA Q546K, and TP53 R282W (PMID: 26272063).",Actionable,8700,9256,colorectal cancer,DOID,26375,KRAS G12V PIK3CA Q546K TP53 R282W,predicted â€“ sensitive,913,Selumetinib,5290,26272063,,,
141,Preclinical - Pdx,"In a preclinical study, BEZ235 delayed tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA Q546K, and TP53 R282W (PMID: 26272063).",Actionable,8701,9256,colorectal cancer,DOID,26375,KRAS G12V PIK3CA Q546K TP53 R282W,decreased response,672,BEZ235,5290,26272063,,,
142,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment resulted in enhanced tumor growth stabilization compared to single agent in patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA Q546K and TP53 R282W (PMID: 26272063).",Actionable,8600,9256,colorectal cancer,DOID,26375,KRAS G12V PIK3CA Q546K TP53 R282W,sensitive,1420,Selumetinib + BEZ235,5290,26272063,,,
143,Phase Ib/II,"In a Phase Ib trial, an estrogen-receptor positive breast cancer patient harboring PIK3CA mutations, E78K, D939G, and E726K, demonstrated progressive disease when treated with a combination of Femara (letrozole) and Alpelisib (BYL719) (PMID: 27126994). ",Actionable,9703,60075,estrogen-receptor positive breast cancer,DOID,26992,PIK3CA E78K PIK3CA D939G PIK3CA E726K,no benefit,1553,Letrozole + BYL719,5290,27126994,,,
144,Preclinical,"In a preclinical study, YM-024 did not inhibit proliferation of glioblastoma cell lines harboring PIK3CA V344G in culture (PMID: 24718026).",Actionable,5183,3068,glioblastoma multiforme,DOID,3729,PIK3CA V344G,no benefit,2967,YM-024,5290,24718026,,,
145,Preclinical,"In a preclinical study, BEZ235 inhibited proliferation of endometrial cancer cells harboring PIK3CA R108H and PTEN mutations in culture (PMID: 22662154).",Actionable,2111,1380,endometrial cancer,DOID,5394,PIK3CA R108H PTEN mut,sensitive,672,BEZ235,5290,22662154,,,
146,Preclinical,"In a preclinical study, CH5132799 inhibited proliferation of endometrial cancer cells harboring PIK3CA G1049R and KRAS G12D mutations in culture (PMID: 21558396).",Actionable,2954,1380,endometrial cancer,DOID,10740,KRAS G12D PIK3CA G1049R,sensitive,2152,CH5132799,5290,21558396,,,
147,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA G1049R in culture (PMID: 26627007).",Actionable,4256,1612,breast cancer,DOID,3629,PIK3CA G1049R,sensitive,2,Trametinib,5290,26627007,,,
148,Preclinical,"In a preclinical study, BEZ235 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA G1049R in culture (PMID: 26627007).",Actionable,4221,1612,breast cancer,DOID,3629,PIK3CA G1049R,sensitive,672,BEZ235,5290,26627007,,,
149,Preclinical,"In a preclinical study, MK2206 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA G1049R in culture (PMID: 26627007).",Actionable,4235,1612,breast cancer,DOID,3629,PIK3CA G1049R,sensitive,816,MK2206,5290,26627007,,,
150,Preclinical,"In a preclinical study, Alpelisib (BYL719) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA G1049R in culture (PMID: 26627007).",Actionable,4228,1612,breast cancer,DOID,3629,PIK3CA G1049R,sensitive,691,BYL719,5290,26627007,,,
151,Preclinical,"In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA G1049R in culture (PMID: 26627007).",Actionable,4242,1612,breast cancer,DOID,3629,PIK3CA G1049R,sensitive,787,Lapatinib,5290,26627007,,,
152,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited survival of transformed cell lines overexpressing PIK3CA G1049R in culture (PMID: 26627007).",Actionable,4264,10000003,Advanced Solid Tumor,JAX,3629,PIK3CA G1049R,sensitive,2,Trametinib,5290,26627007,,,
153,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA G1049R in culture (PMID: 26627007).",Actionable,4249,1612,breast cancer,DOID,3629,PIK3CA G1049R,sensitive,828,Neratinib,5290,26627007,,,
154,Preclinical,"In a preclinical study, AZD5363 inhibited proliferation of the AGS gastric cancer cell line, which has been reported to harbor KRAS G12D and PIK3CA E453K mutations (PMID: 24088382, PMID: 19755509).",Actionable,2860,10534,stomach cancer,DOID,10717,KRAS G12D PIK3CA E453K,sensitive,655,AZD5363,5290,24088382,19755509,,
155,Preclinical,"In a preclinical study, Rapamune (sirolimus) inhibited proliferation in cultured cells expressing PIK3CA M1043V (PMID: 17376864). ",Actionable,2362,10000003,Advanced Solid Tumor,JAX,3663,PIK3CA M1043V,sensitive,917,Sirolimus,5290,17376864,,,
156,Clinical Study,"In a clinical study, PIK3CA V955G was identified as a potential mechanism for acquired Erbitux (cetuximab) resistance in colorectal cancer patients, which is supported by cell culture studies demonstrating resistance to Erbitux (cetuximab) and Fluorouracil combination treatment in colorectal cancer cells over expressing PIK3CA V955G (PMID: 28424201).",Actionable,11718,9256,colorectal cancer,DOID,28197,PIK3CA V955G,resistant,2000,Fluorouracil + Cetuximab,5290,28424201,,,
157,Preclinical - Cell line xenograft,"In a preclinical study, small cell lung carcinoma cell lines harboring wild-type PIK3CA and PTEN R55fs*1 were not sensitive to PF-4989216 induced growth inhibition in culture and in cell line xenograft models (PMID: 24240111).",Actionable,8286,5409,lung small cell carcinoma,DOID,26222,PIK3CA wild-type PTEN R55fs*1,resistant,867,PF-4989216,5290,24240111,,,
158,Preclinical - Cell culture,"In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss did not demonstrate any benefit when treated with a combination of Afinitor (everolimus) and U0126 (PMID: 21358673). ",Actionable,10370,1612,breast cancer,DOID,20306,PIK3CA wild-type PTEN loss,no benefit,5499,Everolimus + U0126,5290,21358673,,,
159,Preclinical - Cell culture,"In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss demonstrated sensitivity to the combination treatment of Torkinib (PP242) and Selumetinib (AZD6244) in culture (PMID: 21358673). ",Actionable,10373,1612,breast cancer,DOID,20306,PIK3CA wild-type PTEN loss,sensitive,5501,Selumetinib + Torkinib,5290,21358673,,,
160,Preclinical - Cell culture,"In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss did not demonstrate any benefit when treated with a combination of Afinitor (everolimus) and Selumetinib (AZD6244) (PMID: 21358673).",Actionable,10371,1612,breast cancer,DOID,20306,PIK3CA wild-type PTEN loss,no benefit,4901,Everolimus + Selumetinib,5290,21358673,,,
161,Preclinical,"In a preclinical study, human breast cancer cells with wild-type PIK3CA and loss of PTEN were resistant to growth inhibition by AZD8835 in culture (PMID: 26839307).",Actionable,5112,1612,breast cancer,DOID,20306,PIK3CA wild-type PTEN loss,resistant,2013,AZD8835,5290,26839307,,,
162,Preclinical - Cell culture,"In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss demonstrated sensitivity to the combination treatment of Torkinib (PP242) and U0126 in culture (PMID: 21358673). ",Actionable,10372,1612,breast cancer,DOID,20306,PIK3CA wild-type PTEN loss,sensitive,5500,Torkinib + U0126,5290,21358673,,,
163,Preclinical - Cell line xenograft,"In a preclinical study, small cell lung carcinoma cell lines harboring wild-type PIK3CA and PTEN inactivating mutations were not sensitive to PF-4989216 induced growth inhibition in culture and in cell line xenograft models (PMID: 24240111).",Actionable,5215,5409,lung small cell carcinoma,DOID,26218,PIK3CA wild-type PTEN inact mut,decreased response,867,PF-4989216,5290,24240111,,,
164,Preclinical,"In a preclinical study, colorectal cancer cell lines with wild-type BRAF, KRAS, NRAS and PIK3CA were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).",Actionable,4944,9256,colorectal cancer,DOID,19839,BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type,resistant,890,Regorafenib,5290,25838391,,,
165,Phase II,"In a Phase II trial, Erbitux (cetuximab) in combination with FOLFOX resulted in improved median progression-free survival (6.9 months) comparing to FOLFOX alone (5.3 months) in BRAF, KRAS, NRAS, and PIK3CA wild-type colorectal cancer patients (hazard ratio =0.56) (PMID: 27002107).",Actionable,5563,9256,colorectal cancer,DOID,19839,BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type,predicted â€“ sensitive,2182,Cetuximab + FOLFOX,5290,27002107,,,
166,Preclinical,"In a preclinical study, Erbitux (cetuximab) inhibited growth of human colorectal cancer cells wild-type for BRAF, KRAS, NRAS and PIK3CA in culture (PMID: 25838391).",Actionable,4934,9256,colorectal cancer,DOID,19839,BRAF wild-type KRAS wild-type NRAS wild-type PIK3CA wild-type,sensitive,694,Cetuximab,5290,25838391,,,
167,Preclinical - Pdx & cell culture,"In a preclinical study, colorectal cancer cell lines harboring mutations in KRAS or NRAS with wild-type PIK3CA demonstrated a trend toward increased sensitivity to TAK-733 in culture, and colorectal cancer patient-derived xenograft (PDX) models with KRAS or BRAF mutations and wild-type PIK3CA demonstrated a trend toward greater tumor growth inhibition (PMID: 26439693).",Actionable,10766,9256,colorectal cancer,DOID,18590,KRAS mutant PIK3CA wild-type,predicted â€“ sensitive,932,TAK-733,5290,26439693,,,
168,Preclinical,"In a preclinical study, Buparlisib (BKM120) inhibited proliferation of colon cancer cell lines harboring mutant KRAS and wild-type PIK3CA in culture and reduced tumor growth in xenograft models (PMID: 26715098).",Actionable,4568,219,colon cancer,DOID,18590,KRAS mutant PIK3CA wild-type,sensitive,680,BKM120,5290,26715098,,,
169,Preclinical,"In a preclinical study, Buparlisib (BKM120) worked synergistically with Erbitux (cetuximab) to inhibit proliferation of colon cancer cell lines harboring mutant KRAS and wild-type PIK3CA in culture and tumor growth in xenograft models (PMID: 26715098).",Actionable,4570,219,colon cancer,DOID,18590,KRAS mutant PIK3CA wild-type,sensitive,3548,BKM120 + Cetuximab,5290,26715098,,,
170,Preclinical - Cell line xenograft,"In a preclinical study, Taselisib (GDC-0032) did not result in delay of cell cycle activity during treatment of a uterine serous carcinoma cell line harboring PIK3CA wild-type and ERBB2 (HER2) amplification in culture, however, did result in tumor growth inhibition in xenograft models (PMID: 26333383). ",Actionable,9063,5750,uterine corpus serous adenocarcinoma,DOID,26704,ERBB2 amp PIK3CA wild-type,sensitive,1016,GDC-0032,5290,26333383,,,
171,Preclinical - Cell culture,"In a preclinical study, the combination of Taselisib (GDC-0032) and Nerlynx (neratinib) delayed cell cycle activity in a uterine serous carcinoma cell line harboring PIK3CA wild-type and ERBB2 (HER2) amplification in culture (PMID: 26333383). ",Actionable,9065,5750,uterine corpus serous adenocarcinoma,DOID,26704,ERBB2 amp PIK3CA wild-type,sensitive,4871,GDC-0032 + Neratinib,5290,26333383,,,
172,Preclinical - Cell line xenograft,"In a preclinical study, Nerlynx (neratinib) delayed cell cycle activity during treatment of a uterine serous carcinoma cell line harboring PIK3CA wild-type and ERBB2 (HER2) amplification in culture, and inhibited tumor growth in xenograft models (PMID: 26333383). ",Actionable,9064,5750,uterine corpus serous adenocarcinoma,DOID,26704,ERBB2 amp PIK3CA wild-type,sensitive,828,Neratinib,5290,26333383,,,
173,Preclinical - Pdx & cell culture,"In a preclinical study, mutations in BRAF, KRAS, or NRAS were associated with sensitivity to TAK-733 in colorectal cancer cell lines in culture, and patient-derived xenograft models harboring KRAS or BRAF mutations with wild-type PIK3CA demonstrated a trend toward higher tumor growth inhibition following TAK-733 treatment (PMID: 26439693).",Actionable,10776,9256,colorectal cancer,DOID,27794,BRAF mut PIK3CA wild-type,predicted â€“ sensitive,932,TAK-733,5290,26439693,,,
174,Preclinical,"In a preclinical study, Selumetinib (AZD6244) and Zelboraf (vemurafenib) worked synergistically to inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).",Actionable,5184,1909,melanoma,DOID,20300,BRAF V600E/K PIK3CA wild-type,sensitive,3773,Selumetinib + Vemurafenib,5290,26137449,,,
175,Preclinical - Cell line xenograft,"In a preclinical study, Selumetinib (AZD6244) and ZSTK474 combination treatment inhibited proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture, and synergistically inhibited tumor growth in cell line xenograft models (PMID: 26137449).",Actionable,5187,1909,melanoma,DOID,20300,BRAF V600E/K PIK3CA wild-type,sensitive,3771,Selumetinib + ZSTK474,5290,26137449,,,
176,Preclinical,"In a preclinical study, ZSTK474 and Zelboraf (vemurafenib) worked synergistically to inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).",Actionable,5186,1909,melanoma,DOID,20300,BRAF V600E/K PIK3CA wild-type,sensitive,3772,Vemurafenib + ZSTK474,5290,26137449,,,
177,Preclinical - Cell line xenograft,"In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment inhibited proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture, and synergitically inhibited tumor growth in cell line xenograft models (PMID: 26137449).",Actionable,5188,1909,melanoma,DOID,20300,BRAF V600E/K PIK3CA wild-type,sensitive,1420,Selumetinib + BEZ235,5290,26137449,,,
178,Preclinical,"In a preclinical study, Zydelig (idelalisib) did not inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).",Actionable,5192,1909,melanoma,DOID,20300,BRAF V600E/K PIK3CA wild-type,no benefit,1023,Idelalisib,5290,26137449,,,
179,Preclinical,"In a preclinical study, BEZ235 and Zelboraf (vemurafenib) worked synergistically to inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).",Actionable,5185,1909,melanoma,DOID,20300,BRAF V600E/K PIK3CA wild-type,sensitive,3774,BEZ235 + Vemurafenib,5290,26137449,,,
180,Preclinical,"In a preclinical study, A66 did not inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).",Actionable,5190,1909,melanoma,DOID,20300,BRAF V600E/K PIK3CA wild-type,no benefit,617,A66,5290,26137449,,,
181,Preclinical,"In a preclinical study, TGX-221 did not inhibit proliferation of melanoma cell lines harboring BRAF V600E/K and wild-type PIK3CA in culture (PMID: 26137449).",Actionable,5191,1909,melanoma,DOID,20300,BRAF V600E/K PIK3CA wild-type,no benefit,2514,TGX-221,5290,26137449,,,
182,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cell lines harboring mutations in KRAS or NRAS and with wild-type PIK3CA demonstrated a trend toward increased sensitivity to TAK-733 in culture (PMID: 26439693).",Actionable,10774,9256,colorectal cancer,DOID,27788,NRAS mut PIK3CA wild-type,predicted â€“ sensitive,932,TAK-733,5290,26439693,,,
183,Preclinical - Cell culture,"In a preclinical study, inhibition of Pi3k signaling by BEZ235 did not sensitize PIK3CA wild-type breast cancer cell lines to WEHI-539 in culture (PMID: 27974663).",Actionable,10088,1612,breast cancer,DOID,430,PIK3CA wild-type,no benefit,5377,BEZ235 + WEHI-539,5290,27974663,,,
184,Preclinical,"In a preclinical study, the combination of Ibrance (palbociclib) and Pictilisib (GDC-0941) did not improve growth inhibition compared to single drug treatment in PIK3CA wild-type, triple-receptor negative breast cancer cell lines in culture (PMID: 27020857).",Actionable,5861,60081,triple-receptor negative breast cancer,DOID,430,PIK3CA wild-type,no benefit,3956,Palbociclib + GDC-0941,5290,27020857,,,
185,Phase I,"In a Phase I study, PX-866 demonstrated efficacy and was well tolerated in patients with advanced solid tumor with both PIK3CA wild-type and mutant status (PMID: 22693357).",Actionable,108,10000003,Advanced Solid Tumor,JAX,430,PIK3CA wild-type,sensitive,881,PX-866,5290,22693357,,,
186,Phase II,"In a Phase II trial, the combination of Taxol (paclitaxel) plus Herceptin (trastuzumab) and Tykerb (lapatinib) resulted in a higher pathologic complete remission rate in ERBB2 (HER2)-receptor positive breast cancer patients with PIK3CA wild-type compared to those harboring a PIK3CA mutation (PMID: 26245675).",Actionable,3359,60079,Her2-receptor positive breast cancer,DOID,430,PIK3CA wild-type,sensitive,3130,Paclitaxel + Lapatinib + Trastuzumab,5290,26245675,,,
187,Preclinical - Cell culture,"In a preclinical study, combination of WEHI-539 and A-1210477 resulted in enhanced apoptosis in PIK3CA wild-type breast cancer cell lines in culture (PMID: 27974663).",Actionable,10110,1612,breast cancer,DOID,430,PIK3CA wild-type,predicted â€“ sensitive,5392,A-1210477 + WEHI-539,5290,27974663,,,
188,Preclinical - Pdx,"In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib)  combination treatment resulted in partial tumor regression in PDX models of PIK3CA wild-type colorectal cancer cells harboring KRAS G12V (PMID: 26369631).",Actionable,5618,9256,colorectal cancer,DOID,21300,KRAS G12V PIK3CA wild-type,sensitive,1368,Palbociclib + Trametinib,5290,26369631,,,
189,Preclinical - Cell line xenograft,"In a preclinical study, small cell lung carcinoma cell lines harboring wild-type PIK3CA and PTEN Y27fs*1 were not sensitive to PF-4989216 induced growth inhibition in culture and in cell line xenograft models (PMID: 24240111).",Actionable,8285,5409,lung small cell carcinoma,DOID,26223,PIK3CA wild-type PTEN Y27fs*1,resistant,867,PF-4989216,5290,24240111,,,
190,Clinical Study,"In a retrospective study, Erbitux (cetuximab) treatment resulted in stable disease in a colorectal carcinoma patient harboring a PIK3CA E542V mutation (PMID: 25714871).",Actionable,3758,9256,colorectal cancer,DOID,3617,PIK3CA E542V,sensitive,694,Cetuximab,5290,25714871,,,
191,Clinical Study,"In a clinical study, two colorectal cancer patients harboring both a PIK3CA E545 and KRAS G12 mutation demonstrated stable disease when treated with Torisel (temsirolimus) (PMID: 21216929). ",Actionable,3312,9256,colorectal cancer,DOID,13163,PIK3CA E545X KRAS G12X,sensitive,936,Temsirolimus,5290,21216929,,,
192,Preclinical - Cell culture,"In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring PIK3CA E545V was sensitive to DS-7423 in culture, demonstrating inhibition of cell proliferation (PMID: 24504419). ",Actionable,10544,5304,ovarian clear cell adenocarcinoma,DOID,3622,PIK3CA E545V,sensitive,722,DS-7423,5290,24504419,,,
193,Preclinical - Cell culture,"In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of ERBB2 (HER2) positive breast cancer cells harboring PIK3CA K111N in culture (PMID: 26920887).",Actionable,7746,60079,Her2-receptor positive breast cancer,DOID,25949,ERBB2 pos PIK3CA I391M,sensitive,1402,trastuzumab emtansine,5290,26920887,,,
194,Clinical Study,"In a clinical study, a uterine cancer patient harboring PIK3CA I391M demonstrated stable disease when treated with Rapamune (sirolimus) (PMID: 28514312). ",Actionable,11051,363,uterine cancer,DOID,2891,PIK3CA I391M,sensitive,917,Sirolimus,5290,28514312,,,
195,Preclinical - Cell culture,"In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of ERBB2 (HER2) positive breast cancer cells harboring PIK3CA C420R in culture (PMID: 26920887).",Actionable,7747,60079,Her2-receptor positive breast cancer,DOID,25950,ERBB2 pos PIK3CA C420R,sensitive,1402,trastuzumab emtansine,5290,26920887,,,
196,Preclinical,"In a preclinical study, CH5132799 inhibited proliferation of a breast cancer cell line harboring PIK3CA C420R and ERBB2 (HER2) amplification (PMID: 21558396).",Actionable,2951,1612,breast cancer,DOID,10738,ERBB2 amp PIK3CA C420R,sensitive,2152,CH5132799,5290,21558396,,,
197,Preclinical,"In a preclinical study, cells expressing PIK3CA C420R were sensitive to Rapamune (sirolimus) in culture (PMID: 17376864).",Actionable,1665,10000003,Advanced Solid Tumor,JAX,2790,PIK3CA C420R,sensitive,917,Sirolimus,5290,17376864,,,
198,Preclinical - Cell culture,"In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring PIK3CA C420R was sensitive to DS-7423 in culture, demonstrating inhibition of cell proliferation (PMID: 24504419). ",Actionable,10542,5304,ovarian clear cell adenocarcinoma,DOID,2790,PIK3CA C420R,sensitive,722,DS-7423,5290,24504419,,,
199,Preclinical - Cell line xenograft,"In a preclinical study, LY3023414 inhibited proliferation of non-small cell lung cancer cells harboring PIK3CA G118D in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 27439478).",Actionable,8940,3908,non-small cell lung carcinoma,DOID,3633,PIK3CA G118D,sensitive,1069,LY3023414,5290,27439478,,,
200,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture (PMID: 23629727).",Actionable,8177,3908,non-small cell lung carcinoma,DOID,26185,EGFR L858R EGFR T790M PIK3CA G118D,sensitive,4656,Everolimus + Pimasertib,5290,23629727,,,
201,Preclinical - Cell line xenograft,"In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited Mapk and Akt signaling, resulted in growth inhibition of non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture and in cell line xenograft models (PMID: 23629727).",Actionable,8181,3908,non-small cell lung carcinoma,DOID,26185,EGFR L858R EGFR T790M PIK3CA G118D,sensitive,1659,Pimasertib + Sorafenib,5290,23629727,,,
202,Preclinical - Cell culture,"In a preclinical study, non-small cell lung cancer cells harboring EGFR L858R, T790M, and PIK3CA G118D demonstrated decreased response to Pimasertib (MSC1936369B) in culture (PMID: 23629727).",Actionable,8172,3908,non-small cell lung carcinoma,DOID,26185,EGFR L858R EGFR T790M PIK3CA G118D,decreased response,871,Pimasertib,5290,23629727,,,
203,Preclinical - Cell line xenograft,"In a preclinical study, Pimasertib (MSC1936369B) and BEZ235 combination treatment inhibited tumor growth in non-small cell lung cancer cell line xenograft models harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture (PMID: 23629727).",Actionable,8187,3908,non-small cell lung carcinoma,DOID,26185,EGFR L858R EGFR T790M PIK3CA G118D,sensitive,1660,Pimasertib + BEZ235,5290,23629727,,,
204,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of non-small cell lung cancer cells harboring EGFR L858R, EGFR T790M, and PIK3CA G118D in culture (PMID: 23629727).",Actionable,8186,3908,non-small cell lung carcinoma,DOID,26185,EGFR L858R EGFR T790M PIK3CA G118D,sensitive,4657,Pimasertib + Regorafenib,5290,23629727,,,
205,Preclinical - Pdx,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12C, PIK3CA H1047R, and TP53 R248W (PMID: 26272063).",Actionable,8577,9256,colorectal cancer,DOID,26366,KRAS G12C PIK3CA H1047R TP53 R248W,no benefit,4771,MLN0128 + PD-0325901,5290,26272063,,,
206,Preclinical,"In a preclinical study, the combination of Herceptin (trastuzumab) and Buparlisib (BKM120) inhibited tumor growth in mouse ERBB2 (HER2)-over expressing breast cancer models expressing PIK3CA H1047R, with moderate efficacy over Buparlisib (BKM120) alone (PMID: 23940356).",Actionable,968,60079,Her2-receptor positive breast cancer,DOID,1575,ERBB2 over exp PIK3CA H1047R,sensitive,1417,BKM120 + Trastuzumab,5290,23940356,,,
207,Preclinical,"In a preclinical study, treatment with Buparlisib (BKM120) resulted in decreased tumor growth, but not tumor regression, in mouse models of ERBB2 (HER2)-over expressing breast cancer expressing PIK3CA H1047R (PMID: 23940356).",Actionable,967,60079,Her2-receptor positive breast cancer,DOID,1575,ERBB2 over exp PIK3CA H1047R,sensitive,1178,BKM120 + Bevacizumab,5290,23940356,,,
208,Preclinical,"In a preclinical study, a mouse breast cancer model with ERBB2 (HER2) over-expression that also expressed the PIK3CA H1047R mutation showed resistance to the combination of Heceptin (trastuzumab) and Perjeta (pertuzumab) (PMID: 23940356).",Actionable,970,60079,Her2-receptor positive breast cancer,DOID,1575,ERBB2 over exp PIK3CA H1047R,resistant,1389,Trastuzumab + Pertuzumab,5290,23940356,,,
209,Preclinical,"In a preclinical study, mouse breast cancer models over expressing ERBB2 (HER2) and expressing PIK3CA H1047R were resistant to Herceptin (trastuzumab) (PMID: 23940356).",Actionable,966,60079,Her2-receptor positive breast cancer,DOID,1575,ERBB2 over exp PIK3CA H1047R,resistant,947,Trastuzumab,5290,23940356,,,
210,Preclinical,"In a preclinical study, the combination of Buparlisib (BKM120), Herceptin (trastuzumab), and Tykerb (lapatinib) inhibited tumor growth in mouse models of ERBB2 (HER2)-over expressing breast cancer expressing PIK3CA H1047R, but efficacy was not significantly improved over Buparlisib (BKM120) alone (PMID: 23940356). ",Actionable,972,60079,Her2-receptor positive breast cancer,DOID,1575,ERBB2 over exp PIK3CA H1047R,no benefit,1419,BKM120 + Trastuzumab + Lapatinib,5290,23940356,,,
211,Preclinical,"In a preclinical study, a mouse breast cancer model with mammary ERBB2 (HER2) over-expression that also expressed the PIK3CA H1047R mutation showed resistance to the combination of Herceptin (trastuzumab) and Tykerb (lapatinib) (PMID: 23940356).",Actionable,969,60079,Her2-receptor positive breast cancer,DOID,1575,ERBB2 over exp PIK3CA H1047R,resistant,1414,Trastuzumab + Lapatinib,5290,23940356,,,
212,Preclinical,"In a preclinical study, the combination of Buparlisib (BKM120), Herceptin (trastuzumab), and Perjeta (pertuzumab) inhibited tumor growth in mouse models of ERBB2 (HER2)-over expressing breast cancer expressing PIK3CA H1047R, with improved efficacy over Buparlisib (BKM120) alone (PMID: 23940356).",Actionable,971,60079,Her2-receptor positive breast cancer,DOID,1575,ERBB2 over exp PIK3CA H1047R,sensitive,1418,BKM120 + Trastuzumab + Pertuzumab,5290,23940356,,,
213,Preclinical - Pdx,"In a preclinical study, BEZ235 stabilized tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R, and TP53 R248W (PMID: 26272063).",Actionable,8697,9256,colorectal cancer,DOID,26372,KRAS G12D PIK3CA H1047R TP53 R248W,predicted â€“ sensitive,672,BEZ235,5290,26272063,,,
214,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment did not improve tumor growth stabilization compared to single agent in patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R and TP53 R248W (PMID: 26272063).",Actionable,8596,9256,colorectal cancer,DOID,26372,KRAS G12D PIK3CA H1047R TP53 R248W,no benefit,1420,Selumetinib + BEZ235,5290,26272063,,,
215,Preclinical - Pdx,"In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R, and TP53 R248W did not respond to Selumetinib (AZD6244) treatment (PMID: 26272063).",Actionable,8695,9256,colorectal cancer,DOID,26372,KRAS G12D PIK3CA H1047R TP53 R248W,resistant,913,Selumetinib,5290,26272063,,,
216,Preclinical - Cell line xenograft,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring KRAS G13D and PIK3CA H1047R in culture and in cell line xenograft models (PMID: 26272063).",Actionable,8567,9256,colorectal cancer,DOID,26360,KRAS G13D PIK3CA H1047R TP53 wild-type,sensitive,4771,MLN0128 + PD-0325901,5290,26272063,,,
217,Preclinical,"In a preclinical study, Sirolimus (rapamycin) failed to inhibit tumor growth in a mouse lung adenocarcinoma model expressing the PIK3CA H1047R mutation (PMID: 19029981).",Actionable,1016,3910,lung adenocarcinoma,DOID,1731,PIK3CA H1047R,no benefit,917,Sirolimus,5290,19029981,,,
218,Preclinical,"In a preclinical study, A66 delayed tumor growth in human tumor xenograft models harboring PIK3CA H1047R mutations (PMID: 21668414).",Actionable,2776,10000003,Advanced Solid Tumor,JAX,1731,PIK3CA H1047R,sensitive,617,A66,5290,21668414,,,
219,Preclinical - Cell culture,"In a preclinical study, a breast cancer cell line harboring PIK3CA H1047R demonstrated sensitivity to treatment with ARQ092 in culture, resulting in inhibition of cell proliferation (PMID: 26469692). ",Actionable,10267,1612,breast cancer,DOID,1731,PIK3CA H1047R,sensitive,635,ARQ092,5290,26469692,,,
220,Phase I,"In a Phase I trial, four patients with breast cancer harboring PIK3CA H1047R demonstrated a confirmed partial response when treated with Taselisib (GDC-0032) (PMID: 28331003).",Actionable,11445,1612,breast cancer,DOID,1731,PIK3CA H1047R,sensitive,1016,GDC-0032,5290,28331003,,,
221,Preclinical - Cell line xenograft,"In a preclinical study, a breast cancer cell line xenograft model harboring PIK3CA H1047R demonstrated tumor regression within the mammary fat pad when treated with Buparlisib (BKM120) (PMID: 28539475). ",Actionable,11515,1612,breast cancer,DOID,1731,PIK3CA H1047R,sensitive,680,BKM120,5290,28539475,,,
222,Preclinical - Pdx,"In a preclinical study, BEZ235 inhibited tumor growth in a patient-derived xenograft (PDX) model of bladder cancer harboring PIK3CA H1047R (PMID: 26270481).",Actionable,7452,11054,urinary bladder cancer,DOID,1731,PIK3CA H1047R,sensitive,672,BEZ235,5290,26270481,,,
223,Preclinical,"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human breast cancer cells harboring PIK3CA H1047R in culture (PMID: 21325073, PMID: 17314276).",Actionable,3127,1612,breast cancer,DOID,1731,PIK3CA H1047R,sensitive,1040,PF-05212384,5290,21325073,17314276,,
224,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells over expressing PIK3CA H1047R were resistant to Erbitux (cetuximab) and Fluorouracil combination treatment in culture (PMID: 28424201).",Actionable,11723,9256,colorectal cancer,DOID,1731,PIK3CA H1047R,resistant,2000,Fluorouracil + Cetuximab,5290,28424201,,,
225,Preclinical,"In a preclinical study, transformed cells expressing PIK3CA H1047R were sensitive to Rapamune (sirolimus), resulting in inhibition of transformation in culture (PMID: 15647370). ",Actionable,6003,10000003,Advanced Solid Tumor,JAX,1731,PIK3CA H1047R,sensitive,917,Sirolimus,5290,15647370,,,
226,Preclinical - Cell line xenograft,"In a preclinical study, PF-04691502 inhibited Pi3k signaling, resulted in growth inhibition of ovarian cancer cells harboring PIK3CA H1047R in culture and in cell line xenograft models (PMID: 21750219).",Actionable,1801,2394,ovarian cancer,DOID,1731,PIK3CA H1047R,sensitive,865,PF-04691502,5290,21750219,,,
227,Preclinical,"In a preclinical study, Sirolimus (rapamycin) did not induce tumor shrinkage in mouse lung cancer models carrying PIK3CA H1047R (PMID: 19029981).",Actionable,1289,1324,lung cancer,DOID,1731,PIK3CA H1047R,no benefit,917,Sirolimus,5290,19029981,,,
228,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007).",Actionable,4251,1612,breast cancer,DOID,1731,PIK3CA H1047R,sensitive,828,Neratinib,5290,26627007,,,
229,Preclinical,"In a preclinical study, CH5132799 inhibited proliferation of breast cancer cells harboring PIK3CA H1047R in culture (PMID: 21558396).",Actionable,2946,1612,breast cancer,DOID,1731,PIK3CA H1047R,sensitive,2152,CH5132799,5290,21558396,,,
230,Phase I,"In a Phase I trial, CH5132799 demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including a partial response in a patient with ovarian cancer harboring PIK3CA H1047R (PMID: 25231405).",Actionable,2837,2394,ovarian cancer,DOID,1731,PIK3CA H1047R,sensitive,2152,CH5132799,5290,25231405,,,
231,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited survival of transformed cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007).",Actionable,4263,10000003,Advanced Solid Tumor,JAX,1731,PIK3CA H1047R,sensitive,2,Trametinib,5290,26627007,,,
232,Preclinical - Cell culture,"In a preclinical study, head and neck squamous cell carcinoma cell lines harboring PIK3CA H1047R demonstrated sensitivity to treatment with Gedatolisib (PF-05212384) in culture (PMID: 25977343). ",Actionable,8244,5520,head and neck squamous cell carcinoma,DOID,1731,PIK3CA H1047R,sensitive,1040,PF-05212384,5290,25977343,,,
233,Preclinical - Cell culture,"In a preclinical study, a breast cancer cell line harboring PIK3CA H1047R demonstrated sensitivity to treatment with ARQ 751 in culture, resulting in inhibition of cell proliferation (PMID: 26469692). ",Actionable,10268,1612,breast cancer,DOID,1731,PIK3CA H1047R,sensitive,4331,ARQ 751,5290,26469692,,,
234,Preclinical - Cell culture,"In a preclinical study, Estybon (rigosertib) inhibited oncogenic transformation in fibroblast cells over-expressing PIK3CA H1047R in culture (PMID: 27104980).",Actionable,8556,10000003,Advanced Solid Tumor,JAX,1731,PIK3CA H1047R,sensitive,1046,rigosertib,5290,27104980,,,
235,Preclinical - Cell line xenograft,"In a preclinical study, Glucophage (metformin) demonstrated efficacy in treating dietary restriction-resistant human colorectal cancer cell line xenograft tumors harboring PIK3CA H1047R (PMID: 23986086).",Actionable,9357,9256,colorectal cancer,DOID,1731,PIK3CA H1047R,sensitive,1031,Metformin,5290,23986086,,,
236,Preclinical,"In a preclinical study, AZD8835 inhibited tumor growth in mouse xenografts of ovarian cancer with a Pik3ca H1047R mutation (AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2830).",Actionable,3752,2394,ovarian cancer,DOID,1731,PIK3CA H1047R,sensitive,2013,AZD8835,5290,None,,,
237,Preclinical - Cell culture,"In a preclinical study, BEZ235 induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing PIK3CA H1047R in culture (PMID: 26013318).",Actionable,7972,3907,lung squamous cell carcinoma,DOID,1731,PIK3CA H1047R,sensitive,672,BEZ235,5290,26013318,,,
238,Preclinical - Cell culture,"In a preclinical study, DHM25 increased cell death in breast cancer cell lines harboring PIK3CA H1047R in culture (PMID: 26237138).",Actionable,10358,1612,breast cancer,DOID,1731,PIK3CA H1047R,sensitive,5494,DHM25,5290,26237138,,,
239,Preclinical - Pdx,"In a preclinical study, AZD5363 inhibited growth in a patient-derived xenograft model of gastric cancer harboring a PIK3CA H1047R mutation (PMID: 24088382).",Actionable,2794,10534,stomach cancer,DOID,1731,PIK3CA H1047R,sensitive,655,AZD5363,5290,24088382,,,
240,Preclinical,"In a preclinical study, BEZ235 reduced tumor size in mouse models of lung cancer carrying PIK3CA H1047R (PMID: 19029981).",Actionable,1288,1324,lung cancer,DOID,1731,PIK3CA H1047R,sensitive,672,BEZ235,5290,19029981,,,
241,Preclinical - Cell culture,"In a preclinical study, Alpelisib (BYL719) induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing PIK3CA H1047R in culture (PMID: 26013318).",Actionable,7973,3907,lung squamous cell carcinoma,DOID,1731,PIK3CA H1047R,sensitive,691,BYL719,5290,26013318,,,
242,Preclinical - Cell line xenograft,"In a preclinical study, BAY1125976 inhibited proliferation of  breast cancer cell lines harboring PIK3CA H1047R in culture, and inhibited AKT signaling and tumor growth in a PIK3CA H1047R-mutant cell line xenograft model (PMID: 27699769).",Actionable,8814,1612,breast cancer,DOID,1731,PIK3CA H1047R,sensitive,994,BAY1125976,5290,27699769,,,
243,Preclinical - Cell line xenograft,"In a preclinical study, Glucophage (metformin) inhibited cell proliferation of a dietary restriction-resistant PIK3CA H1047R-harboring human breast cancer cell line in culture, and inhibited tumor growth in xenograft models (PMID: 23986086).",Actionable,9356,1612,breast cancer,DOID,1731,PIK3CA H1047R,sensitive,1031,Metformin,5290,23986086,,,
244,Preclinical - Cell line xenograft,"In a preclinical study, a breast cancer xenograft model harboring PIK3CA H1047R was sensitive to M2698 (MSC2363318A), demonstrating inhibition of tumor growth (PMID: 27186432).",Actionable,10289,1612,breast cancer,DOID,1731,PIK3CA H1047R,sensitive,1037,MSC2363318A,5290,27186432,,,
245,Preclinical,"In a preclinical study, BEZ235 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007).",Actionable,4223,1612,breast cancer,DOID,1731,PIK3CA H1047R,sensitive,672,BEZ235,5290,26627007,,,
246,Preclinical,"In a preclinical study, MK2206 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007).",Actionable,4237,1612,breast cancer,DOID,1731,PIK3CA H1047R,sensitive,816,MK2206,5290,26627007,,,
247,Preclinical - Cell culture,"In a preclinical study, Buparlisib (BKM120) induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing wild-type Pik3ca in culture (PMID: 26013318).",Actionable,7969,3907,lung squamous cell carcinoma,DOID,1731,PIK3CA H1047R,sensitive,680,BKM120,5290,26013318,,,
248,Preclinical,"In a preclinical study, Alpelisib (BYL719) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007).",Actionable,4230,1612,breast cancer,DOID,1731,PIK3CA H1047R,sensitive,691,BYL719,5290,26627007,,,
249,Preclinical,"In a preclinical study, BEZ235 promoted tumor regression in a mouse lung adenocarcinoma model expressing PIK3CA H1047R (PMID: 19029981).",Actionable,1015,3910,lung adenocarcinoma,DOID,1731,PIK3CA H1047R,sensitive,672,BEZ235,5290,19029981,,,
250,Preclinical,"In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007).",Actionable,4244,1612,breast cancer,DOID,1731,PIK3CA H1047R,sensitive,787,Lapatinib,5290,26627007,,,
251,Preclinical - Cell culture,"In a preclinical study, MK2206 inhibited AKT activation, proliferation, and growth of thyroid cancer cell lines with  PI3K/AKT pathway alterations in culture, including an anaplastic thyroid cancer cell line harboring PIK3CA H1047R (PMID: 21289267).",Actionable,8214,1781,thyroid cancer,DOID,1731,PIK3CA H1047R,sensitive,816,MK2206,5290,21289267,,,
252,Clinical Study,"In a retrospective study, Erbitux (cetuximab) combined with radiation therapy resulted in stable disease for 6 months in a colorectal carcinoma patient harboring a PIK3CA H1047R mutation (PMID: 25714871).",Actionable,3760,9256,colorectal cancer,DOID,1731,PIK3CA H1047R,sensitive,694,Cetuximab,5290,25714871,,,
253,Preclinical - Cell culture,"In a preclinical study, MK2206 and Torisel (temsirolimus) demonstrated synergy in inhibiting growth of an anaplastic thyroid cancer cell line harboring PIK3CA H1047R in culture (PMID: 21289267).",Actionable,8222,1781,thyroid cancer,DOID,1731,PIK3CA H1047R,sensitive,4664,MK2206 + Temsirolimus,5290,21289267,,,
254,Preclinical,"In a preclinical study, Taselisib (GDC-0032) enhanced the effects of radiation induced apoptosis of head and neck squamous carcinoma cells harboring PIK3CA H1047R (PMID: 26589432). ",Actionable,5866,5520,head and neck squamous cell carcinoma,DOID,1731,PIK3CA H1047R,sensitive,3967,GDC-0032 + Radiotherapy,5290,26589432,,,
255,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA H1047R in culture (PMID: 26627007).",Actionable,4258,1612,breast cancer,DOID,1731,PIK3CA H1047R,sensitive,2,Trametinib,5290,26627007,,,
256,Preclinical - Cell line xenograft,"In a preclinical study, A66 delayed tumor growth in an ovarian cancer cell line xenograft model harboring PIK3CA H1047R (PMID: 21668414).",Actionable,7533,2394,ovarian cancer,DOID,1731,PIK3CA H1047R,sensitive,617,A66,5290,21668414,,,
257,Preclinical - Cell line xenograft,"In a preclinical study, Rapamune (sirolimus) worked synergistically with Mekinist (trametinib) to inhibit proliferation of head and neck squamous carcinoma cell lines harboring PIK3CA H1047R in culture and to reduce tumor growth in cell line xenograft models (PMID: 26882569).",Actionable,4688,5520,head and neck squamous cell carcinoma,DOID,1731,PIK3CA H1047R,sensitive,3596,Sirolimus + Trametinib,5290,26882569,,,
258,Clinical Study,"In a clinical case study, a patient with anaplastic thyroid carcinoma co-harboring BRAF V600E and PIK3CA H1047R demonstrated resistance to treatment with Afinitor (everolimus) (PMID: 27797976). ",Actionable,10814,3963,thyroid carcinoma,DOID,26356,BRAF V600E PIK3CA H1047R,resistant,735,Everolimus,5290,27797976,,,
259,Clinical Study,"In a clinical case study, a patient with anaplastic thyroid carcinoma co-harboring BRAF V600E and PIK3CA H1047R demonstrated resistance to the combination therapy, Mekinist (trametinib) and Tafinlar (dabrafenib) (PMID: 27797976).",Actionable,10815,3963,thyroid carcinoma,DOID,26356,BRAF V600E PIK3CA H1047R,resistant,1066,Trametinib + Dabrafenib,5290,27797976,,,
260,Clinical Study,"In a clinical case study, a patient with anaplastic thyroid carcinoma co-harboring BRAF V600E and PIK3CA H1047R demonstrated tumor regression when treated with the triple combination, Tafinlar (dabrafenib), Mekinist (trametinib), and Afinitor (everolimus) (PMID: 27797976).",Actionable,10812,3963,thyroid carcinoma,DOID,26356,BRAF V600E PIK3CA H1047R,sensitive,5650,Dabrafenib + Everolimus + Trametinib,5290,27797976,,,
261,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063).",Actionable,8702,9256,colorectal cancer,DOID,26376,KRAS G12D PIK3CA H1047R TP53 wild-type,decreased response,913,Selumetinib,5290,26272063,,,
262,Preclinical - Pdx,"In a preclinical study, BEZ235 inhibited tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063).",Actionable,8703,9256,colorectal cancer,DOID,26376,KRAS G12D PIK3CA H1047R TP53 wild-type,predicted â€“ sensitive,672,BEZ235,5290,26272063,,,
263,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment did not improve tumor growth stabilization compared to single agent in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063).",Actionable,8601,9256,colorectal cancer,DOID,26376,KRAS G12D PIK3CA H1047R TP53 wild-type,no benefit,1420,Selumetinib + BEZ235,5290,26272063,,,
264,Preclinical - Cell line xenograft,"In a preclinical study, Kadcyla (trastuzumab emtansine) inhibited survival of Herceptin (trastuzumab)-resistant ERBB2 (HER2) positive breast cancer cells harboring PIK3CA H1047R in culture, and induced tumor regression in cell line xenograft models (PMID: 26920887).",Actionable,7748,60079,Her2-receptor positive breast cancer,DOID,25951,ERBB2 pos PIK3CA H1047R,sensitive,1402,trastuzumab emtansine,5290,26920887,,,
265,Preclinical - Cell culture,"In a preclinical study, BAY1125976 inhibited proliferation of a breast cancer cell line harboring PIK3CA H1047R and PTEN E307K in culture (PMID: 27699769).",Actionable,8819,1612,breast cancer,DOID,26449,PIK3CA H1047R PTEN E307K,sensitive,994,BAY1125976,5290,27699769,,,
266,Preclinical - Cell culture,"In a preclinical study, inhibition of Pi3k signaling by BEZ235 sensitized breast cancer cell lines harboring PIK3CA H1047R and PTEN loss to WEHI-539 in culture (PMID: 27974663).",Actionable,10085,1612,breast cancer,DOID,27242,PIK3CA H1047R PTEN loss,predicted â€“ sensitive,5377,BEZ235 + WEHI-539,5290,27974663,,,
267,Preclinical - Cell line xenograft,"In a preclinical study, ABT-737 and BEZ235 combination treatment resulted in tumor regression in cell line xenograft models of triple-receptor negative breast cancer harboring PIK3CA H1047R and PTEN loss (PMID: 27974663).",Actionable,10091,60081,triple-receptor negative breast cancer,DOID,27242,PIK3CA H1047R PTEN loss,predicted â€“ sensitive,5381,ABT-737 + BEZ235,5290,27974663,,,
268,Preclinical - Cell line xenograft,"In a preclinical study, ABT-737 and Sapanisertib (MLN0128) combination treatment resulted in inhibition of tumor growth in cell line xenograft models of triple-receptor negative breast cancer harboring PIK3CA H1047R and PTEN loss (PMID: 27974663).",Actionable,10097,60081,triple-receptor negative breast cancer,DOID,27242,PIK3CA H1047R PTEN loss,predicted â€“ sensitive,5388,ABT-737 + MLN0128,5290,27974663,,,
269,Preclinical - Cell culture,"In a preclinical study, inhibition of Pi3k signaling by BEZ235 did not sensitize breast cancer cell lines harboring PIK3CA H1047R and PTEN loss to Venclexta (venetoclax) in culture (PMID: 27974663).",Actionable,10082,1612,breast cancer,DOID,27242,PIK3CA H1047R PTEN loss,no benefit,5376,BEZ235 + Venetoclax,5290,27974663,,,
270,Preclinical - Cell culture,"In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring PIK3CA H1047R and TP53 S90fs*33 demonstrated reduced sensitivity to DS-7423 in culture (PMID: 24504419). ",Actionable,10545,5304,ovarian clear cell adenocarcinoma,DOID,27594,PIK3CA H1047R TP53 S90fs*33,decreased response,722,DS-7423,5290,24504419,,,
271,Preclinical - Cell culture,"In a preclinical study, Akt1 over expression in breast cancer cells harboring PIK3CA H1047R resulted in resistance to Alpelisib (BYL719) in culture (PMID: 27604488).",Actionable,8881,1612,breast cancer,DOID,26496,AKT1 over exp PIK3CA H1047R,resistant,691,BYL719,5290,27604488,,,
272,Preclinical,"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human breast cancer cells harboring ERBB2 (HER2) amplification and PIK3CA H1047R in culture (PMID: 21325073, PMID: 17314276).",Actionable,3125,1612,breast cancer,DOID,10752,ERBB2 amp PIK3CA H1047R,sensitive,1040,PF-05212384,5290,21325073,17314276,,
273,Preclinical - Cell line xenograft,"In a preclinical study, the combination of CH5132799 and Herceptin (trastuzumab) inhibited tumor growth and overcame Herceptin (trastuzumab) insensitivity in xenograft models of a human breast cancer cell line harboring PIK3CA H1047R and ERBB2 (HER2) amplification (PMID: 21558396).",Actionable,2975,1612,breast cancer,DOID,10752,ERBB2 amp PIK3CA H1047R,sensitive,3039,CH5132799 + Trastuzumab,5290,21558396,,,
274,Preclinical - Cell line xenograft,"In a preclinical study, CH5132799 inhibited cell growth and Akt phosphorylation, and promoted apoptosis in a human breast cancer cell line harboring PIK3CA H1047R and ERBB2 (HER2) amplification, and inhibited tumor growth in xenograft models (PMID: 21558396).",Actionable,2968,1612,breast cancer,DOID,10752,ERBB2 amp PIK3CA H1047R,sensitive,2152,CH5132799,5290,21558396,,,
275,Preclinical - Cell line xenograft,"In a preclinical study, CH5132799 inhibited cell growth in a human ovarian cancer cell line harboring PIK3CA H1047R and ERBB2 (HER2) amplification, and inhibited tumor growth in xenograft models (PMID: 21558396).",Actionable,2970,2394,ovarian cancer,DOID,10752,ERBB2 amp PIK3CA H1047R,sensitive,2152,CH5132799,5290,21558396,,,
276,Preclinical - Pdx,"In a preclinical study, combination of Sprycel (dasatinib) and Demcizumab (OMP-21M18) treatment resulted in durable tumor inhibition in patient-derived animal models of lung adenocarcinoma harboring KRAS G12F and PIK3CA H1047R (PMID: 26855149).",Actionable,10884,3910,lung adenocarcinoma,DOID,27820,KRAS G12F PIK3CA H1047R,sensitive,5671,Dasatinib + Demcizumab,5290,26855149,,,
277,Preclinical - Pdx,"In a preclinical study, treatment with Iclusig (ponatinib) was not effective in inhibiting tumor growth in a patient-derived xenograft model of bladder cancer with SRC over expression, which also over expressed ERBB2 (HER2) and harbored PIK3CA H1047R (PMID: 26270481).",Actionable,7457,11054,urinary bladder cancer,DOID,25513,ERBB2 over exp PIK3CA H1047R SRC over exp,no benefit,877,Ponatinib,5290,26270481,,,
278,Preclinical - Pdx,"In a preclinical study, treatment with Tykerb (lapatinib) was not effective in inhibiting tumor growth in a patient-derived xenograft model of bladder cancer with ERBB2 (HER2) over expression, which also over expressed SRC and harbored PIK3CA H1047R (PMID: 26270481).",Actionable,7456,11054,urinary bladder cancer,DOID,25513,ERBB2 over exp PIK3CA H1047R SRC over exp,no benefit,787,Lapatinib,5290,26270481,,,
279,Preclinical - Pdx,"In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib)  combination treatment did not result in enhanced antitumor activity compared to Ibrance (palbociclib) alone in PDX models of KRAS wild-type colorectal cancer harboring PIK3CA H1047R (PMID: 26369631).",Actionable,5622,9256,colorectal cancer,DOID,21303,KRAS wild-type PIK3CA H1047R,no benefit,1368,Palbociclib + Trametinib,5290,26369631,,,
280,Clinical Study,"In a clinical study, a melanoma patient harboring PTEN Y86fs and BRAF V600X developed the resistance mutation, PIK3CA H1047R, after treatment with Zelboraf (vemurafenib) (PMID: 24265153). ",Actionable,7082,1909,melanoma,DOID,24398,BRAF V600X PIK3CA H1047R PTEN Y86fs,resistant,342,Vemurafenib,5290,24265153,,,
281,Preclinical - Cell line xenograft,"In a preclinical study, CH5132799 inhibited tumor growth in xenograft models of a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R mutations (PMID: 21558396).",Actionable,2836,219,colon cancer,DOID,10711,KRAS G13D PIK3CA H1047R,sensitive,2152,CH5132799,5290,21558396,,,
282,Preclinical,"In a preclinical study, AT-7867 inhibited proliferation of cultured HCT-116 colon cancer cells, which have been reported to harbor KRAS G13D and PIK3CA H1047R mutations (PMID: 20423992, PMID: 24978597).",Actionable,2859,219,colon cancer,DOID,10711,KRAS G13D PIK3CA H1047R,sensitive,2447,AT-7867,5290,24978597,20423992,,
283,Preclinical - Cell line xenograft,"In a preclinical study, Gedatolisib (PKI-587) and Camptostar (irinotecan) synergistically suppressed the growth of a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R (PMID: 24042735) in xenograft models (PMID: 21325073).",Actionable,3901,219,colon cancer,DOID,10711,KRAS G13D PIK3CA H1047R,sensitive,3396,Gedatolisib + Irinotecan,5290,21325073,24042735,,
284,Preclinical,"In a preclinical study, CUDC-907 induced caspase activation in a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R in culture (PMID: 20570890, PMID: 22693356). ",Actionable,3010,219,colon cancer,DOID,10711,KRAS G13D PIK3CA H1047R,sensitive,709,CUDC-907,5290,20570890,22693356,,
285,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Gedatolisib (PF-05212384) and PD-0325901 inhibited tumor growth in colon cancer cell line xenograft models harboring KRAS G13D and PIK3CA H1047R (PMID: 21325073).",Actionable,2856,219,colon cancer,DOID,10711,KRAS G13D PIK3CA H1047R,sensitive,3025,PD-0325901 + Gedatolisib,5290,21325073,,,
286,Preclinical,"In a preclinical study, CC-223 inhibited proliferation of HCT-116 colon cancer cells, which have been reported to harbor KRAS G13D and PIK3CA H1047R mutations, in culture (PMID: 25855786, PMID: 24978597).",Actionable,2876,219,colon cancer,DOID,10711,KRAS G13D PIK3CA H1047R,sensitive,693,CC-223,5290,24978597,25855786,,
287,Preclinical,"In a preclinical study, human colorectal cancer cells harboring KRAS G13D and PIK3CA H1047R were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).",Actionable,4942,9256,colorectal cancer,DOID,10711,KRAS G13D PIK3CA H1047R,resistant,890,Regorafenib,5290,25838391,,,
288,Preclinical,"In a preclinical study, Gedatolisib (PKI-587) and Camptothecin in combination synergistictically enhanced Parp cleavage in a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R in culture (PMID: 21325073, PMID: 24042735). ",Actionable,3903,219,colon cancer,DOID,10711,KRAS G13D PIK3CA H1047R,sensitive,3398,Gedatolisib + Camptothecin,5290,24042735,25688157,,
289,Preclinical,"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human colon cancer cells harboring KRAS G13D and PIK3CA H1047R in culture (PMID: 21325073, PMID: 24042735).",Actionable,3131,219,colon cancer,DOID,10711,KRAS G13D PIK3CA H1047R,sensitive,1040,PF-05212384,5290,21325073,24042735,,
290,Preclinical,"In a preclinical study, Camptostar (irinotecan) suppressed the growth of a human colon cancer cell line harboring KRAS G13D and PIK3CA H1047R in xenograft models (PMID: 21325073, PMID: 16707468).",Actionable,3902,219,colon cancer,DOID,10711,KRAS G13D PIK3CA H1047R,sensitive,1074,Irinotecan,5290,21325073,16707468,,
291,Preclinical - Cell culture,"In a preclinical study, Alpelisib (BYL719) decreased viability of a colorectal cancer cell line harboring KRAS G13D and PIK3CA H1047R in culture (PMID: 27602501).",Actionable,12024,9256,colorectal cancer,DOID,10711,KRAS G13D PIK3CA H1047R,sensitive,691,BYL719,5290,27602501,,,
292,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis of human colorectal cancer cell lines harboring KRAS G13D and PIK3CA H1047R in culture, and reduced tumor growth in cell line xenograft models (PMID: 25838391).",Actionable,4947,9256,colorectal cancer,DOID,10711,KRAS G13D PIK3CA H1047R,sensitive,1305,Regorafenib + Cetuximab,5290,25838391,,,
293,Preclinical - Cell culture,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring BRAF V600E and PIK3CA H1047R in culture (PMID: 26272063).",Actionable,8568,9256,colorectal cancer,DOID,26361,BRAF V600E PIK3CA H1047R TP53 wild-type,sensitive,4771,MLN0128 + PD-0325901,5290,26272063,,,
294,Preclinical,"In a preclinical study, Buparlisib (BKM120) inhibited proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA H1047R in culture (PMID: 26715098).",Actionable,4571,219,colon cancer,DOID,18592,KRAS mutant PIK3CA H1047R,sensitive,680,BKM120,5290,26715098,,,
295,Preclinical,"In a preclinical study, Buparlisib (BKM120) worked synergistically with Erbitux (cetuximab) to inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA H1047R in culture (PMID: 26715098).",Actionable,4573,219,colon cancer,DOID,18592,KRAS mutant PIK3CA H1047R,sensitive,3548,BKM120 + Cetuximab,5290,26715098,,,
296,Preclinical,"In a preclinical study, Erbitux (cetuximab) did not inhibit proliferation of colon cancer cell lines harboring mutant KRAS and PIK3CA H1047R in culture (PMID: 26715098).",Actionable,4572,219,colon cancer,DOID,18592,KRAS mutant PIK3CA H1047R,no benefit,694,Cetuximab,5290,26715098,,,
297,Preclinical - Pdx,"In a preclinical study, treatment with BEZ235 slowed growth of tumors in patient-derived xenograft models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, PTEN R130G (PMID: 26232337).",Actionable,9375,1380,endometrial cancer,DOID,26839,KRAS G12D PIK3CA H1047R PTEN R130G,sensitive,672,BEZ235,5290,26232337,,,
298,Preclinical - Pdx,"In a preclinical study, treatment with the combination of Selumetinib (AZD6244) and BEZ235 resulted in stable disease in patient-derived xenograft (PDX) models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, and PTEN R130G, and demonstrated improved efficacy over either agent alone (PMID: 26232337).",Actionable,9373,1380,endometrial cancer,DOID,26839,KRAS G12D PIK3CA H1047R PTEN R130G,sensitive,1420,Selumetinib + BEZ235,5290,26232337,,,
299,Preclinical - Pdx,"In a preclinical study, treatment with Selumetinib (AZD6244) slowed growth of tumors in patient-derived xenograft models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, PTEN R130G (PMID: 26232337).",Actionable,9374,1380,endometrial cancer,DOID,26839,KRAS G12D PIK3CA H1047R PTEN R130G,sensitive,913,Selumetinib,5290,26232337,,,
300,Clinical Study,"In a clinical study, PIK3CA V955I was identified as a potential mechanism for acquired Erbitux (cetuximab) resistance in colorectal cancer patients, which is supported by cell culture studies demonstrating resistance to Erbitux (cetuximab) and Fluorouracil combination treatment in colorectal cancer cells over expressing PIK3CA V955I (PMID: 28424201).",Actionable,11719,9256,colorectal cancer,DOID,28198,PIK3CA V955I,resistant,2000,Fluorouracil + Cetuximab,5290,28424201,,,
301,Phase I,"In a Phase I trial, a non-small cell lung carcinoma patient harboring a mutation at PIK3CA H1047 demonstrated a confirmed partial response when treated with Taselisib (GDC-0032) (PMID: 28331003). ",Actionable,11447,3908,non-small cell lung carcinoma,DOID,13164,PIK3CA H1047X,sensitive,1016,GDC-0032,5290,28331003,,,
302,Clinical Study,"In a clinical study, a colorectal cancer patient harboring a mutation at PIK3CA H1047 demonstrated progressive disease when treated with Torisel (temsirolimus) and Avastin (bevacizumab) (PMID: 21216929). ",Actionable,3379,9256,colorectal cancer,DOID,13164,PIK3CA H1047X,resistant,3133,Temsirolimus + Bevacizumab,5290,21216929,,,
303,Clinical Study,"In a clinical study, the combination of Torisel (temsirolimus) plus Velcade (bortezomib) and Hycamtin (topotecan) resulted in progressive disease in a patient with small intestine adenocarcinoma harboring a PIK3CA H1047 mutation (PMID: 21216929). ",Actionable,3384,4906,small intestine adenocarcinoma,DOID,13164,PIK3CA H1047X,resistant,3134,Bortezomib + Temsirolimus + Topotecan,5290,21216929,,,
304,Clinical Study,"In a clinical study, a patient with endometrial adenocarcinoma harboring a PIK3CA H1047 mutation demonstrated a partial response when treated with Torisel (temsirolimus) (PMID: 21216929). ",Actionable,3314,2870,endometrial adenocarcinoma,DOID,13164,PIK3CA H1047X,sensitive,936,Temsirolimus,5290,21216929,,,
305,Clinical Study,"In a clinical study, the combination of Torisel (temsirolimus) plus Avastin (bevacizumab) and Doxil (pegylated liposomal-doxorubicin) resulted in a partial response in a patient with ovarian clear cell carcinoma harboring PIK3CA H1047 and BRAF V600 mutations (PMID: 21216929).",Actionable,3381,4001,ovarian carcinoma,DOID,13306,PIK3CA H1047X BRAF V600X,sensitive,1121,Bevacizumab + Temsirolimus + Doxil,5290,21216929,,,
306,Clinical Study,"In a clinical study, the combination of XL147 plus Paraplatin (carboplatin) and Taxol (paclitaxel) resulted in progressive disease in a patient with colorectal cancer harboring a PIK3CA H1047 mutation and KRAS G12 mutation (PMID: 21216929). ",Actionable,3385,9256,colorectal cancer,DOID,13308,PIK3CA H1047X KRAS G12X,resistant,3135,XL147 + Carboplatin + Paclitaxel,5290,21216929,,,
307,Preclinical,"In a preclinical study, human colorectal cancer cells harboring BRAF V600E and PIK3CA P449T were resistant to Erbitux (cetuximab) in culture (PMID: 25838391).",Actionable,4936,9256,colorectal cancer,DOID,19841,BRAF V600E PIK3CA P449T,resistant,694,Cetuximab,5290,25838391,,,
308,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).",Actionable,8199,9256,colorectal cancer,DOID,19841,BRAF V600E PIK3CA P449T,sensitive,1659,Pimasertib + Sorafenib,5290,23629727,,,
309,Preclinical,"In a preclinical study, human colorectal cancer cells harboring BRAF V600E and PIK3CA P449T were resistant to Stivarga (regorafenib) in culture (PMID: 25838391).",Actionable,4940,9256,colorectal cancer,DOID,19841,BRAF V600E PIK3CA P449T,resistant,890,Regorafenib,5290,25838391,,,
310,Preclinical,"In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis of human colorectal cancer cell lines harboring BRAF V600E and PIK3CA P449T in culture (PMID: 25838391).",Actionable,4950,9256,colorectal cancer,DOID,19841,BRAF V600E PIK3CA P449T,sensitive,1305,Regorafenib + Cetuximab,5290,25838391,,,
311,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).",Actionable,8204,9256,colorectal cancer,DOID,19841,BRAF V600E PIK3CA P449T,sensitive,4657,Pimasertib + Regorafenib,5290,23629727,,,
312,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).",Actionable,8194,9256,colorectal cancer,DOID,19841,BRAF V600E PIK3CA P449T,sensitive,4656,Everolimus + Pimasertib,5290,23629727,,,
313,Preclinical - Cell culture,"In a preclinical study, Pimasertib (MSC1936369B) inhibited proliferation of colorectal cancer cells harboring BRAF V600E and PIK3CA P449T in culture (PMID: 23629727).",Actionable,8189,9256,colorectal cancer,DOID,19841,BRAF V600E PIK3CA P449T,sensitive,871,Pimasertib,5290,23629727,,,
314,Preclinical - Cell line xenograft,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and growth of colorectal cancer cells harboring BRAF V600E, PIK3CA P449T, and TP53 R273H in culture and in cell line xenograft models, but did not have synergistic effect on apoptosis (PMID: 26272063).",Actionable,8565,9256,colorectal cancer,DOID,26358,BRAF V600E PIK3CA P449T TP53 R273H,sensitive,4771,MLN0128 + PD-0325901,5290,26272063,,,
315,Clinical Study,"In a clinical study, PIK3CA V952A was identified as a potential mechanism for acquired Erbitux (cetuximab) resistance in colorectal cancer patients, which is consistent with cell culture studies demonstrating moderate resistance to Erbitux (cetuximab) and Fluorouracil combination treatment in colorectal cancer cells over expressing PIK3CA V952A (PMID: 28424201).",Actionable,11725,9256,colorectal cancer,DOID,28201,PIK3CA V952A,resistant,2000,Fluorouracil + Cetuximab,5290,28424201,,,
316,Preclinical - Cell line xenograft,"In a preclinical study, PF-4989216 inhibited proliferation of small cell lung carcinoma cells harboring PIK3CA G106_R108del and wild-type PTEN in culture, and suppressed tumor growth in cell line xenograft models (PMID: 24240111).",Actionable,5217,5409,lung small cell carcinoma,DOID,20307,PIK3CA G106_R108del PTEN wild-type,sensitive,867,PF-4989216,5290,24240111,,,
317,Clinical Study,"In a clinical study, PIK3CA K966E was identified as a potential mechanism for acquired Erbitux (cetuximab) resistance in colorectal cancer patients, which is supported by cell culture studies demonstrating resistance to Erbitux (cetuximab) and Fluorouracil combination treatment in colorectal cancer cells over expressing PIK3CA K966E (PMID: 28424201).",Actionable,11720,9256,colorectal cancer,DOID,28199,PIK3CA K966E,resistant,2000,Fluorouracil + Cetuximab,5290,28424201,,,
318,Preclinical - Pdx,"In a preclinical study, a patient-derived xenograft (PDX) model of endometrial cancer harboring PIK3CA D350G, PIK3CA R93W, and PTEN R130G was sensitive to ARQ092, demonstrating greater than 90% inhibition of tumor growth (PMID: 26469692). ",Actionable,10283,1380,endometrial cancer,DOID,27339,PIK3CA D350G PIK3CA R93W PTEN R130G,sensitive,635,ARQ092,5290,26469692,,,
319,Preclinical,"In a preclinical study, CH5132799 inhibited proliferation of prostate cancer cells harboring PIK3CA Q546R in culture (PMID: 21558396).",Actionable,2953,10283,prostate cancer,DOID,2658,PIK3CA Q546R,sensitive,2152,CH5132799,5290,21558396,,,
320,Clinical Study,"In a clinical case study, a patient with colorectal cancer harboring KRAS G12D and PIK3CA Q546R demonstrated sensitivity to treatment with the combination of Nexavar (sorafenib) and Avastin (bevacizumab), resulting in stable disease for more than 6 months (PMID: 25363205). ",Actionable,7768,9256,colorectal cancer,DOID,27864,KRAS G12D PIK3CA Q546R,sensitive,4517,Bevacizumab + Sorafenib,5290,25363205,,,
321,Preclinical - Pdx,"In a preclinical study, a melanoma patient-derived xenograft (PDX) model harboring BRAF V600E and PIK3CA H1047K was sensitive to the combination treatment of ARQ092 and Mekinist (trametinib), demonstrating a greater inhibition of tumor growth when compared to either agent alone (PMID: 26469692). ",Actionable,10288,1909,melanoma,DOID,27343,BRAF V600E PIK3CA H1047K,sensitive,5456,ARQ092 + Trametinib,5290,26469692,,,
322,Preclinical - Cell culture,"In a preclinical study, a hormone breast cancer cell line harboring PIK3CA E542K was sensitive to ARQ 751 in culture, demonstrating inhibition of cell growth (PMID: 26469692). ",Actionable,10277,1612,breast cancer,DOID,808,PIK3CA E542K,sensitive,635,ARQ092,5290,26469692,,,
323,Preclinical - Cell culture,"In a preclinical study, colorectal cancer cells over expressing PIK3CA E542K were resistant to Erbitux (cetuximab) and Fluorouracil combination treatment in culture (PMID: 28424201).",Actionable,11721,9256,colorectal cancer,DOID,808,PIK3CA E542K,resistant,2000,Fluorouracil + Cetuximab,5290,28424201,,,
324,Preclinical,"In a preclinical study, Rapamune (sirolimus) demonstrated efficacy in inhibiting transformation of cultured cells containing PIK3CA E542K mutations (PMID: 15647370).",Actionable,1360,10000003,Advanced Solid Tumor,JAX,808,PIK3CA E542K,sensitive,917,Sirolimus,5290,15647370,,,
325,Phase I,"In a Phase I trial, Apitolisib (GDC-0980) treatment resulted in a partial response in a patient with head and neck squamous cell carcinoma harboring a PIK3CA E542K mutation (PMID: 26787751).",Actionable,6085,5520,head and neck squamous cell carcinoma,DOID,808,PIK3CA E542K,sensitive,750,GDC-0980,5290,26787751,,,
326,Preclinical - Cell line xenograft,"In preclinical studies, the combination of GDC-0941 and PD-0325901 (PI3K and MEK inhibitors, respectively) inhibited tumor growth in colorectal cancer cell line xenograft models (PMID: 24339963).",Actionable,1298,9256,colorectal cancer,DOID,808,PIK3CA E542K,sensitive,1822,PD-0325901 + GDC-0941,5290,24339963,,,
327,Phase I,"In a Phase I trial, an ovarian cancer patient harboring a PIK3CA E542 mutation demonstrated stable disease when treated with Torisel (temsirolimus) (PMID: 21216929). ",Actionable,3313,2394,ovarian cancer,DOID,808,PIK3CA E542K,predicted â€“ sensitive,936,Temsirolimus,5290,21216929,,,
328,Preclinical - Cell culture,"In a preclinical study, MK2206 inhibited AKT activation, proliferation, and growth of thyroid cancer cell lines with  PI3K/AKT pathway alterations in culture, including a papillary thyroid cancer cell line harboring PIK3CA E542K (PMID: 21289267).",Actionable,8216,3969,papillary thyroid carcinoma,DOID,808,PIK3CA E542K,sensitive,816,MK2206,5290,21289267,,,
329,Preclinical,"In a preclinical study, Nerlynx (neratinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E542K in culture (PMID: 26627007).",Actionable,4247,1612,breast cancer,DOID,808,PIK3CA E542K,sensitive,828,Neratinib,5290,26627007,,,
330,Preclinical - Cell culture,"In a preclinical study, Alpelisib (BYL719) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E542K in culture (PMID: 26627007).",Actionable,4226,1612,breast cancer,DOID,808,PIK3CA E542K,sensitive,691,BYL719,5290,26627007,,,
331,Preclinical,"In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E542K in culture (PMID: 26627007).",Actionable,4240,1612,breast cancer,DOID,808,PIK3CA E542K,sensitive,787,Lapatinib,5290,26627007,,,
332,Preclinical,"In a preclinical study, BEZ235 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E542K in culture (PMID: 26627007).",Actionable,4219,1612,breast cancer,DOID,808,PIK3CA E542K,sensitive,672,BEZ235,5290,26627007,,,
333,Preclinical,"In a preclinical study, Mekinist (trametinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E542K in culture (PMID: 26627007).",Actionable,4254,1612,breast cancer,DOID,808,PIK3CA E542K,sensitive,2,Trametinib,5290,26627007,,,
334,Preclinical,"In preclinical studies, VS-5584 demonstrated efficacy in a variety of cancer cell lines, particularly those harboring PIK3CA mutations (PMID: 23270925).",Actionable,640,234,colon adenocarcinoma,DOID,808,PIK3CA E542K,sensitive,960,VS-5584,5290,23270925,,,
335,Preclinical,"In a preclinical study, MK2206 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA E542K in culture (PMID: 26627007).",Actionable,4233,1612,breast cancer,DOID,808,PIK3CA E542K,sensitive,816,MK2206,5290,26627007,,,
336,Clinical Study,"In a retrospective study, treatment with the combination of Erbitux (cetuximab) and Camptosar (irinotecan) resulted in partial response in 50% (1/2) and stable disease in 50% (1/2) of colorectal carcinoma patients harboring a PIK3CA E542K mutation (PMID: 25714871).",Actionable,3757,9256,colorectal cancer,DOID,808,PIK3CA E542K,sensitive,1874,Cetuximab + Irinotecan,5290,25714871,,,
337,Preclinical,"In a preclinical study, CH5132799 inhibited proliferation of a breast cancer cell line harboring PIK3CA E542K in culture (PMID: 21558396).",Actionable,3002,1612,breast cancer,DOID,808,PIK3CA E542K,sensitive,2152,CH5132799,5290,21558396,,,
338,Preclinical - Cell culture,"In a preclinical study, MK2206 suppressed activation of AKT induced by Torisel (temsirolimus), and MK2206 and Torisel (temsirolimus) demonstrated synergy in inhibiting growth of a papillary thyroid cancer cell line harboring PIK3CA E542K in culture (PMID: 21289267).",Actionable,8223,3969,papillary thyroid carcinoma,DOID,808,PIK3CA E542K,sensitive,4664,MK2206 + Temsirolimus,5290,21289267,,,
339,Phase Ib/II,"In a Phase Ib trial, a patient with cervical squamous cell carcinoma harboring PIK3CA E542K demonstrated a partial response when treated with a combination of LY2780301 and Gemzar (gemcitabine) (PMID: 28750271). ",Actionable,11830,3744,cervical squamous cell carcinoma,DOID,808,PIK3CA E542K,sensitive,6168,Gemcitabine + LY2780301,5290,28750271,,,
340,Preclinical,"In a preclinical study, gastric cancer cells harboring PI3KCA E542K mutations were sensitive to the AKT inhibitor AZD5363 (PMID: 24088382).",Actionable,1362,3119,gastrointestinal system cancer,DOID,808,PIK3CA E542K,sensitive,655,AZD5363,5290,24088382,,,
341,Preclinical - Cell culture,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, but did not induce apoptosis in colorectal cancer cells harboring KRAS Q61L, PIK3CA E542K, and TP53 T118Qfs*5 in culture (PMID: 26272063).",Actionable,8566,9256,colorectal cancer,DOID,26412,KRAS Q61L PIK3CA E542K TP53 T118Qfs*5,sensitive,4771,MLN0128 + PD-0325901,5290,26272063,,,
342,Preclinical - Cell culture,"In a preclinical study, inhibition of Pi3k signaling by BEZ235 sensitized breast cancer cell lines harboring PIK3CA E542K and PTEN loss to WEHI-539 in culture (PMID: 27974663).",Actionable,10087,1612,breast cancer,DOID,27243,PIK3CA E542K PTEN loss,predicted â€“ sensitive,5377,BEZ235 + WEHI-539,5290,27974663,,,
343,Preclinical - Pdx,"In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib)  combination treatment resulted in partial tumor regression in PDX models of colorectal cancer cells harboring KRAS Q61H and PIK3CA E542K (PMID: 26369631).",Actionable,5620,9256,colorectal cancer,DOID,21302,KRAS Q61H PIK3CA E542K,sensitive,1368,Palbociclib + Trametinib,5290,26369631,,,
344,Clinical Study,"In a clinical study, the combination of Torisel (temsirolimus) plus Avastin (bevacizumab) and Doxil (pegylated liposomal-doxorubicin) resulted in a partial response in a patient with ovarian carcinoma harboring both a PIK3CA mutation and a KRAS Q61 mutation (PMID: 21216929).",Actionable,3383,4001,ovarian carcinoma,DOID,13307,PIK3CA mutant KRAS Q61X,sensitive,1121,Bevacizumab + Temsirolimus + Doxil,5290,21216929,,,
345,Preclinical,"In a preclinical study, CUDC-907 inhibited downstream signaling and growth of PIK3CA-mutant breast cancer cells with ERBB2 amplification in culture (PMID: 22693356).",Actionable,3016,1612,breast cancer,DOID,19124,ERBB2 amp PIK3CA mut,sensitive,709,CUDC-907,5290,22693356,,,
346,Preclinical - Cell line xenograft,"In a preclinical study, Aliqopa (copanlisib) promoted tumor regression in xenograft models of a human ERBB2 (HER2)-amplified breast cancer cell line harboring a PIK3CA activating mutation (PMID: 24170767).",Actionable,1374,60079,Her2-receptor positive breast cancer,DOID,19124,ERBB2 amp PIK3CA mut,sensitive,995,Copanlisib,5290,24170767,,,
347,Preclinical - Cell line xenograft,"In a preclinical study, ERBB2 (HER2)-receptor positive breast cancer cell line xenograft models harboring amplification of ERBB2 (HER2) and a PIK3CA mutation demonstrated sensitivity to treatment with Ipatasertib (GDC-0068), resulting in inhibition of tumor growth (PMID: 24141624). ",Actionable,8966,60079,Her2-receptor positive breast cancer,DOID,19124,ERBB2 amp PIK3CA mut,sensitive,747,Ipatasertib,5290,24141624,,,
348,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Nerlynx (neratinib) and Taselisib (GDC-0032), compared to either agent alone, resulted in greater inhibition of cell cycle activity in a uterine serous carcinoma cell line harboring ERBB2 (HER2) amplification and a PIK3CA mutation in culture, and in xenograft models, showed increased tumor growth inhibition and tumor regression (PMID: 26333383). ",Actionable,9067,5750,uterine corpus serous adenocarcinoma,DOID,19124,ERBB2 amp PIK3CA mut,sensitive,4871,GDC-0032 + Neratinib,5290,26333383,,,
349,Preclinical,"In a preclinical study, a breast cancer cell line harboring mutations in PIK3CA and CDKN2A demonstrated sensitivity to Sapanisertib (MLN0128) in culture (PMID: 25261369). ",Actionable,2105,1612,breast cancer,DOID,5388,PIK3CA mutant CDKN2A mutant,sensitive,1282,Sapanisertib,5290,25261369,,,
350,Preclinical,"In a preclinical study, BEZ235 inhibited the growth of an Iressa (gefitinib)-resistant NSCLC cell line with KRAS and PIK3CA mutations (PMID: 24939055).",Actionable,984,3908,non-small cell lung carcinoma,DOID,1630,KRAS mut PIK3CA mut,sensitive,672,BEZ235,5290,24939055,,,
351,Preclinical,"In a preclinical study, the combination of AZD8055 and Selumetinib (AZD6244) inhibited tumor growth in a colorectal cancer xenograft model harboring PIK3CA and KRAS mutations and had increased efficacy compared to either agent alone (PMID: 22271687).",Actionable,2795,9256,colorectal cancer,DOID,1630,KRAS mut PIK3CA mut,sensitive,2561,AZD8055 + Selumetinib,5290,22271687,,,
352,Preclinical,"In a preclinical study, BKM120 suppressed growth of a gastric cancer cell line harboring PIK3CA and KRAS mutations in culture (PMID: 22159814).",Actionable,2799,10534,stomach cancer,DOID,1630,KRAS mut PIK3CA mut,sensitive,680,BKM120,5290,22159814,,,
353,Preclinical - Cell line xenograft,"In a preclinical study, Selumetinib (AZD6244) in combination with BEZ235, synergistically prevented proliferation of an Iressa (gefitinib)-resistant NSCLC cell line harboring KRAS and PIK3CA mutations in culture and in cell line xenograft models (PMID: 24939055).",Actionable,989,3908,non-small cell lung carcinoma,DOID,1630,KRAS mut PIK3CA mut,sensitive,1420,Selumetinib + BEZ235,5290,24939055,,,
354,Preclinical - Cell line xenograft,"In a preclinical study, Navitoclax (ABT-263) improved the therapeutic effects of the combination of CGM097 and Mekinist (trametinib) in colorectal cancer cells, resulting in greater apoptotic activity and growth inhibition in culture, and tumor regression in xenograft models (PMID: 27659046). ",Actionable,9931,9256,colorectal cancer,DOID,1630,KRAS mut PIK3CA mut,sensitive,5315,ABT-263 + CGM097 + Trametinib,5290,27659046,,,
355,Preclinical,"In a preclinical study, a colon cancer cell line harboring PIK3CA and KRAS mutations demonstrated sensitivity to AT13148 in culture (PMID: 22781553).",Actionable,2779,219,colon cancer,DOID,1630,KRAS mut PIK3CA mut,sensitive,3653,AT13148,5290,22781553,,,
356,Preclinical - Cell line xenograft,"In a preclincal study, GDC-0980 delayed tumor growth in colon cancer cell line xenograft models harboring KRAS and PIKC3A mutations (PMID: 21998291).",Actionable,2855,219,colon cancer,DOID,1630,KRAS mut PIK3CA mut,sensitive,750,GDC-0980,5290,21998291,,,
357,Preclinical - Cell culture,"In a preclinical study, a colorectal cancer cell line co-harboring a KRAS mutation and PIK3CA mutation was sensitive to XL765 (SAR245409), demonstrating inhibition of cell proliferation in culture (PMID: 24634413). ",Actionable,10707,9256,colorectal cancer,DOID,1630,KRAS mut PIK3CA mut,sensitive,1051,SAR245409,5290,24634413,,,
358,Preclinical,"In a preclinical study, Deguelin inhibited growth of the AGS gastric cancer cell line, which has been reported to harbor PIK3CA and KRAS mutations, in culture (PMID: 20811676, PMID: 24978597).",Actionable,2844,10534,stomach cancer,DOID,1630,KRAS mut PIK3CA mut,predicted â€“ sensitive,1867,Deguelin,5290,24978597,20811676,,
359,Preclinical - Cell line xenograft,"In a preclinical study, treatment with Aliqopa (copanlisib) inhibited tumor growth in xenograft models of a human colon cancer cell line harboring PIK3CA and KRAS mutations (PMID: 24170767).",Actionable,2722,219,colon cancer,DOID,1630,KRAS mut PIK3CA mut,sensitive,995,Copanlisib,5290,24170767,,,
360,Preclinical - Cell line xenograft,"In a preclinical study, the combination of CGM097 and Mekinist (trametinib) treatment compared to treatment with either agent alone in a colorectal cancer cell line resulted in a greater decrease in colony formation in culture, and improved stable disease in xenograft models (PMID: 27659046). ",Actionable,9930,9256,colorectal cancer,DOID,1630,KRAS mut PIK3CA mut,sensitive,5314,CGM097 + Trametinib,5290,27659046,,,
361,Preclinical,"In a preclinical study, Selumetinib (AZD6244) mildly inhibited the growth of an Iressa (gefitinib)-resistant NSCLC cell line with KRAS and PIK3CA mutations (PMID: 24939055).",Actionable,983,3908,non-small cell lung carcinoma,DOID,1630,KRAS mut PIK3CA mut,decreased response,913,Selumetinib,5290,24939055,,,
362,Preclinical,"In a preclinical study, human solid tumor cell lines harboring coincident PIK3CA and KRAS mutations demonstrated sensitivity to CH5132799 in culture (PMID: 21558396).",Actionable,2835,10000003,Advanced Solid Tumor,JAX,1630,KRAS mut PIK3CA mut,sensitive,2152,CH5132799,5290,21558396,,,
363,Preclinical - Cell line xenograft,"In a preclinical study, PF-04691502 inhibited tumor growth in non-small cell lung cancer cell line xenograft models harboring both PIK3CA and KRAS mutations (PMID: 21750219).",Actionable,8388,3908,non-small cell lung carcinoma,DOID,1630,KRAS mut PIK3CA mut,sensitive,865,PF-04691502,5290,21750219,,,
364,Phase I,"In a Phase I trial, Taselisib (GDC-0032) demonstrated activity in patients with PIK3CA-mutant advanced solid tumors, but preliminary data analysis suggested the presence of a KRAS mutation was associated with lack of response (Cancer Res October 1, 2014 74:915).",Actionable,2851,10000003,Advanced Solid Tumor,JAX,1630,KRAS mut PIK3CA mut,decreased response,1016,GDC-0032,5290,None,,,
365,Preclinical,"In a preclinical study, CUDC-907 inhibited growth and induced apoptosis in a human colon cancer cell line harboring PIK3CA and KRAS mutations (PMID: 22693356).",Actionable,2840,219,colon cancer,DOID,1630,KRAS mut PIK3CA mut,sensitive,709,CUDC-907,5290,22693356,,,
366,Preclinical,"In a preclinical study, Alpelisib (BYL719) inhibited growth in multiple tumor cell lines expressing PIK3CA mutations, and concurrent KRAS mutations was not associated with resistance (PMID: 24608574).",Actionable,2874,10000003,Advanced Solid Tumor,JAX,1630,KRAS mut PIK3CA mut,sensitive,691,BYL719,5290,24608574,,,
367,Preclinical,"In a preclinical study, human cancer cells with PIK3CA mutations demonstrated sensitivity to Afinitor (everolimus), but a coincident KRAS mutation led to Afinitor (everolimus) resistance  (PMID: 20664172).",Actionable,145,10000003,Advanced Solid Tumor,JAX,1630,KRAS mut PIK3CA mut,resistant,735,Everolimus,5290,20664174,20664172,,
368,Phase I,"In a Phase I trial, a colorectal cancer patient co-harboring a PIK3CA mutation and KRAS mutation progressed on treatment with Taselisib (GDC-0032) (PMID: 28331003). ",Actionable,11446,9256,colorectal cancer,DOID,1630,KRAS mut PIK3CA mut,no benefit,1016,GDC-0032,5290,28331003,,,
369,Preclinical,"In a preclinical study, colon cancer cells harboring KRAS and PIK3CA mutations demonstrated resistance to BEZ235 in culture and xenograft models (PMID: 23475782).",Actionable,2724,9256,colorectal cancer,DOID,1630,KRAS mut PIK3CA mut,resistant,672,BEZ235,5290,23475782,,,
370,Preclinical,"In a preclinical study, A-443654 inhibited proliferation of colon cancer cell lines that have been reported to harbor KRAS and PIK3CA mutations in culture (PMID: 24569089, PMID: 24978597).",Actionable,2864,219,colon cancer,DOID,1630,KRAS mut PIK3CA mut,sensitive,2448,A-443654,5290,24978597,24569089,,
371,Phase II,"In a Phase II trial, one patient with Kras and Pikc3a mutant non-squamous NSCLC had a partial response to Buparlisib (BKM120) however, stage 2 of the study was not initiated due to failure of meeting overall stage 1 response endpoints (PMID: 26098748).",Actionable,9817,3908,non-small cell lung carcinoma,DOID,1630,KRAS mut PIK3CA mut,sensitive,680,BKM120,5290,26098748,,,
372,Clinical Study,"In a retrospective study, Erbitux (cetuximab) treatment, alone or in combination, resulted in disease regression or stable disease in 88% (7/8) KRAS/BRAF-wild type colorectal carcinoma patients harboring a PIK3CA mutation (PMID: 25714871).",Actionable,3671,9256,colorectal cancer,DOID,14283,BRAF wild-type KRAS wild-type PIK3CA mutant,sensitive,694,Cetuximab,5290,25714871,,,
373,Preclinical,"In a preclinical study, a rapamycin-resistant colorectal cancer cell line harboring mutations in APC, BRAF, PIK3CA, SMAD4 and TP53 was sensitive to Sapanisertib (MLN0128) resulting in inhibition of MTORC1 signaling (PMID: 25261369). ",Actionable,2135,9256,colorectal cancer,DOID,5415,APC mut BRAF mut PIK3CA mut SMAD4 mut TP53 mut,sensitive,1282,Sapanisertib,5290,25261369,,,
374,Clinical Study,"In a clinical study, a retrospective analysis of the combined treatment, Herceptin (trastuzumab) and Tykerb (lapatinib), in ERBB2 (HER2) positive breast cancer patients demonstrated patients harboring a PIK3CA mutation trended towards a decreased response when compared to patients with wild-type PIK3CA (PMID: 27687302). ",Actionable,9165,60079,Her2-receptor positive breast cancer,DOID,1669,PIK3CA mutant ERBB2 pos,decreased response,1414,Trastuzumab + Lapatinib,5290,27687302,,,
375,Phase II,"In a Phase II trial, ERBB2-positive breast cancer patients harboring PIK3CA mutations demonstrated lower pathologic complete remission rate (12.5%) compared to those with wild-type PIK3CA (48.4%) after Herceptin (trastuzumab) and Tykerb (lapatinib) combination therapy (PMID: 26245675).",Actionable,5246,60079,Her2-receptor positive breast cancer,DOID,1669,PIK3CA mutant ERBB2 pos,decreased response,1414,Trastuzumab + Lapatinib,5290,26245675,,,
376,Clinical Study,"In a clinical study, a colorectal cancer patient harboring a PIK3CA mutation and KRAS mutations at codons 12 and 13 demonstrated stable disease when treated with a combination of Torisel (temsirolimus) and Avastin (bevacizumab) (PMID: 21216929). ",Actionable,3378,9256,colorectal cancer,DOID,13305,PIK3CA mutant KRAS G12X KRAS G13X,sensitive,3133,Temsirolimus + Bevacizumab,5290,21216929,,,
377,Phase I,"In a Phase I trial, CC-223 demonstrated safety and preliminary efficacy in patients with solid tumors, including stable disease for greater than 110 days in 2 patients with PIK3CA mutation or PTEN deletion (PMID: 26177599).",Actionable,1396,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,sensitive,693,CC-223,5290,None,26177599,,
378,Preclinical,"In preclinical studies, VS-5584 demonstrated efficacy in a variety of cancer cell lines, particularly those harboring PIK3CA mutations (PMID: 23270925).",Actionable,1675,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,sensitive,960,VS-5584,5290,23270925,,,
379,Phase I,"In a Phase I clinical trial, carboxyamidotriazole orotate treatment demonstrated some efficacy in patients with various solid tumors, including patients harboring PIK3CA mutations (J Clin Oncol 31, 2013 (suppl; abstr 2518)).",Actionable,1669,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,sensitive,999,Carboxyamidotriazole Orotate,5290,None,,,
380,Preclinical,"In a preclinical study, AZD8835 inhibited tumor growth in breast cancer xenograft models harboring PIK3CA mutations (AACR; 2015. Abstract nr 2665).",Actionable,2718,1612,breast cancer,DOID,429,PIK3CA mutant,sensitive,2013,AZD8835,5290,None,,,
381,Preclinical,"In a preclinical study, PWT33597 decreased signaling of mTOR and PIK3 pathways in non-small cell lung cancer cells with Pik3ca mutations (Cancer Res 2011;71(8 Suppl):Abstract nr 4485).",Actionable,2744,3908,non-small cell lung carcinoma,DOID,429,PIK3CA mutant,sensitive,880,PWT33597,5290,None,,,
382,Phase I,"In a Phase I clinical trial, carboxyamidotriazole orotate treatment demonstrated some efficacy in patients with various solid tumors including squamous cell carcinomas (tonsil) with PI3KCA and NRAS mutations (J Clin Oncol 31, 2013 (suppl; abstr 2518)).",Actionable,1363,1749,squamous cell carcinoma,DOID,429,PIK3CA mutant,sensitive,999,Carboxyamidotriazole Orotate,5290,None,,,
383,Preclinical - Cell line xenograft,"In a preclinical study, a ERBB3 (HER3) positive breast cancer cell line xenograft model harboring a PIK3CA mutation was demonstrated decreased tumor growth when treated with AT13148 (PMID: 22781553). ",Actionable,10801,1612,breast cancer,DOID,429,PIK3CA mutant,sensitive,3653,AT13148,5290,22781553,,,
384,Phase I,"In a Phase I clinical trial, GSK2141795 demonstrated safety and preliminary efficacy in patients with advanced solid tumors, with 4 patients with PIK3CA mutations and/or PTEN loss achieving stable disease for greater than 6 months (J Clin Oncol 29: 2011 (suppl; abstr 3003)). ",Actionable,3875,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,predicted â€“ sensitive,764,GSK2141795,5290,None,,,
385,Phase II,"In a Phase II trial, PIK3CA mutations were more frequent in  muscle-invasive urothelial bladder cancer patients that did not respond to Nexavar (sorafenib), Platinol (cisplatin) and Gemzar (gemcitabine) combination therapy than those who did respond (J Clin Oncol 35, 2017 (suppl 6S; abstract 345)).",Actionable,10324,6477,invasive bladder transitional cell carcinoma,DOID,429,PIK3CA mutant,predicted â€“ resistant,5462,Cisplatin + Gemcitabine + Sorafenib,5290,None,,,
386,Phase I,"In a Phase I clinical trial AZD5363 demonstrated safety and efficacy in patients with advanced solid tumors, including one patient with a PIK3CA mutated ovarian cancer (American Association for Cancer Research; 06 Apr 2013-10 Apr 2013; Abstract LB-66). ",Actionable,1651,2394,ovarian cancer,DOID,429,PIK3CA mutant,sensitive,655,AZD5363,5290,None,,,
387,Phase I,"In a Phase I clinical trial, SAR245409 (XL765) demonstrated equivalent safety and efficacy in patients with PIK3CA mutant or PIK3CA wild-type advanced solid tumors (PMID: 24583798).",Actionable,1216,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,sensitive,1051,SAR245409,5290,24583798,,,
388,Phase Ib/II,"In a Phase Ib trial, Taselisib (GDC-0032) and Femara (letrozole) combination therapy resulted in an overall response rate of 38% in breast cancer patients with PIK3CA mutations, compared to 9% in patients with wild-type PIK3CA (Cancer Res May 1, 2015 75; PD5-2).",Actionable,6343,1612,breast cancer,DOID,429,PIK3CA mutant,sensitive,4118,GDC-0032  + Letrozole,5290,None,,,
389,Preclinical,"In a preclinical study, breast cancer cells with PIK3CA mutations, both with and without ERBB2 (HER2) amplification, demonstrated sensitivity to CH5132799 in culture (PMID: 21558396).",Actionable,2939,1612,breast cancer,DOID,429,PIK3CA mutant,sensitive,2152,CH5132799,5290,21558396,,,
390,Preclinical - Pdx & cell culture,"In a preclinical study, Taselisib (GDC-0032) enhanced the effects of radiation induced apoptosis in HNSCC cell lines, cell line xenograft models, and a patient derived xenograft (PDX) model, all with PIK3CA mutations (PMID: 26589432).",Actionable,3913,5520,head and neck squamous cell carcinoma,DOID,429,PIK3CA mutant,sensitive,3967,GDC-0032 + Radiotherapy,5290,26589432,,,
391,Phase II,"In a Phase II trial, Apitolisib (GDC-0980) was poorly tolerated, but demonstrated efficacy in endometrial cancer patients harboring mutations in PIK3CA, PTEN, or AKT1 (J Clin Oncol 32:5s, 2014 (suppl; abstr 5513)).",Actionable,5203,1380,endometrial cancer,DOID,429,PIK3CA mutant,sensitive,750,GDC-0980,5290,None,,,
392,Phase II,"In a Phase II trial, Torisel (temsirolimus) treatment resulted in stable disease in 9.7% (3/31) of breast cancer patients positive for ER, PR or ERBB2 (HER2), however there was no association between PIK3CA mutational status and clinical benefits (PMID: 22245973).",Actionable,2379,1612,breast cancer,DOID,429,PIK3CA mutant,no benefit,936,Temsirolimus,5290,22245973,,,
393,Preclinical,"In a preclinical study, BAY1082439 inhibited growth of gastric cancer cells harboring PIK3CA mutations in culture and xenograft models (AACR; 2015. Abstract nr 2674).",Actionable,2720,10534,stomach cancer,DOID,429,PIK3CA mutant,sensitive,666,BAY1082439,5290,None,,,
394,Phase II,"In a Phase II trial, the addition of AZD5363 to Taxol (paclitaxel) therapy did not improve progression-free survival compared to placebo (10.9 vs 10.8 months) in patients with PIK3CA-mutant, Esr1-positive, Erbb2 (Her2)-negative breast cancer (Ann Oncol 2017, Vol 28, Suppl 5, Abstract #241PD; NCT01625286).",Actionable,12064,60080,Her2-receptor negative breast cancer,DOID,429,PIK3CA mutant,no benefit,2192,AZD5363 + Paclitaxel,5290,None,,,
395,Phase I,"In a Phase I clinical trial, Torisel (temsirolimus) demonstrated limited efficacy in ovarian cancer patients with PIK3CA mutations (PMID: 22271473).",Actionable,1642,2394,ovarian cancer,DOID,429,PIK3CA mutant,sensitive,936,Temsirolimus,5290,22271473,,,
396,Preclinical,"In a preclinical study, Sapanisertib (MLN0128) demonstrated efficacy in PIK3CA mutant breast cancer xenograft models (PMID: 23085766).",Actionable,410,1612,breast cancer,DOID,429,PIK3CA mutant,sensitive,1282,Sapanisertib,5290,23085766,,,
397,Preclinical,"In a preclinical study, CH5132799 inhibited proliferation of ovarian cancer cells with PIK3CA mutations in culture (PMID: 21558396).",Actionable,2940,2394,ovarian cancer,DOID,429,PIK3CA mutant,sensitive,2152,CH5132799,5290,21558396,,,
398,Phase II,"In a Phase II trial, two patients with head and neck squamous cell carcinoma harboring a PIK3CA mutation who had stable disease demonstrated some tumor regression when treated with the combination of Torisel (temsirolimus), Paraplatin (carboplatin), and Taxol (paclitaxel) (PMID: 28961834). ",Actionable,12183,5520,head and neck squamous cell carcinoma,DOID,429,PIK3CA mutant,predicted â€“ sensitive,6333,Carboplatin + Paclitaxel + Temsirolimus,5290,28961834,,,
399,Clinical Study,"In a clinical study, the combination of Torisel (temisirolimus) plus Avastin (bevacizumab) and Doxil (pegylated liposomal-doxirubicin) resulted in stable disease in patients with advanced solid tumors harboring PIK3CA mutations (PMID: 21216929).",Actionable,3380,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,sensitive,1121,Bevacizumab + Temsirolimus + Doxil,5290,21216929,,,
400,Clinical Study,"In a clinical study, the combination of Torisel (temsirolimus) plus Avastin (bevacizumab) and Doxil (pegylated liposomal-doxorubicin) resulted in a partial response in patients with advanced solid tumors harboring PIK3CA mutations (PMID: 21216929).",Actionable,3382,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,sensitive,1121,Bevacizumab + Temsirolimus + Doxil,5290,21216929,,,
401,Preclinical,"In a preclinical study, AZD5363 inhibited growth in breast cancer cell lines and xenograft models expressing PIK3CA mutations (PMID: 22294718). ",Actionable,2363,1612,breast cancer,DOID,429,PIK3CA mutant,sensitive,655,AZD5363,5290,22294718,,,
402,Preclinical - Cell line xenograft,"In a preclinical study, OSI-027 inhibited tumor growth in ovarian cancer cell line xenograft models harboring PIK3CA mutations (PMID: 21673091).",Actionable,2796,2394,ovarian cancer,DOID,429,PIK3CA mutant,sensitive,841,OSI-027,5290,21673091,,,
403,Preclinical,"In a preclinical study, PI-103 enhanced sensitivity to 5-FU in gastric cancer cells with mutant PIK3CA (PMID: 22336586).",Actionable,2820,3717,gastric adenocarcinoma,DOID,429,PIK3CA mutant,sensitive,3031,PI-103 + 5-FU,5290,22336586,,,
404,Preclinical - Cell line xenograft,"In a preclinical study, CUDC-907 inhibited PIK3CA, blocked downstream AKT pathway activation, and induced apoptosis and cell cycle arrest in both PIK3CA wild-type and PIK3CA mutant human cancer cell lines and xenograft models of multiple solid and hematologic cancers (PMID: 22693356).",Actionable,1311,2531,hematologic cancer,DOID,429,PIK3CA mutant,sensitive,709,CUDC-907,5290,22693356,,,
405,Phase II,"In a Phase II trial, Ipatasertib (GDC-0068) in combination with Abraxane (paclitaxel) resulted in improved progression free survival (6.2 vs 4.9 months) compared to placebo in triple-receptor negative breast cancer patients harboring mutations in PIK3CA, AKT1, or PTEN (J Clin Oncol 35, 2017 (suppl; abstr 1009)).",Actionable,11168,60081,triple-receptor negative breast cancer,DOID,429,PIK3CA mutant,predicted â€“ sensitive,1588,Ipatasertib + Paclitaxel,5290,None,,,
406,Preclinical - Cell line xenograft,"In a preclinical study, CUDC-907 inhibited PIK3CA, blocked downstream AKT pathway activation, and induced apoptosis and cell cycle arrest in both PIK3CA wild-type and PIK3CA mutant human cancer cell lines and xenograft models of multiple tumor types (PMID: 22693356).",Actionable,102,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,sensitive,709,CUDC-907,5290,22693356,,,
407,Preclinical,"In a preclinical study, AZD8835 inhibited growth of a variety of advanced solid tumor models with Pik3ca mutations in culture (PMID: 26839307).",Actionable,3753,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,sensitive,2013,AZD8835,5290,26839307,,,
408,Preclinical - Cell line xenograft,"In a preclinical study, GSK2334470 resensitized Alpelisib (BYL719)-resistant breast cancer cell lines harboring PIK3CA mutations to Alpelisib (BYL719) in culture and in cell line xenograft models (PMID: 27451907).",Actionable,7568,1612,breast cancer,DOID,429,PIK3CA mutant,sensitive,4519,Alpelisib + GSK2334470,5290,27451907,,,
409,Preclinical - Cell line xenograft,"In a preclinical study, OSI-027 induced tumor regression in breast cancer cell line xenograft models harboring PIK3CA mutations (PMID: 21673091).",Actionable,8734,1612,breast cancer,DOID,429,PIK3CA mutant,sensitive,841,OSI-027,5290,21673091,,,
410,Preclinical,"In a preclinical study, GDC-0941 inhibited growth and induced apoptosis in breast cancer cells expressing PIK3CA mutations (PMID: 24601221). ",Actionable,2369,1612,breast cancer,DOID,429,PIK3CA mutant,sensitive,749,GDC-0941,5290,24601221,,,
411,Preclinical,"In a preclinical study, MSC2363318A demonstrated anti-proliferative activity against many solid tumor cell lines with PI3K pathway genomic alterations, and inhibited tumor growth in several human cancer xenograft models of breast, pancreatic, glioblastoma and ovarian cancers (Mol Cancer Ther 2013;12(11 Suppl):A162).",Actionable,423,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,sensitive,1037,MSC2363318A,5290,None,,,
412,Preclinical - Cell line xenograft,"In a preclinical study, Acalisib (GS-9820) resulted in tumor growth inhibition in xenograft models of breast adenocarcinoma harboring a PIK3CA mutation (Mol Cancer Ther 2009;8(12 Suppl):B136).",Actionable,363,3458,breast adenocarcinoma,DOID,429,PIK3CA mutant,sensitive,1021,GS-9820,5290,None,,,
413,Preclinical - Cell culture,"In a preclinical study, Pictilisib (GDC-0941) and MS417 in combination resulted in improved growth inhibition and increased cell death compared to either agent alone in colorectal cancer cell lines harboring PIK3CA mutations in culture (PMID: 26058079).",Actionable,8598,9256,colorectal cancer,DOID,429,PIK3CA mutant,predicted â€“ sensitive,4774,GDC-0941 + MS417,5290,26058079,,,
414,Phase I,"In a Phase I clinical trial, XL147 (SAR24508) was shown to be safe and potentially efficacious, with clinical activity seen irrespective of tumor PI3K pathway molecular alterations (PMID: 24166903).",Actionable,1182,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,sensitive,1050,XL147,5290,24166903,,,
415,Preclinical,"In a preclinical study, tumor cell lines with PIK3CA mutations demonstrated sensitivity to XL147 in culture (PMID:     25637314).",Actionable,6300,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,sensitive,1050,XL147,5290,25637314,,,
416,Phase I,"In a Phase I trial, MLN1117 treatment resulted in partial response in 3 patients with breast cancer harboring PI3CA mutations (PMID: 28490463). ",Actionable,11831,1612,breast cancer,DOID,429,PIK3CA mutant,predicted â€“ sensitive,1033,MLN1117,5290,28490463,,,
417,Preclinical,"In a preclinical study, the combination of Buparlisib (BKM120) and Lynparza (olaparib) worked synergistically to induce apoptosis and inhibit growth of ovarian cancer cell lines harboring PIK3CA mutations, and induced apoptosis and decreased proliferation of PIK3CA-mutant ovarian cancer cells in xenograft models (PMID: 26909613).",Actionable,6930,2394,ovarian cancer,DOID,429,PIK3CA mutant,sensitive,2170,BKM120 + Olaparib,5290,26909613,,,
418,Preclinical,"In a preclinical study, BAY1082439 induced regression in xenograft models of advanced solid tumors with PIK3CA mutations (Cancer Res April 15, 2012 72; 2799). ",Actionable,2365,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,sensitive,666,BAY1082439,5290,None,,,
419,Phase II,"In a Phase II trial, Falsodex (fulvestrant) treatment resulted in similar progression free survival in ER positive breast cancer patients harboring PIK3CA mutations and those who were PIK3CA wild-type (PMID: 27174596).",Actionable,7078,60075,estrogen-receptor positive breast cancer,DOID,429,PIK3CA mutant,no benefit,744,Fulvestrant,5290,27174596,,,
420,Preclinical,"In a preclinical study, CH5132799 inhibited proliferation of endometrial cancer cells with PIK3CA mutations in culture (PMID: 21558396).",Actionable,2942,1380,endometrial cancer,DOID,429,PIK3CA mutant,sensitive,2152,CH5132799,5290,21558396,,,
421,Preclinical,"In a preclinical study, Ibrance (palbociclib) and Pictilisib (GDC-0941) worked synergistically to inhibit the survival of triple-receptor negative breast cancer cell lines harboring PIK3CA mutations in culture (PMID: 27020857).",Actionable,5859,60081,triple-receptor negative breast cancer,DOID,429,PIK3CA mutant,sensitive,3956,Palbociclib + GDC-0941,5290,27020857,,,
422,Clinical Study,"In a Phase I trial, MLN1117 treatment resulted in partial response in 3 patients with gastric cancer harboring PI3CA mutations (PMID: 28490463). ",Actionable,11832,10534,stomach cancer,DOID,429,PIK3CA mutant,predicted â€“ sensitive,1033,MLN1117,5290,28490463,,,
423,Preclinical,"In a preclinical study, CUDC-907 inhibited growth of human breast cancer cell lines harboring PIK3CA mutations in culture (PMID: 22693356).",Actionable,3014,1612,breast cancer,DOID,429,PIK3CA mutant,sensitive,709,CUDC-907,5290,22693356,,,
424,Preclinical,"In a preclinical study, cells expressing mutant PIK3CA demonstrated increased sensitivity to A-443654 compared to cells expressing wild-type PIK3CA (PMID: 19208828).",Actionable,2774,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,sensitive,2448,A-443654,5290,19208828,,,
425,Phase I,"In a Phase I trial, GSK2126458 was well-tolerated and resulted in some efficacy in patients with breast cancer harboring a PIK3CA mutation including stable disease in 22% (2/9), however, objective response rate was not associated with PIK3CA mutations when compared to those without PIK3CA mutations (PMID: 26603258).",Actionable,5828,1612,breast cancer,DOID,429,PIK3CA mutant,no benefit,763,GSK2126458,5290,26603258,,,
426,Preclinical,"In a preclinical study, PIK3CA mutant breast cancer cells showed increased sensitivity to VS-5584 compared to PIK3CA wild-type cells in culture (PMID: 23270925).",Actionable,93,1612,breast cancer,DOID,429,PIK3CA mutant,sensitive,960,VS-5584,5290,23270925,,,
427,Phase II,"In a Phase II trial, Falsodex (fulvestrant) and Pictilisib (GDC-0941) combination treatment resulted in similar progression free survival in ER positive breast cancer patients harboring PIK3CA mutations and those who were PIK3CA wild-type (PMID: 27174596).",Actionable,7077,60075,estrogen-receptor positive breast cancer,DOID,429,PIK3CA mutant,no benefit,4357,Fulvestrant + GDC-0941,5290,27174596,,,
428,Phase I,"In a Phase I trial, PX-866 demonstrated efficacy and was well tolerated in patients with advanced solid tumor with both PIK3CA wild-type and mutant status (PMID: 22693357).",Actionable,121,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,sensitive,881,PX-866,5290,22693357,,,
429,Preclinical,"In a preclinical study, AT-7867 inhibited proliferation in several human tumor cell lines harboring PIK3CA mutations in culture (PMID: 20423992).",Actionable,2792,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,sensitive,2447,AT-7867,5290,20423992,,,
430,Phase I,"In a Phase I trial, Apitolisib (GDC-0980) treatment resulted in partial response in 21% (3/14) and stable disease in 57% (8/14) of patients with advanced solid tumors harboring PIK3CA mutations (PMID: 26787751). ",Actionable,5207,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,sensitive,750,GDC-0980,5290,26787751,,,
431,Preclinical,"In a preclinical study, CH5132799 inhibited proliferation of prostate cancer cells with PIK3CA mutations in culture (PMID: 21558396).",Actionable,2941,10283,prostate cancer,DOID,429,PIK3CA mutant,sensitive,2152,CH5132799,5290,21558396,,,
432,Preclinical - Cell line xenograft,"In a preclinical study, CCT128930 induced growth arrest and inhibited tumor growth in a xenograft model of a ERBB2 (HER2)-positive human breast cancer cell line harboring a PIK3CA mutation (PMID: 21191045).",Actionable,998,60079,Her2-receptor positive breast cancer,DOID,429,PIK3CA mutant,sensitive,1445,CCT128930,5290,21191045,,,
433,Phase I,"In a Phase I trial, Taselisib (GDC-0032) demonstrated activity in patients with PIK3CA-mutant advanced solid tumors, in the absence of alterations in the MAPK or PTEN pathways (Cancer Res October 1, 2014 74:915).",Actionable,2853,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,sensitive,1016,GDC-0032,5290,None,,,
434,Preclinical,"In a preclinical study, AZD8835 inhibited proliferation of estrogen receptor (ER)-positive breast cancer cells harboring PIK3CA mutations in culture and suppressed tumor growth in xenograft models (PMID: 26839307).",Actionable,5111,60075,estrogen-receptor positive breast cancer,DOID,429,PIK3CA mutant,sensitive,2013,AZD8835,5290,26839307,,,
435,Preclinical - Cell culture,"In a preclinical study, triple-receptor negative breast cancer cell lines harboring PIK3CA mutations demonstrated increased sensitivity to Pictilisib (GDC-0941) in culture (PMID: 27196766).",Actionable,8343,60081,triple-receptor negative breast cancer,DOID,429,PIK3CA mutant,sensitive,749,GDC-0941,5290,27196766,,,
436,Phase II,"In a Phase II clinical trial, Erbitux (cetuximab) treatment, in addition to radiochemotherapy, did not result in any complete responses (0/8) and demonstrated a worse disease free survival when compared to radiochemotherapy alone in cervical cancer patients harboring PIK3CA mutations (PMID: 25724520).",Actionable,3874,4362,cervical cancer,DOID,429,PIK3CA mutant,decreased response,694,Cetuximab,5290,25724520,,,
437,Preclinical,"In a preclinical study, endometrioid endometrial cancer cell lines harboring PIK3CA mutations demonstrated increased sensitivity to GDC-0941 (Pictilisib) induced growth inhibition comparing to PIK3CA wild-type cells in culture (PMID: 23674493).",Actionable,4966,1380,endometrial cancer,DOID,429,PIK3CA mutant,sensitive,749,GDC-0941,5290,23674493,,,
438,Preclinical - Cell line xenograft,"In a preclinical study, PF-04691502 inhibited tumor growth in non-small cell lung cancer cell line xenograft models harboring PIK3CA mutations (PMID: 21750219).",Actionable,8387,3908,non-small cell lung carcinoma,DOID,429,PIK3CA mutant,sensitive,865,PF-04691502,5290,21750219,,,
439,Preclinical,"In a preclinical study, BEZ235 demonstrated efficacy in promoting apoptosis of gastric cancer cells harboring a PIK3CA mutation in culture (PMID: 22543857).",Actionable,4391,10534,stomach cancer,DOID,429,PIK3CA mutant,sensitive,672,BEZ235,5290,22543857,,,
440,Preclinical,"In a preclinical study, BEZ235 demonstrated efficacy in promoting apoptosis of colon cancer cells harboring a PIK3CA mutation in culture  (PMID: 22543857).",Actionable,628,219,colon cancer,DOID,429,PIK3CA mutant,sensitive,672,BEZ235,5290,22543857,,,
441,Phase I,"In a Phase I trial, MLN1117 demonstrated safety and preliminary efficacy in a variety of patients with advanced solid tumors carrying PIK3CA mutations (Journal of Clinical Oncology, 2015 ASCO Annual Meeting Vol 33, No 15_suppl., 2015: 2501).",Actionable,2793,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,sensitive,1033,MLN1117,5290,None,,,
442,Preclinical,"In a preclinical study, MLN1117 inhibited proliferation of tumor cells harboring oncogenic PIK3CA mutations in culture and inhibited tumor growth in PIK3CA mutant xenograft models (Cancer Ther 2011;10(11 Suppl):Abstract nr A171).",Actionable,1674,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,sensitive,1033,MLN1117,5290,None,,,
443,Phase II,"In a retrospective study of a Phase II trial, mutation status of PIK3CA was not associated with progression-free survival or response rate in advanced endometrial cancer patients treated with Torisel (temsirolimus) (PMID: 27016228).",Actionable,6403,1380,endometrial cancer,DOID,429,PIK3CA mutant,no benefit,936,Temsirolimus,5290,27016228,,,
444,Preclinical - Cell line xenograft,"In a preclinical study, PIK3CA mutations were associated with sensitivity to Alpelisib (BYL719) in human tumor cell lines in culture and in xenograft models (PMID: 24608574). ",Actionable,4493,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,sensitive,691,BYL719,5290,24608574,,,
445,Phase I,"In a Phase I trial, Alpelisib (BYL719) demonstrated safety and preliminary efficacy in advanced solid tumor patients with PIK3CA genetic alterations (Cancer Res 2012;72(8 Suppl):Abstract nr CT-01. doi:1538-7445.AM2012-CT-01).",Actionable,1668,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,sensitive,691,BYL719,5290,None,,,
446,Preclinical,"In a preclinical study, human cancer cell lines harboring PIK3CA mutations were sensitive to Sapanisertib (MLN0128) as demonstrated by significant growth inhibition (PMID: 25261369). ",Actionable,2066,10000003,Advanced Solid Tumor,JAX,429,PIK3CA mutant,sensitive,1282,Sapanisertib,5290,25261369,,,
447,Preclinical,"In a preclinical study, PWT33597 decreased signaling of mTOR and PIK3 pathways in colon cancer cells with Pik3ca mutations (Cancer Res 2011;71(8 Suppl):Abstract nr 4485).",Actionable,2745,219,colon cancer,DOID,429,PIK3CA mutant,sensitive,880,PWT33597,5290,None,,,
448,Preclinical - Cell culture,"In a preclinical study, an estrogen-receptor positive breast cancer cell line over expressing FGFR1 and expressing a PIK3CA mutation demonstrated sensitivity to the combination of Alpelisib (BYL719) and Lucitanib (E-3810) in culture (PMID: 27126994). ",Actionable,9709,60075,estrogen-receptor positive breast cancer,DOID,26996,FGFR1 over exp PIK3CA mut,sensitive,5164,Alpelisib + Lucitanib,5290,27126994,,,
449,Preclinical - Cell line xenograft,"In a preclinical study, AT13148 inhibited tumor growth in a ERBB2 (HER2)-positive human breast cancer cell line xenograft model harboring mutant PIK3CA (PMID: 22781553).",Actionable,4784,60079,Her2-receptor positive breast cancer,DOID,25947,ERBB2 pos PIK3CA mut,sensitive,3653,AT13148,5290,22781553,,,
450,Clinical Study,"In a clinical study, a retrospective analysis of Tykerb (lapatinib) treatment in ERBB2 (HER2) positive breast cancer patients demonstrated patients harboring a PIK3CA mutation trended towards a decreased response when compared to patients with wild-type PIK3CA (PMID: 27687302). ",Actionable,9163,60079,Her2-receptor positive breast cancer,DOID,25947,ERBB2 pos PIK3CA mut,decreased response,787,Lapatinib,5290,27687302,,,
451,Clinical Study,"In a clinical study, a retrospective analysis of Herceptin (trastuzumab) treatment in ERBB2 (HER2) positive breast cancer patients demonstrated patients harboring a PIK3CA mutation trended towards a decreased response when compared to patients with wild-type PIK3CA (PMID: 27687302). ",Actionable,9164,60079,Her2-receptor positive breast cancer,DOID,25947,ERBB2 pos PIK3CA mut,decreased response,947,Trastuzumab,5290,27687302,,,
452,Phase III,"In a Phase III trial, Tykerb (lapatinib) and Xeloda (capecitabine) combination treatment resulted in decreased median progression free survival (4.3 vs. 6.4 months), median overall survival (17.3 vs. 27.8 months), and overall response rate(17.1% vs. 39.7%) in ERBB2 (HER2) positive breast cancer patients harboring PIK3CA mutations compared to PIK3CA wild type patients (PMID: 26920887). ",Actionable,7744,60079,Her2-receptor positive breast cancer,DOID,25947,ERBB2 pos PIK3CA mut,decreased response,1399,Lapatinib + Capecitabine,5290,26920887,,,
453,Preclinical - Cell line xenograft,"In a preclinical study, a colorectal cancer cell line xenograft model co-harboring BRAF V600E and a PIK3CA mutation demonstrated tumor growth inhibition when treated with ASN003 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B100).",Actionable,11042,9256,colorectal cancer,DOID,27895,BRAF V600E PIK3CA mut,sensitive,5827,ASN003,5290,None,,,
454,Preclinical - Cell line xenograft,"In a preclinical study, a breast cancer xenograft model with ERBB2 (HER2) over expression and harboring a PIK3CA mutation was sensitive to the combination treatment of ARQ092 and Taxol (paclitaxel), demonstrating greater inhibition of tumor growth when compared to treatment with either agent alone (PMID: 26469692). ",Actionable,10287,1612,breast cancer,DOID,26179,ERBB2 over exp PIK3CA mut,sensitive,5455,ARQ092 + Paclitaxel,5290,26469692,,,
455,Preclinical - Cell line xenograft,"In a preclinical study, PKI-179 inhibited growth of breast cancer cells harboring PIK3CA mutations and ERBB2 (HER2) over expression in culture and cell line xenograft models (PMID: 20797855).",Actionable,2737,60079,Her2-receptor positive breast cancer,DOID,26179,ERBB2 over exp PIK3CA mut,sensitive,872,PKI-179,5290,20797855,,,
456,Preclinical - Cell line xenograft,"In a preclinical study, a breast cancer xenograft model with ERBB2 (HER2) over expression and harboring a PIK3CA mutation was sensitive to the combination treatment of ARQ092 and Herceptin (trastuzumab), demonstrating greater inhibition of tumor growth when compared to treatment with either agent alone (PMID: 26469692). ",Actionable,10286,1612,breast cancer,DOID,26179,ERBB2 over exp PIK3CA mut,sensitive,5454,ARQ092 + Trastuzumab,5290,26469692,,,
457,Preclinical - Pdx,"In a preclinical study, AZD6482 and Alpelisib (BYL719) combination treatment inhibited Akt signaling and growth in a breast cancer patient-derived xenograft (PDX) model harboring a PIK3CA mutation and PTEN loss (Cancer Res October 1, 2014 74; LB-327).",Actionable,4990,1612,breast cancer,DOID,19846,PIK3CA mutant PTEN loss,sensitive,3714,AZD6482 + BYL719,5290,None,,,
458,Preclinical - Cell culture,"In a preclinical study, PKI-179 inhibited growth of prostate cancer cells harboring PIK3CA mutations and PTEN loss in culture (PMID: 20797855).",Actionable,8146,10283,prostate cancer,DOID,19846,PIK3CA mutant PTEN loss,sensitive,872,PKI-179,5290,20797855,,,
459,Clinical Study,"In a case study, a breast cancer patient harboring a PIK3CA mutation developed resistance to Alpelisib (BYL719) treatment and progressive disease after initial response, accompanied by a loss of PTEN (Cancer Res October 1, 2014 74; LB-327).",Actionable,4983,1612,breast cancer,DOID,19846,PIK3CA mutant PTEN loss,resistant,691,BYL719,5290,None,,,
460,Preclinical - Pdx,"In a preclinical study, a breast cancer patient-derived xenograft (PDX) model harboring a PIK3CA mutation and PTEN loss was resistant to Alpelisib (BYL719)-induced inhibition of Akt signaling and growth (Cancer Res October 1, 2014 74; LB-327).",Actionable,4988,1612,breast cancer,DOID,19846,PIK3CA mutant PTEN loss,resistant,691,BYL719,5290,None,,,
461,Preclinical - Pdx,"In a preclinical study, Buparlisib (BKM120) inhibited Akt signaling and growth in a PDX model of breast cancer cells harboring a PIK3CA mutation and PTEN loss ( Cancer Res October 1, 2014 74; LB-327 ).",Actionable,4989,1612,breast cancer,DOID,19846,PIK3CA mutant PTEN loss,sensitive,680,BKM120,5290,None,,,
462,Preclinical - Cell culture,"In a preclinical study, some head and neck squamous cell carcinoma cell lines over expressing PIK3CA demonstrated sensitivity to treatment with Gedatolisib (PF-05212384) (PMID: 25977343). ",Actionable,8241,5520,head and neck squamous cell carcinoma,DOID,20299,PIK3CA over exp,sensitive,1040,PF-05212384,5290,25977343,,,
463,Preclinical - Cell line xenograft,"In a preclinical study, Alpelisib (BYL719) induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing wild-type PIK3CA in culture, and inhibited tumor growth in cell line xenograft models (PMID: 26013318).",Actionable,7975,3907,lung squamous cell carcinoma,DOID,20299,PIK3CA over exp,sensitive,691,BYL719,5290,26013318,,,
464,Preclinical - Cell culture,"In a preclinical study, BEZ235 induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing wild-type Pik3ca in culture (PMID: 26013318).",Actionable,7970,3907,lung squamous cell carcinoma,DOID,20299,PIK3CA over exp,sensitive,672,BEZ235,5290,26013318,,,
465,Preclinical - Cell culture,"In a preclinical study, Buparlisib (BKM120) induced apoptosis, inhibited cell proliferation, migration, and invasion of lung squamous cell carcinoma cells over expressing wild-type Pik3ca in culture (PMID: 26013318).",Actionable,7967,3907,lung squamous cell carcinoma,DOID,20299,PIK3CA over exp,sensitive,680,BKM120,5290,26013318,,,
466,Preclinical,"In a preclinical study, YM-024 inhibited proliferation and anchorage-independent growth of glioblastoma cell lines with elevated Pik3ca protein level in culture (PMID: 24718026).",Actionable,5182,3068,glioblastoma multiforme,DOID,20299,PIK3CA over exp,sensitive,2967,YM-024,5290,24718026,,,
467,Phase II,"In a retrospective analysis from a Phase II clinical trial, patients with metastatic renal cell carcinoma treated with Apitolisib (GDC-0980) had no difference in progression free survival when stratified by the presence (n=21) or absence (n=15) of PIK3CA activating mutation or loss of Pten expression (PMID: 26951309).",Actionable,5734,4450,renal cell carcinoma,DOID,21542,PIK3CA act mut PTEN dec exp,no benefit,750,GDC-0980,5290,26951309,,,
468,Phase II,"In a retrospective analysis from a Phase II clinical trial, patients with metastatic renal cell carcinoma treated with Afinitor (everolimus) had no difference in progression free survival when stratified by the presence (n=21) or absence (n=17) of PIK3CA activating mutations (PMID: 26951309).",Actionable,5739,4450,renal cell carcinoma,DOID,21542,PIK3CA act mut PTEN dec exp,no benefit,735,Everolimus,5290,26951309,,,
469,Preclinical - Cell culture,"In a preclinical study, 9/9 breast cancer cell lines harboring a PIK3CA activating mutation and PTEN wild-type demonstrated sensitivity to treatment with Torkinib (PP242) in culture, resulting in decreased cell viability (PMID: 21358673). ",Actionable,10366,1612,breast cancer,DOID,27384,PIK3CA act mut PTEN wild-type,sensitive,2240,Torkinib,5290,21358673,,,
470,Preclinical - Cell culture,"In a preclinical study, 8/9 breast cancer cell lines harboring a PIK3CA activating mutation and PTEN wild-type demonstrated sensitivity to treatment with Afinitor (everolimus) in culture, resulting in decreased cell viability (PMID: 21358673). ",Actionable,10365,1612,breast cancer,DOID,27384,PIK3CA act mut PTEN wild-type,sensitive,735,Everolimus,5290,21358673,,,
471,Preclinical,"In a preclinical study, Taselisib (GDC-0032) inhibited growth of HER2 positive uterine cancer cell lines with PIK3CA mutations (PMID: 25172762).",Actionable,2850,363,uterine cancer,DOID,1409,ERBB2 pos PIK3CA act mut,sensitive,1016,GDC-0032,5290,25172762,,,
472,Phase I,"In a Phase I trial, the combination of Buparlisib (BKM120) and Herceptin (trastuzumab) was well tolerated and resulted in some preliminary efficacy in patients with ERBB2 (HER2)-positive breast cancer harboring PIK3CA activating mutations and/or PTEN mutations that had progressed on trastuzumab-based therapy (PMID: 24470511).",Actionable,286,60079,Her2-receptor positive breast cancer,DOID,1409,ERBB2 pos PIK3CA act mut,predicted â€“ sensitive,1417,BKM120 + Trastuzumab,5290,24470511,,,
473,Preclinical,"In a preclinical study, Ibrance (palbociclib) and Pictilisib (GDC-0941) worked synergistically to inhibit survival of ERBB2 (HER2)-positive breast cancer cell lines harboring PIK3CA mutations in culture (PMID: 27020857).",Actionable,5857,60079,Her2-receptor positive breast cancer,DOID,1409,ERBB2 pos PIK3CA act mut,sensitive,3956,Palbociclib + GDC-0941,5290,27020857,,,
474,Clinical Study,"In a clinical study, ERBB2 (HER2)-positive breast cancer patients with PI3K pathway activation resulting from low PTEN expression and/or PIK3CA activating mutations demonstrated decreased progression-free survival following treatment with Herceptin (trastuzumab) compared to patients without PI3K pathway activation (PMID: 17936563).",Actionable,6664,60079,Her2-receptor positive breast cancer,DOID,1409,ERBB2 pos PIK3CA act mut,decreased response,947,Trastuzumab,5290,17936563,,,
475,Clinical Study,"In a retrospective analysis, ERBB2 (HER2)-positive breast cancer patients with PI3K pathway activation due to PTEN loss and/or PIK3CA activating mutation demonstrated a decreased median progression-free survival of 4.5 months, compared to 9.0 months for patients without PI3K pathway activation following treatment with a Herceptin (trastuzumab) containing regimen (PMID: 21676217).",Actionable,875,60079,Her2-receptor positive breast cancer,DOID,1409,ERBB2 pos PIK3CA act mut,decreased response,947,Trastuzumab,5290,21676217,,,
476,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Navitoclax (ABT-263) and GDC-0941 resulted in increased tumor growth delay and apoptosis in a small cell lung cancer cell line xenograft model harboring a PIK3CA activating mutation compared to either drug alone (PMID: 27197306).",Actionable,7301,5409,lung small cell carcinoma,DOID,743,PIK3CA act mut,predicted â€“ sensitive,4446,GDC-0941 + Navitoclax,5290,27197306,,,
477,Preclinical - Cell culture,"In a preclinical study, inhibition of Pi3k signaling by BEZ235 sensitized breast cancer cell lines harboring PIK3CA activating mutations to WEHI-539 in culture (PMID: 27974663).",Actionable,10084,1612,breast cancer,DOID,743,PIK3CA act mut,predicted â€“ sensitive,5377,BEZ235 + WEHI-539,5290,27974663,,,
478,Preclinical,"In a preclinical study, BAY1125976 demonstrated anti-tumor efficacy in multiple xenograft tumor models of different cancers with PIK3CA mutations or PTEN deletions and displayed synergy with other anti-cancer therapies (Cancer Res 2013;73(8 Suppl):Abstract nr 2050).",Actionable,1346,10000003,Advanced Solid Tumor,JAX,743,PIK3CA act mut,sensitive,994,BAY1125976,5290,None,,,
479,Preclinical - Cell culture,"In a preclinical study, the combination of AZD5363 and 4-hydroxytamoxifen (4-OHT) worked synergistically or additively to inhibit growth of several estrogen receptor-positive breast cancer cell lines in culture, including cell lines with PIK3CA activating mutations, and overcame tamoxifen resistance in a resistant cell line (PMID: 26116361).",Actionable,7397,60075,estrogen-receptor positive breast cancer,DOID,743,PIK3CA act mut,predicted â€“ sensitive,4489,AZD5363 + Tamoxifen,5290,26116361,,,
480,Preclinical - Cell culture,"In a preclinical study, inhibition of Pi3k signaling by BEZ235 did not sensitize breast cancer cell lines harboring PIK3CA activating mutations to Venclexta (venetoclax) in culture (PMID: 27974663).",Actionable,10081,1612,breast cancer,DOID,743,PIK3CA act mut,no benefit,5376,BEZ235 + Venetoclax,5290,27974663,,,
481,Phase I,"In a Phase I clinical trial, Ridaforolimus in combination with MK-2206 demonstrated clinical activity in breast cancer patients expressing a PI3K pathway dependent gene expression signature, with complete response in 14.3% (2/14), partial response in 12.5% (2/16), and 2 patients achieving stable disease (PMID: 26187616).",Actionable,4294,1612,breast cancer,DOID,743,PIK3CA act mut,predicted â€“ sensitive,3478,Ridaforolimus + MK2206,5290,26187616,,,
482,Preclinical - Pdx,"In a preclinical study, two head and neck squamous cell carcinoma patient-derived xenograft (PDX) models harboring a PIK3CA activating mutation demonstrated greater delayed tumor growth when treated with a combination of AZD8055 and Erbitux (cetuximab) compared to either agent alone (PMID: 28446642). ",Actionable,11512,5520,head and neck squamous cell carcinoma,DOID,743,PIK3CA act mut,predicted â€“ sensitive,6008,AZD8055 + Cetuximab,5290,28446642,,,
483,Preclinical - Cell line xenograft,"In preclinical studies, Taselisib (GDC-0032) effectively suppressed growth of multiple tumor types in a cell line xenograft models, with greater selectivity for PIK3CA activating mutants (PMID: 23662903).",Actionable,350,10000003,Advanced Solid Tumor,JAX,743,PIK3CA act mut,sensitive,1016,GDC-0032,5290,23662903,,,
484,Preclinical,"In a preclinical study, various tumor cell lines harboring PI3KCA activating mutations demonstrated increased sensitivity to Afuresertib (GSK2110183) in cultured cells (PMID: 24978597).",Actionable,1399,10000003,Advanced Solid Tumor,JAX,743,PIK3CA act mut,sensitive,625,Afuresertib,5290,24978597,,,
485,Preclinical - Cell line xenograft,"In a preclinical study, PF-4989216 inhibited proliferation of small cell lung carcinoma cell lines harboring activating PIK3CA mutations in culture, and suppressed tumor growth in cell line xenograft models (PMID: 24240111).",Actionable,5213,5409,lung small cell carcinoma,DOID,743,PIK3CA act mut,sensitive,867,PF-4989216,5290,24240111,,,
486,Preclinical - Cell culture,"In a preclinical study, the ATPâ€“competitive mTORC1/2 inhibitor Sapanisertib (MLN0128) sensitized breast cancer cell lines harboring PIK3CA activating mutations to WEHI-539 in culture (PMID: 27974663).",Actionable,10095,1612,breast cancer,DOID,743,PIK3CA act mut,predicted â€“ sensitive,5386,MLN0128 + WEHI-539,5290,27974663,,,
487,Preclinical - Cell line xenograft,"In preclinical studies, the PI3K inhibitor GDC-0941 demonstrated efficacy against NSCLC tumor cell lines in culture and in xenograft models harboring alterations in the PI3K pathway (PMID: 23136191).",Actionable,103,3908,non-small cell lung carcinoma,DOID,743,PIK3CA act mut,sensitive,749,GDC-0941,5290,23136191,,,
488,Preclinical - Cell culture,"In a preclinical study, the ATPâ€“competitive mTORC1/2 inhibitor Vistusertib (AZD2014) sensitized breast cancer cell lines harboring PIK3CA activating mutations to WEHI-539 in culture (PMID: 27974663).",Actionable,10096,1612,breast cancer,DOID,743,PIK3CA act mut,predicted â€“ sensitive,5385,Vistusertib + WEHI-539,5290,27974663,,,
489,Preclinical - Cell culture,"In a preclinical study, Buparlisib (BKM120) did not sensitize breast cancer cell lines harboring PIK3CA activating mutations to WEHI-539 in culture (PMID: 27974663).",Actionable,10092,1612,breast cancer,DOID,743,PIK3CA act mut,no benefit,5382,BKM120 + WEHI-539,5290,27974663,,,
490,Preclinical,"In a preclinical study, PF-05212384 decreased viability of head and neck squamous carcinoma cells harboring a PIK3CA activating mutation in cell culture (PMID: 24823695).",Actionable,1405,5520,head and neck squamous cell carcinoma,DOID,743,PIK3CA act mut,sensitive,1040,PF-05212384,5290,24823695,,,
491,Phase I,"In a Phase I trial, triple-receptor negative breast cancer patients, including those with PIK3CA activating mutations, demonstrated an overall response rate of 21% (11/52) and clinical benefit rate of 40% (21/52) when treated with a combination of Avastin (bevacizumab), Adriamycin (doxorubicin), and either Afinitor (everolimus) or Torisel (temsirolimus) (PMID: 27893038). ",Actionable,10651,60081,triple-receptor negative breast cancer,DOID,743,PIK3CA act mut,predicted â€“ sensitive,5569,Bevacizumab + Doxorubicin + Everolimus,5290,27893038,,,
492,Phase I,"In a Phase I trial, triple-receptor negative breast cancer patients, including those with PIK3CA activating mutations, demonstrated an overall response rate of 21% (11/52) and clinical benefit rate of 40% (21/52) when treated with a combination of Avastin (bevacizumab), Adriamycin (doxorubicin), and either Afinitor (everolimus) or Torisel (temsirolimus) (PMID: 27893038). ",Actionable,10656,60081,triple-receptor negative breast cancer,DOID,743,PIK3CA act mut,predicted â€“ sensitive,5570,Bevacizumab + Doxorubicin + Temsirolimus,5290,27893038,,,
493,Preclinical,"In a preclinical study, solid tumor cell lines harboring PIK3CA activating mutations demonstrated increased sensitivity to GSK1059615 in culture (Clin Cancer Res October 1, 2008 14; B37).",Actionable,5209,10000003,Advanced Solid Tumor,JAX,743,PIK3CA act mut,sensitive,2248,GSK1059615,5290,None,,,
494,Preclinical,"In a preclinical study, BEZ235 demonstrated efficacy in mouse xenograft models of ovarian clear cell adenocarcinoma with PIK3CA mutations (PMID: 24927217). ",Actionable,1653,5304,ovarian clear cell adenocarcinoma,DOID,743,PIK3CA act mut,sensitive,672,BEZ235,5290,24927217,,,
495,Preclinical,"In a preclinical study, Glucophage (metformin) demonstrated efficacy in treating dietary restriction-resistant human xenograft tumors harboring a PIK3CA-activating mutation (PMID: 23986086).",Actionable,1371,10000003,Advanced Solid Tumor,JAX,743,PIK3CA act mut,sensitive,1031,Metformin,5290,23986086,,,
496,Preclinical - Cell line xenograft,"In a preclinical study, Afinitor (everolimus) demonstrated efficacy in multiple cancer cell lines in culture and xenograft models with PIK3CA activating mutations (PMID: 20664172).",Actionable,1356,10000003,Advanced Solid Tumor,JAX,743,PIK3CA act mut,sensitive,735,Everolimus,5290,20664172,,,
497,Preclinical - Cell culture,"In a preclinical study, Alpelisib (BYL719) did not sensitize breast cancer cell lines harboring PIK3CA activating mutations to WEHI-539 in culture (PMID: 27974663).",Actionable,10093,1612,breast cancer,DOID,743,PIK3CA act mut,no benefit,5383,Alpelisib + WEHI-539,5290,27974663,,,
498,Preclinical,"In a preclinical study, breast cancer cell lines with a PIK3CA activating mutation and/or ERBB2 (HER2) over expression demonstrated increased sensitivity to inhibition of proliferation by Aliqopa (copanlisib) in culture, compared to ERBB2 (HER2)-negative and wild-type PIK3CA cell lines (PMID: 24170767).",Actionable,550,1612,breast cancer,DOID,743,PIK3CA act mut,sensitive,995,Copanlisib,5290,24170767,,,
499,Phase Ib/II,"In a Phase Ib trial, Ipatasertib (GDC-0068) in combination with Abraxane (paclitaxel) demonstrated safety and anti-tumor activity in patients with advanced solid tumors, including patients with PIK3CA activating mutations (Annals of Oncology (2014) 25 (suppl_4): iv146-iv164. 10.1093/annonc/mdu331).",Actionable,1398,10000003,Advanced Solid Tumor,JAX,743,PIK3CA act mut,sensitive,1588,Ipatasertib + Paclitaxel,5290,None,,,
500,Preclinical - Cell culture,"In a preclinical study, the ATPâ€“competitive mTORC1/2 inhibitor Torin1 sensitized breast cancer cell lines harboring PIK3CA activating mutations to WEHI-539 in culture (PMID: 27974663).",Actionable,10094,1612,breast cancer,DOID,743,PIK3CA act mut,predicted â€“ sensitive,5384,Torin 1 + WEHI-539,5290,27974663,,,
501,Preclinical,"In a preclinical study, breast cancer cell lines harboring activating mutations in PIK3CA had increased sensitivity to MK2206 in cell culture (PMID: 22932669).",Actionable,1403,1612,breast cancer,DOID,743,PIK3CA act mut,sensitive,816,MK2206,5290,22932669,,,
502,Preclinical,"In a preclinical study, breast cancer cells with mutations in both ERBB2 (HER2) and PIK3CA were more sensitive to VS-5584 (PMID: 23270925). ",Actionable,2894,1612,breast cancer,DOID,10726,PIK3CA act mut ERBB2 act mut,sensitive,960,VS-5584,5290,23270925,,,
503,Preclinical,"In a preclinical study, CH5132799 inhibited proliferation of an endometrial cancer cell line harboring PIK3CA R38C and PTEN loss in culture (PMID: 21558396).",Actionable,2955,1380,endometrial cancer,DOID,10741,PIK3CA R38C  PTEN loss,sensitive,2152,CH5132799,5290,21558396,,,
504,Preclinical,"In a preclinical study, BEZ235 decreased growth of endometrial cancer cells harboring PIK3CA R38C and PTEN mutations in culture and in xenograft models (PMID: 22662154).",Actionable,2112,1380,endometrial cancer,DOID,5397,PIK3CA R38C PTEN mut,sensitive,672,BEZ235,5290,22662154,,,
505,Preclinical - Pdx,"In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib)  combination treatment resulted in partial tumor regression in PDX models of colorectal cancer cells harboring KRAS G12D and PIK3CA Q546L (PMID: 26369631).",Actionable,5619,9256,colorectal cancer,DOID,21301,KRAS G12D PIK3CA Q546L,sensitive,1368,Palbociclib + Trametinib,5290,26369631,,,
0,Clinical Study,"In a clinical study, a melanoma patient harboring a BRAF V600 mutation and PTEN H93D treated with Zelboraf (vemurafenib) for 66 weeks demonstrated a partial response (PMID: 24265153).",Actionable,7083,1909,melanoma,DOID,24401,BRAF V600X PTEN H93D,sensitive,342,Vemurafenib,5728,24265153,,,
1,Preclinical,"In a preclincal study, mucinous ovarian carcinoma cell lines over-expressing PTEN G129R were less sensitive to KX2-391 induced growth inhibition in culture and tumor suppression in xenograft models (PMID: 24100628).",Actionable,5908,6067,ovarian mucinous neoplasm,DOID,4015,PTEN G129R,decreased response,786,KX2-391,5728,24100628,,,
2,Preclinical - Cell culture,"In a preclinical study, expression of AKT1 Q79K in a wild-type PTEN-expressing BRAF V600-mutant melanoma cell line conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 24265152).",Actionable,8106,1909,melanoma,DOID,26173,AKT1 Q79K BRAF V600X PTEN pos,resistant,342,Vemurafenib,5728,24265152,,,
3,Preclinical - Cell culture,"In a preclinical study, the combination of MK2206 and Zelboraf (vemurafenib) inhibited AKT activation and growth of PTEN-expressing BRAF V600-mutant melanoma cells expressing AKT1 Q79K in culture, with increased efficacy over either agent alone (PMID: 24265152).",Actionable,8125,1909,melanoma,DOID,26173,AKT1 Q79K BRAF V600X PTEN pos,sensitive,4635,MK2206 + Vemurafenib,5728,24265152,,,
4,Preclinical - Cell culture,"In a preclinical study, expression of AKT1 E17K in a wild-type PTEN-expressing BRAF V600-mutant melanoma cell line conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 24265152).",Actionable,8103,1909,melanoma,DOID,26172,AKT1 E17K BRAF V600X PTEN pos,resistant,342,Vemurafenib,5728,24265152,,,
5,Preclinical - Cell line xenograft,"In a preclinical study, Glucophage (metformin) inhibited cell proliferation and induced apoptosis in a PTEN-expressing human endometrial cancer cell line harboring KRAS G12D in culture and decreased tumor growth in xenograft models (PMID: 24077915).",Actionable,590,1380,endometrial cancer,DOID,26548,PTEN pos KRAS G12D,sensitive,1031,Metformin,5728,24077915,,,
6,Clinical Study,"In a clinical study, melanoma patients with PTEN positive tumors demonstrated a decrease in tumor size when treated with Keytruda (pembrolizumab) (PMID: 26645196). ",Actionable,4451,1909,melanoma,DOID,18161,PTEN positive,sensitive,1447,Pembrolizumab,5728,26645196,,,
7,Clinical Study,"In a clinical study, melanoma patients with PTEN positive tumors demonstrated a decrease in tumor size when treated with Opdivo (nivolumab) (PMID: 26645196). ",Actionable,4452,1909,melanoma,DOID,18161,PTEN positive,sensitive,1312,Nivolumab,5728,26645196,,,
8,Preclinical,"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human breast cancer cells harboring PTEN A72fs*5 in culture (PMID: 21325073, PMID: 17314276).",Actionable,3126,1612,breast cancer,DOID,11789,PTEN A72fs*5,sensitive,1040,PF-05212384,5728,21325073,17314276,,
9,Preclinical - Cell culture,"In a preclinical study, DHM25 increased cell death in a triple-negative breast cancer cell line harboring PTEN A72fs*5 in culture (PMID: 26237138).",Actionable,10360,60081,triple-receptor negative breast cancer,DOID,11789,PTEN A72fs*5,sensitive,5494,DHM25,5728,26237138,,,
10,Preclinical - Cell culture,"In a preclinical study, lack of PTEN expression was associated with increased sensitivity to GSK2141795 in BRAF V600-mutant melanoma cell lines in culture (PMID: 24265152).",Actionable,8168,1909,melanoma,DOID,26183,BRAF V600X PTEN neg,sensitive,764,GSK2141795,5728,24265152,,,
11,Phase II,"In a Phase II trial, one patient with Pten negative squamous NSCLC had a partial response to Buparlisib (BKM120) however, stage 2 of the study was not initiated due to failure of meeting overall stage 1 response endpoints (PMID: 26098748).",Actionable,9816,3907,lung squamous cell carcinoma,DOID,2077,PTEN negative,sensitive,680,BKM120,5728,26098748,,,
12,Phase II,"In a Phase II trial, Caprelsa (vandetinib), in combination with radiation therapy and Temodar (temozolomide), demonstrated no difference in PFS and OS when compared between glioblastoma patients negative for PTEN versus those positive for PTEN (PMID: 25910950). ",Actionable,3240,3068,glioblastoma multiforme,DOID,2077,PTEN negative,no benefit,3094,Vandetanib + Temozolomide,5728,25910950,,,
13,Preclinical,"In a preclinical study, PTEN deficient cancer cell lines with DNA repair deficiency demonstrated high sensitivity to the PARP inhibitor, BMN673 (PMID: 23881923). ",Actionable,1180,10000003,Advanced Solid Tumor,JAX,2077,PTEN negative,sensitive,682,Talazoparib,5728,23881923,,,
14,Clinical Study,"In a clinical study, a melanoma patient harboring PTEN Y86fs and BRAF V600X developed the resistance mutation, PIK3CA H1047R, after treatment with Zelboraf (vemurafenib) (PMID: 24265153). ",Actionable,7082,1909,melanoma,DOID,24398,BRAF V600X PIK3CA H1047R PTEN Y86fs,resistant,342,Vemurafenib,5728,24265153,,,
15,Phase II,"In a Phase II trial, Ipatasertib (GDC-0068) in combination with Abraxane (paclitaxel) resulted in improved progression free survival (6.2 vs 4.9 months) compared to placebo in triple-receptor negative breast cancer patients with low Pten expression (J Clin Oncol 35, 2017 (suppl; abstr 1009)).",Actionable,11167,60081,triple-receptor negative breast cancer,DOID,13314,PTEN dec exp,predicted â€“ sensitive,1588,Ipatasertib + Paclitaxel,5728,None,,,
16,Phase II,"In a retrospective analysis from a Phase II clinical trial, patients with metastatic renal cell carcinoma treated with Afinitor (everolimus) had no difference in progression free survival when stratified by high expression (n=17) and low expression (n=21) of Pten (PMID: 26951309).",Actionable,5738,4450,renal cell carcinoma,DOID,13314,PTEN dec exp,no benefit,735,Everolimus,5728,26951309,,,
17,Phase Ib/II,"In a Phase I/II trial, GSK2636771 treatment inhibited Akt signaling, and resulted in partial response in 2% (1/53) and stable disease in 25% (13/53) of patients with PTEN-deficient advanced solid tumors (J Clin Oncol 32:5s, 2014 (suppl; abstr 2514)).",Actionable,4965,10000003,Advanced Solid Tumor,JAX,13314,PTEN dec exp,sensitive,765,GSK2636771,5728,None,,,
18,Preclinical - Cell line xenograft,"In a preclinical study, SAR260301 inhibited tumor growth in xenograft models of melanoma cell lines harboring PTEN deficiency (PMID: 24387221).",Actionable,4960,1909,melanoma,DOID,13314,PTEN dec exp,sensitive,1052,SAR260301,5728,24387221,,,
19,Phase I,"In a Phase I clinical trial, low Pten expression or lack of Pten expression was associated with better response to treatment with the combination of Alimta (pemetrexed) and Nexavar (sorafenib) in patients with advanced solid tumors (PMID: 27213589).",Actionable,7308,10000003,Advanced Solid Tumor,JAX,13314,PTEN dec exp,predicted â€“ sensitive,1482,Pemetrexed + Sorafenib,5728,27213589,,,
20,Phase II,"In a retrospective analysis from a Phase II clinical trial, patients with metastatic renal cell carcinoma treated with Apitolisib (GDC-0980) had no difference in progression free survival when stratified by high expression (n=17) and low expression (n=19) of Pten (PMID: 26951309).",Actionable,5733,4450,renal cell carcinoma,DOID,13314,PTEN dec exp,no benefit,750,GDC-0980,5728,26951309,,,
21,Preclinical,"In a preclinical study, knockdown of PTEN expression resulted in a decreased response to treatment with CDX-3379 (KTN3379) in ERBB2 (HER2)-amplified breast cancer cells in culture (PMID: 26880266).",Actionable,6465,60079,Her2-receptor positive breast cancer,DOID,23519,ERBB2 amp PTEN dec exp,decreased response,2054,CDX-3379,5728,26880266,,,
22,Clinical Study,"In a clinical study, ERBB2 (HER2)-positive breast cancer patients with PI3K pathway activation resulting from low PTEN expression and/or PIK3CA activating mutations demonstrated decreased progression-free survival following treatment with Herceptin (trastuzumab) compared to patients without PI3K pathway activation (PMID: 17936563).",Actionable,6663,60079,Her2-receptor positive breast cancer,DOID,23664,ERBB2 pos PTEN dec exp,decreased response,947,Trastuzumab,5728,17936563,,,
23,Preclinical - Pdx,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12D, decreased PTEN expression, and TP53 R306* (PMID: 26272063).",Actionable,8576,9256,colorectal cancer,DOID,26365,KRAS G12D PTEN dec exp TP53 R306*,no benefit,4771,MLN0128 + PD-0325901,5728,26272063,,,
24,Phase II,"In a retrospective analysis from a Phase II clinical trial, patients with metastatic renal cell carcinoma treated with Afinitor (everolimus) had no difference in progression free survival when stratified by the presence (n=21) or absence (n=17) of PIK3CA activating mutations (PMID: 26951309).",Actionable,5739,4450,renal cell carcinoma,DOID,21542,PIK3CA act mut PTEN dec exp,no benefit,735,Everolimus,5728,26951309,,,
25,Phase II,"In a retrospective analysis from a Phase II clinical trial, patients with metastatic renal cell carcinoma treated with Apitolisib (GDC-0980) had no difference in progression free survival when stratified by the presence (n=21) or absence (n=15) of PIK3CA activating mutation or loss of Pten expression (PMID: 26951309).",Actionable,5734,4450,renal cell carcinoma,DOID,21542,PIK3CA act mut PTEN dec exp,no benefit,750,GDC-0980,5728,26951309,,,
26,Preclinical - Cell culture,"In a preclinical study, DHM25 increased cell death and decreased migration of a triple-negative breast cancer cell line harboring PTEN V275* in culture (PMID: 26237138).",Actionable,10364,60081,triple-receptor negative breast cancer,DOID,27383,PTEN V275*,sensitive,5494,DHM25,5728,26237138,,,
27,Preclinical,"In a preclinical study, a triple-receptor negative breast cancer line harboring PTEN and RB1 loss was resistant to Ibrance (palbociclib) induced growth inhibition in culture (PMID: 27020857).",Actionable,5865,60081,triple-receptor negative breast cancer,DOID,21971,PTEN loss RB1 loss,resistant,850,Palbociclib,5728,27020857,,,
28,Preclinical,"In a preclinical study, a triple-receptor negative breast cancer line harboring PTEN and RB1 loss was resistant to Pictilisib (GDC-0941) induced growth inhibition in culture (PMID: 27020857).",Actionable,5864,60081,triple-receptor negative breast cancer,DOID,21971,PTEN loss RB1 loss,resistant,749,GDC-0941,5728,27020857,,,
29,Preclinical,"In a preclinical study, the combination of Ibrance (palbociclib) and Pictilisib (GDC-0941) did not improve growth inhibition compared to single drug treatment in triple-receptor negative breast cancer cell lines harboring PTEN and RB1 loss in culture (PMID: 27020857).",Actionable,5863,60081,triple-receptor negative breast cancer,DOID,21971,PTEN loss RB1 loss,no benefit,3956,Palbociclib + GDC-0941,5728,27020857,,,
30,Preclinical - Cell line xenograft,"In a preclinical study, XL147 inhibited tumor growth in xenograft models of a PTEN-deficient human melanoma cell line harboring BRAF V600D (PMID: 25637314).",Actionable,6320,1909,melanoma,DOID,23100,BRAF V600D PTEN loss,sensitive,1050,XL147,5728,25637314,,,
31,Preclinical - Pdx,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PTEN loss, and TP53 V216M (PMID: 26272063).",Actionable,8575,9256,colorectal cancer,DOID,26364,KRAS G12D PTEN loss TP53 V216M,no benefit,4771,MLN0128 + PD-0325901,5728,26272063,,,
32,Preclinical,"In a preclinical study, the PI3K inhibitor GDC-0941 reduced tumor growth rate in immunodeficient mice engrafted with endometrial tumors from PTEN/STK11 (LKB1) deficient mice (PMID: 24322983).",Actionable,601,1380,endometrial cancer,DOID,18395,PTEN loss STK11 loss,sensitive,749,GDC-0941,5728,24322983,,,
33,Preclinical - Cell line xenograft,"In a preclinical study, SAR260301 and Zelboraf (vemurafenib) synergistically inhibited proliferation of PTEN deficient melanoma cells harboring BRAF mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 27196754).",Actionable,7773,1909,melanoma,DOID,18163,BRAF mut PTEN loss,sensitive,1225,SAR260301 + Vemurafenib,5728,27196754,,,
34,Preclinical - Cell line xenograft,"In a preclinical study, SAR260301 inhibited proliferation of PTEN deficient melanoma cells harboring BRAF mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 27196754).",Actionable,7771,1909,melanoma,DOID,18163,BRAF mut PTEN loss,sensitive,1052,SAR260301,5728,27196754,,,
35,Preclinical,"In a preclinical study, a melanoma mouse model harboring a BRAF mutation and PTEN loss was sensitive to the combination of GSK2636771 and Keytruda (pembrolizumab), demonstrating greater tumor growth inhibition and improved survival when compared to either therapy alone (PMID: 26645196). ",Actionable,4455,1909,melanoma,DOID,18163,BRAF mut PTEN loss,sensitive,3518,GSK2636771 + Pembrolizumab,5728,26645196,,,
36,Preclinical,"In a preclinical study, GSK2636771 resulted in no benefit in a melanoma mouse model co-harboring a BRAF mutation and PTEN loss (PMID: 26645196). ",Actionable,4456,1909,melanoma,DOID,18163,BRAF mut PTEN loss,no benefit,765,GSK2636771,5728,26645196,,,
37,Preclinical,"In a preclinical study, Keytruda (pembrolizumab) resulted in no benefit in a melanoma mouse model co-harboring a BRAF mutation and PTEN loss (PMID: 26645196). ",Actionable,4457,1909,melanoma,DOID,18163,BRAF mut PTEN loss,no benefit,1447,Pembrolizumab,5728,26645196,,,
38,Preclinical - Cell line xenograft,"In a preclinical study, SAR260301 and Selumetinib (AZD6244) synergistically inhibited proliferation of PTEN deficient melanoma cells harboring BRAF mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 27196754).",Actionable,7774,1909,melanoma,DOID,18163,BRAF mut PTEN loss,sensitive,4573,SAR260301 + Selumetinib,5728,27196754,,,
39,Phase I,"In a Phase I clinical trial, an endometrial carcinoma patient harboring PIK3CA T1052K, R88L, and E453del, as well as a PTEN mutation and loss of PTEN protein expression demonstrated a complete response to treatment with Aliqopa (copanlisib) (PMID: 27672108). ",Actionable,9350,2871,endometrial carcinoma,DOID,26828, PIK3CA E453del PIK3CA T1025K PIK3CA R88L PTEN mut PTEN loss,sensitive,995,Copanlisib,5728,27672108,,,
40,Preclinical,"In a preclinical study, the combination of Ibrance (palbociclib) and Pictilisib (GDC-0941) did not improve growth inhibition compared to single drug treatment in ERBB2 (HER2)-positive breast cancer cell lines harboring PTEN loss in culture (PMID: 27020857).",Actionable,5862,60079,Her2-receptor positive breast cancer,DOID,1410,ERBB2 pos PTEN loss ,no benefit,3956,Palbociclib + GDC-0941,5728,27020857,,,
41,Phase I,"In a retrospective analysis, ERBB2 (HER2)-positive breast cancer patients with PTEN loss demonstrated a decreased median progression-free survival of 6.0 months, compared to 9.0 months for patients without PI3K pathway activation following treatment with a Herceptin (trastuzumab) containing regimen (PMID: 21676217).",Actionable,874,60079,Her2-receptor positive breast cancer,DOID,1410,ERBB2 pos PTEN loss ,decreased response,947,Trastuzumab,5728,21676217,,,
42,Preclinical,"In a preclinical study, treatment with the combination of GSK2636771 and a PD-1 antibody resulted in greater tumor infiltration of T-cells and tumor growth inhibition in mouse melanoma models expressing BRAF V600E with PTEN loss compared to either agent alone (PMID: 26645196).",Actionable,10891,1909,melanoma,DOID,23099,BRAF V600E PTEN loss,sensitive,5673,GSK2636771 + unspecified PD-1 antibody,5728,26645196,,,
43,Clinical Study,"In a clinical study, a melanoma patient harboring PTEN loss and BRAF V600E demonstrated resistance to Afinitor (everolimus) treatment, resulting in progressive disease (PMID: 20664172).",Actionable,1233,1909,melanoma,DOID,23099,BRAF V600E PTEN loss,resistant,735,Everolimus,5728,20664174,20664172,,
44,Preclinical - Cell line xenograft,"In a preclinical study, XL147 inhibited tumor growth in xenograft models of a PTEN-deficient human melanoma cell line harboring BRAF V600E (PMID: 25637314).",Actionable,6318,1909,melanoma,DOID,23099,BRAF V600E PTEN loss,sensitive,1050,XL147,5728,25637314,,,
45,Preclinical,"In a preclinical study, a melanoma cell line harboring BRAF V600E and PTEN loss demonstrated sensitivity when treated with a combination of Pictilisib (GDC-0941) and PLX4720, resulting in decreased cell proliferation in culture (PMID: 24265153).",Actionable,7081,1909,melanoma,DOID,23099,BRAF V600E PTEN loss,sensitive,4358,GDC-0941 + PLX4720,5728,24265153,,,
46,Preclinical - Cell culture,"In a preclinical study, GDC0879 and Pictilisib (GDC-0941) synergistically inhibited survival of melanoma cell lines harboring BFAF V600E and PTEN loss in cell culture (PMID: 19276360).",Actionable,7899,1909,melanoma,DOID,23099,BRAF V600E PTEN loss,sensitive,4605,GDC0879 + GDC-0941,5728,19276360,,,
47,Preclinical,"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human glioma cells with PTEN loss in culture (PMID: 21325073).",Actionable,3155,60108,brain glioma,DOID,479,PTEN loss,sensitive,1040,PF-05212384,5728,21325073,,,
48,Phase I,"In a Phase I trial in patients with advanced solid tumors, Estybon (rigosertib) treatment resulted in responses in 2 patients with head and neck squamous cell carcinoma (1 complete response and 1 partial response), 1 harboring PIK3CA amplification and the other harboring PTEN loss (Cancer Res April 15 2013 (73) (8 Supplement) LB-198).",Actionable,10890,5520,head and neck squamous cell carcinoma,DOID,479,PTEN loss,predicted â€“ sensitive,1046,rigosertib,5728,None,,,
49,Preclinical,"In a preclinical study, the combination of Talazoparib (BMN-673) and AZD6482 inhibited growth of triple-negative breast cancer cell lines with PTEN loss in culture (Mol Cancer Res, Feb 2016 14; B12).",Actionable,4995,60081,triple-receptor negative breast cancer,DOID,479,PTEN loss,sensitive,3717,AZD6482 + Talazoparib,5728,None,,,
50,Preclinical - Cell line xenograft,"In preclinical studies, CCT128930 prevented tumor growth in a PTEN-null human glioblastoma cell line xenograft model (PMID: 21191045).",Actionable,997,3068,glioblastoma multiforme,DOID,479,PTEN loss,sensitive,1445,CCT128930,5728,21191045,,,
51,Preclinical - Cell culture,"In a preclinical study, BGT226 treatment in PTEN-deficient acute lymphoblastic leukemia cells resulted in inhibition of PI3K/Akt signaling and apoptotic activity in culture (PMID: 23705826).",Actionable,10531,9952,acute lymphocytic leukemia,DOID,479,PTEN loss,sensitive,675,BGT226,5728,23705826,,,
52,Preclinical - Cell line xenograft,"In a preclinical study, OSI-027 inhibited tumor growth in PTEN-null ovarian cancer cell line xenograft models (PMID: 21673091).",Actionable,8733,2394,ovarian cancer,DOID,479,PTEN loss,sensitive,841,OSI-027,5728,21673091,,,
53,Preclinical - Cell line xenograft,"In a preclinical study, a triple-receptor negative breast cancer xenograft model harboring PTEN loss was sensitive to M2698 (MSC2363318A), demonstrating inhibition of tumor growth and tumor regression (PMID: 27186432). ",Actionable,10290,60081,triple-receptor negative breast cancer,DOID,479,PTEN loss,sensitive,1037,MSC2363318A,5728,27186432,,,
54,Preclinical,"In a preclinical study, human melanoma cells with PTEN loss were sensitive to GSK2636771, resulting in decreased activation of Akt and some inhibition of tumor growth (PMID: 26645196). ",Actionable,4453,1909,melanoma,DOID,479,PTEN loss,sensitive,765,GSK2636771,5728,26645196,,,
55,Preclinical - Cell line xenograft,"In a preclinical study, two PTEN-deficient glioblastoma cell line xenograft models were sensitive to GDC-0084 treatment, resulting in decreased tumor volumes by 70% and 40%, and inhibition of PI3K pathway signaling (PMID: 27638506). ",Actionable,10643,3068,glioblastoma multiforme,DOID,479,PTEN loss,sensitive,2018,GDC-0084,5728,27638506,,,
56,Preclinical - Cell line xenograft,"In a preclinical study, OSI-027 induced tumor regression in PTEN-null breast cancer cell line xenograft models (PMID: 21673091).",Actionable,8735,1612,breast cancer,DOID,479,PTEN loss,sensitive,841,OSI-027,5728,21673091,,,
57,Preclinical,"In a preclinical study, YU238259 demonstrated increased cytotoxicity in PTEN-deficient sarcoma cell lines in culture (PMID: 26116172).",Actionable,5532,1115,sarcoma,DOID,479,PTEN loss,sensitive,3880,YU238259,5728,26116172,,,
58,Preclinical - Cell line xenograft,"In a preclinical study, AT13148 inhibited tumor growth in a PTEN-deficient human uterine sarcoma cell line xenograft model (PMID: 22781553).",Actionable,4786,5165,uterine corpus sarcoma,DOID,479,PTEN loss,sensitive,3653,AT13148,5728,22781553,,,
59,Preclinical,"In a preclinical study, the combination of Lynparza (olaparib) and AZD6482 inhibited growth of triple-negative breast cancer cell lines with PTEN loss in culture (Mol Cancer Res Feb 2016 14; B12).",Actionable,4997,60081,triple-receptor negative breast cancer,DOID,479,PTEN loss,sensitive,3719,AZD6482 + Olaparib,5728,None,,,
60,Preclinical,"In a preclinical study, human renal carcinoma cells with PTEN loss had a decreased response to Gedatolisib (PKI-587) in culture (PMID: 21325073).",Actionable,3156,4451,renal carcinoma,DOID,479,PTEN loss,decreased response,1040,PF-05212384,5728,21325073,,,
61,Phase I,"In a Phase I clinical trial, 8 patients with metastatic, castration-resistant prostate cancer harboring a loss of PTEN did not respond to MK-2206 therapy, but prolonged stable disease was observed in 2 patients (PMID: 26187616).",Actionable,3782,10283,prostate cancer,DOID,479,PTEN loss,no benefit,816,MK2206,5728,26187616,,,
62,Preclinical,"In a preclinical study, KU-55933 induced cell cycle arrest and caspase activation in PTEN deficient human colon cancer cells in culture (PMID: 25870146).",Actionable,4780,219,colon cancer,DOID,479,PTEN loss,sensitive,3116,KU-55933,5728,25870146,,,
63,Preclinical,"In a preclinical study, prostate cancer mouse models deficient for Pten demonstrated inhibition of the PI3K/Akt signaling pathway and a decrease in both tumor size and cell proliferation when treated with OP449 (PMID: 26563471).",Actionable,4755,10283,prostate cancer,DOID,479,PTEN loss,sensitive,3606,OP449,5728,26563471,,,
64,Preclinical,"In a preclinical study, AZD6482 inhibited viability of breast cancer cell lines harboring PTEN deficiency in culture (PMID: 23674493).",Actionable,4974,1612,breast cancer,DOID,479,PTEN loss,sensitive,659,AZD6482,5728,23674493,,,
65,Clinical Study,"In a clinical study, melanoma patients with PTEN loss demonstrated decreased response to antiâ€“PD-1 antibodies, including Opdivo (nivolumab), as compared to patients in which PTEN is present (PMID: 26645196). ",Actionable,4450,1909,melanoma,DOID,479,PTEN loss,decreased response,1312,Nivolumab,5728,26645196,,,
66,Preclinical - Cell line xenograft,"In a preclinical study, Acalisib (GS-9820) resulted in tumor growth inhibition in xenograft models of prostate cancer with PTEN deficiency (Mol Cancer Ther 2009;8(12 Suppl):B136).",Actionable,8288,10283,prostate cancer,DOID,479,PTEN loss,sensitive,1021,GS-9820,5728,None,,,
67,Phase Ib/II,"In a Phase Ib trial, a breast adenocarcinoma patient harboring PTEN loss demonstrated a partial response when treated with a combination of LY2780301 and Gemzar (gemcitabine) (PMID: 28750271). ",Actionable,11828,3458,breast adenocarcinoma,DOID,479,PTEN loss,sensitive,6168,Gemcitabine + LY2780301,5728,28750271,,,
68,Preclinical - Cell line xenograft,"In a preclinical study, a prostate cancer cell line with PTEN loss was sensitive to XL765 (SAR245409) treatment, demonstrating inhibition of the PI3K pathway and decreased colony formation in culture, and inhibition of tumor growth and reduced tumor vascularization in cell line xenograft models (PMID: 24634413).",Actionable,10701,10283,prostate cancer,DOID,479,PTEN loss,sensitive,1051,SAR245409,5728,24634413,,,
69,Phase I,"In a Phase I trial, a patient with castration resistant prostate cancer harboring a loss of PTEN demonstrated an improved prostate specific antigen when treated with Ipatasertib (GDC-0068) (PMID: 27872130). ",Actionable,9712,10283,prostate cancer,DOID,479,PTEN loss,sensitive,747,Ipatasertib,5728,27872130,,,
70,Preclinical - Cell culture,"In a preclinical study, breast cancer cell lines with PTEN loss demonstrated resistance to Torkinib (PP242) in culture (PMID: 21358673). ",Actionable,10369,1612,breast cancer,DOID,479,PTEN loss,resistant,2240,Torkinib,5728,21358673,,,
71,Preclinical,"In a preclinical study, treatment with AZD5363 decreased AKT phosphorylation and downstream signaling and reduced tumor burden in mouse models of PTEN-deficient prostate cancer, including both castration-naive and castration resistant models (PMID: 26910118).",Actionable,10887,10283,prostate cancer,DOID,479,PTEN loss,sensitive,655,AZD5363,5728,26910118,,,
72,Preclinical - Cell culture,"In a preclinical study, a breast adenocarcinoma cell line harboring PTEN loss was sensitive to XL765 (SAR245409), demonstrating inhibition of cell proliferation in culture (PMID: 24634413). ",Actionable,10706,3458,breast adenocarcinoma,DOID,479,PTEN loss,sensitive,1051,SAR245409,5728,24634413,,,
73,Preclinical - Cell line xenograft,"In preclinical studies, the PI3K inhibitor GDC-0941 demonstrated efficacy against NSCLC tumor cell lines in both culture and xenograft models harboring alterations in the PI3K pathway (PMID: 23136191).",Actionable,130,3908,non-small cell lung carcinoma,DOID,479,PTEN loss,sensitive,749,GDC-0941,5728,23136191,,,
74,Preclinical - Cell line xenograft,"In a preclinical study, PF-04691502 inhibited Akt phosphorylation, resulted in growth inhibition of PTEN-null glioblastoma cells in culture and in cell line xenograft models (PMID: 21750219).",Actionable,2620,3068,glioblastoma multiforme,DOID,479,PTEN loss,sensitive,865,PF-04691502,5728,21750219,,,
75,Preclinical - Cell line xenograft,"In a preclinical study, A66 did not inhibit tumor growth in a PTEN-null cell line xenograft model of glioblastoma (PMID: 21668414).",Actionable,7534,3068,glioblastoma multiforme,DOID,479,PTEN loss,resistant,617,A66,5728,21668414,,,
76,Preclinical,"In a preclinical study, AZD6482 inhibited viability of prostate cancer cell lines harboring PTEN deficiency in culture (PMID: 23674493).",Actionable,4973,10283,prostate cancer,DOID,479,PTEN loss,sensitive,659,AZD6482,5728,23674493,,,
77,Preclinical,"In a preclinical study, AZD8186 inhibited tumor growth of PTEN deficient prostate xenografts models (PMID: 25514658).",Actionable,3766,10283,prostate cancer,DOID,479,PTEN loss,sensitive,992,AZD8186,5728,25514658,,,
78,Preclinical - Cell culture,"In a preclinical study, treatment with AZD8055 resulted in antiproliferative activity in head and neck squamous cell carcinoma cells harboring PTEN loss in culture (PMID: 28446642). ",Actionable,11509,5520,head and neck squamous cell carcinoma,DOID,479,PTEN loss,predicted â€“ sensitive,1519,AZD8055,5728,28446642,,,
79,Preclinical,"In a preclinical study, the combination of Veliparib (ABT-888) and AZD6482 inhibited growth of triple-negative breast cancer cell lines with PTEN loss in culture (Mol Cancer Res Feb 2016 14; B12).",Actionable,4999,60081,triple-receptor negative breast cancer,DOID,479,PTEN loss,sensitive,3720,AZD6482 + Veliparib,5728,None,,,
80,Preclinical - Cell line xenograft,"In a preclinical study, DETD-35 treatment resulted in reduced tumor size in cell line xenograft models of Zelboraf (vemurafenib)-resistant melanoma harboring PTEN loss (PMID: 27048951).",Actionable,6675,1909,melanoma,DOID,479,PTEN loss,sensitive,4230,DETD-35,5728,27048951,,,
81,Preclinical - Cell line xenograft,"In a preclinical study, AT13148 inhibited tumor growth in a PTEN-deficient human prostate cancer cell line xenograft model (PMID: 22781553).",Actionable,4785,10283,prostate cancer,DOID,479,PTEN loss,sensitive,3653,AT13148,5728,22781553,,,
82,Preclinical,"In a preclinical study, KU-60019 blocked tumor growth in PTEN-deficient human prostate cancer xenograft models (PMID: 25870146).",Actionable,4781,10283,prostate cancer,DOID,479,PTEN loss,sensitive,3652,KU-60019,5728,25870146,,,
83,Preclinical - Cell culture,"In a preclinical study, the combination of Zejula (niraparib) and AZD6482 inhibited growth of triple-negative breast cancer cell lines with PTEN loss in culture (Mol Cancer Res Feb 2016 14; B12).",Actionable,4996,60081,triple-receptor negative breast cancer,DOID,479,PTEN loss,sensitive,3718,AZD6482 + Niraparib,5728,None,,,
84,Preclinical,"In a preclinical study, BAY1125976 demonstrated anti-tumor efficacy in multiple xenograft tumor models of different cancers with PIK3CA mutations or PTEN deletions and displayed synergy with other anti-cancer therapies (Cancer Res 2013;73(8 Suppl):Abstract nr 2050).",Actionable,1347,10000003,Advanced Solid Tumor,JAX,479,PTEN loss,sensitive,994,BAY1125976,5728,None,,,
85,Phase II,"In a Phase II trial, Afinitor (everolimus) treatment in patients with advanced solid tumors harboring PTEN loss did not reach its primary endpoint, resulting in only stable disease or progressive disease (PMID: 28330462).",Actionable,10529,10000003,Advanced Solid Tumor,JAX,479,PTEN loss,no benefit,735,Everolimus,5728,28330462,,,
86,Preclinical,"In a preclinical study, CX-6258 treatment resulted in decreased carcinoma in situ in PTEN deficient transgenic animal model of prostate cancer (PMID: 27486174).",Actionable,9330,10283,prostate cancer,DOID,479,PTEN loss,predicted â€“ sensitive,3675,CX-6258,5728,27486174,,,
87,Clinical Study,"In a clinical study, melanoma patients with PTEN loss demonstrated decreased response to antiâ€“PD-1 antibodies, including Keytruda (pembrolizumab), compared to patients in which PTEN is present (PMID: 26645196). ",Actionable,4449,1909,melanoma,DOID,479,PTEN loss,decreased response,1447,Pembrolizumab,5728,26645196,,,
88,Preclinical,"In a preclinical study, GSK2636771 inhibited viability of prostate cancer cell lines harboring PTEN deficiency in culture (PMID: 23674493).",Actionable,4975,10283,prostate cancer,DOID,479,PTEN loss,sensitive,765,GSK2636771,5728,23674493,,,
89,Preclinical,"In a preclinical study, the combination of Rubraca (rucaparib) and AZD6482 inhibited growth of triple-negative breast cancer cell lines with PTEN loss in culture (Mol Cancer Res Feb 2016 14; B12).",Actionable,4998,60081,triple-receptor negative breast cancer,DOID,479,PTEN loss,sensitive,3721,AZD6482 + Rucaparib,5728,None,,,
90,Preclinical,"In a preclinical study, KX2-391 and Eloxatin (oxaliplatin) combination treatment did not show improved tumor suppression in xenograft models of ovarian mucinous carcinoma harboring PTEN loss when compared to single agent treatment (PMID: 24100628).",Actionable,5909,6067,ovarian mucinous neoplasm,DOID,479,PTEN loss,no benefit,3979,KX2-391 + Oxaliplatin,5728,24100628,,,
91,Preclinical - Cell line xenograft,"In a preclinical study, DETD-35 and Zelboraf (vemurafenib) combination treatment resulted in further reduction of tumor size in cell line xenograft models of Zelboraf (vemurafenib)-resistant melanoma harboring PTEN loss when compared to single agent treatment (PMID: 27048951).",Actionable,6676,1909,melanoma,DOID,479,PTEN loss,sensitive,4232,DETD-35 + Vemurafenib,5728,27048951,,,
92,Preclinical - Pdx,"In a preclinical study, AZD5363 inhibited growth of renal cancer Pdx models with Pten loss (PMID: 22294718).",Actionable,9813,4451,renal carcinoma,DOID,479,PTEN loss,sensitive,655,AZD5363,5728,22294718,,,
93,Phase I,"In a Phase I trial, SAR260301 demonstrated acceptable safety but undesirable pharmacokinetics, and resulted in no response in patients with advanced solid tumors harboring PTEN loss (J Clin Oncol 33, 2015 (suppl; abstr 2564)).",Actionable,5067,10000003,Advanced Solid Tumor,JAX,479,PTEN loss,no benefit,1052,SAR260301,5728,None,,,
94,Preclinical,"In a preclinical study, GSK2636771 inhibited viability of breast cancer cell lines harboring PTEN deficiency in culture (PMID: 23674493).",Actionable,4976,1612,breast cancer,DOID,479,PTEN loss,sensitive,765,GSK2636771,5728,23674493,,,
95,Preclinical,"In a preclincal study, mucinous ovarian carcinoma cell lines harboring PTEN loss were less sensitive to KX2-391 induced growth inhibition in culture and tumor suppression in xenograft models (PMID: 24100628).",Actionable,5907,6067,ovarian mucinous neoplasm,DOID,479,PTEN loss,decreased response,786,KX2-391,5728,24100628,,,
96,Clinical Study,"In a clinical study, the combination of Ipatasertib (GDC-0068) and Zytiga (abiraterone) resulted in a better progression free survival in metastatic castration resistant prostate cancer patients with PTEN loss when compared to placebo combined with Zytiga (abiraterone) (Ann Oncol (2016) 27 (suppl_6): 718O).",Actionable,10246,10283,prostate cancer,DOID,479,PTEN loss,sensitive,5438,Abiraterone + Ipatasertib,5728,None,,,
97,Preclinical - Cell line xenograft,"In a precliinical study, PTEN deficient prostate carcinoma cells demonstrated reduced response to SAR260301 in cell culture and in cell line xenograft models (PMID: 27196754).",Actionable,7772,10286,prostate carcinoma,DOID,479,PTEN loss,decreased response,1052,SAR260301,5728,27196754,,,
98,Preclinical - Cell culture,"In a preclinical study, breast cancer cells harboring PTEN loss demonstrated resistance to Alpelisib (BYL719) in culture (PMID: 27604488).",Actionable,8905,1612,breast cancer,DOID,479,PTEN loss,resistant,691,BYL719,5728,27604488,,,
99,Preclinical - Cell line xenograft,"In a preclinical study, a glioblastoma cell line harboring PTEN loss (PMID: 24634413) was sensitive to SF1126, demonstrating a 76% decrease in tumor growth in cell line xenograft models (PMID: 18172313). ",Actionable,10710,10283,prostate cancer,DOID,479,PTEN loss,sensitive,915,SF1126,5728,24634413,18172313,,
100,Preclinical - Cell culture,"In a preclinical study, AZD5363 inhibited growth of various solid tumor cell culture models with loss of Pten (PMID: 22294718).",Actionable,9815,10000003,Advanced Solid Tumor,JAX,479,PTEN loss,sensitive,655,AZD5363,5728,22294718,,,
101,Preclinical,"In a preclinical study, BLZ945 resulted in limited benefit in transgenic mouse models of glioblastoma harboring a loss of PTEN (PMID: 27199435). ",Actionable,8587,3068,glioblastoma multiforme,DOID,479,PTEN loss,no benefit,2844,BLZ945,5728,27199435,,,
102,Preclinical - Cell culture,"In a preclinical study, GSK2334470 partially restored sensitivity to Zydelig (idelalisib) in diffuse large B-cell lymphoma cells harboring PTEN loss that acquired resistance to Zydelig (idelalisib), resulting in increased apoptosis in culture (PMID: 28178345).",Actionable,11890,50745,diffuse large B-cell lymphoma,DOID,479,PTEN loss,predicted â€“ sensitive,6201,GSK2334470 + Idelalisib ,5728,28178345,,,
103,Phase II,"In a Phase II trial, 57% (8/14) of transitional cell carcinoma patients that demonstrated uncontrolled disease after treatment with Afinitor (everolimus) harbored PTEN loss compared to 0% of patients with controlled disease demonstrating no evidence of PTEN loss (PMID: 22473592). ",Actionable,10355,2671,transitional cell carcinoma,DOID,479,PTEN loss,resistant,735,Everolimus,5728,22473592,,,
104,Preclinical,"In a preclinical study, CX-6258 and CX-5461 combination treatment resulted in decreased tumor burden in PTEN deficient transgenic animal model of prostate cancer (PMID: 27486174).",Actionable,9331,10283,prostate cancer,DOID,479,PTEN loss,predicted â€“ sensitive,4969,CX-5461 + CX-6258,5728,27486174,,,
105,Preclinical - Cell culture,"In a preclinical study, MK2206 partially restored sensitivity to Zydelig (idelalisib) in diffuse large B-cell lymphoma cells harboring PTEN loss with acquired resistance to Zydelig (idelalisib), resulting in increased apoptosis in culture (PMID: 28178345).",Actionable,11887,50745,diffuse large B-cell lymphoma,DOID,479,PTEN loss,predicted â€“ sensitive,6200,Idelalisib + MK2206,5728,28178345,,,
106,Phase I,"In a Phase I trial, AZD8186 demonstrated preliminary efficacy in patients with tumor types with prevalent PTEN-deficiency, including squamous non-small cell lung cancer (AACR; Cancer Res 2015;75(15 Suppl):Abstract nr CT329).",Actionable,3771,3907,lung squamous cell carcinoma,DOID,479,PTEN loss,predicted â€“ sensitive,992,AZD8186,5728,None,,,
107,Preclinical - Cell culture,"In a preclinical study, BEZ235 resulted in antiproliferative activity in head and neck squamous cell carcinoma cells harboring PTEN loss in culture (PMID: 28446642). ",Actionable,11511,5520,head and neck squamous cell carcinoma,DOID,479,PTEN loss,predicted â€“ sensitive,672,BEZ235,5728,28446642,,,
108,Preclinical - Cell line xenograft,"In a preclinical study, Panulisib (P7170) inhibited tumor growth in PTEN null prostate cancer cell xenograft models (PMID: 25700704).",Actionable,3772,10283,prostate cancer,DOID,479,PTEN loss,sensitive,857,P7170,5728,25700704,,,
109,Phase I,"In a Phase I trial, AZD8186 demonstrated preliminary efficacy in patients with tumor types with prevalent PTEN-deficiency, including triple negative breast cancer (AACR; Cancer Res 2015;75(15 Suppl):Abstract nr CT329).",Actionable,3770,60081,triple-receptor negative breast cancer,DOID,479,PTEN loss,predicted â€“ sensitive,992,AZD8186,5728,None,,,
110,Preclinical,"In a preclinical study, CX-5461 treatment did not result in histological change in PTEN deficient transgenic animal model of prostate cancer (PMID: 27486174).",Actionable,9332,10283,prostate cancer,DOID,479,PTEN loss,no benefit,4963,CX-5461,5728,27486174,,,
111,Phase I,"In a Phase I trial, the combination of AZD8186 and Vistusertib (AZD2014) resulted in a partial response in a patient with PTEN-deficient colorectal cancer (J Clin Oncol 35, 2017 (suppl; abstr 2570)).",Actionable,11126,9256,colorectal cancer,DOID,479,PTEN loss,sensitive,5868,AZD8186 + Vistusertib,5728,None,,,
112,Preclinical - Cell line xenograft,"In a preclinical study, PKI-402 inhibited tumor growth in PTEN-negative glioblastoma multiforme cell line xenograft models (PMID: 20371716).",Actionable,5402,3068,glioblastoma multiforme,DOID,479,PTEN loss,sensitive,3857,PKI-402,5728,20371716,,,
113,Preclinical - Cell culture,"In a preclinical study, 10/12 breast cancer cell lines with PTEN loss demonstrated resistance to Afinitor (everolimus) in culture (PMID: 21358673). ",Actionable,10368,1612,breast cancer,DOID,479,PTEN loss,resistant,735,Everolimus,5728,21358673,,,
114,Preclinical - Cell line xenograft,"In a preclinical study, LY3023414 inhibited Pi3k/mTor signaling and proliferation in PTEN deficient glioblastoma cells in culture, and resulted in tumor growth inhibition in cell line xenograft models (PMID: 27439478).",Actionable,8939,3068,glioblastoma multiforme,DOID,479,PTEN loss,sensitive,1069,LY3023414,5728,27439478,,,
115,Preclinical - Cell culture,"In a preclinical study, PKI-179 inhibited growth of prostate cancer cells harboring PIK3CA mutations and PTEN loss in culture (PMID: 20797855).",Actionable,8146,10283,prostate cancer,DOID,19846,PIK3CA mutant PTEN loss,sensitive,872,PKI-179,5728,20797855,,,
116,Preclinical - Pdx,"In a preclinical study, AZD6482 and Alpelisib (BYL719) combination treatment inhibited Akt signaling and growth in a breast cancer patient-derived xenograft (PDX) model harboring a PIK3CA mutation and PTEN loss (Cancer Res October 1, 2014 74; LB-327).",Actionable,4990,1612,breast cancer,DOID,19846,PIK3CA mutant PTEN loss,sensitive,3714,AZD6482 + BYL719,5728,None,,,
117,Clinical Study,"In a case study, a breast cancer patient harboring a PIK3CA mutation developed resistance to Alpelisib (BYL719) treatment and progressive disease after initial response, accompanied by a loss of PTEN (Cancer Res October 1, 2014 74; LB-327).",Actionable,4983,1612,breast cancer,DOID,19846,PIK3CA mutant PTEN loss,resistant,691,BYL719,5728,None,,,
118,Preclinical - Pdx,"In a preclinical study, a breast cancer patient-derived xenograft (PDX) model harboring a PIK3CA mutation and PTEN loss was resistant to Alpelisib (BYL719)-induced inhibition of Akt signaling and growth (Cancer Res October 1, 2014 74; LB-327).",Actionable,4988,1612,breast cancer,DOID,19846,PIK3CA mutant PTEN loss,resistant,691,BYL719,5728,None,,,
119,Preclinical - Pdx,"In a preclinical study, Buparlisib (BKM120) inhibited Akt signaling and growth in a PDX model of breast cancer cells harboring a PIK3CA mutation and PTEN loss ( Cancer Res October 1, 2014 74; LB-327 ).",Actionable,4989,1612,breast cancer,DOID,19846,PIK3CA mutant PTEN loss,sensitive,680,BKM120,5728,None,,,
120,Preclinical,"In a preclinical study, CH5132799 inhibited proliferation of an endometrial cancer cell line harboring PIK3CA R38C and PTEN loss in culture (PMID: 21558396).",Actionable,2955,1380,endometrial cancer,DOID,10741,PIK3CA R38C  PTEN loss,sensitive,2152,CH5132799,5728,21558396,,,
121,Preclinical,"In a preclinical study, human renal carcinoma cells with PTEN loss and VHL loss had a decreased response to Gedatolisib (PKI-587) in culture (PMID: 21325073).",Actionable,3157,4451,renal carcinoma,DOID,11820,PTEN loss VHL loss,decreased response,1040,PF-05212384,5728,21325073,,,
122,Phase I,"In a Phase I study, a patient with pancreatic adenocarcinoma harboring PTEN loss and KRAS G12D was treated with MK-2206 and demonstrated a 23% reduction in tumor size (PMID: 22025163).",Actionable,2147,4074,pancreatic adenocarcinoma,DOID,5589,PTEN loss KRAS G12D,sensitive,816,MK2206,5728,22025163,,,
123,Preclinical,"In a preclinical study, treatment with AZD5363 improved overall survival and progression-free survival in mouse models of  prostate cancer with inactivated PTEN and TP53 (PMID: 26910118).",Actionable,10888,10283,prostate cancer,DOID,27832,PTEN loss TP53 loss,sensitive,655,AZD5363,5728,26910118,,,
124,Preclinical - Cell culture,"In a preclinical study, inhibition of Pi3k signaling by BEZ235 sensitized breast cancer cell lines harboring PIK3CA E542K and PTEN loss to WEHI-539 in culture (PMID: 27974663).",Actionable,10087,1612,breast cancer,DOID,27243,PIK3CA E542K PTEN loss,predicted â€“ sensitive,5377,BEZ235 + WEHI-539,5728,27974663,,,
125,Preclinical - Cell line xenograft,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring BRAF V600E and PTEN loss in culture and in cell line xenograft models (PMID: 26272063).",Actionable,8569,9256,colorectal cancer,DOID,26362,BRAF V600E PTEN loss TP53 wild-type,sensitive,4771,MLN0128 + PD-0325901,5728,26272063,,,
126,Preclinical - Cell culture,"In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss did not demonstrate any benefit when treated with a combination of Afinitor (everolimus) and Selumetinib (AZD6244) (PMID: 21358673).",Actionable,10371,1612,breast cancer,DOID,20306,PIK3CA wild-type PTEN loss,no benefit,4901,Everolimus + Selumetinib,5728,21358673,,,
127,Preclinical - Cell culture,"In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss did not demonstrate any benefit when treated with a combination of Afinitor (everolimus) and U0126 (PMID: 21358673). ",Actionable,10370,1612,breast cancer,DOID,20306,PIK3CA wild-type PTEN loss,no benefit,5499,Everolimus + U0126,5728,21358673,,,
128,Preclinical,"In a preclinical study, human breast cancer cells with wild-type PIK3CA and loss of PTEN were resistant to growth inhibition by AZD8835 in culture (PMID: 26839307).",Actionable,5112,1612,breast cancer,DOID,20306,PIK3CA wild-type PTEN loss,resistant,2013,AZD8835,5728,26839307,,,
129,Preclinical - Cell culture,"In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss demonstrated sensitivity to the combination treatment of Torkinib (PP242) and U0126 in culture (PMID: 21358673). ",Actionable,10372,1612,breast cancer,DOID,20306,PIK3CA wild-type PTEN loss,sensitive,5500,Torkinib + U0126,5728,21358673,,,
130,Preclinical - Cell culture,"In a preclinical study, breast cancer cells harboring PIK3CA wild-type and PTEN loss demonstrated sensitivity to the combination treatment of Torkinib (PP242) and Selumetinib (AZD6244) in culture (PMID: 21358673). ",Actionable,10373,1612,breast cancer,DOID,20306,PIK3CA wild-type PTEN loss,sensitive,5501,Selumetinib + Torkinib,5728,21358673,,,
131,Preclinical - Cell culture,"In a preclinical study, inhibition of Pi3k signaling by BEZ235 sensitized breast cancer cell lines harboring PIK3CA H1047R and PTEN loss to WEHI-539 in culture (PMID: 27974663).",Actionable,10085,1612,breast cancer,DOID,27242,PIK3CA H1047R PTEN loss,predicted â€“ sensitive,5377,BEZ235 + WEHI-539,5728,27974663,,,
132,Preclinical - Cell culture,"In a preclinical study, inhibition of Pi3k signaling by BEZ235 did not sensitize breast cancer cell lines harboring PIK3CA H1047R and PTEN loss to Venclexta (venetoclax) in culture (PMID: 27974663).",Actionable,10082,1612,breast cancer,DOID,27242,PIK3CA H1047R PTEN loss,no benefit,5376,BEZ235 + Venetoclax,5728,27974663,,,
133,Preclinical - Cell line xenograft,"In a preclinical study, ABT-737 and BEZ235 combination treatment resulted in tumor regression in cell line xenograft models of triple-receptor negative breast cancer harboring PIK3CA H1047R and PTEN loss (PMID: 27974663).",Actionable,10091,60081,triple-receptor negative breast cancer,DOID,27242,PIK3CA H1047R PTEN loss,predicted â€“ sensitive,5381,ABT-737 + BEZ235,5728,27974663,,,
134,Preclinical - Cell line xenograft,"In a preclinical study, ABT-737 and Sapanisertib (MLN0128) combination treatment resulted in inhibition of tumor growth in cell line xenograft models of triple-receptor negative breast cancer harboring PIK3CA H1047R and PTEN loss (PMID: 27974663).",Actionable,10097,60081,triple-receptor negative breast cancer,DOID,27242,PIK3CA H1047R PTEN loss,predicted â€“ sensitive,5388,ABT-737 + MLN0128,5728,27974663,,,
135,Preclinical - Pdx & cell culture,"In a preclinical study, patient-derived EGFR amplified glioblastoma cells harboring PTEN loss demonstrated reduced sensitivity to Dacomitinib induced growth inhibition in culture and in xenograft models (PMID: 25939761).",Actionable,8045,3068,glioblastoma multiforme,DOID,26141,EGFR amp PTEN loss,decreased response,714,Dacomitinib,5728,25939761,,,
136,Preclinical,"In a preclinical study, Alpelisib (BYL719) and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6106,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,no benefit,4047,BYL719 + NVP-AEW541,5728,26577700,,,
137,Preclinical,"In a preclinical study, AZD6482 and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6110,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,4048,AZD6482 + LGX818,5728,26577700,,,
138,Preclinical,"In a preclinical study, Alpelisib (BYL719) and Encorafenib (LGX818) combination treatment did not enhance growth inhibition in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6113,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,no benefit,4049,BYL719 + LGX818,5728,26577700,,,
139,Preclinical - Cell culture,"In a preclinical study, combination treatment consisting of AZD6482, Binimetinib (MEK162), and Alpelisib (BYL719) efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6127,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,4059,AZD6482 + Binimetinib + BYL719,5728,26577700,,,
140,Preclinical,"In a preclinical study, combination treatment consists of AZD6482, Binimetinib (MEK162), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6128,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,4060,AZD6482 + Binimetinib + NVP-AEW541,5728,26577700,,,
141,Preclinical,"In a preclinical study, Pictilisib (GDC-0941) and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6115,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,4053,GDC-0941 + Binimetinib,5728,26577700,,,
142,Preclinical,"In a preclinical study, AZD6482 and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6117,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,4054,AZD6482 + Binimetinib,5728,26577700,,,
143,Preclinical,"In a preclinical study, Pictilisib (GDC-0941) and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6109,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,4056,GDC-0941 + LGX818,5728,26577700,,,
144,Preclinical - Cell line xenograft,"In a preclinical study, combination treatment consisting of GSK2636771, Encorafenib (LGX818), and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).",Actionable,6138,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,4069,GSK2636771 + LGX818 + unspecified IGF-1R antibody,5728,26577700,,,
145,Preclinical,"In a preclinical study, AZD6482 and Alpelisib (BYL719) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6101,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,3714,AZD6482 + BYL719,5728,26577700,,,
146,Preclinical - Cell line xenograft,"In a preclinical study, the combination of GSK2636771 and Alpelisib (BYL719) synergized to inhibit proliferation of human melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture, and inhibited tumor growth in xenograft models of one cell line harboring these mutations (PMID: 26577700).",Actionable,6102,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,4042,BYL719 + GSK2636771,5728,26577700,,,
147,Preclinical,"In a preclincal study, Pictilisib (GDC-0941) inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6099,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,749,GDC-0941,5728,26577700,,,
148,Preclinical,"In a preclinical study, GSK2636771 and Binimetinib (MEK162) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6118,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,4052,GSK2636771 + Binimetinib,5728,26577700,,,
149,Preclinical,"In a preclinical study, combination treatment consisting of AZD6482, Encorafenib (LGX818), and Alpelisib (BYL719) efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6125,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,4062,AZD6482 + LGX818 + BYL719,5728,26577700,,,
150,Preclinical,"In a preclinical study, Pictilisib (GDC-0941) and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6105,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,4046,GDC-0941 + NVP-AEW541,5728,26577700,,,
151,Preclinical - Cell line xenograft,"In a preclinical study, the combination of GSK2636771, Encorafenib (LGX818), and Alpelisib (BYL719) efficiently inhibited tumor growth in xenograft models of a human melanoma cell line harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).",Actionable,6133,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,4065,BYL719 + GSK2636771 + LGX818,5728,26577700,,,
152,Preclinical,"In a preclinical study, combination treatment consists of AZD6482, Binimetinib (MEK162), Encorafenib (LGX818), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6130,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,4064,AZD6482 + Binimetinib + LGX818 + NVP-AEW541,5728,26577700,,,
153,Preclinical,"In a preclincal study, melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations were less sensitive to Alpelisib (BYL719)-induced growth inhibition in culture (PMID: 26577700).",Actionable,6100,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,decreased response,691,BYL719,5728,26577700,,,
154,Preclinical,"In a preclinical study, GSK2636771 and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6104,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,4045,GSK2636771 + NVP-AEW541,5728,26577700,,,
155,Preclinical,"In a preclinical study, GSK2636771 and Encorafenib (LGX818) synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6111,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,4055,GSK2636771 + LGX818,5728,26577700,,,
156,Preclinical,"In a preclinical study, combination treatment consisting of AZD6482, Binimetinib (MEK162), Encorafenib (LGX818), and Alpelisib (BYL719) efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6131,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,4063,AZD6482 + Binimetinib + LGX818 + BYL719,5728,26577700,,,
157,Preclinical,"In a preclincal study, AZD6482 inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6097,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,659,AZD6482,5728,26577700,,,
158,Preclinical,"In a preclinical study, combination treatment consists of AZD6482, Encorafenib (LGX818), and NVP-AEW541 efficiently induced apoptosis in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6126,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,4061,AZD6482 + LGX818 + NVP-AEW541,5728,26577700,,,
159,Preclinical,"In a preclinical study, AZD6482 and NVP-AEW541 synergistically inhibited proliferation of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6103,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,4044,AZD6482 + NVP-AEW541,5728,26577700,,,
160,Preclinical,"In a preclincal study, TGX-221 inhibited Akt activation and proliferation in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6098,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,2514,TGX-221,5728,26577700,,,
161,Preclinical - Cell line xenograft,"In a preclinical study, combination treatment consisting of GSK2636771 and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).",Actionable,6136,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,4067,GSK2636771 + unspecified IGF-1R antibody,5728,26577700,,,
162,Preclinical,"In a preclinical study, Alpelisib (BYL719) and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations in culture (PMID: 26577700).",Actionable,6119,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,no benefit,1311,BYL719 + MEK162,5728,26577700,,,
163,Preclinical,"In a preclinical study, combination treatment consists of Encorafenib (LGX818) and a figitumumab-like antibody inhibited tumor growth in xenograft models of melanoma cell lines harboring BRAF mutations and PTEN inactivating mutations (PMID: 26577700).",Actionable,6137,1909,melanoma,DOID,22705,BRAF mut PTEN inact mut,sensitive,4068,LGX818 + unspecified IGF-1R antibody,5728,26577700,,,
164,Preclinical - Cell culture,"In a preclinical study, small cell lung carcinoma cells harboring PIK3CA D1029Y and PTEN inactivating mutation were resistant to PF-4989216 induced growth inhibition in culture (PMID: 24240111).",Actionable,5214,5409,lung small cell carcinoma,DOID,26219,PIK3CA D1029Y PTEN inact mut,resistant,867,PF-4989216,5728,24240111,,,
165,Preclinical - Cell line xenograft,"In a preclinical study, a glioblastoma cell line harboring a PTEN inactivating mutation (PMID: 24634413) was sensitive to SF1126, demonstrating inhibition of tumor growth in cell line xenograft models (PMID: 18172313). ",Actionable,10709,3068,glioblastoma multiforme,DOID,2095,PTEN inact mut,sensitive,915,SF1126,5728,24634413,18172313,,
166,Preclinical - Cell culture,"In a preclinical study, AZD5363 inhibited growth of various solid tumor cell culture models with inactivating Pten mutations (PMID: 22294718).",Actionable,9814,10000003,Advanced Solid Tumor,JAX,2095,PTEN inact mut,sensitive,655,AZD5363,5728,22294718,,,
167,Preclinical - Cell culture,"In a preclinical study, a PTEN deficient estrogen-receptor (ER) positive breast cancer cell line demonstrated increased sensitivity to treatment in culture when Pictilisib (GDC-0941) was given at a higher dose for a shorter duration, resulting in inhibition of cell growth (PMID: 26733612). ",Actionable,8366,60075,estrogen-receptor positive breast cancer,DOID,2095,PTEN inact mut,sensitive,749,GDC-0941,5728,26733612,,,
168,Preclinical - Cell line xenograft,"In a preclinical study, a glioblastoma cell line harboring a PTEN inactivating mutation was sensitive to XL765 (SAR245409), demonstrating inhibition of cell proliferation in culture, and inhibition of tumor growth in cell line xenograft models (PMID: 24634413).",Actionable,10704,3068,glioblastoma multiforme,DOID,2095,PTEN inact mut,sensitive,1051,SAR245409,5728,24634413,,,
169,Preclinical - Cell line xenograft,"In a preclinical study, LY3023414 inhibited proliferation of renal cancer cells harboring PTEN inactivating mutation in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 27439478).",Actionable,8941,263,kidney cancer,DOID,2095,PTEN inact mut,sensitive,1069,LY3023414,5728,27439478,,,
170,Preclinical - Cell line xenograft,"In a preclinical study, the combination of XL147 and Taxol (paclitaxel) inhibited tumor growth and angiogenesis in xenograft models of a human prostate adenocarcinoma cell line harboring an inactivating mutation in PTEN, with increased efficacy compared to either agent alone (PMID: 25637314).",Actionable,6338,2526,prostate adenocarcinoma,DOID,2095,PTEN inact mut,sensitive,4115,XL147 + Paclitaxel,5728,25637314,,,
171,Preclinical - Cell line xenograft,"In a preclinical study, XL147 inhibited PI3K signaling, growth, and migration of a human prostate adenocarcinoma cell line harboring a PTEN inactivating mutation in culture, and inhibited tumor growth and vascularization in xenograft models (PMID: 25637314).",Actionable,6322,2526,prostate adenocarcinoma,DOID,2095,PTEN inact mut,sensitive,1050,XL147,5728,25637314,,,
172,Preclinical - Cell culture,"In a preclinical study, the combination of Faslodex (fulvestrant) and PIctilisib (GDC-0941) resulted in decreased cell viability and increased apoptotic activity in PTEN deficient estrogen-receptor (ER) positive breast cancer cells in culture (PMID: 26733612).",Actionable,8367,60075,estrogen-receptor positive breast cancer,DOID,2095,PTEN inact mut,sensitive,4357,Fulvestrant + GDC-0941,5728,26733612,,,
173,Preclinical,"In a preclinical study, combination of BEZ235 and Binimetinib (MEK162) did not improve survival compared to single agent in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338).",Actionable,9199,9256,colorectal cancer,DOID,26770,APC inact mut PTEN inact mut,no benefit,4932,BEZ235 + Binimetinib,5728,26206338,,,
174,Preclinical,"In a preclinical study, Binimetinib (MEK162) reduced proliferation in tumors acutely but did not improve survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338).",Actionable,9192,9256,colorectal cancer,DOID,26770,APC inact mut PTEN inact mut,no benefit,807,Binimetinib,5728,26206338,,,
175,Preclinical,"In a preclinical study, BEZ235 inhibited  PI3K/mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation (PMID: 26206338).",Actionable,9189,9256,colorectal cancer,DOID,26770,APC inact mut PTEN inact mut,sensitive,672,BEZ235,5728,26206338,,,
176,Preclinical,"In a preclinical study, Binimetinib (MEK162) increased both apoptosis and proliferation in tumors, resulted in no improvement in survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation and KRAS G12D (PMID: 26206338).",Actionable,9194,9256,colorectal cancer,DOID,26772,APC inact mut KRAS G12D PTEN inact mut,no benefit,807,Binimetinib,5728,26206338,,,
177,Preclinical,"In a preclinical study, combination of BEZ235 and Binimetinib (MEK162) increased survival compared to single agent in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation and KRAS G12D (PMID: 26206338).",Actionable,9201,9256,colorectal cancer,DOID,26772,APC inact mut KRAS G12D PTEN inact mut,sensitive,4932,BEZ235 + Binimetinib,5728,26206338,,,
178,Preclinical,"In a preclinical study, BEZ235 inhibited mTOR signaling in tumors and increased survival in transgenic animal models of colorectal cancer driven by APC and PTEN inactivation, and KRAS G12D (PMID: 26206338).",Actionable,9191,9256,colorectal cancer,DOID,26772,APC inact mut KRAS G12D PTEN inact mut,sensitive,672,BEZ235,5728,26206338,,,
179,Preclinical - Cell line xenograft,"In a preclinical study, small cell lung carcinoma cell lines harboring wild-type PIK3CA and PTEN inactivating mutations were not sensitive to PF-4989216 induced growth inhibition in culture and in cell line xenograft models (PMID: 24240111).",Actionable,5215,5409,lung small cell carcinoma,DOID,26218,PIK3CA wild-type PTEN inact mut,decreased response,867,PF-4989216,5728,24240111,,,
180,Preclinical - Cell culture,"In a preclinical study, BAY1125976 inhibited proliferation of a prostate cancer cell line harboring KRAS G12V and PTEN K6fs*4 in culture (PMID: 27699769).",Actionable,8821,10283,prostate cancer,DOID,26456,KRAS G12V PTEN K6fs*4,sensitive,994,BAY1125976,5728,27699769,,,
181,Preclinical,"In a preclinical study, endometrial cancer cells harboring PIK3CA R88Q. PTEN mutations, and KRAS G12V demonstrated decreased sensitivity to Afinitor (everolimus) compared with cells without KRAS mutations in culture (PMID: 22662154).",Actionable,2140,1380,endometrial cancer,DOID,5418,PIK3CA R88Q PTEN mut KRAS G12V,decreased response,735,Everolimus,5728,22662154,,,
182,Preclinical,"In a preclinical study, endometrial cancer cells harboring PIK3CA R88Q. PTEN mutations, and KRAS G12V demonstrated decreased sensitivity to BEZ235 compared with cells without KRAS mutations in culture (PMID: 22662154).",Actionable,2141,1380,endometrial cancer,DOID,5418,PIK3CA R88Q PTEN mut KRAS G12V,decreased response,672,BEZ235,5728,22662154,,,
183,Preclinical,"In a preclinical study, BEZ235 inhibited proliferation of endometrial cancer cells harboring PIK3CA R88Q and PTEN mutations in culture (PMID: 22662154).",Actionable,2109,1380,endometrial cancer,DOID,5393,PIK3CA R88Q PTEN mut,sensitive,672,BEZ235,5728,22662154,,,
184,Preclinical,"In a preclinical study, Afinitor (everolimus) inhibited proliferation of endometrial cancer cells harboring PIK3CA R88Q and PTEN mutations in culture (PMID: 22662154).",Actionable,2110,1380,endometrial cancer,DOID,5393,PIK3CA R88Q PTEN mut,sensitive,735,Everolimus,5728,22662154,,,
185,Preclinical - Cell line xenograft,"In a preclinical study, Afinitor (everolimus) inhibited growth of endometrial cancer cells harboring a PTEN nonsense mutation in culture and in xenograft models (PMID: 22662154).",Actionable,2138,1380,endometrial cancer,DOID,1213,PTEN mutant,sensitive,735,Everolimus,5728,22662154,,,
186,Preclinical,"In a preclinical study, A66 and AZD6482 combination treatment inhibited viability of endometrioid endometrial cancer cell lines harboring PTEN mutations in culture (PMID: 23674493).",Actionable,4977,1380,endometrial cancer,DOID,1213,PTEN mutant,sensitive,3707,A66 + AZD6482,5728,23674493,,,
187,Preclinical - Cell line xenograft,"In a preclinical study, BI-69A11 resulted in antitumor activity in a melanoma cell line harboring a PTEN mutation, including induction of cell death in culture, and in xenograft models, tumor growth inhibition and tumor regression (PMID: 19175524). ",Actionable,10291,1909,melanoma,DOID,1213,PTEN mutant,sensitive,3308,BI-69A11,5728,19175524,,,
188,Phase II,"In a Phase II trial, Ipatasertib (GDC-0068) in combination with Abraxane (paclitaxel) resulted in improved progression free survival (6.2 vs 4.9 months) compared to placebo in triple-receptor negative breast cancer patients harboring mutations in PIK3CA, AKT1, or PTEN (J Clin Oncol 35, 2017 (suppl; abstr 1009)).",Actionable,11170,60081,triple-receptor negative breast cancer,DOID,1213,PTEN mutant,predicted â€“ sensitive,1588,Ipatasertib + Paclitaxel,5728,None,,,
189,Preclinical,"In a preclinical study, endometrioid endometrial cancer cell lines harboring PTEN mutations demonstrated resistance to GSK2636771 induced growth inhibition in culture (PMID: 23674493).",Actionable,4969,1380,endometrial cancer,DOID,1213,PTEN mutant,resistant,765,GSK2636771,5728,23674493,,,
190,Preclinical - Cell culture,"In a preclinical study, CUDC-907 inhibited growth of breast cancer cells lines harboring Pten mutations and/or deletions (PMID: 22693356).",Actionable,9818,1612,breast cancer,DOID,1213,PTEN mutant,sensitive,709,CUDC-907,5728,22693356,,,
191,Preclinical,"In a preclinical study, Sapanisertib (MLN0128) induced apoptosis and inhibited MTORC1 signaling in breast cancer cells harboring a PTEN mutation (PMID: 25261369).",Actionable,2077,1612,breast cancer,DOID,1213,PTEN mutant,sensitive,1282,Sapanisertib,5728,25261369,,,
192,Preclinical,"In a preclinical study, uterine cancer cells harboring a PTEN mutation were more sensitive to the combination of GSK2256098 and Hycamtin (topotecan) than uterine cancer cells wild-type for PTEN, resulting in decreased tumor growth in culture and in mouse models (PMID: 25833835). ",Actionable,5566,363,uterine cancer,DOID,1213,PTEN mutant,sensitive,3897,GSK2256098 + Topotecan,5728,25833835,,,
193,Preclinical,"In a preclinical study, endometrioid endometrial cancer cell lines harboring PTEN mutations demonstrated resistance to AZD6482 induced growth inhibition in culture (PMID: 23674493).",Actionable,4970,1380,endometrial cancer,DOID,1213,PTEN mutant,resistant,659,AZD6482,5728,23674493,,,
194,Preclinical,"In a preclinical study, BEZ235 decreased growth of endometrial cancer cells harboring a PTEN nonsense mutation in culture and in xenograft models (PMID: 22662154).",Actionable,2137,1380,endometrial cancer,DOID,1213,PTEN mutant,sensitive,672,BEZ235,5728,22662154,,,
195,Phase II,"In a Phase II trial, Apitolisib (GDC-0980) was poorly tolerated, but demonstrated efficacy in endometrial cancer patients harboring mutations in PIK3CA, PTEN, or AKT1 (J Clin Oncol 32:5s, 2014 (suppl; abstr 5513)).",Actionable,5204,1380,endometrial cancer,DOID,1213,PTEN mutant,sensitive,750,GDC-0980,5728,None,,,
196,Phase II,"In a retrospective study of a Phase II trial, mutation status of PTEN was not associated with progression-free survival or response rate in advanced endometrial cancer patients treated with Torisel (temsirolimus) (PMID: 27016228).",Actionable,4967,1380,endometrial cancer,DOID,1213,PTEN mutant,no benefit,936,Temsirolimus,5728,27016228,,,
197,Preclinical,"In a preclinical study, uterine cancer cells harboring a PTEN mutation were more sensitive to the combination of GSK2256098 and Taxol (paclitaxel) than uterine cancer cells wild-type for PTEN, resulting in decreased tumor growth in culture and in mouse models (PMID: 25833835). ",Actionable,5565,363,uterine cancer,DOID,1213,PTEN mutant,sensitive,3896,GSK2256098 + Paclitaxel,5728,25833835,,,
198,Preclinical,"In a preclinical study, endometrioid endometrial cancer cell lines harboring PTEN mutations demonstrated resistance to A66 induced growth inhibition in culture (PMID: 23674493).",Actionable,4972,1380,endometrial cancer,DOID,1213,PTEN mutant,resistant,617,A66,5728,23674493,,,
199,Preclinical - Cell culture,"In a preclinical study, Pictilisib (GDC-0941) and MS417 in combination resulted in improved growth inhibition and increased cell death compared to either agent alone in a PTEN-mutant breast cancer cell line in culture (PMID: 26058079).",Actionable,8599,1612,breast cancer,DOID,1213,PTEN mutant,predicted â€“ sensitive,4774,GDC-0941 + MS417,5728,26058079,,,
200,Preclinical,"In a preclinical study, endometrioid endometrial cancer cell lines harboring PTEN mutations demonstrated resistance to TGX-221 induced growth inhibition in culture (PMID: 23674493).",Actionable,4971,1380,endometrial cancer,DOID,1213,PTEN mutant,resistant,2514,TGX-221,5728,23674493,,,
201,Preclinical,"In a preclinical study, uterine cancer cells harboring a PTEN mutation demonstrated sensitivity to GSK2256098, resulting in inhibition of Ptk2 (Fak) phosphorylation, decreased tumor growth, and apoptosis both in culture and in mouse models (PMID: 25833835).",Actionable,4690,363,uterine cancer,DOID,1213,PTEN mutant,sensitive,3078,GSK2256098,5728,25833835,,,
202,Preclinical,"In a preclinical study, A66 and GSK2636771 combination treatment inhibited viability of endometrioid endometrial cancer cell lines harboring PTEN mutations in culture (PMID: 23674493).",Actionable,4978,1380,endometrial cancer,DOID,1213,PTEN mutant,sensitive,3708,A66 + GSK2636771,5728,23674493,,,
203,Preclinical - Cell line xenograft,"In a preclinical study, head and neck squamous cell carcinoma cell lines and cell line xenograft models with PTEN alterations were resistant to the apoptotic effects of Taselisib (GDC-0032) (PMID: 26589432).",Actionable,3915,5520,head and neck squamous cell carcinoma,DOID,1213,PTEN mutant,resistant,1016,GDC-0032,5728,26589432,,,
204,Preclinical - Cell line xenograft,"In a preclinical study, a melanoma cell line xenograft model co-harboring BRAF V600E and a PTEN mutation demonstrated tumor growth inhibition when treated with ASN003 (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B100).",Actionable,11043,1909,melanoma,DOID,27896,BRAF V600E PTEN mut,sensitive,5827,ASN003,5728,None,,,
205,Preclinical - Cell line xenograft,"In a preclinical study, E6201 resulted in a cytostatic response in melanoma cell lines harboring both BRAF and PTEN mutations in culture and only inhibited tumor growth at very high doses in cell line xenograft models (PMID: 23039341).",Actionable,5628,1909,melanoma,DOID,21306,BRAF mut PTEN mut,decreased response,1011,E6201,5728,23039341,,,
206,Preclinical,"In a preclinical study, BEZ235 decreased growth of endometrial cancer cells harboring PIK3CA R38C and PTEN mutations in culture and in xenograft models (PMID: 22662154).",Actionable,2112,1380,endometrial cancer,DOID,5397,PIK3CA R38C PTEN mut,sensitive,672,BEZ235,5728,22662154,,,
207,Preclinical - Cell culture,"In a preclinical study, the combination of ONC201 (TIC10) and Navitoclax (ABT-263) increased apoptosis and worked synergistically to inhibit proliferation of a glioblastoma cell line harboring mutations in PTEN and TP53 in culture (PMID: 26474387).",Actionable,9825,3068,glioblastoma multiforme,DOID,5387,PTEN mutant TP53 mutant,sensitive,5245,Navitoclax + ONC201,5728,26474387,,,
208,Preclinical,"In a preclinical study, a skin cancer cell line harboring mutations in PTEN and TP53 demonstrated sensitivity to Sapanisertib (MLN0128) in culture (PMID: 25261369). ",Actionable,2104,4159,skin cancer,DOID,5387,PTEN mutant TP53 mutant,sensitive,1282,Sapanisertib,5728,25261369,,,
209,Preclinical,"In a preclinical study, BEZ235 inhibited proliferation of endometrial cancer cells harboring PIK3CA E365K and PTEN mutations in culture (PMID: 22662154).",Actionable,2113,1380,endometrial cancer,DOID,5401,PIK3CA E365K PTEN mut,sensitive,672,BEZ235,5728,22662154,,,
210,Preclinical,"In a preclinical study, BEZ235 inhibited proliferation of endometrial cancer cells harboring PIK3CA E365K and PTEN mutations in culture (PMID: 22662154).",Actionable,2139,7519,endocervical carcinoma,DOID,5401,PIK3CA E365K PTEN mut,sensitive,672,BEZ235,5728,22662154,,,
211,Preclinical,"In a preclinical study, a skin cancer cell line harboring mutations in PTEN, RB1, SMAD4 and TP53 demonstrated sensitivity to Sapanisertib (MLN0128) in culture (PMID: 25261369). ",Actionable,2106,4159,skin cancer,DOID,5389,PTEN mut RB1 mut SMAD4 mut TP53 mut,sensitive,1282,Sapanisertib,5728,25261369,,,
212,Preclinical,"In a preclinical study, BEZ235 inhibited proliferation of endometrial cancer cells harboring PIK3CA R108H and PTEN mutations in culture (PMID: 22662154).",Actionable,2111,1380,endometrial cancer,DOID,5394,PIK3CA R108H PTEN mut,sensitive,672,BEZ235,5728,22662154,,,
213,Phase I,"In a Phase I clinical trial, the combination of Buparlisib (BKM120) and Herceptin (trastuzumab) was well tolerated and resulted in some preliminary efficacy in patients with ERBB2 (HER2)-positive breast cancer harboring PIK3CA activating mutations and/or PTEN mutations that had progressed on Herceptin (trastuzumab)-based therapy (PMID: 24470511).",Actionable,4370,60079,Her2-receptor positive breast cancer,DOID,23651,ERBB2 pos PTEN mut,predicted â€“ sensitive,1417,BKM120 + Trastuzumab,5728,24470511,,,
214,Preclinical - Cell line xenograft,"In a preclinical study, small cell lung carcinoma cell lines harboring wild-type PIK3CA and PTEN R55fs*1 were not sensitive to PF-4989216 induced growth inhibition in culture and in cell line xenograft models (PMID: 24240111).",Actionable,8286,5409,lung small cell carcinoma,DOID,26222,PIK3CA wild-type PTEN R55fs*1,resistant,867,PF-4989216,5728,24240111,,,
215,Preclinical - Cell culture,"In a preclinical study, BAY1125976 inhibited proliferation of a breast cancer cell line harboring PIK3CA H1047R and PTEN E307K in culture (PMID: 27699769).",Actionable,8819,1612,breast cancer,DOID,26449,PIK3CA H1047R PTEN E307K,sensitive,994,BAY1125976,5728,27699769,,,
216,Preclinical - Cell culture,"In a preclinical study, the combination of BGJ398 and Buparlisib (BKM120) resulted in a synergistic effect, demonstrating inhibition of cell proliferation, decreased colony formation, and cell death in an endometrial cancer cell line harboring FGFR2 N550K, PIK3CA I20M and P539R, and PTEN R130Q and T321fs*23 in culture (PMID: 28119489). ",Actionable,10778,1380,endometrial cancer,DOID,27771,FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs*23,sensitive,5612,BGJ398 + BKM120,5728,28119489,,,
217,Preclinical - Cell culture,"In a preclinical study, the combination of BGJ398 and Alpelisib (BYL719) resulted in a synergistic effect, demonstrating inhibition of cell proliferation and induced cell death in an endometrial cancer cell line harboring FGFR2 N550K, PIK3CA I20M and P539R, and PTEN R130Q and T321fs*23 in culture (PMID: 28119489). ",Actionable,10780,1380,endometrial cancer,DOID,27771,FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs*23,sensitive,1293,BGJ398 + BYL719,5728,28119489,,,
218,Preclinical - Cell culture,"In a preclinical study, the combination of BGJ398 and Pictilisib (GDC-0941) resulted in a synergistic effect, demonstrating inhibition of cell proliferation, decreased colony formation, and cell death in an endometrial cancer cell line harboring FGFR2 N550K, PIK3CA I20M and P539R, and PTEN R130Q and T321fs*23 in culture (PMID: 28119489). ",Actionable,10777,1380,endometrial cancer,DOID,27771,FGFR2 N550K PIK3CA I20M PIK3CA P539R PTEN R130Q PTEN T321fs*23,sensitive,5613,BGJ398 + GDC-0941,5728,28119489,,,
219,Phase II,"In a Phase II trial, a patient with head and neck squamous cell carcinoma harboring PTEN R130Q demonstrated a partial response when treated with the combination of Torisel (temsirolimus), Paraplatin (carboplatin), and Taxol (paclitaxel) (PMID: 28961834). ",Actionable,12185,5520,head and neck squamous cell carcinoma,DOID,4174,PTEN R130Q,predicted â€“ sensitive,6333,Carboplatin + Paclitaxel + Temsirolimus,5728,28961834,,,
220,Preclinical - Cell culture,"In a preclinical study, breast cancer cells harboring PTEN C136Y demonstrated resistance to Alpelisib (BYL719) in culture (PMID: 27604488).",Actionable,8904,1612,breast cancer,DOID,3852,PTEN C136Y,resistant,691,BYL719,5728,27604488,,,
221,Preclinical - Cell line xenograft,"In a preclinical study, small cell lung carcinoma cell lines harboring wild-type PIK3CA and PTEN Y27fs*1 were not sensitive to PF-4989216 induced growth inhibition in culture and in cell line xenograft models (PMID: 24240111).",Actionable,8285,5409,lung small cell carcinoma,DOID,26223,PIK3CA wild-type PTEN Y27fs*1,resistant,867,PF-4989216,5728,24240111,,,
222,Preclinical,"In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR amplification, EGFRvIII, and PTEN R308C in culture (PMID: 26561558).",Actionable,6037,3068,glioblastoma multiforme,DOID,22287,EGFR amp EGFR act mut PTEN R308C,sensitive,4008,Gefitinib + Linsitinib,5728,26561558,,,
223,Preclinical,"In a preclinical study, Dacomitinib and BMS-754807 worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR amplification, EGFRvIII, and PTEN R308C in culture (PMID: 26561558).",Actionable,6045,3068,glioblastoma multiforme,DOID,22287,EGFR amp EGFR act mut PTEN R308C,sensitive,4009,BMS-754807 + Dacomitinib,5728,26561558,,,
224,Preclinical,"In a preclinical study, Dacomitinib and BMS-754807 worked synergistically to inhibit survival of glioblastoma cell lines harboring EGFR (A289T, EGFRvIII) and PTEN (N69D, I253N) mutations in culture (PMID: 26561558).",Actionable,6046,3068,glioblastoma multiforme,DOID,22288,EGFR act mut EGFR A289T PTEN I253N PTEN N69D,sensitive,4009,BMS-754807 + Dacomitinib,5728,26561558,,,
225,Preclinical,"In a preclinical study, Iressa (gefitinib) and Linsitinib (OSI-906) worked synergistically to inhibit survival of glioblastoma cell lines harboring mutations in EGFR (EGFRvIII, A289T) and PTEN (I253N, N69D) in culture (PMID: 26561558).",Actionable,6038,3068,glioblastoma multiforme,DOID,22288,EGFR act mut EGFR A289T PTEN I253N PTEN N69D,sensitive,4008,Gefitinib + Linsitinib,5728,26561558,,,
226,Preclinical - Cell line xenograft,"In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring KRAS G13C, PIK3CA H1047Y, PTEN G143fs*4, and PTEN K267fs*9 was sensitive to treatment with DS-7423, demonstrating inhibition of cell proliferation in culture and tumor growth inhibition in xenograft models (PMID: 24504419). ",Actionable,10541,5304,ovarian clear cell adenocarcinoma,DOID,27593,KRAS G13C PIK3CA H1047Y PTEN G143fs*4 PTEN K267fs*9,sensitive,722,DS-7423,5728,24504419,,,
227,Preclinical - Cell culture,"In a preclinical study, MK2206 inhibited AKT activation, proliferation, and growth of thyroid cancer cell lines with  PI3K/AKT pathway alterations in culture, including an follicular thyroid cancer cell line harboring PTEN R130* and loss of one PTEN allele (PMID: 21289267).",Actionable,8215,3962,follicular thyroid carcinoma,DOID,4166,PTEN R130*,sensitive,816,MK2206,5728,21289267,,,
228,Preclinical - Cell line xenograft,"In a preclinical study, XL147 inhibited tumor growth in xenograft models of a human glioblastoma cell line harboring PTEN V54fs (PMID: 25637314).",Actionable,6317,3068,glioblastoma multiforme,DOID,23098,PTEN V54fs,sensitive,1050,XL147,5728,25637314,,,
229,Preclinical - Pdx,"In a preclinical study, treatment with the combination of Selumetinib (AZD6244) and BEZ235 resulted in stable disease in patient-derived xenograft (PDX) models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, and PTEN R130G, and demonstrated improved efficacy over either agent alone (PMID: 26232337).",Actionable,9373,1380,endometrial cancer,DOID,26839,KRAS G12D PIK3CA H1047R PTEN R130G,sensitive,1420,Selumetinib + BEZ235,5728,26232337,,,
230,Preclinical - Pdx,"In a preclinical study, treatment with BEZ235 slowed growth of tumors in patient-derived xenograft models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, PTEN R130G (PMID: 26232337).",Actionable,9375,1380,endometrial cancer,DOID,26839,KRAS G12D PIK3CA H1047R PTEN R130G,sensitive,672,BEZ235,5728,26232337,,,
231,Preclinical - Pdx,"In a preclinical study, treatment with Selumetinib (AZD6244) slowed growth of tumors in patient-derived xenograft models of endometrial cancer harboring KRAS G12D, PIK3CA H1047R, PTEN R130G (PMID: 26232337).",Actionable,9374,1380,endometrial cancer,DOID,26839,KRAS G12D PIK3CA H1047R PTEN R130G,sensitive,913,Selumetinib,5728,26232337,,,
232,Preclinical - Pdx,"In a preclinical study, a patient-derived xenograft (PDX) model of endometrial cancer harboring PIK3CA D350G, PIK3CA R93W, and PTEN R130G was sensitive to ARQ092, demonstrating greater than 90% inhibition of tumor growth (PMID: 26469692). ",Actionable,10283,1380,endometrial cancer,DOID,27339,PIK3CA D350G PIK3CA R93W PTEN R130G,sensitive,635,ARQ092,5728,26469692,,,
233,Preclinical,"In a preclinical study, GSK2636771 and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",Actionable,6122,1909,melanoma,DOID,21308,BRAF mut PTEN wild-type,no benefit,4052,GSK2636771 + Binimetinib,5728,26577700,,,
234,Preclinical,"In a preclinical study, AZD6482 and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",Actionable,6107,1909,melanoma,DOID,21308,BRAF mut PTEN wild-type,no benefit,4044,AZD6482 + NVP-AEW541,5728,26577700,,,
235,Preclinical,"In a preclinical study, GSK2636771 and NVP-AEW541 combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",Actionable,6108,1909,melanoma,DOID,21308,BRAF mut PTEN wild-type,no benefit,4045,GSK2636771 + NVP-AEW541,5728,26577700,,,
236,Preclinical,"In a preclinical study, GSK2636771 and Encorafenib (LGX818) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",Actionable,6124,1909,melanoma,DOID,21308,BRAF mut PTEN wild-type,no benefit,4055,GSK2636771 + LGX818,5728,26577700,,,
237,Preclinical,"In a preclinical study, AZD6482 and Encorafenib (LGX818) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",Actionable,6123,1909,melanoma,DOID,21308,BRAF mut PTEN wild-type,no benefit,4048,AZD6482 + LGX818,5728,26577700,,,
238,Preclinical,"In a preclinical study, AZD6482 and Binimetinib (MEK162) combination treatment did not enhance growth inhibition compared to single agent in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture (PMID: 26577700).",Actionable,6121,1909,melanoma,DOID,21308,BRAF mut PTEN wild-type,no benefit,4054,AZD6482 + Binimetinib,5728,26577700,,,
239,Preclinical - Cell line xenograft,"In a preclinical study, E6201 resulted in a cytocidal response in PTEN wild-type melanoma cell lines harboring BRAF mutations in culture and inhibited tumor growth in cell line xenograft models (PMID: 23039341).",Actionable,5629,1909,melanoma,DOID,21308,BRAF mut PTEN wild-type,sensitive,1011,E6201,5728,23039341,,,
240,Preclinical - Cell culture,"In a preclinical study, 8/9 breast cancer cell lines harboring a PIK3CA activating mutation and PTEN wild-type demonstrated sensitivity to treatment with Afinitor (everolimus) in culture, resulting in decreased cell viability (PMID: 21358673). ",Actionable,10365,1612,breast cancer,DOID,27384,PIK3CA act mut PTEN wild-type,sensitive,735,Everolimus,5728,21358673,,,
241,Preclinical - Cell culture,"In a preclinical study, 9/9 breast cancer cell lines harboring a PIK3CA activating mutation and PTEN wild-type demonstrated sensitivity to treatment with Torkinib (PP242) in culture, resulting in decreased cell viability (PMID: 21358673). ",Actionable,10366,1612,breast cancer,DOID,27384,PIK3CA act mut PTEN wild-type,sensitive,2240,Torkinib,5728,21358673,,,
242,Preclinical - Cell line xenograft,"In a preclinical study, PF-4989216 inhibited proliferation of small cell lung carcinoma cells harboring PIK3CA H1047R, PIK3CA K111R, and wild-type PTEN in culture, and suppressed tumor growth in cell line xenograft models (PMID: 24240111).",Actionable,5218,5409,lung small cell carcinoma,DOID,20308,PIK3CA H1047R PIK3CA K111R PTEN wild-type,sensitive,867,PF-4989216,5728,24240111,,,
243,Preclinical - Cell line xenograft,"In a preclinical study, PF-4989216 inhibited proliferation of small cell lung carcinoma cells harboring PIK3CA G106_R108del and wild-type PTEN in culture, and suppressed tumor growth in cell line xenograft models (PMID: 24240111).",Actionable,5217,5409,lung small cell carcinoma,DOID,20307,PIK3CA G106_R108del PTEN wild-type,sensitive,867,PF-4989216,5728,24240111,,,
244,Preclinical,"In a preclinical study, KX2-391 inhibited survival of PTEN wild-type mucinous ovarian carcinoma cell lines in culture, and reduced tumor growth in xenograft models (PMID: 24100628).",Actionable,5905,6067,ovarian mucinous neoplasm,DOID,683,PTEN wild-type,sensitive,786,KX2-391,5728,24100628,,,
245,Preclinical,"In a preclinical study, 2-Methoxyestradiol (2ME2) inhibited tumor-induced angiogenesis and reduced tumor growth in PTEN reconstituted GBM cell lines and mouse models (PMID: 24162827).",Actionable,848,3068,glioblastoma multiforme,DOID,683,PTEN wild-type,sensitive,1341,2-Methoxyestradiol ,5728,24162827,,,
246,Preclinical,"In a preclinical study, E6201 inhibited proliferation of several melanoma cell lines in culture and sensitivity was associated with wild-type PTEN (PMID: 23039341).",Actionable,4079,1909,melanoma,DOID,683,PTEN wild-type,sensitive,1011,E6201,5728,23039341,,,
247,Preclinical,"In a preclinical study, KX2-391 and Eloxatin (oxaliplatin) synergistically inhibited survival of PTEN wild-type mucinous ovarian carcinoma cell lines in culture, and reduced tumor growth in xenograft models (PMID: 24100628).",Actionable,5906,6067,ovarian mucinous neoplasm,DOID,683,PTEN wild-type,sensitive,3979,KX2-391 + Oxaliplatin,5728,24100628,,,
248,Preclinical,"In a preclinical study, GSK2256098 treatment resulted in a decreased response in uterine cancer cells with PTEN wild-type versus uterine cancer cells harboring a PTEN mutation (PMID: 25833835).",Actionable,4691,363,uterine cancer,DOID,683,PTEN wild-type,decreased response,3078,GSK2256098,5728,25833835,,,
249,Preclinical,"In a preclinical study, AZD8186 and Alpelisib (BYL719) combination treatment resulted in minor inhibition of tumor growth in animal models of prostate cancer harboring PTEN gene deletion (PMID: 25544636).",Actionable,5091,10283,prostate cancer,DOID,2408,PTEN del,sensitive,3749,AZD8186 + BYL719,5728,25544636,,,
250,Preclinical,"In a preclinical study, Rubraca (rucaparib) induced senescence and increased radiosensitivity in PTEN null prostate cancer cells in culture (PMID: 23565244).",Actionable,2700,10283,prostate cancer,DOID,2408,PTEN del,sensitive,906,Rucaparib,5728,23565244,,,
251,Preclinical,"In a preclinical study, head and neck squamous cell carcinoma cells homozygous for PTEN deletion were resistant to Taselisib (GDC-0032) in culture (PMID: 26589432).",Actionable,5867,5520,head and neck squamous cell carcinoma,DOID,2408,PTEN del,resistant,1016,GDC-0032,5728,26589432,,,
252,Preclinical - Cell culture,"In a preclinical study, CUDC-907 inhibited growth of breast cancer cells lines harboring Pten mutations and/or deletions (PMID: 22693356).",Actionable,9819,1612,breast cancer,DOID,2408,PTEN del,sensitive,709,CUDC-907,5728,22693356,,,
253,Phase I,"In a Phase I trial, AZD8186 demonstrated preliminary efficacy in patients with tumor types with prevalent PTEN-deficiency, including prostate cancer (AACR; Cancer Res 2015;75(15 Suppl):Abstract nr CT329).",Actionable,3769,10283,prostate cancer,DOID,2408,PTEN del,predicted â€“ sensitive,992,AZD8186,5728,None,,,
254,Preclinical - Cell line xenograft,"In a preclinical study, CH5132799 induced tumor regression in xenograft models of a human stomach cancer cell line with deletion of PTEN (PMID: 21558396).",Actionable,2971,10534,stomach cancer,DOID,2408,PTEN del,sensitive,2152,CH5132799,5728,21558396,,,
255,Preclinical,"In a preclinical study, AZD8186 and XTANDI (enzalutamide) combination treatment resulted in suppression of tumor growth in animal models of prostate cancer harboring PTEN gene deletion (PMID: 25544636).",Actionable,5093,10283,prostate cancer,DOID,2408,PTEN del,sensitive,3752,AZD8186 + Enzalutamide,5728,25544636,,,
256,Preclinical - Cell line xenograft,"In a preclinical study, VS-5584 inhibited PI3K/mTOR signaling and cell proliferation in a human prostate cancer cell line harboring a PTEN deletion in culture, and inhibited PI3K/MTOR signaling and tumor growth in xenograft models (PMID: 23270925).",Actionable,2509,10283,prostate cancer,DOID,2408,PTEN del,not applicable,960,VS-5584,5728,23270925,,,
257,Preclinical,"In a preclinical study, AZD8186, Alpelisib (BYL719), and Xtandi (enzalutamide) combination treatment resulted in near-complete suppression of tumor growth in animal models of prostate cancer harboring PTEN gene deletion (PMID: 25544636).",Actionable,5092,10283,prostate cancer,DOID,2408,PTEN del,sensitive,3750,AZD8186 + BYL719 + Enzalutamide,5728,25544636,,,
258,Preclinical - Cell line xenograft,"In a preclinical study, prostate cancer cell line xenograft models with PTEN deletion demonstrated sensitivity to treatment with Ipatasertib (GDC-0068), resulting in inhibition of tumor growth (PMID: 24141624). ",Actionable,8965,10283,prostate cancer,DOID,2408,PTEN del,sensitive,747,Ipatasertib,5728,24141624,,,
259,Preclinical,"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human prostate cancer cells harboring PTEN deletion in culture (PMID: 21325073, PMID: 14737113).",Actionable,3138,10283,prostate cancer,DOID,2408,PTEN del,sensitive,1040,PF-05212384,5728,21325073,14737113,,
260,Preclinical,"In a preclinical study, bladder cancer cells with PTEN deletion were sensitive to Glucophage (metformin) in culture, resulting in inhibition of cell growth (PMID: 26921394). ",Actionable,5176,11054,urinary bladder cancer,DOID,2408,PTEN del,sensitive,1031,Metformin,5728,26921394,,,
261,Preclinical - Cell line xenograft,"In a preclinical study, CH5132799 inhibited tumor growth in xenograft models of a human prostate cancer cell line with deletion of PTEN (PMID: 21558396).",Actionable,2972,10283,prostate cancer,DOID,2408,PTEN del,sensitive,2152,CH5132799,5728,21558396,,,
262,Preclinical,"In a preclinical study, GDC-0941 and Zolinza (vorinostat) acted synergistically to inhibit growth of a human prostate cancer cell line harboring a PTEN deletion in culture (PMID: 9661880, PMID: 22693356).",Actionable,3009,10283,prostate cancer,DOID,2408,PTEN del,sensitive,3070,GDC-0941 + vorinostat,5728,22693356,9661880,,
263,Phase I,"In a Phase I trial, CC-223 demonstrated safety and preliminary efficacy in patients with solid tumors, including stable disease for greater than 110 days in 2 patients with PIK3CA mutation or PTEN deletion (PMID: 26177599).",Actionable,4498,10000003,Advanced Solid Tumor,JAX,2408,PTEN del,sensitive,693,CC-223,5728,26177599,,,
264,Preclinical - Cell line xenograft,"In a preclinical study, PF-04691502 inhibited tumor growth in PTEN-deleted non-small cell lung cancer cell line xenograft models (PMID: 21750219).",Actionable,106,3908,non-small cell lung carcinoma,DOID,2408,PTEN del,predicted â€“ sensitive,865,PF-04691502,5728,21750219,,,
265,Phase I,"In a Phase I trial, patients with advanced solid tumors deficient in PTEN lacked benefit from GSK2636771 (PMID: 26117819).",Actionable,3731,10000003,Advanced Solid Tumor,JAX,2408,PTEN del,no benefit,765,GSK2636771,5728,26117819,,,
266,Preclinical - Cell culture,"In a preclinical study, BAY1125976 inhibited proliferation of a breast cancer cell line harboring PTEN L108R in culture (PMID: 27699769).",Actionable,8816,1612,breast cancer,DOID,4086,PTEN L108R,sensitive,994,BAY1125976,5728,27699769,,,
267,Preclinical - Cell culture,"In a preclinical study, DHM25 increased cell death in a breast cancer cell line harboring PTEN L108R in culture (PMID: 26237138).",Actionable,10359,1612,breast cancer,DOID,4086,PTEN L108R,sensitive,5494,DHM25,5728,26237138,,,
268,Preclinical - Cell culture,"In a preclinical study, BAY1125976 inhibited proliferation of a breast cancer cell line harboring PTEN T319fs*1 in culture (PMID: 27699769).",Actionable,8817,1612,breast cancer,DOID,4239,PTEN T319fs*1,sensitive,994,BAY1125976,5728,27699769,,,
269,Phase I,"In a Phase I clinical trial, Refametinib (BAY 86-9766) demonstrated preliminary clinical activity in patients with several tumor types, including prolonged stable disease in an ocular melanoma patient harboring GNAQ Q209L and PTEN R173S (PMID: 23434733).",Actionable,10644,1752,ocular melanoma,DOID,27655,GNAQ Q209L PTEN R173S,predicted â€“ sensitive,888,Refametinib,5728,23434733,,,
270,Preclinical - Cell culture,"In a preclinical study, Alpelisib (BYL719) inhibited Akt signaling and cell migration in prostate cancer cells expressing PTEN A126G in culture (PMID: 26504226).",Actionable,4906,10283,prostate cancer,DOID,19788,PTEN A126G,sensitive,691,BYL719,5728,26504226,,,
271,Preclinical,"In a preclinical study, AZD6482 inhibited Akt signaling and cell migration in prostate cancer cell lines overexpressing PTEN A126G (PMID: 26504226).",Actionable,4907,10283,prostate cancer,DOID,19788,PTEN A126G,sensitive,659,AZD6482,5728,26504226,,,
0,Preclinical - Cell culture,"In a preclinical study, knocking down of Ptpn11 expression via shRNA sensitized BRAF mutant colorectal cancer cell lines to PLX4720 in culture (PMID: 26351322).",Actionable,8668,9256,colorectal cancer,DOID,26402,BRAF mut PTPN11 dec exp,sensitive,1060,PLX4720,5781,26351322,,,
1,Preclinical,"In a preclinical study, Rafemetinib (BAY86-9766) inhibited growth of NSCLC cells harboring activating PTPN11 mutations in culture (J Clin Oncol 33, 2015(Suppl; abstr 11077)). ",Actionable,2639,3908,non-small cell lung carcinoma,DOID,9820,PTPN11 act mut,sensitive,888,Refametinib,5781,None,,,
2,Preclinical,"In a preclinical study, hematopoietic progenitor cells expressing PTPN11 E76K were sensitive to II-B08, resulting in decreased cell proliferation (PMID: 20170098).",Actionable,3984,2531,hematologic cancer,DOID,9830,PTPN11 E76K,sensitive,2963,II-B08,5781,20170098,,,
3,Preclinical,"In a preclinical study, U0126 induced apoptotic activity of leukemia cells expressing PTPN11 E76K in culture (PMID: 17942397).",Actionable,2640,1240,leukemia,DOID,9830,PTPN11 E76K,sensitive,2427,U0126,5781,17942397,,,
4,Preclinical,"In a preclinical study, myeloid cells harboring PTPN11 E76K were sensitive to cryptotanshinone in culture, resulting in decreased cell growth (PMID: 23957426).",Actionable,3983,50458,juvenile myelomonocytic leukemia,DOID,9830,PTPN11 E76K,sensitive,3415,cryptotanshinone,5781,23957426,,,
5,Preclinical,"In a preclinical study, PD98059 induced apoptotic activity of leukemia cells expressing PTPN11 E76K in culture (PMID: 17942397).",Actionable,2641,1240,leukemia,DOID,9830,PTPN11 E76K,sensitive,2617,PD98059,5781,17942397,,,
6,Clinical Study,"In two clinical studies, PTPN11 mutations were frequently identified in patients with juvenile myelomonocytic leukemia and were found to be associated with poor survival (PMID: 19047918, PMID: 21901340), suggesting that this may serve as a future prognostic biomarker.",Emerging,3817,50458,juvenile myelomonocytic leukemia,DOID,9821,PTPN11 mutant,not applicable,1776,N/A,5781,19047918,21901340,,
0,Preclinical,"In a preclinical study, siRNA inhibition of RAD21 in breast cancer cells resulted in increased sensitivity to Toposaur (etoposide) in culture, suggesting RAD21 may be a potential therapeutic target for enhanced sensitivity to chemotherapeutics (PMID: 15767545). ",Emerging,6484,1612,breast cancer,DOID,23596,RAD21 wild-type,not applicable,1776,N/A,5885,15767545,,,
0,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Kisqali (ribociclib) and Adexone (dexamethasone) in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and NOTCH1 resulted in decreased cell viability and reduced phosphorylation of Rb1 in culture, however, survival did not differ between xenograft models treated with the combination or Kisqali (ribociclib) alone (PMID: 28151717). ",Actionable,10044,5602,T-cell adult acute lymphocytic leukemia,DOID,27229,NOTCH1 wild-type RB1 wild-type,conflicting,5355,Ribociclib + Dexamethasone,5925,28151717,,,
1,Preclinical - Cell culture,"In a preclinical study, the addition of Kisqali (ribociclib) to Methotrexate resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717). ",Actionable,10034,5602,T-cell adult acute lymphocytic leukemia,DOID,27229,NOTCH1 wild-type RB1 wild-type,decreased response,5352,Ribociclib + Methotrexate,5925,28151717,,,
2,Preclinical - Cell culture,"In a preclinical study, a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 demonstrated sensitivity to treatment with Kisqali (ribociclib) in culture, resulting in inhibition of cell growth (PMID: 28151717). ",Actionable,10032,5602,T-cell adult acute lymphocytic leukemia,DOID,27229,NOTCH1 wild-type RB1 wild-type,sensitive,790,Ribociclib,5925,28151717,,,
3,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Kisqali (ribociclib) and Afinitor (everolimus) treatment in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 resulted in decreased Rb1 phosphorylation and a greater inhibition of cell growth compared to either agent alone in culture, and prolonged survival in cell-line xenograft models (PMID: 28151717). ",Actionable,10049,5602,T-cell adult acute lymphocytic leukemia,DOID,27229,NOTCH1 wild-type RB1 wild-type,sensitive,5073,Ribociclib + Everolimus,5925,28151717,,,
4,Preclinical - Cell culture,"In a preclinical study, the addition of Kisqali (ribociclib) to Elspar (asparaginase) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717). ",Actionable,10042,5602,T-cell adult acute lymphocytic leukemia,DOID,27229,NOTCH1 wild-type RB1 wild-type,decreased response,5354,Ribociclib + Asparaginase,5925,28151717,,,
5,Preclinical - Cell culture,"In a preclinical study, the combination of Kisqali (ribociclib) and Omnipred (prednisolone) resulted in a synergistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717). ",Actionable,10047,5602,T-cell adult acute lymphocytic leukemia,DOID,27229,NOTCH1 wild-type RB1 wild-type,sensitive,5356,Ribociclib + Prednisolone,5925,28151717,,,
6,Preclinical - Cell culture,"In a preclinical study, the combination of Kisqali (ribociclib) and Velcade (bortezomib) resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717). ",Actionable,10053,5602,T-cell adult acute lymphocytic leukemia,DOID,27229,NOTCH1 wild-type RB1 wild-type,sensitive,5358,Ribociclib + Bortezomib,5925,28151717,,,
7,Preclinical - Cell culture,"In a preclinical study, the combination of Kisqali (ribociclib) and JQ1 resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717). ",Actionable,10051,5602,T-cell adult acute lymphocytic leukemia,DOID,27229,NOTCH1 wild-type RB1 wild-type,sensitive,5357,Ribociclib + JQ1,5925,28151717,,,
8,Preclinical - Cell culture,"In a preclinical study, the addition of Kisqali (ribociclib) to Purixan (mercaptopurine) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and wild-type NOTCH1 in culture (PMID: 28151717). ",Actionable,10036,5602,T-cell adult acute lymphocytic leukemia,DOID,27229,NOTCH1 wild-type RB1 wild-type,decreased response,5353,Ribociclib + Mercaptopurine,5925,28151717,,,
9,Preclinical,"In a preclinical study, R547 inhibited proliferation of osteosarcoma cell lines harboring mutant Tp53 and wild-type Rb1 (PMID: 17121911).",Actionable,4359,3347,osteosarcoma,DOID,17822,TP53 mutant RB1 wild-type,sensitive,3497,R547,5925,17121911,,,
10,Preclinical - Cell line xenograft,"In a preclinical study, R547 inhibited proliferation of breast carcinoma cell lines harboring mutant Tp53 and wild-type Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911).",Actionable,4352,3459,breast carcinoma,DOID,17822,TP53 mutant RB1 wild-type,sensitive,3497,R547,5925,17121911,,,
11,Preclinical,"In a preclinical study, R547 inhibited proliferation of colon carcinoma cell lines harboring mutant Tp53 and wild-type Rb1 (PMID: 17121911).",Actionable,4355,1520,colon carcinoma,DOID,17822,TP53 mutant RB1 wild-type,sensitive,3497,R547,5925,17121911,,,
12,Preclinical,"In a preclinical study, R547 inhibited proliferation of mantle cell lymphoma cell lines harboring mutant Tp53 and wild-type Rb1 (PMID: 17121911).",Actionable,4361,50746,mantle cell lymphoma,DOID,17822,TP53 mutant RB1 wild-type,sensitive,3497,R547,5925,17121911,,,
13,Preclinical - Cell culture,"In a preclinical study, the addition of Kisqali (ribociclib) to Purixan (mercaptopurine) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717). ",Actionable,10035,5602,T-cell adult acute lymphocytic leukemia,DOID,27228,NOTCH1 mut RB1 wild-type,decreased response,5353,Ribociclib + Mercaptopurine,5925,28151717,,,
14,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Kisqali (ribociclib) and Adexone (dexamethasone) treatment in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation resulted in decreased cell viability and reduced phosphorylation of Rb1 in culture, and a greater survival benefit in xenograft models when compared to Kisqali (ribociclib) alone (PMID: 28151717). ",Actionable,10043,5602,T-cell adult acute lymphocytic leukemia,DOID,27228,NOTCH1 mut RB1 wild-type,sensitive,5355,Ribociclib + Dexamethasone,5925,28151717,,,
15,Preclinical - Cell culture,"In a preclinical study, the combination of Kisqali (ribociclib) and JQ1 resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717). ",Actionable,10050,5602,T-cell adult acute lymphocytic leukemia,DOID,27228,NOTCH1 mut RB1 wild-type,sensitive,5357,Ribociclib + JQ1,5925,28151717,,,
16,Preclinical - Cell culture,"In a preclinical study, the addition of Kisqali (ribociclib) to Methotrexate resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717). ",Actionable,10033,5602,T-cell adult acute lymphocytic leukemia,DOID,27228,NOTCH1 mut RB1 wild-type,decreased response,5352,Ribociclib + Methotrexate,5925,28151717,,,
17,Preclinical - Cell culture,"In a preclinical study, the combination of Kisqali (ribociclib) and Omnipred (prednisolone) resulted in a synergistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717). ",Actionable,10046,5602,T-cell adult acute lymphocytic leukemia,DOID,27228,NOTCH1 mut RB1 wild-type,sensitive,5356,Ribociclib + Prednisolone,5925,28151717,,,
18,Preclinical - Cell culture,"In a preclinical study, the combination of Kisqali (ribociclib) and Afinitor (everolimus) treatment in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation resulted in decreased Rb1 phosphorylation and a greater inhibition of cell growth compared to either agent alone in culture (PMID: 28151717). ",Actionable,10048,5602,T-cell adult acute lymphocytic leukemia,DOID,27228,NOTCH1 mut RB1 wild-type,sensitive,5073,Ribociclib + Everolimus,5925,28151717,,,
19,Preclinical - Cell culture,"In a preclinical study, the addition of Kisqali (ribociclib) to Elspar (asparaginase) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717). ",Actionable,10037,5602,T-cell adult acute lymphocytic leukemia,DOID,27228,NOTCH1 mut RB1 wild-type,decreased response,5354,Ribociclib + Asparaginase,5925,28151717,,,
20,Preclinical - Cell culture,"In a preclinical study, a T-cell acute lymphoblastic leukemia cell line co-harboring wild-type RB1 and a NOTCH1 mutation demonstrated sensitivity to treatment with Kisqali (ribociclib) in culture, resulting in inhibition of cell growth (PMID: 28151717). ",Actionable,10031,5602,T-cell adult acute lymphocytic leukemia,DOID,27228,NOTCH1 mut RB1 wild-type,sensitive,790,Ribociclib,5925,28151717,,,
21,Preclinical - Cell culture,"In a preclinical study, the combination of Kisqali (ribociclib) and Velcade (bortezomib) resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717). ",Actionable,10052,5602,T-cell adult acute lymphocytic leukemia,DOID,27228,NOTCH1 mut RB1 wild-type,sensitive,5358,Ribociclib + Bortezomib,5925,28151717,,,
22,Preclinical - Cell line xenograft,"In a preclinical study, R547 inhibited proliferation of melanoma cell lines harboring wild-type Tp53 and Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911).",Actionable,4360,1909,melanoma,DOID,17823,TP53 wild-type RB1 wild-type,sensitive,3497,R547,5925,17121911,,,
23,Preclinical - Cell line xenograft,"In a preclinical study, R547 inhibited proliferation of colon carcinoma cell lines harboring wild-type Tp53 and Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911).",Actionable,4354,1520,colon carcinoma,DOID,17823,TP53 wild-type RB1 wild-type,sensitive,3497,R547,5925,17121911,,,
24,Preclinical,"In a preclinical study, R547 inhibited proliferation of breast carcinoma cell lines harboring wild-type Tp53 and Rb1 (PMID: 17121911).",Actionable,4353,3459,breast carcinoma,DOID,17823,TP53 wild-type RB1 wild-type,sensitive,3497,R547,5925,17121911,,,
25,Preclinical - Cell line xenograft,"In a preclinical study, R547 inhibited proliferation of lung carcinoma cell lines harboring wild-type Tp53 and Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911).",Actionable,4356,3905,lung carcinoma,DOID,17823,TP53 wild-type RB1 wild-type,sensitive,3497,R547,5925,17121911,,,
26,Preclinical,"In a preclinical study, R547 inhibited proliferation of mantle cell lymphoma cell lines harboring wild-type Tp53 and Rb1 (PMID: 17121911).",Actionable,4362,50746,mantle cell lymphoma,DOID,17823,TP53 wild-type RB1 wild-type,sensitive,3497,R547,5925,17121911,,,
27,Preclinical,"In a preclinical study, Sirolimus (rapamycin) decreased tumor occurrence, tumor hypoxia and  tumor vascularization in a retinoblastoma mouse model with functionally inactivated Rb protein (PMID: 21468343, PMID: 1689463).",Actionable,1153,768,retinoblastoma,DOID,2007,RB1 loss,sensitive,917,Sirolimus,5925,21468343,1689463,,
28,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Trilaciclib (G1T28) and Hycamtin (topotecan) inhibited tumor growth in RB1-deficient small cell lung cancer cell line xenograft models, with greater efficacy than Hycamtin (topotecan) alone (PMID: 26826116).",Actionable,6269,5409,lung small cell carcinoma,DOID,2007,RB1 loss,sensitive,4109,Trilaciclib + Topotecan,5925,26826116,,,
29,Preclinical - Cell culture,"In a preclinical study, Trichostatin A (TSA) inhibited growth of retinoblastoma cell lines in culture (PMID: 18483379), which have been demonstrated to be deficient in RB1 (PMID: 23498719).",Actionable,10295,768,retinoblastoma,DOID,2007,RB1 loss,sensitive,2867,Trichostatin A,5925,18483379,23498719,,
30,Preclinical,"In preclinical studies, the CDK4/6 inhibitor, Ibrance (palbociclib), was not effective in a variety of solid tumors with Rb1-deficiency (PMID: 26649278).",Actionable,3904,10000003,Advanced Solid Tumor,JAX,2007,RB1 loss,no benefit,850,Palbociclib,5925,26649278,,,
31,Preclinical - Cell culture,"In a preclinical study, Zolinza (vorinostat) inhibited growth of retinoblastoma cell lines in culture (PMID: 18483379), which have been demonstrated to be deficient in RB1 (PMID: 23498719).",Actionable,10296,768,retinoblastoma,DOID,2007,RB1 loss,sensitive,1077,Vorinostat,5925,18483379,23498719,,
32,Preclinical,"In a preclinical study, Sirolimus (rapamycin) slowed pituitary tumors and decreased the occurrence of thyroid tumors in Rb1+/- mice (PMID: 23454836).",Actionable,1152,169,neuroendocrine tumor,DOID,2007,RB1 loss,sensitive,917,Sirolimus,5925,23454836,,,
33,Preclinical - Cell line xenograft,"In a preclinical study, Entinostat (MS-275) inhibited growth of retinoblastoma cell lines in culture and inhibited tumor growth in a retinoblastoma cell line xenograft model (PMID: 18483379), which have been demonstrated to be deficient in RB1 (PMID: 23498719).",Actionable,10297,768,retinoblastoma,DOID,2007,RB1 loss,sensitive,1541,Entinostat,5925,18483379,23498719,,
34,Preclinical - Cell line xenograft,"In a preclinical study, RB1-deficient small cell lung cancer cell lines were resistant to Trilaciclib (G1T28) in culture and in xenograft models (PMID: 26826116).",Actionable,6268,5409,lung small cell carcinoma,DOID,2007,RB1 loss,resistant,3074,Trilaciclib,5925,26826116,,,
35,Preclinical - Cell culture,"In a preclinical study, a T-cell acute lymphoblastic leukemia cell line harboring wild-type NOTCH1 and loss of RB1 demonstrated resistance to Kisqali (ribociclib) in culture, resulting in limited inhibition of cell growth (PMID: 28151717). ",Actionable,10045,5602,T-cell adult acute lymphocytic leukemia,DOID,27230,NOTCH1 wild-type RB1 loss,resistant,790,Ribociclib,5925,28151717,,,
36,Preclinical,"In a preclinical study, a triple-receptor negative breast cancer line harboring PTEN and RB1 loss was resistant to Ibrance (palbociclib) induced growth inhibition in culture (PMID: 27020857).",Actionable,5865,60081,triple-receptor negative breast cancer,DOID,21971,PTEN loss RB1 loss,resistant,850,Palbociclib,5925,27020857,,,
37,Preclinical,"In a preclinical study, a triple-receptor negative breast cancer line harboring PTEN and RB1 loss was resistant to Pictilisib (GDC-0941) induced growth inhibition in culture (PMID: 27020857).",Actionable,5864,60081,triple-receptor negative breast cancer,DOID,21971,PTEN loss RB1 loss,resistant,749,GDC-0941,5925,27020857,,,
38,Preclinical,"In a preclinical study, the combination of Ibrance (palbociclib) and Pictilisib (GDC-0941) did not improve growth inhibition compared to single drug treatment in triple-receptor negative breast cancer cell lines harboring PTEN and RB1 loss in culture (PMID: 27020857).",Actionable,5863,60081,triple-receptor negative breast cancer,DOID,21971,PTEN loss RB1 loss,no benefit,3956,Palbociclib + GDC-0941,5925,27020857,,,
39,Preclinical - Cell culture,"In a preclinical study, a melanoma cell line with a BRAF mutation and loss of RB1 demonstrated minimal sensitivity when treated with the combination of Ibrance (palbociclib) and Mekinist (trametinib) in culture (PMID: 27488531). ",Actionable,8546,1909,melanoma,DOID,26352,BRAF mut RB1 loss,decreased response,1368,Palbociclib + Trametinib,5925,27488531,,,
40,Preclinical - Cell culture,"In a preclinical study, a melanoma cell line harboring a BRAF mutation and RB1 loss demonstrated reduced sensitivity when treated with Mekinist (trametinib) in culture (PMID: 27488531). ",Actionable,8539,1909,melanoma,DOID,26352,BRAF mut RB1 loss,decreased response,2,Trametinib,5925,27488531,,,
41,Preclinical - Cell culture,"In a preclinical study, a melanoma cell line harboring a BRAF mutation and loss of RB1 demonstrated a decreased response to Ibrance (palbociclib) treatment in culture when compared to treatment of melanoma cell lines wild-type for BRAF (PMID: 27488531). ",Actionable,8536,1909,melanoma,DOID,26352,BRAF mut RB1 loss,decreased response,850,Palbociclib,5925,27488531,,,
42,Clinical Study,"In a clinical case study, RB1 C706F and loss of exons 1-11 in TP53 were identified in the pericardium infiltrating small cell lung cancer that developed while on Lorlatinib (PF-06463922) treatment in a patient with ALK-rearranged non-small cell lung carcinoma (PMID: 28285684).",Actionable,10437,5409,lung small cell carcinoma,DOID,27462,ALK rearrange RB1 C706F TP53 loss,predicted â€“ resistant,869,PF-06463922,5925,28285684,,,
43,Preclinical,"In a preclinical study, a skin cancer cell line harboring mutations in PTEN, RB1, SMAD4 and TP53 demonstrated sensitivity to Sapanisertib (MLN0128) in culture (PMID: 25261369). ",Actionable,2106,4159,skin cancer,DOID,5389,PTEN mut RB1 mut SMAD4 mut TP53 mut,sensitive,1282,Sapanisertib,5925,25261369,,,
44,Preclinical - Cell line xenograft,"In a preclinical study, R547 inhibited proliferation of prostate carcinoma cell lines harboring Tp53 and Rb1 mutations in culture and reduced tumor growth in xenograft models (PMID: 17121911).",Actionable,4358,10286,prostate carcinoma,DOID,17821,RB1 mut TP53 mut,sensitive,3497,R547,5925,17121911,,,
45,Preclinical,"In a preclinical study, R547 inhibited proliferation of breast carcinoma cell lines harboring TP53 and RB1 mutations in culture (PMID: 17121911).",Actionable,4351,3459,breast carcinoma,DOID,17821,RB1 mut TP53 mut,sensitive,3497,R547,5925,17121911,,,
46,Preclinical,"In a preclinical study, R547 inhibited proliferation of cervical carcinoma cell lines harboring Tp53 and Rb1 mutations (PMID: 17121911).",Actionable,4357,4362,cervical cancer,DOID,17821,RB1 mut TP53 mut,sensitive,3497,R547,5925,17121911,,,
47,Preclinical - Cell line xenograft,"In a preclinical study, VCN-01 decreased viability of a human RB1-mutant primary osteosarcoma cell line in culture, and inhibited tumor growth and decreased lung metastases in xenograft models (PMID: 26603261).",Actionable,6090,3347,osteosarcoma,DOID,22588,RB1 mutant,sensitive,4038,VCN-01,5925,26603261,,,
48,Preclinical - Cell line xenograft,"In a preclinical study, Ibrance (palbociclib) inhibited proliferation of RB1-proficient glioblastoma cell lines in culture and inhibited tumor growth in intracranial cell line xenograft models (PMID: 20354191).",Actionable,9353,3068,glioblastoma multiforme,DOID,2395,RB1 positive,predicted â€“ sensitive,850,Palbociclib,5925,20354191,,,
49,Preclinical - Pdx,"In a preclinical study, Ibrance (palbociclib) inhibited Rb1 phosphorylation in tumor tissues and improved survival in patient-derived intracranial xenograft models of medulloblastoma (PMID: 27012813).",Actionable,6864,50902,medulloblastoma,DOID,2395,RB1 positive,sensitive,850,Palbociclib,5925,27012813,,,
50,Phase I,"In a Phase I clinical trial, Kisqali (ribociclib) demonstrated safety and preliminary efficacy in patients with RB1-positive solid tumors and lymphomas, resulting in partial responses in 2.3% (3/132) of patients and stable disease in 32.6% (41/132) of patients, including 8 patients demonstrating stable disease for greater than 6 months (PMID: 27542767).",Actionable,1680,10000003,Advanced Solid Tumor,JAX,2395,RB1 positive,predicted â€“ sensitive,790,Ribociclib,5925,24795392,27542767,,
51,Preclinical - Patient cell culture,"In a preclinical study, patient-derived glioblastoma cells harboring RB1 truncation mutation and expressing Cdkn2a were resistant to Ibrance (palbociclib) in culture (PMID: 22711607).",Actionable,9364,3068,glioblastoma multiforme,DOID,26833,CDKN2A pos RB1 inact mut,resistant,850,Palbociclib,5925,22711607,,,
52,Preclinical,"In a preclinical study, a retinoblastoma cell line was sensitive to BAY 61-3606 in cell culture and in xenograft models, demonstrating increased apoptosis (PMID: 22237022). ",Actionable,2180,768,retinoblastoma,DOID,5891,RB1 inact mut,sensitive,2665,BAY 61-3606,5925,22237022,,,
53,Preclinical,"In a preclinical study, retinoblastoma cell lines demonstrated sensitivity to Fostamatinib resulting in cell death (PMID: 22237022). ",Actionable,2179,768,retinoblastoma,DOID,5891,RB1 inact mut,sensitive,1528,Fostamatinib,5925,22237022,,,
54,Preclinical - Cell line xenograft,"In a preclinical study, Ibrance (palbociclib) failed to inhibit growth of RB1-deficient glioblastoma cell lines in culture and in intracranial cell line xenograft models (PMID: 20354191).",Actionable,9354,3068,glioblastoma multiforme,DOID,5891,RB1 inact mut,resistant,850,Palbociclib,5925,20354191,,,
55,Preclinical,"In a preclinical study, Nutlin-3a induced p53 pathway signaling in MDMX mouse models with retinoblastoma and 69% (70/102) of the eyes harvested from the mouse models demonstrated complete response or stable disease after 18 weeks of therapy (PMID: 21515735). ",Actionable,2181,768,retinoblastoma,DOID,5891,RB1 inact mut,sensitive,1405,Nutlin-3a,5925,21515735,,,
0,Preclinical - Cell culture,"In a preclinical study, transformed human cells co-expressing RET C634R and RET Y806F in culture demonstrated inhibition of Ret phosphorylation and activity in kinase assays when treated with Caprelsa (vandetanib) (PMID: 19029224).",Actionable,10663,10000003,Advanced Solid Tumor,JAX,27719,RET C634R RET Y806F,predicted â€“ sensitive,953,Vandetanib,5979,19029224,,,
1,Preclinical,"In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation in cells expressing RET S891A in culture (PMID: 17664273).",Actionable,1761,10000003,Advanced Solid Tumor,JAX,3187,RET S891A,sensitive,920,Sorafenib,5979,17664273,,,
2,Preclinical,"In a preclinical study, Caprelsa (vandetanib) inhibited Ret autophosphorylation in transformed cells expressing RET S891A in culture (PMID: 15184865).",Actionable,3418,10000003,Advanced Solid Tumor,JAX,3187,RET S891A,sensitive,953,Vandetanib,5979,15184865,,,
3,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET S891A in culture (PMID: 23526464).",Actionable,3253,10000003,Advanced Solid Tumor,JAX,3187,RET S891A,sensitive,877,Ponatinib,5979,23526464,,,
4,Preclinical - Cell culture,"In a preclinical study, transformed human cells co-expressing RET C634R and RET Y806E were resistant to treatment with Caprelsa (vandetanib) in culture (PMID: 19029224). ",Actionable,10662,10000003,Advanced Solid Tumor,JAX,27718,RET C634R RET Y806E,resistant,953,Vandetanib,5979,19029224,,,
5,Clinical Study,"In clinical case study, a patient with olfactory neuroblastoma harboring EGFR R521K, FGFR2 M186T, KDR Q472H, KDR V297I, and RET M1009T demonstrated sensitivity to the combination of Sutent (sunitinib) and Erbitux (cetuximab), resulting in a complete response (PMID: 27149458).",Actionable,7758,369,olfactory neuroblastoma,DOID,26023,EGFR R521K FGFR2 M186T KDR Q472H KDR V297I RET M1009T,sensitive,4568,Cetuximab + Sunitinib,5979,27149458,,,
6,Preclinical,"In a preclinical study, Nexavar (sorafenib) inhibited wild-type RET and RET mutations to prevent cell proliferation in cell culture (PMID: 17664273).",Actionable,905,162,cancer,DOID,1232,RET mutant,sensitive,920,Sorafenib,5979,17664273,,,
7,Preclinical - Cell line xenograft,"In a preclinical study, Iclusig (ponatinib) inhibited proliferation of cancer cell lines harboring RET mutations in cultured and in cell line xenograft models (PMID: 23526464). ",Actionable,904,10000003,Advanced Solid Tumor,JAX,1232,RET mutant,sensitive,877,Ponatinib,5979,23526464,,,
8,Phase II,"In a Phase II clinical trial, Afinitor (everolimus) treatment resulted in stable disease in 71% (5/7) of medullary thyroid cancer patients, including patients harboring RET mutations, with median progression-free survival of 33 weeks (PMID: 26294908).",Actionable,3370,3973,thyroid medullary carcinoma,DOID,1232,RET mutant,sensitive,735,Everolimus,5979,26294908,,,
9,Phase III,"In a Phase III trial, Cometriq (cabozantinib) treatment resulted in improved progression free survival (60 vs 20 weeks) compared to placebo in thyroid medullary carcinoma patients harboring RET mutations (PMID: 27525386).",Actionable,10385,3973,thyroid medullary carcinoma,DOID,1232,RET mutant,sensitive,998,cabozantinib,5979,27525386,,,
10,Preclinical,"In a preclinical study, Iclusig (ponatinib) demonstrated efficacy in RET mutant positive colorectal cancer cell lines (PMID: 23811235). ",Actionable,921,9256,colorectal cancer,DOID,1232,RET mutant,sensitive,877,Ponatinib,5979,23811235,,,
11,Preclinical,"In a preclinical study, transformed cell lines expressing Ret protein carrying both C634R and V804G mutations were more sensitive to Vandetanib induced inhibition of Ret activity than cells expressing Ret C634R alone in culture (PMID: 15184865).",Actionable,3468,10000003,Advanced Solid Tumor,JAX,13345,RET C634R RET V804G,sensitive,953,Vandetanib,5979,15184865,,,
12,Preclinical,"In a preclinical study, Pz-1 inhibited Ret phosphorylation in transformed cells expressing RET V804L (PMID: 26126987).",Actionable,6190,10000003,Advanced Solid Tumor,JAX,2411,RET V804L,predicted â€“ sensitive,4089,Pz-1,5979,26126987,,,
13,Preclinical,"In a preclinical study, transformed human cell lines expressing RET V804L demonstrated sensitivity to Iclusig (ponatinib) (PMID: 23811235).",Actionable,1851,10000003,Advanced Solid Tumor,JAX,2411,RET V804L,sensitive,877,Ponatinib,5979,23811235,,,
14,Preclinical,"In a preclinical study, transformed cells expressing RET V804L demonstrated resistance to growth inhibition by Caprelsa (vandetanib) in culture (PMID: 15184865).",Actionable,3421,10000003,Advanced Solid Tumor,JAX,2411,RET V804L,resistant,953,Vandetanib,5979,15184865,,,
15,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET E884K in culture (PMID: 23526464).",Actionable,3252,10000003,Advanced Solid Tumor,JAX,12968,RET E884K,sensitive,877,Ponatinib,5979,23526464,,,
16,Preclinical,"In a preclinical study, Caprelsa (vandetanib) inhibited Ret autophosphorylation in transformed cells expressing RET Y791F in culture (PMID: 15184865).",Actionable,3417,10000003,Advanced Solid Tumor,JAX,1000,RET Y791F,sensitive,953,Vandetanib,5979,15184865,,,
17,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET Y971F in culture (PMID: 23526464).",Actionable,3232,10000003,Advanced Solid Tumor,JAX,1000,RET Y791F,sensitive,877,Ponatinib,5979,23526464,,,
18,Preclinical - Cell culture,"In a preclinical study, transformed human cells co-expressing RET C634R and RET Y806C were resistant to treatment with Caprelsa (vandetanib) in culture (PMID: 19029224). ",Actionable,10661,10000003,Advanced Solid Tumor,JAX,27717,RET C634R RET Y806C,resistant,953,Vandetanib,5979,19029224,,,
19,Preclinical,"In a preclinical study, Caprelsa (vandetanib) inhibited RET phosphorylation and decreased growth of transformed cells expressing RET C634R in culture (PMID: 15184865).",Actionable,3423,10000003,Advanced Solid Tumor,JAX,2945,RET C634R,sensitive,953,Vandetanib,5979,15184865,,,
20,Phase II,"In a Phase II trial, Nexavar (sorafenib) treatment resulted in partial response in 50% (1/2) and stable disease in 50% (1/2) of patients with medullary thyroid carcinoma harboring RET C634R (PMID: 20368568).",Actionable,10452,3973,thyroid medullary carcinoma,DOID,2945,RET C634R,predicted â€“ sensitive,920,Sorafenib,5979,20368568,,,
21,Preclinical - Cell line xenograft,"In a preclinical study, Pz-1 inhibited Ret signaling in transformed cells over expressing RET C634R and inhibited tumor growth in cell line xenografts models (PMID: 26126987).",Actionable,6188,10000003,Advanced Solid Tumor,JAX,2945,RET C634R,sensitive,4089,Pz-1,5979,26126987,,,
22,Preclinical,"In a preclinical study, transformed human cell lines expressing RET C634R demonstrated sensitivity to Iclusig (ponatinib) (PMID: 23811235).",Actionable,1850,10000003,Advanced Solid Tumor,JAX,2945,RET C634R,sensitive,877,Ponatinib,5979,23811235,,,
23,Preclinical,"In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and decreased growth of cells expressing RET C634R in culture (PMID: 17664273).",Actionable,1765,10000003,Advanced Solid Tumor,JAX,2945,RET C634R,sensitive,920,Sorafenib,5979,17664273,,,
24,Preclinical,"In a preclinical study, Nexavar (sorafenib) inhibited RET kinase activity and proliferation in transformed cells expressing RET C634R in culture (PMID: 16507829). ",Actionable,2190,10000003,Advanced Solid Tumor,JAX,2945,RET C634R,sensitive,920,Sorafenib,5979,16507829,,,
25,Preclinical - Cell culture,"In a preclinical study, transformed human cells co-expressing RET C634R and RET V804M were resistant to treatment with Caprelsa (vandetanib) in culture (PMID: 19029224). ",Actionable,10660,10000003,Advanced Solid Tumor,JAX,27716,RET C634R RET V804M,resistant,953,Vandetanib,5979,19029224,,,
26,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited proliferation of transformed cells harboring RET C634Y in culture (PMID: 23526464).",Actionable,3242,10000003,Advanced Solid Tumor,JAX,3731,RET C634Y,sensitive,877,Ponatinib,5979,23526464,,,
27,Phase II,"In a Phase II trial, Nexavar (sorafenib) treatment resulted in stable disease in one patient with medullary thyroid carcinoma harboring RET C634Y (PMID: 20368568).",Actionable,10453,3973,thyroid medullary carcinoma,DOID,3731,RET C634Y,predicted â€“ sensitive,920,Sorafenib,5979,20368568,,,
28,Preclinical,"In a preclinical study, XMD15-44 inhibited RET phosphorylation and downstream signaling and reduced proliferation of transformed cells expressing RET C634Y in culture (PMID: 26046350).",Actionable,5148,10000003,Advanced Solid Tumor,JAX,3731,RET C634Y,sensitive,3761,XMD15-44,5979,26046350,,,
29,Preclinical,"In a preclinical study, ALW-II-41-27 inhibited RET phosphorylation and downstream signaling and reduced proliferation of transformed cells expressing RET C634Y in culture (PMID: 26046350).",Actionable,5149,10000003,Advanced Solid Tumor,JAX,3731,RET C634Y,sensitive,3274,ALW-II-41-27,5979,26046350,,,
30,Preclinical,"In a preclinical study, HG-6-63-01 inhibited RET phosphorylation and downstream signaling and reduced proliferation of transformed cells expressing RET C634Y in culture (PMID: 26046350).",Actionable,5147,10000003,Advanced Solid Tumor,JAX,3731,RET C634Y,sensitive,3762,HG-6-63-01,5979,26046350,,,
31,Preclinical,"In a preclinical study, Caprelsa (vandetanib) inhibited Ret autophosphorylation in transformed cells expressing RET E768D in culture (PMID: 15184865).",Actionable,3415,10000003,Advanced Solid Tumor,JAX,3746,RET E768D,sensitive,953,Vandetanib,5979,15184865,,,
32,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET E768D in culture (PMID: 23526464).",Actionable,3233,10000003,Advanced Solid Tumor,JAX,3746,RET E768D,sensitive,877,Ponatinib,5979,23526464,,,
33,Clinical Study,"In a clinical case study, addition of Afinitor (everolimus)  to Caprelsa (vandetanib) treatment resulted in significant tumor reduction in a medullary thyroid carcinoma patient harboring ATM L804fs*4, ATM S978fs*12, and RET M918T, that achieved prolonged stable disease on Caprelsa (vandetanib) treatment alone (PMID: 27683183).",Actionable,10637,3973,thyroid medullary carcinoma,DOID,27653,ATM L804fs*4 ATM S978fs*12 RET M918T ,predicted â€“ sensitive,1163,Vandetanib + Everolimus,5979,27683183,,,
34,Preclinical,"In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and decreased growth of colorectal cancer cells harboring a RET M918T mutation in culture (PMID: 17664273).",Actionable,1762,9256,colorectal cancer,DOID,3055,RET M918T,sensitive,920,Sorafenib,5979,17664273,,,
35,Preclinical,"In a preclinical study, HG-6-63-01 inhibited RET phosphorylation and downstream signaling and reduced proliferation of transformed cells expressing RET M918T in culture (PMID: 26046350).",Actionable,5150,10000003,Advanced Solid Tumor,JAX,3055,RET M918T,sensitive,3762,HG-6-63-01,5979,26046350,,,
36,Preclinical,"In a preclinical study, ALW-II-41-27 inhibited RET phosphorylation and downstream signaling and reduced proliferation of medullary thryoid carcinoma cells harboring RET M918T in culture (PMID: 26046350).",Actionable,5158,3973,thyroid medullary carcinoma,DOID,3055,RET M918T,sensitive,3274,ALW-II-41-27,5979,26046350,,,
37,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited RET signaling and decreased proliferation of thyroid carcinoma cells harboring a RET M918T mutation in culture (PMID: 23526464). ",Actionable,1777,3963,thyroid carcinoma,DOID,3055,RET M918T,sensitive,877,Ponatinib,5979,23526464,,,
38,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited growth of small cell lung carcinoma lines expressing RET M918T (PMID: 25122427).",Actionable,2988,5409,lung small cell carcinoma,DOID,3055,RET M918T,sensitive,877,Ponatinib,5979,25122427,,,
39,Preclinical,"In a preclinical study, Caprelsa (vandetanib) inhibited growth of small cell lung carcinoma lines expressing RET M918T (PMID: 25122427).",Actionable,2990,5409,lung small cell carcinoma,DOID,3055,RET M918T,sensitive,953,Vandetanib,5979,25122427,,,
40,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET M918T in culture (PMID: 23526464).",Actionable,3236,10000003,Advanced Solid Tumor,JAX,3055,RET M918T,sensitive,877,Ponatinib,5979,23526464,,,
41,Preclinical,"In a preclinical study, HG-6-63-01 inhibited RET phosphorylation and downstream signaling and reduced proliferation of medullary thyroid carcinoma cells harboring RET M918T in culture (PMID: 26046350).",Actionable,5156,3973,thyroid medullary carcinoma,DOID,3055,RET M918T,sensitive,3762,HG-6-63-01,5979,26046350,,,
42,Preclinical,"In a preclinical study, Pz-1 inhibited Ret phosphorylation in transformed cells expressing RET M918T (PMID: 26126987).",Actionable,6189,10000003,Advanced Solid Tumor,JAX,3055,RET M918T,predicted â€“ sensitive,4089,Pz-1,5979,26126987,,,
43,Preclinical - Cell culture,"In a preclinical study, AZD1480 reduced phosphorylation of RET and downstream effectors, and inhibited growth and increased apoptosis of a medullary thyroid cancer cell line harboring RET M918T in culture (PMID: 23056499).",Actionable,8074,3973,thyroid medullary carcinoma,DOID,3055,RET M918T,sensitive,652,AZD1480,5979,23056499,,,
44,Phase II,"In a Phase II trial, Nexavar (sorafenib) treatment resulted in partial response in 10% (1/10) and stable disease in 90% (9/10) of patients with medullary thyroid carcinoma harboring RET M918T (PMID: 20368568).",Actionable,10451,3973,thyroid medullary carcinoma,DOID,3055,RET M918T,predicted â€“ sensitive,920,Sorafenib,5979,20368568,,,
45,Phase III,"In a Phase III trial, Cometriq (cabozantinib) increased overall survival to 25.4 months in medullary thyroid carcinoma patients with RET M918T (J Clin Oncol 33, 2015, suppl; abstr 6012).",Actionable,2496,3973,thyroid medullary carcinoma,DOID,3055,RET M918T,sensitive,998,cabozantinib,5979,None,,,
46,Phase III,"In a Phase III trial, Cometriq (cabozantinib) treatment resulted in improved progression free survival (61 vs 17 weeks) compared to placebo in thyroid medullary carcinoma patients harboring RET M918T (PMID: 27525386).",Actionable,10386,3973,thyroid medullary carcinoma,DOID,3055,RET M918T,sensitive,998,cabozantinib,5979,27525386,,,
47,Preclinical,"In a preclinical study, ALW-II-41-27 inhibited RET phosphorylation and downstream signaling and reduced proliferation of transformed cells expressing RET M918T in culture (PMID: 26046350).",Actionable,5152,10000003,Advanced Solid Tumor,JAX,3055,RET M918T,sensitive,3274,ALW-II-41-27,5979,26046350,,,
48,Preclinical,"In a preclinical study, Caprelsa (vandetanib) inhibited Ret autophosphorylation and transforming activity in cells expressing RET M918T in culture (PMID: 15184865).",Actionable,3419,10000003,Advanced Solid Tumor,JAX,3055,RET M918T,sensitive,953,Vandetanib,5979,15184865,,,
49,Preclinical,"In a preclinical study, XMD15-44 inhibited RET phosphorylation and downstream signaling and reduced proliferation of medullary thyroid carcinoma cells harboring RET M918T in culture (PMID: 26046350).",Actionable,5157,3973,thyroid medullary carcinoma,DOID,3055,RET M918T,sensitive,3761,XMD15-44,5979,26046350,,,
50,Phase II,"In a Phase II clinical trial, Afinitor (everolimus) treatment resulted in stable disease in 71% (5/7)  of medullary thyroid cancer patients, and 4 of the 7 patients carried a RET M918T mutation (PMID: 26294908).",Actionable,3374,3973,thyroid medullary carcinoma,DOID,3055,RET M918T,sensitive,735,Everolimus,5979,26294908,,,
51,Preclinical,"In a preclinical study, XMD15-44 inhibited RET phosphorylation and downstream signaling and reduced proliferation of transformed cells expressing RET M918T in culture (PMID: 26046350).",Actionable,5151,10000003,Advanced Solid Tumor,JAX,3055,RET M918T,sensitive,3761,XMD15-44,5979,26046350,,,
52,Preclinical,"In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and decreased proliferation of cells expressing RET M918T in culture (PMID: 17664273).",Actionable,1763,10000003,Advanced Solid Tumor,JAX,3055,RET M918T,sensitive,920,Sorafenib,5979,17664273,,,
53,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited growth of small cell lung carcinoma lines expressing wild-type RET (PMID: 25122427).",Actionable,2989,5409,lung small cell carcinoma,DOID,686,RET wild-type,sensitive,877,Ponatinib,5979,25122427,,,
54,Preclinical,"In a preclinical study, Caprelsa (vandetanib) inhibited growth of small cell lung carcinoma lines expressing wild-type RET (PMID: 25122427).",Actionable,2986,5409,lung small cell carcinoma,DOID,686,RET wild-type,sensitive,953,Vandetanib,5979,25122427,,,
55,Phase II,"In a Phase II trial, Caprelsa (vandetanib) treatment resulted in partial remission in 17% (3/18) and stable disease in 44% (8/18) of non-small cell lung adenocarcinoma patients harboring RET fusions (J Clin Oncol 34, 2016 (suppl; abstr 9013)).",Actionable,6990,3908,non-small cell lung carcinoma,DOID,2903,RET fusion,sensitive,953,Vandetanib,5979,None,,,
56,Phase II,"In a Phase II trial, Caprelsa (vandetanib) treatment resulted in a disease control rate of 88% (15/17), median progression-free survival (PFS) of 4.7 months, and partial response in 53% (9/17) of non-small cell lung adenocarcinoma patients harboring RET fusions (J Clin Oncol 34, 2016 (suppl; abstr 9012)).",Actionable,6987,3908,non-small cell lung carcinoma,DOID,2903,RET fusion,sensitive,953,Vandetanib,5979,None,,,
57,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET Y806C in culture (PMID: 23526464).",Actionable,3223,10000003,Advanced Solid Tumor,JAX,12957,RET Y806C,sensitive,877,Ponatinib,5979,23526464,,,
58,Phase II,"In a Phase II trial, Nexavar (sorafenib) treatment resulted in stable disease in one patient with medullary thyroid carcinoma harboring RET C634F (PMID: 20368568).",Actionable,10454,3973,thyroid medullary carcinoma,DOID,4919,RET C634F,predicted â€“ sensitive,920,Sorafenib,5979,20368568,,,
59,Preclinical - Cell line xenograft,"In a preclinical study, Motesanib (AMG 706) inhibited KDR (VEGFR2) phosphorylation, but had minimal activity against RET in a medullary thyroid carcinoma (MTC) cell line harboring RET C634W in culture, however, inhibited both RET and KDR (VEGFR2) phosphorylation and decreased tumor angiogenesis and growth in MTC cell line xenograft models with RET C634W (PMID: 21422803).",Actionable,8334,3973,thyroid medullary carcinoma,DOID,26230,KDR pos RET C634W,predicted â€“ sensitive,824,Motesanib,5979,21422803,,,
60,Preclinical - Cell culture,"In a preclinical study, Stivarga (regorafenib) inhibited proliferation of thyroid cancer cells harboring RET C634W in culture (PMID: 21170960).",Actionable,7720,1781,thyroid cancer,DOID,3188,RET C634W,sensitive,890,Regorafenib,5979,21170960,,,
61,Preclinical,"In a preclinical study, ALW-II-41-27 inhibited RET phosphorylation and downstream signaling and reduced proliferation of medullary thyroid carcinoma cells harboring RET C634W in culture (PMID: 26046350).",Actionable,5154,3973,thyroid medullary carcinoma,DOID,3188,RET C634W,sensitive,3274,ALW-II-41-27,5979,26046350,,,
62,Preclinical - Cell line xenograft,"In a preclinical study, Iclusig (ponatinib) inhibited RET signaling and decreased growth of thyroid carcinoma cells harboring a RET C634W mutation in culture and in cell line xenograft models (PMID: 23526464). ",Actionable,1776,3963,thyroid carcinoma,DOID,3188,RET C634W,sensitive,877,Ponatinib,5979,23526464,,,
63,Preclinical - Cell culture,"In a preclinical study, RXDX-105 (CEP-32496) reduced phosphorylation of RET and downstream signaling and inhibited proliferation of a medullary thyroid cancer cell line harboring RET C634W in culture (PMID: 28011461).",Actionable,11237,3973,thyroid medullary carcinoma,DOID,3188,RET C634W,sensitive,1002,CEP-32496,5979,28011461,,,
64,Preclinical,"In a preclinical study, Lenvima (lenvatinib) inhibited RET phosphorylation and signaling in thyroid cancer cells expressing RET C634W (PMID: 25295214).",Actionable,1894,1781,thyroid cancer,DOID,3188,RET C634W,sensitive,792,Lenvatinib,5979,25295214,,,
65,Preclinical - Cell line xenograft,"In a preclinical study, Cometriq (cabozantinib) inhibited phosphorylation of RET C634W and decreased tumor growth in xenograft models of a human thyroid carcinoma cell line harboring RET C634W mutation (PMID: 23705946).",Actionable,1779,3963,thyroid carcinoma,DOID,3188,RET C634W,sensitive,998,cabozantinib,5979,23705946,,,
66,Preclinical - Cell culture,"In a preclinical study, AZD1480 reduced phosphorylation of RET and downstream effectors, and inhibited growth and increased apoptosis of a thyroid cancer cell line harboring RET C634W in culture (PMID: 23056499).",Actionable,8075,1781,thyroid cancer,DOID,3188,RET C634W,sensitive,652,AZD1480,5979,23056499,,,
67,Preclinical,"In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and decreased growth of thyroid carcinoma cells harboring a RET C634W mutation in culture (PMID: 17664273).",Actionable,1766,3963,thyroid carcinoma,DOID,3188,RET C634W,sensitive,920,Sorafenib,5979,17664273,,,
68,Preclinical,"In a preclinical study, HG-6-63-01 inhibited RET phosphorylation and downstream signaling and reduced proliferation of medullary thyroid carcinoma cells harboring RET C634W in culture (PMID: 26046350).",Actionable,5155,3973,thyroid medullary carcinoma,DOID,3188,RET C634W,sensitive,3762,HG-6-63-01,5979,26046350,,,
69,Preclinical - Cell line xenograft,"In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and inhibited tumor growth in cell line xenograft models of medullary thyroid carcinoma harboring RET C634W (PMID: 16507829).",Actionable,2192,3973,thyroid medullary carcinoma,DOID,3188,RET C634W,sensitive,920,Sorafenib,5979,16507829,,,
70,Preclinical,"In a preclinical study, XMD15-44 inhibited RET phosphorylation and downstream signaling and reduced proliferation of medullary thyroid carcinoma cells harboring RET C634W in culture (PMID: 26046350).",Actionable,5153,3973,thyroid medullary carcinoma,DOID,3188,RET C634W,sensitive,3761,XMD15-44,5979,26046350,,,
71,Preclinical,"In a preclinical study, Pz-1 inhibited Ret phosphorylation in transformed cells expressing RET V804M (PMID: 26126987).",Actionable,6191,10000003,Advanced Solid Tumor,JAX,2412,RET V804M,predicted â€“ sensitive,4089,Pz-1,5979,26126987,,,
72,Preclinical,"In a preclinical study, transformed cells expressing RET V804M demonstrated resistance to growth inhibition by Caprelsa (vandetanib) in culture (PMID: 15184865).",Actionable,3422,10000003,Advanced Solid Tumor,JAX,2412,RET V804M,resistant,953,Vandetanib,5979,15184865,,,
73,Preclinical,"In a preclinical study, transformed human cell lines expressing RET V804M demonstrated sensitivity to Iclusig (ponatinib) (PMID: 23811235).",Actionable,1852,10000003,Advanced Solid Tumor,JAX,2412,RET V804M,sensitive,877,Ponatinib,5979,23811235,,,
74,Preclinical,"In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and decreased growth of transformed cells expressing RET V804M in culture (PMID: 16507829).",Actionable,2191,10000003,Advanced Solid Tumor,JAX,2412,RET V804M,sensitive,920,Sorafenib,5979,16507829,,,
75,Phase II,"In a Phase II trial, Nexavar (sorafenib) treatment resulted in stable disease in one patient with medullary thyroid carcinoma harboring RET C618R (PMID: 20368568).",Actionable,10455,3973,thyroid medullary carcinoma,DOID,3725,RET C618R,predicted â€“ sensitive,920,Sorafenib,5979,20368568,,,
76,Preclinical - Cell line xenograft,"In a preclinical study, Y078-DM1 induced cytotoxicity in a human breast cancer cell line with high levels of RET expression in culture and inhibited tumor growth in xenograft models (PMID: 26240273).",Actionable,5643,1612,breast cancer,DOID,21323,RET over exp,sensitive,3912,Y078-DM1,5979,26240273,,,
77,Preclinical,"In a preclinical study, Y078-DM4 induced cytotoxicity in a RET-expressing medullary thyroid cell line in culture (PMID: 26240273).",Actionable,5642,3973,thyroid medullary carcinoma,DOID,2882,RET positive,sensitive,3913,Y078-DM4,5979,26240273,,,
78,Preclinical - Cell line xenograft,"In a preclinical study, Y078-DM4 induced cytotoxicity in RET-expressing human breast cancer cell lines in culture and inhibited tumor growth in xenograft models (PMID: 26240273).",Actionable,5641,1612,breast cancer,DOID,2882,RET positive,sensitive,3913,Y078-DM4,5979,26240273,,,
79,Phase I,"In a Phase I clinical trial, two patients with germline RET G691S mutations demonstrated sensitivity to Dovitinib (TKI258) treatment (PMID: 25103625).",Actionable,1210,10000003,Advanced Solid Tumor,JAX,724,RET G691S,sensitive,721,Dovitinib,5979,25103625,,,
80,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET A883F in culture (PMID: 23526464).",Actionable,3224,10000003,Advanced Solid Tumor,JAX,12807,RET A883F,sensitive,877,Ponatinib,5979,23526464,,,
81,Preclinical,"In a preclinical study, Caprelsa (vandetanib) inhibited Ret autophosphorylation in transformed cells expressing RET A883F in culture (PMID: 15184865).",Actionable,3420,10000003,Advanced Solid Tumor,JAX,12807,RET A883F,sensitive,953,Vandetanib,5979,15184865,,,
82,Phase II,"In a Phase II clinical trial, treatment with Cometriq (cabozantinib) resulted in an overall response rate of 28% (7/25) in patients with RET-rearranged lung cancer (PMID: 27825636).",Actionable,9722,1324,lung cancer,DOID,1326,RET rearrange,sensitive,998,cabozantinib,5979,27825636,,,
83,Preclinical - Pdx,"In a preclinical study, CEP-32496 (RXDX-105) induced tumor regression in patient-derived xenograft models of several advanced solid tumor type with RET rearrangements (2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; Abstract A174).",Actionable,3689,10000003,Advanced Solid Tumor,JAX,1326,RET rearrange,sensitive,1002,CEP-32496,5979,None,,,
84,Clinical Study,"In a clinical case study, a patient with non-small cell lung cancer harboring a RET rearrangement demonstrated a sustained partial response following treatment with RXDX-105 (CEP-32496) on a Phase Ib clinical trial (PMID: 28011461).",Actionable,11255,3908,non-small cell lung carcinoma,DOID,1326,RET rearrange,sensitive,1002,CEP-32496,5979,28011461,,,
85,Clinical Study,"In a clinical study, analysis of patients with RET-rearranged non-small cell lung cancer treated with RET inhibitors demonstrated a response rate of 18% (2/9, all partial responses), and stable disease in 33% (3/9) of patients following Sutent (sunitinib) treatment (PMID: 28447912).",Actionable,10836,3908,non-small cell lung carcinoma,DOID,1326,RET rearrange,sensitive,930,Sunitinib,5979,28447912,,,
86,Clinical Study,"In a clinical study, analysis of patients with RET-rearranged non-small cell lung cancer treated with RET inhibitors demonstrated a response rate of 18% (2/11, all partial responses) and stable disease in 27% (3/11) of patients following Caprelsa (vandetanib) treatment (PMID: 28447912).",Actionable,10835,3908,non-small cell lung carcinoma,DOID,1326,RET rearrange,sensitive,953,Vandetanib,5979,28447912,,,
87,Preclinical,"In a preclinical study, Iclusig (ponatinib) decreased proliferation of papillary thyroid carcinoma cells harboring the RET/PTC1 rearrangement in culture (PMID: 23526464). ",Actionable,1778,3969,papillary thyroid carcinoma,DOID,1326,RET rearrange,sensitive,877,Ponatinib,5979,23526464,,,
88,Clinical Study,"In a clinical study, Alecensa (alectinib) treatment resulted in objective radiographic response in 50% (2/4) and stable disease in 25% (1/4) of non-small cell lung carcinoma patients harboring RET rearrangement (PMID: 27544060).",Actionable,10416,3908,non-small cell lung carcinoma,DOID,1326,RET rearrange,predicted â€“ sensitive,698,Alectinib,5979,27544060,,,
89,Preclinical,"In a preclinical study, Nexavar (sorafenib) inhibited RET phosphorylation and activation of downstream signaling, and decreased growth of papillary thyroid carcinoma cells harboring the RET/PTC1 oncogene in culture (PMID: 17664273).",Actionable,1768,3969,papillary thyroid carcinoma,DOID,1326,RET rearrange,sensitive,920,Sorafenib,5979,17664273,,,
90,Clinical Study,"In a clinical study, analysis of patients with RET-rearranged non-small cell lung cancer treated with RET inhibitors demonstrated a response rate of 37% (7/19), with complete response in 5% (1/19) and partial response in 32% (6/19) of patients, and stable disease in 26% (5/19) of patients following Cometriq (cabozantinib) treatment (PMID: 28447912).",Actionable,10834,3908,non-small cell lung carcinoma,DOID,1326,RET rearrange,sensitive,998,cabozantinib,5979,28447912,,,
91,Preclinical - Cell culture,"In a preclinical study, Iclusig (ponatinib) inhibited RET phosphorylation and reduced viability of non-small cell lung cancer cells with RET activating mutations (Cancer Res April 15, 2013 73; 2084). ",Actionable,1432,3908,non-small cell lung carcinoma,DOID,2294,RET act mut,sensitive,877,Ponatinib,5979,None,,,
92,Preclinical,"In a preclinical study, Caprelsa (vandetanib) inhibited Ret autophosphorylation in transformed cells expressing RET L790F in culture (PMID: 15184865).",Actionable,3416,10000003,Advanced Solid Tumor,JAX,12809,RET L790F,sensitive,953,Vandetanib,5979,15184865,,,
93,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET L790F in culture (PMID: 23526464).",Actionable,3234,10000003,Advanced Solid Tumor,JAX,12809,RET L790F,sensitive,877,Ponatinib,5979,23526464,,,
94,Phase II,"In a Phase II clinical trial, Afinitor (everolimus) treatment resulted in stable disease of 116 weeks in a MEN2A patient with medullary thyroid cancer carrying a RET C620R mutation (PMID: 26294908).",Actionable,3373,3973,thyroid medullary carcinoma,DOID,11125,RET C620R,sensitive,735,Everolimus,5979,26294908,,,
95,Preclinical,"In a preclinical study, Iclusig (ponatinib) inhibited phosphorylation of Ret in transformed human cells expressing RET D898V in culture (PMID: 23526464).",Actionable,3235,10000003,Advanced Solid Tumor,JAX,12808,RET D898V,sensitive,877,Ponatinib,5979,23526464,,,
0,Phase II,"In a Phase II trial, treatment with Zykadia (ceritinib) resulted in an overall response rate of 62% (20/32, including 1 complete response), a disease control rate of 81% (26/32), and a progression-free survival of 9.3 months in all patients and 19.3 months in Xalkori (crizotinib)-naive patients with non-small cell lung cancer harboring a ROS1 rearrangement (PMID: 28520527; NCT01964157).",Actionable,11444,3908,non-small cell lung carcinoma,DOID,11085,ROS1 rearrange,sensitive,789,Ceritinib,6098,28520527,,,
1,FDA approved,"In a Phase I clinical trial that supported FDA approval, NSCLC patients with ROS1 rearrangements treated with Xalkori (crizotinib) demonstrated an objective response rate of 72% (36/50), with 3 complete responses and 33 partial responses, a median duration of response of 17.6 months, and a median progression-free survival of 19.2 months (PMID: 25264305).",Actionable,5011,3908,non-small cell lung carcinoma,DOID,11085,ROS1 rearrange,sensitive,706,Crizotinib,6098,25264305,,,
2,Clinical Study,"In a clinical case study, a patient with ROS1-rearranged non-small cell lung cancer with acquired resistance to Xalkori (crizotinib) demonstrated partial response to treatment with Cometriq (cabozantinib) prior to progressing after approximately 10 weeks (PMID: 27370605).",Actionable,9718,3908,non-small cell lung carcinoma,DOID,11085,ROS1 rearrange,predicted â€“ sensitive,998,cabozantinib,6098,27370605,,,
3,Preclinical - Cell culture,"In a preclinical study, NPS-1034 inhibited ROS1 activity and proliferation of a non-small cell lung cancer cell line harboring a ROS1 rearrangement in culture (PMID: 24165158).",Actionable,9661,3908,non-small cell lung carcinoma,DOID,11085,ROS1 rearrange,sensitive,5115,NPS-1034,6098,24165158,,,
4,Phase I,"In a clinical study analyzing combined results of 2 Phase I trials, Entrectinib (RXDX-101) treatment resulted in complete response in 2 and partial response in 10 patients with ROS-1 rearranged non-small cell lung carcinoma that were treatment-naive (PMID: 28183697).",Actionable,10492,3908,non-small cell lung carcinoma,DOID,11085,ROS1 rearrange,predicted â€“ sensitive,1455,Entrectinib,6098,28183697,,,
5,Phase I,"In a clinical study analyzing combined results of 2 Phase I trials, Entrectinib (RXDX-101) treatment resulted in an objective response rate of 86% (12/14) in patients with ROS-1 rearranged advanced solid tumors that were treatment-naive, but no response (0/6) in patients received prior Xalkori (crizotinib) (PMID: 28183697).",Actionable,10491,10000003,Advanced Solid Tumor,JAX,11085,ROS1 rearrange,sensitive,1455,Entrectinib,6098,28183697,,,
6,Phase I,"In a Phase I trial, Entrectinib (RXDX-101) treatment resulted in complete response in 13% (1/12) and objection response in 75% (6/8) of patients with advanced solid tumors harboring rearrangement in ROS1 gene (AACR Apr 2016, Abstract # CT007).",Actionable,6728,10000003,Advanced Solid Tumor,JAX,11085,ROS1 rearrange,sensitive,1455,Entrectinib,6098,None,,,
7,Phase II,"In a Phase I trial, Xalkori (crizotinib) treatment resulted in an objective response rate of 69% (89/129), and a median duration of treatment of 7.8 months in ALK negative, ROS1 positive non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9022)).",Actionable,6993,3908,non-small cell lung carcinoma,DOID,24174,ALK neg ROS1 pos,sensitive,706,Crizotinib,6098,None,,,
8,Phase I,"In a Phase I trial, Entrectinib (RXDX-101) treatment resulted in stable disease in a patient with ROS1-positive pancreatic cancer (J Clin Oncol 32:5s, 2014 (suppl; abstr 2502)).",Actionable,10351,1793,pancreatic cancer,DOID,1771,ROS1 positive,predicted â€“ sensitive,1455,Entrectinib,6098,None,,,
9,Phase I,"In a retrospective analysis of Phase I clinical data, Xalkori (crizotinib) resulted in an objective response rate of 80% (24/30) and a median PFS of 9.1 months in patients with ROS1 fusion positive lung adenocarcinoma (PMID: 25667280).",Actionable,2767,3910,lung adenocarcinoma,DOID,1249,ROS1 fusion,sensitive,706,Crizotinib,6098,25667280,,,
10,Phase I,"In a Phase I clinical trial, Lorlatinib (PF-06463922) demonstrated safety and resulted in a 50% (26/52) overall response rate in patients with ALK-positive or ROS1-positive non-small cell lung cancer, including intracranial responses in patients with CNS metastasis (J Clin Oncol 34, 2016 (suppl; abstr 9009)).",Actionable,6818,3908,non-small cell lung carcinoma,DOID,1249,ROS1 fusion,sensitive,869,PF-06463922,6098,None,,,
11,Phase I,"In a Phase I clinical trial, DS-6051b was well-tolerated and demonstrated some preliminary efficacy in patients with advanced solid tumors, including a partial response in a patient with non-small cell lung cancer liver metastases harboring a ROS1 fusion (Cancer Res July 15 2016 (76) (14 Supplement) CT024).",Actionable,9875,3908,non-small cell lung carcinoma,DOID,1249,ROS1 fusion,predicted â€“ sensitive,4343,DS6051b,6098,None,,,
12,Preclinical - Cell culture,"In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ROS1 fusion proteins in culture (PMID: 27780853).",Actionable,9244,10000003,Advanced Solid Tumor,JAX,1249,ROS1 fusion,sensitive,634,AP26113,6098,27780853,,,
0,Clinical Study,"In clinical analyses, RUNX1 mutations were associated with adverse clinical outcome in acute myeloid leukemia patients (PMID: 21343560, PMID: 22689681, PMID: 22753902, PMID: 25652455).",Prognostic,3570,9119,acute myeloid leukemia,DOID,22427,RUNX1 mutant,not applicable,1776,N/A,861,21343560,22689681,22753902,25652455
1,Clinical Study,"In clinical analyses, RUNX1 mutations were associated with poor overall survival in patients with myelodysplastic syndrome (PMID: 21714648, PMID: 22869879).",Actionable,6077,50908,myelodysplastic syndrome,DOID,22427,RUNX1 mutant,not applicable,1776,N/A,861,21714648,22869879,,
2,Preclinical,"In a preclinical study, the combination of I-CBP112 and Doxorubicin worked synergistically to inhibit growth of leukemia cells harboring a RUNX1-RUNX1T1 (AML1-ETO) fusion in culture (PMID: 26552700) ",Actionable,3778,1240,leukemia,DOID,15350,RUNX1-RUNX1T1,sensitive,3299,I-CBP112 + Doxorubicin,861,26552700,,,
3,Clinical Study,"In clinical analyses, the t(8;21) cytogenetic abnormality, which leads to the RUNX1-RUNX1T1 fusion, is associated with core-binding factor acute myeloid leukemia and favorable prognosis (PMID: 22180162, PMID: 9746770, PMID: 25111512).",Prognostic,6079,9119,acute myeloid leukemia,DOID,15350,RUNX1-RUNX1T1,not applicable,1776,N/A,861,22180162,9746770,25111512,
4,Preclinical - Cell culture,"In a preclinical study, GSK690 inhibited growth of acute myeloid leukemia cell lines harboring RUNX1-RUNX1T1 in culture (PMID: 26837761).",Actionable,10464,9119,acute myeloid leukemia,DOID,15350,RUNX1-RUNX1T1,sensitive,5507,GSK690,861,26837761,,,
5,Preclinical,"In a preclinical study, the combination of I-CBP112 and JQ1 worked synergistically to inhibit growth of leukemia cells harboring a RUNX1-RUNX1T1 (AML1-ETO) fusion in culture (PMID: 26552700) ",Actionable,3777,1240,leukemia,DOID,15350,RUNX1-RUNX1T1,sensitive,3298,I-CBP112 + JQ1,861,26552700,,,
6,Preclinical - Cell line xenograft,"In a preclinical study, RN-1 inhibited growth of acute myeloid leukemia cell lines harboring RUNX1-RUNX1T1 in culture, and inhibited tumor growth in xenograft models (PMID: 26837761).",Actionable,10463,9119,acute myeloid leukemia,DOID,15350,RUNX1-RUNX1T1,sensitive,5506,RN-1,861,26837761,,,
7,Preclinical,"In a preclinical study, I-CBP112 inhibited clonogenic growth in a leukemia cell line harboring a RUNX1-RUNX1T1 (AML1-ETO) fusion in culture (PMID: 26552700).",Actionable,3774,1240,leukemia,DOID,15350,RUNX1-RUNX1T1,sensitive,3297,I-CBP112,861,26552700,16384925,,
8,Clinical Study,"In clinical analyses, coincident KIT mutations were associated with higher relapse rate and decreased overall survival in acute myeloid leukemia patients with RUNX1-RUNX1T1 fusions (PMID: 18648004, PMID: 16384925, PMID: 25111512).",Prognostic,6080,9119,acute myeloid leukemia,DOID,22438,RUNX1-RUNX1T1 KIT mut,not applicable,1776,N/A,861,18648004,25111512,,
0,Preclinical,"In a preclinical study, SETPB1 missense mutations conferred a predicted gain-of-function, resulting in transformation of murine myeloid progenitors and increased Pp2ac phosphorylation compared to wild-type SETBP1 in culture, suggesting that Setbp1 may serve as a potential therapeutic target (PMID: 23832012). ",Emerging,1596,4972,myelodysplastic/myeloproliferative neoplasm,DOID,2731,SETBP1 mutant,not applicable,1776,N/A,26040,23832012,,,
0,Preclinical - Cell culture,"In a preclinical study, mouse cells expressing SF3B1 K700E demonstrated sensitivity to E7107 in culture, resulting in decreased viability of cells (PMID: 27622333). ",Actionable,9170,2531,hematologic cancer,DOID,22989,SF3B1 K700E,sensitive,4927,E7107,23451,27622333,,,
1,Preclinical,"In a preclinical study, Spliceostatin A inhibited survival of pancreatic cancer cells harboring SF3B1 K700E in culture (PMID: 25424858).",Actionable,6228,1793,pancreatic cancer,DOID,22989,SF3B1 K700E,sensitive,4096,Spliceostatin A,23451,25424858,,,
2,Preclinical,"In a preclinical study, Spliceostatin A inhibited survival of endometrial cancer cells harboring SF3B1 K666N in culture (PMID: 25424858).",Actionable,6227,1380,endometrial cancer,DOID,22964,SF3B1 K666N,sensitive,4096,Spliceostatin A,23451,25424858,,21998214,
3,Guideline,"In multiple clinical studies, SF3B1 mutations were associated with better overall survival in patients with myelodysplastic syndrome (PMID: 21998214, PMID: 22096241, PMID: 24220272), but may not have independent prognostic significance (PMID: 22096241).",Prognostic,6164,50908,myelodysplastic syndrome,DOID,22743,SF3B1 mutant,not applicable,1776,N/A,23451,24220272,22096241,22504380,
0,Clinical Study,"In clinical and meta-analyses, loss of Smad4 expression and SMAD4 inactivating mutations were associated with decreased survival in patients with pancreatic cancer (PMID: 26947875, PMID: 25760429, PMID: 22504380, PMID: 19584151).",Prognostic,4949,1793,pancreatic cancer,DOID,16537,SMAD4 dec exp,not applicable,1776,N/A,4089,26947875,25760429,25681512,19584151
1,Clinical Study,"In clinical and meta-analyses, decreased expression of Smad4 was correlated with poor prognosis in colorectal cancer (PMID: 25749173, PMID: 19478385, PMID: 25681512, PMID: 26861460).",Prognostic,3859,9256,colorectal cancer,DOID,16537,SMAD4 dec exp,not applicable,1776,N/A,4089,25749173,26861460,,19478385
2,Preclinical,"In a preclinical study, pancreatic cancer cell lines harboring SMAD4 homozygous deletions were half as sensitive to gemcitabine in vitro as wild-type cells (PMID: 22753594).",Actionable,1173,1793,pancreatic cancer,DOID,20413,SMAD4 del,decreased response,755,Gemcitabine,4089,22753594,,,
3,Preclinical,"In a preclinical study, pancreatic cancer cell lines harboring inactivated SMAD4 (mutations or deletion) displayed 4.5-fold greater sensitivity to irinotecan in vitro than wild-type (PMID: 22753594).",Actionable,1172,1793,pancreatic cancer,DOID,20413,SMAD4 del,sensitive,1074,Irinotecan,4089,22753594,,,
4,Preclinical,"In a preclinical study, pancreatic cancer cell lines harboring SMAD4 homozygous deletions were twice as sensitive to cisplatin in vitro as wild-type cells (PMID: 22753594).",Actionable,1171,1793,pancreatic cancer,DOID,20413,SMAD4 del,sensitive,700,Cisplatin,4089,22753594,,,
5,Preclinical,"In a preclinical study, SD-093 reduced the migration and invasiveness of pancreatic carcinoma cell lines lacking Smad4 (PMID: 15289325).",Actionable,2260,4905,pancreatic carcinoma,DOID,2068,SMAD4 loss,sensitive,2750,SD-093,4089,15289325,,,
6,Preclinical,"In a preclinical study, pancreatic cancer cell lines harboring inactivated SMAD4 (mutations or deletion) displayed 4.5-fold greater sensitivity to irinotecan in vitro than wild-type (PMID: 22753594).",Actionable,5253,1793,pancreatic cancer,DOID,20414,SMAD4 inact mut,sensitive,1074,Irinotecan,4089,22753594,,,
7,Clinical Study,"In a clinical study, a melanoma patient harboring a PDGFRA mutation, CDKN2A mutation, MET exon 14 splice site mutation, and SMAD4 Q249H demonstrated a 21 month overall survival when treated with a combination of Gleevec (imatinib), Paraplatin (carboplatin), and Taxol (paclitaxel) (PMID: 28514312).",Actionable,11053,1909,melanoma,DOID,27904,CDKN2A mut MET del exon14 PDGFRA mut SMAD4 Q249H,sensitive,5833,Imatinib + Carboplatin + Paclitaxel,4089,28514312,,,
8,Clinical Study,"In a clinical case study, a pancreatic ductal adenocarcinoma patient harboring EML4-ALK along with CDKN2A deletion, FGFR1 T141R, SMAD4 Q83*, and a TP53 splice site mutation, experienced disease progression after 2 months of Xalkori (crizotinib) treatment, then received Alecensa (alectinib) and remained on treatment for at least 3 months (PMID: 28476735).",Actionable,11543,3498,pancreatic ductal adenocarcinoma,DOID,28131,EML4-ALK CDKN2A del FGFR1 T141R SMAD4 Q83*,resistant,706,Crizotinib,4089,28476735,,,
9,Clinical Study,"In a clinical case study, a pancreatic ductal adenocarcinoma patient harboring EML4-ALK along with CDKN2A deletion, FGFR1 T141R, SMAD4 Q83*, and a TP53 splice site mutation, experienced disease progression after 2 months of Xalkori (crizotinib) treatment, then received Alecensa (alectinib) and remained on treatment for at least 3 months (PMID: 28476735).",Actionable,11544,3498,pancreatic ductal adenocarcinoma,DOID,28131,EML4-ALK CDKN2A del FGFR1 T141R SMAD4 Q83*,predicted â€“ sensitive,698,Alectinib,4089,28476735,,,
10,Preclinical,"In a preclinical study, a skin cancer cell line harboring mutations in PTEN, RB1, SMAD4 and TP53 demonstrated sensitivity to Sapanisertib (MLN0128) in culture (PMID: 25261369). ",Actionable,2106,4159,skin cancer,DOID,5389,PTEN mut RB1 mut SMAD4 mut TP53 mut,sensitive,1282,Sapanisertib,4089,25261369,,,
11,Preclinical,"In a preclinical study, a rapamycin-resistant colorectal cancer cell line harboring mutations in APC, BRAF, PIK3CA, SMAD4 and TP53 was sensitive to Sapanisertib (MLN0128) resulting in inhibition of MTORC1 signaling (PMID: 25261369). ",Actionable,2135,9256,colorectal cancer,DOID,5415,APC mut BRAF mut PIK3CA mut SMAD4 mut TP53 mut,sensitive,1282,Sapanisertib,4089,25261369,,,
0,Preclinical,"In a preclinical study, Ibrance (palbociclib) inhibited growth of  SMARCB1-negative malignant rhabdoid tumor cell lines in culture, and sensitivity was associated with low levels of p16 expression (PMID: 21871868).",Actionable,5768,3672,rhabdoid cancer,DOID,2085,SMARCB1 negative,sensitive,850,Palbociclib,6598,21871868,,,
1,Preclinical,"In a preclinical study, the combination of Zolinza (vorinostat) and fenretinide induced apoptosis and inhibited growth of rhabdoid tumor cell lines in culture (PMID: 23764045).",Actionable,5764,3672,rhabdoid cancer,DOID,2085,SMARCB1 negative,sensitive,3923,Fenretinide + Vorinostat,6598,23764045,,,
2,Preclinical,"In a preclinical study, Tazemetostat (EPZ-6438) inhibited growth of SMARCB1-deficient malignant rhabdoid tumore cell lines in culture (PMID: 23620515).",Actionable,5772,3672,rhabdoid cancer,DOID,2085,SMARCB1 negative,sensitive,2683,Tazemetostat,6598,23620515,,,
3,Preclinical - Cell line xenograft,"In a preclinical study, Alvocidib (flavopiridol) induced cell-cycle arrest and inhibited growth of human rhabdoid tumor cell lines with SMARCB1 biallelic deficiency in culture and inhibted tumor growth in SMARCB1-deficient cell line xenograft models (PMID: 18223228).",Actionable,1181,3672,rhabdoid cancer,DOID,2085,SMARCB1 negative,sensitive,628,Alvocidib,6598,18223228,,,
4,Preclinical,"In a preclinical study, DZNep induced apoptosis and cell-cycle arrest and inhibited growth of SMARCB1-negative atypical teratoid rhabdoid tumor cell lines in culture (PMID: 23190500).",Actionable,5765,2129,atypical teratoid rhabdoid tumor,DOID,2085,SMARCB1 negative,sensitive,2702,DZNeP,6598,23190500,,,
5,Preclinical,"In a preclinical study, DZNep increased radiosensitivity in SMARCB1-negative atypical teratoid rhabdoid tumor cell lines in culture (PMID: 23190500).",Actionable,5766,2129,atypical teratoid rhabdoid tumor,DOID,2085,SMARCB1 negative,sensitive,3924,DZNeP + radiotherapy,6598,23190500,,,
6,Preclinical,"In a preclinical study, CDKN2A (p16) over expression was associated with decreased sensitivity to Ibrance (palbociclib) in a SMARCB1-negative malignant rhabdoid tumor cell line in culture (PMID: 21871868).",Actionable,5767,3672,rhabdoid cancer,DOID,21572,CDKN2A over exp SMARCB1 negative,decreased response,850,Palbociclib,6598,21871868,,,
7,Preclinical - Cell culture,"In a preclinical study, over expression of EZH2 Y111D in rhabdoid tumor cells harboring an SMARCB1 inactivating mutation resulted in resistance to Tazemetostat (EPZ-6438) treatment in culture (PMID: 26360609).",Actionable,7826,3672,rhabdoid cancer,DOID,26057,EZH2 Y111D SMARCB1 inact mut,resistant,2683,Tazemetostat,6598,26360609,,,
8,Preclinical - Cell culture,"In a preclinical study, CFI-400945 inhibited proliferation and decreased survival and migration of SMARCB1-deficient atypical teratoid rhabdoid tumor cells in culture (PMID: 28398638).",Actionable,10779,2129,atypical teratoid rhabdoid tumor,DOID,13297,SMARCB1 loss,sensitive,4029,CFI-400945,6598,28398638,,,
9,Preclinical - Cell line xenograft,"In a preclinical study, Tazemetostat (EPZ-6438) inhibited H3K27 trimethylation and induced tumor regression in SMARCB1-deleted human cell line xenograft models of  malignant rhabdoid tumors (PMID: 23620515).",Actionable,5774,3672,rhabdoid cancer,DOID,21573,SMARCB1 del,sensitive,2683,Tazemetostat,6598,23620515,,,
0,Preclinical,"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO T241M on the background of PTCH1 and TP53 deletion demonstrated reduced response to Odomzo (sonidegib) induced growth inhibition in cell culture (PMID: 25759019).",Actionable,6291,10000003,Advanced Solid Tumor,JAX,23090,SMO T241M,decreased response,1428,Sonidegib,6608,25759019,,,
1,Preclinical,"In a preclinical study, JQ1 inhibited proliferation of primary cerebellar granule neuron precursor cells over expressing SMO T241M on the background of PTCH1 and TP53 deletion in cell culture (PMID: 25759019).",Actionable,6298,10000003,Advanced Solid Tumor,JAX,23090,SMO T241M,sensitive,1574,JQ1,6608,25759019,,,
2,Preclinical,"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO T241M on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019).",Actionable,6277,10000003,Advanced Solid Tumor,JAX,23090,SMO T241M,decreased response,1587,Taladegib,6608,25759019,,,
3,Preclinical,"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO T241M on the background of PTCH1 and TP53 deletion demonstrated reduced response to Erivedge (vismodegib) induced growth inhibition in cell culture (PMID: 25759019).",Actionable,6275,10000003,Advanced Solid Tumor,JAX,23090,SMO T241M,decreased response,956,Vismodegib,6608,25759019,,,
4,Clinical Study,"In a single patient study, the SMO D473H mutant conferred secondary resistance to the hedgehog pathway inhibitor Erivedge (vismodegib) in a medulloblastoma patient (PMID: 19726788).",Actionable,1142,50902,medulloblastoma,DOID,1973,SMO D473H,resistant,956,Vismodegib,6608,19726788,,,
5,Phase I,"In an open-label clinical trial, treatment with Sonidegib (LDE225) resulted in progressive disease in a basal cell carcinoma patient harboring SMO D473H with resistance to Erivedge (vismodegib) (PMID: 26546616).",Actionable,4279,2513,basal cell carcinoma,DOID,1973,SMO D473H,resistant,1428,Sonidegib,6608,26546616,,,
6,Preclinical,"In a preclinical study, TAK-441 inhibited Gli-reporter activation in cells transfected with SMO D473H in culture (PMID: 24291104).",Actionable,6074,10000003,Advanced Solid Tumor,JAX,1973,SMO D473H,predicted â€“ sensitive,2425,TAK-441,6608,24291104,,,
7,Preclinical,"In a preclinical study, LY2940680, inhibited the activity of SMO D473H, which is a mutant that confers resistance to the treatment of vismodegib (Cancer Research: April 15, 2011; Volume 71, Issue 8, Supplement 1, Abstract #2819).",Actionable,1141,10000003,Advanced Solid Tumor,JAX,1973,SMO D473H,sensitive,1587,Taladegib,6608,None,,,
8,Preclinical,"In a preclinical study, transformed human cells expressing SMO L325F displayed reduced binding to MRT-92 (PMID: 25636740).",Actionable,5021,10000003,Advanced Solid Tumor,JAX,19860,SMO L325F,predicted â€“ resistant,2418,MRT-92,6608,25636740,,,
9,Preclinical,"In a preclinical study, transformed human cells expressing SMO D384A displayed reduced binding to MRT-92 (PMID: 25636740).",Actionable,5017,10000003,Advanced Solid Tumor,JAX,19856,SMO D384A,predicted â€“ resistant,2418,MRT-92,6608,25636740,,,
10,Preclinical,"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO C469Y on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019).",Actionable,6284,10000003,Advanced Solid Tumor,JAX,23088,SMO C469Y,decreased response,1587,Taladegib,6608,25759019,,,
11,Preclinical,"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO C469Y on the background of PTCH1 and TP53 deletion demonstrated reduced response to Odomzo (sonidegib) induced growth inhibition in cell culture (PMID: 25759019).",Actionable,6285,10000003,Advanced Solid Tumor,JAX,23088,SMO C469Y,decreased response,1428,Sonidegib,6608,25759019,,,
12,Preclinical,"In a preclinical study, JQ1 inhibited proliferation of primary cerebellar granule neuron precursor cells over expressing SMO C469Y on the background of PTCH1 and TP53 deletion in cell culture (PMID: 25759019).",Actionable,6292,10000003,Advanced Solid Tumor,JAX,23088,SMO C469Y,sensitive,1574,JQ1,6608,25759019,,,
13,Preclinical,"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO C469Y on the background of PTCH1 and TP53 deletion demonstrated reduced response to Erivedge (vismodegib) induced growth inhibition in cell culture (PMID: 25759019).",Actionable,6271,10000003,Advanced Solid Tumor,JAX,23088,SMO C469Y,decreased response,956,Vismodegib,6608,25759019,,,
14,Preclinical,"In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO D477G (corresponding to human SMO D473G) were resistant to Erivedge (vismodegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493).",Actionable,6307,10000003,Advanced Solid Tumor,JAX,6248,SMO D473G,resistant,956,Vismodegib,6608,26823493,,,
15,Preclinical,"In a preclinical study, a transformed cell line expressing SMO D473G was resistant to Erivedge (vismodegib) as demonstrated by elevated gene expression levels of GLI1 resulting in increased signaling of the hedgehog pathway (PMID: 25759020). ",Actionable,2197,2513,basal cell carcinoma,DOID,6248,SMO D473G,resistant,956,Vismodegib,6608,25759020,,,
16,Preclinical,"In a preclinical study, Posaconazole inhibited Hedghog signaling in mouse fibroblasts over expressing murine SMO D477G (corresponding to human SMO D473G) in culture (PMID: 26823493).",Actionable,6325,10000003,Advanced Solid Tumor,JAX,6248,SMO D473G,sensitive,4108,Posaconazole,6608,26823493,,,
17,Phase I,"In an open-label clinical trial, treatment with Sonidegib (LDE225) resulted in progressive disease in a basal cell carcinoma patient harboring SMO D473G with resistance to Erivedge (vismodegib) (PMID: 26546616).",Actionable,4280,2513,basal cell carcinoma,DOID,6248,SMO D473G,resistant,1428,Sonidegib,6608,26546616,,,
18,Preclinical,"In a preclinical study, combination of Posaconazole and Trisenox (Arsenic trioxide) demonstrated enhanced inhibition of Hedghog signaling in mouse fibroblasts over expressing murine SMO D477G (corresponding to human SMO D473G) in culture (PMID: 26823493).",Actionable,6335,10000003,Advanced Solid Tumor,JAX,6248,SMO D473G,sensitive,4117,Arsenic trioxide + Posaconazole,6608,26823493,,,
19,Preclinical,"In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO S391N (corresponding to human SMO S387N) were resistant to Erivedge (vismodegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493).",Actionable,6310,10000003,Advanced Solid Tumor,JAX,23084,SMO S387N,resistant,956,Vismodegib,6608,26823493,,,
20,Preclinical,"In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO S391N (corresponding to human SMO S387N) were resistant to Odomzo (sonidegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493).",Actionable,6311,10000003,Advanced Solid Tumor,JAX,23084,SMO S387N,resistant,1428,Sonidegib,6608,26823493,,,
21,Preclinical,"In a preclinical study, Posaconazole inhibited Hedghog signaling in mouse fibroblasts over expressing murine SMO S391N (corresponding to human SMO S387N) in culture (PMID: 26823493).",Actionable,6327,10000003,Advanced Solid Tumor,JAX,23084,SMO S387N,sensitive,4108,Posaconazole,6608,26823493,,,
22,Preclinical,"In a preclinical study, combination of Posaconazole and Trisenox (Arsenic trioxide) demonstrated enhanced inhibition of Hedghog signaling in mouse fibroblasts over expressing murine SMO S391N (corresponding to human SMO S387N) in culture (PMID: 26823493).",Actionable,6333,10000003,Advanced Solid Tumor,JAX,23084,SMO S387N,sensitive,4117,Arsenic trioxide + Posaconazole,6608,26823493,,,
23,Preclinical,"In a preclinical study, mouse sarcoma cell lines over expressing SMO S387N demonstrated reduced response to Erivedge (vismodegib) induced Hedgehog pathway inhibition in cell culture (PMID: 25759019).",Actionable,6304,1115,sarcoma,DOID,23084,SMO S387N,decreased response,956,Vismodegib,6608,25759019,,,
24,Preclinical,"In a preclinical study, Vismodegib (GDC-0449) inhibited Hedgehog pathway signaling, increased apoptosis, and decreased proliferation of a gastric cancer cell line in culture (PMID: 26676867).",Actionable,5026,10534,stomach cancer,DOID,691,SMO wild-type,predicted â€“ sensitive,956,Vismodegib,6608,26676867,,,
25,Preclinical,"In a preclinical study, LY2940680 was demonstrated to bind to the Smo receptor and inhibit hedgehog signaling in a human medulloblastoma tumor cell line (Cancer Research: April 15, 2011; Volume 71, Issue 8, Supplement 1, Abstract #2819).",Actionable,1140,50902,medulloblastoma,DOID,691,SMO wild-type,sensitive,1587,Taladegib,6608,None,,,
26,Preclinical,"In a preclinical study, amplification of SMO conferred acquired resistance to Iressa (gefitinib) in non-small cell lung cancer cells harboring EGFR E746_A750del in culture (PMID: 26124204).",Actionable,2547,3908,non-small cell lung carcinoma,DOID,9076,EGFR E746_A750del SMO amp,resistant,751,Gefitinib,6608,26124204,,,
27,Preclinical,"In a preclinical study, Odomzo (sonidegib) did not decrease viability or migration of non-small cell lung cancer cells harboring EGFR E746_A750del and amplification of SMO in culture (PMID: 26124204).",Actionable,2656,3908,non-small cell lung carcinoma,DOID,9076,EGFR E746_A750del SMO amp,no benefit,1428,Sonidegib,6608,26124204,,,
28,Preclinical,"In a preclinical study, the combination of Odomzo (sonidegib) and Iressa (gefitinib) decreased viability and migration of non-small cell lung cancer (NSCLC) cells harboring an EGFR E746_A750del mutation and SMO amplification in culture and inhibited tumor growth in NSCLC xenograft models with EGFR E746_A750del and SMO amplification (PMID: 26124204).",Actionable,2657,3908,non-small cell lung carcinoma,DOID,9076,EGFR E746_A750del SMO amp,sensitive,2986,Gefitinib + Sonidegib,6608,26124204,,,
29,Preclinical,"In a preclinical study, the combination of Odomzo (sonidegib) and PHA-665752 decreased viability and migration of non-small cell lung cancer (NSCLC) cells harboring EGFR E746_A750del and SMO amplification in culture, and resulted in complete response in 100% (8/8) of NSCLC xenograft models with EGFR E746_A750del and SMO amplification (PMID: 26124204).",Actionable,2658,3908,non-small cell lung carcinoma,DOID,9076,EGFR E746_A750del SMO amp,sensitive,2987,PHA-665752 + Sonidegib,6608,26124204,,,
30,Phase I,"In an open-label clinical trial, treatment with Sonidegib (LDE225) resulted in stable disease in a basal cell carcinoma patient harboring SMO W535L with resistance to Erivedge (vismodegib) (PMID: 26546616).",Actionable,4277,2513,basal cell carcinoma,DOID,3611,SMO W535L,predicted â€“ sensitive,1428,Sonidegib,6608,26546616,,,
31,Preclinical,"In a preclinical study, Posaconazole did not inhibit Hedghog signaling in mouse fibroblasts over expressing murine SMO W539L (corresponding to human SMO W535L) in culture (PMID: 26823493).",Actionable,6321,10000003,Advanced Solid Tumor,JAX,3611,SMO W535L,resistant,4108,Posaconazole,6608,26823493,,,
32,Preclinical,"In a preclinical study, a transformed cell line expressing SMO W535L demonstrated resistance to Erivedge (vismodegib) (PMID: 25759020).",Actionable,2169,10000003,Advanced Solid Tumor,JAX,3611,SMO W535L,resistant,956,Vismodegib,6608,25759020,,,
33,Preclinical,"In a preclinical study, treatment with arsenic trioxide resulted in improved survival in a transgenic mouse model of medulloblastoma expressing SMO W535L (PMID: 21183792).",Actionable,1466,50902,medulloblastoma,DOID,3611,SMO W535L,sensitive,640,Arsenic trioxide,6608,21183792,,,
34,Preclinical,"In a preclinical study, a transformed cell line expressing SMO L412F demonstrated resistance to Erivedge (vismodegib) (PMID: 25759020). ",Actionable,2196,10000003,Advanced Solid Tumor,JAX,6247,SMO L412F,resistant,956,Vismodegib,6608,25759020,,,
35,Preclinical,"In a preclinical study, a transformed cell line expressing SMO Q477E was resistant to Erivedge (vismodegib) as demonstrated by elevated gene expression levels of GLI1 resulting in increased signaling of the hedgehog pathway (PMID: 25759020). ",Actionable,2205,2513,basal cell carcinoma,DOID,6279,SMO Q477E,resistant,956,Vismodegib,6608,25759020,,,
36,Phase I,"In an open-label clinical trial, treatment with Sonidegib (LDE225) resulted in progressive disease in a basal cell carcinoma patient harboring SMO Q477E with resistance to Erivedge (vismodegib) (PMID: 26546616).",Actionable,4278,2513,basal cell carcinoma,DOID,6279,SMO Q477E,no benefit,1428,Sonidegib,6608,26546616,,,
37,Preclinical,"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO W281C on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019).",Actionable,6279,10000003,Advanced Solid Tumor,JAX,6277,SMO W281C,decreased response,1587,Taladegib,6608,25759019,,,
38,Preclinical,"In a preclinical study, a transformed cell line expressing SMO W281C was resistant to Erivedge (vismodegib) as demonstrated by elevated gene expression levels of GLI1 resulting in increased signaling of the hedgehog pathway (PMID: 25759020). ",Actionable,2203,2513,basal cell carcinoma,DOID,6277,SMO W281C,resistant,956,Vismodegib,6608,25759020,,,
39,Preclinical,"In a preclinical study, JQ1 inhibited proliferation of primary cerebellar granule neuron precursor cells over expressing SMO W281C on the background of PTCH1 and TP53 deletion in cell culture (PMID: 25759019).",Actionable,6297,10000003,Advanced Solid Tumor,JAX,6277,SMO W281C,sensitive,1574,JQ1,6608,25759019,,,
40,Preclinical,"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO W281C on the background of PTCH1 and TP53 deletion demonstrated reduced response to Odomzo (sonidegib) induced growth inhibition in cell culture (PMID: 25759019).",Actionable,6290,10000003,Advanced Solid Tumor,JAX,6277,SMO W281C,decreased response,1428,Sonidegib,6608,25759019,,,
41,Preclinical,"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO T241M on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019).",Actionable,6280,10000003,Advanced Solid Tumor,JAX,5734,SMO V321M,decreased response,1587,Taladegib,6608,25759019,,,
42,Preclinical,"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO C469Y on the background of PTCH1 and TP53 deletion demonstrated reduced response to Odomzo (sonidegib) induced growth inhibition in cell culture (PMID: 25759019).",Actionable,6289,10000003,Advanced Solid Tumor,JAX,5734,SMO V321M,decreased response,1428,Sonidegib,6608,25759019,,,
43,Preclinical,"In a preclinical study, JQ1 inhibited proliferation of primary cerebellar granule neuron precursor cells over expressing SMO V321M on the background of PTCH1 and TP53 deletion in cell culture (PMID: 25759019).",Actionable,6296,10000003,Advanced Solid Tumor,JAX,5734,SMO V321M,sensitive,1574,JQ1,6608,25759019,,,
44,Preclinical,"In a preclinical study, a transformed cell line expressing SMO V321M demonstrated resistance to Erivedge (vismodegib) (PMID: 25759020).",Actionable,2170,10000003,Advanced Solid Tumor,JAX,5734,SMO V321M,resistant,956,Vismodegib,6608,25759020,,,
45,Preclinical,"In a preclincal, transformed human cells expressing SMO R400A displayed reduced binding to MRT-92 (PMID: 25636740).",Actionable,5019,10000003,Advanced Solid Tumor,JAX,19859,SMO R400A,predicted â€“ sensitive,2418,MRT-92,6608,25636740,,,
46,Preclinical,"In a preclinical study, transformed human cells expressing SMO T466F displayed reduced binding to MRT-92 (PMID: 25636740).",Actionable,5023,10000003,Advanced Solid Tumor,JAX,19865,SMO T466F,predicted â€“ resistant,2418,MRT-92,6608,25636740,,,
47,Preclinical,"In a preclinical study, transformed human cells expressing SMO V329F displayed reduced binding to MRT-92 (PMID: 25636740).",Actionable,5022,10000003,Advanced Solid Tumor,JAX,19862,SMO V329F,predicted â€“ resistant,2418,MRT-92,6608,25636740,,,
48,Preclinical,"In a preclinical study, transformed human cells expressing SMO M525G displayed reduced binding to MRT-92 (PMID: 25636740).",Actionable,5024,10000003,Advanced Solid Tumor,JAX,19867,SMO M525G,predicted â€“ resistant,2418,MRT-92,6608,25636740,,,
49,Preclinical,"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO A459V on the background of PTCH1 and TP53 deletion demonstrated reduced response to Odomzo (sonidegib) induced growth inhibition in cell culture (PMID: 25759019).",Actionable,6287,10000003,Advanced Solid Tumor,JAX,23091,SMO A459V,decreased response,1428,Sonidegib,6608,25759019,,,
50,Preclinical,"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO A459V on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019).",Actionable,6282,10000003,Advanced Solid Tumor,JAX,23091,SMO A459V,decreased response,1587,Taladegib,6608,25759019,,,
51,Preclinical,"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO A459V on the background of PTCH1 and TP53 deletion demonstrated reduced response to Erivedge (vismodegib) induced growth inhibition in cell culture (PMID: 25759019).",Actionable,6274,10000003,Advanced Solid Tumor,JAX,23091,SMO A459V,decreased response,956,Vismodegib,6608,25759019,,,
52,Preclinical,"In a preclinical study, JQ1 inhibited proliferation of primary cerebellar granule neuron precursor cells over expressing SMO A459V on the background of PTCH1 and TP53 deletion in cell culture (PMID: 25759019).",Actionable,6293,10000003,Advanced Solid Tumor,JAX,23091,SMO A459V,sensitive,1574,JQ1,6608,25759019,,,
53,Preclinical,"In a preclinical study, SANT1 inhibited survival of osteosarcoma cell lines with reduced SMO mRNA level in culture (PMID: 26781311).",Actionable,7021,3347,osteosarcoma,DOID,24364,SMO dec exp,predicted â€“ sensitive,3990,SANT1,6608,26781311,,,
54,Preclinical,"In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO N223D (corresponding to human SMO N219D) were resistant to Odomzo (sonidegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493).",Actionable,6314,10000003,Advanced Solid Tumor,JAX,23086,SMO N219D,resistant,1428,Sonidegib,6608,26823493,,,
55,Preclinical,"In a preclinical study, Posaconazole inhibited Hedghog signaling in mouse fibroblasts over expressing murine SMO N223D (corresponding to human SMO N219D) in culture (PMID: 26823493).",Actionable,6329,10000003,Advanced Solid Tumor,JAX,23086,SMO N219D,sensitive,4108,Posaconazole,6608,26823493,,,
56,Preclinical,"In a preclinical study, mouse sarcoma cell lines over expressing SMO N219D demonstrated reduced response to Erivedge (vismodegib) induced Hedgehog pathway inhibition in cell culture (PMID: 25759019).",Actionable,6306,1115,sarcoma,DOID,23086,SMO N219D,decreased response,956,Vismodegib,6608,25759019,,,
57,Preclinical,"In a preclinical study, combination of Posaconazole and Trisenox (Arsenic trioxide) demonstrated enhanced inhibition of Hedghog signaling in mouse fibroblasts over expressing murine SMO N223D (corresponding to human SMO N219D) in culture (PMID: 26823493).",Actionable,6331,10000003,Advanced Solid Tumor,JAX,23086,SMO N219D,sensitive,4117,Arsenic trioxide + Posaconazole,6608,26823493,,,
58,Phase I,"In an open-label clinical trial, treatment with Sonidegib (LDE225) resulted in progressive disease in a basal cell carcinoma patient with resistance to Erivedge (vismodegib) harboring SMO D533N (PMID: 26546616).",Actionable,4454,2513,basal cell carcinoma,DOID,18162,SMO S533N,resistant,1428,Sonidegib,6608,26546616,,,
59,Preclinical,"In a preclinical study, a transformed cell line expressing SMO H231R was resistant to Erivedge (vismodegib) as demonstrated by elevated gene expression levels of GLI1 resulting in increased signaling of the hedgehog pathway (PMID: 25759020). ",Actionable,2204,2513,basal cell carcinoma,DOID,6278,SMO H231R,resistant,956,Vismodegib,6608,25759020,,,
60,Preclinical,"In a preclinical study, transformed human cells expressing SMO Y394A displayed reduced binding to MRT-92 (PMID: 25636740).",Actionable,5018,10000003,Advanced Solid Tumor,JAX,19858,SMO Y394A,predicted â€“ resistant,2418,MRT-92,6608,25636740,,,
61,Preclinical,"In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO D388N (corresponding to human SMO D384N) were resistant to Odomzo (sonidegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493).",Actionable,6313,10000003,Advanced Solid Tumor,JAX,23085,SMO D384N,resistant,1428,Sonidegib,6608,26823493,,,
62,Preclinical,"In a preclinical study, Posaconazole inhibited Hedghog signaling in mouse fibroblasts over expressing murine SMO D388N (corresponding to human SMO D384N) in culture (PMID: 26823493).",Actionable,6328,10000003,Advanced Solid Tumor,JAX,23085,SMO D384N,sensitive,4108,Posaconazole,6608,26823493,,,
63,Preclinical,"In a preclinical study, combination of Posaconazole and Trisenox (Arsenic trioxide) demonstrated enhanced inhibition of Hedghog signaling in mouse fibroblasts over expressing murine SMO D388N (corresponding to human SMO D384N) in culture (PMID: 26823493).",Actionable,6332,10000003,Advanced Solid Tumor,JAX,23085,SMO D384N,sensitive,4117,Arsenic trioxide + Posaconazole,6608,26823493,,,
64,Preclinical,"In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO D388N (corresponding to human SMO D384N) were resistant to Erivedge (vismodegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493).",Actionable,6315,10000003,Advanced Solid Tumor,JAX,23085,SMO D384N,resistant,956,Vismodegib,6608,26823493,,,
65,Preclinical,"In a preclinical study, mouse sarcoma cell lines over expressing SMO D384N demonstrated reduced response to Erivedge (vismodegib) induced Hedgehog pathway inhibition in cell culture (PMID: 25759019).",Actionable,6305,1115,sarcoma,DOID,23085,SMO D384N,decreased response,956,Vismodegib,6608,25759019,,,
66,Preclinical,"In a preclinical study, a transformed cell line expressing SMO F460L demonstrated resistance to Erivedge (vismodegib) as compared to wild-type (PMID: 25759020).",Actionable,2195,10000003,Advanced Solid Tumor,JAX,6246,SMO F460L,resistant,956,Vismodegib,6608,25759020,,,
67,Preclinical,"In a preclinical study, Posaconazole inhibited Hedghog signaling in mouse fibroblasts over expressing murine SMO E522K (corresponding to human SMO E518K) in culture (PMID: 26823493).",Actionable,6326,10000003,Advanced Solid Tumor,JAX,19866,SMO E518K,sensitive,4108,Posaconazole,6608,26823493,,,
68,Preclinical,"In a preclinical study, transformed human cells expressing SMO E518K displayed reduced binding to MRT-92 (PMID: 25636740).",Actionable,5020,10000003,Advanced Solid Tumor,JAX,19866,SMO E518K,predicted â€“ resistant,2418,MRT-92,6608,25636740,,,
69,Preclinical,"In a preclinical study, combination of Posaconazole and Trisenox (Arsenic trioxide) demonstrated enhanced inhibition of Hedghog signaling in mouse fibroblasts over expressing murine SMO E522K (corresponding to human SMO E518K) in culture (PMID: 26823493).",Actionable,6334,10000003,Advanced Solid Tumor,JAX,19866,SMO E518K,sensitive,4117,Arsenic trioxide + Posaconazole,6608,26823493,,,
70,Preclinical,"In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO E522K (corresponding to human SMO E518K) demonstrated decreased response to Odomzo (sonidegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493).",Actionable,6316,10000003,Advanced Solid Tumor,JAX,19866,SMO E518K,decreased response,1428,Sonidegib,6608,26823493,,,
71,Preclinical,"In a preclinical study, transformed mouse fibroblast cells over expressing murine SMO E522K (corresponding to human SMO E518K) were resistant to Erivedge (vismodegib) induced Hedgehog pathway inhibition in cell culture (PMID: 26823493).",Actionable,6308,10000003,Advanced Solid Tumor,JAX,19866,SMO E518K,resistant,956,Vismodegib,6608,26823493,,,
72,Preclinical,"In a preclinical study, JQ1 inhibited proliferation of primary cerebellar granule neuron precursor cells over expressing SMO I408V on the background of PTCH1 and TP53 deletion in cell culture (PMID: 25759019).",Actionable,6295,10000003,Advanced Solid Tumor,JAX,23087,SMO I408V,sensitive,1574,JQ1,6608,25759019,,,
73,Preclinical,"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO I408V on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019).",Actionable,6281,10000003,Advanced Solid Tumor,JAX,23087,SMO I408V,decreased response,1587,Taladegib,6608,25759019,,,
74,Preclinical,"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO I408V on the background of PTCH1 and TP53 deletion demonstrated reduced response to Odomzo (sonidegib) induced growth inhibition in cell culture (PMID: 25759019).",Actionable,6288,10000003,Advanced Solid Tumor,JAX,23087,SMO I408V,decreased response,1428,Sonidegib,6608,25759019,,,
75,Preclinical,"In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO I408V on the background of PTCH1 and TP53 deletion demonstrated reduced response to Erivedge (vismodegib) induced growth inhibition in cell culture (PMID: 25759019).",Actionable,6272,10000003,Advanced Solid Tumor,JAX,23087,SMO I408V,decreased response,956,Vismodegib,6608,25759019,,,
0,Preclinical,"In a preclinical study, BIRB-796 in combination with Sprycel (dasatinib) resulted in improved growth inhibition in both 2D and 3D cultures of triple-receptor negative breast cancer cell lines with elevated Src activity compared to single agent treatment (PMID: 27154914).",Actionable,6877,60081,triple-receptor negative breast cancer,DOID,4696,SRC act mut,sensitive,4289,BIRB-796 + Dasatinib,6714,27154914,,,
1,Preclinical - Cell line xenograft,"In a preclinical study, UM-164 inhibited proliferation and induced apoptosis in human triple-receptor negative breast cancer cell lines with elevated Src activity in culture, and inhibited tumor growth in cell line xenograft models (PMID: 27154914).",Actionable,6876,60081,triple-receptor negative breast cancer,DOID,4696,SRC act mut,predicted â€“ sensitive,4287,UM-164,6714,27154914,,,
2,Preclinical,"In a preclinical study, lung cancer cell lines harboring EML4-ALK and elevated Src activity were resistant to Xalkori (crizotinib) induced growth inhibition in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).",Actionable,5835,1324,lung cancer,DOID,21947,EML4 - ALK SRC act mut,resistant,706,Crizotinib,6714,None,,,
3,Preclinical,"In a preclinical study, lung cancer cell lines harboring EML4-ALK and elevated Src activity were resistant to Zykadia (ceritinib) induced growth inhibition in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).",Actionable,5836,10000003,Advanced Solid Tumor,JAX,21947,EML4 - ALK SRC act mut,resistant,789,Ceritinib,6714,None,,,
4,Preclinical,"In a preclinical study, TPX-0005 inhibited Alk and Src signaling, and cell proliferation in lung cancer cell lines harboring EML4-ALK and elevated Src activity in culture (AACR, Cancer Res: April 2016; Volume 57, Abstract #2132).",Actionable,5831,1324,lung cancer,DOID,21947,EML4 - ALK SRC act mut,sensitive,3950,TPX-0005,6714,None,,,
5,Phase I,"In a Phase I trial, ARQ 087 treatment resulted in 24% tumor reduction and stable disease for 32 weeks in a squamous non-small cell lung carcinoma patient harboring SRC amplification (J Clin Oncol 33, 2015 (suppl; abstr 2545)).",Actionable,3991,3908,non-small cell lung carcinoma,DOID,17091,SRC amp,sensitive,2900,ARQ 087,6714,None,,,
6,Preclinical - Cell line xenograft,"In a preclinical study, Sprycel (dasatinib) and Mekinist (trametinib) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture, and resulted in sustained tumor suppression and prolonged survival in cell line xenograft models (PMID: 27222538).",Actionable,7867,1781,thyroid cancer,DOID,26068,HRAS G13R KRAS G12R SRC T341M,sensitive,4599,Dasatinib + Trametinib,6714,27222538,,,
7,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) and SCH772984 synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture (PMID: 27222538).",Actionable,7870,1781,thyroid cancer,DOID,26068,HRAS G13R KRAS G12R SRC T341M,sensitive,4601,Dasatinib + SCH772984,6714,27222538,,,
8,Preclinical - Cell culture,"In a preclinical study, Selumetinib (AZD6244) inhibited growth of Sprycel (dasatinib)-resistant thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture (PMID: 27222538).",Actionable,7860,1781,thyroid cancer,DOID,26068,HRAS G13R KRAS G12R SRC T341M,sensitive,913,Selumetinib,6714,27222538,,,
9,Preclinical - Cell line xenograft,"In a preclinical study, thyroid cancer cell lines harboring HRAS G13R and KRAS G12R with an acquired SRC T341M mutation demonstrated resistance to Sprycel (dasatinib) in culture and in cell line xenograft models (PMID: 27222538).",Actionable,7839,1781,thyroid cancer,DOID,26068,HRAS G13R KRAS G12R SRC T341M,resistant,717,Dasatinib,6714,27222538,,,
10,Preclinical - Cell culture,"In a preclinical study, Sprycel (dasatinib) and Selumetinib (AZD6244) synergistically inhibited proliferation and induced apoptosis in thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M mutation in culture (PMID: 27222538).",Actionable,7868,1781,thyroid cancer,DOID,26068,HRAS G13R KRAS G12R SRC T341M,sensitive,4600,Dasatinib + Selumetinib,6714,27222538,,,
11,Preclinical - Cell line xenograft,"In a preclinical study, Mekinist (trametinib) inhibited growth of Sprycel (dasatinib)-resistant thyroid cancer cell lines harboring KRAS G13R, HRAS G12R, and an acquired SRC T341M in culture and in cell line xenograft models (PMID: 27222538).",Actionable,7855,1781,thyroid cancer,DOID,26068,HRAS G13R KRAS G12R SRC T341M,sensitive,2,Trametinib,6714,27222538,,,
12,Preclinical - Pdx,"In a preclinical study, treatment with Tykerb (lapatinib) was not effective in inhibiting tumor growth in a patient-derived xenograft model of bladder cancer with ERBB2 (HER2) over expression, which also over expressed SRC and harbored PIK3CA H1047R (PMID: 26270481).",Actionable,7456,11054,urinary bladder cancer,DOID,25513,ERBB2 over exp PIK3CA H1047R SRC over exp,no benefit,787,Lapatinib,6714,26270481,,,
13,Preclinical - Pdx,"In a preclinical study, treatment with Iclusig (ponatinib) was not effective in inhibiting tumor growth in a patient-derived xenograft model of bladder cancer with SRC over expression, which also over expressed ERBB2 (HER2) and harbored PIK3CA H1047R (PMID: 26270481).",Actionable,7457,11054,urinary bladder cancer,DOID,25513,ERBB2 over exp PIK3CA H1047R SRC over exp,no benefit,877,Ponatinib,6714,26270481,,,
14,Phase II,"In a Phase II clinical trial, baseline expression of SRC was not predictive for response to Saracatinib (AZD0530) and Recentin (cediranib) relative to Recentin (cediranib) in patients with metastatic clear-cell renal cell carcinoma (PMID: 26802156).",Actionable,5936,4467,renal clear cell carcinoma,DOID,2760,SRC over exp,no benefit,3922,Cediranib + Saracatinib,6714,26802156,,,
15,Preclinical - Patient cell culture,"In a preclinical study, the combination of Saracatinib (AZD0530) and (Zykadia) ceritinib demonstrated efficacy in non-small cell lung cancer patient derived cells harboring an ALK fusion and upregulation of SRC in culture (PMID: 25394791).",Actionable,1618,3908,non-small cell lung carcinoma,DOID,26396,ALK rearrange SRC pos,sensitive,1939,Saracatinib + Ceritinib,6714,25394791,,,
16,Preclinical - Cell line xenograft,"In a preclinical study, Si306 inhibited SRC phosphorylation and proliferation of SRC-expressing glioblastoma cell lines in culture, and inhibited tumor growth and increased survival in cell line xenograft models (PMID: 27196762).",Actionable,7272,3068,glioblastoma multiforme,DOID,1875,SRC positive,sensitive,4430,Si306,6714,27196762,,,
17,Preclinical,"In a preclinical study, KX2-392 inhibited Src signaling and proliferation in triple-receptor negative breast cancer cell lines in culture, and suppressed tumor growth in xenograft models (PMID: 22784709).",Actionable,5903,60081,triple-receptor negative breast cancer,DOID,1875,SRC positive,sensitive,786,KX2-391,6714,22784709,,,
18,Preclinical - Cell line xenograft,"In a preclinical study, Bosulif (bosutinib) inhibited Src signaling, resulted in cell cycle arrest and decreased invasion of billary tract cancer cell lines in culture, and delayed tumor growth in cell line xenograft models (PMID: 27196758).",Actionable,9453,4607,biliary tract cancer,DOID,1875,SRC positive,sensitive,690,Bosutinib,6714,27196758,,,
19,Preclinical,"In a preclinical study, KX2-392 and Taxol (paclitaxel) worked synergistically to inhibit Src signaling and proliferation of triple-receptor negative breast cancer cell lines in culture, induced tumor regression and suppressed metastasis in xenograft models (PMID: 22784709).",Actionable,5904,60081,triple-receptor negative breast cancer,DOID,1875,SRC positive,sensitive,3978,KX2-391 + Paclitaxel,6714,22784709,,,
20,Preclinical - Cell line xenograft,"In a preclinical study, Bosulif (bosutinib) and Platinol (cisplatin) synergistically inhibited Src signaling, decreased proliferation and migration of billary tract cancer cell lines in culture, and inhibited tumor growth in cell line xenograft models (PMID: 27196758).",Actionable,9455,4607,biliary tract cancer,DOID,1875,SRC positive,sensitive,5021,Bosutinib + Cisplatin,6714,27196758,,,
21,Preclinical - Cell line xenograft,"In a preclinical study, Si306 in combination with radiotherapy decreased growth of radiotherapy-sensitive SRC-positive glioblastoma cells in culture and decreased tumor growth in cell line xenograft models, with increased efficacy compared to Si306 or radiotherapy alone (PMID: 27196762).",Actionable,7273,3068,glioblastoma multiforme,DOID,1875,SRC positive,sensitive,4431,Si306 + Radiotherapy,6714,27196762,,,
22,Preclinical - Cell line xenograft,"In a preclinical study, Bosulif (bosutinib) and Gemzar (gemcitabine) synergistically inhibited Src signaling, decreased proliferation and migration of billary tract cancer cell lines in culture, and inhibited tumor growth in cell line xenograft models (PMID: 27196758).",Actionable,9454,4607,biliary tract cancer,DOID,1875,SRC positive,sensitive,5020,Bosutinib + Gemcitabine,6714,27196758,,,
23,Preclinical,"In a preclinical study, Sprycel (dasatinib) exhibits a strong antitumoral effect in GBM cell lines with high levels of SRC phosphorylation (PMID: 19098899).",Actionable,1103,3068,glioblastoma multiforme,DOID,1875,SRC positive,sensitive,717,Dasatinib,6714,19098899,,,
24,Preclinical,"In a preclinical study, intrahepatic cholangiocarcinoma cells harboring IDH1 R132S acquired resistance to Sprycel (dasatinib) after over expressing SRC T341I in culture (PMID: 27231123).",Actionable,7355,4928,intrahepatic cholangiocarcinoma,DOID,25297,IDH1 R132C SRC T341I,resistant,717,Dasatinib,6714,27231123,,,
0,Clinical Study,"In multiple clinical studies, SRSF2 mutations were associated with shortened survival in patients with myelodysplastic syndrome (PMID: 26769228, PMID: 26508027).",Prognostic,6212,50908,myelodysplastic syndrome,DOID,22843,SRSF2 mutant,not applicable,1776,N/A,6427,26769228,26508027,,
0,Preclinical,"In a preclinical study, colorectal cancer cells with knockdown of STAG2 expression demonstrated increased sensitivity to treatment with Lynparza (olaparib) in culture (PMID: 24356817).",Actionable,6217,9256,colorectal cancer,DOID,22919,STAG2 dec exp,sensitive,837,Olaparib,10735,24356817,,,
1,Preclinical - Cell culture,"In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in NRAS mutated melanoma cell lines resulted in decreased response to Mekinist (trametinib) in culture (PMID: 27500726).",Actionable,7794,1909,melanoma,DOID,26045,NRAS mut STAG2 dec exp,decreased response,2,Trametinib,10735,27500726,,,
2,Preclinical - Cell culture,"In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cells resulted in decreased response to Mekinist (trametinib) and Tafinlar (dabrafenib) combination treatment in culture (PMID: 27500726).",Actionable,7793,1909,melanoma,DOID,26042,BRAF mut STAG2 dec exp,decreased response,1066,Trametinib + Dabrafenib,10735,27500726,,,
3,Preclinical - Cell culture,"In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cell lines resulted in decreased response to Tafinlar (dabrafenib) in culture (PMID: 27500726).",Actionable,7790,1909,melanoma,DOID,26042,BRAF mut STAG2 dec exp,decreased response,3,Dabrafenib,10735,27500726,,,
4,Preclinical - Cell line xenograft,"In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cell lines resulted in decreased response to Zelboraf (vemurafenib) both in culture and in cell line xenograft models (PMID: 27500726).",Actionable,7791,1909,melanoma,DOID,26042,BRAF mut STAG2 dec exp,decreased response,342,Vemurafenib,10735,27500726,,,
5,Preclinical - Cell culture,"In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cells resulted in decreased response to Mekinist (trametinib) in culture (PMID: 27500726).",Actionable,7792,1909,melanoma,DOID,26042,BRAF mut STAG2 dec exp,decreased response,2,Trametinib,10735,27500726,,,
6,Preclinical,"In a preclinical study, glioblastoma cells harboring STAG2 S653* demonstrated increased sensitivity to the combination of Lynparza (olaparib) and camptothecin compared to isogenic cells with wild-type STAG2 in culture (PMID: 24356817, PMID: 21852505).",Actionable,6220,3068,glioblastoma multiforme,DOID,22907,STAG2 S653*,sensitive,3397,Camptothecin,10735,21852505,24356817,,
7,Preclinical,"In a preclinical study, a glioblastoma cell line harboring STAG2 S653* demonstrated increased sensitivity to treatment with Lynparza (olaparib) in culture compared to isogenic cells with wild-type STAG2 (PMID: 24356817, PMID: 21852505).",Actionable,6216,3068,glioblastoma multiforme,DOID,22907,STAG2 S653*,sensitive,837,Olaparib,10735,21852505,24356817,,
8,Preclinical - Cell culture,"In a preclinical study, a glioblastoma cell line harboring a STAG2 mutation (reported as STAG2 N357fs, PMID: 21852505) demonstrated increased sensitivity to treatment with Veliparib (ABT-888) in culture compared to isogenic cells with wild-type STAG2 (PMID: 24356817).",Actionable,6214,3068,glioblastoma multiforme,DOID,22904,STAG2 N357fs,sensitive,954,Veliparib,10735,21852505,24356817,,
9,Preclinical,"In a preclinical study, a glioblastoma cell line harboring a STAG2 mutation (reported as STAG2 N357fs, PMID: 21852505), demonstrated increased sensitivity to treatment with Rubraca (rucaparib) in culture compared to isogenic cells with wild-type STAG2 (PMID: 24356817).",Actionable,6215,3068,glioblastoma multiforme,DOID,22904,STAG2 N357fs,sensitive,906,Rucaparib,10735,21852505,24356817,,
10,Preclinical - Cell culture,"In a preclinical study, glioblastoma cells harboring a STAG2 mutation (reported as STAG2 N357fs, PMID: 21852505) demonstrated increased sensitivity to the combination of Lynparza (olaparib) and camptothecin compared to isogenic cells with wild-type STAG2 in culture (PMID: 24356817).",Actionable,6219,3068,glioblastoma multiforme,DOID,22904,STAG2 N357fs,sensitive,4095,Camptothecin + Olaparib,10735,21852505,24356817,,
11,Preclinical - Cell culture,"In a preclinical study, a glioblastoma cell line harboring a STAG2 mutation (reported as STAG2 N357fs, PMID: 21852505)  demonstrated increased sensitivity to treatment with Lynparza (olaparib) in culture, resulting in decreased proliferation and colony formation, and increased DNA damage compared to isogenic cells with wild-type STAG2 (PMID: 24356817).",Actionable,6213,3068,glioblastoma multiforme,DOID,22904,STAG2 N357fs,sensitive,837,Olaparib,10735,24356817,,,
12,Preclinical - Cell culture,"In a preclinical study, glioblastoma cells harboring a STAG2 mutation (reported as STAG2 N357fs, PMID: 21852505) demonstrated increased sensitivity to the combination of Lynparza (olaparib) and Temodar (temozolomide) compared to isogenic cells with wild-type STAG2 in culture (PMID: 24356817).",Actionable,6218,3068,glioblastoma multiforme,DOID,22904,STAG2 N357fs,sensitive,1438,Olaparib + Temozolomide,10735,21852505,24356817,,
0,Preclinical - Cell culture,"In a preclinical study, non-small cell lung cancer cell lines harboring STK11 inactivating mutations, such as STK11 E57fs, demonstrated increased sensitivity to Mekinist (trametinib) in culture (PMID: 27821489).",Actionable,10532,3908,non-small cell lung carcinoma,DOID,27555,STK11 E57fs,sensitive,2,Trametinib,6794,27821489,,,
1,Preclinical - Cell culture,"In a preclinical study, the presence an STK11 loss expression signature, which correlates with STK11 inactivating mutations, was associated with increased sensitivity to CI-1040 (PD184352) in human tumor cell lines in culture (PMID: 27821489).",Actionable,9800,10000003,Advanced Solid Tumor,JAX,8084,STK11 inact mut,sensitive,699,CI-1040,6794,27821489,,,
2,Preclinical,"In a preclinical study, Rapamune (sirolimus) reduced S6K phosphorylation and inhibited tumor growth in mouse models of STK11 (LKB1)-deficient endometrial cancer, including models with advanced tumors (PMID: 20142330).",Actionable,5447,1380,endometrial cancer,DOID,8084,STK11 inact mut,sensitive,917,Sirolimus,6794,20142330,,,
3,Preclinical - Cell culture,"In a preclinical study, the presence of an STK11 loss expression signature, which correlated to STK11 inactivating mutations, was associated with increased sensitivity to Mekinist (trametinib) in human tumor cell lines in culture (PMID: 27821489).",Actionable,9793,10000003,Advanced Solid Tumor,JAX,8084,STK11 inact mut,sensitive,2,Trametinib,6794,27821489,,,
4,Preclinical - Cell culture,"In a preclinical study, the presence of an STK11 loss expression signature, which correlates with STK11 inactivating mutations, was associated with increased sensitivity to PD-0325901 in human tumor cell lines in culture (PMID: 27821489).",Actionable,9801,10000003,Advanced Solid Tumor,JAX,8084,STK11 inact mut,sensitive,849,PD-0325901,6794,27821489,,,
5,Preclinical - Cell culture,"In a preclinical study, the presence of an STK11 loss expression signature, which correlates with STK11 inactivating mutations, was associated with increased sensitivity to RDEA119 in human tumor cell lines in culture (PMID: 27821489).",Actionable,9799,10000003,Advanced Solid Tumor,JAX,8084,STK11 inact mut,sensitive,887,RDEA119,6794,27821489,,,
6,Clinical Study,"In a clinical case study, a patient with adenocorticotropic pituitary carcinoma harboring an STK11 inactivating mutation demonstrated clinical efficacy for greater than 6 months when treated with a combination of Afinitor (everolimus) and radiotherapy (PMID: 27615706).",Actionable,9512,4916,pituitary carcinoma,DOID,8084,STK11 inact mut,sensitive,5060,Everolimus + Radiotherapy,6794,27615706,,,
7,Preclinical - Cell culture,"In a preclinical study, the presence of an STK11 inactivating mutation and STK11 loss expression signature was associated with increased sensitivity to Selumetinib (AZD6244) in human tumor cell lines in culture (PMID: 27821489).",Actionable,9792,10000003,Advanced Solid Tumor,JAX,8084,STK11 inact mut,sensitive,913,Selumetinib,6794,27821489,,,
8,Preclinical - Cell culture,"In a preclinical study, non-small cell lung cancer cell lines harboring STK11 inactivating mutations demonstrated increased sensitivity to Mekinist (trametinib) in culture (PMID: 27821489).",Actionable,9794,3908,non-small cell lung carcinoma,DOID,8084,STK11 inact mut,sensitive,2,Trametinib,6794,27821489,,,
9,Preclinical,"In a preclinical study, Sapanisertib (MLN0128) inhibited lung tumor growth in mouse models with KRAS G12D and inactivation of STK11 (LKB1), and demonstrated limited efficacy in tumors with KRAS G12D and wild-type STK11 (PMID: 26574479).",Actionable,5409,1324,lung cancer,DOID,20862,KRAS G12D STK11 inact mut,sensitive,1282,Sapanisertib,6794,26574479,,,
10,Preclinical - Cell culture,"In a preclinical study, MK-1775 and Platinol (cisplatin) combination treatment demonstrated enhanced growth inhibition in non-small cell lung carcinoma cell lines harboring KRAS mutations and STK11 inactivating mutations compared to cells expressing wild-type STK11 in culture (PMID: 28652249).",Actionable,11857,3908,non-small cell lung carcinoma,DOID,20861,KRAS mut STK11 inact mut,predicted â€“ sensitive,1725,MK-1775 + Cisplatin,6794,28652249,,,
11,Preclinical - Cell culture,"In a preclinical study, MK-1775 combined with radiation therapy demonstrated enhanced growth inhibition in non-small cell lung carcinoma cell lines harboring KRAS mutations and STK11 inactivating mutations compared to cells expressing wild-type STK11 in culture (PMID: 28652249).",Actionable,11858,3908,non-small cell lung carcinoma,DOID,20861,KRAS mut STK11 inact mut,predicted â€“ sensitive,4186,MK-1775 + Radiotherapy,6794,28652249,,,
12,Preclinical,"In a preclinical study, Sapanisertib (MLN0128) in combination with phenformin induced apoptosis and energetic stress in human lung adenocarcinoma cell lines with concurrent KRAS and STK11 (LKB1) mutations in culture, with higher levels than either therapy as a single agent (PMID: 26574479).",Actionable,5408,3910,lung adenocarcinoma,DOID,20861,KRAS mut STK11 inact mut,sensitive,3861,MLN0128 + Phenformin,6794,26574479,,,
13,Preclinical - Cell line xenograft,"In a preclinical study, a non-small cell lung carcinoma cell line harboring a KRAS mutation and STK11 inactivating mutation was sensitive to XL765 (SAR245409), demonstrating inhibition of cell proliferation in culture, and inhibition of tumor growth in cell line xenograft models (PMID: 24634413). ",Actionable,10705,3908,non-small cell lung carcinoma,DOID,20861,KRAS mut STK11 inact mut,sensitive,1051,SAR245409,6794,24634413,,,
14,Preclinical - Cell culture,"In a preclinical study, non-small cell lung carcinoma cell lines harboring KRAS mutations and STK11 inactivating mutations demonstrated increased sensitivity to MK-1775 compared to cells expressing wild-type STK11 in culture (PMID: 28652249).",Actionable,11856,3908,non-small cell lung carcinoma,DOID,20861,KRAS mut STK11 inact mut,predicted â€“ sensitive,822,MK-1775,6794,28652249,,,
15,Preclinical - Cell line xenograft,"In a preclinical study, XL147 inhibited tumor growth in xenograft models of a human non-small cell lung cancer cell line harboring KRAS G12S and an STK11(LKB) inactivating mutation (PMID: 25637314).",Actionable,6336,3908,non-small cell lung carcinoma,DOID,23102,KRAS G12S STK11 inact mut,sensitive,1050,XL147,6794,25637314,,,
16,Clinical Study,"In a clinical case study, a pancreatic cancer patient with Peutz-Jeghers syndrome harboring STK11 D194E and loss of heterozygosity of the other STK11 allele in the tumor achieved a partial response following treatment with Afinitor (everolimus), but progressed after 9 months (PMID: 21189378).",Actionable,5451,1793,pancreatic cancer,DOID,20914,STK11 D194E STK11 loss,sensitive,735,Everolimus,6794,21189378,,,
17,Preclinical - Cell culture,"In a preclinical study, non-small cell lung cancer cell lines harboring STK11 inactivating mutations, such as STK11 E199*, demonstrated increased sensitivity to Mekinist (trametinib) in culture (PMID: 27821489).",Actionable,9796,3908,non-small cell lung carcinoma,DOID,11914,STK11 E199*,sensitive,2,Trametinib,6794,27821489,,,
18,Preclinical - Cell line xenograft,"In a preclinical study, PKI-402 inhibited growth of a non-small cell lung cancer cell line harboring both KRAS and STK11 mutations in culture and in cell line xenograft models (PMID: 20371716).",Actionable,5398,3908,non-small cell lung carcinoma,DOID,20858,KRAS mut STK11 mut,sensitive,3857,PKI-402,6794,20371716,,,
19,Clinical Study,"In a clinical study, mutant STK11 correlated with a worse response to Opdivo (nivolumab) compared to wild-type STK11 in non-small cell lung carcinoma patients (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 1138PD).",Actionable,12098,3908,non-small cell lung carcinoma,DOID,1246,STK11 mutant,decreased response,1312,Nivolumab,6794,None,,,
20,Preclinical,"In a preclinical study, Gedatolisib (PF-05212384) inhibited growth of human non-small cell lung carcinoma cells harboring an STK11 mutation in culture (PMID: 21325073).",Actionable,3154,3908,non-small cell lung carcinoma,DOID,1246,STK11 mutant,sensitive,1040,PF-05212384,6794,21325073,,,
21,Preclinical - Cell culture,"In a preclinical study, non-small cell lung cancer cell lines harboring STK11 inactivating mutations, such as STK11 K48fs, demonstrated increased sensitivity to Mekinist (trametinib) in culture (PMID: 27821489).",Actionable,9802,3908,non-small cell lung carcinoma,DOID,27553,STK11 K48fs,sensitive,2,Trametinib,6794,27821489,,,
22,Preclinical - Cell culture,"In a preclinical study, non-small cell lung cancer cell lines harboring STK11 inactivating mutations, such as STK11 W332*, demonstrated increased sensitivity to Mekinist (trametinib) in culture (PMID: 27821489).",Actionable,9797,3908,non-small cell lung carcinoma,DOID,18157,STK11 W332*,sensitive,2,Trametinib,6794,27821489,,,
23,Preclinical - Cell line xenograft,"In a preclinical study, knockdown of STK11 increased sensitivity to Mekinist (trametinib) in non-small cell lung cancer cell lines in culture and in xenograft models (PMID: 27821489).",Actionable,9798,3908,non-small cell lung carcinoma,DOID,27096,STK11 dec exp,sensitive,2,Trametinib,6794,27821489,,,
24,Preclinical - Cell culture,"In a preclinical study, non-small cell lung cancer cell lines harboring STK11 inactivating mutations, such as STK11 Q37*, demonstrated increased sensitivity to Mekinist (trametinib) in culture (PMID: 27821489).",Actionable,9795,3908,non-small cell lung carcinoma,DOID,12105,STK11 Q37*,sensitive,2,Trametinib,6794,27821489,,,
25,Preclinical,"In a preclinical study, AZD8055 inhibited tumor growth in a mouse model of spontaneous breast cancer harboring an ERBB2 (HER2) activating mutation and loss of STK11 (LKB1), which was enhanced by the addition of 2-DG (2-deoxyglucose) (PMID: 25436981).",Actionable,5405,1612,breast cancer,DOID,20860,ERBB2 act mut STK11 loss,sensitive,1519,AZD8055,6794,25436981,,,
26,Preclinical,"In a preclinical study,  MK-1775 and Platinol (cisplatin) combination treatment resulted in improved survival in transgenic animal models of non-small cell lung carcinoma harboring KRAS G12D and STK11 loss compared to Platinol (cisplatin) alone (PMID: 28652249).",Actionable,11860,3908,non-small cell lung carcinoma,DOID,28318,KRAS G12D STK11 loss,predicted â€“ sensitive,1725,MK-1775 + Cisplatin,6794,28652249,,,
27,Preclinical,"In a preclinical study, Glucophage (metformin) was unable to inhibit cancer cell growth in cancer cell lines with biallelic loss of STK11 (PMID: 17062558, 18006825).",Actionable,1111,10000003,Advanced Solid Tumor,JAX,1882,STK11 loss,no benefit,1031,Metformin,6794,18006825,17062558,,
28,Preclinical,"In a preclinical study, PD-1 antibodies were ineffective in treating Stk11 (also known as Lkb1) deficient lung tumors in mice (PMID: 26833127).",Actionable,5597,1324,lung cancer,DOID,1882,STK11 loss,resistant,3890,unspecified PD-1 antibody,6794,26833127,,,
29,Preclinical - Cell culture,"In a preclinical study,  non-small cell lung carcinoma cells harboring KRAS mutation, STK11 and TP53 loss demonstrated increased sensitivity to MK-1775 and Platinol (cisplatin) combination treatment in culture compared to isogenic cell lines expressing wild-type Tp53 or Stk11 (PMID: 28652249).",Actionable,11859,3908,non-small cell lung carcinoma,DOID,28317,KRAS mut STK11 loss TP53 loss,predicted â€“ sensitive,1725,MK-1775 + Cisplatin,6794,28652249,,,
30,Preclinical,"In a preclinical study, the PI3K inhibitor GDC-0941 reduced tumor growth rate in immunodeficient mice engrafted with endometrial tumors from PTEN/STK11 (LKB1) deficient mice (PMID: 24322983).",Actionable,601,1380,endometrial cancer,DOID,18395,PTEN loss STK11 loss,sensitive,749,GDC-0941,6794,24322983,,,
31,Preclinical,"In a preclinical studies, Glucophage (metformin) inhibited cancer cell growth by activating the AMP kinase pathway in a variety of cancer cell lines that retained one functional allele of STK11 (PMID: 17062558, 18006825).",Actionable,1109,10000003,Advanced Solid Tumor,JAX,693,STK11 wild-type,sensitive,1031,Metformin,6794,18006825,17062558,,
0,Clinical Study,"In a clinical study, myelodysplastic syndrome patients carrying wild-type ASXL1 and TET2 mutations demonstrated increased response to the DNA hypomethylating agents Dacogen (decitabine) or Vidaza (azacitidine) (PMID: 25224413).",Actionable,6169,4972,myelodysplastic/myeloproliferative neoplasm,DOID,22786,ASXL1 wild-type TET2 mutant,sensitive,651,Azacitidine,54790,25224413,,,
1,Clinical Study,"In a clinical study, myelodysplastic syndrome patients carrying wild-type ASXL1 and TET2 mutations demonstrated increased response to the DNA hypomethylating agents Dacogen (decitabine) or Vidaza (azacitidine) (PMID: 25224413).",Actionable,6170,4972,myelodysplastic/myeloproliferative neoplasm,DOID,22786,ASXL1 wild-type TET2 mutant,sensitive,650,Decitabine,54790,25224413,,,
2,Clinical Study,"In multiple clinical studies, including a meta-analysis, TET2 mutations were associated with shorter overall survival in patients with acute myeloid leukemia (PMID: 24524305, PMID: 25412851, PMID: 24994606).",Prognostic,6223,9119,acute myeloid leukemia,DOID,13182,TET2 mutant,not applicable,1776,N/A,54790,24524305,25412851,24507812,24994606
3,Clinical Study,"In clinical analyses, TET2 mutations correlated with favorable prognosis and increased response to treatment in patients with myelodysplastic syndrome (PMID: 25224413, PMID: 26769228, PMID: 19666869, PMID: 23099237, PMID: 24507812).",Prognostic,3333,50908,myelodysplastic syndrome,DOID,13182,TET2 mutant,not applicable,1776,N/A,54790,25224413,26769228,23099237,19666869
4,Phase I,"In a retrospective analysis, presence of a TET2 mutation correlated with higher overall response rate (ORR) in patients with myelodysplastic syndrome and acute myeloid leukemia following treatment with Vidaza (azacitidine), with an ORR of 85% (11/3) in TET2-mutated patients, compared to 47% (34/47) in patients with wild-type TET2, but did not correlate with overall survival (PMID: 21494260).",Actionable,3330,9119,acute myeloid leukemia,DOID,13182,TET2 mutant,predicted â€“ sensitive,651,Azacitidine,54790,21494260,,,
0,Preclinical - Patient cell culture,"In a preclinical study, the combination of APR-246 and Platinol (cisplatin) resulted in strong synergism, thereby reducing cell viability in patient derived fallopian tube cancer cells harboring TP53 C238F in culture (PMID: 27179933). ",Actionable,9806,1964,fallopian tube cancer,DOID,26954,TP53 C238F,sensitive,3443,APR-246 + Cisplatin,7157,27179933,,,
1,Preclinical,"In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and TP53 P177T in culture (PMID: 26438783).",Actionable,4738,769,neuroblastoma,DOID,18889,"ALK	wild-type TP53 P177T",no benefit,3601,Crizotinib + Cyclophosphamide + Topotecan,7157,26438783,,,
2,Preclinical,"In a preclinical study, TP53 P177T resulted in secondary resistance in an osteosarcoma cell line acquired during Nutlin-3 treatment (PMID: 21643018).",Actionable,914,3347,osteosarcoma,DOID,1484,TP53 P177T,resistant,1405,Nutlin-3a,7157,21643018,,,
3,Preclinical - Pdx,"In a preclinical study, BEZ235 delayed tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA Q546K, and TP53 R282W (PMID: 26272063).",Actionable,8701,9256,colorectal cancer,DOID,26375,KRAS G12V PIK3CA Q546K TP53 R282W,decreased response,672,BEZ235,7157,26272063,,,
4,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment resulted in enhanced tumor growth stabilization compared to single agent in patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA Q546K and TP53 R282W (PMID: 26272063).",Actionable,8600,9256,colorectal cancer,DOID,26375,KRAS G12V PIK3CA Q546K TP53 R282W,sensitive,1420,Selumetinib + BEZ235,7157,26272063,,,
5,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) inhibited tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA Q546K, and TP53 R282W (PMID: 26272063).",Actionable,8700,9256,colorectal cancer,DOID,26375,KRAS G12V PIK3CA Q546K TP53 R282W,predicted â€“ sensitive,913,Selumetinib,7157,26272063,,,
6,Preclinical - Patient cell culture,"In a preclinical study, the combination of APR-246 and Platinol (cisplatin) resulted in strong synergism, thereby reducing cell viability in patient derived ovarian cancer cells harboring TP53 P151H in culture (PMID: 27179933). ",Actionable,9804,2394,ovarian cancer,DOID,5647,TP53 P151H,sensitive,3443,APR-246 + Cisplatin,7157,27179933,,,
7,Preclinical - Pdx,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K, and TP53 R335fs (PMID: 26272063).",Actionable,8578,9256,colorectal cancer,DOID,26368,KRAS G12V PIK3CA E545K TP53 R335fs,no benefit,4771,MLN0128 + PD-0325901,7157,26272063,,,
8,Phase I,"In a Phase I clinical trial, a breast cancer patient carrying TP53 P72R and Y220C mutations demonstrated incomplete response to treatment with an Ellence (epirubicin)-Cytoxan (cyclophosphamide) combination regimen (PMID: 17388661).",Actionable,745,1612,breast cancer,DOID,1050,TP53 P72R TP53 Y220C,no benefit,1087,Epirubicin + Cyclophosphamide,7157,17388661,,,
9,Phase I,"In a Phase I clinical trial, breast cancer patients harboring TP53 P72R mutations were reported to have a better response to anthracycline-based neoadjuvant therapies (PMID: 16243804).",Actionable,329,1612,breast cancer,DOID,621,TP53 P72R,predicted â€“ sensitive,1008,Doxil,7157,16243804,,,
10,Phase I,"In a Phase I clinical trial, breast cancer patients harboring TP53 P72R mutations, who were also hormone receptor negative, demonstrated a favorable response to Ellence (epirubicin) in combination with other chemotherapeutic agents (PMID: 22903472).",Actionable,341,1612,breast cancer,DOID,621,TP53 P72R,sensitive,1013,epirubicin,7157,22903472,,,
11,Phase I,"In a Phase I clinical trial, sarcoma patients harboring TP53 P72R mutations had longer progression-free survival after treatment with Cyfos (ifosfamide) and Adriamycin (doxorubicin) (PMID: 23165797).",Actionable,845,1115,sarcoma,DOID,621,TP53 P72R,sensitive,1472,Doxorubicin + Ifosfamide,7157,23165797,,,
12,Phase I,"In a Phase I clinical trial, breast cancer patients harboring TP53 P72R mutations were reported to have a better response to anthracycline-based neoadjuvant therapies (PMID: 16243804).",Actionable,324,1612,breast cancer,DOID,621,TP53 P72R,predicted â€“ sensitive,1006,Daunorubicin,7157,16243804,,,
13,Phase I,"In a Phase I clinical trial, breast cancer patients harboring TP53 P72R mutations were reported to have a better response to anthracycline-based neoadjuvant therapies (PMID: 16243804).",Actionable,325,1612,breast cancer,DOID,621,TP53 P72R,predicted â€“ sensitive,1007,Daunoxome,7157,16243804,,,
14,Phase I,"In a Phase I clinical trial, breast cancer patients harboring TP53 P72R who were estrogen receptor negative had a more favorable response to Doxil (doxorubicin) in combination with Adrucil (fluorouracil) and Cytoxan (cyclophosphamide) (PMID: 16243804).",Actionable,330,60076,estrogen-receptor negative breast cancer,DOID,621,TP53 P72R,sensitive,1706,Doxorubicin + Flourouracil + Cyclophosphamide,7157,16243804,,,
15,Phase I,"In phase I clinical studies, NSCLC patients with TP53 P72R mutations had a longer progression-free survival than wild-type TP53 patients, after combined treatment with Camptosar (irinotecan) and  Platinol (cisplatin) (PMID: 18618574).",Actionable,925,3908,non-small cell lung carcinoma,DOID,621,TP53 P72R,sensitive,1406,Camptosar + Cisplatin,7157,18618574,,,
16,Phase II,"In a Phase II trial, Paraplatin (carboplatin) and MK-1775 combination treatment resulted in partial response in an ovarian cancer patient harboring TP53 E298* and mutations in BRCA1 (PMID: 27998224). ",Actionable,11779,2394,ovarian cancer,DOID,28241,BRCA1 mut TP53 E298*,predicted â€“ sensitive,1194,MK-1775 + Carboplatin ,7157,27998224,,,
17,Preclinical - Pdx,"In a preclinical study, combination of Sprycel (dasatinib) and Demcizumab (OMP-21M18) treatment resulted in durable tumor inhibition in patient-derived animal models of lung adenocarcinoma harboring KRAS G12D and TP53 S127Y (PMID: 26855149).",Actionable,10885,3910,lung adenocarcinoma,DOID,27819,KRAS G12D TP53 S127Y,sensitive,5671,Dasatinib + Demcizumab,7157,26855149,,,
18,Preclinical - Patient cell culture,"In a preclinical study, the combination of APR-246 and Platinol (cisplatin) resulted in strong synergism, thereby reducing cell viability in patient derived ovarian cancer cells harboring TP53 P278R in culture (PMID: 27179933). ",Actionable,9809,2394,ovarian cancer,DOID,27100,TP53 P278R,sensitive,3443,APR-246 + Cisplatin,7157,27179933,,,
19,Preclinical - Pdx,"In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K, and TP53 R273* did not respond to BEZ235 treatment (PMID: 26272063).",Actionable,8699,9256,colorectal cancer,DOID,26374,KRAS G12V PIK3CA E545K TP53 R273*,resistant,672,BEZ235,7157,26272063,,,
20,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment did not improve tumor growth stabilization compared to single agent in patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K and TP53 R273* (PMID: 26272063).",Actionable,8597,9256,colorectal cancer,DOID,26374,KRAS G12V PIK3CA E545K TP53 R273*,no benefit,1420,Selumetinib + BEZ235,7157,26272063,,,
21,Preclinical - Pdx,"In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12V, PIK3CA E545K, and TP53 R273* did not respond to Selumetinib (AZD6244) treatment (PMID: 26272063).",Actionable,8698,9256,colorectal cancer,DOID,26374,KRAS G12V PIK3CA E545K TP53 R273*,resistant,913,Selumetinib,7157,26272063,,,
22,Preclinical,"In a preclinical study, the combination of APR-246 and Platinol (cisplatin) worked synergistically to inhibit growth of small lung cancer cells harboring TP53 Y163C in culture (PMID: 26086967).",Actionable,4098,5409,lung small cell carcinoma,DOID,5742,TP53 Y163C,sensitive,3443,APR-246 + Cisplatin,7157,26086967,,,
23,Preclinical,"In a preclinical study, Ganetespib inhibited growth of human prostate cancer cells harboring TP53 P223L and V274F in culture (PMID: 26009011).",Actionable,5016,10283,prostate cancer,DOID,19855,TP53 P223L TP53 V274F,resistant,745,Ganetespib,7157,26009011,,,
24,Phase II,"In a Phase II trial, Paraplatin (carboplatin) and MK-1775 combination treatment resulted in partial response in an ovarian cancer patient harboring TP53 G105C, V157fs and mutations in Kras (PMID: 27998224). ",Actionable,11778,2394,ovarian cancer,DOID,28237,KRAS mut TP53 G105C TP53 V157fs,predicted â€“ sensitive,1194,MK-1775 + Carboplatin ,7157,27998224,,,
25,Preclinical,"In a preclinical study, the combination of APR-246 and Platinol (cisplatin) worked synergistically to inhibit growth of non-small lung cancer cells harboring TP53 R248W in culture (PMID: 26086967).",Actionable,4096,3908,non-small cell lung carcinoma,DOID,3386,TP53 R248W,sensitive,3443,APR-246 + Cisplatin,7157,26086967,,,
26,Preclinical - Cell culture,"In a preclinical study, TP53 R248W was associated with resistance to PT2399 in VHL-defective clear cell renal cell carcinoma cell lines in culture (PMID: 27595393).",Actionable,8269,4467,renal clear cell carcinoma,DOID,26217,TP53 R248W VHL inact mut,resistant,4670,PT2399,7157,27595393,,,
27,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment did not improve tumor growth stabilization compared to single agent in patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R and TP53 R248W (PMID: 26272063).",Actionable,8596,9256,colorectal cancer,DOID,26372,KRAS G12D PIK3CA H1047R TP53 R248W,no benefit,1420,Selumetinib + BEZ235,7157,26272063,,,
28,Preclinical - Pdx,"In a preclinical study, BEZ235 stabilized tumor growth of patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R, and TP53 R248W (PMID: 26272063).",Actionable,8697,9256,colorectal cancer,DOID,26372,KRAS G12D PIK3CA H1047R TP53 R248W,predicted â€“ sensitive,672,BEZ235,7157,26272063,,,
29,Preclinical - Pdx,"In a preclinical study, patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PIK3CA H1047R, and TP53 R248W did not respond to Selumetinib (AZD6244) treatment (PMID: 26272063).",Actionable,8695,9256,colorectal cancer,DOID,26372,KRAS G12D PIK3CA H1047R TP53 R248W,resistant,913,Selumetinib,7157,26272063,,,
30,Preclinical - Pdx,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12C, PIK3CA H1047R, and TP53 R248W (PMID: 26272063).",Actionable,8577,9256,colorectal cancer,DOID,26366,KRAS G12C PIK3CA H1047R TP53 R248W,no benefit,4771,MLN0128 + PD-0325901,7157,26272063,,,
31,Preclinical,"In a preclinical study, Xalkori (crizotinib) demonstrated synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) in neuroblastoma cell lines harboring Alk amplification and functional TP53, resulting in growth inhibition in culture (PMID: 26438783).",Actionable,4740,769,neuroblastoma,DOID,18891,ALK amp Tp53 wild-type,sensitive,3601,Crizotinib + Cyclophosphamide + Topotecan,7157,26438783,,,
32,Preclinical - Cell culture,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring BRAF V600E and PIK3CA H1047R in culture (PMID: 26272063).",Actionable,8568,9256,colorectal cancer,DOID,26361,BRAF V600E PIK3CA H1047R TP53 wild-type,sensitive,4771,MLN0128 + PD-0325901,7157,26272063,,,
33,Preclinical,"In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and wild-type TP53 in culture (PMID: 26438783).",Actionable,4741,769,neuroblastoma,DOID,18892,ALK wild-type TP53 wild-type,no benefit,3601,Crizotinib + Cyclophosphamide + Topotecan,7157,26438783,,,
34,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063).",Actionable,8702,9256,colorectal cancer,DOID,26376,KRAS G12D PIK3CA H1047R TP53 wild-type,decreased response,913,Selumetinib,7157,26272063,,,
35,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment did not improve tumor growth stabilization compared to single agent in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063).",Actionable,8601,9256,colorectal cancer,DOID,26376,KRAS G12D PIK3CA H1047R TP53 wild-type,no benefit,1420,Selumetinib + BEZ235,7157,26272063,,,
36,Preclinical - Pdx,"In a preclinical study, BEZ235 inhibited tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D and PIK3CA H1047R (PMID: 26272063).",Actionable,8703,9256,colorectal cancer,DOID,26376,KRAS G12D PIK3CA H1047R TP53 wild-type,predicted â€“ sensitive,672,BEZ235,7157,26272063,,,
37,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Xalkori (crizotinib), Topotecan, and Cytoxan (cyclophosphamide) synergized to sustain tumor regression in xenograft models of a crizotinib-resistant human neuroblastoma cell line harboring ALK F1174L and wild-type TP53 (PMID: 26438783).",Actionable,4731,769,neuroblastoma,DOID,18879,"ALK	F1174L TP53	wild-type",sensitive,3601,Crizotinib + Cyclophosphamide + Topotecan,7157,26438783,,,
38,Preclinical,"In a preclinical study, Xalkori (crizotinib) demonstrated synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) in patient-derived neuroblastoma cell lines harboring Alk mutations and functional TP53, resulting in growth inhibition in culture and tumor regression in animal models (PMID: 26438783).",Actionable,4736,769,neuroblastoma,DOID,18888,ALK mutant TP53 wild-type,sensitive,3601,Crizotinib + Cyclophosphamide + Topotecan,7157,26438783,,,
39,Preclinical - Pdx,"In a preclinical study, BEZ235 delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12V and PIK3CA E545K (PMID: 26272063).",Actionable,8704,9256,colorectal cancer,DOID,26377,KRAS G12V PIK3CA E545K TP53 wild-type,decreased response,672,BEZ235,7157,26272063,,,
40,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) and BEZ235 combination treatment resulted in enhanced tumor growth stabilization compared to single agent in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12V and PIK3CA E545K (PMID: 26272063).",Actionable,8603,9256,colorectal cancer,DOID,26377,KRAS G12V PIK3CA E545K TP53 wild-type,sensitive,1420,Selumetinib + BEZ235,7157,26272063,,,
41,Preclinical - Pdx,"In a preclinical study, Selumetinib (AZD6244) delayed tumor growth in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12V and PIK3CA E545K (PMID: 26272063).",Actionable,8705,9256,colorectal cancer,DOID,26377,KRAS G12V PIK3CA E545K TP53 wild-type,decreased response,913,Selumetinib,7157,26272063,,,
42,Preclinical - Cell line xenograft,"In a preclinical study, R547 inhibited proliferation of colon carcinoma cell lines harboring wild-type Tp53 and Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911).",Actionable,4354,1520,colon carcinoma,DOID,17823,TP53 wild-type RB1 wild-type,sensitive,3497,R547,7157,17121911,,,
43,Preclinical - Cell line xenograft,"In a preclinical study, R547 inhibited proliferation of melanoma cell lines harboring wild-type Tp53 and Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911).",Actionable,4360,1909,melanoma,DOID,17823,TP53 wild-type RB1 wild-type,sensitive,3497,R547,7157,17121911,,,
44,Preclinical,"In a preclinical study, R547 inhibited proliferation of mantle cell lymphoma cell lines harboring wild-type Tp53 and Rb1 (PMID: 17121911).",Actionable,4362,50746,mantle cell lymphoma,DOID,17823,TP53 wild-type RB1 wild-type,sensitive,3497,R547,7157,17121911,,,
45,Preclinical - Cell line xenograft,"In a preclinical study, R547 inhibited proliferation of lung carcinoma cell lines harboring wild-type Tp53 and Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911).",Actionable,4356,3905,lung carcinoma,DOID,17823,TP53 wild-type RB1 wild-type,sensitive,3497,R547,7157,17121911,,,
46,Preclinical,"In a preclinical study, R547 inhibited proliferation of breast carcinoma cell lines harboring wild-type Tp53 and Rb1 (PMID: 17121911).",Actionable,4353,3459,breast carcinoma,DOID,17823,TP53 wild-type RB1 wild-type,sensitive,3497,R547,7157,17121911,,,
47,Preclinical - Cell line xenograft,"In a preclinical study, AMG 232 inhibited growth of a melanoma cell line with wild-type TP53, that also harbored a BRAF mutation, in culture and inhibited tumor growth in a TP53 wild-type BRAF-mutant melanoma cell line xenograft model (PMID: 25567130).",Actionable,8097,1909,melanoma,DOID,3307,BRAF mut + TP53 wild-type,sensitive,1452,AMG 232,7157,25567130,,,
48,Preclinical - Cell culture,"In a preclinical study, the combination of Navitoclax (ABT-263), CGM097, Tafinlar (dabrafenib), and PF04217903 resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a BRAF mutation and wild-type TP53 in culture compared to the double or triple combinations of the therapies (PMID: 27659046). ",Actionable,9933,9256,colorectal cancer,DOID,3307,BRAF mut + TP53 wild-type,sensitive,5317,ABT-263 + CGM097 + Dabrafenib + PF-04217903,7157,27659046,,,
49,Preclinical,"In a preclinical study, the combination of CGM097 and Encorafenib (LGX818) synergized to inhibit cell growth of a human melanoma cell line harboring mutant BRAF and wild-type TP53 in culture, and promoted tumor regression in xenograft models (Cancer Res October 1, 2014 74; 5466).",Actionable,1787,1909,melanoma,DOID,3307,BRAF mut + TP53 wild-type,sensitive,2285,CGM097 + LGX818,7157,None,,,
50,Phase I,"In a Phase I trial, MK-8242 demonstrated safety and some preliminary clinical activity in patients with TP53 wild-type advanced solid tumors, particularly those with liposarcoma (LPS), with an overall response rate (ORR) of 6.4% (3/41; all partial responses), all in patients with LPS (ORR in LPS 11.1% (3/27)), and 75.6% (31/41) of patients achieving stable disease (PMID: 28240971).",Actionable,10721,10000003,Advanced Solid Tumor,JAX,642,TP53 wild-type,unknown,3153,MK-8242,7157,28240971,,,
51,Preclinical - Cell line xenograft,"In a preclinical study, AMG 232 enhanced radiation-induced cytotoxicity in TP53 wild-type osteosarcoma cells in culture and in cell line xenograft models (PMID: 26162687).",Actionable,8260,3347,osteosarcoma,DOID,642,TP53 wild-type,sensitive,4671,AMG 232 + Radiotherapy,7157,26162687,,,
52,Phase I,"In a Phase I trial, treatment with ALRN-6924 in patients with advanced solid tumors and lymphomas resulted in a disease control rate of 45% (25/55), with 2 patients experiencing a complete response, 2 patients achieving a partial response, and 21 patients demonstrating stable disease (J Clin Oncol 35, 2017 (suppl; abstr 2505)).",Actionable,11082,60058,lymphoma,DOID,642,TP53 wild-type,predicted â€“ sensitive,2273,ALRN-6924,7157,None,,,
53,Preclinical - Cell line xenograft,"In a preclinical study, a TP53 wild-type dedifferentiated papillary thyroid carcinoma cell line treated with APG-115 demonstrated decreased cell viability and induction of cell cycle arrest and apoptosis in culture, and tumor growth suppression and tumor regression in xenograft models (PMID: 28498808).",Actionable,11033,3969,papillary thyroid carcinoma,DOID,642,TP53 wild-type,sensitive,5826,APG-115,7157,28498808,,,
54,Preclinical - Cell culture,"In a preclinical study, Roscovotine (seliciclib) induced substantial apoptosis in non-small cell lung carcinoma cells overexpressing wild-type TP53 in culture (PMID: 22862161).",Actionable,11749,3908,non-small cell lung carcinoma,DOID,642,TP53 wild-type,sensitive,1129,Seliciclib,7157,22862161,,,
55,Preclinical - Cell line xenograft,"In a preclinical study, SAR405838 inhibited growth of TP53 wild-type prostate cancer cells in culture and resulted in tumor regression in cell line xenograft models (PMID: 25145672).",Actionable,1790,10283,prostate cancer,DOID,642,TP53 wild-type,sensitive,2078,SAR405838,7157,25145672,,,
56,Preclinical - Cell line xenograft,"In a preclinical study, RO6839921 demonstrated anti-tumor activity in TP53 wild-type disseminated acute myeloid leukemia cell line xenograft models (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A156).",Actionable,9316,9119,acute myeloid leukemia,DOID,642,TP53 wild-type,sensitive,2155,RO6839921,7157,None,,,
57,Preclinical - Cell line xenograft,"In a preclinical study, AMG 232 induced activation of Tp53 target genes and inhibited growth of a non-small cell lung cancer (NSCLC) cell line with wild-type TP53 in culture and inhibited tumor growth in a TP53 wild-type NSCLC cell line xenograft model (PMID: 25567130).",Actionable,8093,3908,non-small cell lung carcinoma,DOID,642,TP53 wild-type,sensitive,1452,AMG 232,7157,25567130,,,
58,Preclinical,"In a preclinical study, CPUY201112 reduced viability and induced apoptosis in a colon cancer cell line with wild-type TP53 in culture, and had a limited effect on a colon cancer cell line lacking TP53 (PMID: 26743233).",Actionable,4644,219,colon cancer,DOID,642,TP53 wild-type,sensitive,3589,CPUY201112,7157,26743233,,,
59,Preclinical,"In a preclinical study, GSK283071 and Adriamycin (doxorubicin) worked synergistically to inhibit proliferation of neuroblastoma cell lines carrying wild-type TP53 (PMID: 25658463).",Actionable,5285,769,neuroblastoma,DOID,642,TP53 wild-type,predicted â€“ sensitive,3815,Doxorubicin + GSK2830371,7157,25658463,,,
60,Phase I,"In a Phase I trial, ALRN-6924 treatment in a patient with peripheral T-cell lymphoma resulted in a complete response (J Clin Oncol 35, 2017 (suppl; abstr 2505)). ",Actionable,11085,50749,peripheral T-cell lymphoma,DOID,642,TP53 wild-type,sensitive,2273,ALRN-6924,7157,None,15297186,,
61,Phase I,"In Phase I and Phase II clinical trials, various forms of p53 gene therapy (such as adenoviral-p53) have been shown to be generally safe and have demonstrated clinical efficacy in patients with ovarian cancer (PMID: 12082455; PMID: 19621448; PMID: 21927947; PMID: 15297186; PMID: 12082456).",Actionable,232,2394,ovarian cancer,DOID,642,TP53 wild-type,predicted â€“ sensitive,978,Ad.p53-DC vaccine,7157,12082455,12082456,19621448,21927947
62,Preclinical - Cell culture,"In a preclinical study, AMG 232 activated Tp53 signaling, resulted in growth inhibition of TP53 wild-type breast cancer cells in culture (PMID: 26162687).",Actionable,8250,1612,breast cancer,DOID,642,TP53 wild-type,sensitive,1452,AMG 232,7157,26162687,,,
63,Preclinical - Cell culture,"In a preclinical study, treatment with Trifluridine (FTD) resulted in Tp53-dependent cell-cycle arrest and decreased expression of CyclinB1 and Cdk1 in a Tp53-proficient colon cancer cancer cell line in culture (PMID: 25700705).",Actionable,7840,219,colon cancer,DOID,642,TP53 wild-type,sensitive,4586,Trifluridine,7157,25700705,,,
64,Phase I,"In a Phase I trial, ALRN-6924 treatment resulted in a partial response in a patient with colorectal cancer (J Clin Oncol 35, 2017 (suppl; abstr 2505)).",Actionable,11088,9256,colorectal cancer,DOID,642,TP53 wild-type,sensitive,2273,ALRN-6924,7157,None,,,
65,Preclinical - Cell line xenograft,"In a preclinical study, RO6839921 and Cytosar-U (cytarabine) combination treatment demonstrated anti-tumor activity in TP53 wild-type disseminated acute myeloid leukemia cell line xenograft models (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A156).",Actionable,9317,9119,acute myeloid leukemia,DOID,642,TP53 wild-type,sensitive,4968,Cytarabine + RO6839921,7157,None,,,
66,Preclinical - Cell line xenograft,"In a preclinical study, APR-246 inhibited growth of TP53 wild-type melanoma cells in 3D culture and in cell line xenograft models (PMID: 21239882).",Actionable,10708,1909,melanoma,DOID,642,TP53 wild-type,sensitive,1946,APR-246,7157,21239882,,,
67,Preclinical - Pdx & cell culture,"In a preclinical study, the combination of MK-1775 and Gemzar (gemcitabine) induced cell death in a variety of sarcoma cell lines and inhibited tumor growth in a patient-derived sarcoma xenograft model, independent of TP53 mutational status (PMID: 23520471).",Actionable,842,1115,sarcoma,DOID,642,TP53 wild-type,sensitive,1279,MK-1775 + Gemcitabine,7157,23520471,,,
68,Phase I,"In a Phase I trial, MK-8242 demonstrated safety and some preliminary clinical activity in patients with advanced solid tumors, particularly those with TP53 wild-type liposarcoma (LPS), with an overall response rate (ORR) of 6.4% (3/41; all partial responses), all in patients with LPS (ORR in LPS 11.1% (3/27)), and a median progression-free survival in LPS of 237 days (PMID: 28240971).",Actionable,10720,3382,liposarcoma,DOID,642,TP53 wild-type,predicted â€“ sensitive,3153,MK-8242,7157,28240971,,,
69,Preclinical - Pdx,"In a preclinical study, SAR405838 (MI-77301) induced p53 signaling and inhibited tumor growth in patient-derived xenograft models of endocrine therapy-resistant breast cancer  with wild-type TP53, and induced cell-cycle arrest and inhibited growth of patient-derived  endocrine therapy-resistant breast cancer cells in culture (PMID: 27765850).",Actionable,9542,1612,breast cancer,DOID,642,TP53 wild-type,predicted â€“ sensitive,2078,SAR405838,7157,27765850,,,
70,Phase I,"In a Phase I trial, treatment with ALRN-6924 in patients with advanced solid tumors and lymphomas resulted in a disease control rate of 45% (25/55), with 2 patients experiencing a complete response, 2 patients achieving a partial response, and 21 patients demonstrating stable disease (J Clin Oncol 35, 2017 (suppl; abstr 2505)).",Actionable,11081,10000003,Advanced Solid Tumor,JAX,642,TP53 wild-type,predicted â€“ sensitive,2273,ALRN-6924,7157,None,,,
71,Preclinical - Cell culture,"In a preclinical study, AZD6738 treatment increased sensitivity to radiotherapy in a lung carcinoma cell line harboring wild-type TP53 in culture, resulting in a greater decrease in cell survival compared to radiation treatment alone (PMID: 28062704). ",Actionable,10015,3905,lung carcinoma,DOID,642,TP53 wild-type,sensitive,5346,AZD6738 + Radiotherapy,7157,28062704,,,
72,Preclinical - Cell line xenograft,"In a preclinical study, the combination of AMG 232 and Platinol (cisplatin) worked synergistically to inhibit tumor growth in a TP53 wild-type non-small cell lung cancer cell line xenograft model, with increased efficacy over either agent alone, resulting in tumor stasis (PMID: 25567130).",Actionable,8133,3908,non-small cell lung carcinoma,DOID,642,TP53 wild-type,sensitive,4637,AMG 232 + Cisplatin,7157,25567130,,,
73,Preclinical - Pdx,"In a preclinical study, the combination of SAR405838 (MI-773) and Platinol (cisplatin) resulted in increased Tp53 and Mdm2 expression, and demonstrated improved efficacy over either agent alone in TP53 wild-type patient-derived xenograft (PDX) models of salivary gland adenoid cystic carcinoma, resulting in tumor regression without tumor rebound after cessation of therapy (PMID: 27550999).",Actionable,10030,4866,salivary gland adenoid cystic carcinoma,DOID,642,TP53 wild-type,predicted â€“ sensitive,2078,SAR405838,7157,27550999,,,
74,Preclinical - Cell line xenograft,"In a preclinical study, RO6839921 and Doxil combination treatment demonstrated sustained survival benefit in TP53 wild-type fibrosarcoma cell line xenograft models (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A156).",Actionable,9315,3355,fibrosarcoma,DOID,642,TP53 wild-type,sensitive,4967,Doxil + RO6839921,7157,None,,,
75,Preclinical - Cell line xenograft,"In a preclinical study, Kevetrin (thioureidobutyronitrile) treatment increased Tp53 and Cdkn1a protein levels, resulted in growth inhibition of TP53 wild-type endometrioid ovary carcinoma cells in culture and in cell line xenograft models (Proceedings of the AACR, Vol 58, Apr 2017, abstract # 3221).",Actionable,10735,5828,endometrioid ovary carcinoma,DOID,642,TP53 wild-type,sensitive,2999,thioureidobutyronitrile,7157,None,,,
76,Preclinical - Cell line xenograft,"In a preclinical study, HDM201 treatment resulted in tumor regression in various cell line xenograft models of Tp53 wild-type tumors (Cancer Res 2016;76(14 Suppl):Abstract nr 4855).",Actionable,9985,10000003,Advanced Solid Tumor,JAX,642,TP53 wild-type,sensitive,2186,HDM201,7157,None,,,
77,Preclinical,"In a preclinical study, CTX-1 improved survival time in mouse models of acute myeloid leukemia using TP53 wild-type primary human acute myeloid leukemia cells (PMID: 26883273).",Actionable,5578,9119,acute myeloid leukemia,DOID,642,TP53 wild-type,sensitive,3899,CTX-1,7157,26883273,,,
78,Preclinical - Cell culture,"In a preclinical study, MK-8745 treatment resulted in apoptosis in Tp53 wild-type colorectal cancer cells in culture (PMID: 22293494).",Actionable,10681,9256,colorectal cancer,DOID,642,TP53 wild-type,predicted â€“ sensitive,2328,MK-8745,7157,22293494,,,
79,Preclinical,"In a preclinical study, Prodigiosin inhibited self-renewal of Tp53 wild-type colorectal cancer cell lines in culture (PMID: 26759239).",Actionable,5769,9256,colorectal cancer,DOID,642,TP53 wild-type,sensitive,3925,Prodigiosin,7157,26759239,,,
80,Phase I,"In a Phase I study, patients with advanced solid tumor harboring TP53 mutations had increased progression-free survival and overall survival than TP53 wild-type patients after treatment with Votrient (pazopanib) in combination with Zolinza (vorinostat) (J Clin Oncol 32:5s, 2014 (suppl; abstr 2576)).",Actionable,838,10000003,Advanced Solid Tumor,JAX,642,TP53 wild-type,decreased response,1211,Pazopanib + Vorinostat,7157,None,,,
81,Preclinical - Cell line xenograft,"In a preclinical study, AMG 232 enhanced radiation-induced cytotoxicity in TP53 wild-type colon cancer cells in culture and in cell line xenograft models (PMID: 26162687).",Actionable,8259,219,colon cancer,DOID,642,TP53 wild-type,sensitive,4671,AMG 232 + Radiotherapy,7157,26162687,,,
82,Preclinical,"In a preclinical study, CPUY201112 reduced viability and induced apoptosis in an osteosarcoma cell line with wild-type TP53 in culture, and had a limited effect on an osteosarcoma cell line lacking TP53 (PMID: 26743233).",Actionable,4646,3347,osteosarcoma,DOID,642,TP53 wild-type,sensitive,3589,CPUY201112,7157,26743233,,,
83,Preclinical,"In a preclinical study, medulloblastoma cell lines with TP53 mutations had significantly less sensitivity to the BET inhibitor, JQ1, than cell lines carrying wild-type TP53 (PMID: 24231268).",Actionable,1134,50902,medulloblastoma,DOID,642,TP53 wild-type,sensitive,1574,JQ1,7157,24231268,,,
84,Preclinical,"In a preclinical study the TTK (MPS1) inhibitor, MPI-0479605, inhibited cell cycle progression of colon carcinoma cells deficient for Tp53 with equivalent efficacy to cells with wild-type Tp53 (PMID: 21980130).",Actionable,4206,1520,colon carcinoma,DOID,642,TP53 wild-type,sensitive,3458,MPI-0479605,7157,21980130,,,
85,Preclinical - Cell line xenograft,"In a preclinical study, SAR405838 inhibited growth of TP53 wild-type colon cancer cells in culture and resulted in tumor regression in cell line xenograft models (PMID: 25145672).",Actionable,1791,219,colon cancer,DOID,642,TP53 wild-type,sensitive,2078,SAR405838,7157,25145672,,,
86,Preclinical,"In a preclinical study, CTX-1 induced cell death in several solid tumor cell lines with wild-type TP53 in culture (PMID: 26883273).",Actionable,5570,10000003,Advanced Solid Tumor,JAX,642,TP53 wild-type,sensitive,3899,CTX-1,7157,26883273,,,
87,Preclinical - Cell line xenograft,"In a preclinical study, the combination of AMG 232 and Paraplatin (carboplatin) worked synergistically to inhibit tumor growth in a TP53 wild-type non-small cell lung cancer cell line xenograft model, with increased efficacy over either agent alone (PMID: 25567130).",Actionable,8135,3908,non-small cell lung carcinoma,DOID,642,TP53 wild-type,sensitive,4638,AMG 232 + Carboplatin,7157,25567130,,,
88,Preclinical,"In a preclinical study, MK-1775, in combination with the Chk1 inhibitor, PF-00477736, showed efficacy in various human cancer cell lines (breast, ovarian, colon, prostate), independently of p53 status (PMID: 22713237).",Actionable,1126,219,colon cancer,DOID,642,TP53 wild-type,sensitive,1566,MK-1775 + PF-00477736,7157,22713237,,,
89,Preclinical - Cell line xenograft,"In a preclinical study, SAR405838 inhibited growth of TP53 wild-type acute leukemia cells in culture and resulted in tumor regression in cell line xenograft models (PMID: 25145672).",Actionable,1789,12603,acute leukemia,DOID,642,TP53 wild-type,sensitive,2078,SAR405838,7157,25145672,,,
90,Preclinical - Cell culture,"In a preclinical study, AMG 232 activated Tp53 signaling, resulted in growth inhibition of TP53 wild-type osteosarcoma cells in culture (PMID: 26162687).",Actionable,8254,3347,osteosarcoma,DOID,642,TP53 wild-type,sensitive,1452,AMG 232,7157,26162687,,,
91,Phase I,"In a Phase I trial, ALRN-6924 treatment resulted in a partial response in a patient with liposarcoma (J Clin Oncol 35, 2017 (suppl; abstr 2505)).",Actionable,11089,3382,liposarcoma,DOID,642,TP53 wild-type,sensitive,2273,ALRN-6924,7157,None,,,
92,Preclinical,"In a preclinical study, CTX-1 and Nutlin-3 worked cooperatively to induce cell death in several TP53 wild-type human tumor cell lines in culture (PMID: 26883273).",Actionable,5584,10000003,Advanced Solid Tumor,JAX,642,TP53 wild-type,sensitive,3900,CTX-1 + Nutlin-3,7157,26883273,,,
93,Preclinical - Cell culture,"In a preclinical study, AMG 232 activated Tp53 signaling, resulted in growth inhibition of TP53 wild-type colon cancer cells in culture (PMID: 26162687).",Actionable,8252,219,colon cancer,DOID,642,TP53 wild-type,sensitive,1452,AMG 232,7157,26162687,,,
94,Preclinical - Cell line xenograft,"In a preclinical study, NSC319726 did not inhibit tumor growth in xenograft models of TP53 wild-type lung large cell carcinoma (PMID: 22624712).",Actionable,10714,4556,lung large cell carcinoma,DOID,642,TP53 wild-type,resistant,3405,NSC319726,7157,22624712,,,
95,Preclinical - Cell culture,"In a preclinical study, AMG 232 activated Tp53 signaling, resulted in growth inhibition of TP53 wild-type lung cancer cell lines in culture (PMID: 26162687).",Actionable,8249,1324,lung cancer,DOID,642,TP53 wild-type,sensitive,1452,AMG 232,7157,26162687,,,
96,Preclinical,"In a preclinical study, GSK283071 and Paraplatin (carboplatin) worked synergistically to inhibit proliferation of neuroblastoma cell lines carrying wild-type TP53 (PMID: 25658463).",Actionable,5284,769,neuroblastoma,DOID,642,TP53 wild-type,predicted â€“ sensitive,3814,Carboplatin + GSK2830371,7157,25658463,,,
97,Preclinical - Cell line xenograft,"In a preclinical study, AMG 232 induced activation of Tp53 target genes and inhibited growth of several human tumor cell lines with wild-type TP53 in culture and in cell line xenograft models (PMID: 25567130).",Actionable,8091,10000003,Advanced Solid Tumor,JAX,642,TP53 wild-type,sensitive,1452,AMG 232,7157,25567130,,,
98,Phase II,"In a Phase II trial, p53-SLP vaccine was demonstrated to be safe, well tolerated and to induce p53-specific T-cell responses in ovarian cancer patients; however clinical impact was lacking (PMID: 19621448, PMID: 21328579).",Actionable,433,2394,ovarian cancer,DOID,642,TP53 wild-type,no benefit,1039,p53-SLP vaccine,7157,19621448,21328579,,
99,Preclinical,"In a preclinical study, the combination of CTX-1 and Nutlin-3 resulting in improved survival time in mouse models of acute myeloid leukemia using TP53 wild-type primary human acute myeloid leukemia cells (PMID: 26883273).",Actionable,5583,9119,acute myeloid leukemia,DOID,642,TP53 wild-type,sensitive,3900,CTX-1 + Nutlin-3,7157,26883273,,,
100,Preclinical - Cell line xenograft,"In a preclinical study, AMG 232 enhanced radiation-induced cytotoxicity in TP53 wild-type breast cancer cells in culture (PMID: 26162687).",Actionable,8258,1612,breast cancer,DOID,642,TP53 wild-type,sensitive,4671,AMG 232 + Radiotherapy,7157,26162687,,,
101,Preclinical - Cell line xenograft,"In a preclinical study, AMG 232 enhanced radiation-induced cytotoxicity in TP53 wild-type melanoma cells in culture and in cell line xenograft models (PMID: 26162687).",Actionable,8257,1909,melanoma,DOID,642,TP53 wild-type,sensitive,4671,AMG 232 + Radiotherapy,7157,26162687,,,
102,Preclinical,"In a preclinical study, the combination of CEP-8983 and Platinol (cisplatin) worked synergistically to induce cell death in non-small cell lung cancer cell lines in culture, irrespective of TP53 status (PMID: 23428903).",Actionable,4555,3908,non-small cell lung carcinoma,DOID,642,TP53 wild-type,sensitive,3537,CEP-8983 + Cisplatin,7157,23428903,,,
103,Preclinical - Cell culture,"In a preclinical study, AMG 232 activated Tp53 signaling, resulted in growth inhibition of TP53 wild-type melanoma cells in culture (PMID: 26162687).",Actionable,8253,1909,melanoma,DOID,642,TP53 wild-type,sensitive,1452,AMG 232,7157,26162687,,,
104,Preclinical - Pdx & cell culture,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically induced apoptosis in TP53 wild-type but not TP53 mutated colorectal cancer cell lines in culture, and demonstrated anti-tumor activity in TP53 wild-type but not TP53 mutated patient-derived xenograft models (PMID: 26272063).",Actionable,8570,9256,colorectal cancer,DOID,642,TP53 wild-type,predicted â€“ sensitive,4771,MLN0128 + PD-0325901,7157,26272063,,,
105,Preclinical - Cell line xenograft,"In a preclinical study, AMG 232 enhanced radiation-induced cytotoxicity in TP53 wild-type lung cancer cell lines in culture and in cell line xenograft models (PMID: 26162687).",Actionable,8256,1324,lung cancer,DOID,642,TP53 wild-type,sensitive,4671,AMG 232 + Radiotherapy,7157,26162687,,,
106,Phase I,"In a Phase I trial, ALRN-6924 treatment in a patient with Merkel cell carcinoma resulted in a complete response (J Clin Oncol 35, 2017 (suppl; abstr 2505)). ",Actionable,11086,3965,Merkel cell carcinoma,DOID,642,TP53 wild-type,sensitive,2273,ALRN-6924,7157,None,,,
107,Preclinical,"In a preclinical study, GSK2830371 inhibited proliferation of neuroblastoma cell lines carrying wild-type TP53 in culture (PMID: 25658463).",Actionable,5282,769,neuroblastoma,DOID,642,TP53 wild-type,predicted â€“ sensitive,3735,GSK2830371,7157,25658463,,,
108,Preclinical - Pdx,"In a preclinical study, Xalkori (crizotinib) worked synergistically with Topotecan and Cytoxan (cyclophosphamide), resulting in sustained tumor regression in crizotinib-resistant neuroblastoma PDX models harboring ALK F1245C and wild-type Tp53 (PMID: 26438783).",Actionable,4732,769,neuroblastoma,DOID,18883,"ALK	F1245C TP53	wild-type",sensitive,3601,Crizotinib + Cyclophosphamide + Topotecan,7157,26438783,,,
109,Clinical Study,"In a clinical study, treatment with first-line tyrosine kinase inhibitors resulted in a median progression free survival of 4.2 months in non-small cell lung carcinoma patients harboring both TP53 exon 8 and EGFR mutations, compared to 16.8 months in patients harboring TP53 exon 8 wild-type and EGFR exon 19 deletion (J Clin Oncol 34, 2016 (suppl; abstr 9052)).",Actionable,7001,3908,non-small cell lung carcinoma,DOID,24186,EGFR exon 19 del TP53 wild-type,sensitive,1776,N/A,7157,None,,,
110,Preclinical - Cell line xenograft,"In a preclinical study, the combination of Xalkori (crizotinib), Topotecan, and Cytoxan (cyclophosphamide) synergized to delay tumor growth in xenograft models of a human neuroblastoma cell line harboring constitutively phosphorylated wild-type Alk and wild-type TP53 (PMID: 26438783).",Actionable,4733,769,neuroblastoma,DOID,18886,ALK act mut TP53 wild-type,predicted â€“ sensitive,3601,Crizotinib + Cyclophosphamide + Topotecan,7157,26438783,,,
111,Preclinical - Pdx,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment resulted in tumor growth stabilization in patient-derived xenograft models of TP53 wild-type colorectal cancer harboring KRAS G12D, PIK3CA E545K and H1047L (PMID: 26272063).",Actionable,8581,9256,colorectal cancer,DOID,26369,KRAS G12D PIK3CA E545K PIK3CA H1047L TP53 wild-type,sensitive,4771,MLN0128 + PD-0325901,7157,26272063,,,
112,Preclinical - Cell line xenograft,"In a preclinical study, the combination of AMG 232 and Camptosaur (irinotecan) inhibited tumor growth in a TP53 wild-type colorectal cancer cell line xenograft model, which also harbors a KRAS mutation, with increased efficacy over either agent alone (PMID: 25567130).",Actionable,8140,9256,colorectal cancer,DOID,2521,KRAS mut + TP53 wild-type,sensitive,4639,AMG 232 + Irinotecan,7157,25567130,,,
113,Preclinical,"In a preclinical study, Eloxatin (oxaliplatin), in combination with ABT-737, was only effective in tumor cell lines carrying KRAS mutants and wild-type TP53 (PMID: 21468686).",Actionable,1443,10000003,Advanced Solid Tumor,JAX,2521,KRAS mut + TP53 wild-type,sensitive,1773,Oxaliplatin + ABT-737,7157,21468686,,,
114,Preclinical - Cell line xenograft,"In a preclinical study, AMG 232 induced activation of Tp53 target genes and inhibited growth of a colorectal cancer (CRC) cell line with wild-type TP53, that also harbored a KRAS mutation, in culture and inhibited tumor growth in a TP53 wild-type KRAS-mutant CRC cell line xenograft model (PMID: 25567130).",Actionable,8094,9256,colorectal cancer,DOID,2521,KRAS mut + TP53 wild-type,sensitive,1452,AMG 232,7157,25567130,,,
115,Preclinical - Cell culture,"In a preclinical study, the combination of Navitoclax (ABT-263), Alpelisib (BYL719), Mekinist (trametinib), and CGM097 resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a KRAS mutation and wild-type TP53 in culture compared to the double or triple combinations of the therapies (PMID: 27659046). ",Actionable,9935,9256,colorectal cancer,DOID,2521,KRAS mut + TP53 wild-type,sensitive,5319,ABT-263 + Alpelisib + CGM097 + Trametinib,7157,27659046,,,
116,Preclinical - Cell line xenograft,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring KRAS G13D and PIK3CA H1047R in culture and in cell line xenograft models (PMID: 26272063).",Actionable,8567,9256,colorectal cancer,DOID,26360,KRAS G13D PIK3CA H1047R TP53 wild-type,sensitive,4771,MLN0128 + PD-0325901,7157,26272063,,,
117,Preclinical - Cell line xenograft,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, induced apoptosis in TP53-wild-type colorectal cancer cells harboring BRAF V600E and PTEN loss in culture and in cell line xenograft models (PMID: 26272063).",Actionable,8569,9256,colorectal cancer,DOID,26362,BRAF V600E PTEN loss TP53 wild-type,sensitive,4771,MLN0128 + PD-0325901,7157,26272063,,,
118,Preclinical - Cell culture,"In a preclinical study, NSC319726 did not inhibit tumor growth in xenograft models of breast cancer harboring TP53 R273W (PMID: 22624712).",Actionable,10715,1612,breast cancer,DOID,27738,TP53 R273W,resistant,3405,NSC319726,7157,22624712,,,
119,Preclinical - Cell culture,"In a preclinical study, non-small cell lung carcinoma cells overexpressing TP53 A159V demonstrated reduced sensitivity to Roscovotine (seliciclib) induced apoptosis in culture (PMID: 22862161).",Actionable,11747,3908,non-small cell lung carcinoma,DOID,28222,TP53 A159V,decreased response,1129,Seliciclib,7157,22862161,,,
120,Clinical Study,"In a clinical case study, Capmatinib (INC280) treatment resulted in decreased tumor volume by 53% in a patient with large cell lung carcinoma harboring MET del exon14 and TP53 N30fs*14 (PMID: 25971938).",Actionable,9562,4556,lung large cell carcinoma,DOID,26905,MET del exon14 TP53 N30fs*14,sensitive,1065,Capmatinib,7157,25971938,,,
121,Preclinical - Cell culture,"In a preclinical study, shRNA knock-down of Tp53 in Met over-expressing gastric carcinoma cells enhanced sensitivity to the combination of EMD 1214063 and radiation in culture (PMID: 26358474).",Actionable,9470,5517,stomach carcinoma,DOID,26857,MET over exp TP53 dec exp,sensitive,5024,EMD 1214063 + Radiotherapy,7157,26358474,,,
122,Preclinical,"In a preclinical study, TP53 E258Q resulted in secondary resistance in an osteosarcoma cell line acquired during Nutlin-3 treatment (PMID: 21643018).",Actionable,913,3347,osteosarcoma,DOID,1552,TP53 E258Q,resistant,1405,Nutlin-3a,7157,21643018,,,
123,Phase II,"In a Phase II trial, Paraplatin (carboplatin) and MK-1775 combination treatment resulted in partial response in an ovarian cancer patient harboring TP53 Y163* (PMID: 27998224). ",Actionable,11782,2394,ovarian cancer,DOID,28224,TP53 Y163*,predicted â€“ sensitive,1194,MK-1775 + Carboplatin ,7157,27998224,,,
124,Preclinical - Cell culture,"In a preclinical study, the combination of Platinol (cisplatin) and NSC59984 worked synergistically to decrease viability of a colorectal cancer cell line harboring TP53 R273H and TP53 P309S in culture (PMID: 26294215).",Actionable,8270,9256,colorectal cancer,DOID,26216,TP53 R273H TP53 P309S,sensitive,4675,Cisplatin + NSC59984,7157,26294215,,,
125,Preclinical - Cell culture,"In a preclinical study, treatment with NSC59984 induced Tp53 pathway signaling, degradation of mutant Tp53, and cell death in a colorectal cancer cell line harboring TP53 R273H and TP53 P309S in culture (PMID: 26294215).",Actionable,8267,9256,colorectal cancer,DOID,26216,TP53 R273H TP53 P309S,sensitive,3402,NSC59984,7157,26294215,,,
126,Preclinical - Patient cell culture,"In a preclinical study, the combination of APR-246 and Platinol (cisplatin) resulted in strong synergism, thereby reducing cell viability in patient derived peritoneum cancer cells harboring TP53 C135Y in culture (PMID: 27179933). ",Actionable,9805,1725,peritoneum cancer,DOID,13303,TP53 C135Y,sensitive,3443,APR-246 + Cisplatin,7157,27179933,,,
127,Preclinical - Cell culture,"In a preclinical study, non-small cell lung carcinoma cells overexpressing TP53 S215G were resistant to Roscovotine (seliciclib) induced apoptosis in culture (PMID: 22862161).",Actionable,11744,3908,non-small cell lung carcinoma,DOID,28223,TP53 S215G,resistant,1129,Seliciclib,7157,22862161,,,
128,Phase II,"In a Phase II trial, Paraplatin (carboplatin) and MK-1775 combination treatment resulted in disease progression in an ovarian cancer patient harboring TP53 P98fs, R175C, and S215G (PMID: 27998224). ",Actionable,11784,2394,ovarian cancer,DOID,28235,TP53 P98fs TP53 R175C TP53 S215G,predicted â€“ resistant,1194,MK-1775 + Carboplatin ,7157,27998224,,,
129,Preclinical - Cell line xenograft,"In a preclinical study, Xalkori (crizotinib) did not improve the effect of Topotecan and Cytoxan (cyclophosphamide) on tumor growth suppression in xenograft models of a human neuroblastoma cell line harboring wild-type ALK and TP53 H168R (PMID: 26438783).",Actionable,4734,769,neuroblastoma,DOID,18884,"ALK	wild-type TP53 H168R",no benefit,3601,Crizotinib + Cyclophosphamide + Topotecan,7157,26438783,,,
130,Preclinical,"In a preclinical study, Topotecan and Cytoxan (cyclophosphamide) combination treatment resulted in mild  tumor growth suppression in neuroblastoma xenograft models harboring wild-type Alk and TP53 H168R (PMID: 26438783).",Actionable,4742,769,neuroblastoma,DOID,18884,"ALK	wild-type TP53 H168R",not applicable,2590,Cyclophosphamide + Topotecan,7157,26438783,,,
131,Clinical Study,"In a clinical study, treatment with first-line tyrosine kinase inhibitors resulted in a disease control rate (DCR) of 67% (8/13) in EGFR mutated, non-small cell lung carcinoma patients harboring nondisruptive TP53 mutations, compared to a DCR of 87% (21/24) in patients harboring disruptive TP53 mutations (J Clin Oncol 34, 2016 (suppl; abstr 9052)).",Actionable,7000,3908,non-small cell lung carcinoma,DOID,24180,EGFR mut TP53 inact mut,sensitive,1776,N/A,7157,None,,,
132,Preclinical - Cell line xenograft,"In a preclinical study, APR-246 induced apoptosis in small-cell lung cancer (SCLC) cell lines and decreased tumor growth in SCLC cell line xenograft models harboring Tp53 inactivating mutations (PMID: 21415220).",Actionable,1986,5409,lung small cell carcinoma,DOID,489,TP53 inact mut,sensitive,1946,APR-246,7157,21415220,,,
133,Preclinical,"In a preclinical study, ReACp53 induced cell death and decreased proliferation of ovarian carcinoma cells harboring TP53 mutations in culture, but did not effect viability of ovarian carcinoma cells with wild-type TP53 (PMID: 26748848).",Actionable,3982,4001,ovarian carcinoma,DOID,489,TP53 inact mut,sensitive,3406,ReACp53,7157,26748848,,,
134,Preclinical,"In a preclinical study, LB100 treatment decreased PP2A activity and increased sensitivity to Platinol (cisplatin) in a cisplatin-resistant ovarian cancer cell line harboring a TP53 inactivating mutation in culture (PMID: 25376608).",Actionable,4446,2394,ovarian cancer,DOID,489,TP53 inact mut,sensitive,3515,LB-100 + Cisplatin,7157,25376608,,,
135,Preclinical,"In a preclinical study, Nutlin-3 and cisplatin worked cooperatively to induce apoptosis in ovarian cancer cell lines with TP53 inactivating mutations in culture (PMID: 25964101).",Actionable,6068,2394,ovarian cancer,DOID,489,TP53 inact mut,sensitive,4018,Nutlin-3 + Cisplatin,7157,25964101,,,
136,Preclinical,"In a preclinical study, breast cancer cell lines with TP53 loss of function mutations had more pronounced apoptosis after treatment with AMG 900 in culture (PMID: 24091768).",Actionable,1009,1612,breast cancer,DOID,489,TP53 inact mut,sensitive,983,AMG 900,7157,24091768,,,
137,Preclinical,"In a preclinical study, MK-1775 increased the efficacy of radiation in breast cancer cells with defective TP53 in culture (PMID: 21799033).",Actionable,908,1612,breast cancer,DOID,489,TP53 inact mut,sensitive,4186,MK-1775 + Radiotherapy,7157,21799033,,,
138,Preclinical,"In a preclinical study, AZD6482 induced cell death in TP53-deficient chronic lymphocytic leukemia cells in culture and inhibited tumor growth in xenograft models (PMID: 26563132).",Actionable,5521,1040,chronic lymphocytic leukemia,DOID,489,TP53 inact mut,predicted â€“ sensitive,659,AZD6482,7157,26563132,,,
139,Preclinical,"In a preclinical study, AZD6738 sensitized TP53-deficient chronic lymphocytic leukemia cells to Imbruvica (Ibrutinib) treatment in culture (PMID: 26563132).",Actionable,5523,1040,chronic lymphocytic leukemia,DOID,489,TP53 inact mut,sensitive,3877,AZD6738 + Ibrutinib,7157,26563132,,,
140,Phase I,"In a Phase I trial, ovarian patients with TP53 deficiency had a 78.6% response rate to MK-1775 in combination with carboplatin and paclitaxel (J Clin Oncol 31, 2013 (suppl; abstr 5518)).",Actionable,174,2394,ovarian cancer,DOID,489,TP53 inact mut,sensitive,3800,MK-1775 + Carboplatin + Paclitaxel,7157,None,,,
141,Preclinical - Cell culture,"In a preclinical study, non-small cell lung carcinoma cells overexpressing TP53 Y234C demonstrated reduced sensitivity to Roscovotine (seliciclib) induced apoptosis in culture (PMID: 22862161).",Actionable,11748,3908,non-small cell lung carcinoma,DOID,16659,TP53 Y234C,decreased response,1129,Seliciclib,7157,22862161,,,
142,Preclinical,"In a preclinical study, ReACp53 induced cell death in human primary ovarian carcinoma cells harboring TP53 Y234C in culture (PMID: 26748848).",Actionable,3980,4001,ovarian carcinoma,DOID,16659,TP53 Y234C,sensitive,3406,ReACp53,7157,26748848,,,
143,Preclinical - Cell culture,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, but did not induce apoptosis in colorectal cancer cells harboring KRAS Q61L, PIK3CA E542K, and TP53 T118Qfs*5 in culture (PMID: 26272063).",Actionable,8566,9256,colorectal cancer,DOID,26412,KRAS Q61L PIK3CA E542K TP53 T118Qfs*5,sensitive,4771,MLN0128 + PD-0325901,7157,26272063,,,
144,Preclinical - Pdx,"In a preclinical study, combination of Sprycel (dasatinib) and Demcizumab (OMP-21M18) treatment resulted in durable tumor inhibition in patient-derived animal models of lung adenocarcinoma harboring KRAS G12R and TP53 R248L (PMID: 26855149).",Actionable,10886,3910,lung adenocarcinoma,DOID,27821,KRAS G12R TP53 R248L,sensitive,5671,Dasatinib + Demcizumab,7157,26855149,,,
145,Phase I,"In a Phase I clinical trial, APR-246 demonstrated safety and preliminary clinical activity in patients with hematological cancers, including an acute myeloid leukemia patient harboring TP53 V173M that achieved a decrease in bone marrow blast percentage from 46% to 26% (PMID: 22965953).",Actionable,8039,9119,acute myeloid leukemia,DOID,26139,TP53 V173M,predicted â€“ sensitive,1946,APR-246,7157,22965953,,,
146,Preclinical,"In a preclinical study, ReACp53 induced cell death and decreased proliferation of human primary ovarian carcinoma cells harboring both TP53 I195* and TP53 R248Q in culture (PMID: 26748848).",Actionable,3979,4001,ovarian carcinoma,DOID,16640,TP53 I195* TP53 R248Q,sensitive,3406,ReACp53,7157,26748848,,,
147,Preclinical,"In a preclinical study, Gedatolisib (PKI-587) inhibited growth of human non-small cell lung carcinoma cells harboring TP53 R138G in culture (PMID: 21325073, PMID: 23980093).",Actionable,3139,3908,non-small cell lung carcinoma,DOID,11799,TP53 R158G,sensitive,1040,PF-05212384,7157,21325073,23980093,,
148,Preclinical - Patient cell culture,"In a preclinical study, the combination of APR-246 and Platinol (cisplatin) resulted in strong synergism, thereby reducing cell viability in patient derived ovarian cancer cells harboring TP53 Y163H in culture (PMID: 27179933). ",Actionable,9808,2394,ovarian cancer,DOID,27099,TP53 Y163H,sensitive,3443,APR-246 + Cisplatin,7157,27179933,,,
149,Preclinical - Cell culture,"In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring PIK3CA H1047R and TP53 S90fs*33 demonstrated reduced sensitivity to DS-7423 in culture (PMID: 24504419). ",Actionable,10545,5304,ovarian clear cell adenocarcinoma,DOID,27594,PIK3CA H1047R TP53 S90fs*33,decreased response,722,DS-7423,7157,24504419,,,
150,Preclinical - Cell culture,"In a preclinical study, treatment with NSC59984 resulted in increased degradation of mutant Tp53 and cell death in a colorectal cancer cell line harboring TP53 R175L in culture (PMID: 26294215).",Actionable,8264,9256,colorectal cancer,DOID,4502,TP53 R175L,sensitive,3402,NSC59984,7157,26294215,,,
151,Preclinical - Cell culture,"In a preclinical study, lung large cell carcinoma cells harboring TP53 R175L demonstrated increased sensitivity to NSC319726 in culture (PMID: 22624712).",Actionable,10712,4556,lung large cell carcinoma,DOID,4502,TP53 R175L,sensitive,3405,NSC319726,7157,22624712,,,
152,Preclinical,"In a preclinical study, TP53 I232S resulted in secondary resistance in an osteosarcoma cell line acquired during Nutlin-3 treatment (PMID: 21643018).",Actionable,912,3347,osteosarcoma,DOID,1554,TP53 I232S,resistant,1405,Nutlin-3a,7157,21643018,,,
153,Preclinical - Cell line xenograft,"In a preclinical study, APR-246 demonstrated efficacy in cell line xenograft models of small cell lung cancer harboring TP53 R273L (PMID: 21415220).",Actionable,8284,5409,lung small cell carcinoma,DOID,3604,TP53 R273L,sensitive,1946,APR-246,7157,21415220,,,
154,Preclinical - Cell culture,"In a preclinical study, TP53-null non-small cell lung carcinoma cells demonstrated reduced sensitivity to Roscovotine (seliciclib) induced apoptosis in culture (PMID: 22862161).",Actionable,11742,3908,non-small cell lung carcinoma,DOID,1647,TP53 negative,decreased response,1129,Seliciclib,7157,22862161,,,
155,Phase I,"In a pilot trial, TP53-negative breast cancer patients demonstrated increased survival following treatment with Avastin (bevacizumab) in combination with chemotherapy agents, Adriamycin (doxorubicin) and Taxotere (docetaxel), compared to patients with TP53-positive tumors (PMID: 21399868).",Actionable,992,1612,breast cancer,DOID,1647,TP53 negative,sensitive,1421,Avastin + Doxorubicin + Docetaxel,7157,21399868,,,
156,Preclinical,"In a preclinical study, Gemzar (gemcitabine) resulted in enhanced antitumor efficacy, including decreased tumor volume, when combined with SRA737 (CCT245737) in a pancreatic ductal adenocarcinoma transgenic mouse model harboring KRAS G12D and TP53 R175H (PMID: 27167172). ",Actionable,9549,3498,pancreatic ductal adenocarcinoma,DOID,18195,KRAS G12D TP53 R175H,sensitive,5070,Gemcitabine + SRA737,7157,27167172,,,
157,Preclinical,"In a preclinical study, SRA737 (CCT245737) resulted in some decreased tumor volume in a pancreatic ductal adenocarcinoma transgenic mouse model harboring KRAS G12D and TP53 R175H when compared to control (PMID: 27167172). ",Actionable,9550,3498,pancreatic ductal adenocarcinoma,DOID,18195,KRAS G12D TP53 R175H,sensitive,5069,SRA737,7157,27167172,,,
158,Preclinical,"In a preclinical study, Rapamune (sirolimus) treatment in transgenic animal models of pancreatic ductal adenocarcinoma harboring KRAS G12D and TP53 R175H resulted in proliferation of tumor cells in interior, hypovascularized tumor regions, but inhibited proliferation in outer, vascularized tumor regions, despite inhibition of mTORC signaling in both regions (PMID: 26144316).",Actionable,8856,3498,pancreatic ductal adenocarcinoma,DOID,18195,KRAS G12D TP53 R175H,conflicting,917,Sirolimus,7157,26144316,,,
159,Preclinical,"In a preclinical study, PI-3065 treatment prolonged survival and decreased metastasis in allograft animal models of pancreatic ductal adenocarcinoma harboring KRAS G12D and TP53 R175H through upregulation of host anti-tumor immune response(PMID: 24919154).",Actionable,5164,3498,pancreatic ductal adenocarcinoma,DOID,18195,KRAS G12D TP53 R175H,not applicable,2965,PI-3065,7157,24919154,,,
160,Preclinical,"In a preclinical study, the combination of pimasertib and Gemzar (gemcitabine) inhibited tumor growth in a syngeneic mouse model of pancreatic cancer expressing KRAS G12D and TP53 R175H (PMID: 26228206).",Actionable,4467,1793,pancreatic cancer,DOID,18195,KRAS G12D TP53 R175H,sensitive,3526,Pimasertib + Gemcitabine,7157,26228206,,,
161,Preclinical,"In a preclinical study, Alvespimycin (17-DMAG) and Zolinza (vorinostat) extended survival by 59% in mice with tumors expressing Tp53 R172H (which corresponds to R175H in the human Tp53 protein) (PMID: 26009011).",Actionable,5005,10000003,Advanced Solid Tumor,JAX,838,TP53 R175H,sensitive,3723,Alvespimycin + Vorinostat,7157,26009011,,,
162,Preclinical - Cell culture,"In a preclinical study, breast cancer cells harboring TP53 R175H demonstrated increased sensitivity to NSC319726 in culture (PMID: 22624712).",Actionable,10713,1612,breast cancer,DOID,838,TP53 R175H,sensitive,3405,NSC319726,7157,22624712,,,
163,Preclinical - Cell culture,"In a preclinical study, ovarian cancer cells harboring TP53 R175H demonstrated increased sensitivity to NSC319726-induced growth inhibition in culture and in cell line xenograft models (PMID: 22624712).",Actionable,10711,2394,ovarian cancer,DOID,838,TP53 R175H,sensitive,3405,NSC319726,7157,22624712,,,
164,Preclinical,"In a preclinical study, Ganetespib inhibited growth of human breast cancer cells harboring TP53 R175H in culture (PIMD: 26009011).",Actionable,5014,1612,breast cancer,DOID,838,TP53 R175H,sensitive,745,Ganetespib,7157,26009011,,,
165,Preclinical - Cell culture,"In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring TP53 S241F demonstrated reduced sensitivity to DS-7423 in culture (PMID: 24504419). ",Actionable,10548,5304,ovarian clear cell adenocarcinoma,DOID,838,TP53 R175H,decreased response,722,DS-7423,7157,24504419,,,
166,Preclinical - Cell culture,"In a preclinical study, treatment with NSC59984 resulted in increased degradation of mutant Tp53 and cell death in a colorectal cancer cell line harboring TP53 R175H in culture (PMID: 26294215).",Actionable,8265,9256,colorectal cancer,DOID,838,TP53 R175H,sensitive,3402,NSC59984,7157,26294215,,,
167,Preclinical,"In a preclinical study, ReACp53 induced cell death and decreased proliferation of head and neck carcinoma cells harboring TP53 R175H in culture (PMID: 26748848).",Actionable,3977,11934,head and neck cancer,DOID,838,TP53 R175H,sensitive,3406,ReACp53,7157,26748848,,,
168,Preclinical - Cell culture,"In a preclinical study, non-small cell lung carcinoma cells overexpressing TP53 R175H were resistant to Roscovotine (seliciclib) induced apoptosis in culture (PMID: 22862161).",Actionable,11743,3908,non-small cell lung carcinoma,DOID,838,TP53 R175H,resistant,1129,Seliciclib,7157,22862161,,,
169,Preclinical,"In a preclinical study, treatment with ReACp53 induced cell death in primary human uterine fibroblasts expressing TP53 R175H in culture (PMID: 26748848).",Actionable,3974,10000003,Advanced Solid Tumor,JAX,838,TP53 R175H,sensitive,3406,ReACp53,7157,26748848,,,
170,Clinical Study,"In a clinical case study, Xalkori (crizotinib) treatment resulted in a decrease in tumor volume by more than 60% in a patient with histiocytic sarcoma harboring MET del exon14 and TP53 R175H (PMID: 25971938).",Actionable,9561,5621,histiocytic and dendritic cell cancer,DOID,26903,MET del exon14 TP53 R175H,sensitive,706,Crizotinib,7157,25971938,,,
171,Preclinical,"In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and TP53 C176F in culture (PMID: 26438783).",Actionable,4737,769,neuroblastoma,DOID,18880,"ALK	wild-type TP53 C176F",no benefit,3601,Crizotinib + Cyclophosphamide + Topotecan,7157,26438783,,,
172,Preclinical - Cell line xenograft,"In a preclinical study, treatment with CP-31398 resulted in decreased proliferation, increased apoptosis, and cell-cycle arrest in a hepatocellular carcinoma cell line harboring TP53 R249S in culture, and inhibited tumor growth in xenograft models (PMID: 26250460).",Actionable,8985,684,hepatocellular carcinoma,DOID,3052,TP53 R249S,sensitive,3404,CP-31398,7157,26250460,,,
173,Preclinical,"In a preclinical study, ReACp53 induced cell death in human primary ovarian carcinoma cells harboring TP53 Y327L in culture (PMID: 26748848).",Actionable,3981,4001,ovarian carcinoma,DOID,16642,TP53 Y327L,sensitive,3406,ReACp53,7157,26748848,,,
174,Clinical Study,"In a clinical case study, RB1 C706F and loss of exons 1-11 in TP53 were identified in the pericardium infiltrating small cell lung cancer that developed while on Lorlatinib (PF-06463922) treatment in a patient with ALK-rearranged non-small cell lung carcinoma (PMID: 28285684).",Actionable,10437,5409,lung small cell carcinoma,DOID,27462,ALK rearrange RB1 C706F TP53 loss,predicted â€“ resistant,869,PF-06463922,7157,28285684,,,
175,Preclinical - Cell culture,"In a preclinical study,  non-small cell lung carcinoma cells harboring KRAS mutation, STK11 and TP53 loss demonstrated increased sensitivity to MK-1775 and Platinol (cisplatin) combination treatment in culture compared to isogenic cell lines expressing wild-type Tp53 or Stk11 (PMID: 28652249).",Actionable,11859,3908,non-small cell lung carcinoma,DOID,28317,KRAS mut STK11 loss TP53 loss,predicted â€“ sensitive,1725,MK-1775 + Cisplatin,7157,28652249,,,
176,Preclinical,"In a preclinical study, treatment with AZD5363 improved overall survival and progression-free survival in mouse models of  prostate cancer with inactivated PTEN and TP53 (PMID: 26910118).",Actionable,10888,10283,prostate cancer,DOID,27832,PTEN loss TP53 loss,sensitive,655,AZD5363,7157,26910118,,,
177,Preclinical - Cell culture,"In a preclinical study, TP53-null lung cancer cells were resistant to AMG 232 induced growth inhibition in culture (PMID: 26162687).",Actionable,8255,1324,lung cancer,DOID,630,TP53 loss,resistant,1452,AMG 232,7157,26162687,,,
178,Preclinical,"In a preclinical study, Ad5CMV-p53 gene therapy suppressed growth of allograft colorectal cancer in rat models (PMID: 15608394).",Actionable,233,9256,colorectal cancer,DOID,630,TP53 loss,predicted â€“ sensitive,979,Ad5CMV-p53 gene,7157,15608394,,,
179,Preclinical - Cell line xenograft,"In a preclinical study, AMG 232 did not enhance radiation-induced cytotoxicity in TP53-null lung cancer cells in culture and in cell line xenograft models (PMID: 26162687).",Actionable,8261,1324,lung cancer,DOID,630,TP53 loss,resistant,4671,AMG 232 + Radiotherapy,7157,26162687,,,
180,Preclinical,"In a preclincial study, ReACp53 did not induce cell death in ovarian cancer cells with loss of TP53 in culture (PMID: 26748848).",Actionable,4273,2394,ovarian cancer,DOID,630,TP53 loss,no benefit,3406,ReACp53,7157,26748848,,,
181,Preclinical,"In a preclinical study the TTK (MPS1) inhibitor, MPI-0479605, inhibited cell cycle progression of colon carcinoma cells deficient for Tp53 with equivalent efficacy to cells with wild-type Tp53 (PMID: 21980130).",Actionable,4205,1520,colon carcinoma,DOID,630,TP53 loss,sensitive,3458,MPI-0479605,7157,21980130,,,
182,Preclinical,"In a preclinical study, colon cancer cells lacking TP53 had a decreased response to CPUY201112 in culture, when compared to colon cancer cells with wild-type TP53 (PMID: 26743233).",Actionable,4645,219,colon cancer,DOID,630,TP53 loss,decreased response,3589,CPUY201112,7157,26743233,,,
183,Preclinical,"In a preclinical study, tumor cell lines carrying deficient TP53 were sensitized to DNA-damaging agents upon MK-1775 administration (PMID: 19887545).",Actionable,1123,10000003,Advanced Solid Tumor,JAX,630,TP53 loss,sensitive,822,MK-1775,7157,19887545,,,
184,Preclinical,"In a preclinical study, treatment with BLZ945 demonstrated some efficacy, specifically a 56% tumor reduction, in transgenic mouse models of glioblastoma with a loss of TP53 (PMID: 27199435). ",Actionable,8588,3068,glioblastoma multiforme,DOID,630,TP53 loss,sensitive,2844,BLZ945,7157,27199435,,,
185,Preclinical - Pdx,"In a preclinical study, PHA-680632 synergized with radiotherapy to decrease tumor growth in Pdx models deficient in Tp53 (PMID: 18026198).",Actionable,10393,9256,colorectal cancer,DOID,630,TP53 loss,sensitive,5503,PHA-680632 + Radiotherapy,7157,18026198,,,
186,Preclinical - Pdx,"In a preclinical study, the combination of MK-1775 and Gemzar (gemcitabine) inhibited Wee1 expression, Cdc2 phosphorylation, and tumor growth in several patient-derived xenograft models of pancreatic cancer harboring TP53 mutations (PMID: 21389100).",Actionable,403,1793,pancreatic cancer,DOID,630,TP53 loss,sensitive,1279,MK-1775 + Gemcitabine,7157,21389100,,,
187,Preclinical,"In a preclinical study, an osteosarcoma cell line lacking TP53 demonstrated a decreased response to CPUY201112 in culture, when compared to osteosarcoma cells with wild-type TP53 (PMID: 26743233).",Actionable,4647,3347,osteosarcoma,DOID,630,TP53 loss,decreased response,3589,CPUY201112,7157,26743233,,,
188,Preclinical,"In a preclinical study, CTX-1 induced cell death in TP53-deficient human tumor cell lines in culture, but had a greater effect on cell lines with wild-type TP53 compared to isogenic cell lines with TP53 loss (PMID: 26883273).",Actionable,5571,10000003,Advanced Solid Tumor,JAX,630,TP53 loss,decreased response,3899,CTX-1,7157,26883273,,,
189,Preclinical,"In a preclinical study, LB100 treatment decreased PP2A activity and increased sensitivity to Platinol (cisplatin) in cisplatin-resistant ovarian cancer cells with TP53 loss in culture and in xenograft models (PMID: 25376608).",Actionable,4445,2394,ovarian cancer,DOID,630,TP53 loss,sensitive,3515,LB-100 + Cisplatin,7157,25376608,,,
190,Preclinical - Cell line xenograft,"In a preclinical study, AZD6738 increased sensitivity to radiotherapy in colorectal cancer xenograft models harboring a loss of TP53, resulting in a greater delay of tumor growth compared to radiation alone and an improved survival compared to control or either agent alone (PMID: 28062704). ",Actionable,10018,9256,colorectal cancer,DOID,630,TP53 loss,sensitive,5346,AZD6738 + Radiotherapy,7157,28062704,,,
191,Preclinical,"In a preclinical study, Prodigiosin inhibited self-renewal of colorectal cancer cell lines harboring TP53 loss in culture (PMID: 26759239).",Actionable,5771,9256,colorectal cancer,DOID,630,TP53 loss,sensitive,3925,Prodigiosin,7157,26759239,,,
192,Preclinical,"In a preclinical study, SP600125 induced cell death in colon carcinoma cells deficient for p53 (PMID: 22438244).",Actionable,4085,1520,colon carcinoma,DOID,630,TP53 loss,sensitive,3366,SP600125,7157,22438244,,,
193,Preclinical,"In a preclinical study, mouse breast cancer models harboring BRCA1 C61G with conditional loss of Tp53 had a decreased response to Lynparza (olaparib) compared to models with conditional loss of Brca1 and Tp53 (PMID: 22172724).",Actionable,2016,1612,breast cancer,DOID,4728,BRCA1 C61G TP53 loss,decreased response,837,Olaparib,7157,22172724,,,
194,Preclinical,"In a preclinical study, a breast cancer model lacking BRCA1 and TP53 demonstrated sensitivity to treatment with AZD2461, which resulted in decreased tumor volume (PMID: 27550455). ",Actionable,8945,1612,breast cancer,DOID,26544,BRCA1 loss TP53 loss,sensitive,2542,AZD2461,7157,27550455,,,
195,Preclinical - Cell line xenograft,"In a preclinical study, YW3-56 inhibited proliferation of a human triple-negative breast cancer (TNBC) cell line harboring TP53 R280K in culture and inhibited tumor growth in TP53 R280K-mutant TNBC cell line xenograft models (PMID: 25612620).",Actionable,6021,60081,triple-receptor negative breast cancer,DOID,17595,TP53 R280K,sensitive,4006,YW3-56,7157,25612620,,,
196,Preclinical,"In a preclinical study, Ganetespib inhibited growth of human breast cancer cells harboring TP53 R280K in culture (PMID: 26009011).",Actionable,5012,1612,breast cancer,DOID,17595,TP53 R280K,sensitive,745,Ganetespib,7157,26009011,,,
197,Preclinical - Patient cell culture,"In a preclinical study, the combination of APR-246 and Platinol (cisplatin) worked synergistically in culture, resulting in reduced cell viability in patient derived ovarian cancer cells harboring TP53 R280K (PMID: 27179933). ",Actionable,9803,2394,ovarian cancer,DOID,17595,TP53 R280K,sensitive,3443,APR-246 + Cisplatin,7157,27179933,,,
198,Phase I,"In a phase I study, Ankara (MVAp53) demonstrated safety and efficacy in patients with metastatic colon, gastric and pancreas cancer stained positive for p53 (J Clin Oncol 31, 2013 (suppl; abstr 3089)).",Actionable,424,10000003,Advanced Solid Tumor,JAX,2836,TP53 positive,sensitive,1038,MVAp53,7157,None,,,
199,Phase I,"In a Phase I trial, treatment with p28 was well-tolerated and demonstrated preliminary efficacy in patients with Tp53-positive advanced solid tumors, with complete response in 6% (1/15), partial response in 20% (3/15), and stable disease in 46% (7/15) of patients (PMID: 23449360).",Actionable,8309,10000003,Advanced Solid Tumor,JAX,2836,TP53 positive,predicted â€“ sensitive,4694,p28,7157,23449360,,,
200,Phase I,"In a Phase I trial, Serdemetan (JNJ-26854165) treatment increased Tp53 expression in tumor and surrogate tissue, resulted in partial response in 1.8% (1/57) and stable disease in 38.6% (22/57) of patients with advanced solid tumors (PMID: 21831953).",Actionable,10724,10000003,Advanced Solid Tumor,JAX,2836,TP53 positive,sensitive,2309,Serdemetan,7157,21831953,,,
201,Preclinical - Cell culture,"In a preclinical study, NU6027 enhanced the efficacy of Temodar (temozolomide) in ovarian cancer cells with mismatch repair activity and positive for TP53 in culture, demonstrating a 50% greater decrease in cell survival compared to Temodar (temozolomide) alone (PMID: 21730979). ",Actionable,11883,2394,ovarian cancer,DOID,2836,TP53 positive,predicted â€“ sensitive,6196,NU6027 + Temozolomide,7157,21730979,,,
202,Phase I,"In a Phase I trial, Serdemetan (JNJ-26854165) treatment induced a 102% increase of Tp53 expression in tumor tissue, resulted in partial response in a patient with breast cancer (PMID: 21831953).",Actionable,10725,1612,breast cancer,DOID,2836,TP53 positive,sensitive,2309,Serdemetan,7157,21831953,,,
203,Preclinical - Cell line xenograft,"In a preclinical study, Kevetrin (thioureidobutyronitrile) treatment resulted in Tp53-independent increase of Cdkn1a expression and apoptosis of ovarian clear cell carcinoma cells harboring TP53 deletion in culture and in cell line xenograft models (Proceedings of the AACR, Vol 58, Apr 2017, abstract # 3221).",Actionable,10737,50934,ovarian clear cell carcinoma,DOID,17613,TP53 del,predicted â€“ sensitive,2999,thioureidobutyronitrile,7157,None,,,
204,Preclinical - Cell culture,"In a preclinical study, MK-8745 treatment resulted in polyploidy in TP53-null colorectal cancer cells in culture (PMID: 22293494).",Actionable,10682,9256,colorectal cancer,DOID,17613,TP53 del,predicted â€“ sensitive,5579,TC-A2317,7157,22293494,,,
205,Preclinical,"In a preclinical study, treatment with Nutlin-3 had little effect on growth of ovarian cancer cells with deletion of TP53 in culture (PMID: 25964101).",Actionable,6069,2394,ovarian cancer,DOID,17613,TP53 del,no benefit,1405,Nutlin-3a,7157,25964101,,,
206,Preclinical,"In a preclinical study, Nutlin-3 and etoposide worked cooperatively to induce apoptosis and decrease growth of ovarian cancer cells with TP53 deletion in culture (PMID: 25964101).",Actionable,6071,2394,ovarian cancer,DOID,17613,TP53 del,sensitive,4017,Nutlin-3 + Etoposide,7157,25964101,,,
207,Preclinical - Cell culture,"In a preclinical study, sequential administration of Roscovotine (seliciclib) followed by Adriamycin (doxorubicin) synergistically induced apoptosis in TP53-null colorectal cancer cells in culture (PMID: 26826118).",Actionable,10907,9256,colorectal cancer,DOID,17613,TP53 del,predicted â€“ sensitive,5678,Doxorubicin + Seliciclib,7157,26826118,,,
208,Preclinical,"In a preclinical study, Nutlin-3 and cisplatin worked cooperatively to induce apoptosis and decrease growth of ovarian cancer cells with TP53 deletion in culture (PMID: 25964101).",Actionable,6070,2394,ovarian cancer,DOID,17613,TP53 del,sensitive,4018,Nutlin-3 + Cisplatin,7157,25964101,,,
209,Preclinical,"In a preclinical study, Xalkori (crizotinib) treatment resulted in complete tumor regression in transplant models of TP53-null-luminal breast cancer harboring MET amplification (PMID: 27149990).",Actionable,11535,1612,breast cancer,DOID,28118,MET amp TP53 del,sensitive,706,Crizotinib,7157,27149990,,,
210,Preclinical,"In a preclinical study, 7RH treatment had no effect on tumor cell apoptosis in KRAS G12V-driven animal models of lung cancer with TP53 knockout background (PMID: 26855149).",Actionable,10882,1324,lung cancer,DOID,27818,KRAS G12V TP53 del,resistant,5669,7RH,7157,26855149,,,
211,Preclinical,"In a preclinical study, 7RH and LY411575 combination treatment induced apoptosis in KRAS G12V-driven animal models of lung cancer with TP53 knockout background (PMID: 26855149).",Actionable,10883,1324,lung cancer,DOID,27818,KRAS G12V TP53 del,sensitive,5670,7RH + LY411575,7157,26855149,,,
212,Preclinical,"In a preclinical study, a skin cancer cell line harboring mutations in PTEN, RB1, SMAD4 and TP53 demonstrated sensitivity to Sapanisertib (MLN0128) in culture (PMID: 25261369). ",Actionable,2106,4159,skin cancer,DOID,5389,PTEN mut RB1 mut SMAD4 mut TP53 mut,sensitive,1282,Sapanisertib,7157,25261369,,,
213,Preclinical,"In a preclinical study, R547 inhibited proliferation of mantle cell lymphoma cell lines harboring mutant Tp53 and wild-type Rb1 (PMID: 17121911).",Actionable,4361,50746,mantle cell lymphoma,DOID,17822,TP53 mutant RB1 wild-type,sensitive,3497,R547,7157,17121911,,,
214,Preclinical - Cell line xenograft,"In a preclinical study, R547 inhibited proliferation of breast carcinoma cell lines harboring mutant Tp53 and wild-type Rb1 in culture and reduced tumor growth in xenograft models (PMID: 17121911).",Actionable,4352,3459,breast carcinoma,DOID,17822,TP53 mutant RB1 wild-type,sensitive,3497,R547,7157,17121911,,,
215,Preclinical,"In a preclinical study, R547 inhibited proliferation of colon carcinoma cell lines harboring mutant Tp53 and wild-type Rb1 (PMID: 17121911).",Actionable,4355,1520,colon carcinoma,DOID,17822,TP53 mutant RB1 wild-type,sensitive,3497,R547,7157,17121911,,,
216,Preclinical,"In a preclinical study, R547 inhibited proliferation of osteosarcoma cell lines harboring mutant Tp53 and wild-type Rb1 (PMID: 17121911).",Actionable,4359,3347,osteosarcoma,DOID,17822,TP53 mutant RB1 wild-type,sensitive,3497,R547,7157,17121911,,,
217,Phase I,"In a clinical study, a retrospective analysis of a Phase I trial demonstrated four non-small cell lung carcinoma (NSCLC) patients co-harboring  a TP53 mutation and KRAS mutation had greater progression free survival compared to NSCLC patients harboring a single TP53 mutation or single KRAS mutation when treated with Keytruda (pembrolizumab) (PMID: 28039262). ",Actionable,11296,3908,non-small cell lung carcinoma,DOID,25456,KRAS mutant TP53 mutant,predicted â€“ sensitive,1447,Pembrolizumab,7157,28039262,,,
218,Phase I,"In a Phase I trial, a colorectal cancer patient co-harboring a KRAS mutation and TP53 mutation demonstrated sensitivity when treated with Abemaciclib (LY2835219), which resulted in stable disease (PMID: 27217383). ",Actionable,7460,9256,colorectal cancer,DOID,25456,KRAS mutant TP53 mutant,sensitive,802,Abemaciclib,7157,27217383,,,
219,Preclinical - Cell culture,"In a preclinical study, the combination of Navitoclax (ABT-263), Mekinist (trametinib), Alpelisib (BYL719), and Tarceva (erlotinib) resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a KRAS mutation and TP53 mutation compared to the double or triple combinations of the therapies (PMID: 27659046). ",Actionable,9932,9256,colorectal cancer,DOID,25456,KRAS mutant TP53 mutant,sensitive,5316,ABT-263 + Alpelisib + Erlotinib + Trametinib,7157,27659046,,,
220,Phase I,"In a retrospective analysis of a Phase I trial, MK-1775 combined with a chemotherapy resulted in a 21% (4/19) response rate in advanced solid tumor patients harboring a TP53 mutation and in those without a TP53 mutation, a 12% (4/33) response rate was observed (PMID: 27601554).",Actionable,9288,10000003,Advanced Solid Tumor,JAX,434,TP53 mutant,sensitive,822,MK-1775,7157,27601554,,,
221,Preclinical - Cell culture,"In a preclinical study, AMG 232 did not inhibit growth of human tumor cell lines harboring TP53 mutations in culture (PMID: 25567130).",Actionable,8090,10000003,Advanced Solid Tumor,JAX,434,TP53 mutant,resistant,1452,AMG 232,7157,25567130,,,
222,Preclinical - Cell line xenograft,"In a preclinical study, the combination of MK-1775 and radiation therapy synergized to inhibit tumor growth in a human glioblastoma multiforme cell line xenograft model harboring mutant TP53 (PMID: 21992793).",Actionable,1149,3068,glioblastoma multiforme,DOID,434,TP53 mutant,sensitive,4186,MK-1775 + Radiotherapy,7157,21992793,,,
223,Preclinical - Cell culture,"In a preclinical study, combination of an unspecified EGFR antibody and an unspecified Erbb3 (Her3) antibody resulted in inhibition of survival in TP53 mutated hypopharyngeal carcinoma cancer cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767).",Actionable,7782,8533,hypopharynx cancer,DOID,434,TP53 mutant,predicted â€“ sensitive,4579,unspecified EGFR antibody + unspecified ERBB3 antibody,7157,27196767,,,
224,Phase I,"In a Phase I trial, the combination of Votrient (pazopanib) and Zolinza (vorinostat) resulted in improved progression-free survival and overall survival in metastatic sarcoma and colorectal cancer patients harboring TP53 hotspot mutations, and resulted in a stable disease rate of 83% (5/6), compared to a stable disease rate of 9% (1/11) in patients without detected TP53 mutations (PMID: 25669829).",Actionable,3424,9256,colorectal cancer,DOID,434,TP53 mutant,sensitive,1211,Pazopanib + Vorinostat,7157,25669829,,,
225,Preclinical,"In a preclinical study, neuroblastoma cell lines harboring TP53 mutations were resistant to GSK2830371 induced growth inhibition in culture (PMID: 25658463).",Actionable,5283,769,neuroblastoma,DOID,434,TP53 mutant,resistant,3735,GSK2830371,7157,25658463,,,
226,Preclinical - Cell culture,"In a preclinical study, AZD6738 treatment increased sensitivity to radiotherapy in a tongue squamous cell carcinoma cell line harboring a TP53 mutation in culture, resulting in a greater decrease in cell survival compared to radiation treatment alone (PMID: 28062704). ",Actionable,10016,50865,tongue squamous cell carcinoma,DOID,434,TP53 mutant,sensitive,5346,AZD6738 + Radiotherapy,7157,28062704,,,
227,Preclinical,"In a preclinical study, neuroblastoma cell lines harboring TP53 mutant were resistant to MI-63 mediated growth inhibition (PMID: 21725357).",Actionable,2994,769,neuroblastoma,DOID,434,TP53 mutant,resistant,1582,MI-63,7157,21725357,,,
228,Clinical Study,"In a retrospective study, advanced sarcoma patients with TP53 mutations displayed improved progression-free survival (208 days versus 136 days) relative to patients with wild-type TP53 when treated with Votrient (pazopanib) (PMID: 26646755).",Actionable,4932,1115,sarcoma,DOID,434,TP53 mutant,sensitive,848,Pazopanib,7157,26646755,,,
229,Preclinical,"In a preclinical study, the combination of CEP-8983 and Platinol (cisplatin) worked synergistically to induce cell death in non-small cell lung cancer cell lines in culture, irrespective of TP53 status (PMID: 23428903).",Actionable,4556,3908,non-small cell lung carcinoma,DOID,434,TP53 mutant,sensitive,3537,CEP-8983 + Cisplatin,7157,23428903,,,
230,Preclinical,"In a preclinical study, the treatment of a head and neck squamous cell carcinoma cell line with mutant TP53 (C176F and A161S) with AZD7762, a pan Chk1/2 inhibitor, sensitizes the cells to Platinol (cisplatin) (PMID: 23839309).",Actionable,1505,5520,head and neck squamous cell carcinoma,DOID,434,TP53 mutant,sensitive,1755,AZD7762 + Cisplatin,7157,23839309,,,
231,Preclinical - Cell culture,"In a preclinical study, Kevetrin (thioureidobutyronitrile) treatment decreased mutant Tp53 level, resulted in apoptosis of ovarian serous carcinoma cells harboring TP53 mutations in culture (Proceedings of the AACR, Vol 58, Apr 2017, abstract # 3221).",Actionable,10736,50933,ovarian serous carcinoma,DOID,434,TP53 mutant,sensitive,2999,thioureidobutyronitrile,7157,None,,,
232,Preclinical - Cell line xenograft,"In a preclinical study, NSC59984 treatment resulted in increased Tp53 signaling and cell death in colorectal cancer cell lines harboring TP53 mutations, and inhibited tumor growth in TP53-mutant cell line colorectal cancer xenograft models (PMID: 26294215).",Actionable,8263,9256,colorectal cancer,DOID,434,TP53 mutant,predicted â€“ sensitive,3402,NSC59984,7157,26294215,,,
233,Preclinical - Cell culture,"In a preclinical study, combination of two unspecified EGFR antibodies targeting nonoverlapping epitopes of Egfr did not inhibit proliferation of Tp53 mutated hypopharyngeal carcinoma cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767).",Actionable,7777,8533,hypopharynx cancer,DOID,434,TP53 mutant,resistant,4575,unspecified EGFR antibody,7157,27196767,,,
234,Phase I,"In a Phase I clinical trial, the majority of 19 leukemia patients with identified TP53 mutations did not demonstrate response to treatment with RG7112, with 2 acute myeloid leukemia patients harboring TP53 mutations showing clinical activity, but not improvement, and 1 sCLL/CLL patient achieving stable disease (PMID: 26459177).",Actionable,5068,1240,leukemia,DOID,434,TP53 mutant,decreased response,2076,RG7112,7157,26459177,,,
235,Phase II,"In a Phase II trial, Paraplatin (carboplatin) and MK-1775 combination treatment resulted in an overall response rate of 43% (9/21), a median progression-free survival of 5.3 months and a median overall survival of 12.6 months in ovarian cancer patients harboring TP53 mutations (PMID: 27998224).",Actionable,11765,2394,ovarian cancer,DOID,434,TP53 mutant,predicted â€“ sensitive,1194,MK-1775 + Carboplatin ,7157,27998224,,,
236,Preclinical,"In a preclinical study, neuroblastoma cell lines harboring TP53 mutant were resistant to nutlin-3 mediated growth inhibition (PMID: 21725357).",Actionable,2993,769,neuroblastoma,DOID,434,TP53 mutant,resistant,1405,Nutlin-3a,7157,21725357,,,
237,Clinical Study,"In a retrospective study, Avastin (bevacizumab) treatment was associated with increased progression-free survival in cancer patients carrying TP53 mutations (PMID: 23670029).",Actionable,209,10000003,Advanced Solid Tumor,JAX,434,TP53 mutant,sensitive,667,Bevacizumab,7157,23670029,,,
238,Clinical Study,"In a clinical study, 106 advanced solid tumor patients harboring a TP53 mutation demonstrated a greater sensitivity to VEGF/VEGFR inhibitors, such as Avastin (bevacizumab), when compared to 82 treated patients harboring TP53 wild-type, resulting in improved rates of SD, PR, and CR, better time-to-treatment failure, and overall survival (PMID: 27466356).",Actionable,7787,10000003,Advanced Solid Tumor,JAX,434,TP53 mutant,sensitive,667,Bevacizumab,7157,27466356,,,
239,Phase I,"In a Phase I trial, Duvelisib (IPI-145) treatment inhibited Akt phosphorylation, resulted in complete response in 2% (1/49), partial response in 53% (26/49), and stable disease in 43% (21/49) of chronic lymphocytic leukemia patients, of which 49% (23/47) carried TP53 mutations (Blood 124 (21): 3334).  ",Actionable,5145,1040,chronic lymphocytic leukemia,DOID,434,TP53 mutant,predicted â€“ sensitive,1024,Duvelisib,7157,None,,,
240,Phase I,"In a Phase I trial, the combination of Votrient (pazopanib) and Zolinza (vorinostat) improved progression-free survival and overall survival in advanced solid tumor patients harboring TP53 hotspot mutations, and resulted in an increased stable disease rate of 45% (5/11), compared to a stable disease rate of 16% (4/25) in patients without detected TP53 mutations (PMID: 25669829).",Actionable,3413,10000003,Advanced Solid Tumor,JAX,434,TP53 mutant,sensitive,1211,Pazopanib + Vorinostat,7157,25669829,,,
241,Preclinical - Cell line xenograft,"In a preclinical study, Prodigiosin inhibited self-renewal of colorectal cancer cell lines harboring TP53 mutations in culture and suppressed tumor growth in cell line xenograft models (PMID: 26759239).",Actionable,5770,9256,colorectal cancer,DOID,434,TP53 mutant,sensitive,3925,Prodigiosin,7157,26759239,,,
242,Preclinical - Cell culture,"In a preclinical study, combination of an unspecified EGFR antibody, an unspecified Erbb3 (Her3) antibody, and an unspecified Igf-1r antibody resulted in potent inhibition of survival in TP53 mutated hypopharyngeal carcinoma cancer cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767).",Actionable,7784,8533,hypopharynx cancer,DOID,434,TP53 mutant,predicted â€“ sensitive,4580,EGFR antibody + ERBB3 antibody + IGF-1R antibody,7157,27196767,,,
243,Preclinical - Cell culture,"In a preclinical study, TP53-mutated breast cancer cell lines demonstrated increased sensitivity to PK11007 compared to TP53-wild type cells in culture, regardless of Esr1 and Erbb2 (Her2) status (J Clin Oncol 35, 2017 (suppl; abstr e14099)).",Actionable,11113,1612,breast cancer,DOID,434,TP53 mutant,sensitive,5862,PK11007,7157,None,,,
244,Preclinical,"In a preclinical study, treatment with Nutlin-3 had little effect on growth of ovarian cancer cells with TP53 mutations in culture (PMID: 25964101).",Actionable,6065,2394,ovarian cancer,DOID,434,TP53 mutant,no benefit,1405,Nutlin-3a,7157,25964101,,,
245,Phase I,"In a clinical study, a retrospective analysis of a Phase I trial demonstrated non-small cell lung carcinoma (NSCLC) patients harboring either a TP53 mutation (n=15) or KRAS mutation (n=8) had greater progression free survival compared to NSCLC patients harboring wild-type TP53 or KRAS (n=15) (14.5mo vs 14.7mo vs 3.5mo, respectively) when treated with Keytruda (pembrolizumab) (PMID: 28039262). ",Actionable,11294,3908,non-small cell lung carcinoma,DOID,434,TP53 mutant,predicted â€“ sensitive,1447,Pembrolizumab,7157,28039262,,,
246,Preclinical,"In a preclinical study, CTX-1 induced increased Tp53 protein levels and cell death in human tumor cell lines with mutant Tp53 in culture (PMID: 26883273).",Actionable,5574,10000003,Advanced Solid Tumor,JAX,434,TP53 mutant,sensitive,3899,CTX-1,7157,26883273,,,
247,Preclinical - Cell culture,"In a preclinical study, combination of an unspecified EGFR antibody and an unspecified Igf-1r antibody resulted in inhibition of survival in TP53 mutated hypopharyngeal carcinoma cancer cells that developed Erbitux (cetuximab) resistance in culture (PMID: 27196767).",Actionable,7783,8533,hypopharynx cancer,DOID,434,TP53 mutant,predicted â€“ sensitive,4578,unspecified EGFR antibody + unspecified IGF-1R antibody,7157,27196767,,,
248,Preclinical - Pdx,"In a preclinical study, treatment with MK-1775 decreased CDK1 phosphorylation and reduced tumor growth in patient-derived xenograft models of glioblastoma multiforme that harbor TP53 mutations (PMID: 27196784).",Actionable,7043,3068,glioblastoma multiforme,DOID,434,TP53 mutant,sensitive,822,MK-1775,7157,27196784,,,
249,Phase I,"In a Phase I trial, treatment with GDC-0425 followed by Gemzar (gemcitabine) resulted in a partial response in a patient with triple-receptor negative breast cancer harboring a TP53 mutation (PMID: 27815358). ",Actionable,10956,60081,triple-receptor negative breast cancer,DOID,434,TP53 mutant,predicted â€“ sensitive,5734,GDC-0425 + Gemcitabine,7157,27815358,,,
250,Preclinical - Cell culture,"In a preclinical study, AZD6738 treatment increased sensitivity to radiotherapy in a pharynx squamous cell carcinoma cell line harboring a TP53 mutation in culture, resulting in a greater decrease in cell survival compared to radiation treatment alone (PMID: 28062704). ",Actionable,10017,50921,pharynx squamous cell carcinoma,DOID,434,TP53 mutant,sensitive,5346,AZD6738 + Radiotherapy,7157,28062704,,,
251,Preclinical,"In a preclinical study, medulloblastoma cell lines with TP53 mutations had significantly less sensitivity to the BET inhibitor, JQ1, than cell lines carrying wild-type TP53 (PMID: 24231268).",Actionable,1133,50902,medulloblastoma,DOID,434,TP53 mutant,decreased response,1574,JQ1,7157,24231268,,,
252,Preclinical,"In a preclinical study, ovarian clear cell adenocarcinoma cell lines harboring TP53 mutations demonstrated reduced sensitivity to DS-7423 induced apoptosis in culture compared to TP53 wild-type cells (PMID: 24504419).",Actionable,5200,5304,ovarian clear cell adenocarcinoma,DOID,434,TP53 mutant,decreased response,722,DS-7423,7157,24504419,,,
253,Phase I,"In a Phase I trial, the combination of Votrient (pazopanib) and Zolinza (vorinostat) resulted in improved progression-free survival and overall survival in metastatic sarcoma and colorectal cancer patients harboring TP53 hotspot mutations, and resulted in a stable disease rate of 83% (5/6), compared to a stable disease rate of 9% (1/11) in patients without detected TP53 mutations (PMID: 25669829).",Actionable,3414,1115,sarcoma,DOID,434,TP53 mutant,sensitive,1211,Pazopanib + Vorinostat,7157,25669829,,,
254,Preclinical,"In a preclinical study, Nutlin-3 and etoposide worked cooperatively to induce apoptosis in ovarian cancer cell lines with TP53 inactivating mutations in culture (PMID: 25964101).",Actionable,6067,2394,ovarian cancer,DOID,434,TP53 mutant,sensitive,4017,Nutlin-3 + Etoposide,7157,25964101,,,
255,Preclinical - Cell culture,"In a preclinical study, Nutlin-3 and Paraplatin (carboplatin) synergistically inhibited growth in TP53 mutated triple-receptor negative breast cancer cell lines in culture and in cell line xenograft models (PMID: 26494859).",Actionable,9183,60081,triple-receptor negative breast cancer,DOID,434,TP53 mutant,predicted â€“ sensitive,4928,Carboplatin + Nutlin-3,7157,26494859,,,
256,Preclinical - Cell line xenograft,"In a preclinical study, sequential administration of Roscovotine (seliciclib) followed by Adriamycin (doxorubicin) synergistically induced apoptosis in TP53-mutant triple-receptor negative breast cancer cell lines in culture, and inhibited tumor growth, prolonged survival in cell line xenograft models (PMID: 26826118).",Actionable,10906,60081,triple-receptor negative breast cancer,DOID,434,TP53 mutant,predicted â€“ sensitive,5678,Doxorubicin + Seliciclib,7157,26826118,,,
257,Phase III,"In a Phase III trial, Avastin (bevacizumab), in combination with chemotherapy, provided a significant survival benefit in patients with colorectal cancers regardless of mutational status in KRAS, BRAF, and TP53 (PMID: 17145525).",Actionable,915,9256,colorectal cancer,DOID,434,TP53 mutant,sensitive,667,Bevacizumab,7157,17145525,,,
258,Preclinical,"In a preclinical study, PD0166285 sensitizes colorectal cancer cells with TP53 mutation to radiation induced cell death (PMID: 11719452).",Actionable,138,9256,colorectal cancer,DOID,434,TP53 mutant,sensitive,851,PD0166285,7157,11719452,,,
259,Preclinical,"In a preclinical study, a rapamycin-resistant colorectal cancer cell line harboring mutations in APC, BRAF, PIK3CA, SMAD4 and TP53 was sensitive to Sapanisertib (MLN0128) resulting in inhibition of MTORC1 signaling (PMID: 25261369). ",Actionable,2135,9256,colorectal cancer,DOID,5415,APC mut BRAF mut PIK3CA mut SMAD4 mut TP53 mut,sensitive,1282,Sapanisertib,7157,25261369,,,
260,Clinical Study,"In a clinical study, treatment with first-line tyrosine kinase inhibitors resulted in a disease control rate (DCR) of 70% (26/37) in non-small cell lung carcinoma patients harboring both EGFR and TP53 mutations, compared to a DCR of 88% (76/86) in TP53 wild-type, EGFR mutated patients (J Clin Oncol 34, 2016 (suppl; abstr 9052)).",Actionable,6998,3908,non-small cell lung carcinoma,DOID,24178,EGFR mut TP53 mut,decreased response,1776,N/A,7157,None,,,
261,Preclinical,"In a preclinical study, Xalkori (crizotinib) did not demonstrate synergy with the combination of Topotecan and Cytoxan (cyclophosphamide) on growth inhibition in neuroblastoma cell lines harboring wild-tpye Alk and TP53 mutations in culture (PMID: 26438783).",Actionable,4739,769,neuroblastoma,DOID,18890,"ALK	wild-type TP53 mutant",no benefit,3601,Crizotinib + Cyclophosphamide + Topotecan,7157,26438783,,,
262,Preclinical - Cell culture,"In a preclinical study, the combination of Navitoclax (ABT-263), Alpelisib (BYL719), Tafinlar (dabrafenib), and Tarceva (erlotinib) resulted in the greatest synergistic effect and inhibition of cell growth in colorectal cancer cells harboring a BRAF mutation and TP53 mutation in culture compared to the double or triple combinations of the therapies (PMID: 27659046). ",Actionable,9934,9256,colorectal cancer,DOID,27213,BRAF mut TP53 mut,sensitive,5318,ABT-263 + Alpelisib + Dabrafenib + Erlotinib,7157,27659046,,,
263,Preclinical - Cell line xenograft,"In a preclinical study, R547 inhibited proliferation of prostate carcinoma cell lines harboring Tp53 and Rb1 mutations in culture and reduced tumor growth in xenograft models (PMID: 17121911).",Actionable,4358,10286,prostate carcinoma,DOID,17821,RB1 mut TP53 mut,sensitive,3497,R547,7157,17121911,,,
264,Preclinical,"In a preclinical study, R547 inhibited proliferation of breast carcinoma cell lines harboring TP53 and RB1 mutations in culture (PMID: 17121911).",Actionable,4351,3459,breast carcinoma,DOID,17821,RB1 mut TP53 mut,sensitive,3497,R547,7157,17121911,,,
265,Preclinical,"In a preclinical study, R547 inhibited proliferation of cervical carcinoma cell lines harboring Tp53 and Rb1 mutations (PMID: 17121911).",Actionable,4357,4362,cervical cancer,DOID,17821,RB1 mut TP53 mut,sensitive,3497,R547,7157,17121911,,,
266,Preclinical - Cell culture,"In a preclinical study, the combination of ONC201 (TIC10) and Navitoclax (ABT-263) increased apoptosis and worked synergistically to inhibit proliferation of a glioblastoma cell line harboring mutations in PTEN and TP53 in culture (PMID: 26474387).",Actionable,9825,3068,glioblastoma multiforme,DOID,5387,PTEN mutant TP53 mutant,sensitive,5245,Navitoclax + ONC201,7157,26474387,,,
267,Preclinical,"In a preclinical study, a skin cancer cell line harboring mutations in PTEN and TP53 demonstrated sensitivity to Sapanisertib (MLN0128) in culture (PMID: 25261369). ",Actionable,2104,4159,skin cancer,DOID,5387,PTEN mutant TP53 mutant,sensitive,1282,Sapanisertib,7157,25261369,,,
268,Clinical Study,"In a clinical case study, a patient with gastric adenocarcinoma containing amplification of ERBB2 (HER2) and a TP53 R158H mutation progressed and developed metastases while being treated with AMG 337 (PMID: 26432108).",Actionable,4099,3717,gastric adenocarcinoma,DOID,17302,ERBB2 amp TP53 R158H,predicted â€“ resistant,1064,AMG 337,7157,26432108,,,
269,Preclinical - Pdx & cell culture,"In a preclinical study, ReACp53 rescued p53 activity and decreased viability of ovarian cancer cells harboring TP53 R248Q in culture, and induced tumor regression in patient-derived ovarian cancer xenograft models harboring TP53 R248Q (PMID: 26748848).",Actionable,3978,2394,ovarian cancer,DOID,3457,TP53 R248Q,sensitive,3406,ReACp53,7157,26748848,,,
270,Preclinical,"In a preclinical study, Ganetespib extended survival by 48% in mice with tumors expressing TP53 R248Q (PMID: 26009011).",Actionable,5004,10000003,Advanced Solid Tumor,JAX,3457,TP53 R248Q,sensitive,745,Ganetespib,7157,26009011,,,
271,Preclinical,"In a preclinical study, the combination of APR-246 and Platinol (cisplatin) worked synergistically to inhibit growth of a Platinol (cisplatin)-resistant ovarian cancer cell line harboring TP53 R248Q in culture and inhibited tumor growth in TP53 R248Q-carrying ovarian cancer cell line xenograft models (PMID: 26086967).",Actionable,4095,2394,ovarian cancer,DOID,3457,TP53 R248Q,sensitive,3443,APR-246 + Cisplatin,7157,26086967,,,
272,Clinical Study,"In a clinical study, treatment with first-line tyrosine kinase inhibitors resulted in a disease control rate (DCR) of 42% (5/12), median PFS and OS of 4.2 and 16.2 months in non-small cell lung carcinoma patients harboring both TP53 exon 8 and EGFR mutations, compared to 87% (97/111),  12.5 and 32.3 months in TP53 exon 8 wild-type patients (J Clin Oncol 34, 2016 (suppl; abstr 9052)).",Actionable,6999,3908,non-small cell lung carcinoma,DOID,24179,EGFR mut TP53 exon 8,decreased response,1776,N/A,7157,None,,,
273,Preclinical,"In a preclinical study, Ganetespib inhibited growth of human breast cancer cells harboring TP53 L194F in culture (PIMD: 26009011).",Actionable,5013,1612,breast cancer,DOID,19851,TP53 L194F,sensitive,745,Ganetespib,7157,26009011,,,
274,Preclinical - Cell line xenograft,"In a preclinical study, Tanespimycin (17-AAG) inhibited tumor growth in human breast cancer cell line xenograft models harboring TP53 L194F (PMID: 26009011).",Actionable,5007,1612,breast cancer,DOID,19851,TP53 L194F,sensitive,934,Tanespimycin,7157,26009011,,,
275,Preclinical - Cell line xenograft,"In a preclinical study, Tanespimycin (17-AAG) and Zolinza (vorinostat) were synergistic towards tumor growth inhibition in human breast cancer cell line xenograft models harboring TP53 L194F (PMID: 26009011).",Actionable,5006,1612,breast cancer,DOID,19851,TP53 L194F,sensitive,4644,Tanespimycin + Vorinostat,7157,26009011,,,
276,Preclinical - Cell line xenograft,"In a preclinical study, Zolinza (vorinostat) inhibited tumor growth in human breast cancer cell line xenograft models harboring TP53 L194F (PMID: 26009011).",Actionable,5008,1612,breast cancer,DOID,19851,TP53 L194F,sensitive,1077,Vorinostat,7157,26009011,,,
277,Clinical Study,"In a clinical study, a colon cancer patient harboring BRAF V600E and TP53 Q192K demonstrated a partial response when treated with a combination of Zelboraf (vemurafenib) and Vectibix (panitumumab) (PMID: 28514312). ",Actionable,11052,219,colon cancer,DOID,27902,BRAF V600E TP53 Q192K,sensitive,1717,Vemurafenib + Panitumumab,7157,28514312,,,
278,Preclinical - Cell culture,"In a preclinical study, non-small cell lung carcinoma cells overexpressing TP53 P98A demonstrated reduced sensitivity to Roscovotine (seliciclib) induced apoptosis in culture (PMID: 22862161).",Actionable,11746,3908,non-small cell lung carcinoma,DOID,1477,TP53 P98A,decreased response,1129,Seliciclib,7157,22862161,,,
279,Preclinical - Cell line xenograft,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and growth of colorectal cancer cells harboring BRAF V600E, PIK3CA P449T, and TP53 R273H in culture and in cell line xenograft models, but did not have synergistic effect on apoptosis (PMID: 26272063).",Actionable,8565,9256,colorectal cancer,DOID,26358,BRAF V600E PIK3CA P449T TP53 R273H,sensitive,4771,MLN0128 + PD-0325901,7157,26272063,,,
280,Preclinical,"In a preclinical study, the combination of APR-246 and Platinol (cisplatin) worked synergistically to inhibit growth of non-small lung cancer cells harboring TP53 R248W in culture (PMID: 26086967).",Actionable,4097,3908,non-small cell lung carcinoma,DOID,837,TP53 R273H,sensitive,3443,APR-246 + Cisplatin,7157,26086967,,,
281,Phase I,"In a Phase I trial, VX-970 and Paraplatin (carboplatin) combination treatment resulted in partial response for 6 months in a PARP inhibitor-resistant ovarian cancer patient harboring a germline BRCA1 mutation and TP53 Y220C (J Clin Oncol 34, 2016 (suppl; abstr 2504)).",Actionable,6711,2394,ovarian cancer,DOID,23675,BRCA1 mut TP53 Y220C,sensitive,4253,Carboplatin + VX-970,7157,None,,,
282,Preclinical - Cell culture,"In a preclinical study, non-small cell lung carcinoma cells overexpressing TP53 Y220C were resistant to Roscovotine (seliciclib) induced apoptosis in culture (PMID: 22862161).",Actionable,11745,3908,non-small cell lung carcinoma,DOID,1043,TP53 Y220C,resistant,1129,Seliciclib,7157,22862161,,,
283,Preclinical - Cell culture,"In a preclinical study, treatment with CP-31398 resulted in decreased proliferation, increased apoptosis, and cell-cycle arrest in a hepatocellular carcinoma cell line harboring TP53 Y220C in culture (PMID: 26250460).",Actionable,8984,684,hepatocellular carcinoma,DOID,1043,TP53 Y220C,sensitive,3404,CP-31398,7157,26250460,,,
284,Preclinical,"In a preclinical study, TP53 R280M resulted in secondary resistance in an osteosarcoma cell line acquired during Nutlin-3 treatment (PMID: 21643018).",Actionable,911,3347,osteosarcoma,DOID,1553,TP53 R280M,resistant,1405,Nutlin-3a,7157,21643018,,,
285,Preclinical - Pdx,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12D, PTEN loss, and TP53 V216M (PMID: 26272063).",Actionable,8575,9256,colorectal cancer,DOID,26364,KRAS G12D PTEN loss TP53 V216M,no benefit,4771,MLN0128 + PD-0325901,7157,26272063,,,
286,Preclinical,"In a preclinical study, LY3009120 modestly inhibited soft agar growth of human melanoma cancer cells harboring TP53 D259Y in culture (PMID: 26343583).",Actionable,6595,1909,melanoma,DOID,23639,TP53 D259Y,sensitive,3268,LY3009120,7157,26343583,,,
287,Preclinical,"In a preclinical study, Selumetinib (AZD6244) inhibited proliferation of human melanoma cells harboring TP53 D259Y in culture (PMID: 26343583).",Actionable,6607,1909,melanoma,DOID,23639,TP53 D259Y,sensitive,913,Selumetinib,7157,26343583,,,
288,Preclinical,"In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of human melanoma cells TP53 D259Y in culture (PMID: 26343583).",Actionable,6608,1909,melanoma,DOID,23639,TP53 D259Y,sensitive,342,Vemurafenib,7157,26343583,,,
289,Preclinical - Cell culture,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 synergistically inhibited Erk and PI3K signaling and proliferation, but did not induce apoptosis in colorectal cancer cells harboring KRAS G13D, PIK3CA E545K, and TP53 S241F in culture (PMID: 26272063).",Actionable,8564,9256,colorectal cancer,DOID,26357,KRAS G13D PIK3CA E545k TP53 S241F,sensitive,4771,MLN0128 + PD-0325901,7157,26272063,,,
290,Preclinical - Cell line xenograft,"In a preclinical study, APR-246 demonstrated efficacy in xenograft models of small cell lung cancer harboring TP53 S241F (PMID: 21415220).",Actionable,8283,5409,lung small cell carcinoma,DOID,16831,TP53 S241F,sensitive,1946,APR-246,7157,21415220,,,
291,Preclinical,"In a preclinical study, Ganetespib inhibited growth of human ovarian cancer cells harboring TP53 S241F in culture (PMID: 26009011).",Actionable,5015,2394,ovarian cancer,DOID,16831,TP53 S241F,sensitive,745,Ganetespib,7157,26009011,,,
292,Preclinical - Cell culture,"In a preclinical study, an ovarian clear cell adenocarcinoma cell line harboring TP53 S241F demonstrated reduced sensitivity to DS-7423 in culture (PMID: 24504419). ",Actionable,10547,5304,ovarian clear cell adenocarcinoma,DOID,16831,TP53 S241F,decreased response,722,DS-7423,7157,24504419,,,
293,Preclinical - Patient cell culture,"In a preclinical study, the combination of APR-246 and Platinol (cisplatin) resulted in strong synergism, thereby reducing cell viability in patient derived ovarian cancer cells harboring TP53 L111Q in culture (PMID: 27179933). ",Actionable,9807,2394,ovarian cancer,DOID,27098,TP53 L111Q,sensitive,3443,APR-246 + Cisplatin,7157,27179933,,,
294,Preclinical - Pdx,"In a preclinical study, Sapanisertib (MLN0128) and PD-0325901 combination treatment did not result in tumor growth stabilization in patient-derived xenograft models of colorectal cancer harboring KRAS G12D, decreased PTEN expression, and TP53 R306* (PMID: 26272063).",Actionable,8576,9256,colorectal cancer,DOID,26365,KRAS G12D PTEN dec exp TP53 R306*,no benefit,4771,MLN0128 + PD-0325901,7157,26272063,22389253,,
0,Clinical Study,"In multiple clinical studies, the presence of U2AF1 mutations was associated with a trend toward risk of progression to acute myeloid leukemia, however, the prognostic significance of U2AF1 mutations is still unclear (PMID: 25465125, PMID: 22158538, PMID: 22389253).",Emerging,6424,50908,myelodysplastic syndrome,DOID,23383,U2AF1 mutant,not applicable,1776,N/A,7307,25465125,22158538,,
0,Phase II,"In a Phase II clinical study, baseline expression of VHL was not predictive for response to Saracatinib (AZD0530) and Recentin (cediranib) relative to Recentin (cediranib) in patients with metastatic clear-cell renal cell carcinoma (PMID: 26802156).",Actionable,5935,4467,renal clear cell carcinoma,DOID,22001,VHL over exp,no benefit,3922,Cediranib + Saracatinib,7428,26802156,,,
1,Preclinical - Cell line xenograft,"In a preclinical study, Stivarga (regorafenib) inhibited angiogenesis and tumor growth in cell line xenograft models of renal cell carcinoma harboring VHL gene deletion (PMID: 21170960).",Actionable,7721,4450,renal cell carcinoma,DOID,25932,VHL del,predicted â€“ sensitive,890,Regorafenib,7428,21170960,,,
2,Preclinical - Pdx,"In a preclinical study, PT2399 had variable impact on tumor growth in clear cell renal cell carcinoma (ccRCC) cell line and patient-derived xenograft (PDX) models with defective VHL, with decreased tumor growth in a VHL-defective ccRCC PDX model and some VHL-defective ccRCC cell line xenograft models, and no tumor suppression in other cell line xenograft models (PMID: 27595393).",Actionable,8268,4467,renal clear cell carcinoma,DOID,6849,VHL inact mut,conflicting,4670,PT2399,7428,27595393,,,
3,Clinical Study,"In a retrospective analysis, VHL alterations did not impact overall survival or objective response in renal cell carcinoma patients treated with a VEGF-targeted therapy,including Avastin (bevacizumab) and Alpha 2 Interferon combination therapy, but were associated with a prolonged time to progression (PMID: 16827904).",Actionable,9339,4450,renal cell carcinoma,DOID,6849,VHL inact mut,predicted â€“ sensitive,2511,Bevacizumab + Alpha 2 Interferon,7428,16827904,,,
4,Phase II,"In a retrospective analysis from a Phase II clinical trial, patients with metastatic renal cell carcinoma treated with Afinitor (everolimus) had a trend towards improved in progression free survival when stratified by the presence (median PFS=8.6 months, n=15) or absence (median PFS=5.5 months, n=16) of deleterious VHL mutations (PMID: 26951309).",Actionable,5740,4450,renal cell carcinoma,DOID,6849,VHL inact mut,predicted â€“ sensitive,735,Everolimus,7428,26951309,,,
5,Phase II,"In a retrospective analysis from a Phase II clinical trial, patients with metastatic renal cell carcinoma treated with Apitolisib (GDC-0980) had no difference in progression free survival when stratified by the presence (n=5) or absence (n=17) of deleterious VHL mutations (PMID: 26951309).",Actionable,5735,4450,renal cell carcinoma,DOID,6849,VHL inact mut,no benefit,750,GDC-0980,7428,26951309,,,
6,Preclinical - Cell culture,"In a preclinical study, TP53 R248W was associated with resistance to PT2399 in VHL-defective clear cell renal cell carcinoma cell lines in culture (PMID: 27595393).",Actionable,8269,4467,renal clear cell carcinoma,DOID,26217,TP53 R248W VHL inact mut,resistant,4670,PT2399,7428,27595393,,,
7,Phase I,"In a Phase I study, Afinitor (everolimus), as compared to Apitolisib (GDC-0980), resulted in a greater progression free survival and overall survival in patients with renal cell carcinoma harboring VHL mutations (J Clin Oncol 32:5s, 2014 (suppl; abstr 4525)). ",Actionable,2280,4450,renal cell carcinoma,DOID,4973,VHL mut,sensitive,735,Everolimus,7428,None,,,
8,Phase I,"In a Phase I study, 33% (6/18) of renal cell carcinoma archived patient samples with VHL mutations demonstrated partial response when treated with Sutent (sunitinib) (PMID: 22105611).",Actionable,2271,4450,renal cell carcinoma,DOID,4973,VHL mut,sensitive,930,Sunitinib,7428,22105611,,,
9,Preclinical - Pdx,"In a preclinical study, combination of Mekinist (trametinib) and Sutent (sunitinib) inhibited tumor growth in patient-derived xenograft models of renal cancer harboring VHL V155fs*4 (PMID: 26487278).",Actionable,9079,263,kidney cancer,DOID,26715,VHL V155fs,predicted â€“ sensitive,4874,Sunitinib + Trametinib,7428,26487278,,,
10,Preclinical,"In a preclinical study, STF-62247 induced selective cytotoxicity and inhibited tumor growth of renal cell carcinoma cells lacking VHL (PMID: 18769110, PMID: 18598947).",Actionable,1112,4450,renal cell carcinoma,DOID,1883,VHL negative,sensitive,1561,STF-62247,7428,18769110,18598947,,
11,Preclinical,"In a preclinical study, human renal carcinoma cells with PTEN loss and VHL loss had a decreased response to Gedatolisib (PKI-587) in culture (PMID: 21325073).",Actionable,3157,4451,renal carcinoma,DOID,11820,PTEN loss VHL loss,decreased response,1040,PF-05212384,7428,21325073,,,
12,Preclinical - Cell culture,"In a preclinical study, VHL-deficient renal cell carcinoma cells demonstrated growth inhibition in culture when treated with CB-839 (PMID: 28346230).",Actionable,10900,4450,renal cell carcinoma,DOID,6901,VHL loss,sensitive,1667,CB-839,7428,28346230,,,
13,Preclinical - Cell line xenograft,"In a preclinical study, the combination of CB-839 and Lynparza (olaparib) resulted in a synergistic effect, demonstrating greater reduction in tumor volume compared to either agent alone in renal carcinoma cell xenograft models deficient for VHL (PMID: 28346230). ",Actionable,10901,4450,renal cell carcinoma,DOID,6901,VHL loss,sensitive,5675,CB-839 + Olaparib,7428,28346230,,,
14,Preclinical - Cell culture,"In a preclinical study, VHL-deficient renal cell carcinoma cells demonstrated growth inhibition and suppression of DNA synthesis in culture when treated with BPTES (PMID: 28346230).",Actionable,10899,4450,renal cell carcinoma,DOID,6901,VHL loss,sensitive,5194,BPTES,7428,28346230,,,
15,Preclinical,"In a preclinical study, clear cell renal cell carcinoma xenograft models with VHL loss demonstrated sensitivity to Avastin (bevacizumab) (PMID: 22931246).",Actionable,2272,4450,renal cell carcinoma,DOID,6901,VHL loss,sensitive,667,Bevacizumab,7428,22931246,,,
16,Preclinical - Cell line xenograft,"In a preclinical study, renal cell carcinoma cells deficient for VHL were sensitive to ELR510444 both in culture and in cell line xenograft models (PMID: 22295124).",Actionable,2273,4450,renal cell carcinoma,DOID,6901,VHL loss,sensitive,2790,ELR510444,7428,22295124,,,
17,Preclinical - Cell culture,"In a preclinical study, the combination of BPTES and Lynparza (olaparib) resulted in a synergistic effect, demonstrating growth inhbition of VHL-deficient renal cell carcinoma cells in culture (PMID: 28346230). ",Actionable,10903,4450,renal cell carcinoma,DOID,6901,VHL loss,sensitive,5677,BPTES + Olaparib,7428,28346230,,,